



In Memoriam:



# Final Program

XXV Congress of the International Society  
on Thrombosis and Haemostasis  
and 61st Annual SSC Meeting

June 20 – 25, 2015  
Toronto, Canada

[www.isth2015.org](http://www.isth2015.org)



# Join Us!

**Isth**  
International Society on  
Thrombosis and Haemostasis



ISTH membership is an essential investment in your future at every stage in your career. With membership, you receive the ISTH's highly regarded, *Journal of Thrombosis and Haemostasis (JTH)*, timely information regarding thrombotic and bleeding disorders, targeted educational programs and networking opportunities.

Visit us online to arrive at your career and education destination today.

[www.isth.org](http://www.isth.org)  
**Visit the ISTH at Booth 1036!**

*The ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.*

## ISTH Membership Benefits

- International network that spans more than 85 countries
- Priority registration and meeting discounts
- Complimentary print subscription to JTH
- E-learning opportunities
- Access to the ISTH members-only online resources
- Eligibility to hold elected and/or appointed offices
- Vote on Society matters and serve on subcommittees and working groups
- Career center

## Final Program

### Table of Contents

3	Venue and Contacts
5	Invitation and Welcome Message
12	ISTH 2015 Committees
24	Congress Support
25	Sponsors and Exhibitors
27	ISTH Awards
32	ISTH Society Information
37	Program Overview
41	Program Day by Day
55	SSC and Educational Program
83	Master Classes and Career Mentorship Sessions
87	Nurses Forum
93	<b>Scientific Program, Monday, June 22</b>
94	Oral Communications 1
102	Plenary Lecture
103	State of the Art Lectures
105	Oral Communications 2
112	Abstract Symposia
120	Poster Session
189	<b>Scientific Program, Tuesday, June 23</b>
190	Oral Communications 3
198	Plenary Lecture
198	State of the Art Lectures
200	Oral Communications 4
208	Plenary Lecture
209	Abstract Symposia
216	Poster Session
285	<b>Scientific Program, Wednesday, June 24</b>
286	Oral Communications 5
294	Plenary Lecture
294	State of the Art Lectures
296	Oral Communications 6
304	Abstract Symposia
311	Poster Session
381	<b>Scientific Program, Thursday, June 25</b>
382	Oral Communications 7
390	Plenary Lecture
390	Abstract Symposia
397	Highlights of ISTH
399	<b>Exhibition Floor Plan</b>
402	<b>Exhibitor List</b>
405	<b>Congress Information</b>
406	Venue Plan
407	Congress Information
417	Social Program
418	Toronto & Canada Information
421	Transportation in Toronto
423	<b>Future ISTH Meetings and Congresses</b>
427	<b>Authors Index</b>

**Isth**  
**2015 Congress**  
**TORONTO JUNE 20-25**  
Reaching for Unprecedented Peaks

# Thank You to Everyone Who Supported the 2014 World Thrombosis Day Campaign!



Together, we've elevated the global conversation about potentially deadly blood clots.



**WORLD THROMBOSIS DAY**  
13 OCTOBER

WWW.WORLDTHROMBOSISDAY.ORG



Visit us at Booth 1036

FOUNDING GLOBAL PARTNER



GLOBAL PARTNERS



GLOBAL PATRON



## Venue and Contacts

### Venue

**Metro Toronto Convention Center (MTCC)**  
**MTCC South Building**  
222 Bremner Boulevard  
Toronto, Ontario M5V 2W6  
Canada

**T: +1 (416) 585-8000**

**E : [info@mtccc.com](mailto:info@mtccc.com)**

**W: <http://www.mtccc.com>**

### Contacts

#### ISTH Headquarters:

610 Jones Ferry Road, Suite 205  
Carrboro, NC 27510  
USA

**T: +1 919 929-3807**

**F: +1 919 929-3935**

[headquarters@isth.org](mailto:headquarters@isth.org)  
[www.isth.org](http://www.isth.org)

#### Executive Meeting Matters:

##### Lisa Astorga

ISTH Director of Meetings  
[lisa\\_astorga@isth.org](mailto:lisa_astorga@isth.org)

#### Sponsorship and Exhibition:

##### Thomas Reiser

Executive Director  
**T: +1 919 929-3807**  
[tom\\_reiser@isth.org](mailto:tom_reiser@isth.org)

#### Marketing and Media:

##### Louise M. Bannon

Director of Marketing and Membership  
**T: +1 919 929-3807**  
[louise\\_bannon@isth.org](mailto:louise_bannon@isth.org)

#### Membership Questions or any General Inquiries about the ISTH:

##### ISTH Membership Staff

**T: +1 919 929-3807**  
[membership@isth.org](mailto:membership@isth.org)

#### ISTH 2015 Organizing Secretariat:

(Registration, Logistics, Exhibition, Hotel Accommodations)

##### c/o MCI Suisse SA

MCI Suisse SA  
Rue de Lyon 75  
1211 Geneva 13  
Switzerland

**T: +41 22 33 99 728**  
[isth.reg@mci-group.com](mailto:isth.reg@mci-group.com)

#### Abstract Questions:

[isth2015abs@mci-group.com](mailto:isth2015abs@mci-group.com)

# jth<sup>®</sup>

## journal of thrombosis and haemostasis

Editors in Chief: Pieter Reitsma and Frits Rosendaal



The  
**NUMBER ONE**  
international  
specialty  
journal in  
your field!

**ISTH**<sup>™</sup>  
International Society on  
Thrombosis and Haemostasis

**WILEY**

13-53385

## Invitation and Welcome Message

Dear ISTH Congress attendees,

We are happy to welcome you to Toronto, which in the Iroquois language means “place where trees stand in the water,” and this was likely the initial native local name. From 1795 to 1834 it was the town of York, then becoming the City of Toronto with a population of 9,000. The population of the Toronto metropolitan area has grown to just over six million in 2015. Toronto is known for its multi-ethnicity and diverse neighbourhoods, where culture and food from many parts of the world can be enjoyed. Similarly, delegates from a large number of countries will convene at this congress to exchange new research data, ideas, opinions and suggestions for future collaboration.

The ISTH Congress, now counting as the 25th since the first congress in Montreux, Switzerland, in 1970, is the largest and most important event every two years for all scientists and clinicians with an interest in thrombosis and hemostasis. The ISTH Congress has expanded - from the previous one in Toronto in 1981 of about 2,000 attendees to more than 8,000 today. Different from many other large meetings, the ISTH Congress takes much of its features from the Local Organizing Committee, which – with logistic support from ISTH Headquarters and the professional congress organizer – has substantial liberty to decide on the format of the sessions as well as the social components. For those established in the field of thrombosis and hemostasis, attending consecutive congresses in different countries and continents generates fond memories and stimulates comparisons. Those joining the ISTH Congress for the first time will hopefully get a very positive impression, encouraging further contributions to science and a return to future meetings.

Saturday and the first half of Sunday are, in keeping with tradition, devoted to the annual meeting (the 61st) of the Scientific and Standardization Committee (SSC) of the ISTH. Work in progress, preliminary or final reports from the multitude of projects of the SSC will be mixed with a wide variety of educational lectures. The latter have been carefully chosen not to duplicate presentations of invited speakers during the following congress. At the end of the SSC meeting, on Sunday at lunch, we extend a warm welcome to the recipients of the Young Investigator and the Reach-The-World awards and invite them to a special reception. Last year was the exciting premier for World Thrombosis Day (WTD), in which more than 175 organizations were involved and spread important educational messages to millions of people. On Sunday afternoon, you can enjoy a special presentation of the experiences and highlights from this inaugural WTD.

The actual ISTH Congress kicks off with the Opening Ceremony on Sunday evening and we are excited to give you a taste of Canadian music and culture from coast to coast. It will be followed by a networking reception in the Exhibition Hall.

The scientific congress is composed of a variety of sessions – five plenary lectures by front-line scientists, 53 state-of-the-art lectures by leaders in the respective fields and accompanied by corresponding articles in the educational book, 52 abstract symposia with an introductory review lecture followed by oral presentations of top-scoring abstracts on the topic, two late-breaking-sessions on Monday and Wednesday, respectively, with piping hot results from 10 clinical trials, 89 oral communication sessions, and from Monday to Wednesday poster sessions as well. For those that have reserved tickets, there are Master Classes covering 40 different topics in the early morning of Sunday to Wednesday. As a new feature we also have Career Mentorship sessions for small groups at lunch time.

We are grateful to the industry for their generous support to the congress and we hope you will take time to visit the exhibition and exchange ideas with the representatives from the diagnostic and pharmaceutical industry. And don't forget the ISTH booth! During the lunch break, after grabbing a complimentary lunch box, you may attend a satellite symposium, stroll through the poster area or just sit and network with colleagues.

The All Congress Party on Wednesday evening will be a social highlight for you and your friends. You will taste the food of the ethnic neighbourhoods of Toronto while listening to different music bands, culminating with a performance by the rock band the Barenaked Ladies. Make sure you have tickets!

The congress ends on Thursday at noon with a novelty – the Highlights of ISTH session. Here you will get a recap of selected, top-scoring presentations both from basic and from clinical science. Since there are many simultaneous sessions during the congress and you therefore cannot possibly attend everything in your interest, this is the perfect chance to catch up on the important presentations you may have missed.

The congress app, available for download on your mobile device, will help you stay organized, select your sessions and find your way. It will also provide you with the daily news from the congress. In this Program Book the trainees can follow special tracks, identified by symbols, if they have specific interest in Platelets-basic science, Coagulation-basic science, Bleeding-clinical, Thrombosis-clinical, Pediatric thrombosis and hemostasis, or Cardiovascular-basic and clinical science.



**Sam Schulman, M.D., Ph.D.**  
ISTH XXV Congress  
2015 President



**Nigel Key, M.D., Ch.B.**  
ISTH Council Chair



**Sabine Eichinger, M.D.**  
ISTH SSC Chair

**JOIN US! WEDNESDAY, JUNE 24, 2015 | 12:15 hrs – 13:45 hrs | CONFERENCE ROOM: Room 717, Level 700**

## Emerging Trends and Strategies in Thrombosis Medicine


### Practical Dimensions of NOAC-Based Management



# Acute and Extended Treatment of VENOUS THROMBOEMBOLISM

**Focus on the Role of Factor Xa Inhibition for Acute and Extended Duration Treatment of PE and DVT**

Principles of Practice at the Front Lines of Thrombosis Care



Practical Clinical and Cased-Based Approaches for Oral Factor Xa Inhibition Across the Spectrum of VTE Care

#### PROGRAM CO-CHAIRS and DISTINGUISHED FACULTY



**Professor Samuel Z. Goldhaber, MD**  
Program Chairman  
Professor of Medicine | Harvard Medical School | Director, Thrombosis Research Group | Cardiovascular Division | Brigham and Women's Hospital | President, North American Thrombosis Forum (NATF) | Boston, Massachusetts



**Professor The Lord Ajay Kakkar, MD**  
Program Chairman  
Professor of Surgery | University College London | Director, Thrombosis Research Institute | London, UK



**Professor Stavros V. Konstantinides, MD, PhD, FESC**  
Distinguished Faculty  
Professor, Clinical Trials, and Medical Director | Center for Thrombosis and Hemostasis (CTH) | Johannes Gutenberg University Mainz | Mainz, Germany

## Save the Date: Wednesday, June 24, 2015 — CME Lunch Symposium

Registration and Boxed Lunch: 11:45 hrs – 12:15 hrs (11:45 AM – 12:15 PM) | Scientific Program: 12:15 hrs – 13:45 hrs (12:15 PM – 1:45 PM)  
City: Toronto, Ontario | Location: Metro Toronto Convention Centre | Conference Room: Room 717, Level 700

**NO PRE-REGISTRATION REQUIRED TO ATTEND!**

Funded by an independent educational grant from **Bayer Healthcare**

Jointly Sponsored by the University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC

This Satellite Program is not part of the official scientific program of the ISTH 2015 Congress





I am pleased to extend my warmest greetings to everyone attending the 25th Congress of the International Society on Thrombosis and Haemostasis (ISTH) and 61st Annual Meeting of ISTH's Scientific and Standardization Committee (SSC).

These events will provide an excellent opportunity for clinicians and researchers to exchange ideas, best practices, and information about the latest developments in thrombosis, haemostasis, and vascular biology, as well as their application to patient care.

Over the years, ISTH has worked diligently to improve global health. I commend your efforts to provide the best outcomes for patients through your commitment to the highest standards of excellence in the prevention, diagnosis, and treatment of thrombotic and bleeding disorders.

On behalf of the Government of Canada, I offer my best wishes for a memorable and productive gathering in Toronto.

The Rt. Hon. Stephen Harper, P.C., M.P.

OTTAWA  
2015



Premier of Ontario - Première ministre de l'Ontario



On behalf of the Government of Ontario, I am delighted to extend warm greetings to everyone attending The International Society on Thrombosis and Haemostasis (ISTH) XXV Congress and 61st Annual Scientific and Standardization Committee (SSC) Meeting. I would like to take this opportunity to commend the ISTH for its commitment to supporting members in the ongoing advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

As Premier, I am proud that Ontario has the opportunity to host an event that facilitates fruitful discourse between clinicians, researchers, educators and practitioners with the noble aim to improve patients' lives. With an impressive array of lectures, educational sessions and workshops, this conference is sure to both enlighten and inform.

I would like to thank the ISTH for choosing our province to host this wonderful event. I am confident that all the delegates and guests will enjoy their time in Toronto, our vibrant and diverse capital city.

Please accept my best wishes for an informative and memorable congress.

Kathleen Wynne  
Premier



Mayor John Tory  
City of Toronto



It is my esteemed pleasure to extend greetings and a warm welcome to everyone attending the International Society on Thrombosis & Haemostasis' (ISTH) XXV Congress and 61st Annual Scientific and Standardization Committee Meeting.

A global non-profit organization, the International Society on Thrombosis & Haemostasis is dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

This convention will host thousands of delegates consisting of leading experts on thrombosis, haemostasis and vascular biology from around the world. They will gather together for a productive exchange on the latest in science and clinical applications and to present the most recent advances, in a setting designed for professional development.

I wish to welcome everyone to our city and encourage you to enjoy Toronto at this time of the year as well as learn about vibrant neighborhoods.

On behalf of Toronto City Council, please accept my best wishes for an informative and enjoyable event.

Yours truly,

Mayor John Tory  
City of Toronto

## Pfizer Satellite Symposium at the XXV Congress of the International Society on Thrombosis and Haemostasis

### Managing Hemophilia for Life **Optimizing responses to therapy in hemophilia B: treatment individualization in an era of expanding options**

Monday 22<sup>nd</sup> June 2015, 12:15–13:45  
Room 716, Level 700, Metro Toronto Convention Centre, Toronto, Canada  
Chair: Alfonso Iorio (Canada)

- 12:15 Welcome and introduction  
Chair: Alfonso Iorio (Canada)
- 12:20 Review of new Phase III data for BeneFix®: once-weekly prophylactic dosing in hemophilia B  
Michael Tarantino (USA)
- 12:40 Review of new Phase III data for BeneFix®: additional analysis  
Bartholomew Tortella (Pfizer)
- 12:50 Investigating the science behind FIX in the extravascular space  
Darrel Stafford (USA)
- 13:10 Patient-centered approaches to dosing: treatment individualization with PK modeling  
Alfonso Iorio (Canada)
- 13:30 Panel discussion  
Moderated by Chair
- 13:40 Meeting summary and close



### Managing Hemophilia for Life **The role of ultrasound in hemophilia joint health: progress and perspectives from clinical practice**

Tuesday 23<sup>rd</sup> June 2015, 12:15–13:45  
Room 716, Level 700, Metro Toronto Convention Centre, Toronto, Canada  
Chair: Giovanni DiMinno (Italy)

- 12:15 Welcome and introduction  
Chair: Giovanni DiMinno (Italy)
- 12:20 Innovative approaches to hemophilia joint assessment: insights from the European Ultrasound Program  
Giovanni DiMinno (Italy)
- 12:35 Optimizing joint health outcomes with ultrasound: practical application of the Hemophilia Early Arthropathy Detection with UltraSound (HEAD-US) technique for joint assessment  
Carlo Martinoli (Italy)
- 13:05 Practical approaches to the implementation of ultrasound in hemophilia practice: case studies from Canada  
Shannon Jackson (Canada)  
Karen Strike (Canada)
- 13:25 Panel discussion  
Moderated by Chair
- 13:40 Meeting summary and close

Toronto Waterfront

Royal Ontario Museum



## ISTH 2015 Committees

### ISTH Organizing Committee

#### Local Organizing Committee

<b>Sam Schulman</b>	President
<b>Philip Wells</b>	Vice President
<b>Victor Blanchette</b>	Treasurer
<b>Jeffrey Weitz</b>	Scientific Chair

#### State-of-the-Art Book Editors

<b>David Lillicrap</b>	Editor
<b>James Douketis</b>	Co-Editor

#### Scientific Program Subcommittee Chairs

<b>Laurie Sardo</b>	Allied Health Professionals Program
<b>Geoff Werstuck</b>	Atherothrombosis
<b>John Eikelboom</b>	Clinical Cardiovascular
<b>Paula James</b>	Coagulation Factors and Inhibitors
<b>Jeffrey Weitz</b>	Fibrinolysis and Proteolysis
<b>Jerry Teitel</b>	Hemorrhagic Disorders
<b>John Semple</b>	Inflammation and Immunology
<b>Mark Crowther</b>	Innovation and Technology
<b>Patti Massicotte</b>	Pediatric Hemostasis and Thrombosis
<b>Margaret Rand</b>	Platelets - Basic
<b>Peter Gross</b>	Platelets - Clinical
<b>Donald M. Arnold</b>	Transfusion
<b>Ed Conway</b>	Vascular Biology
<b>Marc Rodger</b>	Venous Thrombotic Disorders



## ISTH 2015 Committees

#### Scientific and Standardization Committee Liaison

**Sabine Eichinger**, Austria, SSC Chair  
**Lori Linkins**, Canada, SSC Liaison

#### Educational Program

**Shannon Bates**, Canada, Co-chair  
**Agnes Lee**, Canada, Co-chair

#### Social Events Committee

**Rita Selby**, Canada, Chair

#### Trainee Program Committee

**Carol Gonsalves**, Canada, Chair  
**Mandy Lauw**, The Netherlands

#### ISTH 2015 Senior Advisory Board

**Morris Blajchman**, Canada  
**Cedric Carter**, Canada  
**Bernadette Garvey**, Canada  
**Jeff Ginsberg**, Canada  
**Jack Hirsh**, Canada  
**John Kelton**, Canada  
**Raelene Kinlough-Rathbone**, Canada  
**Michael Mant**, Canada  
**Marian Packham**, Canada  
**Graham Pineo**, Canada  
**Georges Rivard**, Canada  
**Alexander G. Turpie**, Canada

#### Scientific Program Subcommittees

##### Platelets – Basic

**Margaret Rand**, Canada, Chair  
**Patrick Provost**, Canada  
**Lawrence (Skip) Brass**, United States  
**Sara Israels**, Canada  
**Archie McNicol**, Canada  
**Heyu Ni**, Canada

##### Platelets – Clinical

**Peter Gross**, Canada, Chair  
**Walter Kahr**, Canada  
**John Freedman**, Canada  
**Ted Warkentin**, Canada  
**Alan Michelson**, United States  
**Jean-Francois Tanguay**, Canada

##### Coagulation Factors and Inhibitors

**Paula James**, Canada, Chair  
**Ed Pryzdial**, Canada  
**Patricia Liaw**, Canada  
**Rodney Camire**, United States  
**Alfonso Iorio**, Canada

##### Fibrinolysis and Proteolysis

**Jeffrey Weitz**, Canada, Chair  
**Jim Fredenburgh**, Canada  
**Paul Kim**, Canada  
**Katherine Hajjar**, United States



## ISTH 2015 Committees

### Vascular Biology

**Ed Conway**, Canada, Chair  
**Mark Blostein**, Canada  
**William Aird**, United States  
**Nigel Mackman**, United States

### Hemorrhagic Disorders

**Jerry Teitel**, Canada, Chair  
**Leonard Valentino**, United States  
**Craig Kessler**, United States  
**Man-Chiu Poon**, Canada  
**Steven Pipe**, United States

### Venous Thrombotic Disorders

**Marc Rodger**, Canada, Chair  
**Susan Kahn**, Canada  
**Clive Kearon**, Canada  
**Bill Geerts**, Canada  
**Mary Cushman**, United States  
**David Garcia**, United States

### Atherothrombosis

**Geoff Werstuck**, Canada, Chair  
**Dino Trigatti**, Canada  
**Murray Huff**, Canada  
**Myron Cybulsky**, Canada  
**Avrum Gotlieb**, Canada

### Clinical Cardiovascular

**John Eikelboom**, Canada, Chair  
**Robert Hart**, Canada  
**Chris Granger**, United States  
**William Hiatt**, United States

### Inflammation and Immunology

**John Semple**, Canada, Chair  
**Andy Weyrich**, United States  
**Dave Kuter**, United States  
**Jane Freedman**, United States  
**Eric Boilard**, Canada

### Innovation and Technology

**Mark Crowther**, Canada, Chair  
**Cathy Hayward**, Canada  
**Adam Cuker**, United States  
**Karen Moffatt**, Canada  
**Scott Diamond**, United States  
**James Zehnder**, United States

### Transfusion

**Donnie Arnold**, Canada, Chair  
**Sunny Dzik**, United States  
**Richard Kaufman**, United States  
**Yulia Lin**, Canada  
**Charles Quinn**, United States

### Pediatric Hemostasis and Thrombosis

**Patti Massicotte**, Canada, Chair  
**Michele David**, Canada  
**Manuel Carcao**, Canada  
**Lynette Bowes**, United States  
**Neil Goldenberg**, Canada  
**Leslie Raffini**, United States



## COMMITTED TO PATIENTS

**HOPE IS WHAT SANOFI BRINGS EACH DAY, OVERCOMING NEW CHALLENGES TO PROTECT LIFE FOR SEVEN BILLION PEOPLE.**

One of the world's leading health care companies, Sanofi researches, develops, manufactures and markets innovative therapeutic solutions that prevent disease, heal and improve quality of life for patients and their families.

[www.sanofi.com](http://www.sanofi.com)

## International Advisory Board

**Walter Ageno**  
Italy

**Pantep Angchaisuksiri**  
Thailand

**Yujiro Asada**  
Japan

**Patricia Casais**  
Argentina

**Barry Collier**  
United States

**Javier Corral**  
Spain

**Shaun Coughlin**  
United States

**Björn Dahlbäck**  
Sweden

**Hans Deckmyn**  
Belgium

**Cécile Denis**  
France

**Donna DiMichele**  
United States

**Sabine Eichinger**  
Austria

**Anna Falanga**  
Italy

**Bruce Furie**  
United States

**Christian Gachet**  
France

**Shinya Goto**  
Japan

**Andreas Greinacher**  
Germany

**John-Bjarne Hansen**  
Norway

**Paul Harrison**  
United Kingdom

**Beverley Hunt**  
United Kingdom

**James Huntington**  
United Kingdom

**Raül Izaguirre**  
Mexico

**Barry Jacobson**  
South Africa

**Sriram Krishnaswamy**  
United States

**Paul Kyrle**  
Austria

**Bernhard Lämmle**  
Switzerland

**Nigel Mackman**  
United States

**Diego Mezzano**  
Chile

**Toshiyuki Miyata**  
Japan

**Stephan Moll**  
United States

**Laurent Mosnier**  
United States

**Bernhard Nieswandt**  
Germany

**Doyeun Oh**  
South Korea

**Bjarne Østerud**  
Norway

**Yukio Ozaki**  
Japan

**Flora Peyvandi**  
Italy

**Margaret Ragni**  
United States

**Francesco Rodeghiero**  
Italy

**Wolfram Ruf**  
United States

**Evan Sadler**  
United States

**Uri Seligsohn**  
Israel

**Simon Stanworth**  
United Kingdom

**Scott Stevens**  
United States

**Yoshiyuki Tomiyama**  
Japan

**Tetsumei Urano**  
Japan

**Christopher Ward**  
Australia

**Steve Watson**  
United Kingdom

**Alisa Wolberg**  
United States

## ISTH 2015 Abstract Reviewers

**Rezan Abdul-Kadir**, United Kingdom  
**Thomas Abshire**, United States  
**Yolanda Adamczuk**, Argentina  
**Murray Adams**, Australia  
**Dorothy Adcock**, United States  
**Walter Ageno**, Italy  
**Giancarlo Agnelli**, Italy  
**Josefin Ahnström**, United Kingdom  
**Ingo Ahrens**, Germany  
**Ramzi Ajjan**, United Kingdom  
**Nadine Aizenberg**, France  
**Lorenzo Alberio**, Switzerland  
**Marie-Christine Alessi**, France  
**Julia Anderson**, Scotland  
**Robert Andrews**, Australia  
**Pantep Angchaisuksiri**, Thailand  
**Dominick Angiolillo**, United States  
**Gail Annich**, Canada  
**Jack Ansell**, United States  
**Jovan Antovic**, Sweden  
**Morio Arai**, Japan  
**Robert Ariens**, United Kingdom  
**Donald Arnold**, Canada  
**Valder Arruda**, United States  
**Roopen Arya**, United Kingdom  
**Yujiro Asada**, Japan  
**Tatsuya Atsumi**, Japan  
**Simona Avram**, Romania  
**Cihan Ay**, Austria  
**Lina Badimon**, Spain  
**Caroline Baglin**, United Kingdom  
**Trevor Baglin**, United Kingdom  
**Wadie Bahou**, United States  
**Tamam Bakhoul**, Germany  
**Alessandra Balduini**, Italy  
**Carlo Balduini**, Italy  
**Shannon Bates**, Canada  
**Angelika Batorova**, Slovakia  
**Kenneth Bauer**, United States  
**Cecilia Becattini**, Italy  
**Richard Becker**, United States  
**Joel Bennett**, United States  
**Wolfgang Bergmeier**, United States  
**David Bergqvist**, Sweden  
**Francesco Bernardi**, Italy  
**Erik Berntorp**, Sweden  
**Victor Blanchette**, Canada  
**Alicia Blanco**, Argentina  
**Mark Blostein**, Canada  
**Paul Bock**, United States  
**Michael Boffa**, Canada  
**Vladimir Bogdanov**, United States  
**Eric Boilard**, Canada  
**Mariana Bonduel**, Argentina  
**Nuala Booth**, United Kingdom  
**Federico Bottaro**, Argentina  
**Henri Bounameaux**, Switzerland  
**Lynette Bowes**, Canada  
**Leonardo Brandao**, Canada

**Paul Bray**, United States  
**Benjamin Brenner**, Israel  
**George Broze**, United States  
**Kathleen Brummel-Ziedins**, United States  
**Harry Büller**, The Netherlands  
**Saulius Butenas**, United States  
**Suzanne Cannegieter**, The Netherlands  
**Manuel Carcao**, Canada  
**Anders Carlsson**, Sweden  
**Marc Carrier**, Canada  
**Cedric Carter**, Canada  
**Patricia Casais**, Argentina  
**Elisabetta Castoldi**, The Netherlands  
**Spero Cataland**, United States  
**Marco Cattaneo**, Italy  
**Elizabeth Chalmers**, United Kingdom  
**Howard Chan**, Canada  
**Douglas Cines**, United States  
**Kenneth Clemetson**, Switzerland  
**Christine Cockhill**, Canada  
**Barry Collier**, United States  
**Ed Conway**, Canada  
**Michiel Coppens**, The Netherlands  
**Ramón Corbalan**, Chile  
**Javier Corral**, Spain  
**Judith Cosemans**, The Netherlands  
**Benilde Cosmi**, Italy  
**Jonathan Coutinho**, The Netherlands  
**Jim Crawley**, United Kingdom  
**Adam Cuker**, United States  
**Armando D'Angelo**, Italy  
**Björn Dahlbäck**, Sweden  
**Martina Daly**, United Kingdom  
**Simon Davidson**, United Kingdom  
**Raimondo De Cristofaro**, Italy  
**Philip de Groot**, The Netherlands  
**Moniek de Maat**, The Netherlands  
**Philippe de Moerloose**, Switzerland  
**Valerio De Stefano**, Italy  
**Najet Debili**, France  
**Hans Deckmyn**, Belgium  
**Paul Declerck**, Belgium  
**Herve Decousus**, France  
**Cécile Denis**, France  
**Francesco Dentali**, Italy  
**Scott Diamond**, United States  
**Ludovic Drouet**, France  
**Sabine Eichinger**, Austria  
**Jeroen Eikenboom**, The Netherlands  
**Petra Elfvinge**, Sweden  
**Jessica Emed**, Canada  
**Joseph Emmerich**, France  
**Miguel Escobar**, Spain  
**Koji Eto**, Japan  
**Anna Falanga**, Italy  
**Emmanuel Favaloro**, Australia  
**Augusto Federici**, Italy  
**Karin Fijnvandraat**, The Netherlands  
**Kathelijin Fischer**, The Netherlands

## ISTH 2015 Abstract Reviewers

Garret Fitzgerald, United States  
Robert Flaumenhaft, United States  
Veronica Flood, United States  
Georgina Floros, Canada  
Jonathan Foley, United Kingdom  
Charles Francis, United States  
Jim Fredenburgh, Canada  
Jane Freedman, United States  
John Freedman, Canada  
Al Frelinger III, United States  
Satoshi Fujii, Japan  
Christian Gachet, France  
David Gailani, United States  
Monica Galli, Italy  
Alex Gallus, Australia  
Sophie Gandrille, France  
David Garcia, United States  
Chris Gardiner, United Kingdom  
Bernadette Garvey, Canada  
Pascale Gaussem, France  
William Geerts, Canada  
Jonathan Gibbins, United Kingdom  
Hollie Gilmore, Australia  
David Ginsburg, United States  
Neil Goldenberg, United States  
Samuel Goldhaber, United States  
Rebecca Goldsmith, Canada  
Anne Goodeve, United Kingdom  
Shinya Goto, Japan  
Jenny Goudemand, France  
Chris Granger, United States  
Andreas Greinacher, Germany  
Paolo Gresele, Italy  
John Griffin, United States  
Jean-Christophe Gris, France  
Peter Gross, Canada  
Yves Gruel, France  
Chris Guelcher, United States  
Sylvia Haas, Germany  
Tilman Hackeng, The Netherlands  
Margaret Hall, United States  
John-Bjarne Hansen, Norway  
Job Harenberg, Germany  
Paul Harrison, United Kingdom  
Robert Hart, Canada  
Tatsuya Hayashi, Japan  
Cathy Hayward, Canada  
Mary Heeb, United States  
Johan Heemskerck, The Netherlands  
John Heit, United States  
Stan Heptinstall, United Kingdom  
William Hiatt, United States  
Karin Hoffmeister, United States  
Philip Hogg, Australia  
Keith Hoots, United States  
Marie Horellou, France  
Hisanori Horiuchi, Japan  
Marc Hoylaerts, Belgium  
Menno Huisman, The Netherlands

Beverley Hunt, United Kingdom  
Jim Huntington, United Kingdom  
Akitada Ichinose, Italy  
Aida Inbal, Israel  
Alfonso Iorio, Canada  
Sara Israels, Canada  
Raül Izaguirre, Mexico  
Marc Jacquemin, Belgium  
Joseph Jakubowski, United States  
Andra James, United States  
Paula James, Canada  
Martine Jandrot-Perrus, France  
Bernd Jilma, Austria  
Gerhard Johnson, United States  
Scott Kaatz, United States  
Susan Kahn, Canada  
Michael Kalafatis, United States  
Farhad Kamali, United Kingdom  
Pieter Willem Kamphuisen, The Netherlands  
Carol Kasper, United States  
Nevine Kassim, Egypt  
Clive Kearon, Canada  
David Keeling, United Kingdom  
Christine Kempton, United States  
Dermot Kenny, Ireland  
Steven Kerrigan, Ireland  
Nigel Key, United States  
Kate Khair, United Kingdom  
Paul Kim, Canada  
Manjunatha Kini, Singapore  
Steve Kitchen, United Kingdom  
Erik Klok, The Netherlands  
Tetsuhito Kojima, Japan  
Koichi Kokame, Japan  
Krasimir Kolev, Hungary  
Barbara Konkle, United States  
Timo Korhonen, Finland  
Johanna Kremer, Switzerland  
Steven Krilis, Australia  
Marieke Kruip, The Netherlands  
Thomas Kuehne, Switzerland  
Satya Kunapuli, United States  
Shinichiro Kurosawa, United States  
Paul Kyrle, Austria  
David Lane, United Kingdom  
Francois Lanza, France  
Sarah Lapner, Canada  
Riitta Lassila, Finland  
Daniel Lawrence, United States  
Alan Lazarus, Canada  
Alejandro Lazo-Langner, Canada  
Bernard Le Bonniec, France  
Grégoire Le Gal, Canada  
Ramón Lecumberri, Spain  
Agnes Lee, Canada  
Peter Lenting, France  
Marcel Levi, The Netherlands  
Willem Lijfering, The Netherlands  
Roger Lijnen, Belgium

## ISTH 2015 Abstract Reviewers

Wendy Lim, Canada  
Shu-Wha Lin, Taiwan  
Yulia Lin, Canada  
Ton Lisman, The Netherlands  
Rolf Ljung, Sweden  
Colin Longstaff, United Kingdom  
Marie Lordkipanidzé, United Kingdom  
Gordon Lowe, United Kingdom  
Aharon Lubetsky, Israel  
Christopher Ludlam, United Kingdom  
Brenda Luken, United Kingdom  
Florea Lupu, United States  
Jeanne Lusher, United States  
Ian Mackie, United Kingdom  
Nigel Mackman, United States  
Maria Magnusson, Sweden  
Mike Makris, United Kingdom  
Asrar Malik, United States  
Maura Malone Dumas, United States  
Naveen Manchanda, United States  
Maria Mancuso, Italy  
Marina Marchetti, Italy  
Ida Martinelli, Italy  
Steffen Massberg, Germany  
Patti Massicotte, Canada  
Alan Mast, United States  
Yumiko Matsubara, Japan  
Osamu Matsuo, Japan  
Tadashi Matsushita, Japan  
Owen McCarty, United States  
Keith McCrae, United States  
Brian McCrindle, Canada  
Archie McNicol, Canada  
Simon McRae, Australia  
John McVey, United Kingdom  
Robert Medcalf, Australia  
Leonid Medved, United States  
Shannon Meeks, United States  
Karina Meijer, The Netherlands  
Joost Meijers, The Netherlands  
Koen Mertens, The Netherlands  
Guy Meyer, France  
Saskia Middeldorp, The Netherlands  
Lindsey Miles, United States  
Jonathan Miller, United States  
Toshiyuki Miyata, Japan  
Jun Mizuguchi, Japan  
Karen Moffat, Canada  
Stephan Moll, United States  
Paul Monahan, United States  
Manuel Monreal, Spain  
Dougald Monroe, United States  
Robert Montgomery, United States  
Pierre-Emmanuel Morange, France  
Massimo Morfini, Italy  
James Morrissey, United States  
John Morser, United States  
Per Morten Sandset, Norway  
Laurent Mosnier, United States  
David Motto, United States

Jim Munn, United States  
László Muszbek, Hungary  
Nicola Mutch, United Kingdom  
Khalid Naseem, United Kingdom  
Marguerite Neerman-Arbez, Switzerland  
Claude Negrier, France  
Fiona Newall, Australia  
Heyu Ni, Canada  
Timothy Nichols, United States  
Rienk Nieuwland, The Netherlands  
Marina Noris, Italy  
Agata Nowak, United Kingdom  
Alan Nurden, France  
Paquita Nurden, France  
Doyeun Oh, South-Korea  
Tsukasa Ohmori, Japan  
Johannes Oldenburg, Germany  
Pall Óundarson, Iceland  
Bjarne Østerud, Norway  
Hans-Martin Otten, The Netherlands  
Yukio Ozaki, Japan  
Bunis Packham, United Kingdom  
Joseph Palumbo, United States  
Guillaume Paré, Canada  
Paola Patrignani, Italy  
Carlo Patrono, Italy  
Rafal Pawlinski, United States  
Bernard Payrastra, France  
Ian Peake, United Kingdom  
Kathelijne Peerlinck, Belgium  
Vanessa Pellegrielli, United Kingdom  
Vittorio Pengo, Italy  
Jaime Pereira, Chile  
Egon Persson, Sweden  
Marjolein Peters, The Netherlands  
Flora Peyvandi, Italy  
Helen Philippou, United Kingdom  
Gregory Piazza, United States  
Graham Pineo, Canada  
Steven Pipe, United States  
Ed Plow, United States  
Mortimer Poncz, United States  
Man-Chiu Poon, Canada  
Paolo Prandoni, Italy  
Kathleen Pratt, United States  
Patrick Provost, Canada  
Charles Quinn, United States  
Leslie Raffini, United States  
Margaret Ragni, United States  
Janusz Rak, Canada  
Jacob Rand, United States  
Margaret Rand, Canada  
Anna Randi, United Kingdom  
A. Koneti Rao, United States  
Gary Raskob, United States  
Pieter Reitsma, The Netherlands  
Thomas Renné, Sweden  
Alireza Rezaie, United States  
Suely Rezende, Brazil  
Frederick Rickles, United States

## ISTH 2015 Abstract Reviewers

Dick Rijken, The Netherlands  
Georges Rivard, Canada  
Francesco Rodeghiero, Italy  
Marc Rodger, Canada  
Mark Roest, The Netherlands  
Frits Rosendaal, The Netherlands  
Jan Rosing, The Netherlands  
Changeng Ruan, China  
Wolfram Ruf, United States  
Evan Sadler, United States  
Jean-Marie Saint-Remy, Belgium  
Marc Samama, France  
Per Morten Sandset, Norway  
Elena Santagostino, Italy  
Sentot Santoso, Germany  
Laurie Sardo, Canada  
Ravi Sarode, United States  
Anna Savoia, Italy  
Rüdiger Scharf, Germany  
Inge Scharrer, Germany  
Alvin Schmaier, United States  
Simone Schoenwaelder, Australia  
Sam Schulman, Canada  
Jean-François Schved, France  
Marie Scully, United Kingdom  
Rita Selby, Canada  
Uri Seligsohn, Israel  
John Semple, Canada  
Yotis Senis, United Kingdom  
Amy Shapiro, United States  
Midori Shima, Japan  
Robyn Shoemark, Australia  
Pierre Sie, France  
Deborah Siegal, Canada  
Bob Siegerink, The Netherlands  
Wolfgang Siess, Germany  
Angela Silveira, Sweden  
Robert Silver, United States  
Roy Silverstein, United States  
Sergio Siragusa, Italy  
Nicholas Smith, United States  
Kenji Soejima, Japan  
Henrik Toft Sørensen, Denmark  
Arnold Spek, The Netherlands  
Catherine Sperlich, Canada  
Henri Spronk, The Netherlands  
Alex Spyropoulos, United States  
Deborah Stearns-Kurosawa, United States  
Dana Stephens, United States  
Scott Stevens, United States  
Guus Sturk, The Netherlands  
Peter Svensson, Sweden  
Campbell Tait, United Kingdom  
Jerome Teitel, Canada  
Hugo ten Cate, The Netherlands

Arina ten Cate-Hoek, The Netherlands  
Andreas Tiede, Germany  
Cheng-Hock Toh, United Kingdom  
Yoshiyuki Tomiyama, Japan  
Mauro Torti, Italy  
Alberto Tosetto, Italy  
Paula Tracy, United States  
David Trégouët, France  
Bernardo Trigatti, Canada  
Hiroko Tsuda, Japan  
Alexander G. Turpie, Canada  
Shirley Uitte de Willige, The Netherlands  
Anetta Undas, Poland  
Tetsumei Urano, Japan  
Rolf Urbanus, The Netherlands  
Elizabeth Van Cott, United States  
Ton van den Besselaar, The Netherlands  
Anske van der Bom, The Netherlands  
Felix van der Meer, The Netherlands  
Chris van Greet, Belgium  
Waander van Heerde, The Netherlands  
Victor van Hinsbergh, The Netherlands  
Astrid van Hylckama Vlieg, The Netherlands  
Heleen van Ommen, The Netherlands  
Suresh Vedantham, United States  
Peter Verhamme, Belgium  
Henri Versteeg, The Netherlands  
Sara Vesely, United States  
Vicente Vicente, Spain  
Shoshana Vilks, Israel  
Jan Voorberg, The Netherlands  
Hideo Wada, Japan  
Theodore Warkentin, Canada  
Henry Watson, United Kingdom  
Steve Watson, United Kingdom  
Hartmut Weiler, United States  
Jeffrey Weitz, Canada  
Philip Wells, Canada  
Geoff Werstuck, Canada  
Randal Westrick, United States  
Gilbert White, United States  
Richard White, United States  
David Wilcox, United States  
Suzan Williams, Canada  
Alisa Wolberg, United States  
Tim Woods, United Kingdom  
Renchi Yang, China  
Masahiro Yasaka, Japan  
Irene York, Canada  
Neil Zakai, United States  
Susan Zappa, United States  
James Zehnder, United States  
Ying Zheng, United States  
Michelle Zondag, Canada

## ISTH Council

Nigel Key, United States  
Chair of Council (2014 – 2016)

Ingrid Pabinger, Austria  
Secretary / Chair-Elect (2014 – 2016)

Björn Dahlbäck, Sweden  
Treasurer (2015 – 2018)

### Class of 2016

Marco Cattaneo, Italy  
Björn Dahlbäck, Sweden  
Andreas Greinacher, Germany  
Yukio Ozaki, Japan  
Paula Tracy, United States

### Class of 2018

Peter Lenting, France  
Claire McLintock, New Zealand  
James Morrissey, United States  
Ingrid Pabinger, Austria  
Jeffrey Weitz, Canada

### Class of 2020

Anna Falanga, Italy  
David Lillicrap, Canada  
Jose Lopez, United States  
Suely Rezende, Brazil  
Steve Watson, United Kingdom

### Ex-Officio Council Members

J. Evan Sadler, United States  
Secretary General

Michael Berndt, Australia  
Immediate Past Chair, ISTH Council

Sam Schulman, Canada  
President, XXV ISTH Congress,  
Toronto, 2015

Philip Wells, Canada  
Vice-President, XXV ISTH Congress  
Toronto, 2015

Pieter Reitsma, The Netherlands  
Editor-in-Chief, Journal of Thrombosis  
and Haemostasis

Frits Rosendaal, The Netherlands  
Past President, XXIV ISTH  
Congress Amsterdam, 2013 and  
Editor-in-Chief, Journal of Thrombosis  
and Haemostasis

Sabine Eichinger, Austria  
Chair, Scientific and Standardization  
Committee

## ISTH Scientific and Standardization Committee

### SSC Executive Committee 2014-2016

**Sabine Eichinger**, Austria  
Chair

**Walter Ageno**, Italy  
Secretary/Chair-elect

**David Lillicrap**, Canada  
Immediate Past Chair

**Jean-François Schved**, France  
Ex-Officio: President, SSC 2016

### Standing Committees

**Bleeding Assessment Tool**  
Francesco Rodeghiero, Italy

**Coagulation Standards**  
Anthony Hubbard, United Kingdom

**WHO-ISTH Standards Liaison Group**  
Peter Lenting, France

### Subcommittees

**Animal, Cellular and Molecular Models**  
Susan Smyth, United States

**Biorheology**  
Keith Neeves, United States

**Control of Anticoagulation**  
Walter Ageno, Italy

**Disseminated Intravascular Coagulation**  
Jecko Thachil, United Kingdom

**Exogenous Hemostatic Factors**  
Ivo Francischetti, United States

**Factor VIII, Factor IX and Rare  
Coagulation Disorders**  
Guy Young, United States

**Factor XI and the Contact System**  
Jonas Emsley, United Kingdom

**Factor XIII and Fibrinogen**  
Helen Philippou, United Kingdom

**Fibrinolysis**  
Nicola Mutch, United Kingdom

**Hemostasis and Malignancy**  
Alok Khorana, United States

**Lupus Anticoagulant/Phospholipid-  
Dependent Antibodies**  
Bas de Laat, The Netherlands

**Pediatric and Neonatal Hemostasis and  
Thrombosis**  
Anthony Chan, Canada

**Plasma Coagulation Inhibitors**  
Richard Marlar, United States

**Platelet Immunology**  
Yves Gruel, France

**Platelet Physiology**  
Paolo Gresele, Italy

**Predictive Hemostatic Variables**  
Paul Kyrle, Austria

**Vascular Biology**  
Rienk Nieuwland, The Netherlands

**von Willebrand Factor**  
Jorge DiPaola, United States

**Women's Health Issues in Thrombosis and  
Hemostasis**  
Rezan Abdul-Kadir, United Kingdom

SAVE THE DATES

octapharma®



### Haemophilia A: Individualised solutions to global challenges

**Tuesday, June 23, 2015**  
**12:15 - 13:45**

Symposium Room 801

This symposium will focus on the future of haemophilia A treatment including major challenges - the development of inhibitors and the need for frequent venous access for FVIII injections. Importance of individually tailored prophylaxis and the final results of personalised prophylaxis study, NuPreviq, will be presented.

#### Symposium chaired by Craig Kessler

**New generation rFVIII concentrates: where do we stand?**  
Craig Kessler, USA

**NuProtect: update on human cell-line derived rFVIII in PUPs**  
Anthony Chan, Canada

**Every patient is unique: the need for a personalised  
approach to treatment**  
Massimo Morfini, Italy

**NuPreviq: update on human cell-line derived rFVIII  
in personalised prophylaxis**  
John Pasi, UK

Lunch will be served

### Addressing complex issues in VWD & haemophilia care

**Wednesday, June 24, 2015**  
**12:15 - 13:45**

Symposium Room 801

This symposium aims to provide a platform for sharing experiences on critical questions in the management of von Willebrand disease (VWD) and haemophilia A.

#### Symposium chaired by Jerry Teitel

**Should prophylaxis be the standard of care for  
severe VWD?**  
Ulrike Nowak Göttl, Germany

**How to manage labour & delivery in VWD**  
Paula James, Canada

**Management of surgeries in VWD: final results  
of a clinical study**  
Alok Srivastava, India

**Canadian experience with 1:1 VWF/FVIII concentrate**  
Mark Belletrutti, Canada

Lunch will be served



Symposium

## Congress Support

ISTH wishes to recognize the following companies and organizations for their support of ISTH 2015

### PLATINUM SPONSORS

Baxalta  
Bayer HealthCare  
Biogen and Sobi  
Novo Nordisk Health Care AG  
Octapharma AG

### GOLD SPONSORS

Boehringer Ingelheim GmbH  
CSL Behring GmbH  
Pfizer  
Pfizer Canada Inc. / Bristol-Myers Squibb Canada

### SILVER SPONSORS

Daiichi Sankyo, Inc.  
Kedrion Biopharma  
Siemens Healthcare and Sysmex Corporation  
STAGO

### BRONZE SPONSORS

Alexion Pharmaceuticals, Inc.  
GRIFOLS  
HYPHEN BioMed  
Instrumentation Laboratory  
LEO Pharma  
Portola Pharmaceuticals, Inc.  
Roche Diagnostics International Ltd.

## Sponsors and Exhibitors

3i - Intelligent Imaging Innovations	HYPHEN BioMed
Accriva Diagnostics	Immucor
Affinity Biologicals, Inc.	Instrumentation Laboratory
Alexion Pharmaceuticals, Inc.	International Initiative on Thrombosis and Cancer (ITAC-CME)
ALNYLAM PHARMACEUTICALS	International Society on Thrombosis and Haemostasis (ISTH)
Aniara Diagnostica & CoaChrom Diagnostica	ISTH SSC 2016 - Montpellier, France
Answering T.T.P. (Thrombotic Thrombocytopenic Purpura) Foundation	ISTH 2017 - Berlin, Germany
Aspen Pharma	Journal of Thrombosis and Haemostasis (JTH)
Baxalta	Kedrion Biopharma
Bayer HealthCare	LABTEK Science & Development Co., Ltd
Bio Products Laboratory USA, Inc.	LEO Pharma
Biogen and Sobi	LFB BIOMEDICAMENTS
bioMérieux	MediRox
Biotest AG	Novo Nordisk Haemophilia Foundation (NNHF)
Boehringer Ingelheim GmbH	Novo Nordisk Health Care AG
Canadian Hemophilia Society (CHS)	Octapharma AG
CEDARLANE®	Pfizer
Chrono-log Corp.	Pfizer Canada Inc./Bristol-Myers Squibb Canada
CMEology	Portola Pharmaceuticals, Inc.
Covidien	Precision BioLogic
CSL Behring GmbH	Roche Diagnostics International Ltd
Daiichi Sankyo, Inc.	Sanofi Canada
Diapharma Group	Schattauer Publishers
DSM Nutritional Products Ltd Branch	Sekisui Diagnostics
Pentapharm	Siemens Healthcare
Enzyme Research / r2 Diagnostics	STAGO
European and Mediterranean League Against Thrombotic Diseases (EMLTD)	Sysmex Corporation
Ferrer inCode	TECHNOCLONE
Foundation for Women & Girls with Blood Disorders (FWGBD)	Thrombosis.TV
George King Bio-Medical, Inc.	Wiley
GRIFOLS	World Federation of Hemophilia
Haematologic Technologies, Inc.	World Thrombosis Day (WTD) - 13 October
Hemostasis Reference Laboratory Inc.	

Please see the ISTH 2015 Show Guide for more detailed information about our corporate supporters, exhibitors and sponsored programs.

# Reach-the-World Fellowships



## ISTH Reach-the-World Fellowship Program

The ISTH Reach-the-World Fellowship Program, for early-career professionals from developing\* countries, promotes advanced knowledge and expertise in one or all of the following areas related to thrombosis and hemostasis:

- Medical care
- Laboratory methods
- Research

**Deadlines for submission of applications are June 1 and January 1 of each year.**

For more information on the Fellowship Program and ISTH Reach-the-World Membership, please visit [www.isth.org](http://www.isth.org) or contact the ISTH via email at [headquarters@isth.org](mailto:headquarters@isth.org).

*\*Countries designated as 'developing' by the classification of the World Bank*



The ISTH Reach-the-World Fellowship Program is supported thanks to an unrestricted educational grant from Bayer.

## Mission

The ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

**Join the conversation online!**

[www.isth.org](http://www.isth.org)   

# Call for Applications!

Visit us at Booth 1036!

## ISTH Awards

### ISTH 2015 Awards

#### Robert P. Grant Medal

The Robert P. Grant Medal is the ISTH's highest award. It is presented during the biennial ISTH Congress in honor of research achievements, organizational activities, support of research activities, facilitation of institutional cooperation and communication, unusual teaching or educational initiatives and/or the development of concepts that result in a clearer understanding of research data.

The medal is named after Robert P. Grant, a renowned cardiologist who spent many years as a representative of the National Institutes of Health in Europe, traveling extensively and facilitating American-European collaboration in medical research and education.

**The ISTH Grant Medal will be presented at the Opening Ceremony on Sunday, June 21.**

#### Harold R. Roberts Award

The ISTH Harold R. Roberts Award honors mentorship service to the Scientific and Standardisation Committee of the ISTH, beyond expectations and over a significant period of time.

**The Roberts Award will be presented at the Presidents Dinner on Monday, June 22.**

#### Biennial Awards for Contributions to Hemostasis

The ISTH's Biennial Awards for Contributions to Hemostasis (BACH) are presented during the ISTH Congress to individuals who, in the

opinion of their peers, have made significant contributions to research and education in blood coagulation.

The Investigator Recognition Awards recognize ISTH members whose accomplishments are internationally regarded as exemplary models of excellence in research and teaching.

The Distinguished Career Awards recognize ISTH members whose career contributions have significantly advanced the scientific community's understanding of the diseases and disorders affecting hemostasis.

**The ISTH BACH Awards will be presented at the President's Dinner on Monday, June 22.**

#### 2015 Recipients of the Biennial Awards for Contributions to Hemostasis (BACH) Award

##### Distinguished Career

**Harry Büller**, The Netherlands  
**Nigel Mackman**, United States  
**Wolfram Ruf**, United States, Germany  
**Ulla Hedner**, Sweden  
**Gilbert White**, United States

##### Investigator Recognition

**Steffen Massberg**, Germany  
**Tim Springer**, United States  
**Sriram Krishnaswamy**, United States  
**Willem Ouwehand**, United Kingdom  
**Alisa Wolberg**, United States

## Congress Travel Stipends

### Young Investigator Travel Stipends

The Young Investigators Travel Stipends were provided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of June 21, 2015) who submitted highly rated abstracts.

We hope that you will find attendance at ISTH 2015 fruitful in your continued research, clinical and educational activities.

### Recipients of an ISTH 2015 Young Investigator Travel Stipend

Gregory Adams, United States  
Sonia Aguila, Spain  
Huda Omar Ali, Norway  
Ashley Ambrose, United Kingdom  
Ana Belén Arroyo Rodríguez, Spain  
Dario Balestra, Italy  
Elena Barbon, Italy  
Anthony Battram, United Kingdom  
Paul Batty, United Kingdom  
Roelof Bekendam, United States  
Suzanne Bleker, The Netherlands  
Johan Boender, The Netherlands  
Luca Bologna, Switzerland  
Oliver Borst, Germany  
Yacine Boulaftali, France  
Tara Bracken, United States  
Sigrid Braekkan, Norway  
Alessio Branchini, Italy  
Katherine Bridge, United Kingdom  
Tomasz Brzoska, Japan  
Loredana Bury, Italy  
James Byrnes, United States  
Elena Campello, Italy  
Naadiya Carrim, Canada  
Caterina Casari, France  
Lara Casey, Canada  
Elizabeth Chappell, United States  
Jorien Claes, Belgium  
Theodora Claushuis, The Netherlands  
Audrey Cleuren, United States  
Jagmanpreet Dang, Canada  
Esterina D'Asti, Canada  
Karen De Ceunynck, United States  
Hugoline de Haan, The Netherlands  
Maria Eugenia De La Morena-Barrio, Spain  
Louis Deforche, Belgium  
Celine Delierneux, Belgium  
Paul den Exter, The Netherlands  
Carsten Deppermann, Germany  
Marco Domingues, United Kingdom  
Sebastian Dütting, Germany  
Eduard Ebberink, The Netherlands  
John Eicher, United States  
Laura Elbers, The Netherlands

Xuemei Fan, China  
Hendrik Feys, Belgium  
Déborah François, France  
Florian Gaertner, Germany  
Maxime Gauberti, France  
Xiaomei Ge, United States  
Johanna Gebhart, Austria  
Mitchell Geer, United Kingdom  
Maria Georgescu, Canada  
Ewelina Golebiewska, Japan  
Sanjeev Kiran Gotru, Germany  
Lindsey Greene, United States  
Angèle Gros, France  
Kamlesh Gupta, United States  
Elizabeth Haining, Germany  
Hendrika Hazendonk, The Netherlands  
Sara Henderson, Canada  
Christoph Hofbauer, Austria  
Lars Daae Horvei, Norway  
Craig Hughes, United Kingdom  
James Lawrence Hutchinson, United Kingdom  
Ivan Ivanov, United States  
Iqbal Jaffer, Canada  
Ben Johnson, United Kingdom  
Lining Ju, Australia  
Alev Karasu, The Netherlands  
Noah Kastelowitz, United States  
Alexandre Kauskot, France  
Avinash Khandagale, Germany  
Hilde Kooistra, The Netherlands  
Colin Andrew Kretz, United States  
Jesse Lai, Canada  
Jostein Lappegård, Norway  
Mandy Lauw, The Netherlands  
Vincenzo Leo, United Kingdom  
Rong Li, China  
Laurens Liesenborghs, Belgium  
Ruzica Livaja-Koshlar, Sweden  
Viola Lorenz, Germany  
Kate Lowe, United Kingdom  
Christopher John Lynch, United Kingdom  
Kellie Machlus, United States  
Bhanukanth Manne, United States  
Giorgia Manni, Italy

## Congress Travel Stipends

Oscar A Marcos-Contreras, United States  
Simone Merlin, Italy  
Kahia Messaoudi, France  
Soraya Mezouar, France  
Kristina Modjeski, United States  
J.E. Molhoek, The Netherlands  
Samantha Moore, United Kingdom  
Vincent Muczynski, France  
Ahmad Mufti, United Kingdom  
Patrick Münzer, Germany  
Moe Murata, Japan  
Giang Nguyen, United States  
Agata Anna Nowak, United Kingdom  
Kaisa Otteby, Sweden  
Marta Palomo De Udaeta, Spain  
Leonie Pelkmans, The Netherlands  
Behnaz Pezeshkpoor, Germany  
Raymond Piatt, United States  
Tom Plug, The Netherlands  
Irina Portier, Belgium  
Cristina Puy, United States  
Julia Riedl, Austria  
Ludvig Balteskard Rinde, Norway  
Rachel Roach, The Netherlands  
Ina Rye-Holmboe, Norway  
Daniela Scalet, Italy  
Sarah Schießl, Germany  
Maaike Schillemans, The Netherlands  
Shana Aadl Shaya, Canada  
Birgit Småbrekke, Norway  
Bryn Smith, United States  
Michelle Alida Helena Sonneveld, The Netherlands  
Erin Soule, United States  
Erica Sparkenbaugh, United States

Lucia Stefanini, United Kingdom  
David Stegner, Germany  
Saravanan Subramaniam, Germany  
Pierre Suchon, France  
Laura Swystun, Canada  
Maria Talmon, Italy  
Chaojun Tang, China  
Claudia Tersteeg, Belgium  
Cheng-Hock Toh, United Kingdom  
Nagaharu Tsukiji, Japan  
Robert Turnbull, United Kingdom  
Kristin Utne, Norway  
Bart van den Eshof, The Netherlands  
Tom Van Der Hulle, The Netherlands  
Judith Van Eeuwijk, Germany  
Nick van Es, The Netherlands  
Nienke Van Rein, The Netherlands  
Christophe Vandenbriele, Belgium  
Imre Varjú, Hungary  
Sebastien Verhenne, Belgium  
Daniël Verhoef, The Netherlands  
Britta Walker, Germany  
Simon James Webster, United Kingdom  
John Welsh, United States  
Anouck Wijgaerts, Belgium  
Christopher Williams, United Kingdom  
Gary Woods, United States  
Binggong Xiang, United States  
Aizhen Yang, China  
Jonathan Wai-hon Yau, Canada  
Patricia Young, United States  
Diego Zanolini, Italy  
Xiaohua Zhou, Belgium

### Reach-the-World Travel Stipends

In recognition of the expanding educational format of the ISTH meetings and congresses, the Society is extending its Reach-the-World initiative by providing travel stipends to enable participation by scientists from all areas of the world in ISTH 2015.

We hope that you will find attendance at ISTH 2015 fruitful in your continued research, clinical and educational activities.

### Recipients of an ISTH 2015 Reach-the-World Travel Stipend

Salma Abdel Ghany Shawkat, Egypt  
Al-Zamzam Abubakar, Philippines  
Yolanda Adamczuk, Argentina  
Mukul Aggarwal, India  
Hebe Agustina Mena, Argentina  
José Antonio Alvarado-Moreno, Mexico

Nadia Arshad, Pakistan  
Yanyan Bai, China  
Xia Bai, China  
Ergul Berber, Turkey  
Luis Bittar, Brazil  
Jelena Bodrozić, Serbia



## Congress Travel Stipends

Munira Borhany, Pakistan  
Daniela Calderaro, Brazil  
Jose Manuel Ceresetto, Argentina  
Yao-Wen Chang, Taiwan, China  
Zhenping Chen, China  
Yingyong Chinthammitr, Thailand  
Dorothy Chioma Okpokam, Nigeria  
Andra Costache, Romania  
Lv Cuicui, China  
Jing Dai, China  
Maria das Garças Carvalho, Brazil  
Zelda De Lange, South Africa  
Maria De Lourdes Herrera, Argentina  
Ernesto De Meis, Brazil  
Lais De Paula, Brazil  
Chang-Qing Deng, China  
Vrushali Deshpande, India  
Pratibha Dhiman, India  
Zhongren Ding, China  
Valentina Djordjevic, Serbia  
Luci Dusse, Brazil  
Fernanda Dutra Santiago Bassora, Brazil  
Yi Fang, China  
Miguel Farfan, Colombia  
Mariane Flores-Nascimento, Brazil  
Juan Pablo Frontrouth, Argentina  
Rongfeng Fu, China  
Tainá Gomes, Brazil  
Marcelo Luide Goncalves, Brazil  
Lallindra Gooneratne, Sri Lanka  
Hugo Guglielmo, Argentina  
Yang He, China  
Mirta Hepner, Argentina  
Diego Higuera, Venezuela, Bolivarian Republic Of  
Hu Hu, China  
Khon Huynh, Vietnam  
Obinna Iheanacho, Nigeria  
Leticia Jardim, Brazil  
Anjali Jaydeep Kelkar, India  
Peipei Jin, China  
Sornsith Jirungda, Thailand  
Bat-Erdene Jugder, Mongolia  
Rajani Kanth Vangala, India  
Patcharee Komvilaisak, Thailand  
Huiyuan Li, China  
Junling Li, China  
Qian Liang, China  
Wenjie Liu, China  
Liu Liu, China  
Yeling Lu, China  
Rita Marchi, Venezuela, Bolivarian Republic Of  
Marta Martinuzzo, Argentina  
Muriel Meiring, South Africa

Lyu Mingen, China  
Pravas Mishra, India  
Daniella Mizurini, Brazil  
Bushra Moiz, Pakistan  
Robson Monteiro, Brazil  
Katia Morais, Brazil  
Lakshmi Mundkur, India  
Béla Nagy, Hungary  
Nida Najmi, Pakistan  
Hannah Omunakwe, Nigeria  
Fernanda Orsi, Brazil  
Juvenal Paiva, Argentina  
Krisztina Péntzes-Daku, Hungary  
Benedito Prezoto, Brazil  
Alessandra Prezotti, Brazil  
Lucia Remotti, Argentina  
Daniel Ribeiro, Brazil  
Theera Ruchutrakool, Thailand  
Emelyn Salazar, Venezuela, Bolivarian Republic Of  
Analia Sanchez-Luceros, Argentina  
Priyanka Saxena, India  
Mirta Schattner, Argentina  
Tanusree Sengupta, India  
Yanyan Shao, China  
Ankit Sharma, India  
Weihong Shen, China  
Shrimati Shetty, India  
Nongnuch Sirachainan, Thailand  
Samuel Souza Medina, Brazil  
Tiantian Sun, China  
Vikas Suri, India  
Bundarika Suwanawiboon, Thailand  
Anna Tanka-Salamon, Hungary  
Noemi Klara Toth, Hungary  
Fernando Vazquez, Argentina  
Biljana Vuckovic, Serbia  
Anyou Wang, China  
Yao Wang, China  
Luciana Wermelinger Serrão, Brazil  
Adriana Ines Woods, Argentina  
Jianbo Wu, China  
Xiaolin Wu, China  
Xiaodong Xi, China  
Zhang Xian, China  
Shilong Xiong, China  
Jingyi Yang, China  
Hao Yating, China  
Ziqiang Yu, China  
Han Yue, China  
Donglei Zhang, China  
Bo Zhang, China  
Zeping Zhou, China  
Jingyi Zhou, China  
Hu Zhou, China

# DUBAI

## Topics

Blood Coagulation

Bleeding Disorders

Venous Thrombosis

Platelets

Platelet Disorders

**Isth**<sup>TM</sup>  
International Society on  
Thrombosis and Haemostasis

## ISTH Advanced Training Course in Thrombosis and Hemostasis September 14-17, 2015

Organized by  
**The ISTH Education  
Committee**

Meeting Chairs  
**Flora Peyvandi  
Nevine Kassim**

Location  
**The Crowne Plaza Hotel  
Dubai, UAE**

Early Registration Deadline: **July 16, 2015**  
Register at [ISTH.org](http://ISTH.org)  
Questions? Call +1 919 929 3807  
or email [headquarters@isth.org](mailto:headquarters@isth.org)

Join the International Society on Thrombosis and Haemostasis (ISTH) for three full days of intense examination on the subjects of coagulation, bleeding disorders, platelets and venous thrombosis. Leading international scientists will deliver focused lectures followed by ample time for discussion and close interaction with the participants.

This Advanced Training Course will be especially interesting to trainees in hemostasis, hematology, transfusion medicine, vascular medicine, or intensive care medicine. Senior hematologists looking for an update or a Ph.D. wishing to acquire clinical and basic knowledge in the field will also benefit tremendously from this course. **Join us in Dubai!**

**Visit us at Booth 1036!**

Endorsed by



Supported by an Unrestricted  
Educational Grant from



## ISTH Society Information



The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

As a professional membership organization, the ISTH is dedicated to transformative scientific discoveries and clinical practices as well as the development of next generation and the education of physicians, scientists and allied health professionals wherever they may live.

With over 3,700 members in more than 90 countries, the ISTH supports a community of specialists in bleeding and clotting disorders through the creation and promotion of education and outreach initiatives, scientific meetings, research activities, peer reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world.

A highly regarded Society poised on the leading edge of science, the ISTH offers a comprehensive membership offering that includes the following benefits:

### ISTH membership benefits:

- An international professional network of 3,700 members spanning more than 90 countries.
- Priority registration and discounted fees for ISTH meetings and congresses.
- Complimentary print (for regular members only) and online subscriptions to ISTH's *Journal of Thrombosis and Haemostasis* (JTH) as well as subscription to the ISTH monthly e-newsletter.
- Full access to the ISTH Academy, featuring webinars, webcasts, online courses and more. The ISTH also offers a free ISTH Academy membership, with limited access to online educational resources at [academy.isth.org](http://academy.isth.org).
- Access to ISTH member-only resources, including an increasing array of educational materials, communication and membership directory.
- Exclusive access and reduced fees for other educational activities, programs and publications.
- Engagement opportunities, such as World Thrombosis Day each year on 13 October. Learn more at [www.worldthrombosisday.org](http://www.worldthrombosisday.org).
- ISTH Career Center.
- The right to nominate, elect, vote and serve on ISTH committees and working groups.

## ISTH Society Information



### ISTH membership categories include:

- Regular:** for active researchers, educators and clinicians in the field
- Associate:** for students, trainees, research staff, post-doctoral fellows as well as allied health professionals
- Reach-the-World:** for researchers, educators and clinicians in non-industrialized countries
- Nurse:** registered nurses
- Allied Health:** laboratory and radiological technicians, occupational and physical therapists, pharmacists, and other health professions distinct from medicine and nursing

### For more information, or to join the Society, please contact:

#### ISTH Headquarters Office

610 Jones Ferry Road, Suite 205  
Carrboro, NC 27510  
United States





**T: +1 919 929-3807**

**F: +1 919 929-3935**

[headquarters@isth.org](mailto:headquarters@isth.org)

[www.isth.org](http://www.isth.org)

#### Join the Conversation Online!

-  [www.facebook.com/internationalsocietythrombosisandhaemostasis](https://www.facebook.com/internationalsocietythrombosisandhaemostasis)
-  [www.twitter.com/isth](https://www.twitter.com/isth)
-  [www.linkedin.com/company/international-society-on-thrombosis-and-haemostasis-isth-](https://www.linkedin.com/company/international-society-on-thrombosis-and-haemostasis-isth-)
-  [www.instagram.com/isthofficeteam](https://www.instagram.com/isthofficeteam)



Learn more about World Thrombosis Day, an ISTH-lead yearly campaign at [www.worldthrombosisday.org](http://www.worldthrombosisday.org).

Visit us at our booth (# 1036) in the Exhibition Area on Level 800.



## From Baxter's BioScience to Baxalta...

Baxter's BioScience is expected to become Baxalta in mid-2015.

At Baxter's BioScience, we see a world of endless possibilities for our patients. And although our name may be changing to Baxalta, our commitment to you is as strong as ever. At our foundation is an enduring heritage of innovation and advocacy. Your life is our inspiration to make a meaningful difference, so you can dream big, and experience life. We are excited about the future and hope you are too!

Visit the Baxalta booth #1602 to learn more.

## Program Overview


**Isth**  
**2015 Congress**  
**TORONTO JUNE 20-25**

---

Reaching for Unprecedented Peaks

# Program at a Glance

From Saturday, June 20 – Thursday, June 25, 2015



### On Saturday, June 20

**Break:** 11:00 – 11:30 (Coffee)  
**Break:** 13:30 – 14:30 (Lunch)  
**Break:** 16:30 – 17:00 (Coffee)

Coffee and lunches will be served in the Foyers of the session rooms on Levels 700 and 800.


### On Sunday, June 21

**Break:** 10:00 – 10:30 (Coffee)  
**Break:** 12:15 – 13:00 (Lunch)  
**Break:** 15:00 – 15:30 (Coffee)

Coffee and lunches will be served in the Foyers of the session rooms on Levels 700 and 800.

# Program at a Glance

From Saturday, June 20 – Thursday, June 25, 2015



### From Monday, June 22 – Wednesday, June 24

**Break:** 09:15 – 09:45 (Coffee)  
**Break:** 10:30 – 10:45  
**Break:** 11:45 – 12:15 (Lunch)  
 Lunch boxes available in the Exhibition Hall on Level 800 as well as in the Foyers of rooms on Levels 700 and 800  
**Break:** (Exhibition): 15:15 - 15:45 (Coffee)

### On Thursday, June 25

**Break:** 09:15 – 09:30 (Coffee)  
 Coffee will be served in the Foyers of the session rooms on Levels 700 and 800.



# Saturday, June 20, 2015

Room 701

Room 713

Room 714

Room 715

Women's Issues in Thrombosis and Haemostasis  
09:00 - 11:00

Fibrinolysis  
09:00 - 11:00

Vascular Biology  
09:00 - 11:00

Predictive and diagnostic variables in thrombotic disease  
09:00 - 11:00

Coffee Break

Women's Issues in T&H Education Session  
11:20 - 12:20

Fibrinolysis Education Session  
11:20 - 12:20

Vascular Biology Education Session  
11:20 - 12:20

Predictive Variables Education Session  
11:20 - 12:20

Women's Issues in Thrombosis and Haemostasis (cont'd)  
12:20 - 13:20

Fibrinolysis (cont'd)  
12:20 - 13:20

Vascular Biology (cont'd)  
12:20 - 13:20

Predictive Variables (cont'd)  
12:20 - 13:30

Lunch

Exogenous Factors Education Sessions  
14:30 - 15:30

Factor XIII and Fibrinogen Education Sessions  
14:30 - 15:30

Plasma Coag Inhibitors Education Sessions  
14:30 - 15:30

Exogenous Factors Session  
15:30 - 16:30

Factor XIII and Fibrinogen Session  
15:30 - 16:30

Plasma Coag Inhibitors Sessions  
15:30 - 16:30

Coffee Break

Exogenous Factors Session (cont'd)  
16:50 - 18:15

Factor XIII and Fibrinogen Session (cont'd)  
16:50 - 18:50

Plasma Coag Inhibitors Sessions (cont'd)  
16:50 - 18:50

# Saturday, June 20, 2015

Room 716

Room 717

Room 718

Room 801

Lupus Anticoagulants  
09:00 - 11:00

Factor VIII, IX and Rare Coagulation Disorders, Part I  
09:00 - 11:00

Platelet Immunology  
09:00 - 11:00

Coffee Break

Lupus Anticoagulants Education Session  
11:20 - 12:20

Factor VIII, IX and Rare Coagulation Disorders, Part I Education Session  
11:20 - 12:20

Platelet Immunology Education Session  
11:20 - 12:20

Lupus Anticoagulants (cont'd)  
12:20 - 13:20

Factor VIII, IX and Rare Coagulation Disorders, Part I (cont'd)  
12:20 - 13:20

Platelet Immunology (cont'd)  
12:20 - 13:20

Lunch

Biorheology Education Sessions  
14:30 - 15:30

Pediatric/Neonatal T&H Education Session  
14:30-15:30

VWF Education Sessions  
14:30 - 15:30

Hemostasis & Malignancy Education Sessions  
14:30 - 15:30

Biorheology Session  
15:30 - 16:30

Pediatric/Neonatal T&H Session  
15:30 - 16:30

VWF Session  
15:30 - 16:30

Hemostasis & Malignancy Session  
15:30 - 16:30

Coffee Break

Biorheology Session (cont'd)  
16:50 - 18:50

Pediatric/Neonatal T&H Session (cont'd)  
16:50 - 18:30

VWF Session (cont'd)  
16:50 - 18:50

Hemostasis & Malignancy Session (cont'd)  
16:50 - 18:50

# Sunday, June 21, 2015

Exhibit Hall D & E   Plenary Hall G&F   Room 701   Room 707   Room 713   Room 714   Room 715

Genomics 08:00 - 12:20	Working Group on Perioperative T&H 08:00 - 10:00	Animal Models 08:00 - 10:00	DIC 08:00 - 10:00
	Coffee Break 10:00-10:20	Coffee Break 10:00-10:20	
Lunch 12:20 - 13:00	BAT Standing Committee 10:30 - 11:30	Animal Models Education Session 10:20 - 11:20	DIC Education Session 10:20 - 11:20
	RtW/YIA Reception and Session	Animal Models (cont'd) 11:20 - 12:20	DIC (cont'd) 11:20 - 12:20
Coffee Break 15:00-15:30		Lunch 12:20 - 13:00	
Special Industry Symposia 15:30-17:30	Special Industry Symposia 15:30-17:30	WFH / Bayer 13:00 - 15:00	
		Coffee Break 15:00-15:30	

Opening Ceremony  
18:15 - 19:15

WELCOME RECEPTION  
19:30 - 22:00

# Sunday, June 21, 2015

Room 716   Room 717   Room 718   Room 801   Room 803A   Room 803B   Intercontinental

Factor XI and the contact system 08:00 - 10:00	Control of Anticoagulation 08:00 - 10:00	Factor VIII and IX, part 2 08:00 - 10:00	Platelet Physiology 08:00 - 10:00	Master Class 7:00-7:50
F XI & Contact Education Session 10:20 - 11:20	Control of Anticoag Education Session 10:20-11:20	Factor VIII and IX, part 2 (cont'd) 10:20 - 12:20	Pit Physiology Education Session 10:20 - 11:20	Career Mentorship Sessions 12:00-13:00
F XI & Contact (cont'd) 11:20 - 12:20	Control of Anticoag (cont'd) 11:20-12:20		Pit Physiology (cont'd) 11:20-12:20	
Lunch 12:20 - 13:00				Nurse Forum
WDT 13:00 - 15:00				
Coffee Break 15:00-15:30				Special Industry Symposia 15:30-17:30
Special Industry Symposia 15:30-17:30				



# Monday, June 22, 2015

Exhibit Hall D & E   Plenary Hall G&F   Room 701   Room 705   Room 707   Room 709   Room 711   Room 713

EXHIBITION 09:00 - 18:30	OC Late breaking abstract session - Thrombosis and Anticoagulation 08:00-09:15	OC Atherosclerosis 08:00-09:15	OC Endothelium and vessel wall 08:00-09:15	OC Tissue factor – factor VII – I 08:00-09:15	OC Heparin-induced thrombocytopenia 08:00-09:15	OC Mechanical circulatory support and devices 08:00-09:15	OC Acquired Disorders – treatment – I 08:00-09:15
	Coffee Break 09:15 - 09:45						
	Presidential Plenary 9:45-10:30						
	Break						
	SOA Hemophilia gene therapy: A Joint ISTH-WFH Symposium 10:45 - 11:45	SOA Controversies in VTE management 10:45 - 11:45					SOA Extracorporeal circulation in children 10:45 - 11:45
	Lunch 11:45 - 12:15						
	Lunch Symposia 12:15-13:45						
	OC NOACs in clinical practice 14:00 - 15:15	OC Venous thromboembolism – epidemiology – I 14:00 - 15:15	OC Factor VIII – I 14:00 - 15:15	OC Platelets – kinases-I 14:00 - 15:15	OC Stroke 14:00 - 15:15	OC Innate and acquired Immunity 14:00 - 15:15	OC Antiphospholipid antibodies – I 14:00 - 15:15
	Coffee Break 15:15 - 15:45						
	AS New alternatives for treating bleeding disorders 15:45 - 17:15	AS Antiphospholipid antibodies 15:45 - 17:15	AS Modulation of atherothrombosis 15:45 - 17:15	AS Sickle cell disease 15:45 - 17:15	AS Innovation and Technology 15:45 - 17:15	AS Platelets and bacteria 15:45 - 17:15	AS Protease activated receptors 15:45 - 17:15
Posters with refreshments 17:15 - 18:30							
	Technical Sessions 18:30-20:00						

# Monday, June 22, 2015

Room 714   Room 715   Room 716   Room 717   Room 718   Room 801   Room 803 A   Room 803 B   Intercontinental

OC Anti-platelets – basic 08:00-09:15	OC Reproductive Issues 08:00-09:15	OC VWD – classification, subtypes – I 08:00-09:15	OC Animal models 08:00-09:15	OC Platelet Disorders 08:00-09:15	OC Hemophilia – clinical 08:00-09:15
Coffee Break 09:15 - 09:45					
SOA Mechanisms of thrombosis 10:45 - 11:45	SOA Hijacking of proteolytic mechanisms by pathogens 10:45 - 11:45			SOA Platelet function and dysfunction 10:45 - 11:45	SOA Perioperative cardiovascular complications 10:45 - 11:45
Lunch 11:45 - 12:15					
Lunch Symposia 12:15-13:45					
OC Megakaryocytes and thrombopoiesis I 14:00 - 15:15	OC Vitamin K antagonists 14:00 - 15:15	OC Von Willebrand Disease 14:00 - 15:15	OC Hemophilia – prophylaxis 14:00 - 15:15	OC Management of bleeding 14:00 - 15:15	OC Thrombophilia 14:00 - 15:15
Coffee Break 15:15 - 15:45					
AS Coagulation, fibrinolysis, immunity and inflammation 15:45 - 17:15	AS Genetic basis of platelet disorders 15:45 - 17:15	AS Fibrinogen 15:45 - 17:15	AS Obesity – bench to bedside 15:45 - 17:15	AS Microparticles 15:45 - 17:15	AS Women's issue in venous thrombosis 15:45 - 17:15
Technical Sessions 18:30-20:00	Technical Sessions 18:30-20:00	Technical Sessions 18:30-20:00	Technical Sessions 18:30-20:00		

Master Class  
7:00-7:50

Nurse Forum  
08:00 - 16:30

Career Mentorship Sessions  
12:00-13:00

# Tuesday, June 23, 2015

Exhibit Hall D & E   Plenary Hall G & F   Room 701   Room 705   Room 707   Room 709   Room 711

EXHIBITION 09:00 - 18:30	OC Cancer and thrombosis – clinical – I 08:00-09:15	OC Immune thrombocytopenia – Basic 08:00-09:15	OC Microparticles – I 08:00-09:15	OC Rare bleeding disorders 08:00-09:15	OC Platelets – Signal Transduction I 08:00-09:15	OC Antiphospholipid antibodies – II 08:00-09:15
	Coffee Break 09:15 - 09:45					
	Plenary 9:45-10:30					
	Break					
	SOA Long-acting clotting factor concentrates 10:45 - 11:45	SOA Making Platelets for Transfusion 10:45 - 11:45				
	Lunch 11:45 - 12:15					
	Lunch Symposia 12:15-13:45					
	OC VTE diagnosis 14:00 - 15:15	OC VWD clinical 14:00 - 15:15	OC Tissue factor – factor VII – II 14:00 - 15:15	OC Platelets – signal transduction II 14:00 - 15:15	OC Coagulation factors, V, X, XIII 14:00 - 15:15	OC Arterial vascular disease 14:00 - 15:15
	Coffee Break 15:15 - 15:45					
	Plenary 15:45-16:30					
Break						
AS Cancer and thrombosis - basic 16:45 - 18:00	AS Inhibitors - basic 16:45 - 18:00	AS Mechanisms of ITP 16:45 - 18:00	AS Vascular progenitor cells and vascular disease 16:45 - 18:00	AS Developmental hemostasis 16:45 - 18:00	AS Endothelial cell wall + signaling 16:45 - 18:00	

Posters with refreshments  
18:00 - 19:30

# Tuesday, June 23, 2015

Room 713   Room 714   Room 715   Room 716   Room 717   Room 718   Room 801   Intercontinental

OC Pediatric thrombosis 08:00-09:15	OC Risk factors for venous thrombosis – I 08:00-09:15	OC Factor VIII – II 08:00-09:15	OC TTP and PNH 08:00-09:15	OC Inflammation 08:00-09:15	OC VTE epidemiology – II 08:00-09:15	OC Hemophilia inhibitors 08:00-09:15
Coffee Break 09:15 - 09:45						
SOA Thrombotic Thrombocytopenic Purpura 10:45 - 11:45	SOA Evolving role of the intrinsic pathway 10:45 - 11:45	SOA Atherothrombosis 10:45 - 11:45		SOA Opening vessels: From fibrinolysis to interventions 10:45 - 11:45	SOA Genetics of megakaryocytes and platelets 10:45 - 11:45	
Lunch 11:45 - 12:15						
Lunch Symposia 12:15-13:45						
OC Pediatric hemostasis 14:00 - 15:15	OC Hemophilia – novel treatments 14:00 - 15:15	OC Cancer and thrombosis – clinical – II 14:00 - 15:15	OC Acquired Disorders – Clinical – II 14:00 - 15:15	OC Megakaryocytes and thrombopoiesis II 14:00 - 15:15	OC NOAC – bleeding risk factors and management 14:00 - 15:15	OC Platelets – I 14:00 - 15:15
Coffee Break 15:15 - 15:45						
Break						
AS Hemostasis and infection 16:45 - 18:00	AS Vessel wall in health and disease annexins 16:45 - 18:00	AS Alloimmune and autoimmune platelet disorders 16:45 - 18:00	AS Tools for evaluation of bleeding 16:45 - 18:00	AS Platelet signalling 16:45 - 18:00	AS Non-vitamin K antagonist oral anticoagulants 16:45 - 18:00	AS VWF 16:45 - 18:00

Master Class  
7:00-7:50

Career Mentorship Sessions  
12:00-13:00

# Wednesday, June 24, 2015

Exhibit Hall D & E Plenary Hall G&F Room 701 Room 705 Room 707 Room 709 Room 711 Room 713

EXHIBITION 09:00 - 18:30	OC Late breaking abstract session - Bleeding disorders, TTP 08:00-09:15	OC ITP - Clinical 08:00-09:15	OC Factor VIII and IX 08:00-09:15	OC Blood coagulation tests - I 08:00-09:15	OC Heparin and heparinoids 08:00-09:15	OC Microparticles - II 08:00-09:15	OC Platelets - II 08:00-09:15
	Coffee Break 09:15 - 09:45						
	Plenary 9:45-10:30						
	Break						
	SOA Treatment of anticoagulant-associated bleeding 10:45 - 11:45	SOA Small thrombosis - a big deal? 10:45 - 11:45					Transplantation medicine in childhood 10:45 - 11:45
	Lunch 11:45 - 12:15						
	Lunch Symposia 12:15-13:45						Lunch Symposia 12:15-13:45
	OC Non-vitamin K oral anticoagulants and reversal 14:00 - 15:15	OC Postthrombotic syndrome, thrombophilia 14:00 - 15:15	OC ADAMTS 13 14:00 - 15:15	OC Natural anticoagulants 14:00 - 15:15	OC Fibrinogen and fibrin I 14:00 - 15:15	OC Fibrinolytic system - I 14:00 - 15:15	OC Hemophilia B 14:00 - 15:15
	Coffee Break 15:15 - 15:45						
	AS Therapeutic management of venous thrombosis 15:45 - 17:15	AS Factor VIII 15:45 - 17:15	AS Modulators of fibrinolytic activity 15:45 - 17:15	AS Determinants of thrombus structure and susceptibility to lysis 15:45 - 17:15	AS Assay challenges 15:45 - 17:15	AS Membrane scrambling 15:45 - 17:15	AS Platelet activation 15:45 - 17:15
Posters with refreshments 17:15 - 18:30							

# Wednesday, June 24, 2015

Room 714 Room 715 Room 716 Room 717 Room 718 Room 801 Room 803A Room 803B Intercontinental

OC Non-vitamin K oral anticoagulants and surgery 08:00-09:15	OC Contact system I 08:00-09:15	OC Platelets - kinases - II 08:00-09:15	OC Cancer and thrombosis - clinical - III 08:00-09:15	OC VTE treatment - I 08:00-09:15	OC Risk Factors for venous thrombosis - II 08:00-09:15
Coffee Break 09:15 - 09:45					
SOA Platelets and Inflammation 10:45 - 11:45	SOA Innovations and Technology 10:45 - 11:45	SOA Trauma-induced coagulopathy 10:45 - 11:45		SOA Controversies in antiplatelet therapy for coronary artery disease 10:45 - 11:45	
Lunch 11:45 - 12:15					
Lunch Symposia 12:15-13:45				Lunch Symposia 12:15-13:45	
OC Platelet disorders - bleeding 14:00 - 15:15	OC Contact system II 14:00 - 15:15	OC Platelets and cancer 14:00 - 15:15	OC Cancer and thrombosis - basic - I 14:00 - 15:15	OC VTE Epidemiology III 14:00 - 15:15	OC WMF - I 14:00 - 15:15
Coffee Break 15:15 - 15:45					
AS Platelet structure and function 15:45 - 17:15	AS Pregnancy related bleeding complications 15:45 - 17:15	AS Factor V and regulation 15:45 - 17:15	AS Vascular remodeling 15:45 - 17:15	AS Prevention of thrombosis in children 15:45 - 17:15	AS Platelet function testing assays 15:45 - 17:15
Career Mentorship Sessions 12:00-13:00					

# Thursday, June 25, 2015

Plenary Hall G&F    Room 701    Room 705    Room 707    Room 709    Room 711

OC Venous thromboembolism – therapy II 08:00-09:15    OC Risk factors for venous thrombosis - III 08:00-09:15    OC Blood coagulation tests – II 08:00-09:15    OC Fibrinogen and fibrin II 08:00-09:15    OC Cancer and thrombosis – basic – II 08:00-09:15    OC Fibrinolytic system – II 08:00-09:15

Coffee Break 09:15 - 09:30

Plenary 9:30-10:15

AS Novel anti-platelet agents 10:30-11:45    AS Atherosclerosis, inflammation and cancer 10:30-11:45    AS Chronic kidney disease and coagulation 10:30-11:45    AS Fibrinolysis in health and disease 10:30-11:45    AS Atherosclerosis: progression and development 10:30-11:45    AS Glycobiology 10:30-11:45

Coffee Break 11:45 - 12:00

Highlights of ISTH 12:00 - 13:00

# Thursday, June 25, 2015

Room 713    Room 714    Room 715    Room 716    Room 717    Room 718    Room 801

OC Factor VIII – III 08:00-09:15    OC Megakaryocytes and thrombopoiesis III 08:00-09:15    OC Platelets – III 08:00-09:15    OC VWF – II 08:00-09:15    OC Regulation of coagulation and fibrinolysis 08:00-09:15    OC Hemophilia – joint disease and clinical 08:00-09:15    OC Anti-platelet agents - clinical 08:00-09:15

Coffee Break 09:15 - 09:30

AS Stroke 10:30-11:45    AS Protein C and sepsis 10:30-11:45    AS Endothelial cell-VTE models 10:30-11:45    AS Cancer and thrombosis clinical 10:30-11:45    AS ADAMTS13 10:30-11:45    AS Unusual site venous thrombosis 10:30-11:45    AS Inhibitors - clinical 10:30-11:45

Coffee Break 11:45 - 12:00



# SSC PROGRAM

Saturday, June 20, 2015 9:00-13:20

Factor VIII and IX, part 1

Room 718

Chairman: Guy Young (United States)  
Co-chairs: Manuel Carcao (Canada), Danijela Mikovic (Serbia), Flora Peyvandi (Italy), Steve Pipe (United States), Elena Santagostino (Italy), Mike Makris (United Kingdom)

09:00 - 09:15 **Welcome and introduction**  
Guy Young (United States)

## PROJECT UPDATES

Moderators: Flora Peyvandi (Italy), Mike Makris (United Kingdom)

09:15 - 09:30 **Standardization of post-registration surveillance**  
Flora Peyvandi (Italy)  
09:30 - 09:40 **Prophylaxis in patients without inhibitors**  
Victor Blanchette (Canada), Kathelijin Fischer (The Netherlands)  
09:40 - 09:50 **Prophylaxis in patients with inhibitors**  
Carmen Escuriola (Germany)  
09:50 - 10:00 **Bleeding score in hemophilia**  
Maria Elisa Mancuso (Italy)  
10:00 - 10:10 **ITI definitions**  
Elena Santagostino (Italy)  
10:10 - 10:20 **Mild hemophilia definitions**  
Mike Makris (United Kingdom)  
10:20 - 10:30 **Inhibitor reporting standardization in previously treated patients**  
Alfonso Iorio (Canada)  
10:30 - 10:40 **Standardization of genetic assays for diagnosis of hemophilia**  
Vince Jenkins (Ireland)  
10:40 - 11:00 **Discussion**

## COFFEE BREAK

## EDUCATION SESSION

Moderators: Guy Young (United States), Manuel Carcao (Canada)

11:20 - 11:50 **From Alexie Romanov to Stephen Christmas to 2015: What is different about factor IX deficiency?**  
Elena Santagostino (Italy)  
11:50 - 12:20 **What is the "true" incidence of inhibitors in haemophilia?**  
Michael Soucie (United States)

# SSC PROGRAM

## RARE BLEEDING DISORDERS

Moderator: Elena Santagostino (Italy)

12:20 - 12:40 **Update on afibrinogenemia and dysfibrinogenemia**  
Philippe de Moerloose (Switzerland), Alessandro Casini (Switzerland)  
12:40 - 13:00 **PRO-RBDD project: Prospective evaluation of the intensity of bleeding episodes in patients with fibrinogen and FXIII deficiency**  
Flora Peyvandi (Italy)  
13:00 - 13:20 **Discussion**

Lupus anticoagulant/Phospholipid-dependent antibodies

Room 716

Chairman: Bas de Laat (The Netherlands)  
Co-chairs: Tatsuay Atsumi (Japan), Maria Laura Bertolaccini (United Kingdom), Katrien M. Devreese (Belgium), Rolf T. Urbanus (The Netherlands), Denis G. Wahl (France)  
09:00 - 09:01 **Opening**  
09:01 - 09:10 **The effect of different types of reagents on LAC detection**  
Osamu Kumano (Japan)  
09:10 - 09:25 **Multicenter study on cut-off values for solid phase assays**  
Katrien M. Devreese (Belgium)  
09:25 - 09:35 **Conformation of beta2GPI**  
Leonie Pelkmans (The Netherlands)  
09:35 - 09:55 **Anti-beta2GPI IgA antibodies & anti-PT/PS antibodies**  
Maria Laura Bertolaccini (United Kingdom)  
09:55 - 10:10 **Thrombin generation in APS**  
Denis G. Wahl (France)  
10:10 - 10:25 **Unravelling the mechanism behind LAC**  
Rolf T. Urbanus (The Netherlands)  
10:25 - 10:45 **Resistance to Annexin A5 anticoagulant activity is a biomarker for adverse clinical outcomes**  
Jacob H. Rand (United States), Lucia R. Wolgast (United States)  
10:45 - 11:00 **Domain I and risk stratification**  
Vittorio Pengo (Italy)

## COFFEE BREAK

## EDUCATION SESSION

11:20 - 11:50 **The activity of antiphospholipid antibodies in vitro and in vivo**  
Philip G. de Groot (The Netherlands)

## SSC PROGRAM

11:50 - 12:20 **The antiphospholipid syndrome (APS), a clinician's perspective**  
Vittorio Pengo (Italy)

### SUBCOMMITTEE CONTINUES

12:20 - 12:35 **Global anti-phospholipid syndrome score (GAPSS)**  
Denis G. Wahl (France)

12:35 - 12:50 **APS scoring**  
Tatsuya Atsumi (Japan)

12:50 - 13:05 **LAC in APS patients on rivaroxaban**  
Deepa Arachchillage (United Kingdom)

13:05 - 13:19 **Rivaroxaban in antiphospholipid syndrome**  
Hannah Cohen (United Kingdom)

13:19 - 13:20 **Closing remarks**  
Bas de Laat (The Netherlands)

### Platelet immunology

Room 801

Chairman: Yves Gruel (France)

Co-chairs: Donald Arnold (Canada), Tamam Bakchoul (Germany), Francois Mullier (Belgium)  
Sentot Santoso (Germany), Yoshiaki Tomiyama (Japan), Chris Ward (Australia)

09:00 - 09:10 **Welcome**  
Donald Arnold (Canada)

### AUTOIMMUNE AND DRUG-INDUCED ITP

*Moderators: Donald Arnold (Canada), Yoshiaki Tomiyama (Japan)*

09:10 - 09:25 **Recommendations for platelet autoantibody testing in ITP**  
Donald Arnold (Canada)

09:25 - 09:40 **Immature platelet fraction measurement for the diagnosis of ITP**  
Yoshiaki Tomiyama (Japan)

09:40 - 09:55 **Recommendations for cutoff values for positive results of DITP testing and sample materials**  
Tamam Bakchoul (Germany), Brian Curtis (United States)

### HEPARIN-INDUCED THROMBOCYTOPENIA

*Moderators: Chris Ward (Australia), Yves Gruel (France)*

09:55 - 10:15 **Standardized protocol of Multiplate assay for HIT diagnosis; and results of a national survey of functional testing**  
Chris Ward (Australia), Tamam Bakchoul (Germany)

10:15 - 10:30 **5B9, a potential standard for HIT laboratory assays?**  
Yves Gruel (France)

## SSC PROGRAM

10:30 - 10:45 **Protamine-induced thrombocytopenia**  
Ted Warkentin (Canada)

10:45 - 11:00 **Discussion**

### COFFEE BREAK

### EDUCATION SESSION

11:20 - 11:50 **Platelet alloantigens in other tissues, and implications in immunohematology**  
Sentot Santoso (Germany)

11:50 - 12:20 **New insights explaining the variability in platelet response to HIT antibodies**  
Yves Gruel (France)

### ALLOIMMUNE THROMBOCYTOPENIA

*Moderators: Tamam Bakchoul (Germany), Sentot Santoso (Germany)*

12:20 - 12:35 **NAIT- Should surface plasmon resonance (SPR) and antibody titre be part of routine investigations and reporting?**  
Gerald Bertrand (France)

12:35 - 12:50 **A new alloantigen (Cab 4) carried by GPIbIX in a context of severe neonatal alloimmune thrombocytopenia**  
Rachel Petermann (France)

12:50 - 13:20 **Re-cap of ongoing and new proposals**  
Donald Arnold (Canada)

### Vascular biology

Room 714

Chairman: Rienk Nieuwland (The Netherlands)

Co-Chairs: Alexander Brill (United Kingdom), Elizabeth E. Gardiner (Australia)  
Chris Gardiner (United Kingdom), Anna Randi (United Kingdom)  
Florence Sabatier (France), Pia Siljander (Finland)

### CIRCULATING ENDOTHELIAL PROGENITOR CELLS

*Moderators: Anna Randi (United Kingdom), Florence Sabatier (France)*

09:00 - 09:20 **From VSELs to endothelial progenitor cells: What is the "perfect" vasculogenic cell?**  
David Smadja (France)

09:20 - 09:40 **Blood outgrowth endothelial cells offer novel insights into von Willebrand disease**  
Richard Starke (United Kingdom)

09:40 - 10:00 **Derivation of endothelial colony forming cells from pluripotent stem cells**  
Nuttan Prasain (United States)

## SSC PROGRAM

### RECEPTOR SHEDDING FROM PLATELETS IN THE INFLAMED VASCULATURE

Moderators: Elizabeth E. Gardiner (Australia), Alexander Brill (United Kingdom)

- 10:00 - 10:20 Platelets and the inflamed vasculature  
Paul Kubes (Canada)
- 10:20 - 10:40 Mechanistic insights into platelet receptor shedding  
Yotis Senis (United Kingdom)
- 10:40 - 11:00 Glycoprotein Ib-alpha shedding and platelet clearance  
Renhao Li (United States)

### COFFEE BREAK

### EDUCATION SESSION

Moderators: Rienk Nieuwland (The Netherlands)

- 11:20 - 11:50 Multiple applications of endothelial colony forming cells  
Juan Melero-Martin (United States)
- 11:50 - 12:20 Measurement of tissue factor in clinical samples  
Nigel Mackman (United States)

### MICROPARTICLES AND STANDARDIZATION

Moderators: Pia Siljander (Finland), Chris Gardiner (United Kingdom)

- 12:20 - 12:40 Vesicle size approximation enables interlaboratory comparison of vesicle measurements by flow cytometry  
Rienk Nieuwland (The Netherlands)
- 12:40 - 13:00 Studies of the microparticle cargo and its functional components  
Eric Boilard (Canada)
- 13:00 - 13:20 Progress of endothelial microparticle detection and characterization by flow cytometry  
Romaric Lacroix (France)

Predictive and diagnostic variables in thrombotic disease

Room 715

- Chairman: Paul A. Kyrle (Austria)
- Co-chairs: Suzanne Cannegieter (The Netherlands), Shinya Goto (Japan)  
Karel Moons (The Netherlands), Marc C. Samama (France)  
Alexander C. Spyropoulos (United States)

- 09:00 - 09:05 Welcome, information on the new scope of the subcommittee

## SSC PROGRAM

### PREDICTIVE AND DIAGNOSTIC VARIABLES IN THROMBOTIC DISEASE

Moderators: Paul A. Kyrle (Austria), Gregoire Le Gal (Canada)

- 09:05 - 09:20 Decision rules in suspected DVT and PE; towards personalized strategies  
Geert-Jan Geersing (The Netherlands)
- 09:20 - 09:35 Diagnosis of recurrent VTE  
Frederikus A. Klok (The Netherlands)
- 09:35 - 09:50 Diagnosing small clots: Subsegmental pulmonary embolism  
Marc Carrier (Canada)
- 09:50 - 10:15 Diagnosing small clots: Distal deep vein thrombosis  
Marc Righini (Switzerland)
- 10:15 - 11:00 On-going studies (ADJUST-DVT, THEIA, CLOT 3, "D-dimer and pre-test clinical probability score in cancer patients with suspected deep vein thrombosis of the legs", 4D, PEGED)  
Marc Righini (Switzerland), Frederikus A. Klok (The Netherlands), Scott Stevens (United States), Marcello Di Nisio (Italy), Clive Kearon (Canada)

### COFFEE BREAK

### EDUCATION SESSION

Moderators: Marc C. Samama (France), Alexander C. Spyropoulos (United States)

- 11:20 - 11:50 Etiology in clinical research: Possibilities and limitations  
Suzanne Cannegieter (The Netherlands)
- 11:50 - 12:20 Clinical prediction modelling: Do's and don'ts  
Karel Moons (The Netherlands)

### PREDICTIVE VARIABLES IN THROMBOTIC DISEASE

Moderators: Suzanne Cannegieter (The Netherlands), Shinya Goto (Japan)

- 12:20 - 12:40 Extracellular nucleic acids as potential biomarkers of thrombosis and cardiovascular disease  
Hector Cabrera-Fuentes (Germany)
- 12:40 - 13:00 The use of a bivariate model of thrombosis and bleeding in antithrombotic trials  
Alexander C. Spyropoulos (United States)
- 13:00 - 13:20 Should we shorten or even skip VTE prophylaxis after day case surgery and/or surgery with enhanced recovery?  
Marc C. Samama (France)
- 13:20 - 13:30 Closing remarks



## SSC PROGRAM

### Women's issues in thrombosis and haemostasis

Room 701

Chairman: Rezan Abdul-Kadir (United Kingdom)  
Co-chairs: Claudia Chi (Singapore), Hannah Cohen (United Kingdom)  
Ida Martinelli (Italy), Saskia Middeldorp (The Netherlands)  
Maha Othman (Canada), Rochelle Winikoff (Canada)

### WELCOME AND INTRODUCTION

Moderator: Rezan Abdul-Kadir (United Kingdom)

09:00 - 09:05 **Outline of the SSC and overview of activities**  
Rezan Abdul-Kadir (United Kingdom)  
09:05 - 09:10 **Report on the Women's Health Issues in Thrombosis and Hemostasis Symposium 2015**  
Benjamin Brenner (Israel)

### UPDATES ON REGISTRIES AND PROJECTS

Moderators: Saskia Middeldorp (The Netherlands), Maha Othman (Canada)

09:10 - 09:15 **NOAC and pregnancy: Registry**  
Saskia Middeldorp (The Netherlands)  
09:15 - 09:20 **Thrombophilia screening after recurrent failures in assisted reproductive techniques: Registry**  
Elvira Grandone (Italy)  
09:20 - 09:25 **Thrombophilia and outcomes of assisted reproduction technologies: Summary of systematic review and meta-analysis**  
Marcello Di Nisio (Italy)  
09:25 - 09:35 **YEARS diagnostic study in PE**  
Menno Huisman (The Netherlands)  
09:35 - 09:45 **The use of thrombo-elastography in pregnancy: Registry**  
Maha Othman (Canada)  
09:45 - 09:55 **Obstetric issues in mothers of children with severe protein C deficiency**  
Adrian Minford (United Kingdom)  
09:55 - 10:00 **Discussion**

### THROMBOSIS ISSUES

Moderators: Hannah Cohen (United Kingdom), Ida Martinelli (Italy)

10:00 - 10:20 **Management of non-vitamin K oral anticoagulants (NOAC) in women of childbearing age**  
Deepa Arachchilage (United Kingdom)  
10:20 - 10:40 **Management of obstetric antiphospholipid syndrome: New developments**  
Beverly Hunt (United Kingdom)

## SSC PROGRAM

10:40 - 11:00 **Management of thrombotic thrombocytopenic purpura in pregnancy**  
Marie Scully (United Kingdom)

### COFFEE BREAK

### EDUCATION SESSION

Moderators: Rezan Abdul-Kadir (United Kingdom), Andra James (United States)

11:20 - 11:45 **Preeclampsia – the role of haemostasis in its pathophysiology**  
Chris Gardiner (United Kingdom)  
11:45 - 12:20 **Women and bleeding disorders – the role of bleeding assessment tools**  
Paula James (Canada)

### HEMOSTASIS ISSUES

Moderators: Rochelle Winikoff (Canada), Peter Kouides (United States)

12:20 - 12:30 **Women and platelet function defects**  
Sarah O'Brien (United States)  
12:30 - 12:45 **Can carriers of hemophilia with normal factor levels bleed?**  
Robert Sidonio (United States)  
12:45 - 13:00 **Postpartum hemorrhage in carriers of hemophilia and women with VWD**  
Jeroen Eikenboom (The Netherlands)  
13:00 - 13:15 **Abnormal uterine bleeding in adolescents: Patterns, diagnoses and clinical outcomes**  
Ayesha Zia (United States)  
13:15 - 13:20 **Foundation for women and girls with blood disorders (FWGBD)**  
Ann-Marie Nazzaro (United States)

### Fibrinolysis

Room 713

Chairman: Nicola J. Mutch (United Kingdom)  
Co-chairs: Jonathan H. Foley (United Kingdom), Krasimir Kolev (Hungary)  
Craig Thelwell (United Kingdom), Shirley Uitte de Willige (The Netherlands)  
Waander van Heerde (The Netherlands), Paul Y. Kim (Canada)  
09:00 - 09:05 **Opening remarks & announcements**  
Nicola J. Mutch (United Kingdom)

### STANDARDIZATION OF FIBRINOLYTIC PROTEINS

09:05 - 09:15 **Standardization of D-dimer**  
Colin Longstaff (United Kingdom)

## SSC PROGRAM

- 09:15 - 09:25 **Development of standards for plasmin, streptokinase, anicrod and batroxoban**  
Craig Thelwell (United Kingdom)
- 09:25 - 09:40 **Standardization of TAFI (CPU)**  
Craig Thelwell (United Kingdom)

### DIVERSE ROLES OF PLASMIN

- 09:40 - 10:00 **Plasmin and von Willebrand factor in thrombotic thrombocytopenic purpura**  
Claudia Tersteeg (The Netherlands)
- 10:00 - 10:20 **Plasmin generation by staphylokinase during skin infections with Staphylococcus aureus**  
Marijke Peetermans (Belgium)

### IMPACT OF CELLS ON FIBRINOLYSIS

- 10:20 - 10:40 **Effect of hematocrit on clot structure and resistance to lysis**  
Paraskevi Untiveros (United Kingdom)
- 10:40 - 11:00 **Neutrophils as key modulators of fibrin structure and lysis in thrombi**  
Imre Varjú (Hungary)

### COFFEE BREAK

### EDUCATION SESSION

- 11:20 - 11:50 **Influence of alpha-2AP on the pathogenesis of stroke**  
Guy Reed (United States)
- 11:50 - 12:20 **Plasminogen activation in the brain**  
Manuel Yepes (United States)

### INHIBITORS OF FIBRINOLYSIS IN DISEASE

- 12:20 - 12:40 **Thrombolysis induced by a diabody against PAI-1 and TAFI**  
Paul Declerck (Belgium)
- 12:40 - 13:00 **Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis**  
Travis Gould (Canada)
- 13:00 - 13:20 **Measurement of active CPU (TAFIa) in samples from patients with acute coronary syndrome**  
Dorien Leenaerts (Belgium)

## SSC PROGRAM

### Pediatric and neonatal thrombosis and hemostasis

Room 717

- Chairman: Anthony K. Chan (Canada)
- Co-Chairs: Mariana Bonduel (Argentina), Leonardo R. Brandao (Canada)  
Elizabeth A. Chalmers (United Kingdom), Neil Goldenberg (United States)  
Shoshana Revel-Vilk (Israel), Heleen van Ommen (The Netherlands)

### EDUCATION SESSION

*Moderators: Anthony Chan (Canada), Elizabeth Chalmers (United Kingdom)*

- 14:30-15:00 **Direct oral anticoagulants: Current status in pediatric trials**  
Heleen van Ommen (The Netherlands)
- 15:00-15:30 **Antithrombin concentrate: What is the evidence on its use?**  
Paul Monagle (Australia)

### SUBCOMMITTEE SESSION 1

*Moderators: Anthony Chan (Canada), Heleen van Ommen (The Netherlands)*

- 15:30-15:50 **Report from catheter-related arterial thrombosis working group**  
Manuela Albisetti (Switzerland)
- 15:50-16:10 **Report from radiological diagnosis working group**  
Leonardo Brandao (Canada)
- 16:10-16:30 **Report from pulmonary embolism working group**  
Neil Goldenberg (United States)

### SUBCOMMITTEE SESSION 2

*Moderators: Leonardo Brandao (Canada), Neil Goldenberg (United States)*

- 16:50-17:05 **Report from VTE prevention working group**  
Brian Branchford (United States), Julie Jaffray (United States)
- 17:05-17:20 **RCT: Do we need anti-Xa monitoring for use of enoxaparin?**  
Mihir Bhatt (Canada)
- 17:20-17:35 **Management of coagulopathy in children with liver disease**  
Maria Magnusson (Sweden)
- 17:35-17:50 **Purpura fulminans registry**  
Victoria Price (Canada)
- 17:50-18:00 **DIC registry**  
Jecko Thachil (United Kingdom)
- 18:00-18:10 **Management guide: CVL related thrombosis**  
Ketan Kulkarni (Canada)
- 18:10-18:20 **Antithrombin registry**  
Riten Kumar (United States)

## SSC PROGRAM

18:20-18:25 **Menorrhagia in adolescence**  
Ayesha Zia (United States)

18:25-18:30 **Conclusion**  
Anthony Chan (Canada)

### Biorheology

Room 716

Chairman: Keith Neeves (United States)

Co-chairs: Judith Cosemans (The Netherlands), David N. Ku (United States)  
Pierre Mangin (France), Owen J. Mccarty (United States)  
Mitsuhiko Sugimoto (Japan), Erik Westein (Australia)

## JOINT BIORHEOLOGY AND PLATELET PHYSIOLOGY EDUCATION SESSION

14:30 - 15:00 **Bioreactors for the study of the biophysical mechanisms that regulate platelet function?**  
José Lopez (United States)

15:00 - 15:30 **Bioreactors for the study of the biophysical mechanisms that regulate platelet function?**  
Shaun Jackson (Australia)

15:30 - 16:30 **Joint Biorheology & VWF session on acquired von Willebrand syndrome in room 718**  
Jorge A. Di Paola (United States), Keith Neeves (United States)

## COFFEE BREAK

### VWF-MEDIATED MECHANISMS IN COMPLEX AND PATHOLOGICAL FLOWS

Moderators: Mitsuhiko Sugimoto (Japan), Pierre Mangin (France)

16:50 - 17:05 **Biomechanical regulation of VWF and thrombus formation under complex flow conditions**  
Erik Westein (Australia)

17:05 - 17:20 **From single VWF molecules to collective aggregates: Towards an understanding of thrombus formation**  
Matthias Schneider (United States)

17:20 - 17:35 **Relative roles of VWF and platelets in formation of occlusive arterial thrombosis**  
David N. Ku (United States)

### NOVEL FLOW-DEPENDENT MECHANISMS OF PLATELET FUNCTION, COAGULATION AND FIBRINOLYSIS

Moderators: Erik Westein (Australia), Judith Cosemans (The Netherlands)

17:45 - 18:00 **Shear effects on platelet surface receptor shedding**  
Elizabeth E. Gardiner (Australia)

## SSC PROGRAM

18:00 - 18:15 **Assessment of platelet-dependent coagulation and fibrinolysis under flow**  
Paola van der Meijden (The Netherlands)

18:15-18:30 **Platelet adhesion and aggregation under disturbed blood flow: A focus on the role of pulsatility**  
Pierre Mangin (France)

18:30 - 18:50 **Discussion: Challenges and needs for standardization of flow assays**

### Exogenous hemostatic factors

Room 713

Chairman: Ivo Francishetti (United States)

Co-Chairs: Tur-Fu Huang (Taiwan), Manjunatha R. Kini (Singapore)  
Francis Markland Jr. (United States), Robson Monteiro (Brazil)  
Kenneth J. Clemetson (Switzerland)

## EDUCATION SESSION

14:30 - 15:00 **Exogenous factor XIa inhibitors from snake venoms**  
Manjunatha R. Kini (Singapore)

15:00 - 15:30 **Hematophagy, neutrophils and contact pathway**  
Ivo Francischetti (United States)

## SUBCOMMITTEE SESSION

15:30 - 15:50 **Structure of Pseutarin-C, a snake venom prothrombin activator**  
Jim Huntington (United Kingdom)

15:50 - 16:10 **Rational strategy applied to a tick salivary FXa inhibitor in order to develop a potential antitumor drug candidate**  
Ana Marisa Chudzinski-Tavassi (Brazil)

16:10 - 16:30 **Exogenous inhibitors as tools for the study of new players in haemostasis and thrombosis**  
Robson D. Monteiro (Brazil)

## COFFEE BREAK

16:50 - 17:10 **Exogenous hemostatic factors as tools in platelet research**  
Kenneth J. Clemetson (Switzerland)

17:10 - 17:30 **Anfibatide and other exogenous platelet GPIIb antagonists**  
Heyu Ni (Canada)

17:30 - 17:50 **The second generation of platelet GPIIb/IIIa antagonists derived from snake venom disintegrins**  
Tur-Fu Huang (Taiwan)

17:50 - 18:10 **Towards an understanding of the cellular and molecular events that underlie quick wound healing in salamanders**  
Ren Lai (China)

## SSC PROGRAM

18:10 - 18:15 **Closing remarks**  
Ivo Francischetti (United States)

### Hemostasis and malignancy

Room 801

Chairman: Alok A. Khorana (United States)

Co-Chairs: Marc Carrier (Canada), Howard Liebman (United States)  
Nigel Mackman (United States), Simon I. Noble (United Kingdom)  
Ingrid Pabinger (Austria) Joseph S. Palumbo (United States)

### EDUCATION SESSION

*Moderators: Marc Carrier (Canada), Alok A. Khorana (United States)*

14:30 - 15:00 **Occult VTE: Do new trial results change practice?**  
Marc Carrier (Canada)

15:00 - 15:30 **Qualitative research into cancer associated thrombosis: Who needs it?**  
Simon I. Noble (United Kingdom)

### SUBCOMMITTEE SESSION 1

*Moderators: Nigel Mackman (United States), Ingrid Pabinger (Austria)*

15:30 - 16:10 **Platelets, hemostatic factors and malignancy**  
Ingrid Pabinger (Austria), Nigel Mackman (United States), Joseph S. Palumbo (United States)

16:10 - 16:30 **Predicting recurrent VTE: New biomarkers and risk factor analyses from CATCH**  
Alok A. Khorana (United States)

### COFFEE BREAK

### SUBCOMMITTEE SESSION 2

*Moderators: Jeffrey Zwicker (United States), Cihan Ay (Austria)*

16:50 - 17:10 **Hypercoagulation screening as a marker of thrombosis and poor disease prognosis in cancer patients: The HYPERCAN prospective study**  
Marina Marchetti (Italy), Anna Falanga (Italy)

17:10 - 17:25 **Incidental VTE: Emerging data**  
Casey O'Connell (United States)

17:25 - 17:40 **Incidental VTE: SSC guidance statement**  
Marcello Di Nisio (Italy)

17:40 - 18:00 **Treating CAT: Indirect comparison of anticoagulants**  
Cihan Ay (Austria), Florian Posch (Australia)

18:00 - 18:10 **Coagulopathy and prostate cancer**  
Maha Othman (Canada)

## SSC PROGRAM

18:10 - 18:30 **New guidance proposals: Pediatric VTE and intracranial hemorrhage**  
Joseph S. Palumbo (United States), Jeffrey Zwicker (United States)

18:30 - 18:50 **Update on new studies: Longheva registry; Prophylaxis**  
Pieter W. Kamphuisen (The Netherlands), Marc Carrier (Canada)

### Plasma coagulation inhibitors

Room 715

Chairman: Richard Marlar (United States)

Co-chairs: Ian Jennings (United Kingdom), Jun Teruya (United States)  
Hiroko Tsuda (Japan)

### PLASMA COAGULATION INHIBITORS: RELATIONSHIP OF PHENOTYPE, PLASMA LEVELS AND CLINICAL PHENOTYPE (THROMBOSIS)

*Moderator: Richard Marlar (United States)*

14:30 - 15:00 **Molecular defects in protein S**  
Pieter H. Reitsma (The Netherlands)

15:00 - 15:30 **Comparison of phenotype and genotype for AT, PC and PS**  
Anna Pavlova (Germany)

### SUBCOMMITTEE SESSION 1

*Moderators: Jun Teruya (United States), Richard Marlar (United States)*

15:30 - 15:45 **Current project: Mutation repository**  
Richard Marlar (United States)

15:45 - 16:00 **Current project: Protein S testing**  
Ian Jennings (United Kingdom)

16:00 - 16:10 **Current project: Racial differences**  
Hiroko Tsuda (Japan)

16:10 - 16:15 **Manuscript progress for clinical testing for AT, PC, PS and APC-R: Protein C**  
Steve Kitchen (United Kingdom)

16:15 - 16:20 **Manuscript progress for clinical testing for AT, PC, PS and APC-R: Protein S**  
Richard Marlar (United States)

16:20 - 16:25 **Manuscript progress for clinical testing for AT, PC, PS and APC-R: Antithrombin**  
TBD

16:25 - 16:30 **Manuscript progress for clinical testing for AT, PC, PS and APC-R: APC resistance**  
Richard Marlar (United States)

## SSC PROGRAM

### COFFEE BREAK

- 16:50 - 17:10 **Other plasma Inhibitors: Review of other inhibitors**  
Jun Teruya (United States)
- 17:10 - 17:25 **Other plasma Inhibitors: Clinical work on heparin cofactor II**  
Jun Teruya (United States)
- 17:25 - 17:40 **Other plasma Inhibitors: Clinical work on TFPI**
- 17:40 - 17:50 **Comparative schemes for thrombophilia testing by region-country: UK**  
Steve Kitchen (United Kingdom)
- 17:50 - 18:00 **Comparative schemes for thrombophilia testing by region-country: Europe**  
Piet Meijer (The Netherlands)
- 18:00 - 18:10 **Comparative schemes for thrombophilia testing by region-country: Japan**  
Hiroko Tsuda (Japan)
- 18:10 - 18:20 **Comparative schemes for thrombophilia testing by region-country: India**  
TBD
- 18:20 - 18:30 **Comparative schemes for thrombophilia testing by region-country: Australia**  
TBD
- 18:30 - 18:40 **Comparative schemes for thrombophilia testing by region-country: United States**  
Dorothy Adcock (United States)
- 18:40 - 18:45 **Summary of schemes**  
Richard Marlar (United States)
- 18:45 - 18:50 **Conclusions**

### Von Willebrand factor

Room 718

- Chairman: Jorge A. Di Paola (United States)
- Co-chairs: Sandra Haberichter (United States), Daniel J. Hampshire (United Kingdom)  
Koichi Kokame (Japan), Johanna A. Kremer Hovinga (Switzerland)  
Frank W. Leebeek (The Netherlands), Alberto Tosetto (Italy)

### EDUCATION SESSION

Moderators: Jorge A. Di Paola (United States)

- 14:30 - 15:00 **Factor VIII and VWF, rekindling a longstanding relationship**  
Peter Lenting (France)
- 15:00 - 15:30 **ADAMTS13 deficiency, TTP and beyond**  
Johanna A. Kremer Hovinga (Switzerland)

## SSC PROGRAM

### JOINT BIORHEOLOGY & VWF SESSION ON ACQUIRED VON WILLEBRAND SYNDROME

Moderators: Jorge A. Di Paola (United States), Keith Neeves (United States)

- 15:30 - 15:45 **Flow mediated interactions of VWF and ADAMTS13: Shear ecstasy**  
David Lillicrap (Canada)
- 15:45 - 16:00 **Acquired von Willebrand syndrome in patients with VAD or ECMO**  
Barbara Zieger (Germany)
- 16:00 - 16:15 **Effects of high shear millisecond exposure on platelets**  
David Schmidtke (United States)
- 16:15 - 16:30 **Discussion for speakers and proposed AWS working group**

### COFFEE BREAK

### LABORATORY AND CLINICAL UPDATES

Moderators: Frank W. Leebeek (The Netherlands), Alberto Tosetto (Italy)

- 16:50 - 17:05 **Update of VWF functional assays**  
Sandra Haberichter (United States)
- 17:05 - 17:20 **ADAMTS13 assays, the need for multicenter studies**  
Johanna A. Kremer Hovinga (Switzerland), Koichi Kokame (Japan)
- 17:20 - 17:35 **Development and validation of assessment tools for clinical trials in VWD**  
Paula James (Canada), Alberto Tosetto (Italy)

### STUDYING VWF AND VWD UNDER FLOW

Moderators: Johanna A. Kremer Hovinga (Switzerland), Daniel J. Hampshire (United Kingdom)

- 17:35 - 17:50 **Studying VWF mutations under flow**  
Maria Brehm (Germany)
- 17:50 - 18:05 **Studying VWD with microfluidic devices**  
Chris Ng (United States)

### VISUALIZING VWF

Moderators: Koichi Kokame (Japan), Sandra Haberichter (United States)

- 18:05 - 18:20 **VWF in megakaryocytes**  
Walter Kahr (Canada)
- 18:20 - 18:35 **Optimization of immunocytochemical staining and high resolution imaging of VWF in HEK293 cells**  
Simon Webster (United Kingdom)
- 18:35 - 18:50 **Visualizing VWF exocytosis**  
Jeroen C. Eikenboom (The Netherlands)

# SSC PROGRAM

Factor XIII and fibrinogen

Room 714

Chairman: Helen Philippou (United Kingdom)  
Co-Chairs: Zsuzsa Bagoly (Hungary), Matthew J. Flick (United States)  
Vytautas Ivaskevicius (Germany), Marlien Pieters (South Africa)  
Verena Schroeder (Switzerland), Alisa S. Wolberg (United States)

## EDUCATION SESSION

14:30 - 15:00 **Roles of the alpha chains of fibrinogen**  
Leonid Medved (United States)

15:00 - 15:30 **A historic recollection of factor XIII research**  
Aki Ichinose (Japan)

## SUBCOMMITTEE SESSION

15:30 - 15:50 **Standardisation of turbidity and fibrinolysis measurements**  
Marlien Pieters (South Africa)

15:50 - 16:10 **FXIII-B standardisation update**  
Éva Katona (Hungary), Verena Schroeder (Switzerland)

16:10 - 16:30 **New insights into automated fibrinogen Clauss assays**  
Sanj Raut (United Kingdom)

## COFFEE BREAK

16:50 - 17:15 **Fibrinogen and factor XIII in chronic inflammation**  
Matthew J. Flick (United States)

17:15 - 17:40 **Fibrinogen density decreases slightly and fiber stiffness decreases strongly with increasing fibrin fiber diameter**  
Martin Guthold (United States)

17:40 - 18:05 **Novel functions of fibrin(ogen) in liver repair and fibrosis**  
James P. Luyendyk (United States)

18:05 - 18:30 **The role of crosslinking in fibrin structure and function**  
Robert Ariëns (United Kingdom)

18:30 - 18:50 **A ten year genotype-clinical phenotype assessment of fibrinogen disorders from Bonn**  
Vytautas Ivaskevicius (Germany)

# SSC PROGRAM

Sunday, June 21, 2015 8:00-12:20

Disseminated Intravascular Coagulation (DIC)

Room 715

Chairman: Jecko Thachil (United Kingdom)  
Co-Chairs: Marcello Di Nisio (Italy), Satoshi Gando (Japan)  
Takashi Ito (Japan), Bernd Jilma (Austria)  
Shinichiro Kurosawa (United States), Sacha Zeerleder (The Netherlands)

## SUBCOMMITTEE SESSION 1

08:00 - 08:20 **DIC in obstetrical disorders**  
Offer Erez (Israel)

08:20 - 08:40 **DAMPS and DIC in sepsis**  
Patricia Liaw (Canada)

08:40 - 09:00 **Sepsis, thrombosis and organ injury**  
Hala Chabaan (United States)

09:00 - 09:20 **Hyperfibrinolytic afibrinogenemia in overt DIC**  
Bernd Jilma (Austria)

09:20 - 09:40 **Where to use thrombomodulin and antithrombin in DIC?**  
Toshiaki Iba (Japan)

09:40 - 10:00 **Discussion**

## COFFEE BREAK

## EDUCATION SESSION

10:20 - 10:50 **Zebrafish modelling in DIC**  
Jordan Shavit (United States)

10:50 - 11:20 **Management of DIC in a critical care unit**  
Jerrod Levy (United States)

## SUBCOMMITTEE SESSION 2

11:20 - 11:40 **DIC in trauma**  
Satoshi Gando (Japan)

11:40 - 12:00 **Fibrin-related markers - current status and further prospects in the detection of in vivo fibrin formation and dissolution**  
Carl-Eric E. Dempfle (Germany)

12:00 - 12:20 **International DIC survey and call for DIC registry**  
Marcello Di Nisio (Italy)

## SSC PROGRAM

### Factor VIII and IX, part 2

Room 718

Chairman:	Guy Young (United States)
Co-chairs:	Manuel Carcao (Canada), Danijela Mikovic (Serbia), Flora Peyvandi (Italy) Steven Pipe (United States), Elena Santagostino (Italy) Mike Makris (United Kingdom)

### LABORATORY ISSUES 1

*Moderators: Steven Pipe (United States), Elena Santagostino (Italy)*

08:00 - 08:15	<b>Update on Nijmegen group's high sensitivity inhibitor assay</b> Bert Verbruggen (The Netherlands)
08:15 - 08:30	<b>Inhibitor measurement using SMIA: A new approach in inhibitor measurement</b> Sanj Raut (United Kingdom)
08:30 - 08:40	<b>Discussion</b>
08:40 - 08:55	<b>Establishment of the 5th International Standard for FIX</b> Elaine Gray (United Kingdom)
08:55 - 09:10	<b>Update on EAHAD coagulation factor variant genotype database</b> Keith Gomez (United Kingdom)
09:10 - 09:20	<b>Discussion</b>
09:20 - 09:40	<b>IU vs %: Clearing up the confusion and a proposal for a position paper</b> Steve Kitchen (United Kingdom)
09:40 - 09:50	<b>WAPPS Project (Web-accessible population pharmacokinetics service)</b> Alfonso Iorio (Canada)
09:50 - 10:00	<b>Discussion</b>

### COFFEE BREAK

### CLINICAL ISSUES

*Moderators: Manuel Carcao (Canada), Mike Makris (United Kingdom)*

10:20 - 10:45	<b>Moderate hemophilia update</b> Kathelijin Fischer (The Netherlands)
10:45 - 11:10	<b>Clinical use of extended half-life factor products</b> Guy Young (United States)

### LABORATORY ISSUES 2

*Moderators: Steven Pipe (United States), Guy Young (United States)*

11:10 - 11:30	<b>Extended half-life factors and laboratory assays--overview of the problem</b> Steven Pipe (United States)
---------------	---

## SSC PROGRAM

11:30 - 11:45	<b>Overview of chromogenic assay basics</b> Kenneth Friedman (United States)
11:45 - 12:00	<b>Implementation of the chromogenic assay into the clinical lab</b> Richard Ko (United States)
12:00 - 12:20	<b>Discussion</b>

### Factor XI and the contact system

Room 716

Chairman:	Jonas Emsley (United Kingdom)
Co-Chairs:	Jose W. Govers-Riemslog (The Netherlands), Christine Mannhalter (Austria) Joost Meijers (The Netherlands), James Morrissey (United States) Ophira Salomon (Israel), Evi X. Stavrou (United States)

### ACTIVATORS AND BASIC SCIENCE OF FXI AND THE CONTACT SYSTEM

08:00 - 08:30	<b>Propagation of blood coagulation by extracellular nucleosomes/neutrophil extracellular traps</b> Bernd Engelmann (Germany)
08:30 - 08:50	<b>Structure of contact factors</b> Jonas Emsley (United Kingdom)
08:50 - 09:00	<b>The factor XII registry database</b> Ammar Majeed (Sweden)
09:00 - 09:30	<b>Driving plasminogen activation by factor XIIa</b> Nicola J. Mutch (United Kingdom)
09:30 - 10:00	<b>Kininogen, overlooked but not forgotten</b> Keith McCrae (United States)

### COFFEE BREAK

### EDUCATION SESSION

10:20 - 10:50	<b>Autoantibodies to factor XII and kininogens in patients with recurrent pregnancy loss</b> Toshitaka Sugi (Japan)
10:50 - 11:20	<b>Effect of plant inhibitors of the contact system on a mouse thrombosis model</b> Maria Luiza Vilela Oliva (Brazil)

### INHIBITORS OF FXI AND THE CONTACT SYSTEM: SAFER ANTICOAGULATION

11:20 - 11:40	<b>An update on factor XI structure function relationships</b> David Gailani (United States)
---------------	---

## SSC PROGRAM

- 11:40 - 12:00 **Antisense reduction of FXI for thromboprophylaxis: A novel therapeutic approach**  
Sanjay Bhanot (United States)
- 12:00 - 12:20 **Open discussion on topics of factor XI and the contact system that are now very current and relevant**  
Joost Meijers (The Netherlands)

### Working Group on Perioperative Thrombosis and Hemostasis

Room 707

Chairman: James Douketis (Canada)

Moderators: Jim Douketis (Canada), Jerrold Levy (United States)

- 08:00 - 08:10 **Working group on perioperative thrombosis and hemostasis**  
James Douketis (Canada)
- 08:10 - 08:30 **Management of patients on DAPT who need urgent or elective surgery**  
Pierre Albaladejo (France)
- 08:30 - 08:50 **Management of patients on NOACs who need urgent reversal for surgery**  
Jerrold Levy (United States)
- 08:50 - 09:00 **Discussion**
- 09:00 - 09:20 **Management of perioperative bleeding**  
Marc C. Samama (France)
- 09:20 - 09:40 **What are the landmark studies (completed and planned) in perioperative anticoagulant management?**  
Alexander C. Spyropoulos (United States)
- 09:40 - 10:00 **Panel discussion**

### Platelet physiology

Room 801

Chairman: Paolo Gresele (Italy)

Co-Chairs: Hans Deckman (Belgium), Andrew L. Frelinger III (United States)  
Paul Harrison (United Kingdom), Diego Mezzano (Chile)  
Andrew D. Mumford (United Kingdom), Patrizia Noris (Italy)

Moderators: Jim Douketis (Canada), Jerrold Levy (United States)

### SUBCOMMITTEE SESSION

Moderators: Paolo Gresele (Italy), Hans Deckmyn (Belgium)

- 08:00 - 08:10 **Overview of platelet physiology SSC and projects**  
Paolo Gresele (Italy)
- 08:10 - 08:20 **BAT in IPFD study**  
Paolo Gresele (Italy), Paul Harrison (United Kingdom)

## SSC PROGRAM

- 08:20 - 08:40 **Position statement on the methods for the study of platelet secretion**  
Diego Mezzano (Chile)
- 08:40 - 09:00 **Position statement on the laboratory monitoring of P2Y12 inhibitors**  
Andrew L. Frelinger III (United States)
- 09:00 - 09:10 **Prospective evaluation of the bleeding phenotype in PT-VWD to support evidence-based diagnosis and management**  
Maha Othman (Canada)
- 09:10 - 09:30 **The measurement of platelet dimensions: Methods and clinical use**  
Patrizia Noris (Italy)
- 09:30 - 10:00 **RNA signatures in platelets from cancer patients**  
Thomas Wurdinger (The Netherlands)

### COFFEE BREAK

### JOINT PLATELET PHYSIOLOGY AND BIORHEOLOGY EDUCATIONAL SESSION

Moderators: Paolo Gresele (Italy), Owen McCarty (United States)

- 10:20 - 10:50 **Bioreactors for megakaryocyte studies and platelet formation: Where do we stand?**  
Jonathan Thon (United States)
- 10:50 - 11:20 **Bioreactors for megakaryocyte studies and platelet formation: Where do we stand?**  
Alessandra Balduini (Italy)

### SUBCOMMITTEE CONTINUED

Moderators: Paul Harrison (United States), Diego Mezzano (Chile)

- 11:20 - 11:50 **The use of platelets in regenerative medicine: Contribution of platelets to vascular and tissue remodelling**  
Harald Langer (Germany)
- 11:50 - 12:20 **The use of platelets in regenerative medicine: Use of PRP for Achilles tendon rupture and burn injuries**  
Paul Harrison (United Kingdom)

### Animal, cellular and molecular models of thrombosis

Room 714

- Chairman: Susan Smyth (United States)
- Co-Chairs: Cecile V. Denis (France), Jose A. Diaz (United States)  
Tom Knudsen (Denmark), Leslie Parise (United States)  
Denise Sabatino (United States), David Motto (United States)
- 08:00 - 08:20 **Session introduction**  
Susan Smyth (United States), Jose A. Diaz (United States)
- 08:20 - 08:40 **Animal Model of VT: Where we are**  
Jose A. Diaz (United States)



## SSC PROGRAM

- 08:40 - 09:00 **The use of IVC stenosis model in VT**  
Steve Grover (United States)
- 09:00 - 09:20 **The use of femoral vein electrolytic model in VT**  
Brian Cooley (United States)
- 09:20 - 09:40 **The use of IVC models in VT (Ligation - EIM - RVT)**  
Jose A. Diaz (United States)
- 09:40 - 10:00 **Open Discussion**

### COFFEE BREAK

### EDUCATION SESSION

- 10:20 - 11:00 **VWF and NETs in venous thrombosis**  
Denisa Wagner (United States)
- 11:00 - 11:30 **Role of P-selectin in venous thrombosis**  
Tom Wakefield (United States)
- 11:30 - 11:50 **Insight into the role of fibrin in VT animal models**  
Alisa Wolberg (United States)
- 11:50 - 12:20 **Insight into the role of tissue factor in VT animal models**  
Nigel Mackman (United States)

#### Genomics in thrombosis and hemostasis

Room 701

- Chairman: Willem H. Ouwehand (United Kingdom)
- Co-Chairs: Paul Bray (United States), Kathleen Freson (Belgium)  
Anne Goodeve (United Kingdom), Michele P. Lambert (United States)  
Pieter H. Reitsma (The Netherlands)

### PART 1: NGS IN DIAGNOSTICS

*Moderators: Willem H. Ouwehand (United Kingdom), Michele Lambert (United States)*

- 08:00 - 08:15 **Welcome**  
Willem H. Ouwehand (United Kingdom)
- 08:15 - 08:30 **Inherited bleeding/coagulation disorder**  
Char Witmer (United States)
- 08:30 - 08:45 **Hemostasis NGS panel in routine diagnostic use**  
Anne Goodeve (United Kingdom)
- 08:45 - 09:00 **ThromboGenomics platform**  
Ilenia Simeoni (United Kingdom)

## SSC PROGRAM

### PART 2: NGS IN DIAGNOSTICS

*Moderators: Anne Goodeve (United Kingdom), Walter Kahr (Canada)*

- 09:15 - 09:30 **Coagulation factor variant database - an update**  
Daniel J. Hampshire (United Kingdom)
- 09:30 - 09:45 **Challenges in the interpretation of variants from next generation sequencing**  
Andrew Paterson (Canada)
- 09:45 - 10:00 **Discussion: Sharing sequencing data – All**

### COFFEE BREAK

### EDUCATION SESSION

*Moderators: Pieter H. Reitsma (The Netherlands), Paul Bray (United States)*

- 10:20 - 10:50 **Statistical and methodological challenges for gene discovery by NGS**  
Ernest Turro (United Kingdom)
- 10:50 - 11:20 **Inherited platelet disorders**  
Walter Kahr (Canada)

### REPORTING OF CLINICAL VARIANTS

*Moderators: Kathleen Freson (Belgium), Daniel Bellissimo (United States)*

- 11:40 - 12:00 **International guidelines to annotate pathogenic variants**  
Kathleen Freson (Belgium), Daniel Bellissimo (United States)
- 12:00 - 12:20 **New large control data: Opportunities & pitfalls**  
Karyn Megy (United Kingdom), Daniel J. Hampshire (United Kingdom)

#### Control of anticoagulation

Room 717

- Chairman: Walter Ageno (Italy)
- Co-Chairs: Rebecca Beyth (United States), Benilde Cosmi (Italy)  
Mark Crowther (Canada), Ismail Elalamy (France)  
Elanie Hylek (United States), Peter Verhamme (Belgium)  
Henry G. Watson (United Kingdom),  
Pieter W. Kamphuisen (The Netherlands)
- 08:00 - 08:05 **Introduction**  
Walter Ageno (Italy)

### UPDATE ON CURRENT SSC PROJECTS: REGISTRIES

*Moderators: Benilde Cosmi (Italy), Rebecca Beyth (United States)*

- 08:05 - 08:25 **Perioperative management of NOACs**  
Alexander C. Spyropoulos (United States)

## SSC PROGRAM

- 08:25 - 08:45 **START-EVENTS SSC register**  
Walter Ageno (Italy)
- 08:45 - 09:05 **Pregnancy outcomes in patients who become pregnant while on NOACs**  
Saskia Middeldorp (The Netherlands)

### UPDATE ON CURRENT SSC PROJECTS: STANDARDIZATION

*Moderators: Henry G. Watson (United Kingdom), Pieter W. Kamphuisen (The Netherlands)*

- 09:05 - 09:25 **Non-major bleeding**  
Scott Kaatz (United States)
- 09:25 - 09:45 **Clinical outcome for patients treated for a major oral anticoagulant-related bleed**  
Nakisa Khorsand (The Netherlands)
- 09:45 - 10:05 **Nomenclature of the novel oral anticoagulants**  
Geoffrey Barnes (United States)
- 10:05 - 10:15 **Progress report on replacement of international standards for thromboplastin**  
Anton van den Besselaar (The Netherlands), Veena Chantarangkul (Italy), Armando Tripodi (Italy)

### COFFEE BREAK

### EDUCATION SESSION: THE CONTRIBUTION OF PROF. MM SAMAMA TO CONTROL OF ANTICOAGULATION

*Moderators: Marc C. Samama (France), Jacqueline Conard (France)*

- 10:30 - 11:00 **Clinical: Risk assessment models, VTE prophylaxis, thrombophilia**  
Jacqueline Conard (France)
- 11:00 - 11:30 **Biological: Pharmacology analysis, mechanisms of action of antithrombotics, global assays**  
Grigoris Gerotziafas (France)

### A LOOK INTO FUTURE INITIATIVES OF THE SSC ON CONTROL OF ANTICOAGULATION

*Moderators: Mark Crowther (Canada), Elaine Hylek (United States)*

- 11:30 - 11:55 **Update on the clinical experience of the direct oral anticoagulants in real life. What have we learned and what can we learn from registries?**  
Jan Beyer (Germany)
- 11:55 - 12:20 **The "white book": Proposal for a position paper on the role of the laboratory with the direct oral anticoagulants**  
Ismail Elalamy (France)

## SSC PROGRAM

### Bleeding Assessment Tool (BAT) Standing Committee

Room 707

- Chairman: Francesco Rodeghiero (Italy)
- Secretary: Alberto Tosetto (Italy)
- 10:30 - 10:35 **Introduction**  
Francesco Rodeghiero (Italy)

### REPORT OF NEW AND ONGOING STUDIES

*Moderator: Barry Coller (United States)*

- 10:35 - 10:45 **Bleeding phenotype in children with moderate/severe VWD**  
Yvonne Sanders (The Netherlands), Frank Leebeek (The Netherlands)
- 10:45 - 10:55 **The Vienna Bleeding Biobank**  
Johanna Gebhart (Austria)
- 10:55 - 11:05 **The REBEL Study**  
Alberto Tosetto (Italy)

### FUTURE DEVELOPMENTS IN BLEEDING ASSESSMENT TOOLS

*Moderator: Francesco Rodeghiero (Italy)*

- 11:05 - 11:20 **Integrating genotypic and phenotypic data: the perspective of the Subcommittee on Genomics in Thrombosis and Hemostasis**  
Willem H. Ouwehand (United Kingdom)
- 11:20 - 11:30 **Update on BAT and beyond**  
Francesco Rodeghiero (Italy)

### RTW and Young Investigator Networking Reception

This will take place on **Sunday, June 21, from 12:00 – 13:00** in room 713 at the Metro Toronto Convention Center

If you have been awarded a RtW or Young Investigator Grant from the 2015 ISTH congress we cordially invite you to attend RtW and Young Investigator Networking Reception.

### WFH/RTW symposia:

This will take place on **Sunday, June 21 from 13:00 – 15:00** in room 715 of the Metro Toronto Convention Center.

#### Building Capacity and Empowering Future Leaders: Lessons from the ISTH and WFH Fellowship Programs

This session will focus on the ISTH Reach the World (RtW) fellowship program and the World Federation of Hemophilia (WFH) International Hemophilia Training Center (IHTC) fellowship program. The event will discuss the need for capacity building programs in hemophilia, hematology and thrombosis. Past fellows and mentors will share experiences and stories from both programs. Future applicants will be able to ask questions and connect with leaders in both programs.

## SSC PROGRAM

### World Thrombosis Day: From Global Conversation to Global Catalyst

Sunday, June 21  
13:00 – 15:00

Now in its second year, World Thrombosis Day (WTD) launched on October 13, 2014, with an important message of awareness and action on a major contributor to the global burden of disease – thrombosis. With one in four people worldwide dying from causes related to thrombosis, the International Society on Thrombosis and Haemostasis (ISTH) launched WTD to help reduce death and disability due to venous thromboembolism (VTE). Highlighting the campaign's traction in its first year and focused on hospital-associated VTE in year two, this session will include members of the WTD Steering Committee, including Chairman Dr. Gary Raskob, representatives from some of the more than 200 partner organizations and comments and support from the WTD Sponsors. In addition to stories from the first day, attendees will be invited to participate going forward as we continue our work to build awareness of potentially deadly blood clots through educational activities, media outreach and communication with the public and health care professionals around the world.

### Special Industry Symposia

15:30 - 17:30

Special Industry Symposia Programs are available in the Show Guide. Please consult the different options to attend the symposium of your choice.

### Opening Ceremony

### Welcome Reception

## Master Classes and Career Mentorship Sessions

---



**ISTH**  
2015 Congress  
TORONTO JUNE 20-25

---

Reaching for Unprecedented Peaks

## MASTER CLASSES

The Master Class sessions are a recently introduced educational feature for the ISTH Congress. Young Investigators and Reach-the-World participants are specifically invited for one-hour sessions with a senior, well-known and established investigator. In small groups (20-25 per class), the session leader will give a short introduction (5-10 minutes), after which there will be an interactive exchange of questions and a discussion, which will last for 50 minutes in total. Attendance had to be pre-booked. Master Classes are held daily between 7:00 and 07:50 am from Sunday, June 21 to Wednesday, June 24. Continental breakfast will be provided during these early morning sessions.

Rooms for the Master Classes are located at the Intercontinental Hotel, which is connected to the Metro Toronto Convention Centre. You can find the room names on the vouchers you will receive as part of your registration pack.

The following Master Classes have been organized:

### Sunday, June 21, 2015 07:00-07:50

<b>Room Grenadier: Cathy Hayward (Canada)</b>	Platelet function testing and diagnosis of platelet function disorders
<b>Room High Park: Susan Kahn (Canada)</b>	Post-thrombotic syndrome
<b>Room Wellington: Agnes Lee (Canada)</b>	Cancer and thrombosis: Prevention and treatment – where do the new direct acting anticoagulants fit in?
<b>Room Haliburton: Jeff Weitz (Canada)</b>	Mechanisms of clotting on blood-contacting medical devices
<b>Room Oakville: Donnie Arnold (Canada)</b>	ITP: clinical aspects and laboratory testing
<b>Room Wentworth: Margaret Rand (Canada)</b>	The procoagulant platelet
<b>Room Halton: Steve Watson (United Kingdom)</b>	Platelet signaling
<b>Room Humber: Manuel Carcao (Canada)</b>	Hemophilia (adults, pediatric): prophylaxis, treatment (including use and monitoring of long-acting formulations), and inhibitors
<b>Room Caledon: Barbara Konkle (United States)</b>	Laboratory investigations for bleeding disorders
<b>Room Kingsway: Phil Wells (Canada)</b>	How to get your paper published

### Monday, June 22, 2015 07:00-07:50

<b>Room Haliburton: Walter Ageno (Italy)</b>	Treatment of thrombosis in unusual sites
<b>Room High Park: James Douketis (Canada)</b>	Practical issues of antithrombotic therapy: bleeding and reversal, perioperative management and drug interactions
<b>Room Humber: Alex Spyropoulos (United States)</b>	Perioperative anticoagulant management
<b>Room Oakville: Paul Cubes (Canada)</b>	NETs
<b>Room Wentworth: Shirley Uitte de Willige (The Netherlands)</b>	Maintaining vascular flow: from liquid to solid to liquid again: the dynamics of clot formation and lysis
<b>Room Grenadier: Sara Israels (Canada)</b>	Platelet disorders in children and newborns
<b>Room Kingsway: Bernhard Nieswandt (Germany)</b>	Targeting platelet receptors by antibodies
<b>Room Halton: Flora Peyvandi (Italy)</b>	Rare bleeding disorders
<b>Room Caledon: Thomas Ortel (United States)</b>	Tests of global hemostasis: What do they mean and why would we use them?
<b>Room Humber: Harry Büller (The Netherlands)</b>	Tips for preparing successful grant applications

## MASTER CLASSES

### Tuesday, June 23, 2015 07:00-07:50

<b>Room Haliburton: Shannon Bates (Canada)</b>	Assisted reproduction, pregnancy, and thrombosis
<b>Room Wellington: John Eikelboom (Canada)</b>	Atrial fibrillation: anticoagulant choice and monitoring
<b>Room High Park: Anthony Chan (Canada)</b>	Management issues in pediatric thrombosis
<b>Room Halton: Ed Pryzdial (Canada)</b>	Links between viruses and heart disease
<b>Room Kingsway: Sara Vesely (United States)</b>	TTP with an emphasis on registries
<b>Room Caledon: Patrick Provost (Canada)</b>	Platelet microRNAs
<b>Room Oakville: David Lillicrap (Canada)</b>	VWD - biology, diagnosis, therapy
<b>Room Humber: Ken Bauer (United States)</b>	Coagulation system: mechanisms and big unanswered questions
<b>Room Grenadier: Mitchell Cohen (United States)</b>	Trauma-induced coagulopathy
<b>Room Wentworth: Fred Spencer (Canada)</b>	Understanding and using guidelines to care for your patients

### Wednesday, June 24, 2015 07:00-07:50

<b>Room Oakville: Mark Crowther (Canada)</b>	Antiphospholipid antibodies: testing, treatment, prognosis
<b>Room High Park: Martin O'Donnell (Ireland)</b>	Antithrombotic and antiplatelet therapy in the elderly
<b>Room Caledon: Rita Selby (Canada)</b>	Laboratory measurements and the direct oral anticoagulants
<b>Room Wellington: Charles "Chuck" Esmon (United States)</b>	The ups and downs of thrombin generation
<b>Room Halton: Ted Warkentin (Canada)</b>	HIT: clinical and laboratory testing pitfalls
<b>Room Haliburton: Eric Boilard (Canada)</b>	Platelet microparticles
<b>Room Wentworth: Heyu Ni (Canada)</b>	Platelet integrins and their ligands in thrombosis and hemostasis
<b>Room Kingsway: Lawrence Brass (United States)</b>	Platelet thrombus formation
<b>Room Humber: Paula James (Canada)</b>	Bleeding scores
<b>Room Grenadier: Ed Conway (Canada)</b>	Coagulation and the complement system

## CAREER MENTORSHIP SESSIONS

These sessions are a novelty for the ISTH congress. The intention is to provide mentorship in a truly interactive session, which therefore will be limited to 10 participants. The Career Mentorship Sessions are dedicated to the young investigators and recipients of the Reach The World awards. There are a total of 16 sessions and thus maximum 160 attendees, which is less than the total number of eligible attendees at the congress. Therefore, participation is strictly limited to one session per attendee. There are different themes aiming at 3 target groups – basic scientists, clinical investigators, and clinician educators. We have also endeavoured to provide female and male mentors within each subset.

Attendance had to be pre-booked. Career Mentorship Sessions are held daily between 12:00 and 13:00 from Sunday, June 21 to Wednesday, June 24. A lunch will be provided during these sessions.

Rooms for the Career Mentorship Sessions are located at the Intercontinental Hotel, main floor, which is connected to the Metro Toronto Convention Centre. You can find the room names on the vouchers you will receive as part of your registration pack.

The following Career Mentorship Sessions have been organized:

### Sunday, June 21, 2015 12:00-13:00

Room Humber: Agnes Lee (Canada)	Clinical Investigators
Room Halton: Nigel Mackman (United States)	Basic Scientists
Room Wellington: Paula James (Canada)	Clinical Investigators
Room Haliburton: Walter Kahr (Canada)	Basic Scientists

### Monday, June 22, 2015 12:00-13:00

Room Humber: Elaine Hylek (United States)	Clinical Investigators
Room Halton: Marcel Levi (The Netherlands)	Clinician Educators
Room Wellington: Donnie Arnold (Canada)	Clinical Investigators
Room Haliburton:	
Charles "Chuck" Esmon (United States)	Basic Scientists

### Tuesday, June 23, 2015 12:00-13:00

Room Humber: Phil Wells (Canada)	Clinical Investigators
Room Halton:	
Saskia Middeldorp (The Netherlands)	Clinical Investigators
Room Wellington: Cathy Hayward (Canada)	Basic Scientists
Room Haliburton: Shannon Bates (Canada)	Clinician Educators

### Wednesday, June 24, 2015 12:00-13:00

Room Humber: Susan Kahn (Canada)	Clinical Investigators
Room Halton: Margaret Rand (Canada)	Basic Scientists
Room Wellington: Jeff Weitz (Canada)	Basic Scientists

## Nurses Forum

---

**Isth**  
2015 Congress  
TORONTO JUNE 20-25

---

Reaching for Unprecedented Peaks

# NURSES FORUM

Sunday, June 21, 2015 9:00-13:20

Nurses Forum

Room 803 A & B

The Nurses' Forum takes place Sunday and Monday, June 21-22, 2015, during the Congress. On the morning of Monday, June 22, a scientific session with oral presentation of peer-reviewed abstracts will be held. Nurses and allied health professionals that have ongoing projects, or who can perform and complete a study by the end of 2014, have been encouraged to strongly consider submitting their results as an abstract to the ISTH Congress.

*Moderator: Maura Malone (United States)*

09:00-09:15 **Welcome and overview of Nursing Forum**  
Maura Malone (United States)

## Host nurses' perspective on managing patient populations with thrombotic and haemostatic disorders

*Moderator: Maura Malone (United States)*

09:15 - 09:30 **Thrombosis management in Canada**  
Laurie Sardo (Canada)

09:30 - 09:45 **The Structure of Hemophilia Care and HTC in Canada**  
Rebecca Goldsmith (Canada)

09:45-11:00 **Selected oral communications and posters**

*Moderator: Ann O'Sullivan (Ireland)*

09:45 - 10:00 **How participating in a clinical trial has had a far reaching effect-A case study**  
Claire McGregor (Australia)

10:00 - 10:15 **Barriers to inform hemophilic carriers of the possibility in Japan**  
Tomie Fujii (Japan)

10:15 - 10:30 **Review of HTC needs assessment**  
Ann Forsberg (United States)

10:30 - 10:45 **Hemophilia and aging: Promoting healthy aging through proactive engagement with general practitioners**  
Olivia Hollingdrake (Australia)

10:45 - 11:00 **Review of research on hematuria disorders**  
Greta Mulders (The Netherlands)

11:00 - 11:20 **Coffee Break**

11:20 - 12:30 **Innovation in nursing practice**

11:20 - 11:40 **Epidemiology of asymptomatic thrombosis and PTS following the use of central lines**  
Fiona Newall (Australia)

# NURSES FORUM

12:00 - 12:20 **Cardiology thrombosis project collaboration between 2 services and nurse practitioners**  
Marilyn Blumenstein (United States)

12:20 - 12:30 **Questions and Answers**

12:30 - 13:30 **LUNCH**

Concurrent Sessions 13:30 - 15:15

Room 803 A & B

## EDUCATION, ADHERENCE, QOL

*Moderators: Marilyn Blumenstein (United States), Erica Crilly (Canada)*

13:30-13:45 **Thrombosis and anticoagulation program; Home INR monitoring and neonatal prophylactic enoxaparin dosing**  
Kathy Harney (United States)

13:45-14:00 **Adherence with DOACs - Application to clinical practice**  
Bunis Packham (United Kingdom)

14:00-14:15 **Thrombosis and Cancer ; Education and QOL considerations**  
Annie Young (United Kingdom)

14:15-14:35 **Carrier Testing, genetics, education, ethics, age, etc**  
Robyn Shoemark, (Australia)

14:35-14:50 **National Patient Needs Assessment**  
Regina Butler (United States)

14:50-15:05 **Mild hemophilia A: a manageable condition?**  
Daryl Pollock (New Zealand)

15:05-15:15 **Questions and Answer Period**

## Literature Review Workshop – preregistration required (Room 709)

*Facilitator: Fiona Newall (Australia)*

13:30 - 15:15 This interactive workshop aims to confirm the processes supporting development of a collaborative literature review suitable for publication on behalf of the ISTH Nursing Forum.

### The specific objectives of this session are:

- Workshop attendees will be provided with a brief education session regarding the process of preparing a Literature Review for publication in a peer reviewed journal
- Identification of topics for literature review (1 hemophilia and 1 thrombosis)
- Authorship panel will be decided and confirmed during the workshop
- Each working group will brainstorm key words, appropriate limits of the literature search, and a possible structure

15:15 - 15:30 **Break**

## NURSES FORUM

Challenges in delivering care in resource-limited countries

15:30 – 16:00

Moderators: *Caroline Baglin (United Kingdom), Regina Butler (United States)*

- 15:30 – 15:45 **Serbia: Inhibitors and CVL - lessons learned**  
Ljiljana Rakic (Serbia)
- 15:45 – 16:00 **Thrombosis - barriers to care**  
Elizabeth Dotse (Ghana)
- 16:00 – 18:00 **Nurses' Network Reception** Location TBD

Monday, June 22, 2015 08:00-16:30

Nursing and Allied Health Professionals' Research Session 09:00 – 12:00 Room 803 A&B

Peer-reviewed abstracts from Nurses and Allied Health Professionals

Nurses and Allied Health Session - Bleeding

08:00 – 09:15

Moderators: *Laurie Sardo (Canada), Jim Munn (United States)*

- NUR001**  
08:00 – 08:15 **WHEN 2N VWD SHOULD BE CONSIDERED A DIFFERENTIAL DIAGNOSIS**  
Claire Mcgregor, Natalie Gamble-Williams (Australia)
- NUR002**  
08:15 – 08:30 **THE DDAPV CHALLENGE – AN AUDIT TO ASSESS PRACTICE IN A UK HAEMOPHILIA CENTRE**  
D W George, James Uprichard, Anne Wareing (United Kingdom)
- NUR003**  
08:30 – 08:45 **CLOSING THE GAP: A MULTIDISCIPLINARY APPROACH DEVELOPING LOCAL SERVICES FOR RURAL AND REMOTE PATIENTS WITH BLEEDING DISORDERS.**  
James Slade (Australia)
- NUR004**  
08:45 – 09:00 **NON-ADHERENCE TO PROPHYLAXIS IN HAEMOPHILIA: EXTENT AND UNDERLYING REASON**  
Marlies Schrijvers, Marlene Beijlevelt - van der Zande, Marjolein Peters, Janske Lock, Marjon Cnossen, Marieke Schuurmans, Kathelijn Fischer (The Netherlands)
- NUR005**  
09:00 – 09:15 **EXPANDING THE KNOWLEDGE BASE: OPPORTUNITIES AND CHALLENGES FOR ALLIED PROFESSIONALS IN BLEEDING DISORDER RESEARCH IN CANADA**  
Neale Smith, Claude Bartholomew (Canada)

COFFEE BREAK

## NURSES FORUM

Nurses and Allied Health Session – Thrombosis and Anticoagulation

09:45 – 12:00

Moderators: *Jennifer Lowerison (Canada), Michelle Zondag (Canada)*

- NUR006**  
09:45 – 10:00 **DEVELOPING A NURSE LED ULTRASOUND SCANNING SERVICE TO CONFIRM OR EXCLUDE THE DIAGNOSIS OF LOWER LIMB DEEP VEIN THROMBOSIS - IMPROVING PATIENT CARE AND REDUCING THE RISK OF UNECESSARY ANTICOAGULANTS IN A UNITED KINGDOM PRIMARY CARE SETTING.**  
Jo Boyd (United Kingdom)
- NUR007**  
10:00 – 10:15 **OVERWEIGHT IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY DESPITE RIVAROXABAN THROMBOPROPHYLAXIS**  
Christine Cockhill, Owais Mian, MaryAnne Rizzo, Deborah Siegal, Howard Chan, Ellen McDonald (Canada)
- NUR008**  
10:15 – 10:30 **MANAGING ANTICOAGULATION THERAPY RISK THROUGH THE MULTIDISCIPLINARY TEAM (MDT) WARD ROUND AT KING'S COLLEGE HOSPITAL**  
Jignesh Patel, Lara Roberts, Emma Gee, Rosalind Byrne, Julia Czuprynska, Kwesi Kittoo, Alison Brown, Raj Patel, Lynda Bonner, Roopen Arya (United Kingdom)
- NUR009**  
10:30 – 10:45 **SAFE DISCHARGE PLANNING FOR PATIENTS ON ANTICOAGULANTS: LAUNCH OF A NEW QUALITY IMPROVEMENT TOOL FOR NURSES**  
Suzette Chung, Carla Strulovitch, Jessica Emed, Hetal Patel (Canada)
- NUR010**  
10:45 – 11:00 **DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: INSIGHTS INTO APPROPRIATE PRESCRIBING AND MEDICATION USE**  
Jennifer Delaney, Sam Schulman, Mary Salib, Mohamed Panju, Menaka Pai (Canada)
- NUR011**  
11:00 – 11:15 **NOVEL ORAL ANTICOAGULANT CHECKLISTS FOR FRONT LINE CLINICIANS**  
Jennifer Lowerison, Jennifer Bolt, Tammy Bungard, Darcy Lamb (Canada)
- NUR012**  
11:15 – 11:30 **A CROSS-SECTIONAL REGISTRY ON THE INCIDENCE OF GASTROINTESTINAL ASSOCIATED SYMPTOMS WITH PRADAXA USE (GASP REGISTRY)**  
Michelle M. Zondag, Laurie Sardo, Sam Schulman (Canada)
- NUR013**  
11:30 – 11:45 **ASSESSING ORAL ANTICOAGULANT USE IN LONG-TERM CARE RESIDENTS: EVIDENCE FOR ONGOING SUBOPTIMAL USE IN 2014**  
Carlos Rojas-Fernandez, Aein Zarrin, Melissa Warkentin, Jennifer Bonneau, Jennifer Hartwick, Susan Brown (Canada)
- NUR014**  
11:45 – 12:00 **"POST-THROMBOTIC PANIC": PANIC, POSITIVE OUTCOMES AND THE PARADOXICAL IMPACT OF VENOUS THROMBOEMBOLISM (VTE)**  
Rachael Hunter, Paul Bennett, Sarah Lewis, Jaynie Rance, Simon Noble (United Kingdom)
- 12:00-13:45 **LUNCH and Poster viewing**
- 12:15-13:45 **Satellite symposia**

## NURSES FORUM

### Practice guidelines for optimal health: Section 1

14:00 – 14:45

*Moderators: Caroline Baglin (United Kingdom), Maura Malone (United States)*

- 14:00– 14:15      **Review of VWD guidelines/compare/contrast/diagnostic**  
Vanessa Bouskill (Canada)
- 14:15-14:30      **Anticoagulation management for ventricular assist devices: A review**  
Hollie Gilmore (Australia)
- 14:30-14:45      **Cochrane Report and UKHCDO Guidelines**  
Kate Khair (United Kingdom)
- 14:45 – 15:00      **BREAK**

### Practice guidelines for optimal health: Section 2

15:00 -16:30

*Moderators: Kim Schafer (United States), Bunis Packham (United Kingdom)*

- 15:00 - 15:15      **Impact of footwear on ankle arthropathy in patients with hemophilia**  
Karen Strike (Canada)
- 15:15 - 15:30      **Innovative treatment for managing PTS**  
Charlene Gates, PT ((United States)
- 15:30 - 15:45      **Prophylaxis and impact on pain**  
Anne O'Sullivan (Ireland)
- 15:45 - 16:00      **Compression hosiery and PTS**  
Grace Hughes (United Kingdom)
- 16:00 - 16:15      **First experience with the hemoassist: An electronic substitution diary that works on the basis of a personal digital assistant**  
Manuela Siebert (Germany)
- 16:15 - 16:30      **Questions and Answers. Wrap-up**

## Scientific Program

Monday, June 22

### Trainee Tracks (oral sessions only):

- Platelets track
- Basic thrombosis and hemostasis track
- ✚ Clinical bleeding track
- ▲ Clinical thrombosis track
- ★ Pediatric thrombosis and hemostasis track
- ♥ Cardiovascular and arterial diseases track

An asterisk (\*) after a name denotes the presenting author

**Isth**  
**2015 Congress**  
**TORONTO JUNE 20-25**

Reaching for Unprecedented Peaks



## SCIENTIFIC PROGRAM

Monday, June 22, 2015

ORAL COMMUNICATIONS 1 08:00-09:15

### ● Platelet Disorders

Room 718

Moderators: David Wilcox (United States), Paquita Nurden (France)

- 08:00 – 08:15  
OR001 **JAK2 V617F MUTATION AND CARDIOVASCULAR RISK FACTORS DISCRIMINATE YOUNG PATIENTS WITH HIGH RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA**  
Rongfeng Fu\*, Lei Zhang, Huiyuan Li, Liyan Zhang, Mingen Lv, Yating Hao, Renchi Yang (China)
- 08:15 – 08:30  
OR002 **FIRST REPORT OF A NEW HOMOZYGOUS FLI1 MUTATION UNRAVELED BY INCREASED MYH10 EXPRESSION IN AN INHERITED PLATELET DISORDER**  
Marie-Christine Morel-Kopp\*, David Rabbolini, Sara Gabrielli, Qiang Chen, William Stevenson, Christopher Ward (Australia)
- 08:30 – 08:45  
OR003 **A GAIN-OF-FUNCTION MUTATION IN FILAMIN-A POTENTIATES PLATELET INTEGRIN ALPHA-IIIB/BETA-3 ACTIVATION**  
Eliane Berrou, Frédéric Adam, Virginie Planche, Marilyne Lebre, Patricia Fergelot, Isabelle Couprie, Paquita Nurden, Dominique Bonneau, Estelle Colin, Cyril Goizet, Jean-Philippe Rosa, Marijke Bryckaert\* (France)
- 08:45 – 09:00  
OR004 **HISTONE-ASSOCIATED THROMBOCYTOPENIA: A NEW CAUSE OF THROMBOCYTOPENIA IN CRITICALLY ILL PATIENTS**  
Yasir Alhamdi, Simon Abrams, Ingeborg Welters, Guozheng Wang, Cheng-Hock Toh\* (United Kingdom)
- 09:00 – 09:15  
OR005 **PLATELET MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH SEPSIS OR CARDIOGENIC SHOCK**  
Andrea Artoni\*, Alessandro Protti, Silvia La Marca, Anna Lecchi, Francesco Fortunato, Giacomo Comi, Flora Peyvandi (Italy)

### ♥ Atherosclerosis

Room 701

Moderators: Lina Badimon (Spain), Vi Dong (Canada)

- 08:00 – 08:15  
OR006 **SWAPPING OVER TWO PEPTIDE EPITOPES DERIVED FROM APOB AND C5AR LOCATED AT TERMINUSES OF RECOMBINANT PROTEINS MAINTAINS THE SIMILAR EFFECTIVE REDUCTION ON ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB (TM2SGY)/J MICE**  
Min Xia, Valeria Endresz, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu\* (United Kingdom)
- 08:15 – 08:30  
OR007 **EXAMINING THE HEXOSAMINE BIOSYNTHESIS PATHWAY IN HYPERGLYCEMIA-INDUCED ACCELERATED ATHEROSCLEROSIS.**  
Vi T. Dang\*, Christina Petlura, Daniel Beriault, Yuanyuan Shi, Geoff Werstuck (Canada)

## SCIENTIFIC PROGRAM

- 08:30 – 08:45  
OR008 **TOLERANCE TO MULTIANTIGENIC MOLECULE EXPRESSING PEPTIDES FROM APOB100, HSP60 AND OUTER MEMBRANE PROTEIN OF CHLAMYDIA PNEUMONIA REDUCES MARKERS OF PLAQUE INSTABILITY AND STABILIZES ADVANCED ATHEROSCLEROSIS IN APOBTM2SGY/LDLR(TM1HER/J MICE.**  
Sheena Philip, Thiruvvelselvan Ponnusamy, Lakshmi Narasimha Rao, Rameshkumar Krishnan, Xinjie Lu, Vrushali Deshpande, Vijay Kakkar, Lakshmi Mundkur\* (India)
- 08:45 – 09:00  
OR009 **MODULATION OF CLINICALLY RELEVANT PATHWAYS BY POST TRANSLATION MODIFICATION REGULATORY SYSTEM IN CORONARY ARTERY DISEASE.**  
Rajani Kanth Vangala\*, Ankit Sharma, Madankumar Ghatge (India)
- 09:00 – 09:15  
OR010 **GENE CENTRIC ANALYSIS COMBINED WITH NETWORK ANALYSIS TO IDENTIFY GENES ASSOCIATED WITH CORONARY ARTERY DISEASE**  
Jiny Nair\*, Madan Ghatge, Jayashree Shaker, Vijay Kakkar (India)

### Hemophilia – clinical

Room 801

Moderators: Manuel Carcao (Canada), Peter Collins (United Kingdom)

- 08:00 – 08:15  
OR011 **LEOPOLD TRIAL RESULTS: CORRELATION OF VON WILLEBRAND FACTOR ANTIGEN LEVEL WITH BAY 81-8973 PHARMACOKINETIC PARAMETERS OF PATIENTS WITH SEVERE HEMOPHILIA A**  
Shadan Lalezari, Teruhisa Fujii, YL Kwong, Heinz Delesen, Anita Shah, Claudia Tückmantel, Waander van Heerde\*, Monika Maas Enriquez (Germany)
- 08:15 – 08:30  
OR012 **IN HAEMOPHILIC PATIENTS TFPI LEVELS INFLUENCE THROMBIN GENERATION PROFILE AND TFPI NEUTRALIZATION NORMALIZES THROMBIN GENERATION POTENTIAL**  
Brigitte Tardy\*, Fabienne Volot, Michèle Piot, Céline Chapelle, Hervé Chambost, Anne Lienhart, Fabienne Dutrillaux, Yesim Dargaud, Pierre Morange, Patrick Mismetti, Bernard Tardy (France)
- 08:30 – 08:45  
OR013 **DDAVP IN MODERATE HEMOPHILIA A PATIENTS: A TREATMENT STRATEGY WORTH CONSIDERING**  
Janneke I. Loomans\*, Alice Van Velzen, Marjolein Peters, Marieke Kruij, Simon McRae, Manuel Carcao, Kathelijne Peerlinck, Shannon Jackson, Robert Klamroth, Marten Nijziel, Russell Keenan, Maria Mancuso, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)
- 08:45 – 09:00  
OR014 **THE IMPACT OF PATIENT ADHERENCE ON FVIII LEVELS: A COMPARISON OF RFXVIII AND RFXVIII-FC REGIMENS**  
Josh Epstein, Elizabeth Schwartz\*, Yan Xiong, Armin Reininger, Alessandro Gringeri (United States)
- 09:00 – 09:15  
OR015 **FUNCTIONAL EFFECTS OF F8 MISSENSE MUTATIONS ON DDAVP RESPONSE IN NONSEVERE HEMOPHILIA A BROTHERS**  
Janneke I. Loomans\*, Alice Van Velzen, Michael Tanck, Marjolein Peters, Elena Santagostino, Cristina Santoro, Karina Meijer, Erik Beckers, Savita Rangarajan, Thynn Yee, Pia Petrini, Giancarlo Castaman, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)

MONDAY

ORALS

## SCIENTIFIC PROGRAM

### Anti-platelet agents – basic

Room 714

*Moderators: Joseph Jakubowski (United States), Reheman Adili (Canada)*

- 08:00 – 08:15  
OR016 **TICAGRELOR AND CLOPIDOGREL ATTENUATE THE PROTHROMBOTIC STATE INDUCED BY BACTERIAL ENDOTOXEMIA**  
Mark R. Thomas\*, Ramzi Ajjan, Fladia Phoenix, Samuel Outteridge, Heather Judge, David Dockrell, Ian Sabroe, Robert Storey (United Kingdom)
- 08:15 – 08:30  
OR017 **PLATELET SIGNALING AND ENDOTHELIAL FC GAMMA RECEPTOR IIB ARE BOTH REQUIRED FOR ANTIBODY-INDUCED GLYCOPROTEIN VI ECTODOMAIN SHEDDING IN VIVO**  
David Stegner\*, Michael Popp, Viola Lorenz, Sebastian Dütting, J. Engelbert Gessner, Bernhard Nieswandt (Germany)
- 08:30 – 08:45  
OR018 **SMALL MOLECULE DCDBS84 REGULATES PLATELET THROMBUS FORMATION BY TARGETING C-SRC SH3 DOMAIN**  
Zhangbiao Long, Kongkai Zhu, Jiansong Huang, Xiaofeng Shi, Jingqiu Liu, Jichun Yang, Bing Xiao, Lianchun Li, Hong Ding, Yi Wen, Naixia Zhang, Hualiang Jiang, Zhen Ruan, Cheng Luo, Xiaodong Xi\* (China)
- 08:45 – 09:00  
OR019 **CONGENITAL SEVERE DEFICIENCY OR PHARMACOLOGICAL INHIBITION OF THE PLATELET P2Y12 RECEPTOR FOR ADENOSINE DIPHOSPHATE DOES NOT IMPAIR THE CAPACITY OF PLATELET TO SYNTHESIZE THROMBOXANE A2**  
Mariangela Scavone\*, Eti A. Femia, Vera Caroppo, Marco Cattaneo (Italy)
- 09:00 – 09:15  
OR020 **THE P2Y12 ANTAGONIST ACT-246475 CAUSES LESS BLOOD LOSS THAN TICAGRELOR AT COMPARABLE ANTITHROMBOTIC EFFICACY IN A RAT THROMBOSIS MODEL.**  
Markus Rey, Patrick Hess, Keith Morrison, Edgar Weber, Martine Clozel, Markus Riederer, Beat Steiner\* (Switzerland)

### VWD – classification, subtypes – I

Room 716

*Moderators: Shannon Jackson (Canada), Anne Goodeve (United Kingdom)*

- 08:00 – 08:15  
OR021 **GENOTYPING OF VWD PATIENTS IN THE NETHERLANDS: PHENOTYPE-GENOTYPE DISCREPANCIES AND 27 NOVEL VWF GENE MUTATIONS**  
Johan Boender\*, Yvonne Sanders, Waander van Heerde, Marjon Cnossen, Britta Laros-van Gorkom, Karin Fijnvandraat, Selene Schoormans, Natasja Dors, Johanna van der Bom, Karina Meijer, Evelien Mauser-Bunschoten, Jeroen Eikenboom, Frank Leebeek (The Netherlands)
- 08:15 – 08:30  
OR022 **CASE STUDY OF TWO CONSANGUINEOUS BROTHERS WITH TYPE 3 VON WILLEBRAND DISEASE (VWD), INHIBITORS AND ANAPHYLACTOID REACTION TO VWF**  
Loren Dangelo\*, Craig Platt, A Dioun Broyles, Ellis Neufeld, Stacy Croteau (United States)

## SCIENTIFIC PROGRAM

- 08:30 – 08:45  
OR023 **ABNORMAL ANGIOGENESIS IN TYPE 2A AND 2B VON WILLEBRAND DISEASE (VWD): COMPARATIVE STUDIES OF QUANTITATIVE AND QUALITATIVE VWD USING BLOOD OUTGROWTH ENDOTHELIAL CELLS**  
Lara Casey\*, Mackenzie Bowman, Soundarya Selvam, Paula James (Canada)
- 08:45 – 09:00  
OR024 **TYPE 2N VON WILLEBRAND DISEASE: ONE VARIANT BUT MORE THAN ONE DISEASE**  
Jenny Goudemand, Christophe Zawadzki, Pierre Boisseau, Catherine Ternisien, Claudine Caron, Fabienne Volot, Katia Pouymayou, Brigitte Pan-Petesch, Sabine Castet, Agnès Veyradier, Edith Fressinaud, Sophie Susen\* (France)
- 09:00 – 09:15  
OR025 **HETEROGENEITY OF VON WILLEBRAND DISEASE TYPE 3 IN A FRENCH COHORT OF 75 PATIENTS**  
Pierre Boisseau, Edith Fressinaud, Catherine Ternisien, Claudine Caron, Annie Borel-Derlon, Marc Trossaert, Cecile Lavenu-Blombard, Chantal Rothschild, Stephane Beziau, Sophie Susen, Agnès Veyradier, Jenny Goudemand\* (France)

### Acquired disorders – treatment – I

Room 713

*Moderators: Jean St Louis (Canada), Meera Chitlur (United States)*

- 08:00 – 08:15  
OR026 **ACQUIRED VON WILLEBRAND SYNDROME AND RESPONSE TO DESMOPRESSIN**  
Eugenia Biguzzi\*, Franca Franchi, Simona Siboni, Flora Peyvandi (Italy)
- 08:15 – 08:30  
OR027 **ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN ACQUIRED HEMOPHILIA A: AN ITALIAN REGISTRY-THE F.A.I.R. STUDY**  
Ezio Zanon\*, Marta Milan, Gabriella Gamba, Gaetano Giuffrida, Anna Falanga, Augusto Federici, Isabella Cantori, Sergio Siragusa, Maria Mazzucconi (Italy)
- 08:30 – 08:45  
OR028 **PERIOPERATIVE MANAGEMENT OF BLEEDS WITH RECOMBINANT PORCINE FVIII IN PATIENTS WITH ACQUIRED HEMOPHILIA A**  
Aaron Novack, Jean St-Louis\*, Anne Geist, Amy Shapiro, Hedy Smith, Pratima Chowdary, Anja Drebes, Jay Lozier, Christelle Bourgeois, Min Mo, Heinrich Farin (United States)
- 08:45 – 09:00  
OR029 **REAL WORLD DATA ON TREATMENT WITH FEIBA IN PATIENTS WITH CLOTTING FACTOR INHIBITORS**  
Claude Negrier\*, Sophie Voisin, Fariba Baghaei, Aaron Novack, Jennifer Doralt, Roberto Crea, Alessandro Gringeri (France)
- 09:00 – 09:15  
OR030 **“SHORT-TERM PROPHYLAXIS” REGIMEN WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN THE PREVENTION OF BLEEDING RELAPSE IN ACQUIRED HEMOPHILIA**  
Ezio Zanon\*, Marta Milan, Chiara Ambaglio, Graziella Saggiorato, Nadia Montani, Gabriella Gamba (Italy)

MONDAY

ORALS

## SCIENTIFIC PROGRAM

### ★ Reproductive Issues

Room 715

*Moderators: Margaret Ragni (Canada), Anna Ågren (Sweden)*

- 08:00 – 08:15  
OR031 **PATHOLOGY OF PLACENTA IN FETAL AND NEONATAL IMMUNE THROMBOCYTOPENIA: ROLES OF TH17 IMMUNE RESPONSES, ANTI-PLATELET ANTIBODIES AND ANGIOGENIC FACTORS.**  
Issaka Yougbare\*, Wei-She Tai, Darko Zdravic, Brian Vadasz, Alexandra Marshall, Pingguo Chen, Guangheng Zhu, Howard x Howard Leong-Poi, Dawei Qu, Lisa X. Yu, Lee Adamson, John Sled, John Freedman, Heyu Ni (Canada)
- 08:15 – 08:30  
OR032 **CHARACTERISTICS OF VENOUS THROMBOEMBOLISM IN 3072 FRENCH WOMEN USING COMBINED OR PROGESTIN-ONLY CONTRACEPTION.**  
Justine Hugon-Rodin\*, Marie-Hélène Horellou, Jacqueline Conard, Claire Flaujac, Pierre-Yves Scarabin, Geneviève Plu-Bureau (France)
- 08:30 – 08:45  
OR033 **CHARACTERISING FIBRIN MONOMER COMPLEX AND D-DIMER PROFILES IN PREGNANCY**  
Karin Lautmann\*, Ranjit Akolekar, Roopen Arya (United Kingdom)
- 08:45 – 09:00  
OR034 **PRE-PREGNANCY BMI AND DELIVERY BMI AS RISK FACTORS FOR POSTPARTUM VTE: A POPULATION-BASED, CASE-CONTROL STUDY**  
Marc Blondon\*, Laura Harrington, Françoise Boehlen, Helia Robert-Ebadi, Marc Righini, Nicholas Smith (Switzerland, United States)
- 09:00 – 09:15  
OR035 **HIGHER FREQUENCY OF LEFT-SIDED DEEP VEIN THROMBOSIS IN POSTPARTUM PERIOD**  
Annemarie Venemans-Jellema, Laura Elbers\*, Saskia Middeldorp, Victor Gerdes, Suzanne Cannegieter (The Netherlands)

### Animal models

Room 717

*Moderators: Hartmut Weiler (United States), John Welsh (United States)*

- 08:00 – 08:15  
OR036 **ADVANCED IMAGING TECHNIQUES SHOW PROGRESSIVE ARTHROPATHY FOLLOWING EXPERIMENTALLY INDUCED KNEE BLEEDING IN A FACTOR VIII-/- RAT MODEL**  
Kristine Rothaus Sørensen\*, Kirstine Roepstorff, Maj Petersen, Bo Wiinberg, Axel Hansen, Søren Skov, Lise Nielsen (Denmark)
- 08:15 – 08:30  
OR037 **DEVELOPMENT OF A MOUSE CAROTID ARTERY THROMBOLYSIS MODEL FOR THE EVALUATION OF THERAPEUTIC APPROACHES FOR STROKE**  
Simone M. Schoenwaelder\*, Andre Samson, Sharelle Sturgeon, Jessica Lee, Arnold Ju, Shaun Jackson (Australia)
- 08:30 – 08:45  
OR038 **REAL TIME INTRAVITAL IMAGING OF THROMBUS FORMATION IN THE MOUSE FEMORAL ARTERY REVEALS CRITICAL DIFFERENCES FROM EVENTS IN THE MICROVASCULATURE**  
John Welsh\*, Timothy Stalker, Scott Diamond, Lawrence Brass (United States)
- 08:45 – 09:00  
OR039 **GENOME EDITING OF FACTOR X IN ZEBRAFISH REVEALS UNEXPECTED EARLY SURVIVAL AND LATE ONSET HEMORRHAGE**  
Zhilian Hu, Michael Huarng, Marzia Menegatti, Deepak Reyon, Yang Liu, Catherine Richter, J. Keith Joung, Flora Peyvandi, Jordan Shavit\* (United States)

## SCIENTIFIC PROGRAM

09:00 – 09:15  
OR040

**ANTIBODY RESPONSE TO HUMAN RECOMBINANT FACTOR VIII IN A NEW RAT MODEL OF HEMOPHILIA A**

Karin M. Lövgren\*, Henrik Soendergaard, Søren Skov, Karin Weldingh, Bo Wiinberg (Denmark)

### ■ Endothelium and vessel wall

Room 705

*Moderators: Cormack McDonnell (Ireland), David Lane (United Kingdom)*

- 08:00 – 08:15  
OR041 **AUTOPHAGY REGULATES THROMBUS FORMATION IN MICE**  
Jonathan W.-H. Yau\*, Yan Hou, Xi Lei, Krishna Singh, Subodh Verma (Canada)
- 08:15 – 08:30  
OR042 **PLATELET ACTIVATION AND PLATELET-ENDOTHELIAL INTERACTIONS IN THE SIV-INFECTED PIGTAIL MACAQUE MODEL OF HIV-ASSOCIATED CNS DISEASE**  
Claire Lyons, Hannah Schneider, Elizabeth Engle, Kevin Najarro, Suzanne Queen, Craig Morrell, Joseph Mankowski, Kelly Metcalf Pate\* (United States)
- 08:30 – 08:45  
OR043 **VASCULAR ENDOTHELIUM DYSREGULATION FOLLOWING STAPHYLOCOCCUS AUREUS INFECTION : NEW INSIGHTS FOR SEPSIS**  
Cormac McDonnell\*, Elena Bojenov, Alisha McLoughlin, Phil Cummins, Steve Kerrigan (Ireland)
- 08:45 – 09:00  
OR044 **ENDOTHELIAL BAMBI (BMP AND ACTIVIN MEMBRANE BOUND INHIBITOR) IS IMPORTANT FOR FIBRIN GENERATION AND THROMBUS STABILITY**  
Isabelle Salles-Crawley\*, James Monkman, David Lane, James Crawley (United Kingdom)
- 09:00 – 09:15  
OR045 **VALIDATING A 3D TISSUE-ENGINEERED HUMAN BLOOD VESSEL MODEL FOR USE AS A NOVEL MODEL SYSTEM FOR THE ASSESSMENT OF THROMBUS FORMATION**  
F I. Musa\*, Alan Harper, Ying Yang (United Kingdom)

### Tissue factor – factor VII – I

Room 707

*Moderators: Tara Bracken (United States), Wolfram Ruf (United States)*

- 08:00 – 08:15  
OR046 **CROSS-TALK BETWEEN TISSUE FACTOR AND EPHA2 IN CANCER: POTENTIATION OF LIGAND-DEPENDENT EPHA2-SIGNALING IN VITRO AND CO-EXPRESSION IN HUMAN COLORECTAL CANCER SPECIMENS**  
Oskar Eriksson, Åsa Thulin\*, Anna Asplund, Geeta Hedge, Sanjay Navani, Agneta Siegbahn (Sweden)
- 08:15 – 08:30  
OR047 **ANTIBODY-BASED TARGETING OF ALTERNATIVELY SPLICED TISSUE FACTOR IMPEDES THE GROWTH AND AGGRESSIVENESS OF PANCREATIC DUCTAL ADENOCARCINOMA**  
Dusten Unruh, Xiaoyang Qi, Zhengtao Chu, Robert Sturm, Ryan Keil, Syed Ahmad, Timofey Sovershaev, Mariette Adam, Patrick Van Dreden, Barry Woodhams, Janusz Rak, Nigel Mackman, Henri Versteeg, Vladimir Bogdanov\* (United States)
- 08:30 – 08:45  
OR048 **TISSUE FACTOR INHIBITION ATTENUATES NEURONAL DAMAGE AND BEHAVIORAL DEFICIT IN A MOUSE MODEL OF ISCHEMIC STROKE**  
Shaobin Wang, Brandi Reeves, Daniel Kirchofer, Rafal Pawlinski\* (United States)

MONDAY

ORALS

## SCIENTIFIC PROGRAM

- 08:45 – 09:00  
OR049 **LOW FACTOR VII LEVELS FAIL TO REDUCE VASCULAR GRAFT THROMBUS PROPAGATION IN A BABOON MODEL**  
Michael Wallisch\*, Jeffrey Crosby, Jennifer Greisel, Sue Murray, Erik Tucker, Owen McCarty, Monica Hinds, Brett Monia, András Gruber (United States)
- 09:00 – 09:15  
OR050 **GENETIC DETERMINANTS OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX PLASMA CONCENTRATION INCLUDE TISSUE FACTOR, FACTOR VII AND ENDOTHELIAL PROTEIN C RECEPTOR GENE VARIANTS.**  
Filippo Sartori\*, Barbara Lunghi, Federica Tosi, Patrizia Guarini, Daniela Scalet, Marcello Baroni, Giovanna Marchetti, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, Francesco Bernardi, Nicola Martinelli (Italy)

### Heparin-induced thrombocytopenia

Room 709

Moderators: *Lori Linkins (Canada), Yves Gruel (France)*

- 08:00 – 08:15  
OR051 **DYNAMIC MECHANICAL THROMBOPROPHYLAXIS IS A MAJOR HEPARIN-INDEPENDENT RISK FACTOR FOR THE FORMATION OF ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODIES IN PATIENTS UNDERGOING TOTAL KNEE OR HIP ARTHROPLASTY**  
Shigeki Miyata\*, Seiji Bito, Kiyoshi Migita, Mashio Nakamura, Kazuhito Shinohara, Tomotaro Sato, Takeharu Tonai, Motoyuki Shimizu, Yasuhiro Shibata, Kazuhiko Kishi, Chikara Kubota, Shinnosuke Nakahara, Toshihito Mori, Kazuo Ikeda, Shusuke Ota, Takeshi Minamizaki, Shigeru Yamada, Naofumi Shiota, Masataka Kamei, Satoru Motokawa (Japan)
- 08:15 – 08:30  
OR052 **IS THE INCIDENCE TREND OF HEPARIN-INDUCED THROMBOCYTOPENIA DECREASED BY THE INCREASED USE OF LOW-MOLECULAR-WEIGHT-HEPARIN?**  
Fahad Aleidan\* (Saudi Arabia)
- 08:30 – 08:45  
OR053 **THE IMPACT OF OPTICAL DENSITY CUT-OFF ON SENSITIVITY AND SPECIFICITY FOR THE DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Lisa D. Duffett\*, Marc Carrier, Grégoire Le Gal, Marc Rodger, Esteban Gándara (Canada)
- 08:45 – 09:00  
OR054 **HIT OR PIT- CLINICAL RELEVANCE OF THE ZYMUTEST HIA IGG (HYPHEN BIOMED) IN A ROUTINE LABORATORY SETTING**  
Andreas Czwalińska, Bärbel Steggewentz, Burghard Arndt, Arndt Gröning, Frauke Bergmann\* (Germany)
- 09:00 – 09:15  
OR055 **EVALUATION OF FLOW CYTOMETRIC ASSAY IN THE DIAGNOSIS OF HIT**  
Brigitte Tardy\*, Aurélie Montmartin, Michele Piot, Céline Chapelle, Madjid Akrou, Martine Alhenc-Gelas, Emmanuel De Maistre, Ismaïl Elalamy, Pierre Fontana, Andreas Greinacher, Marie-Hélène Horellou, Dominique Lasne, Thomas Lecompte, Gregoire Legal, Agnes Lillo-LeLouet, François Mullier, Philippe Nguyen, Claire Pouplard, Marie Toussaint-Hacquard, Aaron Tomer, Bernard Tardy (France)

## SCIENTIFIC PROGRAM

### Mechanical circulatory support and devices

Room 711

Moderators: *Michelle K. Brenner (United States), Paul Dobesh (United States)*

- 08:00 – 08:15  
OR056 **ACQUIRED VON WILLEBRAND SYNDROME IS A COMMON AND PROGRESSIVE CONDITION AMONG PEDIATRIC ECMO PATIENTS**  
Shiu-Ki R. Hui\*, Gregory Pelkey, Vadim Kostousov, Trung Nguyen, Laura Loftis, James Thomas, Jun Teruya (United States)
- 08:15 – 08:30  
OR057 **COMPARISON OF THE EFFECT OF DABIGATRAN AND WARFARIN ON MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION**  
Iqbal Jaffer\*, Alan Stafford, Jim Fredenburgh, Richard Whitlock, Jeffrey Weitz (Canada)
- 08:30 – 08:45  
OR058 **ASSESSMENT OF PLATELET FUNCTION AND HEMOSTASIS IN NEONATES UNDERGOING CARDIOPULMONARY BYPASS**  
Michelle K. Brenner\*, Rachel Bercovitz, Regina Cole, Robert Niebler, Jake Scott, Eckehard Stuth, Michael Mitchell, James Tweddell, Ronald Woods, D. Woodrow Benson, Debra Newman (United States)
- 08:45 – 09:00  
OR059 **USE OF FIBINOLYTIC THERAPY IN TREATMENT OF VENTRICULAR ASSIST DEVICE THROMBOSIS**  
Paul Dobesh\*, Brian Trevarrow, Sara Varnado, Ashley Schenk, Eric Rome (United States)
- 09:00 – 09:15  
OR060 **APPLICATION OF A MICROFLUIDIC FLOW-BASED THROMBOSIS ASSAY FOR POST-OPERATIVE PEDIATRIC CARDIOVASCULAR SURGERY PATIENTS**  
Nabil Othman\*, Xiufeng Gao, Henry Walters, Patrick Hines (United States)

### ▲ Late breaking abstract session - Thrombosis and Anticoagulation

Plenary Hall F&G

Moderators: *Charles Francis (United States), Frits Rosendaal (The Netherlands)*

- 08:00 – 08:15  
LB001 **SCREENING FOR OCCULT MALIGNANCY IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM: AN OPEN RANDOMIZED CONTROLLED TRIAL USING A COMPREHENSIVE ABDOMEN/PELVIS COMPUTED TOMOGRAPHY (SOME TRIAL).**  
Marc Carrier\*, Alejandro Lazo-Langner, Sudeep Shivakumar, Vicky Tagalakakis, Ryan Zarychanski, Susan Solymoss, Nathalie Routhier, James Douketis, Kim Danovitch, Agnes Lee, Gregoire Le Gal, Phil Wells, Tim Ramsay, Doug Coyle, Isabelle Chagnon, Zahra Kassam, Donald Taves, Marc Rodger, Hardy Tao (Canada)
- 08:15 – 08:30  
LB002 **BRIDGING ANTICOAGULATION IN PATIENTS WHO REQUIRE TEMPORARY INTERRUPTION OF WARFARIN THERAPY FOR AN ELECTIVE INVASIVE PROCEDURE OR SURGERY (THE BRIDGE TRIAL)**  
James Douketis, Alex Spyropoulos, Scott Kaatz, Joseph Caprini, Andrew Dunn, David Garcia, Alan Jacobson, Amir Jaffer, Andrei Kindzelski, Sam Schulman, Alexander Turpie, Richard Becker, Nathan Clark, Barbara Conti, Stacey Ellsworth, Robert Harrison, David Kong, Gerhard Johnson, Arun Krishnamoorthy, Sebastian Palmeri, Wanda Parker, Jorge Saucedo, Patricia Schoch, Debbie Tallman, Dan Witt, Vic Hasselblad, Thomas L. Ortel\* (United States)

MONDAY

ORALS

## SCIENTIFIC PROGRAM

- 08:30 – 08:45  
LB003  
**RAPS (RIVAROXABAN IN ANTIPHOSPHOLIPID SYNDROME): A PROSPECTIVE RANDOMISED CONTROLLED PHASE II/III CLINICAL TRIAL OF RIVAROXABAN VERSUS WARFARIN IN PATIENTS WITH THROMBOTIC ANTIPHOSPHOLIPID SYNDROME, WITH OR WITHOUT SLE**  
Hannah Cohen\*, Beverley Hunt, Maria Efythymiou, Deepa Arachchilage, Maria Ruiz, Simon Clawson, Nicola Muirhead, Yvonne Sylvestre, Samuel Machin, Maria Bertolaccini, Caroline Dore, Ian Mackie, David Isenberg, Munther Khamashta (United Kingdom)
- 08:45 – 09:00  
LB004  
**ANNEXA™-A PART 2: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL DEMONSTRATING SUSTAINED REVERSAL OF APIXABAN-INDUCED ANTICOAGULATION IN OLDER SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE FOR FACTOR XA (FXA) INHIBITORS**  
Mark Crowther\*, Alex Gold, Genmin Lu, Janet Leeds, Brian Wiens, Vandana Mathur, Janice Castillo, Pamela Conley, Stuart Connolly, John Curnutte (Canada)
- 09:00 – 09:15  
LB005  
**INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS**  
Charles Pollack\*, Paul Reilly, Peter Verhamme, Richard Bernstein, Robert Dubiel, John Eikelboom, Menno Huisman, Elaine Hylek, Chak-Wah Kam, Pieter Kamphuisen, Joerg Kreuzer, Jerrold Levy, Frank Sellke, Thorsten Steiner, Bushi Wang, Jeffrey Weitz (United States)

Coffee break time in the exhibition (Level 800)  
From 09:15 to 09:45

Monday, June 22, 2015

PLENARY SESSION 09:45-10:30

Frank Schofield Plenary Lecture

Hall F&G

Moderator: Jeffrey Weitz (Canada)

- 09:45 - 10:30  
**75 years of progress in antithrombotic therapy for cardiovascular disease**  
Eugene Braunwald (United States)



Frank Schofield, 1889-1970

## SCIENTIFIC PROGRAM

Monday, June 22, 2015

STATE-OF-THE-ART LECTURES 10:45-11:45

● J. Fraser Mustard SoA: Platelet function and dysfunction Room 718

Moderator: Peter Gross (Canada)

- 10:45 - 11:05  
**Inherited disorders of platelet function**  
Alan Nurden (France)
- 11:05 - 11:25  
**The P2Y12 ADP receptor: Structure and function**  
Marco Cattaneo (Italy)
- 11:25 - 11:45  
**αIIbβ3: structure and function**  
Barry Coller (United States)

Hijacking of proteolytic mechanisms by pathogens Room 716

Moderator: Jim Fredenburg (Canada)

- 10:45 - 11:15  
**Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella enterica**  
Timo K. Korhonen (Finland)
- 11:15 - 11:45  
**Pathogen activators of plasminogen**  
Paul Bock (United States)

■ Mechanisms of thrombosis Room 714

Moderator: Uri Seligsohn (Israel)

- 10:45 - 11:05  
**Thrombosis as a key regulator of innate immunity**  
Steffen Massberg (Germany)
- 11:05 - 11:25  
**Fibrinogen, factor XIII, and red blood cells: novel mechanisms in thrombosis**  
Alisa Wolberg (United States)
- 11:25 - 11:45  
**New insights into the biology of tissue factor pathway inhibitor**  
Alan Mast (United States)

✚ Hemophilia gene therapy; A Joint ISTH-WFH Symposium Plenary Hall F&G

Moderators: Marijke van den Berg (The Netherlands); Alok Srivastava (India)

- 10:45 - 11:05  
**New approaches to gene and cell therapy for hemophilia**  
Tsukasa Ohmori (Japan)
- 11:05 - 11:25  
**Platelet directed gene therapy**  
Mortimer Poncz (United States)

## SCIENTIFIC PROGRAM

11:25 - 11:45 **Gene therapy for hemophilia B**  
Paul Monahan (United States)

### ▲ Controversies in VTE management Room 701

*Moderators: Henri Bounameaux (Switzerland); Alexander S. Gallus (Australia)*

10:45 - 11:15 **Pulmonary embolism – Whom to thrombolysed? Whom to discharge?**  
Guy Meyer (France)

11:15 - 11:45 **Controversies in VTE diagnosis**  
Gregoire Le Gal (Canada)

### ♥ Burden, prevention and management of periop cardiovascular complications Room 801

*Moderators: Giancarlo Agnelli (Italy); James Douketis (Canada)*

10:45 - 11:05 **Perioperative myocardial injury**  
Dan Sessler (United States)

11:05 - 11:25 **What is the role of aspirin for prevention and treatment of perioperative cardiovascular events?**  
Philip J. Devereaux (Canada)

11:25 - 11:45 **New paroxysmal perioperative atrial fibrillation: how important is it for patients and what should I do about it?**  
Pablo Alonso Coello (Spain)

### ★ Extracorporeal circulation in children: can we restore normal hemostasis? Room 713

*Moderators: Leonardo Brandao (Canada); Ulrike Nowak-Göttl (Germany)*

10:45 - 11:15 **ECMO: The precarious balance of hemostasis**  
Gail Annich (United States)

11:15 - 11:45 **Ventricular assist devices and antithrombotic therapy: Do we really know what to do?**  
Patti Massicotte (Canada)

**Lunch in the exhibition (Level 800)**  
**From 11:45 to 12:15**

**Lunch Symposia**  
**From 12:15 to 13:45**

Lunch Symposia Programs are available in the Show Guide.  
Please consult the different options to attend the symposium of your choice.

## SCIENTIFIC PROGRAM

### ORAL COMMUNICATIONS 2 14:00-15:15

### ▲ NOACs in clinical practice Plenary Hall F&G

*Moderators: Deepa Suryanarayan (Canada), Pantep Angchaisuksiri (Thailand)*

14:00 – 14:15 **ADHERENCE TO ANTICOAGULANT TREATMENT WITH DABIGATRAN AND RIVAROXABAN IN A REAL-WORLD SETTING**  
OR061  
Faris Al Khalili\*, Deepa Suryanarayan, Catrine Lindström, Sam Schulman, Ammar Majeed (Sweden)

14:15 – 14:30 **THE IMPACT OF THE INTRODUCTION OF DABIGATRAN ON ANTICOAGULANT MANAGEMENT IN NEW ZEALAND**  
OR062  
Paul L. Harper\*, Daryl Pollock, Laura Chen, Su Chen Fong (New Zealand)

14:30 – 14:45 **REAL-WORLD RIVAROXABAN LEVELS FROM KING'S COLLEGE HOSPITAL**  
OR063  
Kathryn Lan\*, Jignesh Patel, Paradzai Chitongo, Julia Czuprynska, Lara Roberts, Raj Patel, Roopen Arya (United Kingdom)

14:45 – 15:00 **PROSPECTIVE SURVEY OF ADVERSE EFFECTS OF NON-VITAMIN K ORAL ANTICOAGULANTS IN TWO UK HOSPITAL TRUSTS**  
OR064  
Owain Myers, Sue Pavord, Marissa Hagan, Bethan Myers\* (United Kingdom)

15:00 – 15:15 **DABIGATRAN BUT NOT RIVAROXABAN OR APIXABAN REDUCES FIBRINOLYTIC RESISTANCE IN PATIENTS WITH ATRIAL FIBRILLATION**  
OR065  
Concetta T. Ammollo\*, Fabrizio Semeraro, Francesca Incampo, Claudia Dellanoce, Oriana Paoletti, Sophie Testa, Mario Colucci (Italy)

### ✚ Management of bleeding? Room 718

*Moderators: Ravindra Sarode (United States), Peter Kouides (United States)*

14:00 – 14:15 **ROLE OF TRANEXAMIC ACID IN REDUCING BLEEDING EPISODES AND REQUIREMENT OF PLATELET SUPPORT IN PATIENTS WITH APLASTIC ANEMIA**  
OR066  
Pravas Mishra\*, Sudhir Kumar, Manoranjan Mahapatra, Tulika Seth (India)

14:15 – 14:30 **EFFECTS OF IDARUCIZUMAB, GIVEN AS A SPLIT DOSE, IN A BLUNT LIVER DOUBLE TRAUMA MODEL IN PIGS RECEIVING DABIGATRAN**  
OR067  
Markus Honickel, Joanne van Ryn, Rolf Rossaint, Hugo ten Cate, Henri Spronk, Oliver Grottko\* (Germany)

14:30 – 14:45 **HEMODIALYSIS FOR THE TREATMENT OF DABIGATRAN-ASSOCIATED BLEEDING: A SYSTEMATIC REVIEW OF THE LITERATURE**  
OR068  
Chatree Chai-Adisaksopha\*, Christopher Hillis, Wendy Lim, Kochawan Boonyawat, Mark Crowther (Canada)

14:45 – 15:00 **OPTIMAL TIMING OF WARFARIN RESUMPTION AFTER WARFARIN RELATED UPPER GASTROINTESTINAL BLEEDING**  
OR069  
Ammar Majeed\*, Joakim Eriksson, Niklas Wallvik, Sam Schulman (Sweden)

## SCIENTIFIC PROGRAM

15:00 – 15:15  
OR070 **FIBRINOGEN CONCENTRATE IMPROVES FIBRIN NETWORK STRUCTURE DURING ORTHOTOPIC LIVER TRANSPLANTATION.**  
Dafna Groeneveld\*, Jelle Adelmeijer, Greg Hugenholtz, Robert Porte, Ton Lisman (The Netherlands)

### Venous thromboembolism – epidemiology – I

Room 701

*Moderators: Ophira Salomon (Israel), Marco Donadini (Italy)*

14:00 – 14:15  
OR071 **IMPACT OF INCIDENT MYOCARDIAL INFARCTION ON FUTURE RISK OF VENOUS THROMBOEMBOLISM**  
Ludvig B. Rinde\*, Birgit Småbrekke, Caroline Lind, Inger Njølstad, Ellisiv Mathiesen, Erin Hald, Sigrid Brækkan, John-Bjarne Hansen (Norway)

14:15 – 14:30  
OR072 **DEVELOPMENT AND VALIDATION OF A PATIENT SELF-ADMINISTERED VILLALTA SCALE FOR PATIENT SELF-ASSESSMENT OF THE POST-THROMBOTIC SYNDROME**  
Kristin Utne\*, Waleed Ghanima, Per Sandset, Susan Kahn, Hilde Wik (Norway)

14:30 – 14:45  
OR073 **OUTCOMES FROM THE NATIONAL VENOUS THROMBOEMBOLISM PREVENTION PROGRAMME IN ENGLAND**  
Lara Roberts, Helen Morrison, Tim Abbott, Frances Healey, Mike Durkin, Roopen Arya\* (United Kingdom)

14:45 – 15:00  
OR074 **RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM BASED ON PRESENCE OR ABSENCE OF DEEP VEIN THROMBOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS**  
Cecilia Becattini, Alexander Cohen, Giancarlo Agnelli, Luke Howard, Borja Castejon, Javier Trujillo-Santos, Manuel Monreal, Arnaud Perrier, Roger Yusen, David Jimenez\* (Spain)

15:00 – 15:15  
OR075 **REGULAR PHYSICAL ACTIVITY AND FUTURE RISK OF MYOCARDIAL INFARCTION AND VENOUS THROMBOSIS – THE TROMSØ STUDY**  
Sigrid Braekkan\*, Ellen Brodin, Anders Vik, Tom Wilsgaard, Inger Njølstad, Ellisiv Mathiesen, John-Bjarne Hansen (Norway)

### Thrombophilia

Room 801

*Moderators: Cynthia Wu (Canada), Ken Bauer (United States)*

14:00 – 14:15  
OR076 **ANTITHROMBIN DUBLIN (P.VAL30GLU): A POLYMORPHISM WITH MODERATE RISK OF THROMBOSIS THAT CAUSES A TRANSIENT ANTITHROMBIN DEFICIENCY BY INTRACELLULAR FOLDING INTO THE LATENT CONFORMATION**  
José Navarro-Fernández\*, María de la Morena-Barrio, José Padilla, Antonia Miñano, Nataliya Bohdan, Sonia Águila, Irene Martínez-Martínez, Teresa Sevivas, Carmen de Cos, Nuria Fernández-Mosteirin, Pilar Llamas, Susana Asenjo, Pilar Medina, Juan Souto, Kim Overvad, Søren Kristensen, Vicente Vicente, Javier Corral (Spain)

14:15 – 14:30  
OR077 **AGE-DEPENDENT FACTOR IX ACTIVITY IN ASSOCIATION WITH THE A/A-GENOTYPE OF F9 G32023A -POLYMORPHISM (RS440051) AND CONSEQUENT RISK OF VENOUS THROMBOEMBOLISM (VTE)**  
Rainer B. Zotz\*, Daniel Szafarczyk, Ruediger Scharf, Andrea Gerhardt (Germany)

## SCIENTIFIC PROGRAM

14:30 – 14:45  
OR078 **THE INCIDENCE OF VTE IN ASYMPTOMATIC CARRIERS OF A DEFICIENCY OF AT, PC OR PS: A PROSPECTIVE COHORT STUDY**  
Daniela Tormene\*, Laura Guerra, Sabrina Gavasso, Cristiana Bulato, Francesca Sartorello, Elena Campello, Fabio Dalla Valle, Luca Spiezia, Paolo Simioni (Italy)

14:45 – 15:00  
OR079 **ANTITHROMBIN HEPARIN BINDING SITE DEFICIENCY: A CHALLENGING DIAGNOSIS OF A NOT SO BENIGN THROMBOPHILIA**  
Christelle Orlando\*, Olivier Heylen, Willy Lissens, Kristin Jochmans (Belgium)

15:00 – 15:15  
OR080 **HIGH NEUTROPHIL AND BASOPHIL BLOOD COUNTS ARE ASSOCIATED WITH INCREASED FACTOR II PLASMA COAGULANT ACTIVITY AND MAY BE PREDICTORS OF MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE.**  
Nicola Martinelli\*, Domenico Girelli, Federica Tosi, Filippo Sartori, Giovanna Marchetti, Roberto Corrocher, Francesco Bernardi, Oliviero Olivieri (Italy)

### Megakaryocytes and thrombopoiesis I

Room 714

*Moderators: Koji Eto (Japan), Rochelle Winikoff (Canada)*

14:00 - 14:15  
OR081 **GENETIC ABLATION OF TRPM7 ALTERS MAGNESIUM HOMEOSTASIS AND INDUCES MACROTHROMBOCYTOPENIA IN MICE**  
Simon Stritt, Sanjeev Gotru, Vladimir Chubanov, Thomas Gudermann, Harald Schulze, Paquita Nurden, Bernhard Nieswandt, Attila Braun\* (Germany)

14:15 - 14:30  
OR082 **OF MEN AND MICE: DIVERGENCE EFFECT OF HDAC6 ON PROPLATELET FORMATION**  
Kahia Messaoudi\*, Ali Ashfaq, Alberta Palazzo, Olivier Bluteau, Philippe Rameau, Hana Raslova, Isabelle Plo, William Vainchenker, Najet Debili (France)

14:30 - 14:45  
OR083 **GLYCOPROTEIN VI INTERACTIONS WITH COLLAGEN TYPE I SELECTIVELY INHIBIT PROPLATELET FORMATION**  
Harald Schulze\*, David Stegner, Daniela Semeniak, Beate Eckes, Bernhard Nieswandt, Rebecca Kulawig (Germany)

14:45 - 15:00  
OR084 **RAPID 'RUPTURE'-TYPE THROMBOPOIESIS PROCESSES FROM BONE MARROW MEGAKARYOCYTE IN RESPONSE TO ACUTE PLATELET NEEDS IS REGULATED BY IL-1ALPHA**  
Satoshi Nishimura\*, Asuka Sakata, Kinya Seo, Tsukasa Ohmori, Koji Eto (Japan)

15:00 - 15:15  
OR085 **SYNTHESIS OF MARCKS IN THE LATE STAGES OF MEGAKARYOCYTE MATURATION DRIVES PROPLATELET FORMATION**  
Kellie Machlus\*, Stephen Wu, Debbie Stumpo, Robert Campbell, Andrew Weyrich, Perry Blackshear, Joseph Italiano (United States)

### Von Willebrand Disease

Room 716

*Moderators: Ian Peake (United Kingdom), Jordan Shavit (United States)*

14:00 – 14:15  
OR086 **DETECTION OF LARGE EXONIC AND INTERGENIC DELETIONS IN THE VWF LOCUS OF VWD PATIENTS USING ARRAY COMPARATIVE GENOMIC HYBRIDISATION (ACGH)**  
Simon J. Webster\*, Daniel Hampshire, Reinhard Schneppenheim, Daniel Bellissimo, Paula James, Bimal Theophilus, Ian Peake, Anne Goodeve (United Kingdom)

## SCIENTIFIC PROGRAM

14:15 – 14:30  
OR087

### LONG-TERM EXPRESSION OF VON WILLEBRAND FACTOR VIA SLEEPING BEAUTY SANDWICH TRANSPOSON-MEDIATED GENE THERAPY

Irina Portier\*, Karen Vanhoorelbeke, Sebastien Verhenne, Inge Pareyn, Hans Deckmyn, Zsuzsanna Izsvák, Simon De Meyer (Belgium)

14:30 – 14:45  
OR088

### SAFETY, EFFICACY AND PHARMACOKINETICS OF A RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE: A PROSPECTIVE CLINICAL TRIAL

Joan Gill, Giancarlo Castaman, Jerzy Windyga, Peter Kouides, Margaret Ragni\*, Frank Leebeek, Ortrun Obermann-Slupetzky, Miranda Chapman, Sandor Fritsch, Borislava Pavlova, Isabella Presch, Bruce Ewenstein (Austria)

14:45 – 15:00  
OR089

### NO DIFFERENCE IN VWF LEVELS NOR VWF SURVIVAL IN INDEX CASES AND FAMILY MEMBERS WITH AND WITHOUT P.Y1584C ENROLLED IN ZIMMERMAN PROGRAM FOR THE MOLECULAR AND CLINICAL BIOLOGY OF VWD (ZPMCB-VWD)

Pamela A. Christopherson, Daniel Bellissimo, Veronica Flood, Kenneth Friedman, Joan Gill, Robert Montgomery, Sandra Haberichter\* (United States)

15:00 – 15:15  
OR090

### PREVALENCE AND RISK FACTORS ASSOCIATED WITH HYPERTENSION IN VON WILLEBRAND DISEASE

Mariya Apostolova\*, Craig Seaman, Diane Comer, Jonathan Yabes, Margaret Ragni (United States)

## ■ Antiphospholipid antibodies – I

Room 713

Moderators: Wendy Lim (Canada), Thomas Ortel (United States)

14:00 – 14:15  
OR091

### EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES ON VASCULAR SMOOTH MUSCLE CELLS

Camille Rouillon\*, Stéphanie Makhoul, Patrick Lacolley, Véronique Regnault, Denis Wahl (France)

14:15 – 14:30  
OR092

### IMPACT OF HYDROXYCHLOROQUINE TREATMENT ON PREGNANCY OUTCOME IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES

Savino Sciascia\*, Beverley Hunt, Eva Talavera, Gloria Lliso, Munther Khamashta, Maria Cuadrado (United Kingdom)

14:30 – 14:45  
OR093

### THROMBIN GENERATION IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES

Patrizia Della Valle, Chiara Novelli\*, Paola Pradella, Benedetto Morelli, Armando D'Angelo (Italy)

14:45 – 15:00  
OR094

### INFLAMMATION AND CARDIOVASCULAR RISK FACTORS ARE ASSOCIATED WITH RECURRENT THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME

Sabrina Saraiva\*, Isadora Custódio, Bruna Mazzeto, Marina Collela, Erich de Paula, Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda A. Orsi (Brazil)

15:00 – 15:15  
OR095

### OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: HIGH COMPARATIVE PREVALENCE OF COMMON MENTAL DISORDERS DURING FOLLOW-UP.

Jean-Christophe R. Gris\*, Géraldine Lavigne, Sylvie Bouvier, Eva Nouvellon, Erick Mercier, Céline Chaleur, Jean-Philippe Galanaud, Isabelle Quééré, Pierre Marès (France)

## SCIENTIFIC PROGRAM

## Vitamin K antagonists

Room 715

Moderators: Karina Meijer (The Netherlands), Jack Ansell (United States)

14:00 – 14:15  
OR096

### QUALITY OF VITAMIN K ANTAGONIST CONTROL AND 1-YEAR OUTCOMES: A GLOBAL PERSPECTIVE FROM THE GARFIELD-AF REGISTRY

Hugo ten Cate\*, Sylvia Haas, Gabriele Accetta, Pantep Angchaisuksiri, John Camm, Ramon Corbalan, John Eikelboom, David Fitzmaurice, Samuel Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Alexander Turpie, Ajay Kakkar (The Netherlands)

14:15 – 14:30  
OR097

### INDEPENDENT PREDICTORS OF POOR VITAMIN K ANTAGONIST CONTROL IN VENOUS THROMBOEMBOLISM PATIENTS: DATA FROM THE EINSTEIN-DVT AND PE STUDIES.

Hilde A. Kooistra\*, Martin Gebel, Kurtulus Sahin, Anthonie Lensing, Karina Meijer (The Netherlands)

14:30 – 14:45  
OR098

### BLEEDING RISKS ARE HIGH IN ELDERLY PERSONS WHO USE VITAMIN K ANTAGONISTS COMBINED WITH PLATELET AGGREGATION INHIBITORS

Nienke Van Rein\*, Uffe Heide-Jørgensen, Willem Lijfering, Lars Pedersen, Olaf Dekkers, Henrik Sørensen, Suzanne Cannegieter (Denmark, The Netherlands)

14:45 – 15:00  
OR099

### THE EFFECT OF CYP2C9 POLYMORPHISM ON INR DECLINE IN PATIENTS STOPPING WARFARIN BEFORE SURGERY

Salah Abohelaika\*, Hilary Wynne, Peter Avery, Farhad Kamali (United Kingdom)

15:00 – 15:15  
OR100

### IMPACT OF VITAMIN K ANTAGONISTS (VKA) ON QUALITY OF LIFE (QOL) IN A PROSPECTIVE COHORT OF 807 ATRIAL FIBRILLATION (AF) PATIENTS

Hilde A. Kooistra\*, Margriet Piersma-Wichers, Hanneke Kluin-Nelemans, Nic Veeger, Karina Meijer (The Netherlands)

## ★ Hemophilia – prophylaxis

Room 717

Moderators: Victor Blanchette (Canada), Kathelijn Fischer (The Netherlands)

14:00 – 14:15  
OR101

### SPINART TRIAL 3-YEAR RESULTS WITH BAYER'S SUCROSE-FORMULATED RECOMBINANT FACTOR VIII: RELATIONSHIP BETWEEN BLEEDING FREQUENCY AND JOINT HEALTH IN ADULTS WITH SEVERE HEMOPHILIA A USING PROPHYLAXIS

Mark T. Reding\*, Christine Kempton, Sharon Funk, Sylvia Engelen, Dale Walker, Walter Hong (United States)

14:15 – 14:30  
OR102

### DISCONTINUING EARLY PROPHYLAXIS IN YOUNG ADULTS WITH SEVERE HAEMOPHILIA A: DETERIORATION OF JOINT STATUS AFTER 10 YEARS DESPITE LOW BLEEDING RATES

Annelies Nijdam, Wouter Foppen, Piet de Kleijn, Evelien Mauser-Bunschoten, Goris Roosendaal, Karin van Galen, Roger Schutgens, Kathelijn Fischer\* (The Netherlands)

14:30 – 14:45  
OR103

### RETROSPECTIVE 28-YEAR LONG TERM FOLLOW-UP OF PROPHYLAXIS IN A COHORT OF 49 PATIENTS WITH SEVERE HAEMOPHILIA A

Johannes Oldenburg\*, LEMONIA Krämer, Georg Goldmann, Natascha Marquardt, Hans-Hermann Brackmann (Germany)



## SCIENTIFIC PROGRAM

14:45 – 15:00  
OR104 **PROPHYLAXIS IN CHILDREN WITH SEVERE AND MODERATE HAEMOPHILIA: A SURVEY OF UK PRACTICE.**  
Ryan Rodgers\*, Jay Alamelu, Peter Collins, Mary Mathias, Jeanette Payne, Mike Richards, Oliver Tunstall, Mike Williams, David Young, Tina Biss, Angela Thomas, Elizabeth Chalmers (United Kingdom)

15:00 – 15:15  
OR105 **PROPHYLAXIS IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A OR B WITHOUT INHIBITORS**  
Louis Aledort\*, Laura Avila, Victor Blanchette, Thierry Lambert (United States)

Factor VIII – I

Room 705

*Moderators: Paul Moorehead (Canada), Roland Herzog (United States)*

14:00 – 14:15  
OR106 **TRANSGENE EXPRESSION UNDER THE CONTROL OF FVIII PROMOTER FOR HEMOPHILIA A TARGETED THERAPY**  
Diego Zanolini\*, Simone Merlin, Valentina Brusca, Antonia Follenzi (Italy)

14:15 – 14:30  
OR107 **ROLE OF THE IGG BACKBONE IN B CELL DEPLETION AND INHIBITOR REVERSAL IN HEMOPHILIA A WITH ANTI-CD20 ANTIBODIES**  
Geoffrey L. Rogers\*, Alexandra Sherman, David Markusic, Haiyan Jiang, Roland Herzog (United States)

14:30 – 14:45  
OR108 **HIGH THROUGHPUT AMINO ACID SEQUENCE EPI TOPE MAPPING OF INHIBITORY ANTIBODIES IN SEVERE HEMOPHILIA A**  
Paul Batty\*, Stuart Skelton, Adrian Shepherd, Maria Mancuso, Elena Santagostino, Flora Peyvandi, Daniel Hart (United Kingdom)

14:45 – 15:00  
OR109 **ADOPTIVE TRANSFER OF IN VITRO EXPANDED FVIII-SPECIFIC REGULATORY T CELLS TO MEDIATE TOLERANCE IN HEMOPHILIA A MICE**  
Bryn Smith\*, Meghan Lyle, Carol Miao (United States)

15:00 – 15:15  
OR110 **HEPATOCELLULAR DISTRIBUTION OF FVIII IN EX VIVO PERFUSED RAT LIVER: LIVER SINUSOIDAL ENDOTHELIAL CELLS ARE THE CELLS PRIMARILY RESPONSIBLE FOR UPTAKE OF FVIII**  
Kirstine Roepstorff\*, Mette Loftager, Jes Clausen, Marianne Kjalke, Frederik Rode, Jesper Haaning, Rupa Appa (Denmark)

Platelets – kinases-I

Room 707

*Moderators: Diego Mezzano (Chile), Satya Kunapuli (United States)*

14:00 – 14:15  
OR111 **DISTINCT PATHWAYS REGULATE SYK ACTIVATION DOWNSTREAM OF ITAM AND HEMI-ITAM RECEPTORS IN PLATELETS**  
Bhanukanth Manne\*, Rachit Badolia, Carol Dangelmaier, Wilfried Ellmeier, Mark Kahn, Satua P Kunapuli (United States)

14:15 – 14:30  
OR112 **GLYCOGEN SYNTHASE KINASE-3 PHOSPHORYLATION PREVENTS PATHOLOGICAL GPVI-MEDIATED PLATELET ACTIVATION AND THROMBOSIS**  
Samantha F. Moore\*, Thomas Blair, Ingeborg Hers (United Kingdom)

## SCIENTIFIC PROGRAM

14:30 – 14:45  
OR113 **MEKK3 CONTROLS THE ERK1/2- AND JNK2-MEDIATED PLATELET ACTIVATION AND ARTERIAL THROMBOSIS**  
Xuemei Fan\*, Conghui Wang, Xue Chen, Jing Dai, Xiaolin Wu, Kemin Wang, Junling Liu (China)

14:45 – 15:00  
OR114 **CASEIN KINASE 2B IS CRITICAL PLAYER IN PLATELET ACTIVATION, ARTERIAL THROMBOSIS AND ISCHEMIC STROKE**  
Oliver Borst\*, Patrick Münzer, Britta Walker, Friederike Langhauser, Mita Chatterjee, Anna Fotinos, Christoph Kleinschnitz, Florian Lang, Meinrad Gawaz (Germany)

15:00 – 15:15  
OR115 **THE FOCAL ADHESION KINASE PYK2 MEDIATES CA2+-DEPENDENT ACTIVATION OF THE SRC FAMILY KINASES FYN AND LYN IN THROMBIN-STIMULATED PLATELETS**  
Ilaria Canobbio\*, Lina Cipolla, Gianni Guidetti, Daria Manganaro, Soochong Kim, Mitsuhiro Okigaki, Marco Falasca, Satya Kunapuli, Mauro Torti (Italy)

Stroke

Room 709

*Moderators: Alessandro Squizzato (Italy), Ajay Kakkar (United Kingdom)*

14:00 – 14:15  
OR116 **CM352, A NEW ANTIFIBRINOLYTIC, REDUCES HEMATOMA GROWTH AND IMPROVES FUNCTIONAL RECOVERY IN A COLLAGENASE-INDUCED RAT MODEL OF INTRACEREBRAL HEMORRHAGE**  
Josune Orbe\*, Tomas Sobrino, Jose Rodriguez, Francisco Campos, Julen Oyarzabal, Jose Castillo, Jose A. Paramo (Spain)

14:15 – 14:30  
OR117 **ASSESSMENT OF THE DIAGNOSTIC VALUE OF PLASMA LEVELS, ACTIVITIES AND THEIR RATIOS OF VON WILLEBRAND FACTOR AND ADAMTS13 IN PATIENTS WITH CEREBRAL INFARCTION**  
Yiming Zhao, Le Qu\*, Miao Jiang, Changgeng Ruan (China)

14:30 – 14:45  
OR118 **IS ANEMIA A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS?**  
Jonathan M. Coutinho\*, Susanna Zuurbier, Jan Stam, Saskia Middeldorp, Suzanne Cannegieter (The Netherlands)

14:45 – 15:00  
OR119 **RISK PROFILES AND 1-YEAR OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED ATRIAL FIBRILLATION: RESULTS FROM GARFIELD-AF**  
Ajay K. Kakkar\*, Gabriele Accetta, Giancarlo Agnelli, Pantep Angchaisuksiri, Jean-Pierre Bassand, Karen Chiswell, Frank Cools, David Fitzmaurice, Harry Gibbs, Samuel Goldhaber, Shinya Goto, Sylvia Haas, Barry Jacobson, Carlos Jerjes-Sanchez, Gloria Kayani, Lorenzo Mantovani, Frank Misselwitz, Hugo ten Cate, Alexander Turpie, Martin van Eickels, Freek Verheugt, John Camm (United Kingdom)

15:00 – 15:15  
OR120 **RED CELL DISTRIBUTION WIDTH IS ASSOCIATED WITH FUTURE RISK OF INCIDENT STROKE. THE TROMSØ STUDY**  
Jostein Lappegård\*, Trygve Ellingsen, Tove Skjelbakken, Ellisiv Mathiesen, Inger Njølstad, Tom Wilsgaard, Jan Brox, Sigrid Brækkan, John-Bjarne Hansen (Norway)

MONDAY

ORALS

## SCIENTIFIC PROGRAM

### Innate and acquired Immunity

Room 711

*Moderators: Anne Zufferey Bakos (Canada), Craig Morrell (United States)*

- 14:00 – 14:15  
OR121 **NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION IN PATIENTS WITH POST-BURN SEPSIS**  
Robert J. Dinsdale\*, Peter Hampson, Chris Wearn, Jon Hazeldine, Alexander Brill, Janet Lord, Naiem Moiemem, Paul Harrison (United Kingdom)
- 14:15 – 14:30  
OR122 **COMPARED TO B220/CD45R+ B LYMPHOCYTES, SPLENIC DENDRITIC CELLS AND MACROPHAGES HAVE LIMITED PROPENSITY TO BIND FACTOR VIII AND DEMONSTRATE DOWN-REGULATION OF CO-STIMULATORY MOLECULES.**  
Jesse Lai\*, Dominique Cartier, Alice van Velzen, Christine Hough, David Lillicrap (Canada)
- 14:30 – 14:45  
OR123 **MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 ARE ASSOCIATED WITH MORTALITY IN CRITICALLY ILL PATIENTS**  
Sarah Ruhittel, Konstantin Krychtiuk\*, Philipp Hohensinner, Lorenz Koller, Christoph Kaun, Max Lenz, Benedikt Bauer, Lisa Wutzelhofer, Dominik Draxler, Gerald Maurer, Kurt Huber, Johann Wojta, Gottfried Heinz, Alexander Niessner, Walter Speidl (Austria)
- 14:45 – 15:00  
OR124 **AKI DEVELOPMENT UPON SIRS IS ASSOCIATED WITH PLATELET ACTIVATION, POSSIBLY TRIGGERED BY MITOCHONDRIAL DNA DERIVED FROM DAMAGED CELLS**  
Marcel P. B. Jansen\*, Wilco Pulskens, Loes Butter, Nike Claessen, Diba Emal, Sandrine Florquin, Nicole Juffermans, Joris Roelofs, Jaklien Leemans (The Netherlands)
- 15:00 – 15:15  
OR125 **DIPHOSPHORYLATED LIPID A TRIGGERS TISSUE FACTOR MRNA SPLICING IN HUMAN PLATELETS**  
Krystin Krauel\*, Ulrike Thorack, Anne Schumacher, Hansjörg Schwertz (Germany)

**Coffee break time in the exhibition (Level 800)  
From 15:15 to 15:45**

Monday, June 22, 2015

ABSTRACT SYMPOSIA 15:45-17:15

### Fibrinogen

Room 716

*Moderators: Matthew Flick (United States), Kellie Machlus (United States)*

- 15:45 - 16:15  
AS001 **REGULATORS OF STRUCTURE IN THE FIBRIN CLOT**  
Helen Philippou (United Kingdom)
- 16:15 – 16:35  
AS002 **TRANSCRIPTOME ANALYSIS REVEALS HNF4A AS A MIR-29C TARGET LINKED TO REDUCED FIBRINOGEN EXPRESSION**  
Samuel Lukowski, Richard J. Fish\*, Marguerite Neerman-Arbez (Switzerland)

## SCIENTIFIC PROGRAM

16:35 – 16:55  
AS003

### CHARACTERISATION OF CELLULAR FIBRINOGEN PHOSPHORYLATION AND ITS FUNCTIONAL IMPLICATIONS IN CLOT FORMATION

Kerrie A. Smith\*, Esther Cooke, Paul Cordell, Richard Pease, Jane Brown, Cora Beckers, Kingsley Simpson, Peter Grant (United Kingdom)

16:55 – 17:15  
AS004

### MECHANISMS BY WHICH DNA, HISTONES AND NEUTROPHIL EXTRACELLULAR TRAPS STABILISE CLOTS TOWARDS MECHANICAL AND FIBRINOLYTIC BREAKDOWN

Imre Varjú\*, Colin Longstaff, László Szabó, Veronika Judit Varga-Szabó, Ádám Zoltán Farkas, Erzsébet Komorowicz, Krasimir Kolev (Hungary)

### Platelets and bacteria

Room 711

*Moderators: John Semple (Canada), Archie McNichol (Canada)*

15:45 - 16:15  
AS005

### THROMBUS FORMATION CAUSED BY INVADING PATHOGENS: THE ROLE OF PLATELETS

Steven Kerrigan (Ireland)

16:15 – 16:30  
AS006

### CLEC-2 IS REQUIRED FOR THE ACTIVATION OF MOUSE PLATELETS BY BACTERIAL DNA MIMETICS

Celine Delierneux\*, Alexandre Hego, Christelle Lecut, Maud Vandereyken, Lucia Musumeci, Souad Rahmouni, Vincent Bours, Patrizio Lancellotti, Cécile Oury (Belgium)

16:30 – 16:45  
AS007

### PLATELET MYD88 ENHANCES CYTOKINE PRODUCTION INDUCED BY TLR AGONISTS AND KLEBSIELLA PNEUMONIAE

Theodora A. Claushuis\*, Sacha de Stoppelaar, Cornelis van 't Veer, Tom van der Poll (The Netherlands)

16:45 – 17:00  
AS008

### POLYPHOSPHATE CHAIN LENGTH DETERMINES ANTIGENICITY OF COMPLEXES FORMED WITH PLATELET FACTOR 4 (PF4) AND PF4-BINDING TO BACTERIA

Mihaela Delcea\*, Sven Brandt, Krystin Krauel, Miriam Jaax, Thomas Renné, Christiane Helm, Sven Hammerschmidt, Andreas Greinacher (Germany)

17:00 – 17:15  
AS009

### SHEAR-RESISTANT BINDING TO VON WILLEBRAND FACTOR ALLOWS STAPHYLOCOCCUS LUGDUNENSIS TO ADHERE TO THE CARDIAC VALVES AND INITIATE ENDOCARDITIS

Laurens Liesenborghs\*, Marijke Peetermans, Jorien Claes, Marleen Lox, Christophe Vandenberghe, Maarten Criel, Thomas Vanassche, Marc Hoylaerts, Peter Verhamme (Belgium)

### Genetic basis of platelet disorders

Room 715

*Moderators: Kathleen Freson (Belgium), Matthew Rondina (United States)*

15:45 - 16:15  
AS010

### PLATELET GRANULE BIOGENESIS

Walter Kahr (Canada)

## SCIENTIFIC PROGRAM

16:15 – 16:30  
AS011 **CONSECUTIVE SLFN14 MUTATIONS IN 3 UNRELATED FAMILIES WITH AN INHERITED BLEEDING DISORDER, THROMBOCYTOPENIA AND SECRETION DEFECTS**

Sarah Fletcher, Ben Johnson, Gill Lowe, Danai Bem, Sian Drake, Marie Lordkipanidzé, Isabel Sánchez Guiú, Ban Dawood, José Rivera, Michael Simpson, Martina Daly, Jayashree Motwani, Peter Collins, Steve Watson, Neil V. Morgan\* (United Kingdom)

16:30 – 16:45  
AS012 **UNRAVELLING RARE BLEEDING AND PLATELET DISORDERS (BPD) USING COMPREHENSIVE PHENOTYPING AND GENOME SEQUENCING**

Claire Lentaigne\* (United Kingdom)

16:45 – 17:00  
AS013 **A DOMINANT GAIN-OF-FUNCTION MUTATION IN A TYROSINE KINASE GENE CAUSES A NEW GRAY PLATELET-LIKE SYNDROME WITH BONE PATHOLOGIES**

Anouck Wijgaerts\* (Belgium)

17:00 – 17:15  
AS014 **MUTATION IN ETS VARIANT GENE 6 ASSOCIATES WITH AUTOSOMAL DOMINANT THROMBOCYTOPENIA AND RAISED LEVELS OF CIRCULATING CD34+ CELLS**

Marjorie Poggi, Véronique Baccini, Marie Favier, Matthias Canault\*, Anna Mezzapesa, Dorsaf Ghalloussi, Nadjim Chelghoum, Badreddine Mohand-Oumoussa, Céline Falaise, Franck Peiretti, Pierre Morange, Noémie Saut, Jacques Ghysdael, Alan Nurden, Fabien Guidez, Denis Bernot, Paquita Nurden, Hana Raslova, David-Alexandre Tregouet, Marie-Christine Alessi (France)

### 🏥 New alternatives for treating bleeding disorders

Plenary Hall F&G

*Moderators: Jerry Teitel (Canada), Jerzy Windyga (Poland)*

15:45 - 16:15  
AS015 **THE POTENTIAL OF BISPECIFIC ANTIBODIES FOR TREATMENT OF HEMOPHILIA**

Craig Kessler (United States)

16:15 – 16:30  
AS016 **A RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR VIIA WITH ALBUMIN (RVIIA-FP) BINDS TO NEONATAL FC RECEPTOR AND TISSUE FACTOR IN VITRO**

Susann Catterpoel, Annette Gaida, Marlies Illi, Rolf Spirig, Eva Herzog, Jenny Chia, Anne Verhagen, Ineke Muir, Hal Braley, Sabine Zollner\* (Switzerland)

16:30 – 16:45  
AS017 **LONG-TERM SAFETY AND PROPHYLACTIC EFFICACY OF ONCE-WEEKLY SUBCUTANEOUS ADMINISTRATION OF ACE910, IN JAPANESE HEMOPHILIA A PATIENTS WITH AND WITHOUT FVIII INHIBITORS: INTERIM RESULTS OF THE EXTENSION STUDY OF A PHASE 1 STUDY**

Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Hoyu Takahashi, Keiji Nogami\* (Japan)

16:45 – 17:00  
AS018 **PHARMACODYNAMICS AND PHARMACOKINETICS OF TFPI-NEUTRALIZING ANTIBODY (BAY1093884) IN CYNOMOLGUS MONKEYS AND PREDICTION OF HUMAN DOSE**

Jian-Ming Gu\*, Elena Ho, Xiao-yan Zhao, Thomas Schwarz, Joachim Schuhmacher, Babu Subramanyan, Kathy Tran, Chandra Patel, Maria Koellnberger (United States)

## SCIENTIFIC PROGRAM

17:00 – 17:15  
AS019 **THROMBIN GENERATION IS INCREASED IN PLASMA FROM HEALTHY MALES WHO HAVE RECEIVED CONCIZUMAB, AN ANTIBODY AGAINST TISSUE FACTOR PATHWAY INHIBITOR (EXPLORERTM2)**

Emily K. Waters\*, Jens Sigh, Mirella Ezban, Ida Hilden (Denmark)

### ▲ Women's issues in venous thrombosis

Room 801

*Moderators: Shannon Bates (Canada), Lisa Baumann-Kreuziger (United States)*

15:45 - 16:15  
AS020 **ANTITHROMBOTIC THERAPY TO PREVENT PLACENTA MEDIATED COMPLICATIONS**

Robert M. Silver (United States)

16:15 – 16:35  
AS021 **TIME TO LIVE BIRTH IN WOMEN WITH RECURRENT MISCARRIAGE AND INHERITED THROMBOPHILIA**

Paulien G. de Jong\*, Stef Kaandorp, Remi Kool, Barbara Hutten, Saskia Middeldorp, Mariëtte Goddijn (The Netherlands)

16:35 – 16:55  
AS022 **HORMONAL THERAPY AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN WOMEN RECEIVING ANTICOAGULANT TREATMENT**

Ida Martinelli\*, Anthonie Lensing, Jan Beyer-Westendorf, Mila Trajanovic, Martin Gebel, Phuong Lam, Martin Prins (Italy)

16:55 – 17:15  
AS023 **THE PROPORTION OF NONDIAGNOSTIC COMPUTED TOMOGRAPHIC PULMONARY ANGIOGRAPHY AND VENTILATION/PERFUSION LUNG SCANS IN PREGNANT WOMEN WITH SUSPECTED PULMONARY EMBOLISM: A SYSTEMATIC REVIEW.**

Arabesque Parker\*, Ghazi Alotaibi, Cynthia Wu, Sarah Takach Lapner (Canada)

### ♥ Modulation of atherothrombosis

Room 705

*Moderators: Xinjie Lu (United Kingdom), Ed Plow (United States)*

15:45 - 16:15  
AS024 **THE HEMOSTATIC SYSTEM AS A MODULATOR OF ATHEROSCLEROSIS**

Hugo Ten Cate (The Netherlands)

16:15 – 16:30  
AS025 **ADOPTIVE TRANSFER OF ANTIGEN-INDUCED SPECIFIC REGULATORY T CELLS (TREG) PROTECTS AGAINST ATHEROSCLEROTIC LESION FORMATION IN B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE**

Min Xia, Valeria Endresz, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu\* (United Kingdom)

16:30 – 16:45  
AS026 **DISRUPTION OF SEMAPHORIN 7A DECREASES PLAQUE SIZE INDUCED BY DISTURBED FLOW AND CONFERS PROTECTION AGAINST THE DEVELOPMENT OF ATHEROSCLEROSIS**

Chaojun Tang\*, Shuhong Hu, Fei Yang, Li Zhu (China)

16:45 – 17:00  
AS027 **CHANGES IN PERIPHERAL IMMUNE MARKERS IN RESPONSE TO IMMUNE TOLERANCE AND ITS CORRELATION WITH PROGRESSION OF ATHEROSCLEROSIS IN APOBTM2SGY LDLRTM1HER MICE**

Thota Lakshmi narasimha Rao, Sheena Philip, Thiruvvelselvan Ponnusamy, Xinjie Lu, Vijay Kakkar, Lakshmi Mundkur\* (India)

## SCIENTIFIC PROGRAM

17:00 – 17:15  
AS028 **BONE MORPHOGENETIC PROTEIN (BMP)-7 UPREGULATES ADHESIVE AND MIGRATORY PROPERTIES OF HUMAN MONOCYtic CELLS VIA BETA2 INTEGRIN-BMP RECEPTOR TYPE II (BMPRII) CROSSTALK**  
Timofey Sovershaev\*, Dusten Unruh, John-Bjarne Hansen, Vladimir Bogdanov, Mikhail Sovershaev (Norway, United States)

### Coagulation, fibrinolysis, immunity and inflammation

Room 714

*Moderators: Paul Kim (Canada), Lawrence Leung (United States)*

15:45 - 16:15  
AS029 **CROSS-TALK BETWEEN COAGULATION AND FIBRINOLYSIS**  
John Morser (United States)

16:15 – 16:35  
AS030 **IMAGING ANALYSES OF COAGULATION-DEPENDENT INITIATION OF FIBRINOLYSIS ON ACTIVATED PLATELETS AND ITS MODIFICATION BY TAFI**  
Tomasz Brzoska\*, Yuko Suzuki, Hideto Sano, Martyna Tomczyk, Tetsumei Urano (Japan)

16:35 – 16:55  
AS031 **ACTIVATION OF PROHEMERIN BY FACTOR XIA REPRESENTS A NEW MOLECULAR LINK BETWEEN INNATE IMMUNITY AND BLOOD COAGULATION**  
Xiaomei Ge\*, Yasuto Yamaguchi, Lei Zhao, Shwu Shin Chang, John Morser, Lawrence Leung (United States)

16:55 – 17:15  
AS032 **INTRAVENOUS THROMBOLYSIS GENERATES LARGE AMOUNTS OF BRADYKININ IN STROKE PATIENTS: NEUROTOXIC IMPACT.**  
Maxime Gauberti\*, Sara Martinez de Lizarrondo, Oscar Marcos-Contreras, Denis Vivien (France)

### Antiphospholipid antibodies

Room 701

*Moderators: Bas de Laat (The Netherlands), Philip de Groot (The Netherlands)*

15:45 - 16:15  
AS033 **UNRAVELLING THE ANTIPHOSPHOLIPID SYNDROME: FROM EMPIRIC DESCRIPTION TO PATHOGENIC MECHANISMS**  
Jacob Rand (United States)

16:15 – 16:30  
AS034 **INCREASED MORTALITY IN PATIENTS WITH THE LUPUS ANTICOAGULANT: THE VIENNA LUPUS ANTICOAGULANT AND THROMBOSIS STUDY (LATS)**  
Johanna Gebhart\*, Florian Posch, Silvia Koder, Thomas Perkmann, Peter Quehenberger, Claudia Zoghliani, Cihan Ay, Ingrid Pabinger (Austria)

16:30 – 16:45  
AS035 **LUPUS ANTICOAGULANT ACTIVITY CAN BE EXPLAINED BY INTERFERENCE OF ANTI- $\beta$ 2GPI ANTIBODIES WITH THE PROTHROMBINASE COMPLEX**  
J.E. Molhoek\*, Ph.G. de Groot, J.C.M. Meijers, R.T. Urbanus (The Netherlands)

16:45 – 17:00  
AS036 **CIRCULATING ENDOTHELIAL CELLS IDENTIFY PATIENTS WITH ANTIPHOSPHOLIPID-ANTIBODIES AND ASSOCIATED AUTO-IMMUNE DISEASES AT RISK FOR THROMBOSIS.**  
Stéphane Zuily\*, Marie Heymonet, Qian Tu, Marcelo De Carvalho Bittencourt, Gilbert Faure, Denis Wahl (France)

## SCIENTIFIC PROGRAM

17:00 – 17:15  
AS037 **ANNEXIN A5 RESISTANCE CORRELATES WITH MULTIPOSITIVITY FOR ANTIPHOSPHOLIPID ASSAYS AND IS A PROSPECTIVE BIOMARKER FOR ADVERSE EVENTS**  
Lucia Wolgast\*, Xiao Wu, Vittorio Pengo, Jacob Rand (United States)

### Microparticles

Room 718

*Moderators: Ashley Ambrose (United Kingdom), Nigel Mackman (United States)*

15:45 - 16:15  
AS038 **MICROPARTICLES IN HEALTH AND DISEASE**  
Rienk Nieuwland (The Netherlands)

16:15 – 16:30  
AS039 **MICROPARTICLES FROM PATIENTS WITH ACUTE CORONARY SYNDROME AND HEART TRANSPLANTED PATIENTS INDUCE PREMATURE ENDOTHELIAL SENEESCENCE AND THROMBOGENICITY: ROLE OF OXIDATIVE STRESS AND OF THE LOCAL ANGIOTENSIN SYSTEM**  
Malak Abbas\*, Laurence Jesel, Phuong Nga Nguyen, Cyril Auger, Nathan Messas, Thais Ribeiro, Grazielle C Silva, Patrick Ohlman, Olivier Morel, Valerie Schini-Kerth, Florence Toti (France)

16:30 – 16:45  
AS040 **THE GAS6-AXL INTERACTION MEDIATES ENDOTHELIAL UPTAKE OF PLATELET MICROPARTICLES**  
Kaisa Otteby\*, Sinh Tran, Matthias Mörgelin, Björn Dahlbäck (Sweden)

16:45 – 17:00  
AS041 **PLATELETS RELEASE EXTRACELLULAR VESICLES IN AN AGONIST DEPENDENT MANNER BUT RELEASE A CONSISTENT PROFILE OF MICRORNA**  
Ashley R. Ambrose\*, J Pringle, Alison Goodall (United Kingdom)

17:00 – 17:15  
AS042 **A PROSPECTIVE EVALUATION OF THE PROTHROMBOTIC AND PROGNOSTIC POTENTIAL OF CIRCULATING MICROPARTICLES IN GLIOBLASTOMA MULTIFORME (GBM), PANCREATIC ADENOCARCINOMA (PAC) AND ESOPHAGEAL-GASTRIC CANCER (EGC).**  
Elena Campello\*, Claudia Radu, Luca Spiezia, Sabrina Gavasso, Barry Woodhams, Paolo Simioni (Italy)

### Obesity – bench to bedside

Room 717

*Moderators: Michele David (Canada), Brian McCrindle (Canada)*

15:45 - 16:15  
AS043 **ROLE OF ENDOTHELIAL CELLS IN ADIPOSE TISSUE INFLAMMATION AND ADIPOCYTE ALTERATIONS DURING OBESITY**  
Vanessa Pellegrinelli (United Kingdom)

16:15 – 16:30  
AS044 **SILENCING OF SEC23A AND FLOTILIN PROTECTS ENDOTHELIAL CELLS FROM DEVELOPING A PROINFLAMMATORY / PROTHROMBOTIC PHENOTYPE IN OBESITY**  
Marta Palomo De Udaeta\*, Rebeca Fernandez-Ruiz, Sergi Torramadé, Ginés Escolar, Ramón Gomis, Felicia Hanzu, Maribel Díaz-Ricart (Spain)

## SCIENTIFIC PROGRAM

- 16:30 – 16:45  
AS045 **DNA METHYLATION PROFILING IDENTIFIES A LOCUS NEAR A HMG-COA SYNTHASE GENE ASSOCIATED WITH TRIGLYCERIDE LEVELS AND MODIFIED BY BMI**  
Vinh Truong\*, Nora Zwingerman, Irfahan Kassam, Dylan Aïssi, Jessica Dennis, Michael Wilson, Philip Wells, Pierre-Emmanuel Morange, David-Alexandre Trégouët, France Gagnon (Canada)
- 16:45 – 17:00  
AS046 **OBESITY MEASURES, CRP AND RISK OF VENOUS THROMBOEMBOLISM AND MYOCARDIAL INFARCTION**  
Lars Daae Horvei\*, Sigrd Brækkan, Ellisiv Mathiesen, Inger Njølstad, Tom Wilsgaard, Jan Brox, John-Bjarne Hansen (Norway)
- 17:00 – 17:15  
AS047 **VISCERAL ADIPOSITY INDEPENDENTLY DETERMINES THROMBIN GENERATION LAG TIME AND PEAK THROMBIN IN MORBID OBESITY**  
Paradzai Chitongo\*, Lara Roberts, Lyall Rebecca, Raj Patel, Simon Aylwin, Roopen Arya (United Kingdom)

### ★ Sickle cell disease

Room 707

Moderators: Michael DeBaun (United States), Madeleine Verhovsek (Canada)

- 15:45 - 16:15  
AS048 **THE OPPORTUNITIES FOR PRIMARY AND SECONDARY STROKE PREVENTION IN SICKLE CELL DISEASE**  
Michael DeBaun (United States)
- 16:15 – 16:30  
AS049 **KININOGEN DEFICIENCY ATTENUATES THROMBIN GENERATION IN A MOUSE MODEL OF SICKLE CELL DISEASE**  
Erica Sparkenbaugh\*, Nigel Key, Kasemsiri Chandarajoti, Andras Gruber, Nigel Mackman, Keith McCrae, Rafal Pawlinski (United States)
- 16:30 – 16:45  
AS050 **MICROPARTICLES GENERATED DURING STORAGE OF PACKED RED BLOOD CELL UNITS SUPPORT THROMBIN GENERATION**  
Beth A. Bouchard\*, Hollis Keith, Elizabeth Lavoie, Thomas Orfeo, Kenneth Mann (United States)
- 16:45 – 17:00  
AS051 **SPECIFIC INHIBITION OF GPIIb/IIIa SHEDDING IMPROVES POST-TRANSFUSION RECOVERY AND ADHESIVE FUNCTION OF OUTDATED HUMAN APHERESIS PLATELETS**  
Xin Liang, Yue Tao, Anum Syed, Paula Jessup, William Church, Cassandra Josephson, Xi Mo, Renhao Li\* (United States)
- 17:00 – 17:15  
AS052 **THE GLOBAL IMPACT OF PATHOGEN REDUCTION SYSTEMS ON THE PLATELET MRNA TRANSCRIPTOME, ANALYSED BY DIFFERENTIAL EXPRESSION OF RNA-SEQ DATA**  
Abdimajid Osman\*, Walter Hitzler, Patrick Provost (Sweden)

### Innovation and Technology

Room 709

Moderators: Deborah Siegal (Canada), Benjamin Brenner (Israel)

- 15:45 - 16:15  
AS053 **HIGH THROUGHPUT MICROFLUIDICS**  
Shaun Jackson (Australia)

## SCIENTIFIC PROGRAM

- 16:15 – 16:35  
AS054 **WHOLE EXOME SEQUENCING IN PATIENTS WITH INHERITED THROMBOCYTOPENIA AND EXCESSIVE BLEEDING IS AN EFFICIENT WAY TO IDENTIFY GENETIC VARIANTS IN KNOWN AND NOVEL GENES**  
Ben Johnson\*, Gillian Lowe, Michael Simpson, Isabel Sánchez Guiú, Sian Drake, David MacDonald, Danai Bem, Sarah Fletcher, Jane Fütterer, Vincenzo Leo, Marie Lordkipanidzé, Ban Dawood, Tina Biss, Paula Bolton-Maggs, Peter Collins, Nicola Curry, Mike Makris, Jayashree Motwani, Sue Pavord, Katherine Talks, Jecko Thacil, Jonathan Wilde, Mike Williams, Paul Harrison, Paul Gissen, Stuart Mundell, Andrew Mumford, Martina Daly, Steve Watson, Neil Morgan (United Kingdom)
- 16:35 – 16:55  
AS055 **A NOVEL PLATFORM TO STUDY THE MECHANO-SENSING MECHANISM ON A SINGLE ASPIRED PLATELET**  
Lining Ju\*, Yunfeng Chen, Shaun Jackson, Cheng Zhu (United States, Australia)
- 16:55 – 17:15  
AS056 **FACTOR XA OVERCOMES INHIBITION BY THE DIRECT FACTOR XA-INHIBITORS FOLLOWING INSERTION OF A STRUCTURAL ELEMENT FROM THE SERINE PROTEASE DOMAIN OF SNAKE VENOM FACTOR XA**  
Daniël Verhoef\*, Mark Schreuder, Carljin van der Sluijs, Ka Lei Cheung, Xiaoxun Yang, Pieter Reitsma, Mettine Bos (The Netherlands)

### Protease activated receptors

Room 713

Moderators: Marc Hoylaerts (Belgium), Katherine Hajjar (United States)

- 15:45 - 16:15  
AS057 **COAGULATION PROTEINASES, PROTEINASE-ACTIVATED RECEPTORS (PARs) AND INFLAMMATION**  
Morley Hollenberg (Canada)
- 16:15 – 16:35  
AS058 **UNRAVELLING PAR1 SIGNALING IN ENDOTHELIAL CELLS USING QUANTITATIVE PHOSPHOPROTEOMICS**  
Bart L. van den Eshof\*, Floris van Alphen, Koen Mertens, Alexander Meijer, Maartje van den Biggelaar (The Netherlands)
- 16:35 – 16:55  
AS059 **THROMBIN, STROMAL CELL-ASSOCIATED PAR-1, AND FIBRIN(OGEN) PROMOTE COLON CANCER PROGRESSION**  
Gregory Adams\*, Leah Rosenfeldt, Malinda Frederick, Whitney Miller, Dusty Waltz, Keith Kombrinck, Brett Monia, Alexey Revenko, Joseph Palumbo (United States)
- 16:55 – 17:15  
AS060 **TUMOR-DERIVED TISSUE FACTOR-EXPRESSING MICROVESICLES PROMOTE A PROADHESIVE PHENOTYPE IN ENDOTHELIAL CELLS**  
Sara Che\*, Tracy Stokol (United States)

Poster with refreshments

17:15 - 18:30 in the Exhibition on Level 800

Technical Sessions

The Technical Session Programs are in the Show Guide. Please consult the different options to attend the session of your choice.

# SCIENTIFIC PROGRAM

Monday, June 22, 2015

POSTER SESSION 17:15-18:30

Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:

Monday, June 22, 2015, from 17.15-18.30

Tuesday, June 23, 2015, from 18.00-19.30

Wednesday, June 24, 2015, from 17.15-18.30

The Poster Area is located inside the Exhibition on Level 800.

Poster setup times are as follows:

Monday, June 22, 2015, from 07.30 - 09.15

Tuesday, June 23, 2015, from 07.30 - 09.15

Wednesday, June 24, 2015, from 07.30 - 09.15

Poster dismantling times are as follows:

Monday, June 22, 2015, from 18.30 - 19.00

Tuesday, June 23, 2015, from 19.30 - 20.00

Wednesday, June 24, 2015, from 18.30 - 19.00

Posters not taken down after the dismantling time will be discarded.

If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:

Monday, June 22, 2015, from 07.30 - 19.00

Tuesday, June 23, 2015, from 19.30 - 20.00

Wednesday, June 24, 2015, from 18.30 - 19.00

Pins are provided on the poster boards directly

## ADAMTS13 I

- PO001-MON **PROTECTIVE EFFECT OF ADAMTS13 HAPLOTYPE ON CORONARY ARTERY DISEASE**  
Supakanya Lasom\*, Nantarat Komanasin, Nongnuch Settatsatian, Chatri Settatsatian, Upa Kukongviriyapan, Vichai Senthong, Pongsak Intharapetch (Thailand)
- PO002-MON **AN UNBALANCE BETWEEN VON WILLEBRAND FACTOR AND ADAMTS13 FOLLOWING A MAJOR PARTIAL HEPATECTOMY**  
Dafna Groeneveld\*, Edris Alkozai, Jelle Adelmeijer, Robert Porte, Ton Lisman (The Netherlands)
- PO003-MON **THE NOVEL C.774\_775 INS CCGCGCC MUTATION COMBINED WITH C.4085 T>A IN THE ADAMTS13 GENE CONTRIBUTES TO THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)**  
Juvenal Paiva\*, Ana Kempfer, Adriana Woods, María Casinelli, Analía Sanchez-Luceros, María Lazzari (Argentina)
- PO004-MON **THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A MEMBER OF A FAMILY WITH ADAMTS13 GENE ABNORMALITIES**  
Juvenal Paiva\*, Ana Kempfer, Adriana Woods, María Casinelli, Fabiana Alberto, Alicia Blanco, María Lazzari, Analía Sanchez-Luceros (Argentina)

# SCIENTIFIC PROGRAM

- PO005-MON **CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) CAUSED BY COMPOUND HETEROZYGOSITY OF C.1225C>T AND A NOVEL C.2321DELG ADAMTS13 GENE MUTATIONS**  
Ana Kempfer, Juvenal Paiva\*, Adriana Woods, Analía Sanchez-Luceros, María Lazzari (Argentina)
- PO006-MON **QUALITY ASSESSMENT FOR ADAMTS-13 TESTING: A CANADIAN EXPERIENCE**  
Arnaud Bonnefoy\*, Michael Keeney (Canada)
- PO007-MON **PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS: THE ROLE OF ADAMTS13**  
Raimondo De Cristofaro\*, Maria Basso, Vito Veca, Stefano Lancellotti, Laura Riccardi, Maurizio Pompili (Italy)
- PO008-MON **IMPORTANCE OF MONITORING ACTIVITY AND ANTI-ADAMTS-13 ANTIBODIES LEVELS IN PREGNANCY WITH SEVERE PREECLAMPSIA HISTORY**  
Victoria Bitsadze\*, Svetlana Akinshina, Ekaterina Zhuravleva, Alexander Makatsaria (Russian Federation)

## Angiogenesis/vasculogenesis

- PO009-MON **PAR1-STIMULATED PLATELETS ENHANCE ANGIOGENIC ACTIVITIES OF ENDOTHELIAL PROGENITOR CELLS MORE POTENTLY THAN PAR4-STIMULATED PLATELETS**  
Zhangsen Huang, Xinyan Miao, Yun Luan, Feng Kong, Nailin Li\* (Sweden)
- PO010-MON **DEVELOPMENT OF AN EX OVO CHICKEN EMBRYO MODEL FOR MEASURING TRACTION FORCES DURING IN VIVO ANGIOGENESIS**  
Sandra Baker-Groberg\*, Dobryna Zalvidea, Arlyng González, Xavier Trepát, Owen McCarty (United States)
- PO011-MON **MICRORNA-126 REDUCES BLOOD-RETINAL BARRIER BREAKDOWN IN OXYGEN-INDUCED RETINOPATHY MOUSE MODEL**  
Yanyan Bai\*, Xia Bai, Zhaoyue Wang (China)
- PO012-MON **STIMULATION OF PAR-1 OR PAR-4 PROMOTES A SIMILAR PATTERN OF PLATELET-MEDIATED ANGIOGENESIS**  
Julia Etulain, Agustina Mena, Soledad Negrotto, Mirta Schattner\* (Argentina)
- PO013-MON **PLATELET MEMBRANE GLYCOPROTEIN CD151 PROMOTES ENDOTHELIAL PROGENITOR CELL ANGIOGENESIS**  
Zhangsen Huang\*, Gunnar Nilsson, John Pernow, Xinyan Miao, Nailin Li (Sweden)
- PO014-MON **PROANGIOGENIC PROPERTIES OF FUCOIDAN IS ASSOCIATED WITH RECRUITMENT AND MODULATION OF MACROPHAGE POLARIZATION**  
Elene Sapharikas\*, Amel Mohamadi, Blandine Dizier, Anna Lokajczyk, Isabelle Gally-fauroux, Dominique Helley, Anne-Marie Fischer, Catherine Boisson-Vidal (France)
- PO015-MON **UNALTERED ANGIOGENESIS-REGULATORY ACTIVITIES OF PLATELETS FROM MILD TYPE 2 DM PATIENTS DESPITE A MARKED PLATELET HYPERREACTIVITY**  
Xinyan Miao, Wei Zhang, Zhangsen Huang, Nailin Li\* (Sweden)

## SCIENTIFIC PROGRAM

- PO016-MON **HUMAN PLATELET LYSATE GEL (HPLG) SUPPORTS AND STIMULATES ENDOTHELIAL PROGENITOR CELL-DRIVEN VASCULOGENESIS**  
Giordano Pula\*, Tiago Fortunato, Paul DeBank (United Kingdom)
- PO017-MON **TF-MEDIATED POSITIVE FEEDBACK CROSSTALK BETWEEN ENDOTHELIAL CELLS AND PATROLLING CD14+/CD16+ MONOCYTES STIMULATES ANGIOGENESIS**  
Sonia Espinosa, Gemma Arderiu, Esther Pena, Vladimir Bogdanov, Javier Crespo, Lina Badimon\* (Spain)
- PO019-MON **PAR2-DEPENDENT SIGNALING VIA SMAD3 IN TF-INDUCED ANGIOGENESIS**  
Gemma Arderiu, Esther Pena, Sonia Espinosa, Lina Badimon\* (Spain)
- PO020-MON **INCREASE OF REACTIVE OXYGEN SPECIES AND SENESCENCE DOWN THE PROLIFERATIVE RATE OF ENDOTHELIAL PROGENITOR CELLS FROM PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE**  
José Antonio Alvarado-Moreno\*, José Rubicel Hernandez-López, María Antonieta Chávez-González, Mervin C. Yoder, Irma Isordia-Salas, Jesús Hernández-Juárez, Abraham Majluf-Cruz (Mexico)

### Animal models I

- PO021-MON **PLASMIN, NOT THROMBIN, ACTIVATES COMPLEMENT IN ARTERIAL AND VENOUS THROMBOSIS**  
Jonathan H. Foley\*, Bethany Walton, Alice O'Byrne, Victor Lei, Kimberley Foley, Jay Degen, Alisa Wolberg, Edward Conway (Canada, United Kingdom)
- PO022-MON **ESTABLISHMENT OF A VASCULAR INJURY MODEL DEMONSTRATING DIFFERENT EFFICACIES OF ANTITHROMBOTIC AGENTS ON THROMBUS FORMATION IN MICE**  
Chaojun Tang\*, Daoxi Lei, Lu Huang, Guixue Wang, Li Zhu (China)
- PO023-MON **FERRIC CHLORIDE-INDUCED VENOUS THROMBOSIS MODEL IN RATS: FINDING THE OPTIMAL CONCENTRATION OF FERRIC CHLORIDE**  
Polina Alekseeva\*, Natalia Pitukhina (Russian Federation)
- PO025-MON **THROMBIN GENERATION IN ZEBRAFISH**  
Evelien Schurgers, Martijn Moorlag, Hilde Kelchtermans\*, Coenraad Hemker, Bas de Laat (The Netherlands)
- PO026-MON **CLOT CONTRACTION AND POLYHEDROCYTES IN CLOTS FORMED AFTER SAPHENOUS VEIN PUNCTURE IN THE MOUSE**  
John W. Weisel\*, Chandrasekaran Nagaswami, Yifan Xu, Irina Chernysh, Zeldá de Lange, Sofia Kosolapova, Lilley Leong, Katalin Kausser, Derek Sim (United States)
- PO027-MON **BENEFICIAL THERAPEUTIC PROPERTIES OF DIETARY ALPHA-LINOLENIC ACID (ALA) IN A MOUSE MODEL OF SICKLE CELL DISEASE**  
Simona Stivala\*, Sara Gobatto, Martin Reiner, Thomas Lüscher, Jürg Beer (Switzerland)
- PO028-MON **RABBIT MODEL OF FERRIC CHLORIDE-INDUCED CAROTID ARTERIAL THROMBOSIS OPTIMIZED FOR TRANSLATIONAL DRUG DISCOVERY**  
Xinkang Wang\*, Stan Kurowski, Xueping Zhou, Weizhen Wu, Michael Wismer, Lin Chu, Dietmar Seiffert (United States)

## SCIENTIFIC PROGRAM

- PO029-MON **DISSECTION OF THE THERAPEUTIC EFFICACY OF FIX-TRIPLE FOR REDUCING HAEMOPHILIC ARTHROPATHY IN HEMOPHILIA B USING A BLOOD-INDUCED JOINT INJURY MURINE MODEL**  
Guan-Ying Zheng\*, Shu-Jhu Yang, Chun-Yu Chen, Mi-Hua Tao, Yu-Chen Hsu, I-Shing Yu, Sh-Feng Yang, Shu-Wha Lin (Taiwan)
- PO030-MON **STANDARDIZING ENOXAPARIN DOSING IN MOUSE MODELS OF DEEP VEIN THROMBOSIS**  
Joshua Rainey, Kelsey Krus, Daniel Myers, Shirley Wroblewski, Diana Farris, Angela Hawley, Thomas Wakefield, José A. A. Dia\* (United States)
- PO031-MON **GENERATION OF HEMOPHILIA B MICE IN NSG BACKGROUND USING CRISPR/CAS9 TECHNOLOGY**  
Meng-Ni Fan\*, I-Shing Yu, Sheng-Kai Chang, Sheng-Chieh Chou, Ching-tzu Yen, Hsien-Wei Hsieh, Shu-Wha Lin, Yung-Li Yang (Taiwan)
- PO032-MON **ACUTE BONE LOSS IN FVIII AND FIX BUT NOT VWF DEFICIENT MICE FROM JOINT INJURY**  
Ted Bateman\*, William Hanna, Anthony Lau, Eric Livingston, Junjiang Sun, Dominique Heymann, Paul Monahan (United States)
- PO033-MON **ENOXAPARIN ACUTELY WORSENS HEMODYNAMIC MEASUREMENTS COMPARED WITH TPA IN A LARGE ANIMAL MODEL OF SUBMASSIVE PULMONARY EMBOLISM**  
Daren M. Beam\*, Jeffrey Kline, Evandro Neto-Neves (United States)
- PO034-MON **GENOME-WIDE KNOCKDOWNS IN ZEBRAFISH TO STUDY THROMBOCYTE FUNCTION**  
Pudur Jagadeeswaran, Hemalatha Sundaramoorthi\*, Gauri Khandekar (United States)

### Antiphospholipid syndrome I

- PO035-MON **BRAIN WHITE MATTER MICROSTRUCTURE IS ALTERED IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EVIDENCES FROM DIFFUSION-TENSOR MRI IN ASYMPTOMATIC NEUROLOGICAL PATIENTS**  
Jean-Christophe R. Gris\*, Géraldine Lavigne, Sylvie Bouvier, Eva Nouvellon, Erick Mercier, Fabricio Pereira, Francesco Macri, Marcel Jackowski, Jean-Paul Beregi, Choukri Mekkaoui (France)
- PO036-MON **THROMBOTIC RISK OF REDUCED ADAMTS13 ACTIVITY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES**  
Hyun Kyung Kim\* (Korea, Republic Of)
- PO037-MON **MIXING TEST SPECIFIC CUT-OFF IS MORE SENSITIVE AT DETECTING IN VITRO LUPUS ANTICOAGULANT INHIBITION THAN THE INDEX OF CIRCULATING ANTICOAGULANT**  
Gary W. Moore\*, Aidan Culhane, Christopher Daw, Charlotte Noronha, Osamu Kumano (United Kingdom)

## SCIENTIFIC PROGRAM

- PO038-MON **A MULTICONTROL KIT FOR ANTIPHOSPHOLIPID AND ANTI-PLATELET FACTOR 4-HEPARIN ANTIBODIES: NINE DIFFERENT ANALYTES IN A SINGLE VIAL**  
Josep Puig\*, Fernando Cavalcanti, Raquel Torres, Sandra Matilla, Josep Serra (Spain)
- PO039-MON **PERSISTENT LUPUS ANTICOAGULANT IN CLINICAL SETTINGS OTHER THAN ANTIPHOSPHOLIPID SYNDROME**  
Lucia Remotti\*, Silvia Grosso, Marcelo Ingrassi, Maria Vera Morandini, Emilse Bermejo, Analía Sanchez Luceros, Susana Meschengieser, Maria Lazzari, Alicia Blanco (Argentina)
- PO040-MON **HOW APPROPRIATE IS THE ANTIPHOSPHOLIPID ANTIBODIES TESTING AT SIRIRAJ HOSPITAL?**  
Yingyong Chinthammitr\*, Thanitsak Thaweekhot, Panutsaya Tientadukul, Chaicharoen Tantamate (Thailand)
- PO041-MON **THROMBOMODULIN DOWN-REGULATION IS RELATED TO THE THROMBOSIS RISK IN ANTIPHOSPHOLIPID SYNDROME PATIENTS**  
Osamu Kumano\*, Masahiro Ieko, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi, Takeshi Suzuki, Takashi Aoki (Japan)
- PO042-MON **USE OF D DIMER IN BIOLOGICAL CONTROL OF PREGNANCY**  
Ana Otero, Ana M. Lena\*, Elena De Lisa, Datevig Attarian, Enrique Pons, Ricardo Pou, Nora Mota, Gabriela Domínguez, Sebastián De Los Santos, Cecilia Carrizo (Uruguay)
- PO043-MON **ANTI-ANNEXIN V ANTIBODIES IN PATIENTS WITH OBSTETRIC MORBIDITY**  
Alberto Maneyro\*, Susana Ouviaña, Laila Noya, Luis Palmer (Argentina)
- PO044-MON **INTERACTIONS BETWEEN RIVAROXABAN AND ANTIPHOSPHOLIPID ANTIBODIES IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME**  
Deepa Jayakody Arachchillage\*, Ian Mackie, Maria Efthymiou, David Isenberg, Samuel Machin, Hannah Cohen (United Kingdom)
- PO045-MON **PROPOSED TRIAL: HYPATIA - A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYDROXYCHOROQUINE VERSUS PLACEBO DURING PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID ANTIBODIES**  
Karen Schreiber\*, Savino Sciascia, Karen Breen, Soren Jacobsen, Roy Farquharson, Saskia Middeldorp, Lesley Regan, Beverley Hunt (United Kingdom, Denmark)
- PO046-MON **RIVAROXABAN LIMITS COMPLEMENT ACTIVATION IN PATIENTS WITH THROMBOTIC ANTIPHOSPHOLIPID SYNDROME**  
Deepa Jayakody Arachchillage, Ian Mackie, Maria Efthymiou, Andrew Chitolie, Beverly Hunt, David Isenberg, Munther Khamashta, Samuel Machin, Hannah Cohen (United Kingdom)
- PO048-MON **ANALYTICAL AND CLINICAL PERFORMANCE OF A NEW AUTOMATED CHEMILUMINESCENT ASSAY (CIA)**  
Teresa Iwaniec\*, Marcin Kaczor, Magdalena Celinska-Löwenhoff, Stanisław Polanski, Jacek Musiał (Poland)
- PO049-MON **FALSE POSITIVE RESULTS OF PLATELET NEUTRALIZATION PROCEDURE (PNP) IN LUPUS ANTICOAGULANT (LA) TESTING OF PATIENTS WITH COAGULATION FACTOR DEFICIENCIES**  
Geoffrey D. Wool\*, Krzysztof Mikrut, Jonathan Miller (United States)

## SCIENTIFIC PROGRAM

- PO050-MON **FREQUENCY OF CLINICALLY SIGNIFICANT ANTIPHOSPHOLIPID ANTIBODIES PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISM, STROKE, MYOCARDIAL INFARCTION, PERIPHERAL ARTERIAL DISEASE AND PREGNANCY MORBIDITY**  
Benilde Cosmi\*, Cristina Legnani, Michela Cini, Gualtiero Palareti (Italy)
- PO051-MON **CLINICAL ASSESSMENT OF ANTIPHOSPHOLIPID ANTIBODIES AGAINST  $\beta$ 2-GLYCOPROTEIN DOMAIN I IN ANTIPHOSPHOLIPID SYNDROME.**  
Pascual Marco\*, Ana Marco, Virgilio Cabrera, Vanessa González (Spain)
- PO052-MON **MULTIPLE POSITIVITY AND APA PROFILE IN WOMEN WITH FETAL LOSS SYNDROME**  
Natalya Makatsariya, Nadezhda Stuleva, Jamilya Khizroeva\* (Russian Federation)
- Antiplatelet agents I**
- PO054-MON **IMPACT OF PREANALYTICAL DELAY ON RESULTS OF LIGHT TRANSMITTANCE AGGREGOMETRY IN STEMI PATIENTS**  
Anna Vybivantseva\*, Olga Demkova, Natalia Saraeva, Larisa Koryakina, Elena Andreeva, Galina Lifshits, Konstantin Apartsin (Russian Federation)
- PO055-MON **ASSOCIATION OF PLATELET RESPONSE TO CILOSTAZOL WITH CLINICAL OUTCOME AND CYP GENOTYPES IN PATIENTS WITH CEREBRAL INFARCTION**  
Jun Yamanouchi\*, Takaaki Hato, Masaki Yasukawa (Japan)
- PO056-MON **PLATELET REACTIVITY BASED RISK ASSESSMENT FOR PATIENTS WITH CORONARY ARTERY DISEASE ON P2Y12 INHIBITORS IS NOT CONSISTENT BETWEEN DIFFERENT PLATELET FUNCTION TESTS**  
M.J.A. Vries\*, R.H. Olie, L.F. Veenstra, J.C.A. Hoorntje, A.J. Ten Cate-Hoek, H.M.H. Spronk, P.E.J. van der Meijden, Y.M.C. Henskens, H. Ten Cate (The Netherlands)
- PO057-MON **PLATELET FUNCTION TESTING IN ACS PATIENTS USING MEASUREMENT OF PLATELET P-SELECTIN: COMPARISON WITH OTHER COMMERCIAL TESTS**  
Jane May\*, Natalia Dovlatova, Ashwin Radhakrishnan, Stan Heptinstall, Sue Fox (United Kingdom)
- PO058-MON **EFFICACY OF PRASUGREL ADMINISTRATION IMMEDIATELY AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE MYOCARDIAL INFARCTION**  
Andreas Schäfer\*, Ulrike Flierl, Johann Bauersachs (Germany)
- PO059-MON **THE ANTITHROMBOTIC EFFECTS OF SYNTHETIC POLYPEPTIDES DERIVED FROM SNACLECS: INVOLVEMENT OF PLATELET GLYCOPROTEIN VI ANTAGONISM**  
Chien-Hsin Chang\*, Ching-Hu Chung, Chun-Chieh Hsu, Tur-Fu Huang (Taiwan)
- PO060-MON **CORRELATION BETWEEN PLATELET MRP4 EXPRESSION AND PLATELET FUNCTION IN PATIENTS UNDER CHRONIC ASPIRIN TREATMENT**  
Isabella Massimi\*, Flavia Temperilli, Maria Luisa Guarino, Teresa Maltese, Lavinia Vittoria Lotti, Luigi Frati, Fabio Maria Pulcinelli (Italy)



## SCIENTIFIC PROGRAM

- PO061-MON **PLATELET FUNCTION MONITORING IN PATIENTS ON DUAL ANTIPLATELET THERAPY UNDERGOING URGENT HIP SURGERY: PRELIMINARY RESULTS.**  
Luca Spiezia\*, Francesco Vasques, Astrid Behr, Elena Campello, Sara Maggiolo, Paolo Simioni (Italy)
- PO062-MON **PLATELET REACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION CHRONICALLY TREATED WITH BETA-BLOCKERS BEFORE THE ONSET OF THE ACUTE EVENT.**  
Maria T. Santos\*, Antonio Moscardó, Ana Latorre, Isabel Madrid, Maria Paz Fuset, Juana Valles (Spain)
- PO063-MON **PROTEOMIC PROFILING OF PLATELET RESPONSE TO ANTIPLATELET AGENTS REVEALS A WIDE INTER-INDIVIDUAL VARIABILITY AND DISTINCT SIGNATURES OF DRUGS ALONE AND IN COMBINATION**  
Simone Marcone\*, Desmond Fitzgerald (Ireland)
- PO064-MON **DUAL ANTIPLATELET THERAPY COMBINING ASPIRIN AND TICAGRELOR IN INTRACRANIAL ANEURYSMAL EMBOLIZATION. A 13-MONTH FRENCH EXPERIENCE.**  
Ana Paula Narata, Yves Gruel\*, Denis Angoulvant, Denis Herbreteau (France)
- PO065-MON **INHIBITION OF THIOREDOXIN INHIBITS GPVI-MEDIATED PLATELET ACTIVATION**  
Clive Metcalfe, Anjana Ramasubramoni, Giordana Pula, Matthew Harper, Stuart Mundell, Carmen Coxon\* (United Kingdom)
- PO066-MON **PREDICTION OF HIGH ON-TREATMENT PLATELET REACTIVITY IN CLOPIDOGREL-TREATED PATIENTS WITH ACUTE CORONARY SYNDROMES, USING ADVANCED ARTIFICIAL NEURAL NETWORKS**  
Gian Marco Podda\*, Enzo Grossi, Tullio Palmerini, Massimo Buscema, Eti A. Femia, Andrea Mariani, Diego Della Riva, Marco Cattaneo (Italy)
- PO067-MON **ASPIRIN RESISTANCE IN MEDICAL INPATIENTS ON CHRONIC ASPIRIN TREATMENT**  
Alessia Fabbri, Elisa Grifoni, Maddalena Pazzi, Rita Paniccia, Anna Maria Gori\*, Sara Bucherelli, Alessandro Morettini, Rossella Marcucci, Rosanna Abbate (Italy)
- PO068-MON **TXA<sub>2</sub>-BINDING PROTEINS, DIPETALODIPIN AND TRIPLATIN, BLOCK PLATELET-MEDIATED NETS FORMATION IN VITRO AND INHIBIT THROMBOSIS IN VIVO WITHOUT IMPAIRING HEMOSTASIS**  
Daniella Mizurini\*, Jorgeane Aslan, Taina Gomes, Dongying Ma, Ivo Francischetti, Robson Monteiro (Brazil)

### Arterial vascular disorders - clinical I

- PO069-MON **ADAMTS13 AND THE RISK OF MYOCARDIAL INFARCTION: AN INDIVIDUAL PATIENT DATA META-ANALYSIS**  
Alberto Maino\*, Bob Siegerink, Luca Lotta, James Crawley, Saskia le Cessie, Frank Leebeek, David Lane, Gordon Lowe, Flora Peyvandi, Frits Rosendaal (Italy)

## SCIENTIFIC PROGRAM

- PO070-MON **DIVERSE EFFECTS OF PAI-1 ON VASCULAR SMOOTH MUSCLE CELLS PHENOTYPE SWITCH**  
Xin Deng\*, Mao Luo, Rong Li, Meiping Ren, Ni Chen, Kai Yan, Min Zeng, Jianbo Wu (China)
- PO071-MON **RETINAL VESSEL CALIBERS AND HAEMOSTASIS IN BLACK AND WHITE SOUTH AFRICANS: THE SABPA STUDY**  
Leandi Lammertyn\*, Aletta Schutte, Wayne Smith, Marlien Pieters, Rudolph Schutte (South Africa)
- PO072-MON **PROGNOSTIC VALUE OF THE CHA2DS2VASC SCORE IN PATIENTS EXPERIENCING A MYOCARDIAL INFARCTION**  
Serenella Conti\*, Maria Cristina Vedovati, Roberta Molle, Giorgio Maragoni (Italy)
- PO073-MON **GENETIC RISK FACTORS ON ATHEROTHROMBOTIC DISEASE: COMPARISON BETWEEN TWO TERRITORIES.**  
Irma Isordia-Salas\*, Lorena Mendoza-Valéz, José Antonio Alvarado-Moreno, David Santiago-Germán, María Guadalupe Valades-Mejía, Jesús Hernández-Juárez, Rosa María Jiménez-Alvarado, Abraham Majluf-Cruz (Mexico)
- PO074-MON **CARDIOLOGICAL AND THROMBOPHILIC RISK PROFILE IN PATIENTS WITH OCULAR ARTERIAL OCCLUSION**  
Jerzy Dropinski\*, Agnieszka Kubicka-Trzaska, Teresa Domagala, Marek Sanak, Teresa Iwaniec, Jacek Musiał (Poland)
- PO075-MON **A NOVEL ASSAY DEMONSTRATES PROCOAGULANT PLATELETS ARE INCREASED IN PATIENT UNDERGOING CORONARY ANGIOGRAPHY WITH DIFFERENTIAL EFFECTS BY ANTI-PLATELET AND ANTI-COAGULANT THERAPY**  
Leonardo Pasalic\*, Heather Campbell, Edwina Wing-Lun, Philip Hogg, David Connor, David Muller, Vivien Chen (Australia)
- PO076-MON **RELATION BETWEEN INVASIVE CENTRAL PULSE PRESSURE AND THROMBOGENICITY**  
Gailing Chen, Kevin Bliden, Fang Liu, Udaya Tantry, Paul Gurbel\* (United States)
- PO077-MON **DRUG-ELUTING CORONARY STENTS GENERATE LOWER LEVEL OF CELLULAR ACTIVATION COMPARED TO BARE METAL STENTS IN STABLE ANGINA PATIENTS**  
Béla Nagy Jr\*, Tibor Szük, Ildikó Debreceni, Zsolt Fejes, Adrienne Kerényi, István Édes, János Kappelmayer (Hungary)
- PO078-MON **NEUTROPHIL EXTRACELLULAR TRAPS IN CORONARY ARTERY THROMBI IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION**  
Anouchka Autar\*, Mie Kurata, Danielle Mensink, Evelyn Regar, Marco Valgimigli, Frank Leebeek, Felix Zijlstra, Moniek De Maat, Heleen Van Beusekom (The Netherlands)
- PO079-MON **ASSOCIATION BETWEEN GLUCOMETABOLIC CONTROL AND DEGREE OF HYPERCOAGULABILITY IN PATIENTS WITH COMBINED TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE.**  
Vibeke Bratset\*, Rune Byrkjeland, Svein Solheim, Harald Arnesen, Ingebjørg Seljeflot (Norway)

## SCIENTIFIC PROGRAM

- PO079.1-MON **THE COBALT-CHROMIUM ALLOY COMPOSING STENT IS THROMBOGENIC**  
Veronique Ollivier\*, Caroline Roques, Elmina Mammadova-Bach, Matthias Gratz, Christian Gachet, Didier Letourneur, Pierre Mangin, Martine Jandrot-Perrus (France)

### Atherosclerosis I

- PO080-MON **ASSOCIATION OF ABCB1 C3435T POLYMORPHISM WITH BLOOD GLUCOSE LEVELS AND RISK OF CORONARY ARTERY DISEASE IN THAIS**  
Sornsith Jirungda\*, Nantarat Komanasin, Nongnuch Settassatian, Chatri Settassatian, Upa Kukongwiriyanan, Pongsak Intharapetch, Vichai Senthong (Thailand)
- PO081-MON **UNDERSTANDING GENE EXPRESSION IN CORONARY ARTERY DISEASE THROUGH GLOBAL PROFILING, NETWORK ANALYSIS AND INDEPENDENT VALIDATION OF KEY CANDIDATE GENES**  
Prathima Arvind\* (India)
- PO082-MON **INSIGHTS INTO THE GENETIC ARCHITECTURE OF CORONARY ARTERY DISEASE IN ASIAN INDIANS**  
Jiny Nair\*, Prathima Aravind, Jayashree Shanker, Vijay Kakkar (India)
- PO083-MON **CIRCULATING LYMPHOCYTES AND MONOCYTES AS RISK FACTORS FOR CORONARY ARTERY DISEASE IN INDIAN POPULATION**  
Thiruvvelselvan Ponnusamy, Srikanth Venkatachala, Manjunatha Ramanjappa, Vijay Kakkar, Lakshmi Mundkur\* (India)
- PO084-MON **TRANSLATIONAL INFORMATICS APPROACH LINKING RISK OF CORONARY ARTERY DISEASE, INFECTION AND INFLAMMATION**  
Rajani Kanth Vangala, Ankit Sharma\*, Madankumar Ghatge (India)
- PO085-MON **IDENTIFICATION OF NOVEL GENETIC MUTATIONS IN LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) GENE CAUSING FAMILIAL HYPERCHOLESTEROLEMIA IN SAUDI ARAB HOMOZYGOUS CHILDREN**  
Faisal A. Al-Allaf\*, Mohammad Athar, Zainularifeen Abduljaleel, Mohiuddin Taher, Abdellatif Bouazzaoui, Halah Abalkhail, Rakan Own, Ahmad Al-Allaf, Iman AboMansoor, Zohor Azhar, Faisal Ba-hammam, Abdullah Alashwal (Saudi Arabia)
- PO086-MON **ROLE OF RS4988300 AND RS3781590 LRP5 GENE AND RS1466535 LRP1 GENE POLYMORPHISMS IN THE COHORT OF THE PROSPECTIVE MONTIGNOSO STUDY**  
Alice Sereni\*, Betti Giusti, Francesco Sofi, Claudia Saracini, Silvia Galora, Rosina De Caro, Daniele Della Latta, Dante Chiappino, Rosanna Abbate, Gian Franco Gensini (Italy)

### Blood coagulation tests I

- PO087-MON **ACTIVE THROMBIN ASSAY FOR IMPROVED TREATMENT OF THROMBOSIS**  
Vera Ignjatovic, Leslie Berry, Anthony Chan, Paul Monagle\* (Australia)

## SCIENTIFIC PROGRAM

- PO088-MON **ACCURATE RECOVERY OF PEGYLATED AND NON-PEGYLATED THERAPEUTIC FVIII, USING A SPECIFIC APTT REAGENT, AND APPLICATION ON AN AUTOMATED COAGULATION ANALYZER**  
Mary J. Doyle\*, Anuja Khan, Karen DiStasio, Alexandra Sullivan, Mark Triscott (United States)
- PO089-MON **THROMBIN GENERATION CAPACITY AND PHENOTYPIC ASSOCIATION IN ABO BLOOD GROUPS**  
Romy Kremers\*, Abdulrahman Mohamed, Leonie Pelkmans, Salwa Hindawi, Coenraad Hemker, Bas de Laat, Dana Huskens, Raed Al Dieri (The Netherlands)
- PO090-MON **HAEMOSTASIS IN CARDIAC ARREST PATIENTS TREATED WITH THERAPEUTIC HYPOTHERMIA**  
Anne Katrine Wulff Nielsen\*, Anni Jeppesen, Hans Kirkegaard, Anne-Mette Hvas (Denmark)
- PO091-MON **IS TGA ABLE TO DISCRIMINATE A DIFFERENT COAGULATION PROFILE IN INHIBITOR PATIENTS WITH SEVERE HEMOPHILIA A AS COMPARED TO NON-INHIBITOR PATIENTS?**  
Maria Elisa Mancuso\*, Veena Chantarangkul, Marigrazia Clerici, Maria Fasulo, Lidia Padovan, Erica Scalabrino, Flora Peyvandi, Armando Tripodi, Elena Santagostino (Italy)
- PO092-MON **IMPACT OF EDOXABAN ON A LARGE PANEL OF ROUTINE OR MORE SPECIFIC COAGULATION ASSAYS**  
Jonathan Douxfils\*, Tania Del Bianco, Justine Baudar, Sarah Lessire, Bernard Chate-lain, Jean-Michel Dogné, François Mullier (Belgium)
- PO093-MON **MODIFICATION OF A THROMBIN GENERATION TEST TO IDENTIFY NEW COFACTORS OF THE PROTEIN C PATHWAY IN PLASMA**  
Laura Martos, Hiroshi Deguchi, Elena Bonet, Pilar Medina, Luis A Ramon, Saturnino Haya, Ana R Cid, Santiago Bonanad, John H Griffin, Francisco España, Silvia Navarro\* (Spain)
- PO094-MON **PRELIMINARY PERFORMANCE DATA OF A NEW ASSAY FOR THE QUANTITATIVE DETERMINATION OF THE ACTIVITY OF UNFRACTIONATED HEPARIN (UFH) AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) USING A SINGLE CALIBRATION CURVE FOR BOTH TYPES OF HEPARIN\***  
Matthias Wilkens\*, Beate Becker-Scheidemann, Anja Borchert, Sabine Halilovic, Anja Hecker, Regina Hoffmann, Irene Jennemann-Watzka, Markus Muth, Ruth Neunziger, Juergen Patzke, André Scheidler, Stephanie Schmidt, Bettina Wecht, Andrea Lichte (Germany)
- PO095-MON **PROVISION OF EXTERNAL QUALITY ASSURANCE FOR THROMBOELASTOGRAPHY (TEG) AND THROMBOELASTOMETRY (ROTEM)**  
Dianne P. Kitchen\*, Shelene Munroe-Pearl, Ian Jennings, Steve Kitchen, Tim Woods, Isobel Walker (United Kingdom)
- PO096-MON **ANTICOAGULATION ASSESSMENT WITH PROTHROMBIN TIME AND ANTI-XA ASSAYS IN REAL-WORLD PATIENTS ON TREATMENT WITH RIVAROXABAN**  
Oliver Königsbrügge\*, Peter Quehenberger, Sabine Belik, Günter Weigel, Christoph Seger, Andrea Griesmacher, Ingrid Pabinger, Cihan Ay (Austria)

## SCIENTIFIC PROGRAM

- PO097-MON **GLOBAL HEMOSTASIS ASSAYS THROMBOELASTOGRAPHY AND THROMBODYNAMICS EVALUATE HYPERCOAGULATION IN CHILDREN WITH HEMOLYTIC ANEMIA**  
Elena A. Seregina\*, Janna Kuzminova, Alexander Poletaev, Asmik Sepoyan, Fazoil Ataullakhanov, Natalya Smetanina, Anna Balandina (Russian Federation)
- PO098-MON **CLINICALLY IMPORTANT DIFFERENCES IN PHARMACODYNAMIC EFFECTS OF RIVAROXABAN AND APIXABAN**  
Ross I. Baker\*, Roza Szollosi, Scott McGregor (Australia)
- PO099-MON **MONITORING NEW ORAL ANTICOAGULANTS (NOACS) USING NEW-GENERATION THROMBELASTOGRAPHY TEG®6S SYSTEM**  
Kevin Bliden, Adina Muresan, Gabriel Raviv, Eli Cohen, Fowzia Zaman, Katayoon Saadin, Nafees Mohammed, Rahul Chaudhary, Rahil Rafeedheen, Udaya Tantry, Paul Gurbel\* (United States)
- PO100-MON **IN VITRO MODELS OF THROMBOSIS USING HUMAN WHOLE BLOOD UNDER FLOW CONDITIONS**  
Lewis Hardy\*, Emma Hethershaw, Amy La Corte, Helen Philippou (United Kingdom)
- PO101-MON **FXII618, A NEW FACTOR XII INHIBITOR: VALIDATION FOR THROMBIN GENERATION ASSAY**  
Sara Calzavarini\*, Vanessa Baeriswyl, Claudia Quarroz, Christian Heinis, Anne Angelillo-Scherrer (Switzerland)
- PO102-MON **PF4-R, A NOVEL HEPARIN NEUTRALIZING REAGENT SUITABLE FOR AUTOMATED COAGULOMETERS: COMPARISON WITH HEPARINASE IN ROUTINE COAGULATION TESTS**  
Steven Raynard\*, Ali Sadeghi-Khomami, Zhou Hui (Canada)
- PO103-MON **GLOBAL ASSAYS DO NOT PREDICT BLEEDING PHENOTYPE IN HEMOPHILIA A.**  
Marilyn J. Manco-Johnson\*, Taylor Blades, John Kittelson, Elizabeth Vilalobos-Menuy, Linda Jacobson (United States)
- PO104-MON **TESTING AN IN VITRO MODEL OF LAMINAR FLOW FOR USE IN LARGE-SCALE APTAMER SCREENING**  
Laura Sommerville\*, George Pitoc, Bruce Sullenger, Maureane Hoffman (United States)
- PO105-MON **POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH TYPE 2 DIABETES**  
Jakub Siudut\*, Michał Zabczyk, Anetta Undas (Poland)

### Cancer and thrombosis/hemostasis I

- PO106-MON **ACTIVATION OF COAGULATION BY ANTINEOPLASTIC DRUGS FOR LYMPHOID TUMORS**  
Misae Tsunaka\*, Reina Arai, Ayaka Ohashi, Takatoshi Koyama (Japan)
- PO107-MON **PROCOAGULANT TUMOR MICROENVIRONMENT AS TARGET FOR A TFPI-LIKE MOLECULE**  
Katia Morais\*, Mário Pacheco, Kerly Pasqualoto, Carolina Berra, Juliana Sciani, Mariana Schmidt, Maria Teresa Lamy, Evandro Duarte, Ana Marisa Chudzinski-Tavassi (Brazil)

## SCIENTIFIC PROGRAM

- PO108-MON **MODELISATION OF THE PROCOAGULANT PROPERTIES OF ADENOCARCINOMA PANCREATIC CELLS (BXPC3) AND BREAST CANCER CELLS (MCF7) AND ANALYSIS OF THEIR SPECIFIC INTERACTIONS WITH THE COAGULATION SYSTEM**  
Aurélie Rousseau, Patrick Van Dreden\*, Grigoris Gerotziafas (France)
- PO109-MON **EFFECT OF HYPOXIA ON TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION IN BREAST CANCER CELLS**  
Cui Xue Yan, Benedicte Stavik, Grethe Skretting, Anders Erik Astrup Dahm, Nina Iversen, Sebastian Seidl, Sandip Kanse, Per Morten Sandset (Norway)
- PO110-MON **THE THROMBOTIC POTENTIAL OF CIRCULATING TUMOR MICROEMBOLI**  
Annachiara Mitrugno\*, Kevin Phillips, Michael King, Siddarth Chandrasekaran, Paul Newton, Peter Kuhn, Craig Williams, Owen McCarty (United States)
- PO111-MON **FIBRIN DEGRADATION BY RTPA IMPROVES NANOPARTICLE DRUG DELIVERY FOR TUMORS**  
Bo Zhang\*, Yu Hu (China)
- PO112-MON **HUMAN ANGIOSARCOMA CELLS EXPRESS TISSUE FACTOR AND GENERATE THROMBIN IN A TISSUE FACTOR-DEPENDENT MANNER**  
Lauren Witter, Tracy Stokol\* (United States)
- PO113-MON **ROLE OF AUTOANTIBODIES TO PLASMINOGEN AT ONCOLOGIC DISEASES**  
Roza Aisina\*, E Goufman, V Yakovlev V.N., L Mukhametova, N Tikhonova, K Gershkovich K.B., D Gulin (Russian Federation)
- PO115-MON **PROTHROMBOTIC RISK ASSOCIATED WITH INTRAVENOUSLY GIVEN HIGH DOSE VITAMIN C: ANOTHER EVIDENCE WARNING AGAINST THE BLIND FAITH IN VITAMINS?**  
Keunyoung Kim\*, Ok-Nam Bae, Sung-Hee Koh, Seojin Kang, Kyung-Min Lim, Ji-Yoon Noh, Sue Shin, Inho Kim, Jin-Ho Chung (Korea, Republic Of)
- PO116-MON **DOXORUBICIN-INDUCED MDR1/P-GP IN MCF-7 BREAST CANCER CELLS WAS ASSOCIATED WITH TISSUE FACTOR OVEREXPRESSION AND THROMBIN GENERATION**  
Amir Khaterchi\*, asmae Karroum, Elisabeth Mbemba, Aurelie Rousseau, Patrick Van Dreden, Vasiliki Gkalea, Ismail Elalamy, Mohamed Hatmi, Grigoris Gerotziafas (France)
- PO117-MON **ACTIVATED PROTEIN C UP-REGULATES THE OVARIAN CANCER CELL MIGRATION AND PROMOTES UNCLOTTABILITY OF CANCER PERITONEAL FLUID**  
Hamda Althawadi\*, Halema Alfarsi, Shahsoltan Mirshahi, Jean Chidiac, Samaher Besbes, Amu Therwath, Marc Pocard, Jeannette Soria, Massoud Mirshahi (France, Qatar)
- PO118-MON **ESTROGENS UPREGULATE TFPI-2 EXPRESSION IN MCF-7 CELLS PROBABLY BY PROMOTER DEMETHYLATION**  
Marianne Andresen, Huda Ali, Nina Iversen, Benedicte Stavik, Christiane Myklebust, Per Morten Sandset, Grethe Skretting\* (Norway)
- PO119-MON **ENDOTHELIAL PROTEIN C RECEPTOR IN BREAST CANCER CELLS, CO-EXPRESSED WITH MULTIDRUG RESISTANCE PROTEIN, INHIBITS FIBRIN FORMATION IN TUMOR MICRO ENVIRONMENT**  
Halema Alfarsi\*, Hamda Althawadi, Shahsoltan Mirshahi, Elodie Ducros, Amu Therwath, Marc Pocard, Jeannette Soria, Massoud Mirshahi (France, Qatar)

## SCIENTIFIC PROGRAM

- PO120-MON **CHANGES IN COAGULATION IN ACUTE PROMYELOCYTIC LEUKAEMIA**  
Richard Dillon, Kiran Parmar, David Grimwade, Beverley Hunt\* (United Kingdom)
- PO121-MON **FIBRINOLYTIC ACTIVATION IN ACUTE PROMYELOCYTIC LEUKAEMIA**  
Richard Dillon, Kiran Parmar, David Grimwade, Beverley Hunt\* (United Kingdom)
- PO122-MON **CONDITIONAL INACTIVATION OF INTEGRIN AV SUBUNIT IN VASCULAR SMOOTH MUSCLE CELLS DECREASES THROMBIN GENERATION IN VESSELS AND BLOOD.**  
Amel Mohamadi\*, Zhenlin Li, Huguette Louis, Mustapha Bourhim, Patrick Lacolley\*, Véronique Regnault (France)
- PO123-MON **OESTROGENS REGULATE TFPI EXPRESSION THROUGH OESTROGEN RESPONSE ELEMENTS IN TFPI 5' FLANKING REGION**  
Huda O. Ali\*, Benedicte Stavik, Christiane Myklebust, Elisabeth Dørum, Nina Iversen, Per Morten Sandset, Grethe Skretting (Norway)
- PO124-MON **MONOCYTIC LEUKEMIA CELL LINES POSSESS ENHANCED PROCOAGULANT ACTIVITY, THE ROLE OF FLT3-ITD MUTATION**  
Renáta Hudák\*, Ildikó Debreceni, Gabriella Gál, Péter Antal-Szalmás, János Kappel-mayer (Hungary)
- PO125-MON **THROMBIN DRIVES PANCREATIC DUCTAL ADENOCARCINOMA GROWTH AND DISSEMINATION THROUGH MECHANISMS LINKED TO FIBRINOGEN AND PROTEASE-ACTIVATED RECEPTOR-1**  
Cheryl Rewerts, Carolina Cruz, Joseph Palumbo, James Luyendyk, Yi Yang, Stephen Konieczny, Matthew Flick\* (United States)
- PO126-MON **MICROCIRCULATION THROMBOSIS IN BONE: A POSSIBLE MECHANISM FOR BONE PAIN**  
Eli Peled\*, Mai Assalia, Elena Axelman, Doron Norman, Benjamin Brenner, Yona Nadir (Israel)
- PO127-MON **PROCOAGULANT EFFECTS OF LUNG CANCER CHEMOTHERAPY THROUGH RELEASE OF MICROPARTICLES AND CELL-FREE DNA.**  
Zakhar Lysov\*, Dhruva Dwivedi, Patricia Liaw (Canada)
- PO128-MON **THE REED STERNBERG CELL COAGULOME**  
Gabriela N. Cesarman-Maus\*, Jonathan Reichel, Mikhail Roshal, Esteban Braggio, Rafael Fonseca, Ethel Cesarman (Mexico)
- PO129-MON **FACTOR VII DERIVED PROTEIN EGFP-EGF1 MEDIATE DRUG DELIVERY SYSTEM FOR HUMAN TUMOR**  
Shi Wei\*, Zhang Bo, Hu Yu (China)
- PO130-MON **THE ROLE OF M-COMPONENTS AND IMMUNOGLOBULINS IN PATIENTS WITH MULTIPLE MYELOMA - PROCOAGULANT AND PROGNOSTIC?**  
Thøger Nielsen\*, Henrik Gregersen, Anna-Marie Bloch Münster, Ann Katharina Staush-olm-Møller, Søren Risom Kristensen, Shona Pedersen (Denmark)
- PO131-MON **HYPOXIA-INDEPENDENT TUMOR PROGRESSION: ACTIVATION OF TRANSCRIPTION FACTOR HIF 1 VIA PAR1 AND PAR2 RECEPTORS IN BREAST CANCER.**  
Tainá Gomes\*, Robson de Queiroz Monteiro, Sandra König (Brazil)

## SCIENTIFIC PROGRAM

- PO132-MON **THE PHOTODYNAMIC THROMBI-SPECIFIC NANOPARTICLES STARVE SOLID LYMPHOMA TO DEATH**  
Yao Wang\*, Wei Shi, Bo Zhang, Yu Hu (China)
- PO133-MON **NEUTROPHIL EXTRACELLULAR TRAPS MEDIATE ARTERIAL AND VE-NOUS THROMBUS FORMATION IN A MURINE BREAST CANCER MODEL**  
Robson Q. Monteiro\*, Ana Carolina Leal, Natalia Rochael, Susana Ortiz-Costa, Claudio Wernek, Elvira Saraiva, Cristina Vicente, Daniella Mizurini (Brazil)
- Coagulation factor V, X, II, XIII - I**
- PO135-MON **PROTEOLYTIC INACTIVATION OF COAGULATION FACTOR V BY OMPT FROM ENTEROHEMORRHAGIC ESCHERICHIA COLI.**  
John A. Samis\*, Derek Tilley, Veena Premjani, Samantha Gruenheid, Herve Le Moul, Jeffrey Weitz (Canada)
- PO136-MON **COMBINED FV AND FVIII DEFICIENCY (F5F8D) IN A CHINESE FAMILY WITH A NOVEL MISSENSE MUTATION IN MCFD2 GENE**  
Anyou Wang\*, Xin Liu, Jingsheng Wu (China)
- PO137-MON **SUCCESSFUL ABDOMINAL OPERATION WITHOUT REPLACEMENT THER-APY IN A PATIENT WITH COMBINED FV AND FVIII DEFICIENCY DUE TO NOVEL HOMOZYGOUS MUTATION IN LMAN1**  
Anyou Wang\*, Qiaohong Duan, Xin Liu, Jingsheng Wu (China)
- PO138-MON **ENGAGEMENT OF THE ACTIVE SITE OF THROMBIN BY DABIGATRAN OR ARGATROBAN MODULATES ITS EXOSITE-MEDIATED INTERACTIONS WITH FIBRIN AND FACTOR VA**  
Calvin Yeh\*, Alan Stafford, Beverly Leslie, James Fredenburgh, Jeffrey Weitz (Canada)
- PO139-MON **FACTOR VA IN SYNERGY WITH PROTEIN S ENHANCES ACTIVATED PRO-TEIN C BINDING TO PHOSPHOLIPIDS**  
Magdalena Gierula\*, Isabelle I. Salles-Crawley, James T.B. Crawley, David A. Lane\*, Josefin Ahnström (United Kingdom)
- PO140-MON **MEMBRANE CHOLESTEROL IS A CRITICAL REGULATOR OF PLATE-LET-ASSOCIATED PROTHROMBINASE COMPLEX ASSEMBLY**  
Laura M. Haynes\*, Paula Tracy (United States)
- PO141-MON **REFERENCE VALUE AND STABILITY OF FACTOR V**  
Rahajuningsih Dharma\*, Rudianto Rudianto (Indonesia)
- PO143-MON **ACTIVATED FACTOR V INHIBITS THE ACTIVATION OF FACTOR IX BY TIS-SUE FACTOR/FACTOR VIIA COMPLEX**  
Dana Huskens\*, Minka Vries, Joke Konings, Rob Wagenvoord, Saartje Bloemen, Raed Al Dieri, Mark Roest, H. Hemker, Marcus Lance, Henri Spronk, Hugo Ten Cate, Yvonne Henkens, Bas de Laat (The Netherlands)
- PO144-MON **THE C-DOMAINS OF PSEUDONAJA TEXTILIS VENOM FACTOR V CON-TRIBUTE TO COFACTOR STABILITY BUT ARE DISPENSABLE FOR LIP-ID-INDEPENDENT PROTHROMBINASE FUNCTION**  
Daniël Verhoef\*, Rodney Camire, Pieter Reitsma, Mettine Bos (The Netherlands)

## SCIENTIFIC PROGRAM

PO145-MON **ASSESSING THE ROLE OF COMPLEX N-LINKED GLYCANS ON THE FACTOR V LIGHT CHAIN IN ENDOCYTOSIS BY MEGAKARYOCYTES**  
 Jacqueline M. Gertz\*, Mark Jennings, Cody Couperus, Jay Silveira, Paula Tracy, Beth Bouchard (United States)

### Coagulation factor VIII and IX - I

PO146-MON **N9-GP OVERESTIMATION IN ONE-STAGE CLOT METHOD DUE TO SILICA-MEDIATED CONVERSION TO FIXA DURING CONTACT ACTIVATION**  
 Per Rosén\*, Steffen Rosén, Mirella Ezban, Egon Persson (Denmark)

PO147-MON **IN VIVO EFFECT OF RECOMBINANT FVIIA (NOVOSEVEN®) AND RFX IN A REFINED TAIL VEIN TRANSECTION BLEEDING MODEL IN MICE WITH HAEMOPHILIA A AND B**  
 Peter B. Johansen, Mikael Tranholm, Carsten Ley\*, Torben Elm, Jesper Haaning, Mirella Ezban, Tom Knudsen (Denmark)

PO148-MON **EARLY IMMUNOLOGICAL EVENTS IN AAV-F9 MEDIATED ITI FOR HEMOPHILIA B MICE WITH PATHOGENIC FIX INHIBITORS**  
 David Markusic\*, Geoffrey Rogers (United States)

PO149-MON **RECOMBINANT LONG-ACTING GLYCOPEGYLATED FACTOR IX (NONACOG BETA PEGOL) IN HEMOPHILIA B: ASSESSMENT OF TARGET JOINTS IN THE MULTINATIONAL RANDOMIZED PHASE 3 CLINICAL TRIAL**  
 Claude Negrier\*, Faraizah Abdul Karim, Hideji Hanabusa, Peter Collins, Torben Colberg, Bryan Goldman, Christopher Walsh (France)

PO150-MON **ASSESSMENT OF RECOMBINANT FACTOR IX-FC FUSION PROTEIN (RFX-FC) CLOTTING ACTIVITY IN PLASMA SAMPLES AT CANADIAN HAEMOPHILIA TREATMENT CENTRES**  
 F. Jon Geske\*, Ali Sadeghi-Khomami, Hina Chaudhry, Michelle Sholzberg, Jerry Teitel (Canada)

PO151-MON **A CASE OF SEVERE HEMOPHILIA B ASSOCIATED WITH A LARGE INSERTION OF SVA RETROTRANSPOSON IN THE COAGULATION FACTOR IX GENE**  
 Naoki Mizutani\*, Yuki Nakamura, Moe Murata, Yuki Takagi, Ryo Hasebe, Toshihiro Kozuka, Yukiko Nakata, Akira Takagi, Jun-ichi Kitazawa, Midori Shima, Tetsuhito Kojima (Japan)

PO152-MON **TISSUE DISTRIBUTION OF RIX-FP AFTER INTRAVENOUS APPLICATION TO RODENTS**  
 Sabrina Schenk, Bärbel Doerr, Frauke May, Eva Herzog, Gerhard Dickneite, Marc W. Nolte\* (Germany)

PO153-MON **THE EFFECTS OF A NOVEL LONG-ACTING FACTOR IX PRODUCT (N9-GP) ON WOUND HEALING**  
 Elizabeth Chappell\*, Mirella Ezban, Maureane Hoffman, Dougald Monroe (United States)

PO154-MON **INHERITED FACTOR VIII AND IX DEFICIENCY IN PATIENTS REPORTED TO A TERTIARY CARE UNIVERSITY HOSPITAL IN INDIA: A RETROSPECTIVE COHORT ANALYSIS**  
 Benson Babu\* (India)

## SCIENTIFIC PROGRAM

PO155-MON **PROTEIN S, A NEW AGENT IN ADJUNCT THERAPY OF HEMOPHILIA B**  
 Rinku Majumder\*, Howard Fried, Valder Arruda (United States)

PO156-MON **IN VIVO EFFICACY OF HUMAN RECOMBINANT FACTOR IX PRODUCED BY THE HUMAN HEPATOMA CELL LINE HUH-7**  
 Nathalie Enjolras\*, Eloise Perot, Sandra Le Quellec, Alice Indalecio, Jonathan Girard, Claude Negrier, Yesim Dargaud (France)

PO157-MON **INCORPORATION OF MUTATIONS AT E410 OF FACTOR IX IMPROVES CLOTTING ACTIVITY IN VITRO AND IN VIVO**  
 Eloise Perot, Nathalie Enjolras\*, Sandra Le Quellec, Jonathan Girard, Alice Indalecio, Claude Negrier, Yesim Dargaud (France)

PO158-MON **THE SLEEPING-BEAUTY TRANSPOSON TECHNOLOGY FOR THE GENERATION OF CELLULAR AND ANIMAL MODELS OF HAEMOPHILIA B AND THE ASSESSMENT OF RNA-BASED THERAPEUTIC APPROACH**  
 Elena Barbon\*, Mattia Ferrarese, Giuseppe Ronzitti, Fanny Collaud, Mirko Pinotti, Federico Mingozzi (Italy)

PO159-MON **COMPARISON OF FACTOR IX GLYCOSYLATION IN DIFFERENT AGE GROUPS**  
 Helen M. Atkinson\*, Leslie Berry, Anthony Chan (Canada)

PO160-MON **INVESTIGATIONS INTO ANTICOAGULANT RESISTANCE AND ENHANCED ACTIVATION AS PUTATIVE MOLECULAR MECHANISMS OF THE HYPERACTIVITY OF FACTOR IX PADUA**  
 Ben Samelson-Jones\*, Jonathan Finn, Rodney Camire, Valder Arruda (United States)

PO161-MON **VARIETY OF F9 MUTATION IDENTIFIED IN 43 JAPANESE HEMOPHILIA B PATIENTS**  
 Keiko Shinozawa\*, Hiroshi Inaba, Takashi Suzuki, Masato Bingo, Ikuo Seita, Takeshi Hagiwara, Kagehiro Amano, Katsuyuki Fukutake (Japan)

PO162-MON **LOCATION OF TWO NOVEL LARGE GENE DELETIONS IN CHINESE HAEMOPHILIA B PATIENTS**  
 Qingyun Wang\*, Hui Liu, Liang Tang, Bei Hu, Yu Hu (China)

PO163-MON **QUANTITATION AND VISUALISATION OF NANOSIZE PROTEIN AGGREGATES IN RFX AND PDFIX CONCENTRATES**  
 Martin Brodde\*, Martin Wiemann, Anja Müller, Beate Kehrel (Germany)

PO164-MON **INHIBITOR DEVELOPMENT IN RELATION TO TREATMENT DURATION IN SEVERE HEMOPHILIA A IN PREVIOUSLY UNTREATED PATIENTS: RESULTS FROM THE SIPPET TRIAL**  
 Flora Peyvandi\*, Pier Mannuccio Mannucci, Isabella Garagiola, Massimo Boscolo Anzoletti, Amal El-Beshlawy, Mohsen El-Alfy, Vijay Ramanan Madatha, Peyman Eshghi, Ramabadrán Varadarajan, Suresh Hanagavadi, Mehran Karimi, Mamta Vijay Manglani, Cecil Ross, Guy Young, Tulika Seth, Shashikant Apte, Dinesh Nayak, Elena Santagostino, Elisa Mancuso, Adriana Carolina Sandoval Gonzalez, M. Tarek Owaidah, Frits Rosendaal (Italy)

## SCIENTIFIC PROGRAM

- PO165-MON **USING HPSEC TO QUANTIFY THE EFFECT OF GAMMA-CARBOXYLATION ON DIVALENT METAL-INDUCED COMPACTION OF VKD-PROTEINS AND BIOLOGICAL FUNCTION**  
Nicholas Vanderslice\*, Amanda Messer, Kanagasabai Vadivel, S. Paul Bajaj, Martin Phillips, Mostafa Fatemi, Weijie Xu, William Velander (United States)
- PO166-MON **INCREASED IMMUNOGENICITY OF FACTOR IX ADMINISTERED SUBCUTANEOUSLY VERSUS INTRAVENOUSLY DEMONSTRATED IN HEMOPHILIA B MICE EXPRESSING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX II HAPLOTYPE**  
Yasmina Abajas\*, Junjiang Sun, Genlin Hu, Paul Monahan (United States)
- PO167-MON **PHARMACOKINETIC (PK) AND CLINICAL DATA SUPPORT FOR EFFECTIVENESS OF ONCE-WEEKLY RECOMBINANT COAGULATION FACTOR IX (RFIX) DOSING FOR PROPHYLAXIS IN PATIENTS WITH MODERATELY SEVERE OR SEVERE HEMOPHILIA B**  
Joan Korth-Bradley, Lynne Smith, Joanne Fuiman, Pablo Rendo\* (United States)
- PO168-MON **EVALUATION OF HOST CELL PROTEIN IMMUNOGENICITY OF A POLISHED RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT, IB1001 IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B**  
Bojan Drobic\*, Yi Hua, Tim Babinchak, Edward Gomperts, Christine Hall (Canada)
- PO169-MON **FACTOR IX IMMUNOGENICITY IN HEMOPHILIA B PATIENTS ON REPLACEMENT THERAPY WITH A RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT (IB1001)**  
Bojan Drobic, Yi Hua, Tim Babinchak\*, Edward Gomperts, Christine Hall (United States)
- PO170-MON **INDIRECT COMPARISONS OF FACTOR CONSUMPTION, BLEEDING RATES, AND INFUSION FREQUENCIES DURING ROUTINE PROPHYLAXIS WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN AND OTHER RECOMBINANT FACTOR VIII PRODUCTS**  
Alfonso Iorio\*, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Paul Karner (Canada)
- PO171-MON **INDIRECT COMPARISONS OF FACTOR CONSUMPTION, BLEEDING RATES, AND INFUSION FREQUENCIES DURING ROUTINE PROPHYLAXIS WITH RECOMBINANT FACTOR IX FC FUSION PROTEIN AND OTHER RECOMBINANT FACTOR IX PRODUCTS**  
Alfonso Iorio\*, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Paul Karner (Canada)
- PO172-MON **SAFETY AND EFFICACY OF A NOVEL AAV VECTOR FOR TREATMENT OF HEMOPHILIA B**  
Xavier Anguela\*, Raffaella Toso, Linda Couto, Yifeng Chen, Daniel Hui, Martha DiPietro, Benjamin Lee, Guang Qu, Bernd Hauck, Romu Corbau, Fraser Wright, Katherine High (United States)
- PO173-MON **COMPARISON OF FIX ACTIVITY OF SELECT NOVEL RECOMBINANT FIX REPLACEMENT PRODUCTS IN COMMONLY USED FDA APPROVED ONE-STAGE CLOT ASSAY SYSTEMS**  
Mary M. Robinson\*, Stefan Tiefenbacher, Erika Ross, Patrick Williams, Caroline Cogswell, Tyrelle Wham, Dorothy Adcock (United States)

## SCIENTIFIC PROGRAM

- PO174-MON **MOYAMOYA SYNDROME IN A HEMOPHILIA A PATIENT WITH A HIGH-TITRE FVIII INHIBITOR**  
Wolf A. Hassenpflug\*, Johanna Schrum, Manuela Albisetti, Nadia Khan, Reinhard Schneppenheim (Germany)
- PO175-MON **OPTIMIZING PROCOAGULANT ACTIVITY FOR MUTANT RECOMBINANT FACTOR IX WITH RESISTANCE TO HEPARIN- AND ANTITHROMBIN**  
John P. Sheehan\*, Pamela Westmark (United States)
- Disseminated intravascular coagulation**
- PO176-MON **TO EVALUATE THE UTILITY OF ISTH SCORING SYSTEM, APTT AND SCHISTOCYTES AS MARKERS OF SEVERITY IN CASES OF DISSEMINATED INTRAVASCULAR COAGULATION.**  
Anjali J. Kelkar\*, Amit Nisal, Parineeta Shelke, Ravindra Nimbargi (India)
- PO177-MON **ROLE OF PLASMA HIGH MOBILITY GROUP BOX 1 IN DISSEMINATED INTRAVASCULAR COAGULATION WITH LEUKEMIA.**  
Manzhi Wang, Heng Mei\*, Haiming Kou, Jun Deng, Yu Hu (China)
- PO178-MON **ROLE OF ACTIVATED PROTEIN C AND SOLUBLE FIBRIN IN THE EARLY PHASE OF TRAUMA WITH DISSEMINATED INTRAVASCULAR COAGULATION: COMPARISON WITH ACUTE COAGULOPATHY OF TRAUMA-SHOCK**  
Satoshi Gando\*, Atsushi Sawamura, Mineji Hayakawa, Takeshi Wada, Yuichiro Yanagida, Daisuke Miyamoto, Kunihiko Maekawa, Yuichi Ono, Asumi Mizugaki, Subrina Jesmin (Japan)
- PO179-MON **EVALUATION OF NEW CHINESE DIAGNOSTIC SCORING SYSTEM FOR DISSEMINATED INTRAVASCULAR COAGULATION.**  
Manzhi Wang, Heng Mei\*, Haiming Kou, Jun Deng, Huafang Wang, Yu Hu (China)
- PO180-MON **A NOVEL MURINE MODEL OF DISSEMINATED INTRAVASCULAR COAGULATION (DIC) TO AID THE DEVELOPMENT OF NOVEL THERAPEUTICS TO TREAT DIC**  
Majid Ali\*, Keith Norman, Helen Philippou (United Kingdom)
- PO181-MON **THE PRESENCE OF OVERT DISSEMINATED INTRAVASCULAR COAGULATION AT DIAGNOSIS OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA**  
Tadej Pajic\*, Irena Zupan, Helena Podgornik, Uroš Mlakar, Peter Cernelc (Slovenia)
- PO182-MON **BIOMARKER PROFILE OF SEPSIS-ASSOCIATED COAGULOPATHY USING BIOCHIP ASSAYS FOR INFLAMMATORY CYTOKINES**  
Amanda Walborn\*, Debra Hoppensteadt, Daneyal Syed, Schuhrarazad Abro, Michael Mosier, Jawed Fareed (United States)
- Endothelium/vessel wall I**
- PO183-MON **HYPOXIA INDUCES DYSREGULATION OF MIR-126 AND AFFECTS VEGF AND MMP-9 EXPRESSION IN ENDOTHELIAL CELLS**  
Satoshi Fujii\*, Misa Ogasawara, Soichiro Iwaki (Japan)

## SCIENTIFIC PROGRAM

- PO184-MON **ANTIOXIDANT PHARMACOLOGICAL STRATEGIES FOR THE PREVENTION OF ENDOTHELIAL DYSFUNCTION IN UREMIA**  
Susana Martin-Rodriguez\*, Manel Vera, Enrique Mir, Jose Rivera, Josep Cruzado, Aleix Cases, Ginés Escolar, Maribel Diaz-Ricart (Spain)
- PO185-MON **ANTI-THROMBOTIC AND PRO-FIBRINOLYTIC EFFECTS OF LEVOSIMENDAN IN HUMAN ENDOTHELIAL CELLS IN VITRO**  
Konstantin Krychtiuk\*, Christoph Kaun, Stefan Stojkovic, Stefan Kastl, Andreas Zuckermann, Wolfgang Eppel, Gerald Maurer, Kurt Huber, Johann Wojta, Walter Speidl (Austria)
- PO186-MON **RNA-SEQ ANALYSIS OF HUMAN MAJOR LIVER CELL TYPES REVEALS DIFFERENTIAL EXPRESSION PROFILE OF SINUSOIDAL VERSUS OTHER HEPATIC VASCULAR ENDOTHELIAL CELLS**  
Tina Shahani\*, Peyman Zarrineh, Kris Covens, Majid Ashtiani, Renaud Lavend'Homme, Hassan Rokni Zadeh, Kathelijne Peerlinck, Marc Jacquemin (Iran, Islamic Republic Of)
- PO187-MON **ENDOTHELIAL FIBRINOLYTIC RESPONSE ONTO AN EVOLVING MATRIX OF FIBRIN**  
Rita Marchi\*, Oscar Castillo, Héctor Rojas, Zury Dominguez, Eduardo Anglés-Cano (Venezuela, Bolivarian Republic Of)
- PO188-MON **A MICROFLUIDIC VASCULAR INJURY MODEL USING HEAT-ACTIVATED ENDOTHELIAL CELLS**  
Joanna L. Sylman\*, Dylan Artzer, Keith Neeves (United States)
- PO189-MON **EVIDENCE OF DEFIBROTIDE INTERNALIZATION AND ITS ENDOTHELIAL PROTECTIVE EFFECT IN HEPATIC ENDOTHELIAL IN VITRO MODEL**  
Marta Palomo De Udaeta\*, Enrique Mir, Montse Rovira, Ginés Escolar, Enric Carreras, Maribel Díaz-Ricart (Spain)
- PO190-MON **CIRCULATING ENDOTHELIAL CELLS ARE INCREASED IN POST-THROMBOTIC SYNDROME PATIENTS**  
Mariane Flores-Nascimento\*, Bruna Mazetto, Fernanda Orsi, Joyce Annichino-Bizzacchi (Brazil)
- PO191-MON **ENDOTHELIAL DYSFUNCTION AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IS ENHANCED IN ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD)**  
Enrique Mir\*, Marta Palomo, Montse Rovira, Ginés Escolar, Enric Carreras, Maribel Diaz-Ricart (Spain)
- PO192-MON **EFFECT OF MATERNAL ANTI-HPA-1A ANTIBODIES ON ENDOTHELIAL CELLS**  
Rima Dardik\*, Nurit Rosenberg, Ron Loewenthal, Ophira Salomon (Israel)
- PO193-MON **ENDOTHELIAL DYSFUNCTIONS IN CIRRHOSIS PATIENTS**  
Claudia Maria Radu\*, Cristiana Bulato, Kryssia Rodriguez-Castro, Patrizia Zerbinati, Graziella Saggiorato, Marco Senzolo, Paolo Simioni (Italy)
- PO194-MON **KINDLINS ARE ACTIN BINDING PROTEINS**  
Katarzyna Bialkowska\*, Kamila Bledzka, Elzbieta Pluskota, Jun Qin, Edward Plow (United States)

## SCIENTIFIC PROGRAM

### Fibrinogen/fibrin/D-dimer I

- PO195-MON **EVALUATION OF DIFFERENT ASSAYS OF D-DIMER AND SOLUBLE FIBRIN IN EMERGENCY DEPARTMENT PATIENTS WITH SUSPECTED VENOUS THROMBOEMBOLISM**  
Maria Farm\*, Anwar Siddiqui, Liselotte Onelöv, Ingela Järnberg, Jaak Eintrei, Anders Kallner, Jovan Antovic (Sweden)
- PO196-MON **PERFORMANCE OF AGE ADJUSTED D-DIMER CUT OFF VALUE: A STEP TOWARDS IMPROVING CLINICAL UTILITY IN DIAGNOSIS OF ASYMPTOMATIC VENOUS THROMBOEMBOLISM**  
Salma A. Shawkat\*, Shaimaa Pessar, Tamer Farid, Nevine Kassim (Egypt)
- PO197-MON **EVALUATION OF THE RATIOS OF HIGH MOLECULAR WEIGHT FIBRIN DEGRADATION PRODUCTS (HMW FDP) TO D-DIMER IN PATIENTS' BLOOD BY THE IMMUNOASSAY EQUALLY RECOGNIZING D-DIMER AND HMW FDP**  
Alexander Kogan\*, Kadriya Mukharyamova, Anastasia Bereznikova, Ekaterina Koshkina, Andrei Kara, Alexey Katrukha (Finland)
- PO198-MON **ISOCRONOUS DESIGN TO STUDY THE STABILITY OF LIQUID D-DIMER CONTROLS**  
Miquel Sales\*, Begoña Arza, Susana Perez-Alvarez, Lidia del Toro (Spain)
- PO199-MON **THE FACTORS ASSOCIATED WITH ELEVATED D-DIMER LEVEL IN PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM**  
Natalya Vorobyeva\*, Anatoly Dobrovolsky, Elena Titaeva, Olga Ermolina, Tatyana Balakhonova, Alexandr Kirienko, Elizaveta Panchenko (Russian Federation)
- PO200-MON **BASELINE D-DIMER LEVELS AS A PREDICTOR FOR RECANALISATION IN PATIENTS WITH FIRST EPISODE OF DEEP VENOUS THROMBOSIS(DVT) OF THE LOWER LIMB**  
Vikas Suri\*, Nikhil P, Mukesh Yadav, Jaismina Ahluwalia, Narender Kumar, Pankaj Malhotra, Gaurav Prakash, Alka Khadwal, Savita Kumari, Sanjay Jain, Neelam Varma, Subhash Varma (India)
- PO201-MON **AN EVALUATION OF THE TOSOH BIOSCIENCE ST AIA-PACK DDIMER PERFORMED WITH THE AIA-360 AUTOMATE**  
Julie M Smith\*, Steve Kitchen (United Kingdom)
- PO202-MON **EVALUATION OF DIAGNOSTIC ACCURACY OF TWO D-DIMER ASSAYS IN PULMONARY EMBOLISM**  
Wallace Feese, James Dunnington, Jeffrey Kline\* (United States)

### Fibrinolytic system

- PO203-MON **DS-1040: A NOVEL SELECTIVE INHIBITOR OF ACTIVATED FORM OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR**  
Kengo Noguchi\*, Naoko Edo, Yusuke Ito, Takanori Maejima, Kyoji Yamaguchi (Japan)
- PO204-MON **THE STATE OF FIBRINOLYTIC SYSTEM IN ATHLETES AT RUSSIAN NORTH**  
Nadezda Vorobyeva\*, Natalia Bushueva (Russian Federation)

## SCIENTIFIC PROGRAM

- PO205-MON **MIR-30C REGULATES THROMBUS FORMATION IN TYPE 2 DIABETIC MELLITUS**  
Mao Luo\*, Fei Liu, Rong Li, Ni Chen, Ming Zeng, Xin Deng, Yan Yang, Qin Wan, Jianbo Wu (China)
- PO206-MON **THE INFLUENCE OF THE PEPTIDE PRO-ARG-GLY ON THE REGULATION OF THE FIBRINOLYTIC AND INSULAR SYSTEMS OF THE BODY ON THE MODEL OF DIABETES MELLITUS TYPE 2**  
Tatiana Shubina\*, Tomara Obergan, Ludmila Lyapina (Russian Federation)
- PO207-MON **EXPERIMENTAL VALIDATION OF A STOCHASTIC MULTISCALE MODEL OF FIBRINOLYSIS**  
Brittany Bannish\*, Krasimir Kolev, Colin Longstaff (United States)
- PO208-MON **THROMBOLYTIC PREPARATION LONGOLYTIN FROM LOW FUNGUS RESOLVES SUPERFICIAL HAEMATOMAS**  
Podorolskaya Lidya\*, Sharkova Tamara (Russian Federation)
- PO209-MON **THE ANTIFIBRINOLYTIC EFFECT OF FACTOR XIII STRONGLY DEPENDS ON CLOT COMPACTION/RETRACTION**  
Dick C. Rijken\*, Joyce Malfliet, Shiraaz Abdul, Frank Leebeek, Shirley Uitte de Willige (The Netherlands)
- PO210-MON **THE ASSOCIATION OF PAI-1 AND CLOT LYSIS TIME WITH BODY COMPOSITION IN AFRICANS IS SEX DEPENDENT**  
Zelda De Lange\*, Philna Eksteen, Marlien Pieters, H. Salome Kruger (South Africa)
- PO211-MON **FIBRINOLYTIC DYSREGULATION IN ARTHROPLASTY PATIENTS MAY CONTRIBUTE TO POSTOPERATIVE HEMOSTATIC COMPLICATIONS.**  
Nil Guler\*, Drew Burleson, Debra Hoppensteadt, Harold Rees, Jawed Fareed, William Hopkinson (United States)
- PO212-MON **PRE AND PERIOPERATIVE FACTORS MODULATE FIBRINOLYSIS IN ARTHROPLASTY PATIENTS**  
Drew Burleson\*, Nil Guler, Jennifer Saluk, Andrew Banos, Debra Hoppensteadt, Harold Rees, Jawed Fareed, William Hopkinson (United States)
- PO213-MON **KINETIC AND THROMBOLYTIC PROPERTIES OF PROUROKINASE-PAMAM CONJUGATES**  
Liliya Mukhametova\*, E. Ivanova, E. Zaharyan, R. Aisina, S. Varfolomeyev (Russian Federation)
- PO214-MON **THE INFLUENCE OF RESIDUAL PLATELETS ON PLASMA PAI-1 ASSAYS**  
Sunelle Barnard\*, Marlien Pieters, Du Toit Loots, Dingeman Rijken (South Africa)
- PO215-MON **CLOT LYSIS PARAMETERS ARE HIGHER IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH A HISTORY OF THROMBOEMBOLISM**  
Lize Bollen\*, Niels Vande Castele, Miet Peeters, Séverine Vermeire, Ann Gils (Belgium)
- PO216-MON **TISSUE PLASMINOGEN ACTIVATOR (T-PA) RELEASED FROM HUMAN CELLS BY "SOFT RUSH" [JUNCUS EFFUSUS L. VAR. DECIPENS]**  
Hiroyuki Sumi\*, Masatoshi Imai, Hisaya Mizote (Japan)

## SCIENTIFIC PROGRAM

- PO217-MON **GLOBAL FIBRINOLYTIC PROFILE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION**  
Aurélien Lebreton\*, Alessandro Casini, Frédéric Lador, Philippe de Moerloose, Marguerite Neerman-Arbez (France)
- PO218-MON **MEASUREMENT OF IN VIVO GENERATED CARBOXYPEPTIDASE U (CPU, CPB2, TAFIA) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION**  
Dorien Leenaerts\*, Johan Bosmans, Pieter Van Der Veken, Yani Sim, Anne-Marie Lambeir, Dirk Hendriks (Belgium)
- PO219-MON **CHARACTERISTICS OF CARBOXYPEPTIDASE U (CPU, CPB2 OR TAFIA) GENERATION DURING IN VITRO CLOT LYSIS**  
Dorien Leenaerts\*, Jef Aernouts, Yani Sim, Anne-Marie Lambeir, Dirk Hendriks (Belgium)
- PO220-MON **CELL-FREE DNA MODULATES CLOT STRUCTURE AND IMPAIRS FIBRINOLYSIS IN SEPSIS.**  
Travis J. Gould\*, Trang Vu, Dhruva Dwivedi, Jeffrey Weitz, Patricia Liaw (Canada)
- PO221-MON **IDENTIFICATION OF FUNCTIONAL PROCARBOXYPEPTIDASE U (PROCPU, TAFI) IN CEREBROSPINAL FLUID AND ITS ENHANCEMENT IN THE ACUTE PHASE OF BRAIN INJURY**  
Dorien Leenaerts\*, Bart Feyen, Süleyman Sener, Andrew Maas, Yani Sim, Margareta Ieven, Anne-Marie Lambeir, Dirk Hendriks (Belgium)
- PO222-MON **IN-VITRO IMAGING OF PLATELET/FIBRIN CLOT FORMATION AND LYSIS IN FLOW CONDITION**  
Stéphane Loyau\*, Yacine Boulaftali, Benoit Ho Tin Noe, Martine Jandrot-Perrus (France)
- PO223-MON **PAI-1 REGULATES FIBRIN CLOT STABILITY AND LYSIS**  
Carhel Dassi\*, Sylviane Fontaine, Olivier Mathieu, Landry Seyve, Raphaël Marlu, Benoît Polack, François Caton, Geneviève Contant (France)
- PO224-MON **THE EFFECT OF ALPHA-2 PLASMIN INHIBITOR ARG6TRP POLYMORPHISM ON THE RISK OF CORONARY ARTERY DISEASE**  
Éva Katona\*, Adrienn Orosz, Zoltán Mezei, László Balogh, István Czuriga, István Édes, László Muszbek (Hungary)
- PO225-MON **THROMBI FORMED AT LOW HAEMATOCRIT ARE RESISTANT TO FIBRINOLYSIS VIA A FACTOR XIII-MEDIATED MECHANISM**  
Paraskevi Untiveros\*, Ausrá Lionikiene, Michael Greaves, Henry Watson, Nicola Mutch (United Kingdom)
- PO226-MON **IMPAIRED FIBRINOLYSIS IN BEHÇET SYNDROME**  
Elena Silvestri, Giacomo Emmi, Anna Cellai, Emilia Antonucci, Danilo Squatrito, Lucia Ciucciarelli, Caterina Cenci, Rosanna Abbate, Lorenzo Emmi, Domenico Prisco\* (Italy)
- PO227-MON **VARIABLE RESISTANCE TO PLASMINOGEN ACTIVATOR INITIATED FIBRINOLYSIS FOR INTERMEDIATE-RISK PULMONARY EMBOLISM**  
William Stubblefield\*, Jeff Kline, Matt Rondina (United States)



## SCIENTIFIC PROGRAM

### Hemophilia – clinical I

- PO228-MON **CARRIER AND PRENATAL DIAGNOSIS OF CHINESE HAEMOPHILIA A FAMILIES IN ONE CENTER FROM 2007 TO 2014**  
Yeling Lu\*, Jin Dai, Qiulan Ding, Xuefeng Wang (China)
- PO229-MON **GENETIC ALTERATIONS IN HEMOPHILIC PATIENTS WITH INHIBITOR IN THE REGION OF MURCIA, SPAIN**  
Faustino García-Candel\*, Antonia Melero-Amor, Noemi Marin-Atucha, Paola Romecín (Spain)
- PO230-MON **A RETROSPECTIVE EVALUATION OF BLEEDING EPISODES IN PATIENTS WITH HAEMOPHILIA A, B AND VON WILLEBRAND'S DISEASE**  
Aylin Canbolat Ayhan\*, Cetin Timur, Enise Avci, Ayse Ulusoy, Asim Yoruk (Turkey)
- PO231-MON **ANTIBODIES OF HIGH AVIDITY IS THE HALLMARK OF SEVERE HEMOPHILIA A PATIENTS WITH FVIII INHIBITORS**  
Daniel Chaves\*, Amanda Silveira, Hayama Araújo, Mariana Ruckert, Olindo Martins-Filho (Brazil)
- PO232-MON **THE ROLE OF LARGE POPULATION-BASED DATABASES IN THE EVALUATION OF SAFETY OF BYPASSING AGENTS IN HEMOPHILIA PATIENTS WITH INHIBITORS**  
Katsiaryna Bykov\*, Rhonda Bohn, Bruce Ewenstein, Jerry Avorn, John Seeger (United States)
- PO233-MON **EFFICACY OF SECONDARY PROPHYLAXIS ON ANNUAL BLEEDING RATIO (ABR) IN ADULT PATIENTS WITH HEMOPHILIA: A SINGLE CENTER OBSERVATION STUDY IN JAPAN.**  
Teruhisa Fujii\*, Seiji Saito, Naoya Yamasaki, Tomie Fujii (Japan)
- PO234-MON **IMPACT OF THE INTRINSIC PATHWAY IN INDIVIDUAL THROMBIN GENERATION AMONG HEMOPHILIA B PATIENTS**  
Vuokko H. Jokela\*, Annukka Jouppila, Riitta Lassila (Finland)
- PO235-MON **SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIII FC) FOR THE PREVENTION AND TREATMENT OF BLEEDING IN PREVIOUSLY-TREATED ADULT AND ADOLESCENT SUBJECTS WITH HEMOPHILIA A: INTERIM ANALYSIS OF THE ASPIRE STUDY**  
Shannon Jackson\*, David Perry, Doris Quon, Pratima Chowdary, Amy Shapiro, Ingrid Pabinger, Elena Santagostino, Xiaoxi Li, Desilu Glazebrook, Geoffrey Allen (Canada)
- PO236-MON **NEW ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILIC PATIENTS –EXPECTATIONS TO CURE HEPATITIS C**  
Katalin Koehler-Vajta\*, Gerald Denk, Matthias Wettstein (Germany)
- PO237-MON **ANALYSIS OF BLEEDING RATES IN PEDIATRIC SUBJECTS WITH TARGET JOINTS AND SEVERE HEMOPHILIA A RECEIVING PROPHYLAXIS WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIII FC) IN KIDS A-LONG**  
Beatrice Nolan\*, Guy Young, Savita Rangarajan, Michael Wang, Bryce Kerlin, Alex Leung, Elisa Tsao, Desilu Glazebrook, Glenn Pierce, Geoffrey Allen (Ireland)

## SCIENTIFIC PROGRAM

- PO238-MON **BURDEN OF ILLNESS AMONG PERSONS WITH HEMOPHILIA B: DIRECT AND INDIRECT COSTS**  
Christina X. Chen\*, Judith Baker, Barbara Konkle, Megan Ullman, Roshni Kulkarni, Jeffrey Hord, Mimi Lou, Michael Nichol (United States)
- PO239-MON **TREATMENT OF BLEEDING WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN PREVIOUSLY-TREATED PEDIATRIC SUBJECTS WITH HEMOPHILIA A IN THE PHASE 3 KIDS A-LONG STUDY**  
Elizabeth Chalmers\*, Guy Young, Johnny Mahlangu, Michael Recht, Amy Geddis, Jayanthi Alamelu, Giulia Gambino, Glenn Pierce, Geoffrey Allen (United Kingdom)
- PO240-MON **ACUTE EFFECTS OF EXERCISE ON SPECIFIC AND GLOBAL COAGULATION PARAMETERS IN SEVERE HEMOPHILIA A**  
Eva Zetterberg, Henric Ek Olsson\*, Lövdahl Susanna, Ola Thorsson, Erik Berntorp (Sweden)
- PO241-MON **FIRST PROSPECTIVE RESULTS OF JOINT DISTRACTION IN HAEMOPHILIC ANKLE ARTHROPATHY**  
L.F.D. van Vulpen, H.Ch. Vogely, G. Roosendaal, P. de Kleijn, P.M. van Roermund, S.C. Mastbergen, F.P.J.G. Lafeber, R.E.G. Schutgens\* (The Netherlands)
- PO242-MON **INITIAL RESULTS OF A CLINICAL TRIAL EVALUATING A FULL-LENGTH PEGYLATED RECOMBINANT FACTOR VIII WITH EXTENDED HALF-LIFE FOR THE PERIOPERATIVE CONTROL OF HEMOSTASIS IN HEMOPHILIA A**  
Brigitte Brand, Ralph Gruppo, Tung Wynn, Laimonas Griskevicius, Maria Fernanda Lopez Fernandez, Feriandas Grebliskas\*, Thomas Dvorak, Lisa Patrone, Monika Fuerlinger, Brigitt Abbuehl (United States)
- PO243-MON **EVALUATION OF JOINT DAMAGE IN BOYS WITH HEMOPHILIC ARTHROPATHY BY ULTRASONOGRAPHY AND BIOMARKER OF CARTILAGE TURNOVER URINARY C TERMINAL TELOPEPTIDE OF TYPE II COLLAGEN (U-CTX-II)**  
Hoda Hassab\*, Wessam El-Gendy, Khaled EL-Noueam, Hayam Abd EL Ghani, Nirmeen Abdallah (Egypt)
- PO244-MON **SYSTEMATIC MONITORING OF HEMOSTATIC MANAGEMENT IN HEMOPHILIA A PATIENTS WITH INHIBITOR IN THE PERIOPERATIVE PERIOD USING ROTATIONAL THROMBOELASTOMETRY**  
Shoko Furukawa\*, Keiji Nogami, Kenichi Ogiwara, Hiroaki Minami, Midori Shima (Japan)
- PO245-MON **SYMPTOMATIC FEMALE HEMOPHILIA SEEN IN TAIWAN**  
Ming-Ching Shen\*, Ming Chen, Shun-Ping Chang, Woei Tsai, Ching-Yeh Lin, Shyuan-Yuh Lin (Taiwan)
- PO246-MON **NO RELATION BETWEEN PLATELET ACTIVITY AND HEMOPHILIA B PHENOTYPE**  
Roger EG Schutgens\*, Esther R van Bladel, Kathelijin Fischer, Mark Roest, Rolf T Urbanus (The Netherlands)
- PO247-MON **OUTCOME OF LONG TERM PLASMA DERIVED FVIII CONCENTRATE FAN-HDI® USE IN THE MATURE HAEMOPHILIA POPULATION.**  
Pu-Lin Luo\*, Savita Rangarajan, Ruth Pink, Steve Austin (United Kingdom)

## SCIENTIFIC PROGRAM

- PO248-MON **RACE AND THE IMMUNE RESPONSE TO FACTOR VIII REPLACEMENT THERAPY**  
Kenneth G. Mann\*, Saulius Butenas, Glenn Pierce, Robert Peters, Siyuan Tan, Jeanne Lusher, David Lillicrap, Christine Kempton, Johnny Mahlangu, Afshin Ameri, Nigel Key, Raymond Watts, Alexis Thompson, Cindy Leissing, Kevin McRedmond, Christopher Walsh, Craig Kessler, Neil Josephson, Dana Matthews, Kathleen Pratt (United States)
- PO249-MON **ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEALTHY SUBJECTS – MYTH OR REALITY?**  
Christian Lubich, Peter Allacher, Alexander Bauer, Thomas Prenninger, Frank Horling, Jürgen Siekmann, Friedrich Scheifflinger, Birgit Reipert\* (Austria)
- PO250-MON **CORRELATION BETWEEN ABR AND PK PARAMETERS IN PATIENTS WITH SEVERE HAEMOPHILIA A RECEIVING TUROCTOCOG ALFA (NOVO-EIGHT®) FOR PROPHYLAXIS**  
Victor Jiménez-Yuste\*, Sandra Lejniece, Anders Rosholm, Nikola Tripkovic, Elena Santagostino (Spain)
- PO251-MON **EXPRESSION OF PLATELET PROTEIN DISULFIDE ISOMERASE (PDI) IS INCREASED IN PATIENTS WITH HEMOPHILIA OR VON WILLEBRAND DISEASE**  
Minna Voigtländer\*, Katharina Holstein, Christina Dicke, Brigitte Spath, Carsten Bokemeyer, Florian Langer (Germany)
- PO252-MON **ALTERNATIONS OF OXIDATIVE STRESS MARKERS IN PATIENTS WITH SEVERE HAEMOPHILIA TREATED BY DIFFERENT PROPHYLAXIS REGIMENS**  
Irena Djunic\*, Violeta Dopsaj, Predrag Miljic, Aleksandra Novkovic, Nada Suvajdzic-Vukovic, Dragica Tomin, Ivo Elezovic (Serbia)
- PO253-MON **HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOFILIA A AND B IN BRAZIL**  
Tassila Salomon, Daniel Chaves\*, Stela Brener, Sérgio Peixoto (Brazil)
- PO254-MON **COMPARISON OF PROPHYLAXIS AND EPISODIC TREATMENT IN CHILDREN WITH MODERATE TO SEVERE HEMOPHILIA A**  
Darinr Sosohtikul\*, Rachaneekorn Songnuy, Panya Seksarn (Thailand)
- PO255-MON **USING MINUTE DOSES OF APTT REAGENT AND TISSUE FACTOR AS THE COAGULATION TRIGGER TO QUANTIFY THE COAGULATION PROFILE IN HEMOPHILIA A**  
Shu He\*, Anna Eelde, Pia Petrini, Margareta Blombäck (Sweden)
- PO256-MON **USER EXPERIENCE ASSESSMENT OF THE THERAPY MANAGEMENT SYSTEM HAEMOASSIST® 2**  
Charlotte Böttger, Jörg Grimm, Susan Halimeh, Michael Sigl-Kraetzig, Johannes Oldenburg, Andreas Tiede, Ian Winburn\*, Martin Schulz (Germany)
- PO257-MON **ONCE WEEKLY NONACOG ALFA IN HEMOPHILIA B (HEMB): A TIME COURSE PROFILE OF SPONTANEOUS BLEEDS IN PATIENTS FROM A PIVOTAL TRIAL**  
Bartholomew J. Tortella\*, Marcus Carr, Pablo Rendo, Lynne Smith, Kaan Kavakli (United States)

## SCIENTIFIC PROGRAM

- PO258-MON **RESULTS FROM THE PUP-GCP CLINICAL TRIAL: LOW INHIBITOR RATE IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HAEMOPHILIA A TREATED WITH A PLASMA DERIVED FVIII CONCENTRATE**  
Anna Klukowska, Sigurd Knaub, Vladimir Komrska, Pawel Laguna, Vladimir Vdovin, Martina Jansen\* (Austria)
- PO259-MON **DESIGNING A STUDY FOR REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF RIXUBIS (NONACOG GAMMA) IN PEOPLE WITH HEMOPHILIA B**  
Andreas Tiede\*, Robert Klamroth, Carmen Escuriola-Ettingshausen, Karin Kurnik, Florian Langer, Cornelia Wermes, Nirjhar Chatterjee, Ingrid Rauter, Alessandro Gringeri (Germany)
- PO260-MON **BLEEDING PATTERNS EVALUATED DURING PROPHYLAXIS WITH A FULL-LENGTH PEGYLATED RECOMBINANT FACTOR VIII (BAX 855) WITH EXTENDED HALF-LIFE IN HEMOPHILIA A**  
Barbara Konkle, Oleksandra Stasyshn, Tung Wynn, Marilyn Manco-Johnson, Ralph Gruppo, Pratima Chowdary, Vladimir Komrska, Laimonas Griskevicius, M. Eyster, Krzysztof Chojnowski, Werner Engl, Lisa Patrone, Brigitt E. Abbuehl\* (Austria)
- PO261-MON **BAYESIAN APPROACH TO THE ASSESSMENT OF THE POPULATION SPECIFIC RISK OF INHIBITORS**  
Alfonso Iorio\*, Ji Cheng, Maura Marcucci, Vadim Romanov, Lehana Thabane (Canada)
- PO262-MON **PHARMACOKINETIC CHARACTERISTICS OF FACTOR VIII AND IX CONCENTRATES – A SYSTEMATIC REVIEW**  
Mengchen Xi, Victor Blanchette, Jan Blatny, Peter Collins, Amy Dunn, Kathleen Fischer, Cedric Hermans, Tamara Navarro-Ruan, Kaan Kavakli, Shannon Jackson, Paula James, Sunil Mammen, Massimo Morfini, Ellis Neufeld, Margarete Ozelo, Paolo Radossi, Savita Rangarajan, Arlette Ruiz-Sáez, Jerry Teitel, Lehana Thabane, Guy Young, Alfonso Iorio\* (Canada)
- PO263-MON **IMMUNE TOLERANCE INDUCTION WITH HAEMATE® P IN HEMOPHILIA A: EXPERIENCE FROM A SINGLE CENTER.**  
Ralf Knöfler\*, Gabriele Siegert, Julia Stächele, Judith Lohse (Germany)
- PO264-MON **2003-2014 TWELVE YEAR RESULTS OF INHERITED BLEEDING DISORDERS REGISTRY OF THE EMILIA ROMAGNA REGION IN ITALY**  
Gianna Franca Rivolta, Caterina Di Perna, Federica Riccardi, Gabriele Quintavalle, Giuseppina Rodorigo, Lelia Valdrè, Chiara Biasoli, Attilia Pizzini, Maria Luisa Serino, Mariacristina Arbasì, Silvia Macchi, Paola Pedrazzi, Annarita Tagliaferri\* (Italy)
- PO265-MON **CONGENITAL FACTOR DEFICIENCIES: TWENTY-FIVE-YEAR FOLLOW-UP**  
Zafer Salcioglu\*, Hulya Sayilan Sen, Deniz Tugcu, Tugce Kalayci, Gonul Aydogan, Ferhan Akici, Zafer Baslar (Turkey)
- PO266-MON **THERE IS A DIRECT RELATIONSHIP BETWEEN THE PHYSICAL ACTIVITY SCORE AND HDL CHOLESTEROL LEVEL IN HEMOPHILIA PATIENTS**  
Fahri Sahin\*, Miray Bozgul Kilincer, Ugur Turk, Gunes Basol, Burcu Barutcuoglu, Kaan Kavakli, Guray Saydam (Turkey)
- PO267-MON **MEASUREMENT OF GAIT VARIABILITY IN PATIENTS WITH AND WITHOUT HEMOPHILIC ARTHROPATHY: MOVE-STUDY (NTR 4561)**  
Sara C. Stoof\*, Diana Hodgins, Frank Leebeek, Marjon Cnossen, Herwin Horemans, Stephan Praet, Marieke Kruij (The Netherlands)

## SCIENTIFIC PROGRAM

- PO268-MON **THE EFFECTIVENESS OF EXERCISE PROGRAMME AND RADIOISOTOPE SYNOVECTOMY IN HEMOPHILIC PATIENTS**  
Melike Sezgin Evim, Ufuk Sekir, Birol Baytan, Adalet Meral Günes\* (Turkey)
- PO269-MON **ADHERENCE TO TREATMENT IN PATIENTS WITH HAEMOPHILIA IN GERMANY**  
Wolfgang Miesbach\*, Werner Kalnins (Germany)
- PO270-MON **PROPHYLAXIS PRACTICES IN CHILDREN AND ADULTS WITH HEMOPHILIA A OR B AND INHIBITORS**  
Manuel Carcao\*, Laura Avila, Louis Aledort, Cindy Leissingner (Canada)
- PO271-MON **CURRENT STATUS OF OLDER PATIENTS WITH HEMOPHILIA: INSIGHTS FROM A CROSS-SECTIONAL PAN-EUROPEAN STUDY**  
Pål Andre Holme\*, Robert Tait, Christophe Combescure, Erik Berntorp, Stephan Rauchensteiner, Philippe de Moerloose (Norway)
- PO272-MON **COMPARING THROMBIN GENERATION IN PATIENTS WITH HAEMOPHILIA A AND PATIENTS ON VITAMIN K ANTAGONISTS**  
Marie-Sophie L. Y. De Koning, Kathelijn Fischer, Bas De Laat, Albert Huisman, Marisa Ninivaggi, Roger Schutgens\* (The Netherlands)
- PO273-MON **COATED PLATELET LEVELS IN SEVERE HEMOPHILIA DO NOT CORRELATE TO BLEEDING PHENOTYPE**  
Kelly L. Lastrapes\*, Bassem Mohammed, Erika Martin, Dougald Monroe, Maureen Hoffman, Melinda Nolte, Janice Kuhn, John Barrett, Donald Brophy (United States)
- PO274-MON **SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN AN ADULT WITH HEMOPHILIA A AND CHRONIC INHIBITOR – A CASE STUDY**  
Michelle Sholzberg\*, Georgina Floros, Jerry Teitel (Canada)
- PO275-MON **PROPHYLACTIC APPROACH TO RECURRENT BLEEDING IN HEMOPHILIA WITH INHIBITORS**  
Bulent Zulfikar\*, Basak Koc, Nihal Ozdemir (Turkey)
- PO276-MON **UTILIZATION OF ANTI-INHIBITORS PRODUCTS AND INHIBITORS STATUS OF SEVERE HEMOPHILIA PATIENTS: 5 YEARS NATIONAL DATA FROM THE CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE MANAGEMENT SYSTEM**  
Aicha N. Traore\*, Anthony Chan, Alfonso Iorio, Nancy Heddle, Irwin Walker (Canada)
- PO277-MON **RELIABILITY OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN US ADULT PEOPLE WITH HEMOPHILIA (PWH): THE PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ) STUDY**  
Michael Wang\*, Anne Neff, Amy Shapiro, Roshni Kulkarni, Mark Reding, Philip Kuria-kose, Craig Kessler, Michelle Witkop, Christine Kempton, David Cooper (United States)
- PO278-MON **ACQUIRED HEMOPHILIA IN PATIENT WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML1)-A CASE REPORT.**  
Bernadeta Ceglarek, Robert Wasilewski, Ksenia Bykowska, Anna Sikorska, Beata Baran, Edyta Odnoczek, Adam Wiszniewski\*, Jerzy Windyga (Poland)

## SCIENTIFIC PROGRAM

- PO279-MON **RESULTS OF RADIOSYNOVECTOMY IN CHILDREN WITH SEVERE HEMOPHILIA AND FACTOR VIII OR IX INHIBITOR**  
Pawel Laguna\*, Jaroslaw Cwikla, Piotr Zbikowski, Anna Klukowska, Michal Matysiak (Poland)
- PO280-MON **F8 MUTATION AND INHIBITOR DEVELOPMENT IN SEVERE FACTOR VIII DEFICIENCY: RESULTS FROM THE IRISH NATIONAL DATABASE**  
Vince Jenkins\*, Catriona Keenan, Barry White, James O'Donnell, Kevin Ryan, Beatrice Nolan, Niamh O'Connell (Ireland)
- PO281-MON **PATIENT PREFERENCES FOR FVIII AND BAX 855: RESULTS FROM THE BAX 855 PIVOTAL TRIAL**  
Josh Epstein, Elizabeth Schwartz\*, Brigit Abbuehl, Bruce Ewenstein (United States)
- PO282-MON **RECURRENT HEMATURIA IN HEMOPHILIA PATIENTS IS NOT INDICATIVE OF THE PRESENCE OF AN UNDERLYING CAUSE**  
Greta Mulders\*, Sara Stooft, Frank Leebeek, Martijn Busstra, Marieke Kruip (The Netherlands)
- PO283-MON **SPONTANEOUS INTRACRANIAL BLEEDING IS A MAJOR CAUSE OF DEATH IN NONSEVERE HEMOPHILIA A PATIENTS**  
Janneke I. Loomans\*, Corien Eckhardt, Alice Van Velzen, Marjolein Peters, Evelien Mauser-Bunschoten, Rainer Schwaab, Maria Mazzucconi, Annarita Tagliaferri, Berthold Siegmund, Sylvia Reitter-Pfoertner, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)
- PO284-MON **RELIABLE RNA RETRIEVAL FROM LOW-VOLUME PAXGENE TUBES IN SIMULATED "REAL WORLD" NEXT GENERATION SEQUENCING (RNA-SEQ): GENA-05 SUBSTUDY PILOT**  
Paul Batty\*, Charles Mein, Eva Wozniak, Daniel Hart (United Kingdom)
- PO285-MON **U.S. SURVEILLANCE OF PROPHYLAXIS USE AMONG PERSONS WITH HEMOPHILIA A RECEIVING CARE AT HEMOPHILIA TREATMENT CENTERS (HTCS)**  
Marilyn J. Manco-Johnson\*, Vanessa Byams, Brandi Cooke, Michael Recht, Diane Aschman, Becky Dudley, Mariam Voutsis, Meredith Oakley (United States)
- PO286-MON **ASSESSMENT OF INHIBITOR RISK AFTER SWITCHING FROM PLASMA-DERIVED FACTOR VIII CONCENTRATE TO RECOMBINANT FACTOR VIII (BRASIL-RFVIII): BRAZILIAN STUDY OF INHIBITOR LINKED TO RECOMBINANT FACTOR VIII)**  
Alessandra Prezotti\*, Silmara Aparecida Montalvão, Ana Paula Marques, Clarissa Ferreira, Luciana Oliveira, Paula Villaça, Luiz Ivando Ferreira Filho, Cláudia Lorenzato, Samuel Medina, Fatima Araujo, Margareth Ozelo (Brazil)
- PO287-MON **PHENOTYPIC PROFILE OF A CHILD WITH SEVERE HEMOPHILIA B AND INHIBITORS WITH NOVEL MUTATION IN THE FIX (F9) GENE**  
Zorica Trajkova Antevska\*, Sofijanka Glamocanin, Biljana Coneska, Violeta Dejanova Ilijevska, Emilija Sukarova Stefanovska (Macedonia, The Former Yugoslav Republic Of)
- PO288-MON **MILD HEMOPHILIA A COMPLICATED BY INHIBITOR AFTER SURGERY AND FACTOR REPLACEMENT THERAPY**  
Miguel Escobar\*, Shivika Chandra, Eric Wilson, Keneth Chong (United States)

## SCIENTIFIC PROGRAM

### Heparin and heparinoids

- PO290-MON **DISTURBANCE OF THE HEMOSTATIC BALANCE BY CARDIOPULMONARY BYPASS SURGERY**  
Romy Kremers\*, Yvonne Bosch, Edwin Mannens, Saartje Bloemen, Rob Wagenvoort, Raed Al Dieri, Coenraad Hemker (The Netherlands)
- PO291-MON **BOVINE AND PORCINE MUCOSAL HEPARINS EXHIBIT SIMILAR BIOLOGICAL PROFILES**  
Jawed Fareed\*, Helena Nader, Marcelo Lima, Debra Hoppensteadt, Jeanine Walenga, Walter Jeske, Mary Lewis, Emmanuele Kumar, Wolfram Raake, Mamdouh Bakhos (United States)
- PO292-MON **CHARACTERIZATION OF THE ANTITHROMBOTIC FINGERPRINT OF THE BRANDED AND COPIES OF THE LOW MOLECULAR WEIGHT ENOXAPARIN USING THROMBIN GENERATION ASSAY.**  
Grigoris Gerotziapas\*, Patrick Van Dreden, Elisabeth Mbemba, Amir Khartechi, Jeanine Walenga, Jawed Fareed, Ismail Elalamy (France)
- PO293-MON **COMPARATIVE STUDIES ON THE MOLECULAR AND FUNCTIONAL PROFILE OF SHEEP MUCOSAL DERIVED ENOXAPARIN WITH VARYING ANHYDRO-MANNO GROUPS**  
Schuharazad Abro\*, Emmanuel Kumar, Omer Iqbal, Daniel Kahn, Daneyal Syed, Debra Hoppensteadt, Jawed Fareed (United States)
- PO294-MON **SEVUPARIN; EFFECTS ON HEMOSTASIS OF A NOVEL POLYSACCHARIDE DRUG DERIVED FROM HEPARIN**  
Maria Lindgren\*, Joost Meijers, Bart Biemond, Sofia Ramström, Tomas Lindahl, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, John Hogwood, Elaine Gray, Erik Holmer (Sweden)
- PO295-MON **REVERSAL OF THE HEPARINOID EFFECT WITH PROTHROMBIN COMPLEX CONCENTRATE – AN IN VITRO STUDY USING THE THROMBIN GENERATION ASSAY**  
Emma L. Fosbury\*, Colleen Hamid, Anne Riddell, Pratima Chowdary (United Kingdom)
- PO296-MON **PERFORMANCE EVALUATION OF A NEW ASSAY FOR THE QUANTITATIVE DETERMINATION OF BOTH UNFRACTIONATED HEPARIN (UFH) AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) USING A HYBRID CALIBRATION CURVE.**  
Mechthild Merz, Sascha Lange\*, Katharina Madlener (Germany)
- PO297-MON **STRATEGIES AND OUTCOMES OF PERIPROCEDURAL BRIDGING THERAPY WITH LOW-MOLECULAR-WEIGHT- HEPARIN IN PATIENTS WITH MECHANICAL HEART VALVES**  
Jacqueline Schulman\*, Ammar Majeed, Eva Mattsson, Sam Schulman, Margareta Holmström, Anna Ågren (Sweden)
- PO298-MON **BIOPHYSICAL CHARACTERIZATION OF THE INTERACTION BETWEEN PLATELET FACTOR 4 AND SYNTHETIC LOW MOLECULAR WEIGHT HEPARINS**  
Mihaela Delcea\*, Thi-Huong Nguyen, Sven Brandt, Martin Kreimann, Wen Zhou, Jian Liu, Andreas Greinacher (Germany)

## SCIENTIFIC PROGRAM

- PO299-MON **MEASUREMENT OF HEPARANASE ACTIVITY IN PLASMA REQUIRES THE USE OF SAMPLE ANTITHROMBIN-DEPLETION**  
Shahsoltan Mirshahi\*, Marc Pocard, Massoud Mirshahi, Soria Jeannette (France)
- PO300-MON **NOVEL SYNTHETIC COPOLYMERS ABLE TO BIND UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS.**  
Bartłomiej Kalaska, Kamil Kaminski, Emilia Sokolowska, Joanna Miklosz, Shin-ichi Yusa, Krzysztof Szczubialka, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki\* (Poland)
- PO301-MON **DIFFERENCES BETWEEN NORMAL AND CANCER CELLS IN THE BIO-RESPONSE TO HEPARIN**  
Yunliang Chen\*, Michael Scully, Christopher Goodwin, Ajay Kakkar (United Kingdom)
- PO302-MON **MONITORING UNFRACTIONATED HEPARIN IN CHILDREN – APTT, ANTI-XA AND ACT IN A RANDOMIZED CONTROLLED TRIAL OF COMPARING TWO DOSE PROTOCOLS**  
Katharina Ellen Thom\*, Andreas Hanslik (Austria)
- PO303-MON **OVINE MUCOSAL HEPARIN AND ENOXAPARIN ARE BIOSIMILAR TO THEIR PORCINE COUNTERPARTS**  
Emmanuel Kumar\*, Yiming Yao, Daniel Kahn, Debra Hoppensteadt, Omer Iqbal, Walter Jeske, Jawed Fareed (United States)
- PO304-MON **THE EFFICACY AND SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN CRITICALLY ILL ADULT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Annukka Ylönen\*, Anne Kuitunen, Suvi Vaara, Ville Pettilä, Heini Huhtala (Finland)
- PO305-MON **COMPARATIVE ANTICOAGULANT AND ANTI-INFLAMMATORY EFFECTS OF SULODEXIDE AND ENOXAPARIN IN CITRATED WHOLE BLOOD**  
Schuharazad Abro\*, Cafer Adiguzel, Daneyal Syed, Debra Hoppensteadt, Walter Jeske, Jeanine Walenga, Jawed Fareed (United States)
- PO306-MON **IN VITRO EVALUATION OF NOVEL SYNTHETIC HEPARAN SULFATES MIMETICS TO PREVENT XENOGENIC RELATED-THROMBOSIS**  
Prabhjot Benipal, Hayato Iwase, Rami Al-Horani, Akul Mehta, Rajesh Karuturi, Lars Burdorf, Xiangfei Cheng, Donald Harris, Richard Pierson, Simon Robson, David Cooper, Umesh Desai, Agnes M. Azimzadeh\* (United States)
- PO307-MON **ARGATROBAN VS FONDAPARINUX IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS: A RESPONSE COMPARATIVE STUDY**  
Fahad Aleidan\*, Saud Alokran (Saudi Arabia)
- PO308-MON **ANTICOAGULANT AND FIBRINOLYTIC EFFECTS OF COMPLEXES OF DI-PEPTIDE PRO-GLY WITH LOW-MOLECULAR-WEIGHT HEPARINS ANIMAL AND PLANT ORIGIN**  
Tamara Obergan\*, Tatiana Shubina (Russian Federation)

## SCIENTIFIC PROGRAM

### Immune thrombocytopenia (ITP) I

- PO309-MON **USAGE OF ELTHROMBOPAG IN A 9 YEAR OLD SYRIAN PATIENT WITH IMMUNE THROMBOCYTOPENIC PURPURA AND FAMILIAL DEAFNESS-FIRST PEDIATRIC EXPERIENCE IN TURKEY**  
Fatma Burcu Belen\*, Meltem Polat, Ulker Kocak, Shinji Kunishima (Turkey)
- PO310-MON **ACUTE IMMUNE THROMBOCYTOPENIC PURPURA FOLLOWING COMBINED VACCINE**  
Sinan Akbayram\*, Kamuran Karaman, Hatice Akbayram, Mesut Garipardic, Ahmet Oner (Turkey)
- PO311-MON **THROMBOPOIETIN RECEPTOR AGONISTS DO NOT CAUSE COAGULATION ACTIVATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Lamya Garabet\*, Waleed Ghanima, Soo Lee, Marie-Christine Mowinckel, Howard Liebman, Christine Jonassen, James Bussel, Per Morten Sandset (Norway)
- PO312-MON **TREATMENT-RELATED ADVERSE EVENT BURDEN IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP)**  
Prina Donga\*, S. Pinar Bilir, Julie Munakata, Gregg Little, Tim Babinchak (United States)
- PO313-MON **HASHIMOTO'S THYROIDITIS IN CHILDREN WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIA**  
Muge Gokce\*, Tubanur Tahtakesen, Cengiz Bayram, Deniz Tugcu, Zafer Salcioglu, Gonul Aydogan, Gonca Keskindemirci, Ferhan Akici (Turkey)
- PO314-MON **SERIAL MEAN PLATELET VOLUMES IN IMMUNE THROMBOCYTOPENIA**  
Mala Varma\* (United States)
- PO315-MON **RITUXIMAB EXPERIENCE IN CHILDHOOD IMMUNE THROMBOCYTOPENIC PURPURA FROM A TERTIARY CENTER IN TURKEY**  
Gonca Keskindemirci, Muge Gokce\*, Deniz Tugcu, Sevinç Genç, Arzu Akcay, Gonul Aydogan (Turkey)
- PO316-MON **ITP WITH THYROID DYSFUNCTION: NOT MERELY AN ASSOCIATION-PROSPECTIVE ANALYSIS**  
Mukul Aggarwal\*, Manoranjan Mahapatra, Renu Saxena (India)
- PO317-MON **LEVELS OF CYTOKINES SECRETED BY T LYMPHOCYTE AND THE RELATIONSHIP WITH PROGNOSIS IN CHILDREN IMMUNE THROMBOCYTOPENIA**  
Jingyao Ma\*, Zhenping Chen, Runhui Wu (China)
- PO318-MON **ELEVATED EXPRESSION OF IL-37 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Liu Liu\*, Ke Feng, Hu Zhou (China)
- PO319-MON **ANALYSIS OF HISTOCOMPATIBILITY LOCUS ANTIGEN (HLA)-G AND IMMUNOGLOBULIN-LIKE TRANSCRIPTS (ILTS) ON PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Qi Feng\*, Ji Ma, Miao Xu, Yu Hou, Yingyi Yu, Jun Peng (China)

## SCIENTIFIC PROGRAM

- PO320-MON **AN INCREASED MAJOR LIPID RAFT PROTEIN RAFTLIN ASSOCIATED WITH B CELLS SIGNALING IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Zhang Xian\*, Yang Li, Zhang Donglei, Li Huiyuan, Fu Rongfeng, Yang Renchi (China)

### Inflammation II

- PO321-MON **NEUTROPHIL ELASTASE IS NOT REQUIRED FOR NEUTROPHIL EXTRACELLULAR TRAP OR DEEP VEIN THROMBUS FORMATION IN MICE**  
Kimberly Martinod\*, Maureen Gallant, Denisa Wagner (United States)
- PO322-MON **TISSUE FACTOR-DEPENDENT PLATELET ACTIVATION SUPPORTS NEUTROPHIL RECRUITMENT, ROLLING AND TRANSMIGRATION DURING INFLAMMATION**  
Soraya Mezouar\*, Roxane Darbousset, Peter Lenting, Cécile Denis, Jean-louis Mege, Nigel Mackman, Françoise Dignat-George, Laurence Panicot-Dubois, Christophe Dubois (France)
- PO323-MON **EFFECT OF GLUCOSE LEVELS IN INCREASED NEUTROPHIL EXTRACELLULAR TRAP FORMATION (NETS) IN TYPE 2 DIABETES PATIENTS AT DIAGNOSIS AND AFTER 6 AND 12 MONTHS OF METABOLIC CONTROL.**  
Mirta A. Schattner\*, Agostina Carestia, Gustavo Frechtel, Gloria Cerrone, Claudio Gonzalez, Maria Linari, Patricia Casais (Argentina)
- PO324-MON **IMPACT OF PCSK9 IN A MURINE MOUSE MODEL OF SEPSIS.**  
Dhruva J. Dwivedi\*, Momina Khan, Zakhar Lysov, Annik Prat, Alison Fox-Robichaud, Nabil Seidah, Patricia Liaw (Canada)
- PO325-MON **PLASMA CELL-FREE DNA LEVELS ARE ELEVATED IN PATIENTS WITH ACUTE ISCHEMIC HEART FAILURE PARTIALLY DUE TO NEUTROPHIL EXTRACELLULAR TRAP FORMATION**  
Alexander Brill\*, Eduard Shantsila, Tatyana Ponomaryov, Robert Dinsdale, Paul Harrison, Gregory Lip (United Kingdom)
- PO326-MON **THE HISTONE-CLEAVING FACTOR SEVEN ACTIVATING PROTEASE DOES NOT PROMOTE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS**  
Brenda M. Luken\*, Ingrid Bulder, Melissa Stunnenberg, Gerben Marsman, Marein Schimmel, Sacha Zeerleder (The Netherlands)
- PO327-MON **MECHANISM OF E- VINIFERIN INHIBITS SUPEROXIDE GENERATION IN HUMAN NEUTROPHIL**  
Chin-Hsuan Lin, Hsiang Ruei Liao\*, Jih-Jung Chen (Taiwan)
- PO328-MON **INHIBITORY EFFECT OF NKSE-5A ON SUPEROXIDE ANION GENERATION IN HUMAN NEUTROPHILS**  
Tzu-Chi Tseng\*, Ih-Sheng Chen, Hsiang-Ruei Liao (Taiwan)
- PO329-MON **DIABETES PRIMES NEUTROPHILS TO UNDERGO NETOSIS WHICH SEVERELY IMPAIRS WOUND HEALING**  
Siu Ling Wong\*, Melanie Demers, Kimberly Martinod, Maureen Gallant, Yanming Wang, Allison Goldfine, C. Ronald Kahn, Denisa Wagner (United States)

## SCIENTIFIC PROGRAM

- PO330-MON **DETERMINANTS OF THE REGULATORY ACTION OF PLATELETS TOWARDS NEUTROPHIL ACTIVITIES**  
Angèle Gros\*, Véronique Ollivier, Varouna Syvannarath, Martine Jandrot-Perrus, Benoît Ho-Tin-Noé (France)
- PO331-MON **THE LEUKOCYTE INTEGRIN  $\beta$ 2 PRIMES NEUTROPHILS FOR NETOSIS IN SICKLE CELL DISEASE**  
Laila Elsherif\*, Jessica Shen, Dell Strayhorn, Kenneth Ataga, Claire Doerschuk, Leslie Parise (United States)
- PO332-MON **NEUTROPHIL INCORPORATION OF MEMBRANE FRAGMENTS FROM DYING PLATELETS**  
Shaun Jackson, Yuping Yuan\*, David Bark Jr (Australia)

### Microparticles I

- PO333-MON **GENERAL DECREASE OF CIRCULATING MICROPARTICLES IS RELATED TO THE PRESENCE OF FVIII INHIBITORS IN HEMOPHILIA A PATIENTS**  
Daniel Chaves\*, Amanda Silveira, Marcela Moreira, Samantha Béla, Hayama Araújo, Andrea Teixeira-Carvalho, Fernanda Campos-Nunes, Olindo Martins-Filho (Brazil)
- PO334-MON **PRO-COAGULANT ACTIONS OF CIRCULATING MICROPARTICLES IN SICKLE CELL ANEMIA AND SEPSIS ASSOCIATED COAGULOPATHY AND THEIR MODULATION BY A TRIBLOCK POLYMER MST 1-88.**  
Jawed Fareed\*, Debra Hoppensteadt, Marty Emanuele, Daneyal Syed, Schuharazad Abro, Walter Jeske, Rakesh Wahli (United States)
- PO335-MON **THE ROLE OF MICROVESICLES DERIVED FROM MYELOMA CELLS IN THROMBOGENICITY AND ANGIOGENESIS**  
Moran Zarfati, Tami Katz, Irit Avivi, Anat Aharon\* (Israel)
- PO336-MON **ANTITHROMBIN IS INCORPORATED INTO EXOSOMES AND ITS PRESENCE IN THESE VESICLES IS MODULATED BY LOW MOLECULAR WEIGHT HEPARIN**  
Irene Martínez-Martínez\*, Patricia Carrasco, Ester Martín-Villar, Antonio García-Andreo, Nataliya Bohdan, Salvador Espín, Javier Corral, Vicente Vicente, Miguel Quintanilla (Spain)
- PO337-MON **SINGLE CASE REPORT: MONITORING THE BALANCE OF MICROPARTICLE-ASSOCIATED PROCOAGULANT AND FIBRINOLYTIC POTENTIALS AFTER ORTHOPEDIC SURGERY.**  
Philippe Poncelet\*, Coralie Judicone, Jérémie Bez, Tarik Bouriche, Benjamin François, Etienne Forestier, Olivier Béréziat, José Sampol, Romaric Lacroix, Françoise George (France)
- PO338-MON **PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM HAVE HIGHER CONCENTRATION OF LARGE EXTRACELLULAR VESICLES WITH AUGMENTED POTENTIAL TO INITIATE COAGULATION ACTIVATION**  
Simin Jamaly\*, Irina Starikova, Vladimir Tichelaar, Cathrine Ramberg, Nadezhda Latysheva, John-Bjarne Hansen (Norway)
- PO339-MON **INFLUENCE OF CALR AND JAK2 MUTATIONS ON PROCOAGULANT POTENTIAL OF PLATELET-DERIVED MICROPARTICLES IN ESSENTIAL THROMBOCYTHEMIA (ET)**  
Marina Marchetti\*, Sara Gamba, Alfonso Vignoli, Laura Russo, Carmen Tartari, Guido Finazzi, Anna Falanga (Italy)

## SCIENTIFIC PROGRAM

- PO340-MON **TF- AND UPA-BEARING MICROPARTICLES MODULATE FIBRIN NANOSTRUCTURE**  
Genevieve Contant, Olivier Mathieu, Sylvie Cointe, Tarik Bouriche, Jeremie Bez, Carhel Dassi, Benoit Polack, François Caton, Romaric Lacroix, Philippe Poncelet\* (France)
- PO341-MON **MODULATING THROMBOTIC DIATHESIS IN HEREDITARY THROMBOPHILIA: A ROLE FOR CIRCULATING MICROPARTICLES?**  
Elena Campello\*, Luca Spiezia, Claudia Radu, Cristiana Bulato, Sabrina Gavasso, Daniela Tormene, Barry Woodhams, Paolo Simioni (Italy)
- PO342-MON **CIRCULATING EXTRACELLULAR VESICLE (EV) AFTER ACUTE HINDLIMB ISCHEMIA**  
Violeta Gomez-Rodriguez, Anita Böing, Josune Orbe, Rienk Nieuwland, José A. Parra-mo, Carmen Roncal\* (Spain)
- PO343-MON **COMPARISON OF INTRACARDIAC AND VENOUS BLOOD LEVELS OF MICROVESICLES, TISSUE FACTOR AND PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION**  
Morten Mørk\*, Shona Pedersen, Lars Rasmussen, Jan Andreasen, Søren Risom Kristensen (Denmark)

### Non-vitamin K antagonist oral anticoagulants I

- PO344-MON **ANTICOAGULATION IN PATIENTS UNDERGOING CARDIOVERSION**  
Sufyan Benamer\*, Kandiah Chandrakumaran, Debbie Lusty, Tamara Everington (United Kingdom)
- PO345-MON **EVALUATION OF DABIGATRAN, RIVAROXABAN AND APIXABAN TARGET-SPECIFIC ASSAYS IN A MULTICENTER FRENCH STUDY.**  
Isabelle Gouin-Thibault\*, Emmanuel de Maistre, Sophie Susen, Geneviève Freyburger, Jean-Louis Golmard, Yves Gruel, Pierre Sié (France)
- PO346-MON **VALIDATION STUDIES ON COAGULATION LABORATORY ASSAYS USEFUL FOR ASSESSING THE PLASMA LEVELS OF APIXABAN**  
Debra Hoppensteadt\*, Daneyal Syed, Marc Goldford, Anne Bisset, Leon Zuckerman, Walter Jeske, Job Harenberg, Jawed Fareed (United States)
- PO347-MON **HOW DO REAL-WORLD APIXABAN CONCENTRATIONS COMPARE TO EXPECTED CONCENTRATIONS?**  
Hawre Yones, Jignesh Patel\*, Paradzai Chitongo, Rosalind Byrne, Alison Brown, Magdalena Watras, Kathryn Lang, Julia Czuprynska, Lara Roberts, Raj Patel, Roopen Arya (United Kingdom)
- PO348-MON **THE DAILY PRACTICE OF NOACS; AN OBSERVATIONAL COHORT STUDY**  
Arina Ten Cate-Hoek\*, Yvonne Henskens, René van Oerle, Rick Wetzels, Henri Spronk, Simon Schalla, Harry Crijns, Hugo ten Cate (The Netherlands)
- PO349-MON **POTENT ANTITHROMBOTIC EFFECT OF A NOVEL, SMALL-MOLECULE AND DIRECT INHIBITOR OF FACTOR XIA IN PREVENTION AND TREATMENT OF THROMBOSIS IN RABBIT MODEL OF ARTERIAL THROMBOSIS AT DOSES THAT PRESERVE HAEMOSTASIS**  
Pancras C. Wong\*, Mimi Quan, Carol Watson, Earl Crain, Alan Rendina, Joseph Luettgen, Ruth Wexler, Dietmar Seiffert (United States)

## SCIENTIFIC PROGRAM

- PO350-MON **COMPARING FEIBA WITH RECOMBINANT FVIIA FOR REVERSAL OF RIVAROXABAN WITH A MODIFIED ANTI-XA ASSAY IN UNDILUTED PLASMA**  
Jorell Gantioqui\*, Ivan Stevic, Frank Lee, Anthony Chan, Howard Chan (Canada)
- PO351-MON **DISCOVERY OF ONO-7750512, AN ORALLY BIOAVAILABLE SMALL MOLECULE FACTOR XIA INHIBITOR: THE PHARMACOKINETIC AND PHARMACOLOGICAL PROFILES**  
Sho Koyama\*, Takehiro Ono, Kazutsune Harada, Aiko Fujioka, Keiko Tsukamoto, Shinya Sakimoto, Masashi Gohda, Tetsuya Hagio, Tomoyuki Koda, Naoya Matsumura, Yoshiyuki Yamaura, Ai Hashimoto, Motoyuki Tanaka, Takashi Kondo, Masaru Sakai, Kenji Tanaka, Hidekazu Matsuya, Akira Imagawa, Yasushi Hirota, Kazuhito Kawabata (Japan)
- PO352-MON **MONITORING NOVEL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN AND APIXABAN USING THE NEW FULLY AUTOMATED THROMBELASTOGRAPHY TECHNIQUE TEG®6S**  
Ramin Artang\*, Gregg Galloway, Jean Amiral, Jorn Dalsgaard Nielsen (United States)
- PO353-MON **ENHANCEMENT OF FIBRINOLYSIS BY A FACTOR XA INHIBITOR EDOXABAN AND COMBINATION WITH AN INHIBITOR OF ACTIVATED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN VITRO**  
Yoshiyuki Morishima\*, Chikako Kamisato, Taketoshi Furugohri (Japan)
- PO354-MON **NOVEL ORAL ANTICOAGULANTS: INCIDENCE AND MANAGEMENT OF MAJOR BLEEDING. RETROSPECTIVE REVIEW AT A SINGLE CENTER.**  
Juan Peris\*, Queral Salas, Miren Gabilondo, Elena Pina, Elena Rosselló, Pere Domech (Spain)
- PO355-MON **INITIATING THROMBOPROPHYLAXIS WITH RIVAROXABAN UP TO 26 HOURS AFTER ELECTIVE KNEE ARTHROPLASTY DOES NOT INCREASE THE INCIDENCE OF VENOUS THROMBOEMBOLISM**  
Owais Mian\*, Christine Cockhill, Mary Ann Rizzo, Deborah Siegal, Howard Chan, Ellen McDonald (Canada)
- PO356-MON **EVALUATION OF THE SAFETY AND TOLERABILITY OF TARGET SPECIFIC ORAL ANTICOAGULANTS AT A LARGE UNIVERSITY SETTING**  
Gina Woodhouse, Patrick Klem\*, Renjbar Zebari, Kathryn Hassell, Toby Trujillo (United States)
- PO357-MON **EVALUATION OF ANTICOAGULANT THERAPY WITH DABIGATRAN BASED ON ECARIN CLOTTING TIME**  
Takeshi Suzuki\*, Masahiro Ieko, Ichiro Sakuma, Sumiyoshi Naito, Mika Yoshida, Osamu Kumano, Nobuhiko Takahashi (Japan)
- PO358-MON **SWITCH FROM VITAMIN K ANTAGONISTS (VKAS) TO DIRECT ORAL ANTICOAGULANTS (DOACS): A PRACTICAL APPROACH**  
Samantha Pasca, Ugo Venturelli, Antonella Bertone, Giovanni Barillari\* (Italy)
- PO359-MON **WARFARIN AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE "REAL WORLD" OF PATIENTS WITH ATRIAL FIBRILLATION**  
Pasquale Pignatelli, Daniele Pastori\*, Gregory Lip, Francesco Violi (Italy)
- PO360-MON **GLOBAL ANTICOAGULANT SCREENING USING A DILUTE RVV REAGENT**  
Zhenghua Cao\*, Ralph Bottenus, Mark Triscott (United States)

## SCIENTIFIC PROGRAM

- PO361-MON **A CHROMOGENIC FACTOR XA INHIBITOR ASSAY FOR QUANTIFYING RIVAROXABAN LEVELS: OPTIMIZATION AND VALIDATION ON THE ACL TOP 700**  
Paula M. Jacobi\*, Sharniece Covill, Kenneth Friedman, Sandra Haberichter (United States)
- PO362-MON **BLEEDING AND THROMBOEMBOLIC OUTCOMES IN WARFARIN- AND DABIGATRAN-TREATED PATIENTS IN THE RE-LY TRIAL WHO REQUIRED AN URGENT SURGERY OR PROCEDURE**  
James Douketis\*, Jeff Healey, Martina Brueckmann, Mandy Fraessdorf, Alex Spyropoulos, Lars Wallentin, Jonas Oldgren, Paul Reilly, Michael Ezekowitz, Stuart Connolly, Salim Yusuf (Canada)
- PO363-MON **FROM LABORATORY TO CLINICAL PRACTICE: DABIGATRAN EFFECTS ON THROMBIN GENERATION AND COAGULATION IN PATIENT SAMPLES**  
Tuukka Helin\*, Marja Lemponen, Paul Hjemdahl, Yuko Rönquist-Nii, Riitta Lassila, Lotta Joutsis-Korhonen (Finland)
- PO364-MON **THE ADDITION OF IDARUCIZUMAB TO PLASMA SAMPLES CONTAINING DABIGATRAN ALLOWS THE USE OF ROUTINE COAGULATION ASSAYS FOR THE DIAGNOSIS OF HEMOSTASIS DISORDERS**  
Marc Jacquemin\*, Jelle Toelen, Joke Schoeters, Marijke Peetermans, Kathelijne Peerlinck, Joanne van Ryn, Peter Verhamme (Belgium)
- PO365-MON **IMPACT OF DABIGATRAN, RIVAROXABAN AND APIXABAN TREATMENT ON HEMOSTASIS POINT-OF-CARE TESTING IN PATIENTS WITH ATRIAL FIBRILLATION.**  
Rita Paniccia\*, Rossella Marcucci, Raffaella Piora, Daniela Poli, Yusuf Ahmed, Carlo Fanciullacci, Agatina Alessandrello Liotta, Rosanna Abbate (Italy)
- PO366-MON **ANTICOAGULANT EFFECT OF DABIGATRAN, RIVAROXABAN AND APIXABAN TREATMENT ON DIFFERENT LABORATORY HEMOSTASIS TESTS IN PATIENTS WITH ATRIAL FIBRILLATION.**  
Rita Paniccia\*, Rossella Marcucci, Raffaella Piora, Daniela Poli, Gaia Lembo, Carlo Fanciullacci, Elisa Grifoni, Maddalena Pazzi, Agatina Alessandrello Liotta, Rosanna Abbate (Italy)
- PO367-MON **A NOVEL PROTHROMBIN TIME (PT) METHOD TO MEASURE ALL NON-VITAMIN K DEPENDENT ORAL ANTICOAGULANTS (NOACS)**  
Tomas L. Lindahl\*, Maria Wallstedt, Marie Danielsson-Rånby, Kerstin Arbring, Mats Rånby (Sweden)
- PO368-MON **EFFECTS OF NEW ORAL ANTICOAGULANTS ON FIBRIN-NETWORK PERMEABILITY AND THROMBIN GENERATION**  
Mika Skeppholm, Michal Zabczyk, Faris Al-Khalili, Rickard Malmström, Anna Ågren, Margareta Blombäck, Shu He, Håkan Wallén\* (Sweden)
- PO369-MON **KNOWLEDGE OF THE NEW ORAL ANTICOAGULANTS (NOACS) AMONGST UNIVERSITY TEACHING HOSPITAL DOCTORS**  
Mahin Ahmad\*, Manish Gautam, Tina Dutt (United Kingdom)

## SCIENTIFIC PROGRAM

- PO370-MON **REAL-LIFE USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN COMPARISON WITH VITAMIN K ANTAGONISTS FOR NON-VALVULAR ATRIAL FIBRILLATION: DATA FROM A PROSPECTIVE COHORT**  
Michela Giustozzi\*, Maria Cristina Vedovati, Federica Cianella, Paolo Verdecchia, Melina Verso, Serenella Conti, Esmeralda Filippucci, Emanuela Marchesini, Giancarlo Agnelli, Cecilia Becattini (Italy)
- PO371-MON **THE MODULATION OF PROTHROMBINASE LIFETIME BY RIVAROXABAN**  
Maria Cristina Bravo\*, Tom Orfeo, Matthew Gissel, Elizabeth Lavoie, Laura Haynes, Kenneth Mann (United States)
- PO372-MON **PHARMACOKINETICS AND -DYNAMICS OF DABIGATRAN ETEXILATE AND RIVAROXABAN IN PATIENTS REQUIRING PARENTERAL NUTRITION FOR SHORT BOWEL SYNDROME (THE PDER PAN STUDY)**  
Stefano L. Barco\*, Yuk Cheung, Michiel Coppens, Mireille Serlie, Ron Mathot, Saskia Middeldorp (The Netherlands)
- PO373-MON **IS IT POSSIBLE TO ASSES RIVAROXABAN ACTIVITY WITHOUT SPECIFIC CALIBRATORS?**  
Maria De Lourdes Herrera\*, Alicia Grinson, Silvina Pons, Carolina Mahuad, Alejandra Scazziota (Argentina)
- PO374-MON **A NEW ASSAY FOR THE MEASUREMENT OF RIVAROXABAN CONCENTRATIONS IN HUMAN PLASMA**  
Valeri Krougliak\*, Zhenghua Cao, Hency Patel, Jessy Mathew, Asley Belanger, Chun Kung, Ralph Bottenus (United States)
- PO375-MON **MONITORING VITAMIN K ANTAGONIST TREATMENT : INTERESTS OF GOOD THERAPEUTIC EDUCATION**  
Dalila Aïtchafa Tadlaoui\*, Amina Taboukouyout, Z'hor Guechi (Algeria)

### Nursing and Allied Health

- PO376-MON **HOW PARTICIPATING IN A CLINICAL TRIAL HAS HAD A FAR REACHING EFFECT – A CASE STUDY.**  
Claire McGregor\*, Marina Goruppi (Australia)
- PO377-MON **BARRIERS TO INFORM HEMOPHILIC CARRIERS OF THAT POSSIBILITY IN JAPAN**  
Tomie Fujii\*, Ayana Murakami, Teruhisa Fujii, Yukiko Miyakoshi (Japan)
- PO378-MON **MECHANICAL THROMBOPROPHYLAXIS – SOLVING DILEMMAS**  
Cara Doyle\*, Emma Gee (United Kingdom)
- PO379-MON **THE NURSES ROLE IN IDIOPATHIC THROMBOCYTOPENIA**  
Vashti Ragoonanan\* (United Kingdom)
- PO380-MON **THE IMPACT OF FOOTWEAR ON ANKLE ARTHROPATHY IN PATIENTS WITH HEMOPHILIA.**  
Karen Strike\*, Jherica Irwin (Canada)

## SCIENTIFIC PROGRAM

- PO381-MON **DEVELOPMENT OF INPATIENT PEDIATRIC ANTICOAGULATION MANAGEMENT SERVICE: THE ADVANCED PRACTICE NURSE PRACTITIONER SERVICE MODEL**  
Jennifer Meldau\*, Christine Guelcher, Carole Hennessey, Deepika Darbari, Michael Guerrero, Yaser Diab (United States)
- PO382-MON **FIRST EXPERIENCE WITH THE HAEMOASSIST, AN ELECTRONIC SUBSTITUTION DIARY THAT WORKS ON THE BASIS OF A PERSONAL DIGITAL ASSISTANT (PDA)**  
Manuela Siebert\*, Michaela Bicker, Anja Börtz, Britta Lachmann (Germany)
- PO383-MON **AN EVALUATION OF A MYELOPROLIFERATIVE NEOPLASM SPECIALIST NURSE LED CLINIC**  
Vashti Ragoonanan\* (United Kingdom)
- PO384-MON **PHARMACIST SUPPORTED ANTICOAGULATION MANAGEMENT CLINIC - IMPROVING PATIENT CARE IN AN EMERGING COUNTRY**  
Nida Najmi\*, Bushra Moiz, Sumaira Khan (Pakistan)
- PO385-MON **NURSING MANAGEMENT OF VENOUS THROMBOEMBOLISM (VTE) TREATMENT WITH RIVAROXABAN AT THE UNIVERSITY HOSPITAL OF PADUA: A 6-MONTH EXPERIENCE**  
Chiara Tonello\*, Elisabetta Baracco, Marianna Bettella, Lorenza Cacco, Nicola Griggio, Stefano Morandin, Fabiana Nalin, Alessandra Noventa, Ornella Scarpazza, Paolo Zulian, Giampiero Avruscio (Italy)
- PO386-MON **RESPONSE OF LEUCOCYTE COUNT, LEUCOCYTE DIFFERENTIAL COUNT AND THROMBOCYTE COUNT ON FREQUENT BLOOD DONATIONS AMONG MALE SUBJECTS IN UNIVERSITY OF CALABAR TEACHING HOSPITAL DONOR CLINIC, CALABAR, NIGERIA**  
Dorathy C. Okpokam\*, Ifeyinwa Okafor, Josephine Akpotuzor, Eme Osim, Esien Usanga, Ogha Okpokam (Nigeria)
- PO387-MON **PARTICIPATION OF NURSES IN PREPARATION OF PATIENTS WITH HEMOPHILIA FOR SURGERY OF COLON CANCER**  
Ljiljana Rakic\* (Serbia)
- PO388-MON **MILD HAEMOPHILIA A: A MANAGEABLE CONDITION?**  
Daryl Pollock\* (New Zealand)
- PO389-MON **SOURCE DATA VERIFICATION PILOT: USING CENTRAL MONITORING IN AN OBSERVATIONAL CRITICAL CARE BIOMARKER STUDY**  
Ellen McDonald\*, Davinder Jain, Roxanne Ward, Patricia Liaw, Alison Fox-Robichaud (Canada)
- PO390-MON **RAISING AWARENESS OF VENOUS THROMBOEMBOLISM PREVENTION: HOW THE JEWISH GENERAL HOSPITAL IS MEETING THE REQUIREMENTS FOR HOSPITAL ACCREDITATION**  
Jessica Emed\*, Carla Strulovitch, Suzette Chung, Hetal Patel (Canada)
- PO391-MON **HAEMOPHILIA AND AGEING. PROMOTING HEALTHY AGEING THROUGH PROACTIVE ENGAGEMENT WITH GENERAL PRACTITIONERS – LITERATURE REVIEW AND PILOT SURVEY.**  
Olivia Hollingdrake\*, Beryl Zeissink (Australia)



## SCIENTIFIC PROGRAM

- PO392-MON **A SURVEY OF CLINICAL RESEARCH COORDINATORS TO MANAGE THE CLINICAL RESEARCH PAPERWORK MOUNTAIN**  
Terri Schnurr\*, Susan Cooke, Dori Kazimer, Mary Jane Sayles, Ellen McDonald (Canada)
- PO393-MON **THE JEWISH GENERAL EXPERIENCE IN DEVELOPING PATIENT TEACHING MATERIALS ON WARFARIN AND VENOUS THROMBOEMBOLISM**  
Carla Strulovitch\*, Jessica Emed, Suzette Chung, Hetal Patel (Canada)

### Platelet activation/adhesion/aggregation I

- PO394-MON **THE IMPACT OF  $\beta$ 3 CYTOPLASMIC TAIL MIMETIC PEPTIDES ON PLATELET AGGREGATION AND  $\alpha$ IIb $\beta$ 3 ACTIVATION**  
Huong T. T. Nguyen\*, Khon Huynh, Rudiger Scharf, Volker Stoldt (Germany)
- PO395-MON **BILE SALT CHENODEOXYCHOLATE SUPPRESSES NORMAL PLATELET FUNCTIONS THROUGH CYCLIC AMP ACTIVATION PATHWAY**  
Pat Metharom\*, Fergal O'Gara, Michael Berndt (Australia)
- PO396-MON **THE ROLE OF HETEROTRIMERIC G PROTEINS IN REGULATION OF GPIIb-IIIa ACTIVATION AND PLATELET CONTRACTILITY**  
Ivan Budnik, Boris Shenkman, Naphtali Savion\* (Israel)
- PO397-MON **THE GUT MICROBIOTA REGULATES VON WILLEBRAND FACTOR EXPRESSION AND PLATELET PROTHROMBOTIC FUNCTION VIA TOLL-LIKE RECEPTOR-2**  
Sven Jäckel\*, Maren Lillich, Klytaimnistra Kiouptsi, Nives Hörmann, Cora Reiss, Katharina Alber, Kerstin Jurk, Ulrich Walter, Wolfram Ruf, Christoph Reinhardt (Germany)
- PO398-MON **NUCLEAR RECEPTOR DEPENDENT FORMATION OF COATED PLATELETS INHIBITS PLATELET RESPONSES TO STIMULI.**  
Amanda J. Unsworth\*, Tanya Sage, Neline Kriek, Michael Schenk, Christopher Jones, Leonardo Moraes, Jonathan Gibbins (United Kingdom)
- PO399-MON **CONSIDERABLE VARIABILITY OF PLATELET RESPONSE TO TISSUE FACTOR IN HEALTHY INDIVIDUALS AND POTENTIAL ROLE OF FXa INHIBITOR AS AN ANTI-PLATELET AGENT**  
Kagari M. Murasaki\*, Kaori Ishigaki, Nobuhisa Hagiwara (Japan)
- PO400-MON **PHYSIOLOGICAL REGULATION OF PLATELET AGGREGATION BY THE GASOTRANSMITTER HYDROGEN SULFIDE**  
Michael Emerson\*, Oumid Ahmad, Francesca Rauzi, Erica Smyth, Mark Wood, Matthew Whiteman (United Kingdom)
- PO401-MON **PLATELET-SPECIFIC GARP DEFICIENCY DOES NOT AFFECT THROMBOSIS AND HEMOSTASIS IN MICE**  
Elien Vermeersch\*, Karen Vanhoorelbeke, Simon De Meyer, Hans Deckmyn, Claudia Tersteeg (Belgium)
- PO402-MON **CONSTRUCTION OF EXPRESSION SYSTEM FOR BIOLOGICALLY FUNCTIONAL RECOMBINANT RHODOCYTIN**  
Tomoyuki Sasaki\*, Shogo Tamura, Toshiaki Shirai, Nagaharu Tsukiji, Kaneo Satoh, Katsue Suzuki-Inoue, Yukio Ozaki (Japan)

## SCIENTIFIC PROGRAM

- PO403-MON **LOCALIZATION OF ZN<sup>2+</sup> IN DENSE GRANULES OF HUMAN PLATELETS AND THE EXTENT OF ITS RELEASE UPON PLATELET ACTIVATION**  
Sara J. Henderson\*, Fred Pluthero, Alan Stafford, Ji Zhou, Nima Vaezzadeh, Ran Ni, James Fredenburgh, Walter Kahr, Jeffrey Weitz (Canada)
- PO404-MON **NEUTROPHILS CONTRIBUTE TO THE GENERATION OF PROCOAGULANT PLATELETS BY A MYELOPEROXIDASE INDEPENDENT MECHANISM**  
Leonardo Pasalic\*, Latasha Abeynaike, Elias Glaros, Shane Thomas, Philip Hogg, Vivien Chen (Australia)
- PO405-MON **IMPAIRED RESPONSE TO COLLAGEN OF PLATELETS FROM HYPERLIPIDEMIC MICE**  
Marco van der Stoep\*, Inge Snoeren, Menno Hoekstra, Philip de Groot, Miranda Van Eck, Suzanne Korporaal (The Netherlands)
- PO406-MON **IMPROVING THE QUANTIFICATION OF IN VITRO THROMBUS FORMATION**  
Kjersti Claesson\*, Lars Faxälv, Tomas Lindahl (Sweden)
- PO407-MON **RS6929846-DEPENDENT REGULATION OF BTN2A1 EXPRESSION IN INNATE AND ADAPTIVE IMMUNE CELLS AFFECTS PLATELET REACTIVITY TO THROMBIN**  
Ann-Stephan Gori, Christelle Lecut, Julia Dmitrieva, Céline Delierneux, Emilie Théâtre, Patrizio Lancellotti, Michel Georges, Cécile Oury\* (Belgium)
- PO408-MON **MOUSE CLEC-2 CAN SUPPORT PLATELET ADHESION TO MOUSE PODOPLANIN UNDER ARTERIAL FLOW**  
Stephanie Lombard\*, Matthew Harrison, Marie Lordkipanidzé, Alice Pollitt, G Rainger, Steve Watson (United Kingdom)
- PO409-MON **AKT TRANSLOCATION AND PHOSPHORYLATION REGULATES PLATELET AGGREGATION DOWNSTREAM OF G12/13 AND GI PATHWAYS**  
Zhongren Ding\*, Yan Zhang, Leilei Chen, Shuang Zheng, Lin Chang, Liang Hu, Si Zhang (China)
- PO410-MON **EFFECTS OF CYCLIC NUCLEOTIDES ON PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIER RELEASE INDUCED BY STREPTOCOCCUS SANGUINIS STRAIN 2017-78**  
Archie McNicol\*, Ahmed Abdulrehman, Elke Jackson, Sara Israels, Hind Hamzeh-Cognasse, Fabrice Cognasse (Canada)
- PO411-MON **COMBINED ROLES OF FACTOR XIIIa AND GLYCOPROTEIN IIb/IIIa IN PLATELET-DRIVEN FIBRIN FORMATION**  
Nadine Mattheij\*, Frauke Swieringa, Michelle Berny-Lang, Frauke May, Paola van der Meijden, Dennis Suylen, Marc Nolte, Tilman Hackeng, Owen McCarty, Johan Heemskerck, Judith M. Cosemans (The Netherlands)
- PO412-MON **PIVOTAL ROLE OF SGK1 IN THE REGULATION OF PLATELET SECRETORY PROTEOME, DENSE GRANULE BIOGENESIS AND SECRETION**  
Britta Walker\*, Evi Schmid, Antonella Russo, Patrick Münzer, Eva-Maria Schmidt, Oliver Burk, Ana Velic, Boris Macek, Martin Schaller, Matthias Schwab, Miguel C. Seabra, Meinrad Gawaz, Florian Lang, Oliver Borst (Germany)
- PO413-MON **IMPACT OF ELEVATED SHEAR STRESS ON INTEGRIN ALPHAIIb BETA3 – LIGAND INTERACTION**  
Marianna Gyenes\*, Volker R. Stoldt, Rudiger E. Scharf (Germany)

## SCIENTIFIC PROGRAM

- PO414-MON **PLATELET FUNCTION IS REGULATED BY ACETYLATION AND DEACETYLATION MECHANISMS CONTROLLED BY SIRTUINS.**  
Ana M. Latorre\*, Maria Santos, Juana Valles, Maria Angeles Dasi, Antonio Moscardo (Spain)
- PO415-MON **FIBRIN STIMULATES SPREADING AND ACTIVATION OF PLATELETS THROUGH GPVI**  
Osama M. Alshehri\*, Craig Hughes, Samantha Montague, Jon Frampton, Steve Watson (United Kingdom)
- PO416-MON **KINDLIN-2 IN MEGAKARYOCYTE AND PLATELET FUNCTIONS**  
Dorsaf Ghalloussi, Pierre Dillard, Gaëtan Chicanne, Bernard Payrastre, Alan Nurden, Véronique Baccini, Laurent Limozin, Marie-Christine Alessi, Matthias Canault\* (France)
- PO417-MON **THE PRO33 (HPA-1B) ISOFORM OF INTEGRIN ALPHAII BETA3 IS INDEED A PROTHROMBOTIC RECEPTOR VARIANT**  
Rudiger. E Scharf\*, Marianna Gyenes, Volker R. Stoldt (Germany)
- PO418-MON **THE PRO33 VARIANT OF PLATELET ALPHAII BETA3: ALLOSTERIC CHANGES RESULTING FROM A POINT MUTATION IN THE INTEGRIN ECTODOMAIN ARE ASSOCIATED WITH A PROTHROMBOTIC RECEPTOR PHENOTYPE**  
Giulia Pagani\*, Joana Ventura Pereira, Nadine Homeyer, Volker R. Stoldt, Holger Gohlke, Rüdiger E. Scharf (Germany)
- PO419-MON **VASCULAR SMOOTH MUSCLE CELLS STIMULATE PLATELETS VIA CLEC-2: INVOLVEMENT OF INTRACELLULAR AND EXTRACELLULAR LIGANDS OF CLEC-2**  
Katsue Suzuki-Inoue\*, Osamu Inoue, Nagaharu Tsukiji, Yukio Ozaki (Japan)
- PO420-MON **PLATELET-FIBRIN THROMBI CAN KILL STENOTROPHOMONAS MALTOPHILI**  
Volker R. Stoldt\*, Rudiger E. Scharf (Germany)
- PO421-MON **ENGINEERING PLATELETS FOR THE DELIVERY OF RNA**  
Stefanie Novakowski\*, Vivienne Chan, Simon Law, Christian Kastrup (Canada)
- PO422-MON **INHIBITION OF SORBITOL DEHYDROGENASE INCREASES PLATELETS ADHESION IN MICE TREATED WITH FIDARESTAT**  
Mariane Flores-Nascimento\*, Kiara Zapponi, Regiane Ferreira, Lúcia Helena Siqueira, Thaís Fornari, Bruna Mazetto, Fernanda Orsi, Erich De Paula, Joyce Annichino-Bizzacchi (Brazil)
- PO423-MON **THE RAP1-GAP RASA3 PREVENTS CLEARANCE OF CIRCULATING PLATELETS**  
Caterina Casari\*, David Paul, Lucia Stefanini, Yacine Boulaftali, Robert Campbell, Daniel Kechele, Kathleen Caron, Andrew Weyrich, Dale Cowley, Matthew Parrott, Luanne Peters, Wolfgang Bergmeier (United States)
- PO424-MON **BIOMECHANICS OF BLOOD CLOT CONTRACTION**  
Valerie Tutwiler\*, Hailong Wang, Rustem Litvinov, John Weisel, Vivek Shenoy (United States)

## SCIENTIFIC PROGRAM

- PO425-MON **REVERSAL OF THE ANTITHROMBOTIC PROPERTIES OF QUERCETIN-3-RUTINOSIDE WITH THE B' DOMAIN OF PDI IN A MOUSE THROMBOSIS MODEL**  
Lin Lin\*, Srila Gopal, Anish Sharda, Freda Passam, Sheryl Bowley, Jack Stopa, Robert Flaumenhaft, Mingdong Huang, Bruce Furie (United States)
- PO426-MON **PLATELET IN RATS WITH ACUTE RENAL FAILURE PRESENT HYPERREACTIVITY IN VITRO**  
Zhang-Yin Ming\*, Guang-qiang Yao, Ming-lu Liang, Ao-di He, Xin-Wen Da, Wen Xie (China)
- PO427-MON **FACTOR XI-DEPENDENT PLATELET THROMBIN GENERATION INDUCED BY THROMBIN IS REGULATED BY CD36**  
Mareike Döhrmann\*, Kathrin Schwierczek, Ivo Volf, Ulrich Walter, Kerstin Jurk (Germany)
- PO428-MON **DELETION OF PI3K P110A RESULTS IN ENHANCED PRIMER-MEDIATED REGULATION OF PLATELET FUNCTION AND THROMBOSIS.**  
Thomas Blair\*, Samantha Moore, Ingeborg Hers (United Kingdom)
- PO429-MON **PROFILING OXYLIPINS RELEASED BY GPVI-ACTIVATED PLATELETS AND THE EFFECT OF INHIBITORS OF CYCLOOXYGENASE-1 AND 12-LIPOXYGENASE**  
Robert E. Turnbull\*, Katrin Sander, David Barrett, Alison Goodall (United Kingdom)
- PO430-MON **ROLE OF HYDRODYNAMIC SHEAR MEDIATED PLATELET DEFORMATION ON CELL TETHERING, TRANSLOCATION AND ACTIVATION**  
Changjie Zhang\*, Sriram Neelamegham (United States)
- PO431-MON **THE ACTIVATING EFFECTS OF SHEAR STRESS GRADIENTS ON THROMBUS FORMATION**  
Thomas Hoefler\*, Elizabeth Gardiner, Robert Andrews, Karlheinz Peter, Erik Westein (Australia)
- PO432-MON **MEMBRANE ESTROGEN RECEPTOR (MER) – PROTEASE ACTIVATED RECEPTOR (PAR) CROSS TALK MODULATES PLATELET FUNCTION**  
Joseph E. Aslan\*, Ishan Patel, Peizhong Mao, Fuchun Xie, Xiangshu Xiao, Oline Rønnekleiv, Martin Kelly, Owen McCarty (United States)
- Platelet disorders I**
- PO433-MON **PLATELET CD34 EXPRESSION IS INCREASED IN FAMILIES WITH DISTINCT GF11B MUTATIONS: UTILITY AS A SCREENING TEST**  
Marie-Christine Morel-Kopp\*, David Rabbolini, Sara Gabrielli, Qiang Chen, Christopher Ward\*, William Stevenson (Australia)
- PO434-MON **A CASE OF MYH9 DISORDERS CAUSED BY A NOVEL MUTATION (P.K74E)**  
Takeshi Kanematsu\*, Nobuaki Suzuki, Mayuko Kishimoto, Tomohiro Aoki, Mika Ogawa, Yoshitoyo Kagami, Shinji Kunishima, Hitoshi Kiyoi, Tadashi Matsushita (Japan)

## SCIENTIFIC PROGRAM

- PO435-MON **CALR MUTATIONS ARE ASSOCIATED WITH LOWER PLATELET AND ENDOTHELIAL ACTIVATION THAN THE JAK2 MUTATION IN ESSENTIAL THROMBOCYTHEMIA**  
Eduardo Arellano-Rodrigo\*, Alberto Alvarez-Larrán, Juan-Carlos Reverter, Dolores Colomer, Beatriz Bellosillo, Francisco Cervantes (Spain)
- PO436-MON **DIFFERENT MICROTUBULE ABNORMALITIES IN TWO CASES OF MACROTHROMBOCYTOPENIA ASSOCIATED WITH TUBB1 VARIANTS**  
Simon Stritt, Ernest Turro, Noémie Saut, Marie-Christine Alessi, Nicole Schlegel, Alan Nurden, Willem Ouwehand, Bernhard Nieswandt, Paquita Nurden\* (Germany)
- PO437-MON **SOLUBLE GLYCOPROTEIN VI: A POTENTIAL BIOMARKER FOR DISEASE ACTIVITY AND PLATELET REACTIVITY IN ACUTE GOUT.**  
Geraldine McCarthy\*, Claire Louise Murphy, Anne Madigan, Paul MacMullan, Laura Durcan, Eimear Dunne (Ireland)
- PO438-MON **PERSONALIZED REFERENCE INTERVALS FOR PLATELET COUNT REDUCE THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA AND INCREASE THAT OF REACTIVE THROMBOCYTOSIS IN ELDERLY PEOPLE**  
Patrizia Noris\*, Carlo Zaninetti, Ginevra Biino, Elisa Civaschi, Federica Melazzini, Carlo Balduini (Italy)
- PO439-MON **MYH9 DISEASE: IDENTIFICATION OF TWO MUTATIONS ASSOCIATED WITH UNCOMMON CLINICAL PHENOTYPE**  
María Isabel Sánchez Guiu\*, Begoña Muiña, Adela Periago, Daniel Jaimes Albornoz, María Soler, Vicente Vicente, María Luisa Lozano, José Rivera (Spain)
- PO440-MON **ACTN1-RELATED THROMBOCYTOPENIAS (ACTN1-RT): PHENOTYPE/GENOTYPE OF A SERIES OF 13 NEW CASES**  
Anne Vincenot\*, Olivier Rene, Sylvie Binard, Marie-Christine Alessi, Eric Durot, Paul Gueguen, Felipe Guerrero, Véronique Le Cam-Duchez, Elisabeth Mazoyer, Stéphanie Muller, Bénédicte Neven, Catherine Pouymayou, Bruno Royer, Pierre Sie, Catherine Trichet, Nathalie Trillot, Nicole Schlegel (France)
- PO441-MON **ROCK1 OR FLI1 MUTATIONS IN PATIENTS WITH MILD THROMBOCYTOPENIA**  
Marjorie Poggi, Matthias Canault\*, Pauline Lucca, Catherine Pouymayou, Dorsaf Ghaloussi, Noémie Saut, Pierre Morange, Davd-Alexandre Tregouet, Marie-Christine Alessi (France)
- PO442-MON **CONGENITAL THROMBOCYTOPENIAS AND IMMUNE THROMBOCYTOPENIC PURPURA : A MISLEADING DIAGNOSIS**  
Maria Coutinho, Ana Spínola, Catarina Lau, Sara Morais\*, Mónica Pereira, Rui Matos, Manuel Campos (Portugal)
- PO443-MON **FIVE NEW HETEROZYGOUS MUTATIONS IN THE GPIB AND GPIX ARE ASSOCIATED WITH THE BOLZANO PHENOTYPE**  
Véronique Baccini\*, Noémie Saut, Catherine Pouymayou, Matthias Canault, Dorsaf Ghaloussi, Céline Falaise, Xavier Pillois, François Lanza, Pierre Morange, Marie-Christine Alessi (France)
- PO444-MON **INCREASE THE NUMBER OF GP IIB-IIIA AND P2Y12 RECEPTORS IN ACTIVATED PLATELETS – POSSIBLE EVIDENCE FOR PROTEINS' SYNTHESIS DE NOVO**  
Olga Sirotkina\*, Pavel Andoskin, Anton Emelyanov, Tatiana Vavilova (Russian Federation)

## SCIENTIFIC PROGRAM

### Pediatric thrombosis and hemostasis

- PO445-MON **RISK FACTORS AND CO-MORBIDITIES IN ADOLESCENT THROMBOEMBOLISM ARE DIFFERENT THAN THOSE IN YOUNGER CHILDREN**  
Susan Kirk, Titilope Ishola\*, Katherine Voigt, Mona Shah, Lakshmi Srivaths (United States)
- PO446-MON **DO PRETERM INFANTS WITH PATENT DUCTUS ARTERIOSUS (PDA) WHO FAIL INDOMETHACIN TREATMENT HAVE LOWER PLATELET COUNTS?: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Souvik Mitra\*, Bosco Paes, Anthony Chan (Canada)
- PO447-MON **CATHETER DIRECTED THROMBOLYSIS AS SAFE AND EFFECTIVE THERAPY FOR PROXIMAL LOWER LIMB DEEP VEIN THROMBOSIS IN ADOLESCENTS**  
Kathryn Musgrave\*, Adriano Tenna, Tina Biss (United Kingdom)
- PO448-MON **AGE-DEPENDENCY OF COAGULATION PARAMETERS DURING CHILDHOOD. RESULTS OF A MULTICENTER STUDY.**  
Pierre Toulon\*, Micheline Berruyer, François Grand, Marie Brionne-François, Dominique Lasne, Neila DePooter (France)
- PO449-MON **CLINICAL FEATURES IN CHILDREN PRESENTING FROM THE COMMUNITY WITH PULMONARY EMBOLISM**  
Charlie Y. Wang\*, Peter Francis, Timothy Cain, Vera Ignjatovic, Fiona Newall, Ed Oakley, Paul Monagle (Australia)
- PO450-MON **EFFECTS OF MATERNAL HYPERTENSION ON NEONATAL HEMOGRAM IN SOUTH-SOUTH NIGERIA**  
Helen Okoye\*, Lisa Eweputanna, Kaladada Korubo, Oseikhuemen Ejele (Nigeria)
- PO451-MON **TREATMENT WITH ROMIPLOSTIM IN CHILDREN. INCIDENCE AND QUALITY OF THE RESPONSE.**  
Maria Del Carmen Gómez Del Castillo\* (Spain)
- PO452-MON **OFF-LABEL USE OF RECOMBINANT FACTOR VIIA FOR DIFFUSE PULMONARY HEMORRHAGE IN CHILDREN**  
Te-Fu Weng\*, Kang-Hsi Wu Wu, Ching-Tien Peng (Taiwan)
- PO453-MON **INVESTIGATING THE ROLE OF POLYPHOSPHATES IN NEONATAL HEMOSTASIS**  
Axel Schlagenhaut\*, Andrea Ehammer-Rosenkranz, Harald Haidl, Bettina Leschnik, Siegfried Gallistl, Wolfgang Muntean (Austria)
- PO454-MON **RATIONALE AND DESIGN OF AESOP: APIXABAN FOR PREVENTION OF DEEP VEIN THROMBOSIS IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOMA TREATED WITH L-ASPARAGINASE**  
Vilmarie Rodriguez\*, Sarah O'Brien, Lillian Sung, Luz Ramirez, Danshi Li, Lesley Mitchell (United States)
- PO455-MON **USE OF PROTHROMBIN COMPLEX CONCENTRATES (PCC) IN PAEDIATRIC EXTRACORPOREAL LIFE SUPPORT PATIENTS**  
Tom Noga, Susan Nahirniak, Jennifer Conway, Holger Buchholz, Mary Bauman, Patti Massicotte, Aisha Bruce\* (Canada)

## SCIENTIFIC PROGRAM

- PO456-MON **ANTITHROMBIN PLASMA LEVELS AND FIBTEM DETERMINATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ASPARAGINASE TREATMENT**  
Luca Spiezia\*, Maria Putti, Elena Campello, Sara Maggiolo, Maria Sartori, Alessandra Todesco, Maria Petris, Laura Sainati, Giuseppe Basso, Paolo Simioni (Italy)
- PO457-MON **WARFARIN THERAPY IN CHILDREN: CAN FAMILIES SAFELY AND EFFICIENTLY MONITOR INRS AT HOME?**  
Kathy Harney\*, Juliann Duzan, Jenna Murray, Peter Forbes, Kathleen O'Neil, Karen Mittler, Rosemary Galvin, Ellis Neufeld, Alan Michelson, Christopher Almond (United States)
- PO458-MON **PROPHYLACTIC ENOXAPARIN IN YOUNG INFANTS – ARE THE CURRENTLY RECOMMENDED DOSES TOO LOW?**  
Kathy M. Harney\*, Juliann Duzan, Stacy Croteau, Rachael Grace, Kathleen Houlahan\*, Ellis Neufeld, Alan Michelson, Cameron Trenor (United States)
- PO459-MON **THROMBOEMBOLIC EVENTS IN CHILDREN**  
Zafer Salcioglu\*, Hulya Sayilan Sen, Deniz Tugcu, Gonul Aydogan, Muge Gokce, Cengiz Bayram, Ali Aycicek, Ferhan Akici (Turkey)
- PO460-MON **BIVALIRUDIN USE IN CHILDREN ON ECMO FOLLOWING HEPARIN FAILURE**  
Mary Bauman, Patti Massicotte, Aisha Bruce\*, Don Granoski, Laurance Lequier, Lindsay Ryerson (Canada)
- PO461-MON **THROMBOEMBOLIC EVENTS IN PEDIATRIC PATIENTS WITH CYANOTIC CONGENITAL HEART DISEASES IN SRINAGARIND HOSPITAL**  
Patcharee Komvilaisak\*, Yuttapong Wongswadiwat, Arnkisa Chaikitpinyo (Thailand)
- PO462-MON **PHENOMENON OF HYPERCOAGULABILITY IN CHILDREN WITH DEEP VEIN THROMBOSIS**  
Marina Gracheva\*, Pavel Zharkov, Elena Seregina, Hasmik Sepoyan, Alexandr Poletaev, Fazoil Ataulakhanov (Russian Federation)
- PO463-MON **IMPACT OF INHERITED AND ACQUIRED PROTHROMBOTIC DEFECTS (PD) ON THE DEVELOPMENT OF SYMPTOMATIC THROMBOEMBOLISM (STE) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED ACCORDING TO THE DANA-FARBER CANCER INSTITUTE (DFCI) 05-01 ALL-THERAPY PROTOCOL**  
Uma Athale\*, Caroline Laverdiere, Trishana Nayiager, Yves-Line Delva, Gary Foster, Lehana Thabane, Anthony Chan (Canada)
- PO464-MON **EXAMINING THE FEASIBILITY OF RECOMBINANT FACTOR VIIA TO COMPENSATE FOR PHYSIOLOGICAL OR DRUG-INDUCED IMPAIRMENT OF PLATELET FUNCTION: AN IN-VITRO STUDY.**  
Harald Haidl\*, Axel Schlagenhaut, Gernot Grangl, Gerhard Cvrin, Siegfried Gallistl, Wolfgang Muntean (Austria)
- PO465-MON **ASSESSING THE ASSOCIATION OF FVIII AND ABO BLOOD GROUP WITH DEEP VEIN THROMBOSIS IN PEDIATRIC ONCOLOGY PATIENTS.**  
Jackie Halton, Maria Spavor, Kevin Dietrich, Sarah Israels, Leonardo Brandao, Qi Liu, Yutaka Yasui, Lesley G. Mitchell\* (Canada)

## SCIENTIFIC PROGRAM

### Post-thrombotic syndrome

- PO466-MON **DENSER CLOTS PREDISPOSE TO POST THROMBOTIC SYNDROME**  
Annemieke C. Bouman\*, Helen McPherson, Yuk Cheung, Marije ten Wolde, Hugo ten Cate, Robert Ariëns, Arina ten Cate-Hoek (The Netherlands)
- PO467-MON **PRACTICE VARIATION IN THE TREATMENT OF DVT AND PREVENTION OF POST THROMBOTIC SYNDROME BETWEEN INTERNISTS AND VASCULAR SURGEONS: A CANADIAN SURVEY OF PHYSICIAN PRACTICES.**  
Rick T. Ikesaka\*, Susan Kahn, Jean-Philippe Galanaud, Fernando Vazquez, Graham Roche-Nagle, Marc Carrier, Gregoire Le Gal, Marc Rodger, Esteban Gandara (Canada)
- PO468-MON **TWO WEEKS OF LOW MOLECULAR WEIGHT HEPARIN FOR ISOLATED SYMPTOMATIC DISTAL VEIN THROMBOSIS (TWISTER STUDY): INTERIM ANALYSIS OF FIRST 100 PATIENTS – POST THROMBOTIC SYNDROME SUB-STUDY**  
Eileen Merriman\*, Sanjeev Chunilal, Simon McRae, Tim Brighton, Huyen Tran (New Zealand)
- PO469-MON **TITLE: FREQUENCY OF PERSISTENTLY ABNORMAL ECHOCARDIOGRAPHY AFTER ACUTE PULMONARY EMBOLISM**  
Emily Gundert\*, Jeffrey Kline, David Jimenez, Llorenç Font, Manuel Lorente, Barbara Pagan, Radovan Maly, Peter Vehamme, Manuel Monreal (United States)
- PO470-MON **TOLL-LIKE 9 GENE EXPRESSION IN THE POST THROMBOTIC SYNDROME, RESIDUAL THROMBOSIS AND RECURRENT DEEP VEIN THROMBOSIS: A CASE-CONTROL STUDY**  
Whitney Cheung\*, Annemieke Bouman, Elisabetta Castoldi, Simone Wielders, Henri Spronk, Hugo ten Cate, Arina ten Cate-Hoek, Marije ten Wolde (The Netherlands)
- PO471-MON **PATIENTS' PREFERENCES REGARDING ELASTIC COMPRESSION STOCKING THERAPY FOR THE PREVENTION OF POST THROMBOTIC SYNDROME**  
Annemieke C. Bouman\*, Arina ten Cate-Hoek, Carmen Dirksen, Manuela Joore (The Netherlands)
- PO472-MON **COMPARISON OF SELF-RATED AND PROFESSIONAL-RATED SCORES OF THE VILLALTA SCALE FOR EVALUATION OF THE POST-THROMBOTIC SYNDROME IN PATIENTS WITH PROXIMAL DEEP VEIN THROMBOSIS**  
Trond Isaksen\*, Vladimir Tichelaar, Finn Egil Skjeldestad, Ellen Brodin, Anders Vik, Kulbir Singh, John-Bjarne Hansen (Norway)
- PO473-MON **IS POST THROMBOTIC SYNDROME PERCEIVED TO BE A CLINICALLY RELEVANT OUTCOME?: A SURVEY OF PHYSICIAN PRIORITIES**  
Rick T. Ikesaka\*, Susan Kahn, Jean-Philippe Galanaud, Fernando Vazquez, Graham Roche-Nagle, Marc Carrier, Gregoire Le Gal, Marc Rodger, Esteban Gandara (Canada)
- PO474-MON **EXERCISE LIMITATION IN CHRONIC POST-THROMBOTIC ILLIOFEMORAL VEIN OBSTRUCTION**  
Jacob Luboshitz\*, Michael Segal, Ronen Reuveny, Issachar Ben Dov (Israel)

## SCIENTIFIC PROGRAM

- PO475-MON **ADVANCING THE DIAGNOSIS OF PEDIATRIC POST-THROMBOTIC SYNDROME: A FOUNDATION FOR THE IMPROVEMENT AND STANDARDIZATION OF ITS MEASUREMENT TOOLS**  
Laura Avila\*, Leonardo Brandao, Suzan Williams, Madeline Montoya, Jennifer Stinson, Alex Kiss, Leigh Ward, Irene Lara Corrales, Brian Feldman (Canada)
- PO476-MON **FIBRINOGEN CHARACTERISTICS HELP PREDICT CHRONIC THROMBOTIC VENOUS DISEASE AFTER ACUTE DEEP VEIN THROMBOSIS**  
Timothy Fernandes, James Marsh, Peter Chiles, Anthony Gamst, Tanya Wolfson, Roger Moore, Gabriel Gugiu, Terry Lee, Timothy A. Morris\* (United States)
- PO477-MON **RESIDUAL THROMBUS MASS AND INCIDENCE OF POST THROMBOTIC SYNDROME IN PATIENTS TREATED WITH VKA OR NON-VKA ORAL ANTI-COAGULANTS IN PHASE-III DVT TREATMENT TRIALS**  
Sebastian Werth\*, Ines Paternoga, Luise Tittl, Norbert Weiss, Jan Beyer-Westendorf (Germany)
- PO478-MON **THE ROLE OF INFLAMMATION IN POST-THROMBOTIC SYNDROME AFTER PREGNANCY-RELATED VENOUS THROMBOSIS**  
Hilde Skuterud Wik\*, Anne Jacobsen, Per Sandset (Norway)
- PO479-MON **MOM, WHY SHOULD I WEAR THESE SOCKS? TAKING THE FIRST STEP IN THE JOURNEY TO UNDERSTANDING THE ROLE OF COMPRESSION GARMENTS IN THE TREATMENT OF PEDIATRIC POST-THROMBOTIC SYNDROME**  
Madeline I. Montoya\*, Maria Laura Avila, Jennifer Vincelli, Leonardo Brandão (Canada)
- PO480-MON **INADEQUATE ANTICOAGULATION IS THE ONLY RISK FACTOR FOR DEVELOPMENT OF POST THROMBOTIC SYNDROME IN UNPROVOKED DEEP VEIN THROMBOSIS**  
Pravas Mishra\*, Kamal Kishor, Tulika Seth, Manoranjan Mahapatra, Renu Saxena (India)
- PO481-MON **PATIENT COMPRESSION HOSIERY CONCORDANCE**  
Gary Benson\*, Rosemary Lavery, Hilary Speers (United Kingdom)

### Rare bleeding disorders I

- PO482-MON **THE UTILITY OF THROMBELASTOGRAPHY AND MULTIPLATE AS SCREENING TOOLS FOR RARE INHERITED BLEEDING DISORDERS NOT ASSOCIATED WITH A COAGULATION FACTOR DEFICIENCY**  
Eva B. Leinoe\*, Jakob Stensballe, Peter Kampmann, Jens P Goetze (Denmark)
- PO483-MON **BLEEDING SCORE AND CLOTTING SCREENING TEST PERFORMED BEFORE ELECTIVE SURGERY TO DIAGNOSE UNKNOWN HEMORRHAGIC DISEASES.**  
Federica Zane, Catherine Klersy, Luigia Scudeller, Chiara Ambaglio, Mariaconchetta Russo, Nicola Ghidelli, Nicolò Allorto, Gabriella Gamba\* (Italy)

## SCIENTIFIC PROGRAM

- PO484-MON **EFFICACY OF FGTW FIBRINOGEN CONCENTRATE IN THE TREATMENT OF BLEEDING EPISODES AND PREVENTION OF EXCESSIVE BLEEDING DURING SURGERY IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY**  
Claudia Djambas Khayat\*, Mohamed El Khorassani, Valérie Gay, Malika Barthez-Toullec, Céline Henriët, Françoise Bridey, Luis Carreras, Claude Négrier, Philippe de Moerloose (Lebanon)
- PO485-MON **A NEW SWISS FAMILY WITH CONSTITUTIONAL HYPOFIBRINOGENEMIA AND LIVER DISEASE**  
Alessandro Casini\*, Christiane Sokollik, Samuel Lukowski, Eberhard Lurz, Claudine Rieubland, Philippe de Moerloose, Marguerite Neerman-Arbez (Switzerland)
- PO486-MON **SAFE USE OF FXI CONCENTRATE IN A SINGLE CENTRE EXPERIENCE OVER 19 YEARS**  
Gavin Ling\*, Huseini Kagdi, Pratima Chowdary, Keith Gomez (United Kingdom)
- PO487-MON **THE EPIDEMIOLOGY OF INHERITED BLEEDING DISORDERS IN NEW-FOUNDLAND AND LABRADOR, CANADA**  
Aaron Wiseman\*, Sarah Boyd, Mary-Frances Scully (Canada)
- PO488-MON **PHARMACOKINETIC AND PHARMACODYNAMIC RESULTS OF A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY WITH A FIBRINOGEN CONCENTRATE (FGTW) IN SUBJECTS WITH AFIBRINOGENEMIA**  
Claudia Djambas Khayat\*, Mohamed El Khorassani, Thierry Lambert, Anne Bellon, Malika Barthez-Toullec, Françoise Bridey, Luis Carreras, Claude Négrier, Philippe de Moerloose (Lebanon)
- PO489-MON **ALTERNATIVE STRATEGY TO TREAT HEMOPHILIA TROUGH PROTEIN S INACTIVATION: INSIGHT FROM A MOUSE MODEL**  
Luca Bologna\*, Sara Calzavarini, Raja Prince, Natacha Dewarrat, Francois Saller, Anne Angelillo-Scherrer (Switzerland)
- PO490-MON **GENOTYPE AND PHENOTYPE REPORT ON PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY IN SOUTH OF IRAN**  
Mehran Karimi\*, Mohammad Mostafa Safarpour, Sezaneh Haghpanah, Aidin Meshkarsar\*, Abdolreza Afrasiabi, Javad Gerdabi, Rezvan Ardeshiri (Iran, Islamic Republic Of)
- PO491-MON **FVIII MIMICKING BISPECIFIC ANTIBODY, ACE910 IMPROVES IN VITRO COAGULATION FUNCTION OF FXI DEFICIENCY PATIENT'S PLASMA**  
Hiroaki Minami\*, Keiji Nogami, Takehisa Kitazawa, Kunihiko Hattori, Midori Shima (Japan)
- PO492-MON **SPECTRUM OF FACTOR XI MUTATIONS IN THE CHINESE POPULATION**  
Yanyan Shao\*, Qiulan Ding, Yelin Lu, Jing Dai, Xiaodong Xi, Xuefeng Wang, Hongli Wang (China)
- PO493-MON **CHARACTERIZING MECHANISMS OF FACTOR VIII BINDING TO THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1**  
Patricia Young\*, Molly Migliorini, Joni Prasad, Andrey Sarafanov, Dudley Strickland (United States)

## SCIENTIFIC PROGRAM

- PO494-MON RARE BLEEDING DISORDERS : 17 YEARS OF DIAGNOSIS IN THE HEMOSTASIS LABORATORY OF THE HEMOSTASIS LABORATORY OF THE DEPARTMENT OF HEMATOLOGY OF THE UNIVERSITY HOSPITAL OF BENI MESSOUS, ALGIERS, ALGERIA**  
Karima W. Chenoukh\*, Meriem Bensadok, Mylade Aribi, Nadia Zidani, Mohamed Ramaoun, Meriem Belhani, Salim Nekkal (Algeria)
- PO495-MON THE THROMBIN GENERATION ASSAY IS SUPERIOR TO THROMBOELASTOGRAPHY AT DETERMINING BLEEDING PHENOTYPE IN CONGENITAL FXI DEFICIENCY.**  
Gillian N. Pike\*, Anthony Cumming, Charles Hay, John Burthem, Paula Bolton-Maggs (United Kingdom)
- PO496-MON A NEW MUTATION IN THE SVIL GENE IS ASSOCIATED WITH AUTOSOMAL DOMINANT FAMILIAL GRAY PLATELET SYNDROME**  
Irina Demina\*, Maria Kumskova, Artem Artemov, Sofya Lushchekina, Alyona Ivanova, Maria Suntsova, Sergey Vasiliev, Anton Buzdin, Alexey Maschan, Galina Novichkova, Mikhail Pantelev (Russian Federation)
- PO497-MON ACQUIRED GPVI DEFICIENCY IN TWO UNRELATED PATIENTS WITH MILD THROMBOCYTOPENIA**  
Marta Romera\*, Eva Caparrós-Pérez, José Vicente Sánchez-Méndez, María Isabel Sánchez Guiu, Irene Martínez Martínez, José Padilla, Francisca Ferrer-Marin, Raúl Teruel-Montoya, Vicente Vicente, Steve P Watson, Robert Andrews, Elizabeth Gardiner, María Luisa Lozano, José Rivera (Spain)
- PO498-MON IDENTIFICATION OF THE PATHOPHYSIOLOGICAL MECHANISM OF THE VKCFD2 CAUSING MUTATION P.ARG98TRP IN HUMAN VKORC1 GENE**  
Katrin Czogalla\*, Arijit Biswas, Matthias Watzka, Johannes Oldenburg (Germany)
- PO499-MON SCOTT SYNDROME PLATELETS SHOW ALTERATIONS IN PROTEIN EXPRESSION LEVELS, CALCIUM-DEPENDENT PHOSPHORYLATION AND CLEAVAGE AS REVEALED BY PROTEOMICS**  
Nadine Mattheij, Fiorella Solari, Julia Burkhart, Frauke Swieringa, Peter Collins, Judith Cosemans, Albert Sickmann, René Zahedi, Johan W. Heemskerck\* (The Netherlands)
- PO500-MON A FAILURE TO DIAGNOSE DYSFIBRINOGENAEMIA: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES.**  
Ian Jennings\*, Flora Peyvandi, Steve Kitchen, Marzia Menegatti, Roberta Palla, Isobel Walker, Mike Makris (United Kingdom)
- PO501-MON POST AUTHORIZATION SAFETY STUDY OF A TRIPLY SECURED FIBRINOGEN CONCENTRATE IN CONGENITAL AFIBRINOGENEMIA. A PROSPECTIVE OBSERVATIONAL STUDY.**  
Zéra Tellier\*, Claude Négrier, Chantal Rothschild, Jeanne-Yvonne Borg, Thierry Lambert, Natalie Stieltjes, Ségolène Claeysens, Laurence Sanhes, Arnaud Bertrand, Marie-Hélène André, Pierre Sié, Yves Gruel (France)

## SCIENTIFIC PROGRAM

- PO502-MON FIBRINOGEN DEFICIENCY: PRELIMINARY RESULTS OF THE PRO-RBDD PROJECT**  
Flora Peyvandi\*, Marzia Menegatti, Roberta Palla, Simona Siboni, Marco Boscarino, Helen Pergantou, Helen Platokouki, Britta Lachmann, Susan Halimeh, Marlies van Lent, Paul Brons, Britta Laros-van Gorkom, Naveena Fatima, Munira Borhany, Ay Ylmaz, Adrianna Williamson, Amy Shapiro, Alessandro Casini, Nihal Ozdemir, Ondrej Zapletal, Jan Blanty, Fraustina Hsu, John Chapin, Muriel Giansily-Blaizot, Jean Francois Schved, Andrew Harvey, Andrew Mumford, Pearl Quartey, Steve Austin, Marko Saracevic, Danijela Mikovic, Philippe de Moerloose (Italy)
- PO503-MON DECREASED FIBRINOLYTIC RESISTANCE IN FXI-DEFICIENCY IS INDEPENDENT OF CLOTTING IMPAIRMENT**  
Francesca Incampo\*, Antonio Cannavò, Marzia Menegatti, Eugenia Biguzzi, Nicola Semeraro, Mario Colucci, Flora Peyvandi (Italy)
- PO504-MON IMPACT OF ASSAY METHOD ON CLINICAL DOSING OF A PURIFIED FACTOR X CONCENTRATE**  
Joanne Lloyd\*, Miranda Norton (United Kingdom)

### Regulation of gene expression in vascular cells

- PO506-MON BIOGENESIS, SUBCELLULAR LOCALIZATION AND MOBILIZATION OF TWO ABUNDANT PLATELET THIOL ISOMERASES**  
Marilena Crescente, Fred Pluthero, Michael Schenk, Ling Li, Richard Lo, Marfoua Ali, Sakthivel Vaiyapuri, Lisa-marie Holbrook, Herve Falet, Walter Kahr, Jonathan Gibbins\* (United Kingdom)

### Reproductive issues I

- PO507-MON RISK FACTORS FOR OBSTETRIC BLEEDING IN VON WILLEBRAND DISEASE (VWD)**  
Gavin D. Roach\*, David Elashoff, Judith Baker (United States)
- PO508-MON PLACENTAL INSUFFICIENCY RESOLUTION WITH FULL ANTICOAGULATION IN PATIENTS WITH PRIOR BAD OBSTETRIC OUTCOME AND DYSLIPIDAEMIA DURING PREGNANCY.**  
Roberta Santos\*, Venina Barros, Ana Igai, Rossana Pulcinelli, Marcelo Zugaib (Brazil)
- PO509-MON D-DIMER MEASUREMENT HAS NO DIAGNOSTIC VALUE DURING PREGNANCY – A LONGITUDINAL STUDY OF 4314 SAMPLES FROM 791 HEALTHY WOMEN**  
Katrine Hedengran\*, Malene Andersen, Steen Stender, Pal Szecsi (Denmark)
- PO510-MON MEN WITH FACTOR V LEIDEN HAVE INCREASED SPERM COUNTS**  
Thijs E. Van Mens\*, Cindy Korver, Danny Cohn, Joost Meijers, Saskia Middeldorp, Sjoerd Repping (The Netherlands)

## SCIENTIFIC PROGRAM

- PO511-MON **INCIDENCE OF VENOUS THROMBOSIS IN PREGNANCIES AFTER SPONTANEOUS AND ART CONCEPTION - AN ITALIAN COHORT STUDY -**  
Michela Villani\*, Francesco Dentali, Donatella Colaizzo, Giovanni Tiscia, Patrizia Vergura, Tiziana Petruccelli, Francesco Petruzzelli, Walter Ageno, Maurizio Margaglione, Elvira Grandone (Italy)
- PO512-MON **POST-PARTUM PROPHYLAXIS IN PRACTICE.**  
Emmanuelle Le Moigne\*, Pascal Nicolas, Aurelien Delluc, Karine Lacut, Michel Collet, Dominique Mottier, Brigitte Pan-Petes (France)
- PO513-MON **THE M2 HAPLOTYPE WITHIN THE ANNEXIN A5 GENE AND ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED PREGNANT WOMEN- A PROSPECTIVE HOSPITAL- BASED STUDY-**  
Michela Villani\*, Elena Chinni, Filomena Cappucci, Pasquale Martinelli, Giuseppe Maruotti, Giovanni Tiscia, Donatella Colaizzo, Lucia Fischetti, Maurizio Margaglione, Elvira Grandone (Italy)
- PO514-MON **AGE OF MENARCHE AND RISK OF VENOUS THROMBOEMBOLISM**  
Luuk Scheres\*, Saskia Middeldorp, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)
- PO515-MON **EFFECT OF PROPHYLAXIS WITH LMWH ON IMPLANTATION IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE PROCEDURES (IVF OR ICSI): A PROSPECTIVE RANDOMIZED STUDY**  
Daniela Tormene\*, Federica Esposito, Libera Falcone, Francesca Viganò, Michele Gangemi, Giovanni Battista Nardelli, Paolo Simioni (Italy)
- PO516-MON **PREDICTION OF VENOUS THROMBOEMBOLIC RELATED FETAL LOSSES BY A NEW GENETIC RISK SCORE**  
Eduardo Salas, Jose A. Paramo\*, Ramon Lecumberri, Ana Alfonso, Kevin Guillen, Sara Pich, Oriol Casagran, Ana Ferro, Jose Soria (Spain)
- PO517-MON **MONITORING OF COAGULATION ACTIVATION MARKER AND APPLICATION OF LMWH IN PREGNANCY**  
Annelie Siegemund\*, Ute Scholz, Thomas Siegemund (Germany)
- PO518-MON **MECHANISM OF THE INCREASED THROMBOSIS RISK INDUCED BY BLOOD LOSS DURING CAESARIAN SECTION**  
Victoria Kuhn\*, Maria Thomassen, Tilman Hackeng, Ana Zenclussen, Serban-Dan Costa, Svetlana Tchaiikovski (Germany)

### Risk factors in thrombosis I

- PO519-MON **IDENTIFYING COMMON AND RARE GENETIC VARIANTS ASSOCIATED WITH SERUM LEVELS OF ATHEROSCLEROTIC BIOMARKER PROTEINS**  
Terry Solomon\*, Erin Smith, Sigrid Braekkan, Tom Wilsgaard, John-Bjarne Hansen, Kelly Frazer (United States)
- PO520-MON **COMPARISON OF THROMBIN GENERATION TEST AND MARKERS OF COAGULATION ACTIVATION IN UNCOMPLICATED PREGNANCY AND PREGNANCY-RELATED VENOUS THROMBOEMBOLISM**  
Berangere Joly, Virginie Barbay, Jeanne-Yvonne Borg, Veronique Le Cam-Duchez\* (France)

## SCIENTIFIC PROGRAM

- PO521-MON **ALL CAUSE MORTALITY AND USE OF ANTITHROMBOTICS WITHIN 90 DAYS OF DISCHARGE IN ACUTELY ILL MEDICAL PATIENTS**  
Charles E. Mahan\*, Larry Fields, Roger Mills, Judith Stephenson, An-Chen Fu, Maxine Fisher, Alex Spyropoulos (United States)
- PO522-MON **RISK OF VENOUS THROMBOSIS AND COAGULATION PROFILE IN DUTCH NATIVES AND IMMIGRANTS IN THE NETHERLANDS: RESULTS FROM THE MEGA STUDY**  
Suely Rezende\*, Willem Lijfering, Mettine Bos, Joost Meijers, Frits Rosendaal, Suzanne Cannegieter (Brazil)
- PO523-MON **IMPACT OF TORNADOES ON HOSPITAL ADMISSIONS FOR VENOUS THROMBOEMBOLISM AND CARDIOVASCULAR EVENTS**  
Ana I. Casanegra\*, Federico Silva, Alan Shapiro, Minh Phan, Beau Hawkins, Ji Li, Julie Stoner, Alfonso Tafur (United States)
- PO524-MON **JOINT EFFECTS OF F5 GENE VARIANTS AND TALL STATURE ON VTE RISK**  
Tine S. Lønneberg\*, Erin Smith, Sigrid Brækkan, Lars Horvei, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
- PO525-MON **JOINT EFFECT OF OBESITY AND RISK ALLELES IN THE KNG1 GENE ON RISK OF VENOUS THROMBOEMBOLISM.**  
Tine Lønneberg\*, Erin Smith, Sigrid Brækkan, Lars Horvei, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
- PO526-MON **JOINT EFFECT OF CANCER AND THE GP6 RS1613662 SINGLE NUCLEOTIDE POLYMORPHISM ON VTE RISK**  
Olga Dziewiecka\*, Erin Smith, Sigrid Brækkan, Hilde Jensvoll, Kristine Blix, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
- PO527-MON **SEX HORMONE-BINDING GLOBULIN AND HEMOSTATIC VARIABLES IN WOMEN USING COMBINED OR PROGESTIN-ONLY PILLS.**  
Justine Hugon-Rodin\*, Marianne Canonico, Martine Alhenc-Gelas, H.Coenraad Hemker, Sylvie Brailly-Tabard, Anne Guiochon-Mantel, Geneviève Plu-Bureau, Pierre-Yves Scarabin (France)
- PO528-MON **INVOLVEMENT OF HEREDITARY THROMBOPHILIA IN CEREBRAL VENOUS THROMBOSIS OCCURRING IN YOUNG PATIENTS**  
Héla Baccouche\*, Eya Chakroun, Sonia Mahjoub, Montaha Ben Jemaa, Samia Ben Sassi, Zeineb Manai, Neila Ben Romdhane (Tunisia)
- PO529-MON **CHRONIC LIVER DISEASE IS A SIGNIFICANT RISK FACTOR FOR VENOUS THROMBOEMBOLISM AMONG MEDICAL PATIENTS IN SINGAPORE GENERAL HOSPITAL**  
Lai Heng Lee\*, Xiao Zhu Zhang, Han Seong Ng, Jeffrey Hui, Yong Yang (Singapore)
- PO530-MON **THE EFFECT OF HEMODIAFILTRATION AND HEMODIALYSIS ON COAGULATION PARAMETERS IN PATIENTS WITH END-STAGE RENAL DISEASE**  
Krisztina Péntes-Daku\*, Gergely Becs, Boglárka Hurják, Éva Molnár, Judit Csapó, Éva Katona, József Balla, László Muszbek (Hungary)

## SCIENTIFIC PROGRAM

- PO531-MON **MIR-15A, MIR-96, MIR-144, MIR-150, MIR-155, MI210, MIR-212, MIR-223, MIR-424 AND MIR-451 ARE DIFFERENTLY EXPRESSED IN PLATELETS FROM DVT PATIENTS**  
Mariane Flores-Nascimento\*, Regiane Ferreira, Thaís Fornari, Lúcia Helena Siqueira, Bruna Mazetto, Fernanda Orsi, Erich De Paula, Marina Collela, Joyce Annichino-Biz-zacchi (Brazil)
- PO532-MON **PREVENTION OF VENOUS THROMBOSIS AFTER AN ANTERIOR CRUCI-ATE LIGAMENT RECONSTRUCTION: COMPRESSION STOCKINGS ALONE VERSUS ITS COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN.**  
Raymond A. Van Adrichem\*, Nicole Tolen, Lucas Goldman, Anna Boef, Nienke van Rein, Marcel Driessen, Manfred Vischjager, Inger Schipper, Rob Nelissen, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)
- PO533-MON **EFFECT OF N-HOMOCYSTEINYLAATION PROCESS ON TISSUE PLASMINO-GEN ACTIVATOR.**  
Heliana Hernández Herrera, Lucía Kordich, Irene Quintana\*, Ana María Lauricella (Argentina)
- PO534-MON **INCREASED CIRCULATING DNA, CALPROTECTIN AND MIELOPEROXI-DASE, AS NEUTROPHIL EXTRACELLULAR TRAP MARKERS, ARE RISK FACTORS FOR DEEP VEIN THROMBOSIS**  
Laura Martos, Silvia Navarro, Luis Ramón, Fernando Ferrando, Ana Cid, Santiago Bonanad, Francisco España, Pilar Medina\* (Spain)
- PO535-MON **IN-HOSPITAL COSTS AND CLINICAL DETERMINANTS OF COSTS OF ACUTE PULMONARY EMBOLISM: A PROSPECTIVE STUDY**  
Jean-Philippe Galanaud\*, Aurelie Ternissien, Vera Georgescu, Daniel Pontal, Isabelle Quere, Pierre Aubas, Gregoire Mercier (France)
- PO536-MON **IDENTIFICATION AND VALIDATION OF PLASMA MICRORNAS INVOLVED IN VENOUS AND ARTERIAL THROMBOSIS.**  
Luis A Ramon, Laura Martos, Joaquin Rueda, Miguel A Arnau, Esther Zorio, Fernando Ferrando, Yolanda Mira, Santiago Bonanad, Pilar Medina, Francisco España, Silvia Navarro\* (Spain)
- PO537-MON **THE INCIDENCE OF CATHETER-RELATED THROMBOSIS IN PATIENTS ON LONG-TERM PARENTERAL NUTRITION: A SYSTEMATIC REVIEW AND META-ANALYSIS.**  
Stefano L. Barco\*, Bram Salman, Mireille Serlie, Saskia Middeldorp, Michiel Coppens (The Netherlands)
- PO538-MON **VENA CAVA THROMBOSIS IN ADULTHOOD VS PEDIATRICS PATIENTS: DIFFERENT PHENOTYPES AND RISK FACTORS FOR THE SAME ENTITY.**  
Georgina Daher\*, Verónica Pons, Inés Valcarce, Gonzalo Artaza, Pavel Olivera, Laura López, Amparo Santamaría, Francesc Bosch (Spain)
- Thrombophilia I**
- PO539-MON **A CLINICAL AUDIT OF HERITABLE THROMBOPHILIA TEST PROFILE IN A TERTIARY HEALTH CARE FACILITY, PAKISTAN.**  
Anila Rashid, Bushra Moiz\*, Humaira Perveen, Bushra Rizvi (Pakistan)

## SCIENTIFIC PROGRAM

- PO540-MON **THROMBOPHILIC PROFILE IN EXTRAHEPATIC PORTAL VEIN OBSTRUC-TION- EXPERIENCE FROM A TERTIARY CENTRE IN INDIA**  
Pratibha Dhiman\*, Priyanka Saxena, Chhagan Bihari, Archana Rastogi, Sk Sarin (India)
- PO541-MON **ISTH'S CLARION CALL: "TO RAISE THE AWARENESS OF THROMBOSIS WORLDWIDE - A GLOBAL DISEASE BURDEN"**  
Thiruchelvam Ayadurai\*, Afandi Faridah, Faraizah Karim (Malaysia)
- PO542-MON **RISK FACTORS OF THROMBOSIS AND SICKLE CELL ANEMIA**  
Toure Awa Oumar\*, Sall Abibatou, Fall Seynabou, Cisse Samba, Seck Moussa, Faye Blaise, Gadji Macoura, Ndiaye Fatou Samba, Dieye Tandakha, Diop Saliou (Senegal)
- PO543-MON **GENETIC VARIABILITY OF KNG1 AND F11 GENES USING NEXT GENERA-TION SEQUENCING**  
Laura Martin-Fernandez\*, Irene Corrales, Lorena Ramirez, Angel Martinez-Perez, Hele-na Brunel, Juan Carlos Souto, Francisco Vidal, José Manuel Soria (Spain)
- PO544-MON **LABORATORY MARKERS OF THROMBOPHILIA**  
Violeta Neceva\*, Dejanova Violeta (Macedonia, The Former Yugoslav Republic Of)
- PO545-MON **EVALUATION OF PROTEIN S SPECIFIC ACTIVITY PERMITS ACCURATE DIAGNOSIS OF PROTEIN S TOKUSHIMA, A MISSENSE MUTATION WITH TYPE II PROTEIN S DEFICIENCY**  
Hiroko Tsuda\*, Kenta Noguchi, Eri Nakazono, Tomohide Tsuda, Xiuri Jin (Japan)
- PO546-MON **HYPOXIA INDUCES A PROTHROMBOTIC STATE INDEPENDENTLY OF THE PHYSICAL ACTIVITY**  
Marisa Ninivaggi, Marieke de Laat, Marcus Lancé, Cécile Kicken, Tessa Peters, Saartje Bloemen\*, Marlou Dirks, Luc van Loon, José Govers-Riemslog, Ganeshram Krishna-moorthy, Theo Lindhout, Joke Konings, Bas de Laat (The Netherlands)
- PO547-MON **THE POSSIBLE ROLE OF C.1824C>T PROTHROMBIN GENE VARIANT IN PATHOGENESIS OF THROMBOPHILIA**  
Valentina Djordjevic\*, Iva Pruner, Maja Gvozdenov, Branko Tomi , Mira Kovac, Predrag Miljic, Dragica Radokovic (Serbia)
- PO548-MON **PATHOGENETIC PROPHYLAXIS PRE-ECLAMPSIA IN PATIENTS WITH THROMBOPHILIA AND THE HISTORY OF PRE-ECLAMPSIA**  
Alexander Makatsaria\*, Victoria Bitsadze, Ekaterina Zhuravleva (Russian Federation)
- PO549-MON **THE CLINICAL AND LABORATORY ANALYSIS OF HOMOZYGOUS CARRI-ERS FACTOR V LEIDEN MUTATION.**  
Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Paulina Adamczyk-Wojciech-owska, Magdalena Marchewka, Adam Wiszniewski\*, Jerzy Windyga (Poland)
- PO550-MON **MOLECULAR CHARACTERIZATION OF NEW ANTITHROMBIN MUTATIONS**  
Zsuzsanna Bereczky\*, Réka Gindele, Marianna Speker, Ágnes Udvari, Zsolt Oláh, Anna Selmeczi, Ágota Schlammadinger, Helga Bárdos, István Komáromi, Gizella Haramura, László Muszbek (Hungary)
- PO551-MON **A REASON TO INCLUDE HOMOCYSTEINE IN THE HYPERCOAGULABLE WORKUP**  
Mala Varma\* (United States)



## SCIENTIFIC PROGRAM

### Tissue factor - Factor VII - I

- PO552-MON **PATHOLOGICAL DETERMINANTS OF HUMAN CORONARY THROMBUS FORMATION: DISTINCT PROCOAGULANT ACTIVITY AND LACTATE PRODUCTION OF M1/M2 POLARIZED MACROPHAGES.**  
Shuntaro Matsuda, Atsushi Yamashita\*, Sayaka Moriguchi-Goto, Naoki Sameshima, Takashi Iwakiri, Yunosuke Matsuura, Yuichiro Sato, Yujiro Asada (Japan)
- PO553-MON **SINGLE PHOSPHORYLATION OF THE CYTOPLASMIC DOMAIN OF TISSUE FACTOR AT SERINE 253 IS SUFFICIENT FOR THE BINDING OF TISSUE FACTOR TO FILAMIN-A**  
Mary E. W. Collier\*, Ben Goult, Anthony Maraveyas, Camille Ettelaie, Alison Goodall (United Kingdom)
- PO554-MON **THE INTERPLAY BETWEEN TISSUE FACTOR AND ALTERNATIVELY SPLICED TISSUE FACTOR AND ITS EFFECT ON THROMBOSIS AND HEMOSTASIS.**  
Betul Unlu\*, Henri Versteeg (The Netherlands)
- PO555-MON **K63-LINKED POLYUBIQUITINATION OF LYSINE 255 WITHIN TF PROMOTES SELECTIVE TF-DEPHOSPHORYLATION, TRIGGERS TF-ENDOCYTOSIS AND TERMINATES TF ACTIVITY**  
Camille Ettelaie\*, Anthony Maraveyas, Mary Collier (United Kingdom)
- PO556-MON **CHARACTERISATION OF TF UBIQUITINATION: INVOLVEMENT OF MDM2 AND THE UBE2D FAMILY OF E2 ENZYMES**  
Camille Ettelaie\*, Mary Collier, Sophie Featherby, Anthony Maraveyas (United Kingdom)
- PO557-MON **HIGH LEVEL OF TISSUE FACTOR INDUCES CELL APOPTOSIS IN ENDOTHELIAL CELLS, MEDIATED THROUGH ACTIVATION OF P38 AND P53**  
Azza ElKeeb, Mary Collier, Anthony Maraveyas, Camille Ettelaie\* (United Kingdom)
- PO558-MON **THE POTENTIAL OF CANCER CELL LINES TO RELEASE TISSUE FACTOR-CONTAINING MICROVESICLES CORRELATES WITH TISSUE FACTOR AND PAR2 MRNA LEVELS BUT NOT TISSUE FACTOR PROTEIN OR SURFACE ACTIVITY**  
Camille Ettelaie\*, Mary Collier, Sophie Featherby, John Greenman, Anthony Maraveyas (United Kingdom)
- PO559-MON **TISSUE FACTOR IS INDUCED BY INTERLEUKIN-33 IN HUMAN ENDOTHELIAL CELLS: A NEW LINK BETWEEN COAGULATION AND INFLAMMATION**  
Stefan Stojkovic\*, Christoph Kaun, José Basilio, Sabine Rauscher, Lena Hell, Konstantin Krychtiuk, Wolfgang Holnthoner, Christoph Neumayer, Cihan Ay, Wolfgang Eppel, Ihor Huk, Rainer De Martin, Kurt Huber, Svitlana Demyanets, Johann Wojta (Austria)
- PO560-MON **SOLUBLE TISSUE FACTOR IMPROVES DETECTION OF THROMBIN GENERATION RESPONSES TO WIDE RANGE OF FACTOR VIIA DOSES**  
Alexey Shibeko, Alireza Rezaie, Timothy Lee, Mikhail V. Ovanesov\* (United States)

## SCIENTIFIC PROGRAM

- PO561-MON **NATURALLY OCCURRING NEISSERIA MENINGITIDIS WITH MUTATED LIPID A MOIETY IS A WEAKER INDUCER OF TISSUE FACTOR EXPRESSION AND -ACTIVITY IN HUMAN MONOCYTES AND MONOCYTE-DERIVED MICROVESICLES THAN THE WILDTYPE MENINGOCOCCI**  
Marit Hellum, Anne Marie Siebke Troseid, Jens Petter Berg, Petter Brandtzaeg, Reidun Ovstebo, Carola Henriksson\* (Norway)
- PO562-MON **DO ELEVATED COAGULATION FACTOR LEVELS AFFECT THE TISSUE FACTOR-THRESHOLD IN THROMBIN GENERATION?**  
Inge M. Rietveld\*, Pieter Reitsma, Mettine Bos (The Netherlands)
- PO563-MON **TISSUE FACTOR/FACTOR VIIA SIGNALING PROMOTES CYTOKINE-INDUCED BETA CELL DEATH AND IMPAIRS GLUCOSE STIMULATED INSULIN SECRETION FROM HUMAN PANCREATIC ISLETS.**  
Desirée Edén\*, Agneta Siegbahn, Dariush Mokhtari (Sweden)
- PO564-MON **TISSUE FACTOR ACTIVATION IN PREGNANCY COMPLICATIONS**  
Martin Prochazka\*, Ludek Slavik, Jana Procházková, Jana Úlehlová, Martin Novák, Eliska Hostinska, Petr Polák (Czech Republic)
- PO565-MON **ACTIVATED PLATELETS REGULATE MONOCYTE TFPI GENE EXPRESSION THROUGH THE NUCLEAR TRANSCRIPTION FACTOR PPAR $\gamma$**   
Robert E. Turnbull\*, Katrin Sander, Peter Watson, David Barrett, John Schwabe, Alison Goodall (United Kingdom)
- PO566-MON **TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR ASSESSMENT IN EARLY AND LATE SEVERE PREECLAMPSIA**  
Lara C. Godoi\*, Patrícia Alpoim, Karina Borges, Maria das Graças Carvalho, Melina Pinheiro, Luci Dusse (Brazil)

### Transfusion I

- PO567-MON **LEVONORGESTREL-RELEASING INTRA-UTERINE DEVICE USE IN ADOLESCENT FEMALES WITH HEAVY MENSTRUAL BLEEDING AND BLEEDING DISORDERS: SINGLE INSTITUTION REVIEW**  
Oluyemi A. Adeyemi, Xiomara Santos, Jennifer Dietrich, Lakshmi Srivaths\* (United States)
- PO568-MON **A NEW ALLOANTIGEN (CAB4) CARRIED BY GPIX IDENTIFIED IN A CONTEXT OF SEVERE NEONATAL ALLOIMMUNE THROMBOCYTOPENIA.**  
Vincent Jallu, Thomas Beranger, Frederic Bianchi, Cecile Casale, Christophe Chenet, Nicolas Ferre, Sebastien Philippe, Jeannine Quesne, Corinne Martageix, Rachel Petermann\* (France)
- PO569-MON **ASSESSMENT OF QUALITY AND CLINICAL EFFECTIVENESS OF APHERESIS PLATELET CONCENTRATES TREATED WITH MIRASOL PATHOGEN REDUCTION SYSTEM IN PLASMA OR IN PLATELET ADDITIVE SOLUTION SSP+**  
Anastasia Ignatova\*, Oksana Karpova, Pavel Trahtman, Sergey Rumyantsev, Mikhail Pantelev (Russian Federation)

## SCIENTIFIC PROGRAM

- PO570-MON **QUANTIFICATION OF CELL FREE DNA IN RED BLOOD CELL CONCENTRATES PRODUCED VIA BUFFY COAT (B1) OR WHOLE BLOOD (B2) METHODS**  
Andrew Shih\*, Vinai Bhagirath, Patricia Liaw, Jason Acker, John Eikelboom, Nancy Heddle (Canada)
- PO571-MON **RESPONSIVENESS OF PLATELETS DURING STORAGE STUDIED WITH FLOW CYTOMETRY – FORMATION OF PLATELET SUBPOPULATIONS AND LAMP-1 AS NEW MARKERS FOR THE PLATELET STORAGE LESION**  
Anna L. Södergren\*, Nahreen Tynngård, Gösta Berlin, Sofia Ramström (Sweden)
- PO572-MON **PRESERVED ULTRASTRUCTURE AND BIOCHEMICAL CHARACTERISTICS OF PLATELET COMPONENTS PREPARED WITH AMOTOSALEN AND UVA FOR PATHOGEN INACTIVATION**  
Beatrice Hechler\*, Catherine Ravanat, Philippe Ohlmann, Anita Eckly, Marjorie Leduc, François Guillonnet, Hervé Isola, Christian Gachet (France)
- PO573-MON **PLATELET TRANSFUSIONS AT THE CLINIC OF CHEMOTHERAPY: A HOSPITAL-BASED COHORT STUDY**  
Gevorg Tamamyan\*, Samvel Danielyan, Liana Safaryan, Davit Zohrabyan, Lilit Sargsyan, Astghik Voskanyan, Lusine Hakobyan, Lilit Harutyunyan, Armen Avagyan, Samvel Bardakchyan (Armenia)
- PO574-MON **RELATIVE EFFECTS OF FRESH FROZEN PLASMA, FIBRINOGEN CONCENTRATE, AND FACTOR XIII IN MASSIVE TRANSFUSION REGIMENS: A LABORATORY STUDY**  
David Schmidt\*, Agneta Wikman, Anna Ågren, Anders Östlund (Sweden, Netherlands)
- PO575-MON **HPA BEADCHIP GENOTYPING STUDY: COMPARISON BETWEEN DNA EXTRACTED FROM BLOOD SAMPLES AND BUCCAL SWABS**  
Rachel Petermann\*, Christophe Chenet, Thomas Beranger, Frederic Bianchi, Cecile Casale, Nicolas Ferre, Sebastien Philippe, Quesne Jeannine, Corinne Martageix, Vincent Jallu, Olivier Garraud (France)
- PO576-MON **PROTHROMBIN ACTIVATION IN PACKED RED BLOOD CELL UNITS OVER THEIR STORAGE LIFETIME**  
Thomas Orfeo\*, Hollis Keith, Elizabeth Lavoie, Beth Bouchard, Matthew Gissel, Mark Fung, Kenneth Mann (United States)
- PO577-MON **EXPLORING THE CHALLENGES OF EFFECTIVE FACTOR DISTRIBUTION AND MANAGEMENT IN THE PROVINCE OF SASKATCHEWAN**  
Karen L. Dallas\*, Roona Sinha (Canada)

### TTP/thrombotic microangiopathies I

- PO578-MON **NEURO-IMAGING DOES NOT CORRELATE WITH DISEASE SEVERITY IN ACUTE THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP), BUT MAY PREDICT LONG TERM SEQUELAE.**  
Indrani Karpha\*, Clare Kay-Jones, Jennifer Burgiss, Vanessa Martlew, Cheng Toh, Paul Fitzsimmons\*, Tina Dutt (United Kingdom)

## SCIENTIFIC PROGRAM

- PO579-MON **PHASE II STUDY OF DANAZOL WITH PLASMA EXCHANGE AND CORTICOSTEROIDS FOR THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA**  
Vamsee Torri\*, Mark Friedman, Ilan Shapira, Amit Patel, Joseph Yoe, Vijay Shah, Tahir Mirzoyev\*, Maria Machuca, Mala Varma (United States)
- PO580-MON **DENSE GENOTYPING OF IMMUNE-RELATED DISEASE REGIONS FOR THE IDENTIFICATION OF GENETIC RISK FACTORS IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA.**  
Ilaria Mancini\*, Emanuela Pappalardo, Andrea Cairo, Marcin Gorski, Barbara Ferrari, Isis Ricaño-Ponce, Cisca Wijmenga, Flora Peyvandi (Italy)
- PO581-MON **CHARACTERIZATION OF SINGLE SORTED ANTI-ADAMTS13 SPECIFIC B CELLS FROM THE SPLEEN OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) PATIENTS**  
Magdalena Skowronska\*, Monica Schaller, Johanna Kremer Hovinga (Switzerland)
- PO582-MON **THE NATURAL MUTATION ASP173GLY IN THE CATALYTIC SITE OF THE ADAMTS-13 GENE CAUSES A SEVERE UPSHAW-SCHULMAN SYNDROME: CLINICAL COURSE, BIOCHEMISTRY AND MOLECULAR DYNAMICS INVESTIGATION**  
Stefano Lancellotti\*, Flora Peyvandi, Maria Teresa Pagliari, Andrea Cairo, Safwat Abdel-Azeim, Edrisse Chermak, Ilaria Lazzareschi, Stefano Mastrangelo, Luigi Cavallo, Romina Oliva, Raimondo De Cristofaro (Italy)
- PO583-MON **DEFECTIVE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS IS ASSOCIATED WITH ACUTE THROMBOTIC MICROANGIOPATHIES**  
Miguel Jiménez-Alcázar\*, Markus Napirei, Rachita Panda, Elodie Köhler, Johanna Kremer Hovinga, Hans Mannherz, Sven Peine, Thomas Renné, Bernhard Lämmle, Tobias Fuchs (Germany)
- PO584-MON **PLATELET INHIBITION IN TTP: A MECHANISM TO ESCAPE THROMBOSIS**  
Mark Roest\*, Rob Fijnheer, Loes Cornelissen, Judith Zandstra, Silvie Sebastian, Rolf Urbanus (The Netherlands)
- PO585-MON **TREATMENT OF A JEHOVAH'S WITNESS WITH RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA WITH RITUXIMAB**  
Fnu Kirti\*, Gabriel Ibarra, Alejandro Calvo (United States)
- PO586-MON **PATHOGENICITY OF ANTI-ADAMTS13 AUTOANTIBODIES IN ACQUIRED TTP**  
Mari Thomas\*, Rens De Groot, James Crawley, Marie Scully (United Kingdom)
- PO587-MON **MAJOR CLINICAL OUTCOMES ARE SIMILAR BETWEEN INITIAL AND RE-LAPSED EPISODES OF THROMBOTIC THROMBOCYTOPENIC PURPURA**  
Shangbin Yang\*, Susan Geyer, Elizabeth Biller, Haiwa Wu, Spero Cataland, Haifeng Wu (United States)
- PO588-MON **ACTIVATION OF THE COMPLEMENT SYSTEM AND REDUCTION OF ADAMTS13 ACTIVITY BOTH PRECEDE CLINICAL EVENTS OF TTP RE-LAPSE**  
Shangbin Yang\*, Spero Cataland, Haiwa Wu, Ming Jin, Yi Wang, Ante Lundberg, Haifeng Wu (United States)

## SCIENTIFIC PROGRAM

- PO589-MON** **BASELINE DEMOGRAPHICS AND CHARACTERISTICS OF 570 PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME IN THE GLOBAL AHUS REGISTRY**  
Christoph Licht\*, Gianluigi Ardissino, Gema Ariceta, David Cohen, Christoph Gasteyer, Larry Greenbaum, Sally Johnson, Masayo Ogawa, Varant Kupelian, Franz Schaefer, Johan Vande Walle, Veronique Fremeaux-Bacchi (Canada)
- PO590-MON** **A CASE OF THROMBOTIC MICROANGIOPATHY WITH CFH GENE ALTERATIONS THAT ARE NOT ASSOCIATED WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME**  
Yesim Oymak\*, Tuba Karapinar, Yilmaz Ay, Erkin Serdaroglu, Neryal Muminoglu, Canan Vergin (Turkey)
- PO591-MON** **SEVERE FIRST MANIFESTATION OF TTP IN A 96-YEAR-OLD FEMALE**  
Markus Munder, Lothar van den Abeelen, Roland Hardt, Charis von Auer, Ina Pretzell, Annette Shresthna, Inge Scharrer\* (Germany)
- PO592-MON** **GENOTYPE AND PHENOTYPE FEATURES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS (MILAN TTP REGISTRY).**  
Andrea Cairo, Ilaria Mancini\*, Gloria Casoli, Andrea Artoni, Barbara Ferrari, Haifeng Wu, Flora Peyvandi (Italy)
- PO593-MON** **NEUROLOGICAL AND PSYCHOLOGICAL CONSEQUENCES AFTER RECOVERY FROM THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)**  
Veronique Schmitt, Stephanie Herold, Veronika Weyer, Charis Von Auer, Heidi Rossmann, Karl Lackner, Inge Scharrer, Bernhard Lämmle, Tanja Falter\* (Germany)

### Venous thromboembolism - diagnosis I

- PO594-MON** **THE NEW CLINICAL PREDICTION SCORE FOR DIAGNOSIS OF LOWER LIMB DEEP VEIN THROMBOSIS IN UNSELECTED POPULATION OF OUTPATIENTS AND INPATIENTS**  
Nuttawut Sermsathanasawadi\* (Thailand)
- PO595-MON** **OVER-REPRESENTATION OF SEVERE SUBCLAVIAN VEIN OCCLUSION IN THE AFFECTED ARM, COMPARED WITH THE CONTRALATERAL ARM, IN PATIENTS WITH UNPROVOKED UNILATERAL UPPER EXTREMITY DEEP VEIN THROMBOSIS**  
Shuoyan Ning\*, Ryan Rebello, Anthony Chan, Howard Chan (Canada)
- PO596-MON** **THE PERFORMANCE OF THE AGE-ADJUSTED D-DIMER THRESHOLD FOR SUSPECTED PULMONARY EMBOLISM IN RELEVANT SUBGROUPS : AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF 7,000 PATIENTS**  
Nick van Es\*, Tom van der Hulle, Josien van Es, Paul den Exter, Renée Douma, Robbert Goekoop, Inge Mos, Pieter Kamphuisen, Patrick Bossuyt, Menno Huisman, Frederikus Klok, Harry Büller (The Netherlands)
- PO597-MON** **A SIMPLE DECISION RULE INCLUDING THE D-DIMER TEST TO REDUCE THE NEED FOR CT-SCANNING IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM**  
Josien Van Es\*, Ludo Beenen, Renee Douma, Paul den Exter, Inge Mos, Karin Kaasjager, Menno Huisman, Pieter Kamphuisen, Patrick Bossuyt (The Netherlands)

## SCIENTIFIC PROGRAM

- PO598-MON** **ACCURACY OF X-RAY WITH PERFUSION SCAN IN YOUNG PATIENTS WITH SUSPECTED PULMONARY EMBOLISM**  
Josien Van Es\*, Renee Douma, Rachel Hezemans, Andrea Penalzoza, Serge Motte, Petra Erkens, Marc Durian, Berthe van Eck-Smit, Pieter Kamphuisen (The Netherlands)
- PO599-MON** **DEVELOPMENT OF ELISA SYSTEM FOR DETECTION OF PROTEIN S K196E MUTATION, A GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM**  
Keiko Maruyama\*, Masashi Akiyama, Koichi Kokame, Akiko Sekiya, Eriko Morishita, Toshiyuki Miyata (Japan)
- PO600-MON** **MODIFIED COMPUTER-ASSISTED STRAIN GAUGE PLETHYSMOGRAPHY AS A SIMPLE SCREENING TEST FOR PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A COHORT STUDY.**  
Andrew S. Hughes\*, Benjamin Hall, Kate Jennings, Victoria Webb, Georgia Page, Christine Smith, Florence Charova (United Kingdom)
- PO601-MON** **MODIFIED STRAIN GAUGE PLETHYSMOGRAPHY CAN DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A RETROSPECTIVE MULTI-CENTRE COHORT STUDY.**  
Andrew S. Hughes\*, Benjamin Hall, Jane Strong, Rachel Clarke-Drury, Mark Bennett, Lyn Hooton, Nimal Muttucumaru, Tracy Muttucumaru (United Kingdom)
- PO602-MON** **ULTRASOUND DIAGNOSTIC CRITERIA AND CLOT DIAMETERS OF ISOLATED DISTAL DEEP VENOUS THROMBOSIS**  
Michelangelo Sartori\*, Gianfranco Lessiani, Elisabetta Favaretto, Ludovica Migliaccio, Matteo Iotti, Angelo Ghirarduzzi, Benilde Cosmi (Italy)
- PO603-MON** **OUTCOME OF SCREENING FOR OCCULT MALIGNANCY IN PATIENTS PRESENTING WITH UNPROVOKED VENOUS THROMBOEMBOLISM AT A LARGE TERTIARY HOSPITAL IN CENTRAL LONDON**  
Anne Mwirigi\*, Vickie McDonald, Richard Glaves, Johanna Young, Susie Shapiro, Beverley Hunt, Karen Breen (United Kingdom)

### Venous thromboembolism - epidemiology I

- PO604-MON** **A PROSPECTIVE STUDY OF VENOUS THROMBOEMBOLISM INCIDENCE AND RISK FACTORS IN SEVERE SEPSIS AND SEPTIC SHOCK**  
David Kaplan\*, Charles Casper, Larry Kraiss, Andrew Weyrich, Colin Grissom, Shaohua Men, Robert Pendleton, Guy Zimmerman, Matthew Rondina (United States)
- PO605-MON** **VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUSTRALIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREATMENT STRATEGIES IN THE WARFARIN ERA.**  
Pralhad Ho\*, Hui Yin Lim, Chyn Chua, Matthew Sleeman, Lachlan Hayes (Australia)
- PO606-MON** **LOW INCIDENCE OF DEEP VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN AN ASIAN POPULATION**  
Stephrene S. W. Chan\*, Jing Loong Moses Loh, Sanjay De Mel, Deborah Chew, Keng Lin Wong, Eng Soo Yap (Singapore)

## SCIENTIFIC PROGRAM

- PO607-MON **ASYMPTOMATIC THROMBOSIS FOLLOWING THE USE OF CENTRAL VENOUS LINES IN CHILDREN**  
Sophie E. Jones\*, Fiona Newall, Warwick Butt, Paul Monagle (Australia)
- PO608-MON **DOES DIABETES INFLUENCE OUTCOME WITHIN THREE MONTHS AFTER VENOUS THROMBOEMBOLISM? FINDINGS FROM 4,011 CASES ENROLLED IN THE WORLDWIDE RIETE REGISTRY**  
Stefania Frasson, Gualberto Gussoni, Pierpaolo Di Micco, Laurent Bertoletti, Alicia Lorenzo, Olga Madridano, Javier Trujillo-Santos, Antonio Ceriello, Paolo Prandoni, Manuel Monreal\* (Italy)
- PO609-MON **TIME TRENDS IN INCIDENCE RATES OF VENOUS THROMBOEMBOLISM IN A LARGE COHORT RECRUITED FROM THE GENERAL POPULATION**  
Nadia Arshad\*, Trond Isaksen, John-Bjarne Hansen, Sigrid Brækkan (Norway)
- PO610-MON **POOR SELF-RATED HEALTH IS ASSOCIATED WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM IN WOMEN. THE TROMSØ STUDY.**  
Sigrid Brækkan\*, Trond Isaksen, John-Bjarne Hansen (Norway)
- PO611-MON **ORAL AND INHALED CORTICOSTEROID USE HAS A TIME-DEPENDENT ASSOCIATION WITH RECURRENT PULMONARY EMBOLISM**  
Marlous Sneehoer, Barbara Hutten, Christof Majoor, Pieter-Willem Kamphuisen\*, Elisabeth Bel (The Netherlands)
- PO612-MON **CASE FATALITY AND RECURRENCE RATES AFTER FIRST VENOUS THROMBOEMBOLISM IN A LARGE POPULATION-BASED COHORT**  
Nadia Arshad\*, Trond Isaksen, John-Bjarne Hansen, Sigrid Brækkan (Norway)
- PO613-MON **TIME TRENDS AND CASE FATALITY RATE OF PULMONARY EMBOLISM DURING 11 YEARS OF OBSERVATION IN NORTHWESTERN ITALY**  
Francesco Dentali\*, Walter Ageno, Fulvio Pomerio, Luigi Fenoglio, Alessandro Squizzato, Matteo Bonzini (Italy)
- PO614-MON **NATURAL HISTORY AND ANTITHROMBOTIC TREATMENT OF INCIDENTALLY DETECTED SPLANCHNIC VEIN THROMBOSIS: FINDINGS FROM THE ISTH REGISTRY**  
Nicoletta Riva\*, Walter Ageno, Sam Schulman, Jan Beyer-Westendorf, Soo-Mee Bang, Samantha Pasca, Daniela Poli, Peter Verhamme, Adriano Alatri, Donatella Colaizzo, Elena Rancan, Suely Meireles Rezende, Antonietta Piana, Mario Bazzan, Maria T. De Sancho, Etienne Ciantar, Elena Elli, Krystyna Zawilska, Francesco Dentali, IRSVT study investigators (Italy)
- PO615-MON **DEEP VEIN THROMBOSIS IN SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT**  
Vaia Florou\*, Gregoris Komodikis, Damodar Penigalapati, Paris Charilaou, Haris Rana (United States)
- PO616-MON **FACTOR V IS ASSOCIATED WITH A MODERATELY INCREASED RISK OF VENOUS THROMBOSIS**  
Inge M. Rietveld\*, Mettine Bos, Frits Rosendaal, Pieter Reitsma, Suzanne Cannegieter (The Netherlands)

## SCIENTIFIC PROGRAM

- PO617-MON **THROMBIN GENERATION AND THE RISK OF VENOUS THROMBOSIS: RESULTS FROM A LARGE POPULATION-BASED CASE-CONTROL STUDY**  
Kristien Winckers\*, Astrid van Hylckama Vlieg, Stella Thomassen, Tilman Hackeng, Frits Rosendaal (The Netherlands)

### Venous thromboembolism - therapy I

- PO618-MON **TWO WEEKS OF LOW MOLECULAR WEIGHT HEPARIN FOR ISOLATED SYMPTOMATIC DISTAL VEIN THROMBOSIS (TWISTER STUDY): INTERIM ANALYSIS OF FIRST 100 PATIENTS**  
Eileen Merriman\*, Sanjeev Chunilal, Simon McRae, Tim Brighton, Huyen Tran (New Zealand)
- PO619-MON **A CANADIAN CONSENSUS ON VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS PREVENTION IN THORACIC SURGERY, A NATIONAL DELPHI CONSENSUS SURVEY**  
Yaron Shargall\*, Lori-Ann Linkins, Laura Schneider, Mark Crowther, Marc De Perrot, Christian Finley, Wael Hanna, Colin Schieman (Canada)
- PO620-MON **ADHERENCE TO INTERNATIONAL GUIDELINES IN TREATMENT OF THROMBOEMBOLIC EVENTS IN CANCER PATIENTS: A HOSPITAL-BASED COHORT STUDY IN PARIS, FRANCE**  
Isabelle Mahé\*, Hortense Puget, Jean Chidiac, Andrey Strukov, Jean-Claude Buzzi, Helene Helfer, Michele Lamuraglia, Anne Perozziello (France)
- PO621-MON **A FIRST-IN-HUMAN, SINGLE ASCENDING DOSE STUDY OF DS-1040, AN INHIBITOR OF THE ACTIVATED FORM OF THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR (TAFIA), IN HEALTHY SUBJECTS**  
Jin Zhou\*, Cynthia Zamora, George Atiee, Vance Warren, Ophelia Yin, Jarema Kochan, Joseph Pav, Yasushi Orihashi, Vijay Kumar Vashi, Victor Dishy (United States)
- PO622-MON **A RETROSPECTIVE MEDICATION USE EVALUATION OF ANTITHROMBOTIC THERAPY AFTER TOTAL HIP ARTHROPLASTY OR TOTAL KNEE ARTHROPLASTY AT UNIVERSITY OF COLORADO HEALTH.**  
Patrick Klem\*, Toby Trujillo, Larry Golightly, Megan Wong, Craig Hogan (United States)
- PO623-MON **PLATELET REACTIVITY IN PATIENTS WITH A HISTORY OF VENOUS THROMBOSIS WHO USE ROSUVASTATIN: RANDOMIZED CLINICAL TRIAL**  
Joseph Biedermann\*, Suzanne Cannegieter, Felix van der Meer, Marieke Kruij, Pieter Reitsma, Willem Lijfering (The Netherlands)
- PO624-MON **LONG-TERM USE OF LOW-MOLECULAR-WEIGHT HEPARINS (LMWH) FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (CAT): FACTORS ASSOCIATED WITH NON-COMPLIANCE WITH TREATMENT RECOMMENDATIONS (NCTR) IN CLINICAL PRACTICE.**  
Francis Cajfinger\*, Philippe Debourdeau, Anne Lamblin, Dominique Farge-Bancel (France)
- PO625-MON **HOSPITAL LENGTH OF STAY FOR DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM AMONG PATIENTS RECEIVING RIVAROXABAN OR WARFARIN**  
Steven Deitelzweig\*, Monika Raut, Jay Margolis, Oth Tran, David Smith, Ibrahim Bookhart, Jeff Schein, William Olson (United States)

## SCIENTIFIC PROGRAM

- PO626-MON **ACUTE PULMONARY EMBOLISM: EXTERNAL VALIDATION OF THE 2014 RISK STRATIFICATION MODEL OF THE EUROPEAN SOCIETY OF CARDIOLOGY**  
Cecilia Becattini\*, Giancarlo Agnelli, Mareike Lankeit, Luca Masotti, Piotr Pruszczyk, Franco Casazza, Simone Vanni, Cinzia Nitti, Pieter Kamphuisen, Maria Vedovati, Maria De Natale, Stavros Konstantinides (Italy)
- PO627-MON **RISK FACTORS FOR RECURRENCE AND THROMBOEMBOLIC EVENTS AFTER ISOLATED SUPERFICIAL VEIN THROMBOSIS OF LOWER LIMBS**  
Michelangelo Sartori\*, Elisabetta Favaretto, Ludovica Migliaccio, Giuseppina Rodorigo, Gualtiero Palareti, Benilde Cosmi (Italy)
- PO628-MON **EFFICACY AND SAFETY OF TREATMENT WITH ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA**  
Hun Gyu Hwang\*, Myung Shin Kim, Gune-Il Lim, Eunju Sim, Won-Il Choi (Korea, Republic Of)

### Vitamin K antagonists I

- PO629-MON **PREVALENCE OF VKORC-1 POLYMORPHISMS ACROSS CAUCASIANS AND AMERICANS**  
Maria Paula Vera Morandini, Lucia Remotti, Silvia Grosso, Marcelo Ingratti, Fabiana Alberto, Vanesa Caruso, Analia Sanchez Luceros, Susana Sara Meschengieser, Maria Lazzari, Alicia Blanco\* (Argentina)
- PO630-MON **INFLUENCE VITAMIN K ANTAGONISTS ON THE THROMBINEMIA AND HOMOCYSTEINE LEVELS**  
Nadezda Vorobyeva\*, Aleksandra Rogozina (Russian Federation)
- PO631-MON **SUSCEPTIBILITY OF VKORC1 AND ITS PARALOG VKORC1L1 TOWARDS DIFFERENT 4-HYDROXYCOUMARINS**  
Kerstin Liphardt\*, Katrin Czogalla, Klara Höning, Veit Hornung, Matthias Watzka, Johannes Oldenburg (Germany)
- PO632-MON **ZYMOGEN-LIKE FXA VARIANT AS NOVEL WARFARIN REVERSAL STRATEGY: PRE-CLINICAL EVALUATION AND MECHANISM OF ACTION**  
Lindsey A. Greene\*, Nabil Thalji, Rodney Camire (United States)
- PO633-MON **CLINICAL AUDIT OF ANTICOAGULATION REVERSAL AND OUTCOME IN WARFARIN-ASSOCIATED INTRACRANIAL HAEMORRHAGE (WAICH)**  
Danielle Blunt\*, Safoorah Sagheer, Simon McRae (Australia)
- PO634-MON **EFFECT OF INR PRECISION AND ACCURACY ON THERAPEUTIC QUALITY CONTROL IN PATIENTS RECEIVING VITAMIN K-ANTAGONISTS**  
Anton Van Den Besselaar\*, Felix van der Meer (The Netherlands)
- PO635-MON **HEMIZYGOUS DELETION OF 7Q11.21-Q11.23 ELIMINATING VKORC1L1 DOES NOT IMPAIR BLOOD COAGULATION BUT REVEALS ACCUMULATION OF MENAQUINONE-4**  
Sol Schulman\*, Xueyan Fu, Sarah Booth, Benno Rothlisberger, Barbara Furie, Bruce Furie (United States)

## SCIENTIFIC PROGRAM

- PO636-MON **SELECTION, MANAGEMENT AND OUTCOME OF VKA PATIENTS WITH ATRIAL FIBRILLATION NOT SWITCHED TO NOVEL ORAL ANTICOAGULANTS – RESULTS FROM THE DRESDEN NOAC REGISTRY (NCT01588119)**  
Franziska Michalski, Sebastian Werth, Luise Tittl, Sandra Marten, Norbert Weiss, Jan Beyer-Westendorf\* (Germany)
- PO637-MON **ANTAGONIZATION OF WARFARIN IN CELLS: WARFARIN BINDING ON HUMAN VKORC1 IS REVERSIBLE**  
Katrin Czogalla\*, Arijit Biswas, Matthias Watzka, Klara Höning, Veit Hornung, Johannes Oldenburg (Germany)
- PO638-MON **RELATIONSHIP BETWEEN VITAMIN K ANTAGONISTS AND RECURRENT BLEEDING EVENTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: REAL-WORLD FINDINGS FROM ENGLAND**  
Raza Alikhan\*, Cinira Lefevre, Ian Menown, Steven Lister, Laure Lacoïn, Alex Bird, Min You, Essra Ridha, David Evans (United Kingdom)
- PO639-MON **RISK FACTORS FOR GASTRO-INTESTINAL BLEEDING IN ATRIAL FIBRILLATION PATIENTS ON VKA TREATMENT: PROSPECTIVE ANALYSIS OF TWO COHORTS OF PATIENTS**  
Daniela Poli\*, Emilia Antonucci, Sophie Testa, Alberto Toso, Walter Ageno, Gualtiero Palareti (Italy)
- PO640-MON **PREDICTORS OF ICH RECURRENCE ON VKA: SEVERITY OF THE FIRST EPISODE AND HASBLED SCORE FAIL TO IDENTIFY HIGH RISK PATIENTS FROM THE CHIRONE STUDY**  
Daniela Poli\*, Emilia Antonucci, Francesco Dentali, Sophie Testa, Gualtiero Palareti (Italy)
- PO641-MON **PERIOPERATIVE INTERRUPTION OF WARFARIN ANTICOAGULATION**  
Joseph Shaw\*, Dimitri Scarvelis, Lana Castellucci, Esteban Gandara, Wendy Riches, Kerstin Hogg, Philip Wells (Canada)

### Von Willebrand disease I

- PO642-MON **COST OF TREATING THROMBOTIC EVENTS IN A US POPULATION OF VON WILLEBRAND DISEASE PATIENTS**  
Alexandra Khachatryan\*, Yan Xiong (United States)
- PO643-MON **AN OPEN-LABEL, MULTI-CENTER EXTENSION STUDY TO ASSESS THE EFFICACY AND SAFETY OF A PLASMA-DERIVED VON WILLEBRAND FACTOR/FACTOR VIII (VWF/FVIII) CONCENTRATE IN PEDIATRIC, ADOLESCENT, AND ADULT SUBJECTS WITH VON WILLEBRAND DISEASE**  
Toshko Lissitchkov, Anna Klukowska, Kazimierz Kuliczowski, Evgeny Buevich, Guenter Auerswald, Olexandra Stasyshyn, Wilfried Seifert\* (Germany)
- PO644-MON **THROMBOCYTOPENIA DURING DDAVP TEST IN TWO CHILDREN WITH TYPE 2A VON WILLEBRAND DISEASE**  
Juan P. Frontróth\*, Carolina Pepe, Mirta Hepner, Gabriela Sciuccati, Graciela Pieroni, Silvina Annetta, Carolina Cervio, Aurora Feliu-Torres, Mariana Bonduel (Argentina)

## SCIENTIFIC PROGRAM

- PO645-MON **RULING OUT VON WILLEBRAND DISEASE IN PREOPERATIVE PATIENTS WITH BLEEDING SYMPTOMS**  
M.J.A. Vries\*, M.D. Lance, C.G.M. Van Oerle, R.J.H. Wetzens, E.A.M. Beckers, P.J. Nelemans, H. Ten Cate, Y.M.C. Henskens (The Netherlands)
- PO646-MON **HEALTH-RELATED QUALITY OF LIFE AMONG VON WILLEBRAND DISEASE PATIENTS IS NOT RELATED TO DISEASE SEVERITY.**  
Yan Xu\*, Meghan Deforest, Julie Grabell, Wilma Hopman, Paula James (Canada)
- PO647-MON **PLASMA-DERIVED, PURIFIED, PASTEURISED VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE IN THE TREATMENT OF PATIENTS WITH VON WILLEBRAND DISEASE AND HAEMOPHILIA A: UPDATE OF A LONG-TERM OBSERVATIONAL STUDY**  
Cornelia Wermes\*, Susanne Holzhauser, Susan Halimeh, Bettina Kemkes-Matthes, Patrick Sommerer, Ivonne Wieland, Manuela Krause (Germany)
- PO648-MON **EVALUATION OF AN ELISA BASED ASSAY FOR DETECTION OF TYPE 2N VON WILLEBRAND DISEASE**  
Rachel R. Leger\*, Adam Tricker, Julie Tange, Dong Chen, Rajiv Pruthi (United States)
- PO649-MON **NEW INSIGHTS INTO TYPE 3 VON WILLEBRAND DISEASE: THE TYPE 3 VON WILLEBRAND DISEASE INTERNATIONAL REGISTRIES AND INHIBITOR PROSPECTIVE STUDY (3WINTERS-IPS) PROJECT UPDATE**  
Augusto B Federici\*, Flora Peyvandi, Ulrich Budde, Giancarlo Castaman, Jeroen Eikenboom, Peyman Eshghi, Anne Goodeve, Jenny Goodemand, Hamid Hoorfar, Mehran Karimi, Ian Peake, Reinhard Schneppenheim, Alberto Tosetto, Pier M Mannucci (Italy)
- PO650-MON **EFFICACY AND SAFETY OF VON WILLEBRAND FACTOR CONCENTRATE WITH A LOW FVIII CONTENT IN SEVERE VWD CHILDREN LESS THAN 6 YEARS OF AGE**  
Emna Gouider\*, Anna Klukowska, Philippe Maes, Helen Platokouki, Wanda Badowska, Nathalie Knuchel, Céline Henriet, Françoise Bridey, Claudine Caron, Annie Borel-Derlon, Balkis Meddeb, Christel Van Geet (Tunisia)
- PO651-MON **OVERDOSING OF REPLACEMENT THERAPY IN PERIOPERATIVE VON WILLEBRAND PATIENTS: A LOT "TO WIN"**  
Hilde C. Veerman\*, Hendrika C.A.M. Hazendonk, Yvonne V. Sanders, Karina Meijer, Frank W.G. Leebeek, Marjon H. Cnossen (The Netherlands)
- PO652-MON **A MICROCHIP FLOW-CHAMBER SYSTEM (T-TAS®) REFLECTS THE CLINICAL PHENOTYPES IN PATIENTS WITH TYPE 1 VON WILLEBRAND DISEASE**  
Keiji Nogami\*, Koji Yada, Yasuaki Shida, Kenichi Ogiwara, Shoko Furukawa, Hiroaki Minami, Hiroaki Yaoi, Tomoko Matsumoto, Midori Shima (Japan)
- PO653-MON **THE USE OF NEXT-GENERATION SEQUENCING TO SCREEN FOR DISORDERS OF COAGULATION USING A 24 GENE PANEL.**  
Patricia Bignell\*, Nicola Curry, Joanne Mason, Pamela Wright, David Keeling, Paul Giangrande, Shirley Henderson, Anna Schuh (United Kingdom)
- PO654-MON **COURSE OF VON WILLEBRAND FACTOR (VWF) DURING PREGNANCY IN WOMEN WITH VON WILLEBRAND DISEASE (VWD)**  
Mario von Depka\*, Carsten Detering, Anja Henkel-Klene, Stefanie Döpke, Emilie von Depka, Mahnaz Ekhlesi-Hundrieser (Germany)

## SCIENTIFIC PROGRAM

- PO655-MON **IDENTIFICATION OF LARGE VWF GENE DELETIONS AND DUPLICATIONS BY MLPA IN THE SOUTH MORAVIAN (CZECH REPUBLIC) VWD COHORT IN THE BRNO-VWD STUDY**  
Inge Vangenechten\*, Petr Smejkal, O Zapletal, J Zavrelva, J Blatny, M Penka, Jan Jacques Michiels, Alain Gadisseur (Belgium)
- PO656-MON **BASELINE FACTOR VIII PLASMA LEVELS AND AGE AT FIRST BLEEDING IN PATIENTS WITH SEVERE FORMS OF VON WILLEBRAND DISEASE**  
Simona Maria Siboni, Eugenia Biguzzi\*, Valeria Caiani, Claudia Mistretta, Paolo Bucciarelli, Flora Peyvandi (Italy)
- PO657-MON **TYPE 1 VWD DOES NOT LEAD TO INCREASED GINGIVAL BLEEDING**  
Lisa Weickert, Peter Eickholz, Katrin Nickles, Stefanie Krekeler, Wolfgang Miesbac\* (Germany)
- PO658-MON **JOINT SURGERY IN MODERATE AND SEVERE VON WILLEBRAND DISEASE: A CROSS-SECTIONAL STUDY.**  
Karin van Galen, Frank Leebeek, Roger Schutgens\*, Marjon Cnossen, Jeroen Eikenboom, Charles Vogely, Karin Fijnvandraat, Karina Meijer, Evelien Mauser-Bunschoten (The Netherlands)
- PO659-MON **ETHNIC AND RACIAL VARIATION OF PLASMA VWF IN HEALTHY CONTROLS**  
Robert R. Montgomery\*, Joan Gill, Pamela Christopherson, Veronica Flood, Sandra Haberichter, Thomas Abshire (United States)
- PO660-MON **A COMPARATIVE STUDY OF MICROFLUIDIC FLOW ASSAYS AND CLINICAL ASSAYS IN TYPE I VON WILLEBRAND'S DISEASE**  
Marcus Lehmann\*, Christopher Ng, Jorge Di Paola, Keith Neeves (United States)
- PO661-MON **TOTAL THROMBUS-FORMATION ANALYSIS SYSTEM (T-TAS) FOR THE MONITORING OF VON WILLEBRAND FACTOR-FVIII CONCENTRATE TREATMENT IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 3.**  
Anna Ågren\*, Paul Hjemdahl, Margareta Blombäck, Kazuya Hosokawa, Margareta Holmström (Sweden)
- PO662-MON **SURVEILLANCE STUDY OF SAFETY AND EFFICACY OF A VWF/FVIII CONCENTRATE IN PATIENTS WITH VON WILLEBRAND DISEASE (WIL-20) – A PLANNED INTERIM ANALYSIS**  
Kate Khair, Maria Sol Cruz\*, Sylvia Werner, Sigurd Knaub, Alfonso Iorio (United Kingdom)
- PO663-MON **PREDICTORS OF COMPLETE RESPONSE TO DDAVP IN PATIENTS WITH VON WILLEBRAND DISEASE**  
Eugenia Biguzzi\*, Paolo Bucciarelli, Franca Franchi, Francesca Stufano, Simona Siboni, Luciano Baronciani, Flora Peyvandi (Italy)
- PO664-MON **MAJOR SURGERIES IN CHILDREN AND ADULTS WITH VON WILLEBRAND DISEASE MANAGED WITH A HIGH-PURITY HUMAN VWF/FVIII CONCENTRATE IN A PHYSIOLOGICAL 1:1 RATIO**  
Alok Srivastava, Sylvia Werner, Margit Serban, Bruce Schwartz, Sigurd Knaub, Craig Kessler\* (United States)

## SCIENTIFIC PROGRAM

- PO665-MON **THE INFLUENCE OF PAI-1 LEVELS ON BLEEDING PHENOTYPE IN MODERATE AND SEVERE VON WILLEBRAND DISEASE**  
S Abdul\*, J Boender, JMC Malfliet, HCJ Eikenboom, K Fijnvandraat, EP Mauser-Bunschoten, K Meijer, FWG Leebeek, DC Rijken, S Uitte de Willige (The Netherlands)
- PO666-MON **DYNAMIC THROMBUS FORMATION IN THE WHOLE BLOOD UNDER THE SHEAR STRESS RAPIDLY REFLECTS CLINICAL SEVERITY IN TYPE 2N VON WILLEBRAND DISEASE**  
Koji Yada\*, Keiji Nogami, Yasuaki Shida, Masahiro Takeyama, Tomoko Matsumoto, Kazuya Hosokawa, Midori Shima (Japan)
- PO667-MON **FUNCTIONAL CHARACTERISATION OF A NOVEL SPLICE MUTATION, C.7887+2T>A, ASSOCIATED WITH TYPE 1 VON WILLEBRAND DISEASE**  
Ashley Cartwright, Simon Webster, Paula Jacobi, Nicholas Hickson, Ulrich Budde, Ian Peake, Anne Goodeve, Sandra Haberichter, Daniel J. Hampshire\* (United Kingdom)
- PO668-MON **DYNAMIC THROMBUS FORMATION IN THE WHOLE BLOOD UNDER THE SHEAR STRESS RAPIDLY REFLECTS THE HEMOSTATIC POTENTIAL(S) OF TYPE 2A VON WILLEBRAND DISEASE UNEVALUABLE BY PLASMA-BASED STATIC ASSAY.**  
Koji Yada\*, Keiji Nogami, Yasuaki Shida, Masahiro Takeyama, Tomoko Matsumoto, Kazuya Hosokawa, Midori Shima (Japan)
- PO669-MON **CO-OCCURRENCE OF V.WILLEBRAND DISEASE AND BERNARD SOULIER-SYNDROME**  
Carl-Erik Dempfle\*, Parviz Ahmad-Nejad, Thomas Alef, Andrea Dornbach, Bernhard Thiele (Germany)

### Von Willebrand Factor I

- PO670-MON **IDENTIFICATION AND CHARACTERIZATION OF ABERRANT SPLICING FROM A NOVEL BRANCH SITE MUTATION IN VON WILLEBRAND FACTOR**  
Lindsey Hawke\*, Georges Rivard, Paula James (Canada)
- PO671-MON **FUNCTIONAL LINK BETWEEN VON WILLEBRAND FACTOR (VWF) AND TISSUE FACTOR (TF) IN FLOW-DEPENDENT THROMBUS FORMATION: AUGMENTATION OF INTRA-THROMBUS FIBRIN GENERATION BY CATHEPSIN G ON VWF-TF COMPLEX**  
Yasunori Matsunari\*, Hideto Matsui, Masahiko Kawaguchi, Mitsuhiko Sugimoto (Japan)
- PO672-MON **THROMBIN-DEPENDENT INCORPORATION OF VON WILLEBRAND FACTOR INTO A FIBRIN NETWORK**  
Adam Miszta, Leonie Pelkmans\*, Theo Lindhout, Philip de Groot, Coenraad Hemker, Johan Heemskerk, Hilde Kelchtermans, Bas de Laat (The Netherlands)
- PO673-MON **MIR-24 REGULATES VON WILLEBRAND FACTOR IN DIABETES**  
Yaozu Xiang\*, Jijun Cheng, Jun Lu, Kathleen Martin, John Hwa (United States)
- PO674-MON **THE FIRST CASE OF AN INTRON RETENTION RESULTING FROM A SILENT MUTATION IN THE VWF WHICH EXERTS A STRUCTURAL IMPACT ON THE 5' SPLICE SITE**  
Hamideh Yadegari Baharanchi\*, Arijit Biswas, Julia Diesen, Vytautas Ivaskevicius, Natascha Marquardt, Johannes Oldenburg (Germany)

## SCIENTIFIC PROGRAM

- PO675-MON **ASSESSMENT OF VON WILLEBRAND FACTOR PANEL AND PLATELET FUNCTION IN PATIENTS WITH MODERATE TO SEVERE RENAL INSUFFICIENCY UNDERGOING RENAL BIOPSY**  
Bundarika Suwanawiboon\*, Aksara Kajornkijaroen, Yupa Nakkinkun, Tasneem Binham, Ratana Chawanasantorapoj (Thailand)
- PO676-MON **MISSENSE MUTATIONS LOCATED IN THE VON WILLEBRAND FACTOR (VWF) D1 DOMAIN CAUSE QUANTITATIVE VWF DEFICIENCY THROUGH IMPAIRMENT OF VWF PACKAGING INTO STORAGE ORGANELLES**  
Mellita Dsouza, Simon Webster, Jessica McMaster, Ashley Cartwright, Ulrich Budde, Ian Peake, Anne Goodeve, Daniel J. Hampshire\* (United Kingdom)
- PO677-MON **MINIMUM LEVELS OF VON WILLEBRAND FACTOR AND PLATELETS TO CREATE OCCLUSIVE HIGH SHEAR THROMBOSIS**  
Lauren D. C. Casa\*, Scott Gillespie, David Ku (United States)
- PO678-MON **AGING AND ABO BLOOD TYPE REGULATE VON WILLEBRAND FACTOR AND FACTOR VIII LEVELS THROUGH DISTINCT PATTERNS OF BOTH SECRETION AND CLEARANCE**  
Silvia Albáñez\*, Kenichi Ogiwara, Julie Grabell, Paula James, David Lillicrap (Canada)





# SCIENTIFIC PROGRAM

Tuesday, June 23, 2015 8:00-09:15

ORAL COMMUNICATIONS 3 08:00-09:15

Cancer and thrombosis –clinical – I

Plenary Hall F&G

Moderators: *Simon Noble (United Kingdom), Howard Liebman (United States)*

- 08:00 – 08:15  
OR126 **RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH BCR-ABL TKIS: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Jonathan Douxfils\*, H el ene Hagu et, Fran ois Mullier, Christian Chatelain, Carlos Graux, Jean-Michel Dogn e (Belgium)
- 08:15 – 08:30  
OR127 **DIFFERENCES IN VENOUS THROMBOEMBOLIC EVENTS IN SUBJECTS ENROLLED IN STANDARD PHASE I CLINICAL TRIALS AND THOSE ON PHASE I HEPATIC DYSFUNCTION CLINICAL TRIALS**  
Aaron Mansfield\*, Alfonso Tafur, Diana Vulih, Gary Smith, Pamela Jo Harris, S. Percy Ivy (United States)
- 08:30 – 08:45  
OR128 **RISK FACTORS FOR INCIDENT VENOUS THROMBOEMBOLISM IN ACTIVE CANCER PATIENTS: A POPULATION BASED CASE-CONTROL STUDY**  
Aneel A. Ashrani\*, Rachel Gullerud, Tanya Petterson, Randolph Marks, Kent Bailey, John Heit (United States)
- 08:45 – 09:00  
OR129 **COHORT PROFILE: THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY**  
Hilde Jensvoll\*, Marianne Severinsen, Jens Hammerstr om, Sigrid Br ekkan, S oren Kristensen, Suzanne Cannegieter, Kristine Blix, Anne Tj nneland, Frits Rosendaal, Olga Dziewiecka, Kim Overvad, Inger Anne N ess, John-Bjarne Hansen (Norway)
- 09:00 – 09:15  
OR130 **PREDICTION OF VENOUS THROMBOEMBOLISM IN LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY**  
Simon Noble\*, Andrew Robbins, Raza Alikhan, Kerenza Hood, Fergus Macbeth (United Kingdom)

♥ Venous thromboembolism – epidemiology – II

Room 718

Moderators: *Sarah Lapner (Canada), Daniel Witt (United States)*

- 08:00 – 08:15  
OR131 **RISK OF VENOUS THROMBOSIS IN INDIVIDUALS USING VITAMIN SUPPLEMENTS: A CASE-CONTROL STUDY**  
Biljana Vuckovic\*, Nienke van Rein, Suzanne Cannegieter, Frits Rosendaal, Willem Lijfering (Serbia)
- 08:15 – 08:30  
OR132 **THE INCIDENCE OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AND THE PREDICTIVE VALUE OF RESIDUAL ARTERIAL PULMONARY OBSTRUCTION: RESULTS FROM A LARGE, MULTICENTRE, PROSPECTIVE COHORT STUDY**  
Raffa e Pesavento\*, Lucia Filippi, Antonio Palla, Annachiara Frigo, Adriana Vison a, Carlo Bova, Stefano Cuppini, Fernando Porro, Sabina Villalta, Maurizio Ciammaichella, Eugenio Bucherini, Giovanni Nante, Sandra Battistelli, Giampietro Beltramello, Domenico Prisco, Paolo Prandoni (Italy)

# SCIENTIFIC PROGRAM

- 08:30 – 08:45  
OR133 **CROSS-SECTIONAL ASSOCIATIONS OF 25-HYDROXYVITAMIN D WITH HEMOSTATIC AND INFLAMMATORY BIOMARKERS IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS**  
Marc Blondon, Mary Cushman, Nancy Jenny, Erin Michos, Nicholas Smith, Bryan Kestenbaum, Ian de Boer (Switzerland)
- 08:45 – 09:00  
OR134 **UNPROVOKED DEEP VEIN THROMBOSIS IS ASSOCIATED WITH FUTURE RISK OF DISABILITY PENSION**  
Sigrid Braekkan, Scott Grosse, Ekwutosi Okoroh, James Tsai, Suzanne Cannegieter, Inger Anne Naess, Steinar Krokstad, John-Bjarne Hansen, Finn-Egil Skjeldestad (Norway)
- 09:00 – 09:15  
OR135 **SEX DIFFERENCE IN THE RISK OF VENOUS THROMBOSIS: A DETAILED ANALYSIS IN FOUR EUROPEAN COHORTS**  
Rachel Roach\*, Willem Lijfering, R. Tait, Trevor Baglin, Paul Kyrle, Suzanne Cannegieter, Frits Rosendaal (The Netherlands)

● Immune thrombocytopenia – basic

Room 701

Moderators: *Alan Lazarus (Canada), Michelle Lambert (United States)*

- 08:00 – 08:15  
OR136 **THE DEFECTIVE IL-21/IL-21R PATHWAY IN THE B LYMPHOCYTES OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Donglei Zhang\*, Liu Wenjie, Li Huiyuan, Zhang Xian, Xue Feng, Yang Renchi (China)
- 08:15 – 08:30  
OR137 **SOLUBLE COSTIMULATORY FACTORS SB7-H2, SB7-H3 IN RELATION TO PLATELET AUTOANTIBODIES IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA**  
Weihong Shen\*, Yang He (China)
- 08:30 – 08:45  
OR138 **HIGH-DOSE DEXAMETHASONE CORRECTS IMPAIRED MYELOID-DERIVED SUPPRESSOR CELL FUNCTIONS VIA POSITIVE CROSSTALK BETWEEN GLUCOCORTICOID RECEPTOR AND ETS1 IN IMMUNE THROMBOCYTOPENIA**  
Yu Hou\*, Miao Xu, Qi Feng, Yingyi Yu, Xuena Liu, Ming Hou, Jun Peng (China)
- 08:45 – 09:00  
OR139 **SUPPRESSION OF CELL-MEDIATED IMMUNE THROMBOCYTOPENIA (ITP) BY B CELL DEPLETION THERAPY IN A MURINE MODEL.**  
Li Guo\*, Edwin Speck, Rukhsana Aslam, Rick Kapur, Heyu Ni, John Semple (Canada)
- 09:00 – 09:15  
OR140 **STAT1 SINGLE NUCLEOTIDE POLYMORPHISMS AND SUSCEPTIBILITY TO IMMUNE THROMBOCYTOPENIA**  
Zhenping Chen\*, Zhenxing Guo, Jingyao Ma, Chao Gao, Runhui Wu (China)

✚ Hemophilia inhibitors

Room 801

Moderators: *Georges Rivard (Canada), P al Andre Holme (Norway)*

- 08:00 – 08:15  
OR141 **DO VACCINATIONS INFLUENCE THE RISK OF INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A?**  
SM Hashemi\*, K Fischer, SC Gouw, A Rafowicz, M Carcao, H Platokouki, G Kenet, R Liesner, K Kurnik, G Rivard, HM van den Berg (The Netherlands)

TUESDAY

ORALS

## SCIENTIFIC PROGRAM

08:30 – 08:45  
OR143  
**PLASMA-DERIVED FACTOR VIII PRODUCTS AND INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED BOYS WITH SEVERE HEMOPHILIA A : REPORT OF THE FRANCECOAG NETWORK**  
Jenny Goudemand\*, Chantal Rothschild, Roseline d'Oiron, Virginie Demiguel, Vincent Dalibard, Marguerite Micheau, Patrick Lutz, Yves Gruel, Christine Vinciguerra, Hervé Chambost, Thierry Calvez (France)

08:45 – 09:00  
OR144  
**DETERMINANTS OF INHIBITOR DEVELOPMENT IN PREVIOUSLY TREATED HEMOPHILIA A PATIENTS**  
Alfonso Iorio\*, Angela Barbara, Giancarlo Castaman, Katheleijn Fischer, Estelle Gilman, Jenny Goudemand, Khan Kavakli, Cornelia Kubicek-Hofmann, Thierry Lambert, T Lissitchkov, Michael Makris, Prasad Matthew, Maria Eva Mingot Castelano, Nahil Ozdemir, R Parra, Kathelijne Peerlinck, G Rivolta, Vadim Romanov, Valérie Rous-sel-Robert, Annarita Tagliaferri, Jerzy Windyga, Ezio Zanon (Canada)

09:00 – 09:15  
OR145  
**ITI FOR INHIBITORY ANTIBODIES IN BOYS WITH SEVERE HAEMOPHILIA A AT EIGHT UK CHILDREN'S CENTRES 2003-2013**  
Mary Mathias\*, Jayanthi Alamelu, Peter Collins, Jeanette Payne, Mike Richards, Oliver Tunstall, Mike Williams, Tina Biss, Elizabeth Chalmers (United Kingdom)

### ▲ Risk factors for venous thrombosis – I

Room 714

Moderators: *Scott Stevens (United States), Stephan Moll (United States)*

08:00 – 08:15  
OR146  
**RISK FACTORS OF RESIDUAL PERFUSION DEFECTS AFTER A FIRST EPISODE OF UNPROVOKED PE: RESULTS FROM THE PADIS PE MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL**  
Olivier Sanchez\*, Cécile Tromeur, Pierre Yves Leroux, Emilie Presles, Patrick Mismetti, Patrick Jego, Gilles Pernod, Elisabeth Duhamel, Karine Provost, Philippe Castellant, Florence Parent, Pierre Yves Salaun, Michel Nonent, Philippe Girard, Karine Lacut, Solen Mélaç, Marie Guégan, Gisèle Marhic, Silvy Laporte, Christophe Leroyer, Hervé Décousus, Dominique Mottier, Guy Meyer, Francis Couturand (France)

08:15 – 08:30  
OR147  
**EVOLUTIONARY CONSERVATION OF AUTOINHIBITORY B-DOMAIN REGIONS IN BLOOD COAGULATION FACTOR V OF THE SUBORDER SERPENTES**  
Daniël Verhoef\*, Ka Lei Cheung, Hans Vos, Ryan McCleary, Manjunatha Kini, Pieter Reitsma, Mettine Bos (The Netherlands)

08:30 – 08:45  
OR148  
**IDENTIFICATION OF NEW GENETIC RISK FACTORS FOR RECURRENT VENOUS THROMBOSIS**  
Hugoline G. de Haan\*, Marine Germain, Trevor Baglin, Jean-Francois Deleuze, David-Alexandre Trégouët, Frits Rosendaal, Astrid van Hylckama Vlieg (The Netherlands)

08:45 – 09:00  
OR149  
**RISK FACTORS OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH A FIRST EPISODE OF UNPROVOKED PULMONARY EMBOLISM: RESULTS FROM THE PADIS PE MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL**  
Francis Couturand\*, Olivier Sanchez, Emilie Presles, Pierre Yves Salaun, Gilles Pernod, Patrick Mismetti, Patrick Jego, Elisabeth Duhamel, Karine Provost, Claire Bal Dit Solier, Philippe Castellant, Florence Parent, Luc Bressollette, Philippe Girard, Karine Lacut, Solen Mélaç, Marie Guégan, Silvy Laporte, Christophe Leroyer, Hervé Décousus, Guy Meyer, Dominique Mottier (France)

## SCIENTIFIC PROGRAM

09:00 – 09:15  
OR150  
**LIPID LEVELS AND RISK OF VENOUS THROMBOSIS: RESULTS FROM THE MEGA STUDY**  
Vânia M. Morelli\*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Netherlands)

### TTP and PNH – from basic science to clinical practice

Room 716

Moderators: *Ian J. Mackie (United Kingdom), Karen Vanhoorelbeke (Belgium)*

08:00 – 08:15  
OR151  
**RECOMBINANT ADAMTS13 AS AN EFFECTIVE THERAPY FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA IN RATS**  
Claudia Tersteeg\*, Alexandra Schiviz, Barbara Plaimauer, Simon De Meyer, Friedrich Scheiflinger, Karen Vanhoorelbeke, Hanspeter Rottensteiner (Belgium)

08:15 – 08:30  
OR152  
**HEREDITARY TTP – A YOUNG PATIENT POPULATION WITH HIGH PREVALENCE OF ARTERIAL THROMBOEMBOLIC EVENTS. FIRST RESULTS FROM THE HEREDITARY TTP REGISTRY**  
Magnus Mansouri, Masanori Matsumoto, Zuzana Cermakova, Kenneth Friedman, James George, Ingrid Hrachovinova, Paul Knöbl, Koichi Kokame, Anne Sophie von Krogh, Reinhard Schneppenheim, Sara Vesley, Yoshihiro Fujimura, Bernhard Lämmle, Johanna A. Kremer Hovinga\* (Switzerland)

08:30 – 08:45  
OR153  
**ENDOGENOUS PLASMIN LEVELS CONTROL THE DEVELOPMENT OF ACUTE EPISODES OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN MICE**  
Claudia Tersteeg\*, Louis Deforche, Ann Gils, Hans Deckmyn, Paul Declerck, Hanspeter Rottensteiner, Coen Maas, Simon De Meyer, Karen Vanhoorelbeke (Belgium)

08:45 – 09:00  
OR154  
**COVERSIN, A NOVEL COMPLEMENT C5 INHIBITOR AND POTENTIAL THERAPEUTIC AGENT, PREVENTS C5 ACTIVATION IN PATIENTS WITH C5 POLYMORPHISMS**  
Ian J. Mackie\*, Andrew Chitolie, Miles Nunn, Wynne Weston-Davies, Samuel Machin (United Kingdom)

09:00 – 09:15  
OR155  
**LONG-TERM GENE THERAPY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA USING THE 'SLEEPING BEAUTY' TRANSPOSON SYSTEM**  
Sebastien Verhenne\*, Nele Vandeputte, Inge Pareyn, Zsuzsanna Izsvak, Hanspeter Rottensteiner, Hans Deckmyn, Simon F De Meyer, Karen Vanhoorelbeke (Belgium)

### ★ Pediatric thrombosis

Room 713

Moderators: *Laura Avila (Canada), Brian Branchford (United States)*

08:00 – 08:15  
OR156  
**CHILDREN'S HOSPITAL-ACQUIRED THROMBOSIS DATABASE (CHAT): A MULTI-INSTITUTIONAL DATABASE FOR PROSPECTIVE IDENTIFICATION OF INDEPENDENT RISK FACTORS**  
Brian R. Branchford\*, Julie Jaffray, Arash Mahajerin, Neil Goldenberg, Guy Young (United States)

08:15 – 08:30  
OR157  
**CORRELATION BETWEEN ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) AND ANTI-FXA ASSAY IN CHILDREN ON UNFRACTIONATED HEPARIN (UFH) THERAPY: AN INSTITUTIONAL EXPERIENCE**  
Gary Woods\*, Sheilah Harrison, Karen Texter, Joseph Stanek, Amy Dunn, Bryce Kerlin, Riten Kumar (United States)

TUESDAY

ORALS

## SCIENTIFIC PROGRAM

- 08:30 – 08:45  
OR158 **AGE IS MAIN CLINICAL RISK FACTOR FOR VENOUS THROMBOEMBOLISM WITHIN A LARGE COHORT OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA**  
Mandy N. Lauw\*, Irene Klaassen, Marianne Van de Wetering, Inge Van der Sluis, Rob Pieters, C. Heleen Van Ommen (The Netherlands)
- 08:45 – 09:00  
OR159 **OUTCOMES OF LOWER LIMB DEEP VEIN THROMBOSIS AND PREDICTORS OF LOWER LIMB POST-THROMBOTIC SYNDROME IN PEDIATRIC PATIENTS**  
Laura L. Avila\*, Aida Gordanpour, Hosay Said, Heather Rotz, Suzan Williams, Walter Kahr, Leonardo Brandao (Canada)
- 09:00 – 09:15  
OR160 **DIAGNOSIS AND MANAGEMENT OF VENOUS THROMBOEMBOLISM (VTE) IN CHILDREN: A PROSPECTIVE 22-YEAR REGISTRY FROM A SINGLE TERTIARY CENTER IN ARGENTINA**  
Gabriela Sciuccati, Mirta Hepner, Carolina Cervio\*, Graciela Pieroni, Eliana Annetta, Aurora Feliu Torres, Nicolás Fernández Ponce, Juan Frontrouth, Mariana Bonduel (Argentina)

### Factor VIII – II

Room 715

*Moderators: Antonia Follenzi (Italy), Juan Souto (Spain)*

- 08:00 – 08:15  
OR161 **HEMATOPOIETIC CELLS A NOVEL TARGET FOR HEMOPHILIA A CELL THERAPY**  
Diego Zanolini\*, Simone Merlin, Alessio Stevano, Mauro Zaffaroni, Guido Valente, Maria Prat, Antonia Follenzi (Italy)
- 08:15 – 08:30  
OR162 **RELATIONS BETWEEN FACTOR ACTIVITY LEVEL AND JOINT BLEEDING IN A LARGE COHORT OF MALES WITH MILD AND MODERATE HEMOPHILIA IN THE UNITED STATES**  
Mike Soucie\*, Paul Monahan, Marshall Mazepa, Roshni Kulkarni, Barbara Konkle (United States)
- 08:30 – 08:45  
OR163 **CHARACTERIZATION OF INTERACTIVE SITES OF ACTIVATED COAGULATION FACTOR VIII AND LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1**  
James Kurasawa, Svetlana Shestopal, Timothy Lee, Andrey G. Sarafanov\* (United States)
- 08:45 – 09:00  
OR164 **ACCUCOPY QUANTIFICATION COMBINED WITH PRE-AMPLIFICATION OF LONG-DISTANCE PCR FOR FAST GENOTYPING OF INT22H-RELATED INVERSIONS IN HEMOPHILIA A**  
Qian Liang\*, Qiulan Ding, Xi Wu, Zhengwen Jiang, Xuefeng Wang (China)
- 09:00 – 09:15  
OR165 **IN VIVO STUDIES OF EFFICACY AND POTENTIAL IMMUNOGENICITY OF HUMAN FACTOR VIII PACE-FURIN DELETION VARIANTS**  
Giang N. Nguyen\*, Lindsey Greene, Robert Davidson, Denise Sabatino (United States)

## SCIENTIFIC PROGRAM

### Inflammation

Room 717

*Moderators: Ed Conway (Canada), Emilie Lameignere (Canada)*

- 08:00 – 08:15  
OR166 **PLATELET FACTOR 4 REGULATES B CELL DIFFERENTIATION**  
Craig Morrell\*, David Field, Sara Ture (United States)
- 08:15 – 08:30  
OR167 **EXTRACELLULAR RNA INDUCES VENOUS THROMBOSIS THROUGH TLR3**  
Catherine A. Lemarie\*, Manraj Sidhu, Le Angela, Sandrine Laurance, Francois-Rene Bertin, Mark Blostein (Canada)
- 08:30 – 08:45  
OR168 **CIRCULATING HISTONES DISTURB INTRACELLULAR CALCIUM HOMEOSTASIS AND CAUSE CALCIUM OVERLOAD TO INDUCE CARDIOVASCULAR ABNORMALITIES IN SEPSIS**  
Yasir Alhamdi, Simon Abrams, Min Zi, Ingeborg Welters, Elizabeth Cartwright, Guozheng Wang, Cheng-Hock Toh\* (United Kingdom)
- 08:45 – 09:00  
OR169 **PLATELET GRANULE RELEASE IS CRUCIAL FOR VASCULAR INTEGRITY IN THE ISCHEMIC BRAIN BUT NOT IN THE INFLAMED SKIN OR LUNG**  
Carsten Deppermann\*, Peter Kraft, Karen Wolf, Paquita Nurden, Guido Stoll, David Stegner, Bernhard Nieswandt (Germany)
- 09:00 – 09:15  
OR170 **DUAL ACTION OF PLATELETS AND GLYCOPROTEIN-VI IN IMMUNE COMPLEX-MEDIATED INFLAMMATION**  
Angèle Gros\*, Lamia Lamrani, Véronique Ollivier, Varouna Syvannarath, Stéphane Loyau, Tobias Goerge, Bernhard Nieswandt, Martine Jandrot-Perrus, Benoît Ho-Tin-Noé (France)

### Microparticles – I

Room 705

*Moderators: Eric Boilard (Canada), Rafal Pawlinski (United States)*

- 08:00 – 08:15  
OR171 **THE ROLE OF BREAST CANCER CELL MICROVESICLES IN THROMBOGENICITY, ANGIOGENESIS AND APOPTOSIS FOLLOWING CHEMOTHERAPY**  
Anat Aharon\*, Gil Barsela, David Loven, Benjamin Brenner (Israel)
- 08:15 – 08:30  
OR172 **CIRCULATING MICROPARTICLES IN DEFICIENCY OF THE NATURAL ANTICOAGULANTS**  
Elena Campello\*, Luca Spiezia, Claudia Radu, Cristiana Bulato, Sabrina Gavasso, Daniela Tormene, Barry Woodhams, Paolo Simioni (Italy)
- 08:30 – 08:45  
OR173 **CELLULAR MICROPARTICLES AS PREDICTIVE MARKERS FOR THROMBOSIS AND OTHER CLINICAL EVENTS IN PATIENTS WITH IMPLANTED LVADS**  
Jeanine M. Walenga\*, Bryan Menapace, Walter Jeske, Erin Coglianesi, Vicki Escalante, Emmanuel Kumar, Jeffrey Schwartz, Alain Heroux, Mamdouh Bakhos (United States)
- 08:45 – 09:00  
OR174 **ANALYSIS OF EXOSOME-LIKE MEMBRANE MICROPARTICLES RELEASED FROM TRAP-ACTIVATED PLATELETS**  
Silvia De Paoli, Tseday Tegegn, Michael Strader, Ivan Tarandovskiy, Martina Orecna, Oumsalama Elhelu, Mikhail Ovanesov, Abdu Alayash, Jan Simak\* (United States)

## SCIENTIFIC PROGRAM

09:00 – 09:15  
OR175  
**PEPTIDYL-PROLYL ISOMERASE 1 (PIN1) PRESERVES THE PHOSPHORYLATION STATE OF TISSUE FACTOR AND PROLONGS THE RELEASE OF TF WITHIN MICROVESICLES**  
Camille Ettelaie\*, Anthony Maraveyas, Mary Collier (United Kingdom)

### Rare bleeding disorders

Room 707

*Moderators: John Wu (Canada), David Ginsburg (United States)*

08:00 – 08:15  
OR176  
**DIAGNOSIS OF INHERITED BLEEDING, THROMBOTIC AND PLATELET DISEASES BY NEXT GENERATION SEQUENCING**  
Ilenia Simeoni\* (United Kingdom)

08:15 – 08:30  
OR177  
**ANTITHROMBIN REDUCTION IMPROVES COAGULATION IN RARE BLEEDING DISORDER PLASMA**  
Alfca Sehgal\*, Kun Qian, Julia Hettinger, Benny Sorensen, Akin Akinc (United States)

08:30 – 08:45  
OR178  
**LONG-TERM CORRECTION OF CANINE FVII DEFICIENCY USING AAV-MEDIATED EXPRESSION OF ZYMOGEN FVII**  
Oscar A Marcos-Contreras\*, Shannon Smith, Dwight A Bellinger, Elizabeth Merricks, Armida Faella, Giulia Pavani, Shangzhen Zhou, Timothy Nichols, Katherine High, Paris Margaritis (United States)

08:45 – 09:00  
OR179  
**ENGINEERED TRANSCRIPTION FACTORS (TALE-TF) AS POTENTIAL THERAPEUTIC STRATEGY FOR COAGULATION FACTOR DEFICIENCIES CAUSED BY PROMOTER MUTATIONS**  
Elena Barbon\*, Silvia Pignani, Alessio Branchini, Francesco Bernardi, Mirko Pinotti, Matteo Bovolenta (Italy)

09:00 – 09:15  
OR180  
**STUDIES OF MCFD2 KNOCKOUT MICE SUGGEST ALTERNATIVE PATHWAYS FOR FV, FVIII AND ALPHA-1-ANTITRYPSIN SECRETION**  
Bin Zhang\*, Chunlei Zheng, Min Zhu, Lesley Everret, David Ginsburg (United States)

### Platelets – Signal Transduction I

Room 709

*Moderators: Stephen Watson (United Kingdom), José Lopez (United States)*

08:00 – 08:15  
OR181  
**A NOVEL KNOCK-IN MOUSE REVEALS AN ESSENTIAL ROLE FOR THE-CLEC-2 HEMITAM IN DEVELOPMENT**  
Elizabeth Haining\*, David Stegner, Bernhard Nieswandt (Germany)

08:15 – 08:30  
OR182  
**APOLIPOPROTEIN A-I ENHANCES PROTEASE-ACTIVATED RECEPTOR 1-DEPENDENT CYTOPROTECTIVE SIGNALING BY ACTIVATED PROTEIN C**  
Eimear Gleeson, Owen Smith, James O'Donnell, Roger J. Preston\* (Ireland)

08:30 – 08:45  
OR183  
**REGULATION OF INTEGRIN ALPHAIIIBETA3-MEDIATED PLATELET SPREADING BY THE RECEPTOR-LIKE TYROSINE PHOSPHATASES PTPRA AND PTPRE**  
Jun Mori, Luke Boothman\*, Craig Hughes, Joao Correia, Silke Heising, Jeroen Den Hertog, Ilaria Canobbio, Mauro Torti, Jan Sap, David Varon, Ari Elson, Yotis Senis (United Kingdom)

## SCIENTIFIC PROGRAM

08:45 – 09:00  
OR184  
**G PROTEIN-COUPLED RECEPTOR KINASE 6 REGULATES PLATELET ACTIVATION AND THROMBUS FORMATION THROUGH SELECTIVE GPCR DESENSITIZATION**  
Dheeraj Bhavanasi, Rachit Badolia, Soochoong Kim\* (United States)

09:00 – 09:15  
OR185  
**PROCOAGULANT PLATELETS ARE UNDERGOING CYCLOPHILIN D MEDIATED NECROSIS WITH DIFFERENTIAL INVOLVEMENT IN OCCLUSIVE VERSUS NON-OCCLUSIVE MODELS OF THROMBOSIS.**  
Minh Hua\*, Latasha Abeynaike, Robert Lindeman, Philip Hogg, Vivien Chen (Australia)

### Antiphospholipid antibodies – II

Room 711

*Moderators: Jacob Rand (United States), Stéphane Zuily (France)*

08:00 – 08:15  
OR186  
**ACTIVATED PROTEIN C RESISTANCE DETERMINED BY THROMBIN GENERATION IS PREDICTIVE OF THROMBOSIS IN ANTIPHOSPHOLIPID-POSITIVE PATIENTS AND ASSOCIATED AUTO-IMMUNE DISEASES. A MULTICENTER PROSPECTIVE COHORT STUDY**  
Stéphane Zuily\*, Veronique Regnault, Shirine Mohamed, Claire Lamboux-Matthieu, Anne-Christine Rat, Jacques Ninet, Nadine Magy-Bertrand, Jean-Louis Pasquali, Marc Lambert, Bernard Lorcerie, Pierre Kaminsky, Francis Guillemin, Denis Wahl (France)

08:15 – 08:30  
OR187  
**EFFECTS OF NEW (DIRECT) ORAL ANTICOAGULANTS ON LUPUS ANTICOAGULANT ASSAYS**  
Jovan Antovic\*, Aleksandra Antovic, Eva-Marie Norberg, Maria Berndtsson, Mika Skeppholm (Sweden)

08:30 – 08:45  
OR188  
**OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EARLY LMWH-INDUCED VARIATIONS OF ANGIOGENIC FACTORS PREDICT PLACENTA-MEDIATED PREGNANCY COMPLICATIONS.**  
Jean-Christophe R. Gris\*, Sylvie Bouvier, Géraldine Lavigne, Eva Nouvellon, Erick Mercier, Jean-Philippe Galanaud, Isabelle Quéré, Céline Chauleur, Pierre Marès (France)

08:45 – 09:00  
OR189  
**INCREASED RISK FOR PULMONARY HYPERTENSION ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. A META-ANALYSIS OF ECHOCARDIOGRAPHIC STUDIES**  
Stéphane Zuily\*, Vinicius Domingues, Denis Wahl (France)

09:00 – 09:15  
OR190  
**OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EARLY LMWH-INDUCED VARIATIONS OF ANGIOGENIC FACTORS PREDICT PREGNANCY LOSS.**  
Jean-Christophe R. Gris\*, Sylvie Bouvier, Géraldine Lavigne, Eva Nouvellon, Erick Mercier, Jean-Philippe Galanaud, Isabelle Quéré, Pierre Marès (France)

**Coffee break time in the exhibition (Level 800)  
From 09:15 to 09:45**

TUESDAY

ORALS

# SCIENTIFIC PROGRAM

Tuesday, June 23, 2015


PLENARY SESSION 09:45-10:30

J. Fraser Mustard Plenary Lecture

Hall F&G

Moderator: Margaret Rand (Canada)

09:45 -10:30 **Platelets, NETs and Immunity**  
Paul Kubes (Canada)



J. Fraser Mustard, 1927-2011

Tuesday, June 23, 2015

STATE-OF-THE-ART LECTURES 10:45-11:45

● Genetics of megakaryocytes and platelets

Room 801

Moderator: Jane Freedman (United States)

10:45 -11:15 **Genetic regulation of megakaryocyte and platelet function**  
Andy Weyrich (United States)

11:15 - 11:45 **The formation of platelets: Lessons learned from population and rare disease cases genomics**  
Willem Ouwehand (United Kingdom)

Making Platelets for Transfusion

Room 701

Moderator: Erik Yeo (Canada)

10:45 - 11:15 **Towards a self-renewing megakaryocyte**  
Koji Eto (Japan)

11:15 - 11:45 **Road blocks in making platelets for transfusion**  
Jonathan Thon (United States)

# SCIENTIFIC PROGRAM

■ Evolving role of the intrinsic pathway

Room 714

Moderator: Harry R. Büller (The Netherlands)

10:45 - 11:05 **Medical device-induced thrombosis: What causes it and how can we prevent it?**  
Jeff Weitz (Canada)

11:05 - 11:25 **Extracellular DNA and histones: Double-edged swords in immunothrombosis**  
Patricia Liaw (Canada)

11:25 - 11:45 **Polyphosphate as modulator of hemostasis and thrombosis**  
Jim Morrissey (United States)

▲ Opening vessels: From fibrinolysis to interventions

Room 718

Moderator: Robert Medcalf (Australia)

10:45 - 11:05 **Basic mechanisms and regulation of fibrinolysis**  
Colin Longstaff (United Kingdom)

11:05 - 11:25 **Interventional therapy for VTE**  
Suresh Vedantham (United States)

11:25 - 11:45 **Treatment of acute ischemic stroke: From fibrinolysis to neurointervention**  
Brian van Adel (Canada)

★+ Longer-acting clotting factor concentrates

Plenary Hall F&G

Moderators: Rita Lassila (Finland); Alfonso Iorio (Canada)

10:45 - 11:05 **FVIII-Fc fusion protein for the treatment of hemophilia A**  
Jerry Powell (United States)

11:05 - 11:25 **Half-life extended factor VIII for the treatment of hemophilia A**  
Andreas Tiede (Germany)

11:25 - 11:45 **Hepatic stem cells and related microparticles as treatment for hemophilia**  
Etienne Sokal (Belgium)

♥ Atherothrombosis

Room 716

Moderator: Per Morten Sandset (Norway)

10:45 -11:15 **Genetics and genomics of coronary artery disease**  
Tim Assimes (United States)

11:15 - 11:45 **Persistent platelet activation and coagulant activity in atherothrombosis**  
Judith Cosemans (The Netherlands)

TUESDAY

STATE OF THE ART

## SCIENTIFIC PROGRAM

### Thrombotic Thrombocytopenic Purpura

Room 713

*Moderator: Kenneth Clemetson (Switzerland)*

10:45 - 11:15 **Long-term outcomes and pregnancy outcomes in TTP**  
Sara Vesely (United States)

11:15 - 11:45 **ADAMTS13, thrombotic microangiopathies, and eculizumab**  
Spero Cataland (United States)

**Lunch in the exhibition (Level 800)**  
**From 11:45 to 12:15**

**Lunch Symposia**  
**From 12:15 to 13:45**

Lunch Symposia Programs are available in the Show Guide. Please consult the different options to attend the symposium of your choice.

### ORAL COMMUNICATIONS 4 14:00-15:15

#### ▲ Venous thromboembolism – diagnosis

Plenary Hall F&G

*Moderators: Clive Kearon (Canada), Nakisa Khorsand (The Netherlands)*

14:00 – 14:15 **WITHHOLDING ANTICOAGULATION AFTER NORMAL CTPA IS SAFE IN PATIENTS WITH A HIGH CLINICAL PROBABILITY OF PE IN THE ABSENCE OF A PRIOR EPISODE OF VTE**  
OR191  
Tom van der Hulle\*, Nick van Es, Paul den Exter, Josien van Es, Inge Mos, Renée Douma, Pieter Kamphuisen, Harry Büller, Menno Huisman, Frederikus Klok (The Netherlands)

14:15 – 14:30 **REPRODUCIBILITY OF CLINICAL EVENTS ADJUDICATIONS IN A TRIAL OF VENOUS THROMBOEMBOLISM PREVENTION**  
OR192  
Philippe Girard\*, Florence Parent, Beatrice Gable, Olivier Sanchez, Pierre Durieux, Pierre Hausfater, Andrea Penaloza, Sophie Dambrine, Aurore Armand-Perroux, Marie Beziaud, Jean-Pierre Nguyen, Guy Meyer, Pierre-Marie Roy (France)

14:30 – 14:45 **DNA IN PLASMA INDICATES DISEASE EXTENT AND PREDICTS MORTALITY IN PATIENTS WITH VENOUS THROMBOEMBOLISM**  
OR193  
Tobias A. Fuchs\*, Miguel Jiménez-Alcázar, Andreas Limacher, Marie Méan, Thomas Renné, Drahomir Aujesky, Bernhard Lämmle (Sweden, Germany)

14:45 – 15:00 **LOW END-TIDAL CO<sub>2</sub> SIGNIFICANTLY INCREASES PRETEST PROBABILITY OF PULMONARY EMBOLISM**  
OR194  
Jeffrey Kline\*, Franck Verschuren, Kerstin Hogg, Pierre-Marie Roy, Andrea Penaloza, Donna Prentice (United States)

## SCIENTIFIC PROGRAM

15:00 – 15:15 **A PROSPECTIVE ALGORITHM INCORPORATING LIMITED AND WHOLE-LEG ASSESSMENT OF THE DEEP VENOUS SYSTEM IN SYMPTOMATIC OUTPATIENTS (THE PALLADIO STUDY)**  
OR195  
Walter Ageno\*, Giuseppe Camporese, Nicoletta Riva, Angelo Ghirarduzzi, Eugenio Bucherini, Marc Righini, Pieter Kamphuisen, Peter Verhamme, James Douketis, Chiara Tonello, Paolo Prandoni (Italy)

### NOAC – bleeding risk factors and management

Room 718

*Moderators: Steen Husted (Denmark), Kerstin de Wit (Canada)*

14:00 – 14:15 **INFLUENCE OF ABCB1 GENOTYPE AND OF A P-GP DRUG INHIBITOR, CLARITHROMYCIN, ON DABIGATRAN AND RIVAROXABAN PHARMACOKINETIC PROFILES IN HEALTHY VOLUNTEERS**  
OR196  
Isabelle Gouin-Thibault\*, Xavier Delavenne, Anne Blanchard, Virginie Siguret, Pascale Gaussem, Christian Funck-Brentano, Michel Azizi, Patrick Mismetti, Marie-Anne Lorient (France)

14:15 – 14:30 **NEW ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY HIGH RISK ATRIAL FIBRILLATION WITH HISTORY OF INTRACRANIAL HEMORRHAGE**  
OR197  
Dimitry Arioli\*, Elisa Romagnoli, Valentina Cocchi, Monica Casella, Angela Muoio, Maria Del Mar, Jordana Sanchez, Attilia Pizzini, Annamaria Casali, Ido Iori (Italy)

14:30 – 14:45 **INTRACRANIAL BLEEDING WITH THE NEW ORAL ANTICOAGULANT DRUGS**  
OR198  
Kerstin Hogg\*, Bharat Bahl, Lana Castellucci, Ian Stiell (Canada)

14:45 – 15:00 **CLINICAL IMPACT AND COURSE OF MAJOR BLEEDING WITH EDOXABAN VERSUS VITAMIN K ANTAGONISTS**  
OR199  
Marjolein P. Brekelmans\*, Suzanne Bleker, Rupert Bauersachs, Zoltán Boda, Harry Büller, Youngsook Choi, Alex Gallus, Michael Grosso, Michele Mercuri, Saskia Middeldorp, Doyeun Oh, Gary Raskob, Lee Schwocho, Ander Cohen (The Netherlands)

15:00 – 15:15 **CHARACTERISTICS AND REVERSAL STRATEGIES OF REAL-WORLD ANTICOAGULATION-RELATED HEMORRHAGE IN THE NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANT ERA: PRELIMINARY DATA FROM A MULTICENTRE CHART REVIEW.**  
OR200  
Yan Xu\*, Sam Schulman, Dar Dowlathshahi, Anne Holbrook, Chris Simpson, Lois Shepherd, Philip Wells, Antonio Giulivi, Eliot Frymire, Ana Johnson (Canada)

### Von Willebrand disease – clinical

Room 701

*Moderators: Karl Desch (United States), Jeroen Eikenboom (The Netherlands)*

14:00 – 14:15 **VON WILLEBRAND DISEASE: DOES VON WILLEBRAND FACTOR DEFICIENCY DECREASE THE RISK OF CARDIOVASCULAR DISEASE?**  
OR201  
Craig Seaman\*, Margaret Ragni, Jonathan Yabes, Diane Comer (United States)

14:15 – 14:30 **QUALITATIVE AND QUANTITATIVE MODIFICATIONS OF VON WILLEBRAND FACTOR IN ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PLATELETS AND NON-ADAMTS13-DEPENDENT PROTEOLYTIC PROCESSING**  
OR202  
Stefano Lancellotti\*, Alfredo Dragani, Paola Ranalli, Giovanna Petrucci, Maria Basso, Raffaele Tartaglione, Bianca Rocca, Raimondo De Cristofaro (Italy)

TUESDAY

ORALS

## SCIENTIFIC PROGRAM

### 14:30 – 14:45 OR203 **IMPACT OF ANNEXIN A2 SNP ON VON WILLEBRAND FACTOR LEVELS IN PATIENTS WITH MODERATE AND SEVERE VON WILLEBRAND DISEASE**

Waander Van Heerde\*, Jelmer van Puffelen, Iris Kloots, Johan Boender, Yvonne Sanders, Marjon Cnossen, Britta Laros-van Gorkom, Karin Fijnvandraat, Selene Schoormans, Johanna van der Bom, Karina Meijer, Evelien Mauser-Bunschoten, Jeroen Eikenboom, Lambertus Kiemeneij, Frank Leebeek (The Netherlands)

### 14:45 – 15:00 OR204 **VARIABILITY IN VON WILLEBRAND FACTOR ANTIGEN (VWF:AG) LEVELS IN PROSPECTIVE STUDIES OF THE ZIMMERMAN PROGRAM FOR THE MOLECULAR AND CLINICAL BIOLOGY OF VON WILLEBRAND DISEASE (ZPMCB-VWD) SUBJECTS**

Kenneth D. Friedman\*, Pamela Christopherson, Veronica Flood, Joan Gill, Sandra Haberichter, Robert Montgomery (United States)

### 15:00 – 15:15 OR205 **CHARACTERIZATION OF A NEW GENETICALLY-ENGINEERED VON WILLEBRAND DISEASE TYPE 2B MOUSE MODEL.**

Frédéric Adam\*, Caterina Casari, Alexandre Kauskot, Cécile Loubière, Paulette Legendre, Christelle Reperant, Dominique Baruch, Jean-Philippe Rosa, Marijke Bryckaert, Olivier Christophe, Peter Lenting, Cécile Denis (France)

## ● Platelets – I

Room 801

*Moderators: Alan Nurden (France), Steffen Massberg (Germany)*

### 14:00 – 14:15 OR206 **SINGLE CELL TRACKING REVEALS AUTONOMOUS LOCOMOTION AS A PLATELET FUNCTION FACILITATING THROMBUS REORGANIZATION**

Florian Gaertner\* (Germany)

### 14:15 – 14:30 OR207 **MORE THAN JUST RED CELLS: HOW DO HEMOSTATIC THROMBI PREVENT THE LOSS OF PLASMA-BORNE MOLECULES?**

John D. Welsh\*, Ryan Muthard, Timothy Stalker, Joshua Taliaferro, Scott Diamond, Lawrence Brass (United States)

### 14:30 – 14:45 OR208 **DICER, THE KEY ENZYME OF RNA INTERFERENCE, IS REGULATED BY THROMBIN STIMULATION IN HUMAN PLATELETS.**

Giorgia Manni\*, Loredana Bury, Elisa Piselli, Paolo Gresele (Italy)

### 14:45 – 15:00 OR209 **REPLICATION OF PLATELET REACTIVITY GENOME-WIDE ASSOCIATION SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CAERPHILLY PROSPECTIVE STUDY**

John D. Eicher\*, Luting Xue, Yoav Ben-Shlomo, Andrew Beswick, Andrew Johnson (United States)

### 15:00 – 15:15 OR210 **VPS33B REGULATES VWF POSITIVE VESICLES TRANSPORTATION TO PROPLATELET**

Jing Dai\*, Yeling Lu, Conghui Wang, Xue Chen, Panlai Shi, Xuemei Fan, Xiaolin Wu, Keming Wang, Xuefeng Wang, Junling Liu (China)

## SCIENTIFIC PROGRAM

## ✚ Hemophilia – novel treatments

Room 714

*Moderators: Johnny Mahlangu (South Africa), Craig Kessler (United States)*

### 14:00 – 14:15 OR211 **PERSONALIZATION OF TREATMENT REGIMENS FOR ACTIVE PATIENTS: A COMPARISON OF FACTOR VIII AND EXTENDED HALF-LIFE TREATMENT REGIMENS**

Elizabeth Schwartz\*, Yan Xiong, Josh Epstein, Bruce Ewenstein, Leonard Valentino (United States)

### 14:15 – 14:30 OR212 **CLINICAL EVALUATION OF NOVEL RECOMBINANT GLYCOPEGYLATED FVIII (TUROCTOCOG ALFA PEGOL, N8-GP): EFFICACY AND SAFETY IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A – RESULTS OF PATHFINDER™2 INTERNATIONAL TRIAL**

Paul Giangrande\*, Pratima Chowdhary, Silke Enhrenforth, Hideji Hanabusa, Frank Leebeek, Steven Lentz, Laszlo Nemes, Lone Poulsen, Elena Santagostino, Chur You, Wan Hui Clausen, Johannes Oldenburg (United Kingdom)

### 14:30 – 14:45 OR213 **A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNA THERAPEUTIC (ALN-AT3) TARGETING ANTITHROMBIN FOR TREATMENT OF HEMOPHILIA: INTERIM PHASE 1 STUDY RESULTS IN PATIENTS WITH HEMOPHILIA A OR B**

Benny Sorensen\*, Tim Mant, Pencho Georgiev, Savita Rangarajan, K. John Pasi, Desmond Creagh, David H. Bevan, Steve Austin, Charles Hay, Brigitte Brand, Amy Simon, Lauren Melton, Christian Lynam, Andrew Strahs, Alfica Sehgal, Renta Hutabarat, Prasoon Chaturvedi, Scott Barros, Pushkal Garg, Askhay Vaishnav, Akin Akinc (United States)

### 14:45 – 15:00 OR214 **BAY 81-8973 PROPHYLAXIS EFFICACY IN PATIENTS WITH SEVERE HEMOPHILIA A: ANALYSES OF ANNUALIZED BLEEDING RATE OUTCOMES IN THE LEOPOLD I TRIAL**

Maria Elisa Mancuso\*, Horst Beckmann, Monika Maas Enriquez (Germany)

### 15:00 – 15:15 OR215 **FACTORS INFLUENCING THE PHARMACOKINETICS OF PEGYLATED RECOMBINANT FACTOR VIII (BAX 855) ADMINISTERED FOR PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A**

Oleksandra Stasyshyn, Werner Engl, Brigitt E. Abbuehl\*, Victoria Empson, Bruce Ewenstein (Austria)

## Acquired disorders – clinical – II

Room 716

*Moderators: Claude Negrier (France), Elena Santagostino (Italy)*

### 14:00 – 14:15 OR216 **COMPARATIVE ANALYSIS OF VON WILLEBRAND FACTOR PROFILES IN LEFT VENTRICULAR ASSIST DEVICE AND TOTAL ARTIFICIAL HEART RECIPIENTS**

Heidi Reich, Francisco Arabia, Lawrence Czer, Jaime Moriguchi, Danny Ramzy, Fardad Esmailian, Lee Lam, Julie Dunhill, Oxana Tcherniantchouk\* (United States)

### 14:15 – 14:30 OR217 **RELAPSE PATTERN AND LONG TERM OUTCOMES IN 111 SUBJECTS WITH ACQUIRED HEMOPHILIA A**

Terry Mizrahi\*, Karine Doyon, Arnaud Bonnefoy, Margaret Warner, Christine Demers, Stéphanie Cloutier, Jean-François Castilloux, Georges-Etienne Rivard, Jean St-Louis (Canada)

TUESDAY

ORALS

## SCIENTIFIC PROGRAM

- 14:30 – 14:45  
OR218 **THROMBIN GENERATION VARIES WITH FIBROSIS SCORE IN PATIENTS WITH WELL-COMPENSATED LIVER CIRRHOSIS OF MIXED AETIOLOGY.**  
Karl Egan\*, Audrey Dillon, Zita Galvin, Barry Kevane, Elaine Neary, Stephen Stewart, Fionnuala Ni Ainle (Ireland)
- 14:45 – 15:00  
OR219 **EARLY VON WILLEBRAND FACTOR DEGRADATION UPON ACUTE EXPOSURE TO HIGH SHEAR STRESS UNDER CONTINUOUS-FLOW CIRCULATORY ASSIST DEVICES**  
Antoine Rauch\*, Eric Van Belle, André Vincentelli, Emmanuelle Jeanpierre, Paulette Legendre, Francis Juthier, Natacha Rousse, Carlo Banfi, Anne Godier, Claudine Caron, Dupont Annabelle, Christophe Zawadski, Delphine Corseaux, Bart Staels, Jenny Goude- mand, Brigitte Jude, Peter Lenting, Sophie Susen (France)
- 15:00 – 15:15  
OR220 **HEMOSTATIC DISORDER OF UREMIA: PATIENTS WITH TERMINAL CHRONIC RENAL FAILURE (CRF) HAVE INCREASED PLATELET TISSUE FACTOR DERIVED INTRAVASCULAR CLOTTING ACTIVATION WITH DELAYED CLOT LYSIS TIME IN PLATELET RICH PLASMA (CLT-PRP)**  
Olga Panes\*, César González, M. Macarena Ruiz, Camila Sandoval, Marcela Cayuleo, Alejandro Rojas, Mariana Soto, Melan Peralta, Jaime Pereira, Mireya Ortiz, Diego Mezzano (Chile)

### ★ Pediatric hemostasis

Room 713

*Moderators: Lesley Raffini (United States), Veerle Labarque (Belgium)*

- 14:00 – 14:15  
OR221 **ROLE OF THE G PROTEINS AND SYNTAXIN-11 IN THE DIFFERENCES OF PLATELET REACTIVITY AND SECRETION BETWEEN NEONATES AND ADULTS.**  
Eva Caparrós-Pérez\*, José Miguel Torregrosa, Raúl Teruel-Montoya, José Eliseo Blanco, José Rivera, Vicente Vicente, Constantino Martínez, Francisca Ferrer-Marín (Spain)
- 14:15 – 14:30  
OR222 **DISSEMINATED INTRAVASCULAR COAGULATION CONTRIBUTES AN INDEPENDENT MORTALITY RISK IN CRITICALLY ILL CHILDREN.**  
James B. Ford, John Kittelson, Marilyn Manco-Johnson (United States)
- 14:30 – 14:45  
OR223 **IMPAIRED COLLAGEN RESPONSE IN NEONATAL PLATELETS: THE BALANCE BETWEEN ACTIVATION AND INHIBITION PATHWAYS**  
Sara J. Israels\*, Eileen McMillan-Ward, Archie McNicol (Canada)
- 14:45 – 15:00  
OR224 **THE CONTRIBUTION OF PRO- AND ANTICOAGULANT PROCESSES TO THROMBIN GENERATION IN THE COURSE OF MATURATION**  
Romy Kremers\*, Rob Wagenvoort, Bas de Laat, Paul Monagle, Coenraad Hemker, Vera Ignjatovic (The Netherlands)
- 15:00 – 15:15  
OR225 **PEDIATRIC REFERENCE VALUES OF THROMBIN GENERATION MEASURED BY THE CALIBRATED AUTOMATED THROMBOGRAM (CAT)**  
Inge Appel\*, Tineke Henniphof, Rene van Oerle, Marjon Cnossen, Auke Beishuizen, Henri Spronk (The Netherlands)

## SCIENTIFIC PROGRAM

### Cancer and thrombosis – clinical – II

Room 715

*Moderators: Huyen Tran (Australia), Rupert Bauersachs (Germany)*

- 14:00 – 14:15  
OR226 **LONG-TERM CANCER RISK AFTER VENOUS THROMBOEMBOLISM**  
Lisbeth Eischer\*, Paul Kyrle, Michael Kammer, Sabine Eichinger (Austria)
- 14:15 – 14:30  
OR227 **HYPERCOAGULABILITY, VENOUS THROMBOEMBOLISM AND DEATH IN PATIENTS WITH CANCER: A MULTI-STATE MODEL**  
Florian Posch\*, Eva-Maria Reitter, Julia Riedl, Ingrid Pabinger, Cihan Ay (Austria)
- 14:30 – 14:45  
OR228 **CHARACTERISTICS AND RISK FACTORS OF MAJOR AND CLINICALLY RELEVANT NON-MAJOR BLEEDING IN CANCER PATIENTS RECEIVING ANTICOAGULANT TREATMENT FOR ACUTE VENOUS THROMBOEMBOLISM – THE CATCH STUDY**  
Pieter W. Kamphuisen\*, Agnes Y.Y. Lee, Guy Meyer, Rupert Bauersachs, Mette S. Janas, Mikala F. Jarner, Alok A. Khorana (The Netherlands)
- 14:45 – 15:00  
OR229 **THROMBIN GENERATION AND VENOUS THROMBOEMBOLISM AMONG MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE AND PREDNISOLONE MAINTENANCE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION**  
Huyen Tran\*, James McFadyen, Anna Kalff, Andrew Spencer (Australia)
- 15:00 – 15:15  
OR230 **INCIDENTAL VENOUS THROMBOEMBOLISM AT THORACOABDOMINAL STAGING CT IN COLORECTAL CANCER**  
Andreas Nordholm-Carstensen, Morten S. Rasmussen\*, Hanne Hansen, Henrik Harling, Lars Jorgensen (Denmark)

### Megakaryocytes and thrombopoiesis II

Room 717

*Moderators: Li Guo (Canada), A. Koneti Rao (United States)*

- 14:00 – 14:15  
OR231 **SYNDROMES WITH GRAY PLATELETS: NBEAL2 EXPRESSION IS REGULATED BY TRANSCRIPTION FACTOR GATA1**  
Anouck Wijgaerts\*, Marie-Christin Wittevrongel, Timothy Devos, Marloes Tijssen, Kathelijne Peerlinck, Chris Van Geet, Kathleen Freson (Belgium)
- 14:15 – 14:30  
OR232 **DYNEIN-DEPENDENT MICROTUBULE SLIDING DRIVES PROPLATELET ELONGATION**  
Markus Bender,\* Jonathan Thon, Allen Ehrlicher, Stephen Wu, Linas Mazutis, Eموke Deschmann, Martha Sola-Visner, Joseph Italiano, John Hartwig (United States)
- 14:30 – 14:45  
OR233 **β4GALACTOSYLTRANSFERASE 1 (β4GALT1) IS A KEY REGULATOR OF HEMATOPOIETIC STEM CELL FUNCTION AND THROMBOPOIESIS.**  
Silvia Giannini\*, Max Adelman, Antonija Jurak Begonja, Karin Hoffmeister (United States)
- 14:45 – 15:00  
OR234 **TYPE 2B VON WILLEBRAND DISEASE (VWD) IS CHARACTERIZED BY A CYTOSKELETAL DESORGANIZATION IN MEGAKARYOCYTES LEADING TO MACROTHROMBOCYTOPENIA.**  
Alexandre Kauskot\*, Sonia Poirault-Chassac, Caterina Casari, Frédéric Adam, Audrey Pietrzyk-Nivau, Eliane Berrou, Marijke Bryckaert, Jean-Philippe Rosa, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis, Dominique Baruch (France)



## SCIENTIFIC PROGRAM

15:00 – 15:15  
OR234 **RECEPTOR-MEDIATED ENDOCYTOSIS IS REQUIRED FOR NORMAL MEGAKARYOCYTE DEMARCATION MEMBRANE SYSTEM FORMATION AND PLATELET PRODUCTION**  
Silvia Giannini, Fred Pluthero, Hilary Christensen, Richard Leung, Richard Lo, Jan Kormann, Markus Plomann, Walter Kahr, Karin Hoffmeister, Hervé Falet\* (United States)

### Tissue factor and factor VII – II

Room 705

*Moderators: Nima Vaezzadeh (Canada), Bjarne Østerud (Norway)*

14:00 – 14:15  
OR236 **GENOME-WIDE SERINE PROTEASE KNOCKDOWNS IN ZEBRAFISH: IDENTIFICATION OF PROSTASIN IN FACTOR VII ACTIVATION PATHWAY**  
Pudur Jagadeeswaran\*, Gauri Khandekar (United States)

14:15 – 14:30  
OR237 **TISSUE-FACTOR INDUCED ALLOSTERIC ENHANCEMENT OF FACTOR VIIIA ACTIVITY BY STABILIZATION OF SEGMENT 215-219 AND TAMING OF W215 FLEXIBILITY**  
Anders Sorensen, Jesper Madsen, Anders Svensson, Henning Stennicke, Henrik Østergaard, Michael Overgaard, Ole Olsen, Prafull S. Gandhi\* (Denmark)

14:30 – 14:45  
OR238 **RELATIONSHIPS OF CIRCULATING COAGULATION FACTOR VIIIA (FVIIA) WITH COMMON SINGLE NUCLEOTIDE POLYMORPHISMS AND RISK OF INCIDENT ISCHEMIC STROKE: THE CARDIOVASCULAR HEALTH STUDY**  
Nels C. Olson\*, Leslie Lange, Alex Reiner, Russell Tracy (United States)

14:45 – 15:00  
OR239 **EPIDERMAL TISSUE FACTOR IN WOUND HEALING**  
Elizabeth Chappell\*, Dougald Monroe, Maureane Hoffman, Nigel Mackman (United States)

### Platelets – signal transduction II

Room 707

*Moderators: Katsue Suzuki-Inoue (Japan), Kristina Modjeski (United States)*

14:00 – 14:15  
OR241 **GLUTAMATE RECEPTOR INTERACTING PROTEIN 1 MEDIATES PLATELET ADHESION AND THROMBUS FORMATION**  
Kristina Modjeski\*, Sara Ture, David Field, Scott Cameron, Craig Morrell (United States)

14:15 – 14:30  
OR242 **UNEXPECTED ROLE OF PLATELETS IN LUNG DEVELOPMENT DEPENDING ON A PLATELET ACTIVATION RECEPTOR, CLEC-2**  
Nagaharu Tsukiji\*, Osamu Inoue, Shogo Tamura, Toshiaki Shirai, Tomoyuki Sasaki, Kaneo Satoh, Katsue Suzuki-Inoue, Yukio Ozaki (Japan)

14:30 – 14:45  
OR243 **NON-GENOMIC ACTIVITIES OF RETINOIC ACID RECEPTOR ALPHA CONTROL ACTIN CYTOSKELETAL EVENTS IN HUMAN PLATELETS**  
Hansjorg Schwertz\*, Martin Freitag, Jesse Rowley, Larry Kraiss, Zechariah Franks, Guy Zimmerman, Andrew Weyrich, Matthew Rondina (Germany, United States)

14:45 – 15:00  
OR244 **LEUKEMIA-ASSOCIATED RHOGF (LARG) PLAYS A MINOR ROLE IN RHOA ACTIVATION, YET IS CRITICAL FOR PLATELET ACTIVATION IN MICE**  
Christopher M. Williams\*, Matthew Harper, Robert Goggs, Tony Walsh, Stefan Offermanns, Alastair Poole (United Kingdom)

## SCIENTIFIC PROGRAM

15:00 – 15:15  
OR245 **CALPAIN-CONTROLLED DETACHMENT OF MAJOR GLYCOPROTEINS FROM CYTOSKELETON REGULATES ADHESIVE PROPERTIES OF PHOSPHATIDYLSERINE-POSITIVE ACTIVATED PLATELETS**  
Elena Artemenko, Alena Yakimenko, Alexey Pichugin, Fazly Ataullakhanov, Mikhail Pantelev\* (Russian Federation)

### Coagulation factors V, X, and XIII

Room 709

*Moderators: Cathy Hayward (Canada), Sriram Krishnaswamy (United States)*

14:00 – 14:15  
OR246 **MACROPHAGE-SPECIFIC RECEPTOR SR-AI PLAYS A CRUCIAL PROTECTIVE ROLE IN THE REGULATION OF COAGULATION FACTOR X PLASMA LEVELS**  
Vincent Muczynski\*, Amine Bazaa, Amélie Harel, Cécile Loubière, Ghislaine Chérel, Peter Lenting, Cécile Denis, Olivier Christophe (France)

14:15 – 14:30  
OR247 **CB-FXA: AN IMPROVED SECOND GENERATION FXA VARIANT**  
Edwin Madison\*, Christopher Thanos, Mark Fox, Kerryn McCluskie, Jodi Gureasko, Tony Byun, David Sloane (United States)

14:30 – 14:45  
OR248 **CHARACTERIZATION OF A NOVEL FV MUTATION (A512V, FV BONN) ASSOCIATED WITH DEEP VEIN THROMBOSIS AND APC RESISTANCE**  
Behnaz Pezeshkpoor\*, Elisabetta Castoldi, Nasim Hamedani, Arijit Biswas, Johannes Oldenburg, Anna Pavlova (Germany)

14:45 – 15:00  
OR249 **PLATELET-DERIVED FACTOR V REGULATES ARTERIAL THROMBOSIS**  
Jianbo Wu\*, Meiping Ren, Yongjie Li, Ningbo Pang, Ni Chen, Xin Deng, Yan Yang, Namei Xiao, Hongmin Sun (China)

15:00 – 15:15  
OR250 **DEVELOPMENT OF A NOVEL ASSAY METHOD OF COAGULATION FACTOR XIII ACTIVITY FOR THE DETECTION OF ITS INHIBITOR IN PLASMA**  
Masayoshi Souri\*, Tsukasa Osaki, Akitada Ichinose (Japan)

### Arterial vascular disease

Room 711

*Moderators: John Eikelboom (Canada), Michiel Coppens (The Netherlands)*

14:00 – 14:15  
OR251 **THE EFFECT OF INTRACORONARY STEM CELL INJECTION ON MARKERS OF LEUKOCYTE ACTIVATION IN ACUTE MYOCARDIAL INFARCTION**  
Ragnhild Helseth\*, Trine Opstad, Svein Solheim, Ketil Lunde, Harald Arnesen, Ingebjørg Seljeflot (Norway)

14:15 – 14:30  
OR252 **PLATELET NEUTROPHIL COMPLEX FORMATION AND INFILTRATION IS REGULATED BY PERIPHERAL SEROTONIN IN A MOUSE MODEL OF MYOCARDIAL INFARCTION**  
Maximilian Mauler\*, Thilo Witsch, Ludwig Dörner, Kelly Blanz, Christoph Koentges, Daniela Stallmann, Christoph Bode, Heiko Bugger, Daniel Duerschmied (Germany)

14:30 – 14:45  
OR253 **POST-PCI THROMBIN GENERATION AND CARDIOVASCULAR MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS.**  
Monica Attanasio, Rossella Marcucci, Annamaria Gori\*, Rita Paniccia, Raffaella Priora, Serafina Valente, Daniela Balzi, Alessandro Barchielli, Rosanna Abbate, Gian Franco Gensini (Italy)

TUESDAY

ORALS

## SCIENTIFIC PROGRAM

- 14:45 – 15:00  
OR254 **REPEATED MEASURES OF MODIFIABLE ATHEROSCLEROTIC RISK FACTORS OVER TIME AND RISK OF MYOCARDIAL INFARCTION AND VENOUS THROMBOSIS**  
Birgit Småbrekke\*, Ludvig Rinde, Erin Hald, Anders Vik, Tom Wilsgaard, Inger Njølstad, Ellisiv Mathiesen, Sigrid Brækkan, John-Bjarne Hansen (Norway)
- 15:00 – 15:15  
OR255 **RECURRENCE AND MORTALITY IN YOUNG WOMEN WITH MYOCARDIAL INFARCTION OR ISCHEMIC STROKE: 19-YEAR FOLLOW-UP OF THE RISK OF ARTERIAL THROMBOSIS IN RELATION TO ORAL CONTRACEPTIVES (RATIO) STUDY.**  
Alberto Maino\*, Bob Siegerink, Ale Algra, Flora Peyvandi, Frits Rosendaal (Italy)

**Coffee break time in the exhibition (Level 800)  
From 15:15 to 15:45**

Tuesday, June 23, 2015

PLENARY SESSION 15:45-16:30

Maureen Andrew Plenary Lecture

Hall F&G

*Moderator: Patti Massicotte (Canada)*

- 15:45 - 16:30 **Why do we miss the mark on preventing cardiovascular disease? Is it too little, too late or just futile?**  
Brian McCrindle (Canada)



Maureen Andrew, 1952-2001

## SCIENTIFIC PROGRAM

Tuesday, June 23, 2015

ABSTRACT SYMPOSIA 16:45-18:00

Von Willebrand factor

Room 801

*Moderators: Laura Swystun (Canada), Jorge di Paola (United States)*

- 16:45-17:05  
AS061 **THE MULTIPLE ROLES OF VON WILLEBRAND FACTOR: REGULATION OF ANGIOGENESIS**  
Anna Randi (United Kingdom)
- 17:05 - 17:19  
AS062 **VON WILLEBRAND FACTOR IS INDISPENSABLE FOR VENOUS HEMOSTASIS IN A NOVEL MURINE BLEEDING MODEL**  
Amine Bazaa\*, Vincent Muczynski, Amélie Harel, Tom Knudsen, Cécile V. Denis, Olivier D. Christophe, Peter J. Lenting (France)
- 17:19 - 17:33  
AS063 **THE INTRODUCTION OF A MUCIN INSERT AT THE N-TERMINUS OF VWF-A1, BUT NOT THE C-TERMINUS, ENHANCES PLATELET GPIB $\alpha$  BINDING TO VWF**  
Anju Kelkar, Changjie Zhang\*, Daniel Swartz, Sriram Neelamegham (United States)
- 17:33 - 17:47  
AS064 **HIGH RESOLUTION MICROSCOPIC CHARACTERISATION OF VWF BIOSYNTHESIS, STORAGE AND SECRETION IN TYPE 1 VWD PATIENTS WITH LARGE IN-FRAME VWF DELETIONS**  
Simon J. Webster\*, Ashley Cartwright, Daniel Hampshire, Ian Peake, Anne Goodeve (United Kingdom)
- 17:47 - 18.00  
AS065 **THE RECOGNITION OF COLLAGEN BY THE VWF A DOMAINS**  
Samir W. Hamaia\*, Kirsty Ferguson, Emma Hunter, Dominique Bihan, Richard Farn-dale (United Kingdom)

Platelet signaling

Room 717

*Moderators: Attila Braun (Germany), Wolfgang Bergmeier (United States)*

- 16:45-17:05  
AS066 **TYROSINE PHOSPHATASES IN PLATELET SIGNAL TRANSDUCTION**  
Yotis Senis (United Kingdom)
- 17:05 - 17:19  
AS067 **RUNX1 REGULATES MEGAKARYOCYTIC/PLATELET RAS-RELATED SMALL GTPASE RAB1B: POTENTIAL ROLE IN PLATELET DYSFUNCTION WITH RUNX1 HAPLODEFICIENCY.**  
Gauthami S. Jalagadugula\*, A. Koneti Rao (United States)
- 17:19 - 17:33  
AS068 **TRPM7 KINASE REGULATES ITAM-SIGNALING AND PLAYS A CRITICAL ROLE IN THROMBOSIS AND ISCHEMIC STROKE**  
Attila Braun\*, Wenchun Chen, Carsten Schmitz, Rene Zahedi, Sanjeev Gotru, Peter Kraft, Karen Wolf, Simon Stritt, Heike Hermanns, Masayuki Matsushita, Susanna Zierler, Vladimir Chubanov, Thomas Gudermann, Guido Stoll, Bernhard Nieswandt (Germany)

TUESDAY

SYMPOSIA

## SCIENTIFIC PROGRAM

- 17:33 - 17:47  
AS069 **TYROSINE PHOSPHORYLATION OF THE ITIM-CONTAINING RECEPTOR G6B-B IS ESSENTIAL FOR PLATELET HOMEOSTASIS**  
Mitchell Geer\*, Silke Heising, Louise Tee, Ralph Gareus, Steve Watson, Alexandra Mazharian, Yotis Senis (United Kingdom)
- 17:47 - 18:00  
AS070 **RASA3 IS A CRITICAL INHIBITOR OF PLATELET ACTIVATION AND THE MISSING LINK IN THE P2Y12/RAP1 SIGNALING PATHWAY.**  
Lucia Stefanini\*, David Paul, Raymond Robledo, Todd Getz, Caterina Casari, Raymond Piatt, Yacine Boulaftali, Luanne Peters, Wolfgang Bergmeier (United Kingdom)

### Mechanisms of ITP

Room 705

*Moderators: Rick Kapour (Canada), Barbara Konkle (United States)*

- 16:45-17:05  
AS071 **THE ROLE OF T CELLS IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA**  
John Semple (Canada)
- 17:05 - 17:19  
AS072 **ALTERED PLASMA MICRORNA LEVELS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA**  
Yang He\*, Bin Zuo, Yunxiao Zhao, Qingyu Wu (China)
- 17:19 - 17:33  
AS073 **CD40L AND ITS DNA METHYLATION IN PRIMARY IMMUNE THROMBOCYTOPENIA**  
Huiyuan Li\*, Donglei zhang, Renchi Yang (China)
- 17:33 - 17:47  
AS074 **CYCLOSPORINE ENHANCES IMMUNOSUPPRESSIVE FUNCTIONS OF MYELOID-DERIVED SUPPRESSOR CELLS IN IMMUNE THROMBOCYTOPENIA**  
Yu Hou\*, Miao Xu, Qi Feng, Yingyi Yu, Xuena Liu, Ming Hou, Jun Peng (China)
- 17:47 - 18:00  
AS075 **ELEVATED SEMA5A IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Lyu Mingen\*, Li yang, Hao Yating, Sun Tiantian, Liu wenjie, Iyu Cuicui, Li Huiyuan, Xue Feng, Liu Xiaofan, Zhang Lei, Yang Renchi (China)

### Tools for evaluation of bleeding

Room 716

*Moderators: Flora Peyvandi (Italy), Samantha Gouw (The Netherlands)*

- 16:45-17:15  
AS076 **THE CLINICAL UTILITY OF BLEEDING SCORES**  
Paula James (Canada)
- 17:15 - 17:30  
AS077 **ACCURACY OF THREE CLINICAL PREDICTION TOOLS FOR MAJOR BLEEDING IN PATIENTS ON EXTENDED ORAL ANTICOAGULANT FOR VENOUS THROMBOEMBOLISM**  
Phil Wells\*, Parvaneh Fallah, Michael Kovacs, David Anderson, Susan Kahn, Vinay Shah, Scott Kaatz, Clive Kearon, Susan Solymoss, David Keeling, Russell Zide, Sam Schulman, Isabelle Chagnon, Rosendo Rodriguez, Daniel Corsi, Marc Rodger (Canada)

## SCIENTIFIC PROGRAM

- 17:30 - 17:45  
AS078 **UTILITY OF BLEEDING SCORES AND A STANDARDIZED LABORATORY EVALUATION IN IDENTIFYING DEFECTS IN PRIMARY HEMOSTASIS IN CHILDREN REFERRED TO A TERTIARY-CARE PEDIATRIC CENTRE**  
Veerle Labarque\*, Victor Blanchette, Dewi Clark, Ann Marie Stain, Cindy Wakefield, Vanessa Bouskill, William Brien, Leonardo Brandao, Walter Kahr, Manuel Carcao, Margaret Rand (Belgium)
- 17:45 - 18:00  
AS079 **ASSESSING BLEEDING PHENOTYPE IN CHILDREN WITH MODERATE OR SEVERE VON WILLEBRAND DISEASE USING THE ISTH-BAT AND THE RELEVANCE OF PEDIATRIC-SPECIFIC BLEEDING SYMPTOMS**  
Yvonne Sanders, Karin Fijnvandraat, Johan Boender\*, Evelien Mauser-Bunschoten, Johanna van der Bom, Joke de Meris, Frans Smiers, Bernd Granzen, Paul Brons, Rienk Tamminga, Marjon Cnossen, Frank Leebeek (The Netherlands)

### Vascular progenitor cells and vascular disease

Room 707

*Moderators: David Smadja (France), Joyce Bischoff (United States)*

- 16:45-17:15  
AS085 **ENDOTHELIAL PROGENITORS CELLS: FROM PATHOPHYSIOLOGY TO EMERGENT THERAPY OF VASCULAR DISORDERS**  
Françoise Dignat-George (France)
- 17:15 - 17:30  
AS086 **CD34+ HEMATOPOIETIC STEM CELL COUNT IS PREDICTIVE FOR VASCULAR EVENT OCCURRENCE IN SICKLE CELL DISEASE CHILDREN**  
Manoelle Kossorotoff, Marianne de Montalembert, Dominique Lasne, Valentine Brousse, Emmanuel Curis, David Smadja, Romaric Lacroix, Sebastien Bertil, Isabelle Desguerre, Damien Bonnet, Pascale Gaussem\* (France)
- 17:30 - 17:45  
AS087 **TREPROSTINIL INDIRECTLY REGULATES ENDOTHELIAL COLONY FORMING CELL ANGIOGENIC PROPERTIES BY INCREASING VEGF-A PRODUCED BY MESENCHYMAL STEM CELLS**  
David Smadja\*, Marilyn Levy, Lan Huang, Elisa rossi, Dominique Israel-Biet, Pascale Gaussem, Joyce Bischoff (France)
- 17:45 - 18:00  
AS088 **INDUCED PLURIPOTENT STEM CELL- (IPSC) BASED STRATEGY TO CORRECT THE BLEEDING PHENOTYPE IN HEMOPHILIA A**  
Maria Talmon\*, Cristina Olgasi, Simone Merlin, Gabriella Ranaldo, Angelo Lombardo, Donato Colangelo, Giovanni Berta, Luigi Naldini, Angel Raya, Federica Valeri, Piercarla Schinco, Maria Messina, Antonia Follenzi (Italy)

### Vessel wall in health and disease, annexins

Room 714

*Moderators: Colin Kretz (Canada), Robert Flaumenhaft (United States)*

- 16:45-17:15  
AS089 **ANNEXIN A2 IN HEALTH AND DISEASE**  
Katherine Hajjar (United States)
- 17:15 - 17:30  
AS090 **THE ENDOTHELIAL CELL TRANSCRIPTOME IS HIGHLY HETEROGENEOUS ACROSS DIFFERENT VASCULAR BEDS**  
Audrey Cleuren\*, Hui Jiang, Kristina Hunker, Andrew Yee, Santhi Ganesh, David Ginsburg (United States)

## SCIENTIFIC PROGRAM

17:30 – 17:45  
AS091 **A CLASS OF BIASED PAR1 AGONISTS THAT STIMULATE CYTOPROTECTIVE SIGNALING IN ENDOTHELIAL CELLS**  
Omozuanbo R. Aisiku\*, Christian Peters, Karen De Ceunyk, Jennifer Fitch-Tewfik, James Dilks, Susanna Fustulo-Gunnink, Christopher Dockendorff, Robert Flaumenhaft (United States)

17:45 – 18:00  
AS092 **PODOPLANIN AND CLEC-2 DRIVE CEREBROVASCULAR PATTERNING AND INTEGRITY DURING DEVELOPMENT**  
Kate Lowe\*, Brenda Finney, René Hägerling, Carsten Deppermann, Jon Frampton, Bernhard Nieswandt, Christopher Buckley, Friedemann Kiefer, Steve Watson (United Kingdom)

### ■ Cancer and thrombosis – basic

Plenary Hall F&G

*Moderators: Esterina d'Asti (Canada), Gary Lyman (United States)*

16:45-17:15  
AS093 **THROMBOSIS, INFLAMMATION AND CANCER**  
Tatiana V. Byzova (United States)

17:15 – 17:30  
AS094 **GPV IS A CENTRAL REGULATOR OF HEMOSTASIS, THROMBOSIS AND THROMBO-INFLAMMATORY BRAIN INFARCTION IN MICE**  
Sarah Schiebl\*, David Stegner, Ina Hagedorn, Peter Kraft, Ina Thielmann, Guido Stoll, Bernhard Nieswandt (Germany)

17:30 – 17:45  
AS095 **PLATELET INTEGRIN ALPHA 6 BETA 1 PROMOTES METASTATIC DISSEMINATION**  
Elmina Mammadova-Bach\*, Monique Freund, Dominique Bagnard, Christian Gachet, Pierre Mangin (France)

17:45 – 18:00  
AS096 **PEPTIDES INHIBITING HEPARANASE PROCOAGULANT ACTIVITY SIGNIFICANTLY REDUCE TUMOR GROWTH AND VASCULARIZATION IN A MOUSE MODEL**  
Yonatan Crispel, Elena Axelman, Mifleh Tatour, Inna Kogan, Yona Nadir\* (Israel)

### ▲ Non-vitamin K antagonist oral anticoagulants

Room 718

*Moderators: Mark Crowther (Canada), Paul Harper (New Zealand)*

16:45-17:05  
AS097 **NOACs IN VENOUS THROMBOEMBOLISM STRENGTHS AND CAVEATS**  
Sam Schulman (Canada)

17:05 - 17:19  
AS098 **REAL LIFE EFFICACY AND SAFETY OF APIXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION – RESULTS OF THE PROSPECTIVE NOAC REGISTRY (NCT01588119)**  
Jan Beyer-Westendorf\*, Sebastian Werth, Luise Tittl, Franziska Michalski, Sandra Marten, Norbert Weiss (Germany)

17:19 - 17:33  
AS099 **FIXED-DOSE RIVAROXABAN IS NOT ASSOCIATED WITH INCREASED RECURRENT VENOUS THROMBOEMBOLISM OR MAJOR BLEEDING IN PATIENTS WITH A HIGH OR LOW BODY WEIGHT**  
Martin H. Prins\*, Marcello Di Nisio, Maria Cristina Vedovati, Antoni Riera-Mestre, Katharina Mueller, Alexander Cohen, Philip Wells, Jan Beyer-Westendorf, Timothy Brighton, Henri Bounameaux, Jonas Schneider, Anthonie Lensing (The Netherlands)

## SCIENTIFIC PROGRAM

17:33 - 17:47  
AS100 **DABIGATRAN PERSISTENCE AND ADHERENCE IN NEW ZEALAND**  
Paul L. Harper\*, Su Chen Fong, Laura Chen (New Zealand)

17:47 - 18:00  
AS101 **INCREASED RISK OF THROMBOTIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION SHORTLY AFTER DABIGATRAN OR RIVAROXABAN DISCONTINUATION**  
Nina Vene, Alenka Mavri, Mirjam Gubensek, Gregor Tratar, Tjasa Vizintin Cuderman, Maja Pohar Perme, Ales Blinc\* (Slovenia)

### ★ Developmental hemostasis

Room 709

*Moderators: Paul Monagle (Australia), Aisha Bruce (Canada)*

16:45-17:15  
AS102 **DEVELOPMENTAL HEMOSTASIS: CONSEQUENCES FOR CLINICAL PRACTICE**  
Heleen van Ommen (The Netherlands)

17:15 – 17:30  
AS103 **REDUCED DOSING OF ENOXAPARIN TO TREAT DEEP VEIN THROMBOSIS (DVT) OR PULMONARY EMBOLI (PE) IN OVERWEIGHT AND OBESE PEDIATRIC PATIENTS**  
Stephanie Hoffman, Chi L. Braunreiter\* (United States)

17:30 – 17:45  
AS104 **DEVELOPMENT OF A RIVAROXABAN DOSING REGIMEN FOR TREATMENT OF VTE IN CHILDREN AGED 12 TO 18 YEARS**  
Guy Young\*, Dagmar Kubitzka, Anthony Chan, Gili Kenet, Christoph Male, Patti Massicotte, Angelo Claudio Molinari, Paul Monagle, Ulrike Nowak-Goettl, Rolf Burghaus, Jan Stampfuss, Anthonie Lensing (United States)

17:45 – 18:00  
AS105 **DEVELOPMENTAL DIFFERENCES IN FIBRIN CLOT FORMATION UNDER VENOUS AND ARTERIAL LAMINAR FLOW**  
Hilde Kelchtermans\*, Leonie Pelkmans, Paul Monagle, Bas deLaat, Vera Ignjatovic (Australia)

### ● Alloimmune and autoimmune platelet disorders

Room 715

*Moderators: Ted Warkentin (Canada), Cindy Neunert (United States)*

16:45-17:05  
AS106 **UPDATE ON CURRENT ATTEMPTS TO PREVENT NEONATAL ALLOIMMUNE THROMBOCYTOPENIA**  
Tamam Bakchoul (Germany)

17:05 - 17:19  
AS107 **IMPACT OF PLATELET ACTIVATION DETECTED BY THE WASHED PLATELET ACTIVATION ASSAY ON THROMBOTIC OUTCOMES IN PATIENTS CLINICALLY SUSPECTED OF HAVING HEPARIN-INDUCED THROMBOCYTOPENIA.**  
Takuma Maeda\*, Yoshiaki Kanaumi, Shiori Kawamura, Shu Seguchi, Mayumi Kodama, Takeshi Kawai, Toshimitsu Hamasaki, Hitoshi Okazaki, Shigeki Miyata (Japan)

17:19 - 17:33  
AS108 **DEVELOPMENT AND CHARACTERIZATION OF 5B9, A POTENTIAL INTERNATIONAL STANDARD FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA**  
Jérôme Rollin\*, Claire Pouplard, Claire Kizlik-Masson, Gaël Champier, Steven McKenzie, Yves Gruel (France)

## SCIENTIFIC PROGRAM

- 17:33 - 17:47  
AS109 **DIFFERENT DOSAGES OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN TREATING ADULT IMMUNE THROMBOCYTOPENIA WITH LONG-TERM FOLLOW-UP OF THREE YEARS: RESULTS OF A CASE-CONTROL STUDY INCLUDING 91 CASES.**  
Zeping Zhou\*, Zhuoqing Qiao, Huiyuan Li, Xian Zhang, Feng Xue, Renchi Yang (China)
- 17:47 - 18:00  
AS110 **HIGHER OR LOWER DOSE CORTICOSTEROIDS FOR PRIMARY IMMUNE THROMBOCYTOPENIA: SYSTEMATIC REVIEW AND META-ANALYSIS**  
Siraj Mithoowani\*, Kathleen Gregory-Miller, Jennifer Goy, Matthew Miller, Nastaran Noroozi, Donald Arnold (Canada)

### Hemostasis and infection

Room 713

*Moderators: Ed Pryzdial (Canada), Travis Gould (Canada)*

- 16:45-17:15  
AS111 **HEMOSTASIS-PATHOGEN INTERPLAY: THE VIRUS ENVELOPE**  
Ed Pryzdial (Canada)
- 17:15 - 17:30  
AS112 **MUTATIONS IN THE CONTROL OF VIRULENCE SENSOR GENE FROM STREPTOCOCCUS PYOGENES AFTER INFECTION IN MICE LEAD TO CLONAL BACTERIAL VARIANTS WITH INCREASED VIRULENCE**  
Jeff Mayfield\*, Zhong Liang, Victoria Ploplis, Francis Castellino (United States)
- 17:30 - 17:45  
AS113 **SECRETED STAPHYLOCOCCAL VON WILLEBRAND FACTOR-BINDING PROTEIN BINDS TO A SORTASE A-DEPENDENT FACTOR TO ENABLE S. AUREUS BINDING TO VON WILLEBRAND FACTOR**  
Jorien Claes\*, Thomas Vanassche, Marijke Peetermans, Laurens Liesenborghs, Dominique Missiakas, Olaf Schneewind, Ruth Heying, Marc Hoylaerts, Peter Verhamme (Belgium)
- 17:45 - 18:00  
AS114 **MINIMAL TISSUE FACTOR EXPRESSION REDUCES BLOOD BRAIN BARRIER PERMEABILITY AND SUSCEPTIBILITY TO NEUROLOGICAL SYMPTOMS IN EXPERIMENTAL CEREBRAL MALARIA**  
Tara Bracken\*, Catherine Smith, Caitlin Cooper, Demba Sarr, Julie Moore (United States)

### ♥ Endothelial cell wall and signaling

Room 711

*Moderators: Maxime Gauberti (France), Bill Aird (United States)*

- 16:45-17:15  
AS115 **ENGINEERING THE VASCULATURE**  
Ying Zheng (United States)
- 17:15 - 17:30  
AS116 **INHIBITION OF RHOA-RHO KINASE PATHWAY ATTENUATES COCAINE-INDUCED MICROVASCULAR ENDOTHELIAL CELL DYSFUNCTION: STUDIES UNDER STATIC AND SHEAR FLOW CONDITIONS**  
Jaime Pereira\*, Claudia Sáez, Karla Pereira-Flores, Alberto Leguina, Eduardo Fuentes, Marcelo Alarcón, Iván Palomo, Diego Mezzano (Chile)

## SCIENTIFIC PROGRAM

- 17:30 - 17:45  
AS117 **MAPPING ENDOTHELIAL CELL ACTIVATION IN THE CARDIOVASCULAR TARGET ORGANS USING ULTRA-SENSITIVE MOLECULAR MAGNETIC RESONANCE IMAGING**  
Maxime Gauberti\*, Julie Bellière, Sara Martinez de Lizarrondo, Denis Vivien (France)
- 17:45 - 18:00  
AS118 **REGULATION OF STIMULATED AND BASAL RELEASE OF WEIBEL-PALADE BODIES BY SYNTAXIN-3 CONTAINING SNARE-COMPLEXES.**  
Maaik Schillemans\*, Dorothee van Breevoort, Maryam Wahedi, Stephan Huvenneers, Maartje van den Biggelaar, Jan Voorberg, Ruben Bierings (The Netherlands)

### Inhibitors - basic

Room 701

*Moderators: Steven Pipe (United States), Paul Monahan (United States)*

- 16:45-17:15  
AS190 **THE IMMUNOGENICITY OF FACTOR VIII**  
Shannon Meeks (United States)
- 17:15 - 17:30  
AS191 **CHEMOTACTIC ANTIGEN COMPETITION DECREASES THE INCIDENCE OF FACTOR VIII INHIBITORS IN HEMOPHILIA A MICE IMMUNIZED WITH INFLUENZA, WITH AND WITHOUT THE ADJUVANT MF59C.1.**  
Jesse Lai\*, Paul Moorehead, Kate Sponagle, Katharina Steinitz, Birgit Reipert, Christine Hough, David Lillicrap (Canada)
- 17:30 - 17:45  
AS192 **FACTOR VIII TOLERANCE INDUCTION IN HAEMOPHILIA A MICE VIA TRANSPLACENTAL TRANSFER OF RECOMBINANT FACTOR VIII FC**  
Maria Georgescu\*, Tongyao Liu, Kate Sponagle, Cassandra Hebert, Douglas Drager, Susannah Patarroyo-White, Christine Hough, Haiyan Jiang, David Lillicrap (Canada)
- 17:45 - 18:00  
AS193 **CAN A "CENTER EFFECT" BE THE REASON FOR THE HIGHER FREQUENCY INHIBITORS FOR A SECOND GENERATION RECOMBINANT FACTOR VIII PRODUCT?**  
H.Marijke Van den Berg\*, Rolf Ljung (The Netherlands)

### Poster with refreshments

From 18:00 - 19:30 in the Exhibition on Level 800

TUESDAY

SYMPOSIA

# SCIENTIFIC PROGRAM

Tuesday, June 23, 2015

POSTER SESSION 17:15-18:15

Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:

**Monday, June 22, 2015, from 17.15-18.30**  
**Tuesday, June 23, 2015, from 18.00-19.30**  
**Wednesday, June 24, 2015, from 17.15-18.30**

The Poster Area is located inside the Exhibition on Level 800.

Poster setup times are as follows:

**Monday, June 22, 2015, from 07.30 - 09.15**  
**Tuesday, June 23, 2015, from 07.30 - 09.15**  
**Wednesday, June 24, 2015, from 07.30 - 09.15**

Poster dismantling times are as follows:

**Monday, June 22, 2015, from 18.30 - 19.00**  
**Tuesday, June 23, 2015, from 19.30 - 20.00**  
**Wednesday, June 24, 2015, from 18.30 - 19.00**

Posters not taken down after the dismantling time will be discarded.

If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:

**Monday, June 22, 2015, from 07.30 - 19.00**  
**Tuesday, June 23, 2015, from 19.30 - 20.00**  
**Wednesday, June 24, 2015, from 18.30 - 19.00**

Pins are provided on the poster boards directly

## Animal models II

**PO001-TUE POLYPHOSPHATE AS A NOVEL THERAPEUTIC FOR AGE-RELATED MACULAR DEGENERATION**

Linnette M. Ocariza\*, Alice O'Byrne, Stephanie Smith, James Morrissey, Jing Cui, Joanne Matsubara, Edward Conway (Canada)

**PO002-TUE ANTI-OXIDANT TREATMENT IMPROVES CARDIAC DYSFUNCTION IN BMAL1 DEFICIENT MICE**

Bianca Hemmeryckx\*, Philipp Hohensinner, Melissa Swinnen, Ward Heggmont, Johann Wojta, Henri Lijnen (Belgium)

**PO003-TUE NOVEL MOUSE HEMOSTASIS MODEL FOR REAL-TIME DETERMINATION OF BLEEDING TIME AND HEMOSTATIC PLUG COMPOSITION.**

Raymond Piatt\*, Todd Getz, Wolfgang Bergmeier (United States)

**PO004-TUE TARGETING EXTRACELLULAR CYCLOPHILIN A-MEDIATED NEUROVASCULAR DYSFUNCTION**

Georgette Suidan\*, Marissa Ilardi, Andrew Cameron, Natasha Kablaoui, Kari Fonseca, Robert Bell (United States)

# SCIENTIFIC PROGRAM

**PO005-TUE MODIFICATION OF THE BDNF GENE THAT INDUCES DEPRESSION-LIKE STATES IS ASSOCIATED TO PRO-INFLAMMATORY AND PRO-THROMBOTIC PHENOTYPE IN MICE.**

Silvia S. Barbieri\*, Patrizia Amadio, Sara Gianellini, Eva Tarantino, Alessandro Ieraci, Maura Briocchi, Cristina Banfi, Francis Lee, Elena Tremoli (Italy)

**PO006-TUE FAMILIAL FELINE HYPERTROPHIC CARDIOMYOPATHY: A MODEL FOR EVALUATING PLATELET ACTIVATION AND CLOPIDOGREL THERAPY**

Ronald Li\*, Joshua Stern, Fern Tablin (United States)

**PO007-TUE PLATELET EFFECTS OF EPISODIC OZONE AND PM EXPOSURE DURING POSTNATAL DEVELOPMENT**

Fern Tablin\*, Monica Pombo (United States)

**PO008-TUE EVALUATION OF FACTOR XIA PHARMACOKINETICS IN MICE WITH A THROMBIN GENERATION ASSAY**

Yideng Liang, Evi Struble, William Chang, Dorothy Scott, Mikhail Ovanesov\* (United States)

## Antiplatelets agents II

**PO009-TUE RESISTANCE TO ANTI-PLATELET AGENTS IN PATIENTS WITH ISCHEMIC STROKE**

Anil Pathare\*, Karima Al Falahi, Arun Gujjar, Badriya Al-Belushi, Nandagopal R, Jacob PC, Abdullah Al Asmi (Oman)

**PO010-TUE MECHANISM OF ANTIPLATELET ACTION INDUCED BY GUANOSINE VIA INCREASE IN CAMP LEVELS AND ITS ANTITHROMBOTIC ACTIVITY**

Eduardo Fuentes\*, Marcelo Alarcon, Julio Caballero, Iván Palomo (Chile)

**PO011-TUE IMPACT OF NON-INHIBITED PLATELET SUPPLEMENTATION ON PLATELET REACTIVITY IN PATIENTS TREATED WITH PRASUGREL OR TICAGRELOR FOR AN ACUTE CORONARY SYNDROME: AN EX-VIVO STUDY**

Fanny Bonhomme, Robert Bonvini, Jean-Luc Reny, Antoine Poncet, Pierre Fontana\* (Switzerland)

**PO012-TUE THE EFFECTS OF TWO COMMONLY USED HERBAL PRODUCTS ON HAEMOSTATIC SYSTEM AND THEIR INTERACTIONS WITH ASPIRIN**

Wan Hui Wong\*, Seng Kok Ang, Foon Yin Fung, Hwee Ling Koh, Mei Ching Kun, Lai Heng Lee, Xiaomei Li, Heng Joo Ng, Chuen Wen Tan, Yan Zhao, Yeh Ching Linn (Singapore)

**PO013-TUE EFFICACY OF PLATELET INHIBITION WITH PRASUGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING THERAPEUTIC HYPOTHERMIA AFTER CARDIOPULMONARY RESUSCITATION**

Andreas Schäfer\*, Ulrike Flierl, Johann Bauersachs (Germany)

**PO014-TUE ANTIBODY TARGETED, THROMBIN-SENSITIVE POLYMER CAPSULES FOR UROKINASE DELIVERY**

Sylvia Gunawan, Kristian Kempe, Thomas Bonnard, Jiwei Cui, Karen Alt, Xiaowei Wang, Lok Law, Georgina Such, Karlheinz Peter, Frank Caruso, Christoph E. Hagemeyer\* (Australia)

## SCIENTIFIC PROGRAM

- PO015-TUE **PLATELET TRANSFUSION MIGHT BE A POTENT ANTIDOTE FOR THIENOPYRIDINES, BUT NOT FOR TICAGRELOR**  
Anne Bertling\*, Kira Mergemeier, Georg Georg Geissler, Walter Sibrowski, Reinhard Kelsch, Johannes Waltenberger, Joseph Jakubowski, Beate Kehrel (Germany)
- PO016-TUE **TICAGRELOR REVERSAL: IN VITRO ASSESSMENT OF VARIOUS HEMOSTATIC AGENTS**  
Leyla Calmette, Anne-Céline Martin, Bernard Le Bonniec, Isabelle Gouin-Thibault, Christilla Bachelot-Loza, Pascale Gaussem, Anne Godier\* (France)
- PO017-TUE **TWO DISINTEGRINS, TFV-1 AND TFV-3, PURIFIED FROM TRIMERESURUS FLAVOIRIDIS SNAKE VENOM, EXHIBIT DISTINCT EFFECTS ON PLATELET ACTIVATION**  
Tzu Yu Pan\*, Chun-Chieh Hsu, Tur-Fu Huang (Taiwan)
- PO018-TUE **PLATELET INHIBITION MONITORING WITH THROMBOELASTOGRAPHY (TEG) PLATELET MAPPING IN PEDIATRIC PATIENTS WITH VENTRICULAR ASSIST DEVICE**  
Tiphaine Belleville, Chiara Giorni, Christilla Bachelot-Loza, Philippe Pouard, Tiffany Pascreau, Vanessa Lopez, Camilla Biselli, Claudio Barbanti, Delphine Borgel, Dominique Lasne\* (France)
- PO019-TUE **THE PROGNOSTIC UTILITY OF PLATELET FUNCTION TESTING FOR THE DETECTION OF 'ASPIRIN RESISTANCE' IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE**  
Marie Lordkipanidze\*, Janine Dretzke, Richard Riley, Sue Jowett, Jennifer O'Donnell, Joie Ensor, Eoin Moloney, Malcolm Price, Smriti Raichand, James Hodgkinson, Sue Bayliss, David Moore, David Fitzmaurice (Canada)
- PO020-TUE **A TIME COURSE STUDY OF HIGH ON TREATMENT PLATELET REACTIVITY IN ACS PATIENTS ON DUAL ANTIPLATELET THERAPY**  
Alessia Fabbri, Rossella Marcucci, Anna Maria Gori\*, Betti Giusti, Rita Paniccia, Daniela Balzi, Alessandro Barchielli, Serafina Valente, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini (Italy)
- PO021-TUE **INHIBITION OF PLATELET AGGREGATION BY GLS-409, AN ANTAGONIST OF BOTH P2Y1 AND P2Y12, IS DISTINCT FROM INHIBITION BY SELECTIVE P2Y1 AND P2Y12 ANTAGONISTS**  
Thomas Gremmel\*, Ivan Yanachkov, George Wright, Alan Michelson, Andrew Frelinger (Austria, United States)
- PO022-TUE **P2Y12 IS NOT INVOLVED IN THE INITIATION AND STABILIZATION OF MURAL THROMBI AFTER LASER INJURY OF AN ARTERY.**  
Roxane Darbousset\*, Eva Caroff, Francis Hubler, Markus Riederer, Laurence Panicot-Dubois, Christophe Dubois (France)
- PO023-TUE **SAFETY OF RIVAROXABAN: EFFECTS ON PLATELET FUNCTION**  
Jesus Hernandez\*, Hugo Espejo, Manuel Moreno, Jose Hernandez, Irma Isordia, Abraham Majluf (Mexico)
- PO024-TUE **THE START-ANTIPLATELETS REGISTER: A MULTICENTER OBSERVATIONAL PROSPECTIVE STUDY TO ASSESS THE RISK-BENEFITS OF ANTI-THROMBOTIC THERAPY IN ACS PATIENTS.**  
Rossella Marcucci, Vittorio Pengo\*, Giuseppe Patti, Paolo Gesele, Emilia Antonucci, Serafina Valente, Alessia Bracco, Tiziana Fierro, Ilaria Cavallari, Gian Franco Gensini, Gualtiero Palareti (Italy)

## SCIENTIFIC PROGRAM

### Arterial vascular disorders - clinical II

- PO025-TUE **ASSOCIATION OF THE MEAN PLATELET VOLUME (MPV) WITH THE DIAGNOSIS OF ACUTE CORONARY SYNDROMES (ACS) AMONG PATIENTS WHO PRESENT WITH CHEST PAIN AT THE EMERGENCY ROOM (ER)**  
Al-Zamzam Abubakar\* (Philippines)
- PO026-TUE **RESIDUAL PLATELET FUNCTION IN ACS PATIENTS TREATED WITH PRA-SUGREL IS LOWER THAN IN PATIENTS TREATED WITH CLOPIDOGREL BUT NOT IN PATIENTS WITH HYPERTENSION**  
Phakwan Laohathai\*, Rashi Joshi, Ashwin Radhakrishnan, Jane May, Natalia Dvlatova, Stan Heptinstall, Sue Fox (Thailand, United Kingdom)
- PO027-TUE **PREDICTORS OF NEW ONSET ATRIAL FIBRILLATION AFTER MYOCARDIAL INFARCTION**  
Serenella Conti\*, Maria Cristina Vedovati, Roberta Molle, Giorgio Maragoni (Italy)
- PO028-TUE **EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON THE RISK OF MORTALITY, THROMBOSIS AND BLEEDING IN PATIENTS WITH SECONDARY HYPERALDOSTERONISM: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS**  
Laura Elbers\*, Barbara Sjouke, Victor Gerdes, Alessandro Squizzato (The Netherlands)
- PO029-TUE **URINARY 11-DEHYDRO-THROMBOXANE B2 IS ASSOCIATED WITH CARDIOVASCULAR EVENTS AND MORTALITY IN ATRIAL FIBRILLATION PATIENTS.**  
Pasquale Pignatelli\*, Daniele Pastori, William Hiatt, Gregory Lip, Francesco Violi (Italy)
- PO030-TUE **ASSOCIATION BETWEEN CIRCULATING PROTEINS AND CORRESPONDING GENES EXPRESSED IN CORONARY THROMBI IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION**  
Ragnhild Helseth\*, Thomas Weiss, Trine Opstad, Svein Solheim, Matthias Freynhofer, Kurt Huber, Harald Arnesen, Ingebjørg Seljeflot (Norway)
- PO031-TUE **VASCULAR SMOOTH MUSCLE CELLS ARE RESPONSIBLE FOR A PRO-THROMBOTIC PHENOTYPE OF SPONTANEOUSLY HYPERTENSIVE RAT ARTERIES**  
Amel Mohamadi\*, Karima Ait Aissa, Jérémy Lagrange, Huguette Louis, Bénédicte Houppert, Pascal Challande, Denis Wahl, Patrick Lacolley, Véronique Regnault (France)
- PO032-TUE **PLATELET ERK5 REGULATES THROMBOSIS AND MYOCARDIAL INFARCT EXTENSION VIA MATRIX METALLOPROTEINASES**  
Scott J. Cameron\*, Sara Ture, Kristina Modjeski, Deanne Mickelsen, Enakshi Chakrabarti, David Field, Jun-ichi Abe, Craig Morrell (United States)
- PO033-TUE **ELEVATED ARTERIAL STIFFNESS AND THROMBIN GENERATION IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING HEMODIALYSIS**  
Lucie Tran, Tomas Serrato, Yvonnick Bezie, Sylvain Marchais, Patrick Lacolley, Bruno Pannier, Véronique Regnault\* (France)

## SCIENTIFIC PROGRAM

PO034-TUE **THROMBOGENIC STATE AFTER VASCULAR SURGERY AND PERIOPERATIVE CARDIOVASCULAR EVENTS**

Daniela Calderaro\*, Tania Rubia Rocha, Adriana Pastana, Fernanda Justo, Danielle Gualandro, Pai Yu, Mariana Matheus, Elbio D'Amico, Bruno Caramelli (Brazil)

PO035-TUE **CLINICAL FEATURES OF VASCULAR EVENTS IN PATIENTS WITH AL AMYLOIDOSIS**

Hyunkyung Park\*, Ji-Won Kim, Youngil Koh, Jeong-Ok Lee, Ki Hwan Kim, Soo-Mee Bang, Inho Kim, Junglim Lee, Sung-Soo Yoon, Jeong-Wook Seo, Dae-Won Sohn, Seonyang Park (Korea, Republic Of)

### Atherosclerosis II

PO036-TUE **SIMULTANEOUS OBSERVATION OF PERIPHERAL MONONUCLEAR CELL AND PLASMA TF'S EXPRESSION FOR PREVENTION AND TREATMENT OF ISCHEMIC CARDIOCEREBROVASCULAR DISEASES**

Rui Wang\*, Tong Ma (China)

PO037-TUE **TOTAL CHEMICAL SYNTHESIS OF COVALENT RANTES-PF4 HETERODIMERS TO STUDY INITIATION AND PROGRESSION OF ATHEROSCLEROSIS**

Stijn Agten, Dennis Suylen\*, Hans Ippel, Kevin Mayo, Rory Koenen, Christian Weber, Tilman Hackeng (The Netherlands)

PO038-TUE **ENDOTHELIAL DELETION OF THIOREDOXIN-INTERACTING PROTEIN PRESERVES MOUSE ARTERIES FROM AGING INDUCED BY METABOLIC DISORDERS**

Tatiana Bedarida, Elise Dreano\*, Françoise Vibert, Charles-Henry Cottart, Christilla Bachelot-Loza, Pascale Gaussem, Stephanie Baron, Valerie Nivet-Antoine (France)

PO039-TUE **HIGH LIPOPROTEIN(A) LEVELS ARE ASSOCIATED WITH CORONARY CALCIUM SCORE IN THE MONTIGNOSO STUDY POPULATION**

Alice Sereni, Anna Maria Gori\*, Rossella Marcucci, Betti Giusti, Francesco Sofi, Dante Chiappino, Daniele Della Latta, Rosanna Abbate, Gian Franco Gensini (Italy)

PO040-TUE **ASSOCIATION OF GAMMA-GLUTAMYL TRANSFERASE TO THE PREMATURE CORONARY ARTERY DISEASE IN YOUNG ASIAN INDIANS**

Madankumar Ghatge\*, Ankit Sharma, Rajani kanth Vangala (India)

PO041-TUE **CORONARY ARTERY DISEASE SEVERITY IS A MARKER OF THE ANTI-INFLAMMATORY RESPONSE TO STATIN THERAPY**

Rahil Rafeedheen, Kevin Bliden, Anand Singla, Martin Gesheff, Shachi Pandya, Rohit Gosain, Udaya Tantry, Paul A. Gurbel\* (United States)

PO042-TUE **EFFECTS OF 12 MONTHS EXERCISE INTERVENTION ON ADIPOSE TISSUE EXPRESSION OF CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES AND STABLE CORONARY ARTERY DISEASE: A SUBSTUDY OF A RANDOMIZED CONTROLLED TRIAL (RCT).**

Ida Unhammer Njerve\*, Rune Byrkjeland, Harald Arnesen, Sissel Åkra, Svein Solheim, Ingebjørg Seljeflot (Norway)

## SCIENTIFIC PROGRAM

PO043-TUE **ATHEROSCLEROTIC CARDIOVASCULAR MORTALITY IN GOUTY ARTHRITIS AND RHEUMATOID ARTHRITIS: IS IT ASSOCIATED WITH MEAN PLATELET VOLUME AND NEUTROPHIL/LYMPHOCYTE RATIO**

Gulsum Pamuk\*, Muhammet Maden, Mehmet Uyanik, Omer PAMUK (Turkey)

### Blood coagulation tests II

PO044-TUE **EVALUATION OF THE LABORATORY METHOD IN PREGNANT WOMEN WITH COMPLICATED OBSTETRIC HISTORY FOR HAEMOSTASIS MONITORING**

Nadezda Vorobyeva\*, Yulia Pavlovskaia (Russian Federation)

PO045-TUE **EFFECTS OF LOW AND HIGH LEVELS OF NON VKA ORAL ANTICOAGULANTS ON A COMPREHENSIVE PANEL OF ROUTINE AND SPECIALTY COAGULATION TESTS**

Séverine Perroche, Nathalie Barat, François Depasse\*, François Nicham, Anne Magdelaine, David Courtois, Tristan Hervé, Jérôme Beltran (France)

PO046-TUE **FVIII SENSITIVE AUTOMATED THROMBIN GENERATION TEST OF CANINE PLASMA**

Daniel Elenius Madsen\*, Timothy Nichols, Emily Waters, Pernille Holm, Elizabeth Merricks, Alisa Wolberg, Bo Wiinberg (Denmark)

PO047-TUE **DIFFERENT CENTRIFUGATION CONDITIONS DO NOT INTERFERE WITH D-DIMER RESULTS**

Carlos Aguilar\*, Sylvaine Savigny (Spain)

PO048-TUE **THROMBIN GENERATION IN THE NORMAL POPULATION – FLATTENED THROMBIN GENERATION CURVES ASSOCIATED WITH POOR LIPID PROFILE AND MALE SEX.**

Prahlad Ho\*, Carole Smith, Joseph Rigano, Geoffrey Donnan (Australia)

PO049-TUE **THE RIVAROXABAN-CALIBRATED ANTI-FXA ASSAY CAN RELIABLY IDENTIFY PRESENCE OF RIVAROXABAN IN PLASMA**

Jerzy Windyga\*, Beata Baran, Mirosław Lis, Edyta Odnoczek, Ewa Stefanska-Windyga (Poland)

PO050-TUE **A FULLY AUTOMATED AID FOR THE IMPROVEMENT OF HIL INTERFERENCE MANAGEMENT IN THE HEMOSTASIS LABORATORY: TEST ASSAY-SPECIFIC FLAGGING OF LABORATORY RESULTS FOR HEMOLYSIS, ICTERUS AND LIPEMIA/TURBIDITY**

Janos Polgar\*, Hui-Feng Lin, Jack Havelick, Mary Doyle, Mark Triscott (United States)

PO051-TUE **HANDLING OF THE HEMOCLOT THROMBIN INHIBITOR ASSAY REAGENTS ON SYSMEX CS-2100I WHEN MONITORING DABIGATRAN IN ACUTE CLINICAL SITUATIONS**

Louise Faaborg\*, Willemijn Comuth, Anna-Marie Bloch-Münster, Linda Henriksen, Steen Husted (Denmark)

PO052-TUE **TIME IN THERAPEUTIC RANGE AND COMPLICATIONS OF ANTITHROMBOTIC TREATMENT**

Milena Scekic\* (Serbia)



## SCIENTIFIC PROGRAM

- PO053-TUE **USEFULNESS OF DILUTE RUSSELL'S VIPER VENOM CLOTTING TIME (DRVVT) FOR THE ROUTINE MONITORING OF NEW ORAL ANTICOAGULANTS**  
Debra Hoppensteadt\*, Jake Kola, Mark Brayne, Omer Iqbal, Jawed Fareed (United States)
- PO054-TUE **PERFORMANCE OF HEMOSIL DIRECT THROMBIN INHIBITOR (DTI) ASSAY ON THE ACL TOP FAMILY INSTRUMENTS**  
Judith Hammelburger\*, Zhenghua Cao, Ralph Bottenus, Mark Triscott (United States)
- PO055-TUE **IN VITRO CORRECTION OF IMPAIRED BLOOD COAGULATION IN A MODEL OF SEVERE THROMBOCYTOPENIA BY FIBRINOGEN AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE**  
Boris Shenkman\* (Israel)
- PO056-TUE **NEW IMMUNODEPLETED PLASMA FOR DETERMINATION OF FACTOR XI ACTIVITY**  
Vicente Cortina\*, Carmen Altisent, Anna Castro, Rafael Parra, Verónica Pons, Laura López Andreoni, Pavel Olivera, Ana Marín, Francesc Bosch, Amparo Santamaría (Spain)
- PO057-TUE **ASSESSMENT OF THROMBIN GENERATION TEST FOR BYPASSING THERAPY MONITORING IN HAEMOPHILIA PATIENT WITH INHIBITOR**  
Olga Smirnova\*, Yuriy Namestnikov, Inna Markova, Olga Golovina, Ludmila Papayan (Russian Federation)
- PO058-TUE **EVALUATION OF A NEW ASSAY FOR THE MEASUREMENT OF THE DIRECT FXA INHIBITOR RIVAROXABAN (DG-CHROM ANTI-XA) ON THE Q HEMOSTASIS ANALYZER (GRIFOLS)**  
Kieron Hickey\*, Steve Kitchen (United Kingdom)
- PO059-TUE **HOW THE DIRECT ORAL ANTICOAGULANT APIXABAN AFFECTS THROMBIN GENERATION PARAMETERS**  
Erica Scalabrino\*, Lidia Padovan, Veena Chantarangkul, Sophie Testa, Flora Peyvandi, Armando Tripodi (Italy)
- PO060-TUE **THE CORRELATION OF ATYPICAL APTT CURVES WITH TYPE OF COAGULATION DEFECT**  
Ludek Slavik\*, Jana Ulehlova, Antonin Hlusi, Jana Prochazkova, Vera Krcova (Czech Republic)
- PO061-TUE **EFFICACY OF NOVEL ORAL ANTICOAGULANTS (NOACS) USING DILUTED RUSSELL'S VIPER VENOM TEST (DRVVT)**  
Makoto Kaneko\*, Nobuko Kanno, Yutaka Yatomi (Japan)
- PO062-TUE **EX-VIVO AND IN-VITRO COMPARATIVE ASSESSMENT OF MOD-5014 (FACTOR VIIA-CTP), A NOVEL LONG-ACTING COAGULATION FACTOR TO RECOMBINANT FVIIA**  
Gili Hart, Tami Livnat\*, Boris Shenkman, Ahuva Bar -Ilan, Lior Binder, Malka Hoffman, Gili Kenet (Israel)
- PO063-TUE **IMPACT OF EDOXABAN ON HAEMOSTASIS DIAGNOSIS ASSAYS: PRACTICAL RECOMMENDATIONS**  
Jonathan Douxfils\*, Tania Del Bianco, Justine Baudar, Sarah Lessire, Bernard Chate-lain, Jean-Michel Dogné, François Mullier (Belgium)

## SCIENTIFIC PROGRAM

- PO064-TUE **INTRODUCTION OF A LIQUID ANTI-XA METHOD FOR QUANTIFICATION OF CURRENT THERAPEUTIC XA INHIBITORS**  
Helen Lewis\*, Jane Needham, Nina Harrison, Savita Rangarajan (United Kingdom)
- PO065-TUE **PRELIMINARY PERFORMANCE DATA OF A NEW CHROMOGENIC DIRECT ANTI-XA ASSAY EVALUATED FOR THE QUANTIFICATION OF RIVAROXABAN**  
Sabine Pilgrim\*, Viktoria Esch, Karin Kolbe-Scheu, Barbara Krumpholz, Matthias Schleifer, Andrea Lichte (Germany)
- PO066-TUE **PRELIMINARY EVALUATION OF A NEW CHROMOGENIC ASSAY FOR THE QUANTITATIVE DETERMINATION OF DABIGATRAN IN HUMAN PLASMA**  
Julia Mueller\*, Sabine Halilovic, Isabell Kieper-Rupp, Dieter Koch, Juergen Kurz, Andrea Lichte (Germany)
- PO067-TUE **PREDICTION OF BLEEDING TENDENCY IN HEMOPHILIA A AND B USING THROMBODYNAMICS ASSAY**  
Natalia M. Dashkevich\*, Mikhail Pantelev, Fazoil Ataulkhanov, Claude Negrier (France, Russian Federation)
- PO068-TUE **DO PT AND APTT SENSITIVITIES TO FACTOR DEFICIENCIES CALCULATED BY THE H47-A2 2008 CLSI GUIDELINE REFLECT THE DEFICIENCIES FOUND IN PLASMA FROM PATIENTS?**  
Marta Martinuzzo\*, Luis Barrera, Marcos Rodriguez, Azogaray Viviana, María D'Adamo, Marina López, Juan Otaño (Argentina)
- PO069-TUE **MARKERS OF HEMOSTASIS ACTIVATION AFTER EARLY DISCONTINUATION OF FONDAPARINUX IN LOW-RISK PATIENTS HOSPITALIZED WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME**  
Igor S. Yavelov\*, Anatoly Knyazev, Anatoly Dobrovolsky, Nikolay Gratsiansky (Russian Federation)
- PO070-TUE **NEW INSIGHTS FOR FACTOR ANALYSIS WITH APTT AND PT FOR FACTORS IX, VIII, XI AND FACTOR V.**  
Cornelis Klufft\*, Cornelis van Leuven (The Netherlands)
- PO071-TUE **RELIABILITY OF A NEW POINT-OF-CARE PORTABLE COAGULOMETER FOR PT-INR TEST PERFORMED IN THE HOSPITAL ANTICOAGULATION CLINIC.**  
Rita Paniccia\*, Raffaella Piora, Rossella Marcucci, Lucia Mannini, Daniela Poli, Eleonora Tafuro, Fanny Attinasi, Laura Gori, Agatina Alessandrello Liotta, Rosanna Abbate (Italy)
- PO072-TUE **STRENUOUS EXERCISE INDUCES A PROTHROMBOTIC STATE THAT IS MORE PRONOUNCED IN MEN THAN IN WOMEN**  
Dana Huskens\*, Mark Roest, Jasper Remijn, Saartje Bloemen, Joke Konings, Evelien Schurgers, Romy Kremers, Hilde Kelchtermans, Rinaldo van Meel, Rolf Urbanus, Marisa Ninivaggi, Bas de Laat (The Netherlands)
- PO073-TUE **WHOLE BLOOD PLATELET ACTIVITY MEASUREMENTS MULTIPLEXED WITH QUANTITATIVE FIBRINOGEN, CLOT TIME AND FIBRINOLYSIS MEASUREMENTS BY T2MR**  
Roger Smith\*, Vyacheslav Papkov, Pierrette Andre, Oleg Yerov, Chuck Ritterhaus, Thomas Lowery (United States)

## SCIENTIFIC PROGRAM

- PO074-TUE **VARIABILITY IN NORMAL RANGES OF THROMBIN GENERATION BETWEEN LABORATORIES IS WIDE AND DEPENDENT ON TEST METHODOLOGY**  
Hartirathpal Kaur\*, Chuen Wen Tan, Wan Hui Wong, Yeh Ching Linn, Heng Joo Ng (Singapore)
- PO075-TUE **RESISTANCE TO THROMBOMODULIN BUT NOT TO ACTIVATED PROTEIN C IN CIRRHOTIC PATIENTS**  
Thomas Sinegre\*, Cedric Duron, Alain Marques-Verdier, Géraldine Lamblin, Anne-Françoise Sapin, Armand Abergel, Aurelien Lebreton (France)
- PO076-TUE **HYPERCOAGULABILITY AND HIGH RESIDUAL PLATELET REACTIVITY IN ACS PATIENTS ON DUAL ANTIPLATELET THERAPY.**  
Rita Paniccia\*, Rossella Marcucci, Monica Attanasio, Elisa Grifoni, Raffaella Priora, Yusuf Ahmed, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini (Italy)
- PO077-TUE **EMERGENCY ASSESSEMENT OF PATIENTS IN DOACS: THE ROLE OF POINT-OF-CARE TESTING.**  
Paolo Carraro\*, Haleh Afshar, Seena Padayattil Jose, Giacomo Zoppellaro, Gentian Denas, Manuela Miolo, Giovanni Nante, Mario Plebani, Vittorio Pengo (Italy)
- PO078-TUE **EVALUATING DABIGATRAN AND ITS SPECIFIC REVERSAL WITH IDARUCIZUMAB USING A FULLY AUTOMATED THROMBELASTOGRAPH TEG®65**  
Fowzia Zaman\*, Marc Doubleday, Oliver Grottke, Joanne Van Ryn (United States)
- PO079-TUE **EFFECT OF THE RESIDUAL PLATELET COUNT ON DIFFERENT COAGULATION PARAMETERS IN FREEZE-THAW PLASMA SAMPLES AT -20°C**  
Yolanda Adamczuk\*, Sebastián de Vega, Marcela Pagano, Mabel Viola, María Lamas, Gilda Lumelsky, María Brizuela, Ana Zerdiew (Argentina)
- PO080-TUE **CORRELATION TO FVIII:C IN TWO THROMBIN GENERATION ASSAYS: TGA CAT AND INNOVANCE ETP**  
Marcus Ljungqvist\*, Maria Berndtsson, Margareta Holmström, Jovan Antovic, Erik Berntorp, Danijela Micovic, Ivo Elezovic, Eva Zetterberg (Sweden)
- PO081-TUE **INFLUENCE OF VARIOUS CONCENTRATIONS OF ANTICOAGULANTS ON THE THROMBODYNAMICS ASSAY: AN IN VITRO STUDY**  
Gaetan Flament, Laurence Rozen, Sara Derdabi, Anne Demulder\* (Belgium)
- PO082-TUE **OVERALL HEMOSTATIC POTENTIAL ASSAY IS SENSITIVE TO DIFFERENT PLASMA FREEZING TECHNIQUES**  
Mojca Bozic-Mijovski\*, Blanka Ulaga (Slovenia)
- PO083-TUE **DEFINING THE REFERENCE RANGE FOR BLOOD CLOT GEL POINT AND FRACTAL DIMENSION**  
Lindsay D'silva, Raza Alikhan\*, Sophia Stanford, Ahmed Sabraa, Matthew Lawrence, Rhodri Williams, Phillip Evans (United Kingdom)
- PO084-TUE **EFFECT OF HYPOTHERMIA AND HEMODILUTION ON CLOTTING ACTIVATION: ROTATIONAL THROMBOELASTOMETRY ANALYSIS IN AN ARTIFICIAL ENVIRONMENT FROM HEALTHY SUBJECTS.**  
Sabrina Boraso\*, Giuseppe Gagliardi, Alessandro Agnoli, Cinzia Bettin, Paolo Carraro, Haleh Afshar, Gaia Lembo, Domenico Prisco, Rita Paniccia (Italy)

## SCIENTIFIC PROGRAM

- PO085-TUE **TEST SPECIFIC ASSESSMENT OF EFFECTS OF HAEMOLYSIS ON CITRATED BLOOD SAMPLES USING SYSMEX CS SERIES ANALYSERS**  
Anita Woolley\*, Yuka Tabuchi, Steve Kitchen (United Kingdom)
- PO086-TUE **PROVINCE WIDE IMPLEMENTATION OF THE THROMBIN TIME FOR QUALITATIVE ASSESSMENT OF DABIGATRAN CLEARANCE**  
Artur Szkotak\*, Gwen Clarke, Lisa Vandergouwe, Linda Stang (Canada)
- PO087-TUE **EFFECTS OF RIVAROXABAN ON PT AND APTT AS DETERMINED WITH A FULL RANGE OF REAGENTS: RESULTS OF A UK NEQAS BLOOD COAGULATION EXERCISE**  
Stephen Kitchen\*, Ian Jennings, Rob Jones, Dianne Kitchen, Tim Woods, Isobel Walker (United Kingdom)
- PO088-TUE **A NOVEL PLASMA-BASED FACTOR XA GENERATION ASSAY DEFINES INTERACTION BETWEEN FVIII AND EACH COMPONENT OF XASE COMPLEX IN MILD HEMOPHILIA A.**  
Nao Kamiya\*, Koji Yada, Midori Shima, Keiji Nogami (Japan)
- PO089-TUE **THE FVIII PLASMA ACTIVITY OF RVIII-SINGLE CHAIN CAN BE MEASURED IN BOTH THE ONE-STAGE AND CHROMOGENIC SUBSTRATE ASSAYS**  
Katie St.Ledger\*, Annette Feussner, Uwe Kalina, Carsten Horn, Hubert Metzner, Anthony Stowers, Debbie Bensen Kennedy (United States)
- PO090-TUE **USEFULNESS OF COAGULATION SCREENING TESTS FOR DIAGNOSIS OF COAGULOPATHY**  
Maria Rosaria Fasulo\*, Eugenia Biguzzi, Simona Siboni, Antonino Cannavò, Claudia Mistretta, Maria Elisa Mancuso, Elena Santagostino, Flora Peyvandi (Italy)
- PO091-TUE **BLEEDING SYMPTOMS OR BLEEDING DISORDER? THAT IS THE QUESTION**  
Maria Rosaria Fasulo\*, Eugenia Biguzzi, Simona Siboni, Antonino Cannavò, Claudia Mistretta, Maria Elisa Mancuso, Elena Santagostino, Flora Peyvandi (Italy)
- PO092-TUE **EVALUATION OF AN AUTOMATED COAGULOMETER IN A NEW HAEMOPHILIA CARE CENTER**  
Mirta Arias, Emanuel Sueldo, Beatriz Erramouspe, Rodrigo Porsella, Gabriela Guerrero, Patricia Do Nascimento\*, Alejandra Baques (Argentina)
- PO093-TUE **FACTOR VIII INHIBITORS QUANTIFIED USING CLOT WAVEFORM ANALYSIS**  
Thomas Siegemund\*, Rosemarie Schobess, Ute Scholz, Annelie Siegemund (Germany)

### Cancer and thrombosis/hemostasis II

- PO094-TUE **TISSUE FACTOR DOWNREGULATION BY THE PUTATIVE ONCOGENIC MICRORNA, MIR-520G, IN EMBRYONAL BRAIN TUMOUR CELLS**  
Esterina D'Asti\*, Annie Huang, Marcel Kool, Andrey Korshunov, Stefan Pfister, Janusz Rak (Canada)
- PO095-TUE **VTE RECURRENCE AND BLEEDING IN PATIENTS WITH CANCER. RESULTS OF THE OPTIMEV STUDY**  
Marie Sevestre\*, Celine Genty, Carole Rolland, Gilles Pernod, Jean-Luc Bosson (France)

## SCIENTIFIC PROGRAM

- PO096-TUE **COLLABORATIVE EFFORTS OF THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE AND THE NATIONAL CANCER INSTITUTE IN CANCER AND THROMBOSIS**  
Michelle A. Berny-Lang\*, Andrei Kindzelski, Traci Mondoro, Emily Greenspan (United States)
- PO097-TUE **PATIENTS EXPERIENCES OF LIVING WITH CANCER ASSOCIATED THROMBOSIS: THE PELICAN STUDY**  
Simon Noble\*, Hayley Prout, Annmarie Nelson (United Kingdom)
- PO098-TUE **CANCER ASSOCIATED THROMBOSIS: DEVELOPING CONSENSUS GUIDANCE TO IMPROVE PATIENT CARE AND OUTCOMES**  
Simon Gwynn, Roopen Arya\*, John McPhelim, Toby Talbot, John Pasi, Gail Fortes-Mayer, Nitil Kedia, Stefan Kokiet, Malgosia King (United Kingdom)
- PO099-TUE **REDUCING CLOT RISK IN POST-OPERATIVE CANCER PATIENTS: WHAT IS THE COMMON GROUND AMONG INTERNATIONAL VTE PREVENTION GUIDELINES?**  
Carol Jackson\* (United States)
- PO100-TUE **AGE-ADJUSTED D-DIMER CUT-OFF LEVEL INCREASES THE NUMBER OF CANCER PATIENTS IN WHOM PULMONARY EMBOLISM CAN BE SAFELY EXCLUDED WITHOUT CTPA IMAGING: THE ADJUST-PE CANCER SUB-STUDY**  
Dorienke Wilts\*, Grégoire Le Gal, Paul den Exter, Josien van Es, Marc Carrier, Benjamin Planquette, Harry Büller, Marc Righini, Menno Huisman, Pieter Kamphuisen (The Netherlands)
- PO101-TUE **RATES OF VENOUS THROMBOEMBOLISM DESPITE THROMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE OR POMALIDOMIDE: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Miriam Kimpton\*, Marc Carrier, Jason Tay, Alexandra Davis, Gregoire Le Gal (Canada)
- PO102-TUE **PROSPECTIVE EVALUATION OF RISK ASSESSMENT MODELS AND BIOLOGICAL MARKERS OF HYPERCOAGULABILITY FOR THE IDENTIFICATION OF HIGH VTE RISK PATIENTS WITH LUNG ADENOCARCINOMA. THE ROADMAP STUDY.**  
Ilias Evmorfiadis, Boura Paraskevi, Aurélie Rousseau, Ariadni Charpidou, Patrick Van Dreden, Giannis Giozos, Konstantinos Syrigos, Anastasia Spanoudaki, Matthieu Grusse, Ismail Elalamy, Grigoris Gerotziapas\* (France)
- PO103-TUE **UNSUSPECTED PULMONARY EMBOLISM IN CANCER PATIENTS: AN INTERNATIONAL, ONGOING, PROSPECTIVE, OBSERVATIONAL STUDY**  
Suzanne M. Bleker\*, Nick van Es, Ankie Kleinjan, Harry Büller, Joke Baars, Laurent Bertoletti, Jan Beyer - Westendorf, Joel Constans, Francis Couturaud, Anna Falanga, Diana Iosub, Isabelle Mahé, Guy Meyer, Andrés Munoz Martín, Ettore Porreca, Sebastian Werth, Marcello Di Nisio (The Netherlands)
- PO104-TUE **RISK OF SUBSEQUENT CANCER AFTER A VENOUS THROMBOEMBOLISM - THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY**  
Hilde Jensvoll\*, Marianne Severinsen, Jens Hammerstrøm, Sigrid Brækkan, Søren Kristensen, Suzanne Cannegieter, Kristine Blix, Anne Tjønneland, Frits Rosendaal, Olga Dziewiecka, Kim Overvad, Inger Anne Næss, John-Bjarne Hansen (Norway)

## SCIENTIFIC PROGRAM

- PO105-TUE **MANAGEMENT OF CANCER ASSOCIATED THROMBOSIS IN FRANCE : A NATIONAL SURVEY IN VASCULAR DISEASE AND SUPPORTIVE CARE SPECIALISTS**  
Isabelle Mahé\*, Jean-Baptiste Rey, Ismail Elalamy, Anne Lamblin, Didier Mayeur, Gilles Pernod (France)
- PO106-TUE **VENOUS THROMBOEMBOLISM AFTER SURGICAL TREATMENT OF SKELETAL METASTASES – AN UNDERDIAGNOSED COMPLICATION**  
Riitta Lassila\*, Maire Ratasvuori, Minna Laitinen (Finland)
- PO107-TUE **MAJOR AND NON-MAJOR CLINICALLY RELEVANT BLEEDING IN PATIENTS HOSPITALIZED IN PALLIATIVE CARE UNITS: RESULTS OF A FRENCH MULTICENTRE OBSERVATIONAL STUDY.**  
Bernard Tardy\*, Céline Chapelle, Stéphane Picard, Didier De Broucker, Marie Delerue, Thomas Celarier, Pascale Vassal, Jean-François Ciais, Sébastien Salas, Elise Perceau, Marilène Filbet, Frédéric Guirimand, Jean-Marie Gomas, Christine Decherf, Laurent Bertoletti, Aline Guillot, Jean-Baptiste Gaultier, Madjid Akrou, Florence Rancon, Adel Merah, Silyv Laporte (France)
- PO108-TUE **HEALTHCARE RELATED COST OF THROMBOTIC EVENTS IN ELDERLY PATIENTS: A RETROSPECTIVE DATABASE ANALYSIS**  
Abiola Oladapo\*, Yan Xiong, Aaron Novack, Joshua Epstein (United States)
- PO109-TUE **THE UTILITY OF PEMB-QOL AND VEINES-QOL/SYM QUESTIONNAIRES IN EVALUATING QUALITY OF LIFE IN THE CANCER ASSOCIATED THROMBOSIS PATIENT.**  
Hayley Prout, Annmarie Nelson, Simon Noble\* (United Kingdom)
- PO110-TUE **PATIENTS' PREFERENCES FOR THE TREATMENT OF CANCER ASSOCIATED THROMBOSIS**  
Simon Noble, Anthony Maraveyas, Axel Matzdorff, Majbrit Vindt Holm, Giovanni Pisa (United Kingdom)
- PO111-TUE **AGE SHOULD NOT BE CONSIDERED A RISK FACTOR FOR CANCER-RELATED VENOUS THROMBOEMBOLISM: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER STUDY**  
Kristine Blix\*, Marianne Severinsen, Sigrid Brækkan, Hilde Jensvoll, Olga Dziewiecka, Søren Kristensen, Kim Overvad, Anne Tjønneland, Inger Anne Næss, Jens Hammerstrøm, Frits Rosendaal, Suzanne Cannegieter, John-Bjarne Hansen (Norway)
- PO112-TUE **CANCER-RELATED VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY**  
Kristine Blix\*, Marianne Severinsen, Sigrid Brækkan, Hilde Jensvoll, Olga Dziewiecka, Søren Kristensen, Kim Overvad, Anne Tjønneland, Inger Anne Næss, Jens Hammerstrøm, Frits Rosendaal, Suzanne Cannegieter, John-Bjarne Hansen (Norway)
- PO113-TUE **INCIDENCE, RISK FACTORS, AND OUTCOME OF EARLY HEMOSTATIC COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY OF 551 PATIENTS**  
HAN Yue\*, Wu Depei, HAN Wei, Wang Jie, WANG Zhaoyue, RUAN Changgeng (China)

## SCIENTIFIC PROGRAM

- PO114-TUE **DETECTION OF HYPERCOAGULABILITY IN HEPATOCELLULAR CARCINOMA (HCC).**  
Luca Spiezia\*, Kryssia Rodriguez-Castro, Elena Campello, Alberto Zanetto, Sabrina Gavasso, Barry Woodhams, Marco Senzolo, Patrizia Burra, Paolo Simioni (Italy)
- PO115-TUE **ROLE OF ARTERIAL CARDIOVASCULAR RISK FACTORS IN THE PATHOGENESIS OF CANCER RELATED VTE.**  
Francesco Dentali\*, Graziella Pinotti, Mara Mantiero, Alessia Pastore, Walter Ageno (Italy)
- PO116-TUE **FACTORS INFLUENCING THE USE OF THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS IN THE REAL WORLD CLINICAL PRACTICE**  
Elena Panizo, Ana Alfonso, Alberto García-Mouriz, José López-Picazo, Ignacio Gil-Bazo, José Hermida, José Páramo, Ramón Lecumberri\* (Spain)
- PO117-TUE **RESIDUAL VEIN THROMBOSIS TO ASSES THE DURATION OF LOW MOLECULAR WEIGHT HEPARIN (THE EXTENDED CANCER-DACUS)**  
Mariasanta Napolitano\*, Giorgia Saccullo, Simona Raso, Salvatrice Mancuso, Alessandra Casuccio, Sergio Siragusa (Italy)
- PO118-TUE **BETWEEN A ROCK AND A HARD PLACE: CONUNDRUMS IN THE MANAGEMENT OF CEREBRAL SINOVENOUS THROMBOSIS (CSVT) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOMA.**  
Uma Athale\*, Jeremy Robertson, Martha Rolland, Mahendranath Moharir, Suzan Williams, Anthony Chan, Leonardo Brandao (Canada)
- PO119-TUE **A PROSPECTIVE STUDY ON THE INCIDENCE OF POSTOPERATIVE VENOUS THROMBOEMBOLISM IN KOREAN COLORECTAL CANCER PATIENTS**  
Eunyoung Lee\*, Sung-Bum Kang, Sang Il Choi, Eun Ju Chun, Soo-Mee Bang, Duck-Woo Kim, Heung-Kwon Oh, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee, Keun-Wook Lee (Korea, Republic Of)
- PO120-TUE **THROMBOEMBOLIC EVENTS IN CHILDREN WITH CANCER IN SRINAGARIND HOSPITAL**  
Patcharee Komvilaisak\*, Arunee Jetsrisuparb, Surapon Wiangnon, Paiporn Sripraya (Thailand)
- PO121-TUE **THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH LYMPHOMA**  
Darko Antic\*, Srdjan Nikolovski, Natasa Milic, Vladislava Djurasinovic, Vojin Vukovic, Biljana Mihaljevic (Serbia)
- PO122-TUE **SELECTION OF ANTICOAGULATION THERAPY IN CANCER PATIENTS**  
Alexander Vorobev\*, Alexander Makatsaria (Russian Federation)
- PO123-TUE **DIC AND THROMBOPHILIA DURING CHEMOTHERAPY AND ITS PREVENTION APPROACHES IN OVARIAN CANCER PATIENTS**  
Alexander Vorobev\* (Russian Federation)
- PO124-TUE **MORTALITY FOLLOWING VENOUS THROMBOEMBOLISM: A POPULATION-BASED COHORT STUDY IN PATIENTS WITH ACTIVE CANCER**  
Carlos Martinez\*, Anja Katholing, Stephan Rietbrock, Alexander Cohen (Germany)

## SCIENTIFIC PROGRAM

- PO125-TUE **EVALUATION OF MEAN PLATELET VOLUME AS A PREDICTIVE MARKER FOR VENOUS THROMBOEMBOLISM AND MORTALITY IN PATIENTS TREATED FOR DIFFUSED LARGE B-CELL LYMPHOMA**  
Joanna Rupa-Matysek\*, Lidia Gil, Mieczyslaw Komarnicki (Poland)
- PO126-TUE **A NEW GENERIC RISK SCORE FOR PREDICTING VENOUS THROMBOEMBOLIC EVENTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY**  
Andres Muñoz\*, Andrey Ziyatdinov, Juan Carlos Souto, Jose Manuel Soria (Spain)
- PO127-TUE **THROMBOPROPHYLAXIS OF AMBULANT PANCREATIC CANCER PATIENTS: SINGLE CENTRE EXPERIENCE UTILIZING THE LESSONS FROM FRAGEM AND CONKO-04.**  
Iqtedar Ahmed Muazzam\*, Anthony Maraveyas (United Kingdom)
- PO128-TUE **TREATMENT OF CANCER ASSOCIATED THROMBOSIS AFTER THE INITIAL 6 MONTH PERIOD.**  
Petr Kessler\*, Hynek Poul, Michaela Harudova (Czech Republic)
- Coagulation factor V, X, II, XIII - II**
- PO129-TUE **DEFINING THE DIFFERENTIAL EFFECTS OF NOVEL ANTICOAGULANTS: FXA VERSUS FIIA INHIBITION ON COAGULATION AND INFLAMMATION**  
Khurum Shahzad\*, Fabian Bock, Dong Wei, Wang Hongjie, Ina Thielmann, Bernhard Nieswandt, Madhusudhan Thati, Berend Isermann (Pakistan, Germany)
- PO130-TUE **RIVAROXABAN ASSOCIATES WITH FACTOR XA FASTER THAN APIXABAN: A POTENTIAL EXPLANATION FOR THEIR DIFFERENT EFFECTS ON TESTS OF COAGULATION**  
Calvin Yeh\*, Brian Dale, Beverly Leslie, Paul Kim, James Fredenburgh, Jack Hirsh, John Eikelboom, Jeffrey Weitz (Canada)
- PO131-TUE **GENERATION OF A RECOMBINANT TRUNCATED ACTIVATED FACTOR X AS ANTI-HEMOPHILIC AGENT**  
Toufik Abache, Anne-Sophie Dezetter, Alain Longue, Dominique Grenier, Céline Bourdon, Marie-Claire Dagher, Raphael Marlu, Alexandre Fontayne, Benoit Polack, Jean-Luc Plantier\* (France)
- PO132-TUE **PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF SEVERE FACTOR VII DEFICIENCY PATIENTS IN CENTRAL CHINA**  
Hui Liu\*, Huafang Wang, Liang Tang, Zhipeng Cheng, Qingyun Wang, Bei Hu, Yu Hu, Wei Zeng, Yingying Wu (China)
- PO133-TUE **FRAGMENT-2 INHIBITION OF PROTHROMBINASE REVEALS A UNIQUE ENZYME-SUBSTRATE INTERFACE FOR THE PLATELET-BOUND ENZYME**  
Francis Ayombil\*, Laura Haynes, Paula Tracy (United States)
- PO134-TUE **NOVEL F10: P. CYS57ARG MUTATION IN A PAKISTANI SEVERE FX-DEFICIENT PROBAND**  
Munira Borhany\*, Olivier Guillot, Florence Rousseau, Christelle Delbes, Naveena Fatima, Tahir Shamsi, Muriel Giansily-Giansily-Blaizot (Pakistan)

## SCIENTIFIC PROGRAM

### Coagulation factor VIII and IX - II

- PO135-TUE **THE IL-10 POLARIZED CYTOKINE PATTERN IN INNATE AND ADAPTIVE IMMUNITY CELLS CONTRIBUTE TO THE DEVELOPMENT OF FVIII INHIBITORS**  
Daniel Chaves\*, Amanda Silveira, Márcio Santana, Olindo Martins-Filho (Brazil)
- PO136-TUE **EVALUATION OF N8-GP LONG TERM SAFETY IN IMMUNE DEFICIENT RATS**  
Hanne Offenberg\*, Julie Larsen, Jette Nowak, Caroline Rasmussen (Denmark)
- PO137-TUE **ASSOCIATION OF ARTERIAL AND VENOUS THROMBOSIS WITH CLOTTING FACTOR USED IN PATIENTS WITH HEMOPHILIA**  
Jiaan-Der Wang\* (Taiwan)
- PO138-TUE **ASSESSING THE INDICATION AND SUCCESS OF TREATMENT FOR HAEMOPHILIA PATIENTS: RESULTS FROM A DELPHI PANEL**  
Alfonso Iorio\*, Anne Rentz, Zaneta Balantac, Christina Hoxer (Canada)
- PO139-TUE **ASSESSING THE BURDEN OF DISEASE IN HAEMOPHILIA PATIENTS: A QUALITATIVE STUDY**  
Ulla Slothuus\*, Michelle Field, Christina Hoxer (Denmark)
- PO140-TUE **COMPARISON OF RECOMBINANT FACTOR VIII PRODUCTS WITH RESPECT TO HMWP CONTENT AND GENERAL HETEROGENEITY**  
Per Nielsen\*, Anders Nielsen (Denmark)
- PO141-TUE **DEVELOPMENT OF AN ELISA FOR THE DETECTION OF BINDING ANTIBODIES AGAINST HUMAN COAGULATION FACTOR VIII IN RAT PLASMA**  
Karin M. Lövgren\*, Karin Weldingh, Kristina Larsson, Mads Kjelgaard-Hansen, Bo Wiinberg (Denmark)
- PO142-TUE **THE TYPE OF REAGENTS DETERMINES THE ACCURACY OF CALIBRATION WITH A PRODUCT SPECIFIC STANDARD FOR THE MEASUREMENT OF THE B-DOMAIN DELETED RFXVIII MOROCTOCOG ALFA-AF ACTIVITY.**  
Marc Jacquemin\*, Alexandra Vodolazkaia, Evelien Heylen, Jelle Toelen, Joke Schoeters, Kathelijne Peerlinck (Belgium)
- PO143-TUE **HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH HAEMOPHILIA FROM TURKEY**  
Yasemin Isik Balci\*, Onder Ozturk, Burge Kabukcu Basay, Omer Basay, Aziz Polat, Elif Kazanci, Omer Faruk Tuncbilek, Funda Akpinar (Turkey)
- PO144-TUE **STRUCTURAL CHARACTERISATION OF RECOMBINANT FACTOR IX FUSION PROTEIN LINKED WITH HUMAN ALBUMIN**  
Andreas Meister\*, Nicholas Grammel, Matthias Pelzing (Australia)
- PO145-TUE **TISSUE FACTOR EXERTS FACTOR XA-CATALYZED FACTOR VIII ACTIVATION IN THE PRESENCE OF VON WILLEBRAND FACTOR IN A FACTOR VIIA-INDEPENDENT MECHANISM**  
Shoko Furukawa\*, Keiji Nogami, Kenichi Ogiwara, Midori Shima (Japan)

## SCIENTIFIC PROGRAM

- PO146-TUE **PHYSICOCHEMICAL CHARACTERIZATION OF RECOMBINANT SINGLE-CHAIN FACTOR VIII (RVIII-SINGLECHAIN)**  
Stefan Schmidbauer\*, Lars Robbel, Petra Sebastian, Reinhild Witzel, Nicolas Grammel, Hubert Metzner, Stefan Schulte (Germany)
- PO147-TUE **FVIII ACTIVITY OF LONG-ACTING TUROCTOCOG ALFA PEGOL (N8-GP) CAN BE ACCURATELY AND PRECISELY MEASURED BY DIFFERENT COMMERCIAL CHROMOGENIC ASSAYS**  
William Pickering\*, Martin Hansen, Mirella Ezban, Marianne Kjalke (Denmark)
- PO148-TUE **MOLECULAR GENOTYPING OF HAEMOPHILIA A IN SAUDI ARABIAN POPULATION: REPORT OF NOVEL MUTATIONS.**  
Faisal A. Al-Allaf\*, Mohiuddin Taher, Zainularifeen Abduljaleel, Mohammed Athar, Faisal Ba-hammam, Munir Abdulla, Abdellatif Bouazzaoui, Halah Abalkhail, Tarek Owaidah (Saudi Arabia)
- PO149-TUE **DIFFERENT STRATEGIES FOR TREATMENT ON HEMOPHILIA PATIENTS WITH INHIBITOR, COSTS VERSUS BENEFITS**  
Mohammad Reza Baghaipour\* (Iran, Islamic Republic Of)
- PO150-TUE **A PLASMA- AND CELL-BASED THROMBIN GENERATION ASSAY TO ASSESS THE ANTICOAGULANT EFFECT OF TISSUE FACTOR PATHWAY INHIBITOR ON ENDOTHELIAL CELLS**  
Gabriele Gerstenbauer, Sabine Knappe, Erwin Panholzer, Katerina Prohaska, Fabian Knofl, Nadja Ullrich, Robert Pachlinger, Friedrich Scheiflinger, Michael Dockal\* (Austria)
- PO151-TUE **LETHALITY OF MOUSE TISSUE FACTOR PATHWAY INHIBITOR GENE DISRUPTION IS RESCUED BY TRANSGENIC HUMAN TISSUE FACTOR PATHWAY INHIBITOR KNOCK IN**  
Robert Pachlinger, Rudolf Hartmann, Andrea Kolm, Erwin Panholzer, Nadja Ullrich, Fabian Knofl, Maria Schuster, Werner Hoellriegel, Friedrich Scheiflinger, Michael Dockal\* (Austria)
- PO152-TUE **LONGITUDINAL MONITORING OF TFPI LEVELS AND THEIR CORRELATION WITH COAGULATION PARAMETERS IN HEALTHY SUBJECTS: A ONE-YEAR OBSERVATION**  
Rudolf Hartmann, Jadranka Koehn, Erwin Panholzer, Bianca Marchula, Elisabeth Schoenegger, Birgit Reipert, Friedrich Scheiflinger, Michael Dockal\* (Austria)
- PO153-TUE **COMPARATIVE STUDY OF FULL-LENGTH AND B-DOMAIN MODIFIED RFXVIII PRODUCTS SHOWS NO RELATION BETWEEN B-DOMAIN MODIFICATION AND THE CONTENT OF SUBVISIBLE PARTICLES**  
Dorrit Baunsgaard\*, Anette Henriksen, Heidi Bagger, Mirella Ezban (Denmark)
- PO154-TUE **THROMBIN GENERATION IN HUMAN HEMOPHILIA PLASMA AT REDUCED ANTITHROMBIN LEVELS AND CONCOMITANT FACTOR OR BYPASS AGENT ADDITION**  
Akin Akinc\*, Alfica Sehgal, Kun Qian, Harsha Prabhala, Ole Larsen, Benny Sorensen (United States)
- PO155-TUE **RATE-LIMITING ROLES OF TENASE COMPLEX OF FACTORS VIII AND IX IN PLATELET PROCOAGULANT ACTIVITY AND FORMATION OF PLATELET-FIBRIN THROMBI UNDER FLOW**  
Frauke Swieringa, Marijke Kuijpers, Moniek Lamers, Paola van der Meijden, Johan W. Heemskerk\* (The Netherlands)

## SCIENTIFIC PROGRAM

- PO156-TUE **TREATMENT OF SEVERE BLEEDING AND PROPHYLAXIS WITH RFXIIA IN A CHILD WITH FVIII INHIBITOR**  
Adalet Meral Gunes\*, Melike Sezgin Evim, Birol Baytan (Turkey)
- PO157-TUE **MISFOLDED PROTEINS IN PLASMA-DERIVED FVIII CONCENTRATES ACTIVATE PLATELETS AND INHIBIT HEME OXYGENASE-1 UPREGULATION IN MACROPHAGES BY SECRETED PLATELET FACTOR 4 (CXCL4)**  
Anne Bertling\*, Martin Brodde, Mayken Visser, Lisa Smits, Janina Treffon, Michelle Fennen, Beate Kehrel (Germany)
- PO158-TUE **CIRCUMCISION IN TURKISH PATIENTS WITH BLEEDING DISORDERS: A SOCIOCULTURAL PERSPECTIVE**  
Yasemin Isik Balci\*, Önder Öztürk, Burke Kabukcu Basay, Omer Basay, Mehmet Akin, Funda Ozgurler Akpınar, Nazli Kapubagli, Aziz Polat (Turkey)
- PO159-TUE **INTRA-LABORATORY VARIATION IN FVIII:C INHIBITOR ASSAY: RESULTS OF A STUDY IN THREE FRENCH CENTERS**  
Christophe Nougier\*, Camille Seignover, Carine Crampe, Raphaël Marlu (France)
- PO160-TUE **STABILITY OF FVIII PRODUCTS - FORMATION OF SUBVISIBLE PARTICLES UPON PHYSICAL STRESS**  
Mantas Malisauskas\*, Christian Lubich, Thomas Prenninger, Friedrich Scheiflinger, Birgit Reipert (Austria)
- PO161-TUE **COMPARISON OF FVIII ACTIVITY OF SELECT NOVEL RECOMBINANT FVIII REPLACEMENT PRODUCTS IN COMMONLY USED FDA APPROVED ONE-STAGE CLOT ASSAY SYSTEMS**  
Stefan Tiefenbacher\*, Mary Robinson, Erika Ross, Patrick Williams, Caroline Cogswell, Tyrelle Wham, Geoff Chow, Dorothy Adcock (United States)
- PO162-TUE **INVESTIGATING POTENTIAL DETERMINANTS OF ITI SUCCESS USING IMMUNE GENE EXPRESSION PROFILING: A PRELIMINARY STUDY**  
Davide Matino\*, Marco Gargaro, Cristina Santoro, Giancarlo Castaman, Francesca Fallarino, Alfonso Iorio (Canada)
- PO163-TUE **FACTOR VIII DEFICIENCY: INHIBITION OR ABNORMAL CONTACT?**  
Ana Azevedo\*, Isabel Freire, Teresa Gago (Portugal)
- PO164-TUE **IN VITRO FACTOR VIII ACTIVITY AFTER RECONSTITUTION WITH DILUENT FLUID FOR CONTINUOUS INFUSION**  
Kun Soo Lee\*, Ji Yoon Kim, Jin Kyung Seo, Uk Hyun Kim, Ji Hye Lee, Ye-Jee Shim, Hwi-Joong Yoon, Shin Young Hyun, Sae Yun Baik (Korea, Republic Of)
- PO165-TUE **APPLICATION OF CLOT WAVEFORM ANALYSIS ON HEMOSTATIC MONITORING FOR FACTOR (F)VIII MIMICKING ANTI-FIXA/FX BISPECIFIC ANTIBODY (ACE910)**  
Tomoko Matsumoto\*, Keiji Nogami, Koji Yada, Takehisa Kitazawa, Kunihiro Hattori, Midori Shima (Japan)

### Contact pathway

- PO166-TUE **EFFICACY OF A NOVEL CONTACT PATHWAY INHIBITOR, IR-CPI, IN AN EXTRACORPOREAL MEMBRANE OXYGENATOR MODEL**  
Sophie Combe\*, Yves Fromes, Chantal Krezel, Pierre Gueret, Jean Amiral, Michel Guyaux, Edmond Godfroid (France, Belgium)

## SCIENTIFIC PROGRAM

- PO167-TUE **MOST OF LUPUS ANTICOAGULANT IN RECURRENT PREGNANCY LOSS PATIENTS RECOGNIZE HIGH MOLECULAR WEIGHT KININOGEN AND/OR FACTOR XII.**  
Yoshihiro Sato\*, Toshitaka Sugi, Rie Sakai (Japan)
- PO168-TUE **FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY IN BLUNT TRAUMA PATIENTS**  
Saulius Butenas\*, Chelsea Manning, Kalev Freeman (United States)
- PO169-TUE **COAGULATION MONITORING OF VENTRICULAR ASSIST DEVICE RECIPIENTS REVEALS NEW INSIGHTS IN DISTURBED HAEMOSTASIS**  
Thomas Siegemund\*, Stefan Feder, Andreas Oberbach, Annelie Siegemund, Friedrich Mohr (Germany)
- PO170-TUE **HISTIDINE-RICH GLYCOPROTEIN BINDS DNA AND RNA AND ATTENUATES THEIR CAPACITY TO ACTIVATE THE INTRINSIC PATHWAY OF COAGULATION**  
Trang T. Vu\*, Beverly Leslie, Alan Stafford, Ji Zhou, James Fredenburgh, Jeffrey Weitz (Canada)
- PO171-TUE **LOCALIZATION OF FACTOR XI IN PLATELETS IS NOT RESTRICTED TO ALPHA GRANULES.**  
Michal Zucker\*, Uri Seligsohn, Hagit Hauschner, Nurit Rosenberg (Israel)
- PO172-TUE **THE 2,5-DICHLOROPHENYL FRAGMENT AS STARTING POINT IN THE DESIGN OF NEW FXIIA INHIBITORS**  
Charlotte Bouckaert\*, Silvia Serra, Jean-Michel Dogné, Raphaël Frédérick, Lionel Pochet (Belgium)
- PO173-TUE **DSR-130787, A NOVEL ORALLY-ACTIVE FACTOR XIA INHIBITOR WITH LOW RISK OF BLEEDING**  
Masaya Mori\*, Toshihiro Goto, Masakazu Shintome, Masako Toda, Shiori Taga, Keizo Matsushita, Katsuya Fujita, Yohei Ikuma, Masato Iwata, Kuniko Suzuki, Nobuhisa Fukuda, Hiroshi Kato, Isao Shimizu (Japan)
- PO174-TUE **EVALUATION OF THE EFFECTS OF A NOVEL CONTACT PATHWAY INHIBITOR, IR-CPI, ON IN VITRO PLATELET FUNCTION AND COAGULATION**  
Lisa Jennings\*, Jayaprakash Kotha\*, Juan Cardenas, Michael Herr, Vinay Bhal, Mason Dixon, Melanie White, Sophie Combe, Edmond Godfroid (United States)
- PO175-TUE **BLOOD GROUP, BLEEDING PHENOTYPE AND POST-PARTUM HAEMORRHAGE IN FACTOR XI-DEFICIENT WOMEN**  
Bethan Myers\*, Rebecca Neal, Nicola Curry, Rezan Kadir, Sue Pavord (United Kingdom)
- PO176-TUE **IDENTIFICATION OF THREE NOVEL FACTOR XII MUTATIONS ASSOCIATED WITH CONGENITAL FACTOR XII DEFICIENCY**  
Peipei Jin\*, Wenli Jiang, Hui Yan, Lanbo Liu, Song Gu, Xuefeng Wang, Lisong Shen, Xi Mo (China)
- PO177-TUE **FXI-INDEPENDENT CEREBRAL HEMOSTASIS IN EXPERIMENTAL TRAUMATIC BRAIN INJURY**  
Christina Lorentz\*, Suzanne Schwarzmaier, Ciaran de Chaumont, Matilde Balbi, Nicole Terpolilli, Erik Tucker, Owen McCarty, Christoph Kleinschnitz, Andras Gruber, Nikolaus Plesnila (United States)

## SCIENTIFIC PROGRAM

- PO178-TUE **ACTIVATION OF FACTOR XII BY PLASMIN LEADS TO BRADYKININ FORMATION IN HEREDITARY ANGIOEDEMA**  
Steven De Maat\*, Jenny Björkqvist, Chiara Suffritti, Philip de Groot, Marco Cicardi, Thomas Renné, Coen Maas (The Netherlands)
- PO179-TUE **UNEXPECTED HEPATOCYTE GROWTH FACTOR ACTIVATOR (HGFA) ACTIVITY ALLOWS A POSSIBLE CROSSTALK BETWEEN ACTIVATED FACTOR XII AND THE HGF/C-MET PATHWAY IN HUMAN PLASMA**  
Benedito Prezoto\*, Guacyara Motta, Mariana Viana, Catarina Teixeira, Priscila Araujo, Douglas Mariano, Daniel Pimenta (Brazil)
- PO180-TUE **FXI AND FXII ACTIVITY LEVELS IN YOUNG PATIENTS WITH CRYPTOGENIC ISCHEMIC STROKE**  
Cristina Duboscq\*, Jose Ceresetto, German Stemmelin, Claudia Shanley, Oscar Rabinovich, Silvina Palmer, Eduardo Bullorsky (Argentina)
- PO181-TUE **ANTITHROMBOTIC EFFECTS OF IR-CPI IN AN ARTERIO-VEIN SHUNT MODEL IN THE RABBIT**  
Michel Guyaux\*, Pierre Gueret, Francois Becher, Jean Amiral, Stephanie Simon, Edmond Godfroid (Belgium)
- PO182-TUE **SURFACE PLASMON RESONANCE: SENSIQ PIONEER AS A MEANS TO SCREEN DRUG DISCOVERY FRAGMENTS FOR HITS**  
Clare Wishart\*, Lewis Hardy, Amy Cilia La Corte, Emma Hethershaw, Charlotte Revill, Colin Fishwick, Richard Foster, Robert Ariens, Helen Philippou (United Kingdom)
- PO183-TUE **MODELLING OF SURFACE-DEPENDENT ACTIVATION OF CONTACT ACTIVATION FACTOR XII IN A BUFFER SOLUTION**  
Vladislava Terenteva\*, Mikhail Panteleev (Russian Federation)
- PO184-TUE **EFFECT OF A PLANT INHIBITOR OF THE CONTACT SYSTEM ON A MOUSE THROMBOSIS MODEL**  
Maria Luiza Oliva\*, Marlon Brito, Bruno Salu, José Walber Cruz, Alexander Wlodawer, Francisco Maffei (Brazil)

### Endothelium and vessel wall II

- PO185-TUE **ENDOTHELIAL CELL INCREASES ITS RIGIDITY DURING INFLAMMATION THROUGH MODIFICATION OF THE GAP JUNCTION**  
Takayuki Okamoto\*, Eiji Kawamoto, Nobuyuki Akita, Tatsuya Hayashi, Koji Suzuki, Motomu Shimaoka (Japan)
- PO186-TUE **ANALYSIS OF THE EXPRESSION AND LOCALIZATION OF RNASE AND RNASE INHIBITOR IN BLOOD CELLS AND VASCULAR ENDOTHELIAL CELLS INVOLVED IN HOMEOSTASIS IN THE VASCULAR SYSTEM**  
Ayaka Ohashi\*, Yuichiro Cho, Shizuko Ichinose, Osamu Hoshi, Takatoshi Koyama (Japan)
- PO187-TUE **CHANGES IN THE ENDOTHELIAL EXPRESSION OF GENES RELATED TO INFLAMMATION AND ATHEROTHROMBOSIS IN RESPONSE TO UREMIA**  
Susana Martin-Rodriguez, Manel Vera, Enrique Mir, Marcelina Párrizas, Aleix Cases, Josep Cruzado, Gínés Escolar, Maribel Diaz-Ricart\* (Spain)

## SCIENTIFIC PROGRAM

- PO188-TUE **UPREGULATION OF MATRIX METALLOPROTEINASE-2 EXPRESSION BY ACTIVATED PROTEIN C IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS REQUIRES ENDOTHELIAL PROTEIN C RECEPTOR AND ACTIVATION OF PROTEASE-ACTIVATED RECEPTORS-1 AND -3**  
Helena Liang\*, Meilang Xue, Chris Jackson (Australia)
- PO189-TUE **BIOMARKERS OF ENDOTHELIAL DAMAGE AND INFLAMMATORY PROCESS IN PATIENTS WITH ALZHEIMER DISEASE OR WITH MILD COGNITIVE IMPAIRMENT.**  
Melina B. Pinheiro, Marcos Vinícius Silva, Gisele Gonçalves, Mayara Faria, Edgar Moraes, Maria Aparecida Bicalho, Luci Maria Dusse, Maria das Graças Carvalho\* (Brazil)
- PO190-TUE **ACTIVATION OF THE ENDOTHELIUM MAY BE INVOLVED IN THE HEMOSTATIC ALTERATIONS INDUCED BY MICRURUS TENER TENER VENOM IN C57BL/6 MICE**  
Emelyn Salazar\*, Ana Salazar, Karin Perez, Izaskun Urdanibia, Alexis Rodriguez-Acosta, Peter Taylor, Betsy Guerrero (Venezuela, Bolivarian Republic Of)
- PO191-TUE **INCREASED ENDOCAN LEVELS AND ITS ASSOCIATION WITH SEVERITY IN STEVENS JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS.**  
Daneyal Syed\*, Omer Iqbal, Charles Bouchard, Michael Mosier, Debra Hoppensteadt, Jawed Fareed (United States)
- PO192-TUE **ENDOTHELIAL PATHOGENESIS RESULTS IN THE GENERATION OF A PROTEOGLYCAN ENDOCAN IN VARIOUS DISEASES**  
Debra Hoppensteadt\*, Amanda Walborn, Omer Iqbal, Daneyal Syed, Vinod Bansal, Michael Mosier, Charles Bouchard, Nil Guler, Jawed Fareed (United States)
- PO193-TUE **UPREGULATION OF CHEMOKINE EXPRESSION BY STREPTOCOCCUS MUTANS BEARING COLLAGEN-BINDING PROTEIN IN CULTURED BRAIN ENDOTHELIAL CELLS**  
Yuji Matsumoto\*, Kazuya Hokamura, Kazuo Umemura (Japan)

### Fibrinogen/fibrin/D-dimer I

- PO194-TUE **TWO NOVEL DIFFERENT SUBSTITUTIONS OF FIBRINOGEN AALPHA 98**  
Roman Kotlín\*, Zuzana Reicheltova-Riedelova, Eliška Ceznerová, Jana Štikarová, Ondrej Pastva, Jirí Suttner, Peter Salaj, Jan Dyr (Czech Republic)
- PO195-TUE **CLINICAL FEATURES AND MOLECULAR BASIS OF 102 CHINESE PATIENTS WITH CONGENITAL DYSFIBRINOGENEMIA**  
Jingyi Zhou\*, Qiulan Ding, Yaopeng Chen, Qi Ouyang, Linlin Jiang, Jing Dai, Yeling Lu, Xi Wu, Qian Liang, Hongli Wang, Xuefeng Wang (China)
- PO196-TUE **COEXISTENCE OF CONGENITAL FIBRINOGEN DEFICIENCY AND HEREDITARY PROTEIN C DEFICIENCY IN AN INFANT PRESENTING WITH PURPURA FULMINANS**  
Özcan Bör\*, Zeynep Özdemir, Ayse Turhan (Turkey)
- PO197-TUE **INTERNATIONAL STUDY TO ASSESS THE PERFORMANCES OF A NEW LIQUID ASSAY FOR DETERMINATION OF FIBRINOGEN**  
Neil Harris\*, Jacqueline Valadier, Sophie Testa (United States)

## SCIENTIFIC PROGRAM

- PO198-TUE **PHARMACOKINETIC (PK) COMPARISON OF TWO FIBRINOGEN CONCENTRATES FOR THE TREATMENT OF CONGENITAL FIBRINOGEN DEFICIENCY**  
Bruce Schwartz\*, Savita Rangarajan, Mehran Karimi, Sigurd Knaub, Flora Peyvandi (United States)
- PO199-TUE **FIBRINOGEN AND FACTOR XIII ARE MODIFIED BY N-HOMOCYSTEINYLACTION REACTIONS**  
Valeria Genoud, Ana Maria Lauricella, Lucia Kordich, Irene Quintana\* (Argentina)
- PO200-TUE **A CASE OF THROMBOSIS IN CONGENITAL AFIBRINOGENEMIA PATIENT: A PHYSIOPATHOLOGIC AND MANAGEMENT DILEMMA**  
Cristina Santoro\*, Fulvio Massaro, Vera Capria, Salvatore Venosi, Erminia Baldacci, Roberta Abbruzzese, Francesco Barone, Raffaele Bochicchio, Federico De Angelis, Paola Volpicelli, Maria Gabriella Mazzucconi (Italy)
- PO201-TUE **CTEPH-ASSOCIATED DYSFIBRINOGENEMIA WITH ENHANCED ACCESSIBILITY ON FIBRIN OF LIGANDS FOR VE-CADHERIN**  
Benjamin Planquette\*, Peter Chiles, James Marsh, Olivier Sanchez, Guy Meyer, Timothy Morris (France, United States)
- PO202-TUE **NON-ENZYMATIC FIBRINOGEN SELF-ASSEMBLY UNVEILED**  
Dennis Galanakis\*, Liu Zhang, Miriam Rafailovich, Brendan Case (United States)
- PO203-TUE **ASSESSMENT OF A TEST FOR FUNCTIONAL FIBRINOGEN IN WHOLE BLOOD USING ULTRASOUND TECHNOLOGY COMPARED TO CLAUS FIBRINOGEN IN PLASMA**  
Kiev Blasier\*, Elisa Ferrante, Jennifer Terrasi, Timothy Fischer, Francesco Viola (United States)

### Hemophilia – clinical II

- PO204-TUE **HAEMOPHILIA PRESENTATIONS....LET ME COUNT THE WAYS.**  
Vaughan Williams\*, Samantha Reardon (Australia)
- PO205-TUE **INTRACRANIAL HEMORRHAGE IN EARLY NEONATES WITH HEMOPHILIA IN JAPAN**  
Masashi Taki\*, Midori Shima (Japan)
- PO206-TUE **A PHASE III, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE PHARMACOKINETICS OF A PLASMA-DERIVED VON WILLEBRAND FACTOR/ FACTOR VIII (VWF/FVIII) CONCENTRATE IN PEDIATRIC SUBJECTS WITH HAEMOPHILIA A (SWIFTLY-HA STUDY).**  
Maria Teresa Pompa, Genadi Iosava, Claudia Khayat, Irina Romashevskaya, Olga Aleinikova, Oleksandra Stasyshyn, Liudmyla Vashchenko, Marta Julia Lopez, Wilfried Seifert\* (Germany)
- PO207-TUE **NATIONAL INHIBITOR SURVEY IN HAEMOPHILIA PATIENTS (NISH) FROM INDIA**  
Shrimati Shetty\*, Patricia Pinto, Tejashree Shelar, Vidhya Nawadkar, Darshana Mirgal, Alfiya Mukaddam, Kanjalksha Ghosh (India)

## SCIENTIFIC PROGRAM

- PO208-TUE **IMMUNOGENICITY ASSESSMENT OF THE FIRST EXTENDED HALF-LIFE FACTOR VIII PRODUCT, RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIII FC), IN HUMANS**  
Darshana Jani, Jason Pennucci, Jaya Goyal, Jenny Dumont, Geoffrey Allen, Glenn Pierce, Jurg M. Sommer\* (United States)
- PO209-TUE **A STUDY OF DEPRESSION IN FAMILY MEMBERS OF HEMOPHILIC PATIENTS**  
Mi Kyung Kim\*, Jiwon Park, Tae Hyeong Kim, Sunah Lee (Korea, Republic Of)
- PO210-TUE **HAEMTRACK: UK PATIENT HOME THERAPY REPORTING SYSTEM**  
Rob Hollingsworth\*, Hua Xiang, Gerry Dolan, Charles Hay\* (United Kingdom)
- PO211-TUE **JOINT LAVAGE FOLLOWED BY VISCOSUPPLEMENTATION AND TRIAMCINOLONE IN PATIENTS WITH SEVERE HEMOPHILIC ARTHROPATHY. OBJECTIVE FUNCTIONAL RESULTS.**  
Thiago Pasqualin\*, Marcia Rezende, Felix Andrusaitis, Gustavo Campos, Renato Fruchi, Alexandre Pailo, Erica Okazaki, Paula Villaça (Brazil)
- PO212-TUE **ENDOVASCULAR ABDOMINAL AORTIC ANEURYSM REPAIR IN A PATIENT WITH MILD HEMOPHILIA A ON DABIGATRAN FOR ATRIAL FIBRILLATION**  
Beatriz Delgado\*, Manuela Carvalho, Luciana Gonçalves, Susana Fernandes, Carla Monteiro, Joel Sousa, Dalila Rolim, Sergio Sampaio, Fernando Araújo (Portugal)
- PO213-TUE **ANALYSIS OF MODERATE PHENOTYPE OF HEMOPHILIA A WITH NOVEL MISSENSE MUTATION, W2229R IN C2 DOMAIN, OF WHICH FVIII HAS NO RESPONSIVENESS WITH DDAVP.**  
Takashi Suzuki\*, Keiko Shinozawa, Hiroshi Inaba, Ikuo Seita, Takashi Muramatsu, Kagehiro Amano, Katsuyuki Fukutake (Japan)
- PO214-TUE **RUSSIAN NATIONAL REGISTRY OF INHIBITOR HEMOPHILIA PATIENTS: FIRST CUT-OFF ANALYSIS**  
Nadezhda Zozulya\*, Tatiana Andreeva, Vladimir Vdovin, Farida Perina, Elena Parovichnicova (Russian Federation)
- PO215-TUE **SEPTIC ARTHRITIS IN HEMOPHILIC TARGET JOINTS – A NOT UNCOMMON COMPLICATION – AWARENESS IS THE MAIN DIAGNOSTIC FEATURE**  
Peter Staritz\*, Rainer Zimmermann, Angela Huth-Kuehne (Germany)
- PO216-TUE **MANAGING MODERN MAJOR ORTHOPAEDIC SURGERY WITH PLASMA DERIVED FVIII CONCENTRATE (FANHDI®) IN SEVERE HAEMOPHILIA A PATIENTS WITH ADVANCED ARTHROPATHY**  
Pu-Lin Luo\*, Steve Austin, Ruth Pink, Savita Rangarajan (United Kingdom)
- PO217-TUE **THROMBOELASTOGRAM FOR INTRA-OPERATIVE MONITORING OF HEMOPHILIA PATIENTS DURING CORONARY ARTERY BYPASS GRAFT SURGERY**  
Mudi Misgav\*, Gili Kenet, Tal Mandelbaum, Yigal Kassif, Yariv Fruchtman, Ilia Tamarin (Israel)
- PO218-TUE **FACTORS INFLUENCING RISK OF BLEEDING AFTER DENTAL EXTRACTION IN HEMOPHILIA PATIENTS**  
Predrag Miljic\*, Jelena Bodrožic, Ivo Elezovic, Milan Jurišic, Božidar Brkovic, Darko Antic, Danijela Lekovic, Mirjana Mitrovic (Serbia)



## SCIENTIFIC PROGRAM

- PO219-TUE **FACTORS INFLUENCING THE OUTCOME OF IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH HAEMOPHILIA A AND INHIBITORS**  
Natascha Marquardt\*, Bernhard Bailer, Georg Goldmann, Silvia Horneff, Anna Pavlova, Hans-Hermann Brackmann, Johannes Oldenburg (Germany)
- PO220-TUE **INDIVIDUALISED TREATMENT IN HAEMOPHILIA A – VARIABILITY IN FACTOR VIII ACTIVITY MEASUREMENT FOR PHARMACOKINETIC DOSING**  
Jane Needham\*, Helen Lewis, Niamh McIndoe, Sarah Mangles, Savita Rangarajan (United Kingdom)
- PO221-TUE **CYCLOPHOSPHAMIDE EFFICACY AND TOXICITIES IN THE FIRST LINE TREATMENT OF ACQUIRED HEMOPHILIA**  
John Chapin\*, Sarah Rutherford, Maria DeSancho (United States)
- PO222-TUE **TWO YEAR USE OF SHARED GUIDELINES AND A DEDICATED WEB SITE TO IMPROVE MANAGEMENT OF INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT**  
Annarita Tagliaferri\*, Caterina Di Perna, Gianna Franca Rivolta, Chiara Biasoli, Gabrielle Quintavalle, Laura Benedettini, Gianfranco Cervellin, Corrado Pattacini (Italy)
- PO223-TUE **EVIDENCE OF APCC MODE OF ACTION IN A CLINICAL STUDY TREATING HEMOPHILIA A INHIBITOR PATIENTS WITH PROPHYLAXIS THERAPY**  
Katalin Varadi, Srilatha Tangada\*, Gerald Schrenk, Jennifer Doralt, Bruce Ewenstein, Peter Turecek (United States)
- PO224-TUE **A CASE OF MODERATE HEMOPHILIA A WITH P.R1800H MUTATION COMPLICATED WITH JUVENILE IDIOPATHIC ARTHRITIS**  
Yasuaki Shida\*, Yuka Kondo, Tomoaki Ishikawa, Koji Yada, Masahiro Takeyama, Keiji Nogami, Midori Shima (Japan)
- PO225-TUE **LONG TERM FOLLOW-UP IN THE USE OF DIFFERENT TYPES OF CENTRAL VENOUS CATHETERS IN CHILDREN WITH HEMOPHILIA ON PROPHYLAXIS OR IMMUNE-TOLERANCE REGIMEN**  
Marta Milan\*, Guendalina Mognato, Piergiorgio Gamba, Bertilla Ranzato, Ezio Zanon (Italy)
- PO226-TUE **SUCCESSFUL MULTI-VESSEL PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME IN A SEVERE TAIWANESE HEMOPHILIC WITH HIV INFECTION UNDER HARRT: THE FIRST REPORTED CASE IN CHINESE POPULATION**  
Chia-Yau Chang\*, Chun-Yao Huang, Chen-Hua Tsai, Ming-Ching Shen, Yeu-Chin Chen, Jia-Ruey Tsai, Geng-Chang Yeh, Yen-Lin Liu (Taiwan)
- PO227-TUE **RELATIONSHIP BETWEEN QUALITY OF LIFE AND COAGULATION FACTOR LEVEL IN HEMOPHILIA CARRIERS: PRELIMINARY RESULTS**  
Jane Young\*, Julie Grabell, Natalia Rydz, Wilma Hopman, David Good, Johnny Mahlan-gu, Paula James (Canada)
- PO228-TUE **DOES QUALITY OF TREATMENT INFLUENCE GLOBAL HEMOSTASIS IRRESPECTIVELY OF FVIII LEVELS IN PATIENTS WITH HEMOPHILIA A?**  
Maria Berndtsson\*, Eva Zetterberg, Margareta Holmström, Nida Mahmoud Hourani Soutari, Danijela Mikovic, Ivo Elezovic, Jovan Antovic (Sweden)

## SCIENTIFIC PROGRAM

- PO229-TUE **OBSERVATIONAL IMMUNE TOLERANCE INDUCTION RESEARCH PROGRAM (OBSITI) – A MULTIFACETED APPROACH TO EXPLORE IMMUNE TOLERANCE INDUCTION**  
Carmen Escuriola Ettingshausen\*, Erik Berntorp, Yesim Dargaud, Zeynep Gutowski, Sébastien Lacroix-Desmazes, Claude Négrier, Johannes Oldenburg, Anna Pavlova, Wolfhart Kreuz (Germany)
- PO230-TUE **DEFINING ADHERENCE TO PROPHYLAXIS IN HAEMOPHILIA: RESULTS OF A DELPHI CONSENSUS PROCEDURE**  
Liesbeth Schrijvers\*, Marjon Cnossen, Marlene Beijlvelt - van der Zande, Marjolein Peters, Marieke Schuurmans, Kathelijn Fischer (The Netherlands)
- PO231-TUE **UTILIZATION PREDICTABILITY FOR BAX 855 VS. BIIB031: A DESCRIPTIVE COMPARISON FROM PIVOTAL TRIALS**  
Elizabeth L. Schwartz\*, Yan Xiong, Joshua Epstein, Andrea Hafeman, Leonard Valentino (United States)
- PO232-TUE **ORIGIN OF MUTATION AND MOSAICISM IN FAMILIES WITH SPORADIC CASES OF HEMOPHILIA A IN SWEDEN**  
Annika Mårtensson\*, Stina Ivarsson, Rolf Ljung (Sweden)
- PO233-TUE **DIFFERENCES IN THE TROUGH LEVELS OF FACTOR VIII DEPENDING ON BLOOD GROUPS**  
Tomoko Ashikaga\*, Atsuki Yamashita, Chiai Nagae, Mika Mori, Masashi Taki (Japan)
- PO234-TUE **CONTINUOUS INFUSION OF FVIII IN OBESE PATIENTS WITH SEVERE HAEMOPHILIA A: IS WEIGHT-BASED DOSE-ADJUSTMENT REQUIRED?**  
Ana Boban\*, Severine Henrard, Catherine Lambert, Cedric Hermans (Belgium)
- PO235-TUE **USE OF APCC IN COMBINATION WITH TRANEXAMIC ACID: A SINGLE CENTRE EXPERIENCE**  
Jerzy Windyga\*, Beata Baran, Edyta Odnoczek, Ewa Stefanska-Windyga (Poland)
- PO236-TUE **NON-NEUTRALIZING ANTIBODIES MODULATE FACTOR VIII PHARMACOKINETIC IN PATIENTS WITH HEMOPHILIA A WITHOUT FVIII INHIBITORS**  
Christoph J. Hofbauer\*, Sylvia Kepa, Michael Schemper, Peter Quehenberger, Sylvia Reitter-Pfoertner, Christine Mannhalter, Birgit Reipert, Ingrid Pabinger (Austria)
- PO237-TUE **IPAQ SCORING AND CAROTID INTIMA MEDIA THICKNESS IN PATIENTS WITH HAEMOPHILIA**  
Fahri Sahin\*, Miray Bozgul Kilincer, Ugur Turk, Kaan Kavakli, Guray Saydam (Turkey)
- PO238-TUE **LEFT VENTRICLE DIASTOLIC FUNCTIONS AND PHYSICAL ACTIVITY SCORE IN ADULT HEMOPHILIA PATIENTS: AEGEAN HAEMOPHILIA CENTER EXPERIENCE**  
Fahri Sahin\*, Miray Bozgul Kilincer, Ugur Turk, Kaan Kavakli, Guray Saydam (Turkey)
- PO239-TUE **REGIONAL DATA SUPPORTS NEED FOR UNIFORM APPROACH TO EXTENDED HALF-LIFE (EHL) PRODUCT TRANSITION**  
Stacy E. Croteau\*, Chris Holmes, Joanne Porter, Aric Parnes, Ellis Neufeld (United States)

## SCIENTIFIC PROGRAM

- PO240-TUE **DDAVP-INDUCED RISE IN PRE-INFUSION VON WILLEBRAND FACTOR LEVELS MAY SLIGHTLY AFFECT THE PHARMACOKINETICS OF PLASMA-DERIVED FACTOR VIII CONCENTRATE IN SEVERE HEMOPHILIA A PATIENTS**  
Eva Stokhuijzen\*, Janneke Loomans, Marjolein Peters, Karin Fijnvandraat (The Netherlands)
- PO241-TUE **POPULATION PHARMACOKINETIC MODEL OF RECOMBINANT SINGLE-CHAIN FACTOR VIII (RVIII SINGLECHAIN) IN PATIENTS WITH HEMOPHILIA A**  
Ying Zhang\*, Tharin Limsakun, Debra Bensen-Kennedy, Alex Veldman, Jagdev Sidhu (United States)
- PO242-TUE **DISCREPANCY BETWEEN THE FACTOR VIII LEVELS AND SEVERITY OF HEMOPHILIA A IN TWO MATERNAL COUSINS' PATIENTS**  
Hadjira Ahmidatou\*, Meriem Bensadok, Karima Chennoukh, Amar Arour, Nadia Zidani, Mohamed Ramaoun, Meriem Belhani, Salim Nekkal (Algeria)
- PO243-TUE **THE AHEAD STUDY: EFFECTIVENESS INTERIM RESULTS AFTER ONE YEAR OF OBSERVATION, AN ANALYSIS OF THE EUROPEAN PATIENTS COHORT**  
Johannes Oldenburg\*, Dimitrios Tsakiris, Cedric Hermans, Ri Liesner, Maria Mazzucconi, Rafael Parra, Katharina Steinitz, Lydia Abad-Franch, Alexandra Loew-Baselli (Germany)
- PO244-TUE **THE AHEAD STUDY: SAFETY REAL WORLD DATA AFTER 1 YEAR OF OBSERVATION, AN ANALYSIS OF THE EUROPEAN COHORT OF PATIENTS**  
Johannes Oldenburg\*, Dimitrios Tsakiris, Cedric Hermans, Ri Liesner, Maria Mazzucconi, Rafael Parra, Katharina Steinitz, Alexandra Loew-Baselli, Lydia Abad-Franch (Germany)
- PO245-TUE **A CORE SET OF OUTCOME MEASUREMENT TOOLS IN PATIENTS WITH HEMOPHILIA: A SYSTEMATIC REVIEW OF THE MEASUREMENT PROPERTIES**  
Victor Blanchette, Alok Srivastava, Samantha Gouw\*, Brian Feldman, Pamela Hilliard, Audrey Abad, Andrea Doria, Kathelijin Fischer (The Netherlands)
- PO246-TUE **CLINICAL SIGNIFICANCE OF TYPE 1, TYPE 2 T CELLS, TH17 AND TREG IN THE DEVELOPMENT OF FVIII INHIBITOR IN PEDIATRIC HEMOPHILIA A PATIENTS.**  
Zhenping Chen, Runhui Wu\*, Qiqi Wei, Gang Li, Ling Tang, Yingzi Zhen, Xinyi Wu (China)
- PO247-TUE **EVALUATE THE QUALITY OF LIFE IN THE ELDERLY WITH HAEMOPHILIA**  
Mohammad Reza Shaverdi Niasari\*, Gholamreza Toogeh, Samin Roostaei, Jayran Zebardast, Elham Ale booye, Shadi Shaverdi, Alireza Rahimi, Hossein Eftekhari Ardebili, Fariba Zarrabi (Iran, Islamic Republic Of)
- PO248-TUE **RESULTS OF ANKLE PROSTHESIS IN PATIENTS WITH SEVERE HAEMOPHILIC ARTHROPATHY – FOLLOW UP**  
Manuela Krause, Daniele Pillitteri\*, Markus Preis, Carl Kirchmaier, Ute Scholz, Roger Scholz (Germany)

## SCIENTIFIC PROGRAM

- PO249-TUE **IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A AND B WITH INHIBITOR. SINGLE CENTRE EXPERIENCE.**  
Angelika Batorova\*, Eva Bubanska, Denisa Jankovicova, Anna Morongova, Tatiana Prigancova, Erika Balazova (Slovakia)
- PO250-TUE **PUPS WITH SEVERE HAEMOPHILIA A - A GCP STUDY EVALUATING THE IMMUNOGENICITY, EFFICACY AND SAFETY OF HUMAN-CL RHFVIII**  
Raina Liesner, Martina Jansen\*, Natalya Kavardakova, Marina Abashidze, Sigurd Knaub (Austria)
- PO251-TUE **POPULATION PHARMACOKINETICS IN HEMOPHILIA A: TOWARDS INDIVIDUALIZATION OF PERIOPERATIVE REPLACEMENT THERAPY**  
Hendrika C. Hazendonk\*, Karin Fijnvandaat, Mariëtte Driessens, Felix van der Meer, Karina Meijer, Marieke Kruip, Britta Laros-van Gorkom, Marjolein Peters, Saskia de Wildt, Frank Leebeek, Marjon Cnossen, Ron Mathôt (The Netherlands)
- PO252-TUE **PRENATAL DIAGNOSIS FOR HAEMOPHILIA: UMBILICAL CORD BLOOD SAMPLE USED**  
Jing Zhong\*, Jing Dai, Xuefeng Wang (China)
- PO253-TUE **BLEEDING AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEOPLE WITH HAEMOPHILIA PATIENTS (PWH) – EVEN A SINGLE BLEED MATTERS**  
Sylvia von Mackensen\*, Hermann Eichler, Katharina Holstein, Kate Khair, Wolfgang Schramm (Georgia)
- PO254-TUE **INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY, ADANA, TURKEY**  
Ilgen Sasmaz\*, Bulent Antmen, Barbaros Karagun, Dervis Yilmaz, Gokdel Leblebisatan, Yurdanur Kilinc (Turkey)
- PO255-TUE **EXPLORING COST EFFECTIVENESS OF VARIOUS PROPHYLACTIC TREATMENT STRATEGIES FOR SEVERE HAEMOPHILIA USING A COMPUTER SIMULATION MODEL**  
Kathelijin Fischer\*, Mart Janssen (The Netherlands)
- PO256-TUE **ULTRASOUND EVALUATION OF HAEMOPHILIC JOINTS BY HAEMOPHILIA PHYSICIANS: A RELIABILITY STUDY**  
Kathelijin Fischer\*, Johannes Oldenburg, Jan Astermark, Gerald Dolan, Massimo Morfini, Natascha Marquardt, Carlo Martinoli (The Netherlands)
- PO257-TUE **DOSING OF RVIIA-FP IN CLINICAL STUDIES IN HEMOPHILIA WITH INHIBITORS AND FACTOR VII DEFICIENCY**  
Britta Laros-van Gorkom\*, Pal Holme, Waander van Heerde, Johnny Mahlangu, Faraizah Dato' Abd Karim, Pratima Chowdary, Debbie Bensen Kennedy, Alex Veldman, Regina Clementi, Claude Negrier (The Netherlands)
- PO258-TUE **EFFICACY AND SAFETY OF RVIII-SINGLECHAIN IN SURGICAL PROPHYLAXIS**  
Claudia Djambas Khayat\*, Johnny Mahlangu, Cindy Leisinger, Stephanie P'ng, Elena Santagostino, Fernanda Lopez Fernandez, Debbie Bensen Kennedy, Alex Veldman, Clementi Regina, Ingrid Pabinger (Lebanon)

## SCIENTIFIC PROGRAM

- PO259-TUE **INHIBITORS IN HEMOPHILIA (HA): EXPERIENCE OF A SINGLE CENTER IN THE LAST 22 YEARS.**  
Cristina Santoro\*, Erminia Baldacci, Maura Acquila, Maria Patrizia Bicocchi, Maria Basso, Federico De Angelis, Ferrara Grazia, Laura Parlanti, Paola Volpicelli, Roberta Abbruzzese, Francesco Barone, Maria Gabriella Mazzucconi (Italy)
- PO260-TUE **SYSTEMATIC LITERATURE REVIEW OF ECONOMICS ANALYSES COMPARING APCC AND RFVIIA ACROSS ON-DEMAND, PROPHYLAXIS AND SURGERY**  
Darshan Mehta\*, Joel Hay (United States)
- PO261-TUE **ADDRESSING THE GAP IN TREATMENT ADHERENCE: DEVELOPMENT OF THE HEMOPHILIA JOINT VISUALIZER TOOL**  
Hiruyeki Takedani\*, Luigi Solimeno, Kapil Saxena, Prasad Mathew (Japan)
- PO262-TUE **RVIII-SINGLECHAIN PHARMACOKINETICS IN ADULTS, ADOLESCENTS AND CHILDREN**  
Johnny Mahlangu\*, Lynda Lepatan, Kateryna Vilchevska, Johannes Oldenburg, Oleksandra Stasyshyn, Kathelijin Fischer, Genadi Iosava, Claudia Djambas Khayat, Mindy Simpson, Michael Wang, Debbie Bensen Kennedy, Nicolas France, Katie St.Ledger, Tharin Limsakun, Ingrid Pabinger (South Africa)

### Heparin-induced thrombocytopenia (HIT) I

- PO263-TUE **ARGATROBAN IN THE MANAGEMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II: AN OPEN-LABEL, MULTICENTER CLINICAL TRIAL IN FRANCE**  
Brigitte Tardy\*, Philippe Nguyen, Jean-Claude Thiranos, Pierre-Emmanuel Morange, Christine Biron Andréani, Yves Gruel, Jerome Morel, Alain Wynckel, Lelia Grunebaum, Judith Villacorta-Torres, Sandrine Grosjean, Emmanuel De Maistre (France)
- PO264-TUE **CASE REPORT: DABIGATRAN USE IN A POSTOPERATIVE ORTHOPEDIC PATIENT WITH HEPARIN INDUCED THROMBOCYTOPENIA**  
Luciana Goncalves\*, Ana Leite, Helena Gomes, Ana Freixo, Luisa Fonseca, Manuela Carvalho, Paulo Bettencourt, Fernando Araujo (Portugal)
- PO265-TUE **RIVAROXABAN FOR TREATMENT OF HEPARIN INDUCED THROMBOCYTOPENIA**  
Nikhil Mukhi\*, FNU Kirti, Hana Lim, Olcay Batuman (United States)
- PO266-TUE **THE INCIDENCE OF HEPARIN-INDUCED THROMBOCYTOPENIA IN CRITICALLY ILL MEDICAL PATIENTS**  
Rattaporn Vichitratchaneekorn, Benjaporn Akkawat, Ponlapat Rojnuckarin, Noppacharn Uaprasert\* (Thailand)
- PO267-TUE **EVALUATING EFFICACY, SAFETY AND COMPLIANCE OF ARGATROBAN DOSING NOMOGRAM AT CANADIAN TEACHING HOSPITAL**  
Harsimran Saini\*, Gary Wong, Jin-Hyeun Huh, Bill Brien, Laura Murphy, Amita Woods (Canada)
- PO268-TUE **RAPID FUNCTIONAL ASSAY FOR HEPARIN-INDUCED THROMBOCYTOPENIA USING A PRACTICAL FLOW CYTOMETRY APPROACH**  
Michal Cipok\*, Sigi Kay, Shoshana Bar On, Ilya Kirgner, Aaron Tomer, Varda Deutsch (Israel)

## SCIENTIFIC PROGRAM

- PO269-TUE **HEPARIN-INDUCED THROMBOCYTOPENIA AND CALIBRATED THROMBIN GENERATION ASSAY.**  
Valentine Minet, Charlotte Bouckaert\*, Jean-Michel Dogné, François Mullier (Belgium)

### Immune thrombocytopenia (ITP) II

- PO270-TUE **THE ROLE OF CELLULAR IMMUNITY IN CHILDREN WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA**  
Erol Erduran\*, Fulya Celikturk, Gokce Pinar Reis, Aysenur Bahadir (Turkey)
- PO271-TUE **DIAGNOSIS OF VENOUS THROMBOEMBOLISM DURING ELTROMBOPAG THERAPY FOR IMMUNE THROMBOCYTOPENIA AND SUCCESSFUL REPLACEMENT WITH ROMIPLOSTIM.**  
Odelia Amit\*, Ilya Kirgner, Irit Avivi (Israel)
- PO272-TUE **RE-EVALUATION OF NEED FOR BONE MARROW EXAMINATION IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA TREATED WITH STEROIDS AS FIRST LINE THERAPY**  
Mukul Aggarwal\*, Abhishek Purohit, Pravas Mishra, Tulika Seth, Seema Tyagi, Manoranjan Mahapatra, Hara Pati, Renu Saxena (India)
- PO273-TUE **GLYCOPROTEIN IBA CLUSTERING INDUCES MACROPHAGE-MEDIATED PLATELET CLEARANCE IN THE LIVER**  
Rong Yan, Mengxing Chen, Kesheng Dai\* (China)
- PO274-TUE **EXTENDED PLATELET PARAMETERS AS A MEANS TO DIFFERENTIATE IMMUNE THROMBOCYTOPENIA FROM HYPOPROLIFERATIVE THROMBOCYTOPENIAS**  
Hrvoje Melinscak\*, Tahir Mirzoyev, Mala Varma (United States)
- PO275-TUE **TREATMENT OF ATRAUMATIC SPLENIC RUPTURE IN AN ADOLESCENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND AUTOIMMUNE CYTOPENIAS: A CASE REPORT**  
Rungrote Natesirinilkul\*, Pimlak Charoenkwan, Wattana Chartapisak, Sanit Ruangrongrat, Sauwalak Opastirakul, Trichak Sandhu, Prapan Jutavijittum (Thailand)
- PO276-TUE **CD70 MOLECULE INVOLVED IN THE DENDRITIC CELLS DYSFUNCTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Zhang Xian\*, Zhou Zeping, Hao Yating, Zhang Donglei, Li Huiyuan, Yang Renchi (China)
- PO277-TUE **MEGAKARYOCYTES AND MACROPHAGE -LYMPHOCYTE INTERACTIONS IN VITRO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Tamar Saralidze\*, Tinatin Shvelidze, Bela Metreveli, Tinatin Saralidze (Georgia)
- PO278-TUE **THE INVOLVEMENT OF NEUROFILIN-1 IN PRIMARY IMMUNE THROMBOCYTOPENIA**  
Hu Zhou\*, Jingyi Yang, Yongping Song (China)
- PO279-TUE **SUCCESSFUL TREATMENT OF REFRACTORY ITP WITH CYCLOSPORINE A, TWO CASE REPORTS**  
Antonin Hlusi\*, Tomas Sztokowski (Czech Republic)

## SCIENTIFIC PROGRAM

PO280-TUE **EFFICACY AND PROGNOSIS OF SHORT TERM AND VERY LOW-DOSE IVIG THERAPY (200 MG/KG/D) FOR NEWLY DIAGNOSED ACUTE IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN**  
Kun Soo Lee\*, Jung Eun Kim, Uk Hyun Kim, Ye-Jee Shim, Ji Yoon Kim (Korea, Republic Of)

### Inflammation II

PO281-TUE **A SYNTHETIC PEPTIDE, CORRESPONDING TO THE NONCANONICAL PAR1- TETHERED LIGAND, MIMICS THE APC-INDUCED STIMULATION OF WOUND HEALING IN VITRO**  
Ekaterina Kiseleva\*, Lyubov Gorbacheva, Svetlana Strukova, Maria Sidorova (Russian Federation)

PO282-TUE **DIFFERENTIAL IN VIVO ACTIVATION OF MONOCYTE SUBSETS DURING EXPERIMENTAL ENDOTOXEMIA IN HUMANS**  
Barbara Thaler\*, Philipp Hohensinner, Konstantin Krychtiuk, Lorenz Koller, Mira Brekalo, Gerald Maurer, Bernd Jilma, Johann Wojta, Walter Speidl (Austria)

PO283-TUE **REGULATION OF IL-10 AND HIGH MOBILITY GROUP BOX 1 (HMGB1) EXPRESSION IN HUMAN MONOCYTES BY PLATELETS AND NEUTROPHILS**  
Bjarne Østerud\*, Jan Ole Olsen (Norway)

PO284-TUE **EFFECT OF LIPOPOLYSACCHARIDE AND VARIOUS CYTOKINES ON PROTEIN C INHIBITOR PRODUCTION BY HEPG2 CELLS**  
Tatsuya Hayashi\*, Nobuyuki Akita, Takayuki Okamoto, Junji Nishioka, Koji Suzuki (Japan)

PO285-TUE **DOES THE COAGULATION CASCADE PLAY A ROLE IN RETINAL PATHOLOGIES?**  
Tami Livnat\*, Alon Zahavi, Ruth Axer-Siegel, Ayelet Dreznik, Elinor Megiddo, Mor Dachbash, Yael Nisgav, Gili Kenet, Dov Weinberger, Rita Ehrlich (Israel)

PO286-TUE **CLINICAL PRESENTATION OF THROMBOEMBOLIC EVENTS IN INFLAMMATORY BOWEL DISEASE**  
Lize Bollen\*, Niels Vande Casteele, Vera Ballet, Séverine Vermeire, Ann Gils (Belgium)

PO287-TUE **LOSS OF PAR-4 RECEPTOR AFFECTS RENAL ISCHEMIA REPERFUSION IN MICE**  
Marcel P. B. Jansen\*, Sandrine Florquin, Joris Roelofs (The Netherlands)

PO288-TUE **TIPE2 IS INDUCED BY SIMULATED MICROGRAVITY IN MONOCYTES**  
Shilong Xiong\*, Zhi Wei Wang, Xiao Yan Li (China)

PO289-TUE **MOUSE MACROPHAGES UPREGULATE PODOPLANIN UNDER INFLAMMATORY AND APOPTOTIC CONDITIONS**  
Julie Rayes\*, Samantha Montague, Stephanie Watson, Steve Watson (United Kingdom)

PO290-TUE **ANTI-INFLAMMATORY EFFECT OF NON-CANONICAL PEPTIDE-AGONIST OF PAR-1 ON RAT MAST CELLS RESEMBLES ACTIVATED PROTEIN C ACTION**  
Irina Babkina\*, Maria Sidorova, Lyubov Gorbacheva, Svetlana Strukova (Russian Federation)

## SCIENTIFIC PROGRAM

PO291-TUE **HIGH-FAT DIET IS ASSOCIATED WITH INCREASED VON WILLEBRAND FACTOR-RELATED PROCOAGULANT ACTIVITY IN HUMAN AND MURINE MODELS**  
Alison Michels\*, Laura Swystun, Silvia Albáñez, Jeffrey Mewburn, Kate Sponagle, David Lillcrap (Canada)

PO292-TUE **INFLAMMATORY AND ENDOTHELIAL MARKERS AND THEIR RELATIONS TO THE HAEMOSTATIC POTENTIAL DURING THE MENSTRUAL CYCLE.**  
Roza Chaireti\*, Tomas Lindahl, Katarina Bremme, Anders Larsson (Sweden)

PO293-TUE **CIGARETTE SMOKING SIGNIFICANTLY REDUCES GEN- AND PROTEIN EXPRESSION OF THE PRO-INFLAMMATORY CYTOKINE IL-12**  
Trine Baur Opstad\*, Harald Arnesen, Alf-Åge Pettersen, Ingebjørg Seljeflot (Norway)

PO294-TUE **THE INTERACTION BETWEEN EXPRESSION OF COXSACKIE-ADENOVIRUS RECEPTOR ON THE SURFACE OF PLATELETS AND CARDIOMYOCYTES, INFLAMMATION AND VIRUS PERSISTENCE INSIDE CELLS**  
Elena Gupalo\*, Liudmila Buryachkovskaya, Petr Chumachenko, Natalia Mironova (Russian Federation)

PO295-TUE **THE ROLE OF INFLAMMATION IN PREGNANCY-RELATED VENOUS THROMBOSIS**  
Hilde Skuterud Wik\*, Anne Jacobsen, Per Sandset (Norway)

PO296-TUE **THE EXTRACELLULAR FIBRINOGEN-BINDING PROTEIN (EFB) SECRETED BY STAPHYLOCOCCUS AUREUS BINDS P-SELECTIN AND COMPETITIVELY INHIBITS ITS INTERACTION WITH P-SELECTIN GLYCOPROTEIN LIGAND-1 (PSGL-1)**  
Giordano Pula\*, Stefan Bagby, Mareike Posner, Abhishek Upadhyay (United Kingdom)

### Innate and acquired Immunity

PO297-TUE **CRITICAL BEHAVIOR OF SUBCELLULAR DENSITY ORGANIZATION DURING NEUTROPHIL ACTIVATION AND MIGRATION**  
Sandra Baker-Groberg\*, Kevin Phillips, Laura Healy, Asako Itakura, Juliana Porter, Paul Newton, Owen McCarty (United States)

PO298-TUE **NATURALLY OCCURRING ANTIBODIES TO OXIDATION-SPECIFIC EPI-TOPIES IN PATIENTS WITH VENOUS THROMBOEMBOLISM**  
Sabine Eichinger\*, Paul Kyrle, Michael Kammer, Maria Ozsvar Kozma, Lisbeth Eischer, Christoph Binder (Austria)

PO299-TUE **C. CANIMORSUS AFFECTS COAGULATION BY PROTEOLYTIC CLEAVAGE OF FACTOR X**  
Katrin Hack\*, Jonathan Douxfils, Jean-Michel Dogné, Guy Cornelis (Belgium)

PO300-TUE **POLYPHOSPHATE ACTS AS A COFACTOR FOR C1-INHIBITOR-MEDIATED REGULATION OF THE CLASSICAL PATHWAY OF COMPLEMENT**  
Emilie Lameignere\*, Lakshmi Wijeyewickrema, Alice O'Byrne, Linnette Ocariza, Toshikazu Shiba, Stephanie Smith, James Morrissey, Robert Pike, Edward Conway (Canada)

## SCIENTIFIC PROGRAM

- PO301-TUE **HUMAN MONOCYTE SUBSETS DIFFERENTLY EXPRESS TISSUE FACTOR**  
Konstantin Krychtiuk\*, Barbara Thaler, Philipp Hohensinner, Max Lenz, Kurt Huber, Gerald Maurer, Johann Wojta, Gottfried Heinz, Walter Speidl (Austria)
- PO302-TUE **MHC CLASS I ANTIGEN PRESENTATION BY MEGAKARYOCYTES.**  
Anne Zufferey\*, Edwin Speck, Li Guo, Rukhsana Aslam, Rick Kapur, John Semple (Canada)
- PO303-TUE **PROTHROMBIN MUTANTS REVEAL A NEW MECHANISM OF MASP-1 MEDIATED CLOTTING**  
Lorenz Jenny, József Dobó, Péter Gál, Verena Schroeder\* (Switzerland)
- PO304-TUE **COMPLEMENT AND TISSUE-FACTOR INDUCED THROMBIN GENERATION IN THE PATHOGENESIS OF VENOUS THROMBOEMBOLISM**  
Ina Isabella Høiland\*, Robin Liang, Erin Hald, Nadezhda Latysheva, Cathrine Ramberg, Vladimir Tichelaar, Tom Eirik Mollnes, John-Bjarne Hansen (Norway)
- PO305-TUE **UNIQUE GENETIC VARIATION IN AN INVASIVE SEROTYPE M23ND STRAIN OF STREPTOCOCCUS PYOGENES INFLUENCES BACTERIUM-HOST CELL INTERACTIONS AND COMPLEMENT-MEDIATED OPSONIZATION**  
Garima Agrahari\*, Zhong Liang, Dustin Higashi, Shaun Lee, Victoria Ploplis, Francis Castellino (United States)
- PO306-TUE **CD44 ANTIBODIES CAN DIRECTLY INHIBIT MURINE MACROPHAGE FC-GAMMA RECEPTOR AND COMPLEMENT RECEPTOR 3 – MEDIATED PHAGOCYTOSIS**  
Alaa Amash\*, Yawen Wang, Lin Wang, Alan Lazarus (Canada)
- PO307-TUE **EXOGENOUS AND ENDOGENOUS TOLL-LIKE RECEPTOR LIGANDS INDUCE THE FORMATION OF PLATELET-NEUTROPHIL AND PLATELET-MONOCYTE COMPLEXES IN HUMAN WHOLE BLOOD**  
Julia Seyfert\*, Christoph Bode, Daniel Duerschmied, Ingo Ahrens (Germany)
- PO308-TUE **COMPLEMENT ACTIVATION AND THROMBIN GENERATION IN HEALTHY INDIVIDUALS SUBJECTED TO MILD ISOBARIC HYPOXIA AND VENOUS STASIS**  
Ina Isabella Høiland\*, Robin Liang, Erin Hald, Trond B;rvik, Nadezhda Latysheva, Cathrine Ramberg, Tom Mollnes, John Bjarne Hansen (Norway)

### Management of bleeding I

- PO309-TUE **RETROSPECTIVE EVALUATION OF THE USE OF RECOMBINANT FACTOR VIIA BEFORE AND AFTER THE IMPLEMENTATION OF A PHARMACIST-LED FACTOR STEWARDSHIP PROGRAM**  
Taylor White\*, Lindsey Amerine, Sheh Li Chen (United States)
- PO310-TUE **USE OF A 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE IN A UNITED STATES COMMUNITY HOSPITAL SYSTEM**  
Linda R. Kelly\*, Bente Garcia (United States)

## SCIENTIFIC PROGRAM

- PO311-TUE **IN VITRO OPTIMIZATION OF AN INNOVATIVE BIOLOGICAL GLUE COMPOSITION**  
Jean-Luc Plantier\*, Véronique Duret, Sami Chtourou, Philippe Mondon (France)
- PO312-TUE **4F-PCC (BERIPLEX® P/N) IS SUPERIOR TO 3F-PCC FOR REVERSAL OF COUMARIN ANTICOAGULATION IN A RAT BLEEDING MODEL**  
Eva Herzog\*, Franz Kaspereit, Wilfried Krege, Peter Niebl, Gerhard Dickneite (Germany)
- PO313-TUE **EVALUATION OF THE PERFORMANCE OF EIGHT SCORES FOR PREDICTION OF BLEEDING RISK IN BRAZILIAN HEART DISEASE OUTPATIENTS TREATED WITH WARFARIN**  
Joao Oliveira, Antonio Ribeiro, Daniel D. Ribeiro\*, Vandack Nobre Junior, Manoel Rocha, Maria Martins (Brazil)
- PO314-TUE **IDARUCIZUMAB SPECIFICALLY REVERSES DABIGATRAN ANTICOAGULATION BUT DOES NOT INDUCE A PROCOAGULANT STATE IN A PORCINE TRAUMA MODEL WITH DABIGATRAN ANTICOAGULATION**  
Markus Honickel, Joanne van Ryn, Johanna Schurer, Rolf Rossaint, Oliver Grottk\* (Germany)
- PO315-TUE **WHOLE BLOOD THROMBOELASTOMETRY PROFILES IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY.**  
Luca Spiezia\*, Francesco Vasques, Astrid Behr, Elena Campello, Sara Maggiolo, Mariangela Fadin, Paolo Simioni (Italy)
- PO317-TUE **A MULTICENTER OBSERVATIONAL STUDY OF THE EFFECTIVENESS OF PROTHROMBIN COMPLEX CONCENTRATE FOR TREATMENT OF BLEEDING IN THE PERIOPERATIVE AND INTENSIVE CARE SETTING: PROBE STUDY**  
Pratima Chowdary\*, Augustine Tang, Dale Watson, Martin Besser, Peter Collins, Michael Creagh, Hafiz Qureshi, Margaret Rokicka, Tim Nokes, Paul Diprose, Surekha Frith, Ravi Gill (United Kingdom)
- PO318-TUE **BLEEDING COMPLICATIONS AFTER INVASIVE DENTAL PROCEDURES IN PATIENTS UNDER VITAMIN K ANTAGONISTS**  
Ana Spinola, Maria Coutinho, Fernanda Leite, Sara Morais\*, Rui Moreira, Eva Pacheco, Norival Pinho, Nilza Seidi, Eugenia Cruz, Manuel Campos (Portugal)
- PO319-TUE **AN ANALYSIS OF MANAGEMENT STRATEGIES AND OUTCOMES IN NVAF PATIENTS TREATED WITH DABIGATRAN: A MULTI-CENTER RETROSPECTIVE COHORT OF PATIENTS WITH MAJOR BLEEDING EVENTS**  
Truman J. Milling, Jr\*, Michael Ganetsky, Carol Duffy, Heather Paden, Adam Singer (United States)
- PO320-TUE **USE OF PROTHROMBIN COMPLEX CONCENTRATE AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF DIRECT ORAL ANTICOAGULANT ASSOCIATED BLEEDING**  
Lana A. Castellucci\*, Joseph Shaw, Gregoire Le Gal, Melanie Tokessy, Nancy Cober, Elianna Saidenberg, Marc Carrier (Canada)
- PO321-TUE **TREATMENT APPROACHES IN SPONTANEOUS RECTUS SHEATH HEMATOMAS IN CLINICAL PRACTICE. A SINGLE-CENTER EXPERIENCE**  
Veronica Pons\*, Josep M Suriñach, Laura Lopez-Andreoni, Jose Loureiro, Pavel Olivera, Antonieta Guliana Molero, Ana Marin, Francesc Bosch, Amparo Santamaria (Spain)

## SCIENTIFIC PROGRAM

### Microparticles II

- PO322-TUE **SYNTHESIS AND IN VITRO STUDIES OF NANOXIDES AS HEMOSTATIC AGENTS FOR THE BLOOD COAGULATION ACCELERATION**  
Juliana Bergamasco\*, Gabriel Zazeri, Tânia Da Rocha, Élbio D'Amico, Moacir De Godoy, José Geraldo Nery (Brazil)
- PO323-TUE **COMPOSITION-DEPENDENT EFFECTS OF NANOPARTICLES ON COAGULATION**  
Kamran Bakhtiari\*, Joost Meijers, Sophie Laurent, Svetlana Mintova, Eng-Poh Ng, Hussein Awala, Somayyeh Mirsadeghi, Morteza Mahmoudi, Farhad Rezaee (The Netherlands)
- PO324-TUE **PLATELET ACTIVATION RELEASES MATURE MIR-494 IN MICROPARTICLES**  
Jasmine Tay\*, Jessica Jorritsma, Quintin Hughes, Ross Baker (Australia)
- PO325-TUE **CHARACTERISTICS AND ROLE OF EXTRACELLULAR VESICLES IN THE PATHOPHYSIOLOGY OF TRANSFUSION DEPENDENT B-THALASSEMIA**  
Carina Levin\*, Annie Sabbah, Benjamin Brenner, Anat Aharon (Israel)
- PO326-TUE **MICROPARTICLES : WHAT'S PLASMA MADE OF ?**  
Alain R. Brisson\*, Nicolas Arraud, Celine Gounou, Romain Linares, Sisareuth Tan (France)
- PO327-TUE **COAGULATION ACTIVITY OF MICROPARTICLES FROM DIFFERENT CELLULAR SOURCES. INVOLVEMENT OF ACTIVE TISSUE FACTOR.**  
Alexey Mazurov\*, Svetlana Khaspekova, Olga Antonova, Olga Shustova, Nina Golubeva, Vladimir Yakushkin, Anatoly Dobrovolsky (Russian Federation)
- PO328-TUE **IMPACT OF VARIOUS ANTICOAGULANTS AND STORAGE TIME ON PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES**  
Simin Jamaly\*, Vladimir Tichelaar, Randi Olsen, Erin Hald, Cathrine Ramberg, Nadezhda Latysheva, John-Bjarne Hansen (Norway)
- PO329-TUE **PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES IN HEALTHY INDIVIDUALS SUBJECTED TO MILD ISOBAR HYPOXIA AND VENOUS STASIS**  
Trond Børvik\*, Ina Høiland, Erin Mathiesen Hald, Cathrine Ramberg, Nadezhda Latysheva, John-Bjarne Hansen (Norway)
- PO330-TUE **NEW TECHNIQUE TO STUDY CELL-DERIVED MICROPARTICLES**  
Åsa Thulin\*, Junhong Yan, Masood Kamali-Moghaddam, Agneta Siegbahn (Sweden)
- PO331-TUE **MICROPARTICLE LEVEL AND ORIGIN DURING PROGRESSION OF NORMAL PREGNANCY: A LONGITUDINAL STUDY IN HEALTHY WOMEN.**  
Elena Campello\*, Claudia Radu, Luca Spiezia, Sonila Dhima, Silvia Visetin, Sabrina Gavasso, Barry Woodhams, Erich Cosmi, Paolo Simioni (Italy)
- PO332-TUE **CIRCULATING MICROPARTICLES IN CORD BLOOD OF NORMAL PREGNANCY AND OF PREGNANCY WITH PREECLAMPSIA (PET).**  
Elena Campello\*, Luca Spiezia, Claudia Radu, Sonila Dhima, Silvia Visetin, Sabrina Gavasso, Barry Woodhams, Erich Cosmi, Paolo Simioni (Italy)

## SCIENTIFIC PROGRAM

### Natural anticoagulants

- PO333-TUE **A GAIN-OF-FUNCTION VARIANT OF PROTEIN C MANIFESTS ITSELF AS TYPE II PROTEIN C DEFICIENCY IN A HEALTHY SUBJECT**  
Qiulan Ding\*, Likui Yang, Peyman Dinarvand, Xuefeng Wang, Alireza Rezaie (China)
- PO334-TUE **EVALUATION OF PROTEIN C LEVELS IN SICKLE CELL DISEASE SUBJECTS SEEN AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY, NIGERIA.**  
Obinna Iheanacho\*, Benedict Nwogoh (Nigeria)
- PO335-TUE **POSSIBLE MECHANISM OF ACTIVATED PROTEIN C-INDUCED INHIBITION OF OSTEOCLAST DIFFERENTIATION**  
Nobuyuki Akita\*, Kakunoshin Yoshida, Takayuki Okamoto, Kunihiro Asanuma, Junji Nishioka, Koji Suzuki, Tatsuya Hayashi (Japan)
- PO336-TUE **PHARMACOKINETIC STUDY OF THE NOVEL ANTICOAGULANT PEPTIDE VARIEGIN USING LC-MS/MS, CHROMOGENIC SUBSTRATE AND MODIFIED THROMBIN TIME ASSAYS**  
Norrapat Shih\*, R. Manjunatha Kini (Singapore)
- PO337-TUE **THROMBOMODULIN INHIBITS TISSUE FACTOR MEDIATED THROMBIN GENERATION IN BLOOD AND PROTHROMBIN COMPLEX CONCENTRATES**  
Jawed Fareed\*, Debra Hoppensteadt, Daneyal Syed, Daniel Kahn, Michael Mosier, Inder Kaul (United States)
- PO338-TUE **HEPARANASE ACTIVATES ANTITHROMBIN THROUGH THE BINDING TO ITS HEPARIN BINDING SITE**  
Nataliya Bohdan, Salvador Espín, Sonia Águila, Raúl Teruel-Montoya, Javier Corral, Vicente Vicente, Irene Martínez-Martínez\* (Spain)
- PO339-TUE **ANTITHROMBIN BINDS TO AND ENHANCES THE BARRIER FUNCTION OF HUVECS INDEPENDENTLY OF CELL-SURFACE HEPARAN SULFATE PROTEOGLYCAN**  
François Saller\*, Stéphane Pautus, Yasmine Bourti, Allan De Carvalho, Toufik Abache, Elsa Bianchini, Jean-Luc Plantier, Delphine Borgel (France)
- PO340-TUE **TETRAMETHYLPYRAZINE DECREASES RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) VIA SUPPRESSION OF FOXA2 AND INDUCTION OF NOS IN HEPG2 CELLS**  
Junling Li\*, Wenhui Zhu, Ping Zhou (China)
- PO341-TUE **QUANTITATIVE TRANSCRIPTOME AND PROTEOME ANALYSIS OF DERMACENTOR RETICULATUS SALIVARY GLANDS FOR THE IDENTIFICATION OF NOVEL ANTICOAGULANTS AND IMMUNOMODULATORY PROTEINS**  
Janaki Iyer\*, Mirko Slovak, Ivo Francischetti, Jose Ribeiro, Manjunatha Kini (Singapore)
- PO342-TUE **SIMILAR RESPONSES OF PHOSPHATIDYLSERINE AND PHOSPHATIDYLETHANOLAMINE TOWARDS COFACTOR ACTIVITY OF HUMAN PROTEIN Z, A NATURAL ANTICOAGULANT**  
Tanusree Sengupta\*, N Manoj (India)

## SCIENTIFIC PROGRAM

- PO343-TUE **THE EFFECT OF AGE ON GLYCAN MICROHETEROGENEITY OF HUMAN ALPHA-2-MACROGLOBULIN**  
Laura S. Calvert\*, Helen Atkinson, Leslie Berry, Anthony Chan (Canada)
- PO344-TUE **QUANTITATIVE IMMUNOASSAY FOR THE MEASUREMENT OF ACTIVATED PROTEIN C COMPLEXES WITH ALFA-2-MACROGLOBULIN (APC:A2M)**  
Francisco España\*, Silvia Navarro, Laura Martos, Luis Ramón, Elena Bonet, Pilar Medina (Spain)
- PO345-TUE **IDENTIFICATION OF A NOVEL MUTATION P.K234EFS\*24 IN THE PROC GENE AND A PHENOTYPE-GENOTYPE CHARACTERISTICS OF THAI PATIENTS DIAGNOSED WITH HEREDITARY PROTEIN C DEFICIENCY AND SYMPTOMATIC THROMBOEMBOLISM**  
Bundarika Suwanawiboon\*, Wanna Thongnopkakhun, Chanin Limwongse (Thailand)
- PO346-TUE **THE PDI INHIBITOR ISOQUERCETIN REDUCES THROMBIN GENERATION IN HEALTHY ADULTS AND IN PATIENTS WITH ELEVATED ANTIPHOSPHO-LIPID ANTIBODIES**  
Jack D. Stopa\*, Bruce Furie, Robert Flaumenhaft, Jeffrey Zwicker (United States)
- PO347-TUE **INVESTIGATION OF PROTEIN S DEFICIENCY INDUCED PURPURA FULMI-NANS**  
Raja Prince\*, Sara Calzavarini, François Saller, Luca Bologna, Federica Bisignani, Anne Angelillo-Sherrer (Switzerland)
- PO348-TUE **QUANTITATIVE PLATELET TFPI-ALPHA RELEASE IS NOT INFLUENCED BY SEX AND ORAL CONTRACEPTIVE USE.**  
Kristien Winckers, Stella Thomassen, Hugo ten Cate, Tilman Hackeng\* (The Netherlands)
- PO349-TUE **ROLE OF TISSUE FACTOR PATHWAY INHIBITOR-ALPHA IN PLATELET-DEPENDENT FIBRIN FORMATION UNDER FLOW**  
Stella Thomassen\*, Tom Mastenbroek, Kristien Winckers, Marion Feijge, Judith Cosemans, Tilman Hackeng, Johan Heemskerk (The Netherlands)

### Non-vitamin K antagonist oral anticoagulants II

- PO350-TUE **ASSOCIATION RATE CONSTANTS RATIONALIZE THE SENSITIVITY OF PROTHROMBIN TIME AND THROMBIN GENERATION ASSAY TO APIXABAN AND RIVAROXABAN**  
Georges Jourdi\*, Virginie Siguret, Anne-Céline Martin, Jean-Louis Golmard, Anne Godier, Charles-Marc Samama, Pascale Gaussem, Isabelle Gouin-Thibault, Bernard Le Bonniec (France)
- PO351-TUE **INTERACTION OF ANDEXANET ALFA, A UNIVERSAL ANTIDOTE TO FXA INHIBITORS, WITH TISSUE FACTOR PATHWAY INHIBITOR ENHANCES REVERSAL OF FXA INHIBITOR-INDUCED ANTICOAGULATION**  
Genmin Lu\*, Joyce Lin, Gregory Coffey, John Curnutte, Pamela Conley (United States)
- PO352-TUE **DIRECT ORAL ANTICOAGULANTS: OUR EXPERIENCE**  
Rita Santoro\*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy)

## SCIENTIFIC PROGRAM

- PO353-TUE **CLINICAL PRESENTATION, IMPACT AND COURSE OF MAJOR BLEEDING EVENTS WITH APIXABAN AND WARFARIN**  
Suzanne M. Bleker\*, Alexander Cohen, Harry Büller, Giancarlo Agnelli, Alexander Gallus, Gary Raskob, Jeffrey Weitz, Madelyn Curto, Melanie Sisson, Saskia Middeldorp (The Netherlands)
- PO354-TUE **DABIGATRAN PREVENTS THROMBOSIS WITH ENHANCEMENT OF SECONDARY FIBRINOLYSIS IN A MOUSE VENOUS THROMBOSIS MODEL**  
Asuka Sakata\*, Tsukasa Ohmori, Kinya Seo, Satoshi Nishimura (Japan)
- PO355-TUE **DABIGATRAN AND RIVAROXABAN ADHERENCE STUDY- REAL WORLD EXPERIENCE IN DIFFERENT CLINICS AND EXTENDED FOLLOW UP (DARIVA STUDY)**  
Deepa Suryanarayan\*, Faris Al-Khalili, Ammar Majeed, Sam Schulman (Canada)
- PO356-TUE **A QUALITATIVE POINT OF CARE TEST TO ASSESS ANTICOAGULANT ACTIVITY IN URINE SAMPLES OF PATIENTS TREATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS – A GERMAN CONSENSUS**  
Job Harenberg\*, Ingo Ahrens, Rupert Bauersachs, Sylvia Haas, Jürgen Koscielny, Roland Krämer, Edelgard Lindhoff-Last, Jürgen Prochaska, Sebastian Schellong, Michael Spannagl, Philipp Wild, Jan Beyer-Westendorf (Germany)
- PO357-TUE **PARADOXICAL ENHANCEMENT OF THE INTRINSIC PATHWAY-INDUCED THROMBIN GENERATION IN HUMAN PLASMA BY MELAGATRAN, A DIRECT THROMBIN INHIBITOR, BUT NOT EDOXABAN, A DIRECT FACTOR XA INHIBITOR**  
Taketoshi Furugohri\*, Yoshiyuki Morishima (Japan)
- PO358-TUE **EVALUATION OF ANTICOAGULATION WITH RIVAROXABAN BY ANTI-XA ACTIVITY, THROMBIN GENERATION AND COMPLEX THROMBIN ANTI-THROMBIN LEVELS IN PATIENTS WITH NEW ONSET NON VALVULAR ATRIAL FIBRILLATION.**  
Victor M. Neira Vidal\*, Ramón Corbalan Herreros, Jaime Pereira Garcés, Olga Panes Becerra, Bernardita Garayar Pulgar, Andrés Aizman Sevilla, Silvana LLevaneras Madariaga, Luis Villarroel del Pino (Chile)
- PO359-TUE **LOW DOSE RIVAROXABAN FOR SECONDARY PROPHYLAXIS AFTER FULL ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM**  
Alan Zhou\*, Anthony Chan, Keith Lau, Howard Chan (Canada)
- PO360-TUE **INTRA-INDIVIDUAL VARIABILITY IN TROUGH AND PEAK DABIGATRAN LEVELS IN “REAL-LIFE” ATRIAL FIBRILLATION PATIENTS**  
Nina Vene\*, Petra Šinigoj, Rickard Malmström, Yuko Rönquist-Nii, Mojca Božič-Mijovski, Anton Pohanka, Jovan Antović, Alenka Mavri (Slovenia)
- PO361-TUE **DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: INSIGHTS INTO HEALTH CARE PROVIDERS’ UNDERSTANDING OF MEDICATION DOSING AND USE**  
Menaka Pai\*, Mary Salib, Jennifer Delaney, Mohamed Panju, Sam Schulman (Canada)
- PO362-TUE **DIRECT ORAL ANTICOAGULANTS IN CLINICAL PRACTICE - REAL WORLD AUDIT DATA**  
Sarah Bond,\* Sue Rhodes (United Kingdom)

## SCIENTIFIC PROGRAM

- PO363-TUE **NUANCES OF NOAC'S IN A DEVELOPING COUNTRY - A SINGLE CENTER EXPERIENCE**  
Shamanna Iyengar\*, Roopa Ravibabu, Sumithra Lakshman, Anand Shenoy, Sridhar G, Mukul Fulmali, Subash Chandra V (India)
- PO364-TUE **RIVAROXABAN PHARMACOKINETICS BEFORE AND AFTER BARIATRIC SURGERY: A CASE AND DISCUSSION**  
George Dresser\*, Markus Gulilat, Richard Kim (Canada)
- PO365-TUE **RENAL FUNCTION COURSE IN PATIENTS TREATED WITH NEW ORAL ANTICOAGULANTS.**  
Elisa Grifoni, Rossella Marcucci, Daniela Poli, Raffaella Priora, Maddalena Pazzi, Alessia Fabbri, Cinzia Fatini, Lucia Mannini, Anna Maria Gori\*, Rosanna Abbate, Gian Franco Gensini (Italy)
- PO366-TUE **THE EFFECTS OF DIRECT ORAL ANTICOAGULANTS APIXABAN AND RIVAROXABAN ON HAEMOSTASIS TESTS: RESULTS FROM A COMPREHENSIVE CROSS-LABORATORY EXERCISE.**  
Roslyn A. Bonar\*, Emmanuel Favaloro, Katherine Marsden, John Sioufi (Australia)
- PO367-TUE **EFFECT OF NEW ORAL ANTICOAGULANTS ON PROTEIN C SYSTEM.**  
Irina Geltcer\*, Olga Golovina, Olga Smirnova, Olesya Matvienko, Ludmila Papayan (Russian Federation)
- PO368-TUE **A STUDY OF DOAC AWARENESS INDICATING INADEQUATE RECOGNITION WITH POTENTIAL FOR PATIENT HARM**  
Henry Watson\*, Adetomilola Olaiya, Blair Watt, Brenda Lurie, Lyn McDonald (United Kingdom)
- PO369-TUE **CIRCULATING CONCENTRATION OF RIVAROXABAN OR DABIGATRAN ANTICOAGULANTS IN CLINICALLY SELECTED PATIENTS**  
Jane Needham\*, Helen Lewis, Amanda McMullen, Tamara Everington, Savita Rangarajan, Sarah Mangles (United Kingdom)
- PO370-TUE **COMPARING REVERSAL EFFECT OF FACTOR X CONCENTRATE AND BY-PASSING AGENTS ON RIVAROXABAN IN AN EX VIVO SPIKING STUDY WITH ROTEM**  
Anja Drebes\*, Anne Riddell (United Kingdom)
- PO371-TUE **MANAGEMENT OF BLEEDING AND EMERGENCY SITUATIONS FOR PATIENTS TREATED WITH DABIGATRAN- SINGLE CENTRE EXPERIENCE.**  
Tatiana Prigancova\*, Angelika Batorova, Denisa Jankovicova (Slovakia)
- PO372-TUE **BLEEDING AND TREATMENT FAILURE IN PATIENTS TAKING DIRECT ORAL ANTICOAGULANTS REFERRED TO EMERGENCY DEPARTMENT: A COHORT MANAGEMENT STUDY**  
Caterina Compostella, Foscarina Della Rocca, Seena Padayattil Jose, Giacomo Zoppellaro, Gentian Denas, Alessia Bracco, Gianna Vettore, Vittorio Pengo\* (Italy)
- PO373-TUE **PERFORMANCES OF A NEW COMMERCIAL CHROMOGENIC ASSAY FOR THE MEASUREMENT OF APIXABAN CONCENTRATION IN PLASMA**  
Jean-Marc Minon\*, Myriam Vasbien, Thierry Gougard, H el ene Appeltans, Philippe Borgoens (Belgium)

## SCIENTIFIC PROGRAM

- PO374-TUE **TREATMENT OPTIONS FOR MAJOR HAEMORRHAGE AND URGENT INTERVENTION IN PATIENTS ON A NOAC - INTERIM RESULTS FROM THE ANTICOAGULATION REVERSAL AND EVENTS STUDY (ARES) COLLABORATIVE**  
Ross Baker\*, Alex Gallus, Timothy Brighton, Paul Harper, Laura Young, Joanna Joseph, Amanda Hugman, Krys Hiscock, Scott McGregor, Jennifer Curnow (Australia)
- PO375-TUE **PROTHROMBINASE INDUCED CLOTTING TIME (PICT ) FOR MEASURING THE ACTIVITY OF DIRECT FACTOR XA INHIBITORS IN CLINICAL SETTING.**  
P avel E. Olivera\*, Vicente Cortina, Ver onica Pons, Brayan Merch an, Laura L opez-Androni, Gonzalo Artaza, Eva Menino, Ana Mar in, Francesc Bosch, Amparo Santamar a (Spain)
- PO376-TUE **AN OPEN-LABEL STUDY OF DABIGATRAN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH MODERATE RENAL IMPAIRMENT UNDERGOING PRIMARY UNILATERAL ELECTIVE TOTAL KNEE OR HIP REPLACEMENT SURGERY**  
Bengt Eriksson\*, Zsolt Mikuska, Martin Feuring, Jean Amiral, Sebastian Haertter, Joachim Stangier, Gerhard Nehmiz, Maximilian Lobmeyer, Jeffrey Weitz (Sweden)
- PO377-TUE **QUALITATIVE FOLLOW UP OF EMERGENCY DEPARTMENT (ED) PATIENTS DISCHARGED ON RIVAROXABAN FOR LOW RISK VENOUS THROMBOEMBOLISM**  
Kristen E. Nordenholz\*, Elaina Thompson, Toby Trujillo, Gregory Misky (United States)
- PO378-TUE **NET CLINICAL BENEFIT OF DABIGATRAN VERSUS WARFARIN IN PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM: A POOLED ANALYSIS OF RE-COVER AND RE-COVER II**  
Sam Schulman\*, Henry Eriksson, Ajay Kakkar, Clive Kearon, Sebastian Schellong, Martin Feuring, Stefan Hantel, Joerg Kreutzer, Samuel Goldhaber (Canada)
- PO379-TUE **IDENTIFICATION OF POSSIBLE DRUG RELATED PROBLEMS IN PATIENTS ON ORAL ANTICOAGULANTS. A SYSTEMATIC REVIEW OF MEDICATION CHARTS BY PHARMACIST.**  
Anne Fj rkenstad\*, Eva-Marie Jacobsen, Liv Mathiesen, Espen Molden (Norway)
- PO380-TUE **INFLUENCE OF DOACS ON THROMBIN GENERATION ASSAY**  
Kazuo Kawasaki\*, Tadashi Yamamoto, Naoki Shirafuji (Japan)

### Platelet activation/adhesion/aggregation II

- PO381-TUE **NEW FACTOR OF PLATELET HEMOSTASIS PATHOLOGY RISK MARKER IN POPULATION OF NENETS AUTONOMOUS DISTRICT**  
Nadezda Vorobyeva\*, Natalia Belova (Russian Federation)
- PO382-TUE **THE EFFECT OF IGG OF ISCHEMIC STROKE PATIENTS ON PLATELET PROTEINS SECRETION**  
Tetiana B. Katrui\*, Olexiy Savchuk, Ludmila Ostapchenko (Ukraine)



## SCIENTIFIC PROGRAM

- PO383-TUE **MEAL-INDUCED PLATELET ACTIVATION DIFFERS BETWEEN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES AND IS RELATED TO INSULIN SECRETION**  
Galina Spectre\*, Ragnhild Stålesen, Claes-Göran Östenson, Paul Hjerdahl (Israel, Sweden)
- PO384-TUE **INFLUENCE OF PLATELET COUNT IN PLATELET RICH PLASMA FOR ADENOSINE TRIPHOSPHATE RELEASE ASSAY**  
Sylvie Mulliez\*, Katrien Devreese (Belgium)
- PO385-TUE **ACTIVATION OF HUMAN PLATELETS BY STAPHYLOCOCCUS AUREUS SECRETED PROTEASE STAPHOPAIN A**  
Amie K. Waller\*, Katie Birch, Pratik Vikhe, Graeme Cottrell, Jon Gibbins, Simon Clarke (United Kingdom)
- PO386-TUE **LOW PLATELET REACTIVITY IS ASSOCIATED WITH MORE SEVERE ATHEROSCLEROSIS AND INCREASED REVASCLARIZATION DURING FOLLOW UP.**  
Tesse Leunissen\*, Crystel Gijsberts, Peter Paul Wisman, Folkert Asselbergs, Imo Hoefer, Gerard Pasterkamp, Gert Jan de Borst, Frans Moll, Mark Roest (The Netherlands)
- PO387-TUE **EVALUATION OF MULTIPLATE® WHOLE BLOOD IMPEDANCE AGGREGOMETRY IN ROUTINE INVESTIGATION OF BLEEDING DISORDERS**  
Joanne E. Joseph\*, Joyce Low, Susan Jarvis (Australia)
- PO388-TUE **ANALYSIS OF PROCOAGULANT PS-EXPOSING PLATELETS BY IMAGING FLOW CYTOMETRY**  
Emily C. Reddy\*, Hong Wang, Hilary Christensen, Sara Israels, Annie Bang, Margaret Rand (Canada)
- PO389-TUE **THE POTENTIAL OF THE NEW PLATELET ACTIVATION IN UNPROCESSED BLOOD (PACT-UB)- TEST**  
Tesse Leunissen\*, Peter Paul Wisman, Thijs Van Holten, Philip de Groot, Jasper Remijn, Frans Moll, Gert Jan de Borst, Martin Teraa, Marianne Verhaar, Rolf Urbanus, Mark Roest (The Netherlands)
- PO390-TUE **DETERMINATION OF THRESHOLD AGONIST CONCENTRATIONS FOR WHOLE BLOOD AGGREGATION USING THE MULTIPLATE® ANALYZER**  
Sara J. Israels\*, Eileen McMillan-Ward, Hong Wang, Victor Blanchette, Margaret Rand (Canada)
- PO391-TUE **ASSESSMENT OF TIME-RELATED PREANALYTICAL INFLUENCES ON PLATELET FUNCTION: COMPARISON OF THE MULTIPLATE, THE PFA-100 AND THE VERIFY NOW**  
Petra Jilma\*, Franz Ratzinger, Christian Schörghofer, Bernd Jilma, Peter Quehenberger (Austria)
- PO392-TUE **DYNAMICS OF CALCIUM SPIKING, MITOCHONDRIAL COLLAPSE AND PHOSPHATIDYL SERINE EXPOSURE IN SINGLE PLATELETS DURING ACTIVATION**  
Sergei I. Obyednyy\*, Anastasia Sveshnikova, Fazoil Ataullakhanov, Mikhail Panteleev (Russian Federation)

## SCIENTIFIC PROGRAM

- PO393-TUE **GPVI AND THE CLEC-2/PODOPLANIN AXIS AS POTENTIAL BIOMARKERS OF PLATELET ACTIVATION IN INFLAMMATORY CONDITIONS**  
Samantha J. Montague\*, Robert Dinsdale, Eelo Gitz, Elizabeth Gardiner, Robert Andrews, Peter Hampson, Christopher Wear, Christopher Buckley, Gerard Nash, Naiem Moiemien, Paul Harrison, Steve Watson (United Kingdom)
- PO394-TUE **NOVEL WHOLE BLOOD MODEL OF THROMBOCYTOPENIA WITH PRESERVED PLATELET FUNCTION**  
Mette T. Skipper\*, Peter Rubak, Ole Larsen, Anne-Mette Hvas (Denmark)
- PO395-TUE **LOCAL ANAESTHETICS INHIBIT ACTIVATION OF PROTEIN DISULFIDE ISOMERASE (PDI).**  
Christopher Stavermann, Anne Bertling, Mayken Visser, Martin Brodde, Wiebke Gogarten, Beate E. Kehrel\* (Germany)
- PO396-TUE **PROSPECTIVE ANALYSIS OF PLATELET ACTIVATION MARKERS TO PREDICT SEVERE INFECTION AND MORTALITY IN INTENSIVE CARE UNITS.**  
Celine Delierneux\*, Nathalie Layios, Alexandre Hego, Justine Huart, Arnaud Joly, Pierre Geurts, Pierre Damas, Christelle Lecut, André Gothot, Cécile Oury (Belgium)
- PO397-TUE **STAPHYLOCOCCUS AUREUS LIPOPROTEINS INHIBIT PLATELET ACTIVATION.**  
Pratik Vikhe\*, Amie Waller, Jonathan Gibbins, Simon Clarke (United Kingdom)
- PO398-TUE **COMPARATIVE IMPACTS OF ANTIRETROVIRAL HIV THERAPIES ON PLATELET FUNCTION**  
Erica Smyth\*, Mark Nelson, Michael Emerson (United Kingdom)
- PO399-TUE **ANALYZING IN VITRO PLATELET THROMBUS FORMATION OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA UNDER BLOOD FLOW CONDITIONS**  
Takashi Ito\*, Tomoka Nagasato, Takahiro Nakashima, Hitomi Yamashita, Hideki Matsuoka, Kazuya Hosokawa, Ikuro Maruyama (Japan)
- PO400-TUE **GENERATION OF PROCOAGULANT COAT PLATELETS IN STORED PLATELET-CONCENTRATE UNITS DERIVED FROM BUFFY-COAT PREPARATIONS**  
Debora Bertaggia Calderara\*, David Crettaz, Stefano Barelli, Jean-Daniel Tissot, Niels Lion, Michel Prudent, Lorenzo Alberio (Switzerland)
- PO401-TUE **OPIATES MAY ATTENUATE PLATELET ACTIVATION**  
Salumeh Bastami, Nahreen Tynngard, Ankit S. Macwan\*, Tomas Lindahl, Srinivas Uppugunduri (Sweden)
- PO402-TUE **IN VIVO AND PROTEASE-ACTIVATED RECEPTOR 1-MEDIATED PLATELET ACTIVATION IN PATIENTS PRESENTING FOR CARDIAC CATHETERIZATION**  
Thomas Gremmel\*, Alan Michelson, Andrew Frelinger (Austria, United States)
- PO403-TUE **PLATELET FACTOR-3 (PF-3) AVAILABILITY AND PLATELET COUNT OF PREGNANT WOMEN IN IRRUA, EDO STATE.**  
Rose A. Anyanwu\*, Bridget Omaiwoje, Eidangbe Adesuwa (Nigeria)

## SCIENTIFIC PROGRAM

- PO404-TUE **FLOW CYTOMETRY BASED EVALUATION OF PLATELET-NEUTROPHIL COMPLEX FORMATION IN HUMAN AND MURINE WHOLE BLOOD: A DETAILED ANALYSIS OF EX VIVO SAMPLE PREPARATION, CYTOMETER SETTINGS AND MOLECULAR BASICS**  
Maximilian Mauler\*, Julia Seyfert, David Haenel, Hannah Seeba, Janine Guenther, Christoph Bode, Ingo Ahrens, Daniel Duerschmied (Germany)
- PO405-TUE **T2MR PLATELET ANALYSIS CORRELATES WITH LTA AND REVEALS UNIQUE DETAILS OF ADP-MEDIATED PLATELET ACTIVATION IN WHOLE BLOOD**  
Adam Cuker, Tatiana Lebedeva, Holleh Husseinzadeh, Walt Massefski, Joseph Marturano, Thomas Lowery\*, Charles Abrams, Doug Cines (United States)
- PO406-TUE **NEW APPROACH FOR EVALUATION OF PLATELET FUNCTION IN THROMBOCYTOPENIA USING IMPEDANCE AGGREGOMETRY**  
Mette T. Skipper\*, Peter Rubak, Jesper Stentoft, Anne-Mette Hvas, Ole Larsen (Denmark)
- PO407-TUE **DEVELOPMENT AND VALIDATION OF A FLOW CYTOMETRY ASSAY FOR ASSESSING CYCLOOXYGENASE-1 AND 2 IN PLATELETS**  
Peter Rubak\*, Steen Kristensen, Anne-Mette Hvas (Denmark)
- PO408-TUE **PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIERS RELEASE BY COMBINATIONS OF STREPTOCOCCUS SANGUINIS AND PORPHYROMONAS GINGIVALIS**  
Archie McNicol\*, Sara Israels, Hind Hamzeh-Cognasse, Fabrice Cognasse (Canada)
- PO409-TUE **INCREASE IN IONIC STRENGTH INHIBITS PLATELET AGGREGATION IRRESPECTIVE OF SOLUTE TYPE IN VITRO**  
Gordon Ogwenyo\* (Kenya)
- PO410-TUE **A NEW APPROACH TO MEASURING PLATELET AGGREGATION AND PLATELET-LEUCOCYTE CONJUGATE FORMATION IN A SMALL VOLUME OF FIXED WHOLE BLOOD**  
Mohammad Algahtani\*, Natalia Dovlatova, Jane May, Stan Heptinstall, Sue Fox (United Kingdom)
- PO411-TUE **THE AUTOMATION OF ROUTINE LIGHT TRANSMISSION PLATELET AGGREGATION ON SYSMEX CS-2000I**  
Katsushi Kobayashi, Pierre Gueret, Maxime Sansot, Fabienne Nedelec Gac, Jean Amiral (France)
- PO412-TUE **EFFECTS OF PH AND CONCENTRATION OF SODIUM CITRATE ANTICOAGULANT ON PLATELET AGGREGATION MEASURED BY LIGHT TRANSMISSION AGGREGOMETRY INDUCED BY ADENOSINE DIPHOSPHATE**  
Ksenia Germanovich, Eti A. Femia, Chun Yan Cheng\*, Natalia Dovlatova, Marco Cattaneo (Italy)
- PO413-TUE **ANTI-PROTAMINE/HEPARIN ANTIBODIES INDUCED PLATELET ACTIVATION IN THE PRESENCE OF NPH-INSULIN IN HEPARIN DEPENDENT MANNER**  
Tamam Bakchoul\*, Heike Zöllner, Rabie Jouni, Lars Janzen, Jan Wesche, Jessica Fuhrmann, Andreas Greinacher (Germany)

## SCIENTIFIC PROGRAM

- PO414-TUE **CHARACTERISING CELL-TYPE INTERACTIONS FOLLOWING PLATELET ACTIVATION IN A NOVEL LOW VOLUME WHOLE BLOOD ASSAY**  
Paul C. Armstrong\*, Timothy Warner (United Kingdom)
- PO415-TUE **CHARACTERISATION OF PROCOAGULANT PLATELETS IN WHOLE BLOOD USING A NOVEL CELL DEATH MARKER**  
Leonardo Pasalic\*, Heather Campbell, Philip Hogg, Vivien Chen (Australia)
- Platelet disorders II**
- PO416-TUE **NATURAL HISTORY OF ACQUIRED GLANZMANN THROMBASTHENIA : A CASE REPORT**  
Marie Tuffigo, Chloé James, Estibaliz Lazaro, Jean-François Viallard, Mathieu Fiore\* (France)
- PO417-TUE **HOT-WATER EXTRACTS OF THE MUSHROOM, AGARICUS BRASILIENSIS, INHIBITS PLATELET ACTIVATION VIA P2Y1 RECEPTOR.**  
Kaneo Satoh\*, Katsuyuki Akahane, Masato Ohta, Yukio Ozaki (Japan)
- PO418-TUE **A REDUCED RESPONSE TO TRAP-6 IN PLATELET AGGREGATION STUDIES IS NOT USUALLY DUE TO A PAR-1 RECEPTOR DEFECT.**  
Michael Mitchell\*, Aine McCormick, James Maloney, Gary Moore, Steve Austin (United Kingdom)
- PO419-TUE **DIFFERENTIAL REGULATION OF THE PLATELET PROTEOME IN GLANZMANN THROMBASTHENIA TYPE I**  
Kerstin Jurk\*, Stefan Lorocho, Cora Reiss, Kathrin Schwierczek, Wolfgang Behnisch, Barbara Zieger, Rene Zahedi, Ulrich Walter (Germany)
- PO420-TUE **GRANULES SECRETION IN PATIENTS WITH GLANZMANN'S THROMBASTHENIA**  
Ann-Kathrin Pilgrimm-Thorp, Manuela Krause, Daniele Pillitteri\*, Tanja Behrendt, Carl Kirchmaier (Germany)
- PO421-TUE **THE GFI1B C.503G>T MUTATION IN THE FIRST ZINC FINGER DOMAIN PREDICTS A Milder BLEEDING PHENOTYPE THAN THE GFI1B C.880-881INSC MUTATION**  
David Rabbolini\*, Marie-Christine Morel-Kopp, Qiang Chen, Sara Gabrielli, Lindsay Dunlop, Christopher Ward, William Stevenson (Australia)
- PO422-TUE **ABNORMAL PROPLATELET FORMATION AND EMPERIPOLESI IN CULTURED MEGAKARYOCYTES FORM GRAY PLATELET SYNDROME PATIENTS**  
Erica De Candia\*, Christian Di Buduo, Maria Adele Alberelli, Ana Glembostry, Gianmarco Podda, Marco Cattaneo, Raffaele Landolfi, Paula Heller, Alessandra Balduini (Italy)
- PO423-TUE **MULTIPLEX PHOSPHOSPECIFIC FLOW CYTOMETRY FOR THE SCREENING OF PLATELET SIGNALING DISORDERS**  
Marie Levade\*, Cédric Garcia, Sarah Cadot, Jennifer Series, Pierre Sié, Bernard Payrastré (France)

## SCIENTIFIC PROGRAM

PO424-TUE **THIOREDOXIN REDUCTASE PROTECTS PLATELETS FROM CELL DEATH**  
Matthew T. Harper\* (United Kingdom)

PO425-TUE **A NOVEL MUTATION IN NBEAL2 GENE CAUSING GRAY PLATELET SYNDROME**  
Lijuan Cao\*, Zhaoyue Wang, Xia Bai, Jiaming Li, Lijun Xia, Changgeng Ruan (China)

### Pediatric thrombosis and hemostasis II

PO426-TUE **VALIDATION OF THE SELF-PBQ (SELF-ADMINISTERED PEDIATRIC BLEEDING QUESTIONNAIRE) AS A SCREENING TOOL FOR A NEW DIAGNOSIS OF VON WILLEBRAND DISEASE (VWD)**  
Angie Tuttle\*, Julie Grabell, Steven Bae, Paul Moorehead, Victor Blanchette, John Wu, MacGregor Steele, Robert Klaassen, Mariana Silva, Margaret Rand, Paula James (Canada)

PO427-TUE **FAMILY HISTORY OF VENOUS THROMBOEMBOLISM IN THE PAEDIATRIC POPULATION: THE NEED FOR A STANDARDIZED DEFINITION**  
Anna Hau, Eric Wegener\*, Paul Monagle, Shoshana Revel-Vilk, Vera Ignjatovic (Australia)

PO428-TUE **INITIAL DOSE OF ENOXAPARIN IN NEONATES WITH THROMBOSIS**  
Mirta Hepner\*, Gabriela Sciuccati, Carolina Cervio, Graciela Pieroni, Silvina Annetta, Diana Fariña, Juan Frontróth, Lilian Diaz, Aurora Felio Torres, Mariana Bonduel (Argentina)

PO429-TUE **SKIN NECROSIS AND PURPURA FULMINANS IN CHILDREN WITH AND WITHOUT THROMBOPHILIA - A TERTIARY CENTER'S EXPERIENCE**  
Yariv Fruchtman\*, Tzipora Strauss, Marina Rubinstein, Miriam Ben Harosh, Shoshana Revel-Vilk, Joseph Kapelushmik, Gideon Paret, Gili Kenet (Israel)

PO430-TUE **INCIDENCE RATE AND RISK FACTORS OF VENOUS THROMBOEMBOLISM IN ASIAN PEDIATRIC ONCOLOGY PATIENTS.**  
Wai Ming Mendy Ong\*, Koon Mian Foo, Joyce Ching Mei Lam, Mei Yi Loke (Singapore)

PO431-TUE **CLINICAL FEATURES, RISK FACTORS AND OUTCOME OF PULMONARY EMBOLISM IN CHILDREN ADMITTED TO A SINGLE ACADEMIC CENTER IN SÃO PAULO – BRAZIL: LOTS TO LEARN OR READY TO TEACH?**  
Jorge D. A. Carneiro\*, Daniele Celeste, Fernanda Sequeira, Vicente Odone-Filho (Brazil)

PO432-TUE **AN INTERNATIONAL SURVEY REGARDING MANAGEMENT OF COAGULOPATHY IN CHILDREN UNDERGOING LIVER BIOPSY.**  
Maria Magnusson\*, Björn Fischler, Winita Hardikar, Paul Monagle (Sweden)

PO433-TUE **EVALUATION OF THROMBOPHILIA IN CHILDREN BEFORE RENAL TRANSPLANT AND OUTCOME OF PROPHYLACTIC ANTICOAGULATION POST-TRANSPLANT**  
Jorge D. A. Carneiro\*, Andrea Watanabe, Vera Koch, Benita Schwartsman, Marlene Garanito, Gustavo Messi, William Nahas, Elbio D'Amico (Brazil)

## SCIENTIFIC PROGRAM

PO434-TUE **DETERMINING THE USABILITY OF THE PEDIATRIC THROMBOSIS EDUCATIONAL TOOL (P-TET) IN CHILDREN RECEIVING ANTICOAGULATION THERAPY**  
Madeline I. Montoya\*, Leonardo Brandão, Frederica Cassis, Jennifer Stinson, Jorge Carneiro (Canada)

PO435-TUE **RARE LABORATORY PRESENTATION OF TYPE IIB VON WILLEBRAND'S DISEASE IN A 6 YEAR OLD BOY.**  
Irene E. Regan\*, Marie Lyons, Michelle O'Rourke, Brian Philbin, Vince Jenkins, Beatrice Nolan (Ireland)

PO436-TUE **SYNERGISTIC EFFECT OF ELEVATED LIPOPROTEIN (A) LEVELS WITH INHERITED THROMBOPHILIA RISK FACTORS IN CHILDREN WITH ARTERIAL ISCHEMIC STROKE**  
Desiree Coen Herak\*, Jasna Lenicek Krleza, Renata Zrinski Topic, Margareta Radic Antolic, Ivana Horvat, Marija Milos, Vlasta Djuranovic, Renata Zadrio (Croatia)

PO437-TUE **THE ROLE OF FVR2 POLYMORPHISM IN CHILDREN CARRIERS OF FV-LEIDEN**  
Zoey Kapsimali\*, Helen Pergantou, Anna Komitopoulou, Helen Platokouki (Greece)

PO438-TUE **WHOLE BLOOD THROMBOELASTOMETRY (ROTEM®) PROFILES IN CHILDREN WITH CYANOTIC CONGENITAL HEART DISEASES UNDERGOING CARDIAC SURGERY**  
Luca Spiezia\*, Vladimiro Vida, Giacomo Bortolussi, Marta Marchetti, Elena Campello, Demetrio Pittarello, Guido Di Gregorio, Giovanni Stellin, Paolo Simioni (Italy)

PO439-TUE **THE INCIDENCE OF DEEP VEIN THROMBOSIS IN CHILDREN WITH PERIPHERALLY INSERTED CENTRAL CATHETERS VERSUS TUNNELED CENTRALLY INSERTED CATHETERS IN PEDIATRIC PATIENTS: A PROSPECTIVE COHORT STUDY**  
Julie Jaffray\*, Kaitlyn Dang, Brian Vasquez, Jano Boghossian, Chadi Zeinati, Jemily Malvar, Guy Young (United States)

PO440-TUE **BENIGN JOINT HYPERMOBILITY SYNDROME IS PREVALENT IN CHILDREN WITH UNDEFINED BLEEDING DISORDERS**  
MacGregor Steele\*, Sheri VanGunst, Leah Odiaman, Man-Chiu Poon, Shannon Jackson (Canada)

PO441-TUE **THROMBOEMBOLIC COMPLICATION IN CHILDHOOD WITH NEPHROTIC SYNDROME: EXPERIENCE IN THREE PEDIATRIC HOSPITALS IN ARGENTINA.**  
Monica S. Martinez\*, Daniela Morell, Guillermo Arbesu, Carina Calvo, Alejandra Costa, E Hiratmasu, Vanesa Gimenez, Roberto Navarro (Argentina)

PO442-TUE **ACQUIRED VON WILLEBRAND SYNDROME (AVWS) - AN UNDERDIAGNOSED COMPLICATION IN SEVERELY ILL PEDIATRIC PATIENTS WITH BLEEDING COMPLICATIONS**  
Ivonne Wieland\*, Karl-Walter Sykora (Germany)

PO443-TUE **THE IMPACT OF SERUM BILE ACID LEVELS ON THE MRNA EXPRESSION OF PRO-AND ANTICOAGULANT PROTEINS IN LIVER TISSUE.**  
Maria Magnusson\*, Cecilia Gälman, Björn Fischler, Eva Beijer, Henrik Arnell, Antal Németh, Gösta Eggertsen (Sweden)

## SCIENTIFIC PROGRAM

- PO444-TUE **THROMBOMODULIN GENE ANALYSIS IN A CASE OF ATYPICAL HEMOLYTIC-UREMIC SYNDROME**  
Vilalta Noelia\*, Tirado Isabel, Mateo Jose, Coll Immaculada, Cuevas Biel, López-Pardo Jordi, Fraga Gloria, Brió Sonia, Souto Juan Carlos, Martínez-Sánchez Elisabet, Fontcuberta Jordi (Spain)
- PO445-TUE **CLINICAL CHARACTERIZATION OF VENOUS THROMBOEMBOLISM IN CHILDHOOD AT A TERTIARY LEVEL HOSPITAL**  
Laura L. Andreoni\*, Verónica Pons, Pavel Olivera, Carlos Chavez, Vicente Cortina, Ana Marin, Francesc Bosch, Amparo Santamaría (Spain)
- PO446-TUE **LET'S CUT TO THE BONE: RISK FACTORS OF VENOUS THROMBOEMBOLISM IN CHILDREN WITH MUSCULOSKELETAL INFECTIONS**  
Rungrote Natesirinilkul\*, Suzan Williams, Upton Allen, Leonardo Brandao (Canada)
- PO447-TUE **FEASIBILITY AND SAFETY OF ENOXAPARIN WHOLE MILLIGRAM DOSING IN PREMATURE AND TERM NEONATES**  
Rebecca Goldsmith\*, Anthony Chan, Mihir Bhatt (Canada)

### Platelets and cancer

- PO448-TUE **IMMUNOPHENOTYPIC EXPRESSION OF PLATELETS IN MYELODYSPLASTIC SYNDROME**  
Yi-Feng Wu\*, Chao-Zong Liu (Taiwan)
- PO449-TUE **RECURSIVE PARTITIONING WITH AMALGAMATION ANALYSIS OF CANCER SPECIFIC BIOMARKERS IN THE PREDICTION OF CANCER ASSOCIATED THROMBOSIS.**  
Alfonso Tafur\*, George Dale, Aaron Mansfield, Mohamad Cherry, Philip Comp, Suman Rathbun, Julie Stoner (United States)
- PO450-TUE **CANCER CELLS INDUCE THE RELEASE OF MICROPARTICLES FROM HUMAN PLATELETS**  
Gianni F. Guidetti\*, Ilaria Canobbio, Daria Manganaro, Marta Zarà, Caterina Visconte, Mauro Torti (Italy)
- PO451-TUE **THE EFFECTS OF INTERFERON $\alpha$ -2B ON THE DEFECTIVE BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA**  
Tiantian Sun\*, Cuicui Lv, Donglei Zhang, Xian Zhang, Rongfeng Fu, Mingen Lv, Wenjie Liu, Yang Li, Yating Hao, Huiyuan Li, Renchi Yang, Lei Zhang (China)
- PO452-TUE **SUNITINIB IS TAKEN UP BY PLATELETS AND INHIBITS PLATELET ACTIVATION AND THROMBUS FORMATION IN CANCER PATIENTS**  
Siamack Sabrkhan, Sharo Pineda, Linda Sanders, Maureen Aarts, Johan Heemskerk, Arjan Griffioen, Mirjam oude Egbrink, Marijke J. Kuijpers\* (The Netherlands)

### Regulation of coagulation and fibrinolysis I

- PO453-TUE **ALLELIC VARIANTS WITHIN ANXA5 DIFFERENTIALLY IMPACT ON THE CONTROL OF GENE EXPRESSION**  
Giovanni Tiscia\*, Per Morten Sandset, Elisabeth Dørum, Christiane Myklebust, Elvira Grandone, Grethe Skretting (Italy)

## SCIENTIFIC PROGRAM

- PO454-TUE **IMPROVEMENT IN THROMBIN GENERATION BY THE ANTI-TFPI ANTI-BODY, CONCIZUMAB, IN PLASMA FROM INDIVIDUALS WITH HAEMOPHILIA A WITH OR WITHOUT INHIBITORS OR HAEMOPHILIA B, IS NOT AFFECTED BY THE PRESENCE OF CORN TRYPSIN INHIBITOR**  
Emily K. Waters\*, Ida Hilden, Supreet Dhillon, Catherine Rea, Brit Sørensen (Denmark)
- PO455-TUE **CHARACTERIZATION OF PRO-COAGULANT ANTIBODIES BINDING TO KUNITZ DOMAIN-1 OF TFPI**  
Helle Heibroch Petersen\*, Cecilia Augustsson, Berit Olsen Krogh, Jens Breinholt, Jes Thorn Clausen, Birgitte Kjær, Ida Hilden, Lars Christian Petersen (Denmark)
- PO456-TUE **THE EFFECT OF ULTRA HIGH LEVELS OF C-REACTIVE PROTEIN (CRP) ON THE COAGULATION SYSTEM**  
Ramin Artang\*, Daniel Anderson, Jørn Dalsgaard Nielsen (United States)
- PO457-TUE **ASSESSMENT OF THE EFFECT OF INTER-ALPHA TRYPSIN INHIBITOR BY THROMBIN GENERATION ASSAY**  
Jean-Luc Plantier\*, Véronique Devos, Sami Chtourou, Sylvie Jorieux (France)
- PO458-TUE **PROLONGATION OF CLOT LYSIS TIME BY A DIRECT THROMBIN INHIBITOR: INVOLVEMENT OF THROMBIN GENERATION ENHANCEMENT AND THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR**  
Yoshiyuki Morishima\*, Chikako Kamisato (Japan)
- PO459-TUE **ORAL FACTOR XA ANTICOAGULANTS, RIVAROXABAN AND APIXABAN, ENHANCE CLOT DISSOLUTION IN PLASMA**  
Rolinda L. Carter\*, Kimberley Talbot, Tyler Smith, Agnes Lee, Edward Prydzial (Canada)
- PO460-TUE **ULTRASONIC MONITORING OF FIBRIN CLOT FORMATION AND FIBRINOLYSIS IN FLOWING BLOOD**  
Konstantin G. Guria\*, Shakhla Dzhumaeva, Dmitriy Ivlev, Svetlana Uzlova, Georgy Guria (Russian Federation)
- PO461-TUE **A NOVEL APPROACH FOR HEMOPHILIA THERAPY THROUGH ANTIBODY TARGETED TFPI**  
Sumin Lee\*, Kisu Kim, Dong-Sik Kim, Heechun Kwak, Mijung Lee, Jae Chan Park, Young Seoub Park, Hyung-Kwon Lim, SungHo Hwang (Korea, Republic Of)
- PO462-TUE **FUNCTIONAL COMPONENTS OF JAPANESE TRADITIONAL SOYBEAN FOOD "NATTO"-NATTOKINASE, VITAMIN K2 AND POLYAMIN-**  
Hiroyuki Sumi\*, Tadanori Ohsugi, Sawa Naito, Chieko Yatagai (Japan)
- PO463-TUE **FIBRINOLYTIC ACTIVITY PRODUCED BY FERMENTED SWEET CORN WITH BACILLUS SUBTILIS NATTO**  
Hiroyuki Sumi\*, Sawa Naito, Chieko Yatagai (Japan)
- PO464-TUE **INHIBITION OF FIBRINOLYSIS BY HEPARIN, LOW MOLECULAR WEIGHT HEPARIN AND A NOVEL ANTICOAGULANT, ANTITHROMBIN-HEPARIN COVALENT COMPLEX (ATH)**  
Gabriela Chang\*, Helen Atkinson, Leslie Berry, Anthony Chan (Canada)
- PO465-TUE **COMPLEMENT C3 AND HYPOFIBRINOLYSIS: A POTENTIAL ROLE FOR PROTEIN GLYCATION**  
Katharina Schuett, Rhodri King\*, Fladia Phoenix, Kerrie Smith, Sebastian Maxeiner, Katharina Lysaja, Vera Jankowski, Nikolaus Marx, Ramzi Ajjan (Germany)

## SCIENTIFIC PROGRAM

- PO466-TUE **THE ARTERIOVENOUS DIFFERENCE OF HEMOSTASIS PARAMETERS IN CRITICALLY ILL PATIENTS WITH DIFFERENT TYPE OF HYPOERGOSIS**  
Sergei Sinkov\*, Igor Zabolotskikh, Denis Velichko, Sergei Grigoriev (Russian Federation)
- PO467-TUE **EFFECTS OF AN ACIDIC ENVIRONMENT ON COAGULATION DYNAMICS**  
Matthew Gissel\*, Thomas Orfeo, Saulius Butenas, Anthony Pusateri, Kathleen Brummel-Ziedins, Kenneth Mann (United States)
- PO468-TUE **EXERCISE-INDUCED CORE BODY TEMPERATURE ELEVATIONS SHIFT HEMOSTASIS TO A PROTHROMBOTIC STATE**  
Waander Van Heerde\*, Matthijs Veltmeijer, Wideke Barteling, Kitty Verbeek-Knobbe, Thijs Eijsvogels, Maria Hopman (The Netherlands)
- PO469-TUE **IN VITRO INTERACTIONS OF SUGAMMADEX WITH VARIOUS ANTICOAGULANTS**  
Annelieke C. Kruithof\*, Cornelis Klufft, Pieter-Jan de Kam, Ria Laterveer, Matthijs Moerland, Jacobus Burggraaf (The Netherlands)
- PO470-TUE **COAGULOPATHY AND OSMOLAR GAP IN CRITICALLY ILL PATIENTS: AN INTIMATE RELATIONSHIP**  
Vladimir Sukhanov\*, Olga Petrova, Alexander Levit (Russian Federation)
- PO471-TUE **NET AND NEUTROPHIL INDUCED THROMBIN GENERATION**  
Jaewoo Song\*, Eun-Young Lee, Rojin Park, Ye-Jin Song, Yun A Jo, Jongha Yoo (Korea, Republic Of)

### Reproductive issues II

- PO472-TUE **EARLY ANTICOAGULATION AND PREGNANCY OUTCOMES IN PATIENTS REFERRED TO A SERVICE OF THROMBOSIS AND THROMBOPHILIA IN PREGNANCY**  
Tainá Rocha, Venina Barros\*, Roberta Santos, Fernanda Baptista, Rossana Francisco (Brazil)
- PO473-TUE **IMPACT OF HORMONE TREATMENT IN INFERTILE WOMEN UNDERGOING ARTIFICIAL REPRODUCTIVE TECHNIQUES (ART) ON THROMBIN GENERATION, TISSUE FACTOR, THROMBOMODULIN AND PROCOAGULANT PHOSPHOLIPID ACTIVITIES.**  
Patrick Van Dreden\*, Emmanuelle Mathieu d'Argent, Marjorie Comtet, Hela Ketatni, Matthieu Grusse, Vassiliki Galea, Eleftheria Lefkou, Ismail Elalamy, Grigoris Gerotzi-afast (France)
- PO474-TUE **NEW THROMBOPHILIC RISK FACTORS IN PATIENTS WITH VASCULAR PLACENTAL COMPLICATIONS (VPC) AND PREGNANCY OR HORMONAL THERAPY - RELATED THROMBOSIS AND MANAGEMENT IN THE CLINICAL PRACTICE. RESULTS FROM THE INTERNATIONAL TEAM PROJECT.**  
Amparo Santamaria\*, Carmen Medina, Artur Oliver, Edel Marti, Daniella Mussio, Ana Redondo Izal, Cecilia Stevenazzi, Isabel De Diego, A. Rodriguez-Huerta (Spain)
- PO475-TUE **ASSOCIATION BETWEEN POLYMORPHISMS IN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENE AND REPEATED IMPLANTATION FAILURE (RIF)**  
Jung O Kim\*, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Hui Jeong An, Youngsok Choi, Woo Sik Lee, Nam Keun Kim (Korea, Republic Of)

## SCIENTIFIC PROGRAM

- PO476-TUE **MATERNAL DEATH AND VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS ADMITTED IN A MATERNITY OF HIGH RISK: RESULTS PRE AND POST APPLICATION OF A RISK SCORE.**  
Roberta Santos\*, Venina Barros, Ana Igai, Rossana Francisco, Marcelo Zugaib (Brazil)
- PO477-TUE **A COMMON GENETIC BACKGROUND SHARED BY WOMEN WITH HISTORY OF ADVERSE PREGNANCY OUTCOMES AND CARDIOVASCULAR DISEASE: A WINDOW TO FUTURE CARDIOVASCULAR RISK.**  
Ilaria Romagnuolo\*, Elena Sticchi, Elisa Grifoni, Maddalena Pazzi, Agatina Alessandrello Liotta, Raffaella Priora, Monica Attanasio, Rosanna Abbate, Cinzia Fatini (Italy)
- PO478-TUE **POLYMORPHISMS IN TUMOR NECROSIS FACTOR-ALPHA (-863C>A, -857C>T AND +488G>A) ARE ASSOCIATED WITH IDIOPATHIC RECURRENT PREGNANCY LOSS IN KOREAN WOMEN**  
Hui Jeong An\*, Jung O Kim, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Ji Hyang Kim, Nam Keun Kim (Korea, Republic Of)
- PO479-TUE **THE IMPACT OF MODE OF DELIVERY AND POSTPARTUM THROMBOPROPHYLAXIS ON ROTATIONAL THROMBOELASTOMETRY (ROTEM) IN PREGNANT WOMEN WITH A HIGH RISK OF POSTPARTUM VENOUS THROMBOEMBOLISM.**  
Boriana Guimicheva\*, Lara Roberts, Jignesh Patel, Devi Subramanian, Roopen Arya (United Kingdom)
- PO480-TUE **RETROSPECTIVE STUDY OF PATIENTS WHO WERE TREATED WITH FONDAPARINUX PRE-, PERI- AND/OR POSTPARTUM FOR PROPHYLAXIS OR TREATMENT OF VENOUS THROMBOEMBOLISM (FONDAPP)**  
Carl-Erik Dempfle\*, Juergen Koscielny, Edelgard Lindhoff-Last, Johannes Oldenburg, Hartmut Pollmann, Guenther Kappert, Ute Scholz, Stefan Kropff, Sonja Eberle, Andreas Heinken (Germany)
- PO481-TUE **ROTATIONAL THROMBOELASTOMETRY IN PREGNANCY AND ITS ROLE IN ASSESSMENT OF HAEMOSTASIS IN WOMEN WITH FACTOR XI DEFICIENCY**  
Joanna Davies\*, Rezan Kadir (United Kingdom)
- PO482-TUE **THROMBIN GENERATION IN WOMEN UNDERGOING IVF TREATMENT IS PROLONGED, BUT NOT ENHANCED COMPARED TO CONTROLS.**  
Roza Chaireti\*, Katarina Bremme (Sweden)
- PO483-TUE **LOW-MOLECULAR -WEIGHT HEPARIN IN PREGNANCIES AFTER ART -A RANDOMIZED STUDY-**  
Corrado Lodigiani\*, Paola Ferrazzi, Luca Librè, Elena Banfi, Luca Cafaro, Manuela Morengi, Monica Demarco, Ilaria Quaglia, Paolo Levi-Setti (Italy)
- PO484-TUE **EFFECTS OF SILDENAFIL CITRATE ON COAGULATION PROCESS DURING PREGNANCY: A PROMISING THERAPEUTIC APPROACH IN COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN FOR RECURRENT PREGNANCY LOSS**  
Rayana Luna\*, Christina Peixoto, Anne Croy, Maha Othman (Brazil, Canada)

## SCIENTIFIC PROGRAM

### Risk factors in venous thrombosis II

- PO485-TUE **A RISK SCORE FOR PREDICTION OF RECURRENCE IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM (DAMOVES)**  
Ana Isabel Franco Moreno\*, María José García Navarro, Judith Ortiz Sánchez, Rosa María Martín Díaz, Elena Madroñal Cerezo, Cristina Lucía de Ancos Aracil, Victoria Martínez Díaz, Alejandra Gimeno García, Carmen Montero Hernández, Sari Arponen, Noemí Cabello Clotet, José Manuel Ruiz Giardín (Spain)
- PO486-TUE **ANALYSIS OF PROTHROMBIN MUTANTS IN NA+ BINDING DOMAIN AS A POTENTIAL CANDIDATE CONVEYING ANTITHROMBIN RESISTANCE**  
Moe Murata\*, Naoki Mizutani, Yuki Takagi, Ryo Hasebe, Toshihiro Kozuka, Yukiko Nakata, Akira Takagi, Tetsuhito Kojima (Japan)
- PO487-TUE **ORAL ANTICOAGULANT THERAPY FOR THE PREVENTION OF RECURRENT THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA**  
Eduardo Arellano-Rodrigo\*, JC Hernández-Boluda, F Cervantes, A Alvarez-Larrán, M Gómez, P Barba, MI Mata, JR González-Porras, F Ferrer-Marín, V García-Gutiérrez, E Magro, M Moreno, A Kerguelen, M Pérez-Encinas, N Estrada, R Ayala, C Besses, A Pereira (Spain)
- PO488-TUE **ACSF2 EXPRESSION AND RISK OF RECURRENCE AFTER A FIRST UNPROVOKED DEEP VENOUS THROMBOSIS EVENT. RESULTS FROM THE RETRO STUDY**  
Ramón Lecumberri\*, Ramón Montes, Elisabeth Guruceaga, José González-Porras, Joan Reverter, Pascual Marco, Elena Pina, Javier Trujillo, Ángel Bernardo, Pilar Llamas, Alicia Lorenzo, Carmen Fernández-Capitán, David Jiménez, Ana Alfonso, José Páramo, José Hermida (Spain)
- PO489-TUE **PROSPECTIVE OBSERVATIONAL STUDY ON INCIDENCE OF VENOUS THROMBOEMBOLISM IN MEDICALLY-ILL HOSPITALIZED ELDERLY PATIENTS**  
Jeong-Ok Lee\*, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Hwi-Joong Yoon, Soo-Mee Bang (Korea, Republic Of)
- PO490-TUE **INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH INTRACRANIAL VENOUS THROMBOSIS: SINGLE CENTER EXPERIENCE IN TURKEY**  
Turkan Patiroglu\*, Gonca Koc, Mehmet Canpolat, Ekrem Unal, Selim Doganay, Musa Karakukcu, Mehmet Ozdemir (Turkey)
- PO491-TUE **THROMBOPROPHYLAXIS SKIPPED DOSES IN HOSPITALIZED PATIENTS. CAN WE RECOGNIZE WHICH ARE THE CAUSES OR FACTORS?**  
Alicia Beatriz Vilaseca\*, Rubén Barbera, Jimena Bonadeo, Nadia Kujta, Adriana Lopez (Argentina)
- PO492-TUE **IDENTIFICATION OF A NOVEL HOMOZYGOUS MUTATION RESPONSIBLE FOR TYPE II (P.S169F) ANTITHROMBIN DEFICIENCY**  
Ying Y. Wu\*, Liang Tang, Wei Zeng, Yu Hu (China)

## SCIENTIFIC PROGRAM

- PO493-TUE **IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOEMBOLISM (VTE) ON THE ASSOCIATIONS BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VTE.**  
Trygve Ellingsen\*, Jostein Lappegård, Erin Smith, Tom Wilsgaard, Sigrid Brækkan, Terry Solomon, Kelly Frazer, John-Bjarne Hansen (Norway)
- PO494-TUE **IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOSIS ON RISK OF STROKE AND VTE IN ATRIAL FIBRILLATION**  
Ina Rye-Holmboe\*, Erin Smith, Erin Hald, Anders Vik, Ellen Brodin, Sigrid Brækkan, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John Bjarne Hansen (Norway)
- PO495-TUE **IMPACT OF THE FIBRINOGEN GAMMA GENE RS2066865 VARIANT ON THE RISK OF VENOUS THROMBOSIS IN CANCER PATIENTS**  
Olga Dziewiecka\*, Erin Smith, Sigrid Brækkan, Hilde Jensvoll, Kristine Blix, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
- PO496-TUE **CHARACTERISTICS OF HOSPITAL-ASSOCIATED THROMBOSIS ATTRIBUTED TO THROMBOPROPHYLAXIS FAILURE**  
Lara Roberts, Emma Gee\*, Gayle Mulla, Cara Doyle, Melanie Ferreira, Jig Patel, Raj Patel, Roopen Arya (United Kingdom)
- PO497-TUE **ANTI-VIMENTIN ANTIBODIES INCREASE THROMBUS FORMATION AT VENOUS SHEAR RATES IN VITRO AND IN VIVO: IMPLICATION FOR VENOUS THROMBOEMBOLISM IN AUTOIMMUNE DISEASES**  
Qi Da, Rolando Rumbaut, Miguel Cruz\* (United States)
- PO498-TUE **SWITCHING TYPE OF ORAL CONTRACEPTIVE AND RISK OF VENOUS THROMBOEMBOLISM: A CASE-CROSSOVER STUDY**  
Luuk Scheres\*, Willem Lijfering, Astrid van Hylckama Vlieg, Saskia Middeldorp, Suzanne Cannegieter (The Netherlands)
- PO499-TUE **"FORGOTTEN NO MORE" – A CASE OF A 54 YEAR OLD FEMALE WITH LEMIERRE'S SYNDROME**  
Edward Gacrama\* (Philippines)
- PO500-TUE **PREVALENCE OF RISK FACTORS PREDISPOSING TO THROMBOSIS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION**  
Jerzy Dropinski\*, Agnieszka Kubicka-Trzaska, Teresa Domagala, Marek Sanak, Teresa Iwaniec, Jacek Musial (Poland)
- PO501-TUE **NO DIFFERENCES IN THROMBIN GENERATION BETWEEN PATIENTS WITH AND WITHOUT PORTAL VEIN THROMBOSIS IN END-STAGE LIVER DISEASE**  
Dana R. Tomescu\*, Mihai Popescu, Carmen Orban, Lavinia Jipa, Irinel Popescu (Romania)
- PO502-TUE **ENDOGENOUS SEX HORMONE LEVELS IN MEN WITH UNPROVOKED DEEP VEIN THROMBOSIS**  
Nicola Mumoli\*, Marco Cei, Barbara Brondi, Matteo Giorgi Pierfranceschi, Josè Vitale, Francesco Dentali (Italy)

## SCIENTIFIC PROGRAM

- PO503-TUE **A-FIBRINOGEN THR312ALA POLYMORPHISM IS AN INDEPENDENT GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA**  
Sergey Kapustin\*, Anna Demyanenko, Veronika Shmeleva, Vitaly Soldatenkov, Pavel Chechulov, Viktor Kargin, Lyudmila Papayan (Russian Federation)
- PO504-TUE **VENOUS THROMBOEMBOLISM (VTE) IN HOSPITALISED NON-SURGICAL CANCER PATIENTS AND ITS BURDEN ON HEALTHCARE IN AN ASIAN TERTIARY HOSPITAL**  
Lai Heng Lee\*, Arul Earnest, Jeffrey Hui, Yong Yang (Singapore)
- PO505-TUE **A NOVEL MICROFLUIDIC DEVICE DEVELOPMENT FOR VENOUS THROMBUS UNDERSTANDING**  
Naoko Sugita\*, Hideo Hirakata, Kyo Inoue, Kazuya Tatsumi, Kaoru Koike, Toshiya Murai (Japan)
- PO506-TUE **ANTICOAGULANTS FOR PREVENTION OF THROMBOTIC COMPLICATIONS IN PATIENTS ON PARENTERAL NUTRITION: A SYSTEMATIC REVIEW.**  
Stefano L. Barco\*, Jasper Atema, Michiel Coppens, Mireille Serlie, Saskia Middeldorp (The Netherlands)
- PO507-TUE **LONG-TERM PARENTERAL NUTRITION-ASSOCIATED THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS IN 236 SINGLE-CENTER OUTPATIENTS.**  
Stefano L. Barco\*, Michiel Coppens, Caroline Heuschen, Bram Salman, Marjolein Brekelmans, Mireille Serlie, Saskia Middeldorp (The Netherlands)
- PO508-TUE **ROLE OF BODY COMPOSITION MEASUREMENTS IN PREDICTING CANCER ASSOCIATED THROMBOSIS**  
Omer Iftikhar, Federico Silva, Aaron Mansfield, Mohammad Cherry, Alfonso Tafur\* (United States)
- PO508.1-TUE **A NOVEL RS2232710 SINGLE NUCLEOTIDE VARIANT IN THE PROTEIN Z-DEPENDENT PROTEASE INHIBITOR (ZPI, SERPINA10) GENE AND A RISK OF DEEP VEIN THROMBOSIS**  
Marcin M. Gorski\*, Luca A. Lotta, Hugoline de Haan, Astrid van Hylckama Vlieg, Serena Passamonti, Paolo Bucciarelli, Emanuela Pappalardo, Marco Boscarino, Richard A. Gibbs, Ida Martinelli, Frits Rosendaal, Flora Peyvandi (Italy)

### Signal transduction

- PO509-TUE **UROKINASE PLASMINOGEN ACTIVATOR PROTECTS CARDIAC MYOCYTES FROM OXIDATIVE DAMAGE AND APOPTOSIS VIA OGG1**  
Philipp Hohensinner\*, Nikol Takacs, Christoph Kaun, Stefan Pfaffenberger, Konstantin Krychtiuk, Arezu Aliabadi, Andreas Zuckermann, Gerald Maurer, Kurt Huber, Johann Wojta (Austria)
- PO510-TUE **FACTOR VII ACTIVATING PROTEASE (FSAP) EXPRESSION IS NEGATIVELY REGULATED BY TRANSFORMING GROWTH FACTOR-BETA (TGF- $\beta$ ) IN THE LIVER.**  
Sebastian Seidl\*, Silke Leiting, Lars Muhl, Sandip Kanse (Norway)

## SCIENTIFIC PROGRAM

- PO511-TUE **PHOSPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE STIMULATES CA<sup>2+</sup> ELEVATION AND AKT PHOSPHORYLATION TO CONSTITUTE A MAJOR MECHANISM OF THROMBOXANE A<sub>2</sub> FORMATION IN HUMAN PLATELETS.**  
Kalwant S. Authi\*, Nick Kassouf, Archana Ambily, Stephanie Watson, Sheila Hassock, Harmeet Authi, Steve Watson (United Kingdom)
- PO512-TUE **A SYSTEMS BIOLOGY MODEL FOR THE COAGULATION NETWORK DESCRIBES BIOMARKER CHANGES OBSERVED IN A CLINICAL STUDY WITH FVIIA VARIANT**  
Dooyoung Lee, Satryaprakash Nayak, Steven Arkin, Steven Martin, Anne Heatherington, Paolo Vicini, Fei Hua\* (United States)
- PO513-TUE **IMPORTANCE OF TRANSFORMING GROWTH FACTOR BETA-INDUCED SIGNALING FOR CHRONIC POSTTHROMBOTIC VASCULAR REMODELING PROCESSES**  
Katrin Schäfer, Magdalena L. Bochenek\*, Nico Rosinus, Eva Schütz, Mareike Lankeit, Markus Bosmann, Eckard Mayer, Thomas Münzel, Stavros Konstantinides (Germany)
- PO514-TUE **ROLE OF P110ALPHA ISOFORM OF CLASS I PI3-KINASES IN PLATELET ACTIVATION AND FUNCTIONS**  
Pierre-Alexandre Laurent, Sonia Séverin, Béatrice Hechler, Gaëtan Chicanne, Anne-Dominique Terrisse, Gachet Christian, Bart Vanhaesebroeck, Bernard Payrastre, Marie-Pierre Gratacap\* (France)

### Stroke

- PO515-TUE **EVALUATION OF THE THERAPEUTIC EFFECT OF NOVEL STROKE DRUG SMT-7 ON EMBOLIC STROKE IN MONKEYS**  
Eriko Suzuki\*, Yudai Kunikiyo, Naoki Matsumoto, Hironobu Sawada, Naoko Nishimura, Keiko Hasegawa, Keiji Hasumi (Japan)
- PO516-TUE **THE ASSOCIATION OF FACTOR VIII AND VON WILLEBRAND FACTOR LEVELS AND THE OUTCOME OF THROMBOLYSIS IN ISCHEMIC STROKE PATIENTS**  
Noemi Klara Toth\*, Edina Székely, Katalin Kovács, László Csiba, László Muszbek, Zsuzsa Bagoly (Hungary)
- PO517-TUE **ADAMTS13 DESTABILIZES THROMBI IN A MOUSE MODEL OF THROMBOTIC FOCAL CEREBRAL ISCHEMIA**  
Frederik Denorme\*, Friederike Langhauser, Hanspeter Rottensteiner, Barbara Plaimauer, Friedrich Scheiflinger, Christoph Kleinschnitz, Karen Vanhoorelbeke, Simon De Meyer (Belgium)
- PO518-TUE **REMOTE PLATELET FUNCTION TESTING USING MEASUREMENTS OF P-SELECTIN IN PATIENTS WITH ACUTE STROKE OR TIA ALREADY RECEIVING TREATMENT WITH ANTIPLATELET AGENTS**  
Stan Heptinstall\*, Natalia Dovlatova, Jane May, Katie Robson, Philip Bath (United Kingdom)
- PO519-TUE **INHIBITION OF TAFI AND PAI-1 IS PROTECTIVE IN A MOUSE MODEL OF CEREBRAL ISCHEMIA/REPERFUSION INJURY**  
Frederik Denorme\*, Tine Wyseure, Miet Peeters, Ann Gils, Paul Declerck, Simon De Meyer (Belgium)

## SCIENTIFIC PROGRAM

- P0520-TUE **A FACTOR XA VARIANT IMPROVES HEMOSTASIS MODELS OF INTRACEREBRAL HEMORRHAGE**  
Reema Jasuja, Rodney Camire, Steven Arkin, Debra Pittman\* (United States)
- P0521-TUE **GENETIC ABLATION OF EXTRA DOMAIN A OF CELLULAR FIBRONECTIN PROTECTS HYPERCHOLESTEROLEMIC MICE FROM ACUTE STROKE BY REDUCING THROMBO-INFLAMMATION**  
Nirav Dhanesha, Ajmal Ahmad, Prem Prakash, Prakash Doddapattar, Steven Lentz, Anil Chauhan\* (United States)
- P0522-TUE **EFFECTS OF THE MAIN ACTIVE COMPONENT COMBINATION BETWEEN ASTRAGALUS AND PANAX NOTOGINSENG ON INFLAMMATION AND APTOPTOSIS OF NERVE CELL AFTER CEREBRAL ISCHEMIA-REPERFUSION**  
Chang-Qing Deng\*, Xiao-Ping Huang, Huang Ding, Jin-Dong Lu, Ying-Hong Tang, Bing-Xiang Deng (China)
- P0523-TUE **THE ANGIOTENSIN-CONVERTING ENZYME GENE INSERTION/DELETION POLYMORPHISM IS ASSOCIATED WITH INCREASED RISK FOR ISCHEMIC STROKE BUT NOT FOR MYOCARDIAL INFARCTION IN YOUNG MEXICAN POPULATION**  
Irma Isordia-Salas\*, Rosa María Jiménez-Alvarado, Lorena Mendoza-Valdéz, José Antonio Alvarado-Moreno, David Santiago-Germán, María Valades-Mejía, Jesús Hernández-Juárez, Abraham Majluf-Cruz (Mexico)
- P0524-TUE **THROMBOELASTOMETRY (ROTEM®) PROFILES IN PATIENTS UNDERGOING THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE.**  
Elena Campello\*, Filippo Farina, Luca Spiezia, Anna Palmieri, Sara Maggiolo, Letizia Banzato, Fabio Dalla Valle, Claudio Baracchini, Paolo Simioni (Italy)
- P0525-TUE **SEVERE OBESITY IS A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS: A CASE-CONTROL STUDY**  
Jonathan M. Coutinho\*, Susanna Zuurbier, Anne Broeg-Morway, Mirjam Heldner, Frits Rosendaal, Jan Stam, Marcel Arnold, Saskia Middeldorp, Suzanne Cannegieter (The Netherlands)
- P0526-TUE **LIGHT-SHEET FLUORESCENCE MICROSCOPY OF THE ACUTELY ISCHEMIC BRAIN REVEALS DRAMATICALLY REDUCED THROMBOTIC ACTIVITY IN T-CELL DEFICIENT MICE**  
David Stegner\*, Mari Gorelashvili, Judith van Eeuwijk, Oguzhan Angay, Jürgen Pinnecker, Michael Schuhmann, Mike Friedrich, Guido Stoll, Katrin Heinze, Bernhard Nieswandt (Germany)
- P0527-TUE **THE ALTERATION OF IRON TRANSMEMBRANE PROTEINS EXPRESSION IN THE RAT HIPPOCAMPUS FOLLOWING FOCAL CEREBRAL ISCHEMIA**  
Jun Liao\*, Shaowu Cheng, Jinwen Ge (China)
- P0528-TUE **NONCLINICAL AND CLINICAL DEVELOPMENT OF TMS-007, A MEMBER OF THE ANTI-INFLAMMATORY SMALL-MOLECULE THROMBOLYTIC SMTPS**  
Keiji Hasumi\*, Naoko Nishimura, Keiko Hasegawa, Hironobu Sawada, Eriko Suzuki (Japan)

## SCIENTIFIC PROGRAM

- P0529-TUE **ANTITHROMBIN LEVELS IN ADULT STROKE PATIENTS AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL**  
Omolade A. Awoodu\*, Oluomachi Nnachi (Nigeria)
- P0530-TUE **CLOPIDOGREL RESISTANCE AFTER MINOR ISCHEMIC STROKE OR TIA IS ASSOCIATED TO PRE-DIABETES, HYPERTENSION AND CEREBRAL MICROANGIOPATHY**  
Annika Lundström\*, Ann Charlotte Laska, Bruna Gigante, Magnus von Arbin, Gun Jörneskog, Evaldas Laurencikas, Karin Höeg Dembrower, Håkan Wallén (Sweden)
- P0531-TUE **ASSOCIATION BETWEEN POLYMORPHISMS IN MICRORNA MACHINERY GENES (DICER1, DROSHA, RAN, AND XPO5) AND ISCHEMIC STROKE**  
Hui Jeong An\*, Jung O Kim, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Ok Joon Kim, Nam Keun Kim (Korea, Republic Of)
- P0532-TUE **THROMBOLYSIS USING N-ACETYLCYSTEINE IN ACUTE ISCHEMIC STROKE**  
Maxime Gauberti\*, Sara Martinez de Lizarrondo, Clément Gakuba, Denis Vivien (France)
- P0533-TUE **MULTIPLE MENINGIOMAS DOES NOT INCREASE THE RISK OF INTRACRANIAL HEMORRHAGE AFTER INTRAVENOUS THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE**  
Navdeep Lail\*, Ashkan Mowla, Karanbir Singh, Sandhya Mehla, Peyman Shirani (United States)
- P0534-TUE **PATENT FORAMEN OVALE IN PATIENTS WITH PREVIOUS CEREBRAL ISCHEMIC EVENTS:ECHOCARDIOGRAPHIC FEATURES AND RELATIONSHIPS WITH TRANSCRANIAL DOPPLER**  
Paola Ieranò, Antonella Tufano\*, Roberta Esposito, Ciro Santoro, Francesco De Stefano, Anna Maria Cerbone, Giovanni Di Minno, Giovanni de Simone, Maurizio Galderisi (Italy)
- P0535-TUE **HEMORHEOLOGY AND HEMOSTASIS IN ISCHEMIC STROKE PATIENTS TREATED WITH I.V.THROMBOLYSIS**  
Marina Gafarova\*, Maxim Domashenko, Marina Maximova, Mark Loskutnikov, Daria Korobkova, Alla Shabalina, Marina Kostyeva, Rodion Konovalov (Russian Federation)
- P0536-TUE **ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH CEREBRAL SINUS VENOUS THROMBOSIS AND THE RISK OF RECURRENCE.**  
Jakub Siudut\*, Michał Zabczyk, Anetta Undas (Poland)
- P0537-TUE **THE NOVEL BIASED AGONIST FOR PAR-1 PROTECTS BRAIN CELLS FROM TOXICITY SIMILAR TO ACTIVATED PROTEIN C**  
Liubov Gorbacheva\*, Irina Savinkova, Svetlana Strukova (Russian Federation)
- Thrombophilia II**
- P0538-TUE **ROLE OF GENETIC POLYMORPHISMS OF HAEMOSTASIS'S SYSTEM IN CASE OF HABITUAL MISCARRIAGE**  
Nadezda Vorobyeva, Diana Gamirkina (Russian Federation)



## SCIENTIFIC PROGRAM

- PO539-TUE **INDIVIDUAL ABSOLUTE AND RELATIVE RISK (RR) OF PULMONARY EMBOLISM (PE) IN PREGNANCY AND PUERPERIUM IN PRESENCE OF HEREDITARY THROMBOPHILIC RISK FACTORS**  
Rainer B. Zotz\*, Ruediger Scharf, Andrea Gerhardt (Germany)
- PO540-TUE **R147W IN PROC GENE AND THE RISK OF THROMBOEMBOLISM IN THAI CHILDREN**  
Nongnuch Sirachainan\*, Ampaiwan Chuansumrit, Werasak Sasanakul, Lalita Mahaklan, Jarin Vaewpanich, Pimlak Charoenkwan, Somjai Kanjanapongkul, Pakawan Wongwerawattanakoon, Pimpun Kitpoka (Thailand)
- PO541-TUE **ACUTE SUPERIOR MESENTERIC VEIN THROMBOSIS IN A NON-CIRRHOTIC PATIENT WITH HETEROZYGOUS G20210A PROTHROMBIN GENE MUTATION: A CASE REPORT**  
Sagger Mawri\*, David Paje (United States)
- PO542-TUE **THROMBIN GENERATION TEST AT R2 POLYMORPHISM OF FACTOR V**  
Jana Prochazkova\*, Ludek Slavik, Martin Prochazka, Jana Ulehlova (Czech Republic)
- PO543-TUE **FACTOR V LEIDEN IN THE ABSENCE OF APC RESISTANCE IN A PATIENT AFTER LIVER TRANSPLANTATION**  
Edyta Odnoczek, Ksenia Bykowska, Beata Baran, Jerzy Windyga\* (Poland)
- PO544-TUE **VENOUS THROMBOEMBOLISM ASSOCIATED WITH FIRST PREGNANCY IN 80 WOMEN WITH HEREDITARY ANTITHROMBIN DEFICIENCY.**  
Marie Helene Horellou\*, Narymane Benmiloud, Jacqueline Conard, Claire Flaujac, Jacques Lepercq, Martine Alhenc-Gelas, Geneviève Plu-Bureau (France)
- PO545-TUE **MOLECULAR MODELING OF A NOVEL MUTATION IN THE SERPINC1 GENE ASSOCIATED WITH TYPE 1 ANTITHROMBIN DEFICIENCY**  
Tzu-Fei Wang\*, Jennifer Dawson, Julie Forman-Kay, Walter Kahr, Suzan Williams, Anthony Chan, Riten Kumar (United States)
- PO546-TUE **ANTIPHOSPHOLIPID ANTIBODIES AS EMBOLIC RISK MARKER OF INFECTIVE ENDOCARDITIS.**  
Jean Devignes\*, Charles-Henry Maigrat, François Goehringer, Carine Thivillier, Yves Juillère, Thomas Lecompte, Thanh Doco-Lecompte, Christine Selton-Suty (France)
- PO547-TUE **HEREDITARY AND ACQUIRED THROMBOPHILIAS AND WOMEN**  
Ivo Elezovic\*, Darko Antic, Mirjana Mitrovic (Serbia)
- PO548-TUE **CHARACTERIZATION OF A NEW HEREDITARY PROTHROMBIN VARIANT ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM**  
Cristiana Bulato\*, Claudia Radu, Elena Campello, Sabrina Gavasso, Daniela Tormene, Paolo Simioni (Italy)
- PO549-TUE **ARTERIOVENOUS THROMBOSIS IN END STAGE RENAL DISEASE PATIENTS**  
Munira Borhany\*, Naveena Fatima, Asif Hussain, Tahir Shamsi (Pakistan)

### Tissue factor and factor VII - II

- PO550-TUE **EFFECT OF A CARBOXY-TERMINAL PEPTIDE ON FACTOR VIIIA ACTIVITY**  
Dougald M. Monroe\*, Lior Binder, Malka Hoffman, Gili Hart, Maureane Hoffman (United States)

## SCIENTIFIC PROGRAM

- PO551-TUE **A 28-YEARS-OLD WOMAN WITH FACTOR VII DEFICIENCY REVEALED AFTER TWO SEVERE POSTOPERATIVE BLEEDING EPISODES**  
Evangelia Papapetrou\*, Muriel Giansily-Blaizot, Haralambos Harisis, Georgios Vartholomatos, Nikolaos Kolaitis, Jean Francois Schved (Greece)
- PO552-TUE **TISSUE FACTOR / FVIIA TRANSACTIVATES THE IGF-1R IN PROSTATE CANCER CELLS VIA INHIBITION OF CAVEOLIN-1**  
Mikael Åberg\*, Agneta Siegbahn (Sweden)
- PO553-TUE **THE LRP1 RECEPTOR PROMOTES THE IN VIVO CLEARANCE OF ACTIVATED FACTOR VII (FVIIA) IN COMPLEX WITH ANTITHROMBIN**  
Judicael G. Fazavana\*, Nikolett Wohner, Olivier Christophe, Cécile Denis, Peter Lenting (France)
- PO554-TUE **HIGH PLASMA CONCENTRATION OF ACTIVATED FACTOR VII-ANTI-THROMBIN COMPLEX IS ASSOCIATED WITH AN ENHANCED THROMBIN GENERATION**  
Marcello Baroni\*, Alessio Branchini, Patrizia Guarini, Federica Tosi, Filippo Sartori, Matteo Campioni, Francesco Puzzo, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, Francesco Bernardi, Nicola Martinelli (Italy)
- PO555-TUE **TISSUE FACTOR AND FACTOR VII GENE POLYMORPHISMS INFLUENCING FVIIA-AT PLASMA CONCENTRATION ARE NOT UNIFORMLY ASSOCIATED WITH MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE.**  
Filippo Sartori\*, Federica Tosi, Barbara Lunghi, Patrizia Guarini, Marcello Baroni, Alessio Branchini, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, Francesco Bernardi, Nicola Martinelli (Italy)
- PO556-TUE **THE ROLE OF FACTOR VII MUTATIONS IN ENDOPLASMIC RETICULUM STRESS**  
Elisabeth Dørum\*, Maria Eugenia Chollet, Mirko Pinotti, Francesco Bernardi, Per Morten Sandset, Grethe Skretting (Norway)
- PO557-TUE **FVII DEFICIENCY: UNVEILING THE CELLULAR AND MOLECULAR MECHANISMS UNDERLYING THREE MODEL ALTERATIONS (MISSENSE, DELETION, EXTENSION) OF THE FVII CATALYTIC DOMAIN**  
Maria Eugenia Chollet Dugarte\*, Elisabeth Dørum, Ellen Skarpen, Christian Koehler, Bernd Thiede, Jens Preben Morth, Christiane F. Myklebust, Mirko Pinotti, Francesco Bernardi, Per Morten Sandset, Grethe Skretting (Norway)
- PO558-TUE **MICRORNAS MODULATE HUMAN TISSUE FACTOR PATHWAY INHIBITOR-A (TFPIA) EXPRESSION IN RESPONSE TO ANDROGENS IN ENDOTHELIAL CELLS**  
Ana Belén Arroyo Rodríguez\*, Salam Salloum-Asfar, Carlos Pérez-Sánchez, Raul Teruel-Montoya, Nuria García-Barberá, Ginés Luengo-Gil, Silvia Navarro, Pilar Medina, Chary López-Pedrerá, Vicente Vicente, Constantino Martínez, Rocío Gonzalez-Conejero (Spain)
- PO559-TUE **SINGLE CENTRE EXPERIENCE OF FACTOR VII DEFICIENCY**  
Bella Madan\*, Gulnaz Shah, Theodora Vatopoulou, Mike Mitchell, Jacqueline Cutler (United Kingdom)

## SCIENTIFIC PROGRAM

- PO560-TUE **THROMBIN GENERATION IN PATIENTS WITH MILD FACTOR VII DEFICIENCY MEASURED IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN**  
Roza Chaireti, Kerstin Arbring, Egon Persson, Tomas Lindahl\* (Sweden)
- PO561-TUE **MUTATIONS IN THE F7 GENE IN SWEDISH PATIENTS WITH DISCREPANT FACTOR VII ACTIVITY IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN**  
Roza Chaireti, Kerstin Arbring\*, Ole Olsen, Egon Persson, Tomas Lindahl (Sweden)
- PO562-TUE **FVII DEFICIENCY AND THROMBOSIS, COINCIDENCE OR NEW MECHANISM OF THROMBOPHILIA**  
Yacine Larfi\*, I Bachiri, W Zazoua, N Fenni, M Giacily-Blaizot, Jean-François Schved(Algeria)

### TTP/thrombotic microangiopathies II

- PO563-TUE **USE OF A PLASMA DERIVED FVIII PRODUCT FOR PRIMARY PROPHYLACTIC THERAPY IN AN INFANT WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA**  
MacGregor Steele\*, Sheri VanGunst, Michael Leaker (Canada)
- PO564-TUE **ANTI-IDIOTYPIC DARPINS RESTORE ADAMTS13 ACTIVITY IN BABOONS CHALLENGED WITH HUMAN MONOCLONAL ANTIBODIES: FIRST STEP TOWARDS AN ANIMAL MODEL FOR HUMAN ACQUIRED TTP**  
Monica Schaller\*, Magdalena Skowronska, Monique Vogel, Deborah Stearns-Kurosawa, Shinichiro Kurosawa, Johanna Kremer Hovinga (Switzerland)
- PO565-TUE **THE LABORATORY PROFILE THAT PREDICTS FAVORABLE OUTCOME AFTER ECULIZUMAB THERAPY IN PATIENTS WITH CLINICAL FEATURES COMPATIBLE WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME**  
Hira Mian\*, Anthony Chan, Keith Lau, Howard Chan (Canada)
- PO566-TUE **THE CLINICAL ANALYSIS OF 58 THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS**  
Lv Cuicui\*, Sun Tiantian, Ju Mankai, Fu Rongfeng, Lv Minggen, Xue Feng, Liu Xiaofan, Li Huiyuan, Zhang Donglei, Zhang Xian, Liu Wenjie, Li Yang, Hao Yating, Zhang Lei, Yang Renchi (China)
- PO567-TUE **RITUXIMAB THERAPY AS PROPHYLAXIS AGAINST THROMBOTIC THROMBOCYTOPENIC PURPURA: COMPARISON OF STANDARD AND REDUCED DOSE REGIMENS**  
John-Paul Westwood\*, Debra Ellis, Siobhan Mc Guckin, Marie Scully (United Kingdom)
- PO568-TUE **CLINICAL AND BIOCHEMICAL STUDIES OF A PATIENT WITH ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) TREATED WITH N-ACETYLCYSTEINE (NAC)**  
Junmei Chen\*, Tahsin Ozpolat, Colette Norby, Jennie Le, Minhua Ling, Shelby Cate, Dominic Chung, Xiaoyun Fu, Barbara Konkle, José López (United States)

## SCIENTIFIC PROGRAM

- PO569-TUE **AUTOANTIBODY INDUCED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A YOUNG PATIENT WITH METASTASIZING CANCER OF UNKNOWN PRIMARY (CUP) SYNDROME**  
Charis Von Auer\*, Heidi Rossmann, Bernhard Lämmle (Germany)
- PO570-TUE **SEVERE MATERNAL MORBIDITY AND FETAL DEATH IN A PREGNANT WOMAN WITH RECURRENT ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)**  
Charis Von Auer\*, Tanja Falter, Heidi Rossmann, Antje Lebrecht, Dana Marandiu, Inge Scharrer, Bernhard Lämmle (Germany)
- PO571-TUE **OBESITY AS A RISK FACTOR FOR THE DEVELOPMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN ADAMTS13 DEFICIENT MICE**  
Lotte Geys, Elien Roose\*, Ilse Scroyen, Claudia Tersteeg, Hanspeter Rottensteiner, Simon De Meyer, H Roger Lijnen, Karen Vanhoorelbeke (Belgium)
- PO572-TUE **A MULTICENTER, RANDOMIZED STUDY OF CYCLOSPORINE OR CORTICOSTEROIDS AS AN ADJUNCT TO PLASMA EXCHANGE IN INITIAL THERAPY OF THROMBOTIC THROMBOCYTOPENIC PURPURA**  
Spero R. Cataland\*, Shangbin Yang, Susan Geyer, Haifeng Wu (United States)
- PO573-TUE **COMPARING PERFORMANCES OF COMPLEMENT ACTIVATION BIOMARKERS BETWEEN RESPONDERS AND NON-RESPONDERS TO ECULIZUMAB THERAPY**  
Spero R. Cataland\*, Shangbin Yang, Haiwa Wu, Haifeng Wu (United States)
- PO574-TUE **EVALUATION OF LONG TERM NEUROLOGICAL SEQUELAE AFTER A FIRST EPISODE OF THROMBOTIC THROMBOCYTOPENIC PURPURA. Barbara Ferrari, Alberto Maino, Andrea Artoni, Silvia Riva, Lucia Scirpa, Paola Santalucia\*, Gabriella Pravettoni, Antonella Costa, Flora Peyvandi (Italy)**

### Venous thromboembolism - diagnosis II

- PO576-TUE **INCORPORATION OF RIGHT VENTRICULAR DYSFUNCTION INTO THE SIMPLIFIED PULMONARY EMBOLISM SEVERITY INDEX AS A PREDICTOR OF COMPLICATED CLINICAL COURSE IN LOW-RISK PATIENTS PRESENTING WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM**  
David Jimenez\*, Jose Luis Lobo, Ana Portillo, Covadonga Fernandez-Golfin, Remedios Otero, Roger Yusen (Spain)
- PO577-TUE **RADIATION AND BREAST CANCER RISK IN WOMEN DIAGNOSED WITH PULMONARY EMBOLISM: CT PULMONARY ANGIOGRAPHY VERSUS VENILATION-PERFUSION SCANNING**  
Vicky Tagalakis\*, Mark Tulchinsky, Alejandro Lazo-Langner, Samy Suissa, Gregoire Le Gal (Canada)
- PO578-TUE **RISK-ASSESSMENT MODEL OF RECURRENCE WITHIN 3 MONTHS AFTER A FIRST EPISODE OF ACUTE VENOUS THROMBOEMBOLISM: WORCESTER VENOUS THROMBOEMBOLISM STUDY**  
Wei Huang\*, Robert Goldberg, Frederick Anderson, Frederick Spencer (United States)

## SCIENTIFIC PROGRAM

- PO579-TUE **PERFORMANCE OF PULMONARY EMBOLISM RULE-OUT CRITERIA (PERC) COMBINED WITH LOW GESTALT CLINICAL PROBABILITY IN EUROPEAN CHEST PAIN POPULATION**  
Emilie Friou\* , Vanessa Richard-Jourjon, Thomas Moumneh, Betty Mazet, Jacques Choukroun, Thibault Schotte, Andrea Penaloza, Pierre-Marie Roy (France)
- PO580-TUE **AN ELECTRONIC TOOL AND RECORD FOR DEEP VEIN THROMBOSIS (DVT) ASSESSMENT, DIAGNOSIS, TREATMENT AND FOLLOW UP.**  
Jane Strong, Victoria Frimpong, Jo Eggleston\*, Deborah Thornton, Helen Briggs, Tamyka Stewart, Rachel Clarke-Drury, Karen Coultas, Alistair Stewart, George Kitching, Syd Stewart (United Kingdom)
- PO581-TUE **VALIDATION OF THE USE OF AGE ADJUSTED D DIMER CUT OFF VALUES TO REDUCE THE COMPRESSION VENOUS ULTRASOUND RATES IN AN ACUTE AMBULATORY DVT SERVICE**  
Jane Strong\*, Jo Eggleston, Victoria Frimpong, Deborah Thornton, Helen Briggs, Tamyka Stewart, Rachel Clarke-Drury, Karen Coultas (United Kingdom)
- PO582-TUE **THE USE OF AN AGE-ADJUSTED CUT-OFF FOR D-DIMER IN SCREENING PATIENTS FOR SUSPECTED DVT IN THE COMMUNITY CAN SAFELY DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY.**  
Andrew S. Hughes\*, Benjamin Hall, Kate Jennings, Victoria Webb, Georgia Page, Christine Smith, Florence Charova (United Kingdom)
- PO583-TUE **DIAGNOSTIC PREDICTION MODEL VERSUS GESTALT IN THE DIAGNOSIS OF PULMONARY EMBOLISM IN PRIMARY CARE**  
Janneke Hendriksen\*, Geert-Jan Geersing, Wim Lucassen, Petra Erkens, Ruud Oudega, Karel Moons (The Netherlands)
- PO584-TUE **CLINICAL PREDICTION RULES PLUS D-DIMER TESTING DO NOT ENABLE A SAFE EXCLUSION OF DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM IN ELDERLY PATIENTS RESIDING IN NURSING HOMES OR HOMES FOR THE ELDERLY.**  
Geert-Jan Geersing\*, Henrike Schouten, Ruud Oudega, Hans van Delden, Karel Moons, Dineke Koek (The Netherlands)
- PO585-TUE **COMBINED ASSESSMENT OF THROMBOTIC AND HAEMORRHAGIC RISK IN ACUTE MEDICAL PATIENTS**  
Micaela La Regina, Francesco Orlandini, francesca Marchini, Antonio Marinaro, Rosanna Bonacci, Paola Bonanni, Francesca Corsini, Francesco Dentali\* (Italy)
- PO586-TUE **PREDICTION OF SEPSIS DEVELOPMENT IN PUERPERAS WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME**  
Sergei Sinkov\*, Igor Zabolotskikh, Grigoriy Penjoyan, Valeriy Muzychenko, Irina Prokhorova (Russian Federation)
- PO587-TUE **PROSPECTIVE VALIDATION OF THE SIMPLIFIED REVISED GENEVA SCORE**  
Gregoire Le Gal\*, Khaled Mostaguir, Marcel Hovens, Meissa Kare, Arnaud Perrier, Franck Verschuren, Philippe Girard, Menno Huisman, Hélia Robert-Ebadi, Farès Moustafa, Pieter Kamphuisen, Harry Buller, Marc Righini (France, Canada)
- PO588-TUE **REVIEW OF EMERGENCY DEPARTMENT INVESTIGATED DVT**  
Gary Benson, Rosemary Lavery\*, Hilary Speers, Mark Worthington (United Kingdom)

## SCIENTIFIC PROGRAM

### Venous thromboembolism - epidemiology II

- PO589-TUE **PREVALENCE OF VENOUS THROMBOEMBOLISM & RELATED MORBIDITY AND MORTALITY AMONG HOSPITALIZED PATIENTS IN SAUDI ARABIA (SAVTE STUDY)**  
Essam Aboelnazar\* (Saudi Arabia)
- PO590-TUE **BELOW KNEE DEEP VEIN THROMBOSIS (BKDVT): A BENIGN ENTITY OR NOT?**  
Prahlad Ho\*, Hui Yin Lim, Chyn Chua, Matthew Sleeman, Lachlan Hayes (Australia)
- PO591-TUE **ETIOLOGY OF PORTAL VENOUS THROMBOSIS AND BUDD-CHIARI SYNDROME IN ADULTS**  
Anil Tombak\*, Gizem Isguzar, Enver Ucbilek, Serkan Yaras, Aydan Akdeniz, Mehmet Ucar, Emel Gurkan, Eyup Tiftik, Mehmet Sungur (Turkey)
- PO592-TUE **INCIDENCE OF CATHETER-RELATED VENOUS THROMBOEMBOLISM EVENTS IN ACUTE LEUKEMIA PATIENTS; A RETROSPECTIVE STUDY OF THE SAFETY OF PERIPHERALLY-INSERTED CENTRAL CATHETER.**  
Mohammad Refaei\*, Bruna Fernandes, Joseph Brandwein, Cynthia Wu (Canada)
- PO593-TUE **EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN THE FRAMINGHAM HEART STUDY**  
Marja K. Puurunen\*, Philimon Gona, Joanne Murabito, Jared Magnani, Christopher O'Donnell (United States)
- PO594-TUE **IMPACT OF INCIDENT STROKE ON FUTURE RISK OF VENOUS THROMBOEMBOLISM**  
Ludvig B. Rinde\*, Birgit Småbrekke, Caroline Lind, Inger Njølstad, Ellisiv Mathiesen, Erin Hald, Sigrid Brækkan, John-Bjarne Hansen (Norway)
- PO595-TUE **EVALUATING THE ACCURACY OF INTERNATIONAL CLASSIFICATION OF DISEASES 10TH REVISION CODES FOR VENOUS THROMBOEMBOLISM (VTE) AND MAJOR BLEEDING (MB) IN EMERGENCY ROOM (ER) DISCHARGES**  
Fatimah Al-Ani\*, Salimah Shariff, Lenicio Siqueira, Alejandro Lazo-Langner (Canada)
- PO596-TUE **ASYMPTOMATIC CENTRAL VENOUS LINE - RELATED THROMBOSIS IN CHILDREN: FEASIBILITY OF CONDUCTING A CLINICAL STUDY**  
Sophie E. Jones\*, Fiona Newall, Warwick Butt, Paul Monagle (Australia)
- PO597-TUE **CEREBRAL VENOUS THROMBOSIS: A LONGITUDINAL FOLLOW UP**  
Maria Teresa Desancho\*, Mohini Aras (United States)
- PO598-TUE **PULMONARY EMBOLISM: DOES THE SEASONAL EFFECT DEPEND ON AGE? A 10 YEARS NATIONWIDE ANALYSIS OF HOSPITALIZATION AND MORTALITY**  
Valerie Olie\*, Christophe Bonaldi (France)
- PO599-TUE **IMPLICATIONS OF CYTOGENETICS FOR VENOUS THROMBOEMBOLISM IN ACUTE MYELOID LEUKEMIA**  
Yun-Gyoo Lee\*, Inho Kim, Ji-Hyun Kwon, Sung Soo Yoon, Seonyang Park, Jae-Ho Yoon, Seung-Hwan Shin, Woo-Sung Min, Hee-Je Kim (Korea, Republic Of)

## SCIENTIFIC PROGRAM

- PO600-TUE **LONG-TERM HEALTH-RELATED QUALITY OF LIFE AFTER DEEP VEIN THROMBOSIS IS IMPAIRED COMPARED TO CONTROLS.**  
Kristin Utne\*, Waleed Ghanima, Per Sandset, Hilde Wik, Lars-Petter Jelsness-Jørgensen (Norway)
- PO601-TUE **LONG-HAUL TRAVEL AND THE RISK OF RECURRENT VENOUS THROMBOSIS**  
Jasmijn Timp\*, Saskia le Cessie, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)
- PO602-TUE **RECENT DISCHARGE CONFERS RISK FOR VENOUS THROMBOEMBOLISM**  
Hiren Shah\*, Nicholas Christensen (United States)

### Venous thromboembolism - therapy II

- PO603-TUE **A DRUG-DRUG INTERACTION STUDY OF DS-1040 AND ASPIRIN IN HEALTHY SUBJECTS**  
James Dow, Adeep Puri, Penny McPhillips, Yasushi Orihashi, Victor Dishy, Jin Zhou\* (United States)
- PO604-TUE **FEASIBILITY OF COMPARING INTERMITTENT PNEUMATIC COMPRESSION VS. A NOVEL DEVICE FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN TRAUMA PATIENTS WITH CONTRAINDICATION TO ANTICOAGULATION**  
Vinai Bhagirath\*, Nayef Al Onazi, Sam Schulman, Mark Crowther (Canada)
- PO605-TUE **PREDICTION OF THE BLEEDING RISK DURING ANTICOAGULATION TREATMENT FOR PULMONARY THROMBOEMBOLISM**  
Zhenguo Zhai\*, Zhu Zhang, Yuanhua Yang, Chen Wang (China)
- PO606-TUE **RECURRENCES AFTER STOPPING ANTICOAGULANT THERAPY IN THAI PATIENTS WITH NON CANCER-RELATED VENOUS THROMBOEMBOLISM**  
Pitiphong Kijrattanakul\*, Paphatsaphan Thippayanuruksakul, Benjaporn Akkawat, Ponlapat Rojnuckarin (Thailand)
- PO607-TUE **XALIA, A NON-INTERVENTIONAL STUDY COMPARING RIVAROXABAN WITH STANDARD ANTICOAGULATION FOR INITIAL AND LONG-TERM THERAPY IN DEEP VEIN THROMBOSIS: BASELINE DEMOGRAPHICS AND HOSPITALIZATION RATES**  
Alexander G. Turpie\*, Lorenzo Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Walter Ageno (Canada)
- PO608-TUE **APIXABAN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS FROM STUDY CENTRES IN ASIA; A SUBGROUP ANALYSIS OF THE AMPLIFY TRIAL**  
Alexander S. Gallus\*, Giancarlo Agnelli, Harry Buller, Alexander Cohen, Theodore Lee, Raphael Pak, Gary Raskob, Harry Shi, Jeffrey Weitz (Australia)
- PO609-TUE **SHOULD WE USE VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING CHEMOTHERAPY?**  
Adam Wiszniewski\*, Piotr Szopinski, Krzysztof Warzocha (Poland)

## SCIENTIFIC PROGRAM

- PO610-TUE **LOW-RISK PULMONARY EMBOLISM AND LENGTH OF HOSPITAL-STAY: THE LORPELHS STUDY**  
Marco P. Donadini\*, Marco Castellaneta, Paola Gnerre, Micaela La Regina, Fulvio Pomerio, Roberta Re, Andrea Gallo, Francesco Dentali, Walter Ageno, Alessandro Squizzato (Italy)
- PO611-TUE **ANTITHROMBOTIC TREATMENT AND OUTCOMES OF NON-MALIGNANT NON-CIRRHOTIC SPLANCHNIC VEIN THROMBOSIS: A SUB-ANALYSIS FROM THE ISTH REGISTRY**  
Nicoletta Riva\*, Walter Ageno, Sam Schulman, Jan Beyer-Westendorf, Elvira Grandone, Matteo Nicola Dario Di Minno, Maria Teresa Sartori, Alessandra Malato, Ida Martinelli, Elbio Antonio D'amico, Eugenio Bucherini, Valerio De Stefano, Marcello Di Nisio, Renzo Poggio, Barbara Nardo, Asher Winder, Dominique Farge-Bancel, Silvia Betti, Francesco Dentali, IRSVT study investigators (Italy)
- PO613-TUE **A GLOBAL PROSPECTIVE COHORT STUDY OF DABIGATRAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM (RE-COVERY)**  
Samuel Z. Goldhaber\*, Walter Ageno, Ivan Casella, Chee Kok Han, Gary Raskob, Sebastian Schellong, Daniel Singer, Dalia Shash, Marc Desch, Sam Schulman (United States)

### Vitamin K antagonists II

- PO614-TUE **INFLUENCE OF VKA-POTENTIATING DRUGS ON OVER-ANTICOAGULATION IN ATRIAL FIBRILLATION**  
Stijn P. van Vugt\*, Jeroen Jaspers Focks, Robert Joustra, Marjo Albers-Akkers, Lucie Bloem-de Vries, Freek Verheugt, Marc Brouwer (The Netherlands)
- PO615-TUE **AGREEMENT OF POINT-OF-CARE INR TEST WITH STANDARD VENOUS SAMPLING ASSAY AT HIGHER EXTREME RANGES**  
Yi Feng Lai\*, Ming Chai Kong, Fiona Seet Ling Chan, Heng Joo Ng (Singapore)
- PO616-TUE **IN ANTICOAGULATION TREATMENT WITH VITAMIN K ANTAGONISTS (AVKS): WHICH IS THE BEST MONITORING TEST?**  
Gustavo L. Vidmar\*, Claudio D'Antonio, Cecilia Capmany, Jimena Bonadeo, Nadia Kujta, Ruben Barbera, Elizabeth Velasquez, Lorena Meza (Argentina)
- PO617-TUE **COMPARISON OF RISK FACTORS FOR WARFARIN-ASSOCIATED BLEEDING**  
Meric Ozgenel, Elif Umit, Nesrin Turan, Muzaffer Demir\* (Turkey)
- PO618-TUE **EXPANDING TELEMEDICINE TO MEDICAL HOMES FOR COMPREHENSIVE CARE DELIVERY FOR PERSONS WITH HEMOSTATIC DISORDERS: A PILOT STUDY OF THE AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK (ATHN)/NATIONAL HEMOPHILIA PROGRAM COORDINATING CENTER (NHPCC).**  
Roshni Kulkarni\*, Rebecca Malouin, Colleen Vallad-Hix, Laura Carlson, Marcia Bird, Diane Aschman, Ann Forsberg, Zachary Trost, Robert Greenhoe (United States)
- PO619-TUE **ANTICOAGULATION REVERSAL IN WARFARIN-ASSOCIATED INTRACEREBRAL HEMORRHAGE: A SYSTEMATIC REVIEW**  
Darae Ko\*, Zayd Razouki, Elaine Hylek (United States)

## SCIENTIFIC PROGRAM

- PO620-TUE** **THE QUA-VKA STUDY TO IDENTIFY NEW RISK FACTORS FOR BLEEDING DURING TREATMENT WITH VITAMIN K ANTAGONISTS: OBJECTIVES AND DESIGN**  
Nienke Van Rein\*, Mettine Bos, Willem Lijfering, Felix van der Meer, Pieter Reitsma (The Netherlands)
- PO621-TUE** **ASSESSMENT OF THE TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS BY SPECIALISTS IN HAEMOSTASIS IN ARGENTINA. THE TERRA REGISTRY.**  
Jose Manuel Ceresetto\*, Federico Bottaro, Marcelo Casey, Alejandra Marti, Carlos Tajer (Argentina)
- PO622-TUE** **RESULTS FROM THE PROSPECTIVE "FARMAMICO" STUDY: INR VARIATIONS IN WARFARIN-TREATED PATIENTS UNDERGOING ANALGESIC AND ANTI-INFLAMMATORY THERAPIES**  
Anna Falanga\*, Viola Milesi, Giuliana Martini, Daria Bettoni, Laura Russo, Federica Gualandris, Federica Brognoli (Italy)
- PO623-TUE** **USE OF PROTON PUMP INHIBITORS AMONG ANTICOAGULATED PATIENTS: THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE (MAQI2) EXPERIENCE**  
Geoffrey D. Barnes\*, Jacob Kurlander, Xiaokui Gu, Keely Haymart, Eva Kline-Rogers, Steve Almany, Jay Kozlowski, Gregory Krol, Scott Kaatz, Sameer Saini, James Froehlich (United States)
- PO624-TUE** **WHAT BLEEDINGS PREDICT HAS-BLED AND HEMORR2HAGES SCALES IN PATIENTS ON LONG-TERM WARFARIN THERAPY?**  
Olga Moreva\*, Ekaterina Kropacheva, Oksana Zemlyanskaya, Elena Titaeva, Anatoliy Dobrovolsky, Elizaveta Panchenko (Russian Federation)
- PO625-TUE** **VITAMIN K ANTAGONISTS FAVORABLY MODULATE FIBRIN CLOT PROPERTIES IN PATIENTS WITH ATRIAL FIBRILLATION AS EARLY AS AFTER 3 DAYS OF TREATMENT: RELATION TO COAGULATION FACTORS AND THROMBIN GENERATION**  
Michał Zabczyk\*, Jacek Majewski, Grzegorz Karkowski, Anetta Undas (Poland)
- PO626-TUE** **PREVALENCE OF ANEMIA IN PATIENTS UNDER TREATMENT WITH VITAMIN K ANTAGONISTS**  
Marco Sampaio, Maria Faria\*, Lurdes Moreira, Ana Spinola, Fernanda Leite, Eugenia Cruz, Manuel Campos (Portugal)

### Von Willebrand disease II

- PO627-TUE** **GENETIC VARIATIONS IN EXON 28 OF VON WILLEBRAND'S FACTOR GENE IN NIGERIAN POPULATION**  
Eyiuche D. Ezigbo\*, Ernest Ukaejiofo, Theresa Nwagha (Nigeria)
- PO628-TUE** **CLINICAL FEATURES AND TYPES OF VON WILLEBRAND DISEASE IN WOMEN WITH MENORRHAGIA REFERRED TO HEMATOLOGY CLINIC OF KERMANSHAH**  
Mehrdad Payandeh\* (Iran, Islamic Republic Of)

## SCIENTIFIC PROGRAM

- PO629-TUE** **A PHASE III OPEN-LABEL, MULTI-CENTER STUDY WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE TO ASSESS THE PHARMACOKINETICS, EFFICACY, AND SAFETY IN PEDIATRIC SUBJECTS WITH VON WILLEBRAND DISEASE (SWIFTLY-VWD STUDY)**  
Gunter Auerswald, Claudia Khayat, Olexandra Stasyshyn, Genadi Iosova, Irina Ramasheuskaya, Marta Julia Lopez Ruano, Wilfried Seifert\* (Germany)
- PO630-TUE** **VON WILLEBRAND DISEASE AND MENORRHAGIA: MULTIPLE TREATMENT OPTIONS FOR DIFFERENT PATIENTS**  
Kaan Kavakli\*, Can Balkan, Deniz Karapinar (Turkey)
- PO631-TUE** **UNEXPECTED FINDING OF LOW VON WILLEBRAND FACTOR LEVELS OR VON WILLEBRAND DISEASE IN PEDIATRIC PATIENTS WITH SCOLIOSIS**  
Brian Castillo\*, S. Kate Hartman, Michael Gorena, Jamie Wingate, Shiu-Ki Hui, Jun Teruya (United States)
- PO632-TUE** **PERCENTAGE OF PLATELET AGGREGATES AND MACROPLATELETS: A POTENTIAL USEFUL LABORATORY PARAMETER FOR PREDICTING BLEEDING IN VON WILLEBRAND DISEASE TYPE 2B (VWD2B) WITH THE P.VAL1361MET MUTATION**  
Hugo Guglielmone\*, Salvador Minoldo, Gustavo Jarchum, Tara Adams, Jorge DiPaola (Argentina)
- PO633-TUE** **DEVELOPMENT OF APLASTIC ANEMIA IN A PATIENT WITH ACQUIRED VON WILLEBRAND'S SYNDROME AND AUTOIMMUNE PREPONDERANCE**  
Arief Gunawan\*, Gary Moore, Bella Madan (United Kingdom)
- PO634-TUE** **RELATIONSHIP BETWEEN BLEEDING TENDENCY AND THE AFFECTED DOMAIN WITH MUTATIONS RESPONSIBLE OF VWD2M PHENOTYPE**  
Adriana I. Woods\*, Ana Kempfer, Juvenal Paiva, Alicia Blanco, Roberto Chuit, Maria Casinelli, Analia Sanchez-Luceros, Maria Lazzari (Argentina)
- PO635-TUE** **CHARACTERIZATION OF VON WILLEBRAND DISEASE SUBTYPES IN 303 PATIENTS - A SINGLE CENTRE STUDY OVER THE PAST 10 YEARS**  
Anil Pathare\*, Karima Al Falahi, Badriya Al-Belushi, Shoab Al Zadjali, Salam Alkindi (Oman)
- PO636-TUE** **VWD2B PHENOTYPE: ITS PREVALENCE WITHIN FAMILIES AND BLEEDING TENDENCY IN AFFECTED MEMBERS**  
Adriana I. Woods\*, Ana Kempfer, Juvenal Paiva, Emilse Bermejo, Alicia Blanco, Roberto Chuit, Analia Sanchez-Luceros, Maria Lazzari (Argentina)
- PO637-TUE** **VON WILLEBRAND DISEASE (VWD), EXPERIENCE OF ALGERIA IN BENI MEUSSOU CENTER IN ALGIERS**  
Meriem Bensadok\*, Karima Chennoukh, Chahyra Aboura, Mylad Aribi, Nadia Zidani, Meriem Belhani, Mohamed Salim Nekkai (Algeria)
- PO638-TUE** **TWO UNUSUAL CASES OF TYPE 2N VON WILLEBRAND DISEASE.**  
Patricia Bignell\*, Nicola Curry, Pamela Wright, James Beavis, Shirley Henderson, Anna Schuh (United Kingdom)

## SCIENTIFIC PROGRAM

- PO639-TUE **HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH-ECONOMIC ASSESSMENT IN PATIENTS WITH VON WILLEBRAND DISEASE IN FRANCE: THE WISH-QOL STUDY**  
Annie Borel-Derlon\*, Jenny Goudemand, Catherine Boyer-Neumann, Edith Fressinaud, Catherine Ternisien, Marc Trossaert, Agnès Veyradier, WiSH-QoL Study Group, Caroline Martinez, Catherine Chatelanaz, Sylvia Von Mackensen (France)
- PO640-TUE **POOR RESPONSE TO 1-DESAMINO-8-D ARGININE VASOPRESSIN (DDAVP) TEST IN A PATIENT WITH VON WILLEBRAND DISEASE TYPE 2M (VWD2M) WITH P.GLU1549LYS MUTATION**  
Hugo Guglielmone\*, Juan Frontröh, Salvador Minoldo, Mirta Hepner, Marcela Sabagh, Gustavo Jarchum (Argentina)
- PO641-TUE **ALLELE-SPECIFIC SILENCING OF THE VON WILLEBRAND FACTOR GENE TO AMELIORATE THE VON WILLEBRAND DISEASE PHENOTYPE**  
Annika de Jong\*, Richard Dirven, Jeroen Eikenboom (The Netherlands)
- PO642-TUE **EVALUATION OF A NEW AUTOMATED RISTOCETIN COFACTOR ASSAY ON THE STA-R EVOLUTION ANALYZER**  
Heleen Eising\*, Lisan te Roller, Michelle Visser-Koldenhof, Bertil Wildeboer, Jasper Remijn (The Netherlands)
- PO643-TUE **HOW WELL CAN LABORATORIES DIAGNOSE TYPE 2N VWD? DATA FROM A UK NEQAS (BLOOD COAGULATION) EXERCISE.**  
Ian Jennings\*, Steve Kitchen, Dianne Kitchen, Timothy Woods, Mike Makris, Isobel Walker (United Kingdom)
- PO644-TUE **POSTOPERATIVE BLEEDING AND OTHER OUTCOMES IN CHILDREN WITH VON WILLEBRAND DISEASE OR LOW VON WILLEBRAND FACTOR UNDERGOING ADENOTONSILLECTOMY**  
Rosa Diaz\*, Donald Mahoney JR, MaryFrances Musso, Donald Yee (United States)
- PO645-TUE **WILLEBRAND DISEASE MOLECULAR DIAGNOSIS BY HIGH THROUGH-PUT SEQUENCING: WHAT'S ABOUT THE HIGHLY HOMOLOGOUS PSEUDOGENE ?**  
Mathilde Giraud\*, Solenne Dumont, Pierre Boisseau, Patricia Talarmain, Marie Annick Gourlaouen, Jessy Hary, Catherine Ternisien, Edith Fressinaud, Jenny Goudemand, Agnes Veyradier, Stephane Bezieau (France)
- PO646-TUE **CLINICAL AND LABORATORY DETECTION OF TRANSIENT NEUTRALIZING ANTIBODIES IN SEVERE VON WILLEBRAND DISEASE ON LONG TERM PROPHYLAXIS**  
Analia Sánchez-Luceros\*, Maria Alberto, Ana Kempfer, Adriana Woods, Alicia Blanco, Silvia Grosso, Maria Romero, Maria Lazzari, Emilse Bermejo, Susana Meschengieser (Argentina)
- PO647-TUE **VON WILLEBRAND DISEASE: THE PHENOTYPIC CHARACTERIZATION IN THAILAND**  
Theera Ruchutrakool\*, Bundarika Suwanawiboon, Yupa Nakkinkun, Pimlak Charoenwan, Weerasak Nawarawong, Werasak Sasanakul, Ampaiwan Chuansumrit (Thailand)
- PO648-TUE **ACQUIRED VON WILLEBRAND SYNDROME IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA**  
Ksenia Bykowska, Ewa Mendek-Czajkowska, Beata Sokołowska, Adam Wiszniewski\*, Beata Baran, Jerzy Windyga (Poland)

## SCIENTIFIC PROGRAM

- PO649-TUE **IDENTIFICATION OF NOVEL VWF GENE MUTATIONS IN THE TURKISH TYPE 2 VWD PATIENT POPULATION**  
Ergul Berber\*, Yesim Oymak, Oguzhan Baltaci, Reyhan Diz-Küçükkaya, Bulent Zulfikar, Kaan Kavakli (Turkey)
- PO650-TUE **CANCERS IN PATIENTS WITH VON WILLEBRAND DISEASE: A SURVEY FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES**  
Annarita Tagliaferri, Giancarlo Castaman\*, Caterina Di Perna, Cristina Santoro, Simona Maria Siboni, Ezio Zanon, Silvia Linari, Paolo Gresele, Samantha Pasca, Antonio Coppola, Rita Santoro, Ranalli Paola, Mariasanta Napolitano, Massimo Franchini (Italy)
- PO651-TUE **MODIFICATIONS OF HEMOSTATIC THERAPY FOR PATIENTS WITH VON WILLEBRAND DISEASE BASED ON COMORBIDITY**  
Nadezhda Zozulya\*, Elena Likhacheva, Olga Yastrubinskaya (Russian Federation)
- PO652-TUE **ACQUIRED VON WILLEBRAND SYNDROME (AVWS) WITH A TYPE 2B PHENOTYPE SECONDARY TO AN IGA AUTOANTIBODY WITH ANTI-VON WILLEBRAND FACTOR ACTIVITY.**  
Maria Alberto, Emilse Bermejo, Susana Meschengieser, Maria Romero, Adriana Woods, Ana Kempfer, Juvenal Paiva, Marcos Pizzolato, Maria Lazzari, Analia Sanchez-Luceros\* (Argentina)
- PO653-TUE **ACQUIRED VON WILLEBRAND SYNDROME IN PATIENTS TREATED WITH LEFT VENTRICULAR ASSIST DEVICES**  
Kenki Saito\*, Ko Sakatsume, Ryutaro Shirakawa, Tomohiro Kimura, Masatoshi Akiyama, Yoshikatsu Saiki, Hisanori Horiuchi (Japan)
- PO654-TUE **DENTAL INVASIVE PROCEDURES IN VON WILLEBRAND DISEASE (VWD) OUTPATIENTS TREATED WITH HIGH PURITY VWF/FVIII COMPLEX CONCENTRATE: EXPERIENCE OF A SINGLE CENTER.**  
Valeria De Padua\*, Cristina Santoro, Domenico Gaglioti, Francesco Riva, Erminia Baldacci, Caterina Mercanti, Maria Gabriella Mazzucconi (Italy)
- PO655-TUE **RECOGNITION AND CORRELATION OF A RANDOM PATIENT-SPECIFIC ERROR OF THE AUTOMATED VON WILLEBRAND FACTOR ACTIVITY LATEX IMMUNOASSAY**  
Julie I. Tange\*, Rachel Leger, Diane Grill, Rajiv Pruthi, Dong Chen (United States)

### Von Willebrand factor II

- PO656-TUE **LONG TERM EXERCISE SIGNIFICANTLY DECREASES VON WILLEBRAND FACTOR ANTIGEN LEVELS IN ABDOMINALLY OBESE ADULTS**  
Cynthia Pruss\*, Robert Ross, Michael Adams (Canada)
- PO657-TUE **DEVELOPMENT OF A VWF PROPEPTIDE ASSAY**  
Muriel Meiring\* (South Africa)
- PO658-TUE **CROSS-SPECIES INHIBITION OF HUMAN AND MURINE VON WILLEBRAND FACTOR BY A SINGLE DOMAIN VHH-ANTIBODY**  
Ibrahim Habib\*, Paulette Legendre, Amine Bazaa, Cécile Denis, Peter Lenting, Valérie Proulle, Olivier Christophe (France)

## SCIENTIFIC PROGRAM

- PO659-TUE **HIGH ACTIVITY OF VON WILLEBRAND FACTOR AND LEVELS OF VWF-CLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEONATES**  
Tzipora Strauss\*, Naama Elisha, Bruria Ravid, Ariela Zivelin, Ahron Lubetsky, Iris Morag, Gili Kenet (Israel)
- PO660-TUE **ANGIOGENIC CHARACTERISTICS OF BLOOD OUTGROWTH ENDOTHELIAL CELLS FROM PATIENTS WITH VON WILLEBRAND DISEASE**  
Dafna Groeneveld\*, Tamara van Bekkum, Richard Dirven, Jiongwei Wang, Jan Voorberg, Pieter Reitsma, Jeroen Eikenboom (The Netherlands)
- PO661-TUE **REGULATION OF VWF-GPIB INTERACTION WITH MODIFIED RECOMBINANT BOTROCETIN**  
Taei Matsui\*, Arisa Hori, Jiharu Hamako, Fumio Matsushita, Namiho Takagishi, Kazunao Kondo, Taiki Kano, Masaki Hayakawa, Masanori Matsumoto, Yoshihiro Fujimura (Japan)
- PO662-TUE **VON WILLEBRAND FACTOR TO MONITOR PERCUTANEOUS AORTIC VALVE INTERVENTIONS**  
Antoine Rauch\*, Eric Van Belle, André Vincentelli, Emmanuelle Jeanpierre, Paulette Legendre, Francis Juthier, Natacha Rouse, Carlo Banfi, Anne Godier, Claudine Caron, Dupont Annabelle, Christophe Zawadski, Delphine Corseaux, Frederic Mouquet, Cédric Delhay, Bart Staels, Jenny Goudemand, Brigitte Jude, Peter Lenting, Sophie Susen (France)
- PO663-TUE **PLATELET AND ENDOTHELIAL FUNCTION EVALUATION IN PEDIATRIC CHRONIC KIDNEY DISEASE**  
Luci M. S. Dusse\*, Rivia Silva, Leticia Sousa, Fernanda Nunes, Rejane Diniz, Marcos Silva, Cristina Loures, Maria Carvalho, Ana Silva (Brazil)
- PO664-TUE **FUNCTIONAL STUDY OF TWO NEW MUTATIONS IN THE C4 DOMAIN OF VON WILLEBRAND FACTOR**  
Paulette Legendre\*, Maxime Delrue, Pierre Boisseau, Catherine Ternisien, Edith Fresinaud, Agnès Veyradier, Cecile Denis, Peter Lenting, Olivier Christophe (France)
- PO665-TUE **POSTOPERATIVE CHANGES IN VON WILLEBRAND FACTOR (VWF) AFTER ORTHOPAEDIC SURGERY IN HAEMOSTATICALLY HEALTHY PATIENTS**  
Mario von Depka\*, Carsten Detering, Cornelia Wermes, Birgit Nawroth, Emilie von Depka, Mahnaz Ekhlesi-Hundrieser (Germany)
- PO666-TUE **GENERATION OF REFERENCE INTERVALS FOR TWO AUTOMATED, NEW-GENERATION VON WILLEBRAND FACTOR ACTIVITY ASSAYS ON A LARGE DONOR POPULATION.**  
Katarzyna Mayger\*, Gary Moore, Jan Jacques Michiels, Inge Vangenechten, Alain Gadisseur (United Kingdom)
- PO667-TUE **EXPOSURE OF VON WILLEBRAND FACTOR (VWF) TO VORTEX SHEAR SIGNIFICANTLY ENHANCES ITS PROTEOLYSIS BY PLASMIN**  
Teresa M. Brophy\*, James O'Donnell (Ireland)
- PO668-TUE **BELGIAN MULTICENTER STUDY INTO VON WILLEBRAND DISEASE (B-WILL STUDY): FIRST RESULTS**  
Inge Vangenechten\*, Kristin Jochmans, Katrien Devreese, Serge Motte, Alain Gadisseur (Belgium)

## SCIENTIFIC PROGRAM

- PO669-TUE **THE VON WILLEBRAND FACTOR A2 DOMAIN DISULFIDE BOND EXISTS IN OXIDIZED AND REDUCED STATES IN THE CIRCULATION AND REGULATES FUNCTION**  
Philip Hogg\*, Diego Butera, Robert Andrews, Elizabeth Gardiner, Amanda Davis, Deirdre Murphy, Ross Baker, Jim Thom, Vivien Chen, Brenda Luken, Jason Wong, Camilo Aponte-Santamaría, Agnieszka Bronowska, Carsten Baldauf, Frauke Graeter (Australia)
- PO670-TUE **MODIFICATION OF ABO(H) BLOOD GROUP ANTIGENS ON HUMAN VWF WITH PLASMA GLYCOSYLTRANSFERASE**  
Taiki Kano\*, Fumio Matsushita, Jiharu Hamako, Yoshihiro Fujimura, Kazunao Kondo, Taei Matsui (Japan)
- PO671-TUE **REFERENCE VALUE OF VON WILLEBRAND FACTOR ACTIVITY BY IMMUNO-TURBIDIMETRY METHOD**  
Rahajuningsih Dharma\*, Yona Mimanda (Indonesia)
- PO672-TUE **ANALYSIS OF PLASMA VON WILLEBRAND FACTOR AND COMPLEMENT FACTOR H POLYMORPHISMS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION**  
Mariko Yamashita\*, Masanori Matsumoto, Ayami Isonishi, Yoko Yoshida, Masaki Hayakawa, Yoshihiro Fujimura, Nahoko Ogata (Japan)
- PO673-TUE **IMPROVED RESOLUTION OF HIGH MOLECULAR WEIGHT MULTIMERS OF RECOMBINANT VON WILLEBRAND FACTOR-ALBUMIN FUSION PRODUCT BY AGAROSE ELECTROPHORESIS/WESTERN BLOTTING**  
Jeffrey Hey\*, Thomas Barnes, Matthias Zimmermann, Bianca Yarwood, Christophe Pical, Holger Lind (Australia)
- PO674-TUE **ANALYSIS OF OXALIPLATIN-BASED CHEMOTHERAPY INDUCED LIVER INJURY IN PATIENTS WITH ADVANCED COLORECTAL CANCER WITH SPECIAL REFERENCES TO VON WILLEBRAND FACTOR**  
Naoto Nishigori\*, Masanori Matsumoto, Fumikazu Koyama, Masaki Hayakawa, Kinta Hatakeyama, Yoshihiro Fujimura, Yoshiyuki Nakajima (Japan)
- PO675-TUE **DESMOPRESSIN TREATMENT IMPROVES PLATELET FUNCTION UNDER FLOW IN PATIENTS WITH POSTOPERATIVE BLEEDING**  
Frauke Swieringa, Marcus Lance, Birte Fuchs, Marion Feijge, Barbara Solecka, Lieke Verheijen, Kevin Hughes, Hans Deckmyn, Christoph Kannicht, Johan Heemskerck, Paola Van Der Meijden\* (The Netherlands)
- PO676-TUE **O TO AVOID MYOCARDIAL INFARCTION.**  
Eimear Dunne\*, James O'Donnell, Dermot Kenny (Ireland)
- PO677-TUE **VON WILLEBRAND FACTOR'S SHEAR-AND-TIME DEPENDENT DEGRADATION UNDER PULSATILE SHEAR THROUGH A CAPILLARY SHEAR SYSTEM**  
Shuo Yang, Jawaad Sherif, Danny Bluestein, Vincent Turitto\* (United States)
- PO678-TUE **LONGITUDINAL ANALYSIS OF VON WILLEBRAND FACTOR (VWF) LEVELS IN THE PHASE 3 A-LONG STUDY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIII FC) IN SUBJECTS WITH HEMOPHILIA A DEMONSTRATES DIFFERENT MAGNITUDES OF TEMPORAL VARIABILITY**  
David Lillcrap\*, Roshni Kulkarni, Shuanglian Li, Elisa Tsao, Alison Long, Glenn Pierce, Jennifer Dumont (Canada)

## SCIENTIFIC PROGRAM

PO679-TUE **EVALUATION OF AGE AND GLYCAN-RELATED CHANGES ON VON WILLEBRAND FACTOR (VWF) CLEARANCE IN A VWF DEFICIENT MOUSE MODEL**  
Silvia Albáñez\*, Laura Swystun, Kate Sponagle, Julie Grabell, Christine Brown, Paula James, David Lillicrap (Canada)

PO680-TUE **ANNEXIN A2 SNP REGULATES PLASMA VON WILLEBRAND FACTOR LEVELS AND IS ENRICHED IN PATIENTS WITH VON WILLEBRAND DISEASE**  
Waander Van Heerde\*, Iris Kloots, Jelmer van Puffelen, Clint van Duren, Selene Schoormans, Paul Brons, Britta Laros-van Gorkom, Lambertus Kiemeneij (The Netherlands)

## Scientific Program

---

Wednesday, June 24

### Trainee Tracks (oral sessions only):

- Platelets track
- Basic thrombosis and hemostasis track
- ✚ Clinical bleeding track
- ▲ Clinical thrombosis track
- ★ Pediatric thrombosis and hemostasis track
- ♥ Cardiovascular and arterial diseases track

An asterisk (\*) after a name denotes the presenting author

**Isth**  
**2015 Congress**  
**TORONTO JUNE 20-25**

---

Reaching for Unprecedented Peaks



# SCIENTIFIC PROGRAM

Wednesday, June 24, 2015

ORAL COMMUNICATIONS 5 08:00-09:15

Venous thromboembolism – therapy – I

Room 718

Moderators: Sabine Eichinger (Austria), Dimitrios Scarvelis (Canada)

08:00 – 08:15  
OR256 **RESIDUAL VEIN THROMBOSIS AND THE INCIDENCE OF SUBSEQUENT SERIOUS COMPLICATIONS IN PATIENTS TREATED WITH CONVENTIONAL ANTICOAGULATION**

Paolo Prandoni\*, Anthonie Lensing, Martin Prins, Sabina Villalta, Franco Noventa (Italy)

08:15 – 08:30  
OR257 **EFFICACY AND SAFETY OF OUTPATIENT TREATMENT BASED ON THE HESTIA CLINICAL DECISION RULE WITH OR WITHOUT NT-PROBNP TESTING IN PATIENTS WITH ACUTE PULMONARY EMBOLISM: A RANDOMIZED TRIAL**

Paul L. den Exter\*, Wendy Zondag, Frederikus Klok, Rolf Brouwer, Anneke Dolms, Michiel Eijssvogel, Laura Faber, Marco Grootenboers, Roxane Heller-Baan, Marcel Hovens, Ge Jonkers, Klaas van Kralingen, Ronne Mairuhu, Christian Melissant, Henny Peltenburg, Judith Post, Marcel van de Ree, Tom Vlasveld, Marielle de Vreede, Menno Huisman (The Netherlands)

08:30 – 08:45  
OR258 **COMPARISON OF ULTRASOUND ASSISTED CATHETER-DIRECTED THROMBOLYSIS (CDT) AND CDT ALONE FOR TREATMENT OF PROXIMAL DEEP VEIN THROMBOSIS**

Vladimir Tichelaar\*, Ellen Brodin, Anders Vik, Trond Isaksen, Finn-Egil Skjeldestad, Kulbir Singh, John-Bjarne Hansen (Norway)

08:45 – 09:00  
OR259 **LONG-TERM ANTICOAGULATION WITH RIVAROXABAN FOR THE PREVENTION OF RECURRENT DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM: A BENEFIT-RISK ANALYSIS ON THE EINSTEIN EXTENSION TRIAL**

Philip S. Wells\*, Martin Prins, Bennett Levitan, Zhong Yuan, Eva Katz, Jan Beyer-Westendorf, Timothy Brighton, Henri Bounameaux, Alexander Cohen, Bruce Davidson, Gary Raskob, Anthonie Lensing (Canada)

09:00 – 09:15  
OR260 **A NETWORK META-ANALYSIS COMPARING THE EFFICACY AND SAFETY OF ANTICOAGULANTS FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS**

Florian Posch\*, Oliver Koenigsbruegge, Christoph Zielinski, Ingrid Pabinger, Cihan Ay (Austria)

ITP – Clinical

Room 701

Moderators: Donald Arnold (Canada), John Freedman (Canada)

08:00 – 08:15  
OR261 **ALL-TRANS RETINOIC ACID (ATRA) CORRECTS THE IMBALANCE OF MACROPHAGE POLARIZATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**

Qi Feng\*, Miao Xu, Yu Hou, Yingyi Yu, Xin Li, Yuanxin Sun, Jun Peng (China)

# SCIENTIFIC PROGRAM

08:15 – 08:30  
OR262

**RETROSPECTIVE ANALYSIS OF RITUXIMAB THERAPY IN CHILDHOOD CHRONIC AND REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA**  
Yilmaz Ay\*, Tuba Hilkey Karapinar, Yesim Oymak, Ersin Toret, Bengu Demirag, Dilek Ince, Esin Ozcan, Nergial Moueminoğlu, Sultan Aydın Koker, Canan Vergin (Turkey)

08:30 – 08:45  
OR263

**OCCURRENCE OF METHEMOGLOBINEMIA IN IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH DAPSONE**  
Marina P. Colella\*, Fernanda Orsi, Joyce Annichino-Bizzacchi, Erich de Paula (Brazil)

08:45 – 09:00  
OR264

**EFFECT OF CD72 ON B CELLS IN CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA**  
Hao Yating\*, Lyu Mingen, Li Yang, Fu Rongfeng, Liu Wenjie, Zhang Donglei, Zhang Xian, Iyu Cuicui, Sun Tiantian, Li Huiyuan, Yang Renchi (China)

09:00 – 09:15  
OR265

**THE EFFECT OF DANAZOL AND A NEW TREATMENT STRATEGY IN PRIMARY IMMUNE THROMBOCYTOPENIA –AN ANALYSIS OF 412 CASES FROM A SINGLE CENTER IN CHINA**  
Wenjie Liu\*, Xuping Gu, Yang Li, Mingen Lv, Tiantian Sun, Cuicui Lv, Renchi Yang (China)

Risk factors for venous thrombosis – II

Room 801

Moderators: William Geerts (Canada), Scott Kaatz (United States)

08:00 – 08:15  
OR266

**META-ANALYSIS OF 65,734 INDIVIDUALS IDENTIFIES TSPAN15 AND SLC44A2 AS TWO NEW SUSCEPTIBILITY LOCI FOR VENOUS THROMBOEMBOLISM**  
Pierre-Emmanuel Morange\*, Marine Germain, Weihong Tang, Christopher Kabrhel, Pieter Reitsma, John Heit, Daniel Chasman, David Tregouet, Frits Rosendaal, Nicholas Smith (France)

08:15 – 08:30  
OR267

**ASSOCIATIONS BETWEEN ATRIAL FIBRILLATION AND CAUSE-SPECIFIC RISKS OF PULMONARY EMBOLISM AND STROKE**  
Ina Rye-Holmboe\*, Erin Hald, Anders Vik, Ellisiv Mathiesen, Inger Njølstad, Maja-Lisa Løchen, Sigrid Brækkan, John Bjarne Hansen (Norway)

08:30 – 08:45  
OR268

**GLUCOCORTICOID RECEPTOR GENE AND RISK OF VENOUS THROMBOEMBOLISM**  
Laura Elbers\*, Bregje van Zaane, Victor Gerdes, Olaf Dekkers, Astrid van Hylckama Vlieg, Suzanne Cannegieter (The Netherlands)

08:45 – 09:00  
OR269

**F11 IS ASSOCIATED WITH RECURRENT EVENT OF VTE IN WOMEN: A PROSPECTIVE COHORT STUDY**  
Maria Bruzelius\*, Maria Ljungqvist, Matteo Bottai, Annica Bergendal, Rona Strawbridge, Angela Silveira, Helle Kieler, Anders Hamsten, Gerd Lärfars, Jacob Odeberg (Sweden)

09:00 – 09:15  
OR270

**ROLE OF APOLIPOPROTEIN(A) KRINGLE-IV TYPE 2 COPY NUMBER VARIATION IN VENOUS THROMBOEMBOLISM**  
Elena Sticchi\*, Betti Giusti, Alberto Magi, Pia Kamstrup, Domenico Prisco, Ida Martinielli, Pier Mannucci, Rosanna Abbate (Italy)

## SCIENTIFIC PROGRAM

### ● Platelets – II

Room 713

*Moderators: Christian Gachet (France), Heyu Ni (Canada)*

- 08:00 – 08:15  
OR271 **THE DIRECT DENGUE VIRUS-PLATELET INTERACTION: GENERATION OF INFECTIOUS PROGENY**  
Michael R. Sutherland\*, Ayo Simon, Edward Prydzial (Canada)
- 08:15 – 08:30  
OR272 **THE PH-DOMAIN ADAPTOR BAM32/DAPP1 RESTRAINS GPVI-MEDIATED PLATELET ACTIVATION AND THROMBUS FORMATION**  
James L. Hutchinson\*, Tom Durrant, Samantha Moore, Ingeborg Hers (United Kingdom)
- 08:30 – 08:45  
OR273 **IMPAIRED PLATELET ACTIVATION BUT INTACT HEMOSTASIS IN MICE EXPRESSING LOW LEVELS OF THE RAP-GEF, CALDAG-GEFI**  
Raymond Piatt\*, Brian Cooley, Dale Cowley, Wolfgang Bergmeier (United States)
- 08:45 – 09:00  
OR274 **THE CALCIUM-BINDING PROTEIN S100A1 NEGATIVELY REGULATES COLLAGEN-DEPENDENT PLATELET ACTIVATION AND THROMBOSIS IN MICE**  
Yacine Boulaftali\*, David Paul, Raymond Piatt, Dengmin Feng, Brian Cooley, Patrick Most, Wolfgang Bergmeier (France, United States)
- 09:00 – 09:15  
OR275 **DISSECTING ROLES FOR THE SNARE-ASSOCIATED PROTEIN, SNAP29, IN MOUSE PLATELETS**  
Christopher Williams\*, Joshua Savage, Matthew Harper, Samantha Moore, Ingeborg Hers, Alastair Poole (United Kingdom)

### Platelets – kinases – II

Room 716

*Moderators: Joel Bennett (United States), Alexandra Mazharian (United Kingdom)*

- 08:00 – 08:15  
OR276 **A COMPARISON OF BTK/TEC KINASES IN PLATELETS USING IBRUTINIB AND KNOCKOUT MICE**  
Craig E. Hughes\*, Monique Laudat, Michael Tomlinson, Wilfried Ellmeier, Steve Watson (United Kingdom)
- 08:15 – 08:30  
OR277 **PP1C ALPHA NEGATIVELY REGULATES PLATELET THROMBUS FORMATION VIA MAPK P38**  
Subhashree Pradhan, Qi Da, Tanvir Khatlani, K. Vinod Vijayan\* (United States)
- 08:30 – 08:45  
OR278 **DUSP3 PHOSPHATASE DEFICIENCY OR INHIBITION LIMIT PLATELET ACTIVATION AND ARTERIAL THROMBOSIS**  
Souad Rahmouni\*, Lucia Musumeci, Marijke Kuijpers, Karen Gilio, Hego Alexandre, Emilie Théâtre, Yotis Senis, Johan Heemskerk, Marc Thiry, Lutz Tautz, Cécile Oury (Belgium)
- 08:45 – 09:00  
OR279 **CLASS III PI3K POSITIVELY REGULATES PLATELET ACTIVATION AND THROMBUS FORMATION VIA PTDINS3P DIRECTED FUNCTION OF THE NADPH OXIDASE**  
Hu Hu\*, Dongjiao Luo, Yang Yang, Ming Yue, Mengjiao Hu, Shuai Wang, Qian Huang, Zhongzhou Yang (China)

## SCIENTIFIC PROGRAM

09:00 – 09:15  
OR280

### AADACL1 REGULATION OF PKC-DEPENDENT SECRETION IN HUMAN PLATELETS

Stephen Holly\*, Putianqi Wang, Rinku Majumder, Davia Blake, Leslie Parise (United States)

### Non-vitamin K oral anticoagulants and surgery

Room 714

*Moderators: Lama Castellucci (Canada), Marc Samama (France)*

- 08:00 – 08:15  
OR281 **IMPACT OF ORAL ANTICOAGULATION ON TIME TO PROCEDURE IN PATIENTS ADMITTED FOR HIP FRACTURE.**  
Thomas Tran\*, Carine de Wit, Aurelien Delluc, William Petrich, Gregoire Le Gal, Marc Carrier (Canada)
- 08:15 – 08:30  
OR282 **PERIOPERATIVE MANAGEMENT OF DABIGATRAN: A PROSPECTIVE COHORT STUDY**  
Sam Schulman\*, Marc Carrier, Agnes Lee, Sudeep Shivakumar, Mark Blostein, Frederick Spencer, Susan Solymoss, Rebecca Barty, Grace Wang, Nancy Heddle, James Douketis (Canada)
- 08:30 – 08:45  
OR283 **AN OBSERVATIONAL COHORT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DABIGATRAN ETEXILATE IN PATIENTS WITH MODERATE RENAL IMPAIRMENT UNDERGOING ELECTIVE TOTAL HIP OR KNEE REPLACEMENT SURGERY**  
Simon P. Frostick\*, Nadia Rosencher, Eva Kleine, Martin Feuring, Martina Brueckmann, Andreas Clemens, Jenny Gullberg, Charles-Marc Samama (United Kingdom)
- 08:45 – 09:00  
OR284 **EFFICACY OF RIVAROXABAN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER KNEE ARTHROSCOPY: A RANDOMIZED DOUBLE-BLIND TRIAL (ERIKA STUDY)**  
Giuseppe Camporese\*, Enrico Bernardi, Franco Noventa (Italy)
- 09:00 – 09:15  
OR285 **ASSAYS TO MEASURE DIRECT ORAL ANTICOAGULANTS (DOAC) : DATA FROM UK NEQAS MULTICENTRE STUDIES.**  
Ian Jennings\*, Steve Kitchen, Dianne Kitchen, Shelene Munroe-Pearl, Robert Jones, Anna Lowe, Timothy Woods, Isobel Walker (United Kingdom)

### ■ Contact system I

Room 715

*Moderators: Ronit Mor-Cohen (Israel), David Gailani (United States)*

- 08:00 – 08:15  
OR286 **ARTERIAL THROMBOSIS IS ACCELERATED IN HISTIDINE-RICH GLYCOPROTEIN DEFICIENT MICE**  
Trang T. Vu\*, Ji Zhou, Beverly Leslie, Alan Stafford, James Fredenburgh, Ran Ni, Shengjun Qiao, Nima Vaezzadeh, Willi Jahnhen-Dechent, Brett Monia, Peter Gross, Jeffrey Weitz (Canada)
- 08:15 – 08:30  
OR287 **PHOSPHATE POLYMERS AND FACTOR XI ACTIVATION.**  
Anton Matafonov\*, Ivan Ivanov, Mao-fu Sun, Vladimir Serebrov, David Gailani (Russian Federation, United States)
- 08:30 – 08:45  
OR288 **FACTOR XII ACTIVATION BY ACTIVATED FACTOR XI**  
Ivan Ivanov\*, Anton Matafonov, Mao-fu Sun, Dave Gailani (United States)

## SCIENTIFIC PROGRAM

- 08:45 – 09:00  
OR289 **AN ALLOSTERIC DISULFIDE BOND IS INVOLVED IN ENHANCED ACTIVATION OF FACTOR XI BY PROTEIN DISULFIDE ISOMERASE**  
Ronit Mor-Cohen\*, Adva Yehekel, Uri Seligsohn, Michal Zucker (Israel)
- 09:00 – 09:15  
OR290 **DNA AND RNA ACTIVATE THE CONTACT PATHWAY OF COAGULATION BY PROMOTING RECIPROCAL ACTIVATION OF FACTOR XII AND PREKALLIKREIN**  
Jagmanpreet S. Dang\*, Trang Vu, Beverly Leslie, Alan Stafford, James Fredenburgh, Jeffrey Weitz (Canada)

### ▲ Cancer and thrombosis – clinical – III

Room 717

*Moderators: Marc Carrier (Canada), Alok Khorana (United States)*

- 08:00 – 08:15  
OR291 **THROMBOTIC BURDEN AND THE RISK OF SUBSEQUENT MANIFEST CANCER**  
Paolo Prandoni\*, Sabina Villalta, Anthonie Lensing, Martin Prins, Franco Noventa, Andrea Piccioli (Italy)
- 08:15 – 08:30  
OR292 **RECURRENT VENOUS THROMBOEMBOLISM AND MORTALITY IN CANCER PATIENTS WITH UPPER EXTREMITY DEEP VEIN THROMBOSIS**  
Suzanne Bleker\*, Nick van Es, Ankie Kleinjan, Harry Büller, Pieter Kamphuisen, Anita Aggarwal, Jan Beyer-Westendorf, Giuseppe Camporese, Benilde Cosmi, Thomas Gary, Angelo Ghirarduzzi, Karin Kaasjager, Teresa Lerede, Peter Marschang, Karina Meijer, Hans-Martin Otten, Ettore Porreca, Marc Righini, Peter Verhamme, Sanne van Wissen, Marcello Di Nisio (The Netherlands)
- 08:30 – 08:45  
OR293 **INTERRELATION BETWEEN CANCER AND MYOCARDIAL INFARCTION IN THE GENERAL POPULATION**  
Ludvig B. Rinde\*, Birgit Småbrekke, Hilde Jensvoll, Kristine Blix, Inger Njølstad, Ellisiv Mathiesen, Anders Vik, Sigrid Brækkan, John-Bjarne Hansen (Norway)
- 08:45 – 09:00  
OR294 **EPIDEMIOLOGY OF FIRST VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER**  
Alexander Cohen\*, Anja Katholing, Stephan Rietbrock, Carlos Martinez (United Kingdom)
- 09:00 – 09:15  
OR295 **THE RISKS AND BENEFITS OF THROMBOPROPHYLAXIS (TP) AMONG HOSPITALIZED MEDICALLY ILL CANCER PATIENTS.**  
Marc Carrier\*, Cynthia Wu, Erica Peterson, Carine de Wit, Mabel Ma, Julia Tien, Gina Polley, Agnes Lee (Canada)

### Factor VIII and IX

Room 705

*Moderators: Jill Johnsen (United States), Rebecca Kruse-James (United States)*

- 08:00 – 08:15  
OR296 **A UNIQUE EXON SPECIFIC U1SNRNA RESCUES DIFFERENT HAEMOPHILIA B -CAUSING SPLICING-DEFECTIVE FACTOR IX VARIANTS IN MICE.**  
Dario Balestra\*, Daniela Scalet, Franco Pagani, Francesco Bernardi, Mirko Pinotti (Italy)

## SCIENTIFIC PROGRAM

- 08:15 – 08:30  
OR297 **SUPPRESSION OF “LEAKY” NONSENSE MUTATIONS BY RIBOSOME READTHROUGH ACCOUNTS FOR RESIDUAL FACTOR IX LEVELS IN HAEMOPHILIA B PATIENTS**  
Alessio Branchini\*, Mattia Ferrarese, Marcello Baroni, Matteo Campioni, Francesco Burini, Federica Nicolosi, Giancarlo Castaman, Paolo Radossi, Francesco Bernardi, Mirko Pinotti (Italy)
- 08:30 – 08:45  
OR298 **F8 AND F9 GENE VARIANTS, CADD SCORES, AND HEMOPHILIA SEVERITY IN THE MY LIFE, OUR FUTURE GENOTYPING PROJECT**  
Jill Johnsen\*, Shelley Fletcher, Haley Huston, Martin Kircher, Diane Aschman, Val Bias, Sally McAlister, Jay Shendure, Barbara Konkle (United States)
- 08:45 – 09:00  
OR299 **CB-FIX: AN IMPROVED SECOND GENERATION FIX DRUG CANDIDATE**  
Edwin Madison\*, Christopher Thanos, Grant Blouse, Mark Fox, Russell Overbeck, Hoa Ly, Kerry McCluskie, David Sloane (United States)
- 09:00 – 09:15  
OR300 **CORRECTION OF ABERRANT SPLICING CAUSING HAEMOPHILIA B THROUGH THE COMBINATION OF COMPENSATORY U1SNRNAs AND ANTISENSE OLIGONUCLEOTIDES**  
Daniela Scalet\*, Dario Balestra, Elena Barbon, Nicola Cavallari, Daniela Perrone, Francesco Bernardi, Mirko Pinotti (Italy)

### Blood coagulation tests – I

Room 707

*Moderators: Augusto Federici (Italy), Ran Ni (Canada)*

- 08:00 – 08:15  
OR301 **SIMULTANEOUS MEASUREMENT OF THROMBIN GENERATION AND FIBRIN FORMATION IN WHOLE BLOOD APPLYING CONTINUOUS FLOW IS INDICATIVE FOR THE AMOUNT OF BLOOD LOSS DURING/AFTER CARDIOTHORACIC SURGERY**  
Leonie Pelkmans\*, Hilde Kelchtermans, Anne Bouwhuis, Evelien Schurgers, Theo Lindhout, Dana Huskens, Coenraad Hemker, Marcus Lancé, Bas de Laat (The Netherlands)
- 08:15 – 08:30  
OR302 **A NOVEL SUBSTRATE FOR USE IN A POINT OF CARE THROMBIN GENERATION ASSAY**  
Shengjun Qiao, Paul Kim, Ran Ni, Jeffrey Weitz, Peter Gross\* (Canada)
- 08:30 – 08:45  
OR303 **FACTOR XIA AND TISSUE FACTOR ACTIVITY IN TRAUMA PATIENTS**  
Saulius Butenas, Matthew Gissel, Myung Park (United States)
- 08:45 – 09:00  
OR304 **DRVVT AS SIMPLE METHOD FOR MONITORING PATIENTS WITH FXA INHIBITORS**  
Annelie Siegemund\*, Ute Scholz, Thomas Siegemund (Germany)
- 09:00 – 09:15  
OR305 **EFFICACY AND MECHANISM OF CLOT CONTRACTION ARE DETERMINED BY BLOOD COMPOSITION**  
Valerie Tutwiler\*, Rustem Litvinov, Andrey Lozhkin, Alina Peshkova, Tatiana Lebedeva, Fazoil Ataullakhanov, Douglas Cines, John Weisel (United States)

## SCIENTIFIC PROGRAM

### Heparin and heparinoids

Room 709

*Moderators: Andreas Greinacher (Germany), Thomas Lindahl (Sweden)*

- 08:00 – 08:15  
OR306 **IN VIVO CHARACTERIZATION OF ANTI-THROMBOTIC AND ANTI-INFLAMMATORY PROPERTIES OF NEW SYNTHETIC, PROTAMINE-REVERSIBLE LOW MOLECULAR WEIGHT HEPARIN**  
Kasemsiri Chandarajoti, Erica Sparkenbaugh\*, Nigel Key, Yongmei Xu, Brian Cooley, Jian Liu, Rafal Pawlinski (United States)
- 08:15 – 08:30  
OR307 **PARTIALLY DESULFATED HEPARIN MODULATES THE INTERACTIONS BETWEEN ANTI-PROTAMINE/HEPARIN ANTIBODIES AND PLATELETS**  
Rabie Jouni\*, Heike Zöllner, Ahmad Khadour, Jan Wesche, Jessica Fuhrmann, Anne Grotevendt, Krystin Krauel, Andreas Greinacher, Tamam Bakchoul (Germany)
- 08:30 – 08:45  
OR308 **THERMAL STABILITY OF PLATELET FACTOR 4 AND ITS COMPLEXES WITH HEPARINS STUDIED BY DIFFERENTIAL SCANNING CALORIMETRY**  
Mihaela Delcea\*, Martin Kreimann, Andreas Greinacher (Germany)
- 08:45 – 09:00  
OR309 **COMPARISON OF BLEEDING COMPLICATIONS BETWEEN ANTI-XA AND APTT MONITORING IN PATIENTS RECEIVING UNFRACTIONATED HEPARIN**  
Kathy W. Belk\*, Michael Laposata, Christopher Craver (United States)
- 09:00 – 09:15  
OR310 **PROPHYLACTIC ENOXAPARIN IN CRITICALLY ILL PATIENTS WITH SEVERE RENAL INSUFFICIENCY**  
Lana A. Castellucci\*, Joseph Shaw, Shelley Acres, Rebecca Porteous, Brigitte Gomes, Irene Watpool, Cedric Edwards, Antonio Giulivi, Marc Carrier, Rakesh Patel (Canada)

### Microparticles – II

Room 711

*Moderators: Patrick Provost (Canada), Romaric Lacroix (France)*

- 08:00 – 08:15  
OR311 **LEUCOCYTES MPS PROMOTE CLOT DISSOLUTION IN A UPA/UPAR DEPENDENT MANNER**  
Sylvie Cointe\*, Romaric Lacroix, Stephane Robert, Coralie Judicone, Laurence Panicot-Dubois, Christophe Dubois, Françoise Dignat-George (France)
- 08:15 – 08:30  
OR312 **THE CHANGE OF THE AMOUNT OF CIRCULATING MICROPARTICLES AND THEIR ASSOCIATION TO THE GENERAL ATHEROSCLEROTIC BURDEN AFTER ACUTE CORONARY SYNDROME.**  
Christina Christersson, Birgitta Jonelid, Åsa Thulin\*, Agneta Siegbahn (Sweden)
- 08:30 – 08:45  
OR313 **DECREASED MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN MORBID OBESE PATIENTS AFTER BARIATRIC SURGERY**  
Johannes Thaler\*, Leyla Ay, Johanna Brix, Gerit Scherthaner, Cihan Ay, Guntram Scherthaner, Ingrid Pabinger (Austria)
- 08:45 – 09:00  
OR314 **PROTEOLYTIC ACTIVITY OF CIRCULATING MICROPARTICLES FROM ISCHEMIC STROKE PATIENTS REVEALED BY SINGLE PARTICLE LASER SCANNING CONFOCAL MICROSCOPY**  
Sara Martinez De Lizarrondo\*, Aurélien Briens, Jérôme Parcq, Joan Montaner, Denis Vivien, Maxime Gauberti (France)

## SCIENTIFIC PROGRAM

09:00 – 09:15  
OR315

### DETECTION OF PROCOAGULANT AND PROFIBRINOLYTIC EPCAM-POSITIVE MICROPARTICLES IN PLEURAL FLUID: A NEW APPROACH FOR THE DIAGNOSIS OF THE TUMORAL ORIGIN OF PLEURAL EFFUSIONS

Elisa Roca, Romaric Lacroix\*, Coralie Judicone, Sophie Laroumagne, Stephane Robert, Sylvie Cointe, Alexandre Muller, Elise Kaspi, Patrice Roll, Alain Brisson, Claudio Tancucci, Philippe Astoul, Françoise Dignat-George (France)

### ★ Late breaking abstract session - Bleeding disorders, TTP

Plenary Hall F&G

*Moderators: Beverly Hunt (United Kingdom), Miguel Escobar (United States)*

- 08:00 – 08:15  
LB006 **ADDITIONAL DATA FROM THE TITAN TRIAL WITH THE ANTI-VWF NANOBODY CAPLACIZUMAB IN THE TREATMENT OF ACQUIRED TTP**  
Flora Peyvandi\*, Marie Scully, Paul Knöbl, Johanna A. Kremer Hovinga, Haifeng Wu, Spero Cataland, Dominique Tersago (Italy)
- 08:15 – 08:30  
LB007 **TIMING OF PLASMA TRANSFUSION AND MATERNAL MORTALITY AND SEVERE MATERNAL MORBIDITY IN WOMEN WITH PERSISTENT POSTPARTUM HAEMORRHAGE: THE TEMPOH-1 STUDY**  
Dacia D. Henriquez\*, Kitty Bloemenkamp, Saskia le Cessie, Joost Zwart, Jos van Roomalen, Jeroen Eikenboom, Cynthia So-Osman, Leo van de Watering, Jaap Jan Zwaginga, Johanna van der Bom (Netherlands)
- 08:30 – 08:45  
LB008 **RVIII-SINGLECHAIN, RESULTS OF THE PIVOTAL PHASE I/III PK, EFFICACY AND SAFETY CLINICAL TRIAL IN ADULTS AND ADOLESCENTS WITH SEVERE HEMOPHILIA A**  
Johnny Mahlangu\*, Kazimierz Kuliczowski, Oleksandra Stasyshyn, Aleksander Skotricki, Marina Kasinova, Debbie Bensen Kennedy, Nicolas France, Katie St.Ledger, Ingrid Pabinger (South Africa)
- 08:45 – 09:00  
LB009 **SAFETY, EFFICACY AND PHARMACOKINETICS OF RECOMBINANT FACTOR IX FC FUSION PROTEIN IN CHILDREN WITH HAEMOPHILIA B (KIDS B-LONG)**  
Kathelijn Fischer\*, Roshni Kulkarni, Beatrice Nolan, Johnny Mahlangu, Savita Rangarajan, Giulia Gambino, Lei Diao, Lynda Cristiano, Glenn Pierce, Geoffrey Allen (The Netherlands)
- 09:00 – 09:15  
LB010 **UPDATE ON A PHASE 1/2 OPEN-LABEL TRIAL OF BAX335, AN ADENO-ASSOCIATED VIRUS 8 (AAV8) VECTOR-BASED GENE THERAPY PROGRAM FOR HEMOPHILIA B**  
Paul Monahan\*, Christopher Walsh, Jerry Powell, Barbara Konkle, Neil Josephson, Miguel Escobar, Scott McPhee, Boyan Litchev, Michael Cecerle, Bruce Ewenstein, Hanspeter Rottensteiner, Maurus De la Rosa, Birgit Reipert, Richard Samulski, John Orloff, Friedrich Scheifflinger (United States)

WEDNESDAY

ORALS

# SCIENTIFIC PROGRAM

Coffee break time in the exhibition (Level 800)  
From 09:15 to 09:45

Wednesday, June 24, 2015

PLENARY SESSION 09:45-10:30

Michael E. Nesheim Plenary Lecture

Hall F&G

Moderator: Nigel Key (United States)

09:45 - 10:30

**Genetics of thrombosis: from mice to humans**

David Ginsburg (United States)



Michael E. Nesheim, 1945-2011

Wednesday, June 24, 2015

STATE-OF-THE-ART LECTURES 10:45-11:45

Trauma-induced coagulopathy

Room 718

Moderator: Graham Pineo (Canada)

10:45 - 11:05

**Molecular and clinical mechanisms of traumatic coagulopathy**

Mitchell Cohen (United States)

11:05 - 11:25

**Safer than blood: Tranexamic acid in acute severe bleeding**

Ian Roberts (United Kingdom)

11:25 - 11:45

**The challenge of coagulopathy in trauma: Trans-Agency Consortium for Trauma-Induced Coagulopathy (TACTIC)**

Ken Mann (United States)

# SCIENTIFIC PROGRAM

▲ Small thrombosis – a big deal?

Room 701

Moderators: Philip S. Wells (Canada); Gary E. Raskob (United States)

10:45 - 11:15

**Superficial vein thrombosis**

Hervé Decousus (France)

11:15 - 11:45

**Cerebral vein thrombosis**

Jonathan M. Coutinho (The Netherlands)

♥ Controversies in antiplatelet therapy for patients with coronary artery disease

Room 801

Moderator: Andrew Frelinger (United States)

10:45 - 11:05

**Antiplatelet drugs: what are the best targets for which treatments?**

Christian Gachet (France)

11:05 - 11:25

**Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects**

Desmond Fitzgerald (Ireland)

11:25 - 11:45

**Triple therapy for PCI in atrial fibrillation: standard of care, or a nightmare soon to end?**

Freek Verheugt (The Netherlands)

● Platelets and Inflammation

Room 714

Moderator: Peter M. Newman (United States)

10:45 - 11:05

**The role of platelets in tissue regeneration following acute coronary syndrome and stroke**

David Varon (Israel)

11:05 - 11:25

**Reincarnation of ancient links between coagulation and complement**

Ed Conway (Canada)

11:25 - 11:45

**The role of circulating platelet transcripts**

Jane G. Freedman (United States)

■ Innovations and technology

Room 716

Moderators: Bjorn Dahlbäck (Sweden); Pieter H. Reitsma (The Netherlands)

10:45 - 11:05

**Global assays for assessing coagulation: enough data for clinical utility?**

Claude Négrier (France)

11:05 - 11:25

**Use of genetic data to guide therapy in arterial disease**

Guillaume Paré (Canada)

11:25 - 11:45

**Warfarin pharmacogenomics – current best evidence**

Steve Kimmel (United States)

## SCIENTIFIC PROGRAM

### ✚ Treatment of anticoagulant-associated bleeding Plenary Hall F&G

Moderators: *Saskia Middeldorp (The Netherlands); Alex C. Spyropoulos (United States)*

- 10:45 - 11:15 **New strategies to treat bleeding in patients on anticoagulants: More effective treatment**  
Ravi Sarode (United States)
- 11:15 - 11:45 **Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal**  
Sunny Dzik (United States)

### ★ Transplantation medicine in childhood Room 713

Moderators: *Suzan Williams (Canada); Christophe Male (Austria)*

- 10:45 - 11:15 **Preventing thrombosis**  
Jeremy Robertson (Australia)
- 11:15 - 11:45 **Managing bleeds**  
Leslie Raffini (United States)

**Lunch in the exhibition (Level 800)**  
**From 11:45 to 12:15**

**Lunch Symposia**  
**From 12:15 to 13:45**

Lunch Symposia Programs are available in the Show Guide. Please consult the different options to attend the symposium of your choice.

**Wednesday, June 24, 2015**

**ORAL COMMUNICATIONS 6 14:00-15:15**

### ▲ Non-vitamin K oral anticoagulants and reversal Plenary Hall F&G

Moderators: *Dougald Monroe (United States), Alexander Graham Turpie (Canada)*

- 14:00 – 14:15  
OR316 **THROMBOTIC SAFETY OF A FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX P/N) FOR EDOXABAN REVERSAL IN A RABBIT MODEL**  
Eva Herzog\*, Franz Kaspereit, Wilfried Krege, Baerbel Doerr, Yoshiyuki Morishima, Gerhard Dickneite (Germany)
- 14:15 – 14:30  
OR317 **REVERSING THE EFFECT OF RIVAROXABAN -AN IN-VITRO STUDY**  
Nina Schultz\*, Hoa Thi Tuyet Tran, Carola Henriksson, Marissa LeBlanc, Stine Bjoernsen, Per Morten Sandset, Pål Andre Holme (Norway)

## SCIENTIFIC PROGRAM

- 14:30 – 14:45  
OR318 **ANDEXANET ALFA BUT NOT FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE REVERSES RIVAROXABAN-INDUCED ANTICOAGULATION AS MEASURED BY REDUCTION IN BLOOD LOSS IN A RABBIT LIVER LACERATION MODEL**  
Polly Pine\*, Stanley Hollenbach, Francis DeGuzman, Siusze Tan, John Malinowsky, Pratikhya Pratikhya, Genmin Lu, John Curnutte, Pamela Conley (United States)
- 14:45 – 15:00  
OR319 **REVERSAL OF TARGETED ANTICOAGULANTS BY COMPLEXES OF ALPHA-2-MACROGLOBULIN WITH THROMBIN AND FACTOR XA.**  
Dougald M. Monroe\*, Jen-Yea Chang (United States)
- 15:00 – 15:15  
OR320 **IDARUCIZUMAB DOES NOT HAVE PROTHROMBOTIC EFFECTS: ASSESSMENT OF COAGULATION MARKERS IN HEALTHY VOLUNTEERS**  
Joachim Stangier\*, Michael Schmohl, Stephan Glund, Akiko Harada, Susumu Imazu, Marina De Smet, Viktoria Moschetti, Steven Ramael, Ippei Ikushima, Fredrick Gruenfelder, Paul Reilly (Germany)

### Venous thromboembolism – epidemiology III Room 718

Moderators: *Paul Kyrle (Austria), John-Bjarne Hansen (Norway)*

- 14:00 – 14:15  
OR321 **PROGNOSTIC SIGNIFICANCE OF ASYMPTOMATIC DEEP VEIN THROMBOSIS IN PATIENTS PRESENTING WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM**  
David Jimenez\*, Borja Castejon, Jose Luis Lobo, Ana Portillo, Rosa Nieto, Roger Yusen (Spain)
- 14:15 – 14:30  
OR322 **THE INCREASED RISK OF ARTERIAL CARDIOVASCULAR DISEASE IN PATIENTS WITH PRIOR VENOUS THROMBOSIS IS NOT EXPLAINED THROUGH ELEVATED LEVELS OF PROCOAGULANT FACTORS.**  
Eng Soo Yap\*, Jasmijn Timp, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne Cannegieter, Willem Lijfering (Singapore)
- 14:30 – 14:45  
OR323 **INCIDENCE OF VENOUS THROMBOEMBOLISM IN WESTERN FRANCE: COMPARISON BETWEEN 1998 AND 2013**  
Aurelien Delluc\*, Cécile Tromeur, Emmanuelle Le Moigne, Francis Couturaud, Grégoire Le Gal, Luc Bressollette, Maelenn Gouillou, Karine Lacut, Dominique Mottier (France)
- 14:45 – 15:00  
OR324 **RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN WOMEN UNDER COMBINED ORAL CONTRACEPTIVE: THE PILL GENETIC RISK MONITORING (PILGRIM) STUDY**  
Pierre Suchon\*, Fadi Al Frouh, Agathe Henneuse, Manal Ibrahim, Dominique Brunet, Marie-Christine Barthet, Marie-Françoise Aillaud, Marie-Christine Alessi, David Tregouët, Pierre-Emmanuel Morange (France)
- 15:00 – 15:15  
OR325 **SPLENECTOMY AND RISK OF VENOUS THROMBOSIS IN PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)**  
Ted Wun\*, Ann Brunson, Aaron Rosenberg, Richard White (United States)

## SCIENTIFIC PROGRAM

### ★ Post-thrombotic syndrome, thrombophilia

Room 701

*Moderators: Marc Rodger (Canada), Paolo Prandoni (Italy)*

- 14:00 – 14:15  
OR326 **POST THROMBOTIC SYNDROME IN PATIENTS TREATED WITH RIVAROXABAN OR ENOXAPARIN/VITAMIN K ANTAGONISTS FOR ACUTE DEEP VEIN THROMBOSIS**  
Whitney Cheung\*, Saskia Middeldorp, Martin Prins, Akos Pap, Anthonie Lensing, Arina Hoek-ten Cate, Marta Milan, Paolo Prandoni (The Netherlands)
- 14:15 – 14:30  
OR327 **IMPACT OF PRIMARY VENOUS INSUFFICIENCY ON THE PREVALENCE AND RISK OF POST-THROMBOTIC SYNDROME**  
Jean-Philippe Galanaud\*, Thierry Ducruet, Susan Kahn (France)
- 14:30 – 14:45  
OR328 **A SIMPLE PEDIATRIC POST-THROMBOTIC SYNDROME CLASSIFICATION ALGORITHM FOR THE GENERAL PRACTITIONER**  
Laura Avila\*, Leonardo Brandao, Suzan Williams, Alex Kiss, Jennifer Stinson, Madeline Montoya, Brian Feldman (Canada)
- 14:45 – 15:00  
OR329 **HEREDITARY RISK FACTORS OF THROMBOPHILIA AND THE INDIVIDUAL PROBABILITY OF FIRST VENOUS THROMBOEMBOLISM (VTE) IN PREGNANCY AND PUERPERIUM**  
Andrea Gerhardt\*, Ruediger Scharf, Rainer Zotz (Germany)
- 15:00 – 15:15  
OR330 **CLINICAL AND GENETIC FEATURES OF ANTITHROMBIN DEFICIENCY IN 13 TAIWANESE PATIENTS**  
Yeu-Chin Chen\*, Jyh-Pyng Gau, Tsu-Yi Chao (Taiwan)

### Von Willebrand factor – I

Room 801

*Moderators: Cécile Denis (France), Daniel Hampshire (United Kingdom)*

- 14:00 – 14:15  
OR331 **PHAGE DISPLAY AND NEXT GENERATION DNA SEQUENCING ENABLES HIGH RESOLUTION MAPPING OF VWF FUNCTIONAL DOMAINS AND ALLOANTIBODY EPITOPES**  
Andrew Yee\*, Manhong Dai, Steven Pipe, Jordan Shavit, Fan Meng, David Ginsburg (United States)
- 14:15 – 14:30  
OR332 **SCAVENGER RECEPTOR CLASS A MEMBER 5 (SCARA5) BINDS AND INTERNALIZES VWF IN VITRO: A NOVEL CANDIDATE VWF CLEARANCE RECEPTOR.**  
Kenichi Ogiwara\*, Laura Swystun, Christine Brown, Colleen Notley, Juha Ojala, Karl Tryggvason, David Lillicap (Canada)
- 14:30 – 14:45  
OR333 **NEW IN VITRO AND IN VIVO STRATEGIES TO MODULATE VON WILLEBRAND FACTOR GENE MUTATIONS WITH DOMINANT-NEGATIVE EFFECT**  
Caterina Casari\*, Matteo Campioni, Paulette Legendre, Cécile Loubière, Barbara Lung-  
hi, Mirko Pinotti, Olivier Christophe, Peter Lenting, Cécile Denis, Francesco Bernardi (France)

## SCIENTIFIC PROGRAM

- 14:45 – 15:00  
OR334 **ROLE OF CALCIUM IN REGULATING THE INTRA- AND EXTRA- CELLULAR CLEAVAGE OF VON WILLEBRAND FACTOR BY THE METALLOPROTEASE ADAMTS13**  
Sriram Neelamegham\*, Shobhit Gogia, Kannayakanahalli Dayananda, Anju Kelkar (United States)

- 15:00 – 15:15  
OR335 **ROLE OF PROTEIN DISULFIDE ISOMERASE PDI IN VON WILLEBRAND FACTOR DIMERIZATION**  
Maria Alexandra Brehm\*, Svenja Lippok, Katra Kolšek, Dennis Eggert, Tobias Obser, Reinhard Schneppenheim, Frauke Gräter, Carsten Baldauf, Joachim Rädler (Germany)

### Platelet disorders – bleeding

Room 714

*Moderators: Sara Israels (Canada), Paolo Gesele (Italy)*

- 14:00 – 14:15  
OR336 **DEFECTIVE ALPHAIIIBETA3 ACTIVATION CAUSES PLATELET DYSFUNCTION IN VON WILLEBRAND DISEASE PLATELET-TYPE (PT-VWD)**  
Loredana Bury\*, Emanuela Falcinelli, Anna Maria Mezzasoma, Paolo Gesele (Italy)
- 14:15 – 14:30  
OR337 **COMPREHENSIVE EVALUATION OF MECHANISMS ASSOCIATED WITH HYPER-RESPONSIVE PLATELET GPIBA AND THE ROLE OF PROTEIN INHIBITION IN SECURING HEMOSTASIS**  
Harmanpreet Kaur\*, Kathryn Corscadden, Maha Othman (Canada)
- 14:30 – 14:45  
OR338 **OXIDATIVE STRESS ACCELERATES PLATELET RECEPTOR GLYCOPROTEIN GPIBA AND GPVI SHEDDING DURING NON-SURGICAL BLEEDING IN HEART FAILURE PATIENTS SUPPORTED BY CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICE**  
Nandan Mondal\*, Erik Sorensen, Mark Slaughter, Si Pham, Bartley Griffith, Zhongjun Wu (United States)
- 14:45 – 15:00  
OR339 **METHODS FOR IDENTIFYING RARE GENETIC VARIANTS AFFECTING THE FORMATION AND FUNCTION OF PLATELETS**  
Ernest Turro\*, Daniel Greene (United Kingdom)
- 15:00 – 15:15  
OR340 **SEVERE BLEEDING TENDENCY AND IMPAIRED PLATELET FUNCTION IN A PATIENT WITH CALDAG-GEFI DEFICIENCY.**  
Hisashi Kato\*, Yozo Nakazawa, Hirokazu Kashiwagi, Seiji Tadokoro, Yoichiro Morikawa, Daisuke Morita, Yumi Kurokawa, Yuzuru Kanakura, Yoshiaki Tomiyama (Japan)

### ● Platelets and cancer

Room 716

*Moderators: Issaka Youbare (Canada), Maha Othman (Canada)*

- 14:00 – 14:15  
OR341 **15(S)-HETE IS A PRO-ANGIOGENIC FACTOR PRODUCED BY PLATELETS THROUGH COX-1**  
Francesca Rauzi\*, Nicholas Kirkby, Matthew Edin, Darryl Zeldin, James Whiteford, Jane Mitchell, Timothy Warner (United Kingdom)
- 14:15 – 14:30  
OR342 **PLATELETS ENGINEERED TO STORE INTERLEUKIN-24 INHIBITED MELANOMA GROWTH IN MICE**  
Juan Fang, Ming Yao, Weiqing Jing, Beicheng Sun, Bryon Johnson, David A. Wilcox\* (United States)

## SCIENTIFIC PROGRAM

14:30 – 14:45  
OR343 **CLEC-2 FACILITATES HEMATOGENOUS TUMOR METASTASIS AND IN VITRO TUMOR GROWTH, BUT NOT IN VIVO TUMOR GROWTH**  
Toshiaki Shirai\*, Osamu Inoue, Kazuyoshi Hirayama, Hiroshi Endo, Hitomi Sato-Utida, Hideki Fujii, Katsue Suzuki-Inoue, Yukio Ozaki (Japan)

14:45 – 15:00  
OR344 **IDENTIFICATION OF A NOVEL C-TYPE LECTIN-LIKE RECEPTOR 2 INHIBITOR THAT SUPPRESSES PODOPLANIN-INDUCED PLATELET AGGREGATION AND CANCER METASTASIS**  
Yao-Wen Chang\*, Pei-Wen Hsieh, Ju-Chien Cheng, Ching-Ping Tseng (Taiwan)

15:00 – 15:15  
OR345 **SURVIVAL AFTER CANCER-ASSOCIATED VENOUS THROMBOSIS: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY**  
Monique Crobach, Hilde Jensvoll, Marianne Severinsen, Jens Hammerstrom, Sigrid Braekkan, Kristine Blix\*, Soren Kristensen, Anne Tjonneland, Frits Rosendaal, Kim Overvad, John-Bjarne Hansen, Inger Naess, Suzanne Cannegieter (The Netherlands)

### 🏥 Hemophilia B

Room 713

*Moderators: Man-Chiu Poon (Canada), Gili Kenet (Israel)*

14:00 – 14:15  
OR346 **EFFICACY, PHARMACOKINETICS (PK) AND SAFETY RESULTS OF A PHASE 3 CLINICAL STUDY OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP) IN PREVIOUSLY TREATED CHILDREN WITH HEMOPHILIA B**  
Gili Kenet\*, Herve Chambost, Christoph Male, Thierry Lambert, María Álvarez-Román, Susan Halimeh, Anthony Chan, Chris Barnes, Tatiana Chernova, Jan Blatny, Maria Elisa Mancuso, Sandrine Meunier, Vladimir Komrska, Hans-Juergen Laws, Massimo Morfini, Julie Curtain, Bohumir Blazek, Christine Voigt, Iris Jacobs, Elena Santagostino (Israel)

14:15 – 14:30  
OR347 **EFFICACY AND SAFETY RESULTS OF A PHASE 3 PIVOTAL CLINICAL STUDY OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP) IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B**  
Elena Santagostino\*, Uri Martinowitz, Toshko Lissitchkov, Brigitte Pan-Petes, Hideji Hanabusa, Johannes Oldenburg, Lisa Boggio, Claude Negrier, Ingrid Pabinger-Fasching, Mario von Depka Prondzinski, Carmen Altisent, Giancarlo Castaman, Koji Yamamoto, María Álvarez-Román, Christine Voigt, Iris Jacobs (Italy)

14:30 – 14:45  
OR348 **PERIOPERATIVE HEMOSTATIC MANAGEMENT OF MAJOR SURGERY IN HEMOPHILIA B WITH LONG-ACTING RECOMBINANT GLYCOPEGYLATED FACTOR IX: RESULTS FROM THE PARADIGM™3 CLINICAL TRIAL**  
Miguel Escobar\*, Torben Colberg, Faraizah Karim, Umran Caliskan, Pratima Chowdary, Paul Giangrande, Adam Giermasz, Maria Mancuso, Margit Serban, Woei Tsay, Marek Zak, Johnny Mahlangu (United States)

14:45 – 15:00  
OR349 **IMPROVED HEALTH-RELATED QUALITY OF LIFE (QOL) OF HAEMOPHILIA B PATIENTS TREATED WITH A WEEKLY 40 IU/KG DOSE OF A NEW LONG-ACTING RECOMBINANT FACTOR IX (FIX) PRODUCT, NONACOG BETA PEGOL**  
Pratima Chowdary\*, Susan Kearney, Donald Yee, Juliette Meunier, Ulla Slothuus, Christina Hoxer (United Kingdom)

## SCIENTIFIC PROGRAM

15:00 – 15:15  
OR350 **POPULATION PHARMACOKINETICS (PK) OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH RECOMBINANT ALBUMIN (RIX-FP) IN ADULT AND PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA B**  
Tharin Limsakun, Ying Zhang, Jagdev Sidhu, Debra Bensen-Kennedy\*, Annette Feussner, Christine Voigt, Iris Jacobs, Elena Santagostino, Morfini Massimo (United States)

### Contact system II

Room 715

*Moderators: Jim Morrissey (United States), Rodney Camire (United States)*

14:00 – 14:15  
OR351 **ROLE OF FXIIA, FXIA, AND PLATELET-DERIVED POLYPHOSPHATE IN THROMBIN GENERATION USING HUMAN WHOLE BLOOD PERFUSED OVER A COLLAGEN/TISSUE FACTOR SURFACE**  
Shu Zhu\*, Richard Travers, James Morrissey, Scott Diamond (United States)

14:15 – 14:30  
OR352 **ANTITHROMBOTIC EFFECT OF ONO-8610539, A NEW, POTENT AND SELECTIVE SMALL MOLECULE FACTOR XIA INHIBITOR, IN A MONKEY MODEL OF ARTERIOVENOUS SHUNT**  
Masaru Sakai\*, Tetsuya Hagio, Sho Koyama, Masashi Gohda, Keizo Suzuki, Takehiro Ono, Takashi Kondo, Taihei Nishiyama, Kenji Tanaka, Hidekazu Matsuya, Akira Imagawa, Yasushi Hirota, Kazuhito Kawabata (Japan)

14:30 – 14:45  
OR353 **PLATELET POLYPHOSPHATE ACCELERATES THE INHIBITION OF TFPI BY FACTOR XIA.**  
Cristina Puy\*, Erik Tucker, Andrés Gruber, David Gailani, Stephanie Smith, Sharon Choi, James Morrissey, Owen McCarty (United States)

14:45 – 15:00  
OR354 **BINDING OF POLYPHOSPHATE TO CONTACT PATHWAY ENZYMES IS DEPENDENT ON TRANSITION METALS**  
Stephanie A. Smith\*, Julie Collins, Brent Ito, James Morrissey (United States)

15:00 – 15:15  
OR355 **COAGULATION FACTOR XII BINDING TO APOPTOTIC CELLS INITIATES THROMBIN GENERATION**  
Aizhen Yang\*, Robert Colman, Yi Wu (China)

### Cancer and thrombosis – basic – I

Room 717

*Moderators: Ingrid Pabinger (Austria), Yona Nadir (Israel)*

14:00 – 14:15  
OR356 **SYNERGISTIC ANTI-TUMOR EFFECTS WITH DABIGATRAN ETEXILATE AND CISPLATIN IN A MURINE OVARIAN CANCER MODEL**  
Eric Alexander, Candace Hayes, Allyson Minton, Khushboo Jain, Ashley Goss, Joanne Van Ryn, Susan Gilmour\* (United States)

14:15 – 14:30  
OR357 **PODOPLANIN EXPRESSION AND INTRAVASCULAR PLATELET AGGREGATES: THE MISSING LINK BETWEEN CANCER AND THROMBOSIS IN PRIMARY MALIGNANT BRAIN TUMORS**  
Julia Riedl\*, Matthias Preusser, Florian Posch, Christine Marosi, Peter Birner, Johannes Thaler, Johannes Hainfellner, Ingrid Pabinger, Cihan Ay (Austria)



## SCIENTIFIC PROGRAM

- 14:30 – 14:45  
OR358 **THE GENE ENCODING VITAMINE K-DEPENDENT ANTICOAGULANT PROTEIN S: A POSITIVE REGULATOR OF LUNG CANCER CELL MIGRATION AND INVASION.**  
Lutfi Suleiman\* (France)
- 14:45 – 15:00  
OR359 **ANTI-TUMOR ROLE OF ANTITHROMBIN BY INHIBITION OF ENTEROPEPTIDASE THROUGH A NOVEL MECHANISM**  
Sonia Águila, Ginés Luengo-Gil, Ester Martín-Villar, Nataliya Bohdan, Miguel Quintanilla, Ana I. Antón, Salvador Espín, Francisco Ayala, Vicente Vicente, Javier Corral, Irene Martínez-Martínez\* (Spain)
- 15:00 – 15:15  
OR360 **EXPRESSION OF COAGULATION PROTEASES FROM THE APC PATHWAY IN TUMOURS FROM GYNAECOLOGICAL CANCER PATIENTS WITH AND WITHOUT VENOUS THROMBOSIS**  
Fiona Martin, Sharon O'Toole, Jessica Long, John O'Leary, Noreen Gleeson, Feras Abu Saadeh, Lucy Norris\* (Ireland)

### ♥ ADAMTS13

Room 705

*Moderators: Dave Motto (United States), Frank Leebeek (The Netherlands)*

- 14:00 – 14:15  
OR361 **EXOSITE INTERACTIONS UNCOVER A BROAD SUBSTRATE RECOGNITION PROFILE FOR ADAMTS13**  
Colin A. Kretz\*, Kärt Tomberg, Andrew Yee, David Ginsburg (United States)
- 14:15 – 14:30  
OR362 **TIMELY FORMATION OF ULVWF MULTIMERS AND REDUCTION OF ADAMTS13 ACTIVITY PRECEDE CLINICAL EVENTS OF TTP RELAPSE**  
Haiwa Wu, Shangbin Yang, Benjamin Witkoff, Ming Jin, Spero Cataland, Haifeng M. Wu\* (United States)
- 14:30 – 14:45  
OR363 **THE PREDICTIVE VALUE OF ADAMTS13 ACTIVITY FOR TREATMENT MONITORING OF PATIENTS WITH ACQUIRED TTP: DATA FROM THE PHASE II TITAN TRIAL WITH CAPLACIZUMAB**  
Filip Callewaert\*, Hans Ulrichs, Johanna A. Kremer Hovinga, Katelijne De Swert, Dominique Tersago (Belgium)
- 14:45 – 15:00  
OR364 **LOW ADAMTS13 ACTIVITY AND THE RISK OF CORONARY HEART DISEASE: A PROSPECTIVE COHORT STUDY – THE ROTTERDAM STUDY**  
Michelle A. H. Sonneveld\*, Maryam Kavousi, Mohammed Ikram, Fritz Scheiflinger, Albert Hofman, Frank Leebeek, Oscar Franco, Moniek de Maat (The Netherlands)
- 15:00 – 15:15  
OR365 **EVOLUTIONARY VARIATION IN THE ALLOSTERIC PROPERTIES OF ADAMTS13**  
Joshua Muia\*, Jian Zhu, Garima Gupta, Lisa A. Westfield, Suellen Greco, Louis De-forche, Karen Vanhoorelbeke, J. Evan Sadler (United States)

### ■ Natural anticoagulants

Room 707

*Moderators: Paolo Simioni (Italy), Janaki Iyer (Singapore)*

- 14:00 – 14:15  
OR366 **DEVELOPMENT OF A NOVEL PROTEIN S-BASED ANTITHROMBOTIC AGENT**  
Rinku Majumder\*, Anze Testen, Howard Fried, Paulo Simioni (United States)

## SCIENTIFIC PROGRAM

- 14:15 – 14:30  
OR367 **AVATHRIN: A NOVEL FAST AND TIGHT BINDING COMPETITIVE INHIBITOR OF THROMBIN FROM AMBLYOMMA VARIEGATUM**  
Janaki Iyer\*, Maria Kazimirova, Jobichen Chako, Patricia Nuttall, Swaminathan Kunchithapadam, Manjunatha Kini (Singapore)
- 14:30 – 14:45  
OR368 **INCREASED HALF-LIFE AND SELECTIVE FUNCTION OF A GLYCOENGINEERED ANTITHROMBIN VARIANT**  
Sonia Águila\*, Irene Martínez-Martínez, Nataliya Bohdan, Nuria Garcia-Barbera, Vicente Vicente, Jose Rivera, Javier Corral (Spain)
- 14:45 – 15:00  
OR369 **AMINO ACID RESIDUES IN THE LAMININ G DOMAINS OF PROTEIN S INVOLVED IN TISSUE FACTOR PATHWAY INHIBITOR INTERACTION**  
Sofia Somajo, Josefin Ahnström\*, Magdalena Gierula, Juan Fernandez-Recio, Bruno Villoutreix, Björn Dahlbäck (United Kingdom)
- 15:00 – 15:15  
OR370 **SPLICING MUTATIONS ON ANTITHROMBIN DEFICIENCY. DIAGNOSTIC RELEVANCE AND UNEXPECTED CONSEQUENCES.**  
Maria Eugenia De La Morena-Barrio\*, Irene Martínez-Martínez, Susana Asenjo, Teresa Sevivas, José Padilla, Antonia Miñano, Mara Toderici, Raquel López-Gálvez, José Navarro-Fernández, Vicente Vicente, Javier Corral (Spain)

### Fibrinogen and fibrin I

Room 709

*Moderators: Helen Philippou (United Kingdom), Kelly Njine Mouapi (United States)*

- 14:00 – 14:15  
OR371 **INTERACTION OF FIBRIN WITH THE VLDL RECEPTOR ON ENDOTHELIAL CELLS: LOCALIZATION OF THE FIBRIN-BINDING SITE AND IDENTIFICATION OF ITS INHIBITORS**  
Leonid Medved\*, Sergiy Yakovlev (United States)
- 14:15 – 14:30  
OR372 **CHARACTERIZING REACTIVE GLUTAMINES IN FIBRINOGEN ALPHA C (233-425) AND PROBING FACTOR XIII SUBSTRATE SPECIFICITY**  
Kelly Njine Mouapi\*, Jacob Bell, Kerrie Smith, Robert Ariëns, Helen Philippou, Muriel Maurer (United States)
- 14:30 – 14:45  
OR373 **DEVELOPMENT AND VALIDATION OF A JAVA-BASED COMPUTER PROGRAM FOR IMAGE ANALYSIS OF FIBRIN ULTRASTRUCTURE**  
Francis Chan\*, Jorell Gantioqui, Ivan Stevic, Celia Kwan, Keith Lau, Anthony Chan, Howard Chan (Canada)
- 14:45 – 15:00  
OR374 **EFFECT OF FIBRINOGEN GAMMA' PEPTIDE ON FACTOR XI ACTIVATION BY THROMBIN**  
Farida Omarova\*, Shirley Uitte de Willige, Robert Ariëns, Rogier Bertina, Jan Rosing, Elisabetta Castoldi (The Netherlands)
- 15:00 – 15:15  
OR375 **FIBRIN(OGEN) ENGAGEMENT OF INTEGRIN MAC-1 (ALPHA-M BETA-2) LIMITS CHRONIC LIVER FIBROSIS INDUCED BY A BILE DUCT TOXICANT IN MICE**  
Nikita Joshi\*, Anna Kopec, Holly Fedewa, Matthew Flick, James Luyendyk (United States)

## SCIENTIFIC PROGRAM

### Fibrinolytic system – I

Room 711

*Moderators: Nicola Mutch (United Kingdom), Roger Lijnen (Belgium)*

- 14:00 – 14:15  
OR376 **NANOPARTICLE-BASED, MOLECULAR CONTROL OF THE PLASMIN ACTIVE SITE TO ACHIEVE DIRECT FIBRINOLYSIS IN A NOVEL IN-VITRO SYSTEM OF PULMONARY EMBOLISM**  
Jeffrey A. Kline\*, Nathan Alves, Aditya Shah, Daren Beam (United States)
- 14:15 – 14:30  
OR377 **EFFECT OF QUEBEC PLATELET DISORDER ON LEUKOCYTE UROKINASE PLASMINOGEN ACTIVATOR (UPA) LEVELS.**  
Subia Tasneem\*, Asim Soomro, Georges-Étienne Rivard, John Wayne, Catherine Hayward (Canada)
- 14:30 – 14:45  
OR378 **ASSESSMENT OF FIBRINOLYTIC PARAMETERS IN PATIENTS WITH HEMOPHILIA A**  
Marija Milos\*, Desiree Coen Herak, Silva Zupancic-Salek, Renata Zadro (Croatia)
- 14:45 – 15:00  
OR379 **DEFIBROTIDE IMPROVES FIBRINOLYSIS EFFICIENCY IN TPA-RESISTANT ARTERIAL THROMBOSIS**  
Sara Martinez De Lizarrondo\*, Sophie Guettier, Marina Rubio, Clement Gakuba, Emmanuel Touzé, Denis Vivien, Maxime Gauberti (France)
- 15:00 – 15:15  
OR380 **VALPROIC ACID SELECTIVELY INCREASES ENDOTHELIAL, BUT NOT BRAIN, T-PA PRODUCTION AND REDUCES THROMBUS FORMATION IN MOUSE**  
Pia Larsson, Imala Alwis\*, Be'eri Niego, Maithili Sashindranath, Emma Lu, Maria Daglas, Amanda Au, Niklas Bergh, Shaun Jackson, Robert Medcaif, Sverker Jern (Australia)

**Coffee break time in the exhibition (Level 800)  
From 15:15 to 15:45**

Wednesday, June 24, 2015

ABSTRACT SYMPOSIA 15:45-17:15

### Factor VIII

Room 701

*Moderators: Peter Lenting (France), Bob Montgomery (United States)*

- 15:45-16:15  
AS119 **REGULATION OF FACTOR VIII CLEARANCE: A MULTIFACTORIAL PROCESS**  
David Lillcrap (Canada)
- 16:15 – 16:35  
AS120 **ENHANCED FACTOR VIII GENE THERAPY FOR HEMOPHILIA A DOGS WITH A NOVEL FURIN-EVADING FACTOR VIII VARIANT**  
Joshua Siner, Ben Samelson-Jones\*, Julie Crudele, Shanzhen Zhou, Elizabeth Mericks, Timothy Nichols, Rodney Camire, Valder Arruda (United States)

## SCIENTIFIC PROGRAM

16:35 – 16:55  
AS121

### SWAPPING C-DOMAINS BETWEEN FACTOR VIII AND V REVEALS A DIFFERENTIAL ROLE OF THE TWO FACTOR VIII C-DOMAINS IN VON WILLEBRAND FACTOR BINDING AND INTRACELLULAR TRAFFICKING TO WEIBEL-PALADE BODIES IN ENDOTHELIAL CELLS

Eduard H. Ebberink\*, Eveline Bouwens, Mariëtte Boon-Spijker, Esther Bloem, Maartje Van den Biggelaar, Jan Voorberg, Alexander Meijer, Koen Mertens (The Netherlands)

16:55 – 17:15  
AS122

### A POPULATION APPROACH TO HEMOPHILIA PHARMACOKINETICS. WAPPS: A WEB-SERVICE FOR BAYESIAN POST HOC ESTIMATION

Alfonso Iorio\*, Victor Blanchette, Jan Blatny, Peter Collins, Stacy Croteau, Amy Dunn, Kathleen Fischer, Cedric Hermans, Kaan Kavakli, Shannon Jackson, Paula James, Sunil Mammen, Massimo Morfini, Tamara Navarro-Ruan, Ellis Neufeld, Margarete Oze-lo, Paolo Radossi, Savita Rangarajan, Arlette Ruiz-Sàez, Jerry Teitel, Lehana Thabane, Guy Young, Mengchen Xi (Canada)

### Platelet activation

Room 713

*Moderators: Alastair Poole (United Kingdom), Vincenzo Leo (United Kingdom)*

15:45-16:15  
AS123

### REGULATION OF PLATELET MEMBRANE TRAFFICKING

Sidney "Wally" Whiteheart (United States)

16:15 – 16:35  
AS124

### IMPAIRED NUCLEAR ACCUMULATION AND DNA BINDING OF TWO FLI1 VARIANTS RESULTS IN ABNORMALLY LARGE PLATELET ALPHA GRANULES AND A REDUCTION IN PLATELET DENSE GRANULE NUMBER

Vincenzo C. Leo\*, Bart Wagner, Lucinda Nicholson-Goult, Michael Makris, Steve Watson, Martina Daly (United Kingdom)

16:35 – 16:55  
AS125

### DYSREGULATION OF PLDN (PALLIDIN) AS A MECHANISM FOR PLATELET DENSE GRANULE DEFICIENCY IN RUNX1 HAPLODEFICIENCY

Guangfen Mao, Chengxiang Fan, Gauthami Jalagadugula, Robert Freishtat, A. Koneti Rao\* (United States)

16:55 – 17:15  
AS126

### GRANUPHILIN (SYNAPTOTAGMIN-LIKE PROTEIN 4, SLP4) REGULATES PLATELET DENSE GRANULE SECRETION AND AGGREGATION

Ewelina M. Golebiewska\*, Christopher Williams, Tetsuro Izumi, Alastair Poole (Japan)

### Platelet function testing assays

Room 801

*Moderators: Paul Harrison (United Kingdom), Owen McCarty (United States)*

15:45-16:15  
AS127

### CAN PLATELET FUNCTION TESTING TELL WHETHER YOUR PATIENT WILL BLEED OR THROMBOSE?

Marie Lordkipanidzé (Canada)

16:15 – 16:35  
AS128

### UNCOVERING GENETIC NETWORKS UNDERLYING PLATELET RESPONSE TO THIENOPYRIDINES BY EXOME SEQUENCING OF CLOPIDOGREL-TREATED PATIENTS EXHIBITING EXTREME PLATELET REACTIVITY

Jean-Luc Reny\*, Brian Stevenson, Mark Ibberson, Youssef Daali, Mylène Docquier, Ioannis Xenarios, Pierre Fontana (Switzerland)

## SCIENTIFIC PROGRAM

16:35 – 16:55  
AS129 **DEVELOPMENT OF A SMALL VOLUME, WHOLE BLOOD, PLATELET FUNCTION ASSAY TO ASSESS NEONATAL PLATELET ADHESION, ACTIVATION, AND AGGREGATION**  
Sandra Baker-Groberg\*, Kristina Haley, Natalia Dovlatova, Michael Recht, Owen McCarty (United States)

16:55 – 17:15  
AS130 **PLATELET AGGREGATION ASSAYS DO NOT RELIABLY DIAGNOSE PLATELET STORAGE POOL DEFICIENCY**  
Lorene Yoxheimer\*, Mary Smith, William Gunning (United States)

### Assay challenges

Room 709

*Moderators: Pall Ónundarson (Iceland), Sandra Haberichter (United States)*

15:45-16:15  
AS131 **LABORATORY DIAGNOSIS OF VON WILLEBRAND DISEASE**  
Veronica Flood (United States)

16:15 – 16:35  
AS132 **VALIDATION OF A NEXT GENERATION DNA SEQUENCING PANEL FOR HAEMOSTATIC AND PLATELET DISORDERS**  
Anne Goodeve\*, Nicholas Beauchamp (United Kingdom)

16:35 – 16:55  
AS133 **COMPARATIVE ANALYSIS OF STANDARD AND NEW VON WILLEBRAND ASSAYS IN A WELL TYPED COHORT OF PATIENTS WITH VON WILLEBRAND DISEASE**  
Inge Vangenechten\*, Katarzyna Mayger, Petr Smejkal, O Zapletal, Jan Jacques Michiels, Gary Moore, Alain Gadisseur (Belgium)

16:55 – 17:15  
AS134 **ELISA-BASED ASSESSMENT OF EXCESSIVE VON WILLEBRAND FACTOR PROTEOLYSIS**  
Antoine Rauch\*, Claudine Caron, Emmanuelle Jeanpierre, Sylvie Hermoire, Edith Fressinaud, Pierre Boisseau, Agnès Veyradier, Alexandre Ung, Eric Van Belle, André Vincentelli, Catherine Ternisien, Jenny Goudemand, Sophie Susen (France)

### ▲ Therapeutic management of venous thrombosis

Plenary Hall F&G

*Moderators: Susan Kahn (Canada), Ammar Majeed (Sweden)*

15:45-16:15  
AS135 **IVC FILTERS: CLEAR AND NOT SO CLEAR INDICATIONS**  
Patrick Mismetti (France)

16:15 – 16:30  
AS136 **ADDITIONAL CATHETER-DIRECTED THROMBOLYSIS FOR HIGH PROXIMAL DEEP VEIN THROMBOSIS; 5 YEAR RESULTS OF A RANDOMIZED CONTROLLED TRIAL (THE CAVENT STUDY)**  
Ylva Haig\*, Tone Enden, Ole Grøtta, Nils-Einar Kløw, Carl Erik Slagsvold, Waleed Ghanima, Pål Andre Holme, Per Morten Sandset (Norway)

16:30 – 16:45  
AS137 **ANTICOAGULANT THERAPY FOR SYMPTOMATIC DISTAL DEEP VEIN THROMBOSIS: THE CACTUS RANDOMIZED PLACEBO-CONTROLLED TRIAL**  
Marc Righini\*, Jean-Philippe Galanaud, Hervé Guenneguez, Dominique Brisot, Antoine Diard, Pascale Faisse, Marie-Thérèse Barrelier, Claudine Hamel Desnos, Christine Jurus, Olivier Pichot, Myriam Martin, LUCIA Mazzolai, Clarisse Choquet, Sandrine Accasat, Marc Carrier, Grégoire Le Gal, Bernadette Mermillod, Jean-Pierre Laroche, Henri Bounameaux, Arnaud Perrier, Susan Kahn, Isabelle Quééré (Switzerland)

## SCIENTIFIC PROGRAM

16:45 – 17:00  
AS138 **STATIN USE AND RISK OF RECURRENT VENOUS THROMBOSIS: RESULTS FROM THE MEGA FOLLOW-UP STUDY**  
Willem Lijfering\*, Sigrid Braekkan, Camilla Caram-Deelder, Bob Siegerink, Astrid van Hylckama Vlieg, Saskia le Cessie, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)

17:00 – 17:15  
AS139 **LONG -TERM FOLLOW-UP OF A PROSPECTIVE COHORT OF UNPROVOKED VENOUS THROMBOEMBOLISM (VTE) PATIENTS OFF ANTICOAGULANTS- RISK STRATIFICATION EVALUATION (REVERSE)**  
Marc A. Rodger\*, Michael Kovacs, Gregoire Le Gal, Dimitri Scarvelis, Susan Kahn, David Anderson (Canada)

### Membrane scrambling

Room 711

*Moderators: Ejaife Agbani (United Kingdom), Julia Anderson (Scotland)*

15:45-16:15  
AS140 **SCRAMBLING THE MEMBRANE: A REGULATORY MECHANISM FOR PLATELET FUNCTION**  
Johan Heemskerk (The Netherlands)

16:15 – 16:35  
AS141 **PLATELETS MAXIMISE MEMBRANE SURFACE AREA THROUGH COORDINATED BALLOONING AND PROCOAGULANT SPREADING TO AMPLIFY LOCALISED THROMBIN GENERATION**  
Ejaife Agbani\*, Ed Brown, Marion Van Den Bosch, Christopher Williams, Nadine Mattheij, Judith Cosemans, Peter Collin, Johan Heemskerk, Ingeborg Hers, Alastair Poole (United Kingdom)

16:35 – 16:55  
AS142 **HYSTERESIS-LIKE BINDING OF COAGULATION FACTOR X/XA TO LIPIDS PROTECTS FROM BLOOD FLOW**  
Nadezhda Podoplelova, Anastasia Sveshnikova, James Kurasawa, Andrey Sarafanov, Fazly Ataullakhanov, Mikhail Panteleev\* (Russian Federation)

16:55 – 17:15  
AS143 **NOVEL PEPTIDE AND PEPTIDOMIMETIC INHIBITORS OF PROTHROMBINASE ASSEMBLY ON PHOSPHATIDYL SERINE INHIBIT THROMBIN GENERATION AND FIBRIN FORMATION**  
Noah Kastelowitz\*, Abimbola Jarvis, Ormacinda White, Peter Brown, Gary Brodsky, Ryo Tamura, Jorge Di Paola, Hang Yin (United States)

### ■ Modulators of fibrinolytic activity

Room 705

*Moderators: Jim Fredenburg (Canada), Jonathan Foley (United Kingdom)*

15:45-16:15  
AS144 **NOVEL APPROACHES TO MODULATING FIBRINOLYTIC ACTIVITY**  
Paul Declerck (Belgium)

16:15 – 16:35  
AS145 **EFFECT OF DS-1040 ON ENDOGENOUS FIBRINOLYSIS AND IMPACT ON BLEEDING TIME IN RATS**  
Kengo Noguchi\*, Naoko Edo, Yusuke Ito, Kyoji Yamaguchi (Japan)

16:35 – 16:55  
AS146 **A NOVEL METHOD TO DEVELOP PLASMINOGEN ACTIVATOR INHIBITOR-1 ANTAGONIST AS THROMBOLYTIC AGENT**  
Lihu Gong, Valerie Proulle, Zebin Hong, Zhonghui Lin, Min Liu, Cai Yuan, Lin Lin, Barbara Furie, Robert Flaumenhaft, Peter Andreasen, Bruce Furie, Mingdong Huang\* (China, United States)

## SCIENTIFIC PROGRAM

16:55 – 17:15  
AS147 **INHIBITION OF PAI-1 ACCELERATES VENOUS THROMBOSIS RESOLUTION IN TYPE II DIABETIC MICE.**  
Rong Li\*, Xin Deng, Meiping Ren, Ni Chen, Mao Luo, Kai Yan, Min Zeng, Jianbo Wu (China)

### Factor V and regulation

Room 716

*Moderators: Alan Mast (United States), Josefin Ahnström (United Kingdom)*

15:45-16:15  
AS148 **FACTOR V AND TISSUE FACTOR PATHWAY INHIBITOR (TFPI) INTERACTIONS**  
Rodney Camire (United States)

16:15 – 16:35  
AS149 **FV ENHANCES PROTEIN S COFACTOR FUNCTION FOR TFPI IN THE INHIBITION OF FXA**  
Natalia Reglinska-Matveyev, James Crawley, Rodney Camire, David Lane, Josefin Ahnström\* (United Kingdom)

16:35 – 16:55  
AS150 **EAST TEXAS FV-SHORT/TFPI INTERACTION IN INHIBITION OF FXA- AND TF-INITIATED THROMBIN GENERATION**  
Ruzica Livaja-Koshlar\*, Rodney Camire, Michelle Ho, Björn Dahlbäck (Sweden)

16:55 – 17:15  
AS151 **DEVELOPMENT AND CHARACTERIZATION OF AN RNA APTAMER TARGETING FV/FVA**  
Erin Soule\*, Sriram Krishnaswamy, Bruce Sullenger (United States)

### Determinants of thrombus structure and susceptibility to lysis

Room 707

*Moderators: Robert Ariëns (United Kingdom), Marie-Christine Alessi (France)*

15:45-16:15  
AS152 **CELLULAR AND MECHANICAL MODULATORS OF FIBRIN STRUCTURE**  
Krasimir Kolev (Hungary)

16:15 – 16:30  
AS153 **FACTOR XIIIa CROSSLINKING OF FIBRIN A-CHAINS MEDIATES RED BLOOD CELL RETENTION IN CLOTS**  
James R. Byrnes\*, Cédric Duval, Yiming Wang, Micah Mooberry, Susan Lord, Joost Meijers, Heyu Ni, Robert Ariëns, Alisa Wolberg (United States)

16:30 – 16:45  
AS154 **ZN2+ ACCELERATES CLOT FORMATION, MODIFIES CLOT STRUCTURE, AND PROMOTES CLOT STABILITY**  
Sara J. Henderson\*, Jing Xia, Alan Stafford, Beverly Leslie, James Fredenburgh, David Weitz, Jeffrey Weitz (Canada)

16:45 – 17:00  
AS155 **THROMBIN AND FIBRINOGEN GAMMA' REGULATE PROTOFIBRIL PACKING WITHIN THE FIBRIN FIBER LEADING TO CHANGES IN CLOT STRUCTURE AND STRENGTH**  
Marco Domingues\*, Cedric Duval, Helen McPherson, Ramzi Ajjan, Victoria Ridger, Simon Connell, Helen Philippou, Robert Ariens (United Kingdom)

17:00 – 17:15  
AS156 **THE ROLE OF BLOOD MICROPARTICLES IN THE FORMATION, STRUCTURE, AND PROPERTIES OF FIBRIN CLOTS**  
Rustem I. Litvinov\*, Rosa Nabiullina, Ilshat Mustafin, John Weisel, Laily Zubairova (Russian Federation, United States)

## SCIENTIFIC PROGRAM

### ★ Prevention of thrombosis in children

Room 718

*Moderators: Tina Biss (United Kingdom), Guy Young (United States)*

15:45-16:15  
AS157 **WHY DO WE NEED DVT PROPHYLAXIS IN CHILDREN?**  
Suzan Williams (Canada)

16:15 – 16:30  
AS158 **BLOOD GROUP, AGE AND TYPE OF CANCER ARE INDEPENDENTLY ASSOCIATED WITH SYMPTOMATIC VENOUS THROMBOTIC EVENTS IN PEDIATRIC CANCER PATIENTS: A POPULATION BASED STUDY FROM MARITIMES, CANADA**  
Ketan Kulkarni\*, Tamara MacDonald, Victoria Price, Pamala Cox, Conrad Fernandez, Mark Bernstein, Margaret Yhap (Canada)

16:30 – 16:45  
AS159 **VENOUS THROMBOEMBOLISM OCCURRING DURING ADOLESCENCE: IS IT PREVENTABLE?**  
Tina Biss\*, Raza Alikhan, Jeanette Payne, Jayanthi Alamelu, Michael Williams, Michael Richards, Mary Mathias, Oliver Tunstall, Elizabeth Chalmers (United Kingdom)

16:45 – 17:00  
AS160 **VENOUS THROMBO-EMBOLISM (VTE) IN CHILDREN WITH SICKLE CELL DISEASE (SCD): AN INSTITUTIONAL EXPERIENCE**  
Gary Woods\*, Ruchika Sharma, Susan Creary, Amy Dunn, Kan Hor, Jeniffer Young, Cody Young, Riten Kumar (United States)

17:00 – 17:15  
AS161 **HOSPITAL-ASSOCIATED VENOUS THROMBOEMBOLISM (HA-VTE) IN PEDIATRICS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RISK FACTORS AND RISK ASSESSMENT MODELS**  
Arash Mahajerin, Brian R. Branchford\*, Ernest Amankwah, Leslie Raffini, Elizabeth Chalmers, Heleen van Ommen, Neil Goldenberg (United States)

### ✚ Pregnancy related bleeding complications

Room 715

*Moderators: Menaka Pai (Canada), Claire McLintok (New Zealand)*

15:45-16:15  
AS162 **MANAGEMENT OF REPRODUCTIVE HEMORRHAGIC COMPLICATIONS**  
Andra James (United States)

16:15 – 16:30  
AS163 **TRANSFUSION PROTOCOL IN SEVERE POSTPARTUM HEMORRHAGE**  
Giuseppe Colucci\*, Karin Helsing, Franziska Demarmels, Luigi Raio, Balthasar Eberle, Daniel Surbek, Bernhard Lämmle, Lorenzo Alberio (Switzerland)

16:30 – 16:45  
AS164 **MANAGEMENT OF 40 DELIVERIES IN 28 WOMEN WITH TYPE 1 AND TYPE 2 VON WILLEBRAND DISEASE**  
Fatoumata Tall\*, Valérie Roussel-Robert, Sophie Combe, Claire Flaujac, Nadra Ounno-ughene, Firas Ibrahim, Marie-Hélène Horellou, Natalie Stieltjes(France)

16:45 – 17:00  
AS165 **POSTPARTUM BLEEDING AND NEUROAXIAL ANESTHESIA IN PATIENTS WITH FACTOR XI DEFICIENCY**  
Kelsey Klute\*, John Chapin, Paul Christos, Maria DeSancho (United States)

17:00 – 17:15  
AS166 **ENDOTHELIUM DRIVES A PRE-DIC STATE IN ENDOTOXEMIA WITH ENHANCED THROMBOSIS AND PROLONGED BLEEDING SECONDARY TO IMPAIRED TIE2 FUNCTION**  
Karen De Ceunynck\*, Jennifer Fitch-Tewfik, Sarah Higgins, Samir Parikh, Robert Flau- menhaft (United States)

## SCIENTIFIC PROGRAM

### Platelet structure and function

Room 714

**Moderators:** *Bernard Nieswandt (Germany), Emily Catherine Reddy (Canada)*

- 15:45-16:15  
AS167 **THE ROLE OF GAP JUNCTIONS IN PLATELET ACTIVATION**  
Jonathan Gibbins (United Kingdom)
- 16:15 – 16:30  
AS168 **INTEGRIN PSI DOMAIN HAS ENDOGENOUS THIOL ISOMERASE FUNCTION AND IS A NOVEL TARGET FOR ANTI-THROMBOTIC THERAPY**  
Naadiya Carrim\*, Guangheng Zhu, Emily Reddy, Miao Xu, Xiaohong Xu, Yiming Wang, Yan Hou, Li Ma, Christopher Lavalle, Yan Li, Min Rui, Tania Petruzzello, Xi Lei, Adili Reheman, Pingguo Chen, John Wilkins, Richard Hynes, John Freedman, Heyu Ni (Canada)
- 16:30 – 16:45  
AS169 **THE WAVE COMPLEX MEMBER HEM1 IS A CRITICAL REGULATOR OF PLATELET SIZE AND FUNCTION IN MICE**  
Sebastian Dütting\*, Simon Stritt, Sarah Schiebl, Georg Krohne, Theresia Stradal, Bernhard Nieswandt (Germany)
- 16:45 – 17:00  
AS170 **VAMP-7 LINKS GRANULE EXOCYTOSIS TO PLATELET SPREADING**  
Secil Koseoglu, Jennifer Fitch-Tewfik, Christian Peters, Omozuanvbo Aisiku, Lydia Danglot, Thierry Galli, Robert Flaumenhaft\* (United States)
- 17:00 – 17:15  
AS171 **SHEAR-INDUCED GPIB-IX SIGNALING VIA UNFOLDING OF ITS JUXTAMEMBRANE MECHANOSENSORY DOMAIN**  
Wei Deng\*, Anum Syed, Xin Liang, François Lanza, Renhao Li (United States)

### ♥ Vascular remodeling

Room 717

**Moderators:** *Stefania Momi (Italy), Giannoula Klement (United States)*

- 15:45-16:15  
AS172 **CONTROL OF VASCULAR PATTERNING**  
Anne Eichmann (United States)
- 16:15 – 16:30  
AS173 **EXTRACELLULAR HISTONES EXERT A DIFFERENTIAL CYTOTOXIC AND ANTIANGIOGENIC EFFECT IN PROGENITOR AND MATURE ENDOTHELIAL CELLS**  
Hebe A. Mena\*, Agostina Carestia, Mirta Schattner, Soledad Negrotto (Argentina)
- 16:30 – 16:45  
AS174 **BLOOD CELLS-DERIVED MATRIX METALLOPROTEINASE (MMP)-2 CONTRIBUTES TO ABDOMINAL AORTIC ANEURYSM (AAA) DEVELOPMENT IN A MOUSE MODEL OF HYPERTENSION/HYPERCHOLESTEROLEMIA.**  
Stefania Momi\*, Emanuela Falcinelli, Paolo Gresele (Italy)
- 16:45 – 17:00  
AS175 **MECHANISM OF REGULATION OF VEGF-A BY JUNCTIONAL ADHESION MOLECULE-A, AN ENDOGENOUS SUPPRESSOR OF ANGIOGENESIS**  
Meghna Naik\*, Ulhas Naik (United States)
- 17:00 – 17:15  
AS176 **PLATELET ENDOTHELIAL AGGREGATION RECEPTOR -1: A NOVEL MODIFIER OF NEOANGIOGENESIS**  
Christophe Vandenbriele\*, Alexandre Kauskot, Ine Vandersmissen, Maarten Criel, Sander Craps, Aernout Lutun, Stefan Janssens, Peter Verhamme, Marc Hoylaerts (Belgium)

## SCIENTIFIC PROGRAM

### Poster with refreshments

From 17:15 – 18:30 in the Exhibition on Level 800

Wednesday, June 24, 2015

POSTER SESSION 17:15-18:30

Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:

**Monday, June 22, 2015, from 17.15-18.30**

**Tuesday, June 23, 2015, from 18.00-19.30**

**Wednesday, June 24, 2015, from 17.15-18.30**

The Poster Area is located inside the Exhibition on Level 800.

Poster setup times are as follows:

**Monday, June 22, 2015, from 07.30 - 09.15**

**Tuesday, June 23, 2015, from 07.30 - 09.15**

**Wednesday, June 24, 2015, from 07.30 - 09.15**

Poster dismantling times are as follows:

**Monday, June 22, 2015, from 18.30 - 19.00**

**Tuesday, June 23, 2015, from 19.30 - 20.00**

**Wednesday, June 24, 2015, from 18.30 - 19.00**

Posters not taken down after the dismantling time will be discarded.

If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:

**Monday, June 22, 2015, from 07.30 - 19.00**

**Tuesday, June 23, 2015, from 19.30 - 20.00**

**Wednesday, June 24, 2015, from 18.30 - 19.00**

Pins are provided on the poster boards directly

### Acquired coagulation disorders/inhibitors

- PO001-WED **ACQUIRED HAEMOSTATIC DISORDERS BY ORTHOTOPIC LIVER TRANSPLANTATION**  
Dorit Blickstein\*, Marius Braun, Eytan Cohen, Eytan Mor (Israel)
- PO002-WED **CORRELATION BETWEEN ACTIVATED PROTEIN C (APC) RESISTANCE AND STNFR2 IN ALZHEIMER DISEASE PATIENTS CARRYING 'EPSILON'4 ALLELE OF THE APOLIPOPROTEIN E**  
Priscila Moreira\*, Maria das Gracas Carvalho, Gisele Goncalves, Danyelle Rios, Edgar Moraes, Maria Aparecida Bicalho, Luci Maria Dusse, Mayara Faria, Marcos Vinicius Silva, Ana Paula Fernandes, Maria Christella Thomassen, Tilman Hackeng (Brazil)
- PO003-WED **PERSISTENT INTERNATIONAL NORMALIZED RATIO (INR) ELEVATION ASSOCIATED WITH OLMESARTAN-INDUCED ENTEROPATHY IN A PATIENT RECEIVING WARFARIN**  
Alexandra McGrath, Jennifer Lowerison\*, Elizabeth MacKay (Canada)

## SCIENTIFIC PROGRAM

- PO004-WED **DIFFERENTIATION BETWEEN PRO- AND ANTICOAGULANT ACTIVITY DEMONSTRATES REBALANCED THROMBIN GENERATION IN LIVER CIRRHOSIS**  
Romy Kremers\*, Marie-Claire Kleinegris, Hugo ten Cate, Rob Wagenvoort, Coenraad Hemker (The Netherlands)
- PO005-WED **HEMOSTATIC EFFECTS OF REGENERATIVE THERAPY IN PATIENTS WITH ALCOHOLIC CIRRHOSIS-A DEVELOPING COUNTRY EXPERIENCE.**  
Priyanka Saxena\*, Chhagan Bihari, Pratibha Dhiman, Archana Rastogi, S.K. Sarin (India)
- PO006-WED **TWO JAPANESE CASES OF ACQUIRED FACTOR V INHIBITOR WHICH WERE INITIALLY DIAGNOSED WITH CONGENITAL FACTOR V DEFICIENCY**  
Masato Bingo\*, Keiko Shinozawa, Takeshi Hagiwara, Hiroshi Inaba, Takashi Suzuki, Kagehiro Amano, Katsuyuki Fukutake (Japan)
- PO007-WED **TREATMENT OF ACQUIRED FACTOR V INHIBITORS RESULTING IN DISSEMINATED INTRAVASCULAR COAGULATION**  
Julie Tarrant\*, Christopher Hughes, Laura Malins, Martin Howard, Elizabeth Horn (United Kingdom)
- PO008-WED **LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN A 7-YEAR OLD GIRL: A CASE REPORT**  
Turkan Patiroglu\*, Ebru Yilmaz, Ekrem Unal, Musa Karakukcu, Mehmet Ozdemir (Turkey)
- PO009-WED **ACHIEVING HAEMOSTATIC CONTROL IN ACQUIRED HAEMOPHILIA A WITH PLASMA DERIVED FVIII INFUSIONS**  
Pu-Lin Luo\*, Steve Austin, Sangeeta Atwal, Sarah Mangles, Karan Rangarajan, Savita Ranagarajan (United Kingdom)
- PO011-WED **ACQUIRED HAEMOPHILIA A IN POLAND – A REPORT FROM AHA-POL REGISTRY**  
Jerzy Windyga\*, Joanna Zdziarska, Krzysztof Chojnowski, Magdalena Letowska, Krystyna Zawilska (Poland)
- PO012-WED **SUCCESSFUL THERAPY WITH BORTEZOMIB FOR ERADICATION OF INHIBITOR IN A PATIENT WITH MULTIPLE MYELOMA AND ACQUIRED HAEMOPHILIA A**  
Susana Nobre Fernandes, Manuela Carvalho\*, Manuela Lopes, Ricardo Pinto, Rui Bergantim, José Eduardo Guimarães, Fernando Araújo (Portugal)
- PO013-WED **CRITICAL INSIGHTS INTO ACQUIRED HAEMOPHILIA A AND RISK-BENEFIT ASPECTS WITH REGARD TO CLINICAL COMPLICATIONS - A CASE REPORT**  
Bernhard Stephan, H. Lauer, J. Groß, Andreas Link, Joachim F. Schenk\* (Germany)
- PO014-WED **CLINICAL UTILITY OF HEAT INACTIVATED NIJMEGEN MODIFIED BETHESDA ASSAYS IN FVIII DEFICIENCY – A 4 YEAR SINGLE CENTRE EXPERIENCE**  
Tejas Gandhi\*, Pura Lawler, Pratima Chowdary, Anja Drebes, Anne Riddell (United Kingdom)

## SCIENTIFIC PROGRAM

- PO015-WED **COMPARISON OF DIFFERENT COAGULATION ASSAYS FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA**  
Miguel Escobar\*, Elizabeth Donnachie (United States)
- PO016-WED **FVIII/VWF:AG RATIO IS A POWERFULL TOOL TO EARLY PREDICT RELAPSE IN ACQUIRED HAEMOPHILIA A**  
Maxime Halliez, Sophie Voisin, Marc Trossaert\*, Marianne Sigaud, Marc Fouassier, Catherine Ternisien, Antoine Neel, Mohamed Hamidou, Julie Graveleau (France)
- PO017-WED **ASSESSMENT OF PROTHROMBIN TIME PROLONGATION BY THROMBOELASTOMETRY AND THROMBELASTOGRAPHY DURING LIVER TRANSPLANTATION**  
Shu Lu, Tetsuro Sakai, Ezeldeen Abuelkasem, Raymond Planinsic, Kenichi Tanaka\* (United States)
- PO018-WED **A NOVEL DIAGNOSTIC SYSTEM OF ACQUIRED COAGULATION FACTOR INHIBITORS USING COMPREHENSIVE COAGULATION ASSAYS**  
Tomoko Matsumoto\*, Keiji Nogami, Midori Shima (Japan)
- PO019-WED **INHIBITOR OF FACTOR VIII IN THE NEWBORN. CASE REPORT.**  
Pavel Svirin\*, Ekaterina Shiller, Vladimir Vdovin, Viktor Petrov, Artiom Bullih, Igor Donin, Liubov Larina (Russian Federation)
- PO020-WED **USEFULNESS OF VARIOUS SCORING METHODS WITH CROSS-MIXING TEST FOR DETECTION OF LUPUS ANTICOAGULANT**  
Sumiyoshi Naito\*, Masahiro Ieko, Osamu Kumano, Mika Yoshida, Nobuhiko Takahashi, Takeshi Suzuki, Akihide Ito, Nobutaka Wakamiya (Japan)
- PO021-WED **DEFINING COAGULATION DYSFUNCTION IN PATIENTS WITH LEPTOSPIROSIS**  
Lallindra Gooneratne\*, Rasa Threeswaran, Shiroma Handunetti, Senaka Rajapakse, Roopen Arya (Sri Lanka)
- PO022-WED **ACQUIRED VON WILLEBRAND SYNDROME – DIAGNOSIS AND MANAGEMENT.**  
Angelika Batorova\*, Tatiana Prigancova, Denisa Jankovicova, Anna Morongova, Erika Balazova (Slovakia)
- PO023-WED **ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN ELDERLY PEOPLE WITH AND WITHOUT COGNITIVE IMPAIRMENT**  
Maria Das Graças Carvalho\*, Gisele Gonçalves, Danyelle Rios, Edgar Moraes, Maria Aparecida Bicalho, Marcos Bastos, Luci Maria Dusse, Elisabetta Castoldi, Jan Rosing, Maria Christella Thomassen, Tilman Hackeng (Brazil)
- PO024-WED **SINGLE-CENTER EXPERIENCE WITH RITUXIMAB IN THE TREATMENT OF INHIBITOR-ASSOCIATED HEMOSTATIC DISORDERS**  
Danielle Hammond\*, Eliana Saidenberg, Alan Tinmouth (Canada)
- PO025-WED **LUPUS ANTICOAGULANT (LA) TESTING OF A PREGNANT PATIENT REVEALING AN ACQUIRED FACTOR XI AUTOANTIBODY**  
Geoffrey D. Wool\*, Tammy Utset, Jonathan Miller (United States)

## SCIENTIFIC PROGRAM

- PO026-WED **ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN PATIENT WITH HETEROZYGOUS MTHFR C677T MUTATION AND HYPERHOMOCYSTEINEMIA - A CASE REPORT**  
Bernadeta Ceglarek, Ksenia Bykowska, Adam Wiszniewski\*, Jerzy Windyga (Poland)
- PO027-WED **ACQUIRED INHIBITORS TO FACTOR VIII AND IX, A CASE REPORT**  
Saša Anžej Doma, Irena Zupan\*, Tadej Pajic, Dušan Andoljšek, Peter Cernelc (Slovenia)
- PO028-WED **ANTITROMBIN FUNCTION IN INFECTION DEVELOPMENT IN PATIENTS WITH SEVERE BURNS**  
Marina Presnyakova\*, Viktoria Kuznetsova, Artem Borisevich, Irina Strelkova (Russian Federation)
- PO029-WED **EFFICACY OF FVIII IN THE TREATMENT OF PATIENTS WITH ACQUIRED HAEMOPHILIA A AND VASCULAR DISEASES**  
Samantha Pasca, Claudia Battello, Giovanni Barillari\* (Italy)
- PO030-WED **CORRELATION BETWEEN INDICES OF HEMOSTASIS SYSTEM AND BIOCHEMICAL BLOOD METABOLITES IN PATIENTS WITH DIABETIC FOOT SYNDROME**  
Marina Presnyakova\*, Vctoria Kuznetsova, Michail Bobrov, Maksim Kudykin, Irina Strelkova, Olga Kostina (Russian Federation)
- PO031-WED **NEUTRALIZING AUTOANTIBODY AGAINST FACTOR XIII A SUBUNIT WITH MULTIPLE INHIBITORY EFFECT ON FACTOR XIII ACTIVATION/ACTIVITY RESULTED IN SEVERE BLEEDING WITH FATAL OUTCOME**  
Krisztina Péntzes\*, Anna Selmeczi, Éva Katona, Zsuzsanna Bereczky, Adrienne Kerényi, Éva Molnár, Hajnalka Gulyás, Ágota Schlammadinger, Zoltán Boda, László Muszbek (Hungary)
- PO032-WED **THE ACQUIRED DEFICIENCY OF FACTORS II, VII, IX, X IN THE COURSE OF THE INTOXICATION OF SECOND GENERATION ANTICOAGULANT RODENTICIDES IN FEMALE PATIENT SUFFERING WITH SEVERE DIATHE-SIS HAEMORRHAGICA - A CASE REPORT**  
Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Beata Baran, Adam Wiszniewski\*, Jerzy Windyga (Poland)
- PO033-WED **PREDICTION OF BLEEDING COMPLICATIONS AFTER RENAL BIOPSY IN POST-RENAL TRANSPLANT PATIENTS WITH UREMIA**  
Gerhardus J. A. J. M. Kuiper, Monique Mullens, Paul Verhezen, Karly Hamulyak, Maarten Christiaans, Hugo ten Cate, Yvonne Henskens\* (The Netherlands)
- PO034-WED **ANALYSIS OF THE PROFILE OF IMMUNE CELLS, CYTOKINES AND CHEMOKINES IN PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA**  
Leticia Jardim\*, Daniel Chaves, Monica Cerqueira, Alessandra Prezoti, Claudia Lorenzato, Marcio Portugal, Suely Rezende (Brazil)

## SCIENTIFIC PROGRAM

- PO035-WED **PROSPECTIVE VALIDATION OF CLINI-BIOLOGICAL PARAMETERS INCLUDING INITIAL HEMOSTASIS, WHICH IMPROVE THE PREDICTION OF DEATH AT 1 MONTH AMONG PATIENTS WITH SEPTIC SHOCK: SEPSICO-AG STUDY**  
Geraldine Lavigne-Lissalde\*, Jean-Yves Lefrant, Samir Jaber, Christel Castelli, Jean-michel Constantin, Jacques Albanes, Marc Leone, Jean-Christophe Forban, Jérôme Morel, Gilles Seni, Loubna Elotmani, Jean-Christophe Gris (France)

### ADAMTS13 II

- PO036-WED **THE IMPORTANCE OF CONFORMATIONAL ACTIVATION OF ADAMTS13 FOR CONTROL OF PLATELET DEPOSITION UNDER FLOW**  
Kieron South\*, Isabelle Salles-Crawley, James Crawley, David Lane (United Kingdom)
- PO037-WED **THE IMPACT OF TIMELY ADAMTS13 RESULTS ON CLINICAL DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH SUSPECTED THROMBOTIC MICROANGIOPATHY (TMA): MAYO CLINIC'S EXPERIENCE**  
Mohamed Alsammak, Tahir Mehmood\*, Michelle Taylor, Rajiv Pruthi, Jeffrey Winters, Dong Chen (United States)
- PO038-WED **ADAMTS13: VON WILLEBRAND FACTOR CLEAVING PROTEASE GROWTH FACTOR?**  
Justin M. Keener\*, Courtney Hoyt, George Rodgers (United States)
- PO039-WED **DETECTION OF ADAMTS13 ACTIVITY USING THE NATIVE VWF91 PEPTIDE**  
Xia Bai\*, Jian Su, Lijuan Cao, Ziqiang Yu, Zhaoyue Wang, Changgeng Ruan (China)
- PO040-WED **CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UP-SHAW-SCHULMAN SYNDROME RECEIVING MAINTENANCE HEMODIALYSIS DUE TO CHRONIC RENAL FAILURE**  
Masanori Matsumoto\*, Ayami Isonishi, Koichi Kokame, Masaki Hayakawa, Hideo Yagi, Toshiyuki Miyata, Yoshihiro Fujimura (Japan)
- PO041-WED **THE COURSE OF ADAMTS13-PROPERTIES DURING PREGNANCY INDUCED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)**  
Rita Dittmer\* (Germany)
- PO042-WED **ANTI-ADAMTS13 ANTIBODY FEATURES (IG ISOTYPE TITERS, FUNCTIONAL ADAMTS13 INHIBITOR AND CIRCULATING IMMUNE COMPLEXES (CIC)) IN PATIENTS WITH ACQUIRED THROMBOSIS THROMBOCYTOPENIC PURPURA (ATTP) AT FIRST CONSULTATION IN OUR INSTITUTION.**  
Ana Kempfer, Juvenal Paiva\*, Analía Sanchez-Luceros, Fabiana Alberto, Adriana Woods, María Casinelli, María Lazzari (Argentina)
- PO043-WED **ADAMTS13 GENE EXPRESSION IS INCREASED IN KIDNEY AND LIVER IN TYPE 1 DIABETES MELLITUS ANIMAL MODEL**  
Michelle T. Alve\*, Guilherme Reis, Adriana Bosco, Bárbara Quirino, Caroline Domingueti, Ana Fernandes, Karina Gomes (Brazil)
- PO044-WED **AN ACTIVITY-BASED APPROACH TO ANTI-ADAMTS 13 ANTIBODIES**  
Annelie Siegemund\*, Ute Scholz, Thomas Siegemund (Germany)

## SCIENTIFIC PROGRAM

- PO045-WED **DETECTION OF PLASMA ADAMTS13 ACTIVITY USING E. COLI DERIVED VWF-A2 SUBSTRATES AND MICROSPHERE-CYTOMETRY ASSAYS**  
Sriram Neelamegham\*, Shobhit Gogia, Chi Lo (United States)

### Animal models III

- PO046-WED **THE EFFECT OF PEPTIDE-NOOTROPICS ON PLATELET AGGREGATION INDUCED BY EPINEPHRINE**  
Maria Golubeva\* (Russian Federation)
- PO047-WED **EVALUATION OF THE BLEEDING TENDENCY IN MURINE MODELS OF HEMOPHILIA AND HEPARIN THERAPY USING THE THROMBODYNAMICS ASSAY**  
Vladimir Kolyadko\*, Stepan Surov, Semen Buvaliy, Vladislav Kuznetsov, Tatiana Vuimo, Fazoil Ataulakhanov, Mikhail Panteleev (Russian Federation)
- PO048-WED **ASSESSMENT OF MOD-5014, A LONG ACTING FVIIA, PHARMACOKINETIC, PHARMACODYNAMICS AND CORRECTION OF HEMOPHILIC COAGULOPATHY IN DOGS WITH HEMOPHILIA A AS PART OF THE PREPARATION FOR FIRST IN HUMAN STUDY**  
Gili Hart\*, Elizabeth Merricks, Natalie Rigsbee, Robin Raymer, Ahuva Bar-Ilan, Lior Binder, Michal Jaron-Mendelson, Malka Hoffman, Timothy Nichols (Israel)
- PO049-WED **SAFETY EVALUATION OF CHRONIC ANTITHROMBIN SILENCING IN NON-HUMAN PRIMATE AND EXPANDED THERAPEUTIC INDEX IN A HEMOPHILIA A MOUSE MODEL**  
Scott Barros\*, Kun Qian, June Qin, Brian Bettencourt, Alfica Sehgal, Akin Akinc (United States)
- PO050-WED **AN ANTIBODY PRETREATMENT STRATEGY FOR IMPROVING CELL-BASED THERAPY IN A MOUSE MODEL OF HEMOPHILIA B**  
Yu-Chen Hsu\*, Meng-Ni Fan, Yu-Jen Huang, Shu-Jhu Yang, I-Shing Yu, Yao-Ming Wu, Shu-Wha Lin (Taiwan)
- PO051-WED **EFFECTS OF ANKAFERD BLOOD STOPPER ON CUTANEOUS WOUND HEALING: EXPERIMENTAL STUDY**  
Duzgun Ozatli\*, Osman Kelahmetoglu, Ayhan Bozkurt, Volkan Tayfur, Sirri Bilge, Piltan Buyukkaya, Levent Yildiz, Tunc Fisgin (Turkey)
- PO052-WED **ASSESSMENT OF KNEE JOINT BLEEDING IN HEMOPHILIA B MICE BY FLUORESCENCE MOLECULAR TOMOGRAPHY**  
Elizabeth Chappell\*, Junjiang Sun, Paul Monahan, Rupa Appa, Bo Wiinberg, Maureen Hoffman, Dougald Monroe (United States)
- PO053-WED **SERUM ENDOCAN LEVELS AS A POTENTIAL NON-INVASIVE BIOMARKER FOR DIAGNOSING DIFFERENT HEPATIC DISEASES**  
Rachel Palumbo\*, Susan Uprichard, Scott Cotler, Thomas Layden, Jawed Fareed, Debra Hoppensteadt (United States)

## SCIENTIFIC PROGRAM

- PO054-WED **EFFECT OF A RECOMBINANT PLANT ELASTASE INHIBITOR WITH ANTI-INFLAMMATORY ACTION - RBBC1 (BAUHINIA BAUHINIODES CRUZAIN/ CRUZIPAIN INHIBITOR) ON A RAT MODEL OF VENOUS THROMBOSIS**  
Maria Luiza Oliva, Cleide Oliveira, Mayara Valois, Tatiana Ottaiano, Marcelo Lima, Antonio Miranda, Misako Sampaio, Francisco H. Maffei\* (Brazil)

### Antiphospholipid syndrome II

- PO055-WED **EVALUATION OF THE IMPORTANCE OF MIXING PATIENT PLASMA WITH A POOL OF NORMAL PLASMAS WHEN DIAGNOSING LUPUS ANTICOAGULANT**  
Ana María Lena\*, Datevig Attarian, Nora Mota, Sebastian De Los Santos, Gabriela Domínguez, Ana Otero (Uruguay)
- PO056-WED **THE TAIWAN SNAKE VENOM TIME COULD BE A RELIABLE ASSAY FOR THE DETECTION OF LUPUS ANTICOAGULANT IN PATIENT RECEIVING RIVAROXABAN.**  
Clément Berthomet, Bénédicte Delahousse, Yves Gruel\*, Claire Pouplard (France)
- PO057-WED **NEW MIXING TEST INDEX TO DISCRIMINATE BETWEEN LUPUS ANTICOAGULANT AND COAGULATION INHIBITOR**  
Osamu Kumano\*, Masahiro Ieko, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi, Takeshi Suzuki, Takashi Aoki (Japan)
- PO058-WED **PREDICTIVE MARKERS FOR THROMBOTIC EVENTS IN AUTOIMMUNE DISEASES: COMPARISON OF ANTIPHOSPHOLIPID SCORE (APL-S) AND GLOBAL ANTI-PHOSPHOLIPID SYNDROME SCORE (GAPSS)**  
Kenji Oku\*, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda, Tatsuya Atsumi (Japan)
- PO059-WED **DETECTION OF ANTIPHOSPHOLIPID ANTIBODIES IN NORMAL PREGNANT WOMEN AND IN PREGNANT WOMEN AT THE TIME OF PRE-ECLAMPSIA ONSET**  
Beatriz Grand\*, Andrea Avigliano, Monica Gonzalez Alcantara, Liliana Voto (Argentina)
- PO060-WED **HIGH AVIDITY AUTO-ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR ARE FREQUENTLY OBSERVED IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME PATIENTS**  
Maria Efthymiou, Andrew Lawrie, Deepa Jayakody Arachchillage, Samuel Machin, Hannah Cohen, Ian Mackie\* (United Kingdom)
- PO061-WED **PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID SYNDROME.**  
Denisa Jankovicova\*, Angelika Batorova, Tatiana Prigancova, Miroslav Korbel (Slovakia)
- PO062-WED **ANTIPHOSPHOLIPID ANTIBODIES IN CEREBRAL VASCULAR EVENTS**  
Héla Baccouche, Sonia Mahjoub, Montaha Ben Jemaa, Samia Ben Sassi, Meriam Sellami\*, Neila Ben Romdhane (Tunisia)
- PO063-WED **ANTIPHOSPHOLIPID ANTIBODIES AND THE RISK OF STROKE IN TANZANIA: RESULTS FROM A COMMUNITY-BASED CASE-CONTROL STUDY**  
J.E. Molhoek\*, Q. de Mast, Ph.G. de Groot, A.J. van der Ven, W.K. Gray, A. Jusabani, M. Swai, F. Mugusi, R.T. Urbanus, R. Walker (The Netherlands)



## SCIENTIFIC PROGRAM

- PO064-WED **ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CORE LABORATORY VALIDATION EXERCISE: AN INTERNATIONAL PERFORMANCE ASSESSMENT OF LUPUS ANTICOAGULANT (LA) TESTS USING STANDARDISED METHODS AND REAGENTS**  
Ian J. Mackie\*, Vittorio Pengo, Elaine Gray, Danieli Andrade, Steven Krilis, Rohan Willis, Doruk Erkan, Hannah Cohen (United Kingdom)
- PO065-WED **BENEFICIAL EFFECT OF PRAVASTATIN IN FOUR PREGNANT WOMEN WITH ANTIPHOSPHOLIPID SYNDROME AND ISCHAEMIC PLACENTAL DISEASE**  
Eleftheria Lefkou\*, Apostolos Mamopoulos, Themistoklis Dagklis, Christos Vosnakis, Gerorgios Mavromatidis, Efthimios Nounopolos, David Rousso, Guillermina Girardi (Greece)
- PO066-WED **INCREASED LEVELS OF TISSUE FACTOR IN ANTIPHOSPHOLIPID SYNDROME ARE ASSOCIATED WITH THE DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOUS AND MAY HAVE NO IMPACT ON DISEASE PROGNOSIS**  
Bruna Mazzeto, Kiara Zapponi, Isadora Custódio, Sabrina Saraiva, Marina Collela, Erich de Paula, Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda Orsi\* (Brazil)
- PO067-WED **DISTINCT RISK FACTORS FOR ARTERIAL AND VENOUS THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME**  
Isadora Custódio, Bruna Mazzeto, Sabrina Saraiva, Marina Collela, Erich de Paula, Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda Orsi\* (Brazil)
- PO068-WED **CLINICAL RELEVANCE OF THE GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE (GAPSS) IN DIFFERENTIATING BETWEEN TRANSIENT ISCHEMIC ATTACK AND STROKE IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES.**  
Savino Sciascia\*, Giovanni Sanna, Veronica Murru, Dario Roccatello, Munther Khamashta, Maria Bertolaccini (United Kingdom)
- PO069-WED **EVALUATION OF B2-GLYCOPROTEIN I LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME.**  
Teresa Iwaniec\*, Magdalena Celinska-Löwenhoff, Marcin Kaczor, Jacek Musiał (Poland)
- PO070-WED **THE ASSOCIATION OF 3 STAT4 SINGLE NUCLEOTIDE POLYMORPHISMS AND ANTIPHOSPHOLIPID SYNDROME**  
Magdalena M. Celinska-Löwenhoff\*, Teresa Iwaniec, Sylwia Dziedzina, Marcin Kaczor, Marek Sanak, Jacek Musiał (Poland)
- PO071-WED **LABORATORY INTERPRETATION OF LA TEST RESULTS IN THE ERA OF TARGET SPECIFIC ORAL ANTICOAGULANTS**  
Bo Hyun Kim\*, Seongsoo Jang, Mi Hyun Bae, Young-Uk Cho, Chan-Jeoung Park (Korea, Republic Of)

### Antiplatelet agents III

- PO072-WED **PRODUCTION AND PURIFICATION OF VERSATILE ENZYMES FOR POTENTIAL ANTIPLATELET APPLICATIONS**  
Bat-Erdene Jugder\*, Altantsetseg Buyanbat, Tseren Purev (Mongolia)

## SCIENTIFIC PROGRAM

- PO073-WED **ANTIPLATELET EFFECTS OF GLYPROLINE PEPTIDES BY EXPERIMENTAL METABOLIC SYNDROM**  
Marina Grigorjeva\*, Ludmila Lyapina (Russian Federation)
- PO074-WED **PLATELET TRANSFUSION REVERSES BLEEDING EVOKED BY TRIPLE ANTI-PLATELET THERAPY INCLUDING VORAPAXAR, A NOVEL PLATELET THROMBIN RECEPTOR ANTAGONIST**  
Tian-Quan Cai\*, Alexandra Wickham, Gary Sitko, Maria Michener, Richard Raubertas, Larry Handt, Madhu Chintala, Deitmar Seiffert, Michael Forrest (United States)
- PO075-WED **THE ANTIPSYCHOTIC CLOZAPINE IS A POTENT ANTIPLATELET AGENT**  
Karl Egan\*, Jogin Thakore, Ana Lopez Alonso, Eimear Dunne, Niamh Cooke, Nicolas Ramperti, Dermot Kenny (Ireland)
- PO076-WED **AN IN VITRO TRANSFUSION MODEL FOR THE ASSESSMENT OF PLATELET FUNCTION RECOVERY FOLLOWING EXPOSURE TO TRIPLE ANTI-PLATELET AGENTS**  
Lisa K. Jennings\*, Vinay Bhal, Michael Herr, Mason Dixon, Steven Akins, Edward Hord, Dietmar Seiffert, Jayaprakash Kotha (United States)
- PO077-WED **EFFECTS OF SINGLE COMPARED TO DUAL ANTI-PLATELET THERAPY ON HEMOSTATIC SYSTEM ACTIVATION – A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS**  
Ludwig Traby\*, Alexandra Kaider, Marietta Kollars, Sabine Eichinger, Michael Wolzt, Paul Kyrle (Austria)
- PO078-WED **DEVELOPMENT OF A RECEPTOR OCCUPANCY ASSAY FOR ANFIBATIDE, A NOVEL GPIIb/IIIa ANTAGONIST**  
Alysia Cox\*, Dermot Cox, Marian Brennan (Ireland)
- PO079-WED **PEGYLATED DISINTEGRIN EXHIBITS MORE POTENT ANTITHROMBOTIC ACTIVITY IN VIVO**  
Chun-Chieh Hsu\*, Woei-Jer Chuang, Tur-Fu Huang (Taiwan)
- PO080-WED **RESISTANCE TO ASPIRIN IN MYELOPROLIFERATIVE NEOPLASMS. IS IT A REALITY?**  
Nadine Ajzenberg\*, Dorothée Faille, Marie-Geneviève Huisse, Anh Cungh, Lamia Lamrani, Nicolas Dumontier, Martine Jandrot-Perrus, Bruno Cassinat, Christine Chomienne, Christine Dosquet (France)
- PO081-WED **PHARMACOKINETICS AND PHARMACODYNAMICS OF APAC, A DUAL NOVEL ANTICOAGULANT AND ANTIPLATELET HEPARIN COMPLEX**  
Annukka Jouppila\*, Marie-Claude Benoit, Charles-E. Laurent, Dany Salvail, Riitta Lassila (Finland)
- PO082-WED **INHIBITION OF THROMBIN GENERATION BY APIXABAN OR RIVAROXABAN, IN A CELL-BASED MODEL OF COAGULATION PRIMED BY PLATELETS**  
Irene Lopez-Vilchez\*, Lluís Pujadas-Mestres, Nerea Rincon-Tome, Eduardo Arellano-Rodrigo, Ana Galan, Maribel Diaz-Ricart, Gines Escolar (Spain)

## SCIENTIFIC PROGRAM

- PO083-WED **HOW SHOULD WE MEASURE THE EFFECT OF PERSANTINE USING THROMBOELASTOGRAPHY? CORRELATION AND AGREEMENT BETWEEN PERCENT ADP INHIBITION AND ADP NET G**  
Patti Massicotte, Jennifer Conway, Lindsay May, Holger Buchholz, Clara Lo, Aisha Bruce, Tiffany Tesoro, David Rosenthal, Christopher Almond (Canada)
- PO084-WED **NSAIDS IN VIVO TREATMENT AND MRP4 EXPRESSION IN HUMAN PLATELETS**  
Flavia Temperilli\*, Isabella Massimi, Maria Luisa Guarino, Laura Alemanno, Maria Paola Guzzo, Cristina Iannuccelli, Manuela Di Franco, Fabio M. Pulcinelli\* (Italy)
- PO085-WED **THE EFFECTIVENESS OF P2Y12 RECEPTOR BLOCKADE IS STRONGLY DETERMINED BY THE PRESENCE OF ENDOTHELIAL MEDIATORS PROSTACYCLIN AND NITRIC OXIDE**  
Rebecca B. Knowles\*, Melissa Chan, Paul Armstrong, Chih-Chin Shih, Melissa Hayman, Ivana Vojnovic, Arthur Tucker, Adam Timmis, Timothy Warner (United Kingdom)
- PO086-WED **COMPARISON OF THE BIOCYTEX AND THE VASPFIX ASSAYS OF VASP PHOSPHORYLATION IN CORONARY-ARTERY DISEASE PATIENTS TREATED WITH CLOPIDOGREL PLUS ASPIRIN**  
Ksenia Germanovich, Eti A. Femia, Mariangela Scavone, Vera Caroppo, Marco Cattaneo\* (Italy)

### Arterial vascular disorders - clinical III

- PO087-WED **LOCAL PARAMETERS OF HEMOSTASIS ACTIVATION IN THE FIBRILLATING ATRIUM**  
Noemi Klara Toth\*, Zsuzsa Bagoly, Zoltán Csanádi, Alexandra Kiss, Edina Nagy-Baló, Kitti Kovács, László Muszbek, Zsuzsanna Bereczky, László Csiba (Hungary)
- PO088-WED **THE ASSESMENT OF ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION UNDER FIBRINOLYTIC THERAPY OR PRIMARY PERCUTANEOUS CORONARY INTERVENTION**  
Mehmet Sonmez\* Safiye Tuba Kaplan (Turkey)
- PO089-WED **rhADAMTS13 TREATMENT AMELIORATES CARDIAC LONG-TERM REMODELING AFTER ISCHEMIA-REPERFUSION INJURY**  
Thilo Witsch\*, Kimberly Martinod, Katlynn Gwilt, Denisa Wagner (United States)
- PO090-WED **RISK FACTORS FOR CORONARY ARTERY DISEASE IN YOUNG IRANIAN: RESULTS FROM THE MILANO-IRAN (MIRAN) STUDY**  
Alberto Maino\*, Seyed Hesameddin Abbasi, Saeed Sadeghian, Mohammadali Boroumand, Masoumeh Lotfi-Tokaldany, Frits Rosendaal, Flora Peyvandi (Italy)
- PO091-WED **BLOCKING HETEROMERIZATION OF PLATELET CHEMOKINES CCL5 AND CXCL4 REDUCES INFLAMMATION AND PRESERVES HEART FUNCTION AFTER MYOCARDIAL INFARCTION**  
Rory Koenen, Isabella Werner, Tanja Vajen\*, Delia Projahn, Mareike Staudt, Adelina Curaj, Taha Sönmez, Sakine Simseyilmaz, Tilman Hackeng, Philipp von Hundelshausen, Christian Weber, Elisa Liehn (The Netherlands)

## SCIENTIFIC PROGRAM

- PO092-WED **INCREASED CLOT FORMATION IN THE ABSENCE OF INCREASED THROMBIN GENERATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE**  
Marie-Claire Kleinegriss, Joke Konings, Jan-Willem Daemen, Yvonne Henskens, Bas de Laat, Henri Spronk, Arina ten Cate - Hoek, Hugo ten Cate\* (The Netherlands)
- PO094-WED **MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING CORONARY ANGIOPLASTY: ROLE OF NADPH OXIDASE P22PHOX GENE POLYMORPHISMS**  
Betti Giusti\*, Claudia Saracini, Silvia Galora, Rossella Marcucci, Anna Maria Gori, Renato Valenti, Guido Parodi, Gian Franco Gensini, David Antonucci, Francesco Violi, Rosanna Abbate (Italy)
- PO095-WED **THROMBOGENICITY ACCORDING TO THE VASCULAR SITE OF ATHEROSCLEROSIS DISEASE**  
Daniela Calderaro\*, Adriana Pastana, Tania Rubia Rocha, Fernanda Justo, Danielle Gualandro, Pai Yu, Mariana Matheus, Elbio D'Amico, Bruno Caramelli (Brazil)
- PO096-WED **THE ROLES OF TRANSGLUTAMINASE 2 AND FXIII-A IN ABDOMINAL AORTIC ANEURYSM DEVELOPMENT**  
Kathryn Griffin, Kingsley R. Simpson\*, Nadira Yuldasheva, Robert Graham, Peter Grant, Julian Scott, Chris Jackson, Richard Pease (United Kingdom)
- PO097-WED **FACTOR XIA AND THROMBIN GENERATION ARE ELEVATED IN ACUTE CORONARY SYNDROME AND ARE PREDICTORS OF RECURRENT CARDIOVASCULAR EVENTS.**  
Rinske Loeffen\*, Rene van Oerle, Mathie Leers, Harry Crijs, Henri Spronk, Hugo ten Cate (The Netherlands)

### Atherosclerosis III

- PO098-WED **TWO PEPTIDE EPITOPES DERIVED FROM HUMAN AND MYCOBACTERIUM, RESPECTIVELY, REDUCE ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE**  
Min Xia, Daxin Chen, Valeria Endresz, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu\* (United Kingdom)
- PO099-WED **THE GUT MICROBIOTA IMPACTS PLASMA COAGULATION FACTORS AND AUGMENTS ARTERIAL THROMBUS FORMATION.**  
Avinash Khandagale\*, Eivor Wilms, Sven Jäckel, Karl Lackner, Ulrich Walter, Christoph Reinhardt (Germany)
- PO100-WED **THE ROLE OF CLOTTING FACTOR IX IN THE DEVELOPMENT OF ATHEROSCLEROSIS**  
Lais De Paula\*, Devanira Costa, Aline Urban, Joyce Annichino-Bizzacchi (Brazil)
- PO101-WED **PHOSPHORYLATION OF PLATELET ACETYL-COA CARBOXYLASE IS INCREASED IN HUMAN AND MICE ATHEROSCLEROSIS AND COULD BE AN INDICATOR OF PERSISTENT THROMBIN GENERATION.**  
Sophie Lepropre\*, Shakeel Kautbally, Marie-Blanche Onselaeer, David Vancraeynest, Nicolas Barrile, Luc Bertrand, Jean-Louis Vanoverschelde, Christophe Beauloye, Sandrine Horman (Belgium)

## SCIENTIFIC PROGRAM

- PO102-WED **DIFFERENTIAL EFFECTS OF LEPTIN SIGNALING IN ENDOTHELIAL OR SMOOTH MUSCLE CELLS ON NEOINTIMA FORMATION FOLLOWING VASCULAR INJURY IN MICE**  
Katrin Schäfer, Astrid Hubert\*, Magdalena Bochenek, Marco Schroeter, Thomas Münzel (Germany)
- PO103-WED **BINDING OF COAGULATION FACTOR XIII TO ACTIVATED PLATELET SUB-POPULATIONS**  
Yana Kotova\*, Nadezhda Podoplelova, Alexandra Demyanova, Herve Chambost, Marie Christine Alessi, Mikhail Panteleev (Russian Federation)
- PO104-WED **EFFECT OF DABIGATRAN ETEXILATE AND WARFARIN ON ATHEROSCLEROTIC PLAQUE CALCIFICATION IN APOE-/- MICE.**  
Leon J. Schurgers\*, Rick van Gorp, Brecht Willems, Henri Spronk, Chris Reutelingsperger (The Netherlands)
- PO105-WED **HYPERGLYCAEMIC APOLIPOPROTEIN-E DEFICIENT MICE HAVE ACCELERATED ATHEROSCLEROSIS AND ABERRANT VASA VASORUM NEOVASCULARIZATION**  
Heidi Stoute\*, Daniel Venegas-Pino, Kaley Veerman, Peter Shi, Geoff Werstuck (Canada)

### Blood coagulation tests III

- PO106-WED **THE EFFECT OF HOMOCYSTEINE ON THE RESULTS OF THROMBODYNAMICS TEST**  
Nadezda Vorobyeva\*, Yulia Pavlovskaya (Russian Federation)
- PO107-WED **EVALUATION OF A NEW HOMOGENEOUS IMMUNOASSAY FOR QUANTIFICATION OF PROTHROMBIN FRAGMENT 1+2 (F1+2) IN HUMAN PLASMA SAMPLES\***  
Matthias Ehm\*, Doris Kraul, Achim Stangl, Martina Pfeiff, Lisa Feddersen, Verena Smith, Christa Duwe, Uwe Kuhn, Olivia Pohlack-Marsch, Petra Vesper, Elfriede Boucsein-Mueller, Norbert Zander (Germany)
- PO108-WED **IDENTIFYING FACTOR DEFICIENCIES BY USING THE SECOND DERIVATIVE CURVE OF APTT ON AN ACL-TOP COAGULATION ANALYZER**  
Tokunaga Naoki\*, Inoue Chihiro, Sakata Toshiyuki, Kagawa Kumiko, Abe Masahiro, Nakao Takayuki, Takamatsu Norimichi, Doi Toshio (Japan)
- PO109-WED **A RARE COMBINATION: CONGENITAL FACTOR VII DEFICIENCY WITH CHIARI MALFORMATION**  
Ali Bay, Elif Aktekin, Ibrahim Erkutlu (Turkey)
- PO110-WED **CAN COMPARING THE VALUE OF THE PROTHROMBIN TIME RATIO AND THE ACTIVATED PARTIAL THROMBOPLASTIN TIME RATIO HELP DIAGNOSE THE CAUSE OF COAGULOPATHY?**  
Yingyong Chinthammitr\*, Phasakorn Putchakarn (Thailand)
- PO111-WED **THROMBIN GENERATION TEST FOR MONITORING OF CONVENTIONAL HAEMOPHILIA TREATMENT**  
Olga Smirnova\*, Vera Kobilyanskaya, Vitaliy Soldatenkov, Vyacheslav Burakov, Ludmila Papayan (Russian Federation)

## SCIENTIFIC PROGRAM

- PO112-WED **EFFECT OF RECOMBINANT LUBRICIN ON COAGULATION PARAMETERS IN HUMAN BLOOD**  
Jawed Fared\*, Debra Hoppensteadt, Omer Iqbal, Schuharazad Abro, Patrick Sweigert, Ed Truitt, Gregory Jay, William Hopkinson (United States)
- PO113-WED **CHARACTERISTICS OF COAGULATION DYNAMICS IN ACUTE PHASE OF KAWASAKI DISEASE**  
Hiroyuki Yoshizawa\*, Keiji Nogami, Tomoko Matsumoto, Tamaki Hayashi, Midori Shima (Japan)
- PO114-WED **ABILITY OF THROMBOELASTOGRAPHY TO DISTINGUISH THE SEVERITY OF PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA**  
Maria Elisa Mancuso\*, Veena Chantarangkul, Marigrazia Clerici, Maria Fasulo, Lidia Padovan, Erica Scalabrino, Flora Peyvandi, Armando Tripodi, Elena Santagostino (Italy)
- PO115-WED **WHOLE BLOOD COAGULATION ANALYSES ARE DEPENDENT ON THE TEMPERATURE THEY ARE PERFORMED AT**  
Anni N. Jeppesen\*, Hans Kirkegaard, Susanne Ilkjaer, Anne-Mette Hvas (Denmark)
- PO116-WED **CORRELATION OF PEAK THROMBIN CONCENTRATIONS WITH ONE-STAGE ACTIVITY ASSAY LEVELS INDICATES THAT THROMBIN GENERATION ASSAYS CORRELATE WITH FACTOR VIII ACTIVITY IN CLINICAL HEMOPHILIA A PLASMA SAMPLES.**  
Sunita Patel-Hett\*, Julie Lee, Swapnil Rakhe, Steven Arkin, Francois Huard, Debra Pittman, John Murphy, Fei Hua (United States)
- PO117-WED **HEPARIN INTERFERENCE IN ANTI-XA ASSAYS FOR RIVAROXABAN AND APIXABAN**  
Gwyn A. Cutsforth\*, Kathleen Finnegan (United States)
- PO118-WED **USE OF LYOPHILIZED PHOSPHOLIPID VESICLES IN THROMBODYNAMICS ASSAY**  
Natalia Korotina\*, Lubov Sokolova, Elena Ponomareva, Natalia Dashkevich, Fazoil Ataulkhanov (Russian Federation)
- PO119-WED **DOES ANTITHROMBOTIC THERAPY INFLUENCE RESULTS OBTAINED BY THROMBOELASTOMETRY?**  
Mia Hammer Holck\*, Thomas Decker Christensen, Anne-Mette Hvas (Denmark)
- PO120-WED **SCREENING METHOD USING TWO DIFFERENT ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) REAGENTS FOR SPECIMENS WITH PROLONGED APTT**  
Emi Takeo\*, Etsuji Suehisa, Masayuki Toku, Tomio Kawasaki, You Hidaka (Japan)
- PO121-WED **TROMBIN GENERATION; ESTABLISHMENT OF A REFERENCE INTERVAL AND THE EFFECT OF ASPIRIN**  
Vivi Bo Mogensen\*, Mai Therkelsen, Søs Nedergaard-Petersen, Ivy Modrau, Anne-Mette Hvas (Denmark)
- PO122-WED **A NEW ASSAY FOR MEASUREMENT OF THE IN-VIVO THROMBIN ACTIVITY IN COMPARISON TO THE IN-VITRO THROMBIN GENERATION POTENTIAL IN PATIENTS WITH HYPER- AND HYPOCOAGULABLE STATE**  
Silvia M. Koder\*, Oliver Koenigsbruegge, Julia Riedl, Simon Panzer, Ingrid Pabinger, Cihan Ay (Austria)

## SCIENTIFIC PROGRAM

- PO123-WED **INFLUENCE OF PRE-ANALYTICAL HEPARIN ON T-PA INDUCED FIBRINOLYSIS DETERMINED BY THROMBOELASTOGRAPHY DESPITE THE USE OF DISCARD TUBES**  
Floor Moenen\*, Inge Verheijen, Ron Straat, Rick Wetzels, Erik Beckers, Yvonne Henskens (The Netherlands)
- PO124-WED **EFFECT OF FRESH FROZEN PLASMA IN CRITICALLY ILL PATIENTS**  
Emil Vibede\*, Christine Hvas, Else Toennesen, Anne-Mette Hvas (Denmark)
- PO125-WED **A DRVVT-BASED ASSAY TO ESTIMATE THE INTENSITY OF ANTICOAGULATION IN PATIENTS TREATED WITH NOACS**  
Anne-Laure Sennesael\*, Jonathan Douxfils, Tom Exner, Bernard Chatelain, Anne-Sophie Larock, Jean-Michel Dogné, Anne Spinewine, François Mullier (Belgium)
- PO126-WED **PRE-ANALYTICAL SAMPLE CHECK IN HAEMOSTASIS: EVALUATION OF THE NEW COAGULOMETER ACL TOP 750 CTS SYSTEM**  
Chiara Novelli\*, Benedetto Morelli, Maria Gabriella Cozzi, Maria Luisa Duca, Elisa Garghetti, Franca Rampinini (Italy)
- PO127-WED **THROMBIN GENERATION IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY**  
Luca Spiezia\*, Francesco Vasques, Astrid Behr, Fabio Dalla Valle, Barry Woodhams, Sabrina Gavasso, Paolo Simioni (Italy)
- PO128-WED **EVALUATION OF THE AUTOMATED COAGULATION ANALYSER SYSMEX® CS-5100 (SIEMENS)**  
Isabelle Martin Toutain\*, Karim Maloum, Lionel Jobic, Tessy Mancic, Alexandre Brisard, Annick Ankri (France)
- PO129-WED **IMPACT OF ASSAY, PRODUCT, AND PATIENT VARIABILITY ON PRECISION DOSING FOR FACTOR VIII PROPHYLAXIS**  
Leonard A. Valentino\*, Peter Turecek, Kenneth Mann (United States)
- PO130-WED **EVALUATION OF WAVEFORM ANALYSIS ON THE DESTINY MAX COAGULATION ANALYSER**  
Jane Needham\*, Helen Lewis, Nina Harrison, Savita Rangarajan (United Kingdom)
- PO131-WED **FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE SHOWS ANTI-COAGULANT EFFECT WHEN USED FOR IN VITRO EXPERIMENTS**  
Emilie Sandgaard Pedersen\*, Christine Lodberg Hvas, Signe Voigt Lauridsen, Anne-Mette Hvas (Denmark)
- PO132-WED **EVALUATION OF A NEW, INNOVATIVE, INTERMEDIATE THROUGHPUT COAGULATION ANALYSER**  
Philip J. Lane, Irfan Patel\*, Ian Mackie, Sam Machin (United Kingdom)
- PO133-WED **HAEMOPHILIA A CARRIER DETECTION IN SUDANESE FAMILIES: DNA LINKAGE ANALYSIS APPROACHES**  
Rayan Elsheikh, Maria Satti, Elthahir Khalil (Sudan)
- PO134-WED **IMPACT OF SILVER NANOPARTICLES ON HEMOLYSIS, PLATELET FUNCTION, COMPLEMENT SYSTEM AND COAGULATION**  
Julie Laloy\*, Valentine Minet, Lutfiye Alpan, François Mullier, Sonja Beken, Olivier Toussaint, Stéphane Lucas, Jean-Michel Dogné (Belgium)

## SCIENTIFIC PROGRAM

- PO135-WED **DETERMINATION OF INSUFFICIENT ANTICOAGULANT EFFECT IN PATIENTS WITH ATRIAL FIBRILLATION USING THROMBODYNAMICS ASSAY**  
Nikolay N. Topalov\*, Irina Zotova, Dmitriy Zateyshchikov, Fazoil Ataullakhanov, Ilya Serebriyskiy (Russian Federation)
- PO136-WED **NEW LIQUID RECOMBINANT THROMBOPLASTIN (DG PT RECOMBILIQ, DIAGNOSTIC GRIFOLS) SUITABLE FOR ROUTINE USE**  
Anita Woolley\*, Stephen Kitchen (United Kingdom)
- PO137-WED **EVALUATION OF A NEW, HIGHLY SENSITIVE LOCI D-DIMER METHOD FOR THE DETECTION OF VERY LOW CONCENTRATIONS IN HUMAN CITRATED PLASMA\***  
Matthias Ehm\*, Doris Kraul, Achim Stangl, Uwe Kuhn, Olivia Pohlack-Marsch, Petra Vesper, Melanie Preis, Elfriede Boucsein-Mueller, Udo Krupka (Germany)
- PO138-WED **SILICA CLOTTING TIME (SCT) VS DILUTE VENOM RUSSELL VIPER (DVRV) AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) IN THE DIAGNOSIS OF ANTIPHOSPHOLIPID ANTIBODIES SYNDROME.**  
Evelyn Cortina de la Rosa\*, Mara Nuñez Toscano, Omar Coronel Ayala, Alejandra Navarrete Villarruel, Raul Izaguirre Ávila (Mexico)
- PO139-WED **DISCORDANCE BETWEEN ACTIVATED PARTIAL THROMBOPLASTIN TIME AND HEPARIN LEVEL MEASURED WITH ANTI-XA ASSAY IN ANTITHROMBIN-DEFICIENT PLASMA**  
Alice Kun Yi\*, Ivan Stevic, Jorell Gantioqui, Keith Lau, Robin Roberts, Anthony Chan, Howard Chan (Canada)
- PO140-WED **MULTICENTER STUDY OF TWO NEW COAGULATION ANALYZERS IN COMPARISON TO A PREDICATE DEVICE ALREADY IN THE US-MARKET, USING SIEMENS HEALTHCARE REAGENTS**  
Michael R. Weik\*, Ingvild Birschmann, Charles Eby, Kemkes-Matthes Bettina, Stephen Manzella, Ellinor Peerschke, Steven Pipe (Germany)
- PO141-WED **EVALUATION OF THE NEW QSMART FROM GRIFOLS IN COMPARISON TO THE QHEMOSTASIS ANALYZER**  
Anita Woolley\*, Stephen Kitchen (United Kingdom)
- PO142-WED **HEMOCOMPATIBILITY OF ESTETROL AND ESTRADIOL COUPLED TO CYCLODEXTRINES**  
Julie Laloy\*, Claudio Palazzo, Lutfiye Alpan, Jean-Michel Foidart, Géraldine Piel, Jean-Michel Dogné (Belgium)
- PO143-WED **EVALUATION OF PROLONGED PT / APTT TESTS IN PRESURGICAL PLASMA SAMPLES**  
Zühre Kaya\*, Turkiz Gursel (Turkey)
- PO144-WED **VALIDATION OF NEW AUTOMATED LATEX-IMMUNOTURBIDIMETRIC ASSAY FOR MEASURING VWF ACTIVITY**  
Vladimira Rimac, Sanela Simic Vojak, Desiree Coen Herak\*, Renata Zadro (Croatia)
- PO145-WED **LABORATORY EVALUATION OF PATIENTS WITH UNDIAGNOSED BLEEDING DISORDERS**  
Fernanda D. S. Bassora\*, Graziela Alves, Susan Quaino, Silmara Montalvão, Erich de Paula, Fernanda Orsi, Joyce Annichino-Bizzacchi (Brazil)

## SCIENTIFIC PROGRAM

- PO146-WED **COMPARISON OF METHODS OF MEASUREMENT OF FACTOR VIII INHIBITORS IN A NEW HAEMOPHILIA CARE CENTER**  
Mirta Arias, Emanuel Sueldo, Marcela Avalos, Patricia Do Nascimento\*, Gabriela Guerrero, Alejandra Baques (Argentina)
- PO147-WED **THE NORMAL RANGE OF THE THROMBODYNAMICS VALUES FOR APPARENTLY HEALTHY PREGNANT WOMEN**  
Tatiana A. Vuimo\*, Olga Baskova, Olga Gerasimova, Ruzanna Ovsepyan, Stepan Surov, Anastasya Mogilevets, Oleg Brusov, Ekaterina Voroshilina (Russian Federation)
- PO148-WED **FACTOR VIII INHIBITOR TESTING, INTERPRETATION AND STANDARDIZATION – IT'S COMPLICATED**  
Thomas Siegemund\*, Annelie Siegemund, Ute Scholz, Zaverio Ruggeri (Germany)
- PO149-WED **CAN THE OVERALL HAEMOSTATIC POTENTIAL ASSAY PREDICT BLEEDING AND THROMBOSIS RISK IN WARFARINISED PATIENTS?**  
Caroline J. Reddel\*, Kate Burbury, Ray Dauer, Sue Wilson, David Westerman, Bernhard Riedel, Jennifer Curnow (Australia)
- PO150-WED **DETECTION OF HYPERCOAGULATION IN HIP ARTHROPLASTY PATIENTS.**  
Leonid A. Parunov\*, Irina Taranenko, Andrey Momot, Fazoil Ataullakhanov, Ilya Serebriyskiy (Russian Federation)
- PO151-WED **HEPARIN AND PROTAMINE CONFOUND FACTOR ACTIVITY AND INHIBITOR TESTING WHILE ON CARDIOPULMONARY BYPASS**  
Michelle Sholzberg\*, Chai Phua, Hubert Tsui, Hilde Vandenberghe, Georges Rivard, Hina Chaudhry, Jerome Teitel (Canada)
- PO152-WED **HEMOSTASIS ALTERATIONS ASSOCIATED TO COMPLICATIONS IN SICKLE CELL SYNDROME**  
Diego Higuera\*, Martha Bravo, Guerrero Belsy, Emelyn Salazar, Karin Perez (Venezuela, Bolivarian Republic Of)
- PO153-WED **ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) CLOT WAVEFORM ANALYSIS (CWA) ON SYMEX CS 2000 HELPS DIFFERENTIATE MILDLY FROM SEVERE PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA A.**  
Sukesh C. Nair\*, Ramya Vijay, Helen Margaret, Aby Abraham, Auro Vishwabandya, Abraham Sundarsingh, Kavitha ML, Arai Nobuo, Parag Tavkar, Kurono Hiroshi, Alok Srivastava (India)
- PO154-WED **BLOOD COAGULATION TESTS: REVIEW OF VALIDATION REQUIREMENTS FOR FDA CLEARANCE**  
Iwona Fijalkowska\*, Claudia Dollins (United States)

### Cancer and thrombosis/hemostasis III

- PO155-WED **SP-SELECTIN AS A MARKER OF PLATELET ACTIVATION IN AFRICANS WITH PROSTATE CANCER.**  
Hannah Omunakwe\*, Onyeannam Ekeke, Christopher Obiorah, Oseikhuemen Ejele (Nigeria)

## SCIENTIFIC PROGRAM

- PO156-WED **FRACTAL DIMENSION (DF) AS A MARKER OF HYPERCOAGULABILITY, CLOT STRUCTURE AND 12 MONTH SURVIVAL IN LUNG CANCER**  
Nia Davies, Nicholas Harrison, Simon Noble\*, Matthew Lawrence, Vanessa Evans, Roger Morris, Karl Hawkins, Phylip Williams, Philip Evans (United Kingdom)
- PO157-WED **PREDICTION OF CANCER ASSOCIATED THROMBOSIS. PROSPECTIVE BIOMARKER STUDY**  
Alfonso Tafur\*, Aaron Mansfield, Mohammad Cherry, Philip Comp, Suman Rathbun, Julie Stoner (United States)
- PO159-WED **FACTOR V LEIDEN MUTATION AND HIGH FVIII ARE ASSOCIATED WITH AN INCREASED RISK OF VTE IN WOMEN WITH BREAST CANCER DURING ADJUVANT TAMOXIFEN - RESULTS FROM A PROSPECTIVE, SINGLE CENTER, CASE CONTROL STUDY**  
Mirjana Kovac\*, Zeljko Kovac, Zorica Tomasevic, Slavko Vucicevic, Valentina Djordjevic, Iva Pruner, Dragica Radojkovic (Serbia)
- PO161-WED **INCREASING PLATELETS AND OTHER MEASURES ENHANCING HEMOSTASIS ARE BOTH IMPORTANT TO PREVENT BLEEDING EPISODES WHEN THROMBOCYTOPENIC PATIENTS REQUIRING ANTITHROMBOTIC THERAPY – A REVIEW OF THE MEDICAL LITERATURE**  
Linda Chow\*, Mohammed Almakadi, Keith Lau, Anthony Chan, Howard Chan (Canada)
- PO162-WED **PANCREATIC CANCER PATIENTS EXPRESS ELEVATED FVIII LEVELS AND METASTASIS-ASSOCIATED FIBRIN TURNOVER PRIOR TO THEIR DIAGNOSIS**  
Nora Varkila\*, Caj Haglund, Hanna Seppänen, Riitta Lassila (Finland)
- PO163-WED **VARIATIONS OF PLASMA LEVELS OF TFPI AND ACTIVATED FVII-ANTI-THROMBIN COMPLEX IN CANCER PATIENTS: THE INCREASE OF TFPI AS A MAJOR DETERMINANT OF THROMBIN GENERATION.**  
Patrick Van Dreden, Hélène Doubre, Dominique François, Mariette Adam, Matthieu Grusse, Marc Vasse\* (France)
- PO164-WED **PROTEIN C LEVELS ARE ASSOCIATED WITH MORTALITY IN PATIENTS WITH ADVANCED CANCER**  
Dorienke Wilts\*, Barbara Hutten, Joost Meijers, C. Arnold Spek, Harry Büller, Pieter Willem Kamphuisen (The Netherlands)
- PO165-WED **L-ASPARAGINASE LOWERS PLASMA ANTITHROMBIN AND MANNAN-BINDING-LECTIN LEVELS: IMPACT ON THROMBOTIC AND INFECTIOUS EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA**  
Clémence Merlen, Arnaud Bonnefoy\*, Eric Wagner, Anik Cormier, Laurence Dedeken, Jean-Marie Leclerc, Caroline Laverdière, Georges-Etienne Rivard (Canada)
- PO166-WED **LONGITUDINAL ANALYSIS OF HEMOSTATIC BIOMARKERS IN CANCER PATIENTS DURING ANTI-TUMOR TREATMENT**  
Ingrid Pabinger, Alexandra Kaider, Cihan Ay, Christoph Zielinski, Peter Quehenberger, Christine Marosi, Eva-Maria Reitter\* (Austria)
- PO167-WED **MICROVESICLES ARE A POTENTIAL BIOMARKER FOR THROMBOSIS AND DIC IN LEUKEMIC PATIENTS: A CROSS-SECTIONAL STUDY**  
Damien Gheldof\*, Jean-Michel Dogné, Carlos Graux, Fabienne George, Anne Sonet, Bernard Chatelain, François Mullier, Christian Chatelain (Belgium)

## SCIENTIFIC PROGRAM

- PO168-WED **GENETIC VARIANTS IN 3'-UTRS OF METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) PREDICT COLORECTAL CANCER SUSCEPTIBILITY IN KOREANS**  
Jung O Kim\*, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Hui Jeong An, Young Joo Jeon, Doyeun Oh, Hwi Joong Yoon, Nam Keun Kim (Korea, Republic Of)
- PO169-WED **SIGNIFICANCE OF HAEMOSTATIC PARAMETERS IN PATIENTS WITH URINARY CANCER**  
Aristeidis Alevizopoulos, Paraskevi Kotsi\*, Joanna Anastasopoulou, Sofia Gkotsi, Maria Gavalaki, Olga Katsarou (Greece)
- PO170-WED **EVALUATION OF THROMBOELASTOMETRY PARAMETERS AS PREDICTIVE MARKERS FOR SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA**  
Joanna Rupa-Matyszek\*, Lidia Gil, Ewelina Wojtasińska, Zuzanna Kanduła, Mieczysław Komarnicki (Poland)
- PO171-WED **CANCER INDUCING NETOSIS PROMOTES WIDESPREAD ARTERIAL THROMBOSIS PRESENTING AS ISCHEMIC STROKE WITH TROPONIN ELEVATION**  
Charlotte Thålin\*, Melanie Demers, Bo Blomgren, Ann Charlotte Laska, Magnus von Arbin, Håkan Wallén, Denisa Wagner, Sara Aspberg (Sweden)
- PO172-WED **RELEVANCE OF D-DIMER AND IL-6 LEVELS AMONG PATIENTS WITH CANCER AND INCIDENTAL PULMONARY EMBOLISM**  
Casey Oconnell\*, Diana Hanna, Denice Tsao-Wei, Scott Tagawa, Caroline Piatek, David Quinn, Ilene Weitz, Howard Liebman (United States)
- PO173-WED **DIAGNOSTIC APPROACH TO RARE LOCALISATION TROMBOSIS IN CANCER PATIENTS**  
Alexander Vorobev, Alexander Makatsaria\* (Russian Federation)
- PO174-WED **CLINICAL SIGNIFICANCE OF CIRCULATING TISSUE FACTOR (TF) IN WOMEN WITH SUSPECTED OVARIAN CANCER**  
Carlotla Claussen, Alma Rausch, Brigitte Spath, Susanne Lezius, Ali Amirkhosravi, Monica Davila, John Francis, Carsten Bokemeyer, Fritz Jänicke, Sven Mahner, Florian Langer\* (Germany)
- PO175-WED **RIVAROXABAN IN PATIENTS WITH VTE AND CANCER: A SINGLE CENTER EXPERIENCE**  
Samantha Pasca, Ugo Venturelli, Giovanni Barillari\* (Italy)
- PO176-WED **D-DIMER PLASMA LEVELS AS A MARKER OF PULMONARY EMBOLISM IN PATIENTS UNDERGOING SURGERY FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM**  
Andrea Artoni\*, Paolo Bucciarelli, Serena Passamonti, Giorgio Carrabba, Valeria Conte, Massimo Castellani, Erica Scalabrino, Ida Martinelli (Italy)
- PO177-WED **TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IS A MARKER OF TUMOR PROGRESSION AND PROGNOSIS IN BREAST CANCER**  
Mari Tinholt\*, Hans Kristian Vollan, Kristine Sahlberg, Rolf Kåresen, Torill Sauer, Vessela Kristensen, Anne-Lise Børresen-Dale, Per Sandset, Nina Iversen (Norway)

## SCIENTIFIC PROGRAM

- PO178-WED **INCREASED ACTIVATED PROTEIN C RESISTANCE AND D-DIMER IN BREAST CANCER: PHENOTYPIC AND GENOTYPIC DETERMINANTS AND ASSOCIATION WITH TUMOR CHARACTERISTICS**  
Mari Tinholt\*, Hans Kristian Vollan, Øystein Garred, Marie-Christine Mowinckel, Kristine Sahlberg, Marit Sletten, Anne-Lise Børresen-Dale, Vessela Kristensen, Rolf Kåresen, Ellen Schlichting, Grethe Skretting, Per Sandset, Nina Iversen (Norway)
- PO179-WED **THROMBIN GENERATION (TG) IS DOWNREGULATED BY LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM (VTE)**  
Anna Falanga\*, Carmen Tartari, Marina Marchetti, Laura Russo, Kim Lambregts, Davide Resta, Andrea D'Alessio (Italy)
- PO180-WED **HYPERCOAGULABILITY: AN ADDED SIDE EFFECT FOR ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER PATIENTS**  
Harmanpreet Kaur\*, Spencer Barr, Angela Black, Sylvia Robb, Robert Siemens, Maha Othman (Canada)

### Coagulation factor V, X, II, XIII - III

- PO181-WED **IDENTIFICATION OF TWO NOVEL MISSENSE MUTATIONS CAUSING SEVERE FACTOR XIII DEFICIENCY**  
Munira Borhany\*, Helena Handrkova, Verena Schroeder Schroeder, Naveena Fatima, Asif Hussain, Tahir Shamsi, Hans Peter Kohler (Pakistan)
- PO182-WED **FIRST GROUNDING FOR COMPLETE STRUCTURAL CHARACTERIZATION OF FXIII HETEROTETRAMER: SUCCESSFUL DISULFIDES!**  
Sneha Gupta\*, Christoph Reinhart, Christoph Krettler, Mohammad Akhter, Vytautas Ivaskevicius, Hartmut Micheal, Johannes Oldenburg, Arijit Biswas (Germany)
- PO183-WED **REVISITING THE MECHANISM OF COAGULATION FACTOR XIII ACTIVATION IN PLASMA**  
Sneha Gupta\*, Christoph Reinhart, Christoph Krettler, Mohamad Akhter, Johannes Dodt, Hartmut Micheal, Johannes Oldenburg, Arijit Biswas (Germany)
- PO184-WED **MUTATING CORE STRUCTURAL DISULFIDES OF THE FXIII B SUBUNIT AS A MEANS TO UNCOVER THE FUNCTIONAL ROLES OF INDIVIDUAL FXIIIB SUBUNIT SUSHI DOMAINS**  
Mohammad S. Akhter\*, Sneha Gupta, Hamideh Yadegari, Vytautas Ivaskevicius, Johannes Dodt, Johannes Oldenburg, Arijit Biswas (Germany)
- PO185-WED **THE ACTIVATION PEPTIDE OF COAGULATION FACTOR XIII IS VITAL FOR ITS EXPRESSION AND STABILITY**  
Helena Handrkova, Verena Schroeder\*, Hans Kohler (Switzerland)
- PO186-WED **THE B-SUBUNIT OF COAGULATION FACTOR XIII DOES NOT SPECIFICALLY INTERACT WITH COMPLEMENT FACTORS**  
Lorenz Jenny, Zhuoer Lin, Daniel Ricklin, Hans Kohler, Verena Schroeder\* (Switzerland)

## SCIENTIFIC PROGRAM

- PO187-WED **THE EFFECT OF FACTOR XIII B SUBUNIT POLYMORPHISMS ON FACTOR XIII LEVELS AND ON THE RISK OF CORONARY ARTERY DISEASE; INTERACTION WITH FIBRINOGEN LEVEL AND FACTOR XIII A SUBUNIT P.VAL34LEU POLYMORPHISM**  
László Muszbek\*, Zoltán Mezei, Zsuzsanna Bereczky, Éva Katona, Réka Gindele, Szilvia Fialat, László Balogh, István Czuriga, Róza Ádány, István Édes (Hungary)
- PO188-WED **FXIII-A V34L AFFECTS THROMBUS CROSS-LINKING, BUT NOT SIZE, IN A MURINE THROMBOSIS MODEL**  
Cedric Duval\*, Majid Ali, Waleed Chaudhry, Victoria Ridger, Helen Philippou, Robert Ariens (United Kingdom)
- PO189-WED **PLATELET FACTOR XIII-A TRANSLOCATES FROM THE ACTIVATED PLATELET SURFACE ONTO ADJACENT FIBRIN FIBRES**  
Joanne L. Mitchell\*, Nicola Mutch (United Kingdom)
- PO190-WED **RESIDENT TISSUE MACROPHAGES ARE THE PROBABLE SOURCE OF PLASMA CLOTTING FACTOR XIII-A**  
Kingsley R. Simpson\*, Cora Beckers, Kathryn Griffin, Jane Brown, Paul Cordell, Kerrie Smith, Esther Cooke, Mark Kearney, Jean Vacher, Warren Alexander, Richard Pease, Peter Grant (United Kingdom)

### Coagulation factor VIII and IX - III

- PO191-WED **EFFECT OF STABLE GABARAP KNOCKOUT ON THE FVIII SECRETION**  
Heike Singer\*, Behnaz Pezeshkpoor, Nicole Nuesgen, Ursula Schreck, Judith Junen, Johannes Oldenburg, Osman El-Maarri (Germany)
- PO192-WED **DIMERIC ORGANIZATION OF MEMBRANE-BOUND FACTOR VIII ON LIPID NANOTUBES**  
Svetla Stoilova-Mcphie\*, Daniela Dalm, Jesus Galaz-Montoya, Kirill Grushin, Jaimy Miller (United States)
- PO193-WED **IMPACT OF INHIBITORS TO EPITOPES OF FACTOR VIII ON THROMBIN GENERATION**  
Amina Rafique\*, Candace Enockson, Mindy Simpson (United States)
- PO194-WED **MOLAR SPECIFIC ACTIVITY OF FACTOR VIII CONCENTRATES**  
Carsten Horn, Stephanie Steede, Stefan Schmidbauer, Hubert J. Metzner\* (Germany)
- PO195-WED **HIGH-PURITY, PLASMA-DERIVED, PASTEURISED FACTOR VIII CONCENTRATE IN THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A: UPDATE OF A LONG-TERM OBSERVATIONAL STUDY**  
Robert Klamroth\*, Claudia Niekrens, Susanne Holzhauer, Ronald Fischer, Christine Heller, Patrick Sommerer, Karin Kurnik (Germany)
- PO196-WED **EXPRESSION, PURIFICATION AND CHARACTERIZATION OF CODON OPTIMIZED COAGULATION FACTOR VIII**  
Svetlana Shestopal, James Kurasawa, Elena Karnaukhova, John McVey, Timothy Lee, Andrey G. Sarafanov\* (United States)

## SCIENTIFIC PROGRAM

- PO197-WED **WHOLE-EXOME SEQUENCING APPROACH TO STUDY INHIBITOR DEVELOPMENT IN ITALIAN SEVERE HAEMOPHILIA A PATIENTS.**  
Marcin M. Gorski\*, Kevin Blighe, Isabella Garagiola, Sabrina Seregny, Maria Elisa Mancuso, Elena Santagostino, Luca A. Lotta, Flora Peyvandi (Italy)
- PO198-WED **MINIGENE APPROACH TO CHARACTERIZE A NOVEL SPLICE SITE MUTATION IN HUMAN F8 GENE CAUSING SEVERE HAEMOPHILIA A**  
Yohann Jourdy, Christophe Nougier\*, Dominique Bozon, Mathilde Fretigny, Claude Négrier, Christine Vinciguerra (France)
- PO199-WED **CLEARANCE RECEPTOR INTERACTION AND HALF-LIFE PROLONGATION OF PEGYLATED RECOMBINANT FULL-LENGTH FACTOR VIII IN MICE**  
Gerald Schrenk, Alexandra Schiviz, Sabine Knappe, Alexander Bauer, Herbert Gritsch, Manfred Billwein, Schaedler Michaela, Peter Turecek, Michael Dockal\*, Marietta Putz, Werner Hoellriegel, Friedrich Scheifflinger (Austria)
- PO200-WED **SAFETY OF PEG, PEG CONJUGATES AND PEGYLATED RECOMBINANT HUMAN FULL-LENGTH COAGULATION FACTOR VIII (BAX 855)**  
Reinhard Stidl, Sabine Fuchs, Mary Bossard, Juergen Siekmann, Marietta Putz\*, Peter Turecek (Austria)
- PO201-WED **FUNCTIONAL CHARACTERIZATION OF DIFFERENT FACTOR VIII MOLECULES WITH FOCUS ON PHOSPHOLIPID AND PLATELET BINDING**  
Susanne Till, Sylvia Tippl, Michael Palige, Ernst Boehm, Gerald Schrenk, Jadranka Koehn, Herbert Gritsch, Sabine Knappe, Rudolf Hartmann, Friedrich Scheifflinger, Michael Dockal\* (Austria)
- PO202-WED **MOLECULAR SIGNATURE OF LSECS: A F8 SECRETING ENDOTHELIAL CELLS**  
Osman El-Maarri\*, Ahmer Jamil, Nicole Nuesgen, Amit Sharma, Behnaz Pezeshkpoor, Andrea Hofmann, Per Hoffmann, Stefanie Heilmann, Markus Noethen, Holger Froehlich, Johannes Oldenburg (Germany)
- PO203-WED **ANCESTRAL RECONSTRUCTION OF COAGULATION FACTOR VIII**  
Philip M. Zakas\*, Kristopher Knight, H. Trent Spencer, Eric Gaucher, Christopher Doering (United States)
- PO204-WED **A SYNONYMOUS MUTATION IN THE F8 GENE, C.120C>A; P.(L40=), MAY CAUSE MILD HAEMOPHILIA A**  
Hiroshi Inaba\*, Keiko Shinozawa, Kagehiro Amano, Katsuyuki Fukutake (Japan)
- PO205-WED **LONG-TERM PHENOTYPIC CORRECTION OF HAEMOPHILIA A MICE BY NON-VIRAL PIGGYBAC TRANSPOSON VECTOR**  
Hideto Matsui\*, Masahi Noda, Midori Shima, Akitsu Hotta, Mitsuhiro Sugimoto (Japan)
- PO206-WED **DISCORDANT IN VITRO AND IN VIVO ACTIVITY OF FACTOR VIII MUTANTS**  
Amine Bazaa\*, Vincent Muczynski, Cécile Ioubière, Amélie Harel, Tom Knudsen, Olivier D. Christophe, Cécile V. Denis, Peter J. Lenting (France)
- PO207-WED **BENEFICIAL EFFECT OF VWF IN FVIII RECOVERY OF DIFFERENT FVIII CONCENTRATES IN A MOUSE MODEL OF SEVERE HAEMOPHILIA WITH HIGH INHIBITOR TITERS**  
Maria Isabel Bravo\*, Montserrat Costa, Salvador Grancha, Juan Ignacio Jorquera (Spain)

## SCIENTIFIC PROGRAM

- PO208-WED **VARIATION IN FACTOR VIII MEASUREMENT AND CLASSIFICATION OF HAEMOPHILIA A SEVERITY IN THE ECAT EXTERNAL QUALITY ASSESSMENT PROGRAMME**  
Iris van Moort\*, Piet Meijer, Bert Verbruggen, Marjon H. Cnossen, Moniek P.M. de Maat (The Netherlands)
- PO209-WED **PRO-HEMOSTATIC ACTIVITY OF TFPI INHIBITION IN HEMOPHILIA IS WELL REGULATED BY TISSUE FACTOR AND FACTOR VIII**  
Rudolf Hartmann, Erwin Panholzer, Willibald Kammlander, Friedrich Scheiflinger, Michael Dockal\* (Austria)
- PO210-WED **RARE ALTERNATE PRESENTATIONS OF THE F8 INTRON 22 INVERSION MUTATION COMPLICATE DETECTION AND MAY LEAD TO MISDIAGNOSIS.**  
Jacky Cutler\*, Gillian McGaffin, Anne White, Mike Mitchell (United Kingdom)
- PO211-WED **CHARACTERIZATION OF IGA TYPE FVIII INHIBITOR IN AN ADULT PATIENT WITH CONGENITAL MODERATE HEMOPHILIA A SHOWING ABNORMALLY LARGE SUBCUTANEOUS HEMATOMA SIMILAR TO BLEEDING IN PATIENTS WITH ACQUIRED HEMOPHILIA**  
Atsuki Yamashita\*, Chiai Nagae, Mika Mori, Tomoko Ashikaga, Mieko Akita, Noriko Suzuki, Satoshi Yamazaki, Shigenobu Takayama, Masashi Taki (Japan)
- PO212-WED **RECOMBINANT FACTOR VIII INCREASES HEMOPHILIA A CLOT STRENGTH THROUGH ALTERATIONS IN CLOT STRUCTURE AND COMPOSITION**  
Lilley Leong\*, Irina Chernysh, Yifan Xu, Derek Sim, Chandrasekaran Nagaswami, Zelda de Lange, Sofia Kosolapova, Adam Cuker, Katalin Kausser, John Weisel (United States)
- PO213-WED **ADDING MULTIPLE POLYETHYLENE GLYCOL (PEG) MOIETIES FURTHER REDUCES PEG-FACTOR VIII CONJUGATE (PEG-FVIII) CLEARANCE BY HEPATOCYTES IN VITRO, BUT MINIMALLY IMPACTS PEG-FVIII CLEARANCE OR HALF-LIFE IN VIVO.**  
Eric Blasko\*, Elena Ho, James Wu, Derek Sim, Liang Tang, Lilley Leong, Katalin Kausser, Babu Subramanyam (United States)
- PO214-WED **DISTRIBUTION OF 14C-LABELED PEG (60 KDA) IN RATS**  
Andreas Baumann\*, Thomas Schwarz, Dietrich Seidel, Wolfram Steinke, Klaus Buehner (Germany)
- PO215-WED **SINGLE CENTER EXPERIENCE EVALUATING ACTIVITY OF N8-GP WITH ONE-STAGE CLOTTING ASSAY**  
Brigitte Cornelia Brand-Stauber\*, Karin Koch, Stefan Balabanov, Wan Hui Ong Clausen, Mirella Ezban (Switzerland)
- PO216-WED **INTERNATIONAL STUDY TO ASSESS THE PERFORMANCE OF IMMUNODEPLETED PLASMAS FOR DETERMINATION OF FACTORS VIII AND IX ACTIVITY**  
Chris Watson, Siegmund Gehrisch, Stefan Tiefenbacher, Alberto Tosetto\*, Maria Di Paolo, Dorothy Adcock (United Kingdom)
- PO217-WED **GENETIC DETERMINANTS FOR FACTOR VIII LEVELS: GENOME-WIDE LINKAGE AND ASSOCIATION ANALYSES FROM THE GAIT PROJECT**  
Sonia López\*, Andrey Ziyatdinov, Noelia Vilalta, Jordi Fontcuberta, Juan Carlos Souto, Jose Manuel Soria (Spain)

## SCIENTIFIC PROGRAM

- PO218-WED **QUANTITATION OF MISFOLDED PROTEINS AND QUANTITATION AND VISUALISATION OF NANOSIZE PROTEIN AGGREGATES IN RFVIII AND PDVIII CONCENTRATES**  
Martin Brodde\*, Martin Wiemann, Mayken Visser, Lisa Smits, Anja Müller, Beate Kehrel (Germany)
- PO219-WED **HEPAROSAN GLYCO-CONJUGATES OF FVIII AND FIX SHOWS PROLONGED CIRCULATING HALF-LIFE IN HAEMOPHILIA MOUSE MODELS**  
Carsten Behrens, Jens Buchardt, Mie Broberg, Ditte Karpf, Mette Loftager, Mette Jensen, Heidi Bagger, Matthías Thórolfsson, Maria Dainiak, Johan Karlsson, Ernst Hansen, Janus Krarup, Henrik Rahbek-Nielsen, Marianne Kjalke, Paul DeAngelis, F. Michael Haller, Jesper Haaning\* (Denmark)
- PO220-WED **SUPPRESSION OF INHIBITOR FORMATION IN HEMOPHILIA BY LAP+TREG INDUCED BY PLANT-BASED ORAL TOLERANCE**  
Xiaomei Wang\*, Jin Su, Alexandra Sherman, Henry Daniell, Roland Herzog (United States)
- PO221-WED **LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 EXPRESSION IN LIVER IS ASSOCIATED WITH PLASMA FACTOR VIII LEVELS**  
Luis F. Bittar\*, Adriana Duarte, Erich De Paula, Joyce Annichino-Bizzacchi (Brazil)
- PO222-WED **THE IMMUNOGENICITY OF PLATELETS CONTAINING FVIII IN HEMOPHILIA A MICE WITH OR WITHOUT PRE-EXISTING ANTI-FVIII IMMUNITY**  
Yingyu Chen, Jocelyn Schroeder, Xiaofeng Luo, Juan Chen, Christina Baumgartner, Robert Montgomery, Jianda Hu, Qizhen Shi\* (United States)
- PO223-WED **ELEVATED FACTOR VIII LEVELS AND ALL-CAUSE MORTALITY: RESULTS FROM THE MEGA FOLLOW-UP STUDY**  
Eng Soo Yap\*, Jasmijn Timp, Linda Flinterman, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne Cannegieter, Willem Lijfering (Singapore)
- PO224-WED **NOVEL MUTATIONS ASSOCIATED WITH A DISCREPANCY BETWEEN ONE-STAGE AND CHROMOGENIC FVIII ACTIVITY ASSAY**  
Dana Provaznikova\*, Katerina Houskova, Alena Radovska, Ingrid Hrachovinova (Czech Republic)
- PO225-WED **HEMOPHILIA A CAUSED BY RETROTRANSPOSITION OF LONG INTERSPERSED ELEMENT-1 (LINE-1) INTO THE FVIII GENE**  
Rima Dardik\*, Ariella Zivelin, Yariv Fruchtman, Tami Livnat, Einat Avishai, Shirley Azar-Avivi, Gili Kenet, Nurit Rosenberg (Israel)
- PO226-WED **COMPLEMENT MODULATES THE IMMUNE RESPONSE AGAINST THERAPEUTIC FACTOR VIII IN HEMOPHILIA A**  
Julie Rayès, Mathieu Ing\*, Ivan Peyron, Jordan Dimitrov, Sandrine Delignat, David Fritzingier, Carl-Wilhelm Vogel, Véronique Fremeaux-Bacchi, Srinivas Kaveri, Lubka Roumenina, Sébastien Lacroix-Desmazes (France)
- PO227-WED **SURFACE BOUND VON WILLEBRAND FACTOR MODULATES FACTOR VIII PEPTIDE PRESENTATION BY DENDRITIC CELLS**  
Robin B. Hartholt\*, Nicoletta Sorvillo, Magdalena Sedek, Anja ten Brinke, Carmen van der Zwaan, Floris van Alphen, Alexander Meijer, Jan Voorberg (The Netherlands)



## SCIENTIFIC PROGRAM

- PO228-WED **ROLE OF MEMBRANE-INTERACTING RESIDUES WITHIN FACTOR VIII C2 DOMAIN IN IMMUNOGENICITY OF THERAPEUTIC FACTOR VIII.**  
Bagirath Gangadharan\*, Mathieu Ing, Sandrine Delignaut, Ivan Peyron, Olivier Christophe, Srinivas Kaveri, Sebastien Lacroix-Desmazes (France)
- PO229-WED **FVIII ACTIVITY ASSAY VARIABILITY OF THE PEGYLATED FORM OF RFVIII ADVATE (BAX 855) IN CLINICAL HEMOSTASIS LABORATORIES: INTERIM RESULTS FROM A WORLD-WIDE FIELD STUDY.**  
Peter L. Turecek\*, Herbert Gritsch, Claudia Apostol, Stefan Romeder-Finger, Alexander Bauer, Divan Burger, Andrea Hunt (Austria)
- PO230-WED **SIGNIFICANCE OF ENDOGENOUS VON WILLEBRAND FACTOR IN DEVELOPMENT OF FACTOR VIII IMMUNE RESPONSES IN SEVERE EXPERIMENTAL HEMOPHILIA A**  
Bagirath Gangadharan\*, Mathieu Ing, Sandrine Delignaut, Olivier Christophe, Srinivas Kaveri, Sebastien Lacroix-Desmazes (France)
- PO231-WED **COMPARISON OF METHODS FOR THE DOSAGE OF FVIII IN A NEW HEMOPHILIA CENTER CARE**  
Emanuel Sueldo, Mirta Arias, Beatriz Erramouspe, Rodrigo Porsella, Patricia Do Nascimento, Gabriela Guerrero, Alejandra Baques\* (Argentina)
- PO232-WED **CRITICAL QUALITY ATTRIBUTES OF RECOMBINANT FVIII PRODUCTS – PROTEIN AGGREGATES AND SUBVISIBLE PARTICLES**  
Mantas Malisauskas\*, Christian Lubich, Thomas Prenninger, Peter Matthiessen, Peter Turecek, Friedrich Scheiflinger, Birgit Reipert (Austria)
- PO233-WED **FVIII OS/CS RATIOS FOR SELECT NOVEL RECOMBINANT FVIII REPLACEMENT PRODUCTS MEASURED IN FOUR FDA APPROVED FVIII ONE-STAGE CLOT ASSAY SYSTEMS AND ONE CHROMOGENIC ASSAY**  
Stefan Tiefenbacher\*, Mary Robinson, Erika Ross, Patrick Williams, Caroline Cogswell, Tyrelle Wham, Geoff Chow, Dorothy Adcock (United States)
- PO234-WED **PLASMA DERIVED FVIII (PDFVIII) CONCENTRATES ENHANCE SYNOVIAL CELL PROLIFERATION AND MIGRATION BY BINDING OF MISFOLDED PROTEINS TO ADAM15**  
Martin Brodde\*, Martin Wiemann, Robert Klamroth, Mayken Visser, Lisa Smits, Beate Kehrel (Germany)
- PO235-WED **ARE DIFFERENT PLASMA DERIVED FVIII CONCENTRATES EQUALLY EFFICIENT IN TERTIARY PROPHYLAXIS?**  
Jelena Bodrozic\*, Ivo Elezovic, Darko Antic, Predrag Miljic (Serbia)

### Fibrinogen/fibrin/D-dimer III

- PO236-WED **CHANGES OF COAGULATION PARAMETERS DURING HIGH ALTITUDE EXPEDITION.**  
Susana Der Parsehian\*, Miriam Pereiro, Alvaro Ortiz Nareto, Sebastian Donato, Cristina Artana (Argentina)

## SCIENTIFIC PROGRAM

- PO237-WED **RELATIONSHIP BETWEEN OXIDATIVE STRESS AND BLOOD COAGULATION IN PAEDIATRIC CHRONIC KIDNEY DISEASE (CKD)**  
Luci M. S. Dusse\*, Leticia Sousa, Rivia Silva, Maria Carvalho, Rita Duarte, Cristina Loures, Marcos Silva, Rejane Diniz, Sergio Pinheiro, Ana Silva (Brazil)
- PO238-WED **INFLUENCE OF OXIDATIVE STRESS ONTO FIBRIN NET FORMATION, ARCHITECTURE AND LYSIS**  
Jana Stikarova\*, Roman Kotlin, Jiri Suttnar, Tomas Riedel, Pavel Sacha, Pavel Majek, Leona Chrastinova, Alzbeta Hlavackova, Jan Dyr (Czech Republic)
- PO239-WED **CD44 LOCATED IN THE SURFACE OF SICKLE RED BLOOD CELL (SRBC) CORRELATES WITH REDUCED BLOOD HBF LEVELS AND INCREASED SRBC ADHESION TO FIBRIN**  
Luciana W. Serrão\*, Maria Clara Silva, Andrea Soares, Daniela Beghini, Russolina Zingali (Brazil)
- PO240-WED **FREE FATTY ACIDS MODULATE THROMBIN ACTIVITY ON FIBRINOGEN AND DESTABILISE FIBRIN CLOTS**  
Anna Tanka-Salamon\*, Erzsébet Komorowicz, László Szabó, Raymund Machovich, Kraszimir Kolev (Hungary)
- PO241-WED **TEMPORAL EVOLUTION OF FIBRIN NANOSTRUCTURE DURING CLOTTING AND FIBRINOLYSIS**  
Carhel Dassi\*, Emmanuelle Bigo, Landry Seyve, Raphaël Marlu, Benoît Polack, François Caton, Geneviève Contant (France)
- PO242-WED **FIBRINOGEN LEVELS DURING THE LAST STAGE OF PREGNANCY IN MEXICAN WOMEN**  
Jesus Hernandez\*, Hugo Espejo, Nidia Espinoza, Manuel Moreno, Jose Alvarado, Maria Gomez, Abraham Majluf (Mexico)
- PO243-WED **UNDERSTANDING FIBRIN PROTOFIBRILS AT THE MOLECULAR LEVEL: FORMATION AND FLEXIBILITY THROUGH A NEW COARSE-GRAINED PROTEIN MODELLING APPROACH**  
Albert Solernou\*, Sarah Harris, Oliver Harlen, Daniel Read, Kerrie Smith, Stephen Muench (United Kingdom)
- PO244-WED **IMPACT OF MATERNAL D-DIMER LEVELS IN NEWBORN OF PREECLAMPTIC MOTHERS**  
Melina Pinheiro, Sandra Armond, Maria das Graças Carvalho, Lara Godoi, Patrícia Alpoim, Karina Borges, Luci Dusse\* (Brazil)
- PO245-WED **FIBRIN CLOT STRUCTURE IS AFFECTED BY LEVELS OF PARTICULATE AIR POLLUTION EXPOSURE IN PATIENTS WITH VENOUS THROMBOSIS**  
Xiaoxi Pan\*, Yunyun Gong, Ida Martinelli, Pier Mannucci, Michael Routledge, Robert Ariens (United Kingdom)
- PO246-WED **INCREASED PLASMA CLOT PERMEABILITY AND SUSCEPTIBILITY TO LYSIS ARE ASSOCIATED WITH HEAVY MENSTRUAL BLEEDING OF UNKNOWN CAUSE**  
Piotr Szczepaniak, Michał Zabczyk, Anetta Undas\* (Poland)

## SCIENTIFIC PROGRAM

PO247-WED **SEVERE THROMBOSIS IN PREGNANCY IN PATIENT WITH CONGENITAL DYSFIBRINOGENEMIA**  
Vera Geierova\*, Ingrid Hrachovinova, Roman Kotlin, Peter Salaj (Czech Republic)

### Hemophilia – clinical III

PO248-WED **ARTERIOVENOUS FISTULAS FOR REPLACEMENT THERAPY IN ADULTS WITH HEMOPHILIA**  
Jerry Teitel\*, Michelle Sholzberg, Vernon Campbell, Rachel He, Georgina Floros (Canada)

PO249-WED **A PHASE III, OPEN-LABEL, MULTICENTRE STUDY TO EVALUATE EFFICACY AND SAFETY OF A PLASMA-DERIVED VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE IN PEDIATRIC SUBJECTS WITH HEMOPHILIA A (SWIFTLY-HA STUDY)**  
Maria Teresa Pompa, Genadi Iosava, Claudia Khayat, Irina Romashevskaya, Olga Aleinikova, Oleksandra Stasyshyn, Liudmyla Vashchenko, Marta Julia Lopez, Wilfried Seifert\* (Germany)

PO250-WED **JOINT LAVAGE FOLLOWED BY VISCOSUPPLEMENTATION AND TRIAN-CINOLONE IN PATIENTS WITH SEVERE HEMOPHILIC ARTHROPATHY. SUBJECTIVE PAIN, FUNCTION AND QUALITY OF LIFE RESULTS.**  
Thiago Pasqualin\*, Marcia Rezende, Gustavo Campos, Thiago Rosa, Renato Frucchi, Alexandre Pailo, Erica Okazaki, Paula Villaça (Brazil)

PO251-WED **INTERIM RESULTS FROM A LARGE MULTINATIONAL EXTENSION TRIAL (GUARDIAN TM2) USING TUROCTOCOG ALFA FOR PROPHYLAXIS AND TREATMENT OF BLEEDING IN PATIENTS WITH SEVERE HAEMOPHILIA A**  
Steven Lentz\*, Christine Kempton, Dragana Janic, Aleksandar Savic, Monica Cerqueira, Margaret Ozelo, Michael Recht, Johannes Oldenburg, Andreas Tiede, Takashi Suzuki, Irina Matytsina, Niels Zeuthen, Elena Santagostino (United States)

PO252-WED **VALIDATION OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS BLEEDING ASSESSMENT TOOL (ISTH-BAT) IN HEMOPHILIA CARRIERS**  
Paula James\*, Christoph Bidlingmaier, Maria Eva Mingot-Castellano, Meera Chitlur, Patrick Fogarty, Julie Grabell, Prasad Mathew, Johnny Mahlangu (Canada)

PO253-WED **EFFICACY AND SAFETY OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP) IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B UNDERGOING A SURGICAL PROCEDURE**  
Claude Négrier\*, Lynda Mae Lepatan, Aaron Lubetsky, Faraizah Abd Karim, Brigitte Pan-Petes, Annarita Tagliaferri, Carmen Altisent, Julie Curtin, Christoph Male, Anne Lienhart, Denise Wolko, Christine Voigt, Iris Jacobs, Elena Santagostino (France)

PO254-WED **COMPARISON OF ANNUAL BLEEDING RATES IN SUBJECTS WITH SEVERE HEMOPHILIA A RECEIVING PROPHYLAXIS TREATMENT WITH RECOMBINANT FACTOR VIII OR PEGYLATED RECOMBINANT FACTOR VIII (BAX 855).**  
Werner Engl, Birgitt Abbuehl\*, Martin Wolfsegger, Borislava Pavlova, Bruce Ewenstein (Austria)

## SCIENTIFIC PROGRAM

PO255-WED **LOW ANNUALIZED BLEEDING RATES (ABRS) WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIII FC) ACROSS DEMOGRAPHIC SUBGROUPS OF PREVIOUSLY TREATED PEDIATRIC SUBJECTS WITH SEVERE HEMOPHILIA A**  
Guy Young\*, Roshni Kulkarni, Margaret Ragni, Simon Brown, Irena Woznica-Karczmarz, John Puetz, Rien Tamminga, Giulia Gambino, Glenn Pierce, Geoffrey Allen (United States)

PO256-WED **CHILDREN WITH HEMOPHILIA IN THE US – THE HEMOPHILIA ASSOCIATED CAREGIVER BURDEN SCALE (HEMOCABTM)**  
Sylvia von Mackensen\*, Tami Wisniewski, John Urgo, Lisa Boggio (Germany)

PO257-WED **DEVELOPING A MEASURE OF HEMOPHILIA CAREGIVER IMPACT**  
Carolyn Schwartz\*, Adi Eldar-Lissai (United States)

PO258-WED **VENEPUNCTURE VERSUS LABORATORY SAMPLE TIMING DISCREPANCIES: IMPLICATIONS FOR PHARMACOKINETIC PREDICTION OF PROPHYLAXIS DOSING IN SEVERE HEMOPHILIA A: UK-PK PILOT STUDY**  
Paul Batty\*, Mike Spencer Chapman, Sean Platton, Daniel Hart (United Kingdom)

PO259-WED **A NOVEL MISSENSE MUTATION, P.PHE360CYS, IN F9 GENE RESULTS IN HEMOPHILIA B IN FEMALE PATIENT**  
Ziqiang Yu\*, Chunchen Yang, Wei Zhang, Lijuan Cao, Xia Bai, Changgeng Ruan (China)

PO260-WED **INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA A: A FOLLOW-UP COHORT STUDY.**  
Maria Elisa Mancuso\*, H. Marijke van den Berg (Italy)

PO261-WED **SATISFACTION PATIENT SURVEY: A KEY TOOL TO IMPROVE PATIENT DELIVERY OF CARE AT A PORTUGUESE COMPREHENSIVE HEMOPHILIA CENTRE**  
Manuela Carvalho\*, João Martins, Beatriz Delgado, Susana Fernandes, Manuela Reis, Fernando Araújo (Portugal)

PO262-WED **NUMERICAL MODELS OF THROMBIN GENERATION APPLICABLE TO HEMOPHILIA**  
Pierre Chelle, Michel Cournil, Michèle Piot, Aurélie Montmartin, Emilie Presles, Claire Morin, Stéphane Avril, Patrick Mismetti, Bernard Tardy, Brigitte Tardy\* (France)

PO263-WED **THE EFFECT OF NORDIC WALKING ON JOINT STATUS, QUALITY OF LIFE, PHYSICAL ABILITY, EXERCISE CAPACITY AND PAIN IN OLDER MEN WITH HEMOPHILIA**  
Maryem Salim\*, Yvonne Spåls-Abrahamsson, Erik Berntorp, Elistabeth Brodin, Eva Zetterberg (Sweden)

PO264-WED **PERIOPERATIVE MANAGEMENT AND OUTCOME OF URGENT APPENDECTOMY IN A PATIENT WITH SEVERE HEMOPHILIA**  
Murat Söker, Hikmet Zeytun, Sevda Söker, Cahit Sahin (Turkey)

PO265-WED **PREVALENCE, SEVERITY AND CORRELATION FACTORS OF HEMOPHILIC ARTHROPATHY AMONG TAIWANESE HEMOPHILIACS**  
Chia-Yau Chang\*, Tsung-Ying Li, Shin-Nan Cheng, Ru-Yu Pan, Hung-Jung Wang, Shi-Yi Lin, Yeu-Chin Chen (Taiwan)

## SCIENTIFIC PROGRAM

- PO266-WED **SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-05280602 (RECOMBINANT FVIIA VARIANT): PRELIMINARY RESULTS FROM A SINGLE ASCENDING DOSE PHASE I STUDY IN HEMOPHILIA A AND B SUBJECTS**  
Ralph Gruppo\*, Daniel Malan, Judit Kapocsi, Charles Hay, Lisa Boggio, Pratima Chowdary, Giuseppe Tagariello, Annette von Drygalski, Fei Hua, Matthew Scaramozza, Harry Shi, Steven Arkin (United States)
- PO267-WED **SEVERE HEMOPHILIA A PATIENTS WHO DON'T BLEED WHILE ON PROPHYLAXIS: INVESTIGATION INTO POSSIBLE FACTORS INFLUENCING THE OUTCOME**  
Johannes Oldenburg\*, Elena Santagostino, Steven Lentz, Irina Matytsina, Niels Zeuthen (Germany)
- PO268-WED **QUALITY OF LIFE AMONG HAEMOPHILIA IN THAILAND**  
Yingyong Chinthammitr\*, Ploy Pengchata, Bundarika Suwannawiboon, Bunchoo Pongtanakul, Yupa Nakkinkun, Tasneem Binhama, Theera Ruchutrakool (Thailand)
- PO269-WED **IMPACT OF TRANSITION ON CLINICAL OUTCOMES IN HEMOPHILIA: 10 YEARS OF EXPERIENCE AT A MAJOR CANADIAN TREATMENT CENTER**  
Celina Woo\*, Erica Crilly, Deborah Gue, Kam McIntosh, Lawren De Marchi, Sandra Squire, Alexia Silva, Ming Yang, John Wu, Shannon Jackson (Canada)
- PO270-WED **PRO- AND ANTICOAGULANT FACTORS BALANCE THROMBIN GENERATION INDUCED BY APCC**  
Katalin Varadi, Srilatha Tangada, Gerald Schrenk, Jennifer Doralt, Peter Turecek\* (Austria)
- PO271-WED **MUSCLE STRENGTH IN LOAD-BEARING JOINTS IN HAEMOPHILIC PATIENTS: COMPARATIVE VALUES WITH THE GENERAL POPULATION.**  
Santiago Bonanad-Boix\*, Sofia Perez-Alenda, Juan J. Carrasco, José Casaña-Granell, Yasser Alakhdar-Mohamara, Daniel Alonso-Roca, Felipe Querol (Spain)
- PO272-WED **PERSONALIZED PROPHYLAXIS WITH HUMAN-CL RHFVIII IN HEMOPHILIA A PATIENTS**  
Robert Klamroth\*, Toscho Lissitchkov, L Rusen, Olaf Walter, Sigurd Knaub, Johann Bichler, John Pasi, Andreas Tiede (Germany)
- PO273-WED **THROMBOPROPHYLAXIS FOR MAJOR ORTHOPEDIC SURGERY IN HEMOPHILIA: OUTCOMES OF AN EXPERT OPINION SURVEY ON CLINICAL PRACTICE AND APPLICABILITY OF ACCP GUIDELINES BY THE ADVANCE WORKING GROUP**  
Cédric Hermans\*, Ingrid Pabinger, Maria Elisa Mancuso, Claude Négrier, Pål André Holme (Belgium)
- PO274-WED **AGE AND TREATMENT RELATED INFLUENCES ON ANNUAL BLEED RATES (ABR) IN PATIENTS WITH HEMOPHILIA A (PWHA): OBSERVATIONAL STUDY DATA OF PATIENTS TREATED WITH RECOMBINANT FVIII FORMULATED WITH SUCROSE (RFVIII-FS) IN A GLOBAL SETTING**  
Gili Kenet\*, Arlette Ruiz-Sáez, Ming-Ching Shen, Stephan Rauchensteiner, Claudia Tueckmantel, Elke Kellermann, Jose Cabre Marquez, Steve Liang, Monika Brunn, Karin Achilles, Robert Klamroth (Israel)

## SCIENTIFIC PROGRAM

- PO275-WED **MOLECULAR GENETICS AND INHIBITOR DEVELOPMENT IN PATIENTS WITH HEMOPHILIA B**  
Ampaiwan Chuansumrit\*, Werasak Sasanakul, Nongnuch Sirachainan, Praguwan Kadegasem, Pakawan Wongwerawattanakoon (Thailand)
- PO276-WED **HAEMOPHILIA WITH INHIBITORS, UPDATE FROM ALGIERS EXPERIENCE, ABOUT ONE CENTER**  
Meriem Bensadok\*, Wafia Karima Chennoukh, Chahira Aboura, Mylade Aribi, Nadia Zidani, Samira Boutiba, Meriem Fadila Belhani, Salim Nekkal (Algeria)
- PO277-WED **PREVALENCE AND RISK FACTORS ASSOCIATED WITH HYPERTENSION IN HEMOPHILIA**  
Craig D. Seaman\*, Mariya Apostolova, Diane Comer, Jonathan Yabes, Margaret Ragni (United States)
- PO278-WED **A CASE OF ACUTE CEREBRAL INFARCTION IN A PATIENT WITH HEMOPHILIA B**  
Sunah Lee\*, Mi-Kyung Kim (Korea, Republic Of)
- PO279-WED **THE USE OF SECONDARY PROPHYLAXIS IN THE HAEMOPHILIA A PATIENTS**  
Gonul Aydogan\*, Hulya Sen, Zafer Salcioglu, Ferhan Akici, Deniz Tugcu, Ali Aycicek, Muge Gokce, Cengiz Bayram, Gonca Keskindemirci, Nuray Ayaz (Turkey)
- PO280-WED **COMPARATIVE STUDY OF THE PREVALENCE OF CLOTTING FACTOR DEFICIENCY IN CARRIERS OF HEMOPHILIA A AND B**  
Ana Boban\*, Nathalie Lannoy, Catherine Lambert, Cedric Hermans (Belgium)
- PO281-WED **PREVALENCE AND INCIDENCE OF HEMOPHILIA IN THE NORTH OF TUNISIA**  
Melliti Mariem\*, El Mahmoudi Hajer, Achour Mariem, Zahra Kaouther, Meddeb Balkis, Gouider Emna (Tunisia)
- PO282-WED **EFFECTS OF MODERATE-INTENSITY PHYSICAL EXERCISE ON PHARMACOKINETICS OF FACTOR VIII AND VON WILLEBRAND FACTOR IN YOUNG ADULTS WITH SEVERE HAEMOPHILIA A.**  
Nichan Zourikian\*, Clémence Merlen, Arnaud Bonnefoy, Jean St-Louis, Georges-Etienne Rivard (Canada)
- PO283-WED **PROSPECTIVE STUDY ON THE RISK, INCIDENCE AND MANAGEMENT OF CARDIOVASCULAR DISEASE IN OLDER PATIENTS WITH HAEMOPHILIA: THE ADVANCE STUDY**  
Robert Campbell Tait\*, Pål André Holme, Christophe Combescure, Philippe de Mollerose, Erik Berntop, Roger Schutgens, Robert Klamroth, Cedric Hermans, Stephan Rauchensteiner, Gerard Dolan (United Kingdom)
- PO284-WED **LONGEVITY OF NON-PATHOGENIC ANTIBODIES AGAINST HUMAN RECOMBINANT PROTEINS IN HEALTHY INDIVIDUALS**  
Frank Horling\*, Christoph Hofbauer, Peter Allacher, Susanne Till, Brigitt Abbuehl, Friedrich Scheiflinger, Birgit Reipert (Austria)

## SCIENTIFIC PROGRAM

- PO285-WED** **PLASMA PROTEIN ABUNDANCES OF PROTEINS INVOLVED IN COAGULATION AND BONE/CARTILAGE TURNOVER ARE ALTERED AFTER HAEMOPHILIC JOINT BLEED**  
Ileana Rodríguez León\*, Mari Enoksson, Lise Nikolic Nielsen, Kirstine Roepstorff, Mads Kjelgaard-Hansen, Eva Norling Olsen, Brian Vandahl (Denmark)
- PO286-WED** **IMMUNE TOLERANCE INDUCTION EXPERIENCE WITH ADVATE: FINAL RESULTS OF AN INTERNATIONAL PROSPECTIVE ITI REGISTRY (PAIR)**  
Amy Shapiro\*, Kate Khair, Jerry Teitell, Iliana Leony-Lasso, Katharina Steinitz, Alessandro Gringeri, Gerald Spotts (United States)
- PO287-WED** **FREQUENCY OF BLEEDING EVENTS IN PATIENTS WITH HEMOPHILIA ON PROPHYLAXIS BASED ON A COMMERCIAL INSURANCE CLAIMS DATABASE**  
Katharine Batt\*, Anshu Shrestha, Adi Eldar-Lissai, Yanyu Wu, Sangeeta Krishnan, Darius Lakdawalla (United States)
- PO288-WED** **IMPROVEMENT OF THE QUALITY OF HEALTH CARE FOR CHILDREN WITH SEVERE HAEMOPHILIA A USING PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES WITH RECOMBINANT FACTOR VIII**  
Sofijanka Glamocanin\*, Zorica Trajkova-Antevska, Biljana Coneska (Macedonia, The Former Yugoslav Republic Of)
- PO289-WED** **INHIBITOR DEVELOPMENT AS SWITCHING FULL-LENGTH RECOMBINANT FVIII TO B-DOMAIN DELETED RECOMBINANT FVIII IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A: TAIWAN'S EXPERIENCE**  
Chia-Yau Chang\*, Shu-Huey Chen, Geng-Chang Yeh, Chen-Hua Tsai, Jia-Ruey Tsai, Yen-Lin Liu (Taiwan)
- PO290-WED** **ULTRASONOGRAPHY OF JOINTS AND CORRELATION WITH FUNCTION IN HAEMOPHILIC ARTHROPATHY - RESULTS OF A CLINICAL PILOT TRIAL (HÄMARTHROSONOPILOT) AND POTENTIAL IMPORTANCE OF JOINT-ULTRASOUND FOR AN INDIVIDUALIZED PROPHYLAXIS**  
Michael Sigl-Kraetzig\*, Axel Seuser (Germany)
- PO291-WED** **COMPARING CARDIOVASCULAR DISEASE IN PATIENTS WITH HEMOPHILIA WITH DATA IN THE GENERAL POPULATION: METHODOLOGICAL CONSIDERATIONS**  
Karin Berger, Gordon Lowe, Dorothee Schopohl, Campbell Tait, Pål-Andre Holme, Stephan Rauchensteiner, Robert Klamroth\* (Germany)
- PO292-WED** **BLEEDING EVENTS IN CHINESE CHILDREN WITH SEVERE HEMOPHILIA A RECEIVING STANDARD PROPHYLAXIS VS ON-DEMAND TREATMENT WITH BAYER'S SUCROSE-FORMULATED RECOMBINANT FACTOR VIII**  
Yongqiang Zhao, Juan Xiao, Renchi Yang, Runhui Wu, Yu Hu, Horst Beckmann, Junde Wu, Denny Hou, Jing Sun\* (China)
- PO293-WED** **PROPHYLACTIC EFFICACY OF TWICE-WEEKLY VERSUS 3-TIMES-WEEKLY BAY 81-8973 IN SEVERE HEMOPHILIA A: RESULTS OF THE LEOPOLD I AND II CLINICAL TRIALS**  
Johnny N. Mahlangu\*, Kaan Kavakli, L. Hvitfeldt Poulsen, Despina Tseneklidou-Stoeter, Horst Beckmann, Monika Maas Enriquez, Luminita Rusen (South Africa)

## SCIENTIFIC PROGRAM

- PO294-WED** **EXPANDING COMMUNICATIONS ON HEMOPHILIA A OUTCOMES (ECHO) STUDY: A LONGITUDINAL, OBSERVATIONAL DISEASE REGISTRY OF PATIENT-REPORTED AND CLINICAL OUTCOMES IN PATIENTS WITH HEMOPHILIA A**  
Charles R. M. Hay\*, Nikki Church, Shurjeel Choudhri, Craig Kessler (United Kingdom)
- PO295-WED** **EFFECTIVE RAYOACTIVE SYNOVECTOMY IN HEMOPHILIA WITH INHIBITORS**  
Bulent Zulfikar\*, Cuneyt Turkmen, Onder Kilicoglu, Basak Koc, Ata Can Atalar, Fikret Bezglal, Hanife Ozcan (Turkey, Turkey)
- PO296-WED** **IMPROVING HEMOPHILIA CARE IN BRAZIL: AVAILABILITY OF FACTOR CONCENTRATES AND BEYOND – RESULTS OF LEVANTH SURVEY**  
Samuel S. Medin\*, Andrea Sambo, Margareth Ozelo (Brazil)
- PO297-WED** **PREVALENCE, DESCRIPTION, AND MANAGEMENT OF PAIN IN ADULT PEOPLE WITH HEMOPHILIA (PWH): INITIAL LESSONS FROM THE PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ) STUDY**  
Tyler Buckner\*, Michelle Witkop, Michael Wang, Michael Recht, Katharine Batt, David Cooper, Christine Kempton (United States)
- PO298-WED** **IMPACT OF PAIN AND FUNCTIONAL IMPAIRMENT IN US ADULT PEOPLE WITH HEMOPHILIA (PWH): RESULTS FROM RETEST POPULATION IN THE PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ) STUDY**  
Christine Kempton\*, Michael Recht, Anne Neff, Michael Wang, Tyler Buckner, Diane Nugent, Doris Quon, Michelle Witkop, Lisa Boggio, David Cooper (United States)
- PO299-WED** **A RETROSPECTIVE STUDY OF THE CURRENT TREATMENT PRACTICE OF HAEMOPHILIA A AND B IN THE UNITED KINGDOM**  
Charles Hay, Gerry Dolan, Erik Berntorp, Christopher Ludlam, Karl-Johan Myrén, Lisa Osterling Koskinen, Stefan Lethagen\* (Sweden, Denmark)
- PO300-WED** **IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH SEVERE HEMOPHILIA A WITH INHIBITORS IN KOREA**  
Young Shil Park\*, Hwi-Joong Yoon (Korea, Republic Of)
- PO301-WED** **THE USAGE OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) DURING MAJOR AND MINOR SURGERIES IN SEVERE HEMOPHILIA PATIENTS WITH INHIBITOR**  
Bulent A. Antmen\*, Ilgen Sasmaz, Barbaros Karagun, Goksel Leblebisatan, Yurdanur Kilinc, Atilla Aridogan, Iffet Yazicioglu, Cenk Ozkan (Turkey)
- PO302-WED** **INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY, ADANA, TURKEY**  
Ilgen Sasmaz\*, Bulent Antmen, Barbaros Karagun, Goksel Leblebisatan, Dervis Yilmaz, Yurdanur Kilinc (Turkey)
- PO303-WED** **A PROSPECTIVE ITALIAN SURVEY ON INTRACRANIAL HEMORRHAGE IN HEMOPHILIA PATIENTS: CHANGES OVER TIME**  
Ezio Zanon\*, Marta Milan, Chiara Biasoli, Isabella Cantori, Giancarlo Castaman, Antonio Coppola, Matteo Luciani, Claudio Molinari, Piercarla Schinco, Gianluca Sottillotta, Annarita Tagliaferri, Antonino Cannavò, Elena Santagostino (Italy)

## SCIENTIFIC PROGRAM

- PO304-WED **COMBINATION OF BIOMARKERS FOR ASSESSMENT OF HEMOPHILIC ARTHROPATHY**  
Cheng Shin-Nan, Luke Yang, Tsung-Yi Li, Pan Ru-Yu, Hu Shu-Hsia, Yeu-Chin Chen\* (Taiwan)
- PO305-WED **HOW HAEMOPHILIA PATIENTS IN GERMANY PERCEIVE THEIR ACTUAL TREATMENT AND WHAT THEY EXPECT FOR FUTURE TREATMENT WITH NEW LONG-LASTING PRODUCTS**  
Sylvia Von Mackensen\*, Heinrich Struck, Werner Kalnins (Georgia)
- PO306-WED **CHALLENGES IN THE DIAGNOSIS AND MANAGEMENT OF HAEMOPHILIA**  
Sitalakshmi Subramanian, Cecil Ross, Shanthala Devi, Vanamala Alwar (India)
- PO307-WED **FACTOR XI DEFICIENCY AND BLEEDING RISK ON ANTICOAGULATION**  
John Chapin\*, Kelsey Klute, Paul Christos, Maria DeSancho (United States)
- PO308-WED **THE EFFECT OF ADVANCING AGE ON THE RESPONSE TO DDAVP IN RE-EXPOSED NONSEVERE HEMOPHILIA A PATIENTS**  
Janneke I. Loomans\*, Alice Van Velzen, Marjolein Peters, Christoph Königs, Anne Mäkipernaa, Helena Platokouki, Evelien Mauser-Bunschoten, Christoph Male, Britta Laros-van Gorkom, Saturnino Haya, Marjon Cnossen, Johanna Van der Bom, Karin Fijnvandraat (The Netherlands)
- PO309-WED **FOLLOW UP OF FACTOR VIII INHIBITOR KINETICS IN HEMOPHILIA PATIENTS**  
Jaewoo Song\*, Ji Houn Yoon, Jung Woo Han, Rojin Park, Yun A Jo, Jongha Yoo, Moonhee Oh (Korea, Republic Of)
- PO310-WED **THE POTENTIAL CORRELATION BETWEEN PATIENT-REPORTED SYMPTOMS AND THE NEED FOR ADDITIONAL HEMOSTATIC MEDICATION; A POST HOC EXPLORATORY ANALYSIS BASED ON RFVIIA DATA FROM THE ADEPTM2 TRIAL**  
Steven Lentz\*, Savita Rangarajan, Faraizah Karim, Philip Andersen, Per Arkhammar, Gabriela Rosu, Johnny Mahlangu (United States)

### Heparin-induced thrombocytopenia (HIT) II

- PO311-WED **EFFICACY ASSESSMENT OF FONDAPARINUX TREATMENT OF PATIENTS WITH HEPARIN INDUCED THROMBOCYTOPENIA (HIT)**  
Franciszek Grzegorzczak\*, Paweł Kuca, Małgorzata Dybowska, Janusz Burakowski, Cezary Czajka, Barbara Kazanecka, Agnieszka Wróbel, Witold Tomkowski (Poland)
- PO312-WED **SAFETY AND EFFICACY OF STARTING WARFARIN AFTER TWO CONSECUTIVE PLATELET RISES IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA**  
Lydia D. Chen\*, William Dager, A. Josh Roberts (United States)
- PO313-WED **RAPID FUNCTIONAL HEPARIN INDUCED THROMBOCYTOPENIA (HIT) ASSAY USING MULTIPLATE: COMPARISON WITH HEPARIN INDUCED PLATELET ACTIVATION (HIPA) ASSAY AND ACL ACUSTAR ANTIGEN ASSAY**  
Kevin Horner\*, Joost Van Veen, Rhona Maclean, Steve Kitchen (United Kingdom)

## SCIENTIFIC PROGRAM

- PO314-WED **IMMUNOLOGICAL ASSAYS FOR DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Michael Nagler\*, Lucas Bachmann, Hugo ten Cate, Arina ten Cate (Switzerland, Netherlands)
- PO315-WED **IMPACT OF OVERDIAGNOSIS OF HIT IN A LARGE COMMUNITY HOSPITAL**  
Jacqueline King, Davide Ventura, Jason Hodge, Austin Satterthwaite, John Francis\* (United States)
- PO316-WED **NEW PLATELET FUNCTIONAL METHOD TO IDENTIFY PATHOGENIC ANTIBODIES IN HIT PATIENTS**  
Maria Luisa Guarino, Isabella Massimi, Flavia Temperilli, Alessandra Zicari, Fabio M. Pulcinelli\* (Italy)
- PO317-WED **LOW MOLECULAR WEIGHT HEPARIN TREATMENT FOR SUPERFICIAL VEIN THROMBOSIS AND THE RISK OF HEPARIN-INDUCED THROMBOCYTOPENIA**  
Michelangelo Sartori\*, Ludovica Migliaccio, Elisabetta Favaretto, Cristina Legnani, Lelia Valdrè, Giuliana Guazzaloca, Gualtiero Palareti, Benilde Cosmi (Italy)
- PO318-WED **AUDIT OF TEST RESULTS FOLLOWING THE INTRODUCTION OF A TESTING ALGORITHM FOR HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN A REFERRAL LABORATORY**  
Mary B. Byrne\*, Fiona Holden, Caroline Gannon, Barry White, James O'Donnell, Kevin Ryan, Niamh O'Connell (Ireland)

### Immune thrombocytopenia (ITP) III

- PO319-WED **CLINICAL SIGNIFICANCE OF ANTINUCLEAR ANTIBODY TEST AND RISK FACTOR PREDICTORS OF CHILDHOOD CHRONIC IMMUNE THROMBOCYTOPENIA**  
Bunchoo Pongtanakul\*, Suchawadee Horsuwan (Thailand)
- PO320-WED **CLINICAL SIGNIFICANCE OF IPF% OR RP% MEASUREMENT IN DISTINGUISHING PRIMARY IMMUNE THROMBOCYTOPENIA FROM APLASTIC THROMBOCYTOPENIC DISORDERS**  
Mikiko Sakuragi, Satoru Hayashi, Miho Maruyama, Osamu Kabutomori, Tomoko Kiyokawa, Keisuke Nagamine, Hisashi Kato, Hirokazu Kashiwagi, Yuzuru Kanakura, Yoshiaki Tomiyama\* (Japan)
- PO321-WED **INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF CHILDREN IMMUNE THROMBOCYTOPENIA META ANALYSIS OF EFFICACY AND SAFETY IN CHINA**  
Zhixu He\*, Tao Li, Liping Shu (China)
- PO322-WED **VARIATIONS OF MEAN PLATELET VOLUME OF IMMUNE THROMBOCYTOPENIA**  
Kenji Yokoyama\*, Tomoki Ueda (Japan)
- PO323-WED **THE POLYMORPHISMS OF TUMOR NECROSIS FACTOR-INDUCED PROTEIN 3 GENE MAY CONTRIBUTE TO THE SUSCEPTIBILITY OF CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA IN CHINESE POPULATION**  
Jingyi Yang\*, Hu Zhou, Yongping Song, Renchi Yang (China)

## SCIENTIFIC PROGRAM

- PO324-WED **ANTI-PLATELET ANTIBODIES PRESENT IN BREAST MILK OF AN IMMUNE THROMBOCYTOPENIC MOTHER INCREASE AN APOPTOTIC MARKER IN NORMAL PLATELETS**  
Hagit Hauschner\* Uri Seligsohn, Nechama Sharon, Nurit Rosenberg (Israel)
- PO325-WED **CLINICAL OBSERVATION OF 10 CASES OF NEWLY DIAGNOSED ITP PATIENTS RECEIVING LOW-DOSE RITUXIMAB COMBINED WITH HIGH-DOSE DEXAMETHASONE**  
Ke Feng\* (China)
- PO326-WED **ANTI-GPIIIB/IIIa ANTIBODIES INDUCE IMMUNE THROMBOCYTOPENIA IN DISTINCT PATHWAYS: FC-DEPENDENT VS. FC-INDEPENDENT**  
Miao Xu\*, Naadiya Carrim, Guangheng Zhu, Pingguo Chen, Heyu Ni (Canada)
- PO327-WED **COMPARISON OF RELAPSE RATES OF IMMUNE THROMBOCYTOPENIA IN PATIENTS WHO RECEIVED INITIAL TREATMENT WITH STEROIDS VERSUS ANTI-RH(D) WITH OR WITHOUT STEROIDS**  
Mala Varma\* (United States)
- PO328-WED **PATHOGENESIS OF ANTI-INTEGRIN ALPHAIIb-MEDIATED FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA: ESTABLISHMENT OF NOVEL MURINE MODELS IN ALPHAIIb DEFICIENT AND HUMAN ALPHAIIB TRANSGENIC MICE**  
Brian Vadasz, Darko Zdravic\*, Pingguo Chen, Issaka Yougbare, Guangheng Zhu, Jonathan Frampton, Mortimer Poncz, John Freedman, Heyu Ni (Canada)

### Inflammation III

- PO329-WED **ASSOCIATION BETWEEN A PRO-INFLAMMATORY AXIS COMPRISED BY TSP1-TGFB-CTGF WITH THREE MICRO-RNAS, MIR-19A, 122, AND 133A IN THE PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY: A THERAPEUTIC NOVEL MODALITY**  
Raul Dela Cadena\*, Melissa Lester, Alina Shevchenko, John St. Angelo III, Philippe Alvarez DeLa Cadena, Fabiola Del Carpio-Cano, William Foster (United States)
- PO330-WED **FIBRINOGEN IN SEPSIS: CROSSTALK BETWEEN COAGULATION AND INFLAMMATION**  
Mirjam Bachler\*, Dietmar Fries, Christian Niederwanger, Caroline Linhart, Bettina Schenk (Austria)
- PO331-WED **INCREASED BIOMARKERS OF METABOLIC SYNDROME IN TOTAL JOINT ARTHROPLASTY PATIENTS**  
Andrew Banos\*, William Hopkinson, Harold Rees, Daneyal Syed, Schuharazad Abro, Debra Hoppensteadt, Omer Iqbal (United States)
- PO332-WED **END-STAGE RENAL DISEASE ASSOCIATED WITH METABOLIC SYNDROME: A STUDY OF BIOMARKERS RELEVANT TO CARDIOVASCULAR RISK**  
Vinod Bansal\*, Jennifer Saluk, Debra Hoppensteadt, Daneyal Syed, Schuharazad Abro, Nil Guler, Rakesh Wahi, Jawed Fareed (United States)

## SCIENTIFIC PROGRAM

- PO333-WED **BARETTIN: A NATURAL MARINE COMPOUND WITH POTENT ANTICOAGULANT AND ANTI-INFLAMMATORY PROPERTIES**  
Karianne F Lind, Jan Ole Olsen, Bjarne Østerud\* (Norway)
- PO334-WED **PROTECTION EFFECTS OF 4AAQB ISOLATED FROM ANTRODIA CINNAMOMEA ON LPS-INDUCED SEPSIS MODEL.**  
Chien-Hsin Chang, Ching-Hu Chung\* (Taiwan)
- PO335-WED **COAGULATION ACTIVITY INCREASES WITH DISEASE SEVERITY IN PATIENTS WITH ASTHMA**  
Marlous Sneebouer, Christof Majoor, Anne de Kievit, Joost Meijers, Rene Lutter, Tom van der Poll, Pieter-Willem Kamphuisen\*, Peter Sterk, Elisabeth Bel (The Netherlands)
- PO336-WED **ANTI-POLYPHOSPHATE ANTIBODIES AS ANTI-INFLAMMATORY/ANTICOAGULANT THERAPEUTICS**  
Richard J. Travers\*, Catherine Baker, Rachel Breitenfeld, Michael Drake, Xiaomei Zhang, Naomi Esmon, Charles Esmon, James Morrissey (United States)
- PO337-WED **CHLAMYDIA INFECTION IN VENOUS INSUFFICIENCY AND VENOUS ULCERS**  
Tamar Saralidze\*, Giorgi Kavtaradze, Bela Metreveli, Tinatin Shvelidze (Georgia)
- PO338-WED **EARLY MEASUREMENT OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND ACTIVATED TAFI (TAFIA) PREDICT OUTCOME IN PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK**  
Fabrizio Semeraro\*, Serge Masson, Pietro Caironi, Concetta Ammollo, Nicola Semeraro, Mauro Panigada, Caterina Fanizza, Gianni Tognoni, Luciano Gattinoni, Roberto Latini, Mario Colucci (Italy)
- PO339-WED **INFLAMMATORY CYTOKINE UP REGULATION MAY BE AN EARLY MARKER OF THROMBOSIS IN PATIENTS WITH IMPLANTED LVADS**  
Walter Jeske\*, Daneyal Syed, Erin Coglianese, Jeffrey Schwartz, Mamdouh Bakhos, Jeanine Walenga (United States)
- PO340-WED **ANNEXIN A1 CONCENTRATION IS INCREASED IN PATIENTS WITH PRE-ECLAMPSIA**  
Luiza Perucci, Fernanda Carneiro, Cláudia Ferreira, Frederico Soriani, Gustavo Martins, Kátia Lima, Flávia Guimarães, Antônio Teixeira, Luci Dusse\*, Karina Borges, Lirlândia Sousa (Brazil)
- PO342-WED **COMBINED HIGH LEVELS OF IL-18 AND IL-12 ARE ASSOCIATED WITH NEW CLINICAL EVENTS IN CAD PATIENTS.**  
Trine Baur Opstad\*, Harald Arnesen, Alf-Åge Pettersen, Ingebjørg Seljeflot (Norway)
- PO343-WED **DETERMINATION OF HEPARIN LEVEL IN BLOOD PLASMA – SENSITIVITY AND SPECIFICITY AS A MARKER FOR IDENTIFICATION OF SYSTEMIC MAST CELL ACTIVATION DISEASE**  
Hans-Joerg Hertfelder\*, Milda Vysniauskaite, Iris Haussels, Sandra Ohlenforst, Heiko Ruehl, Anne Selbitz, Susanne Unkrig, Peter Dreßen, Stefan Brettner, Juergen Homann, Franz-Josef Dumoulin, Johannes Oldenburg, Gerhard Molderings (Germany)

## SCIENTIFIC PROGRAM

PO344-WED **CYTOKINE-MEDIATED TRIGGERING OF THROMBIN GENERATION AND INFLAMMATION IN PATIENTS WITH STEVENS- JOHNSON SYNDROME/ TOXIC EPIDERMAL NECROLYSIS.**

Omer Iqbal\*, Daneyal Syed, Debra Hoppensteadt, Michael Mosier, Fareed Jawed, Charles Bouchard (United States)

### Management of bleeding II

PO345-WED **NONCLINICAL EVALUATION OF CATIONICALLY MODIFIED POLYSACCHARIDE ANTIDOTES FOR UNFRACTIONATED HEPARIN**

Bartłomiej Kalaska\*, Kamil Kaminski, Emilia Sokolowska, Monika Kujdowicz, Krzysztof Szczubialka, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki (Poland)

PO346-WED **SCREENING TOOL FOR BLEEDING DISORDERS IN WOMEN WITH HEAVY MENSTRUAL BLEEDING**

Sophie Wiewel-Verschueren\*, H. Marieke Knol, Y.I.G. Vladimir Tichelaar, André Mulder, Ellen Klinkert, Hanneke Kluin-Nelemans, Ate G. van der Zee, Karina Meijer (The Netherlands)

PO347-WED **THE IMPACT OF RED BLOOD CELLS ON HEMOSTASIS UNDER WHOLE BLOOD FLOW CONDITIONS**

Hiroaki Yaoi\*, Yasuaki Shida, Keiji Nogami, Tomoko Matsumoto, Kenich Ogiwara, Kazuya Hosokawa, Midori Shima (Japan)

PO348-WED **REVERSAL OF DABIGATRAN COULD BE ACHIEVED BY HEMODIALYSIS WITH OR WITHOUT OTHER HEMOSTATIC AGENTS**

Rachelle Li\*, Francis Chan, Keith Lau, Anthony Chan, Howard Chan (Canada)

PO349-WED **INCREASED COAGULATION AND FIBRINOLYTIC POTENTIAL OF SOLVENT-DETERGENT PLASMA: AN OBSERVATIONAL STUDY BETWEEN SD-TREATED POOLED PLASMA AND FRESH FROZEN QUARANTINE PLASMA**

Joyce van Beers, Lieve van Egmond, Rick Wetzels, Paul Verhezen, Erik Beckers, Rene van Oerle, Henri Spronk, Ron Straat, Yvonne Henskens\* (The Netherlands)

PO350-WED **PROSPECTIVE HEMOSTASIS REGISTRY OF PATIENTS IN CARDIAC SURGERY (HEROES-CS): EVALUATION OF THE INTRODUCTION OF A THROMBOELASTOGRAPHY BASED TRANSFUSION PROTOCOL IN CARDIAC SURGERY.**

Yvonne Henskens\*, Lieve van Egmond, Rick Wetzels, Maurice Theunissen, Wouter van Willigem, Geert-Jan Kuiper, Marcus Lancé (The Netherlands)

PO351-WED **SIDE EFFECTS OF AND RESPONSE TO DDAVP DO NOT CORRELATE WITH OVERWEIGHT IN PATIENTS WITH HEMOPHILIA A OR VON WILLEBRAND DISEASE**

Lisette M. Schutte\*, Sara C.M. Stooft, Marjon Cnossen, Frank W.G. Leebeek, Marieke J.H.A. Kruip (The Netherlands)

## SCIENTIFIC PROGRAM

PO352-WED **THROMBO(ELASTO)GRAPHIC EVALUATION OF THE INFLUENCE OF ANTICOAGULANT CONSTITUENTS ON THE PROHEMOSTATIC POTENTIAL OF PROTHROMBIN COMPLEX CONCENTRATE AND FACTOR IX CONCENTRATE**

Herm Jan M. Brinkman\*, Sanne Patiwaal, Shrijana Tripathi, Alexander Meijer, Joost Meijers (The Netherlands)

PO353-WED **PROTHROMBIN COMPLEX CONCENTRATE CAN INCREASE THROMBIN GENERATION IN THE PRESENCE OF LOW PLATELET NUMBER**

Colleen Hamid\*, John McVey, Anne Riddell, Keith Gomez, David Slatter, Pratima Chowdary (United Kingdom)

PO354-WED **EVALUATION OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE USE AND ITS ROLE IN THE REVERSAL OF NOVEL ORAL ANTICOAGULANTS**

Sarah Sienko\*, Michael Vasovski, Mona Ali (United States)

PO355-WED **THE COST-EFFECTIVENESS OF PD-APCC VERSUS RFXVIA IN PEDIATRIC PATIENTS WITH HAEMOPHILIA A AND INHIBITORS WITH MILD TO MODERATE JOINT BLEEDING IN MEXICO.**

Janet Soto\*, Lourdes González, Amalia Bravo, Adolfin Bergés, Teresa Pompa, Maricarmen Rodríguez, Silva Salvador, Rogelio Paredes, Mark Lamotte (Mexico)

PO356-WED **PLATELET ADP REACTIVITY AND BLEEDING RISK IN LONG-TERM DOUBLE ANTIPLATELET THERAPY PATIENTS WITH CORONARY ARTERY DISEASE**

Ekaterina Guskova\*, Andrey Komarov, Anatoly Dobrovolsky, Alexander Deev, Anatoly Samko, Elizaveta Panchenko (Russian Federation)

PO357-WED **THROMBIN ACTIVATED FIBRINOLYSIS INHIBITOR IS A SIGNIFICANT RISK FACTOR OF RECURRENT BLEEDINGS IN PATIENTS ON LONG-TERM WARFARIN THERAPY.**

Olga Moreva\*, Ekaterina Kropacheva, Oksana Zemlyanskaya, Elena Titaeva, Anatoliy Dobrovolskiy, Elizaveta Panchenko (Russian Federation)

PO358-WED **LOW DOSE FEIBA AND HEMODIALYSIS FOR MANAGING MAJOR BLEEDING ON DABIGATRAN**

William E. Dager\*, Aaron Roberts, Robert Gosselin, Richard White (United States)

PO359-WED **EFFECTIVE USE OF LOW DOSE ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES IN MANAGING MAJOR GI BLEEDING ON RIVAROXABAN**

William E. Dager\*, Aaron Roberts, Robert Gosselin, Richard White (United States)

### Management of bleeding III

PO360-WED **THE COST-EFFECTIVENESS OF PD-APCC VERSUS RFXVIA IN PEDIATRIC PATIENTS WITH HAEMOPHILIA TYPE A AND INHIBITORS WITH MILD TO MODERATE JOINT BLEEDING IN COLOMBIA**

Carlos A. Portilla\*, Andres Felipe Gonzalez, Javier Mauricio Cortés, Angel Castro, Sandra Patricia Sterling, Mafalda Ramos (Colombia)

## SCIENTIFIC PROGRAM

- PO361-WED **IMPROVING EDUCATION AND ADVOCACY FOR YOUNG WOMEN WITH MENORRHAGIA THROUGH USE OF INNOVATIVE TECHNOLOGY**  
Lakshmi Srivaths (United States)
- PO362-WED **REDUCED HEMOSTATIC CAPACITY AFTER CARDIOPULMONARY BYPASS**  
Lakshmi Srivaths\*, Shu He, Margareta Blombäck, Anders Jeppsson, Stefan Grass\* (Sweden)
- PO363-WED **A FIXED DOSE PROTOCOL FOR PROTHROMBIN COMPLEX CONCENTRATE DOES NOT LEAD TO QUICKER AND RELIABLE INR REDUCTION IN VITAMIN K ANTAGONIST RELATED INTRACRANIAL HEMORRHAGE**  
Rahat Abdoellakhan\*, Ishita Miah, Nakisa Khorsand, Korné Jellema, Karina Meijer (The Netherlands)
- PO364-WED **RISKS AND PREDICTORS OF ISCHEMIC/BLEEDING COMPLICATIONS IN CARDIAC PATIENTS UNDERGOING ELECTIVE NON-CARDIAC SURGERY – AN ANALYSIS OF THE PRAGUE-14 STUDY**  
Zuzana Motovska\*, Ladislav Dusek, Martina Ondrakova, Jiri Knot, Lukas Havluj, Robert Gurlich, Radek Bartoska, Valer Dzupa, Lukas Bittner, Petr Widimsky (Czech Republic)
- PO365-WED **THE PHARMACOKINETICS AND IMMUNE RESPONSE OF NEW CATIONIC DEXTRAN ANTIDOTES OF HEPARIN**  
Bartłomiej Kalaska\*, Kamil Kaminski, Dominik Czaplicki, Agnieszka Blazejczyk, Emilia Sokolowska, Monika Kujdowicz, Krystyna Stalinska, Krzysztof Szczubialka, Joanna Wietrzyk, Joanna Bereta, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki (Poland)
- PO366-WED **GENDER AND BLEEDING IN ATRIAL FIBRILLATION: A REAL-WORLD PROSPECTIVE COHORT STUDY**  
Jeroen Jaspers Focks\*, Jaap Seelig, Stijn van Vugt, Alexander Serné, Lucie Bloem-de Vries, Marjo Albers-Akkers, Freek Verheugt, Marc Brouwer (The Netherlands)
- PO367-WED **LOW-DOSE 4-FACTOR PCC FOR URGENT WARFARIN REVERSAL**  
Wesley Zemrak\*, Kathryn Smith, Stephen Rolfe, Timothy Hayes, Robert Trowbridge, David Seder (United States)
- PO368-WED **DEVELOPMENT AND VALIDATION OF AN ASSAY FOR INTRA-SURGICAL (OR PERI-OPERATIVE) MANAGEMENT OF BLEEDING**  
Elisa A. Ferrante\*, Kiev Blasier, Timothy Fischer, Francesco Viola (United States)
- PO369-WED **APTT SCREENING TEST IN THE COHORT OF ADULT PATIENTS UNDERGOING SURGICAL PROCEDURES: INSIGHTS FOR CLINICAL DAILY PRACTICE**  
Paolo Radossi, Lorena Zardo, Roberta Salviato, Silvia Chiappin, Federica Pierobon, Antonino Floridia, Gianpaolo Piaserico, Giuseppe Tagariello\* (Italy)
- PO370-WED **INTRAVENTRICULAR FIBRINOLYSIS RESTORES GLYMPHATIC CIRCULATION AFTER SUBARACHNOID HEMORRHAGE.**  
Maxime Gauberti\*, Thomas Gaberel, Clément Gakuba, Sara Martinez de Lizarrondo, Denis Vivien (France)
- PO371-WED **EVALUATING THE INTER-OBSERVER RELIABILITY OF POTENTIAL PREDICTOR VARIABLES TO DEVELOP A MORE ACCURATE PREDICTION TOOL FOR BLEEDING FOR PATIENTS ON ORAL ANTICOAGULANT**  
Parvaneh Fallah\*, Philip S. Wells, Melissa A Forgie (Canada)

## SCIENTIFIC PROGRAM

- PO372-WED **EFFECTS OF HEMOSTATIC GAUZE WITH SELF-PROPELLING THROMBIN PARTICLES ON SURVIVAL AND BLOOD LOSS IN A SWINE MODEL OF LETHAL ARTERIAL HEMORRHAGE**  
Alex St. John\*, James Baylis, Xu Wang, Esther Lim, Diana Chien, Susan Stern, Christian Kastrup, Nathan White (United States)
- PO373-WED **CLINICAL MANAGEMENT AND OUTCOME OF MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH VITAMIN K ANTAGONISTS: RESULTS FROM THE CLIMBING STUDY.**  
Laura Franco\*, Cecilia Becattini, Luca Masotti, Cinzia Nitti, Sergio Cattinelli, Roberto Cappelli, Giorgia Manina, Rodolfo Sbrojavacca, Fulvio Pomerio, Giancarlo Agnelli (Italy)
- PO374-WED **COMPARATIVE STUDIES ON A BRANDED RECOMBINANT FACTOR VIIA AND ITS GENERIC VERSION TO DEMONSTRATE EQUIVALENCE.**  
Nasir Sadeghi, Paul O'Malley\*, Massimo Iacobelli, Behrouz Vaziri, Daneyal Syed, Daniel Kahn, Debra Hoppensteadt, Nil Guler, Jawed Fareed (United States)
- PO375-WED **SELF-PROPELLING PARTICLES THAT TRANSPORT THROMBIN TO MAN-AGE HEMORRHAGE**  
James Baylis\*, Ju Hun Yeon, Max Thomson, Amir Kazerooni, Xu Wang, Alex St. John, Esther Lim, Diana Chien, Anna Lee, Jesse Zhang, James Piret, Lindsay Machan, Thomas Burke, Nathan White, Christian Kastrup (Canada)

### Megakaryocytes and thrombopoiesis

- PO376-WED **A MICROFLUIDIC CHAMBER FOR ELONGATING MEGAKARYOCYTES AND PRODUCING FUNCTIONAL PLATELETS**  
Antoine Blin, Anne Le Goff, Sonia Poirault-Chassac, Geraldine Sicot, Bruno Teste, Aurelie Magniez, Mathilde Reyssat, Dominique Baruch\* (France)
- PO377-WED **NOVEL ROLES OF THE DUAL-SPECIFICITY PHOSPHATASES 1 AND 6 IN MEGAKARYOPOIESIS AND PROPLATELET FORMATION**  
Alexandra Mazharian\*, Yotis Senis (United Kingdom)
- PO378-WED **FUNCTIONALLY ACTIVE TISSUE FACTOR IS EXPRESSED DURING MEGAKARYOCYTE MATURATION AND IS TRANSFERRED TO A SUBSET OF PLATELETS**  
Marta Brambilla, Laura Facchinetti, Paola Canzano, Laura Rossetti, Nicola Ferri, Alessandra Balduini, Vittorio Abbonante, Daniela Boselli, Luigi De Marco, Matteo Di Minno, Vincenzo Toschi, Alberto Corsini, Elena Tremoli, Marina Camera\* (Italy)
- PO379-WED **FUNCTIONAL ANALYSIS OF NBEAL2 IN HUMAN MEGAKARYOCYTES VIA COLOCALIZATION WITH SUBCELLULAR COMPARTMENTS**  
Richard W. Lo\*, Fred Pluthero, Ling Li, Walter Kahr (Canada)
- PO380-WED **CCL5 RELEASED FROM PLATELETS DRIVES INCREASED MEGAKARYOCYTE MATURATION AND PROPLATELET FORMATION**  
Kellie R. Machlus\*, Kelly Johnson, Rajesh Kulenthirarajan, Saleh El-Husayni, Joseph Italiano, Elisabeth Battinelli (United States)



## SCIENTIFIC PROGRAM

- PO381-WED **ANTI-GPIIB ANTIBODY INHIBITS PLATELET PRODUCTION FROM MEGAKARYOCYTES, BUT NOT MEGAKARYOCYTE MATURATION, ANALYZED IN A MURINE MODEL OF IMMUNE THROMBOCYTOPENIA.**  
Yukinori Kozuma\*, Hiroshi Kojima, Haruhiko Ninomiya (Japan)
- PO382-WED **PLANT FOOD CYANIDIN-3-O- $\beta$ -GLUCOSIDE PROMOTED MEGAKARYOPOIESIS BY REGULATION OF THE APOPTOTIC PATHWAY IN DAMI AND MEG-01 CELL LINES IN VITRO**  
Yan Yang\*, Jing Ren, Fuli Ya, Xiujuan Deng, Yanyan Wang, Wenhua Ling (China)
- PO383-WED **MEGAKARYOCYTES AND PLATELETS EXPRESS NICOTINIC ACETYLCHOLINE RECEPTORS BUT NICOTINE DOES NOT AFFECT MEGAKARYOPOIESIS OR PLATELET FUNCTION**  
Peter Bugert\*, Angelika Schedel, Kerstin Kaiser, Stefanie Uhlig, Florian Lorenz, Anip Sarin, Julian Starigk, Dennis Hassmann, Karen Bieback (Germany)
- PO384-WED **NOVEL REGULATORS OF MEGAKARYOPOIESIS BY RIBOSOME-PROTECTED RNA SEQUENCING**  
Sjoert B. G. Jansen\*, Romina Petersen, Myrto Kostadima, Maria Colzani, Mattia Frontini, Daniel Greene, Ilenia Simeoni, Ernest Turro, Jose Guerrero, Willem Ouwehand (United Kingdom)
- PO385-WED **GENE EXPRESSION PROFILE IN MEGAKARYOCYTES FROM TYPE 2 DIABETIC MICE EMPHASIZES INCREASE IN STEFINA EXPRESSION LEVELS**  
Anna Mezzapesa, Marjorie Poggi, Véronique Baccini, Patricia Ancel, Delphine Bastelica, Dorsaf Ghalloussi, Franck Peiretti, Jean-François Landrier, Matthias Canault\*, Marie-Christine Alessi (France)
- PO386-WED **IDENTIFICATION OF MEGAKARYOCYTIC PROGENITOR CELLS AMONG SUBCUTANEOUS PRE-ADIPOCYTES**  
Keiichi Tozawa\*, Yukako Ono-Uruga, Tadashi Horiuchi, Shinichiro Okamoto, Mitruru Murata, Yasuo Ikeda, Toshio Suda, Yumiko Matsubara (Japan)
- PO387-WED **PLATELET FACTOR XIII: THE RESCUE IN THE FACTOR FXIII DEFICIENCY.**  
Claudia Maria Radu\*, Cristiana Bulato, Elena Campello, Francesca Sartorello, Sabrina Gavasso, Mariangela Fadin, Paolo Simioni (Italy)

### Microparticles III

- PO388-WED **RAC1 REGULATES PLATELET MICROPARTICLES FORMATION AND RHEUMATOID ARTHRITIS DETERIORATION**  
Xue Chen\*, Kemin Wang, Xiaoping Du, Junling Liu (China)
- PO389-WED **ALTERATIONS IN THE EXTRACELLULAR VESICLES PROPERTIES INDICATE HYPERCOAGULABLE STATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**  
Inna Tzoran-Rosenthal\*, Annie Rebibo-Sabbah, Benjamin Brenner, Anat Aharon (Israel)

## SCIENTIFIC PROGRAM

- PO390-WED **EFFECT OF ACETYLSALICYLIC ACID ON THE CONCENTRATION OF MONOCYTE MICROPARTICLES COEXPRESSING TISSUE FACTOR IN PATIENTS WITH DIABETES MELLITUS TYPE 2**  
Marcelo Luide Goncalves\*, Lilian Goncalves, Fernanda Nunes, William Pedrosa, Maria Carvalho, Silvana Santos (Brazil)
- PO391-WED **LOW MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH PERSISTENT LUPUS ANTICOAGULANT AND A HISTORY OF THROMBOSIS**  
Lena Hell\*, Cihan Ay, Florian Posch, Silvia Koder, Johanna Gebhart, Ingrid Pabinger, Johannes Thaler (Austria)
- PO392-WED **MEAL INTAKE INCREASES CIRCULATING PROCOAGULANT MICROPARTICLES IN PATIENTS WITH DIABETES MELLITUS**  
Galia Spectre\*, Fariborz Mobarrez, Ragnhild Stålesen, Håkan Wallén, Claes-Göran Östenson, Paul Hjemdahl (Israel, Sweden)
- PO393-WED **ATRA MODULATES THE EMISSION OF EXTRACELLULAR VESICLES – IMPLICATIONS FOR INTERCELLULAR COMMUNICATION BETWEEN ACUTE PROMYELOCYTIC LEUKEMIA AND ENDOTHELIAL CELLS**  
Yi Fang\*, Delphine Garnier, Tae Hoon Lee, Esterina D'Asti, Laura Montermini, Brian Meehan, Janusz Rak (Canada, China)
- PO394-WED **CLINICAL SIGNIFICANCE OF CIRCULATING MICROPARTICLES IN PH-MYELOPROLIFERATIVE NEOPLASMS (MPN)**  
Han Yue\*, Wu Depei, Zhang Wenjuan, Qi Jiaqian, Zhao Shixiang, Wang Zhaoyue, Ruan Changgeng (China)
- PO395-WED **PLATELET MICROVESICLES IN VASCULAR INFLAMMATION**  
Tanja Vajen\*, Elena Vasina, Leon Schurgers, Christian Weber, Tilman Hackeng, Johan Heemskerk, Rory Koenen (The Netherlands)
- PO396-WED **IMPACT OF A FAT-TOLERANCE TEST ON PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES ASSESSED BY NANOPARTICLE TRACKING ANALYSIS**  
Cathrine Ramberg\*, Simin Jamaly, Nadezhda Latysheva, Erin Mathiesen Hald, Vladimir Tichelaar, John-Bjarne Hansen (Norway)
- PO397-WED **DYNAMICS OF INTERACTIONS AMONG PLATELET MICROPARTICLES, AND INFLAMMATORY, HEMOSTATIC AND OXIDATIVE BIOMARKERS IN ELDERLY INDIVIDUALS WITH AND WITHOUT COGNITIVE IMPAIRMENT.**  
Walter B. Cicarini\*, Gisele Gonçalves, Rita Duarte, Fernanda Campos, Lirlândia Souza, Mayara Faria, Olindo Filho, Maria Bicalho, Josianne Silveira, Maria Carvalho (Brazil)

### Non-vitamin K antagonist oral anticoagulants III

- PO398-WED **PERFORMANCE OF THREE FUNCTIONAL ASSAYS FOR THE MEASUREMENT OF DABIGATRAN PLASMA CONCENTRATIONS**  
Genevieve Freyburger\*, David Girard, Anne-Laure Vervaeke, Marine Rousset, Sylvie Labrousche (France)

## SCIENTIFIC PROGRAM

- PO399-WED **DIRECT ORAL ANTICOAGULANTS (DOAS) PLASMA LEVELS IN PATIENTS FOLLOWED BY A SINGLE CENTER**  
Rita Santoro\*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy)
- PO400-WED **DIRECT ORAL ANTICOAGULANTS AND SURGERY: OUR EXPERIENCE**  
Rita Santoro\*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy)
- PO401-WED **DILUTE RUSSELL VIPER VENOM TIME, A PARTIAL SOLUTION FOR SCREENING AND CONCENTRATION DETERMINATION OF DIRECT ORAL ANTICOAGULANTS**  
An K. Stroobants\*, Erik-Jan van den Dool, Marion Heckman, Michiel Coppens, Auguste Sturk (The Netherlands)
- PO402-WED **DRUG INTERACTIONS OF NEWER ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN, AND APIXABAN WITH ROUTINELY USED NONANTICOAGULANT/ANTIPLATELET DRUGS**  
Shermin Sayani\*, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed (United States)
- PO403-WED **UNEXPECTEDLY STABLE DABIGATRAN LEVELS IN ANTICOAGULATION CLINIC PATIENTS**  
David L. Mcglasson\*, George Fritsma (United States)
- PO404-WED **SUCCESSFUL USE OF HEMODIALYSIS IN A DABIGATRAN OVERDOSE**  
Ana Freixo, Alcina Ferreira, Luciana Gonçalves, Lurdes Santos, Manuela Carvalho, Antonio Sarmento, Fernando Araujo\* (Portugal)
- PO405-WED **CLINICAL IMPACT OF BLEEDING COMPLICATIONS WITH DIRECT ORAL ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ORTHOPAEDIC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS**  
Eleonora Tamborini Permunian\*, Walter Ageno, Francesco Dentali, Nicoletta Riva (Italy)
- PO406-WED **ROLE OF ANTICOAGULANT CLINICS IN THE MANAGEMENT OF PATIENTS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) AT CORK UNIVERSITY HOSPITAL (CUH)**  
Catriona O'leary\*, Virginia Silvari, Muhammad Khan, Susan O'Shea (Ireland)
- PO407-WED **ARE NON-VKA ORAL ANTICOAGULANTS (NOACS) PLASMA CONCENTRATIONS ASSOCIATED WITH THE RISK OF POSTOPERATIVE BLEEDING? PRELIMINARY RESULTS FROM THE REAL LIFE COHORT.**  
Pável E. Olivera\*, Verónica Pons, Vicente Cortina, Laura López-Andreoni, Gonzalo Artaza, Ana Marín, Francesc Bosch, Amparo Santamaría (Spain)
- PO408-WED **A NOVEL APPROACH TO EVALUATING ORAL ANTICOAGULANTS**  
Jeremy B. Chang\*, Ronald Realubit, Charles Karan, Jacob Rand, Nicholas Tatonetti (United States)
- PO409-WED **CLINICAL PRESENTATION AND EXTENT OF CLINICAL CARE OF CLINICALLY RELEVANT NON-MAJOR BLEEDING EVENTS WITH APIXABAN AND WARFARIN**  
Suzanne M. Bleker\*, Alexander Cohen, Harry Büller, Giancarlo Agnelli, Alexander Gallus, Gary Raskob, Jeffrey Weitz, Madelyn Curto, Melanie Sisson, Saskia Middeldorp (The Netherlands)

## SCIENTIFIC PROGRAM

- PO410-WED **INTERFERENCE STUDY OF DIRECT THROMBIN INHIBITORS AND ANTI-XA INHIBITORS ON HEMOSTASIS ASSAYS ON A COBAS T 411 SYSTEM**  
An K. Stroobants\*, Willem van Dam, Bianca Bakker, Erik-Jan van den Dool, Marion Heckman (The Netherlands)
- PO411-WED **NEUTRALIZATION OF BLEEDING INDUCED BY NON-VITAMIN K ORAL ANTICOAGULANTS BY PROTHROMBIN COMPLEX CONCENTRATES ALONE AND IN COMBINATION WITH ANTIFIBRINOLYTIC AGENTS**  
Walter Jeske\*, Vicki Escalante, Elizabeth Mcgeehan, Jeanine Walenga, Rakesh Wahi, Jawed Fareed, Mamdouh Bakhos (United States)
- PO412-WED **THE DILUTE FIIX PROTHROMBIN TIME (DFIIX-PT) FOR ASSESSMENT OF DABIGATRAN, RIVAROXABAN AND WARFARIN EFFECT IN PATIENT SAMPLES**  
Loic Letertre\*, Brynja Gudmundsdottir, Mika Skeppholm, Rickard Malmström, Charles Francis, Pall Öundurason (Iceland)
- PO413-WED **EVALUATION OF APPROPRIATENESS OF RIVAROXABAN PRESCRIPTION IN A TERTIARY CARE HOSPITAL IN SINGAPORE**  
Su Ching Tan\*, Yashi Saw, Nicholas Seah, Edgar Tay, Eng Soo Yap (Singapore)
- PO414-WED **IDARUCIZUMAB ANTAGONIZES DABIGATRAN-INDUCED ALTERATIONS ON PLATELET AND FIBRIN DEPOSITION IN AN IN VITRO THROMBOSIS MODEL WITH CIRCULATING HUMAN BLOOD**  
Eduardo Arellano-Rodrigo\*, Irene Lopez-Vilchez, Patricia Molina, Marcos Pino, Maribel Diaz-Ricart, Joanne van Ryn, Gines Escolar (Spain)
- PO415-WED **DIRECT FACTOR XA INHIBITORS PARADOXICALLY PROLONG THE HALF LIFE OF ACTIVE FACTOR XA IN PLASMA**  
Nabil Thalji\*, Sriram Krishnaswamy, Rodney Camire (United States)
- PO416-WED **DETECTING RELEVANT RIVAROXABAN OR DABIGATRAN LEVELS IN CLINICAL CARE BY ROUTINE COAGULATION TESTS OR THROMBOELASTOGRAPHY IN PATIENTS WITH ATRIAL FIBRILLATION.**  
Yvonne Henskens\*, Rene van Oerle, Rick Wetzels, Henri Spronk, Simon Schalla, Harry Crijns, Hugo ten Cate, Arina ten Cate-Hoek (The Netherlands)
- PO417-WED **CORRELATION OF CHROMOGENIC RIVAROXABAN ANTI-XA AND DABIGATRAN ANTI-IIA ACTIVITY WITH ROUTINE PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME**  
Jane Needham\*, Helen Lewis, Amanda McMullen, Tamara Everington, Savita Rangarajan (United Kingdom)
- PO418-WED **FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (4F-PCC) REVERSES BLEEDING ASSOCIATED WITH NEW ORAL ANTICOAGULANTS (NOAC) DABIGATRAN, RIVAROXABAN, EDOXABAN AND APIXABAN IN A RABBIT MODEL OF ACUTE BLEEDING**  
Eva Herzog\*, Franz Kaspereit, Wilfried Krege, Jochen Mueller-Cohrs, Baerbel Doerr, Peter Niebl, Dickneite Gerhard (Germany)

## SCIENTIFIC PROGRAM

- PO419-WED **STABILITY OF RENAL FUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION SWITCHED FROM WARFARIN TO TARGET-SPECIFIC ORAL ANTICOAGULANTS**  
Anum Minhas\*, Qingmei Jiang, Xiaokui Gu, Keely Haymart, Eva Kline-Rogers, Steve Almany, Jay Kozlowski, Gregory Krol, Scott Kaatz, James Froehlich, Geoffrey Barnes (United States)
- PO420-WED **BLEEDING ON NOVEL ORAL ANTICOAGULATION - OUR EXPERIENCE IN THE NORTHERN REGION, UNITED KINGDOM: PRESENTING FEATURES AND MANAGEMENT OF BLEEDING IN INDIVIDUALS TREATED WITH A NOVEL ORAL ANTICOAGULANT (NOAC):RESULTS OF AN OBSERVATIONAL COHORT STUDY**  
Shikha Chatterjee\*, Adil Iqbal, Janice Robertson, Andrew Mcgregor, Tina Biss (United Kingdom)
- PO421-WED **DRUG USE EVALUATION OF RIVAROXABAN IN TAN TOCK SENG HOSPITAL: A REVIEW OF UTILIZATION TRENDS AMONG ASIAN POPULATION**  
Lee Hwei Khien\*, Choo Theresa (Singapore)
- PO422-WED **IN VITRO ASSESSMENT OF DIRECT ORAL ANTICOAGULANT'S HEMORRHAGIC OR THROMBOTIC RISK BY FIBRIN CLOT NANOSTRUCTURE PROFILES**  
Carhel Dassi\*, Olivier Mathieu, Emmanuelle Bigo, Landry Seyve, Raphaël Marlu, Benoît Polack, François Caton, Geneviève Contant (France)
- PO423-WED **USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION IN REAL-LIFE: COMPARISON WITH PHASE III TRIALS**  
Maria Cristina Vedovati\*, Michela Giustozzi, Cecilia Becattini, Serenella Conti, Paolo Verdecchia, Federica Cianella, Emanuela Marchesini, Melina Verso, Esmeralda Filippucci, Giancarlo Agnelli (Italy)
- PO424-WED **COMPARISON IN ASSESSMENT OF THE KINETICS OF NOACS (DABIGATRAN, RIVAROXABAN, APIXABAN) BETWEEN TARGET SPECIFIC ASSAYS AND COMMON COAGULATION TESTS ASSAYS**  
Ramin Artang\*, Jorn Dalsgaard Nielsen, Claire Dunois, Cedric Amiral, Jean Amiral (United States)
- PO425-WED **ANTICOAGULATION PHARMACOKINETICS DURING DABIGATRAN THERAPY**  
Thomas Orfeo\*, Matthew Gissel, Kenneth Mann (United States)
- PO426-WED **EFFICACY OF PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME AS A GAUGE FOR SPECIFIC FACTOR INHIBITION**  
Catherine Keller\*, Jasmine Dennis, Dougald Monroe, Richard Tidwell, Frank Church (United States)
- PO427-WED **TARGET SPECIFIC ORAL ANTICOAGULANTS CAN CAUSE FALSE-POSITIVITY OF CONFIRMATORY LUPUS ANTICOAGULANT TESTING, ESPECIALLY IN DRVVT TESTING**  
Bo Hyun Kim\*, Seongsoo Jang, Mi Hyun Bae, Young-Uk Cho, Chan-Jeoung Park (Korea, Republic Of)

## SCIENTIFIC PROGRAM

### Platelet activation/adhesion/aggregation III

- PO428-WED **INTRAVITAL THREE-DIMENSIONAL VISUALIZATION AND QUANTIFICATION OF THROMBUS FORMATION BASED ON NON-LINEAR MICROSCOPE**  
Satoshi Nishimura\*, Asuka Sakata, Kinya Seo, Tsukasa Ohmori, Koji Eto (Japan)
- PO429-WED **C-CBL REGULATES GPVI-INDUCED THROMBOXANE A2 GENERATION INDEPENDENTLY OF THE SYK-PLC GAMMA 2 PATHWAY THROUGH Y737 PHOSPHORYLATION**  
Carol Dangelmaier\*, Soochung Kim, Bhanu Kanth Manne, Jianuo Jin, Mauro Torti, Wallace Langdon, Steven McKenzie, Archana Sanjay, James Daniel, Satya Kunapuli (United States)
- PO430-WED **THROMBIN-STIMULATED PHOSPHORYLATION OF DISABLED-2 REGULATES ITS INTERACTION WITH CIN85 DURING HUMAN PLATELET ACTIVATION**  
Hui-Ju Tsai\*, Hung-Pin Chiu, Chien-Sheng Chou, Man-Leng Kao, Yao-Wen Chang, Ju-Chien Cheng, Ching-Ping Tseng (Taiwan)
- PO431-WED **INTEGRIN ALPHA IIB BETA 3-MEDIATED C-SRC ACTIVATION: DIFFERENTIAL BINDING TO INACTIVE AND ACTIVE C-SRC**  
Joel Bennett\*, Lisa Span, Patrik Nygren, Yibing Wu, Hua Zhu, David Moore, Hong Chen, Heinrich Roder, William DeGrado (United States)
- PO432-WED **ORALLY ADMINISTERED TETRAHYDROBIOPTERIN (BH4) SUPPRESSES PLATELET AGGREGATION VIA INTRAPATELET PRODUCTION OF NITRIC OXIDE**  
Yui Suganuma\*, Taiki Kano, Kazuhisa Ikemoto, Chiho Ichinose, Takahide Nomura, Kazunao Kondo (Japan)
- PO433-WED **DROSPIRENONE ENHANCES GPIB-IX-V MEDIATED PLATELET ACTIVATION**  
Xuemei Fan, Xue Chen, Conghui Wang, Jing Dai, Yeling Lu, Yizhu Chen, Kemin Wang, Junling Liu, Junfeng Zhang, Xiaolin Wu\* (China)
- PO434-WED **A PARADOXICAL HAEMORRHAGIC STATE CAUSED BY DELETION OF THE SRC KINASE INHIBITOR CSK IS PARTIALLY RESCUED BY DELETION OF CD148**  
Jun Mori\*, Alexandra Mazharian, Luke Boothman, Silke Heising, Louise Tee, Alexander Tarakhovsky, Arthur Weiss, Steve Watson, Yotis Senis (United Kingdom)
- PO435-WED **EFFECT OF HOMOCYSTEINE AND FOLIC ACID IN CA2+ HOMEOSTASIS AND ROS PRODUCTION IN PLATELETS FROM BILE-DUCT LIGATION RATS.**  
Paola Romecin\*, Noemí Marín, David Iyu, Jose Millán, Faustino García, Clara Ortiz, Esther García, Joaquín García-Estañ (Spain)
- PO436-WED **COMPUTATIONAL MODEL OF MICROVASCULAR THROMBUS FORMATION: THE IMPACT OF DAMAGED AREA SIZE ON THROMBUS DYNAMICS**  
Dmitry Nechipurenko\*, Mikhail Pantelev, Fazoil Ataulkhanov (Russian Federation)

## SCIENTIFIC PROGRAM

- PO437-WED **SPHINGOSINE KINASE DEFICIENCY MODULATES PLATELET ACTIVATION**  
Benoit Decouture\*, Boubacar Mariko, Salomé Gazit, Patrice Thérond, Ludovic Couty, Blandine Dizier, Jessica Ransinan, Pascale Gaussem, Christilla Bachelot-Loza, Eric Camerer (France)
- PO438-WED **MOLECULAR CHARACTERIZATION OF GAP JUNCTION MEDIATED INTER-CELLULAR COMMUNICATION IN PLATELETS**  
Sakthivel Vaiyapuri, Alexander Bye, Michael Benn, Yumiko Sakurai, Wilbur Lam, Jonathan M. Gibbins\* (United Kingdom)
- PO439-WED **IMPAIRED PLATELET RESPONSES TO THROMBOXANE A2 AND THROMBIN IN MICE LACKING RECEPTOR-INTERACTING PROTEIN KINASE 3**  
Yiwen Zhang, Jian Zhang, Kesheng Dai\* (China)
- PO440-WED **LYSINE ACETYLTRANSFER SUPPORTS PLATELET FUNCTION**  
Joseph E. Aslan\*, Rachel Rigg, Sandra Baker, Jiaqing Pang, Larry David, Owen McCarty (United States)
- PO441-WED **GLYCOPROTEIN VI (GPVI) IS INTERNALIZED IN PLATELETS ACTIVATED BY SOLUBLE GPVI-SPECIFIC AGONISTS**  
Stephanie M. Jung\*, Elizabeth Gardiner, Robert Andrews, Hiroyuki Shimizu, Kenji Soejima, Tomohiro Nakagaki, Dominique Bihan, Richard Farndale, Masaaki Moroi (United Kingdom)
- PO442-WED **RELEASE OF EXTRA CELLULAR DNA CONTRIBUTES TO RENAL ISCHEMIA REPERFUSION INJURY THROUGH PLATELET ACTIVATION AND FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS**  
Marcel P. B. Jansen\*, Diba Emal, Gwen Teske, Sandrine Florquin, Joris Roelofs (The Netherlands)
- PO443-WED **TRACPODS: NOVEL INTEGRIN ALPHA(IIB) BETA(3) DEPENDENT PLATELET MEMBRANE ANCHORS PROMOTING PLATELET-ENDOTHELIAL INTERACTIONS AND THROMBO-INFLAMMATION**  
James Mcfadyen\*, Warwick Nesbitt, Imala Alwis, Zane Kaplan, Simone Schoenwaelder, Yuping Yuan, Shaun Jackson (Australia)
- PO444-WED **SPECIFIC REGULATION OF MOUSE PLATELET ADP SECRETION BY SARCO-ENDOPLASMIC RETICULUM CALCIUM ATPASE TYPE 3**  
Ziane Elaib\*, Frédéric Adam, Eliane Berrou, Régis Bobe, Marijke Bryckaert, Jean-Philippe Rosa (France)
- PO445-WED **CD32 ANTIBODIES PROTECT FCGR2A MICE FROM IGG MEDIATED HYPERSENSITIVITY REACTIONS AND THROMBOSIS**  
Ali Amirkhosravi\*, Todd Meyer, Liza Robles-Carrillo, Monica Davila, Meghan Brodie, Hina Desai, Mildred Rivera-Amaya, John Francis (United States)
- PO446-WED **CONVERGING ROLES OF PLATELETS AND CD32A IN IGG-MEDIATED HYPERSENSITIVITY REACTIONS**  
Ali Amirkhosravi\*, Todd Meyer, Monica Davila, Liza Robles-Carrillo, John Francis (United States)
- PO447-WED **PLANT FOOD CYANIDIN-3-GLUCOSIDE INDUCES HUMAN ACTIVATED PLATELET APOPTOSIS VIA BCL-2/BCL-XL INTRINSIC PATHWAY**  
Yan Yang\*, Jinju Tian, Liyi Chen, Like Zhang, Wenhua Ling (China)

## SCIENTIFIC PROGRAM

- PO448-WED **MODULATION OF ACTIN CYTOSKELETON ON SHEAR-DEPENDENT FIBRILLOGENESIS OF FIBRONECTIN**  
Huong T. T. Nguyen\*, Khon Huynh, Rudiger Scharf, Volker Stoldt (Germany)
- PO449-WED **JANUS KINASE 3 (JAK3) DEPENDENT SIGNALING IS CRITICAL TO CA2+-DEPENDENT PLATELET ACTIVATION AND THROMBUS FORMATION**  
Patrick Münzer\*, Britta Walker, Anna Fotinos, Roland Tegtmeier, Florian Lang, Meinrad Gawaz, Oliver Borst (Germany)
- PO450-WED **THE IDENTIFICATION AND CHARACTERIZATION OF CINNAMALDEHYDE ANALOGS, AS NOVEL SMALL MOLECULE INHIBITORS OF PLATELET-SURFACE ERP57**  
Lisa-Marie Holbrook\*, Elizabeth Brunt, Kayleigh Mitchell, Megan Ooms, Christine Galinski, Amanda Unsworth, Jonathan Gibbins, Daniel Kennedy (United Kingdom)
- PO451-WED **POLYPHOSPHATE DECAY IN SERUM IS CHEMICAL, NOT ENZYMATIC**  
Carleigh F. Hebbard\*, Stephanie Smith, Rachel Breitenfeld, Mark Klein, James Morrissey (United States)
- PO452-WED **EFFECT OF PAR-4 TETHERED-LIGAND PEPTIDE ANALOGS ON HUMAN PLATELET ACTIVATION**  
Iraklis Moschonas, Tahsin Kellici, Vasiliki Magafa, Thomas Mavromoustakos, Andreas Tzakos, Alexandros Tselepis\* (Greece)
- PO453-WED **PLATELET HSP70 REGULATES INTEGRIN ALPHAIIIBETA3 ACTIVATION AND PLATELET AGGREGATION**  
Rachel A. Rigg\*, Joseph Aslan, Jiaqing Pang, Marie Nowak, Owen McCarty (United States)
- PO454-WED **INFLUENCE OF PRO-MMP-9 ON PLATELET AGGREGATION AND ADHESION TO FIBRINOGEN**  
Aneta Wrzyszczyk\*, Joanna Urbaniak, Mieczyslaw Wozniak (Poland)
- PO455-WED **THE DEFECTIVE CD36 GENE MUTATIONS CAUSE A MOLECULAR EXPRESSION DIVERSITY ON PLATELETS AND MONOCYTES EVEN IN NON-DEFICIENT PHENOTYPE POPULATION**  
Yuya Masuda, Shogo Tamura\*, Kazuhiko Matsuno, Koji Hayasaka, Chikara Shimizu, Takanori Moriyama (Japan)
- PO456-WED **SHEAR-INDUCED FIBRILLAR-LIKE SUPRAMOLECULE OF PLASMA FIBRONECTIN: A NEW FORM OF FIBRONECTIN WITH ENHANCED ACTIVITY IN PLATELET ADHESION AND AGGREGATION**  
Khon Huynh\*, Huong Nguyen, Volker Stoldt, Thi-Hiep Nguyen, Rudiger Scharf (Viet Nam, Germany)
- PO457-WED **ELASTIN-DERIVED PEPTIDES REGULATE LEUKOCYTE-PLATELET AGGREGATES**  
Valérie Creuza, Charlotte Kawecki, Marie-Christine Mulpas, Laurent Duca, Sébastien Blaise, Béatrice Romier, Laurent Debelle, Philippe Nguyen\*, Nathalie Hézard, Pascal Maurice (France)

## SCIENTIFIC PROGRAM

- PO458-WED** **PLATELET DENSE GRANULE SECRETION DEFECTS MAY OBSCURE OUR UNDERSTANDING OF A-GRANULE SECRETION MECHANISMS: EVIDENCE FROM MUNC13-4-DEFICIENT PLATELETS**  
Matthew T. Harper\*, Marion van den Bosch, Ingeborg Hers, Alastair Poole (United Kingdom)
- PO459-WED** **THE INOSITOL(1,4,5)TRISPHOSPHATE RECEPTOR TYPE 2 IS IMPORTANT IN THROMBIN INDUCED PLATELET ACTIVATION AND IS REQUIRED FOR THROMBUS FORMATION IN VIVO.**  
Kalwant S. Authi\*, Harmeet Authi, Claire Sand, Fulye Argunhan, Manasi Nandi (United Kingdom)
- PO460-WED** **TRANSCRIPTION OF EXOGENOUS RNA IN HUMAN PLATELETS**  
Vivienne Wai Tung Chan\*, Stefanie Novakowski, Simon Law, Christian Kastrop (Canada)
- PO461-WED** **THE PI(3,4,5)P3-BINDING PROTEIN RASA3 NEGATIVELY REGULATES RAP1B AND INTEGRIN AIIIB3-MEDIATED SPREADING**  
Anthony M. Battram\*, Tom Durrant, Ejaife Agbani, Samantha Moore, Alastair Poole, Ingeborg Hers (United Kingdom)
- PO462-WED** **DEXTRAN SULFATE TRIGGERS PLATELET AGGREGATION VIA PEAR1, INDEPENDENT FROM SYK**  
Christophe Vandenbriele\*, Yi Sun, Maarten Criel, Benedetta Izzì, Peter Verhamme, Marc Hoylaerts (Belgium)
- PO464-WED** **IDENTIFICATION OF LOW MOLECULAR WEIGHT FACTORS RELEASED FROM PLATELETS THAT INDUCE PROCR IN MONOCYTES**  
Robert E. Turnbull\*, Jatinderpal Sandhu, Leong Ng, Donald Jones, Alison Goodall (United Kingdom)
- PO465-WED** **CELL SURFACE EXPRESSION OF CHEMERIN RECEPTORS ON HUMAN PLATELETS UPON CELL ACTIVATION**  
Zhifei Shao, John Morser\*, Lawrence Leung (United States)
- PO466-WED** **GPIB $\alpha$  ACTIVATION MEDIATES PLATELET TISSUE FACTOR (TF) PHOSPHORYLATION, TRANSFER TO LIPID RAFTS (LR) AND ACTIVITY. TFPI AND PROTEIN S, RELEASED BY OTHER AGONISTS, WOULD ASSEMBLE THE INHIBITORY COMPLEX (TF/FVIIA/TFPI/PS) IN LR, DAMPENING FXA ACTIVITY**  
Olga Panes, Viviana Romero, César González, Gustavo Soto, Jaime Pereira, Diego Mezzano\* (Chile)
- PO467-WED** **THE IMPACT OF CIRCULATING HISTONES ON PLATELET ACTIVATION AND THROMBUS FORMATION IN VIVO**  
Timothy J. Stalker\*, Jie Wu, Lawrence Brass (United States)
- PO468-WED** **EVALUATION OF ISTH-BLEEDING ASSESSMENT TOOL IN INDIVIDUALS WITH SUSPECTED INHERITED PLATELET FUNCTION DISORDER REFERRED TO TERTIARY HEALTH CARE FACILITY IN PAKISTAN**  
Anila Rashid, Bushra Moiz\*, Bushra Rizvi, Humaira Perveen (Pakistan)

### Platelet disorders III

## SCIENTIFIC PROGRAM

- PO469-WED** **EFFECT OF CARDIOPULMONARY BYPASS PUMP ON THE PLATELET FUNCTION USING PLATELET FUNCTION ANALYZER (PFA-100) PRE AND POSTOPERATIVE CARDIAC SURGERY OPERATION**  
Rashed B. Albakr\* (Saudi Arabia)
- PO470-WED** **DECREASED PLATELET REACTIVITY IN WOMEN WITH HEAVY MENSTRUAL BLEEDING: A NOVEL APPROACH IN THE GYNAECOLOGY CLINIC TO DIAGNOSE THROMBOPATHY USING A NOVEL PLATELET FUNCTION TEST.**  
Heleen Eising\*, Mark Roest, Philip de Groot, Jasper Remijn (The Netherlands)
- PO471-WED** **DIAGNOSTIC ACCURACY OF FLOW CYTOMETRY ANALYSIS OF PLATELET LEUKOCYTE AGGREGATES IN ACUTE CORONARY SYNDROME PATIENTS VERSUS NORMAL VOLUNTEERS**  
Najib Dally\*, Elizabeth Eshel, Tatyana Levinas, Inna Rozenfeld, Adi Sharabi-Nov, Yifat Zivony, Majdi Halabi (Israel)
- PO472-WED** **A STEP FORWARD IN THE EVALUATION OF PLATELET FUNCTION TESTING: ROUTINE, SIMULTANEOUS MEASUREMENT OF PLATELET AGGREGATION, SEROTONIN (5-HT) CONTENT AND SECRETION BY HPLC-ELECTROCHEMICAL DETECTION IN HEMOSTASIS LABORATORIES.**  
Eduardo Aranda, Pablo Riquelme, Viviana Romero, Jaime Pereira, Teresa Quiroga, Oslando Padilla, Olga Panes, Diego Mezzano\* (Chile)
- PO473-WED** **OUTCOMES OF 65 PREGNANCIES IN 34 WOMEN WITH 5 DIFFERENT FORMS OF INHERITED PLATELET FUNCTION DISORDERS ENROLLED IN A RETROSPECTIVE AND MULTICENTRIC STUDY, ON BEHALF OF EHASWG ON THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS**  
Patrizia Noris\*, Elisa Civaschi, Catherine Klersy, Federica Melazzini, Nuria Pujol-Moix, Cristina Santoro, Marco Cattaneo, Cécile Lavenu-Bombléd, Loredana Bury, Pietro Minuz, Paquita Nurden, Ana Rosa Cid-Haro, Adam Cuker, Véronique Latger-Cannard, Remi Favier, Ilaria Nichele, Carlo Balduini (Italy)
- PO474-WED** **THE VALUE OF IMPEDANCE AGGREGOMETRY IN ACUTE LEUKEMIA PATIENTS**  
Andra Costache\*, Silvana Angelescu, Doina Barbu, Delia Mut, Anca Lupu (Romania)
- PO475-WED** **A NATIONAL REGISTRY OF PATIENTS WITH INHERITED PLATELET DISORDERS: BLEEDING SCORE IS ASSOCIATED WITH TIME OF FOLLOW-UP**  
Shoshana Revel-Vilk\*, Tal Ben Ami, Chana Richter, Joanne Yacobovich, Shraga Aviner, Ayelet Ben-Barak, Amir Kuperman, Shira Ben-Barak, Chaim Kaplinsky, Hannah Tamary, Gili Kenet (Israel)
- PO476-WED** **PLASMA MARKERS OF FIBRINOLYSIS, THROMBIN GENERATION AND PLATELET ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS**  
Hung Chang\*, Po-Nan Wang, Po Dunn, Alan Michelson, Andrew Frelinger (Taiwan)
- PO477-WED** **COMPARISON OF A NOVEL AUTOMATED MICROCHIP FLOW-CHAMBER SYSTEM AND CONVENTIONAL PLATELET FUNCTION TESTS IN PATIENTS WITH ISCHEMIC CEREBROVASCULAR DISEASES**  
Masako Yamazaki\*, Tomoko Ohnishi, Kazuya Hosokawa, Kouji Yamaguchi, Taku Yoneyama, Akitsugu Kawashima, Yoshikazu Okada, Kazuo Kitagawa, Shinichiro Uchiyama (Japan)

## SCIENTIFIC PROGRAM

- PO478-WED **GENETIC AND NON-GENETIC DETERMINANTS OF MPV DIFFER IN MALES AND FEMALES – RESULTS FROM THE GUTENBERG HEALTH STUDY**  
Marina Panova-Noeva\*, Vera Grossmann, Iris Hermanns, Andreas Schulz, Johanna Mazur, Stefan Blankenberg, Tanja Zeller, Thomas Münzel, Karl Lackner, Hugo ten Cate, Philipp Wild (Germany)
- PO479-WED **EVALUATION OF PLATELETS COUNT AND ACTIVATION DURING MENSTRUAL CYCLE IN YOUNG WOMEN IN ORAL CONTRACEPTIVE USE**  
Luci M. S. Dusse\*, Leticia Freitas, Cristina Loures, Marcos Silva, Fernanda Nunes, Maria Carvalho (Brazil)
- PO480-WED **REVISITING THE HEMOSTATIC DISORDER OF UREMIA : PATIENTS ON PERITONEAL DIALYSIS (CRF-PD) HAVE NORMAL PLATELET AGGREGATION AND SECRETION BUT INCREASED PLATELET TISSUE FACTOR ACTIVITY (TF-PCA), PROBABLY THE CAUSE OF INTRAVASCULAR CLOTTING ACTIVATION.**  
Olga Panes\*, César González, M. Macarena Ruiz, Camila Sandoval, Marcela Cayuleo, Alejandro Rojas, Mariana Soto, Melan Peralta, Jaime Pereira, Mireya Ortiz, Diego Mezzano (Chile)
- PO481-WED **TREATMENT OF INHERITED PLATELET FUNCTION DISORDERS IN CHILDREN AND ADOLESCENTS – INTERDISCIPLINARY GUIDELINE OF THE GERMAN SOCIETY OF THROMBOSIS AND HAEMOSTASIS RESEARCH (GTH).**  
Ralf Knöfler\*, Wolfgang Eberl, Werner Streif (Germany)
- PO482-WED **CHANGES IN THE EXPRESSION OF PLASMA AND PLATELET MICRORNAS IN TYPE 2 DIABETES MELLITUS AND OBESITY**  
Zsolt Fejes\*, Szilárd Póliska, András Penyige, Miklós Káplár, Ildikó Debreceni, János Kappelmayer, Béla Nagy Jr (Hungary)
- PO483-WED **THROMBIN ACTIVATED FACTOR XI-DRIVEN PLATELET THROMBIN GENERATION: A NEW SENSITIVE MARKER FOR HYPERCOAGULABILITY IN STABLE CORONARY ARTERY DISEASE**  
Karoline Rosenplänter, Mareike Döhrmann, Kathrin Schwierczek, Ulrich Walter, Tommaso Gori, Boris Schnorbus, Kerstin Jurk\* (Germany)
- PO484-WED **CLINICAL AND LABORATORY FEATURES OF PATIENTS WITH PLATELET DENSE GRANULE DEFICIENCY: A SINGLE INSTITUTION EXPERIENCE**  
Deepti Warad\*, Laynalee Cardel, Cindy Uhl, Rong He, Rajiv Pruthi, Dong Chen (United States)
- PO485-WED **SUCCESSFUL USE OF LOCAL PLATELET PELLETS FOR CHILDREN WITH SEVERE EPISTAXIS**  
Davut Albayrak\*, Canan Albayrak (Turkey)
- PO486-WED **ELEVATED SOLUBLE PLATELET GLYCOPROTEIN VI LEVELS IN PATIENTS AFTER LIVING DONOR LIVER TRANSPLANTATION**  
Takeshi Matsumoto\*, Naoki Takahashi, Masanobu Usui, Katsuki Naitoh, Hideo Wada, Kohshi Ohishi, Naoyuki Katayama, Shuji Isaji (Japan)

## SCIENTIFIC PROGRAM

- PO487-WED **NICOTINIC ACETYLCHOLINE RECEPTOR FUNCTION IN PLATELETS FROM ALZHEIMER DISEASE PATIENTS**  
Peter Bugert\*, Angelika Schedel, Lucrezia Hausner, Isabella Wiest, Tim Wiemers, Anip Sarin, Dennis Hassmann, Sabrina Besenfelder, Lutz Frölich (Germany)
- PO488-WED **HEMODIAFILTRATION ELICITS AN ATTENUATED DEGREE OF PLATELET ACTIVATION COMPARED TO HEMODIALYSIS**  
János Kappelmayer\*, Gergely Becs, Renáta Hudák, Ildikó Debreceni, Harjit Bhattoa, József Balla (Hungary)
- PO489-WED **TWICE-DAILY DOSING OF ASA OVERCOMES REDUCED PLATELET RESPONSE TO ONCE-DAILY ASA AFTER CORONARY ARTERY BYPASS GRAFT SURGERY: A RANDOMIZED CONTROLLED TRIAL**  
Jeremy S. Paikin\*, Jack Hirsh, Jeff Ginsberg, Jeff Weitz, Noel Chan, Richard Whitlock, Guillaume Pare, John Eikelboom (Canada)
- PO490-WED **INCREASED MITOCHONDRIAL ELECTRON TRANSPORT ASSOCIATED WITH APOPTOSIS IN HYPER-REACTIVE PLATELETS OF PATIENTS WITH ACUTE PULMONARY EMBOLISM**  
Samin Rezania\*, Michael Puskarich, Scott Mercer, Jeffrey Kline (United States)
- PO491-WED **ANTENATAL GENETIC ANALYSIS OF A JAPANESE TYPE I CD36-DEFICIENT WOMAN IN THE PREGNANCY**  
Naomi Sando\*, Hiroko Endo, Chiaki Kato, Shigeo Nakamura, Tadashi Matsushita (Japan)
- PO492-WED **A RELIABLE AND SIMPLE DIAGNOSTIC APPROACH TO DETECT PLATELET SECRETION DEFECTS IN SUBJECTS WITH MUCOCUTANEOUS BLEEDING**  
Natalia Dovlatova\*, Marie Lordkipanidzé, Gillian Lowe, Ban Dawood, Jane May, Stan Heptinstall, Steve Watson, Sue Fox (United Kingdom)
- PO493-WED **PLATELET CD40L CONTROLS BLEEDING DURING P2Y12 BLOCKERS TREATMENT**  
Charlotte Grosdidier, Pierre Deharo, Denis Bernot, Pierre Morange, Kelly Daryll Blanz, Daniel Duerschmied, Dennis Wolf, Jacques Quilici, Jean-Louis Bonnet, Thomas Cui-sset, Matthias Canault\*, Marie-Christine Alessi (France)
- PO494-WED **CLINICAL AND GENETIC PREDICTORS OF POOR PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION**  
Ayse A. Timur\*, Gurunathan Murugesan, John Barnard, Sanjay Gandhi, Deepak Bhatt, Kandice Kottke-Marchant (United States)
- PO495-WED **NO INCREASE IN PLATELET AGGREGATION IN HEALTHY WOMEN STARTING COMBINED ORAL CONTRACEPTIVES**  
Julie Brogaard Larsen\*, Mustafa Vakur Bor, Anne-Mette Hvas (Denmark)
- PO496-WED **THE PLATELETS CHARACTERISTICS IN TYPE 2 DIABETES MELLITUS (T2DM)**  
Liudmila I. Buryachkovskaya\*, Irina Uchitel, Alexander Sumarokov, Ula Docenko (Russian Federation)

## SCIENTIFIC PROGRAM

PO497-WED **STUDY OF PLATELET FUNCTION IN HEMOPHILIA A IN THE REGION OF MURCIA**  
Antonia Melero-Amor\*, Faustino Garcia-Candel, Noemi Marin Atucha, Paola Romecin, David García Bernal, David Iyu, José Eduardo Millán, José María Moraleda (Spain)

PO498-WED **REDUCED PLATELET ACTIVITY UNDER INDUCED OXIDATIVE STRESS CONDITIONS IN GILBERT'S SYNDROME**  
Avinash Reddy Kundur\*, Abishek Santhakumar, Andrew Bulmer, Indu Singh (Australia)

### Pediatric thrombosis and hemostasis III

PO499-WED **CEREBRAL VENOUS THROMBOSIS OCCURRING DURING OXYMETHOLONE THERAPY IN A PATIENT WITH FANCONI APLASTIC ANEMIA**  
Gokce Pinar Reis, Aysenur Bahadir, Erol Erduran\* (Turkey)

PO500-WED **MANAGEMENT OF ORAL ANTICOAGULANT THERAPY INTERRUPTION IN CHILDREN**  
Fiona Newall\*, Varun Kommidi, Paul Monagle (Australia)

PO501-WED **THROMBOSIS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ENDOGENOUS AND EXOGENOUS RISK FACTORS**  
O.V. Shpitionkova\*, N.S. Podchernyaeva, Y.O. Kostina, M.K. Osminina, E.U. Afonina (Russian Federation)

PO502-WED **EVALUATION OF AGE-DEPENDENT DOSING RECOMMENDATIONS FOR THE ADMINISTRATION OF TINZAPARIN IN THE TREATMENT OF PAEDIATRIC THROMBOSIS**  
Kat Webber, Paul Murphy, Kate Talks, John Hanley, Tina Biss\* (United Kingdom)

PO503-WED **USING A FUNCTIONAL PLATELET ACTIVITY ANALYSIS IN CHILDREN WITH UNEXPLAINED BLEEDING. FIRST RESULTS FROM RUSSIA**  
Pavel A. Zharkov\*, Irina Demina, Aleksey Pshonkin, Galina Novichkova, Mikhail Panteleev, Aleksey Maschan (Russian Federation)

PO504-WED **FOUR YOUNG CHILDREN WITH THROMBOTIC COMPLICATIONS AS A RESULT OF ANTITHROMBIN HEPARIN-BINDING DEFECTS.**  
Michael Mitchell\*, Jacky Cutler, Ruth Wheeler, Jayanthi Alamelu (United Kingdom)

PO505-WED **RISK OF THROMBOSIS IN A COHORT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**  
Sule Unal\*, Fatma Gumruk, Turan Bayhan, Selin Aytac, Betul Tavil, Baris Kuskonmaz, Mualla Cetin (Turkey)

PO506-WED **COMPARISON OF THE IMPACT OF SERPINC1, PROC AND PROS1 MUTATIONS ON THROMBOTIC PHENOTYPES IN CHILDREN AND ADULTS: AN OBSERVATIONAL MULTICENTER COHORT STUDY**  
Verena Limperger\*, Gili Kenet, Christine Heller, Melchior Lauten, Karin Kurnik, Ulrich Klostermeier, Rolf Mesters, Neil Goldenberg, Guy Young, Ulrike Nowak-Göttl (Germany)

PO507-WED **ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH UNDERLYING BECKWITH-WIEDEMANN SYNDROME**  
Fatma Gumruk\*, Sule Unal, Turan Bayhan, Mualla Cetin (Turkey)

## SCIENTIFIC PROGRAM

PO508-WED **NOVEL HOMOZYGOUS MUTATION IN MCFD2 AND HETEROZYGOUS SMALL DELETION IN LMAN1 GENES CAUSING COMBINED FACTOR V AND VIII DEFICIENCY**  
Mualla Cetin\*, Sule Unal, Turan Bayhan, Johannes Oldenburg, Fatma Gumruk (Turkey)

PO509-WED **TREATMENT OF PEDIATRIC THROMBOSIS WITH DALTEPARIN SODIUM.**  
Pavel Svirin\*, Libov Larina, Alena Kazankova, Viktor Petrov, Artiom Bullih (Russian Federation)

PO510-WED **NEONATAL AND ADULT PLATELETS REVEAL A DISTINCT PROTEIN EXPRESSION PROFILE?**  
Eva Stokhuijzen\*, Floris van Alphen, Maartje van den Biggelaar, Annemarie Koorneef, Carmen van der Zwaan, Carlijn Kuijk, Koen Mertens, Karin Fijnvandraat, Alexander Meijer (The Netherlands)

PO511-WED **THE INFLUENCE OF CHILDHOOD IMMUNIZATIONS ON WARFARIN EFFECT**  
Mary Bauman, Patti Massicotte, Suzanne Siddons, Aisha Bruce\* (Canada)

PO512-WED **NIACIN HAS LIMITED EFFECTIVENESS IN REDUCTION OF ELEVATED LIPOPROTEIN(A) IN CHILDREN WITH OR AT RISK OF THROMBOSIS OR STROKE**  
Kavita Patel\*, Rachel Swerdlin, Robert Sidonio (United States)

PO513-WED **HEMOSTASIS PROFILE IN CALVES RECEIVING THE CARMAT BIOPROSTHETIC ARTIFICIAL HEART**  
David Smadja\*, Sophie Susen, Antoine Rauch, Bernard Cholley, Christian Latremouille, Daniel Duveau, Luca Zilberstein, Eric Vanbelle, Antoine Capel, Pascale Gaussem, Piet Jansen, Alain Carpentier (France)

PO514-WED **PEDIATRIC STROKE OCCURRENCE IN ONE CHILDREN HOSPITAL IN CORDOBA, ARGENTINA**  
Maria Morell\*, Elizabeth Hiramatsu, Roberto Navarro (Argentina)

PO515-WED **DOSE REQUIREMENTS OF ACENOCOUMAROL IN PAEDIATRIC PATIENTS – INITIATION OF THERAPY**  
Evelina Doncheva\*, Ivanka Paskaleva (Bulgaria)

PO516-WED **DIRECT THROMBIN INHIBITOR FOR ANTICOAGULATION: ROLE OF ARGATROBAN IN PEDIATRIC POST LIVER TRANSPLANT PATIENTS WITH HEPATIC ARTERY THROMBOSIS**  
Mukta Sharma\*, Richard Hendrickson, Ryan Fischer, James Daniel, Rachel Cisernos, Megan Davis, Walter Andrews, Brian Wicklund (United States)

### Rare bleeding disorders II

PO517-WED **CHARACTERIZATION OF SIX ALTERATIONS IN ITGA2B AND ITGB3 ASSOCIATED WITH GLANZMANN'S THROMBASTHENIA**  
Essa Sabi\*, Vincenzo Leo, Areej Al-Musbahi, Asmaa Al-Marwani, Michael Makris, Martina Daly (United Kingdom)

## SCIENTIFIC PROGRAM

- PO518-WED **TWO FAMILIES FROM ARGENTINA WITH FX DEFICIENCY DUE TO TWO DIFFERENT MUTATIONS (P.CYS241GLY AND P.GLN138ARG).**  
Hugo Guglielmo\*, Luisa Sambado, Maria Molina, Salvador Minoldo, Laura Lopez Galetti, Antonio Girolami (Argentina)
- PO519-WED **PLATELET TYPE - VON WILLEBRAND DISEASE (PT-VWD): A DIAGNOSTIC AND THERAPEUTIC DILEMMA IN CHILDREN**  
Shilpa Shukla\*, Harmanpreet Kaur, Maha Othman, Suchitra Acharya (United States)
- PO520-WED **RARE BLEEDING DISORDERS: 17 YEARS OF DIAGNOSIS IN THE HEMOSTASIS LABORATORY OF THE HEMATOLOGY DEPARTMENT OF THE UNIVERSITY HOSPITAL OF BENI MESSOUS, ALGIERS, ALGERIA**  
Karima W. Chennoukh\*, Meriem Bensadok, Mylade Aribi, Nadia Zidani, Mohamed Ramaoun, Meriem Belhani, Salim Nekkal (Algeria)
- PO521-WED **FACTOR XIII DEFICIENCY: PRELIMINARY RESULTS OF THE PRO-RBDD PROJECT**  
Flora Peyvandi\*, Roberta Palla, Marzia Menegatti, Simona Siboni, Marco Boscarino, Britta Lachmann, Susan Halimeh, Naveena Fatima, Munira Borhany, Nihal Ozdemir, Marko Saracevic, Danijela Mikovic, Andrew Harvey, Andrew Mumford, Fraustina Hsu, John Chapin, Helen Pergantou, Helen Platokouki, Ay Yilmaz, Adrianna Williamson, Amy Shapiro, Alessandro Casini, Philippe de Moerloose, Jeanette Payne, Laszlo Muszbek (Italy)
- PO522-WED **EFFECTS OF FACTOR XIII DEFICIENCY ON THROMBOELASTOGRAPHY. BASAL THROMBOELASTOGRAPH AND LYSIS BY ADDITION OF STREPTOKINASE ARE MORE AFFECTED THAN SOLUBILITY TESTS**  
Marta Martinuzzo\*, Luis Barrera, Diana Altuna, Maria Tisi Baña, Quillen Amigo, María D'Adamo, Marina López, Juan Otaso (Argentina)
- PO523-WED **HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY: A REPORT OF ELEVEN VENEZUELAN CASES**  
Marion Echenagucia\*, AAPSara Boadas, Tibusay Jiménez, Maria Hernández, Carlos Acosta, Maria Dos Santos, Arlette Ruiz-Sáez (Venezuela, Bolivarian Republic Of)
- PO524-WED **DIAGNOSIS OF FXIII DEFICIENCY: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES.**  
Ian Jennings\*, Flora Peyvandi, Steve Kitchen, Marzia Menegatti, Roberta Palla, Isobel Walker, Mike Makris (United Kingdom)
- PO525-WED **THE CLINICAL FINDINGS OF CHILDREN WITH FACTOR X DEFICIENCY AT A SINGLE CENTER IN THE MIDDLE EAST OF TURKEY**  
Gulen Tuysuz, Funda Tayfun\*, Nihal Ozdemir (Turkey)
- PO526-WED **LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN PATIENT - A CASE REPORT.**  
Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Beata Baran, Edyta Odnoczek, Adam Wiszniewski\*, Jerzy Windyga (Poland)
- PO527-WED **INHERITED FXI DEFICIENCY IS NOT A RARE DISEASE IN THE NORTHERN REGION OF TURKEY**  
Davut Albayrak\*, Canan Albayrak (Turkey)

## SCIENTIFIC PROGRAM

- PO528-WED **CHARACTERIZATION OF PATIENTS WITH A MILD TO MODERATE BLEEDING PHENOTYPE: RESULTS OF THE VIENNA BLEEDING BIOBANK (VIBB)**  
Stefanie Hofer\*, Johanna Gebhart, Sylvia Kepa, Cihan Ay, Paul Knöbl, Sabine Eichinger, Paul Kyrle, Peter Quehenberger, Simon Panzer, Ingrid Pabinger (Austria)
- PO529-WED **CLINICOHEMATOLOGICAL PROFILE OF RARE INHERITED COAGULATION DISORDERS.**  
Somasundaram Venkatesan\*, Mukul Aggarwal, Ankur Ahuja, Manoranjan Mahapatra, Renu Saxena (India)
- PO530-WED **CLINICAL PRESENTATION AND MANAGEMENT OF RARE FACTOR DEFICIENCIES: CASE STUDY**  
Bulent A. Antmen\*, Ilgen Sasmaz, Barbaros Karagün, Goksel Leblebisatan, Yurdanur Kilinc (Turkey)
- PO531-WED **SPECTRUM OF RARE BLEEDING DISORDERS**  
Sitalakshmi Subramanian\*, Cecil Ross, Fulton D'souza, Anand Prakash, Parimala Puttaiah, Latha Shaju (India)
- PO532-WED **CONGENITAL FXI DEFICIENCY: A REPORT OF NINE FAMILIES FROM GERMANY AND LITHUANIA**  
Vytautas Ivaskevicius\*, Georg Goldmann, Lina Kryzauskaite, Giedre Rutkauskiene, Silvia Horneff, Natascha Marquardt, Anna Pavlova, Johannes Oldenburg (Germany)
- PO533-WED **TWO FEMALE CASES OF A1- ANTITRYPSIN PITTSBURGH**  
Lijuan Cao\*, Zhaoyue Wang, Ziqiang Yu, Jian Su, Wei Zhang, Changgeng Ruan (China)
- PO534-WED **CONGENITAL FXI DEFICIENCY: PRELIMINARY RESULTS OF PHENOTYPIC (CLINICAL AND LABORATORY) AND GENOTYPIC CHARACTERIZATION OF A CASE SERIES FROM A SINGLE CENTER.**  
Cristina Santoro\*, Roberta Di Mauro, Maria Patrizia Bicocchi, Maura Acquila, Erminia Baldacci, Roberta Abbruzzese, Maria Basso, Francesco Barone, Raffaele Boichicchio, Grazia Ferrara, Paola Volpicelli, Maria Gabriella Mazzucconi (Italy)
- PO535-WED **FACTOR VII DEFICIENCY AND PROPHYLAXIS DUE TO INTERVENTIONS**  
Violeta Dejanova-Ilijevska\*, Emilija Velkova, Violeta Neceva, Slobodan Drakulevski (Macedonia, The Former Yugoslav Republic Of)
- PO536-WED **COURSE OF PREGNANCY, LABOUR AND PERIOPERATIVE MANAGEMENT OF TWO PATIENTS WITH BERNARD-SOULIER SYNDROME – CASE REPORTS AND LITERATURE REVIEW**  
Anna Sikorska\*, Justyna M Teliga-Czajkowska, Ksenia Bykowska, Bernadeta Ceglarek, Wieslaw Schubert, Ewa Dmoch-Gajzlerska, Krzysztof Czajkowski, Jerzy Windyga (Poland)
- PO537-WED **INHERITED FXIII DEFICIENCY IN THE NORTHERN REGION OF TURKEY**  
Davut Albayrak\*, Canan Albayrak (Turkey)
- PO538-WED **VON WILLEBRAND DISEASE: BE OR NOT TO BE, THAT IS THE QUESTION**  
Ana Azevedo\*, Isabel Freire, Teresa Fidalgo, Teresa Gago (Portugal)



## SCIENTIFIC PROGRAM

### Regulation of coagulation and fibrinolysis II

- PO539-WED **IDENTIFICATION OF COAGULATION GENE 3'UTR VARIANTS THAT ARE POTENTIALLY REGULATED BY MIRNAS**  
Astrid van Hylckama Vlieg\*, Constantino Martínez, Carla Vossen, Salam Salloum-Asfar, Hugoline de Haan, Raúl Teruel-Montoya, Javier Corral, Pieter Reitsma, Frits Rosendaal (The Netherlands)
- PO540-WED **IDENTIFICATION OF OESTROGEN RESPONSIVE MIRNAS ASSOCIATED WITH THE REGULATION OF COAGULATION AND THE INCREASED THROMBOTIC RISK IN PREGNANT WOMEN**  
Jasmine Tay\*, Ian James, Quintin Hughes, Ross Baker (Australia)
- PO541-WED **STRUCTURAL AND FUNCTIONAL STUDIES OF MONOCLONAL HIGH AFFINITY ANTIBODIES (MABS) AGAINST THE HUMAN TFPI KUNITZ-TYPE PROTEASE INHIBITOR DOMAIN 1**  
Anders Svensson\*, Birgitte Kjær, Jes Clausen, Berit Krogh, Peder Nørby, Jens Breinholt, Helle Petersen (Denmark)
- PO542-WED **ORM1: A NOVEL REGULATOR OF THROMBIN GENERATION AND POTENTIAL CARDIOVASCULAR RISK FACTOR**  
Mohammed A. Alsahli\*, Matthew Denniff, Unni Krishnan, Ravi Singh, Joy Wright, Nilesh Samani, Alison Goodall (Saudi Arabia, United Kingdom)
- PO543-WED **ROLE OF COAGULATION FACTOR XI IN PROMOTING DISTAL PLATELET AGGREGATION AND THROMBUS FORMATION IN WHOLE BLOOD UNDER FLOW**  
Jevgenia Zilberman-Rudenko\*, Asako Itakura, Erik Tucker, David Gailani, Stephanie Smith, Sharon Choi, James Morrissey, Andrés Gruber, Owen McCarty (United States)
- PO544-WED **NUCLEIC ACIDS AND POLYPHOSPHATE AS MODULATORS OF COAGULATION**  
Joshua M. Gajsiewicz\*, Richard Travers, Stephanie Smith, James Morrissey (United States)
- PO545-WED **SELECTIVE NEUTRALIZATION OF THE SERPIN PROTEASE NEXIN-1 BY A SPECIFIC MONOCLONAL ANTIBODY**  
Marie-Christine Bouton\*, Déborah François, Laurence Venisse, Els Brouwers, Véronique Arocas, Paul Declerck (France)
- PO546-WED **IN SILICO PREDICTION OF MICRORNA BINDING SITES IN HAEMOSTATIC FACTORS**  
Jessica Jorritsma, Jasmine Tay\*, Quintin Hughes, Ross Baker (Australia)
- PO547-WED **ANALYSIS OF THE MECHANISM OF SPECIES DIFFERENCES REGARDING RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN ON PROTEIN C ACTIVATION IN HUMAN AND MOUSE**  
Takashi Arioka\*, Shunsuke Tawara, Takumi Sakai (Japan)
- PO548-WED **THE IMMEDIATE AND LATE EFFECTS OF THYROID HORMONE (TRIIODOTHYRONINE) ON MURINE COAGULATION GENE TRANSCRIPTION**  
Salam Salloum-Asfar\*, Anita Boelen, Pieter H. Reitsma, Bart J. M. van Vlijmen (Netherlands, Spain)

## SCIENTIFIC PROGRAM

- PO549-WED **INDIRECT REGULATION OF HEMOSTATIC PROTEINS BY MIR24 AND MIR34A THROUGH HEPATIC NUCLEAR FACTOR 4 ALPHA (HNF4A)**  
Salam Salloum-Asfar\*, Ana Belen Arroyo, Nuria Garcia-Barbera, Amarjit Chaudhry, Erin Schuetz, Vicente Vicente, Rocío González-Conejero, Constantino Martínez (Spain)
- PO550-WED **INVESTIGATION OF MODE OF ACTION OF SUGAMMADEX EFFECTS ON COAGULATION**  
Annelieke C. Kruithof\*, Cornelis Klufft, Pieter-Jan de Kam, Ria Laterveer, Matthijs Moerland, Jacobus Burggraaf (The Netherlands)
- PO551-WED **IDENTIFYING SUBSTRATES OF PROTEIN DISULFIDE ISOMERASE USING ENZYME VARIANTS WITH ALTERED REDOX POTENTIAL**  
Jack D. Stopa\*, Barbara Furie, Bruce Furie (United States)
- PO552-WED **INHIBITORY EFFECT OF VITAMIN D INTAKE IN PLASMA FACTOR VIII ACTIVITY AND TISSUE FACTOR EXPRESSION IN MONOCYTTIC CELLS**  
Raul Teruel-Montoya\*, Jesus Lozano, Antonia Miñano, Ana Belen Arroyo, MJ Hernández, V Gómez, Salam Salloum-Asfar, Vanessa Roldán, Begoña Muiña, Javier Corral, Maria Teresa Herranz, Vicente Vicente, Rocío González-Conejero, Constantino Martínez (Spain)
- PO553-WED **A NOVEL ANTI-TISSUE FACTOR PATHWAY INHIBITOR ANTIBODY, BAY 1093884, PREVENTS BLEEDING IN HEMOPHILIA A MICE**  
Maria Köllnberger, Perry Liu, Derek Sim\* (Germany)
- PO554-WED **A NOVEL ANTI-TISSUE FACTOR PATHWAY INHIBITOR ANTIBODY, BAY 1093884, RESTORES HEMOSTASIS IN INDUCED HEMOPHILIA A RABBIT WITH REDUCED THROMBOGENIC POTENTIAL**  
Maria Köllnberger, Axel Trabandt, Volker Laux\* (Germany)
- PO555-WED **ANTIBODIES TO INVESTIGATE THE ANTITHROMBOTIC ROLE OF ANTI-THROMBIN IIIBETA**  
Ye Jin, Subramanian Yegneswaran\*, Philip Ramsey, Jian-Ming Gu, Chandra Patel, Frank Dittmer, Uwe Gritzan, Michael Sherath, Lars Linden, Peter Bringmann, Volker Laux, Katalin Kauser, Terry Hermiston (United States)
- PO556-WED **POLYSTAT: A SYNTHETIC POLYMER HEMOSTAT FOR USE IN COMBINATION WITH FACTOR REPLACEMENT THERAPIES FOR HEMOPHILIA A**  
Leslie Chan\*, Carol Miao, Nathan White, Suzie Pun (United States)

### Risk factors for venous thrombosis III

- PO557-WED **THE ASSOCIATION OF ENDOGENOUS STEROID HORMONE, SHBG, AND PRECURSOR STEROID LEVELS WITH HEMOSTATIC FACTOR LEVELS IN POSTMENOPAUSAL WOMEN**  
Laura B. Harrington\*, Brett Marck, Kerri Wiggins, Barbara McKnight, Susan Heckbert, Nancy Woods, Andrea LaCroix, Marc Blondon, Bruce Psaty, Frits Rosendaal, Alvin Matsumoto, Nicholas Smith (United States)
- PO558-WED **OBSTRUCTIVE SLEEP APNOEA DOES NOT ENHANCE HYPERCOAGULABILITY AS MEASURED BY THROMBIN GENERATION IN THE MORBIDLY OBESE**  
Paradzaí Chitongo\*, Lara Roberts, Lyall Rebecca, Raj Patel, Simon Aylwin, Roopen Arya (United Kingdom)

## SCIENTIFIC PROGRAM

- PO559-WED **VEREMA - AN AFFINITY PROTEOMICS STUDY TO IDENTIFY AND TRANS-LATE PLASMA BIOMARKERS FOR VENOUS THROMBOEMBOLISM**  
Maria Bruzelius\*, Maria Jesus Iglesias, Mun-Gwan Hong, David Trégouët, Juan Carles Souto, Margareta Holmström, Mattias Frånberg, Rona Strawbridge, Maria Sabater-Lleal, Bengt Sennblad, Angela Silveira, José Manuel Soria, Pierre Morange, Lynn Butler, Jochen Schwenk, Anders Hamsten, Jacob Odeberg (Sweden)
- PO560-WED **ANALYSIS OF PROTHROMBIN MISSENSE MUTANTS AT 596ARG BY SINGLE NUCLEOTIDE SUBSTITUTION FOR ANTICOAGULANT SYSTEM**  
Yuki Takagi\*, Moe Murata, Yuki Nakamura, Toshihiro Kozuka, Yukiko Nakata, Ryo Hasebe, Akira Takagi, Tetsuhiro Kojima (Japan)
- PO561-WED **RED CELL DISTRIBUTION WIDTH AND FUTURE RISK OF VENOUS THROMBOSIS, MYOCARDIAL INFARCTION, STROKE AND CANCER – A CAUSE SPECIFIC ANALYSIS.**  
Trygve Ellingsen\*, Jostein Lappegård, Tove Skjelbakken, Ellisiv Mathiesen, Inger Njølstad, Sigrid Brækkan, John-Bjarne Hansen (Norway)
- PO562-WED **RISK OF VENOUS THROMBOSIS IN PERSONS WITH INCREASED BODY MASS INDEX AND INTERACTIONS WITH OTHER GENETIC AND ACQUIRED RISK FACTORS: A CASE-CONTROL STUDY**  
Daniel Ribeiro\*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Netherlands)
- PO563-WED **DEHYDRATION AS A POSSIBLE CAUSE OF SEASONAL VARIATIONS IN THE INCIDENCE OF VENOUS THROMBOEMBOLISM**  
Elias Saad\*, Ron Hoffman, Benjamin Brenner, Gleb Saharov, Yona Nadir (Israel)
- PO564-WED **AN AFFINITY PROTEOMICS STUDY FOR PLASMA BIOMARKER CANDIDATES OF CARDIOVASCULAR DISEASE IN VENOUS THROMBOEMBOLISM**  
Maria Jesus Iglesias\*, Maria Bruzelius, Mun-Gwan Hong, David Trégouët, Ljubica Perisic, Mattias Frånberg, Paolo Parini, Andrea Ganna, Erik Ingelsson, Peter Nilsson, Ulf Hedén, Mathias Uhlén, Angela Silveira, Pierre Morange, Anders Hamsten, Jochen Schwenk, Jacob Odeberg (Sweden)
- PO565-WED **LUNG DISORDERS IN ELDERLY PEOPLE ARE ASSOCIATED WITH PULMONARY EMBOLISM AND NOT WITH DEEP VEIN THROMBOSIS**  
Alev Karasu\*, Adeleid C. Jorissen, Marissa J. Engbers, Mary Cushman, Frits R. Rosendaal, Astrid van Hylckama Vlieg (The Netherlands)
- PO566-WED **ASSESSMENT OF RISK FACTORS IN ESTABLISHED CASES OF DEEP VEIN THROMBOSIS (DVT) AND GREAT SAPHENOUS VEIN THROMBOSIS (GSVT) IN INDIAN PATIENTS**  
Chithra Barvadheesh (India)
- PO567-WED **JOINT EFFECT HOMOZYGOUS CARRIERS OF A RISK ALLELE IN THE FIBRINOGEN GAMMA CHAIN AND OVERWEIGHT ON RISK OF VENOUS THROMBOEMBOLISM.**  
Tine Lønneberg\*, Erin Smith, Sigrid Brækkan, Lars Horvei, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
- PO568-WED **IMPACT OF THE ABO RS8176719 SINGLE NUCLEOTIDE POLYMORPHISM ON CANCER-RELATED VENOUS THROMBOEMBOLISM**  
Olga Dziewiecka\*, Erin Smith, Sigrid Brækkan, Hilde Jensvoll, Kristine Blix, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)

## SCIENTIFIC PROGRAM

- PO569-WED **ASSOCIATION BETWEEN THROMBOMODULIN C.1418C>T AND VENOUS THROMBOSIS: A META-ANALYSIS**  
Bei Hu\*, Liang Tang, Yu Hu (China)
- PO570-WED **NEUTROPHILS AND FACTOR XII, UNLIKE PLATELETS, ARE NOT CRUCIAL FOR DEVELOPMENT OF EXPERIMENTAL SPONTANEOUS VENOUS THROMBOSIS**  
Marco Heestermans\*, Salam Salloum-Asfar, El Houari Laghmani, Gerry Wagenaar, Brenda Luken, Pieter Reitsma, Bart van Vlijmen (The Netherlands)
- PO571-WED **ENDOGENOUS THROMBIN POTENTIAL IS DIRECTLY CORRELATED WITH PROTEINURIA SEVERITY AND HYPOALBUMINEMIA IN NEPHROTIC SYNDROME PATIENTS**  
Amanda P. Waller\*, Brad Rovin, Samir Parikh, William Smoyer, Marvin Nieman, Matthias Kretzler, Bryce Kerlin (United States)
- PO572-WED **DIFFERENTIAL EXPRESSION OF MIRNAS IN PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS COLLECTED FROM PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM AND HEALTHY CONTROL INDIVIDUALS**  
Irina Starikova\*, Simin Jamaly, Antonio Sorrentino, Thorarinn Blöndal, Nadezhda Latysheva, Cathrine Ramberg, Mikhail Sovershaev, John-Bjarne Hansen (Norway)
- PO573-WED **THE RISK OF RECURRENT VENOUS THROMBOSIS IN PATIENTS WITH (LOWER) LEG CAST IMMOBILISATION.**  
Banne Nemeth\*, Jasmijn Timp, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)
- PO574-WED **THE PREVALENCE OF CONGENITAL TROMBOPHILIA IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH THROMBOSIS**  
Anna Klukowska\*, Katarzyna Smalisz-Skrzypczyk, Katarzyna Pawelec, Michał Matysiak (Poland)
- PO575-WED **THE ASSESSMENT OF RISK FACTORS FOR THROMBOSIS IN CHILDREN TREATED FOR NON- HODGKIN LYMPHOMA**  
Anna Klukowska\*, Katarzyna Smalisz-Skrzypczyk, Iwona Malinowska, Agata Sobocinska-Mirska, Michał Romiszewski, Michał Matysiak (Poland)
- PO576-WED **GENETIC AND ACQUIRED RISK FACTORS OF VENOUS THROMBOEMBOLISM IN YOUNG PATIENTS IN THE NORTH-WEST REGION OF RUSSIA**  
Anna Demyanenko\*, Sergey Kapustin, Vladimir Soroka, Pavel Chechulov (Russian Federation)
- PO577-WED **LIPID LEVELS AND RISK OF RECURRENT VENOUS THROMBOSIS: RESULTS FROM THE MEGA FOLLOW-UP STUDY**  
Vânia Morelli\*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Netherlands)
- Thrombophilia III**
- PO578-WED **SECONDARY THROMBOPROPHYLAXIS WITH RIVAROXABAN IN MAJOR INHERITED THROMBOPHILIAS**  
Karen Schreiber\*, Savino Sciascia, Alexander Cohen, Beverley Hunt (Denmark, United Kingdom)

## SCIENTIFIC PROGRAM

- PO579-WED **MONITORING DRUG ACTIVITY OF DABIGATRAN AND RIVAROXABAN BY THROMBIN GENERATION USING THE CALIBRATED AUTOMATED THROMBINOSCOPE.**  
Andrés Moret, Noelia Cabrera, Yolanda Mira, Fernando Ferrando, Saturnino Haya, Ana R Cid, Elena Mesa, Rafael Hernani, Virtudes Vila, Santiago Bonanad\* (Spain)
- PO580-WED **DIFFERENT PATTERNS OF THROMBOPHILIA MARKERS IN PREGNANCY COMPLICATIONS**  
Gabiella Gamba\*, Lorenzo Gervaso, Chiara Ambaglio, Nicola Ghidelli, Federica Zane, Fausta Beneventi (Italy)
- PO581-WED **BETA2-GLYCOPROTEIN I DEFICIENCY WITH VENOUS THROMBOSIS: IDENTIFICATION AND IN VITRO EXPRESSION STUDY OF A MISSENSE MUTATION P.LYS38GLU IN APOH GENE**  
Wei Zeng\*, Yu Hu (China)
- PO582-WED **TOWARDS IDENTIFICATION OF GENETIC RISK FACTORS IN TWO DUTCH FAMILIES WITH UNEXPLAINED HEREDITARY VENOUS THROMBOEMBOLISM**  
Marisa Cunha\*, Pieter Reitsma, Frits Rosendaal, Joost Meijers, Saskia Middeldorp (The Netherlands)
- PO583-WED **RECURRENT VENOUS THROMBOEMBOLISM DURING PREGNANCY IN WOMEN WITH QUANTITATIVE ANTITHROMBIN DEFICIENCY WITH OR WITHOUT ANTITHROMBOTIC PROPHYLAXIS**  
Serena Maria Passamonti\*, Andrea Artoni, Paolo Bucciarelli, Francesca Gianniello, Ida Martinelli (Italy)
- PO584-WED **MOLECULAR ANALYSIS OF PROTEIN S DEFICIENCY IN THAILAND**  
Ponlapat Rojnuckarin\*, Rung Settapiboon, Benjaporn Akkawat, Noppacharn Uaprasert (Thailand)
- PO585-WED **INHERITED THROMBOPHILIA AS A HIGH RISK FACTOR OF RECURRENT PREGNANCY LOSS IN GEORGIAN POPULATION**  
Nino Pirtskhelani\*, Nino Kochiashvili, Levan Makhaldiani, Nugzar Pargalava, Ketevan Kartvelishvili, Mamuka Bokuchava (Georgia)
- PO586-WED **DO ENDOTHELIUM-RELATED GENES AND INHERITED THROMBOPHILIA INTERACT IN INCREASING PREGNANCY LOSS RISK?**  
Ilaria Romagnuolo\*, Elena Sticchi, Angela Rogolino, Agatina Alessandrello Liotta, Anna Paola Cellai, Niccolò Maggini, Rosanna Abbate, Cinzia Fatini (Italy)
- PO587-WED **RIVAROXABAN IN LONG-TERM SECONDARY PREVENTION OF VTE IN PATIENTS WITH HEREDITARY OR ACQUIRED THROMBOPHILIA IS AS EFFECTIVE AND SAFE AS STANDARD TREATMENT WITH VITAMIN K ANTAGONISTS**  
Grigoris T. Gerotziapas\*, Eleftheria Lefkou, Vassiliki Gkalea, Anastasia Spanoudaki, Hela Ketatni, Ilias Evmorfiadis, Ismail Elalamy (France)
- PO588-WED **OBSTETRIC HISTORY, COURSE OF PREGNANCY AND LABOUR OF PATIENTS WITH MTHFR MUTATION- CASE REPORT AND LITERATURE REVIEW**  
Justyna M Teliga-Czajkowska\*, Anna Sikorska, Ksenia Bykowska, Bernadeta Ceglarek, Ewa Dmoch-Gajzlerska, Jerzy Windyga, Krzysztof Czajkowski (Poland)

## SCIENTIFIC PROGRAM

- PO589-WED **LMWH IN PROPHYLAXIS OF THE REPEATED PREGNANCY COMPLICATIONS IN WOMEN WITH THROMBOPHILIA AND MULTIPLE PREGNANCY AFTER IVF**  
Natalya Makatsariya\*, Nadezhda Stuleva, Jamilya Khizroeva (Russian Federation)

### Tissue factor and factor VII - III

- PO590-WED **ANTIBODIES TO THE K2 AND K3 DOMAINS OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) DIFFER IN BIODISTRIBUTION AND EFFECT ON PLASMA TFPI CONCENTRATION**  
Kasper Almholt\*, Brian Lauritzen, Torben Elm, Lars Holten-Andersen, Bill Vestergaard, Mette Loftager, Lene Hansen (Denmark)
- PO591-WED **EXPLOITING THE BIOLOGY OF TISSUE FACTOR PATHWAY INHIBITOR: PROSPECT FOR FUTURE THERAPEUTIC TARGETS.**  
Samuel Abegunde (Nigeria)
- PO592-WED **POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF A NEW RECOMBINANT HUMAN FACTOR VIIA (LR769) TO DERIVE THE DOSE TO BE STUDIED IN PHASE 3**  
Johan Frieling\*, Jasper Stevens, Joannes Reijers, Matthijs Moerland, Jacobus Burggraaf, Kees van Leuven, Cornelis Klufft, Jean-François Schved (United States)
- PO593-WED **PRODUCTION OF HIGHLY ACTIVE RECOMBINANT HUMAN TISSUE FACTOR PATHWAY INHIBITOR**  
Mathieu Castellan, Raphaël Marlu, Benoit Polack\*, Marie-Claire Dagher (France)
- PO594-WED **COMPREHENSIVE ASSESSMENT OF THE SAFETY AND EFFICACY OF FACTOR VIIA-CTP SUPPORTING PHASE 2A STUDY**  
Ahuva Bar-Ilan, Lior Binder, Malka Hoffman, Gili Hart\* (Israel)
- PO595-WED **FACTOR VIIA-CTP, A LONG-ACTING COAGULATION FACTOR PROPOSING A NOVEL SUBCUTANEOUS (SC) ROUTE OF ADMINISTRATION FOR PROPHYLACTIC TREATMENT – EFFICACY AND SAFETY IN PREPARATION FOR FIRST IN HUMAN STUDY.**  
Lior Binder, Malka Hoffman, Miri Zakar, Ahuva Bar-Ilan, Gili Hart\* (Israel)
- PO596-WED **THE RECOMBINANT FUSION PROTEIN LINKING ACTIVATED FACTOR VIIA TO HUMAN ALBUMIN (RVIIA-FP) PROVIDES SUPERIOR BLEEDING PROTECTION COMPARED TO RECOMBINANT FVIIA (RFVIIA) IN A NOVEL MONKEY MODEL OF ACQUIRED FACTOR VIII INHIBITORS**  
Eva Herzog\*, Elmar Raquet, Hendrik Peil, Baerbel Doerr, Alex Veldman, Stefan Schulte, Sabine Zollner (Germany)
- PO597-WED **PF-05280602, A FACTOR VIIA VARIANT WITH ENHANCED IN VITRO POTENCY COMPARED TO WILD-TYPE FACTOR VIIA IN HEMOPHILIC HEMOSTASIS ASSAYS.**  
Sunita Patel-Hett\*, Swapnil Rakhe, Michelle Zhao, Edwin Madison, Steven Arkin, John Murphy, Debra Pittman (United States)
- PO598-WED **MATHEMATICAL MODELLING OF MEMBRANE-DEPENDENT FACTOR X ACTIVATION BY EXTRINSIC TENASE**  
Tatiana Kovalenko (Russian Federation)

## SCIENTIFIC PROGRAM

- PO599-WED **IN VITRO MECHANISM OF BAY 1093884 INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR**  
Subramanian Yegneswaran\*, Maria Köllnberger, Vincent Evans, Chandra Patel (United States)
- PO600-WED **EVALUATION OF ARYOSEVEN SAFETY (RECOMBINANT ACTIVATED FACTOR VII) IN PATIENTS WITH BLEEDING DISORDERS (AN OBSERVATIONAL POST-MARKETING SURVEILLANCE, STUDY)**  
Alireza Abdolahi, Gholamreza Toogeh, Mohamad Reza Managhchi, Mohammad Reza Shaverdi\*, Katayon Rahimi, Samin Roostaei, Hassan Abolghasemi, Peyman Eshghi, Jayran Zebardast, Akram Sarbayani, Fatemeh Sori (Iran, Islamic Republic Of)

### Transfusion II

- PO601-WED **DOSE-RELATED PULMONARY COMPLICATION RATES AFTER FRESH FROZEN PLASMA ADMINISTRATION FOR WARFARIN REVERSAL**  
Ariela Marshall\*, Michael Levine, Melissa Howell, Yuchiao Chang, Eric Riklin, Blair Parry, Ryan Callahan, Ikenna Okechukwu, Alison Ayres, Brian Nahed, Walter Dzik, Joshua Goldstein (United States)
- PO603-WED **ANALYSIS OF MEMBRANE MICROPARTICLES AND THROMBIN GENERATION ACTIVITY OF DMSO CRYOPRESERVED PLATELETS**  
Tseday Tegegn, Silvia De Paoli, Martina Orecna, Oumsalama Elhelu, Samuel Woodle, Ivan Tarandovskiy, Mikhail Ovanesov, Jan Simak\* (United States)
- PO604-WED **PHOSPHATIDYLINOSITOL-3-KINASE IS IMPAIRED FOLLOWING AMOTOSALEN AND ULTRAVIOLET A LIGHT TREATMENT OF PLATELETS IN CONCENTRATES FOR TRANSFUSION**  
Hendrik B. Feys\*, Britt Van Aelst, Rosalie Devloo, Philippe Vandekerckhove, Veerle Compernelle (Belgium)
- PO605-WED **INACTIVATION OF EMERGING VIRUSES BY PASTEURIZATION IN PLASMA-DERIVED MEDICINAL PRODUCTS**  
Nathan J. Roth, Wolfram Schäfer, Thomas Nowak, Birgit Popp\*, Josephine Schlosser, Martin Eiden, M Groschup, Albrecht Gröner (United States)
- PO606-WED **PLATELETS ARE DISPENSABLE DURING THE INITIAL STEPS OF IMMUNOLOGICAL TRANSFUSION RELATED ACUTE LUNG INJURY (TRALI)**  
Beatrice Hechler\*, Blandine Maître, Stéphanie Magnenat, Véronique Heim, Marie-Belle El Mdawar, Christian Gachet, Henri de la Salle (France)
- PO607-WED **VOLUME OF FLUID RESUSCITATION IN WOMEN WITH PERSISTENT POSTPARTUM HAEMORRHAGE AND TOTAL BLOOD LOSS, MATERNAL MORTALITY AND SEVERE MATERNAL MORBIDITY**  
Dacia D. Henriquez\*, Kitty Bloemenkamp, Jaap Jan Zwaginga, Johanna van der Bom (Netherlands)
- PO608-WED **RAPID ASSESSMENT OF PLATELET FUNCTION UNDER FLOW FOLLOWING TRAUMA & RECAPITULATION OF TRAUMA-INDUCED COAGULOPATHY IN WHOLE BLOOD MICROFLUIDIC ASSAYS**  
Ruizhi Li\*, Hanna Elmongy, Carrie Sims, Scott Diamond (United States)

## SCIENTIFIC PROGRAM

- PO609-WED **MONITORING PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES MEASURED BY THROMBOELASTOMETRY: A PILOT STUDY.**  
Floor Moenen\*, Inge Verheijen, Ron Straat, Rick Wetzels, Erik Beckers, Yvonne Henskens (The Netherlands)
- PO610-WED **CHARACTERIZATION AND EVALUATION OF THE HEMOSTATIC ACTION OF CRYOPRESERVED PLATELETS**  
Irene Lopez-Vilchez\*, Patricia Molina, Miquel Lozano, Nerea Rincon-Tome, Joan Cid, Ana Galan, Maribel Diaz-Ricart, Gines Escolar (Spain)
- PO611-WED **THROMBIN GENERATION POTENTIAL OF A NEW TREHALOSE-STABILIZED PLATELET-DERIVED HEMOSTATIC AGENT**  
Arthur Bode, Narendra Tandon\*, Evgenia Matveeva, Michael Fitzpatrick (United States)
- PO612-WED **ASPHYXIA BY DROWNING INDUCES MASSIVE BLEEDING DUE TO HYPERFIBRINOLYTIC DISSEMINATED INTRAVASCULAR COAGULATION**  
Michael Schwameis\*, Andreas Schober, Christian Schörghofer, Wolfgang Sperr, Herbert Schöchel, Karin Janata-Schwatzek, Erol Kuerkciyan, Fritz Sterz, Bernd Jilma (Austria)
- PO613-WED **THE STABILITY OF FVIII:C, VON WILLEBRAND FACTOR AND FIBRINOGEN IN FFP AND CRYOPRECIPITATE IN THAI BLOOD DONORS**  
Theera Ruchutrakool\*, Songsri Gledkruemas, Tasneem Binham, Yupa Nakkinkun, Waraporn Meesmat, Usanee Siriboonrit, Parichart Permpikul (Thailand)
- PO614-WED **INFUSION OF CRYOPRESERVED POOLED PLATELETS IN PATIENTS WITH ACUTE LEUKEMIA: PRELIMINARY RESULTS OF A CLINICAL TRIAL (NCT02032134)**  
Mariasanta Napolitano\*, Stefania Arfò, Lucio Lococo, Giorgia Saccullo, Giovanni De Francisci, Amalia Reina, Laura Orlando, Diana Diliberto, Salvatrice Mancuso, Giuseppe Tarantino, Simona Raso, Rosalia Agliastro, Francesco Dieli, Sergio Siragusa (Italy)
- PO615-WED **MASSIVE HAEMORRHAGE MANAGEMENT: FROM CHAOS TO ORDER. LEGNANO HOSPITAL'S EXPERIENCE.**  
Ivo Beverina, Chiara Novelli\*, Matteo Lucchelli, Erika Borotto, Alessandro Aloni, Bruno Brando (Italy)
- PO616-WED **INTERVENTIONS TO REDUCE BLOOD LOSS FROM LABORATORY TESTING IN CRITICALLY ILL PATIENTS AND IMPACT ON TRANSFUSION: A SYSTEMATIC REVIEW**  
Neal Manning\*, Nancy Heddle, Donald Arnold, Mark Crowther, Deborah Siegal (Canada)
- PO617-WED **COMPARISON OF THE EFFECT OF FRESH FROZEN PLASMA PRE- AND POST-TRANSFUSION IN ITU PATIENTS ON STANDARD AND GLOBAL COAGULATION ASSAYS**  
Emma L. Fosbury\*, Jonathan Manguiat, Anne Riddell, Pratima Chowdary (United Kingdom)

## SCIENTIFIC PROGRAM

### Venous thromboembolism - diagnosis III

- PO618-WED **SERUM ALBUMIN AND S PROTEIN ARE BETTER PREDICTORS THAN CLINICAL SCORES IN THE DIAGNOSIS OF DEEP VEIN THROMBOSIS IN PATIENTS WITH SEVERAL COMORBIDITIES**  
Antonella Maria Cardella\*, Giovanni Tripepi, Antonio D'Assoro, Giuseppe Puccia (Italy)
- PO619-WED **DERIVATION OF A NEW SCORE TO PREDICT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM**  
Frederikus A. Klok\*, Olga Dzikowska-Diduch, Maciej Kostrubiec, Hubert Vliegen, Piotr Pruszczyk, Gerd Hasenfuß, Menno Huisman, Stavros Konstantinides, Mareike Lankeit (Germany, Netherlands)
- PO620-WED **THE PREVALENCE OF DEEP VEIN THROMBOSIS IN HOSPITALIZED PATIENTS WITH SUSPECTED PULMONARY EMBOLISM RULED OUT BY MULTISLICE CT ANGIOGRAPHY**  
Fernando Vazquez\*, Maria Lourdes Posadas-Martinez, Bruno Boietti, Alejandra Romero, Fernan Gonzalez Bernaldo de Quiros, Diego Giunta, Esteban Gándara (Argentina)
- PO621-WED **CEREBRAL AND SPLANCHNIC VEIN THROMBOSIS : WHAT MOLECULAR GENETICS RISK FACTORS ?**  
Pascaline Etancelin, Aude Bagan-Triquenot, Odile Gorla, Jeanne-Yvonne Borg, Christian Bastard, Véronique Lecam Duchez\* (France)
- PO622-WED **A PROSPECTIVE EVALUATION OF VENOUS THROMBOEMBOLISM IN SPINE SURGERY: INCIDENCE, COST-EFFECTIVENESS OF PROPHYLAXIS AND BLEEDING COMPLICATIONS**  
Kerry Hitos\*, David Young, John Fletcher (Australia)
- PO623-WED **THROMBOEMBOLIC DISEASE FOLLOWING PANCREATODUODENECTOMY FOR BENIGN OR CONFIRMED MALIGNANCY: EFFICACY OF PROPHYLACTIC MEASURES AND ASSOCIATED BLEEDING COMPLICATIONS**  
Kerry Hitos\*, John Fletcher, Lawrence Yuen, Emma Johnston, Tony Pang, Vincent Lam, Michael Hollands, Arthur Richardson, Henry Pleass (Australia)
- PO624-WED **PERFORMANCE OF A DIAGNOSTIC STRATEGY USING A CLINICAL DECISION RULE AND D-DIMER TESTING TO EXCLUDE UPPER EXTREMITY DEEP VEIN THROMBOSIS IN CLINICALLY IMPORTANT SUBGROUPS**  
Nick van Es\*, Suzanne Bleker, Marcello di Nisio, Ankie Kleinjan, Jan Beyer-Westendorf, Giuseppe Camporese, Pieter Kamphuisen, Hans-Martin Otten, Sebastian Werth, Ettore Porreca, Chiara Tonello, Harry Büller, Patrick Bossuyt (The Netherlands)
- PO625-WED **PREDICTION OF VENOUS THROMBOSIS RISK AFTER ARTHROSCOPY OF THE KNEE.**  
Banne Nemeth\*, Raymond van Adrichem, Saskia le Cessie, Astrid van Hylckama Vlieg, Trevor Baglin, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)
- PO627-WED **RELATIONSHIP OF PATIENT AFFECT TO CLINICIAN-DERIVED PRETEST PROBABILITY ASSESSMENT FOR PULMONARY EMBOLISM**  
Jeffrey A. Kline\*, Dawn Neumann (United States)

## SCIENTIFIC PROGRAM

- PO628-WED **CURRENT PRACTICES IN LUNG SCINTIGRAPHY FOR PULMONARY EMBOLISM (PE) DIAGNOSIS: AN INTERNATIONAL SURVEY IN AUSTRALIA, CANADA AND FRANCE**  
Pierre-Yves Le Roux\*, Matthieu Pelletier-Galarneau, Romain De Laroche, Michael Hofman, Lionel Zuckier, Paul Roach, Jean-Philippe Vuillez, Rod Hicks, Grégoire Le Gal, Pierre-Yves Salaun (France)

### Venous thromboembolism - epidemiology III

- PO629-WED **COMPARISON OF RISK FACTORS AND OUTCOMES ASSOCIATED WITH COMMUNITY (CAT) VERSUS HOSPITAL ACQUIRED THROMBOSIS (HAT).**  
Huw Rowswell\*, Tim Nokes (United Kingdom)
- PO630-WED **ASSOCIATION BETWEEN VENOUS THROMBOEMBOLISM (VTE) MINOR RISK FACTORS AND THE RISK OF RECURRENCE AFTER A FIRST UNPROVOKED EPISODE**  
Luana Farren-Dai\*, Grégoire Le Gal, Marc Carrier, Marc Rodger, Michael J Kovacs (Canada)
- PO631-WED **DO PATIENTS WHO EXPERIENCED VENOUS THROMBOEMBOLISM DESPITE THROMBOPROPHYLAXIS DURING A MEDICAL IMMOBILIZATION HAVE A WORSE OUTCOME ?**  
Adel Merah, Laurent Bertoletti\*, Mouzayan Ginzarly, David Zeltser, Manuel Barrón, Ramon Lecumberri, Paola Ferrazzi, Pablo César Malfante, Maria Guil, Manuel Monreal (France)
- PO632-WED **DISCREPANCIES IN SEVERE RI SCREENING IN THE ELDERLY WITH COCKCROFT-GAULT AND MDRD FORMULAS: 20% OF PATIENTS ARE MISEVALUATED.**  
Nicolas Janus\*, Isabelle Mahé, Ismail Elalamy, Jean-Jacques Boffa, Vincent Launay-Vacher (France)
- PO633-WED **ASSOCIATION BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VENOUS THROMBOEMBOLISM**  
Paolo Bucciarelli\*, Alberto Maino, Irene Felicetta, Maria Abbattista, Serena Passamonti, Andrea Artoni, Ida Martinelli (Italy)
- PO634-WED **PATIENT AND DOCTOR ENGAGEMENT: THE MISSING LINK IN PREVENTING VENOUS THROMBOEMBOLISM**  
Kerry Hitos\*, Travis Stephenson, Tony Poulton, John Fletcher (Australia)
- PO635-WED **EPIDEMIOLOGY OF THROMBOEMBOLIC DISEASE IN PATIENTS UNDERGOING HEPATECTOMY**  
Kerry Hitos\*, John Fletcher, Lawrence Yuen, Emma Johnston, Tony Pang, Vincent Lam, Michael Hollands, Arthur Richardson, Henry Pleass (Australia)
- PO636-WED **IMPACT OF WEIGHT CHANGE ON RISK OF VENOUS THROMBOEMBOLISM: THE TROMSØ STUDY**  
Lars Daas Horvei\*, Tine Lønneberg, Sigrid Brækkan, John-Bjarne Hansen (Norway)

## SCIENTIFIC PROGRAM

- PO637-WED **DEVELOPING A CASE DEFINITION FOR VENOUS THROMBOEMBOLISM-RELATED DEATHS USING DEATH CERTIFICATES**  
Ashley Sword-Buster\*, Aaron Wendelboe, Janis Campbell, Michele Beckman, Nimia Reyes, Gary Raskob (United States)
- PO638-WED **CASE-FATALITY AFTER PULMONARY EMBOLISM AND STROKE IN SUBJECTS WITH ATRIAL FIBRILLATION**  
Ina Rye-Holmboe\*, Erin Hald, Anders Vik, Ellisiv Mathiesen, Inger Njølstad, Maja-Lisa Løchen, Sigrid Brækkan, John Bjarne Hansen (Norway)
- PO639-WED **HOSPITAL ACQUIRED THROMBOSIS (HAT) IN AN IRISH TERTIARY REFERRAL HOSPITAL.**  
Muhammad I. Khan\*, Joe Eustace, Susan O'Shea (Ireland)
- PO640-WED **PREVALENCE AND RISK FACTORS FOR PULMONARY EMBOLISM IN PATIENTS WITH ACUTE EXACERBATION OF COPD: RESULTS OF A LARGE COLLABORATIVE STUDY.**  
Francesco Dentali\*, Dimitriy Arioli, Fulvio Pomerio, Nicola Mumoli, Josè Vitale, Filippo Pieralli, Paola Gnerre, Micaela La Regina (Italy)
- PO641-WED **RISK OF FIRST AND RECURRENT VENOUS THROMBOSIS IN INDIVIDUALS TREATED WITH ANTIBIOTICS**  
Jasmijn F. Timp\*, Suzanne Cannegieter, Vladimir Tichelaar, Sigrid Braekkan, Frits Rosendaal, Saskia le Cessie, Willem Lijfering (The Netherlands)
- PO642-WED **INHOSPITAL MORTALITY AMONG CLINICAL AND SURGICAL INPATIENTS RECENTLY DIAGNOSED WITH VENOUS THROMBOEMBOLIC DISEASE**  
Fernando Vazquez\*, Maria Posadas-Martinez, Maria Grande-Ratti, Jimena Vicens, Bruno Boietti, Paloma Rojas-Saunero, Gabriel Waisman, Fernan Quiros, Diego Giunta (Argentina)
- PO643-WED **LOW PREVALENCE OF SYMPTOMATIC VENOUS THROMBOEMBOLISM AFTER HIP AND KNEE ARTHROPLASTY AT SIRIRAJ HOSPITAL**  
Chompunut Wongprasert\*, Theera Ruchutrakool, Bundarika Suwannawiboon, Keerati Chareancholvanich, Pacharapol Udomkiat, Yupa Nakkinkun, Tasneem Binham, Yingyong Chinthammitr (Thailand)
- PO644-WED **THE PREVALENCE AND DIAGNOSTIC CHARACTERISTICS OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION**  
Timothy Fernandes, Timothy Morris, William Auger\* (United States)
- PO645-WED **PREDICTORS OF VENOUS THROMBOEMBOLISM RECURRENCE, ADJUSTED FOR TREATMENTS AND INTERIM EXPOSURES: A POPULATION-BASED CASE-COHORT STUDY**  
John Heit, Brian Lahr, Aneel A. Ashrani\*, Tanya Petterson, Kent Bailey (United States)
- PO646-WED **DABIGATRAN OR WARFARIN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN ANTIPHOSPHOLIPID SYNDROME**  
Sam Schulman\*, Samuel Goldhaber, Clive Kearon, Ajay Kakkar, Sebastian Schellong, Henry Eriksson, Elke Schueler, Martin Feuring, Jörg Kreutzer (Canada)

## SCIENTIFIC PROGRAM

- PO647-WED **MULTICENTER PROSPECTIVE STUDY OF TREATMENT AND RISK FACTORS FOR UNUSUAL SITE THROMBOSIS: TRUST REGISTRY**  
Kim Ma\*, Phillip Wells, Charlotte Guzman, David Anderson, Mark Blostein, Andrew Hirsch, Michael Kovacs, Alejandro Lazo-Langner, Marc Rodger, Vicky Tagalakakis, Susan Kahn (Canada)
- PO648-WED **THE WITHIN PATIENT EFFECT OF STATIN USE ON COAGULATION IN VITAMIN K ANTAGONIST USERS: A CROSSOVER STUDY**  
Nienke Van Rein\*, Joseph Biedermann, Stacey Bonafacio, Marieke Kruij, Willem Lijfering, Felix van der Meer (The Netherlands)
- PO649-WED **RIVAROXABAN VERSUS VITAMIN K ANTAGONIST IN PROVOKED DEEP VENOUS THROMBOSIS - WHICH TREATMENT IS BETTER FOR THE PATIENT ?**  
Emma Groarke\*, William Courtney, Jane Conway, Elaine Conway, Deborah Bourke, Jean Saunders, Michael Watts, Denis O'Keefe (Ireland)
- PO650-WED **WARFARIN DOSING AND TIME TO THERAPUTIC INTERNATIONAL NORMALIZED RATIO IN PATIENTS WITH HYPERCOAGULABILITY SYNDROMES**  
Pushpinderdeep S. Kahlon\*, Shahzaib Nabi, Haythem Ali (United States)
- PO651-WED **SAFETY OF STOPPING ANTICOAGULANT TREATMENT FOR CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM AFTER REACHING COMPLETE REMISSION FROM CANCER**  
Tom Van Der Hulle\*, Paul den Exter, Pim van den Hoven, Jacobus van der Hoeven, Felix van der Meer, Jeroen Eikenboom, Menno Huisman, Frederikus Klok (The Netherlands)
- PO652-WED **PROLONGED USE OF LMWH DURING PREGNANCY AND BONE SAFETY**  
Päivi J. Galambosi\*, Risto Kaaja (Finland)
- PO653-WED **PRACTICE VARIATION IN THE MANAGEMENT OF DISTAL DVT BETWEEN GPS AND VASCULAR MEDICINE PHYSICIANS: A FRENCH SURVEY OF PHYSICIAN PRACTICES**  
Jean-Philippe Galanaud\*, Jennifer Almosni, Arthur Meusy, Pierre Frances, Isabelle Quere (France)
- PO654-WED **IMPROVING EVIDENCE-BASED DECISIONS IN VTE TREATMENT: SIMULATION IN CONTINUING EDUCATION**  
Jelena Spyropoulos\*, Alex Spyropoulos (United States)
- PO655-WED **RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH A FIRST EPISODE OF UNPROVOKED PULMONARY EMBOLISM: A PRE-SPECIFIED SUBGROUP ANALYSIS FROM THE PADIS PE RANDOMIZED TRIAL**  
Francis Couturaud\*, Olivier Sanchez, Gilles Pernod, Patrick Mismetti, Patrick Jogo, Elisabeth Duhamel, Karine Provost, Claire Bal dit Sollier, Emilie Presles, Philippe Castellant, Florence Parent, Pierre Yves Salaun, Luc Bressollette, Michel Nonent, Philippe Lorillon, Philippe Girard, Karine Lacut, Marie Guégan, Jean Luc Bosson, Silvy Laporte, Christophe Leroyer, Hervé Décousus, Guy Meyer, Dominique Mottier (France)
- PO656-WED **NEW ORAL ANTICOAGULANTS (NOACS) IN VTE TREATMENT: WILL MONITORING DIMINISH THEIR COST-EFFECTIVENESS?**  
Carla Vossen\*, Katya Sion, Andreas Karabis (The Netherlands)

### Venous thromboembolism - therapy III

## SCIENTIFIC PROGRAM

- PO657-WED **COMMUNITY HOSPITALS ARE USING NOVEL ORAL ANTICOAGULANTS AND MORE ASPIRIN AS VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS FOLLOWING TOTAL HIP AND KNEE REPLACEMENT**  
Darae Ko\*, Alok Kapoor, Adam Rose, Amresh Hanchate, Donald Miller, Michael Winter, Joseph Palmisano, Zhaoyang Teng, Lori Henault, Yorghos Tripodis, Anita Karcz, Elaine Hylek (United States)
- PO658-WED **GLOBAL ADHERENCE TO AMERICAN COLLEGE OF CHEST PHYSICIANS GUIDELINES FOR THROMBOPROPHYLAXIS AFTER MAJOR ORTHOPEDIC SURGERY. HAVE WE IMPROVED? A SYSTEMATIC REVIEW OF THE LITERATURE**  
Maria P Bautista, Miguel Farfan\*, Guillermo Bonilla, Adolfo Llinas (Colombia, Colombia)
- PO659-WED **INCIDENCE OF THROMBOEMBOLISM IN KOREAN MULTIPLE MYELOMA PATIENTS WITH THALIDOMIDE INDUCTION CHEMOTHERAPY; COMPARISON PREVIOUS DATA IN KOREA.**  
Hyerim Ha\*, Jeonghwan youk, Hyunkyung Park, Jeong-Ok Lee, Soo-Mee Bang, Ki-Hwan Kim, Jin-Hyun Park, Youngil Koh, Inho Kim, Sung-Soo Yoon, Seonyang Park (Korea, Republic Of)
- PO660-WED **THROMBOPROPHYLAXIS IN A PATIENT WITH MORBID OBESITY**  
Saket Badle\*, Simon Coppack, Peter MacCallum (United Kingdom)
- PO661-WED **COAGULATION TESTS FOR DETECTION OF VKA THERAPY INSUFFICIENCY IN PATIENTS WITH ACUTE DEEP VEIN THROMBOSIS**  
Faina Verkholomova\*, Aleksey Krylov, Aleksander Shulutko, Fazly Ataulakhanov, Ilya Serebriyskiy (Russian Federation)
- PO662-WED **BIOMARKERS FOR PREDICTION OF REOCCURRENCE OF VENOUS THROMBOEMBOLISM**  
Abimbola Jarvis\*, Elizabeth Villalobos-menuey, Linda Jacobson, Julie Smith, Marilyn Manco-Johnson (United States)

### Vitamin K antagonists III

- PO663-WED **MEDICATION ADHERENCE OF NOVEL ORAL ANTICOAGULANT VERSUS WARFARIN**  
Yi Feng Lai\*, Jun Kai Neo, Mcvin Hua Heng Cheen, Ming Chai Kong, Heng Joo Ng (Singapore)
- PO664-WED **RISK OF MAJOR BLEEDING IN PATIENTS TREATED WITH VITAMIN K ANTAGONISTS OR ASPIRIN. A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Fernando Vazquez\*, Joaquin Gonzalez, Marc Carrier, Gregoire Le Gal, Esteban Gandara (Argentina)
- PO665-WED **IMPACT OF POINT-OF-CARE INR MONITORING ON ANTICOAGULANT CONTROL DURING TREATMENT WITH VITAMIN K ANTAGONISTS IN PATIENTS MONITORED BY A SPECIALIZED ANTICOAGULATION CLINIC: A POPULATION BASED COHORT STUDY**  
Joseph Biedermann\*, Nienke van Rein, Peter Buhre, Moniek de Maat, Felix van der Meer, Frank Leebeek, Marieke Kruip (The Netherlands)

## SCIENTIFIC PROGRAM

- PO666-WED **MULTI-DOSE DRUG DISPENSING AS A TOOL TO IMPROVE MEDICATION ADHERENCE: A CROSSOVER STUDY**  
Nienke van Rein\*, Kristel de Geus, Suzanne Cannegieter, Pieter Reitsma, Felix van der Meer, Willem Lijfering (The Netherlands)
- PO667-WED **CYP2C9 POLYMORPHISM CONTROLS PHENPROCOUMON METABOLISM RESULTING IN SEVERE BLEEDING EVENTS**  
Gesa Wiegand\*, Ralf Rauch, Vanya Icheva, Elke Schäffeler, Michael Hofbeck, Matthias Schwab (Germany)
- PO668-WED **INCREASED RISK FOR MAJOR BLEEDS AFTER MINOR BLEEDS IS DETERMINED BY UNKNOWN PERSISTENT COMMON RISK FACTORS**  
Nienke Van Rein\*, Willem Lijfering, Isabelle van Vliet, Felix van der Meer, Saskia le Cessie, Suzanne Cannegieter, Pieter Reitsma (The Netherlands)
- PO669-WED **ACCURACY OF A WARFARIN MAINTENANCE DOSE PREDICTOR AFTER COMPLETION OF THE 10 MG INITIATION NOMOGRAM**  
Parvaneh Fallah\*, Philip S. Wells, Melissa A Forgie, Lisa Duffett (Canada)
- PO670-WED **A NATIONAL ANTICOAGULANT MANAGEMENT SERVICE PROVIDED BY COMMUNITY PHARMACIES IN NEW ZEALAND ACHIEVES A HIGH LEVEL OF ANTICOAGULANT CONTROL WHICH IS SAFE AND CONVENIENT FOR PATIENTS.**  
Paul L. Harper\*, Ian McMichael, Dale Griffiths, Claire Hill (New Zealand)
- PO671-WED **RECURRENT THROMBOTIC EVENTS AFTER DISCONTINUATION OF VITAMIN K ANTAGONIST TREATMENT FOR SPLANCHNIC VEIN THROMBOSIS: A MULTICENTER RETROSPECTIVE COHORT STUDY**  
Nicoletta Riva\*, Walter Ageno, Daniela Poli, Sophie Testa, Simona Pedrini, Lucia Marigo, Piera Sivera, Samantha Pasca, Giuseppe Malcangi, Cavallero Giobatta, Pietro Falco, Lucia Ruocco, Carmelo Paparo, Eugenio Bucherini, Luciano Suriano, Luigi Ria, Alberto Tosetto (Italy)
- PO672-WED **PATIENTS WITH VITAMIN K ANTAGONIST (VKA) RESISTANCE: DOES THE IDENTIFICATION OF VKORC1 MUTATIONS HELP PREDICTING THE MAINTENANCE DOSAGE?**  
Isabelle Gouin-Thibault\*, Emeline Gillet, Julie Fréchaud, Alain Stépanian, Emmanuel de Maistre, Céline Narjoz, Jean-Louis Golmard, Pascale Gaussem, Anne-Marie Fischer, Katell Peoch, Marie-Anne Lorient, Virginie Siguret (France)
- PO673-WED **SIMILAR PERFORMANCE OF HASBLED, CHADS2 AND CHA2DS2VASC SCORES IN BLEEDING RISK PREDICTION: DO WE NEED A BLEEDING SCORE?**  
Daniela Poli\*, Emilia Antonucci (Italy)
- PO674-WED **LOW INCIDENCE OF BLEEDING EVENTS IN A "REAL WORLD", VITAMIN K ANTAGONIST-TREATED PATIENT POPULATION: RESULTS FROM THE START-REGISTER**  
Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo\*, Armando Tripodi, Nicola Magrini, Francesco Marongiu, Gualtiero Palareti (Italy)

## SCIENTIFIC PROGRAM

- PO675-WED **THE START-REGISTER (SURVEY ON ANTICOAGULATED PATIENTS REGISTER): FOCUS ON PATIENTS TREATED FOR NON-VALVULAR ATRIAL FIBRILLATION**  
Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo\*, Armando Tripodi, Nicola Magrini, Francesco Marongiu, Gualtiero Palareti (Italy)
- PO676-WED **EAHAD-DB: A COMBINED COAGULATION FACTOR VARIANT DATABASES RESOURCE FOR THE CLINICAL AND SCIENTIFIC COMMUNITIES**  
Daniel J. Hampshire\*, Andrea Cairo, Gerard Dolan, Muriel Giansily-Blaizot, Keith Gomez, Anne Goodeve, Geoffrey Kemball-Cook, Christopher Ludlam, John McVey, Johannes Oldenburg, Stephen Perkins, Flora Peyvandi, Pavithra Rallapalli (United Kingdom)
- PO677-WED **POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TAKING VITAMIN K ANTAGONISTS: A ROLE OF THE QUALITY OF ANTICOAGULATION**  
Michał Zabczyk\*, Jakub Siudut, Anetta Undas (Poland)

## Scientific Program

---

Thursday, June 25

### Trainee Tracks (oral sessions only):

- Platelets track
- Basic thrombosis and hemostasis track
- ✚ Clinical bleeding track
- ▲ Clinical thrombosis track
- ★ Pediatric thrombosis and hemostasis track
- ♥ Cardiovascular and arterial diseases track

An asterisk (\*) after a name denotes the presenting author

**Isth**  
2015 Congress  
TORONTO JUNE 20-25

---

Reaching for Unprecedented Peaks



# SCIENTIFIC PROGRAM

Thursday, June 24, 2015

ORAL COMMUNICATIONS 7 08:00-09:15

▲ Venous thromboembolism – therapy II

Plenary Hall F&G

Moderators: Michael Kovacs (Canada), Carl-Erik Dempfle (Germany)

- 08:00 – 08:15  
OR381 **PATIENTS WITH CANCER ASSOCIATED THROMBOSIS: LONG-TERM VTE RECURRENCES AND BLEEDINGS ACCORDING TO CANCER SITE; DATA FROM THE RIETE REGISTRY**  
Isabelle Mahé\*, Laurent Bertoletti, Jean Chidiac, Javier Trujillo-Santos, Fares Moustafa, Henri Bounameaux, Llorenç Font, Maria Dolores Adarraga, Pablo Javier Marchena, Manuel Monreal (France)
- 08:15 – 08:30  
OR382 **DURATION OF ANTICOAGULATION FOLLOWING ACUTE VENOUS THROMBOEMBOLISM IN ROUTINE CARE IN ENGLAND: AN OBSERVATIONAL STUDY USING CPRD-HES DATABASES**  
Laure Lacoïn, Essra Ridha\*, Cinira Lefevre, Vidya Moorthy, Mridula Vasudev, Steven Lister, Alex Bird, Ian Minns, Ameet Bakhai, Raza Alikhan (United Kingdom)
- 08:30 – 08:45  
OR383 **NO BENEFICIAL EFFECT OF STATINS IN REDUCING RECURRENT DISEASE IN A META-ANALYSIS OF 21,587 PATIENTS WITH ACUTE SYMPTOMATIC VENOUS THROMBOEMBOLISM TREATED IN PHASE 3 TRIALS COMPARING DIRECT ORAL ANTICOAGULANTS WITH VITAMIN K ANTAGONISTS**  
Mandy N. Lauw\*, Sam Schulman, Martin Gebel, George Zhang, Min Lin, Michael Grosso, Harry Buller (The Netherlands)
- 08:45 – 09:00  
OR384 **NET CLINICAL BENEFIT OF HOSPITALIZATION VERSUS OUTPATIENT MANAGEMENT OF PATIENTS WITH ACUTE PULMONARY EMBOLISM**  
Pierre-Marie Roy\*, Daniel Corsi, Antony Theogene, Carine de Wit, Carole Dennie, Grégoire Le Gal, Marc Rodger, Phillip Wells, Marc Carrier, Esteban Gandara (France)
- 09:00 – 09:15  
OR385 **EXTENDED DURATIONS OF ANTICOAGULATION AND MORTALITY FOLLOWING INCIDENT VENOUS THROMBOEMBOLISM IN THE Q-VTE COHORT**  
Adi Klil-Drori\*, Janie Coulombe, Samy Suissa, Vicky Tagalakis (Canada)

★ + Hemophilia – joint disease and clinical

Room 718

Moderators: Jenny Goudemand (France), Marilyn Manco-Johnson (United States)

- 08:00 – 08:15  
OR386 **INTRACRANIAL HAEMORRHAGE IN CHILDREN WITH INHERITED BLEEDING DISORDERS IN THE UK 2003-2013.**  
Elizabeth Chalmers\*, Jayanthi Alamelu, Peter Collins, Mary Mathias, Jeanette Payne, Mike Richards, Oliver Tunstall, Mike Williams, Ben Palmer, Andrew Mumford (United Kingdom)

# SCIENTIFIC PROGRAM

- 08:15 – 08:30  
OR387 **PERIOPERATIVE TREATMENT OF HEMOPHILIA A PATIENTS: BLOOD GROUP O PATIENTS ARE AT RISK OF BLEEDING COMPLICATIONS**  
Hendrika C. Hazendonk\*, Janske Lock, Ron Mathôt, Karina Meijer, Marjolein Peters, Britta Laros-van Gorkom, Felix van der Meer, Mariëtte Driessens, Karin Fijnvandaat, Frank Leebeek, Marjon Cnossen (The Netherlands)
- 08:30 – 08:45  
OR388 **SPINART 3-YEAR ANALYSES: PATIENT- AND JOINT-LEVEL CHANGES IN COLORADO ADULT JOINT ASSESSMENT SCALE AND MAGNETIC RESONANCE IMAGING SCORES WITH BAYER'S SUCROSE-FORMULATED RECOMBINANT FACTOR VIII IN ADOLESCENTS AND ADULTS**  
Sharon Funk\*, Björn Lundin, Walter Hong (United States)
- 08:45 – 09:00  
OR389 **BLEEDING PHENOTYPE AND BASELINE FVIII LEVEL IN PATIENTS WITH NONSEVERE HEMOPHILIA A: RESULTS FROM THE INSIGHT STUDY**  
Samantha C. Gouw\*, Eva Stokhuijzen, Alice van Velzen, Corien de Groot-Eckhardt, Charles Hay, Jan Astermark, Frans Smiers, Cedric Hermans, Ri Liesner, Massimo Morfini, Marjolein Peters, Johanna van der Bom, Karin Fijnvandraat (The Netherlands)
- 09:00 – 09:15  
OR390 **NOVEL IMAGING TECHNIQUE FOR ASSESSMENT OF EARLY CARTILAGE CHANGES IN HAEMOPHILIC KNEES AND ANKLES**  
Humayun Ahmed\*, Johnny Wang, Afsaneh Amirabadi, Marshall Sussman, Carina Man, Victor Blanchette, Andrea Doria (Canada)

Risk factors for venous thrombosis - III

Room 701

Moderators: Leslie Zypchen (Canada), Jacob Odeberg (Sweden)

- 08:00 – 08:15  
OR391 **AGEING OF THE VENOUS VALVES AS A NEW RISK FACTOR FOR VENOUS THROMBOSIS IN THE ELDERLY – THE BATAVIA STUDY**  
Alev Karasu\*, Alexandr Sramek, Frits R. Rosendaal, Astrid van Hylckama Vlieg (The Netherlands)
- 08:15 – 08:30  
OR392 **IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOSIS ON THE ASSOCIATIONS BETWEEN FAMILY HISTORY OF MYOCARDIAL INFARCTION AND RISKS OF MYOCARDIAL INFARCTION AND VENOUS THROMBOEMBOLISM**  
Birgit Småbrekke\*, Caroline Lind, Ludvig Rinde, Erin Smith, Terry Solomon, Tom Wilsgaard, Inger Njølstad, Ellisiv Mathiesen, Frits Rosendaal, Sigrid Brækkan, Kelly Frazer, John-Bjarne Hansen (Norway)
- 08:30 – 08:45  
OR393 **IMPACT OF VARIANTS IN THE FACTOR 5 GENE ON THE RISK OF VENOUS THROMBOEMBOLISM IN CANCER**  
Olga Dziewiecka\*, Erin Smith, Sigrid Brækkan, Hilde Jensvoll, Kristine Blix, Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
- 08:45 – 09:00  
OR394 **IDENTIFICATION OF NEW GENETIC RISK FACTORS FOR VENOUS THROMBOSIS BY TARGETED SEQUENCING: RESULTS OF THE MILES STUDY**  
Hugoline G. de Haan\*, Astrid van Hylckama Vlieg, Luca Lotta, Marcin Gorski, Paolo Bucciarelli, Ida Martinelli, Trevor Baglin, Flora Peyvandi, Frits Rosendaal (The Netherlands)

## SCIENTIFIC PROGRAM

09:00 – 09:15  
OR395  
**OCCURENCE AND PREDICTORS OF RECURRENCE WITHIN 3 YEARS AFTER A FIRST EPISODE OF ACUTE VENOUS THROMBOEMBOLISM: WORCESTER VENOUS THROMBOEMBOLISM STUDY**  
Wei Huang\*, Robert Goldberg, Frederick Anderson, Frederick Spencer (United States)

### ♥ Anti-platelet agents – clinical

Room 801

*Moderators: Marco Cattaneo (Italy), Alan Michelson (United States)*

08:00 – 08:15  
OR396  
**PLATELET FUNCTION AS A PREDICTOR OF ISCHEMIC AND BLEEDING EVENTS IN PAD PATIENTS UNDERGOING PTA: RESULTS FROM TRIANO STUDY.**  
Rossella Marcucci, Anna Maria Gori\*, Renato Valenti, Rita Paniccia, Stefania Basili, Elisa Grifoni, Giulia Naldini, Guido Parodi, Laura Napoleone, David Antonucci, Francesco Violi, Rosanna Abbate (Italy)

08:15 – 08:30  
OR397  
**IDENTIFICATION OF CANDIDATE GENE MODULATING PLATELET REACTIVITY IN ASPIRIN-TREATED PATIENTS USING A NOVEL NETWORK-BASED APPROACH**  
Anne Zufferey, Mark Ibberson, Jean-Luc Reny, Séverine Nolli, Mylène Docquier, Ioannis Xenarios, Jean-Charles Sanchez, Pierre Fontana\* (Switzerland)

08:30 – 08:45  
OR398  
**PRASUGREL MONOTHERAPY PROVIDES MOST EFFECTIVE PLATELET INHIBITION WITHOUT AFFECTING FIBRIN CLOT DYNAMICS IN INDIVIDUALS WITH DIABETES**  
Robert Storey, Penny rice, Natalie Oxley, Fladia Phoenix, Zeyad Kurdee, Rhodri King, Michal Zabczyk, Peter Grant, Ramzi Ajjan\* (United Kingdom)

08:45 – 09:00  
OR399  
**GENERATION AND CHARACTERIZATION OF A PANEL OF NANOBODIES TOWARDS HUMAN MMP-2: APPLICATION TO THE STUDY OF MMP-2 IN CARDIOVASCULAR PATHOPHYSIOLOGY**  
Alessandro Marturano\*, Maarten Hendrickx, Loredana Bury, Emanuela Falcinelli, Giorgia Manni, Marco Malvestiti, Gholamreza Hassanzadeh-Ghassabeh, Serge Muyl-dermans, Paul Declerck, Paolo Gresele (Italy)

09:00 – 09:15  
OR400  
**HIGH ON ASPIRIN PLATELET REACTIVITY PREDICTS CARDIAC DEATH IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PCI (RECLOSE2-ACS STUDY)**  
Rossella Marcucci\*, Anna Maria Gori\*, Rita Paniccia, Elisa Grifoni, Betti Giusti, Renato Valenti, Guido Parodi, Angela Migliorini, David Antonucci, Gian Franco Gensini, Rosanna Abbate (Italy)

### ● Megakaryocytes and thrombopoiesis III

Room 714

*Moderators: Dominique Baruch (France), Pudur Jagadeeswaran (United States)*

08:00 – 08:15  
OR401  
**MICE LACKING THE INHIBITORY COLLAGEN RECEPTOR LAIR1 EXHIBIT A MILD THROMBOCYTOSIS AND HYPERACTIVE PLATELETS**  
Alexandra Mazharian\*, Steven Thomas, Marie Lordkipanidzé, Danaï Bem, Silke Heising, Linde Meyaard, Yotis Senis, Steve Watson (United Kingdom)

08:15 – 08:30  
OR402  
**IDENTIFICATION OF HOX GENES CONTROLLING THROMBOPOIESIS IN ZEBRAFISH**  
Pudur Jagadeeswaran\*, Hemalatha Sundaramoorthi (United States)

## SCIENTIFIC PROGRAM

08:30 – 08:45  
OR403  
**PROOF OF PRINCIPLE FOR EFFICIENCY IN THROMBOSIS OF SHEAR-GENERATED PLATELETS FROM CULTURED MEGAKARYOCYTES**  
Audrey Pietrzyk-Nivau, Sonia Poirault-Chassac, Alexandre Kauskot, Cécile Denis, Dominique Baruch\* (France)

08:45 – 09:00  
OR404  
**A NOVEL FUNCTION OF CLEC-2 IN MEGAKARYOPOIESIS: CLEC-2/PDPN MICROENVIRONMENT FACILITATES EXPANSION AND MATURATION OF MEGAKARYOCYTES**  
Shogo Tamura\*, Katsue Suzuki-Inoue, Nagaharu Tsukiji, Toshiaki Shirai, Tomoyuki Sasaki, Makoto Osada, Kaneo Satoh, Yukio Ozaki (Japan)

09:00 – 09:15  
OR405  
**THE DENSE BLOOD VESSEL NETWORK IN THE MURINE BONE MARROW SPATIALLY LIMITS MEGAKARYOCYTE MIGRATION**  
Judith M. M. Van Eeuwijk\*, David Stegner, Oğuzhan Angay, Jürgen Pinnecker, Mike Friedrich, Christian Brede, Andreas Beilhack, Bernhard Nieswandt, Katrin Heinze (Germany)

### Von Willebrand factor – II

Room 716

*Moderators: Mackenzie Bowman (Canada), Scott Diamond (United States)*

08:00 – 08:15  
OR406  
**SINGLE NUCLEOTIDE VARIANTS C.2365A>G AND C.2385T>C ARE ASSOCIATED WITH INCREASED VWF PLASMA LEVELS THROUGH AN EFFECT ON MRNA HALF-LIFE**  
Ahmad Mufti\*, Anne Goodeve, Ian Peake, Daniel Hampshire (United Kingdom)

08:30 – 08:45  
OR408  
**PATHOLOGICAL VWF FIBERS RESIST TPA AND ADAMTS13 WHILE FACILITATING THE CONTACT PATHWAY AND SHEAR-INDUCED PLATELET ACTIVATION**  
Bradley A. Herbig\*, Scott Diamond (United States)

08:45 – 09:00  
OR409  
**THE SCAVENGER RECEPTOR STABILIN-2 (STAB-2) MEDIATES CLEARANCE OF HUMAN VON WILLEBRAND FACTOR AND FACTOR VIII BY LIVER SINUSOIDAL ENDOTHELIAL CELLS**  
Laura L. Swystun\*, Colleen Notley, Ilinca Georgescu, Kate Sponagle, Kai Schledzewski, Cyrill Géraud, Sergij Goerdit, Paula James, David Lillcrap (Canada)

09:00 – 09:15  
OR410  
**VON WILLEBRAND FACTOR DEFICIENCY CAUSES INCREASED ANGIOGENESIS FOLLOWING ISCHEMIC TISSUE DAMAGE**  
Richard D. Starke\*, Omary Chillo, Koval Smith, Elisabeth Deindl, Anna Randi (United Kingdom)

### ■ Factor VIII – III

Room 713

*Moderators: Margareth Ozelo (Brazil), Elisa Mancuso (Italy)*

08:00 – 08:15  
OR411  
**CELL-SPECIFIC FVIII EXPRESSION IN HEMOPHILIA A GENE THERAPY TO OVERCOME IMMUNOLOGICAL RESPONSES**  
Simone Merlin\*, Elvira Cannizzo, Valentina Brusca, Kevin Bellofatto, Antonia Follenzi (Italy)

## SCIENTIFIC PROGRAM

- 08:15 – 08:30  
OR412 **INFLUENCE OF VWF-FVIII BINDING ON ARTERIAL THROMBUS FORMATION AND STABILITY IN A MURINE MODEL OF SEVERE TYPE 2N VWD**  
Laura L. Swystun\*, Ilinca Georgescu, Jeff Mewburn, Kate Sponagle, Colleen Notley, David Lillcrap (Canada)
- 08:30 – 08:45  
OR413 **A FVIII/VWF CHIMERIC PROTEIN WITH VWF INDEPENDENT PHARMACOKINETIC PROPERTIES**  
Susannah Patarroyo-White\*, Douglas Drager, Tongyao Liu, Ayman Ismail, Jiayun Liu, Amy Holthaus, Ekta Chhabra, John Kulman, Volker Schellenberger, Robert Peters (United States)
- 08:45 – 09:00  
OR414 **FVIII-VWF INTERACTION ASSESSED BY HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY AND BINDING AFFINITY**  
Johan H. Faber\*, Kasper Lamberth, Jens Hansen, Ole Hvilsted Olsen, Martin Heitmann, Gert Bolt, Thomas Nylandsted Krogh, Frederik Rode, Marianne Kjalke, Jesper Haaning, Lars Thim (Denmark)
- 09:00 – 09:15  
OR415 **IMPROVED PHARMACOKINETICS AND IN VIVO EFFICACY OF PLATELET-TARGETED FACTOR VIIA-XTEN IN HUMAN ALPHA IIB TRANSGENIC / HEMOPHILIA A MICE**  
Arjan Van Der Flier\*, Joe Salas, Zhan Liu, Tamera Ashworth, Elena Kistanova, Sarah Smith, Kai Chen, Deana Rabinovich, Siyuan Tan, Volker Schellenberger, David Light, Robert Peters (United States)

### Platelets – III

Room 715

*Moderators: Kesheng Dai (China), Viola Lorenz (Germany)*

- 08:00 – 08:15  
OR416 **TARGETED DOWNREGULATION OF CLEC-2 OCCURS THROUGH SRC FAMILY KINASE DEPENDENT INTERNALIZATION IN MOUSE PLATELETS**  
Viola Lorenz\*, David Stegner, Simon Stritt, Timo Vögtle, Friedemann Kiefer, Walter Witke, Steve Watson, Barbara Walzog, Bernhard Nieswandt (Germany)
- 08:15 – 08:30  
OR417 **PROTEIN DISULFIDE ISOMERASE DENITROSYLASE ACTIVITY IN PLATELET ACTIVATION**  
Roelof Bekendam\*, Srila Gopal, Pavan Bendapudi, Kristina Cook, James Dilks, Lin Lin, Sheryl Bowley, Jack Stopa, Mingdong Huang, Kevin Croce, Bruce Furie, Phil Hogg, Robert Flaumenhaft (United States)
- 08:30 – 08:45  
OR418 **PEAR1: A NOVEL LINK BETWEEN IGE-MEDIATED ALLERGY AND CARDIOVASCULAR DISEASE**  
Yi Sun, Christophe Vandenbrielle\*, Alexandre Kauskot, Peter Verhamme, Marc Hoylaerts, Gavin Wright (Belgium)
- 08:45 – 09:00  
OR419 **CHARACTERIZATION OF A NOVEL INTEGRIN BINDING PROTEIN THAT IS ESSENTIAL FOR ALPHAIIIBETA3 OUTSIDE-IN SIGNALING AND HEMOSTASIS**  
Binggong Xiang\*, Guoying Zhang, Shaojing Ye, Cai Huang, Jun Liu, Min Tao, Chang-geng Ruan, Susan Smyth, Sidney Whiteheart, Zhenyu Li (United States)
- 09:00 – 09:15  
OR420 **GPVI INTERACTION WITH POLYMERIZED FIBRIN BOOSTS THROMBIN GENERATION AND THROMBUS GROWTH**  
Pierre Mangin\*, Elmina Mammadova-Bach, Bénédicte Dumont, Stéphane Loyau, Christian Gachet, Véronique Ollivier, Martine Jandrot-Perrus (France)

## SCIENTIFIC PROGRAM

### Regulation of coagulation and fibrinolysis

Room 717

*Moderators: William Sheffield (Canada), Maureen Hoffman (United States)*

- 08:00 – 08:15  
OR421 **PLASMINOGEN ACTIVATOR INHIBITOR-1 PARTIALLY PROTECTS MICE AGAINST CARDIAC FIBROSIS BY INHIBITING UROKINASE-TYPE PLASMINOGEN ACTIVATOR-MEDIATED PLASMINOGEN ACTIVATION**  
Kamlesh K. Gupta\*, Deborah Donahue, Mayra Sandoval-Cooper, Donna Emge, Francis Castellino, Victoria Ploplis (United States)
- 08:15 – 08:30  
OR422 **PROTECTIVE ROLE OF PROTEASE NEXIN-1 AGAINST LUNG FIBROSIS IN BLEOMYCIN-TREATED MICE**  
Déborah François\*, Marie-Christine Bouton, Laurence Venisse, Martine Jandrot-Perrus, Véronique Arocas (France)
- 08:30 – 08:45  
OR423 **AN ANTI-STAPHYLOCOAGULASE MONOCLONAL ANTIBODY INHIBITS PROTHROMBIN ACTIVATION AND PROLONGS SURVIVAL IN MICE FOLLOWING STAPHYLOCOCCUS AUREUS INFECTION.**  
Kaitlyn Begins\*, William Church, Ashoka Maddur, Peter Panizzi, Paul Bock (United States)
- 08:45 – 09:00  
OR424 **PROTEIN DISULFIDE ISOMERASE RELEASED DURING THROMBUS FORMATION CLEAVES A DISULFIDE BOND IN PLASMA VITRONECTIN AND ENABLES ITS BINDING TO ALPHAVBETA3 INTEGRIN.**  
Sheryl R. Bowley\*, Barbara Furie, Bruce Furie (United States)
- 09:00 – 09:15  
OR425 **IDENTIFICATION OF ALPHA-1 PROTEINASE INHIBITOR VARIANTS WITH ENHANCED SPECIFICITY FOR ACTIVATED FACTOR XI OVER THROMBIN VIA COMBINED PHAGE DISPLAY AND BACTERIAL LYSATE SCREENING**  
Varsha Bhakta, William Sheffield\* (Canada)

### Blood coagulation tests – II

Room 705

*Moderators: Aida Inbal (Israel), Cedric Carter (Canada)*

- 08:00 – 08:15  
OR426 **ANALYSIS OF FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY IN BURN PATIENTS**  
Saulius Butenas\*, Daniel Jo, Lauren Moffatt, Jeffrey Shupp (United States)
- 08:15 – 08:30  
OR427 **THE WHOLE BLOOD THROMBIN GENERATION TEST PREDICTS BLEEDING RISK IN PATIENTS TAKING VITAMIN K ANTAGONISTS**  
Saartje Bloemen\*, Arina ten Cate-Hoek, Hugo ten Cate, Bas de Laat (The Netherlands)
- 08:30 – 08:45  
OR428 **COMPARATIVE IN VITRO EVALUATION OF THROMBIN GENERATION ASSAY (TGA) AFTER SPIKING FRESH FROZEN PLASMA (FFP) OR PROTHROMBIN COMPLEX CONCENTRATE (PCC) TO SAMPLES FROM PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION (OLT)**  
Mikael Perin, Laurent Ardillon, Benedicte Delahousse, Ephrem Salamé, Yves Gruel\* (France)
- 08:45 – 09:00  
OR429 **EFFECTS OF APIXABAN ON PT AND APTT AS DETERMINED WITH A FULL RANGE OF REAGENTS: RESULTS OF A UK NEQAS EXERCISE**  
Stephen Kitchen, Ian Jennings\*, Anna Lowe, Dianne Kitchen, Tim Woods, Isobel Walker (United Kingdom)

## SCIENTIFIC PROGRAM

09:00 – 09:15  
OR430 **PROTHROMBOTIC MECHANISMS IN A SETTING OF PERI-OPERATIVE BRIDGING WITH LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS UNDERGOING SURGERY**  
Pieter Eijgenraam, Hugo ten Cate, Yvonne Henskens, René van den Ham, Arina ten Cate-Hoek\* (The Netherlands)

### Fibrinogen and fibrin II

Room 707

*Moderators: Michael Nagler (The Netherlands), Nicola Mutch (United Kingdom)*

08:00 – 08:15  
OR431 **SEQUENCING OF FGA, FGB AND FGG REVEALS BOTH NOVEL AND PREVIOUSLY DESCRIBED MUTATIONS IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCIES**  
Natalie Smith\*, Leila Noetzli, Tara Adams, Salvador Minoldo, Hugo Guglielmo, Marilyn Manco-Johnson, Jorge Di Paola (United States)

08:15 – 08:30  
OR432 **HEREDITARY AFIBRINOGENEMIA – LONG-TERM OBSERVATION OF A HIGHLY THROMBOGENIC CONDITION AND IT'S MANAGEMENT**  
Michael Nagler\*, Johanna Kremer Hovinga, Lorenzo Alberio, Kristiina Peter-Salonen, Hendrik von Tengg-Koblighk, Daniel Lottaz, Bernhard Lämmle (Switzerland, Netherlands)

08:30 – 08:45  
OR433 **ELEVATED FIBRINOGEN BUT NOT FIBRINOGEN GAMMA PRIME IN ABDOMINAL AORTIC ANEURYSMAL DISEASE**  
Fraser Macrae\*, Tittu Thomas, Anne Johnson, Katherine Bridge, Helen Philippou, D Scott, Robert Ariens (United Kingdom)

08:45 – 09:00  
OR434 **ROLE OF FIBRINOGEN IN HEPATOCYTE PROLIFERATION AFTER ACETAMINOPHEN OVERDOSE**  
Anna Kopec\*, Nikita Joshi, Keara Towery, Holly Cline-Fedewa, Matthew Flick, James Luyendyk (United States)

09:00 – 09:15  
OR435 **PROTHROMBOTIC PROPERTIES OF FIBRIN CLOTS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE**  
Wilma Potze, Mohammad Siddiqui, Sherry Boyett, Jelle Adelmeijer, Kalyani Daita, Arun Sanyal, Ton Lisman\* (The Netherlands)

### Cancer and thrombosis – basic – II

Room 709

*Moderators: Ali Al-Hashimi (Canada), Cihan Ay (Austria)*

08:00 – 08:15  
OR436 **ANTI-TUMORIGENIC EFFECTS ARE EXERTED BY EXOSOMES DERIVED FROM HEPARIN TREATED HUMAN BREAST CANCER CELLS AND PERSIST EVEN AFTER HEPARIN TREATMENT HAS BEEN DISCONTINUED**  
Yunliang Chen\*, Michael Scully, Christopher Goodwin, Ajay Kakkar (United Kingdom)

08:15 – 08:30  
OR437 **CONTRIBUTION OF ANTI-GRP78 AUTOANTIBODIES TO PROSTATE CANCER PROGRESSION THROUGH TISSUE FACTOR PROCOAGULANT ACTIVITY**  
Ali Al-Hashimi\* (Canada)

08:30 – 08:45  
OR438 **CANCER CELLS BXP3 AND MCF7 DIFFERENTIALLY REVERSE THE INHIBITION OF THROMBIN GENERATION BY APIXABAN, FONDAPARINUX AND ENOXAPARIN**  
Aurélié Rousseau, Patrick Van Dreden, Ismail Elalamy, Grigoris Gerotziafas\* (France)

## SCIENTIFIC PROGRAM

08:45 – 09:00  
OR439 **INHIBITION OF MICROPARTICLE INDUCED TUMOR CELL MIGRATION BY LMWH TINZAPARIN**  
Frank Gieseler\*, Hans Gamperl, Corinna Plattfaut, Rike Theophil, Tabea Quecke (Germany)

09:00 – 09:15  
OR440 **NOVEL REGULATION OF TFPI EXPRESSION BY OESTROGENS IN BREAST CANCER CELLS THROUGH MICRORNAS**  
Huda O. Ali\*, Ana Arroyo, Rocío Conejero, Benedicte Stavik, Nina Iversen, Per Morten Sandset, Constantino Martínez, Grethe Skretting (Norway)

### Fibrinolytic system – II

Room 711

*Moderators: Tom Plug (The Netherlands), Colin Longstaff (United Kingdom)*

08:00 – 08:15  
OR441 **THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) PEPTIDES SELECTIVELY MODULATE TAFI ACTIVATION BY THROMBIN OR THE THROMBIN-THROMBOMODULIN COMPLEX**  
Tom Plug\*, Arnold Marquart, Pauline Marx, Joost Meijers (The Netherlands)

08:15 – 08:30  
OR442 **LYSINE RESIDUES 42, 43, AND 44 OF THROMBIN ACTIVABLE FIBRINOLYSIS INHIBITOR CONTRIBUTE TO ITS ACTIVATION BY THE THROMBIN-THROMBOMODULIN COMPLEX IN A COOPERATIVE FASHION**  
Chengliang Wu\*, Ann Gils, Paul Declerck, James Fredenburgh, Jeffrey Weitz, Paul Kim (Canada)

08:30 – 08:45  
OR443 **ELUCIDATION OF THE MOLECULAR MECHANISMS OF TWO NANOBODIES THAT INHIBIT TAFI ACTIVATION AND TAFIA ACTIVITY**  
Xiaohua Zhou\*, Stephen Weeks, Sergei Strelkov, Nico Callewaert, Paul Declerck (Belgium)

08:45 – 09:00  
OR444 **THE ROLE OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN HUMAN ABDOMINAL AORTIC ANEURYSMS**  
Katherine I. Bridge\*, Mark Hesketh, Lize Bollen, Fraser Macrae, Anne Johnson, Helen Philippou, Julian Scott, Ann Gils, Robert Ariens (United Kingdom)

09:00 – 09:15  
OR445 **MECHANISTIC STUDIES AND FIBRIN SPECIFICITY OF STREPTOKINASE FROM STREPTOCOCCUS PYOGENES**  
Craig Thelwell\*, Sian Huish-Williams, Colin Longstaff (United Kingdom)

**Coffee break time in the Foyers (Levels 700 and 800)  
From 09:15 to 09:30**

# SCIENTIFIC PROGRAM

Thursday, June 25, 2015

PLENARY SESSION 09:30-10:15

Louis B. Jaques Plenary Lecture

Moderator: Geoff Werstuck (Canada)

09:30 - 10:15 **Non-coding RNAs: novel therapeutic targets in cardiovascular disease**  
Stefanie Dimmeler (Germany)



Louis B. Jaques, 1911-1997

Wednesday, June 24, 2015

ABSTRACT SYMPOSIA 10:30-11:45

ADAMTS13

Room 717

Moderators: Johanna Kremmer Hovinga (Switzerland), Andrew Yee (United States)

10:30-10:50 **ADAMTS13: DYNAMIC INTERACTIONS WITH VON WILLEBRAND FACTOR**  
AS177 David Lane (United Kingdom)

10:50 - 11:04 **ADAMTS13-INDUCED UNFOLDING OF THE VON WILLEBRAND FACTOR**  
AS178 **A2 DOMAIN**  
Louis Deforche\*, Hendrik Feys, Karen De Ceunynck, Aline Vandenbulcke, Nele Van-deputte, Elien Roose, Yoshihiro Fujimura, Kenji Soejima, David A. Lane, Brenda Luken, J. Evan Sadler, Hans Deckmyn, Simon De Meyer, Karen Vanhoorelbeke (Belgium)

11:04 - 11:18 **N-LINKED GLYCOSYLATION IS A MODULATOR OF ADAMTS13**  
AS179 **EXPRESSION, STRUCTURE AND FUNCTION.**  
Agata A. Nowak\*, Rens de Groot, Mike Laffan, Thomas McKinnon (United Kingdom)

11:18 - 11:32 **ADAMTS13 DEFICIENCY WORSENS MURINE COLITIS AND TREATMENT**  
AS180 **OF WILD TYPE COLITIC MICE WITH RHADAMTS13 LEADS TO IMPROVEMENT**  
Naamah L. Zitomersky\*, Melanie Demers, Kimberly Martinod, Maureen Gallant, Denisa Wagner (United States)

# SCIENTIFIC PROGRAM

11:32 - 11:45 **VON WILLEBRAND FACTOR, ADAMTS13 AND THE RISK OF MORTALITY:**  
AS181 **THE ROTTERDAM STUDY**

Michelle A. H. Sonneveld\*, Mohammed Ikram, Maryam Kavousi, Albert Hofman, Oscar Franco, Frank Leebeek, Moniek de Maat (The Netherlands)

● Novel anti-platelet agents

Plenary Hall F&G

Moderators: Paul Jurasz (Canada), Jean-François Schved (France)

10:30-11:00 **CHEMOPROTEOMIC DISCOVERY OF NOVEL ANTI-PLATELET TARGETS**  
AS182 Leslie Parise (United States)

11:00 - 11:15 **A SMALL MOLECULE INHIBITOR OF ASK1 PROTECTS MICE FROM**  
AS183 **THROMBOSIS WITH MINIMAL EFFECT ON HEMOSTASIS**  
Meghna Naik\*, Brendan Bachman, David Maloney, Ulhas Naik (United States)

11:15 - 11:30 **SITE SPECIFIC INHIBITION OF THROMBUS FORMATION USING SHEAR**  
AS184 **SENSITIVE ANTI-THROMBOTIC NANOPARTICLES**  
Erik Westein\*, Christopher Molloy, Joy Yao, Karlheinz Peter (Australia)

11:30 - 11:45 **MODULATING PLATELET REACTIVITY THROUGH REGULATED CONTROL**  
AS185 **OF FREE RGS18 LEVELS**  
Peisong Ma\*, Andrew Sinnamon, Kristy Ou, Lawrence Brass (United States)

Glycobiology

Room 711

Moderators: Gilbert White (United States), Silvia Giannini (United States)

10:30-11:00 **PLATELET GLYCOBIOLOGY: THE POWERS OF POSTTRANSLATIONAL**  
AS186 **MODIFICATIONS**  
Karin Hoffmeister (United States)

11:00 - 11:15 **RECESSIVE AND TRANSIENT ANTITHROMBIN DEFICIENCY CAUSED**  
AS187 **BY A WIDE SPECTRUM OF CONGENITAL DISORDERS OF N-GLYCOSYLATION WITH UNUSUAL CLINICAL FEATURES. IDENTIFICATION OF A NEW THROMBOPHILIC DISORDER**  
Maria Eugenia De La Morena-Barrio\*, Irene Martínez-Martínez, Mara Toderici, Carmen De Cos, Teresa Sevivas, Antonia Miñano, José Padilla, Dirk Lefeber, Jaak Jaeken, Vicente Vicente, Javier Corral (Spain)

11:15 - 11:30 **MECHANISM OF N-LINKED GLYCAN STABILISATION OF THE VON**  
AS188 **WILLEBRAND FACTOR A2 DOMAIN**  
Christopher J. Lynch\*, David Lane (United Kingdom)

11:30 - 11:45 **PEPTIDE ANTAGONISTS FOR P-SELECTIN DISCRIMINATE BETWEEN**  
AS189 **SULFATIDE-DEPENDENT PLATELET AGGREGATION AND PSGL-1-MEDIATED CELL ADHESION**  
Suzanne J. Korporaal\*, Tom Molenaar, Bianca Lutters, Illiana Meurs, Sandra Verhoef, Martin Ijsseldijk, Johan Kuiper, Theo Van Berkel, Jan-Willem Akkerman, Erik Biessen (The Netherlands)

## SCIENTIFIC PROGRAM

### ▲ Unusual site venous thrombosis

Room 718

*Moderators: Alejandro Lazo-Langner (Canada), Walter Ageno (Italy)*

- 10:30-11:00  
AS194 **MANAGEMENT OF MESENTERIC VEIN THROMBOSIS**  
Geoffrey Nguyen (Canada)
- 11:00 - 11:15  
AS195 **ANTITHROMBOTIC TREATMENT AND OUTCOMES OF CIRRHOTIC PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS: A SUB-STUDY FROM THE ISTH REGISTRY**  
Nicoletta Riva\*, Walter Ageno, Marco Senzolo, Sam Schulman, Jan Beyer-Westendorf, Rita Duce, Rita Santoro, Pieter Kamphuisen, Doyeun Oh, Cecilia Becattini, Kryssia Rodriguez, Giovanni Barillari, Serena Maria Passamonti, Maria Anna Guardascione, Gianpaolo Vidili, Antonella Vaccarino, Francesco Dentali, IRSVT study investigators (Italy)
- 11:15 - 11:30  
AS196 **NEXT-GENERATION DNA SEQUENCING APPROACH TO IDENTIFY NOVEL GENETIC RISK FACTORS UNDERLYING CEREBRAL VEIN THROMBOSIS.**  
Marcin M. Gorski\*, Hugoline de Haan, Astrid van Hylckama Vlieg, Luca A. Lotta, Paolo Bucciarelli, Serena Passamonti, Ida Martinelli, Frits Rosendaal, Flora Peyvandi (Italy)
- 11:30 - 11:45  
AS197 **THE CURRENT MANAGEMENT STRATEGIES AND CLINICAL OUTCOME OF UPPER EXTREMITY DEEP VEIN THROMBOSIS**  
Suzanne Bleker\*, Nick van Es, Ankie Kleinjan, Harry Büller, Pieter Kamphuisen, Anita Aggarwal, Jan Beyer-Westendorf, Giuseppe Camporese, Benilde Cosmi, Thomas Gary, Angelo Ghirarduzzi, Karin Kaasjager, Teresa Lerede, Peter Marschang, Karina Meijer, Hans-Martin Otten, Ettore Porreca, Marc Righini, Peter Verhamme, Sanne van Wissen, Marcello Di Nisio (The Netherlands)

### ♥ Atherosclerosis: progression and development

Room 709

*Moderators: Hugo Ten Cate (The Netherlands), Tilman Hackeng (The Netherlands)*

- 10:30-10:50  
AS198 **ENDOTHELIAL DYSFUNCTION, INFLAMMATION AND THE INITIATION OF ATHEROSCLEROSIS**  
Myron Cybulsky (Canada)
- 10:50 - 11:04  
AS199 **PLATELET-DERIVED MATRIX METALLOPROTEINASE (MMP)-2 CONTRIBUTES TO ATHEROSCLEROSIS PROGRESSION IN HYPERCHOLESTEROLEMIC MICE**  
Stefania Momi\*, Emanuela Falcinelli, Giorgia Manni, Paolo Gesele (Italy)
- 11:04 - 11:18  
AS200 **MACROPHAGE M2 DIFFERENTIATION INDUCES PAI-1 EXPRESSION VIA A STAT6 DEPENDENT PATHWAY**  
Philipp Hohensinner\*, Barbara Thaler, Christoph Kaun, Benjamin Ebenbauer, Michael Fischer, Gerald Maurer, Kurt Huber, Walter Speidl, Johann Wojta (Austria)
- 11:18 - 11:32  
AS201 **M1 AND M2 MACROPHAGE PROTEOLYTIC AND ANGIOGENIC PROFILES ANALYSIS IN ATHEROSCLEROTIC PATIENTS REVEALS A DISTINCTIVE PROFILE IN TYPE 2 DIABETES**  
Charlotte Roma, Madjid Tagzirt, Christophe Zawadzki, Rodrigo Lorenzi, André Vincenzelli, Stephan Haulon, Francis Juthier, Bart Staels, Brigitte Jude, Eric Van Belle, Giulio Chinetti-Gbaguidi, Sophie Susen, Annabelle Dupont\* (France)

## SCIENTIFIC PROGRAM

### 11:32 - 11:45 AS202 **IDENTIFICATION OF CARDIOVASCULAR DISEASE SPECIFIC GENES AND THEIR REGULATING MIRNA'S**

Urushali Deshpande\*, Madan Ghatge, Lakshmi Mundkur, Vijay Kakkar (India)

### Fibrinolysis in health and disease

Room 707

*Moderators: Francis Castellino (United States), Thijs van Mens (The Netherlands)*

- 10:30-11:00  
AS203 **ROLE OF PLASMINOGEN RECEPTOR KT (PLG-RKT) IN HEALTH AND DISEASE**  
Lindsey Miles (United States)
- 11:00 - 11:15  
AS204 **PLASMINOGEN LOCALIZES TO DISTINCT CAPS ON PHOSPHATIDYLSERINE-EXPOSING PLATELETS AND PROMOTES THROMBUS LYSIS UNDER FLOW**  
Claire S. Whyte, Frauke Swieringa, Tom Mastenbroek, Ausra Lionikiene, Marcus Lance, Paola van der Meijden, Johan Heemskerk, Nicola Mutch\* (United Kingdom)
- 11:15 - 11:30  
AS205 **INHIBITION OF TAFI AFFECTS AAA FORMATION AND RUPTURE IN THE ANGIOTENSIN II MODEL OF ABDOMINAL AORTIC ANEURYSM**  
Katherine I. Bridge\*, Charlotte Revill, Marc Bailey, Nadira Yuldasheva, Stephen Wheatcroft, Roger Butlin, Richard Foster, Julian Scott, Ann Gils, Robert Ariens (United Kingdom)
- 11:30 - 11:45  
AS206 **ROLE OF DNA METHYLATION IN CANDIDATE GENES REGIONS ON TISSUE PLASMINOGEN ACTIVATOR LEVELS**  
Nora Zwingerman\*, Irfahan Kassam, Vinh Truong, Dylan Aïssi, Jessica Dennis, Michael Wilson, Phil Wells, Pierre-Emmanuel Morange, David-Alexandre Trégouët, France Gagnon (Canada)

### Protein C and sepsis

Room 714

*Moderators: Laura Pepler (Canada), Kamlesh Gupta (United States)*

- 10:30-11:00  
AS207 **PROTEIN C (APC) FUNCTIONS IN INFLAMMATORY DISEASES**  
Charles "Chuck" Esmon (United States)
- 11:00 - 11:15  
AS208 **SILENCING ANTITHROMBIN AND PROTEIN C IN APOE KNOCKOUT MICE CAUSES SEVERE COAGULOPATHY BUT NOT ATHEROTHROMBOSIS**  
Amber B. Ouweneel\*, Marco Heestermaans, Bart Van Vlijmen, Miranda Van Eck (The Netherlands)
- 11:15 - 11:30  
AS209 **E-WE THROMBIN ACTIVATES PROTEIN C ON THE PLATELET SURFACE AND RAPIDLY INTERRUPTS EXPERIMENTAL THROMBUS PROGRESSION IN PRIMATES**  
Erik Tucker\*, Michael Wallisch, Norah Verbout, Brandon Markway, Owen McCarty, Andras Gruber (United States)
- 11:30 - 11:45  
AS210 **IMPACT OF THE ENDOTHELIAL PROTEIN C RECEPTOR IN COAGULATION, INFLAMMATION AND HEMATOPOIESIS**  
Laura Pepler\*, Pei Yu, Dhruva Dwivedi, Bernardo Trigatti, Patricia Liaw (Canada)

## SCIENTIFIC PROGRAM

### Chronic kidney disease and coagulation

Room 705

Moderators: Joanne van Ryn (Germany), Rita Selby (Canada)

- 10:30-11:00  
AS211 **CHRONIC KIDNEY DISEASE AS A RISK FACTOR FOR THROMBOTIC AND BLEEDING EVENTS**  
Manish Sood (Canada)
- 11:00 - 11:15  
AS212 **GRP78 INJECTION AMELIORATES HAEMOLYTIC URAEMIC SYNDROME (HUS) PHENOTYPE IN A SUBAB TOXIN INDUCED MOUSE MODEL**  
Sarah Kamel\*, Susanna Freddi, Carly Selan, Anushka Samudra, Anup Sharma, Peter Cowan, Harshal Nandurkar (Australia)
- 11:15 - 11:30  
AS213 **TUMOR NECROSIS FACTOR SUPPRESSES THE GLOMERULAR ENDOTHELIAL CELL SURFACE PROTEIN CD141 (THROMBOMODULIN) AND STIMULATES EXPRESSION OF C3 AND FACTOR B: IMPLICATIONS FOR RENAL INJURY AND THROMBOSIS IN THE ATYPICAL HEMOLYTIC UREMIC SYNDROME**  
Sarah Sartain\*, Nancy Turner, Joel Moake (United States)
- 11:30 - 11:45  
AS214 **LONG-TERM TINZAPARIN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS – ANALYSIS OF RENAL IMPAIRMENT (RI) IN THE CATCH STUDY**  
Rupert Bauersachs\*, Agnes Y.Y. Lee, Pieter W. Kamphuisen, Guy Meyer, Mette S. Janas, Mikala F. Jarner, Alok A. Khorana (Germany)

### Endothelial cell-VTE models

Room 715

Moderators: Iqbal Jaffer (Canada), Anthony Chan (Canada)

- 10:30-10:50  
AS215 **THE ROLE OF GAS6 AND INFLAMMATION IN THE PATHOPHYSIOLOGY OF VENOUS THROMBOEMBOLISM**  
Mark Blostein (Canada)
- 10:50 - 11:04  
AS216 **CORRELATION BETWEEN DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM USING AN IN VIVO MOUSE MODEL OF VENOUS THROMBOEMBOLISM: EFFECT OF THROMBIN INHIBITION**  
Shana A. Shaya\*, Lisa Saldanha, Nima Vaezzadeh, Ran Ni, Ji Zhou, Peter Gross (Canada)
- 11:04 - 11:18  
AS217 **INHIBITION OF PLATELET FUNCTION WITH THE NOVEL 12-LOX INHIBITOR ML355 IMPAIRS THROMBUS GROWTH, STABILITY AND VESSEL OCCLUSION IN VIVO**  
Reheman Adili\*, Jennifer Yeung, Theodore Holman, Michael Holinstat\* (United States)
- 11:18 - 11:32  
AS218 **TISSUE FACTOR PATHWAY INHIBITOR (TFPI): AN ENDOGENOUS SUBSTRATE FOR FACTOR VII ACTIVATING PROTEASE (FSAP) IN VIVO**  
Saravanan Subramaniam\*, Ina Thielmann, Martina Morowski, Ingo Pragst, Per Sandset, Bernhard Nieswandt, Michael Etscheid, Sandip Kanse (Germany)
- 11:32 - 11:45  
AS219 **INTRINSIC AND EXTRINSIC COAGULATION PATHWAYS BOTH CONTRIBUTE TO LIGATION-INDUCED DEEP VEIN THROMBOSIS IN RATS**  
Ji Zhou\*, Peng Liao, Beverly Leslie, Trang Vu, Ran Ni, Alan Stafford, James Fredenburgh, Brett Monia, Peter Gross, Jeffrey Weitz (Canada)

## SCIENTIFIC PROGRAM

### ★ Inhibitors - clinical

Room 801

Moderators: Roshni Kulkarni (United States), Amy Dunn (United States)

- 10:30-10:50  
AS220 **FACTOR VIII INHIBITORS IN PATIENTS WITH NON-SEVERE HEMOPHILIA A**  
Christine Kempton (Canada)
- 10:50 - 11:04  
AS221 **STATE-OF-THE-ART ANALYSIS OF FVIII-BINDING ANTIBODIES REVEALS IGA AS A PROGNOSTIC BIOMARKER FOR POOR TREATMENT OUTCOMES IN ACQUIRED HEMOPHILIA A**  
Christoph J. Hofbauer\*, Sonja Werwitzke, Paul Knoebl, Saskia Gottstein, Ruediger Scharf, Juergen Heinz, Juergen Gross, Katharina Holstein, Christiane Dobbstein, Friedrich Scheiflinger, Birgit Reipert, Andreas Tiede (Austria)
- 11:04 - 11:18  
AS222 **PREDICTORS OF SUCCESS OF IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH HIGH-RESPONDING INHIBITORS. A PROGNOSTIC SCORE FROM THE ITALIAN PROFIT REGISTRY**  
Antonio Coppola\*, Maurizio Margaglione, Angiola Rocino, Maria Elisa Mancuso, Annarita Tagliaferri, Ezio Zanon, Rita Santoro, Piercarla Schinco, Silvia Linari, Giancarlo Castaman, Maria Messina, Dorina Cultrera, Cristina Santoro, Chiara Biasoli, Elena Santagostino, Giovanni Di Minno (Italy)
- 11:18 - 11:32  
AS223 **RISK FOR INHIBITOR DEVELOPMENT IN SEVERE HEMOPHILIA A PUPS IS NOT ASSOCIATED WITH CLASS OF FVIII CONCENTRATES NOR BY HIGH VON-WILLEBRAND FACTOR OR BY TYPE OF VIRAL INACTIVATION PROCEDURE**  
SM Hashemi\*, J Oldenburg, H Platokouki, R Liesner, HM van den Berg (The Netherlands)
- 11:32 - 11:45  
AS224 **MUTATION ANALYSIS OF SWEDISH HEMOPHILIA B FAMILIES - HIGH FREQUENCY OF UNIQUE MUTATIONS**  
Annika Mårtensson\*, Anna Letelier, Rolf Ljung (Sweden)

### Stroke

Room 713

Moderators: Paul Ockelford (New Zealand), Pieter Kamphuisen (The Netherlands)

- 10:30-11:00  
AS225 **WHAT IS THE OPTIMAL ANTITHROMBOTIC THERAPY FOR NON-CARDIOEMBOLIC STROKE?**  
Martin O'Donnell (Ireland)
- 11:00 - 11:15  
AS226 **PRE-EVENT CHA2DS2-VASC SCORE AND SEVERITY OF ACUTE STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: FINDINGS FROM THE RAF STUDY**  
Maurizio Paciaroni\*, Cecilia Becattini, Giancarlo Agnelli, Monica Acciarresi (Italy)
- 11:15 - 11:30  
AS227 **EARLY RECURRENCE AND CEREBRAL BLEEDING IN PATIENTS WITH ACUTE ISCHEMIC STROKE AND ATRIAL FIBRILLATION: EFFECT OF ANTICOAGULATION AND ITS TIMING. THE (RAF) STUDY**  
Maurizio Paciaroni\*, Cecilia Becattini, Giancarlo Agnelli (Italy)

## SCIENTIFIC PROGRAM

11:20 – 11:30  
AS228 **MAGNESIUM TRANSPORTER MAGT1 PLAYS A CRITICAL ROLE IN THROMBO-INFLAMMATORY DISEASES AND HEMOSTASIS IN MICE**  
Sanjeev Kiran Gotru\*, Karen Wolf, Timo Vögtle, Peter Kraft, Simon Stritt, Guido Stoll, Bernhard Nieswandt, Attila Braun (Germany)

### Atherosclerosis, inflammation and cancer

Room 701

*Moderators: Angela Silveira (Sweden), Josune Orbe (Spain)*

10:30 – 11:00  
AS229 **RECEPTORS FOR PLASMINOGEN ACTIVATORS: ROLE IN INFLAMMATION, ATHEROSCLEROSIS, AND CANCER**  
Stevens Gonias (United States)

11:00 – 11:15  
AS230 **CM-352, A NEW MATRIX METALLOPROTEINASE INHIBITOR, IS A POTENT AND SAFE ANTIFIBRINOLYTIC AGENT FOR THE PREVENTION AND TREATMENT OF HEMORRHAGE**  
Josune Orbe\*, Jose Rodriguez, Juan Sanchez, Agustina Salicio, Miriam Belzunce, Ana Ugarte, Haisul Chang, Obdulia Rabal, Julen Oyarzabal, Jose Paramo (Spain)

11:15 – 11:30  
AS231 **INHIBITION OF COMPLEMENT C3 AND FIBRINOGEN INTERACTION: A POTENTIAL NOVEL THERAPEUTIC TARGET TO REDUCE FIBRIN-RELATED THROMBOSIS RISK**  
Rhodri King\*, Christian Tiede, Katie Simmons, Colin Fishwick, Katharina Schuett, Katherine Kearney, Darren Tomlinson, Ramzi Ajjan (United Kingdom)

11:30 – 11:45  
AS232 **MODULATION OF RECOMBINANT ANTIGENIC CONSTRUCTS CONTAINING MULTI-EPITOPES TOWARDS EFFECTIVE REDUCTION OF ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB (TM2SGY)/J MICE**  
Min Xia, Valeria Endresz, Daxin Chen, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar, Xinjie Lu\* (United Kingdom)

### Cancer and thrombosis – clinical

Room 716

*Moderators: Agnes Lee (Canada), Aurelien Delluc (France)*

10:30 – 10:50  
AS080 **CONTROVERSIES IN CANCER-ASSOCIATED THROMBOSIS**  
Marc Carrier (Canada)

10:50 – 11:04  
AS081 **TISSUE FACTOR (TF) AS PREDICTOR OF RECURRENT VENOUS THROMBOEMBOLISM (VTE): RISK FACTOR AND BIOMARKER ANALYSIS FROM THE CATCH TRIAL OF TREATMENT OF CANCER-ASSOCIATED VTE WITH TINZAPARIN OR WARFARIN**  
Alok A. Khorana\*, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette S. Janas, Mikala F. Jarner, Agnes Y.Y. Lee (United States)

11:04 – 11:18  
AS082 **EXTENSIVE SCREENING BASED ON 18F-FDG PET/CT FOR OCCULT MALIGNANT DISEASE IN UNPROVOKED VENOUS THROMBOEMBOLISM: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL**  
Philippe Robin\*, Pierre-Yves Le Roux, Olivier Sanchez, Sandrine Accassat, Pierre-Marie Roy, Francis Couturaud, Nadia Ghazzar, Nathalie Prevot, Olivier Couturier, Aurélien Delluc, Guy Meyer, Bernard Tardy, Grégoire Le Gal, Pierre-Yves Salaun (France)

## SCIENTIFIC PROGRAM

11:18 – 11:32  
AS083 **IMPACT OF INITIAL CANCER STAGE ON THE RISK OF VENOUS THROMBOEMBOLISM: THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY**  
Inger Llise Gade\*, Sigrid Brækkan, Inger Anne Næss, John-Bjarne Hansen, Frits Rosendaal, Suzanne Cannegieter, Kim Overvad, Hilde Jensvoll, Jens Hammerstrøm, Kristine Blix, Anne Tjønneland, Søren Risom Kristensen, Marianne Severinsen (Denmark)

11:32 – 11:45  
AS084 **RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER**  
Alexander Cohen\*, Stephan Rietbrock, Anja Katholing, Carlos Martinez (United Kingdom)

### Highlights of ISTH - Victor Marder Symposium 12:00 - 13:00

*Moderators: Sam Schulman (Canada), Johannes Oldenburg (Germany)*

12:00 – 12:30 **Highlights of the basic science at ISTH 2015**  
Peter Gross (Canada)


12:30 – 13:00 **Highlights of the clinical research at ISTH 2015**  
Wendy Lim (Canada)






# Exhibition Floor Plan

## Metro Toronto Convention Centre South Meeting Room Level 800



# Exhibition Floor Plan



## Exhibitor List

Company Name	Booth Number
3i - Intelligent Imaging Innovations	640
Accriva Diagnostics	1015
Affinity Biologicals, Inc.	737
Aniara Diagnostica & CoaChrom Diagnostica	424
Answering T.T.P. (Thrombotic Thrombocytopenic Purpura) Foundation	1804
Aspen Pharma	512
Baxalta	1602
Bayer HealthCare	1722 + 702 + 502
Bio Products Laboratory USA, Inc.	1017
Biogen and Sobi	922
bioMerieux	741
Biotest AG	1739
Boehringer Ingelheim GmbH	1638+1639
Canadian Hemophilia Society (CHS)	1814
CEDARLANE®	1711
Chrono-log Corp.	638
Covidien	1840
CSL Behring GmbH	1522
Daiichi Sankyo, Inc.	422
Diapharma Group	1016
DSM Nutritional Products Ltd Branch Pentapharm	521
Enzyme Research / r2 Diagnostics	1616
European and Mediterranean League against Thrombotic Disorders (EMLTD)	1542
Ferrer inCode	1802
Foundation for Women & Girls with Blood Disorders (FWGBD)	1808
George King Bio-Medical, Inc.	642
GRIFOLS	1336
Haematologic Technologies, Inc.	1612
Hemostasis Reference Laboratory Inc.	739

## Exhibitor List

Company Name	Booth Number
HYPHEN BioMed	1702
Immucor	648
Instrumentation Laboratory	410
International Initiative on Thrombosis and Cancer (ITAC-CME)	1810
International Society on Thrombosis and Haemostasis (ISTH)	1036
ISTH 2017 - Berlin, Germany	1036
ISTH SSC 2016 - Montpellier, France	1036
Journal of Thrombosis and Haemostasis	1036
Kedrion Biopharma	428
LABTEK Science and Development Co., Ltd.	1828
LFB BIOMEDICAMENTS	1546
MediRox	1709
Novo Nordisk Haemophilia Foundation (NNHF)	1018
Novo Nordisk Health Care AG	1010
Octapharma AG	1301
Pfizer	736
Pfizer Canada Inc./Bristol-Myers Squibb Canada	522
Portola Pharmaceuticals, Inc.	1713
Precision BioLogic	1610
Roche Diagnostics International Ltd	1728
Schattauer Publishers	1822
Sekisui Diagnostics	1800
Siemens Healthcare	436
STAGO	1122
Sysmex Corporation	436
TECHNOCLONE	1538
Thrombosis.TV	1826
Wiley	1614
World Federation of Hemophilia	1812
World Thrombosis Day (WTD) - 13 October	1036



## Reversal of old and newer anticoagulants: evolving evidence from trials

*A lunchtime satellite symposium*

### Programme

**Co-chairs:** *Jerrold Levy (USA), Edelgard Lindhoff-Last (Germany)*

**12:15** Chairs' welcome

Emergency reversal of warfarin: lessons from randomised controlled trials

*Ravi Sarode (USA)*

Reversal of apixaban anticoagulation with 4-factor prothrombin complex concentrates: a healthy volunteer study

*Charles Frost (USA)*

4F-PCC reverses edoxaban-associated bleeding: data from a healthy volunteer study

*Hamim Zahir (USA)*

The role of prothrombin complex concentrate in patients with major bleeding while using NOACs

*Pieter Kamphuisen (The Netherlands)*

Closing remarks

**13:45** Close of symposium

Please visit us at booth 1522

**Tuesday 23 June 2015, 12:15–13:45**

**Room 714, Metro Toronto Convention Centre (MTCC), Toronto, Canada**

CSL Behring-sponsored satellite symposium at the XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH)



Pre-register to receive your post-symposium digital newsletter!

Scan the QR code or visit

[www.POBnews.info](http://www.POBnews.info) to register your interest.

Biotherapies for Life™ **CSL Behring**


The information presented in the symposium will not necessarily reflect the content of the approved Canadian product monograph.

## Congress Information

**Isth**  
**2015 Congress**  
**TORONTO JUNE 20-25**

Reaching for Unprecedented Peaks





## Abstracts

The ISTH 2015 abstracts are available on USB sticks which will be distributed at the ISTH Booth (# 1036). Abstracts will also be available as an online supplement (only) to JTH as an open-access publication on the Congress app and on the Congress website.

## Accommodation

Participants who have booked their accommodation in advance via MCI can visit the Registration Help Desk counter located in the Registration Area for any questions related to their hotel booking. The staff at this counter will also help you to find and book rooms, if required and pending availabilities.

## Badges

Participants will receive their name badges when collecting their meeting documents on site. You are required to wear your name badge during all meeting events, including the All Congress Party (if you have purchased tickets). Please note that admission to scientific sessions and the exhibition is restricted to participants wearing their badges.

Please note:

- Accompanying persons and exhibitors will not be admitted to the scientific sessions.
- Accompanying persons will not be admitted to the Exhibition Area and the Poster area except for the Welcome Reception on Sunday, June 21

The charge for the replacement of a lost badge is CAD 105.

## Automatic Teller Machines (ATM)

In the MTCC Congress venue, ATM machines are located in the North wing inside the main entrance from Front Street; in the South wing on Level 600 in the Registration Area and on Level 800 at the corner of the Plenary Hall and the Exhibition Hall.

## Business Center

MTCC Toronto has its own Business Center that provides the following services:

- Printing (including posters and business cards)
- Copying
- Faxing Scanning
- Laminating
- Binding

Furthermore, the Business Center sells a wide range of office and ICT supplies. You can also ship small packages there.

The Business Center is located between the 2 Exhibition entrance doors on Level 800.

## Certificates of Attendance

Certificates of attendance will be distributed to all registered participants inside the congress bags.

## Charging Stations—"Stay Plugged In"

Conveniently located in the exhibition hall, 10 charging stations for mobile phones are provided for attendees to charge their mobile devices.

## Cloakroom and Luggage

The cloakroom (free of charge) is located near the Registration Area, Level 600.

Saturday, June 20	07:30-18:00
Sunday, June 21	07:30-20:00
Monday, June 22	07:30-20:00
Tuesday, June 23	07:30-19:30
Wednesday, June 24	07:30-18:30
Thursday, June 25	07:30-13:00

## CME

**Royal College MOC credit, AMA PRA credit, ECMEC credit**

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by McMaster University, Continuing Health Sciences Education Program for up to 26 MOC Section 1 hours.

# Transfuse



# Transplant

# Transform a life

Immucor is the leading provider of transfusion and transplantation diagnostic products worldwide. In addition, Immucor also delivers a unique portfolio to assist with the identification of deficiencies in clotting factors and detection of antibodies involved in thrombosis and thrombocytopenia, providing support for the diagnosis of Heparin-Induced Thrombocytopenia (HIT), Von Willebrand Disease (VWD) and Thrombotic Thrombocytopenic Purpura (TTP).

Visit us at Booth #648  
to learn more about:

- PF4 Family of Products
- ATS-13<sup>®</sup> Activity Assay\*
- VWF & Propeptide Assay\*\*
- Factor VIII Antibody Screen



[www.immucor.com](http://www.immucor.com) or call 855.IMMUCOR

\* For Research Use Only  
Not for use in diagnostic procedures

\*\* For Research Use Only  
Not for diagnostic use in US and Canada

## Congress Information

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

Live educational activities, occurring in Canada, recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC®.

Each attendee should only claim the hours they attended.

Please note that the Royal College MOC will send your certificate after the Congress. In order to receive this, please go to the designated computer stations near the Registration Area on Level 600. You will be able to update your profile to your personal e-mail. This can be done as of Monday, June 22, 14:00.

### EHA Accreditation

The European Hematology Association (EHA) has accredited ISTH 2015 in Toronto, Canada (June 20 – 25, 2015) with 35 credit points. All participants may print a European Hematology Association CME System approved CME certificate indicating the number of EHA-CME Credit Points awarded, directly from the system on the CME section of the EHA website at [www.ehaweb.org](http://www.ehaweb.org). All participants will receive the relevant information by e-mail after the meeting.

### Congress Bag

The Congress bag including all delegate material will be distributed to registered participants at the Congress bag desk in the Registration Area. Please note that no replacements for lost bags are available.

### Computers / Cyber Café

If you need access to a computer while at ISTH 2015, you're in luck! A Cyber Café is located for attendees to use in the ISTH booth (# 1036) located in the Exhibition area on Level 800.

### Conference Capture

Plenary and State-of-the-Art lectures of ISTH 2015 will be captured and be available online for meeting attendees and ISTH members in the weeks after the meeting.

### Congress E-daily

The ISTH 2015 Congress will publish its official e-Daily from Monday, June 22 to Wednesday, June 24 and a post-congress issue two weeks following the meeting. The e-Daily will be sent via email to all congress registrants, can be accessed via the Congress App and directly at [www.isthcongressdaily.org](http://www.isthcongressdaily.org).

### Congress Mobile App

Use your mobile device to navigate the ISTH 2015 Congress. Download the Congress App from your respective app store! The ISTH 2015 Mobile App is free for meeting participants and ISTH members. It conveniently provides iPhone/iPad, BlackBerry, Windows, Android and other smartphone and tablet users with on-the-go access to the ISTH 2015's most exciting, informational and interactive features, such as program overviews, speaker and abstract information, general meeting and exhibitor information, venue and city maps and tips.

### Corporate Symposia and Technical Sessions

Corporate Symposia and Technical Sessions will take place during the following times:

#### Special Industry Symposia

Sunday, June 21  
15:30 – 17:30

#### Lunch Symposia

Monday, June 22 - Wednesday, June 24  
12:15 – 13:45

#### Technical Sessions

Monday, June 22  
18:30 – 20:00

For more details and the program of each of these symposia and sessions, please refer to the Show Guide. For the Lunch Symposia, lunchboxes will be served near the session rooms.

## Congress Information

### Duplicating/Recording

Any form of duplication (recording, audio taping, photography and video) of sessions is prohibited without expressed written consent of the author and Congress organizer.

### Exhibition Hours

The ISTH 2015 Industry Exhibition is located in Ballroom D and E on Level 800 of the Metro Toronto Convention Center (MTCC), South Building.

Sunday, June 21  
19:30 - 22:00 (Welcome Reception in the Exhibition Hall)

Monday, June 22  
09:00 - 18:30

Tuesday, June 23  
09:00 - 19:30

Wednesday, June 24  
09:00 - 18:30

### Internet

WiFi is available throughout the MTCC. Wireless Network: ISTH 2015 Password: biogensobi

The Cyber Café, located in the ISTH booth (#1036) in the Exhibition Hall, will be for the exclusive use of meeting attendees.

### Insurance and Liability

It is recommended that participants obtain adequate insurance coverage for travel, health and accidents before they depart from their countries of residence. ISTH and MCI as organizers cannot accept responsibility for personal injuries, or loss of, or damage to private property belonging to the conference participants and accompanying persons.

### ISTH 2015 President's Room

The ISTH 2015 President's Room is located in room 401 on Level 400.

### ISTH Secretariat

The ISTH secretariat is located in room 501 on Level 500.

### Language

The official language of the meeting is English. There is no simultaneous translation service provided.

### Lost and Found

Found articles may be brought to the lost items collected from the Registration Desk on Level 600.

### Lunches and Coffee Breaks

Lunch is provided during the duration of the Congress. Lunch tickets will be provided as part of the registration package. The tickets are valid from Saturday, June 20 to Wednesday, June 24.

From Monday, June 22 to Wednesday, June 24, lunch and coffee will be available in the Exhibition Area (Level 800). There will be continuous complimentary coffee stations throughout the opening times of the Exhibition during those days, too. Lunches will also be available in front of the meeting rooms of the lunch time symposia.

On Saturday and Sunday, June 20 - 21 as well as on Thursday June 25, lunch and coffee will be available in the foyers of the session rooms.

### Mobile Telephones

As a courtesy to speakers and other participants, all mobile phones and pagers must be muted when attending sessions or symposia.

### Notepads and Pens

A notepad and pen are included in the Congress bag.

### Nurses Program

The Nurses' Program takes place Sunday and Monday, June 21-22, 2015, during the Congress. On the morning of the second day (Monday, June 22), there is a scientific session with oral presentation of peer-reviewed abstracts.

### Official Carrier Network

Star Alliance is the official carrier network for ISTH 2015

STAR ALLIANCE 

### Online Disclosures

As part of the CME accreditation procedures, all speakers are obliged to provide disclosure of potential conflicts of interest. On the first slide of every presentation, these disclosures must be presented. The Speaker Ready Room can assist you with drafting this slide.

## Congress Information

### Opening Hours

Date	Friday	Saturday	Sunday	Monday	Tuesday	Wednesday	Thursday
Speaker Ready Room, Level 600	15:30-20:00	07:30-18:00	07:30-18:00	07:30-18:30	07:30-18:30	07:30-18:30	07:30-13:00
Registration Registration Area, Level 600	15:30-20:00	07:30-18:00	06:30-20:00	06:30-20:00	06:30-19:30	06:30-18:30	07:30-13:00
Exhibition Exhibition Area, Level 800			19:30-22:00	09:00-18:30	09:00-19:30	09:00-18:30	
Poster Pick Up Booth Exhibition Area, Level 800			19:30-22:00	07:30-19:00	07:30-20:00	07:30-19:00	
Press Room Registration Area, Level 600				08:00-17:00	08:00-17:00	08:00-17:00	
Cloak Room Registration Area, Level 600	12:30-20:00	07:30-18:00	07:30-20:00	07:30-20:00	07:30-19:30	07:30-18:30	

### Overflow

Be advised that there is an Overflow room in the Exhibition, next to the Poster area. Should any session be full, the Overflow will be activated.

### Passport Program to the ISTH 2015 Exhibition

Participate in the ISTH 2015 Passport Program, learn more about our exhibitors and sponsors and enter to win valuable prizes. Scan the code below or go to: <http://bycell.co/cjzp> to use this web-based application.

Visit the booths of the participating ISTH 2015 exhibitors, answer questions and enter into a drawing of valuable prizes.

Participants may complete their passport program between 09:00 on Monday, June 22 and 12 noon on Wednesday, June 24.



All entries need to be submitted by 13:00 on Wednesday, June 24. Prize winners will be announced at the ISTH booth (# 1036) between 15:15 and 15:45 on Wednesday, June 24.

Make sure you participate!

### Photo Policy

We kindly ask that attendees DO NOT photograph, tape record, film, or use a cellphone to capture images of presentations at any time during the meeting as well as on the exhibit floors.

## Congress Information

### Pocket Program

A pocket program will be provided to participants upon registration. It is an at-a-glance reference. It contains a program-at-a-glance, venue information and map, information about Toronto and other useful tips.

### Poster Printing Service & Pick Up Booth

If you have opted to take advantage of the ISTH 2015 poster printing service, kindly note that you will be able to pick up your poster(s) at the Poster Booth located in the Swing Space on Level 800.

Poster Booth opening times are:

Sunday, June 21, 2015  
from 19:30 - 22:00

Monday, June 22, 2015  
from 07:30 - 19:00

Tuesday, June 23, 2015  
from 07:30 - 20:00

Wednesday, June 24, 2015  
from 07:30 - 19:00

### Poster Sessions

Posters will be presented on different days during the Congress and are accessible at the same times as the exhibition opening hours. The official poster sessions with refreshments will take place as follows:

Monday, June 22, 2015  
from 17:15-18:30

Tuesday, June 23, 2015  
from 18:00-19:30

Wednesday, June 24, 2015  
from 17:15-18:30

The Poster Area is located inside the Exhibition on Level 800.

Poster setup times are as follows:

Monday, June 22, 2015  
from 07:30 - 09:15

Tuesday, June 23, 2015  
from 07:30 - 09:15

Wednesday, June 24, 2015  
from 07:30 - 09:15

Pins are provided on the poster boards directly

Poster dismantling times are as follows:

Monday, June 22, 2015  
from 18:30 - 19:00

Tuesday, June 23, 2015  
from 19:30 - 20:00

Wednesday, June 24, 2015  
from 18:30 - 19:00

Posters not taken down after the dismantling time will be discarded.

### Prayer Room

An all-denomination prayer room is located in room 830 on Level 800.

### Press Room

ISTH 2015 will feature both a press lounge available for journalists attending the Congress to use and ISTH 2015 exhibitors as well as a press briefing room that will hold press briefings from 8:00 through 17:00 beginning Monday, June 22 through Wednesday, June 24.

To use the press lounge, media credentials must be presented. Public relations and company representatives may enter the room to drop off materials to share with the media; however, we ask that they do not stay. All media are asked to follow the media policy in its entirety.

For a full schedule of media briefings, see the board in front of the Press Briefing Room or stop by the press lounge for the schedule. The press lounge is located near the Registration Area on Level 600.

### Program Changes

Program changes will be made public via the official ISTH 2015 mobile app and the website.

# SickKids Handbook of Pediatric Thrombosis and Hemostasis

Editors:


**Victor S. Blanchette** (Toronto, Ont.)

**Vicky R. Breakey** (Hamilton, Ont.)

**Shoshana Revel-Vilk** (Jerusalem)

## Contents

- Pediatric Thrombosis and Hemostasis: A Historical Perspective
- Primary and Secondary Hemostasis, Regulators of Coagulation, and Fibrinolysis: Understanding the Basics
- An Approach to the Bleeding Child
- Bleeding in the Neonate
- Platelet Disorders in Children
- Managing Hemophilia in Children and Adolescents
- von Willebrand Disease in Children
- Rare Congenital Factor Deficiencies in Childhood
- Acquired Bleeding Disorders in Children
- A Diagnostic Approach to a Child with Thrombosis
- Venous Thrombosis
- Arterial Thrombosis
- Thromboembolic Events at Specific Organ Sites
- Pediatric Stroke
- Bleeding and Clotting in Children with Cardiac Disease
- Antithrombotic Therapy in Children
- Reference Ranges for Common Tests of Bleeding and Clotting
- Common Products Used to Manage Bleeding and Clotting



XVIII + 254 p., 23 fig., 9 in color, 9 algorithms, 59 tab., soft cover, 2013  
CHF 98.- / EUR 82.- / USD 155.00

Prices subject to change

EUR price for Germany,

USD price for USA and

Latin America only

ISBN 978-3-318-02197-4



## Congress Information

### Ramadan - Special Considerations Taken

The month of Ramadan will fall during the ISTH 2015 Congress in June 2015. For those of you who are observing Ramadan, we will have boxed meals available for you at the Registration Area on Level 600 to take back to your rooms in the late afternoon each day of the Congress.

### Registration Hours

Registration will start Friday, June 19 in the afternoon. The Registration Area, located on Level 600 at the MTCC in Toronto will be open during the following hours:

Friday, June 19	15:30-20:00
Saturday, June 20	07:30-18:00
Sunday, June 21	06:30-20:00
Monday, June 22	06:30-20:00
Tuesday, June 23	06:30-19:30
Wednesday, June 24	06:30-18:30
Thursday, June 25	07:30-13:00

### Show Guide

The ISTH 2015 Show Guide to Corporate Symposia and the Industry Exhibition is distributed to all participants as part of the delegate materials as well as on-site in literature racks in the registration area and the exhibition hall. It provides an overview and the detailed programs of the corporate symposia (Special Symposia, Satellite Symposia and Technical Sessions) as well as trade show floor plan, exhibitor and sponsor profiles.

### Smoking

Please note that this is a non-smoking meeting. Smoking is neither permitted in or outside the meeting halls nor in the Exhibition Area.


### Social Media

ISTH 2015 encourages the use of social media, such as Twitter, Facebook, LinkedIn, Instagram and other social media platforms at the conference as a way to summarize, highlight, excerpt, review or promote the presented


materials, of the Congress in general, provided that:

1) Copyright law is observed; 2) verbatim information is limited to a few quotes, and; 3) the author or speaker is referenced and cited appropriately. To get the latest updates throughout the Congress, follow ISTH online via the following links.

Congress hashtag via Facebook and Twitter: #isth2015.

 **Facebook:** <https://www.facebook.com/internationalsocietythrombosisandhaemostasis>

 **Twitter:** <https://twitter.com/isth>

 **LinkedIn:** <https://www.linkedin.com/company/international-society-on-thrombosis-and-haemostasis-isth->

 **Instagram:** <http://www.instagram.com/isthofficeeam>

### Speaker Ready Room

Speakers were contacted in advance to upload their presentations but should still report to the Speaker Ready Room at least two hours in advance of their presentation to ensure proper viewing. All conference rooms feature state-of-the-art technical equipment. Audiovisual material will be available for your presentation: The use of your own laptop during your presentation is prohibited.

The Speaker Ready Room is located on Level 600 near the Registration Area. The opening hours of the Speaker Ready Room are as follows:

Friday, June 19	15:30-20:00
Saturday, June 20	07:30-18:00
Sunday, June 21	07:30-20:00
Monday, June 22	07:30-20:00
Tuesday, June 23	07:30-19:30
Wednesday, June 24	07:30-18:30
Thursday, June 25	07:30-13:00

## Congress Information

### State-of-the-Art Book and Abstracts

The ISTH 2015 State-of-the-Art manuscripts and abstracts are available on USB sticks which will be distributed at the ISTH Booth (#1036). Both the State-of-the-Art manuscripts and abstracts will also be available as online supplements (only) to JTH as open-access publications.

Abstracts are also available via the Congress app and on the Congress website.

### Toronto Information Desk

For city and restaurant information, please visit the Toronto Information Desk located near the Registration Area on Level 600.

Saturday, June 20	10:00 – 17:00
Sunday, June 21	09:30 – 18:00
Monday, June 22	09:00 – 16:00
Tuesday, June 23	09:00 – 16:00
Wednesday, June 24	09:00 – 16:00

### Useful Telephone Numbers

Name	Location	Telephone
ISTH Executive Office	Room 401, Level 400	001 416-585-3823
Hotel Information Desk	Registration Area, Level 600	001 416-585-3824
Registration Desk	Registration Area, Level 600	001 416-585-3825

### Venue

#### MTCC - South Building - 222

Bremner Boulevard, Toronto, Ontario M5V 2W6, Canada

Please note that the numbering of the floor levels increases as you go down.

### Water Stations

Keeping hydrated is always important, particularly during a busy day at ISTH 2015. 15 distinct water stations are located in the exhibition hall for the convenience of our attendees.

### Website

Up-to-date information regarding the Congress program, including all abstracts, is available on the website [www.isth2015.org](http://www.isth2015.org)

# THROMBOSIS RESEARCH



Editors in Chief  
**Per Morten Sandset**  
Oslo University Hospital,  
Oslo, Norway

Follow us on

 Facebook:  
[www.facebook.com/  
ELShematology](http://www.facebook.com/ELShematology)

 Twitter:  
[@ELShematology](https://twitter.com/ELShematology)

## About

*Thrombosis Research* is an international journal with a goal of rapid dissemination of new information on **thrombosis, hemostasis, and vascular biology** to advance science and clinical care.

The journal publishes peer-reviewed original research, along with reviews, editorials, and opinions and critics. Both basic and clinical studies are published.

Publication of research which will lead to novel approaches in diagnosis, therapy, prognosis and prevention of **thrombotic and hemorrhagic diseases** is given high priority.

## Your benefit of publishing in *Thrombosis Research*:

- Unrivalled article visibility via inclusion in Scopus, the world's largest abstract and citation database
- Article Usage Alert service: a combination of an email and a dashboard that shows usage data of your article, downloads & article views, social media mentions and from which countries
- Online submission which is fast, efficient and provides step-by-step instructions on how to submit your article
- Advance notification of the publication of your article via ScienceDirect's online alerting service
- The option to enrich your article with graphical abstracts, research highlights, AudioSlides and video content

VISIT THE JOURNAL  
HOMEPAGE FOR DETAILS:  
[www.thrombosisresearch.com](http://www.thrombosisresearch.com)

ELSEVIER

## Social Program

### Opening Ceremony and Welcome Reception

**Sunday, June 21, 2015**  
Time: 18:00 – 22:00  
Venue: MTCC – Metro Toronto  
Convention Center  
Price: included in registration fee



The opening ceremony takes place in the Plenary Hall (Level 800) in the Congress Center from 18:00 – 19:30. The Isth Grant Medal will be awarded during this ceremony. Besides official opening speeches, all participants are invited to enjoy a selection of typical Canadian entertainment and performances.

The welcome reception will take place in the adjacent exhibition hall from 19:30 – 22:00.

### All Congress Party

**Wednesday, June 24, 2015**  
Time: 19:30 – 01:00  
Venue: MUZIK  
Price per person: CAD 100

The All Congress Party is always the talk of the town, and you really don't want to miss out! We have something special planned for you in Toronto – a smashing evening on the penultimate day of the Congress at the **nightclub MUZIK**, which has developed a reputation for style and unsurpassed service. Relaxing in a 1907 building under a 60 foot-high classical glass dome is an experience that one could describe as “a Canadian in Paris.”

The highlight of the night will be the rock band **Barenaked Ladies** with their performance and entertainment.

Please go to the Registration Desk if you still want to buy tickets onsite.

Buses for the All Congress Party will leave in front of the Congress Center South Entrance starting 18:30 until 19:30 at the latest.

MUZIK: 15 Saskatchewan Rd,  
Toronto, ON, M6K 3C3

Notes:

None of the listed events are industry supported

Social events are only open to individuals who are registered (including accompanying persons) with a ticket.

### ISTH 5K Fun Run

**Tuesday, June 23, 2015**  
Time: 20:00 - 21:00  
Venue: Budapest Park, Toronto

Ticketed event, late registration fee  
CAD 45

Register at [http://www.isth.org/  
page/2015FunRun](http://www.isth.org/page/2015FunRun)

Buses will leave in front of the Congress Center South Entrance starting 18:30 until 19:30 at the latest.

### Banks, Banking Services and Automatic Teller Machines (ATM)

The official currency in Canada is the Canadian Dollar (CAD) which is divided into 100 cents. For denominations under five dollars, coins are used.

Only major banks exchange foreign currency. Credit Cards and Travelers checks are accepted at most (but not all) major retailers. Traveler's checks should be issued in Canadian dollars for maximum convenience. Banking hours are Monday to Friday 9 AM to 5 PM. Currency exchange is also available at the airport.

ATMs are widespread and found in most banks, hotels and shopping centers. In the MTCC Congress venue, ATM machines are located in the North wing inside the main entrance from Front Street; in the South wing on Level 600 in the Registration Area and on Level 800 at the corner of the Plenary Hall and the Exhibition Hall.

### Climate

Toronto has a humid continental climate. Summers are usually warm and humid. The average temperature in June is 80 degrees F (27 degrees C) for a high and 65 degrees F (18 degrees C) for a low.

### Electricity

110-120 volts, 60 Hz. Plugs are mainly the two, flat-pin type, although three-pin plugs are also widely used. Appliances without dual voltage capabilities will require an adapter, which can be purchased in most major airports.

### Emergency Phone Numbers

Dial 911 for all emergencies (police, fire, medical). Callers will then be placed through to the appropriate emergency service. Calls are free from pay phones.

### Shopping in Toronto

Shoppers delight in trendy Queen Street West, Yorkville's designer boutiques, fabulous malls like the Toronto Eaton Center and Vaughan Mills and the PATH, which features more than 1,200 shops in over 16 miles of underground concourses.

Visit <http://www.toronto.ca/> for more information.

### Taxes

The Harmonized Sales Tax (HST) is a 13% tax that is applied to most purchases of taxable supplies of goods and services in the Province of Ontario. The HST consists of a 5% federal portion and an 8% retail sales tax portion.

Visitors to Canada may qualify for a refund of some of the Goods and Services Tax/Harmonized Sales Tax (GST/HST) they have paid during their visit in Canada.

Please visit the Canada Revenue Agency website for more information.

<http://www.cra-arc.gc.ca/tx/bsnss/tpcs/gst-tps/rbts/vstrs/fctp-eng.html>

### Time

Standard time zone: UTC/GMT -5 hours  
Daylight Savings Time: +1 hour  
Toronto is on EST (Eastern Standard Time)

### Tipping Etiquette in Canada

**Restaurants:** It is customary to tip approximately 15% on the total bill before tax, 20% for exceptional service. Many restaurants charge an automatic gratuity of 15% or more for larger groups – typically 8 or more persons.

**Hotels:** It is customary to tip the valet service and the staff that brings the baggage to a guest room as well as the chambermaids.

Taxi drivers, hairdressers, manicurists, aestheticians etc: 10% is the common minimum.

Overall, servers/wait staff are not paid well in Canada. However, when you see a "tip jar" on a counter in a bar, cafeteria etc. it is NOT necessary to tip.

### Toronto City Guide App

To learn more about Toronto, download Tourism Toronto's new See Toronto App. Available for iPhone, Android, Blackberry and Windows Phone, it provides tips on things to see and including easy-to-search event, dining, attractions and shopping listings.

Learn more about Toronto online at [www.seetorontonow.com](http://www.seetorontonow.com)

### Dining Out in Toronto and Tipping

Restaurants usually open at 18:00, with busiest time between 20:00 and 22:00. Booking is recommended, particularly on Thursday, Friday and Saturday nights.

If you're happy with the service you receive, a 15-20% tip on the pre-tax bill is a standard expression of appreciation when dining out in the city. Note that some restaurants automatically add this gratuity when serving large groups, so be sure to check your bill. For more information and to find the right restaurant please visit [www.dine.to/](http://www.dine.to/)

# Thrombosis and Haemostasis

International Journal for Vascular Biology and Medicine



## Thrombosis and Haemostasis

International Journal for Vascular Biology and Medicine  
 Volumes 113 and 114 in 2015  
 6 issues per volume | ISSN 0340-6245

Visit our homepage and register for eTOC today at:


 [www.thrombosis-online.com](http://www.thrombosis-online.com)

## Thrombosis and Haemostasis

publishes original contributions of basic and original research and clinical studies in vascular biology and medicine, serving as an international platform for the dissemination and debate of scientific information.

Subscribers to and readers of Thrombosis and Haemostasis enjoy a reliable publication platform in vascular biology and medicine | renowned authors – leaders in their field of research |

Electronic Table of Contents – register online today! | online submission and TH First: epub ahead of print | a broad scope covering expanded areas of interest (Blood coagulation, fibrinolysis and cellular haemostasis | Platelets and blood cells | Endothelium and vascular development | Wound healing and inflammation/infection | Cardiovascular biology and cell signalling etc.)



## Transportation in Toronto

### Public Transport Ticket

The Toronto public transit system is the Toronto Transit Commission (TTC), and it includes subways, buses and streetcars.

GO Transit is Ontario's inter-regional bus and train service. It links Toronto with outlying areas of the Greater Toronto region and beyond.

To learn more about Toronto's parking, taxi and bike resources, visit the Tourism Toronto website.

### Maps and Guides

There are many visitor guides, pedestrian maps and more available via Tourism Toronto. These cover areas such as downtown Toronto as well as the Greater Toronto region.

### How to Reach the MTCC Toronto?

#### From the Airport

The Union Pearson (UP) Express train takes you directly from the airport to the Union Station in downtown Toronto in less than 25 minutes. Union Station is only a few blocks away from the Congress center (Metro Toronto Convention Centre) and most of the Congress hotels.

The adult regular fare is \$27.50, with reduced fares for seniors, children and families. Tickets can be purchased online, in-station, or at the ticket vending machines and counters.

#### By Train

The MTCC is located next to the Union Station Toronto. From Union station you can proceed west on Front Street to the North Building, where you can access the Skywalk to enter the South Building. You can, in case of rainy weather, walk the entire way from Union Train Station to the MTCC indoors and through covered skywalks.

Please visit [www.gotransit.com](http://www.gotransit.com) to plan your trip and find your most convenient connection.

#### By Subway

*Yonge-University-Spadina Line:* Exit at Union station and proceed west on Front Street to the North Building, where you can access the Skywalk to enter the South Building.

*Bloor-Danforth Line:* When travelling west or east, you will need to transfer to the Yonge-University-Spadina Subway Line at either Bloor-Yonge Station, St. George Station or Spadina Station. Then continue until you reach Union Station.

*Scarborough RT Line:* Travel west to Kennedy Station. From Kennedy Station transfer to the Bloor-Yonge Line. Continue on the Bloor-Yonge Line until you reach Union Station.

*Sheppard Line:* Travel west to the Sheppard-Yonge Station and transfer to the Yonge-University Spadina Line. Travel south until you reach Union Station.

### Car Parking

The MTCC Toronto has dedicated parking both for the North and the South building and can accommodate up to 1,700 vehicles.

The following rates apply: (incl. 13% tax)

#### Each Day of the Week (7am – 7pm)

1/2 hr or less:	CAD 4.00
1/2 hr to 1 hr:	CAD 8.00
1 hr to 1.5 hrs:	CAD 12.00
1.5 hrs to 2 hrs:	CAD 16.00
2 hrs to 2.5 hrs:	CAD 20.00
Day max (< 2.5 hrs):	CAD 23.00


#### Evenings (5pm – 7am)

1/2 hr or less:	CAD 4.00
1/2 to 1 hr:	CAD 8.00
1 hr to 1.5 hrs:	CAD 12.00
1.5 hrs to 2 hrs:	CAD 16.00
2 hrs to 2.5 hrs:	CAD 20.00
Eve. Max (< 2.5 hrs):	CAD 23.00
Day Max + 1/2 hr:	CAD 27.00
Day Max + 1 hr:	CAD 28.00
24 hr Max:	CAD 28.00

There are also more than 10,000 alternate spaces within walking distance to the Metro Toronto Convention Center.

Publish your next research article in  
***Thrombosis Journal***

Editors-in-Chief:  
Yukio Ozaki (Japan), Hugo ten Cate (Netherlands)



Hidenori Suzuki, Nippon Medical School, Japan

**Reasons to publish in *Thrombosis Journal***

- Internationally renowned Editorial Board
  - Publishes various article types
- Supports research in the developing world
  - Free color images



www.thrombosisjournal.com



## Future ISTH Meetings and Congresses

Meetings and Congresses	President	Date	Location
62nd Annual SSC Meeting	Jean-François Schved	May 25-28, 2016	Montpellier, France
XXVI ISTH Congress with 63rd Annual SSC Meeting	Johannes Oldenburg	July 8 - 13, 2017	Berlin, Germany
64th Annual SSC Meeting	to be confirmed	to be confirmed	to be confirmed
XXVII ISTH Congress with 65th Annual SSC Meeting	Robert Medcalf	2019	Melbourne, Australia

Learn more at [www.isth.org](http://www.isth.org)





**isth** Academy

**Participate in the ISTH Academy!**  
*Your Personal Resource for Education*

- 2015 Webinar Series Covering Laboratory and Clinical Science
- Webcasts from Congress and SSC Meeting Presentations
- Education Courses - Access the ISTH Course on Venous Thrombosis



The Academy is the online education arm of the **International Society of Thrombosis and Haemostasis (ISTH)**. As part of the Society's mission to advance the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders, the ISTH Academy promotes advanced learning opportunities, networking and the opportunity to build an understanding of a desired topic without managing travel budgets or flight plans.

The ISTH Academy includes a comprehensive webinar series, educational webcasts and online course modules for scientists, physicians and allied health professionals with notable speakers and presenters on a variety of topics related to bleeding and clotting. All accessible from a computer and location of your choice, let the ISTH Academy provide you with the knowledge needed to advance science and patient care to improve the health outcomes for patients around the world.

**Join Us! For more information on upcoming programming, visit [academy.isth.org](http://academy.isth.org).**

## Authors Index

---

**isth**<sup>TM</sup>  
International Society of  
Thrombosis and Haemostasis

[academy.isth.org](http://academy.isth.org)



**Visit us at Booth 1036**

**isth**  
**2015 Congress**  
**TORONTO JUNE 20-25**

---

Reaching for Unprecedented Peaks

## Authors Index

**Aarts M.**, PO452-TUE  
**Abache T.**, PO131-TUE, PO339-TUE  
**Abad A.**, PO245-TUE  
**Abad-Franch L.**, PO243-TUE, PO244-TUE  
**Abajas Y.**, PO166-MON  
**Abalkhail H.**, PO085-MON, PO148-TUE  
**Abashidze M.**, PO250-TUE  
**Abbas M.**, AS039  
**Abbasi S. H.**, PO090-WED  
**Abbate R.**, OR253, OR270, OR396, OR400, PO067-MON, PO086-MON, PO226-MON, PO365-MON, PO366-MON, PO020-TUE, PO039-TUE, PO071-TUE, PO076-TUE, PO365-TUE, PO477-TUE, PO094-WED, PO586-WED  
**Abbattista M.**, PO633-WED  
**Abbonante V.**, PO378-WED  
**Abbott T.**, OR073  
**Abbruzzese R.**, PO200-TUE, PO259-TUE, PO534-WED  
**Abbuehl B.**, PO254-WED  
**Abbuehl B.**, PO281-MON  
**Abbuehl B.**, PO284-WED  
**Abbuehl B.**, OR215, PO242-MON, PO260-MON  
**Abd El Ghani H.**, PO243-MON  
**Abdallah N.**, PO243-MON  
**Abdel-Azeim S.**, PO582-MON  
**Abdoellakhan R.**, PO363-WED  
**Abdollahi A.**, PO600-WED  
**Abdul S.**, PO665-MON  
**Abdul S.**, PO209-MON  
**Abduljaleel Z.**, PO085-MON, PO148-TUE  
**Abdulla M.**, PO148-TUE  
**Abdulrehman A.**, PO410-MON  
**Abe J.-I.**, PO032-TUE  
**Abegunde S.**, PO591-WED  
**Åberg M.**, PO552-TUE  
**Abergal A.**, PO075-TUE  
**Abeynaïke L.**, OR185, PO404-MON  
**Abibatou S.**, PO542-MON  
**Aboelnazar E.**, PO589-TUE  
**Abohelaika S.**, OR099  
**Abolghasemi H.**, PO600-WED  
**Abomansoor I.**, PO085-MON  
**Aboura C.**, PO276-WED  
**Aboura C.**, PO637-TUE  
**Abraham A.**, PO153-WED  
**Abrams C.**, PO405-TUE  
**Abrams S.**, OR004, OR168

**Abro S.**, PO182-MON, PO293-MON, PO305-MON, PO334-MON, PO112-WED, PO331-WED, PO332-WED  
**Abshire T.**, PO659-MON  
**Abu Saadeh F.**, OR360  
**Abubakar A.-Z.**, PO025-TUE  
**Abuelkasem E.**, PO017-WED  
**Accassat S.**, AS082, AS137  
**Accetta G.**, OR096, OR119  
**Acciarresi M.**, AS226  
**Abbasi S. H.**, PO519-WED  
**Achilles K.**, PO274-WED  
**Acker J.**, PO570-MON  
**Acosta C.**, PO523-WED  
**Acquila M.**, PO259-TUE, PO534-WED  
**Acres S.**, OR310  
**Adam F.**, OR003, OR205, OR234, PO444-WED  
**Adam M.**, OR047, PO163-WED  
**Adamczuk Y.**, PO079-TUE  
**Adamczyk-Wojciechowska P.**, PO549-MON  
**Adams G.**, AS059  
**Adams M.**, PO656-TUE  
**Adams T.**, OR431, PO632-TUE  
**Adamson L.**, OR031  
**Ádány R.**, PO187-WED  
**Adarraga M. D.**, OR381  
**Adcock D.**, PO216-WED  
**Adcock D.**, PO173-MON, PO161-TUE, PO233-WED  
**Adelman M.**, OR233  
**Adelmeijer J.**, OR070, OR435, PO002-MON  
**Adesuwa E.**, PO403-TUE  
**Adeyemi O.**, PO567-MON  
**Adiguzel C.**, PO305-MON  
**Adili R.**, AS217  
**Aernouts J.**, PO219-MON  
**Afonina E.**, PO501-WED  
**Afrasiabi A.**, PO490-MON  
**Afshar H.**, PO077-TUE, PO084-TUE  
**Agbani E.**, AS141  
**Agbani E.**, PO461-WED  
**Agno W.**, PO610-TUE, AS195, OR195, PO511-MON, PO613-MON, PO614-MON, PO639-MON, PO115-TUE, PO607-TUE, PO611-TUE, PO613-TUE, PO405-WED, PO671-WED  
**Aboura C.**, PO637-TUE  
**Aggarwal A.**, AS197, OR292  
**Aggarwal M.**, PO316-MON, PO272-TUE, PO529-WED  
**Agiastro R.**, PO614-WED

**Agnelli G.**, AS226, AS227, OR074, OR119, PO370-MON, PO626-MON, PO353-TUE, PO608-TUE, PO373-WED, PO409-WED, PO423-WED  
**Agnoli A.**, PO084-TUE  
**Agrahari G.**, PO305-TUE  
**Ágren A.**, PO297-MON, PO368-MON, PO661-MON  
**Agten S.**, PO037-TUE  
**Aguila S.**, OR368  
**Águila S.**, OR076, OR359, PO338-TUE  
**Aguilar C.**, PO047-TUE  
**Aharon A.**, OR171, PO335-MON, PO325-TUE, PO389-WED  
**Ahluwalia J.**, PO200-MON  
**Ahmad A.**, PO521-TUE  
**Ahmad M.**, PO369-MON  
**Ahmad O.**, PO400-MON  
**Ahmad S.**, OR047  
**Ahmad-Nejad P.**, PO669-MON  
**Ahmed H.**, OR390  
**Ahmed Y.**, PO365-MON, PO076-TUE  
**Ahmidatou H.**, PO242-TUE  
**Ahnström J.**, AS149, OR369, PO139-MON  
**Ahrens I.**, PO307-TUE, PO356-TUE, PO404-TUE  
**Ahuja A.**, PO529-WED  
**Aillaud M.-F.**, OR324  
**Aisiku O.**, AS170  
**Aisiku O.**, AS091  
**Aisina R.**, PO213-MON  
**Aisina R.**, PO113-MON  
**Aïssi D.**, AS045, AS206  
**Ait Aïssa K.**, PO031-TUE  
**Aïtchafa Tadiaoui D.**, PO375-MON  
**Aizman Sevilla A.**, PO358-TUE  
**Ajjan R.**, AS231, OR398, PO465-TUE  
**Ajjan R.**, OR016  
**Ajjan R.**, AS155  
**Ajzenberg N.**, PO080-WED  
**Akahane K.**, PO417-TUE  
**Akbayram H.**, PO310-MON  
**Akbayram S.**, PO310-MON  
**Akcaay A.**, PO315-MON  
**Akdeniz A.**, PO591-TUE  
**Akhter M.**, PO182-WED, PO184-WED  
**Akhter M.**, PO183-WED  
**Akici F.**, PO265-MON, PO459-MON, PO279-WED  
**Akici F.**, PO313-MON  
**Akin M.**, PO158-TUE

## Authors Index

**Akinc A.**, OR177, OR213, PO154-TUE, PO049-WED  
**Akins S.**, PO076-WED  
**Akinshina S.**, PO008-MON  
**Akita M.**, PO211-WED  
**Akita N.**, PO185-TUE, PO284-TUE, PO335-TUE  
**Akiyama M.**, PO599-MON  
**Akiyama M.**, PO653-TUE  
**Akkawat B.**, PO266-TUE, PO606-TUE, PO584-WED  
**Akkerman J.-W.**, AS189  
**Akolekar R.**, OR033  
**Akpınar F.**, PO143-TUE  
**Akpotuzor J.**, PO386-MON  
**Ákra S.**, PO042-TUE  
**Akrour M.**, OR055, PO107-TUE  
**Aktekin E.**, PO109-WED  
**Al Asmi A.**, PO009-TUE  
**Al Dieri R.**, PO089-MON, PO143-MON, PO290-MON  
**Al Falahi K.**, PO009-TUE, PO635-TUE  
**Al Frouh F.**, OR324  
**Al Khalili F.**, OR061  
**Al Onazi N.**, PO604-TUE  
**Al Zadjali S.**, PO635-TUE  
**Alakhadar-Mohamara Y.**, PO271-WED  
**Al-Allaf A.**, PO085-MON  
**Al-Allaf F.**, PO085-MON, PO148-TUE  
**Alamelu J.**, OR104  
**Alamelu J.**, AS159, OR145, OR386, PO239-MON, PO504-WED  
**Al-Ani F.**, PO595-TUE  
**Alarcon M.**, PO010-TUE  
**Alarcón M.**, AS116  
**Alashwai A.**, PO085-MON  
**Alatri A.**, PO614-MON  
**Alayash A.**, OR174  
**Albahr R.**, PO469-WED  
**Albanes J.**, PO035-WED  
**Albáñez S.**, PO678-MON, PO291-TUE, PO679-TUE  
**Albayrak C.**, PO485-WED, PO527-WED, PO537-WED  
**Albayrak D.**, PO485-WED, PO527-WED, PO537-WED  
**Al-Belushi B.**, PO009-TUE, PO635-TUE  
**Alber K.**, PO397-MON  
**Alberelli M. A.**, PO422-TUE  
**Alberio L.**, AS163, OR432, PO400-TUE  
**Albers-Akkers M.**, PO614-TUE  
**Albers-Akkers M.**, PO366-WED

**Alberto F.**, PO004-MON, PO629-MON, PO042-WED  
**Alberto M.**, PO646-TUE, PO652-TUE  
**Albetti M.**, PO174-MON  
**Ale Booye E.**, PO247-TUE  
**Aledort L.**, OR105, PO270-MON  
**Alef T.**, PO669-MON  
**Aleidan F.**, OR052, PO307-MON  
**Aleinikova O.**, PO206-TUE, PO249-WED  
**Alekseeva P.**, PO023-MON  
**Alemanno L.**, PO084-WED  
**Alessandro Liotta A.**, PO365-MON, PO366-MON, PO071-TUE, PO477-TUE, PO586-WED  
**Alessi M. C.**, PO103-WED  
**Alessi M.-C.**, AS014, PO441-MON, PO443-MON, PO385-WED, PO493-WED  
**Alessi M.-C.**, OR324, PO416-MON, PO436-MON, PO440-MON  
**Alevizopoulos A.**, PO169-WED  
**Alexander E.**, OR356  
**Alexander W.**, PO190-WED  
**Alexandre H.**, OR278  
**Alfarsi H.**, PO119-MON  
**Alfarsi H.**, PO117-MON  
**Alfonso A.**, PO516-MON, PO116-TUE, PO488-TUE  
**Algahtani M.**, PO410-TUE  
**Algra A.**, OR255  
**Alhamdi Y.**, OR004, OR168  
**Al-Hashimi A.**, OR437  
**Alhenc-Gelas M.**, OR055, PO527-MON, PO544-TUE  
**Al-Horani R.**, PO306-MON  
**Ali H.**, PO650-WED  
**Ali H.**, PO118-MON  
**Ali H.**, OR440, PO123-MON  
**Ali M.**, PO180-MON, PO188-WED  
**Ali M.**, PO506-MON  
**Ali M.**, PO354-WED  
**Aliabadi A.**, PO509-TUE  
**Alikhan R.**, AS159, OR130, OR382, PO638-MON, PO083-TUE  
**Al-Khalili F.**, PO368-MON, PO355-TUE  
**Alkindi S.**, PO635-TUE  
**Alkozai E.**, PO002-MON  
**Allacher P.**, PO249-MON, PO284-WED  
**Allen G.**, PO237-MON, PO239-MON, PO208-TUE, PO255-WED  
**Allen G.**, PO235-MON  
**Allen U.**, PO446-TUE  
**Allorto N.**, PO483-MON  
**Almakadi M.**, PO161-WED

**Almany S.**, PO623-TUE, PO419-WED  
**Al-Marwani A.**, PO517-WED  
**Almholt K.**, PO590-WED  
**Almond C.**, PO457-MON, PO083-WED  
**Almosni J.**, PO653-WED  
**Al-Musbahi A.**, PO517-WED  
**Aloni A.**, PO615-WED  
**Alonso-Roca D.**, PO271-WED  
**Alotaibi G.**, AS023  
**Alpan L.**, PO134-WED, PO142-WED  
**Alpoim P.**, PO566-MON, PO244-WED  
**Alokan S.**, PO307-MON  
**Alsahli M.**, PO542-WED  
**Alsammak M.**, PO037-WED  
**Alshehri O.**, PO415-MON  
**Alt K.**, PO014-TUE  
**Althawadi H.**, PO117-MON, PO119-MON  
**Altisent C.**, OR347, PO056-TUE, PO253-WED  
**Altuna D.**, PO522-WED  
**Alvarado J.**, PO242-WED  
**Alvarado-Moreno J. A.**, PO020-MON, PO073-MON, PO523-TUE  
**Álvarez Dela Cadena P.**, PO329-WED  
**Álvarez-Larrán A.**, PO487-TUE  
**Álvarez-Larrán A.**, PO435-MON  
**Álvarez-Román M.**, OR346, OR347  
**Alves G.**, PO145-WED  
**Alves M.**, PO043-WED  
**Alves N.**, OR376  
**Alwar V.**, PO306-WED  
**Alwis I.**, OR380, PO443-WED  
**Amadio P.**, PO005-TUE  
**Amankwah E.**, AS161  
**Amano K.**, PO161-MON, PO213-TUE, PO006-WED, PO204-WED  
**Amash A.**, PO306-TUE  
**Ambaglio C.**, OR030, PO483-MON, PO580-WED  
**Ambily A.**, PO511-TUE  
**Ambrose A.**, AS041  
**Amengual O.**, PO058-WED  
**Ameri A.**, PO248-MON  
**Amerine L.**, PO309-TUE  
**Amigo Q.**, PO522-WED  
**Amirabadi A.**, OR390  
**Amiral C.**, PO424-WED  
**Amiral J.**, PO352-MON, PO166-TUE, PO181-TUE, PO376-TUE, PO411-TUE, PO424-WED



## Authors Index

Amirkhosravi A., PO174-WED, PO445-WED, PO446-WED  
Amit O., PO271-TUE  
Ammollo C., OR065, PO338-WED  
An H. J., PO475-TUE, PO478-TUE, PO531-TUE, PO168-WED  
Anastasopoulou J., PO169-WED  
Ancel P., PO385-WED  
Andersen M., PO509-MON  
Andersen P., PO310-WED  
Anderson D., PO456-TUE  
Anderson D., AS077, AS139, PO647-WED  
Anderson F., OR395, PO578-TUE  
Andoljšek D., PO027-WED  
Andoskin P., PO444-MON  
Andrade D., PO064-WED  
Andre P., PO073-TUE  
André M.-H., PO501-MON  
Andreasen J., PO343-MON  
Andreasen P., AS146  
Andreeva E., PO054-MON  
Andreeva T., PO214-TUE  
Andreoni L., PO445-TUE  
Andresen M., PO118-MON  
Andrews R., PO497-MON, PO669-TUE  
Andrews R., PO431-MON  
Andrews W., PO516-WED  
Andrews R., PO393-TUE, PO441-WED  
Andrusaitis F., PO211-TUE  
Ang S. K., PO012-TUE  
Angay O., OR405, PO526-TUE  
Angchaisuksiri P., OR096, OR119  
Angela L., OR167  
Angelescu S., PO474-WED  
Angelillo-Scherrer A., PO101-MON, PO489-MON  
Anglés-Cano E., PO187-MON  
Angoulvant D., PO064-MON  
Anguela X., PO172-MON  
Ankri A., PO128-WED  
Annabelle D., OR219, PO662-TUE  
Anne A.-S., PO347-TUE  
Annetta E., OR160  
Annetta S., PO644-MON, PO428-TUE  
Annichino-Bizzacchi J., OR094, PO066-WED, PO067-WED, PO100-WED  
Annichino-Bizzacchi J., OR263  
Annichino-Bizzacchi J., PO190-MON, PO422-MON, PO531-MON, PO145-WED, PO221-WED  
Antal-Szalmás P., PO124-MON

Antic D., PO121-TUE, PO235-WED  
Antic D., PO547-TUE  
Anti D., PO218-TUE  
Antmen B., PO254-TUE  
Antmen B., PO301-WED, PO302-WED, PO530-WED  
Antón A. I., OR359  
Antonucci D., OR396, OR400, PO094-WED  
Antonova O., PO327-TUE  
Antonucci E., PO226-MON, PO639-MON, PO640-MON, PO024-TUE, PO673-WED, PO674-WED, PO675-WED  
Antovic A., OR187  
Antovic J., PO080-TUE, PO228-TUE  
Antovic J., OR187, PO195-MON  
Antovi J., PO360-TUE  
Anyanwu R., PO403-TUE  
Anžej Doma S., PO027-WED  
Aoki T., PO041-MON, PO057-WED  
Aoki T., PO434-MON  
Apartsin K., PO054-MON  
Aponte-Santamaria C., PO669-TUE  
Apostol C., PO229-WED  
Apostolova M., OR090, PO277-WED  
Appa R., OR110, PO052-WED  
Appel I., OR225  
Appeltans H., PO373-TUE  
Appenzeller S., OR094, PO066-WED, PO067-WED  
Apte S., PO164-MON  
Arabia F., OR216  
Arai R., PO106-MON  
Aranda E., PO472-WED  
Aras M., PO597-TUE  
Araujo F., PO286-MON  
Araujo F., PO264-TUE, PO404-WED  
Araujo P., PO179-TUE  
Araújo F., PO212-TUE, PO012-WED, PO261-WED  
Araújo H., PO231-MON, PO333-MON  
Aravind P., PO082-MON  
Arbasi M., PO264-MON  
Arbesu G., PO441-TUE  
Arbring K., PO367-MON, PO560-TUE, PO561-TUE  
Arderiu G., PO017-MON, PO019-MON  
Ardeshiri R., PO490-MON  
Ardillon L., OR428

Ardisino G., PO589-MON  
Arellano-Rodrigo E., PO435-MON, PO487-TUE, PO082-WED, PO414-WED  
Arfo S., PO614-WED  
Argunhan F., PO459-WED  
Arias M., PO092-TUE, PO146-WED, PO231-WED  
Aribi M., PO637-TUE  
Aribi M., PO494-MON, PO276-WED, PO520-WED  
Ariceta G., PO589-MON  
Aridogan A., PO301-WED  
Ariela Z., PO659-TUE  
Ariens R., AS205, OR433, OR444, PO182-TUE, PO188-WED, PO245-WED  
Ariens R., AS155  
Ariëns R., OR372, OR374  
Ariëns R., PO466-MON  
Ariëns R., AS153  
Arioka T., PO547-WED  
Arioli D., OR197, PO640-WED  
Arkhammar P., PO310-WED  
Arkin S., PO512-TUE, PO520-TUE, PO116-WED, PO266-WED, PO597-WED  
Armand-Perroux A., OR192  
Armond S., PO244-WED  
Armstrong P., PO414-TUE, PO085-WED  
Arnau M. A., PO536-MON  
Arndt B., OR054  
Arnell H., PO443-TUE  
Arnesen H., OR251, PO079-MON, PO030-TUE, PO042-TUE, PO293-TUE, PO342-WED  
Arnold D., PO616-WED  
Arnold D., AS110  
Arnold M., PO525-TUE  
Arocas V., OR422, PO545-WED  
Aroux A., PO242-TUE  
Arponen S., PO485-TUE  
Arraud N., PO326-TUE  
Arroyo A., OR440  
Arroyo A. B., PO549-WED, PO552-WED  
Arroyo Rodríguez A. B., PO558-TUE  
Arruda V., PO155-MON  
Arruda V., AS120, PO160-MON  
Arshad N., PO609-MON, PO612-MON  
Artana C., PO236-WED  
Artang R., PO352-MON, PO456-TUE, PO424-WED  
Artaza G., PO538-MON, PO375-TUE, PO407-WED

## Authors Index

Artemenko E., OR245  
Artemov A., PO496-MON  
Artoni A., OR005, PO592-MON, PO574-TUE, PO176-WED, PO583-WED, PO633-WED  
Arzter D., PO188-MON  
Arvind P., PO081-MON  
Arya R., AS047, NUR008, OR033, OR063, OR073, PO347-MON, PO098-TUE, PO479-TUE, PO496-TUE, PO021-WED, PO558-WED  
Arza B., PO198-MON  
Asada Y., PO552-MON  
Asanuma K., PO335-TUE  
Aschman D., PO285-MON, PO618-TUE  
Aschman D., OR298  
Asenjo S., OR076, OR370  
Ashfaq A., OR082  
Ashikaga T., PO233-TUE, PO211-WED  
Ashrani A., OR128, PO645-WED  
Ashtiani M., PO186-MON  
Ashworth T., OR415  
Aslam R., OR139, PO302-TUE  
Aslan J., PO068-MON  
Aslan J., PO432-MON, PO440-WED  
Aslan J., PO453-WED  
Aspberg S., PO171-WED  
Asplund A., OR046  
Assalia M., PO126-MON  
Asselbergs F., PO386-TUE  
Astermark J., OR389, PO256-TUE  
Astouil P., OR315  
Ataga K., PO331-MON  
Atalar A. C., PO295-WED  
Ataullakhanov F., AS142, OR245, PO661-WED  
Ataullakhanov F., PO462-MON, PO047-WED, PO118-WED, PO150-WED, PO436-WED  
Ataullakhanov F., OR305, PO067-TUE, PO392-TUE, PO135-WED  
Ataullakhanov F., PO097-MON  
Atema J., PO506-TUE  
Athale U., PO463-MON, PO118-TUE  
Athar M., PO085-MON  
Athar M., PO148-TUE  
Atiee G., PO621-MON  
Atkinson H., PO159-MON  
Atkinson H., PO343-TUE  
Atkinson H., PO464-TUE  
Atsumi T., PO058-WED  
Attanasio M., OR253, PO076-TUE, PO477-TUE

Attarian D., PO042-MON, PO055-WED  
Attinasi F., PO071-TUE  
Atwal S., PO009-WED  
Au A., OR380  
Aubas P., PO535-MON  
Auerswald G., PO643-MON, PO629-TUE  
Auger C., AS039  
Auger W., PO644-WED  
Augustsson C., PO455-TUE  
Aujesky D., OR193  
Austin S., OR213, PO247-MON, PO502-MON, PO216-TUE, PO009-WED  
Austin S., PO418-TUE  
Autar A., PO078-MON  
Authi H., PO511-TUE, PO459-WED  
Authi K., PO511-TUE, PO459-WED  
Avagyan A., PO573-MON  
Avalos M., PO146-WED  
Avci E., PO230-MON  
Avery P., OR099  
Avigliano A., PO059-WED  
Avila M., OR105, OR159, OR328, PO270-MON, PO475-MON  
Avila M. L., PO479-MON  
Aviner S., PO475-WED  
Avishai E., PO225-WED  
Avivi I., PO335-MON, PO271-TUE  
Avorn J., PO232-MON  
Avril S., PO262-WED  
Avruscio G., PO385-MON  
Awa Oumar T., PO542-MON  
Awala H., PO323-TUE  
Awodu O., PO529-TUE  
Axelman E., AS096, PO126-MON  
Axe-Siegel R., PO285-TUE  
Ay C., AS034, OR227, OR260, OR313, OR357, PO096-MON, PO559-MON, PO122-WED, PO166-WED, PO391-WED, PO528-WED  
Ay L., OR313  
Ay Y., OR262, PO590-MON  
Ayadurai T., PO541-MON  
Ayala F., OR359  
Ayala R., PO487-TUE  
Ayaz N., PO279-WED  
Aycecek A., PO459-MON, PO279-WED  
Aydin Koker S., OR262  
Aydogan G., PO265-MON, PO313-MON, PO315-MON, PO459-MON, PO279-WED  
Aylwin S., AS047, PO558-WED

Ayombil F., PO133-TUE  
Ayres A., PO601-WED  
Aytaç S., PO505-WED  
Azar-Avivi S., PO225-WED  
Azevedo A., PO163-TUE, PO538-WED  
Azhar Z., PO085-MON  
Azimzadeh A., PO306-MON  
Azizi M., OR196  
B;Rvik T., PO308-TUE  
Baars J., PO103-TUE  
Babichak T., PO168-MON, PO169-MON, PO312-MON  
Babkina I., PO290-TUE  
Babu B., PO154-MON  
Baccini V., AS014, PO416-MON, PO443-MON, PO385-WED  
Baccouche H., PO528-MON, PO062-WED  
Bachelot-Loza C., PO016-TUE, PO018-TUE, PO038-TUE, PO437-WED  
Bachler M., PO330-WED  
Bachman B., AS183  
Bachmann L., PO314-WED  
Badimon L., PO017-MON, PO019-MON  
Badle S., PO660-WED  
Badolia R., OR111, OR184  
Badowska W., PO650-MON  
Bae M. H., PO071-WED, PO427-WED  
Bae O.-N., PO115-MON  
Bae S., PO426-TUE  
Baeriswyl V., PO101-MON  
Bagan-Triqueton A., PO621-WED  
Bagby S., PO296-TUE  
Bagger H., PO219-WED  
Bagger H., PO153-TUE  
Baghaei F., OR029  
Baghaipour M. R., PO149-TUE  
Baglin T., OR135, PO625-WED  
Baglin T., OR148, OR394  
Bagnard D., AS095  
Bagoly Z., PO516-TUE, PO087-WED  
Bahadir A., PO270-TUE, PO499-WED  
Ba-Hammam F., PO085-MON, PO148-TUE  
Bahl B., OR198  
Bai X., PO011-MON, PO425-TUE, PO039-WED, PO259-WED  
Bai Y., PO011-MON  
Baik S. Y., PO164-TUE  
Bailer B., PO219-TUE  
Bailey K., OR128, PO645-WED  
Bailey M., AS205

## Authors Index

**Bajaj S. P.**, P0165-MON  
**Bakchoul T.**, OR307, AS106, P0413-TUE  
**Baker C.**, P0336-WED  
**Baker J.**, P0238-MON  
**Baker J.**, P0507-MON  
**Baker R.**, P0374-TUE, P0669-TUE  
**Baker R.**, P0098-MON, P0324-TUE, P0540-WED, P0546-WED  
**Baker S.**, P0440-WED  
**Baker-Groberg S.**, AS129, P0010-MON, P0297-TUE  
**Bakhai A.**, OR382  
**Bakhos M.**, OR173, P0291-MON, P0339-WED, P0411-WED  
**Bakhtiar K.**, P0323-TUE  
**Bakker B.**, P0410-WED  
**Bal Dit Solier C.**, OR149  
**Bal Dit Sollier C.**, P0655-WED  
**Balabanov S.**, P0215-WED  
**Balakhonova T.**, P0199-MON  
**Balandina A.**, P0097-MON  
**Balantac Z.**, P0138-TUE  
**Balazova E.**, P0249-TUE, P0022-WED  
**Balbi M.**, P0177-TUE  
**Baldacci E.**, P0200-TUE, P0259-TUE, P0654-TUE, P0534-WED  
**Baldauf C.**, OR335, P0669-TUE  
**Balduini A.**, P0422-TUE, P0378-WED  
**Balduini C.**, P0438-MON, P0473-WED  
**Balestra D.**, OR296, OR300  
**Balkan C.**, P0630-TUE  
**Balkis M.**, P0281-WED  
**Balla J.**, P0530-MON, P0488-WED  
**Ballet V.**, P0286-TUE  
**Balogh L.**, P0224-MON, P0187-WED  
**Baltaci O.**, P0649-TUE  
**Balzi D.**, OR253, P0020-TUE  
**Banfi C.**, OR219, P0662-TUE  
**Banfi C.**, P0005-TUE  
**Banfi E.**, P0483-TUE  
**Bang A.**, P0388-TUE  
**Bang S.-M.**, P0614-MON, P0035-TUE, P0119-TUE, P0489-TUE, P0659-WED  
**Bannish B.**, P0207-MON  
**Banos A.**, P0212-MON, P0331-WED  
**Bansal V.**, P0192-TUE, P0332-WED  
**Banzato L.**, P0524-TUE  
**Baptista F.**, P0472-TUE

**Baques A.**, P0092-TUE, P0146-WED, P0231-WED  
**Bar -llan A.**, P0062-TUE  
**Bar On S.**, P0268-TUE  
**Baracchini C.**, P0524-TUE  
**Barasco E.**, P0385-MON  
**Baran B.**, P0278-MON, P0049-TUE, P0235-TUE, P0543-TUE, P0648-TUE, P0032-WED, P0526-WED  
**Barat N.**, P0045-TUE  
**Barba P.**, P0487-TUE  
**Barbanti C.**, P0018-TUE  
**Barbara A.**, OR144  
**Barbay V.**, P0520-MON  
**Barbera R.**, P0616-TUE  
**Barbera R.**, P0491-TUE  
**Barber B.**, P0410-WED  
**Barbieri S.**, P0005-TUE  
**Barbon E.**, OR179, OR300, P0158-MON  
**Barbu D.**, P0474-WED  
**Barchielli A.**, OR253, P0020-TUE  
**Barco S.**, P0372-MON, P0537-MON, P0506-TUE, P0507-TUE  
**Bardakchyan S.**, P0573-MON  
**Bárdos H.**, P0550-MON  
**Barelli S.**, P0400-TUE  
**Bar-Ilan A.**, P0048-WED, P0594-TUE, P0595-WED  
**Barillari G.**, AS195, P0358-MON, P0029-WED, P0175-WED  
**Bark Jr D.**, P0332-MON  
**Barnard J.**, P0494-WED  
**Barnard S.**, P0214-MON  
**Barnes C.**, OR346  
**Barnes G.**, P0623-TUE, P0419-WED  
**Barnes T.**, P0673-TUE  
**Baron S.**, P0038-TUE  
**Baroncini L.**, P0663-MON  
**Barone F.**, P0200-TUE, P0259-TUE, P0534-WED  
**Baroni M.**, OR050, OR297, P0554-TUE, P0555-TUE  
**Barr S.**, P0180-WED  
**Barrelier M.-T.**, AS137  
**Barrera L.**, P0068-TUE, P0522-WED  
**Barrett D.**, P0429-MON, P0565-MON  
**Barrett J.**, P0273-MON  
**Barrile N.**, P0101-WED  
**Barrón M.**, P0631-WED  
**Barros S.**, OR213, P0049-WED  
**Barros V.**, P0472-TUE  
**Barros V.**, P0508-MON, P0476-TUE  
**Barsela G.**, OR171

**Barteling W.**, P0468-TUE  
**Barthel M.-C.**, OR324  
**Barthez-Toullec M.**, P0484-MON, P0488-MON  
**Bartholomew C.**, NUR005  
**Baratosa R.**, P0364-WED  
**Barty R.**, OR282  
**Baruch D.**, OR205, OR234, OR403, P0376-WED  
**Barutcuoglu B.**, P0266-MON  
**Barvadheesh C.**, P0566-WED  
**Bas D. L.**, P0072-TUE  
**Basay O.**, P0143-TUE, P0158-TUE  
**Basili S.**, OR396  
**Basilio J.**, P0559-MON  
**Baskova O.**, P0147-WED  
**Baslar Z.**, P0265-MON  
**Basol G.**, P0266-MON  
**Bassand J.-P.**, OR119  
**Basso G.**, P0456-MON  
**Basso M.**, OR202, P0007-MON, P0259-TUE, P0534-WED  
**Bassora F.**, P0145-WED  
**Bastami S.**, P0401-TUE  
**Bastard C.**, P0621-WED  
**Bastelica D.**, P0385-WED  
**Bastos M.**, P0023-WED  
**Bateman T.**, P0032-MON  
**Bath P.**, P0518-TUE  
**Battle J.**, P0010-WED  
**Batorova A.**, P0249-TUE, P0371-TUE, P0022-WED, P0061-WED  
**Batt K.**, P0287-WED, P0297-WED  
**Battello C.**, P0029-WED  
**Battinelli E.**, P0380-WED  
**Battistelli S.**, OR132  
**Battram A.**, P0461-WED  
**Batty P.**, OR108, P0284-MON, P0258-WED  
**Batuman O.**, P0265-TUE  
**Baudar J.**, P0092-MON, P0063-TUE  
**Bauer A.**, P0249-MON, P0199-WED, P0229-WED  
**Bauer B.**, OR123  
**Bauersachs J.**, P0058-MON, P0013-TUE  
**Bauersachs R.**, AS081, AS214, OR199, OR228, P0356-TUE  
**Bauman M.**, P0455-MON, P0460-MON, P0511-WED  
**Baumann A.**, P0214-WED  
**Baumgartner C.**, P0222-WED  
**Baunsgaard D.**, P0153-TUE  
**Bautista M. P.**, P0658-WED  
**Bay A.**, P0109-WED

## Authors Index

**Bayhan T.**, P0505-WED, P0507-WED, P0508-WED  
**Baylis J.**, P0375-WED  
**Baylis J.**, P0372-WED  
**Bayliss S.**, P0019-TUE  
**Bayram C.**, P0313-MON, P0459-MON, P0279-WED  
**Baytan B.**, P0268-MON, P0156-TUE  
**Bazaa A.**, P0658-TUE  
**Bazaa A.**, AS062, OR246, P0206-WED  
**Bazzan M.**, P0614-MON  
**Beam D.**, OR376, P0033-MON  
**Beauchamp N.**, AS132  
**Beauloye C.**, P0101-WED  
**Beavis J.**, P0638-TUE  
**Becattini C.**, AS226, AS227, AS195, OR074, P0370-MON, P0626-MON, P0373-WED, P0423-WED  
**Becher F.**, P0181-TUE  
**Beckers C.**, P0190-WED  
**Beckers C.**, AS003  
**Beckers E.**, P0645-MON  
**Beckers E.**, P0349-WED  
**Beckers E.**, OR015, P0123-WED, P0609-WED  
**Becker-Scheidemann B.**, P0094-MON  
**Beckman M.**, P0637-WED  
**Beckmann H.**, OR214, P0292-WED, P0293-WED  
**Becs G.**, P0530-MON, P0488-WED  
**Bedarida T.**, P0038-TUE  
**Beenen L.**, P0597-MON  
**Beer J.**, P0027-MON  
**Beghini D.**, P0239-WED  
**Begins K.**, OR423  
**Behnisch W.**, P0419-TUE  
**Behr A.**, P0061-MON, P0315-TUE, P0127-WED  
**Behrendt T.**, P0420-TUE  
**Behrens C.**, P0219-WED  
**Beijer E.**, P0443-TUE  
**Beijlevelt - Van Der Zande M.**, NUR004, P0230-TUE  
**Beilhack A.**, OR405  
**Beishuizen A.**, OR225  
**Beken S.**, P0134-WED  
**Bekendam R.**, OR417  
**Bel E.**, P0611-MON, P0335-WED  
**Béla S.**, P0333-MON  
**Belanger A.**, P0374-MON  
**Belen F. B.**, P0309-MON  
**Belhani M.**, P0494-MON, P0242-TUE, P0637-TUE, P0520-WED

**Belhani M. F.**, P0276-WED  
**Belik S.**, P0096-MON  
**Belk K.**, OR309  
**Bell J.**, OR372  
**Bell R.**, P0004-TUE  
**Belleville T.**, P0018-TUE  
**Belliére J.**, AS117  
**Bellinger D. A.**, OR178  
**Bellissimo D.**, OR086  
**Bellissimo D.**, OR089  
**Bellofatto K.**, OR411  
**Bellon A.**, P0488-MON  
**Bellosillo B.**, P0435-MON  
**Belova N.**, P0381-TUE  
**Belsy G.**, P0152-WED  
**Beltramello G.**, OR132  
**Beltran J.**, P0045-TUE  
**Belzunce M.**, AS230  
**Bem D.**, AS054, AS011, OR401  
**Ben Ami T.**, P0475-WED  
**Ben Dov I.**, P0474-MON  
**Ben Harosh M.**, P0429-TUE  
**Ben Jemaa M.**, P0528-MON, P0062-WED  
**Ben Romdhane N.**, P0528-MON, P0062-WED  
**Ben Sassi S.**, P0528-MON, P0062-WED  
**Benamer S.**, P0344-MON  
**Ben-Barak A.**, P0475-WED  
**Ben-Barak S.**, P0475-WED  
**Bendapudi P.**, OR417  
**Bender M.**, OR232  
**Benedettini L.**, P0222-TUE  
**Beneventi F.**, P0580-WED  
**Benipal P.**, P0306-MON  
**Benmiloud N.**, P0544-TUE  
**Benn M.**, AS167, P0438-WED  
**Bennett J.**, P0431-WED  
**Bennett M.**, P0601-MON  
**Bennett P.**, NUR014  
**Benoit M.-C.**, P0081-WED  
**Bensadok M.**, P0494-MON, P0242-TUE, P0637-TUE, P0276-WED, P0520-WED  
**Bensen Kennedy D.**, P0089-TUE, P0257-TUE, P0258-TUE, P0262-TUE  
**Bensen-Kennedy D.**, OR350, P0241-TUE  
**Ben-Shlomo Y.**, OR209  
**Benson D. W.**, OR058  
**Benson G.**, P0481-MON, P0588-TUE  
**Beranger T.**, P0568-MON, P0575-MON  
**Berber E.**, P0649-TUE  
**Berbert L.**, P0158-WED

**Bercovitz R.**, OR058  
**Bereczky Z.**, P0550-MON, P0031-WED, P0087-WED, P0187-WED  
**Beregi J.-P.**, P0035-MON  
**Bereta J.**, P0365-WED  
**Béréziat O.**, P0337-MON  
**Bereznikova A.**, P0197-MON  
**Berg J. P.**, P0561-MON  
**Bergamasco J.**, P0322-TUE  
**Bergantim R.**, P0012-WED  
**Bergendal A.**, OR269  
**Berger K.**, P0291-WED  
**Bergés A.**, P0355-WED  
**Bergh N.**, OR380  
**Bergmann F.**, OR054  
**Bergmeier W.**, AS070, OR273, OR274, P0423-MON, P0003-TUE  
**Beriault D.**, OR007  
**Berlin G.**, P0571-MON  
**Bermejo E.**, P0646-TUE, P0652-TUE  
**Bermejo E.**, P0039-MON, P0636-TUE  
**Bernardi E.**, OR284  
**Bernardi F.**, OR050, OR080, OR179, OR296, OR297, OR300, OR333, P0554-TUE, P0555-TUE, P0556-TUE, P0557-TUE  
**Bernardo Á.**, P0488-TUE  
**Berndt M.**, P0395-MON  
**Berndtsson M.**, OR187, P0080-TUE, P0228-TUE  
**Bernot D.**, AS014, P0493-WED  
**Bernstein M.**, AS158  
**Berntop E.**, P0283-WED  
**Berntorp E.**, P0240-MON, P0271-MON, P0080-TUE, P0229-TUE, P0263-WED, P0299-WED  
**Berny-Lang M.**, P0411-MON, P0096-TUE  
**Berra C.**, P0107-MON  
**Berrou E.**, OR003, OR234, P0444-WED  
**Berruyer M.**, P0448-MON  
**Berry L.**, P0087-MON  
**Berry L.**, P0343-TUE  
**Berry L.**, P0159-MON, P0464-TUE  
**Berta G.**, AS088  
**Bertaglia Calderara D.**, P0400-TUE  
**Berthomet C.**, P0056-WED  
**Bertil S.**, AS086  
**Bertin F.-R.**, OR167  
**Bertina R.**, OR374  
**Bertling A.**, P0015-TUE, P0157-TUE, P0395-TUE

## Authors Index

Bertolaccini M., PO068-WED  
Bertoletti L., OR381, PO608-MON, PO103-TUE, PO107-TUE, PO631-WED  
Bertone A., PO358-MON  
Bertrand A., PO501-MON  
Bertrand L., PO101-WED  
Besbes S., PO117-MON  
Besenfelder S., PO487-WED  
Besser M., PO317-TUE  
Besses C., PO487-TUE  
Beswick A., OR209  
Bettella M., PO385-MON  
Bettencourt B., PO049-WED  
Bettencourt P., PO264-TUE  
Betti S., PO611-TUE  
Bettin C., PO084-TUE  
Bettina K.-M., PO140-WED  
Bettoni D., PO622-TUE  
Bevan D. H., OR213  
Beverina I., PO615-WED  
Beyer - Westendorf J., PO103-TUE  
Beyer-Westendorf J., AS022, AS098, AS099, AS195, AS197, OR259, OR292, PO477-MON, PO614-MON, PO636-MON, PO356-TUE, PO611-TUE, PO624-WED  
Bez J., PO340-MON  
Bez J., PO337-MON  
Bezgal F., PO295-WED  
Beziau S., OR025  
Beziaud M., OR192  
Bezie Y., PO033-TUE  
Bezieau S., PO645-TUE  
Bhagirath V., PO570-MON, PO604-TUE  
Bhakta V., OR425  
Bhal V., PO174-TUE, PO076-WED  
Bhatt D., PO494-WED  
Bhatt M., PO447-TUE  
Bhattoa H., PO488-WED  
Bhavanasi D., OR184  
Bialkowska K., PO194-MON  
Bianchi F., PO568-MON, PO575-MON  
Bianchini E., PO339-TUE  
Bias V., OR298  
Biasoli C., AS222, PO264-MON, PO222-TUE, PO303-WED  
Bicalho M., PO397-WED  
Bicalho M. A., PO189-TUE, PO023-WED  
Bicalho M. A., PO002-WED  
Bichler J., PO272-WED  
Bicker M., PO382-MON  
Bicocchi M. P., PO259-TUE, PO534-WED

Bidlingmaier C., PO252-WED  
Bieback K., PO383-WED  
Biedermann J., PO623-MON, PO665-WED  
Biedermann J., PO648-WED  
Biel C., PO444-TUE  
Biemond B., PO294-MON  
Bierings R., AS118  
Biessen E., AS189  
Bignell P., PO653-MON, PO638-TUE  
Bigo E., PO241-WED, PO422-WED  
Biguzzi E., OR026, PO503-MON, PO656-MON, PO663-MON, PO090-TUE, PO091-TUE  
Bihan D., AS065, PO441-WED  
Bihari C., PO540-MON, PO005-WED  
Biino G., PO438-MON  
Bilge S., PO051-WED  
Bilir S. P., PO312-MON  
Billier E., PO587-MON  
Billwein M., PO199-WED  
Binard S., PO440-MON  
Binder C., PO298-TUE  
Binder L., PO062-TUE, PO550-TUE, PO048-WED, PO594-WED, PO595-WED  
Bingo M., PO161-MON, PO006-WED  
Binhama T., PO675-MON, PO268-WED, PO613-WED, PO643-WED  
Birch K., PO385-TUE  
Bird A., OR382, PO638-MON  
Bird M., PO618-TUE  
Birner P., OR357  
Biron Andréani C., PO263-TUE  
Birschmann I., PO140-WED  
Bischoff J., AS087  
Biselli C., PO018-TUE  
Biss T., AS054, AS159, OR104, OR145, PO420-WED, PO502-WED  
Biss T., PO447-MON  
Bisset A., PO346-MON  
Biswas A., OR248, PO498-MON, PO637-MON, PO674-MON, PO182-WED, PO183-WED, PO184-WED  
Bito S., OR051  
Bitsadze V., PO008-MON  
Bitsadze V., PO548-MON  
Bittar L., PO221-WED  
Bittner L., PO364-WED  
Bjoernsen S., OR317  
Björkqvist J., PO178-TUE  
Black A., PO180-WED  
Blackshear P., OR085

Blades T., PO103-MON  
Blair T., PO428-MON  
Blair T., OR112  
Blaise F., PO542-MON  
Blaise S., PO457-WED  
Blake D., OR280  
Blanchard A., OR196  
Blanchette V., AS122, OR105, OR390, PO262-MON, PO245-TUE, PO426-TUE  
Blanchette V., AS078  
Blanchette V., PO390-TUE  
Blanco A., PO004-MON, PO629-MON, PO634-TUE, PO636-TUE, PO646-TUE  
Blanco A., PO039-MON  
Blanco J. E., OR221  
Blankenberg S., PO478-WED  
Blanty J., PO502-MON  
Blanz K., OR252  
Blasier K., PO203-TUE  
Blasier K., PO368-WED  
Blasko E., PO213-WED  
Blatny J., PO655-MON  
Blatny J., AS122, OR346, PO262-MON  
Blazejczyk A., PO365-WED  
Blazek B., OR346  
Bledzka K., PO194-MON  
Bleker S., AS197, OR292  
Bleker S., OR199, PO624-WED  
Bleker S., PO103-TUE, PO353-TUE, PO409-WED  
Blickstein D., PO001-WED  
Bliden K., PO076-MON, PO099-MON, PO041-TUE  
Blighe K., PO197-WED  
Blin A., PO376-WED  
Blinc A., AS101  
Blix K., AS083, OR129, OR293, OR345, OR393, PO526-MON, PO104-TUE, PO111-TUE, PO112-TUE, PO495-TUE, PO568-WED  
Bloch Münster A.-M., PO130-MON  
Bloch-Münster A.-M., PO051-TUE  
Bloem E., AS121  
Bloem-De Vries L., PO614-TUE, PO366-WED  
Bloemen S., OR427, PO143-MON, PO290-MON, PO546-MON, PO072-TUE  
Bloemenkamp K., PO607-WED  
Blombäck M., PO255-MON, PO368-MON, PO661-MON, PO362-WED  
Blomgren B., PO171-WED  
Blondal T., PO572-WED

## Authors Index

Blondon M., OR034, OR133, PO557-WED  
Blostein M., OR282, AS215, PO647-WED  
Bloston M., OR167  
Blouse G., OR299  
Bluestein D., PO677-TUE  
Blunt D., PO633-MON  
Bluteau O., OR082  
Bo Z., PO129-MON  
Bo Mogensen V., PO121-WED  
Boadas A., PO523-WED  
Boban A., PO234-TUE, PO280-WED  
Bobe R., PO444-WED  
Bobrov M., PO030-WED  
Bochenek M., PO513-TUE, PO102-WED  
Bochicchio R., PO200-TUE, PO534-WED  
Bock F., PO129-TUE  
Bock P., OR423  
Boda Z., OR199, PO031-WED  
Bode A., PO611-WED  
Bode C., OR252, PO307-TUE, PO404-TUE  
Bodrozic J., PO235-WED  
Bodroži J., PO218-TUE  
Boef A., PO532-MON  
Boehlen F., OR034  
Boehm E., PO201-WED  
Boelen A., PO548-WED  
Boender J., PO665-MON  
Boender J., AS079, OR021, OR203  
Boffa J.-J., PO632-WED  
Bogdanov V., AS028, OR047  
Bogdanov V., PO017-MON  
Boggio L., OR347, PO256-WED, PO266-WED, PO298-WED  
Boghossian J., PO439-TUE  
Bohdan N., OR076, OR359, OR368, PO336-MON, PO338-TUE  
Bohgaki T., PO058-WED  
Bohn R., PO232-MON  
Boietti B., PO620-WED  
Boietti B., PO642-WED  
Böing A., PO342-MON  
Boisseau P., AS134, OR024, OR025, PO645-TUE, PO664-TUE  
Boisson-Vidal C., PO014-MON  
Bojenov E., OR043  
Bokemeyer C., PO251-MON, PO174-WED  
Bokuchava M., PO585-WED  
Bollen L., OR444, PO215-MON, PO286-TUE

Bologna L., PO489-MON  
Bolt G., OR414  
Bolt J., NUR011  
Bolton-Maggs P., AS054  
Bolton-Maggs P., PO495-MON  
Bonacci R., PO585-TUE  
Bonadeo J., PO616-TUE, PO491-TUE  
Bonafacio S., PO648-WED  
Bonaldi C., PO598-TUE  
Bonanad S., PO093-MON, PO534-MON, PO536-MON, PO579-WED  
Bonanad-Boix S., PO271-WED  
Bonanni P., PO585-TUE  
Bonar R., PO366-TUE  
Bond S., PO362-TUE  
Bonduel M., OR160, PO644-MON, PO428-TUE  
Bonet E., PO093-MON, PO344-TUE  
Bonhomme F., PO011-TUE  
Bonilla G., PO658-WED  
Bonnard T., PO014-TUE  
Bonneau D., OR003  
Bonneau J., NUR013  
Bonnefoy A., OR217, PO006-MON, PO165-WED, PO282-WED  
Bonner L., NUR008  
Bonnet D., AS086  
Bonnet J.-L., PO493-WED  
Bonvini R., PO011-TUE  
Bonzini M., PO613-MON  
Bookhart B., PO625-MON  
Boon-Spijker M., AS121  
Boonyawat K., OR068  
Booth S., PO635-MON  
Boothman L., OR183, PO434-WED  
Bor M. V., PO495-WED  
Bör Ö., PO196-TUE  
Boraso S., PO084-TUE  
Borchert A., PO094-MON  
Borel-Derlon A., OR025, PO650-MON, PO639-TUE  
Borg J.-Y., PO501-MON, PO520-MON, PO621-WED  
Borge D., PO018-TUE, PO339-TUE  
Borges K., PO340-WED  
Borges K., PO244-WED  
Borges K., PO566-MON  
Borgeoens P., PO373-TUE  
Borhany M., PO502-MON, PO134-TUE, PO549-TUE, PO181-WED, PO521-WED  
Borisevich A., PO028-WED  
Borotto E., PO615-WED

Boroumand M., PO090-WED  
Bjørresen-Dale A.-L., PO177-WED, PO178-WED  
Borst O., OR114, PO412-MON, PO449-WED  
Bortolussi G., PO438-TUE  
Börtz A., PO382-MON  
Børvik T., PO329-TUE  
Bos M., PO522-MON  
Bos M., AS056, OR147, PO144-MON, PO562-MON, PO616-MON  
Bos M., PO620-TUE  
Boscarino M., OR083, PO502-MON, PO521-WED  
Bosch F., PO538-MON, PO056-TUE, PO321-TUE, PO375-TUE, PO445-TUE, PO407-WED  
Bosch Y., PO290-MON  
Bosco A., PO043-WED  
Boscolo Anzoletti M., PO164-MON  
Boselli D., PO378-WED  
Bosmann M., PO513-TUE  
Bosmans J., PO218-MON  
Bossard M., PO200-WED  
Bossion J. L., PO655-WED  
Bossion J.-L., PO095-TUE  
Bossuyt P., PO596-MON, PO624-WED  
Bossuyt P., PO597-MON  
Bottai M., OR269  
Bottaro F., PO621-TUE  
Bottenus R., PO360-MON, PO374-MON, PO054-TUE  
Böttger C., PO256-MON  
Bouazzaoui A., PO085-MON, PO148-TUE  
Bouchard B., PO145-MON  
Bouchard B., PO576-MON  
Bouchard B., AS050  
Bouchard C., PO191-TUE, PO192-TUE, PO344-WED  
Bouckaert C., PO172-TUE, PO269-TUE  
Boucsein-Mueller E., PO107-WED, PO137-WED  
Boulaftali Y., AS070, OR274, PO222-MON, PO423-MON  
Bouman A., PO466-MON, PO471-MON  
Bouman A., PO470-MON  
Bounameaux H., AS099, AS137, OR259, OR381  
Bourdon C., PO131-TUE  
Bourgeois C., OR028  
Bourhim M., PO122-MON  
Bouriche T., PO337-MON, PO340-MON  
Bourke D., PO649-WED  
Bours V., AS006

## Authors Index

Bourti Y., PO339-TUE  
Bouskill V., AS078  
Boutiba S., PO276-WED  
Bouton M.-C., OR422, PO545-WED  
Bouvier S., OR095, OR188, OR190, PO035-MON  
Bouwens E., AS121  
Bouwuis A., OR301  
Bova C., OR132  
Bovolenta M., OR179  
Bowley S., OR417, PO425-MON  
Bowley S., OR424  
Bowman M., OR023  
Boyd J., NUR006  
Boyd S., PO487-MON  
Boyer-Neumann C., PO639-TUE  
Boyett S., OR435  
Bozgul Kilincer M., PO266-MON, PO237-TUE, PO238-TUE  
Bozic-Mijovski M., PO082-TUE  
Boži -Mijovski M., PO360-TUE  
Bozkurt A., PO051-WED  
Bozon D., PO198-WED  
Bracco A., PO024-TUE, PO372-TUE  
Bracken T., AS114  
Brackmann H.-H., OR103, PO219-TUE  
Brækkan S., AS138, OR075, OR120, OR134, OR345, PO524-MON, PO525-MON, PO610-MON, PO111-TUE, PO112-TUE, PO567-WED  
Brækkan S., AS083, PO519-MON, PO641-WED  
Brækkan S., AS046, OR129, OR267, OR393, PO526-MON, PO104-TUE, PO494-TUE, PO495-TUE, PO568-WED, PO636-WED, PO638-WED  
Brækkan S., OR071, OR254, OR293, OR392, PO609-MON, PO612-MON, PO493-TUE, PO594-TUE, PO561-WED  
Braggio E., PO128-MON  
Brailly-Tabard S., PO527-MON  
Braley H., AS016  
Brambilla M., PO378-WED  
Branchford B., AS161, OR156  
Branchini A., OR179, OR297, PO554-TUE, PO555-TUE  
Brand B., OR213, PO242-MON  
Brandao L., PO465-MON, PO118-TUE  
Brandao L., AS078  
Brandao L., OR159, OR328, PO475-MON, PO446-TUE  
Brandão B., PO158-WED

Brandão L., PO434-TUE  
Brandão L., PO479-MON  
Brando B., PO615-WED  
Brand-Stauffer B. C., PO215-WED  
Brandt S., AS008, PO298-MON  
Brandtzaeg P., PO561-MON  
Brandwein J., PO592-TUE  
Brass L., AS185  
Brass L., OR038, OR207  
Brass L., PO467-WED  
Bratset V., PO079-MON  
Braun A., AS068, AS228, OR081  
Braun M., PO001-WED  
Braunreiter C., AS103  
Bravo A., PO355-WED  
Bravo M. C., PO371-MON  
Bravo M. I., PO207-WED  
Bravo M., PO152-WED  
Brayne M., PO053-TUE  
Brede C., OR405  
Breen K., PO045-MON, PO603-MON  
Brehm M. A., OR335  
Breinholt J., PO455-TUE  
Breinholt J., PO541-WED  
Breitenfeld R., PO451-WED  
Breitenfeld R., PO336-WED  
Brekalo M., PO282-TUE  
Brekelmans M., PO507-TUE  
Brekelmans M., OR199  
Bremme K., PO292-TUE, PO482-TUE  
Brenner S., PO253-MON  
Brennan M., PO078-WED  
Brenner B., OR171, PO126-MON, PO325-TUE, PO389-WED, PO563-WED  
Brenner M., OR058  
Bressollette L., OR149, OR323, PO655-WED  
Brettner S., PO343-WED  
Bridey F., PO488-MON  
Bridey F., PO484-MON, PO650-MON  
Bridge K., OR433  
Bridge K., AS205, OR444  
Brien B., PO267-TUE  
Brien W., AS078  
Briens A., OR314  
Briggs H., PO580-TUE, PO581-TUE  
Brighton T., PO468-MON, PO618-MON  
Brighton T., PO374-TUE  
Brighton T., AS099, OR259  
Brill A., OR121, PO325-MON  
Bringmann P., PO555-WED  
Brinkman H. J., PO352-WED

Brionne-François M., PO448-MON  
Brioschi M., PO005-TUE  
Brisot D., AS137  
Brissard A., PO128-WED  
Brisson A., OR315  
Brisson A., PO326-TUE  
Brito M., PO184-TUE  
Britta Laros-Van Gorkom B., PO257-TUE  
Brix J., OR313  
Brizuela M., PO079-TUE  
Brkovi B., PO218-TUE  
Broberg M., PO219-WED  
Brodde M., PO163-MON, PO218-WED, PO234-WED  
Brodde M., PO157-TUE  
Brodde M., PO395-TUE  
Brodie M., PO445-WED  
Brodin E., PO263-WED  
Brodin E., OR258, PO472-MON  
Brodin E., OR075  
Brodin E., PO494-TUE  
Brodsky G., AS143  
Broeg-Morway A., PO525-TUE  
Brognoli F., PO622-TUE  
Brondi B., PO502-TUE  
Bronowska A., PO669-TUE  
Brons P., AS079, PO502-MON, PO680-TUE  
Brophy D., PO273-MON  
Brophy T., PO667-TUE  
Brousse V., AS086  
Brouwer M., PO366-WED  
Brouwer M., PO614-TUE  
Brouwer R., OR257  
Brouwers E., PO545-WED  
Brown A., NUR008, PO347-MON  
Brown C., OR332, PO679-TUE  
Brown E., AS141  
Brown J., PO190-WED  
Brown J., AS003  
Brown P., AS143  
Brown S., PO255-WED  
Brown S., NUR013  
Brox J., AS046, OR120  
Bruce A., PO455-MON, PO460-MON, PO083-WED, PO511-WED  
Brueckmann M., OR283, PO362-MON  
Brummel-Ziedins K., PO467-TUE  
Brunel H., PO543-MON  
Brunet D., OR324  
Brunn M., PO274-WED  
Brunson A., OR325  
Brunt E., PO450-WED  
Bruria R., PO659-TUE  
Bruscaggini V., OR106, OR411

## Authors Index

Brusov O., PO147-WED  
Bruzelius M., OR269, PO559-WED, PO564-WED  
Bryckaert M., OR003, OR205, OR234, PO444-WED  
Brzoska T., AS030  
Bubanska E., PO249-TUE  
Bucciarelli P., AS196, OR083, OR394, PO656-MON, PO663-MON, PO176-WED, PO583-WED, PO633-WED  
Buchardt J., PO219-WED  
Bucherelli S., PO067-MON  
Bucherini E., OR132, OR195, PO611-TUE, PO671-WED  
Buchholz H., PO455-MON, PO083-WED  
Buckley C., AS092  
Buckley C., PO393-TUE  
Buckner T., PO297-WED, PO298-WED  
Budde U., PO649-MON, PO667-MON, PO676-MON  
Budnik I., PO396-MON  
Buehner K., PO214-WED  
Buevich E., PO643-MON  
Bugert P., PO383-WED, PO487-WED  
Bugger H., OR252  
Buhre P., PO665-WED  
Bulato C., OR078, OR172, PO193-MON, PO341-MON, PO548-TUE, PO387-WED  
Bulder I., PO326-MON  
Buller H., OR383, PO587-TUE, PO608-TUE  
Büller H., OR199, PO596-MON, PO409-WED, PO624-WED  
Büller H., AS197, OR191, OR292, PO100-TUE, PO103-TUE, PO353-TUE, PO164-WED  
Bullih A., PO019-WED, PO509-WED  
Bullorsky E., PO180-TUE  
Bulmer A., PO498-WED  
Bungard T., NUR011  
Burakov V., PO111-WED  
Burakowski J., PO311-WED  
Burbury K., PO149-WED  
Burdorf L., PO306-MON  
Burger D., PO229-WED  
Burggraaf J., PO469-TUE, PO550-WED, PO592-WED  
Burghaus R., AS104  
Burgiss J., PO578-MON  
Burini F., OR297  
Burk O., PO412-MON  
Burke T., PO375-WED  
Burkhart J., PO499-MON

Burleson D., PO211-MON, PO212-MON  
Burra P., PO114-TUE  
Burthem J., PO495-MON  
Bury L., OR208, OR336, OR399, PO473-WED  
Buryachkovskaya L., PO294-TUE  
Buryachkovskaya L., PO496-WED  
Buscema M., PO066-MON  
Bushueva N., PO204-MON  
Bussel J., PO311-MON  
Busstra M., PO282-MON  
Butenas S., OR303, OR426, PO248-MON, PO168-TUE, PO467-TUE  
Butera D., PO669-TUE  
Butler L., PO559-WED  
Butlin R., AS205  
Butt W., PO607-MON, PO596-TUE  
Butter L., OR124  
Buvaliy S., PO047-WED  
Buyanbat A., PO072-WED  
Buyukkaya P., PO051-WED  
Buzdin A., PO496-MON  
Buzzi J.-C., PO620-MON  
Byams V., PO285-MON  
Bye A., AS167, PO438-WED  
Bykov K., PO232-MON  
Bykowska K., PO278-MON, PO549-MON, PO543-TUE, PO648-TUE, PO026-WED, PO032-WED, PO526-WED, PO536-WED, PO588-WED  
Byrkjeland R., PO079-MON, PO042-TUE  
Byrne M., PO318-WED  
Byrne R., NUR008, PO347-MON  
Byrnes J., AS153  
Byun T., OR247  
Byzova T. V., AS093  
C. Jorissen A., PO565-WED  
Caballero J., PO010-TUE  
Cabello Clotet N., PO485-TUE  
Cabre Marquez J., PO274-WED  
Cabrera N., PO579-WED  
Cabrera V., PO051-MON  
Cacco L., PO385-MON  
Cadot S., PO423-TUE  
Cafaro L., PO483-TUE  
Cai T.-Q., PO074-WED  
Caiani V., PO656-MON  
Cain T., PO449-MON  
Cairo A., PO580-MON, PO582-MON, PO592-MON, PO676-WED  
Caironi P., PO338-WED  
Cajfinger F., PO624-MON

Calderaro D., PO034-TUE, PO095-WED  
Caliskan U., OR348  
Callahan R., PO601-WED  
Callewaert F., OR363  
Callewaert N., OR443  
Calmette L., PO016-TUE  
Calvert L., PO343-TUE  
Calvez T., OR143  
Calvo A., PO585-MON  
Calvo C., PO441-TUE  
Calzavarini S., PO101-MON, PO489-MON  
Camera M., PO378-WED  
Camerer E., PO437-WED  
Cameron A., PO004-TUE  
Cameron S., OR241  
Cameron S., PO032-TUE  
Camire R., AS149, PO520-TUE  
Camire R., AS120, AS150, PO144-MON, PO160-MON, PO632-MON, PO415-WED  
Camire R., AS148  
Camm J., OR096, OR119  
Campbell H., PO075-MON, PO415-TUE  
Campbell J., PO637-WED  
Campbell R., OR085, PO423-MON  
Campbell V., PO248-WED  
Campello E., AS042, OR078, OR172, PO061-MON, PO341-MON, PO456-MON, PO114-TUE, PO315-TUE, PO331-TUE, PO332-TUE, PO438-TUE, PO524-TUE, PO548-TUE, PO387-WED  
Campioni M., OR297, OR333, PO554-TUE  
Camporese G., AS197, OR195, OR284, OR292, PO624-WED  
Campos F., PO397-WED  
Campos F., OR116  
Campos G., PO211-TUE, PO250-WED  
Campos M., PO442-MON, PO318-TUE, PO626-TUE  
Campos-Nunes F., PO333-MON  
Canaut M., AS014, PO416-MON, PO441-MON, PO443-MON, PO385-WED, PO493-WED  
Canbolat Ayhan A., PO230-MON  
Cannavò A., PO090-TUE, PO091-TUE, PO303-WED  
Cannavò A., PO503-MON  
Cannegieter S., AS138, OR035, OR131, OR135, OR268, OR345, PO522-MON, PO623-MON

## Authors Index

**Cannegieter S.**, AS083, OR134, OR150, OR322, P0532-MON, P0616-MON, P0601-TUE, P0223-WED, P0562-WED, P0573-WED, P0577-WED, P0625-WED, P0641-WED  
**Cannegieter S.**, OR098, OR118, OR129, P0514-MON, P0104-TUE, P0111-TUE, P0112-TUE, P0498-TUE, P0525-TUE, P0666-WED, P0668-WED  
**Cannizzo E.**, OR411  
**Canobbio I.**, OR115, OR183, P0450-TUE  
**Canonico M.**, P0527-MON  
**Canpolat M.**, P0490-TUE  
**Cantori I.**, OR027, P0303-WED  
**Canzano P.**, P0378-WED  
**Cao L.**, P0425-TUE, P0039-WED, P0259-WED, P0533-WED  
**Cao Z.**, P0360-MON, P0374-MON, P0054-TUE  
**Caparrós-Pérez E.**, OR221, P0497-MON  
**Capel A.**, P0513-WED  
**Capmany C.**, P0616-TUE  
**Cappelli R.**, P0373-WED  
**Cappucci F.**, P0513-MON  
**Capria V.**, P0200-TUE  
**Caram-Deelder C.**, AS138  
**Caramelli B.**, P0034-TUE, P0095-WED  
**Carcao M.**, OR141  
**Carcao M.**, OR013, P0270-MON  
**Carcao M.**, AS078  
**Cardel L.**, P0484-WED  
**Cardella A. M.**, P0618-WED  
**Cardenas J.**, P0174-TUE  
**Carestia A.**, AS173, P0323-MON  
**Carlson L.**, P0618-TUE  
**Carreiro F.**, P0340-WED  
**Carreiro J.**, P0431-TUE, P0433-TUE  
**Carreiro J.**, P0434-TUE  
**Caroff E.**, P0022-TUE  
**Caron C.**, AS134, OR024, OR025, OR219, P0650-MON, P0662-TUE  
**Caron K.**, P0423-MON  
**Caroppo V.**, OR019, P0086-WED  
**Carpentier A.**, P0513-WED  
**Carr M.**, P0257-MON  
**Carrabba G.**, P0176-WED  
**Carraro P.**, P0077-TUE, P0084-TUE  
**Carrasco J. J.**, P0271-WED  
**Carrasco P.**, P0336-MON  
**Carreras E.**, P0189-MON, P0191-MON

**Carreras L.**, P0484-MON, P0488-MON  
**Carrier M.**, AS137, OR053, OR281, OR282, OR295, OR310, OR384, AS080, P0467-MON, P0473-MON, P0100-TUE, P0101-TUE, P0320-TUE, P0630-WED, P0664-WED  
**Carrim N.**, AS168, P0326-WED  
**Carrizo C.**, P0042-MON  
**Carter R.**, P0459-TUE  
**Cartier D.**, OR122  
**Cartwright A.**, AS064, P0667-MON, P0676-MON  
**Cartwright E.**, OR168  
**Caruso F.**, P0014-TUE  
**Caruso V.**, P0629-MON  
**Carvalho M.**, P0212-TUE, P0264-TUE, P0012-WED, P0261-WED, P0404-WED  
**Carvalho M.**, P0390-WED  
**Carvalho M.**, P0663-TUE  
**Carvalho M.**, P0237-WED, P0479-WED  
**Carvalho M.**, P0397-WED  
**Carvalho M. D. G.**, P0023-WED  
**Carvalho M. D. G.**, P0002-WED  
**Carvalho M. D. G.**, P0566-MON, P0189-TUE, P0244-WED  
**Casa L.**, P0677-MON  
**Casagran O.**, P0516-MON  
**Casais P.**, P0323-MON  
**Casale C.**, P0568-MON, P0575-MON  
**Casali A.**, OR197  
**Casaña-Granell J.**, P0271-WED  
**Casanegra A.**, P0523-MON  
**Casari C.**, AS070, OR205, OR234, OR333, P0423-MON  
**Casazza F.**, P0626-MON  
**Case B.**, P0202-TUE  
**Casella I.**, P0613-TUE  
**Casella M.**, OR197  
**Cases A.**, P0184-MON, P0187-TUE  
**Casey L.**, OR023  
**Casey M.**, P0621-TUE  
**Casinelli M.**, P0634-TUE  
**Casinelli M.**, P0003-MON, P0004-MON, P0042-WED  
**Casini A.**, P0217-MON, P0485-MON, P0502-MON, P0521-WED  
**Casoli G.**, P0592-MON  
**Casparo P.**, P0604-MON  
**Cassinat B.**, P0080-WED  
**Cassis F.**, P0434-TUE

**Castaman G.**, AS222, OR015, OR088, OR144, OR297, OR347, P0649-MON, P0162-TUE, P0650-TUE, P0303-WED  
**Castejo B.**, OR074, OR321  
**Castellan M.**, P0593-WED  
**Castellaneta M.**, P0610-TUE  
**Castellani M.**, P0176-WED  
**Castellant P.**, OR146, OR149, P0655-WED  
**Carter R.**, P0035-WED  
**Castelli C.**, P0035-WED  
**Castellino F.**, AS112, OR421, P0305-TUE  
**Castellucci L.**, OR198, P0641-MON  
**Castellucci L.**, OR310, P0320-TUE  
**Castet S.**, OR024  
**Castillo B.**, P0631-TUE  
**Castillo J.**, OR116  
**Castillo O.**, P0187-MON  
**Castilloux J.-F.**, OR217  
**Castoldi E.**, OR248, OR374, P0470-MON, P0023-WED  
**Castro A.**, P0056-TUE  
**Castro A.**, P0360-WED  
**Casuccio A.**, P0117-TUE  
**Cataland S.**, OR362, P0587-MON, P0588-MON, P0572-TUE, P0573-TUE  
**Cate S.**, P0568-TUE  
**Caton F.**, P0223-MON, P0340-MON, P0241-WED, P0422-WED  
**Cattaneo M.**, OR019, P0066-MON, P0412-TUE, P0422-TUE, P0086-WED, P0473-WED  
**Cattepoel S.**, AS016  
**Cattinelli S.**, P0373-WED  
**Cavalcanti F.**, P0038-MON  
**Cavallari I.**, P0024-TUE  
**Cavallari N.**, OR300  
**Cavallo L.**, P0582-MON  
**Cayuleo M.**, OR220, P0480-WED  
**Ceglarek B.**, P0278-MON, P0549-MON, P0026-WED, P0032-WED, P0526-WED, P0536-WED, P0588-WED  
**Cei M.**, P0502-TUE  
**Celarier T.**, P0107-TUE  
**Celeste D.**, P0431-TUE  
**Celikturk F.**, P0270-TUE  
**Celinska-Lowenhoff M.**, P0070-WED  
**Celi ska-Löwenhoff M.**, P0048-MON, P0069-WED  
**Cellai A.**, P0226-MON  
**Cellai A. P.**, P0586-WED  
**Cenci C.**, P0226-MON  
**Cerbone A. M.**, P0534-TUE

## Authors Index

**Ceresetto J.**, P0180-TUE  
**Ceresetto J. M.**, P0621-TUE  
**Ceriello A.**, P0608-MON  
**Cermakova Z.**, OR152  
**Cernel P.**, P0181-MON, P0027-WED  
**Cerqueira M.**, P0034-WED, P0251-WED  
**Cerrone G.**, P0323-MON  
**Cervantes F.**, P0487-TUE  
**Cervantes F.**, P0435-MON  
**Cervellin G.**, P0222-TUE  
**Cervio C.**, OR160, P0644-MON, P0428-TUE  
**César Malfante P.**, P0631-WED  
**Cesarman E.**, P0128-MON  
**Cesarman-Maus G.**, P0128-MON  
**Cetin M.**, P0505-WED, P0507-WED, P0508-WED  
**Ceznerová E.**, P0194-TUE  
**Chagnon I.**, AS077  
**Chai-Adisaksopha C.**, OR068  
**Chaikitpinyo A.**, P0461-MON  
**Chaireti R.**, P0292-TUE, P0482-TUE, P0560-TUE, P0561-TUE  
**Chako J.**, OR367  
**Chakrabarti E.**, P0032-TUE  
**Chakroun E.**, P0528-MON  
**Challande P.**, P0031-TUE  
**Chalmers E.**, AS159, AS161, OR104, OR145, OR386, P0239-MON  
**Chambost H.**, OR346, P0103-WED  
**Chambost H.**, OR012, OR143  
**Champion G.**, AS108  
**Chan A.**, AS104, OR346, P0087-MON, P0463-MON, P0118-TUE, P0447-TUE  
**Chan A.**, P0446-MON  
**Chan A.**, P0276-MON, P0595-MON, P0161-WED  
**Chan A.**, P0343-TUE, P0545-TUE  
**Chan A.**, P0159-MON, P0464-TUE  
**Chan A.**, OR373, P0350-MON, P0359-TUE, P0565-TUE, P0139-WED, P0348-WED  
**Chan F. S. L.**, P0615-TUE  
**Chan F.**, OR373, P0348-WED  
**Chan H.**, NUR007  
**Chan H.**, P0595-MON, P0161-WED  
**Chan H.**, OR373, P0350-MON, P0355-MON, P0359-TUE, P0565-TUE, P0139-WED, P0348-WED  
**Chan L.**, P0556-WED

**Chan M.**, P0085-WED  
**Chan N.**, P0489-WED  
**Chan S.**, P0606-MON  
**Chan V.**, P0421-MON  
**Chan V. W. T.**, P0460-WED  
**Chandarajoti K.**, AS049, OR306  
**Chandra S.**, P0288-MON  
**Chandrakumaran K.**, P0344-MON  
**Chandrasekaran S.**, P0110-MON  
**Chang C.-Y.**, P0226-TUE, P0265-WED, P0289-WED  
**Chang C.-H.**, P0059-MON, P0334-WED  
**Chang G.**, P0464-TUE  
**Chang H.**, AS230  
**Chang H.**, P0476-WED  
**Chang J.-Y.**, OR319  
**Chang J.**, P0408-WED  
**Chang L.**, P0409-MON  
**Chang S.-K.**, P0031-MON  
**Chang S.-P.**, P0245-MON  
**Chang S. S.**, AS031  
**Chang W.**, P0008-TUE  
**Chang Y.-W.**, OR344, P0430-WED  
**Chang Y.**, P0601-WED  
**Changeng R.**, P0113-TUE, P0394-WED  
**Chantarangkul V.**, P0091-MON, P0059-TUE, P0114-WED  
**Chao T.-Y.**, OR330  
**Chapelle C.**, OR012, OR055, P0107-TUE  
**Chapin J.**, AS165, P0502-MON, P0575-TUE, P0307-WED, P0521-WED  
**Chapman M.**, OR088  
**Chappell E.**, OR239, P0153-MON, P0052-WED  
**Chareancholvanich K.**, P0643-WED  
**Charilaou P.**, P0615-MON  
**Charoenkwan P.**, P0275-TUE, P0540-TUE, P0647-TUE  
**Charova F.**, P0600-MON, P0582-TUE  
**Charpidou A.**, P0102-TUE  
**Chartapisak W.**, P0275-TUE  
**Chasman D.**, OR266  
**Chatelain B.**, P0092-MON, P0063-TUE, P0125-WED, P0167-WED  
**Chatelain C.**, OR126, P0167-WED  
**Chatelanaz C.**, P0639-TUE  
**Chatterjee M.**, OR114  
**Chatterjee N.**, P0259-MON  
**Chattree S.**, P0420-WED  
**Chaturvedi P.**, OR213  
**Chaudhary R.**, P0099-MON

**Chaudhry A.**, P0549-WED  
**Chaudhry H.**, P0151-WED  
**Chaudhry H.**, P0150-MON  
**Chaudhry W.**, P0188-WED  
**Chauhan A.**, P0521-TUE  
**Chaulaur C.**, OR095, OR188  
**Chaves D.**, P0231-MON, P0253-MON, P0333-MON, P0135-TUE  
**Chaves D.**, P0034-WED  
**Chavez C.**, P0445-TUE  
**Chávez-González M. A.**, P0020-MON  
**Chawanasuntorapoj R.**, P0675-MON  
**Che S.**, AS060  
**Chechulov P.**, P0503-TUE, P0576-WED  
**Cheen M. H. H.**, P0663-WED  
**Chelghoum N.**, AS014  
**Chelle P.**, P0262-WED  
**Chen C.-Y.**, P0029-MON  
**Chen I.-S.**, P0328-MON  
**Chen C.**, P0238-MON  
**Chen D.**, AS232, P0098-WED  
**Chen D.**, P0648-MON, P0655-TUE, P0037-WED, P0484-WED  
**Chen G.**, P0076-MON  
**Chen H.**, P0431-WED  
**Chen J.**, OR407  
**Chen J.-J.**, P0327-MON  
**Chen J.**, P0222-WED  
**Chen J.**, P0568-TUE  
**Chen K.**, OR415  
**Chen L.**, AS100, OR062  
**Chen L.**, P0409-MON  
**Chen L.**, P0447-WED  
**Chen L.**, P0312-WED  
**Chen M.**, P0273-TUE  
**Chen M.**, P0245-MON  
**Chen N.**, AS147, OR249, P0070-MON, P0205-MON  
**Chen P.**, AS168, OR031, P0326-WED, P0328-WED  
**Chen Q.**, OR002, P0433-MON, P0421-TUE  
**Chen S. L.**, P0309-TUE  
**Chen S.-H.**, P0289-WED  
**Chen V.**, OR185, P0075-MON, P0404-MON, P0415-TUE, P0669-TUE  
**Chen W.**, AS068  
**Chen X.**, OR113, OR210, P0388-WED, P0433-WED  
**Chen Y.**, P0195-TUE  
**Chen Y.-C.**, OR330, P0226-TUE, P0265-WED, P0304-WED  
**Chen Y.**, P0172-MON  
**Chen Y.**, P0222-WED

## Authors Index

Chen Y., PO433-WED  
 Chen Y., AS055  
 Chen Y., OR436, PO301-MON  
 Chen Z., OR140, PO317-MON, PO246-TUE  
 Chenet C., PO568-MON, PO575-MON  
 Cheng C. Y., PO412-TUE  
 Cheng J., PO261-MON  
 Cheng J., PO673-MON  
 Cheng J.-C., OR344, PO430-WED  
 Cheng S., PO527-TUE  
 Cheng S.-N., PO265-WED  
 Cheng X., PO306-MON  
 Cheng Z., PO132-TUE  
 Chennoukh K., PO242-TUE, PO637-TUE  
 Chennoukh K., PO494-MON, PO520-WED  
 Chennoukh W. K., PO276-WED  
 Cherel G., OR246  
 Chermak E., PO582-MON  
 Chernova T., OR346  
 Chernysh I., PO212-WED  
 Chernysh I., PO026-MON  
 Cherry M., PO449-TUE  
 Cherry M., PO508-TUE, PO157-WED  
 Cheung K. L., AS056, OR147  
 Cheung W., OR326, PO470-MON  
 Cheung Y., PO466-MON  
 Cheung Y., PO372-MON  
 Chew D., PO606-MON  
 Chhabra E., OR413  
 Chia J., AS016  
 Chiappin S., PO369-WED  
 Chiappino D., PO086-MON, PO039-TUE  
 Chicanne G., PO416-MON, PO514-TUE  
 Chidiac J., PO117-MON  
 Chidiac J., OR381, PO620-MON  
 Chien D., PO372-WED, PO375-WED  
 Chihiro I., PO108-WED  
 Chiles P., PO201-TUE  
 Chiles P., PO476-MON  
 Chillo O., OR410  
 Chinetti-Gbaguidi G., AS201  
 Chinni E., PO513-MON  
 Chintala M., PO074-WED  
 Chinthammitr Y., PO040-MON, PO110-WED, PO268-WED, PO643-WED  
 Chiswell K., OR119  
 Chitlur M., PO252-WED  
 Chitolie A., OR154, PO046-MON

Chitongo P., AS047, OR063, PO558-WED  
 Chitongo P., PO347-MON  
 Chiu H.-P., PO430-WED  
 Cho Y.-U., PO071-WED, PO427-WED  
 Cho Y., PO186-TUE  
 Choi G. H., PO475-TUE, PO478-TUE, PO531-TUE, PO168-WED  
 Choi S. I., PO119-TUE  
 Choi S., OR353, PO543-WED  
 Choi W.-I., PO628-MON  
 Choi Y., PO475-TUE  
 Choi Y., OR199  
 Chojnowski K., PO260-MON, PO011-WED  
 Chollet M. E., PO556-TUE  
 Chollet Dugarte M. E., PO557-TUE  
 Cholley B., PO513-WED  
 Chomienne C., PO080-WED  
 Chong K., PO288-MON  
 Choquenot C., AS137  
 Chou C.-S., PO430-WED  
 Chou S.-C., PO031-MON  
 Choudhri S., PO294-WED  
 Choukroun J., PO579-TUE  
 Chow G., PO161-TUE, PO233-WED  
 Chow L., PO161-WED  
 Chowdary P., OR028, OR212, OR348, OR349, PO235-MON, PO260-MON, PO295-MON, PO486-MON, PO257-TUE, PO317-TUE, PO014-WED, PO266-WED, PO353-WED, PO617-WED  
 Chrastinova L., PO238-WED  
 Christensen H., OR235, PO388-TUE  
 Christensen N., PO602-TUE  
 Christensen T. D., PO119-WED  
 Christersson C., OR312  
 Christiaans M., PO033-WED  
 Christian G., PO514-TUE  
 Christophe O., PO553-TUE, PO658-TUE, PO228-WED, PO230-WED  
 Christophe O., OR333, PO664-TUE  
 Christophe O., OR205, OR246  
 Christophe O. D., AS062, OR234, PO206-WED  
 Christopherson P., PO659-MON  
 Christopherson P., OR089, OR204  
 Christos P., AS165, PO307-WED  
 Chtourou S., PO311-TUE, PO457-TUE  
 Chu L., PO028-MON

Chu Z., OR047  
 Chua C., PO605-MON, PO590-TUE  
 Chuang W.-J., PO079-WED  
 Chuansumrit A., PO540-TUE, PO647-TUE, PO275-WED  
 Chubanov V., AS068, OR081  
 Chudzinski-Tavassi A. M., PO107-MON  
 Chuit R., PO634-TUE, PO636-TUE  
 Chumachenko P., PO294-TUE  
 Chun E. J., PO119-TUE  
 Chung C.-H., PO059-MON, PO334-WED  
 Chojnowski K., PO260-MON, PO011-WED  
 Chung D., PO568-TUE  
 Chung J.-H., PO115-MON  
 Chung S., NUR009, PO390-MON, PO393-MON  
 Chunilal S., PO468-MON, PO618-MON  
 Church F., PO426-WED  
 Church N., PO294-WED  
 Church W., AS051, OR423  
 Ciaia J.-F., PO107-TUE  
 Ciammaichella M., OR132  
 Cianella F., PO370-MON, PO423-WED  
 Ciantar E., PO614-MON  
 Cicardi M., PO178-TUE  
 Cicarini W., PO397-WED  
 Cid A., PO534-MON  
 Cid A. R., PO093-MON, PO579-WED  
 Cid J., PO610-WED  
 Cid-Haro A. R., PO473-WED  
 Cilia La Corte A., PO182-TUE  
 Cines D., PO405-TUE  
 Cines D., OR305  
 Cini M., PO050-MON  
 Cipok M., PO268-TUE  
 Cipolla L., OR115  
 Cisernos R., PO516-WED  
 Ciucciarelli L., PO226-MON  
 Civaschi E., PO438-MON, PO473-WED  
 Claes J., AS009, AS113  
 Claessen N., OR124  
 Claesson K., PO406-MON  
 Claeysens S., PO501-MON  
 Clark D., AS078  
 Clarke G., PO086-TUE  
 Clarke S., PO397-TUE  
 Clarke S., PO385-TUE  
 Clarke-Drury R., PO601-MON, PO580-TUE, PO581-TUE  
 Clausen J., OR110, PO541-WED  
 Clausen W. H., OR212

## Authors Index

Clausen W. H. O., PO215-WED  
 Claushuis T., AS007  
 Claussen C., PO174-WED  
 Clemens A., OR283  
 Clement K., AS043  
 Clementi R., PO257-TUE  
 Clerici M., PO091-MON, PO114-WED  
 Cleuren A., AS090  
 Cline-Fedewa H., OR434  
 Cloutier S., OR217  
 Clozel M., OR020  
 Cnossen M., AS079, NUR004, OR021, OR203, OR225, PO658-MON, PO230-TUE  
 Cnossen M., PO351-WED  
 Cnossen M., OR387, PO267-MON, PO251-TUE, PO308-WED  
 Cnossen M. H., PO651-MON, PO208-WED  
 Cober N., PO320-TUE  
 Cocchi V., OR197  
 Cockhill C., NUR007, PO355-MON  
 Coen Herak D., OR378, PO436-TUE, PO144-WED  
 Coffey G., PO351-TUE  
 Coglianesi E., OR173, PO339-WED  
 Cognasse F., PO410-MON, PO408-TUE  
 Cogswell C., PO173-MON, PO161-TUE, PO233-WED  
 Cohen A., AS084, OR294, PO124-TUE, PO353-TUE, PO608-TUE, PO409-WED  
 Cohen A., AS099, OR074, OR259  
 Cohen A., OR199  
 Cohen D., PO589-MON  
 Cohen E., PO099-MON  
 Cohen E., PO001-WED  
 Cohen H., PO044-MON, PO046-MON, PO060-WED, PO064-WED  
 Cohen A., PO578-WED  
 Cohn D., PO510-MON  
 Coite S., OR311, OR315, PO340-MON  
 Colaizzo D., PO511-MON, PO513-MON, PO614-MON  
 Colangelo D., AS088  
 Colberg T., OR348, PO149-MON  
 Cole R., OR058  
 Colella M., OR263  
 Colin E., OR003  
 Collaud F., PO158-MON  
 Collela M., OR094, PO531-MON, PO066-WED, PO067-WED  
 Collet M., PO512-MON

Collier M., OR175, PO555-MON, PO556-MON, PO557-MON, PO558-MON  
 Collier M., PO553-MON  
 Collin P., AS141  
 Collins J., OR354  
 Collins P., AS054, AS011, AS122, OR104, OR145, OR386, PO149-MON, PO262-MON  
 Collins P., PO317-TUE  
 Collins P., PO499-MON  
 Colman R., OR355  
 Colomer D., PO435-MON  
 Colucci G., AS163  
 Colucci M., OR065, PO503-MON, PO338-WED  
 Colzani M., PO384-WED  
 Combe S., AS164, PO166-TUE, PO174-TUE  
 Combescure C., PO271-MON, PO283-WED  
 Comer D., OR090, OR201, PO277-WED  
 Comi G., OR005  
 Comp P., PO449-TUE, PO157-WED  
 Compennolle V., PO604-WED  
 Compostella C., PO372-TUE  
 Comtet M., PO473-TUE  
 Cornuth M., PO051-TUE  
 Conard J., OR032, PO544-TUE  
 Conejero R., OR440  
 Coneska B., PO287-MON, PO288-WED  
 Conley P., OR318, PO351-TUE  
 Connell S., AS155  
 Connolly S., PO362-MON  
 Connor D., PO075-MON  
 Constans J., PO103-TUE  
 Constantin J.-M., PO035-WED  
 Contant G., PO340-MON  
 Contant G., PO223-MON, PO241-WED, PO422-WED  
 Conte V., PO176-WED  
 Conti S., PO072-MON, PO370-MON, PO027-TUE, PO423-WED  
 Conway E., PO021-MON, PO001-TUE  
 Conway E., PO300-TUE  
 Conway E., PO649-WED  
 Conway J., PO649-WED  
 Conway J., PO455-MON, PO083-WED  
 Cook K., OR417  
 Cooke B., PO285-MON  
 Cooke E., AS003, PO190-WED  
 Cooke N., PO075-WED  
 Cooke S., PO392-MON

Cooley B., OR273, OR274, OR306  
 Cools F., OR119  
 Cooper C., AS114  
 Cooper D., PO277-MON, PO297-WED, PO298-WED  
 Cooper D., PO306-MON  
 Coppack S., PO660-WED  
 Coppens M., PO372-MON, PO537-MON, PO506-TUE, PO507-TUE, PO401-WED  
 Coppola A., AS222, PO650-TUE, PO303-WED  
 Corbalan R., OR096  
 Corbalan Herreros R., PO358-TUE  
 Corbau R., PO172-MON  
 Cordell P., AS003, PO190-WED  
 Cormier A., PO165-WED  
 Cornelis G., PO299-TUE  
 Cornelissen L., PO584-MON  
 Coronel Ayala O., PO138-WED  
 Corral J., AS187, OR076, OR359, OR368, OR370, PO336-MON, PO338-TUE, PO539-WED, PO552-WED  
 Corrales I., PO543-MON  
 Correia J., OR183  
 Corrocher R., OR080  
 Corscadden K., OR337  
 Corseaux D., OR219, PO662-TUE  
 Corsi D., AS077, OR384  
 Corsini A., PO378-WED  
 Corsini F., PO585-TUE  
 Cortés J. M., PO360-WED  
 Cortina V., PO056-TUE, PO375-TUE, PO445-TUE, PO407-WED  
 Cortina De La Rosa E., PO138-WED  
 Cosemans J., AS141, AS140  
 Cosemans J., PO499-MON  
 Cosemans J., PO411-MON, PO349-TUE  
 Cosmi B., AS197, OR292, PO050-MON, PO602-MON, PO627-MON, PO317-WED  
 Cosmi E., PO331-TUE, PO332-TUE  
 Costa A., PO441-TUE  
 Costa A., PO574-TUE  
 Costa D., PO100-WED  
 Costa M., PO207-WED  
 Costa S.-D., PO518-MON  
 Costache A., PO474-WED  
 Costa-Pinto J., PO010-WED  
 Cotler S., PO053-WED  
 Cottart C.-H., PO038-TUE  
 Cottrell G., PO385-TUE  
 Coulombe J., OR385

## Authors Index

Coultas K., PO580-TUE, PO581-TUE  
Couperus C., PO145-MON  
Coupriy I., OR003  
Cournil M., PO262-WED  
Courtney W., PO649-WED  
Courtois D., PO045-TUE  
Coutinho J., OR118, PO525-TUE  
Coutinho M., PO442-MON, PO318-TUE  
Couto L., PO172-MON  
Couturaud F., AS082, OR146, OR149, OR323, PO103-TUE, PO655-WED  
Couturier O., AS082  
Couty L., PO437-WED  
Covens K., PO186-MON  
Covill S., PO361-MON  
Cowan P., AS212  
Cowley D., OR273  
Cowley D., PO423-MON  
Cox A., PO078-WED  
Cox D., PO078-WED  
Cox P., AS158  
Coxon C., PO065-MON  
Cozzi M. G., PO126-WED  
Crain E., PO349-MON  
Crampe C., PO159-TUE  
Craps S., AS176  
Craver C., OR309  
Crawley J., PO586-MON  
Crawley J., PO069-MON  
Crawley J., AS149  
Crawley J., OR044, PO036-WED  
Crawley J. T., PO139-MON  
Crea R., OR029  
Creagh D., OR213  
Creagh M., PO317-TUE  
Creary S., AS160  
Crescente M., PO506-MON  
Crespo J., PO017-MON  
Crettaz D., PO400-TUE  
Creuza V., PO457-WED  
Criel M., AS009, AS176, PO462-WED  
Crijns H., PO348-MON, PO097-WED, PO416-WED  
Crilly E., PO269-WED  
Crispel Y., AS096  
Crobach M., OR345  
Croce K., OR417  
Crosby J., OR049  
Croteau S., AS122  
Croteau S., OR022  
Croteau S., PO458-MON, PO239-TUE  
Crowther M., OR068, PO619-MON, PO604-TUE

Crowther M., PO616-WED  
Croy A., PO484-TUE  
Crudele J., AS120  
Cruz J. W., PO184-TUE  
Cruz C., PO125-MON  
Cruz E., PO318-TUE, PO626-TUE  
Cruz M. S., PO662-MON  
Cruz M., PO497-TUE  
Cruzado J., PO184-MON, PO187-TUE  
Csanádi Z., PO087-WED  
Csapó J., PO530-MON  
Csiba L., PO516-TUE, PO087-WED  
Cuadrado M., OR092  
Cui J., PO001-TUE  
Cui J., PO014-TUE  
Cuicui L., PO566-TUE  
Cuicui L., AS075, OR264  
Cuisset T., PO493-WED  
Cuker A., PO405-TUE, PO212-WED, PO473-WED  
Culhane A., PO037-MON  
Cultrera D., AS222  
Cumming A., PO495-MON  
Cummins P., OR043  
Cungh A., PO080-WED  
Cunha M., PO582-WED  
Cuppini S., OR132  
Curaj A., PO091-WED  
Curis E., AS086  
Curnow J., PO374-TUE, PO149-WED  
Curnutte J., OR318, PO351-TUE  
Curry N., AS054, PO653-MON, PO175-TUE, PO638-TUE  
Curtain J., OR346  
Curtin J., PO253-WED  
Curto M., PO353-TUE, PO409-WED  
Cushman M., OR133, PO565-WED  
Custódio I., OR094, PO066-WED, PO067-WED  
Cutler J., PO210-WED  
Cutler J., PO504-WED  
Cutler J., PO559-TUE  
Cutsforth G., PO117-WED  
Cvrin G., PO464-MON  
Cwikla J., PO279-MON  
Cybulsky M., AS198  
Czajka C., PO311-WED  
Czajkowski K., PO536-WED, PO588-WED  
Czaplicki D., PO365-WED  
Czer L., OR216  
Czogalla K., PO498-MON, PO637-MON

Czogalla K., PO631-MON  
Czuprynska J., NUR008, OR063, PO347-MON  
Czuriga I., PO224-MON, PO187-WED  
Czwalinna A., OR054  
D'Adamo M., PO068-TUE, PO522-WED  
D'Amico E., PO034-TUE, PO095-WED  
D'Antonio C., PO616-TUE  
D'Asti E., PO393-WED  
Da Q., OR277, PO497-TUE  
Da X.-W., PO426-MON  
Da Rocha T., PO322-TUE  
Daali Y., AS128  
Dachbash M., PO285-TUE  
Daemen J.-W., PO092-WED  
Dager W., PO312-WED, PO358-WED, PO359-WED  
Dagher M.-C., PO131-TUE, PO593-WED  
Dagklis T., PO065-WED  
Daglas M., OR380  
Daher G., PO538-MON  
Dahlbäck B., AS040, AS150, OR369  
Dahm A. E. A., PO109-MON  
Dai J., PO228-MON  
Dai J., OR113, OR210, PO492-MON, PO195-TUE, PO252-TUE, PO433-WED  
Dai K., PO273-TUE, PO439-WED  
Dai M., OR331  
Dainiak M., PO219-WED  
Daita K., OR435  
Dale B., PO130-TUE  
Dale G., PO449-TUE  
D'Alessio A., PO179-WED  
Dalibard V., OR143  
Dalla Valle F., OR078, PO524-TUE, PO127-WED  
Dallas K., PO577-MON  
Dally N., PO471-WED  
Dalm D., PO192-WED  
Dalsgaard Nielsen J., PO352-MON, PO456-TUE, PO424-WED  
Daly M., AS054, AS011  
Daly M., AS124, PO517-WED  
Damas P., PO396-TUE  
Dambrine S., OR192  
D'Amico E., PO433-TUE  
D'Amico É., PO322-TUE  
D'Amico E. A., PO611-TUE  
Dang J., OR290  
Dang K., PO439-TUE  
Dang V., OR007

## Authors Index

Dangelmaier C., OR111, PO429-WED  
Dangelo L., OR022  
D'Angelo A., OR093  
Danglot L., AS170  
Daniel J., PO429-WED  
Daniel J., PO516-WED  
Daniell H., PO220-WED  
Danielsson-Rånby M., PO367-MON  
Danielyan S., PO573-MON  
Darbari D., PO381-MON  
Darbousset R., PO322-MON, PO022-TUE  
Dardik R., PO192-MON, PO225-WED  
Dargaud Y., OR012, PO156-MON, PO157-MON, PO229-TUE  
Daryll Blanz K., PO493-WED  
Dashkevich N., PO118-WED  
Dashkevich N., PO067-TUE  
Dasi M. A., PO414-MON  
Dassi C., PO223-MON, PO340-MON, PO241-WED, PO422-WED  
D'Assoro A., PO618-WED  
D'Asti E., PO094-TUE  
Dato' Abd Karim F., PO257-TUE  
Dauer R., PO149-WED  
David L., PO440-WED  
Davidson B., OR259  
Davidson R., OR165  
Davies J., PO481-TUE  
Davies N., PO156-WED  
Davila M., PO174-WED, PO445-WED, PO446-WED  
Davis A., PO101-TUE  
Davis A., PO669-TUE  
Davis M., PO516-WED  
Daw C., PO037-MON  
Dawood B., AS054, AS011, PO492-WED  
Dawson J., PO545-TUE  
Dayananda K., OR334  
De Ancos Aracil C. L., PO485-TUE  
De Angelis F., PO200-TUE, PO259-TUE  
De Boer I., OR133  
De Borst G. J., PO386-TUE, PO389-TUE  
De Broucker D., PO107-TUE  
De Candia E., PO422-TUE  
De Carlo R., PO086-MON  
De Carvalho A., PO339-TUE  
De Carvalho Bittencourt M., AS036  
De Ceunynck K., AS091  
De Ceunynck K., AS166, AS178  
De Chaumont C., PO177-TUE

De Cos C., AS187, OR076  
De Cristofaro R., OR202, PO007-MON, PO582-MON  
De Diego I., PO474-TUE  
De Francisci G., PO614-WED  
De Geus K., PO666-WED  
De Godoy M., PO322-TUE  
De Groot P., AS035, PO063-WED  
De Groot P., PO389-TUE, PO470-WED  
De Groot P., PO178-TUE  
De Groot P., PO405-MON, PO672-MON  
De Haan H., AS179, PO586-MON  
De Groot R., AS179, PO586-MON  
De Groot-Eckhardt C., OR389,  
De Haan H., AS196, OR083  
De Haan H., OR148, OR394, PO539-WED  
De Jong A., PO641-TUE  
De Jong P., AS021  
De Kam P.-J., PO469-TUE, PO550-WED  
De Kievit A., PO335-WED  
De Kleijn P., PO241-MON  
De Kleijn P., OR102  
De Koning M.-S., PO272-MON  
De La Morena-Barrio M., OR076  
De La Morena-Barrio M. E., AS187, OR370  
De La Salle H., PO606-WED  
De Laat B., OR224, OR301, OR427, PO025-MON, PO089-MON, PO143-MON, PO272-MON, PO546-MON, PO672-MON, PO092-WED  
De Laat M., PO546-MON  
De Lange Z., PO026-MON, PO210-MON, PO212-WED  
De Laroche R., PO628-WED  
De Lisa E., PO042-MON  
De Los Santos S., PO055-WED  
De Los Santos S., PO042-MON  
De Maat M., PO078-MON, PO665-WED  
De Maat M., AS181, OR364  
De Maat M. P., PO208-WED  
De Maat S., PO178-TUE  
De Boer I., OR133  
De Maistre E., OR055, PO345-MON, PO263-TUE, PO672-WED  
De Marchi L., PO269-WED  
De Marco L., PO378-WED  
De Martin R., PO559-MON  
De Mast Q., PO063-WED  
De Meis E., PO158-WED  
De Meis J., PO158-WED  
De Mel S., PO606-MON  
De Meris J., AS079  
De Meyer S., PO401-MON

De Meyer S., AS178, OR087, OR151, OR153, PO517-TUE, PO519-TUE, PO571-TUE  
De Meyer S. F., OR155  
De Moerloose P., PO217-MON, PO271-MON, PO484-MON, PO485-MON, PO488-MON, PO502-MON, PO283-WED, PO521-WED  
De Montalembert M., AS086  
De Natale M., PO626-MON  
De Padua V., PO654-TUE  
De Paoli S., OR174, PO603-WED  
De Paula E., OR263  
De Paula E., OR094, PO066-WED, PO067-WED, PO145-WED  
De Paula E., PO422-MON, PO531-MON, PO221-WED  
De Paula L., PO100-WED  
De Perrot M., PO619-MON  
De Queiroz Monteiro R., PO131-MON  
De Sancho M. T., PO614-MON  
De Santis A., PO158-WED  
De Simone G., PO534-TUE  
De Smet M., OR320  
De Stefano F., PO534-TUE  
De Stefano V., PO611-TUE  
De Stoppelaar S., AS007  
De Swert K., OR363  
De Vega S., PO079-TUE  
De Vreede M., OR257  
De Wildt S., PO251-TUE  
De Wit C., OR295, OR384  
Deangelis P., PO219-WED  
Debank P., PO016-MON  
Debelle L., PO457-WED  
Debili N., OR082  
Debourdeau P., PO624-MON  
Debreteni I., PO488-WED  
Debreteni I., PO077-MON, PO124-MON, PO482-WED  
Decherf C., PO107-TUE  
Deckmyn H., AS178, OR087, OR153, OR155, PO401-MON, PO675-TUE  
Declerck P., OR399, OR442, OR443, PO545-WED  
Declerck P., OR153, AS144, PO519-TUE  
Décousus H., OR146, OR149, PO655-WED  
Decouture B., PO437-WED  
Deleden L., PO165-WED  
Deev A., PO356-WED  
Deforche L., AS178, OR153, OR365  
Deforest M., PO646-MON

## Authors Index

Degen J., PO021-MON  
 Degrado W., PO431-WED  
 Deguchi H., PO093-MON  
 Deguzman F., OR318  
 Deharo P., PO493-WED  
 Deindl E., OR410  
 Deitzelzweig S., PO625-MON  
 Dejanova Ilijevska V., PO287-MON  
 Dejanova-Ilijevska V., PO535-WED  
 Dekkers O., OR098  
 Dekkers O., OR268  
 Del Bianco T., PO092-MON, PO063-TUE  
 Del Carpio-Cano F., PO329-WED  
 Del Toro L., PO198-MON  
 Dela Cadena R., PO329-WED  
 Delaat B., AS105  
 Delahousse B., OR428  
 Delahousse B., PO056-WED  
 Delaney J., NUR010, PO361-TUE  
 Delavenne X., OR196  
 Delbes C., PO134-TUE  
 Delcea M., AS008, OR308, PO298-MON  
 Delerue M., PO107-TUE  
 Delesen H., OR011  
 Deleuze J.-F., OR148  
 Delgado B., PO212-TUE, PO261-WED  
 Delhay C., PO662-TUE  
 Delierneux C., AS006, PO396-TUE  
 Delierneux C., PO407-MON  
 Delignat S., PO226-WED  
 Delignaut S., PO228-WED, PO230-WED  
 Della Latta D., PO086-MON, PO039-TUE  
 Della Riva D., PO066-MON  
 Della Rocca F., PO372-TUE  
 Della Valle P., OR093  
 Dellanoce C., OR065  
 Delluc A., OR281, OR323, PO512-MON  
 Delluc A., AS082  
 Delrue M., PO664-TUE  
 Delva Y.-L., PO463-MON  
 Demarco M., PO483-TUE  
 Demarmels F., AS163  
 Demers C., OR217  
 Demers M., AS180, PO329-MON, PO171-WED  
 Demiguel V., OR143  
 Demina I., PO496-MON  
 Demina I., PO503-WED  
 Demir M., PO617-TUE  
 Demirag B., OR262  
 Demkova O., PO054-MON  
 Dempfle C.-E., PO669-MON, PO480-TUE  
 Demulder A., PO081-TUE  
 Demyanenko A., PO503-TUE, PO576-WED  
 Demyanets S., PO559-MON  
 Demyanova A., PO103-WED  
 Den Exter P., PO596-MON  
 Den Exter P., OR191, OR257, PO597-MON, PO100-TUE, PO651-WED  
 Den Hertog J., OR183  
 Denas G., PO077-TUE, PO372-TUE  
 Deng B.-X., PO522-TUE  
 Deng C.-Q., PO522-TUE  
 Deng J., PO177-MON, PO179-MON  
 Deng W., AS171  
 Deng X., AS147, OR249, PO070-MON, PO205-MON  
 Deng X., PO382-WED  
 Denis C., PO553-TUE  
 Denis C., PO664-TUE  
 Denis C., PO322-MON, PO658-TUE  
 Denis C., OR333, OR403  
 Denis C., OR205, OR246  
 Denis C. V., AS062, OR234, PO206-WED  
 Denk G., PO236-MON  
 Dennie C., OR384  
 Denniff M., PO542-WED  
 Dennis J., PO426-WED  
 Dennis J., AS045, AS206  
 Denorme F., PO517-TUE, PO519-TUE  
 Dentali F., PO610-TUE, AS195, PO511-MON, PO613-MON, PO614-MON, PO640-MON, PO115-TUE, PO502-TUE, PO585-TUE, PO611-TUE, PO405-WED, PO640-WED  
 Depasse F., PO045-TUE  
 Depei W., PO113-TUE, PO394-WED  
 Depooter N., PO448-MON  
 Deppermann C., AS092, OR169  
 Der Parsehian S., PO236-WED  
 Derald S., PO081-TUE  
 Desai H., PO445-WED  
 Desai U., PO306-MON  
 Desancho M., AS165, PO221-TUE, PO307-WED  
 Desancho M. T., PO597-TUE  
 Desch M., PO613-TUE  
 Deschmann E., OR232  
 Desguerre I., AS086  
 Deshpande V., AS202, OR008

Detering C., PO654-MON, PO665-TUE  
 Deutsch V., PO268-TUE  
 Devi S., PO306-WED  
 Devignes J., PO546-TUE  
 Devloo R., PO604-WED  
 Devos T., OR231  
 Devos V., PO457-TUE  
 Devreese K., PO384-TUE, PO668-TUE  
 Dewarrat N., PO489-MON  
 Dewit C., OR281  
 Dezetter A.-S., PO131-TUE  
 Dhanesha N., PO521-TUE  
 Dharma R., PO141-MON, PO671-TUE  
 Dhillon S., PO454-TUE  
 Dhima S., PO331-TUE, PO332-TUE  
 Dhiman P., PO540-MON, PO005-WED  
 Di Buduo C., PO422-TUE  
 Di Franco M., PO084-WED  
 Di Gregorio G., PO438-TUE  
 Di Mauro R., PO534-WED  
 Di Micco P., PO608-MON  
 Di Minno G., AS222, PO534-TUE  
 Di Minno M., PO378-WED  
 Di Minno M. N. D., PO611-TUE  
 Di Nisio M., AS099, AS197, OR292, PO103-TUE, PO611-TUE, PO624-WED  
 Di Paola J., OR431, PO660-MON  
 Di Paola J., AS143  
 Di Paolo M., PO216-WED  
 Di Perna C., PO264-MON, PO222-TUE, PO650-TUE  
 Diab Y., PO381-MON  
 Diacovo A., OR407  
 Diacovo T., OR407  
 Diamond S., OR351  
 Diamond S., OR038, OR207, OR408, PO608-WED  
 Diard A., AS137  
 Diaz J. A., PO030-MON  
 Diaz L., PO428-TUE  
 Diaz R., PO644-TUE  
 Diaz-Ricart M., PO184-MON, PO191-MON, PO187-TUE, PO082-WED, PO414-WED, PO610-WED  
 Díaz-Ricart M., AS044, PO189-MON  
 Dicke C., PO251-MON  
 Dickneite G., OR316, PO152-MON, PO312-TUE  
 Dieli F., PO614-WED  
 Diesen J., PO674-MON

## Authors Index

Dietrich J., PO361-WED  
 Dietrich J., PO567-MON  
 Dietrich K., PO465-MON  
 Dignat-George F., OR311, PO322-MON  
 Dignat-George F., OR315, AS085  
 Diliberto D., PO614-WED  
 Dilks J., OR417  
 Dilks J., AS091  
 Dillard P., PO416-MON  
 Dillon A., OR218  
 Dillion R., PO120-MON, PO121-MON  
 Dimitrov J., PO226-WED  
 Dinarvand P., PO333-TUE  
 Ding H., OR018  
 Ding H., PO522-TUE  
 Ding Q., OR164, PO228-MON, PO492-MON, PO195-TUE, PO333-TUE  
 Ding Z., PO409-MON  
 Diniz R., PO663-TUE, PO237-WED  
 Dinsdale R., PO325-MON  
 Dinsdale R., OR121, PO393-TUE  
 Dioun Broyles A., OR022  
 Dipaola J., PO632-TUE  
 Dipietro M., PO172-MON  
 Diprose P., PO317-TUE  
 Dirks M., PO546-MON  
 Dirksen C., PO471-MON  
 Dirven R., PO641-TUE, PO660-TUE  
 Dishy V., PO621-MON, PO603-TUE  
 Distasio K., PO088-MON  
 Dittmer F., PO555-WED  
 Dittmer R., PO041-WED  
 Dixon M., PO174-TUE, PO076-WED  
 Dizier B., PO014-MON, PO437-WED  
 Domenech P., PO354-MON  
 Diz-Küçükkaya R., PO649-TUE  
 Djambas Khayat C., PO484-MON, PO488-MON, PO258-TUE, PO262-TUE  
 Djordjevic V., PO547-MON, PO159-WED  
 Djunic I., PO252-MON  
 Djuranovic V., PO436-TUE  
 Djurasinovic V., PO121-TUE  
 Dmित्रива J., PO407-MON  
 Dmoch-Gajzlerska E., PO536-WED, PO588-WED  
 Do Nascimento P., PO092-TUE, PO146-WED, PO231-WED  
 Dobbstein C., AS221  
 Dobesh P., OR059

Dobó J., PO303-TUE  
 Dobrovolskiy A., PO357-WED  
 Dobrovolsky A., PO624-TUE  
 Dobrovolsky A., PO199-MON, PO327-TUE, PO356-WED  
 Dobrovolsky A., PO069-TUE  
 Docenko U., PO496-WED  
 Dockal M., PO150-TUE, PO151-TUE, PO152-TUE, PO199-WED, PO201-WED, PO209-WED  
 Dockendorff C., AS091  
 Dockrell D., OR016  
 Doco-Lecompte T., PO546-TUE  
 Docquier M., AS128, OR397  
 Doddapattar P., PO521-TUE  
 Dodt J., PO183-WED, PO184-WED  
 Doering C., PO203-WED  
 Doerr B., OR316, PO418-WED, PO596-WED  
 Doerr B., PO152-MON  
 Doerschuk C., PO331-MON  
 Doganay S., PO490-TUE  
 Dogné J.-M., OR126, PO092-MON, PO063-TUE, PO172-TUE, PO269-TUE, PO299-TUE, PO125-WED, PO134-WED, PO142-WED, PO167-WED  
 Döhrmann M., PO427-MON, PO483-WED  
 D'Oiron R., OR143  
 Dolan G., PO256-TUE  
 Dolan G., PO283-WED, PO676-WED  
 Dolan G., PO210-TUE, PO299-WED  
 Dollins C., PO154-WED  
 Dolsma A., OR257  
 Domagala T., PO074-MON, PO500-TUE  
 Domashenko M., PO535-TUE  
 Domenech P., PO354-MON  
 Domingues M., AS155  
 Domingues V., OR189  
 Domingueti C., PO043-WED  
 Dominguez Z., PO187-MON  
 Dominguez G., PO042-MON, PO055-WED  
 Donadini M., PO610-TUE  
 Donahue D., OR421  
 Donato S., PO236-WED  
 Doncheva E., PO515-WED  
 Donga P., PO312-MON  
 Donglei Z., OR264, PO320-MON, PO276-TUE, PO566-TUE  
 Donin I., PO019-WED  
 Donnachie E., PO015-WED  
 Donnan G., PO048-TUE  
 Döpke S., PO654-MON

Dopsaj V., PO252-MON  
 Dorait J., OR029, PO223-TUE, PO270-WED  
 Doria A., PO245-TUE  
 Doria A., OR390  
 Dornbach A., PO669-MON  
 Dorner L., OR252  
 Dors N., OR021  
 Dørum E., PO123-MON, PO453-TUE, PO556-TUE, PO557-TUE  
 Dos Santos M., PO523-WED  
 Dosquet C., PO080-WED  
 Doubleday M., PO078-TUE  
 Doubre H., PO163-WED  
 Douketis J., OR195, PO362-MON  
 Douketis J., OR282  
 Douma R., PO598-MON  
 Douma R., PO597-MON  
 Douma R., PO596-MON  
 Douma R., OR191  
 Douxfils J., OR126, PO092-MON, PO063-TUE, PO299-TUE, PO492-WED  
 Dovlatova N., AS129, PO057-MON, PO026-TUE, PO410-TUE, PO412-TUE, PO518-TUE, PO492-WED  
 Dow J., PO603-TUE  
 Dowlatshahi D., OR200  
 Doyle C., PO378-MON, PO496-TUE  
 Doyle M., PO050-TUE  
 Dolan G., PO088-MON  
 Doyon K., OR217  
 Dragani A., OR202  
 Drager D., AS192, OR413  
 Drake M., PO336-WED  
 Drake S., AS054, AS011  
 Drakulevski S., PO535-WED  
 Draxler D., OR123  
 Dreano E., PO038-TUE  
 Drebes A., OR028, PO370-TUE, PO014-WED  
 Dreßen P., PO343-WED  
 Dresser G., PO364-TUE  
 Dretzke J., PO019-TUE  
 Dreznik A., PO285-TUE  
 Driessen M., PO532-MON  
 Driessens M., OR387, PO251-TUE  
 Drobic B., PO168-MON, PO169-MON  
 Dropinski J., PO074-MON, PO500-TUE  
 D'Silva L., PO083-TUE  
 Dsouza M., PO676-MON  
 D'Souza F., PO531-WED  
 Du X., PO388-WED



## Authors Index

Duan Q., PO137-MON  
Duarte A., PO221-WED  
Duarte E., PO107-MON  
Duarte R., PO397-WED  
Duarte R., PO237-WED  
Dubois C., OR311, PO322-MON, PO022-TUE  
Duboscq C., PO180-TUE  
Duca L., PO457-WED  
Duca M. L., PO126-WED  
Duce R., AS195  
Ducros E., PO119-MON  
Ducruet T., OR327  
Dudley B., PO285-MON  
Duerschmied D., OR252, PO307-TUE, PO404-TUE, PO493-WED  
Duffett L., PO669-WED  
Duffett L., OR053  
Duffy C., PO319-TUE  
Duhamel E., OR146, OR149, PO655-WED  
Dumont B., OR420  
Dumont J., PO678-TUE  
Dumont J., PO208-TUE  
Dumont S., PO645-TUE  
Dumontier N., PO080-WED  
Dumoulin F.-J., PO343-WED  
Dunhill J., OR216  
Dunlop L., PO421-TUE  
Dunn A., AS122, AS160, OR157, PO262-MON  
Dunn P., PO476-WED  
Dunne E., PO437-MON, PO676-TUE, PO075-WED  
Dunnington J., PO202-MON  
Dunois C., PO424-WED  
Dupont A., AS201  
Durcan L., PO437-MON  
Duretz V., PO311-TUE  
Durian M., PO598-MON  
Durieux P., OR192  
Durkin M., OR073  
Duron C., PO075-TUE  
Durot E., PO440-MON  
Durrant T., PO461-WED  
Durrant T., OR272  
Dusek L., PO364-WED  
Dusse L., PO340-WED  
Dusse L., PO663-TUE, PO237-WED, PO479-WED  
Dusse L., PO244-WED  
Dusse L., PO566-MON  
Dusse L. M., PO189-TUE  
Dusse L. M., PO002-WED, PO023-WED  
Dutrillaux F., OR012  
Dutt T., PO369-MON, PO578-MON

Dütting S., AS169, OR017  
Duval C., AS155, PO188-WED  
Duval C., AS153  
Duveau D., PO513-WED  
Duwe C., PO107-WED  
Duzan J., PO457-MON, PO458-MON  
Dvorak T., PO242-MON  
Duca L., AS210, PO127-MON, PO220-MON, PO324-MON  
Dybowska M., PO311-WED  
Dyr J., PO238-WED  
Dyr J., PO194-TUE  
Dzhumaeva S., PO460-TUE  
Dziedzina S., PO070-WED  
Dziewiecka O., OR129, OR393, PO526-MON, PO104-TUE, PO111-TUE, PO112-TUE, PO495-TUE, PO568-WED  
Dzik W., PO601-WED  
Dzikowska-Diduch O., PO619-WED  
Dzupa V., PO364-WED  
Earnest A., PO504-TUE  
Ebberink E., AS121  
Ebenbauer B., AS200  
Eberl W., PO481-WED  
Eberle B., AS163  
Eberle S., PO480-TUE  
Eby C., PO140-WED  
Echenagucia M., PO523-WED  
Eckes B., PO505-MON  
Eckhardt C., PO283-MON  
Eckly A., PO572-MON  
Edén D., PO563-MON  
Édes I., PO077-MON, PO224-MON, PO187-WED  
Edin M., OR341  
Edo N., AS145, PO203-MON  
Edwards C., OR310  
Eelde A., PO255-MON  
Eftekhkar Ardebili H., PO247-TUE  
Efthymiou M., PO044-MON, PO046-MON, PO060-WED  
Egan K., OR218, PO075-WED  
Eggert D., OR335  
Eggertsen G., PO443-TUE  
Eggleston J., PO580-TUE, PO581-TUE  
Ehammer-Rosenkranz A., PO453-MON  
Ehm M., PO107-WED, PO137-WED  
Ehrlich R., PO285-TUE  
Ehrlicher A., OR232  
Eicher J., OR209  
Eichinger S., OR226, PO298-TUE, PO077-WED, PO528-WED

Eichler H., PO253-TUE  
Eichmann A., AS172  
Eickholz P., PO657-MON  
Eiden M., PO605-WED  
Eijgenraam P., OR430  
Eijsvogel M., OR257  
Eijsvogels T., PO468-TUE  
Eikelboom J., OR096, PO570-MON, PO130-TUE  
Eikelboom J., PO489-WED  
Eikenboom H., PO665-MON  
Eikenboom J., OR021, OR203, PO649-MON, PO658-MON, PO641-TUE, PO660-TUE, PO651-WED  
Eintrei J., PO195-MON  
Eischer L., OR226, PO298-TUE  
Eising H., PO642-TUE, PO470-WED  
Ejele O., PO450-MON, PO155-WED  
Ek Olsson H., PO240-MON  
Ekeke O., PO155-WED  
Ekhlasi-Hundrieser M., PO654-MON, PO665-TUE  
Eksteen P., PO210-MON  
El Khorassani M., PO484-MON, PO488-MON  
El Mdawar M.-B., PO606-WED  
Elaih Z., PO444-WED  
Elalamy I., OR438, PO116-MON, PO292-MON, PO102-TUE, PO105-TUE, PO473-TUE, PO587-WED, PO632-WED  
Elalamy I., OR055  
El-Alfy M., PO164-MON  
Elashoff D., PO507-MON  
Elbers L., OR035, OR268, PO028-TUE  
El-Beshlawy A., PO164-MON  
Eldar-Lissai A., PO257-WED, PO287-WED  
Elezovic I., PO252-MON, PO080-TUE, PO228-TUE, PO547-TUE, PO235-WED  
Elezovi I., PO218-TUE  
El-Gendy W., PO243-MON  
Elhelu O., OR174, PO603-WED  
El-Husayni S., PO380-WED  
Elisabet M.-S., PO444-TUE  
Elisha N., PO659-TUE  
Elkeeb A., PO557-MON  
Elli E., PO614-MON  
Elliingsen T., PO493-TUE, PO561-WED  
Elliingsen T., OR120  
Ellis D., PO567-TUE  
Elmeier W., OR111, OR276  
Elm T., PO147-MON, PO590-WED

## Authors Index

El-Maarri O., PO191-WED, PO202-WED  
Elmongy H., PO608-WED  
El-Noueam K., PO243-MON  
Elotmani L., PO035-WED  
Elsheikh R., PO133-WED  
Elsherif L., PO331-MON  
Elson A., OR183  
Emal D., OR124, PO442-WED  
Emanuele M., PO334-MON  
Emed J., NUR009, PO390-MON, PO393-MON  
Emelyanov A., PO444-MON  
Emerson M., PO400-MON, PO398-TUE  
Emge D., OR421  
Emmi G., PO226-MON  
Emmi L., PO226-MON  
Emna G., PO281-WED  
Empson V., OR215  
Emsley J., OR407  
Enden T., AS136  
Endo H., PO491-WED  
Endo H., OR343  
Endresz V., AS025, AS232, OR006, PO098-WED  
Engelen S., OR101  
Engl W., OR215, PO260-MON, PO254-WED  
Engle E., OR042  
Ehnenforth S., OR212  
Enjolras N., PO156-MON, PO157-MON  
Enocksson C., PO193-WED  
Enoksson M., PO285-WED  
Ensor J., PO019-TUE  
Eppel W., PO185-MON, PO559-MON  
Epstein J., OR014, PO281-MON  
Epstein J., OR211  
Epstein J., PO108-TUE  
Epstein J., PO231-TUE  
Erduran E., PO270-TUE, PO499-WED  
Eriksson B., PO376-TUE  
Eriksson H., PO378-TUE, PO646-WED  
Eriksson J., OR069  
Eriksson O., OR046  
Eriksson P.-O., PO294-MON  
Erkan D., PO064-WED  
Erkens P., PO583-TUE  
Erkens P., PO598-MON  
Erkutlu I., PO109-WED  
Ermolina O., PO199-MON  
Erramouspe B., PO092-TUE, PO231-WED  
Escalante V., OR173, PO411-WED

Esch V., PO065-TUE  
Escobar M., OR348, PO288-MON, PO015-WED  
Escobar G., PO082-WED, PO414-WED, PO610-WED  
Escobar G., AS044, PO184-MON, PO189-MON, PO191-MON, PO187-TUE  
Escuriola Ettingshausen C., PO229-TUE  
Escuriola-Ettingshausen C., PO259-MON  
Eshel E., PO471-WED  
Eshghi P., PO164-MON, PO649-MON, PO600-WED  
Esmailian F., OR216  
Esmon C., AS207, PO336-WED  
Esmon N., PO336-WED  
España F., PO093-MON, PO534-MON, PO536-MON, PO344-TUE  
Espejo H., PO023-TUE, PO242-WED  
Espín S., OR359, PO336-MON, PO338-TUE  
Espinosa S., PO017-MON, PO019-MON  
Espinoza N., PO242-WED  
Esposito F., PO515-MON  
Esposito R., PO534-TUE  
Estrada N., PO487-TUE  
Etancelin P., PO621-WED  
Eto K., OR084, PO428-WED  
Etscheid M., AS218  
Ettelaie C., OR175, PO553-MON, PO555-MON, PO556-MON, PO557-MON, PO558-MON  
Etulain J., PO012-MON  
Eustace J., PO639-WED  
Evans D., PO638-MON  
Evans P., PO156-WED  
Evans P., PO083-TUE  
Evans V., PO156-WED  
Evans V., PO599-WED  
Everington T., PO344-MON, PO369-TUE, PO417-WED  
Everret L., OR180  
Evmorfiadis I., PO102-TUE  
Evnorfiadis I., PO587-WED  
Ewenstein B., OR088, OR211, OR215, PO281-MON, PO223-TUE, PO254-WED  
Ewenstein B., PO232-MON  
Eweputanna L., PO450-MON  
Exner T., PO125-WED  
Eyster M., PO260-MON  
Ezban M., AS019, PO146-MON, PO147-MON, PO153-MON, PO147-TUE, PO153-TUE, PO215-WED

Ezekowitz M., PO362-MON  
Ezigno E., PO627-TUE  
Faaborg L., PO051-TUE  
Fabbri A., PO067-MON, PO020-TUE, PO365-TUE  
Faber J., OR414  
Faber L., OR257  
Facchinetti L., PO378-WED  
Fadin M., PO315-TUE, PO387-WED  
Faella A., OR178  
Faille D., PO080-WED  
Faisse P., AS137  
Falaise C., AS014, PO443-MON  
Falanga A., OR027, PO339-MON, PO103-TUE, PO622-TUE, PO179-WED  
Falasca M., OR115  
Falcinelli E., AS174, AS199, OR336, OR399  
Falco P., PO671-WED  
Falcone L., PO515-MON  
Falet H., PO506-MON  
Falet H., OR235, AS186  
Fallah P., AS077, PO371-WED, PO669-WED  
Fallarino F., PO162-TUE  
Falter T., PO593-MON, PO570-TUE  
Fan C., AS125  
Fan M.-N., PO031-MON, PO050-WED  
Fan X., OR113, OR210, PO433-WED  
Fanciullacci C., PO365-MON, PO366-MON  
Fang J., OR342  
Fang Y., PO393-WED  
Fania C., PO338-WED  
Fareed J., PO182-MON, PO211-MON, PO212-MON, PO291-MON, PO292-MON, PO293-MON, PO303-MON, PO305-MON, PO334-MON, PO346-MON, PO053-TUE, PO191-TUE, PO192-TUE, PO337-TUE, PO053-WED, PO112-WED, PO332-WED, PO374-WED, PO402-WED, PO411-WED  
Farfan M., PO658-WED  
Farge-Bancel D., PO624-MON, PO611-TUE  
Faria M., PO626-TUE  
Faria M., PO189-TUE, PO002-WED, PO397-WED  
Farid T., PO196-MON  
Faridah A., PO541-MON  
Farin H., OR028  
Farina F., PO524-TUE

## Authors Index

Fariña D., PO428-TUE  
 Farkas A. Z., AS004  
 Farm M., PO195-MON  
 Farndale R., PO441-WED  
 Farndale R., AS065  
 Farquharson R., PO045-MON  
 Farren-Dai L., PO630-WED  
 Farris D., PO030-MON  
 Fasulo M., PO091-MON, PO114-WED  
 Fasulo M. R., PO090-TUE, PO091-TUE  
 Fatemi M., PO165-MON  
 Fatima N., PO502-MON, PO134-TUE, PO549-TUE, PO181-WED, PO521-WED  
 Fatini C., PO365-TUE, PO477-TUE, PO586-WED  
 Fatou Samba N., PO542-MON  
 Faure G., AS036  
 Favalaro E., PO366-TUE  
 Favaretto E., PO602-MON, PO627-MON, PO317-WED  
 Favier M., AS014  
 Favier R., PO473-WED  
 Faxälv L., PO406-MON  
 Fazavana J., PO553-TUE  
 Featherby S., PO556-MON  
 Featherby S., PO558-MON  
 Feddersen L., PO107-WED  
 Feder S., PO169-TUE  
 Federica B., PO347-TUE  
 Federici A., OR027  
 Federici A. B., PO649-MON  
 Fedewa H., OR375  
 Feese W., PO202-MON  
 Feijge M., PO349-TUE, PO675-TUE  
 Fejes Z., PO077-MON, PO482-WED  
 Feldman B., OR328, PO475-MON, PO245-TUE  
 Felicetta I., PO633-WED  
 Feliu Torres A., OR160, PO428-TUE  
 Feliu-Torres A., PO644-MON  
 Femia E. A., OR019, PO066-MON, PO412-TUE, PO086-WED  
 Feng D., OR274  
 Feng K., PO318-MON, PO325-WED  
 Feng Q., AS074, OR138, OR261, PO319-MON  
 Feng X., AS075, OR136, PO566-TUE  
 Fennen M., PO157-TUE  
 Fenoglio L., PO613-MON  
 Fergelot P., OR003

Ferguson K., AS065  
 Fernandes A., PO043-WED  
 Fernandes A. P., PO002-WED  
 Fernandes B., PO592-TUE  
 Fernandes S., PO212-TUE, PO261-WED  
 Fernandes T., PO476-MON, PO644-WED  
 Fernandez C., AS158  
 Fernández M., PO010-WED  
 Fernández Ponce N., OR160  
 Fernández-Capitán C., PO488-TUE  
 Fernandez-Golfin C., PO576-TUE  
 Fernández-Mosteirín N., OR076  
 Fernandez-Recio J., OR369  
 Fernandez-Ruiz R., AS044  
 Ferrando F., PO534-MON, PO536-MON, PO579-WED  
 Ferrante E., PO203-TUE, PO368-WED  
 Ferrara G., PO534-WED  
 Ferraresse M., OR297, PO158-MON  
 Ferrari B., PO580-MON, PO592-MON, PO574-TUE  
 Ferrazzi P., PO483-TUE, PO631-WED  
 Ferre N., PO568-MON, PO575-MON  
 Ferreira A., PO404-WED  
 Ferreira C., PO286-MON  
 Ferreira C., PO340-WED  
 Ferreira M., PO496-TUE  
 Ferreira R., PO422-MON, PO531-MON  
 Ferreira Filho L. I., PO286-MON  
 Ferrer-Marín F., PO497-MON  
 Ferrer-Marín F., PO487-TUE  
 Ferrer-Marín F., OR221  
 Ferri N., PO378-WED  
 Ferro A., PO516-MON  
 Feuring M., OR283, PO376-TUE, PO378-TUE, PO646-WED  
 Feussner A., OR350, PO089-TUE  
 Feyen B., PO221-MON  
 Feys H., AS178, PO604-WED  
 Fialat S., PO187-WED  
 Fidalgo T., PO538-WED  
 Field D., OR241  
 Field D., OR166, PO032-TUE  
 Field M., PO139-TUE  
 Fields L., PO521-MON  
 Fierro T., PO024-TUE  
 Fijalkowska I., PO154-WED  
 Fijnheer R., PO584-MON  
 Fijnvandaat K., OR387, PO251-TUE  
 Fijnvandraat K., PO665-MON

Fijnvandraat K., AS079, OR013, OR015, OR021, OR203, OR389, PO283-MON, PO658-MON, PO240-TUE, PO308-WED, PO510-WED  
 Filbet M., PO107-TUE  
 Filho O., PO397-WED  
 Filippi L., OR132  
 Filippucci E., PO370-MON, PO423-WED  
 Finazzi G., PO339-MON  
 Finley C., PO619-MON  
 Finn J., PO160-MON  
 Finnegan K., PO117-WED  
 Finney B., AS092  
 Fiore M., PO416-TUE  
 Fischer A.-M., PO014-MON, PO672-WED  
 Fischer K., OR141  
 Fischer K., OR144  
 Fischer K., NUR004, OR102, PO246-MON, PO272-MON, PO230-TUE, PO245-TUE, PO255-TUE, PO256-TUE, PO262-TUE  
 Fischer K., AS122, PO262-MON  
 Fischer M., AS200  
 Fischer R., PO195-WED  
 Fischer R., PO516-WED  
 Fischer T., PO368-WED  
 Fischer T., PO203-TUE  
 Fischetti L., PO513-MON  
 Fischler B., PO432-TUE, PO443-TUE  
 Fisgin T., PO051-WED  
 Fish R., AS002  
 Fisher M., PO521-MON  
 Fishwick C., AS231, PO182-TUE  
 Fitch-Tewfik J., AS091, AS166  
 Fitch-Tewfik J., AS170  
 Fitzgerald D., PO063-MON  
 Fitzmaurice D., PO019-TUE  
 Fitzmaurice D., OR096, OR119  
 Fitzpatrick M., PO611-WED  
 Fitzsimmons P., PO578-MON  
 Fjörkenstad A., PO379-TUE  
 Flament G., PO081-TUE  
 Flaujac C., AS164, OR032, PO544-TUE  
 Flaumenhaft R., AS091, AS166, AS170, AS146, OR417, PO425-MON, PO346-TUE  
 Fletcher J., PO622-WED, PO623-WED, PO634-WED, PO635-WED  
 Fletcher S., AS054, AS011  
 Fletcher S., OR298  
 Flick M., OR434, PO125-MON  
 Flick M., OR375

## Authors Index

Flier U., PO058-MON, PO013-TUE  
 Flinterman L., PO223-WED  
 Flood V., PO659-MON  
 Flood V., OR089, OR204  
 Flood V., AS131  
 Flores-Nascimento M., PO190-MON, PO422-MON, PO531-MON  
 Floridia A., PO369-WED  
 Floros G., PO274-MON, PO248-WED  
 Florou V., PO615-MON  
 Florquin S., OR124, PO287-TUE, PO442-WED  
 Fogarty P., PO252-WED  
 Foidart J.-M., PO142-WED  
 Foley J., PO021-MON  
 Foley K., PO021-MON  
 Follenzi A., AS088, OR106, OR161, OR411  
 Fong S. C., AS100, OR062  
 Fonseca K., PO004-TUE  
 Fonseca L., PO264-TUE  
 Fonseca R., PO128-MON  
 Font L., PO469-MON  
 Font L., OR381  
 Fontaine S., PO223-MON  
 Fontana P., AS128, OR055, OR397, PO011-TUE  
 Fontayne A., PO131-TUE  
 Fontcuberta J., PO217-WED  
 Foo K. M., PO430-TUE  
 Foppen W., OR102  
 Forban J.-C., PO035-WED  
 Forbes P., PO457-MON  
 Ford J., OR222  
 Forestier E., PO337-MON  
 Forgie M. A., PO371-WED, PO669-WED  
 Forman-Kay J., PO545-TUE  
 Fornari T., PO422-MON, PO531-MON  
 Forrester M., PO074-WED  
 Forsberg A., PO618-TUE  
 Fortes-Mayer G., PO098-TUE  
 Fortunato F., OR005  
 Fortunato T., PO016-MON  
 Fosbury E., PO295-MON, PO617-WED  
 Foster G., PO463-MON  
 Foster R., AS205, PO182-TUE  
 Foster W., PO329-WED  
 Fotinos A., OR114, PO449-WED  
 Fouassier M., PO016-WED  
 Fox M., OR247, OR299  
 Fox S., PO057-MON, PO026-TUE, PO410-TUE, PO492-WED  
 Fox-Robichaud A., PO389-MON

Fox-Robichaud A., PO324-MON  
 Fraessdorf M., PO362-MON  
 Frampton J., AS092, PO415-MON  
 Frampton J., PO328-WED  
 Frånberg M., PO559-WED, PO564-WED  
 France N., PO262-TUE  
 Frances P., PO653-WED  
 Franchi F., OR026, PO663-MON  
 Franchini M., PO650-TUE  
 Francis C., PO412-WED  
 Francis J., PO315-WED  
 Francis J., PO174-WED  
 Francis J., PO445-WED, PO446-WED  
 Francis P., PO449-MON  
 Francischetti I., PO068-MON, PO314-TUE  
 Francisco R., PO476-TUE  
 Franco L., PO373-WED  
 Franco O., AS181, OR364  
 Franco Moreno A. I., PO485-TUE  
 François B., PO337-MON  
 François D., OR422, PO545-WED  
 François D., PO163-WED  
 François S., PO347-TUE  
 Franks Z., OR243  
 Francisco R., PO472-TUE  
 Frasson S., PO608-MON  
 Frati L., PO060-MON  
 Frazer K., OR392, PO524-MON, PO525-MON, PO493-TUE, PO567-WED  
 Frazer K., PO519-MON  
 Frazer K., OR393, PO526-MON, PO494-TUE, PO495-TUE, PO568-WED  
 Fréchaud J., PO672-WED  
 Frechtel G., PO323-MON  
 Freddi S., AS212  
 Fredenburgh J., AS154, AS219, OR286, OR290, PO138-MON, PO403-MON, PO130-TUE, PO170-TUE  
 Fredenburgh J., OR442  
 Fredenburgh J., OR057  
 Frederick M., AS059  
 Frédéric R., PO172-TUE  
 Freedman J., AS168, OR031, PO328-WED  
 Freeman K., PO168-TUE  
 Freire I., PO163-TUE, PO538-WED  
 Freishtat R., AS125  
 Freitag M., OR243  
 Freitas L., PO479-WED  
 Freixo A., PO264-TUE, PO404-WED

Frelinger A., PO021-TUE, PO402-TUE, PO476-WED  
 Fremeaux-Bacchi V., PO589-MON  
 Fremeaux-Bacchi V., PO226-WED  
 Fresson K., OR231  
 Fressinaud E., AS134, OR024, OR025, PO639-TUE, PO645-TUE, PO664-TUE  
 Fretigny M., PO198-WED  
 Freund M., AS095  
 Freyburger G., PO398-WED  
 Freyburger G., PO345-MON  
 Freynhofer M., PO030-TUE  
 Fried H., OR366, PO155-MON  
 Friedman K., OR152, PO361-MON  
 Friedman K., OR089, OR204  
 Friedman M., PO579-MON  
 Friedrich M., OR405, PO526-TUE  
 Frieling J., PO592-WED  
 Fries D., PO330-WED  
 Frigo A., OR132  
 Frimpong V., PO580-TUE, PO581-TUE  
 Friou E., PO579-TUE  
 Frith S., PO317-TUE  
 Fritsch S., OR088  
 Fritsma G., PO403-WED  
 Fritzingler D., PO226-WED  
 Froehlich H., PO202-WED  
 Froehlich J., PO623-TUE, PO419-WED  
 Frölich L., PO487-WED  
 Fromes Y., PO166-TUE  
 Frontini M., PO384-WED  
 Frontroth J., PO640-TUE  
 Frontroth J., OR160  
 Frontroth J., PO644-MON, PO428-TUE  
 Frostick S., OR283  
 Frucchi R., PO211-TUE, PO250-WED  
 Fruchtman Y., PO217-TUE  
 Fruchtman Y., PO429-TUE, PO225-WED  
 Frymire E., OR200  
 Fu A.-C., PO521-MON  
 Fu R., OR001, PO451-TUE  
 Fu X., PO568-TUE  
 Fu X., PO635-MON  
 Freeman K., PO168-TUE  
 Freire I., PO163-TUE, PO538-WED  
 Fuchs B., PO675-TUE  
 Fuchs S., PO200-WED  
 Fuchs T., OR193  
 Fuchs T., PO583-MON  
 Fuentes E., AS116, PO010-TUE  
 Furlerling M., PO242-MON  
 Fuhrmann J., OR307, PO413-TUE  
 Fuiman J., PO167-MON

## Authors Index

Fujii H., OR343  
Fujii S., PO183-MON  
Fujii T., OR011, PO233-MON, PO377-MON  
Fujii T., PO233-MON, PO377-MON  
Fujimura Y., AS178, OR152, PO661-TUE, PO670-TUE, PO672-TUE, PO674-TUE, PO040-WED  
Fujioka A., PO351-MON  
Fujita K., PO173-TUE  
Fukazawa N., AS017  
Fukuda N., PO173-TUE  
Fukutake K., AS017, PO161-MON, PO213-TUE, PO006-WED, PO204-WED  
Fulmali M., PO363-TUE  
Funct-Brentano C., OR196  
Fung F. Y., PO012-TUE  
Fung M., PO576-MON  
Funk S., OR101, OR388  
Furie B., AS146  
Furie B., OR424, PO635-MON, PO551-WED  
Furie B., AS146, OR417, OR424, PO425-MON, PO635-MON, PO346-TUE, PO551-WED  
Furugohri T., PO353-MON, PO357-TUE  
Furukawa S., PO244-MON, PO652-MON, PO145-TUE  
Fuset M. P., PO062-MON  
Fustulo-Gunnink S., AS091  
Fütterer J., AS054  
G S., PO363-TUE  
Gaberel T., PO370-WED  
Gabilondo M., PO354-MON  
Gable B., OR192  
Gabielli S., OR002, PO433-MON, PO421-TUE  
Gachet C., **PO079.1-MON**, **AS095**, **OR420**, **PO572-MON**, **PO606-WED**  
Gacrama E., PO499-TUE  
Gade I. L., AS083  
Gadisseeur A., AS133, PO655-MON, PO666-TUE, PO668-TUE  
Gaertner F., OR206  
Gafarova M., PO535-TUE  
Gagliardi G., PO084-TUE  
Gaglioti D., PO654-TUE  
Gagnon F., AS045, AS206  
Gago T., PO163-TUE, PO538-WED  
Gaida A., AS016  
Gailani D., OR288  
Gailani D., OR287, OR353, PO543-WED

Gajsiewicz J., PO544-WED  
Gakuba C., OR379  
Gakuba C., PO532-TUE, PO370-WED  
Gál G., PO124-MON  
Gál P., PO303-TUE  
Galambosi P., PO652-WED  
Galan A., PO082-WED, PO610-WED  
Galanakis D., PO202-TUE  
Galanaud J.-P., AS137, OR095, OR188, OR190, OR327, PO467-MON, PO473-MON, PO535-MON, PO653-WED  
Galaz-Montoya J., PO192-WED  
Galdersi M., PO534-TUE  
Galea V., PO473-TUE  
Galinski C., PO450-WED  
Gallant M., AS180, PO321-MON, PO329-MON  
Galli T., AS170  
Gallistl S., PO453-MON, PO464-MON  
Gallo A., PO610-TUE  
Galloway G., PO352-MON  
Gallus A., OR199, PO374-TUE  
Gallus A., PO608-TUE  
Gallus A., PO353-TUE, PO409-WED  
Gälman C., PO443-TUE  
Galora S., PO086-MON, PO094-WED  
Galvin R., PO457-MON  
Galvin Z., OR218  
Galy-Fauroux I., PO014-MON  
Gamba G., OR027, OR030, PO483-MON, PO580-WED  
Gamba P., PO225-TUE  
Gamba S., PO339-MON  
Gambino G., PO239-MON, PO255-WED  
Gamble-Williams N., NUR001  
Gamirina D., PO538-TUE  
Gampel H., OR439  
Gamst A., PO476-MON  
Gandara E., OR384, PO467-MON, PO473-MON, PO641-MON, PO664-WED  
Gándara E., OR053, PO620-WED  
Gandhi P., OR237  
Gandhi S., PO494-WED  
Gandhi T., PO014-WED  
Gando S., PO178-MON  
Ganesh S., AS090  
Ganetsky M., PO319-TUE  
Gangadharan B., PO228-WED, PO230-WED  
Gangemi M., PO515-MON

Ganna A., PO564-WED  
Gannon C., PO318-WED  
Gantioqui J., OR373, PO350-MON, PO139-WED  
Gao C., OR140  
Gao X., OR060  
Garabet L., PO311-MON  
Garagiola I., PO164-MON, PO197-WED  
Garanito M., PO433-TUE  
Garayar Pulgar B., PO358-TUE  
García B., PO310-TUE  
García C., PO423-TUE  
García E., PO435-WED  
García F., PO435-WED  
García Bernal D., PO497-WED  
García Navarro M. J., PO485-TUE  
García-Andreo A., PO336-MON  
García-Barbera N., OR368, PO549-WED  
García-Barberá N., PO558-TUE  
García-Candel F., PO497-WED  
García-Candel F., PO229-MON  
García-Estañ J., PO435-WED  
García-Gutiérrez V., PO487-TUE  
García-Mouriz A., PO116-TUE  
Gardiner E., PO497-MON, PO669-TUE  
Gardiner E., PO393-TUE, PO441-WED  
Gardiner E., PO431-MON  
Gareus R., AS069  
Garg P., OR213  
Gargaro M., PO162-TUE  
Garghetti E., PO126-WED  
Garipardic M., PO310-MON  
Garnier D., PO393-WED  
Garrao F., PO575-MON  
Garred Ø., PO178-WED  
Gary T., AS197, OR292  
Gasteyer C., PO589-MON  
Gattinoni L., PO338-WED  
Gau J.-P., OR330  
Gauberti M., AS032, AS117, OR314, OR379, PO532-TUE, PO370-WED  
Gaucher E., PO203-WED  
Gaultier J.-B., PO107-TUE  
Gaussem P., AS086, AS087, OR196, PO016-TUE, PO038-TUE, PO350-TUE, PO437-WED, PO513-WED, PO672-WED  
Gautam M., PO369-MON  
Gavalaki M., PO169-WED

## Authors Index

Gavasso S., AS042, OR078, OR172, PO341-MON, PO114-TUE, PO331-TUE, PO332-TUE, PO548-TUE, PO127-WED, PO387-WED  
Gawaz M., OR114, PO412-MON, PO449-WED  
Gay V., PO484-MON  
Gazit S., PO437-WED  
Ge J., PO527-TUE  
Ge X., AS031  
Gebel M., AS022, OR097, OR383  
Gebhart J., AS034, PO391-WED, PO528-WED  
Geddis A., PO239-MON  
Gee E., NUR008, PO378-MON, PO496-TUE  
Geer M., AS069  
Geersing G.-J., PO583-TUE, PO584-TUE  
Gehrich S., PO216-WED  
Geierova V., PO247-WED  
Geltzer I., PO367-TUE  
Genç S., PO315-MON  
Genoud V., PO199-TUE  
Gensini G. F., OR253, OR400, PO086-MON, PO020-TUE, PO024-TUE, PO039-TUE, PO076-TUE, PO365-TUE, PO094-WED  
Genty C., PO095-TUE  
Georg Geissler G., PO015-TUE  
George D., NUR002  
George F., PO167-WED  
George F., PO337-MON  
George J., OR152  
Georges M., PO407-MON  
Georgescu I., OR409, OR412  
Georgescu M., AS192  
Georgescu V., PO535-MON  
Georgiev P., OR213  
Gerashimova O., PO147-WED  
Géraud C., OR409  
Gerdabi J., PO490-MON  
Gerdes V., OR035  
Gerdes V., OR268, PO028-TUE  
Gerhard D., PO418-WED  
Gerhardt A., OR077, OR329, PO539-TUE  
Germain M., OR148, OR266  
Germanovich K., PO412-TUE, PO086-WED  
Gerotziakas G., PO116-MON  
Gerotziakas G., OR438, PO108-MON, PO102-TUE  
Gerotziakas G., PO587-WED  
Gerotziakas G., PO292-MON, PO473-TUE

Gershkovich K.B. K., PO113-MON  
Gerstenbauer G., PO150-TUE  
Gertz J., PO145-MON  
Gervaso L., PO580-WED  
Gesheff M., PO041-TUE  
Geske F. J., PO150-MON  
Gessner J. E., OR017  
Getz T., PO003-TUE  
Getz T., AS070  
Geurts P., PO396-TUE  
Geyer S., PO587-MON, PO572-TUE  
Geys L., PO571-TUE  
Ghailoussi D., AS014, PO416-MON, PO441-MON, PO443-MON, PO385-WED  
Ghanima W., AS136, OR072, PO311-MON, PO600-TUE  
Ghatge M., AS202  
Ghatge M., OR010  
Ghatge M., OR009, PO084-MON, PO040-TUE  
Ghazzar N., AS082  
Gheldof D., PO167-WED  
Ghidelli N., PO483-MON, PO580-WED  
Ghirarduzzi A., AS197, OR195, OR292, PO602-MON  
Ghosh K., PO207-TUE  
Ghysdael J., AS014  
Gianellini S., PO005-TUE  
Giangrande P., OR212, OR348, PO653-MON  
Gianniello F., PO583-WED  
Giannini S., OR233, OR235, AS186  
Giansily-Blaizot M., PO502-MON, PO551-TUE, PO676-WED  
Giansily-Blaizot M. G.-, PO134-TUE  
Gibbins J., PO385-TUE  
Gibbins J., PO397-TUE, PO450-WED  
Gibbins J., AS167, PO398-MON, PO506-MON, PO438-WED  
Gibbs H., OR119  
Gibbs R. A., OR083  
Giermasz A., OR348  
Gierula M., OR369, PO139-MON  
Gieseler F., OR439  
Gigante B., PO530-TUE  
Giglioli C., PO020-TUE, PO076-TUE  
Gijsberts C., PO386-TUE  
Gil L., PO125-TUE, PO170-WED  
Gil-Bazo I., PO116-TUE  
Gilio K., OR278  
Gill J., OR088

Gill J., OR089  
Gill J., OR204, PO659-MON  
Gill R., PO317-TUE  
Gillespie S., PO677-MON  
Gillet E., PO672-WED  
Gilman E., OR144  
Gilmour S., OR356  
Gils A., AS205, OR153, OR442, OR444, PO215-MON, PO286-TUE, PO519-TUE  
Gimenez V., PO441-TUE  
Gimeno García A., PO485-TUE  
Gindele R., PO550-MON, PO187-WED  
Ginsberg J., PO489-WED  
Ginsburg D., AS090, OR180, OR331, OR361  
Ginzarly M., PO631-WED  
Giobatta C., PO671-WED  
Giorgi Pierfranceschi M., PO502-TUE  
Giorni C., PO018-TUE  
Giozoz G., PO102-TUE  
Girard D., PO398-WED  
Girard J., PO156-MON, PO157-MON  
Girard P., OR146, OR149, OR192, PO587-TUE, PO655-WED  
Girardi G., PO065-WED  
Giraudo M., PO645-TUE  
Girelli D., OR050, OR080, PO554-TUE, PO555-TUE  
Girolami A., PO518-WED  
Gissel M., OR303, PO371-MON, PO576-MON, PO467-TUE, PO425-WED  
Gissen P., AS054  
Gitz E., PO393-TUE  
Giuffrida G., OR027  
Giulivi A., OR200, OR310  
Giunta D., PO620-WED  
Giunta D., PO642-WED  
Giusti B., OR270, OR400, PO086-MON, PO020-TUE, PO039-TUE, PO094-WED  
Giustozzi M., PO370-MON, PO423-WED  
Gkalea V., PO116-MON  
Gkalea V., PO587-WED  
Gkotsi S., PO169-WED  
Glamocanin S., PO287-MON, PO288-WED  
Glaros E., PO404-MON  
Glaves R., PO603-MON  
Glazebrook D., PO235-MON  
Glazebrook D., PO237-MON  
Gledkruemas S., PO613-WED  
Gleeson E., OR182

## Authors Index

Gleeson N., OR360  
 Glembofsky A., PO422-TUE  
 Gloria F., PO444-TUE  
 Glund S., OR320  
 Gnerre P., PO610-TUE, PO640-WED  
 Gobbito S., PO027-MON  
 Goddijn M., AS021  
 Godfroid E., PO166-TUE, PO174-TUE, PO181-TUE  
 Godier A., OR219, PO016-TUE, PO350-TUE, PO662-TUE  
 Godoi L., PO566-MON, PO244-WED  
 Goehringer F., PO546-TUE  
 Goekoop R., PO596-MON  
 Goerdts S., OR409  
 George T., OR170  
 Goetze J. P., PO482-MON  
 Gogarten W., PO395-TUE  
 Goggs R., OR244  
 Gogia S., OR334, PO045-WED  
 Gohda M., OR352, PO351-MON  
 Gohlke H., PO418-MON  
 Goizet C., OR003  
 Gokce M., PO313-MON, PO315-MON, PO459-MON, PO279-WED  
 Goldberg R., OR395, PO578-TUE  
 Goldenberg N., PO506-WED  
 Goldenberg N., AS161, OR156  
 Goldfine A., PO329-MON  
 Goldford M., PO346-MON  
 Goldhaber S., PO646-WED  
 Goldhaber S., OR096, OR119, PO378-TUE, PO613-TUE  
 Goldman B., PO149-MON  
 Goldman L., PO532-MON  
 Goldmann G., OR103, PO219-TUE, PO532-WED  
 Goldsmith R., PO447-TUE  
 Goldstein J., PO601-WED  
 Golebiewska E., AS126  
 Golightly L., PO622-MON  
 Golmard J.-L., PO345-MON, PO350-TUE, PO672-WED  
 Golovina O., PO057-TUE, PO367-TUE  
 Golubeva M., PO046-WED  
 Golubeva N., PO327-TUE  
 Gomas J.-M., PO107-TUE  
 Gomes B., OR310  
 Gomes H., PO264-TUE  
 Gomes K., PO043-WED  
 Gomes T., PO068-MON  
 Gomes T., PO131-MON  
 Gomes T., PO158-WED  
 Gomez K., PO486-MON, PO353-WED, PO676-WED

Gomez M., PO242-WED  
 Gómez M., PO487-TUE  
 Gómez V., PO552-WED  
 Gómez Del Castillo M. D. C., PO451-MON  
 Gómez-Del-Castillo M. D. C., PO010-WED  
 Gomez-Rodriguez V., PO342-MON  
 Gomis R., AS044  
 Gomperts E., PO168-MON, PO169-MON  
 Gona P., PO593-TUE  
 Goncalves G., PO002-WED  
 Goncalves L., PO390-WED  
 Goncalves L., PO264-TUE  
 Goncalves M. L., PO390-WED  
 Gonçalves G., PO189-TUE, PO023-WED, PO397-WED  
 Gonçalves L., PO212-TUE, PO404-WED  
 Gong L., AS146  
 Gong Y., PO245-WED  
 Gonias S., AS229  
 Gonzalez A. F., PO360-WED  
 Gonzalez C., PO323-MON  
 González A., PO010-MON  
 González C., OR220, PO466-WED, PO480-WED  
 González L., PO355-WED  
 González V., PO051-MON  
 Gonzalez J., PO664-WED  
 Gonzalez Alcantara M., PO059-WED  
 Gonzalez Bernaldo De Quiros F., PO620-WED  
 Gonzalez-Conejero R., PO558-TUE  
 González-Conejero R., PO549-WED  
 González-Conejero R., PO552-WED  
 Gonzalez-Porras J., PO488-TUE  
 González-Porras J., PO487-TUE  
 Good D., PO227-TUE  
 Goodall A., AS041, PO429-MON, PO553-MON, PO565-MON, PO464-WED, PO542-WED  
 Goodemand J., PO649-MON  
 Goodeve A., AS132, OR406, PO649-MON  
 Goodeve A., AS064, OR086, PO667-MON, PO676-MON, PO676-WED  
 Goodwin C., OR436, PO301-MON  
 Gooneratne L., PO021-WED  
 Gopal S., OR417, PO425-MON  
 Gorbacheva L., PO537-TUE  
 Gorbacheva L., PO281-TUE, PO290-TUE  
 Gordanpour A., OR159

Gorelashvili M., PO526-TUE  
 Gorena M., PO631-TUE  
 Gori A. M., OR396, OR400, PO067-MON, PO020-TUE, PO039-TUE, PO365-TUE, PO094-WED  
 Gori A., OR253  
 Gori A.-S., PO407-MON  
 Gori L., PO071-TUE  
 Gori T., PO483-WED  
 Goria O., PO621-WED  
 Gorski M., OR394  
 Gorski M., PO580-MON  
 Gorski M. M., AS196, OR083, PO197-WED  
 Goruppi M., PO376-MON  
 Gosain R., PO041-TUE  
 Goss A., OR356  
 Gosselin R., PO358-WED, PO359-WED  
 Gothot A., PO396-TUE  
 Goto S., OR096, OR119  
 Goto T., PO173-TUE  
 Gotru S., AS068, OR081  
 Gotru S. K., AS228  
 Gottstein S., AS221  
 Goudemand J., AS134, OR024, OR025, OR143, OR144, OR219, PO639-TUE, PO645-TUE, PO662-TUE  
 Goufman E., PO113-MON  
 Gougnard T., PO373-TUE  
 Gouider E., PO650-MON  
 Gouillou M., OR323  
 Gouin-Thibault I., OR196, PO345-MON, PO016-TUE, PO350-TUE, PO672-WED  
 Gould T., PO220-MON  
 Goult B., PO553-MON  
 Gounou C., PO326-TUE  
 Gourlaouen M. A., PO645-TUE  
 Gouw S., PO245-TUE  
 Gouw S., OR389  
 Gouw S., OR141  
 Govers-Riemslog J., PO546-MON  
 Goy J., AS110  
 Goyal J., PO208-TUE  
 Grabell J., PO646-MON, PO678-MON, PO227-TUE, PO426-TUE, PO679-TUE, PO252-WED  
 Grace R., PO458-MON  
 Gracheva M., PO462-MON  
 Graeter F., PO669-TUE  
 Graham R., PO096-WED  
 Grammel N., PO144-TUE  
 Grammel N., PO146-TUE  
 Grancha S., PO207-WED  
 Grand B., PO059-WED

## Authors Index

Grand F., PO448-MON  
 Grande-Ratti M., PO642-WED  
 Grandone E., PO511-MON, PO513-MON, PO453-TUE, PO611-TUE  
 Grangl G., PO464-MON  
 Granoski D., PO460-MON  
 Grant P., OR398  
 Grant P., PO096-WED, PO190-WED  
 Grant P., AS003  
 Granzen B., AS079  
 Grass S., PO362-WED  
 Gratacap M.-P., PO514-TUE  
 Gräter F., OR335  
 Gratsiansky N., PO069-TUE  
 Gratz M., PO079.1-MON  
 Graux C., OR126, PO167-WED  
 Graveleau J., PO016-WED  
 Gray E., PO294-MON, PO064-WED  
 Gray W., PO063-WED  
 Grazia F., PO259-TUE  
 Greaves M., PO225-MON  
 Greblikas F., PO242-MON  
 Greco S., OR365  
 Greenbaum L., PO589-MON  
 Greene D., OR339, PO384-WED  
 Greene L., PO632-MON  
 Greene L., OR165  
 Greenhoe R., PO618-TUE  
 Greenman J., PO558-MON  
 Greenspan E., PO096-TUE  
 Gergersen H., PO130-MON  
 Gregory-Miller K., AS110  
 Greinacher A., AS008, OR055, OR307, OR308, PO298-MON, PO413-TUE  
 Greisel J., OR049  
 Greist A., OR028  
 Gremmel T., PO021-TUE, PO402-TUE  
 Grenier D., PO131-TUE  
 Gresele P., AS174, AS199, OR208, OR336, OR399, PO024-TUE, PO650-TUE  
 Griesmacher A., PO096-MON  
 Griffin J. H., PO093-MON  
 Griffin K., PO096-WED, PO190-WED  
 Griffioen A., PO452-TUE  
 Griffith B., OR338  
 Griffiths D., PO670-WED  
 Grifoni E., OR396, OR400, PO067-MON, PO366-MON, PO076-TUE, PO365-TUE, PO477-TUE  
 Griggio N., PO385-MON

Grigoriev S., PO466-TUE  
 Grigorjeva M., PO073-WED  
 Grill D., PO655-TUE  
 Grimm J., PO256-MON  
 Grimwade D., PO120-MON, PO121-MON  
 Gringeri A., OR014, OR029, PO259-MON, PO286-WED  
 Grinspon A., PO373-MON  
 Gris J.-C., OR095, OR188, OR190, PO035-MON  
 Gris J.-C., PO035-WED  
 Griskevicius L., PO242-MON, PO260-MON  
 Grissom C., PO604-MON  
 Gritsch H., PO199-WED, PO201-WED, PO229-WED  
 Gritzan U., PO555-WED  
 Groarke E., PO649-WED  
 Groeneveld D., OR070, PO002-MON, PO660-TUE  
 Gröner A., PO605-WED  
 Gröning A., OR054  
 Groetenboers M., OR257  
 Gros A., OR170, PO330-MON  
 Groschup M., PO605-WED  
 Grosdidier C., PO493-WED  
 Grosjean S., PO263-TUE  
 Groß J., PO013-WED  
 Gross J., AS221  
 Gross P., AS216, AS219, OR286, OR302  
 Grosse S., OR134  
 Grossi E., PO066-MON  
 Grossmann V., PO478-WED  
 Grosso M., OR199, OR383  
 Grosso S., PO629-MON  
 Grosso S., PO646-TUE  
 Grosso S., PO039-MON  
 Grotevendt A., OR307  
 Grötta O., AS136  
 Grottke O., OR067, PO078-TUE, PO314-TUE  
 Grozovsky R., AS186  
 Gruber A., AS049, AS209, PO177-TUE  
 Gruber A., OR049, OR353, PO543-WED  
 Gruel Y., AS108, OR143, OR428, PO064-MON, PO345-MON, PO501-MON, PO263-TUE, PO056-WED  
 Gruenenfelder F., OR320  
 Gruenheid S., PO135-MON  
 Grunebaum L., PO263-TUE  
 Gruppo R., PO242-MON, PO260-MON, PO266-WED  
 Grushin K., PO192-WED

Grusse M., PO102-TUE, PO473-TUE, PO163-WED  
 Grzegorzczak F., PO311-WED  
 Gu J.-M., AS018, PO555-WED  
 Gu S., PO176-TUE  
 Gu X., PO623-TUE, PO419-WED  
 Gu X., OR265  
 Gualandris F., PO622-TUE  
 Gualandro D., PO034-TUE, PO095-WED  
 Guardascione M. A., AS195  
 Guarini P., OR050, PO554-TUE, PO555-TUE  
 Guarino M. L., PO060-MON, PO084-WED, PO316-WED  
 Guazzaloca G., PO317-WED  
 Gubensek M., AS101  
 Gudmundottir B., PO412-WED  
 Gue D., PO269-WED  
 Guechi Z., PO375-MON  
 Guégan M., OR146, OR149, PO655-WED  
 Gueguen P., PO440-MON  
 Guelcher C., PO381-MON  
 Guenneguez H., AS137  
 Guenther J., PO404-TUE  
 Gueret P., PO166-TUE, PO181-TUE, PO411-TUE  
 Guerra L., OR078  
 Guerrero M., PO381-MON  
 Guerrero B., PO190-TUE  
 Guerrero F., PO440-MON  
 Guerrero G., PO092-TUE, PO146-WED, PO231-WED  
 Guerrero J., PO384-WED  
 Guettier S., OR379  
 Gugiu G., PO476-MON  
 Guglielmone H., OR431, PO632-TUE, PO640-TUE, PO518-WED  
 Guidetti G., OR115  
 Guidetti G., PO450-TUE  
 Guidez F., AS014  
 Guil M., PO631-WED  
 Guillemin F., OR186  
 Guillen K., PO516-MON  
 Guillonnet F., PO572-MON  
 Guillot A., PO107-TUE  
 Guillot O., PO134-TUE  
 Guimarães F., PO340-WED  
 Guimarães J. E., PO012-WED  
 Guimicheva B., PO479-TUE  
 Guiochon-Mantel A., PO527-MON  
 Guirimand F., PO107-TUE  
 Gujjar A., PO009-TUE  
 Guler N., PO211-MON, PO212-MON, PO192-TUE, PO332-WED, PO374-WED

## Authors Index

Gulilat M., PO364-TUE  
 Gulin D., PO113-MON  
 Gullberg J., OR283  
 Gullerud R., OR128  
 Gulyás H., PO031-WED  
 Gumruk F., PO505-WED, PO507-WED, PO508-WED  
 Gunawan A., PO633-TUE  
 Gunawan S., PO014-TUE  
 Gundert E., PO469-MON  
 Gunning W., AS130  
 Guo L., OR139, PO302-TUE  
 Guo Z., OR140  
 Gupalo E., PO294-TUE  
 Gupta G., OR365  
 Gupta K., OR421  
 Gupta S., PO182-WED, PO183-WED, PO184-WED  
 Gurbel P., PO076-MON, PO099-MON  
 Gurbel P., PO041-TUE  
 Gureasko J., OR247  
 Guria G., PO460-TUE  
 Guria K., PO460-TUE  
 Gurkan E., PO591-TUE  
 Gurlich R., PO364-WED  
 Gursel T., PO143-WED  
 Guruceaga E., PO488-TUE  
 Guskova E., PO356-WED  
 Gussoni G., PO608-MON  
 Gutowski Z., PO229-TUE  
 Guyaux M., PO166-TUE, PO181-TUE  
 Guzman C., PO647-WED  
 Guzzo M. P., PO084-WED  
 Gvozdenov M., PO547-MON  
 Gwiit K., PO089-WED  
 Gwynn S., PO098-TUE  
 Gyenes M., PO413-MON, PO417-MON  
 H. Reitsma P., PO548-WED  
 Ha H., PO659-WED  
 Haaning J., OR110, OR414, PO147-MON, PO219-WED  
 Haas S., OR096, OR119, PO356-TUE, PO607-TUE  
 Haberichter S., PO361-MON, PO659-MON, PO667-MON  
 Haberichter S., OR089, OR204  
 Habib I., PO658-TUE  
 Hack K., PO299-TUE  
 Hackeng T., PO617-MON, PO037-TUE, PO348-TUE, PO002-WED, PO023-WED  
 Hackeng T., PO411-MON, PO518-MON, PO349-TUE, PO091-WED, PO395-WED  
 Haenel D., PO404-TUE

Haertter S., PO376-TUE  
 Hafeman A., PO231-TUE  
 Hagan M., OR064  
 Hagedorn I., AS094  
 Hagemeyer C., PO014-TUE  
 Hägerling R., AS092  
 Haghanpanah S., PO490-MON  
 Hagio T., OR352, PO351-MON  
 Hagiwara N., PO399-MON  
 Hagiwara T., PO161-MON, PO006-WED  
 Haglund C., PO162-WED  
 Haguét H., OR126  
 Haidl H., PO453-MON, PO464-MON  
 Haig Y., AS136  
 Hainfellner J., OR357  
 Haining E., OR181  
 Hajer E. M., PO281-WED  
 Hajjar K., AS089  
 Hakobyan L., PO573-MON  
 Halabi M., PO471-WED  
 Hald E., OR071, OR254, OR267, PO304-TUE, PO328-TUE, PO494-TUE, PO594-TUE, PO638-WED  
 Hald E., PO308-TUE  
 Haley K., AS129  
 Halilovic S., PO094-MON, PO066-TUE  
 Halimeh S., OR346, PO256-MON, PO502-MON, PO647-MON, PO521-WED  
 Hall B., PO600-MON, PO601-MON, PO582-TUE  
 Hall C., PO168-MON, PO169-MON  
 Haller F. M., PO219-WED  
 Halliez M., PO016-WED  
 Halton J., PO465-MON  
 Hamaia S., AS065  
 Hamako J., PO661-TUE, PO670-TUE  
 Hamasaki T., AS107  
 Hamedani N., OR248  
 Hamel Desnos C., AS137  
 Hamid C., PO295-MON, PO353-WED  
 Hamidou M., PO016-WED  
 Hammelburger J., PO054-TUE  
 Hammerschmidt S., AS008  
 Hammerstrom J., OR345  
 Hammerstrøm J., AS083, OR129, PO104-TUE, PO111-TUE, PO112-TUE  
 Hammond D., PO024-WED  
 Hampshire D., OR406

Hampshire D., AS064, OR086, PO667-MON, PO676-MON, PO676-WED  
 Hampson P., OR121, PO393-TUE  
 Hamsten A., OR269, PO559-WED, PO564-WED  
 Hamulyak K., PO033-WED  
 Hamzeh-Cognasse H., PO410-MON, PO408-TUE  
 Han C. K., PO613-TUE  
 Han J. W., PO309-WED  
 Hanabusa H., AS017, OR212, OR347, PO149-MON  
 Hanagavadi S., PO164-MON  
 Hanchate A., PO657-WED  
 Handrkova H., PO181-WED, PO185-WED  
 Handt L., PO074-WED  
 Handunetti S., PO021-WED  
 Hanley J., PO502-WED  
 Hanna D., PO172-WED  
 Hanna W., PO619-MON  
 Hanna W., PO032-MON  
 Hansen A., OR036  
 Hansen E., PO219-WED  
 Hansen H., OR230  
 Hansen J., OR414  
 Hansen J. B., OR267, PO308-TUE, PO494-TUE, PO638-WED  
 Hansen J.-B., AS046, AS028, AS083, OR071, OR075, OR120, OR129, OR134, OR254, OR258, OR293, OR345, OR392, OR393, PO338-MON, PO472-MON, PO519-MON, PO524-MON, PO525-MON, PO526-MON, PO609-MON, PO610-MON, PO612-MON, PO104-TUE, PO111-TUE, PO112-TUE, PO304-TUE, PO328-TUE, PO329-TUE, PO493-TUE, PO495-TUE, PO594-TUE, PO396-WED, PO561-WED, PO567-WED, PO568-WED, PO572-WED, PO636-WED  
 Hansen L., PO590-WED  
 Hansen M., PO147-TUE  
 Hanslik A., PO302-MON  
 Hantel S., PO378-TUE  
 Hanzu F., AS044  
 Hao Y., OR001, PO451-TUE  
 Harada A., OR320  
 Harada K., PO351-MON  
 Haramura G., PO550-MON  
 Hardikar W., PO432-TUE  
 Hardt R., PO591-MON  
 Hardy L., PO100-MON, PO182-TUE  
 Harel A., AS062, OR246, PO206-WED

## Authors Index

Harenberg J., PO346-MON, PO356-TUE  
 Harissis H., PO551-TUE  
 Harlen O., PO243-WED  
 Harling H., OR230  
 Harney K., PO457-MON  
 Harney K., PO458-MON  
 Harper A., OR045  
 Harper M., PO065-MON  
 Harper M., OR244, OR275, PO424-TUE, PO458-WED  
 Harper P., PO374-TUE  
 Harper P., AS100, OR062, PO670-WED  
 Harrington L., OR034  
 Harrington L., PO557-WED  
 Harris D., PO306-MON  
 Harris N., PO197-TUE  
 Harris P. J., OR127  
 Harris S., PO243-WED  
 Harrison M., PO408-MON  
 Harrison N., PO156-WED  
 Harrison N., PO064-TUE, PO130-WED  
 Harrison S., OR157  
 Harrison P., AS054, OR121, PO325-MON, PO393-TUE  
 Hart D., OR108, PO284-MON, PO258-WED  
 Hart G., PO062-TUE, PO550-TUE, PO048-WED, PO594-WED, PO595-WED  
 Hartholt R., PO227-WED  
 Hartman S. K., PO631-TUE  
 Hartmann R., PO151-TUE, PO152-TUE, PO201-WED, PO209-WED  
 Hartwick J., NUR013  
 Hartwig J., OR232  
 Harudova M., PO128-TUE  
 Harutyunyan L., PO573-MON  
 Harvey A., PO502-MON, PO521-WED  
 Hary J., PO645-TUE  
 Hasebe R., PO151-MON, PO486-TUE, PO560-WED  
 Hasegawa K., PO515-TUE, PO528-TUE  
 Hasenfuß G., PO619-WED  
 Hashemi S., AS223, OR141  
 Hashimoto A., PO351-MON  
 Hassab H., PO243-MON  
 Hassanzadeh-Ghassabeh G., OR399  
 Hassell K., PO356-MON  
 Hassenpflug W., PO174-MON  
 Hassmann D., PO383-WED, PO487-WED  
 Hassock S., PO511-TUE

Hasumi K., PO515-TUE, PO528-TUE  
 Hatakeyama K., PO674-TUE  
 Hatmi M., PO116-MON  
 Hato T., PO055-MON  
 Hattori K., PO491-MON, PO165-TUE  
 Hau A., PO427-TUE  
 Hauck B., PO172-MON  
 Haulon S., AS201  
 Hauschner H., PO171-TUE, PO324-WED  
 Hausfater P., OR192  
 Hausner L., PO487-WED  
 Haussels I., PO343-WED  
 Havelick J., PO050-TUE  
 Havluj L., PO364-WED  
 Hawke L., PO670-MON  
 Hawkins B., PO523-MON  
 Hawkins K., PO156-WED  
 Hawley A., PO030-MON  
 Hay C., OR213, PO210-TUE, PO266-WED, PO299-WED  
 Hay C., PO294-WED  
 Hay C., OR389, PO495-MON  
 Hay J., PO260-TUE  
 Haya S., PO093-MON, PO308-WED, PO579-WED  
 Hayakawa M., PO661-TUE, PO672-TUE, PO674-TUE, PO040-WED  
 Hayakawa M., PO178-MON  
 Hayasaka K., PO455-WED  
 Hayashi S., PO320-WED  
 Hayashi T., PO113-WED  
 Hayashi T., PO185-TUE, PO284-TUE, PO335-TUE  
 Hayashida K., OR142  
 Hayes C., OR356  
 Hayes L., PO605-MON, PO590-TUE  
 Hayes T., PO367-WED  
 Hayman M., PO085-WED  
 Haymart K., PO623-TUE, PO419-WED  
 Haynes L., PO371-MON  
 Haynes L., PO140-MON, PO133-TUE  
 Hayward C., OR377  
 Hazeldine J., OR121  
 Hazendonk H., OR387, PO251-TUE  
 Hazendonk H. C., PO651-MON  
 He A.-D., PO426-MON  
 He R., PO248-WED  
 He R., PO484-WED  
 He S., PO255-MON, PO368-MON, PO362-WED

He Y., AS072, OR137  
 He Z., PO321-WED  
 Healey F., OR073  
 Healey J., PO362-MON  
 Healy L., PO297-TUE  
 Heatherington A., PO512-TUE  
 Hebbard C., PO451-WED  
 Hebert K., AS192  
 Hechler B., PO572-MON, PO606-WED  
 Hechler B., PO514-TUE  
 Heckbert S., PO557-WED  
 Hecker A., PO094-MON  
 Heckman M., PO401-WED, PO410-WED  
 Heddle N., OR282, PO570-MON  
 Heddle N., PO616-WED  
 Heddle N., PO276-MON  
 Hedengran K., PO509-MON  
 Hedge G., OR046  
 Hedin U., PO564-WED  
 Heemskerck J., AS141, OR278, AS140, PO452-TUE, PO675-TUE  
 Heemskerck J., PO395-WED  
 Heemskerck J., AS204, PO411-MON, PO499-MON, PO672-MON, PO155-TUE, PO349-TUE  
 Heestertermans M., AS208, PO570-WED  
 Heggemont W., PO002-TUE  
 Hego A., AS006, PO396-TUE  
 Heibroch Petersen H., PO455-TUE  
 Heide-Jørgensen U., OR098  
 Heilmann S., PO202-WED  
 Heim V., PO606-WED  
 Heinis C., PO101-MON  
 Heinken A., PO480-TUE  
 Heinz G., OR123, PO301-TUE  
 Heinz J., AS221  
 Heinze K., OR405, PO526-TUE  
 Heising S., AS069, OR183, OR401, PO434-WED  
 Heit J., OR266  
 Heit J., OR128, PO645-WED  
 Heitmann M., OR414  
 Heldner M., PO525-TUE  
 Helfer H., PO620-MON  
 Helin T., PO363-MON  
 Hell L., PO559-MON, PO391-WED  
 Heller C., PO195-WED, PO506-WED  
 Heller P., PO422-TUE  
 Heller-Baan R., OR257  
 Helley D., PO014-MON  
 Hellum M., PO561-MON  
 Helm C., AS008  
 Helseth R., OR251, PO030-TUE

## Authors Index

Helsing K., AS163  
**Hemker C.**, OR224, OR301, PO025-MON, PO089-MON, PO290-MON, PO004-WED  
**Hemker C.**, PO672-MON  
**Hemker H.**, PO143-MON  
**Hemker H.**, PO527-MON  
**Hemmerlyck B.**, PO002-TUE  
**Henault L.**, PO657-WED  
**Henderson S.**, AS154, PO403-MON  
**Henderson S.**, PO653-MON, PO638-TUE  
**Hendrickson R.**, PO516-WED  
**Hendrickx M.**, OR399  
**Hendriks D.**, PO218-MON, PO219-MON, PO221-MON  
**Hendriksen J.**, PO583-TUE  
**Henkel-Klene A.**, PO654-MON  
**Henkens Y.**, PO143-MON  
**Hennessey C.**, PO381-MON  
**Henneuse A.**, OR324  
**Henniphof T.**, OR225  
**Henrrad S.**, PO234-TUE  
**Henriet C.**, PO484-MON, PO650-MON  
**Henriksen A.**, PO153-TUE  
**Henriksen L.**, PO051-TUE  
**Henriksson C.**, OR317, PO561-MON  
**Henriquez D.**, PO607-WED  
**Henskens Y.**, PO056-MON, PO645-MON  
**Henskens Y.**, OR430, PO348-MON, PO092-WED, PO349-WED, PO350-WED, PO416-WED  
**Henskens Y.**, PO033-WED  
**Henskens Y.**, PO123-WED, PO609-WED  
**Hepner M.**, OR160, PO644-MON, PO428-TUE, PO640-TUE  
**Heptinstall S.**, PO057-MON, PO026-TUE, PO410-TUE, PO518-TUE, PO492-WED  
**Herbig B.**, OR408  
**Herbreteau D.**, PO064-MON  
**Hermanns H.**, AS068  
**Hermanns I.**, PO478-WED  
**Hermans C.**, AS122, OR389, PO262-MON, PO234-TUE, PO243-TUE, PO244-TUE, PO280-WED, PO283-WED  
**Hermans C.**, PO273-WED  
**Hermida J.**, PO116-TUE, PO488-TUE  
**Hermiston T.**, PO555-WED  
**Hermoire S.**, AS134  
**Hernandez J.**, PO023-TUE, PO242-WED

**Hernandez J.**, PO023-TUE  
**Hernández M.**, PO523-WED  
**Hernández M.**, PO552-WED  
**Hernández Herrera H.**, PO533-MON  
**Hernández-Boluda J.**, PO487-TUE  
**Hernández-Juárez J.**, PO020-MON, PO073-MON, PO523-TUE  
**Hernandez-López J. R.**, PO020-MON  
**Hernani R.**, PO579-WED  
**Herold S.**, PO593-MON  
**Heroux A.**, OR173  
**Herr M.**, PO174-TUE, PO076-WED  
**Herranz M. T.**, PO552-WED  
**Herrera M. D. L.**, PO373-MON  
**Herrero B.**, PO010-WED  
**Hers I.**, AS141, OR112, OR272, OR275, PO428-MON, PO458-WED, PO461-WED  
**Hertfelder H.-J.**, PO343-WED  
**Hervé T.**, PO045-TUE  
**Herzog E.**, AS016, OR316, PO152-MON, PO312-TUE, PO418-WED, PO596-WED  
**Herzog R.**, OR107  
**Herzog R.**, PO220-WED  
**Hesketh M.**, OR444  
**Hess P.**, OR020  
**Hethershaw E.**, PO100-MON, PO182-TUE  
**Hettinger J.**, OR177  
**Heuschen C.**, PO507-TUE  
**Hey J.**, PO673-TUE  
**Heying R.**, AS113  
**Heylen E.**, PO142-TUE  
**Heylen O.**, OR079  
**Heymann D.**, PO032-MON  
**Heymonet M.**, AS036  
**Hézarid N.**, PO457-WED  
**Hezemans R.**, PO598-MON  
**Hiatt W.**, PO029-TUE  
**Hickey K.**, PO058-TUE  
**Hicks R.**, PO628-WED  
**Hickson N.**, PO667-MON  
**Hidaka Y.**, PO120-WED  
**Higashi D.**, PO305-TUE  
**Higgins S.**, AS166  
**High K.**, OR178, PO172-MON  
**Higuera D.**, PO152-WED  
**Hilden I.**, AS019, PO454-TUE, PO455-TUE  
**Hill C.**, PO670-WED  
**Hilliard P.**, PO245-TUE  
**Hillis C.**, OR068  
**Hindawi S.**, PO089-MON  
**Hinds M.**, OR049

**Hines P.**, OR060  
**Hirakata H.**, PO505-TUE  
**Hiramatsu E.**, PO514-WED  
**Hiratmasu E.**, PO441-TUE  
**Hirayama K.**, OR343  
**Hiroshi K.**, PO153-WED  
**Hirota Y.**, OR352, PO351-MON  
**Hirsch A.**, PO647-WED  
**Hirsh J.**, PO130-TUE, PO489-WED  
**Hisada R.**, PO058-WED  
**Hiscock K.**, PO374-TUE  
**Hitos K.**, PO622-WED, PO623-WED, PO634-WED, PO635-WED  
**Hitzler W.**, AS052  
**Hjemdahl P.**, PO363-MON, PO661-MON, PO383-TUE, PO392-WED  
**Hlavackova A.**, PO238-WED  
**Hlusi A.**, PO060-TUE, PO279-TUE  
**Ho E.**, AS018, PO213-WED  
**Ho M.**, AS150  
**Ho P.**, PO605-MON, PO048-TUE, PO590-TUE  
**Ho Tin Noe B.**, PO222-MON  
**Hodge J.**, PO315-WED  
**Hodgins D.**, PO267-MON  
**Hodgkinson J.**, PO019-TUE  
**Hoefer I.**, PO386-TUE  
**Hoefer T.**, PO431-MON  
**Höeg Dembrower K.**, PO530-TUE  
**Hoekstra M.**, PO405-MON  
**Hoek-Ten Cate A.**, OR326  
**Hoellriegl W.**, PO151-TUE, PO199-WED  
**Hofbauer C.**, PO284-WED  
**Hofbauer C.**, AS221, PO236-TUE  
**Hofbeck M.**, PO667-WED  
**Hofer S.**, PO528-WED  
**Hoffman M.**, PO062-TUE, PO550-TUE, PO048-WED, PO594-WED, PO595-WED  
**Hoffman M.**, OR239, PO104-MON, PO153-MON, PO273-MON, PO550-TUE, PO052-WED  
**Hoffman R.**, PO563-WED  
**Hoffman S.**, AS103  
**Hoffmann P.**, PO202-WED  
**Hoffmann R.**, PO094-MON  
**Hoffmeister K.**, OR233, AS186  
**Hoffmeister K.**, OR235  
**Hofman A.**, AS181, OR364  
**Hofman M.**, PO628-WED  
**Hofmann A.**, PO202-WED  
**Hogan C.**, PO622-MON  
**Hogg K.**, OR194, OR198, PO641-MON

## Authors Index

**Hogg P.**, OR417  
**Hogg P.**, OR185, PO075-MON, PO404-MON, PO415-TUE, PO669-TUE  
**Hogwood J.**, PO294-MON  
**Hohensinner P.**, AS200, PO002-TUE, PO282-TUE, PO301-TUE, PO509-TUE  
**Hohensinner P.**, OR123  
**Høiland I.**, PO329-TUE  
**Høiland I. I.**, PO304-TUE, PO308-TUE  
**Hokamura K.**, PO193-TUE  
**Holbrook A.**, OR200  
**Holbrook L.-M.**, PO506-MON, PO450-WED  
**Holck M. H.**, PO119-WED  
**Holden F.**, PO318-WED  
**Holinstat M.**, AS217  
**Hollands M.**, PO623-WED, PO635-WED  
**Hollenbach S.**, OR318  
**Hollenberg M.**, AS057  
**Hollingdrake O.**, PO391-MON  
**Hollingsworth R.**, PO210-TUE  
**Holly S.**, OR280  
**Holly S.**, AS182  
**Holm P.**, PO046-TUE  
**Holman T.**, AS217  
**Holme P.**, PO257-TUE  
**Holme P. A.**, AS136, OR317, PO271-MON  
**Holme P. A.**, PO283-WED  
**Holme P. A.**, PO273-WED  
**Holme P.-A.**, PO291-WED  
**Holmer E.**, PO294-MON  
**Holmes C.**, PO239-TUE  
**Holmström M.**, PO297-MON, PO661-MON, PO080-TUE, PO228-TUE, PO559-WED  
**Holnthoner W.**, PO559-MON  
**Holstein K.**, AS221, PO251-MON, PO253-TUE  
**Holten-Andersen L.**, PO590-WED  
**Holthaus A.**, OR413  
**Holzhauser S.**, PO647-MON, PO195-WED  
**Homann J.**, PO343-WED  
**Homeyer N.**, PO418-MON  
**Hong M.-G.**, PO559-WED, PO564-WED  
**Hong W.**, OR101, OR388  
**Hong Z.**, AS146  
**Hongjie W.**, PO129-TUE  
**Honickel M.**, OR067, PO314-TUE  
**Höning K.**, PO631-MON, PO637-MON  
**Hood K.**, OR130

**Hoorfar H.**, PO649-MON  
**Hoortje J.**, PO056-MON  
**Hooton L.**, PO601-MON  
**Hopkinson W.**, PO211-MON, PO212-MON, PO112-WED, PO331-WED  
**Hopman M.**, PO468-TUE  
**Hopman W.**, PO646-MON, PO227-TUE  
**Hoppensteadt D.**, PO182-MON, PO211-MON, PO212-MON, PO291-MON, PO293-MON, PO303-MON, PO305-MON, PO334-MON, PO346-MON, PO053-TUE, PO191-TUE, PO192-TUE, PO337-TUE, PO053-WED, PO112-WED, PO331-WED, PO332-WED, PO344-WED, PO374-WED, PO402-WED  
**Hor K.**, AS160  
**Hord E.**, PO076-WED  
**Hord J.**, PO238-MON  
**Horellou M.-H.**, AS164  
**Horellou M. H.**, PO544-TUE  
**Horellou M.-H.**, OR032, OR055  
**Horemans H.**, PO267-MON  
**Hori A.**, PO661-TUE  
**Hori T.**, PO058-WED  
**Horiuchi H.**, PO653-TUE  
**Horiuchi T.**, PO386-WED  
**Horling F.**, PO249-MON, PO284-WED  
**Horman S.**, PO101-WED  
**Hörmann N.**, PO397-MON  
**Horn C.**, PO089-TUE, PO194-WED  
**Horn E.**, PO007-WED  
**Horneff S.**, PO219-TUE, PO532-WED  
**Horner K.**, PO313-WED  
**Hornung V.**, PO631-MON, PO637-MON  
**Horsuwan S.**, PO319-WED  
**Horvat I.**, PO436-TUE  
**Horvei L.**, PO524-MON, PO525-MON, PO567-WED  
**Horvei L. D.**, AS046, PO636-WED  
**Hoshi O.**, PO186-TUE  
**Hosokawa K.**, PO661-MON  
**Hosokawa K.**, PO666-MON, PO668-MON, PO399-TUE, PO347-WED, PO477-WED  
**Hostinska E.**, PO564-MON  
**Ho-Tin-Noé B.**, OR170, PO330-MON  
**Hotta A.**, PO205-WED  
**Hou D.**, PO292-WED  
**Hou M.**, AS074, OR138  
**Hou Y.**, AS168, OR041

**Hou Y.**, AS074, OR138, OR261, PO319-MON  
**Hough C.**, AS191, AS192, OR122  
**Houlahan K.**, PO458-MON  
**Houppert B.**, PO031-TUE  
**Houskova K.**, PO224-WED  
**Hovens M.**, PO587-TUE  
**Hovens M.**, OR257  
**Howard L.**, OR074  
**Howard M.**, PO007-WED  
**Howard Leong-Poi H. X.**, OR031  
**Howell M.**, PO601-WED  
**Hoxer C.**, OR349, PO138-TUE, PO139-TUE  
**Hoylaerts M.**, AS009, AS176, PO462-WED  
**Hoylaerts M.**, AS113  
**Hoylaerts M.**, OR418  
**Hoyt C.**, PO038-WED  
**Hrachovinova I.**, OR152, PO224-WED, PO601-WED  
**Hsieh H.-W.**, PO031-MON  
**Hsieh P.-W.**, OR344  
**Hsu Y.-C.**, PO029-MON  
**Hsu C.-C.**, PO059-MON, PO017-TUE, PO079-WED  
**Hsu F.**, PO502-MON, PO521-WED  
**Hsu Y.-C.**, PO050-WED  
**Hu B.**, PO162-MON, PO132-TUE, PO569-WED  
**Hu G.**, PO166-MON  
**Hu H.**, OR279  
**Hu J.**, PO222-WED  
**Hu L.**, PO409-MON  
**Hu M.**, OR279  
**Hu S.**, AS026  
**Hu Y.**, PO111-MON, PO132-MON, PO162-MON, PO177-MON, PO179-MON, PO132-TUE, PO132-TUE, PO492-TUE, PO292-WED, PO569-WED, PO581-WED  
**Hu Z.**, OR039  
**Hua F.**, PO512-TUE, PO116-WED, PO266-WED  
**Hua M.**, OR185  
**Hua Y.**, PO168-MON, PO169-MON  
**Huang C.-Y.**, PO226-TUE  
**Huang Y.-J.**, PO050-WED  
**Huang T.-F.**, PO059-MON  
**Huang A.**, PO094-TUE  
**Huang C.**, OR419  
**Huang J.**, OR018  
**Huang L.**, AS087  
**Huang L.**, PO022-MON  
**Huang M.**, AS146, OR417, PO425-MON

## Authors Index

Huang Q., OR279  
Huang T.-F., PO017-TUE, PO079-WED  
Huang W., OR395, PO578-TUE  
Huang X.-P., PO522-TUE  
Huang Z., PO009-MON, PO013-MON, PO015-MON  
Huard F., PO116-WED  
Huarng M., OR039  
Huart J., PO396-TUE  
Huber K., AS200, OR123, PO185-MON, PO559-MON, PO030-TUE, PO301-TUE, PO509-TUE  
Hubert A., PO102-WED  
Hubler F., PO022-TUE  
Hudák R., PO124-MON, PO488-WED  
Hugenholtz G., OR070  
Hughes A., PO600-MON, PO601-MON, PO582-TUE  
Hughes C., PO007-WED  
Hughes C., OR276, PO415-MON  
Hughes C., OR183  
Hughes K., PO675-TUE  
Hughes Q., PO324-TUE, PO540-WED, PO546-WED  
Hugman A., PO374-TUE  
Hugon-Rodin J., OR032, PO527-MON  
Huh J.-H., PO267-TUE  
Huhtala H., PO304-MON  
Hui D., PO172-MON  
Hui J., PO529-MON, PO504-TUE  
Hui S.-K., OR056, PO631-TUE  
Hui Z., PO102-MON  
Huish-Williams S., OR445  
Huisman A., PO272-MON  
Huisman M., PO596-MON, PO587-TUE, PO619-WED  
Huisman M., OR191, OR257, PO597-MON, PO100-TUE, PO651-WED  
Huisse M.-G., PO080-WED  
Huiyuan L., AS075, OR136, OR264, PO320-MON, PO276-TUE, PO566-TUE  
Huk I., PO559-MON  
Hunker K., AS090  
Hunt A., PO229-WED  
Hunt B., OR092, PO120-MON, PO121-MON, PO603-MON  
Hunt B., PO046-MON  
Hunt B., PO045-MON, PO578-WED  
Hunter E., AS065  
Hunter R., NUR014  
Hurják B., PO530-MON

Huskens D., OR301, PO089-MON, PO143-MON, PO072-TUE  
Hussain A., PO549-TUE, PO181-WED  
Husseinzadeh H., PO405-TUE  
Husted S., PO051-TUE  
Huston H., OR298  
Hutabarat R., OR213  
Hutchinson J., OR272  
Huth-Kuehne A., PO215-TUE  
Hutten B., PO611-MON  
Hutten B., AS021, PO164-WED  
Huveneers S., AS118  
Huynh K., PO456-WED  
Huynh K., PO394-MON, PO448-WED  
Hvas A.-M., PO090-MON, PO394-TUE, PO406-TUE, PO407-TUE, PO115-WED, PO119-WED, PO121-WED, PO124-WED, PO131-WED, PO495-WED  
Hvas C., PO124-WED  
Hvilsted Olsen O., OR414  
Hwa J., PO673-MON  
Hwang H. G., PO628-MON  
Hwang S., PO461-TUE  
Hwei Khien L., PO421-WED  
Hylek E., PO657-WED  
Hylek E., PO619-TUE  
Hynes R., AS168  
Hyun S. Y., PO164-TUE  
Iacobelli M., PO374-WED  
Iannaccaro P., PO352-TUE, PO399-WED, PO400-WED  
Iannuccelli C., PO084-WED  
Ibarra G., PO585-MON  
Ibberson M., AS128, OR397  
Ibrahim M., OR324  
Ibrahim F., AS164  
Icheva V., PO667-WED  
Ichinose A., OR250  
Ichinose C., PO432-WED  
Ichinose S., PO186-TUE  
Ieko M., PO041-MON, PO357-MON, PO020-WED, PO057-WED  
Ieraci A., PO005-TUE  
Ieranó P., PO534-TUE  
Ieven M., PO221-MON  
Iftikhar O., PO508-TUE  
Igai A., PO508-MON, PO476-TUE  
Iglesias M. J., PO559-WED, PO564-WED  
Iglesias T., PO010-WED  
Ignatova A., PO569-MON  
Ignjatovic V., AS105, OR224, PO087-MON, PO449-MON, PO427-TUE  
Iheanacho O., PO334-TUE

Ijsseldijk M., AS189  
Ikeda K., OR051  
Ikeda Y., PO386-WED  
Ikemoto K., PO432-WED  
Ikesaka R., PO467-MON, PO473-MON  
Ikram M., AS181, OR364  
Ikuma Y., PO173-TUE  
Hutchinson J., OR320  
Iliardi M., PO004-TUE  
Ilkjaer S., PO115-WED  
Illi M., AS016  
Imagawa A., OR352, PO351-MON  
Imai M., PO216-MON  
Imamura M., OR142  
Imazu S., OR320  
Immaculada C., PO444-TUE  
Inaba H., PO161-MON, PO213-TUE, PO006-WED, PO204-WED  
Incampo F., OR065, PO503-MON  
Ince D., OR262  
Indalecio A., PO156-MON, PO157-MON  
Ing M., PO226-WED, PO228-WED, PO230-WED  
Ingelsson E., PO564-WED  
Ingratti M., PO629-MON  
Ingratti M., PO039-MON  
Inoue K., PO505-TUE  
Inoue O., OR242, OR343, PO419-MON  
Intharapetch P., PO001-MON, PO080-MON  
Iori I., OR197  
Iorio A., AS122, OR144, PO170-MON, PO171-MON, PO261-MON, PO262-MON, PO276-MON, PO662-MON, PO138-TUE, PO162-TUE  
Iosava G., PO206-TUE, PO262-TUE, PO249-WED  
Iosova G., PO629-TUE  
Iosub D., PO103-TUE  
Iotti M., PO602-MON  
Ippel H., PO037-TUE  
Iqbal A., PO420-WED  
Iqbal O., PO293-MON, PO303-MON, PO053-TUE, PO191-TUE, PO192-TUE, PO112-WED, PO331-WED, PO344-WED, PO402-WED  
Irsvt Study Investigators , AS195, PO614-MON, PO611-TUE  
Irwin J., PO380-MON  
Isabel T., PO444-TUE  
Isaji S., PO486-WED  
Isaksen T., OR258, PO472-MON, PO609-MON, PO610-MON, PO612-MON

## Authors Index

Isenberg D., PO044-MON, PO046-MON  
Isermann B., PO129-TUE  
Isguzar G., PO591-TUE  
Ishigaki K., PO399-MON  
Ishikawa T., PO224-TUE  
Ishola T., PO445-MON  
Isik Balci Y., PO143-TUE, PO158-TUE  
Ismail A., OR413  
Isola H., PO572-MON  
Isonishi A., PO672-TUE, PO040-WED  
Isordia I., PO023-TUE  
Isordia-Salas I., PO020-MON, PO073-MON, PO523-TUE  
Israel-Biet D., AS087  
Israels S., PO410-MON, PO408-TUE  
Israels S., PO388-TUE  
Israels S., OR223, PO390-TUE  
Israels S., PO465-MON  
Itakura A., PO297-TUE, PO543-WED  
Italiano J., OR085, OR232, PO380-WED  
Ito A., PO020-WED  
Ito B., OR354  
Ito T., PO399-TUE  
Ito Y., AS145, PO203-MON  
Ivanov I., OR288  
Ivanov I., OR287  
Ivanova A., PO496-MON  
Ivanova E., PO213-MON  
Ivarsson S., PO232-TUE  
Ivaskevicius V., PO674-MON, PO532-WED  
Ivaskevicius V., PO182-WED, PO184-WED  
Iversen N., OR440, PO109-MON, PO118-MON, PO123-MON, PO177-WED, PO178-WED  
Ivlev D., PO460-TUE  
Ivy S. P., OR127  
Iwaki S., PO183-MON  
Iwakiri T., PO552-MON  
Iwaniec T., PO048-MON, PO074-MON, PO500-TUE, PO069-WED, PO070-WED  
Iwase H., PO306-MON  
Iwata M., PO173-TUE  
Iyengar S., PO363-TUE  
Iyer J., OR367, PO341-TUE  
Iyu D., PO435-WED, PO497-WED  
Izaguirre Avila R., PO138-WED  
Izsvak Z., OR155  
Izsvák Z., OR087  
Izumitani T., AS126

Izzi B., PO462-WED  
J. Engbers M., PO565-WED  
J. M. Van Vlijmen B., PO548-WED  
Jaax M., AS008  
Jaber S., PO035-WED  
Jäckel S., PO397-MON, PO099-WED  
Jackowski M., PO035-MON  
Jackson C., PO099-TUE  
Jackson C., PO188-TUE, PO096-WED  
Jackson E., PO410-MON  
Jackson S., AS122, OR013, PO235-MON, PO262-MON, PO440-TUE, PO269-WED  
Jackson S., AS055, OR380, PO443-WED  
Jackson S., OR037, PO332-MON  
Jacobi P., PO361-MON, PO667-MON  
Jacobs I., OR346, OR347, OR350, PO253-WED  
Jacobsen A., PO478-MON, PO295-TUE  
Jacobsen E.-M., PO379-TUE  
Jacobsen S., PO045-MON  
Jacobson B., OR096, OR119  
Jacobson L., PO103-MON, PO662-WED  
Jacquemin M., PO186-MON, PO364-MON, PO142-TUE  
Jaeken J., AS187  
Jaffer I., OR057  
Jaffray J., OR156, PO439-TUE  
Jagadeeswaran P., OR236, OR402, PO034-MON  
Jahren-Dechent W., OR286  
Jaimes Albornoz D., PO439-MON  
Jain D., PO389-MON  
Jain K., OR356  
Jain S., PO200-MON  
Jakubowski J., PO015-TUE  
Jalagadugula G., AS125  
Jalagadugula G., AS067  
Jallu V., PO568-MON, PO575-MON  
Jamaly S., PO338-MON, PO328-TUE, PO396-WED, PO572-WED  
James A., AS162  
James C., PO416-TUE  
James I., PO540-WED  
James P., AS122, OR023, OR086, AS076, PO262-MON, PO670-MON, PO678-MON, PO227-TUE, PO679-TUE, PO252-WED  
James P., OR409, PO646-MON, PO426-TUE  
Jamil A., PO202-WED  
Jan H. G., PO478-TUE

Janas M. S., AS214  
Janas M. S., AS081, OR228  
Janata-Schwartzek K., PO612-WED  
Jandrot-Perrus M., PO079.1-MON, OR170, OR420, OR422, PO222-MON, PO330-MON, PO080-WED  
Jang H. G., PO475-TUE, PO531-TUE, PO168-WED  
Jang S., PO071-WED, PO427-WED  
Jani D., PO208-TUE  
Janic D., PO251-WED  
Jänicke F., PO174-WED  
Jankovicova D., PO249-TUE, PO371-TUE, PO022-WED, PO061-WED  
Jankowski V., PO465-TUE  
Jansen M., OR124, PO287-TUE, PO442-WED  
Jansen M., PO258-MON, PO250-TUE  
Jansen P., PO513-WED  
Jansen S., PO384-WED  
Janssens M., PO255-TUE  
Janssens S., AS176  
Janus N., PO632-WED  
Janzen L., PO413-TUE  
Jarchum G., PO632-TUE, PO640-TUE  
Jardim L., PO034-WED  
Järnberg I., PO195-MON  
Jarner M. F., AS081, AS214  
Jarner M. F., OR228  
Jaron-Mendelson M., PO048-WED  
Jarvis A., AS143, PO662-WED  
Jarvis S., PO387-TUE  
Jaimes Albornoz D., PO439-MON  
Jain D., PO389-MON  
Jain K., OR356  
Jain S., PO200-MON  
Jakubowski J., PO015-TUE  
Jalagadugula G., AS125  
Jalagadugula G., AS067  
Jallu V., PO568-MON, PO575-MON  
Jamaly S., PO338-MON, PO328-TUE, PO396-WED, PO572-WED  
James A., AS162  
James C., PO416-TUE  
James I., PO540-WED  
James P., AS122, OR023, OR086, AS076, PO262-MON, PO670-MON, PO678-MON, PO227-TUE, PO679-TUE, PO252-WED  
James P., OR409, PO646-MON, PO426-TUE  
Jamil A., PO202-WED  
Jan H. G., PO478-TUE

## Authors Index

Jennings I., OR285, OR429, PO095-MON, PO500-MON, PO087-TUE, PO643-TUE, PO524-WED  
Jennings K., PO600-MON, PO582-TUE  
Jennings L., PO174-TUE, PO076-WED  
Jennings M., PO145-MON  
Jenny L., PO303-TUE, PO186-WED  
Jenny N., OR133  
Jensen M., PO219-WED  
Jensvoll H., AS083, OR129, OR293, OR345, OR393, PO526-MON, PO104-TUE, PO111-TUE, PO112-TUE, PO495-TUE, PO568-WED  
Jeon Y. J., PO168-WED  
Jeppesen A., PO115-WED  
Jeppesen A., PO090-MON  
Jeppsson A., PO362-WED  
Jerjes-Sanchez C., OR119  
Jern S., OR380  
Jesel L., AS039  
Jeske W., OR173, PO291-MON, PO303-MON, PO305-MON, PO334-MON, PO346-MON, PO339-WED, PO411-WED  
Jesmin S., PO178-MON  
Jessup P., AS051  
Jesus J., PO158-WED  
Jetsrisuparb A., PO120-TUE  
Jiang H., AS192, OR107  
Jiang H., OR018  
Jiang H., AS090  
Jiang L., PO195-TUE  
Jiang M., OR117  
Jiang Q., PO419-WED  
Jiang W., PO176-TUE  
Jiang Z., OR164  
Jiaqian Q., PO394-WED  
Jie W., PO113-TUE  
Jilma B., PO282-TUE, PO391-TUE, PO612-WED  
Jilma P., PO391-TUE  
Jimenez D., OR074, OR321, PO469-MON, PO576-TUE  
Jiménez D., PO488-TUE  
Jiménez T., PO523-WED  
Jiménez-Alcázar M., OR193, PO583-MON  
Jiménez-Alvarado R. M., PO073-MON, PO523-TUE  
Jiménez-Yuste V., PO250-MON  
Jin J., PO429-WED  
Jin M., OR362, PO588-MON  
Jin P., PO176-TUE  
Jin X., PO545-MON

Jin Y., PO555-WED  
Jing W., OR342  
Jipa L., PO501-TUE  
Jirungda S., PO080-MON  
Jo D., OR426  
Jo Y. A., PO471-TUE, PO309-WED  
Jobic L., PO128-WED  
Jochmans K., OR079, PO668-TUE  
Johansen P., PO147-MON  
Johnsen J., OR298  
Johnson A., OR200  
Johnson A., OR209  
Johnson A., OR433, OR444  
Johnson B., AS054, AS011  
Johnson B., OR342  
Johnson K., PO380-WED  
Johnson S., PO589-MON  
Johnston E., PO623-WED, PO635-WED  
Jokela V., PO234-MON  
Joly A., PO396-TUE  
Joly B., PO520-MON  
Jonassen C., PO311-MON  
Jonelid B., OR312  
Jones C., PO398-MON  
Jones D., PO464-WED  
Jones R., PO087-TUE  
Jones R., OR285  
Jones S., PO607-MON, PO596-TUE  
Jonkers G., OR257  
Joore M., PO471-MON  
Jordana Sanchez M. D. M., OR197  
Jordi F., PO444-TUE  
Jordi L.-P., PO444-TUE  
Jorgensen L., OR230  
Jorieux S., PO457-TUE  
Jörneskog G., PO530-TUE  
Jorquera J. I., PO207-WED  
Jorritsma J., PO324-TUE, PO546-WED  
Jose M., PO444-TUE  
Jose S. P., PO077-TUE  
Joseph J., PO374-TUE  
Joseph J., PO387-TUE  
Josephson C., AS051  
Josephson N., PO248-MON  
Joshi N., OR375, OR434  
Joshi R., PO026-TUE  
Joung J. K., OR039  
Jouni R., OR307, PO413-TUE  
Jouppila A., PO234-MON, PO081-WED  
Jourdi G., PO350-TUE  
Jourdy Y., PO198-WED

Joustra R., PO614-TUE  
Joutsu-Korhonen L., PO363-MON  
Jowett S., PO019-TUE  
Ju A., OR037  
Ju L., AS055  
Juan Carlos S., PO444-TUE  
Jude B., AS201, OR219, PO662-TUE  
Judge H., OR016  
Judicone C., OR311, OR315, PO337-MON  
Juffermans N., OR124  
Jugder B.-E., PO072-WED  
Juillère Y., PO546-TUE  
Junen J., PO191-WED  
Jung S., PO441-WED  
Jurak Begonja A., OR233  
Juriši M., PO218-TUE  
Jurk K., PO397-MON, PO427-MON, PO419-TUE, PO483-WED  
Jurus C., AS137  
Jusabani A., PO063-WED  
Justo F., PO034-TUE, PO095-WED  
Jutavijittum P., PO275-TUE  
Juthier F., AS201, OR219, PO662-TUE  
Kaaja R., PO652-WED  
Kaandorp S., AS021  
Kaasjager K., AS197, OR292  
Kaasjager K., PO597-MON  
Kaatz S., AS077, PO623-TUE, PO419-WED  
Kablaoui N., PO004-TUE  
Kabrhel C., OR266  
Kabukcu Basay B., PO143-TUE  
Kabukcu Basay B., PO158-TUE  
Kabutomori O., PO320-WED  
Kaczor M., PO069-WED, PO070-WED  
Kaczor M., PO048-MON  
Kadegasem P., PO275-WED  
Kadir R., PO175-TUE  
Kadir R., PO481-TUE  
Kagami Y., PO434-MON  
Kagdi H., PO486-MON  
Kahlon P., PO650-WED  
Kahn C. R., PO329-MON  
Kahn D., PO293-MON, PO303-MON, PO337-TUE, PO374-WED  
Kahn M., OR111  
Kahn S., AS077, AS137, OR072, OR327, PO467-MON, PO473-MON, PO647-WED  
Kahn S., AS139  
Kahr W., OR159  
Kahr W., AS078, PO403-MON, PO506-MON, PO379-WED

## Authors Index

Kahr W., OR235  
Kahr W., PO545-TUE  
Kanno N., AS010  
Kaider A., PO077-WED, PO166-WED  
Kaiser K., PO383-WED  
Kajornkijaroen A., PO675-MON  
Kakkar A., PO301-MON  
Kakkar A., OR436, PO378-TUE  
Kakkar A., OR096, OR119, PO646-WED  
Kakkar V., AS025, AS232, AS202, OR006, PO098-WED  
Kakkar V., AS027, OR008, OR010, PO082-MON, PO083-MON  
Kalaska B., PO300-MON, PO345-WED, PO365-WED  
Kalayci T., PO265-MON  
Kalf A., OR229  
Kalina U., PO089-TUE  
Kallner A., PO195-MON  
Kalmns W., PO269-MON, PO305-WED  
Kamali F., OR099  
Kamali-Moghaddam M., PO330-TUE  
Kamei M., OR051  
Kamel S., AS212  
Kaminski K., PO300-MON, PO345-WED, PO365-WED  
Kaminsky P., OR186  
Kamisato C., PO353-MON, PO458-TUE  
Kamiya N., PO088-TUE  
Kammer M., OR226, PO298-TUE  
Kammlander W., PO209-WED  
Kamphuisen P., AS195, OR195, PO626-MON  
Kamphuisen P., PO596-MON, PO587-TUE, PO624-WED  
Kamphuisen P., AS197, OR191, OR292, PO100-TUE  
Kamphuisen P., PO597-MON, PO598-MON  
Kamphuisen P. W., AS081, AS214, OR228  
Kamphuisen P. W., PO164-WED  
Kamphuisen P.-W., PO611-MON, PO335-WED  
Kampmann P., PO482-MON  
Kamstrup P., OR270  
Kanakra Y., OR340, PO320-WED  
Kanaumi Y., AS107  
Kandula Z., PO170-WED  
Kaneko M., PO061-TUE  
Kanematsu T., PO434-MON  
Kang S., PO115-MON  
Kang S.-B., PO119-TUE

Kanjanapongkul S., PO540-TUE  
Kannicht C., PO675-TUE  
Kanno N., PO061-TUE  
Kano T., PO661-TUE, PO670-TUE, PO432-WED  
Kanse S., PO109-MON, PO510-TUE  
Kanse S., AS218  
Kao M.-L., PO430-WED  
Kaouther Z., PO281-WED  
Kapelushmik J., PO429-TUE  
Kaplan D., PO604-MON  
Kaplan S. T., PO088-WED  
Kaplan Z., PO443-WED  
Káplár M., PO482-WED  
Kaplinsky C., PO475-WED  
Kapocsi J., PO266-WED  
Kapoor A., PO657-WED  
Kappelmayer J., PO077-MON, PO124-MON, PO482-WED, PO488-WED  
Kappert G., PO480-TUE  
Kapsimali Z., PO437-TUE  
Kapubagli N., PO158-TUE  
Kapur R., OR139, PO302-TUE  
Kapustin S., PO503-TUE, PO576-WED  
Kara A., PO197-MON  
Karabis A., PO656-WED  
Karagün B., PO530-WED  
Karagun B., PO254-TUE, PO301-WED, PO302-WED  
Karakukcu M., PO490-TUE, PO008-WED  
Karaman K., PO310-MON  
Karan C., PO408-WED  
Karapinar D., PO630-TUE  
Karapinar T., PO590-MON  
Karapinar T. H., OR262  
Karasu A., OR391, PO565-WED  
Karcz A., PO657-WED  
Kare M., PO587-TUE  
Kåresen R., PO177-WED, PO178-WED  
Kargin V., PO503-TUE  
Karim F., OR348, PO310-WED  
Karim F., PO541-MON  
Karim F. A., PO253-WED  
Karim F. A., PO149-MON  
Karimi M., PO164-MON, PO490-MON, PO649-MON, PO198-TUE  
Karkowski G., PO625-TUE  
Karlsson J., PO219-WED  
Karnaukhova E., PO196-WED  
Karner P., PO170-MON, PO171-MON  
Karpf D., PO219-WED  
Karpa I., PO578-MON

Karpova O., PO569-MON  
Karroum A., PO116-MON  
Kartvelishvili K., PO585-WED  
Karuturi R., PO306-MON  
Kashiwagi H., OR340, PO320-WED  
Kaspereit F., OR316, PO312-TUE, PO418-WED  
Kaspi E., OR315  
Kassam I., AS045, AS206  
Kassif Y., PO217-TUE  
Kassim N., PO196-MON  
Kassouf N., PO511-TUE  
Kastelowitz N., AS143  
Kasti S., PO185-MON  
Kastrup C., PO421-MON, PO460-WED  
Kastrup C., PO372-WED  
Kastrup C., PO375-WED  
Katayama N., PO486-WED  
Katholing A., AS084, OR294, PO124-TUE  
Kato C., PO491-WED  
Kato H., PO173-TUE  
Kato H., OR340, PO320-WED  
Katona É., PO224-MON, PO530-MON, PO031-WED, PO187-WED  
Katrii T., PO382-TUE  
Katrukha A., PO197-MON  
Katsarou O., PO169-WED  
Katz E., OR259  
Katz T., PO335-MON  
Kaul I., PO337-TUE  
Kaun C., AS200, OR123, PO185-MON, PO559-MON, PO509-TUE  
Kaur H., OR337, PO180-WED, PO519-WED  
Kaur H., PO074-TUE  
Kauser K., PO026-MON, PO212-WED, PO213-WED, PO555-WED  
Kauskot A., AS176, OR205, OR234, OR403, OR418  
Kautbally S., PO101-WED  
Kavakli K., AS122, PO257-MON, PO262-MON, PO266-MON, PO237-TUE, PO238-TUE, PO630-TUE, PO649-TUE, PO293-WED  
Kavakli K., OR144  
Kavardakova N., PO250-TUE  
Kaveri S., PO228-WED, PO230-WED  
Kaveri S., PO226-WED  
Kavousi M., AS181, OR364  
Kavtaradze G., PO337-WED  
Kawabata K., OR352, PO351-MON  
Kawaguchi M., PO671-MON  
Kawai T., AS107



## Authors Index

**Kawamoto E.**, PO185-TUE  
**Kawamura S.**, AS107  
**Kawasaki T.**, PO120-WED  
**Kawashima A.**, PO477-WED  
**Kawasugi K.**, PO380-TUE  
**Kawecki C.**, PO457-WED  
**Kay S.**, PO268-TUE  
**Kaya Z.**, PO143-WED  
**Kayani G.**, OR096, OR119  
**Kay-Jones C.**, PO578-MON  
**Kazancı E.**, PO143-TUE  
**Kazanecka B.**, PO311-WED  
**Kazankova A.**, PO509-WED  
**Kazerouni A.**, PO375-WED  
**Kazimer D.**, PO392-MON  
**Kazimirova M.**, OR367  
**Kearney K.**, AS231  
**Kearney M.**, PO190-WED  
**Kearney S.**, OR349  
**Kearon C.**, AS077, PO378-TUE, PO646-WED  
**Kechele D.**, PO423-MON  
**Kedia N.**, PO098-TUE  
**Keeling D.**, AS077, PO653-MON  
**Keenan C.**, PO280-MON  
**Keenan R.**, OR013  
**Keener J. M.**, PO038-WED  
**Keeney M.**, PO006-MON  
**Kehrel B.**, PO163-MON, PO218-WED, PO234-WED  
**Kehrel B.**, PO157-TUE  
**Kehrel B.**, PO015-TUE, PO395-TUE  
**Keil R.**, OR047  
**Keith H.**, AS050  
**Keith H.**, PO576-MON  
**Kelahmetoglu O.**, PO051-WED  
**Kelchtermans H.**, AS105, OR301, PO025-MON, PO672-MON, PO072-TUE  
**Kelkar A.**, PO176-MON  
**Kelkar A.**, AS063, OR334  
**Keller C.**, PO426-WED  
**Kellermann E.**, PO274-WED  
**Kellici T.**, PO452-WED  
**Kelly L.**, PO310-TUE  
**Kelly M.**, PO432-MON  
**Kelsch R.**, PO015-TUE  
**Kemball-Cook G.**, PO676-WED  
**Kemkes-Matthes B.**, PO647-MON  
**Kempe K.**, PO014-TUE  
**Kempfer A.**, PO003-MON, PO004-MON, PO005-MON, PO634-TUE, PO636-TUE, PO646-TUE, PO652-TUE, PO042-WED  
**Kempton C.**, PO248-MON, PO277-MON, PO297-WED, PO298-WED  
**Kempton C.**, OR101, AS220, PO251-WED  
**Kenet G.**, OR141  
**Kenet G.**, AS104, OR346, PO062-TUE, PO217-TUE, PO285-TUE, PO429-TUE, PO659-TUE, PO225-WED, PO274-WED, PO475-WED, PO506-WED  
**Kennedy D.**, PO450-WED  
**Kenny D.**, PO676-TUE, PO075-WED  
**Kepa S.**, PO236-TUE, PO528-WED  
**Kerényi A.**, PO077-MON, PO031-WED  
**Kerguelen A.**, PO487-TUE  
**Kerlin B.**, OR157  
**Kerlin B.**, PO571-WED  
**Kerlin B.**, PO237-MON  
**Kerr B.**, AS093  
**Kerrigan S.**, OR043  
**Kerrigan S.**, AS005  
**Keskindemirci G.**, PO315-MON, PO279-WED  
**Keskindemirci G.**, PO313-MON  
**Kessler C.**, PO248-MON, PO277-MON, PO664-MON  
**Kessler C.**, PO294-WED  
**Kessler P.**, PO128-TUE  
**Kestenbaum B.**, OR133  
**Ketatni H.**, PO473-TUE, PO587-WED  
**Kevane B.**, OR218  
**Key N.**, PO248-MON  
**Key N.**, AS049, OR306  
**Khachatryan A.**, PO642-MON  
**Khadour A.**, OR307  
**Khadwal A.**, PO200-MON  
**Khair K.**, PO662-MON, PO253-TUE, PO286-WED  
**Khalil E.**, PO133-WED  
**Khamashta M.**, OR092, PO046-MON, PO068-WED  
**Khan A.**, PO088-MON  
**Khan M.**, PO324-MON  
**Khan M.**, PO406-WED  
**Khan M.**, PO639-WED  
**Khan N.**, PO174-MON  
**Khan S.**, PO384-MON  
**Khandagale A.**, PO099-WED  
**Khandekar G.**, OR236, PO034-MON  
**Khartechi A.**, PO292-MON  
**Khaspekova S.**, PO327-TUE  
**Khaterchi A.**, PO116-MON  
**Khatlani T.**, OR277  
**Khayat C.**, PO206-TUE, PO629-TUE, PO249-WED

**Khizroeva J.**, PO052-MON, PO589-WED  
**Khorana A. A.**, AS081, AS214, OR228  
**Khorsand N.**, PO363-WED  
**Kicken C.**, PO546-MON  
**Kiefer F.**, AS092, OR416  
**Kieler H.**, OR269  
**Kiemenev L.**, OR203, PO680-TUE  
**Kieper-Rupp I.**, PO066-TUE  
**Kijrattanakul P.**, PO606-TUE  
**Kilicoglu O.**, PO295-WED  
**Kilinc Y.**, PO254-TUE, PO301-WED, PO302-WED, PO530-WED  
**Kim B. H.**, PO071-WED, PO427-WED  
**Kim D.-S.**, PO461-TUE  
**Kim D.-W.**, PO119-TUE  
**Kim H.-J.**, PO599-TUE  
**Kim H. K.**, PO036-MON  
**Kim I.**, PO115-MON, PO035-TUE, PO599-TUE, PO659-WED  
**Kim J. H.**, PO119-TUE, PO489-TUE  
**Kim J. H.**, PO478-TUE  
**Kim J. Y.**, PO164-TUE, PO280-TUE  
**Kim J. W.**, PO119-TUE, PO489-TUE  
**Kim J.-W.**, PO035-TUE  
**Kim J. E.**, PO280-TUE  
**Kim J. O.**, PO475-TUE, PO478-TUE, PO531-TUE, PO168-WED  
**Kim K.**, PO115-MON  
**Kim K. H.**, PO035-TUE  
**Kim K.-H.**, PO659-WED  
**Kim K.**, PO461-TUE  
**Kim M. K.**, PO209-TUE  
**Kim M.-K.**, PO278-WED  
**Kim M. S.**, PO628-MON  
**Kim N. K.**, PO475-TUE, PO478-TUE, PO531-TUE, PO168-WED  
**Kim O. J.**, PO531-TUE  
**Kim P.**, OR302, PO130-TUE  
**Kim P.**, OR442  
**Kim R.**, PO364-TUE  
**Kim S. H.**, PO489-TUE  
**Kim S.**, OR115, OR184  
**Kim S.**, PO429-WED  
**Kim T. H.**, PO209-TUE  
**Kim U. H.**, PO164-TUE, PO280-TUE  
**Kim Y. J.**, PO119-TUE, PO489-TUE  
**Kimpton M.**, PO101-TUE  
**Kimura T.**, PO653-TUE  
**Kindzelski A.**, PO096-TUE  
**King J.**, PO315-WED

## Authors Index

**King M.**, PO098-TUE  
**King M.**, PO110-MON  
**King R.**, AS231, OR398, PO465-TUE  
**Kini M.**, OR367, PO341-TUE  
**Kini M.**, OR147  
**Kini R. M.**, PO336-TUE  
**Kiouptsi K.**, PO397-MON  
**Kircher M.**, OR298  
**Kirchhofer D.**, OR048  
**Kirchmaier C.**, PO248-TUE, PO420-TUE  
**Kirgner I.**, PO268-TUE, PO271-TUE  
**Kirienko A.**, PO199-MON  
**Kirk S.**, PO445-MON  
**Kirkby N.**, OR341  
**Kirkegaard H.**, PO090-MON, PO115-WED  
**Kirti F.**, PO585-MON, PO265-TUE  
**Kiseleva E.**, PO281-TUE  
**Kishi K.**, OR051  
**Kishimoto M.**, PO434-MON  
**Kishor K.**, PO480-MON  
**Kiss A.**, OR328, PO475-MON  
**Kiss A.**, PO087-WED  
**Kistanova E.**, OR415  
**Kitagawa K.**, PO477-WED  
**Kitazawa J.-I.**, PO151-MON  
**Kitazawa T.**, PO491-MON, PO165-TUE  
**Kitchen D.**, OR429, PO087-TUE  
**Kitchen D.**, OR285, PO643-TUE  
**Kitchen D.**, PO095-MON  
**Kitchen S.**, OR429, PO087-TUE, PO136-WED, PO141-WED  
**Kitchen S.**, OR285, PO095-MON, PO201-MON, PO500-MON, PO058-TUE, PO085-TUE, PO643-TUE, PO313-WED, PO524-WED  
**Kitching G.**, PO580-TUE  
**Kitpoka P.**, PO540-TUE  
**Kittelson J.**, OR222, PO103-MON  
**Kittoo K.**, NUR008  
**Kiyoi H.**, PO434-MON  
**Kiyokawa T.**, PO320-WED  
**Kizlik-Masson C.**, AS108  
**Kjær B.**, PO455-TUE, PO541-WED  
**Kjalke M.**, OR110, OR414, PO147-TUE, PO219-WED  
**Kjelgaard-Hansen M.**, PO141-TUE, PO285-WED  
**Klaassen I.**, OR158  
**Klaassen R.**, PO426-TUE

**Klamroth R.**, OR013, PO259-MON, PO195-WED, PO234-WED, PO272-WED, PO274-WED, PO283-WED, PO291-WED  
**Klein M.**, PO451-WED  
**Kleine E.**, OR283  
**Kleinegris M.-C.**, PO004-WED, PO092-WED  
**Kleinjan A.**, AS197, OR292, PO103-TUE, PO624-WED  
**Kleinschnitz C.**, OR114, PO177-TUE, PO517-TUE  
**Klem P.**, PO356-MON, PO622-MON  
**Klersy C.**, PO483-MON, PO473-WED  
**Klil-Drori A.**, OR385  
**Kline J.**, PO227-MON  
**Kline J.**, OR194, PO202-MON, PO490-WED  
**Kline J.**, PO033-MON  
**Kline J.**, OR376, PO627-WED  
**Kline J.**, PO469-MON  
**Kline-Rogers E.**, PO623-TUE, PO419-WED  
**Klinkert E.**, PO346-WED  
**Klok F.**, PO596-MON  
**Klok F.**, OR191, OR257, PO619-WED, PO651-WED  
**Kloots I.**, OR203, PO680-TUE  
**Klostermeier U.**, PO506-WED  
**Kløy N.-E.**, AS136  
**Kluft C.**, PO070-TUE, PO469-TUE, PO550-WED, PO592-WED  
**Kluin-Nelemans H.**, OR100, PO346-WED  
**Klukowska A.**, PO258-MON, PO279-MON, PO643-MON, PO650-MON, PO574-WED, PO575-WED  
**Klute K.**, AS165, PO307-WED  
**Knappe S.**, PO150-TUE, PO199-WED, PO201-WED  
**Knaub S.**, PO258-MON, PO662-MON, PO664-MON, PO198-TUE, PO250-TUE, PO272-WED  
**Knight K.**, PO203-WED  
**Knöbl P.**, PO528-WED  
**Knöbl P.**, OR152  
**Knoel P.**, AS221  
**Knoff F.**, PO150-TUE, PO151-TUE  
**Knöfler R.**, PO263-MON, PO481-WED  
**Knol H. M.**, PO346-WED  
**Knot J.**, PO364-WED  
**Knowles R.**, PO085-WED  
**Knuclen N.**, PO650-MON  
**Knudsen T.**, AS062, PO147-MON, PO206-WED

**Knyazev A.**, PO069-TUE  
**Ko D.**, PO619-TUE, PO657-WED  
**Ko K. H.**, PO475-TUE, PO478-TUE, PO531-TUE, PO168-WED  
**Kobayashi K.**, PO411-TUE  
**Kobilyanskaya V.**, PO111-WED  
**Koc B.**, PO275-MON, PO295-WED  
**Koc G.**, PO490-TUE  
**Kocak U.**, PO309-MON  
**Koch D.**, PO066-TUE  
**Koch K.**, PO215-WED  
**Koch V.**, PO433-TUE  
**Kochan J.**, PO621-MON  
**Kochiashvili N.**, PO585-WED  
**Koda T.**, PO351-MON  
**Kodama M.**, AS107  
**Koder S.**, AS034, PO391-WED  
**Koder S.**, PO122-WED  
**Koehler C.**, PO557-TUE  
**Koehler-Vajta K.**, PO236-MON  
**Koehn J.**, PO152-TUE, PO201-WED  
**Koek D.**, PO584-TUE  
**Koellinger M.**, AS018  
**Koenen R.**, PO037-TUE  
**Koenen R.**, PO091-WED, PO395-WED  
**Koenigsbruegge O.**, OR260, PO122-WED  
**Koentges C.**, OR252  
**Kogan A.**, PO197-MON  
**Kogan I.**, AS096  
**Koh H. L.**, PO012-TUE  
**Koh S.-H.**, PO115-MON  
**Koh Y.**, PO035-TUE, PO659-WED  
**Kohler H.**, PO185-WED, PO186-WED  
**Kohler H. P.**, PO181-WED  
**Köhler E.**, PO583-MON  
**Koike K.**, PO505-TUE  
**Kojima H.**, PO381-WED  
**Kojima T.**, PO151-MON, PO486-TUE, PO560-WED  
**Kokame K.**, OR152, PO599-MON, PO040-WED  
**Kokiet S.**, PO098-TUE  
**Kola J.**, PO053-TUE  
**Kolaitis N.**, PO551-TUE  
**Kolbe-Scheu K.**, PO065-TUE  
**Kolev K.**, AS004, AS152, PO207-MON  
**Kolev K.**, PO240-WED  
**Kollars M.**, PO077-WED  
**Koller L.**, OR123, PO282-TUE  
**Köllnberger M.**, PO553-WED, PO554-WED, PO599-WED  
**Kolm A.**, PO151-TUE

## Authors Index

Kolšek K., OR335  
Kolyadko V., P0047-WED  
Komanasin N., P0001-MON, P0080-MON  
Komarnicki M., P0125-TUE, P0170-WED  
Komáromi I., P0550-MON  
Komarov A., P0356-WED  
Kombrinck K., AS059  
Komitopoulou A., P0437-TUE  
Kommidi V., P0500-WED  
Komodikis G., P0615-MON  
Komorowicz E., AS004, P0240-WED  
Komska V., OR346, P0258-MON, P0260-MON  
Komvilaisak P., P0461-MON, P0120-TUE  
Kondo K., P0661-TUE, P0670-TUE, P0432-WED  
Kondo T., OR352, P0351-MON  
Kondo Y., P0224-TUE  
Kong F., P0009-MON  
Kong M. C., P0615-TUE, P0663-WED  
Konieczny S., P0125-MON  
Konig S., P0131-MON  
Königs C., P0308-WED  
Königsbrügge O., P0096-MON  
Konings J., P0143-MON, P0546-MON, P0072-TUE, P0092-WED  
Konkle B., OR298, P0238-MON, P0568-TUE  
Konkle B., OR162  
Konkle B., P0260-MON  
Konovalov R., P0535-TUE  
Konstantinides S., P0626-MON, P0513-TUE, P0619-WED  
Kooistra H., OR097, OR100  
Kool M., P0094-TUE  
Kool R., AS021  
Koorneef A., P0510-WED  
Kopec A., OR434  
Kopec A., OR375  
Korbel M., P0061-WED  
Kordich L., P0199-TUE  
Kordich L., P0533-MON  
Kormann J., OR235  
Korobkova D., P0535-TUE  
Korotina N., P0118-WED  
Korporaal S., AS189, P0405-MON  
Korshunov A., P0094-TUE  
Korth-Bradley J., P0167-MON  
Korubo K., P0450-MON  
Korver C., P0510-MON  
Koryakina L., P0054-MON  
Koscielny J., P0480-TUE

Koscielny J., P0356-TUE  
Koseoglu S., AS170  
Koshkina E., P0197-MON  
Kosolapova S., P0026-MON, P0212-WED  
Kossorotoff M., AS086  
Kostadima M., P0384-WED  
Kostina Y., P0501-WED  
Kostinck K., P0030-WED  
Kostousov V., OR056  
Kostrubiec M., P0619-WED  
Kostyeva M., P0535-TUE  
Kotha J., P0174-TUE, P0076-WED  
Kotlin R., P0238-WED, P0247-WED  
Kotlín R., P0194-TUE  
Kotova Y., P0103-WED  
Kotsi P., P0169-WED  
Kottke-Marchant K., P0494-WED  
Kou H., P0177-MON, P0179-MON  
Kouides P., OR088  
Kovac M., P0547-MON  
Kovac M., P0159-WED  
Kovac Z., P0159-WED  
Kovacs M., AS139  
Kovacs M., AS077, P0647-WED  
Kovacs M. J., P0630-WED  
Kovács K., P0516-TUE  
Kovács K., P0087-WED  
Kovalenko T., P0598-WED  
Koyama F., P0674-TUE  
Koyama S., OR352, P0351-MON  
Koyama T., P0106-MON, P0186-TUE  
Kozłowski J., P0623-TUE, P0419-WED  
Kozuka T., P0151-MON, P0486-TUE, P0560-WED  
Kozuma Y., P0381-WED  
Kraft P., AS068, AS094, AS228, OR169  
Kraiss L., P0604-MON  
Kraiss L., OR243  
Krämer L., OR103  
Krämer R., P0356-TUE  
Krarup J., P0219-WED  
Krauel K., AS008, OR125, OR307  
Kraul D., P0107-WED, P0137-WED  
Krause M., P0647-MON, P0248-TUE, P0420-TUE  
Krcova V., P0060-TUE  
Krege W., P0418-WED  
Krege W., OR316, P0312-TUE

Kreimann M., OR308, P0298-MON  
Krekeler S., P0657-MON  
Kremer Hovinga J., P0583-MON  
Kremer Hovinga J., OR152, P0581-MON, P0564-TUE  
Kremer Hovinga J., OR432  
Kremer Hovinga J. A., OR363  
Kremers R., OR224, P0089-MON, P0290-MON, P0072-TUE, P0004-WED  
Krettler C., P0182-WED, P0183-WED  
Kretz C., OR361  
Kretzler M., P0571-WED  
Kreutz R., P0607-TUE  
Kreutzer J., P0378-TUE  
Kreutzer J., P0646-WED  
Kreuz W., P0229-TUE  
Krezel C., P0166-TUE  
Kriek N., P0398-MON  
Krilis S., P0064-WED  
Krishnamoorthy G., P0546-MON  
Krishnan R., OR008  
Krishnan U., P0542-WED  
Krishnan S., P0170-MON, P0171-MON, P0287-WED  
Krishnaswamy S., AS151, P0415-WED  
Kristensen S., OR345  
Kristensen S., OR076, OR129, P0104-TUE  
Kristensen S., P0111-TUE, P0112-TUE  
Kristensen S. R., AS083, P0343-MON  
Kristensen S., P0407-TUE  
Kristensen V., P0177-WED, P0178-WED  
Krogh B., P0541-WED  
Krohne G., AS169  
Krokdast S., OR134  
Krol G., P0623-TUE, P0419-WED  
Kropacheva E., P0624-TUE, P0357-WED  
Kropff S., P0480-TUE  
Krougliak V., P0374-MON  
Kruger H. S., P0210-MON  
Kruip M., P0623-MON, P0665-WED  
Kruip M., P0251-TUE  
Kruip M., OR013, P0267-MON, P0282-MON, P0648-WED  
Kruip M. J., P0351-WED  
Kruithof A., P0469-TUE, P0550-WED  
Krumpholz B., P0065-TUE  
Krupka U., P0137-WED  
Krus K., P0030-MON

## Authors Index

Krychtiuk K., OR123, P0185-MON, P0559-MON, P0282-TUE, P0301-TUE, P0509-TUE  
Krylov A., P0661-WED  
Kryzaukaite L., P0532-WED  
Ku D., P0677-MON  
Kubicek-Hofmann C., OR144  
Kubicka-Trzaska A., P0074-MON, P0500-TUE  
Kubitza D., AS104  
Kubota C., OR051  
Kuca P., P0311-WED  
Kudykin M., P0030-WED  
Kuerkciyan E., P0612-WED  
Kuhn J., P0273-MON  
Kuhn P., P0110-MON  
Kuhn U., P0107-WED, P0137-WED  
Kuhnt V., P0518-MON  
Kuijk C., P0510-WED  
Kuijpers M., OR278  
Kuijpers M., P0155-TUE, P0452-TUE  
Kuiper G.-J., P0350-WED  
Kuiper G., P0033-WED  
Kuiper J., AS189  
Kuitunen A., P0304-MON  
Kujdowicz M., P0345-WED, P0365-WED  
Kujta N., P0616-TUE, P0491-TUE  
Kukongviriyapan U., P0001-MON  
Kukongviriyapan U., P0080-MON  
Kulawig R., P0505-MON  
Kulenthirarajan R., P0380-WED  
Kuliczkowski K., P0643-MON  
Kulkarni K., AS158  
Kulkarni R., OR162, P0238-MON, P0277-MON, P0618-TUE, P0678-TUE, P0255-WED  
Kulman J., OR413  
Kumano O., P0037-MON, P0041-MON, P0357-MON, P0020-WED, P0057-WED  
Kumar E., OR173, P0293-MON, P0303-MON  
Kumar E., P0291-MON  
Kumar R., AS160, OR157, P0545-TUE  
Kumar S., OR066  
Kumar N., P0200-MON  
Kumari S., P0200-MON  
Kumiko K., P0108-WED  
Kumskova M., P0496-MON  
Kun M. C., P0012-TUE  
Kunapuli S. P., OR111  
Kunapuli S., OR115, P0429-WED  
Kunchithapadam S., OR367

Kundur A. R., P0498-WED  
Kung C., P0374-MON  
Kunikiyo Y., P0515-TUE  
Kunishima S., P0309-MON, P0434-MON  
Kupelian V., P0589-MON  
Kuperman A., P0475-WED  
Kurasawa J., AS142  
Kurasawa J., OR163, P0196-WED  
Kurata M., P0078-MON  
Kurdee Z., OR398  
Kuriakose P., P0277-MON  
Kurlander J., P0623-TUE  
Kurnik K., OR141  
Kurnik K., P0259-MON, P0195-WED, P0506-WED  
Kurokawa Y., OR340  
Kurosawa S., P0564-TUE  
Kurowski S., P0028-MON  
Kurz J., P0066-TUE  
Kuskonmaz B., P0505-WED  
Kuzminova J., P0097-MON  
Kuznetsov V., P0047-WED  
Kuznetsova V., P0030-WED  
Kuznetsova V., P0028-WED  
Kwak H., P0461-TUE  
Kwan C., OR373  
Kwon J.-H., P0599-TUE  
Kwong Y., OR011  
Kyrle P., OR135, P0298-TUE, P0528-WED  
Kyrle P., OR226, P0077-WED  
La Corte A., P0100-MON  
La Marca S., OR005  
La Regina M., P0610-TUE, P0585-TUE, P0640-WED  
Labarque V., AS078  
Labrousche S., P0398-WED  
Lacasa D., AS043  
Lachmann B., P0382-MON, P0502-MON, P0521-WED  
Lackner K., P0593-MON, P0099-WED  
Lackner K., P0478-WED  
Lacoin L., OR382, P0638-MON  
Lacolley P., OR091, P0122-MON, P0031-TUE, P0033-TUE  
Lacroix A., P0557-WED  
Lacroix R., AS086, OR311, OR315, P0337-MON, P0340-MON  
Lacroix-Desmazes S., P0228-WED, P0230-WED  
Lacroix-Desmazes S., P0229-TUE, P0226-WED  
Lacut K., OR146, OR149, OR323, P0512-MON, P0655-WED  
Ladef F., P0217-MON  
Lafeber F., P0241-MON  
Laffan M., AS179  
Laghmani E. H., P0570-WED  
Lagrange J., P0031-TUE  
Laguna P., P0258-MON, P0279-MON  
Lahr B., P0645-WED  
Lai J., AS191, OR122  
Lai Y. F., P0615-TUE, P0663-WED  
Lail N., P0533-TUE  
Laitinen M., P0106-TUE  
Lakdawalla D., P0287-WED  
Lakshman S., P0363-TUE  
Lalezari S., OR011  
Laloy J., P0134-WED, P0142-WED  
Lam J. C. M., P0430-TUE  
Lam L., OR216  
Lam P., AS022  
Lam V., P0623-WED, P0635-WED  
Lam W., AS167, P0438-WED  
Lamas M., P0079-TUE  
Lamb D., NUR011  
Lambeir A.-M., P0218-MON, P0219-MON, P0221-MON  
Lambert C., P0234-TUE, P0280-WED  
Lambert M., OR186  
Lambert T., OR105, OR144, OR346, P0488-MON, P0501-MON  
Lamberth K., OR414  
Lamblin A., P0624-MON, P0105-TUE  
Lamblin G., P0075-TUE  
Lamboux-Matthieu C., OR186  
Lambregts K., P0179-WED  
Lameignere E., P0300-TUE  
Lamers M., P0155-TUE  
Lammertyn L., P0071-MON  
Lämmle B., AS163, OR152, OR193, OR432, P0583-MON, P0593-MON, P0569-TUE, P0570-TUE  
Lamotte M., P0355-WED  
Lamrani L., OR170, P0080-WED  
Lamuraglia M., P0620-MON  
Lamy M. T., P0107-MON  
Lance M., P0645-MON  
Lance M., P0143-MON, P0675-TUE  
Lance M., AS204  
Lancé M., P0546-MON, P0350-WED  
Lancé M., OR301

## Authors Index

Lancellotti P., AS006, PO407-MON  
 Lancellotti S., OR202, PO007-MON, PO582-MON  
 Landolfi R., PO422-TUE  
 Landrier J.-F., PO385-WED  
 Lane D., AS149, AS188, OR044, AS177, PO036-WED  
 Lane D., PO069-MON  
 Lane D. A., AS178, PO139-MON  
 Lane P., PO132-WED  
 Lang F., OR114, PO412-MON, PO449-WED  
 Lang K., OR063, PO347-MON  
 Langdon W., PO429-WED  
 Lange L., OR238  
 Lange S., PO296-MON  
 Langer F., PO251-MON, PO259-MON, PO174-WED  
 Langhauser F., OR114, PO517-TUE  
 Lankeit M., PO626-MON, PO513-TUE, PO619-WED  
 Lannoy N., PO280-WED  
 Lantos I., AS025, AS232, OR006, PO098-WED  
 Lanza F., AS171, PO443-MON  
 Laohathai P., PO026-TUE  
 Laporte S., OR146, OR149, PO107-TUE, PO655-WED  
 Laposata M., OR309  
 Lappegård J., OR120, PO493-TUE, PO561-WED  
 Lara Corrales I., PO475-MON  
 Lärfsars G., OR269  
 Larfi Y., PO562-TUE  
 Larina L., PO509-WED  
 Larina L., PO019-WED  
 Laroche J.-P., AS137  
 Larock A.-S., PO125-WED  
 Laros-Van Gorkom B., OR387, PO251-TUE, PO308-WED  
 Laros-Van Gorkom B., OR021, OR203, PO502-MON, PO680-TUE  
 Laroumagne S., OR315  
 Larsen J., PO136-TUE  
 Larsen J. B., PO495-WED  
 Larsen O., PO154-TUE  
 Larsen O., PO394-TUE, PO406-TUE  
 Larsson A., PO292-TUE  
 Larsson K., PO141-TUE  
 Larsson P., OR380  
 Laska A. C., PO530-TUE, PO171-WED  
 Lasne D., AS086, OR055, PO448-MON, PO018-TUE  
 Lasom S., PO001-MON

Lassila R., PO234-MON, PO363-MON, PO106-TUE, PO081-WED, PO162-WED  
 Lastrapes K., PO273-MON  
 Laterveer R., PO469-TUE, PO550-WED  
 Latger-Cannard V., PO473-WED  
 Latini R., PO338-WED  
 Latorre A., PO062-MON, PO414-MON  
 Latremouille C., PO513-WED  
 Latysheva N., PO338-MON, PO304-TUE, PO308-TUE, PO328-TUE, PO329-TUE, PO396-WED, PO572-WED  
 Lau A., PO032-MON  
 Lau C., PO442-MON  
 Lau K., OR373, PO359-TUE, PO565-TUE, PO139-WED, PO161-WED, PO348-WED  
 Laudat M., OR276  
 Lauer H., PO013-WED  
 Launay-Vacher V., PO632-WED  
 Laurance S., OR167  
 Laurencikas E., PO530-TUE  
 Laurent C.-E., PO081-WED  
 Laurent P.-A., PO514-TUE  
 Laurent S., PO323-TUE  
 Lauricella A. M., PO199-TUE  
 Lauricella A. M., PO533-MON  
 Lauritzen B., PO590-WED  
 Lauten M., PO506-WED  
 Lautmann K., OR033  
 Lauw M., OR158, OR383  
 Laux V., PO554-WED, PO555-WED  
 Lauzin D., PO158-WED  
 Lavallo C., AS168  
 Lavend'Homme R., PO186-MON  
 Lavenu-Blombed C., OR025  
 Lavenu-Bombed C., PO473-WED  
 Laverdiere C., PO463-MON  
 Laverdiere C., PO165-WED  
 Lavery R., PO481-MON, PO588-TUE  
 Lavigne G., OR095, OR188, OR190, PO035-MON  
 Lavigne-Lissalde G., PO035-WED  
 Lavoie E., PO371-MON  
 Lavoie E., PO576-MON  
 Lavoie E., AS050  
 Law L., PO014-TUE  
 Law S., PO421-MON, PO460-WED  
 Lawler P., PO014-WED  
 Lawrence M., PO083-TUE  
 Lawrence M., PO156-WED  
 Lawrie A., PO060-WED

Laws H.-J., OR346  
 Layden T., PO053-WED  
 Layios N., PO396-TUE  
 Lazaro E., PO416-TUE  
 Lazarus A., PO306-TUE  
 Lazo-Langner A., PO577-TUE, PO595-TUE, PO647-WED  
 Lazzareschi I., PO582-MON  
 Lazzari M., PO629-MON  
 Lazzari M., PO039-MON, PO634-TUE, PO636-TUE, PO646-TUE, PO652-TUE  
 Lazzari M., PO003-MON, PO004-MON, PO005-MON, PO042-WED  
 Le J., PO568-TUE  
 Le Bonniec B., PO016-TUE, PO350-TUE  
 Le Cam-Duchez V., PO520-MON  
 Le Cam-Duchez V., PO440-MON  
 Le Cessie S., AS138, PO601-TUE, PO625-WED, PO641-WED, PO668-WED  
 Le Gal G., AS082, AS137, OR053, OR323, OR384, PO100-TUE, PO628-WED, PO630-WED  
 Le Gal G., AS139, OR281, PO467-MON, PO473-MON, PO101-TUE, PO320-TUE, PO577-TUE, PO587-TUE, PO664-WED  
 Le Goff A., PO376-WED  
 Le Moigne E., OR323, PO512-MON  
 Le Moual H., PO135-MON  
 Le Quéllec S., PO156-MON, PO157-MON  
 Le Roux P.-Y., AS082, PO628-WED  
 Leaker M., PO563-TUE  
 Leal A. C., PO133-MON  
 Lebedeva T., OR305, PO405-TUE  
 Leblanc M., OR317  
 Leblebisatan G., PO254-TUE  
 Leblebisatan G., PO301-WED, PO302-WED, PO530-WED  
 Lebrecht A., PO570-TUE  
 Lebreton M., OR003  
 Lebreton A., PO075-TUE  
 Lebreton A., PO217-MON  
 Lecam Duchez V., PO621-WED  
 Lecchi A., OR005  
 Lecessie S., PO069-MON  
 Leclerc J.-M., PO165-WED  
 Lecompte T., OR055, PO546-TUE  
 Lecumberri R., PO516-MON, PO631-WED  
 Lecumberri R., PO116-TUE, PO488-TUE

## Authors Index

Lecut C., AS006, PO407-MON, PO396-TUE  
 Leduc M., PO572-MON  
 Lee A. Y., AS214  
 Lee A., OR295  
 Lee A., PO459-TUE  
 Lee A., OR282  
 Lee A. Y., AS081, OR228  
 Lee A., PO375-WED  
 Lee B., PO172-MON  
 Lee D., PO512-TUE  
 Lee E., PO119-TUE  
 Lee E.-Y., PO471-TUE  
 Lee F., PO005-TUE  
 Lee F., PO350-MON  
 Lee J.-O., PO035-TUE, PO119-TUE, PO489-TUE, PO659-WED  
 Lee J., OR037  
 Lee J. H., PO164-TUE  
 Lee J. S., PO119-TUE  
 Lee J., PO116-WED  
 Lee J., PO035-TUE  
 Lee K.-W., PO119-TUE, PO489-TUE  
 Lee K. S., PO164-TUE, PO280-TUE  
 Lee L. H., PO529-MON, PO012-TUE, PO504-TUE  
 Lee M., PO461-TUE  
 Lee S., PO305-TUE  
 Lee S., PO311-MON  
 Lee S., PO461-TUE  
 Lee S., PO209-TUE, PO278-WED  
 Lee T. H., PO393-WED  
 Lee T., PO476-MON  
 Lee T., PO608-TUE  
 Lee T., OR163, PO560-MON, PO196-WED  
 Lee W. S., PO475-TUE  
 Lee Y.-G., PO599-TUE  
 Leebeek F., AS079, OR021, OR088, OR203, PO078-MON, PO658-MON, PO665-WED  
 Leebeek F., OR212, OR387, PO069-MON, PO209-MON, PO267-MON, PO282-MON, PO251-TUE  
 Leebeek F., AS181, OR364  
 Leebeek F. W., PO651-MON, PO351-WED  
 Leebeek F., PO665-MON  
 Leemans J., OR124  
 Leenaerts D., PO218-MON, PO219-MON, PO221-MON  
 Leers M., PO097-WED  
 Lefeber D., AS187  
 Lefevre C., OR382, PO638-MON

Lefkou E., PO473-TUE, PO065-WED, PO587-WED  
 Lefrant J.-Y., PO035-WED  
 Legal G., OR055  
 Legendre P., OR205, OR219, OR333, PO658-TUE, PO662-TUE, PO664-TUE  
 Leger R., PO648-MON, PO655-TUE  
 Legnani C., PO050-MON, PO317-WED  
 Leguina A., AS116  
 Lehmann M., PO660-MON  
 Lei D., PO022-MON  
 Lei V., PO021-MON  
 Lei X., AS168, OR041  
 Lei Z., AS075, PO566-TUE  
 Leinoe E., PO482-MON  
 Leisinger C., PO258-TUE  
 Leissinger C., PO248-MON  
 Leissinger C., PO270-MON  
 Leite A., PO264-TUE  
 Leite F., PO318-TUE, PO626-TUE  
 Leitgeb A., PO294-MON  
 Leiting S., PO510-TUE  
 Lejniece S., PO250-MON  
 Lekovic D., PO218-TUE  
 Lemarié C., OR167  
 Lembo G., PO366-MON, PO084-TUE  
 Lemponen M., PO363-MON  
 Lena A., PO042-MON  
 Lena A. M., PO055-WED  
 Lenicek Krleza J., PO436-TUE  
 Lensing A., AS022  
 Lensing A., OR097, OR326  
 Lensing A., AS104, AS099, OR256, OR259, OR291  
 Lentaigne C., AS012  
 Lenting P., OR205, OR219, PO322-MON, PO658-TUE, PO662-TUE  
 Lenting P., OR333, PO664-TUE  
 Lenting P., OR246, PO553-TUE  
 Lenting P. J., AS062, OR234, PO206-WED  
 Lentz S., PO251-WED, PO267-WED, PO310-WED  
 Lentz S., PO521-TUE  
 Lentz S., OR212  
 Lenz M., OR123, PO301-TUE  
 Leo V., AS054  
 Leo V., AS124, PO517-WED  
 Leone M., PO035-WED  
 Leong L., PO026-MON  
 Leong L., PO212-WED, PO213-WED  
 Leony-Lasso I., PO286-WED

Lepatan L., PO262-TUE  
 Lepatan L. M., PO253-WED  
 Lepercq J., PO544-TUE  
 Lepropre S., PO101-WED  
 Lequier L., PO460-MON  
 Lerede T., AS197, OR292  
 Leroux P. Y., OR146  
 Leroyer C., OR146, OR149, PO655-WED  
 Leschnik B., PO453-MON  
 Leslie B., PO138-MON, PO130-TUE  
 Leslie B., AS154, AS219, OR286, OR290, PO170-TUE  
 Lessiani G., PO602-MON  
 Lessire S., PO092-MON, PO063-TUE  
 Lester M., PO329-WED  
 Letelier A., AS224  
 Letertre L., PO412-WED  
 Leithagen S., PO170-MON, PO171-MON, PO299-WED  
 Retourneur D., PO079.1-MON  
 Letowska M., PO011-WED  
 Leung A., PO237-MON  
 Leung L., AS031, PO465-WED  
 Leung R., OR235  
 Leunissen T., PO386-TUE, PO389-TUE  
 Levade M., PO423-TUE  
 Levin C., PO325-TUE  
 Levinas T., PO471-WED  
 Levine M., PO601-WED  
 Levi-Setti P., PO483-TUE  
 Levit A., PO470-TUE  
 Levitan B., OR259  
 Levy M., AS087  
 Lewis H., PO064-TUE, PO220-TUE, PO369-TUE, PO130-WED, PO417-WED  
 Lewis M., PO291-MON  
 Lewis S., NUR014  
 Ley C., PO147-MON  
 Lezius S., PO174-WED  
 Li D., PO454-MON  
 Li G., PO246-TUE  
 Li H., AS109, AS073, OR001, PO451-TUE  
 Li J., PO523-MON  
 Li J., PO425-TUE  
 Li J., PO340-TUE  
 Li L., OR018  
 Li L., PO506-MON, PO379-WED  
 Li N., PO009-MON, PO013-MON, PO015-MON  
 Li R., PO348-WED  
 Li R., AS051, AS171  
 Li R., PO006-TUE

## Authors Index

Li R., AS147, PO070-MON, PO205-MON  
 Li R., PO608-WED  
 Li S., PO678-TUE  
 Li T., PO321-WED  
 Li T.-Y., PO304-WED  
 Li T.-Y., PO265-WED  
 Li X., PO012-TUE  
 Li X., PO235-MON  
 Li X., PO288-TUE  
 Li X., OR261  
 Li Y., AS168  
 Li Y., OR265, PO320-MON, PO451-TUE  
 Li Y., OR249  
 Li Z., PO122-MON  
 Li Z., OR419  
 Liang H., PO188-TUE  
 Liang M.-L., PO426-MON  
 Liang Q., OR164, PO195-TUE  
 Liang R., PO304-TUE, PO308-TUE  
 Liang S., PO274-WED  
 Liang X., AS051, AS171  
 Liang Y., PO008-TUE  
 Liang Z., AS112, PO305-TUE  
 Liao H. R., PO327-MON  
 Liao H.-R., PO328-MON  
 Liao J., PO527-TUE  
 Liao P., AS219  
 Liaw P., PO389-MON, PO570-MON  
 Liaw P., AS210, PO127-MON, PO220-MON, PO324-MON  
 Librè L., PO483-TUE  
 Licht C., PO589-MON  
 Lichte A., PO094-MON, PO065-TUE, PO066-TUE  
 Lidya P., PO208-MON  
 Liebman H., PO311-MON, PO172-WED  
 Liehn E., PO091-WED  
 Lienhart A., OR012, PO253-WED  
 Liesenborghs L., AS009, AS113  
 Liesner R., AS223, OR141  
 Liesner R., PO250-TUE  
 Liesner R., OR389, PO243-TUE, PO244-TUE  
 Lifshits G., PO054-MON  
 Light D., OR415  
 Lijfering W., AS138, OR131, OR135, PO522-MON, PO623-MON  
 Lijfering W., OR150, OR322, PO223-WED, PO562-WED, PO577-WED, PO641-WED

Lijfering W., OR098, PO498-TUE, PO620-TUE, PO648-WED, PO666-WED, PO668-WED  
 Lijnen H. R., PO571-TUE  
 Lijnen H., PO002-TUE  
 Likhacheva E., PO651-TUE  
 Lillich M., PO397-MON  
 Lillicrap D., AS191, AS192, OR122, OR332, OR409, OR412, AS119, PO248-MON, PO678-MON, PO291-TUE, PO678-TUE, PO679-TUE  
 Lillo-Lelouet A., OR055  
 Lim E., PO372-WED  
 Lim E., PO375-WED  
 Lim G.-I., PO628-MON  
 Lim H., PO265-TUE  
 Lim H. Y., PO605-MON, PO590-TUE  
 Lim H.-K., PO461-TUE  
 Lim K.-M., PO115-MON  
 Lim W., OR068  
 Lima K., PO340-WED  
 Lima M., PO291-MON, PO054-WED  
 Limacher A., OR193  
 Limozin L., PO416-MON  
 Limperger V., PO506-WED  
 Limsakun T., OR350, PO241-TUE, PO262-TUE  
 Limwongse C., PO345-TUE  
 Lin C.-Y., PO245-MON  
 Lin C.-H., PO327-MON  
 Lin H.-F., PO050-TUE  
 Lin J., PO351-TUE  
 Lin L., AS146, OR417, PO425-MON  
 Lin M., OR383  
 Lin S.-Y., PO265-WED  
 Lin S.-W., PO029-MON, PO031-MON, PO050-WED  
 Lin S.-Y., PO245-MON  
 Lin Z., AS146  
 Lin Z., PO186-WED  
 Linares R., PO326-TUE  
 Linari M., PO323-MON  
 Linari S., AS222, PO650-TUE  
 Lind C., OR071, OR392, PO594-TUE  
 Lind H., PO673-TUE  
 Lind K. F., PO333-WED  
 Lindahl T., PO401-TUE  
 Lindahl T., PO294-MON, PO367-MON, PO292-TUE, PO560-TUE, PO561-TUE  
 Lindahl T., PO406-MON  
 Lindeman R., OR185  
 Linden L., PO555-WED

Lindgren M., PO294-MON  
 Lindhoff-Last E., PO356-TUE, PO480-TUE  
 Lindhout T., OR301, PO546-MON, PO672-MON  
 Lindström C., OR061  
 Ling G., PO486-MON  
 Ling M., PO568-TUE  
 Ling W., PO382-WED, PO447-WED  
 Linhart C., PO330-WED  
 Link A., PO013-WED  
 Linkins L.-A., PO619-MON  
 Linn Y. C., PO012-TUE, PO074-TUE  
 Lion N., PO400-TUE  
 Lionikiene A., PO225-MON  
 Lionikiene A., AS204  
 Lip G., PO325-MON, PO029-TUE  
 Lip G., PO359-MON  
 Liphardt K., PO631-MON  
 Lippok S., OR335  
 Lis M., PO049-TUE  
 Lisman T., OR070, OR435, PO002-MON  
 Lissens W., OR079  
 Lissitchkov T., OR144  
 Lissitchkov T., PO272-WED  
 Lissitchkov T., OR347, PO643-MON  
 Lister S., OR382, PO638-MON  
 Little G., PO312-MON  
 Litvinov R., OR305, PO424-MON  
 Litvinov R., AS156  
 Liu J., PO433-WED  
 Liu Y.-L., PO226-TUE  
 Liu C.-Z., PO448-TUE  
 Liu F., PO076-MON  
 Liu F., PO205-MON  
 Liu H., PO162-MON, PO132-TUE  
 Liu J., OR306, PO298-MON  
 Liu J., OR413  
 Liu J., OR018  
 Liu J., OR419  
 Liu J., OR113, OR210, PO388-WED  
 Liu L., PO176-TUE  
 Liu L., PO318-MON  
 Liu M., AS146  
 Liu P., PO553-WED  
 Liu Q., PO465-MON  
 Liu T., AS192, OR413  
 Liu W., OR265, PO451-TUE  
 Liu X., PO136-MON, PO137-MON  
 Liu X., AS074, OR138  
 Liu Y., OR039  
 Liu Y.-L., PO289-WED  
 Liu Z., OR415

## Authors Index

Livaja-Koshlar R., AS150  
 Livingston E., PO032-MON  
 Livnat T., PO062-TUE  
 Livnat T., PO285-TUE, PO225-WED  
 Ljung R., AS224, AS193, PO232-TUE  
 Ljungqvist M., PO080-TUE  
 Ljungqvist M., OR269  
 Llamas P., OR076, PO488-TUE  
 Llevaneras Madariaga S., PO358-TUE  
 Llinas A., PO658-WED  
 Lliso G., OR092  
 Lloyd J., PO504-MON  
 Lo C., PO045-WED  
 Lo C., PO083-WED  
 Lo R., PO506-MON, PO379-WED  
 Lo R., OR235  
 Lobmeyer M., PO376-TUE  
 Lobo J. L., OR321, PO576-TUE  
 Løchen M.-L., OR267, PO638-WED  
 Lock J., NUR004, OR387  
 Lococo L., PO614-WED  
 Lodberg Hvas C., PO131-WED  
 Lodigiani C., PO483-TUE  
 Loeffen R., PO097-WED  
 Loew-Baselli A., PO243-TUE, PO244-TUE  
 Loewenthal R., PO192-MON  
 Loftager M., OR110, PO219-WED, PO590-WED  
 Loftis L., OR056  
 Loh J. L. M., PO606-MON  
 Lohse J., PO263-MON  
 Lokajczyk A., PO014-MON  
 Loke M. Y., PO430-TUE  
 Lombard S., PO408-MON  
 Lombardo A., AS088  
 Long A., PO678-TUE  
 Long J., OR360  
 Long Z., OR018  
 Longstaff C., AS004, OR445, PO207-MON  
 Longue A., PO131-TUE  
 Lønneberg T., PO525-MON, PO567-WED  
 Lønneberg T., PO524-MON, PO636-WED  
 Loomans J., OR013, OR015, PO283-MON, PO308-WED  
 Loomans J., PO240-TUE  
 Loots D. T., PO214-MON  
 Lopes M., PO012-WED  
 Lopez A., PO491-TUE  
 Lopez M. J., PO206-TUE, PO249-WED

Lopez V., PO018-TUE  
 López J., PO568-TUE  
 López M., PO068-TUE, PO522-WED  
 López S., PO217-WED  
 López L., PO538-MON  
 Lopez Alonso A., PO075-WED  
 López Andreoni L., PO056-TUE  
 Lopez Fernandez F., PO258-TUE  
 Lopez Fernandez M. F., PO242-MON  
 Lopez Galetti L., PO518-WED  
 Lopez Ruano M. J., PO629-TUE  
 Lopez-Andreoni L., PO321-TUE  
 López-Andreoni L., PO375-TUE, PO407-WED  
 López-Fernández M. F., PO010-WED  
 López-Gálvez R., OR370  
 López-Pedreña C., PO558-TUE  
 López-Picazo J., PO116-TUE  
 Lopez-Vilchez I., PO082-WED, PO414-WED, PO610-WED  
 Lorcier B., OR186  
 Lord J., OR121  
 Lord S., AS153  
 Lordkipanidze M., AS127, PO019-TUE  
 Lordkipanidze M., AS054, AS011, OR401, PO408-MON, PO492-WED  
 Lorente M., PO469-MON  
 Lorentz C., PO177-TUE  
 Lorenz F., PO383-WED  
 Lorenz V., OR017, OR416  
 Lorenzato C., PO034-WED  
 Lorenzato C., PO286-MON  
 Lorenzi R., AS201  
 Lorenzo A., PO608-MON, PO488-TUE  
 Lorillon P., PO655-WED  
 Lorient M.-A., OR196, PO672-WED  
 Loroch S., PO419-TUE  
 Loskutnikov M., PO535-TUE  
 Lotfi-Tokaldany M., PO090-WED  
 Lotta L., OR394  
 Lotta L., PO069-MON  
 Lotta L. A., AS196, OR083, PO197-WED  
 Lottaz D., OR432  
 Lotti L. V., PO060-MON  
 Lou M., PO238-MON  
 Loubière C., OR205, OR246, OR333, PO206-WED  
 Louis H., PO122-MON, PO031-TUE  
 Loureiro J., PO321-TUE  
 Loures C., PO663-TUE

Loures C., PO237-WED, PO479-WED  
 Loven D., OR171  
 Lövgren K., OR040, PO141-TUE  
 Low J., PO387-TUE  
 Lowe A., OR285, OR429  
 Lowe G., AS011  
 Lowe G., AS054  
 Lowe G., PO492-WED  
 Lowe G., PO291-WED  
 Lowe G., PO069-MON  
 Lowe K., AS092  
 Lowerison J., NUR011, PO003-WED  
 Lowery T., PO073-TUE, PO405-TUE  
 Lox M., AS009  
 Loyau S., OR170, OR420, PO222-MON  
 Lozano J., PO552-WED  
 Lozano M. L., PO439-MON, PO497-MON  
 Lozano M., PO610-WED  
 Lozhkin A., OR305  
 Lozier J., OR028  
 Lu E., OR380  
 Lu G., OR318, PO351-TUE  
 Lu J.-D., PO522-TUE  
 Lu J., PO673-MON  
 Lu S., PO017-WED  
 Lu X., AS025, AS027, AS232, OR006, OR008, PO098-WED  
 Lu Y., PO492-MON  
 Lu Y., OR210, PO228-MON, PO195-TUE, PO433-WED  
 Luan Y., PO009-MON  
 Lubetsky A., PO253-WED  
 Lubetsky A., PO659-TUE  
 Lubich C., PO249-MON, PO160-TUE, PO232-WED  
 Luboshitz J., PO474-MON  
 Luca B., PO347-TUE  
 Lucas S., PO134-WED  
 Lucassen W., PO583-TUE  
 Lucca P., PO441-MON  
 Lucchelli M., PO615-WED  
 Luciani M., PO303-WED  
 Ludlam C., PO299-WED  
 Ludlam C., PO676-WED  
 Luengo-Gil G., OR359, PO558-TUE  
 Luettgen J., PO349-MON  
 Luken B., AS178, PO669-TUE  
 Luken B., PO326-MON, PO570-WED  
 Lukowski S., PO485-MON  
 Lukowski S., AS002  
 Lumelsky G., PO079-TUE

## Authors Index

Luna R., PO484-TUE  
**Lundberg A.**, PO588-MON  
**Lunde K.**, OR251  
**Lundin B.**, OR388  
**Lundström A.**, PO530-TUE  
**Lunghi B.**, OR050, OR333, PO555-TUE  
**Luo C.**, OR018  
**Luo D.**, OR279  
**Luo M.**, AS147, PO070-MON, PO205-MON  
**Luo P.-L.**, PO247-MON, PO216-TUE, PO009-WED  
**Luo X.**, PO222-WED  
**Lupu A.**, PO474-WED  
**Lurie B.**, PO368-TUE  
**Lurz E.**, PO485-MON  
**Lüscher T.**, PO027-MON  
**Lushchekina S.**, PO496-MON  
**Lusher J.**, PO248-MON  
**Lusty D.**, PO344-MON  
**Lutter R.**, PO335-WED  
**Lutters B.**, AS189  
**Luttun A.**, AS176  
**Lutz P.**, OR143  
**Luyendyk J.**, OR434, PO125-MON  
**Luyendyk J.**, OR375  
**Lv C.**, OR265, PO451-TUE  
**Lv M.**, OR001, OR265, PO451-TUE  
**Ly H.**, OR299  
**Lyapina L.**, PO206-MON, PO073-WED  
**Lyle M.**, OR109  
**Lynam C.**, OR213  
**Lynch C.**, AS188  
**Lyons C.**, OR042  
**Lyons M.**, PO435-TUE  
**Lysaja K.**, PO465-TUE  
**Lysov Z.**, PO127-MON, PO324-MON  
**Ma D.**, PO068-MON  
**Ma J.**, PO319-MON  
**Ma J.**, OR140, PO317-MON  
**Ma K.**, PO647-WED  
**Ma L.**, AS168  
**Ma M.**, OR295  
**Ma P.**, AS185  
**Ma T.**, PO036-TUE  
**Maas A.**, PO221-MON  
**Maas C.**, OR153, PO178-TUE  
**Maas Enriquez M.**, OR011, OR214, PO293-WED  
**Macbeth F.**, OR130  
**Maccallum P.**, PO660-WED  
**Macchi S.**, PO264-MON  
**Macdonald D.**, AS054  
**Macdonald T.**, AS158

**Macek B.**, PO412-MON  
**Machado E.**, PO158-WED  
**Machan L.**, PO375-WED  
**Machin S.**, PO132-WED  
**Machin S.**, OR154, PO044-MON, PO046-MON  
**Machin S.**, PO060-WED  
**Machlus K.**, OR085  
**Machlus K.**, PO380-WED  
**Machovich R.**, PO240-WED  
**Machuca M.**, PO579-MON  
**Mackay E.**, PO003-WED  
**Mackie I.**, PO044-MON, PO046-MON  
**Mackie I.**, OR154, PO060-WED, PO064-WED, PO132-WED  
**Mackman N.**, AS049, OR047, OR239, PO322-MON  
**Maclean R.**, PO313-WED  
**Macmullan P.**, PO437-MON  
**Macoura G.**, PO542-MON  
**Macrae F.**, OR433, OR444  
**Macri F.**, PO035-MON  
**Macwan A.**, PO401-TUE  
**Madan B.**, PO559-TUE, PO633-TUE  
**Maddur A.**, OR423  
**Maden M.**, PO043-TUE  
**Madigan A.**, PO437-MON  
**Madison E.**, OR247, OR299  
**Madison E.**, PO597-WED  
**Madlener K.**, PO296-MON  
**Madrid I.**, PO062-MON  
**Madridano O.**, PO608-MON  
**Madroñal Cerezo E.**, PO485-TUE  
**Madsen D. E.**, PO046-TUE  
**Madsen J.**, OR237  
**Maeda T.**, AS107  
**Maejima T.**, PO203-MON  
**Maekawa K.**, PO178-MON  
**Maes P.**, PO650-MON  
**Maffei F.**, PO184-TUE, PO054-WED  
**Magafa V.**, PO452-WED  
**Magdelaine A.**, PO045-TUE  
**Maggini N.**, PO586-WED  
**Maggiolo S.**, PO061-MON, PO456-MON, PO315-TUE, PO524-TUE  
**Magi A.**, OR270  
**Magnani J.**, PO593-TUE  
**Magnenat S.**, PO606-WED  
**Magniez A.**, PO376-WED  
**Magnusson M.**, PO432-TUE, PO443-TUE  
**Magrini N.**, PO674-WED, PO675-WED  
**Magro E.**, PO487-TUE

**Magy-Bertrand N.**, OR186  
**Mahajerin A.**, AS161, OR156  
**Mahaklan L.**, PO540-TUE  
**Mahan C.**, PO521-MON  
**Mahapatra M.**, OR066, PO316-MON, PO480-MON, PO272-TUE, PO529-WED  
**Mahé I.**, OR381, PO620-MON, PO103-TUE, PO105-TUE, PO632-WED  
**Mahjoub S.**, PO528-MON, PO062-WED  
**Mahlangu J.**, OR348, PO239-MON, PO248-MON, PO227-TUE, PO257-TUE, PO258-TUE, PO262-TUE, PO252-WED, PO310-WED  
**Mahlangu J.**, PO293-WED  
**Mahmoud Hourani Soutari N.**, PO228-TUE  
**Mahmoudi M.**, PO323-TUE  
**Mahner S.**, PO174-WED  
**Mahoney Jr D.**, PO644-TUE  
**Mahuad C.**, PO373-MON  
**Maigrat C.-H.**, PO546-TUE  
**Maino A.**, OR255, PO069-MON, PO574-TUE, PO090-WED, PO633-WED  
**Mairuhu R.**, OR257  
**Maitre B.**, PO606-WED  
**Majeed A.**, OR061, OR069, PO297-MON, PO355-TUE  
**Majek P.**, PO238-WED  
**Majewski J.**, PO625-TUE  
**Majluf A.**, PO023-TUE, PO242-WED  
**Majluf-Cruz A.**, PO020-MON, PO073-MON, PO523-TUE  
**Majoor C.**, PO611-MON, PO335-WED  
**Majumder R.**, OR280, OR366, AS182, PO155-MON  
**Makatsaria A.**, PO548-MON, PO122-TUE, PO173-WED  
**Makatsaria A.**, PO008-MON  
**Makatsariya N.**, PO052-MON, PO589-WED  
**Makhaldiani L.**, PO585-WED  
**Makhoul S.**, OR091  
**Mäkipernaa A.**, PO308-WED  
**Makris M.**, AS124, OR144, PO517-WED  
**Makris M.**, AS054, PO500-MON, PO643-TUE, PO524-WED  
**Malan D.**, PO266-WED  
**Magnusson M.**, PO611-TUE  
**Malcangi G.**, PO671-WED  
**Male C.**, AS104, OR346, PO253-WED, PO308-WED

## Authors Index

**Malfliet J.**, PO665-MON  
**Malfliet J.**, PO209-MON  
**Malhotra P.**, PO200-MON  
**Malinowska I.**, PO575-WED  
**Malinowsky J.**, OR318  
**Malins L.**, PO007-WED  
**Malisaukas M.**, PO160-TUE, PO232-WED  
**Malmstrom R.**, PO412-WED  
**Malmström R.**, PO368-MON, PO360-TUE  
**Maloney D.**, AS183  
**Maloney J.**, PO418-TUE  
**Malouin R.**, PO618-TUE  
**Maloum K.**, PO128-WED  
**Maltese T.**, PO060-MON  
**Malvar J.**, PO439-TUE  
**Malvestiti M.**, OR399  
**Maly R.**, PO469-MON  
**Mammadova-Bach E.**, **PO079.1-MON, AS095, OR420**  
**Mammen S.**, AS122, PO262-MON  
**Mamopoulos A.**, PO065-WED  
**Man C.**, OR390  
**Managhchi M. R.**, PO600-WED  
**Manai Z.**, PO528-MON  
**Mancic T.**, PO128-WED  
**Mancini I.**, PO580-MON, PO592-MON  
**Manco-Johnson M.**, OR431, PO662-WED  
**Manco-Johnson M.**, OR222, PO103-MON, PO285-MON  
**Manco-Johnson M.**, PO260-MON  
**Mancuso E.**, PO164-MON  
**Mancuso M.**, OR013, OR108, OR348  
**Mancuso M. E.**, AS222, OR214, OR346, PO091-MON, PO090-TUE, PO091-TUE, PO114-WED, PO197-WED, PO260-WED, PO273-WED  
**Mancuso S.**, PO117-TUE, PO614-WED  
**Mandelbaum T.**, PO217-TUE  
**Maneyro A.**, PO043-MON  
**Manganaro D.**, OR115, PO450-TUE  
**Mangin P.**, **PO079.1-MON, AS095, OR420**  
**Manglani M. V.**, PO164-MON  
**Mangles S.**, PO220-TUE, PO369-TUE, PO009-WED  
**Manguiat J.**, PO617-WED  
**Manina G.**, PO373-WED  
**Mankai J.**, PO566-TUE  
**Mankowski J.**, OR042  
**Mann K.**, PO371-MON, PO129-WED

**Mann K.**, PO248-MON, PO576-MON, PO467-TUE, PO425-WED  
**Mann K.**, AS050  
**Manne B. K.**, PO429-WED  
**Manne B.**, OR111  
**Mannens E.**, PO290-MON  
**Mannhalter C.**, PO236-TUE  
**Mannherz H.**, PO583-MON  
**Manni G.**, AS199, OR208, OR399  
**Manning C.**, PO168-TUE  
**Manning N.**, PO616-WED  
**Mannini L.**, PO071-TUE, PO365-TUE  
**Mannucci P.**, PO245-WED  
**Mannucci P.**, OR270  
**Mannucci P. M.**, PO649-MON  
**Mannucci P. M.**, PO164-MON  
**Manoj N.**, PO342-TUE  
**Mansfield A.**, OR127, PO449-TUE, PO508-TUE, PO157-WED  
**Mansouri M.**, OR152  
**Mant T.**, OR213  
**Mantiero M.**, PO115-TUE  
**Mantovani L.**, OR119, PO607-TUE  
**Manzella S.**, PO140-WED  
**Mao G.**, AS125  
**Mao P.**, PO432-MON  
**Maragoni G.**, PO072-MON, PO027-TUE  
**Marandiuc D.**, PO570-TUE  
**Maraveyas A.**, OR175, PO553-MON, PO555-MON, PO556-MON, PO557-MON, PO558-MON, PO110-TUE, PO127-TUE  
**Marchais S.**, PO033-TUE  
**Marchena P. J.**, OR381  
**Marchesini E.**, PO370-MON, PO423-WED  
**Marchetti G.**, OR050, OR080  
**Marchetti M.**, PO339-MON, PO179-WED  
**Marchetti M.**, PO438-TUE  
**Marchewka M.**, PO549-MON  
**Marchi R.**, PO187-MON  
**Marchini F.**, PO585-TUE  
**Marchula B.**, PO152-TUE  
**Marck B.**, PO557-WED  
**Marco A.**, PO051-MON  
**Marco P.**, PO051-MON, PO488-TUE  
**Marcone S.**, PO063-MON  
**Marcos-Contreras O.**, AS032  
**Marcos-Contreras O. A.**, OR178  
**Marcucci M.**, PO261-MON

**Marcucci R.**, OR253, OR396, OR400, PO067-MON, PO365-MON, PO366-MON, PO020-TUE, PO024-TUE, PO039-TUE, PO071-TUE, PO076-TUE, PO365-TUE, PO094-WED  
**Marès P.**, OR095, OR188, OR190  
**Margaglione M.**, AS222, PO511-MON, PO513-MON  
**Margaret H.**, PO153-WED  
**Margaritis P.**, OR178  
**Margolis J.**, PO625-MON  
**Marhic G.**, OR146  
**Mariani A.**, PO066-MON  
**Mariano D.**, PO179-TUE  
**Mariem A.**, PO281-WED  
**Mariem M.**, PO281-WED  
**Marigo L.**, PO671-WED  
**Mariko B.**, PO437-WED  
**Marin A.**, PO321-TUE, PO445-TUE  
**Marin A.**, PO056-TUE, PO375-TUE, PO407-WED  
**Marin N.**, PO435-WED  
**Marin Atucha N.**, PO497-WED  
**Marinaro A.**, PO585-TUE  
**Marin-Atucha N.**, PO229-MON  
**Markova I.**, PO057-TUE  
**Marks R.**, OR128  
**Markusic D.**, OR107, PO148-MON  
**Markway B.**, AS209  
**Marlu R.**, PO131-TUE  
**Marlu R.**, PO223-MON, PO159-TUE, PO241-WED, PO422-WED, PO593-WED  
**Marongiu F.**, PO674-WED, PO675-WED  
**Marosi C.**, OR357, PO166-WED  
**Marquardt N.**, OR103, PO674-MON, PO219-TUE, PO256-TUE, PO532-WED  
**Marquart A.**, OR441  
**Marques A. P.**, PO286-MON  
**Marques-Verdier A.**, PO075-TUE  
**Marschang P.**, AS197, OR292  
**Marsden K.**, PO366-TUE  
**Marsh J.**, PO201-TUE  
**Marsh J.**, PO476-MON  
**Marshall A.**, OR031  
**Marshall A.**, PO601-WED  
**Marsman G.**, PO326-MON  
**Martageix C.**, PO568-MON, PO575-MON  
**Marten S.**, AS098, PO636-MON  
**Mårtensson A.**, AS224, PO232-TUE  
**Marti A.**, PO621-TUE  
**Marti E.**, PO474-TUE

## Authors Index

**Martin A.-C.**, PO016-TUE, PO350-TUE  
**Martin E.**, PO273-MON  
**Martin F.**, OR360  
**Martin K.**, PO673-MON  
**Martin M.**, AS137  
**Martin S.**, PO512-TUE  
**Martín Díaz R. M.**, PO485-TUE  
**Martin Toutain I.**, PO128-WED  
**Martinelli I.**, AS022, AS196, OR083, OR270, OR394, PO611-TUE, PO176-WED, PO245-WED, PO583-WED, PO633-WED  
**Martinelli N.**, OR050, OR080, PO554-TUE, PO555-TUE  
**Martinelli P.**, PO513-MON  
**Martinez C.**, AS084, OR294, PO124-TUE  
**Martinez C.**, PO639-TUE  
**Martinez M.**, PO441-TUE  
**Martinez C.**, OR221, OR440, PO558-TUE, PO539-WED, PO549-WED, PO553-WED  
**Martinez De Lizarrondo S.**, AS032, AS117, OR314, OR379, PO532-TUE, PO370-WED  
**Martínez Díaz V.**, PO485-TUE  
**Martínez Martínez I.**, PO497-MON  
**Martínez-Martínez I.**, OR368  
**Martínez-Martínez I.**, AS187, OR076, OR359, OR370, PO336-MON, PO338-TUE  
**Martínez-Perez A.**, PO543-MON  
**Martin-Fernandez L.**, PO543-MON  
**Martini G.**, PO622-TUE  
**Martinod K.**, AS180, PO321-MON, PO329-MON, PO089-WED  
**Martinoli C.**, PO256-TUE  
**Martinowitz U.**, OR347  
**Martin-Rodríguez S.**, PO184-MON, PO187-TUE  
**Martins G.**, PO340-WED  
**Martins J.**, PO261-WED  
**Martins M.**, PO313-TUE  
**Martins-Filho O.**, PO231-MON, PO333-MON, PO135-TUE  
**Martinuzzo M.**, PO068-TUE, PO522-WED  
**Martín-Villar E.**, OR359, PO336-MON  
**Martlew V.**, PO578-MON  
**Martos L.**, PO093-MON, PO534-MON, PO536-MON, PO344-TUE  
**Marturano A.**, OR399  
**Marturano J.**, PO405-TUE  
**Martuotti G.**, PO513-MON  
**Maruyama I.**, PO399-TUE  
**Maruyama K.**, PO599-MON  
**Maruyama M.**, PO320-WED

**Marx N.**, PO465-TUE  
**Marx P.**, OR441  
**Masahiro A.**, PO108-WED  
**Maschan A.**, PO503-WED  
**Maschan A.**, PO496-MON  
**Mason J.**, PO653-MON  
**Masotti L.**, PO626-MON, PO373-WED  
**Massaro F.**, PO200-TUE  
**Massefski W.**, PO405-TUE  
**Massicotte P.**, AS104, PO455-MON, PO460-MON, PO083-WED, PO511-WED  
**Massimi I.**, PO060-MON, PO084-WED, PO316-WED  
**Massimo M.**, OR350  
**Masson S.**, PO338-WED  
**Mastbergen S.**, PO241-MON  
**Mastenbroek T.**, AS204, PO349-TUE  
**Mastrangelo S.**, PO582-MON  
**Masuda Y.**, PO455-WED  
**Mata M.**, PO487-TUE  
**Matafonov A.**, OR287, OR288  
**Matheus M.**, PO034-TUE, PO095-WED  
**Mathew J.**, PO374-MON  
**Mathew P.**, PO261-TUE, PO252-WED  
**Mathias M.**, AS159, OR104, OR145, OR386  
**Mathiesen E.**, AS046, OR120, OR254, PO561-WED  
**Mathiesen E.**, OR075  
**Mathiesen E.**, OR267, PO638-WED  
**Mathiesen E.**, OR071, OR293, OR392, PO594-TUE  
**Mathiesen U.**, PO379-TUE  
**Mathiesen Hald E.**, PO329-TUE, PO396-WED  
**Mathieu O.**, PO223-MON, PO340-MON, PO422-WED  
**Mathieu D'Argent E.**, PO473-TUE  
**Mathot R.**, PO372-MON  
**Mathôt R.**, OR387, PO251-TUE  
**Matilla S.**, PO038-MON  
**Matino D.**, PO162-TUE  
**Matos R.**, PO442-MON  
**Matsubara J.**, PO001-TUE  
**Matsubara Y.**, PO386-WED  
**Matsuda S.**, PO552-MON  
**Matsui H.**, PO671-MON, PO205-WED  
**Matsui T.**, PO661-TUE, PO670-TUE  
**Matsumoto A.**, PO557-WED

**Matsumoto M.**, OR152, PO661-TUE, PO672-TUE, PO674-TUE, PO040-WED  
**Matsumoto N.**, PO515-TUE  
**Matsumoto T.**, PO486-WED  
**Matsumoto T.**, PO652-MON, PO666-MON, PO668-MON, PO165-TUE, PO018-WED, PO113-WED, PO347-WED  
**Matsumoto Y.**, PO193-TUE  
**Matsumura N.**, PO351-MON  
**Matsunari Y.**, PO671-MON  
**Matsuno K.**, PO455-WED  
**Matsuoka H.**, PO399-TUE  
**Matsushita F.**, PO661-TUE, PO670-TUE  
**Matsushita K.**, PO173-TUE  
**Matsushita M.**, AS068  
**Matsushita T.**, AS017, PO434-MON, PO491-WED  
**Matsuura Y.**, PO552-MON  
**Matsuya H.**, OR352, PO351-MON  
**Mattheij N.**, AS141, AS140  
**Mattheij N.**, PO411-MON, PO499-MON  
**Matthew P.**, OR144  
**Matthews D.**, PO248-MON  
**Matthiessen P.**, PO232-WED  
**Mattsson E.**, PO297-MON  
**Matveeva E.**, PO611-WED  
**Matvienko O.**, PO367-TUE  
**Matysiak M.**, PO279-MON, PO574-WED  
**Matysiak M.**, PO575-WED  
**Matytsina I.**, PO251-WED, PO267-WED  
**Matzdorff A.**, PO110-TUE  
**Mauler M.**, OR252, PO404-TUE  
**Maurer G.**, AS200, OR123, PO185-MON, PO282-TUE, PO301-TUE, PO509-TUE  
**Maurer M.**, OR372  
**Maurice P.**, PO457-WED  
**Mausser-Bunschoten E.**, PO665-MON  
**Mausser-Bunschoten E.**, AS079, OR021, OR102, OR203, PO658-MON  
**Mausser-Bunschoten E.**, PO283-MON  
**Mausser-Bunschoten E.**, PO308-WED  
**Mavri A.**, AS101, PO360-TUE  
**Mavromatidis G.**, PO065-WED  
**Mavromoustakos T.**, PO452-WED  
**Mawri S.**, PO541-TUE  
**Maxeiner S.**, PO465-TUE  
**Maximova M.**, PO535-TUE

## Authors Index

**May F.**, PO152-MON, PO411-MON  
**Mcglason D.**, PO403-WED  
**Mcgregor A.**, PO420-WED  
**Mcgregor C.**, NUR001, PO376-MON  
**May L.**, PO083-WED  
**Mayer E.**, PO513-TUE  
**Mayeur D.**, PO105-TUE  
**Mayfield J.**, AS112  
**Mayger K.**, AS133, PO666-TUE  
**Mayo K.**, PO037-TUE  
**Mazepa M.**, OR162  
**Mazet B.**, PO579-TUE  
**Mazetto B.**, PO190-MON, PO422-MON, PO531-MON  
**Mazharian A.**, AS069, OR401, PO377-WED, PO434-WED  
**Mazoyer E.**, PO440-MON  
**Mazur J.**, PO478-WED  
**Mazuurov A.**, PO327-TUE  
**Mazutis L.**, OR232  
**Mazzeto B.**, OR094, PO066-WED, PO067-WED  
**Mazzolai L.**, AS137  
**Mazzucconi M.**, PO283-MON  
**Mazzucconi M.**, PO243-TUE, PO244-TUE  
**Mazzucconi M.**, OR027  
**Mazzucconi M. G.**, PO200-TUE, PO259-TUE, PO654-TUE, PO534-WED  
**Mbamba E.**, PO116-MON, PO292-MON  
**Mc Grath A.**, PO003-WED  
**Mc Guckin S.**, PO567-TUE  
**McAlister S.**, OR298  
**Mccarthy G.**, PO437-MON  
**Mccarty O.**, AS209, PO010-MON, PO297-TUE  
**Mccarty O.**, PO411-MON  
**Mccarty O.**, PO110-MON  
**Mccarty O.**, OR049, PO432-MON, PO440-WED, PO453-WED, PO543-WED  
**Mccarty O.**, AS129, OR353, PO177-TUE  
**Mccleary R.**, OR147  
**Mccluskie K.**, OR247, OR299  
**Mccormick A.**, PO418-TUE  
**Mccormick N.**, PO170-MON, PO171-MON  
**Mccrae K.**, AS049  
**Mcdonald E.**, NUR007, PO355-MON, PO389-MON, PO392-MON  
**Mcdonald L.**, PO368-TUE  
**Mcdonald V.**, PO603-MON  
**Mcdonnell C.**, OR043  
**Mcfadyen J.**, OR229, PO443-WED  
**Mcgaffin G.**, PO210-WED

**Mcgeehan E.**, PO411-WED  
**Mcglason D.**, PO403-WED  
**Mcgregor A.**, PO420-WED  
**Mcgregor C.**, NUR001, PO376-MON  
**Mcgregor S.**, PO374-TUE  
**Mcgregor S.**, PO098-MON  
**Mcindoe N.**, PO220-TUE  
**Mcintosh K.**, PO269-WED  
**Mckenzie S.**, AS108, PO429-WED  
**Mckinnon T.**, AS179  
**Mcknight B.**, PO557-WED  
**Mcloughlin A.**, OR043  
**Mcmaster J.**, PO676-MON  
**Mcmichael I.**, PO670-WED  
**Mcmillan-Ward E.**, OR223, PO390-TUE  
**Mcmullen A.**, PO369-TUE, PO417-WED  
**Mcnicol A.**, OR223, PO410-MON, PO408-TUE  
**Mcpheilm J.**, PO098-TUE  
**Mcpheerson H.**, PO466-MON  
**Mcpheerson H.**, AS155  
**McpPhillips P.**, PO603-TUE  
**Mcrae S.**, OR013, PO468-MON, PO618-MON, PO633-MON  
**Mcredmond K.**, PO248-MON  
**Mcvey J.**, PO196-WED, PO353-WED  
**Mcvey J.**, PO676-WED  
**Méan M.**, OR193  
**Medcalf R.**, OR380  
**Meddeb B.**, PO650-MON  
**Medina C.**, PO474-TUE  
**Medina P.**, OR076, PO093-MON, PO534-MON, PO536-MON, PO344-TUE, PO558-TUE  
**Medina S.**, PO286-MON  
**Medina S.**, PO296-WED  
**Medved L.**, OR371  
**Meehan B.**, PO393-WED  
**Meeks S.**, AS190  
**Meesmat W.**, PO613-WED  
**Mege J.-L.**, PO322-MON  
**Megiddo E.**, PO285-TUE  
**Mehla S.**, PO533-TUE  
**Mehmood T.**, PO037-WED  
**Mehta A.**, PO306-MON  
**Mehta D.**, PO260-TUE  
**Mei H.**, PO177-MON, PO179-MON  
**Meijer A.**, PO352-WED  
**Meijer A.**, AS058, AS121, PO510-WED  
**Meijer A.**, PO227-WED  
**Meijer K.**, PO665-MON

**Meijer K.**, AS197, OR015, OR021, OR097, OR100, OR203, OR292, OR387, PO651-MON, PO658-MON, PO251-TUE, PO346-WED, PO363-WED  
**Meijer P.**, PO208-WED  
**Meijers J.**, AS035  
**Meijers J.**, OR441, PO522-MON, PO335-WED, PO582-WED  
**Meijers J.**, PO294-MON, PO510-MON, PO352-WED  
**Meijers J.**, AS153  
**Meijers J.**, PO323-TUE, PO164-WED  
**Mein C.**, PO284-MON  
**Meiring M.**, PO657-TUE  
**Meister A.**, PO144-TUE  
**Mekkaoui C.**, PO035-MON  
**Mélac S.**, OR146, OR149  
**Melazzini F.**, PO473-WED  
**Melazzini F.**, PO438-MON  
**Meldau J.**, PO381-MON  
**Melero-Amor A.**, PO229-MON, PO497-WED  
**Melinscak H.**, PO274-TUE  
**Melissant C.**, OR257  
**Melton L.**, OR213  
**Men S.**, PO604-MON  
**Mena A.**, PO012-MON  
**Mena H.**, AS173  
**Menapace B.**, OR173  
**Mendek-Czajkowska E.**, PO648-TUE  
**Mendoza-Valdez L.**, PO523-TUE  
**Mendoza-Valéz L.**, PO073-MON  
**Menegatti M.**, OR039, PO500-MON, PO502-MON, PO503-MON, PO521-WED, PO524-WED  
**Meng F.**, OR331  
**Menino E.**, PO375-TUE  
**Menown I.**, PO638-MON  
**Mensink D.**, PO078-MON  
**Merah A.**, PO107-TUE, PO631-WED  
**Meral Güne A.**, PO156-TUE  
**Meral Güne A.**, PO268-MON  
**Mercanti C.**, PO654-TUE  
**Mercer S.**, PO490-WED  
**Merchán B.**, PO375-TUE  
**Mercier E.**, OR095, OR188, OR190, PO035-MON  
**Mercier G.**, PO535-MON  
**Mercuri M.**, OR199  
**Mergemeier K.**, PO015-TUE  
**Merlen C.**, PO165-WED, PO282-WED  
**Merlin S.**, AS088, OR106, OR161, OR411  
**Merrillod B.**, AS137

## Authors Index

Merricks E., AS120, OR178, PO048-WED  
Merricks E., PO046-TUE  
Merriman E., PO468-MON, PO618-MON  
Mertens K., AS058, AS121, PO510-WED  
Merz M., PO296-MON  
Mesa E., PO579-WED  
Meschengieser S., PO646-TUE, PO652-TUE  
Meschengieser S., PO039-MON  
Meschengieser S. S., PO629-MON  
Meshksar A., PO490-MON  
Messaoudi K., OR082  
Messas N., AS039  
Messer A., PO165-MON  
Messi G., PO433-TUE  
Messina M., AS088, AS222  
Mesters R., PO506-WED  
Metcalf Pate K., OR042  
Metcalf C., PO065-MON  
Metharom P., PO395-MON  
Metreveli B., PO277-TUE, PO337-WED  
Metzner H., PO089-TUE  
Metzner H., PO146-TUE, PO194-WED  
Meunier J., OR349  
Meunier S., OR346  
Meurs I., AS189  
Meusy A., PO653-WED  
Mewburn J., OR412  
Mewburn J., PO291-TUE  
Meygaard L., OR401  
Meyer G., AS214  
Meyer G., AS081, AS082, OR146, OR149, OR192, OR228, PO103-TUE, PO201-TUE, PO655-WED  
Meyer T., PO445-WED, PO446-WED  
Meza L., PO616-TUE  
Mezei Z., PO224-MON  
Mezei Z., PO187-WED  
Mezouar S., PO322-MON  
Mezzano D., AS116, OR220, PO466-WED, PO472-WED, PO480-WED  
Mezzapesa A., AS014, PO385-WED  
Mezzasoma A. M., OR336  
Miah I., PO363-WED  
Mian H., PO565-TUE  
Mian O., NUR007, PO355-MON  
Miao C., PO556-WED  
Miao C., OR109  
Miao X., PO009-MON, PO013-MON, PO015-MON

Michaela S., PO199-WED  
Michalski F., AS098, PO636-MON  
Michaël H., PO182-WED, PO183-WED  
Micheau M., OR143  
Michels A., PO291-TUE  
Michelson A., PO457-MON, PO458-MON, PO021-TUE, PO402-TUE, PO476-WED  
Michener M., PO074-WED  
Michiels J. J., AS133, PO655-MON, PO666-TUE  
Michos E., OR133  
Mickelsen D., PO032-TUE  
Micovic D., PO080-TUE  
Middelorp S., AS021, OR035, OR118, OR199, OR326, PO045-MON, PO372-MON, PO510-MON, PO514-MON, PO537-MON, PO353-TUE, PO498-TUE, PO506-TUE, PO507-TUE, PO525-TUE, PO409-WED, PO582-WED  
Miesbach W., PO269-MON, PO657-MON  
Migita K., OR051  
Migliaccio L., PO602-MON, PO627-MON, PO317-WED  
Migliorini A., OR400  
Migliorini M., PO493-MON  
Mihaljevic B., PO121-TUE  
Miklosz J., PO300-MON  
Mikovic D., PO502-MON, PO228-TUE, PO521-WED  
Mikrut K., PO049-MON  
Mikuska Z., PO376-TUE  
Milan M., OR027, OR030, OR326, PO225-TUE, PO303-WED  
Miles L., AS203  
Milesi V., PO622-TUE  
Milic N., PO121-TUE  
Milijic P., PO252-MON, PO547-MON, PO235-WED  
Milji P., PO218-TUE  
Millán J., PO435-WED  
Millán J. E., PO497-WED  
Miller D., PO657-WED  
Miller J., PO192-WED  
Miller J., PO049-MON, PO025-WED  
Miller M., AS110  
Miller W., AS059  
Milling, Jr T., PO319-TUE  
Mills R., PO521-MON  
Milos M., OR378, PO436-TUE  
Mimanda Y., PO671-TUE  
Min W.-S., PO599-TUE  
Minami H., PO244-MON, PO491-MON, PO652-MON  
Minamizaki T., OR051

Miñano A., AS187, OR076, OR370, PO552-WED  
Minet V., PO269-TUE, PO134-WED  
Ming Z.-Y., PO426-MON  
Mingen L., PO566-TUE  
Mingen L., AS075, OR264  
Mingot Castellano M. E., OR144  
Mingot-Castellano M. E., PO252-WED  
Mingozi F., PO158-MON  
Minhas A., PO419-WED  
Minici R., PO352-TUE, PO399-WED, PO400-WED  
Minns I., OR382  
Minoldo S., OR431, PO632-TUE, PO640-TUE, PO518-WED  
Minon J.-M., PO373-TUE  
Minton A., OR356  
Mintova S., PO323-TUE  
Minuz P., PO473-WED  
Miolo M., PO077-TUE  
Mir E., PO184-MON, PO189-MON, PO191-MON, PO187-TUE  
Mira Y., PO536-MON, PO579-WED  
Miranda A., PO054-WED  
Miral D., PO207-TUE  
Mironova N., PO294-TUE  
Mirsadeghi S., PO323-TUE  
Mirshahi S., PO117-MON, PO119-MON  
Mirshahi M., PO117-MON, PO119-MON, PO299-MON  
Mirshahi S., PO299-MON  
Mirzoyev T., PO579-MON, PO274-TUE  
Misgav M., PO217-TUE  
Mishra P., OR066, PO480-MON, PO272-TUE  
Misky G., PO377-TUE  
Mismetti P., OR012, OR146, OR149, OR196, PO262-WED, PO655-WED  
Misselwitz F., OR119  
Missiakas D., AS113  
Mistretta C., PO656-MON, PO090-TUE, PO091-TUE  
Miszta A., PO672-MON  
Mitchell J., OR341  
Mitchell J., PO189-WED  
Mitchell K., PO450-WED  
Mitchell L., PO454-MON, PO465-MON  
Mitchell M., OR058, PO418-TUE, PO504-WED  
Mitchell M., PO559-TUE, PO210-WED  
Mithoowani S., AS110

## Authors Index

Mitra S., PO446-MON  
Mitrovic M., PO218-TUE, PO547-TUE  
Mitrugno A., PO110-MON  
Mittler K., PO457-MON  
Miyakoshi Y., PO377-MON  
Miyamoto D., PO178-MON  
Miyata S., AS107, OR051  
Miyata T., PO599-MON, PO040-WED  
Mizote H., PO216-MON  
Mizrahi T., OR217  
Mizugaki A., PO178-MON  
Mizurini D., PO068-MON  
Mizurini D., PO133-MON  
Mizutani N., PO151-MON, PO486-TUE  
MI K., PO153-WED  
Mlakar U., PO181-MON  
Mo M., OR028  
Mo X., AS051, PO176-TUE  
Moake J., AS213  
Mobarrez F., PO392-WED  
Modjeski K., OR241  
Modjeski K., PO032-TUE  
Modrau I., PO121-WED  
Moenen F., PO123-WED, PO609-WED  
Moerland M., PO469-TUE, PO550-WED  
Moerland M., PO592-WED  
Moffatt L., OR426  
Mogielnicki A., PO300-MON, PO345-WED, PO365-WED  
Mogilevets A., PO147-WED  
Mognato G., PO225-TUE  
Mohamadi A., PO014-MON, PO122-MON, PO031-TUE  
Mohamed A., PO089-MON  
Mohamed S., OR186  
Mohammed B., PO273-MON  
Mohammed N., PO099-MON  
Mohand-Oumoussa B., AS014  
Moharir M., PO118-TUE  
Mohr F., PO169-TUE  
Moimen N., OR121, PO393-TUE  
Moiz B., PO384-MON, PO539-MON, PO468-WED  
Mokhtari D., PO563-MON  
Molden E., PO379-TUE  
Molderings G., PO343-WED  
Molenaar T., AS189  
Molero A. G., PO321-TUE  
Molhoek J., AS035, PO063-WED  
Molina M., PO518-WED  
Molina P., PO414-WED, PO610-WED

Molinari A. C., AS104  
Molinari C., PO303-WED  
Moll F., PO386-TUE, PO389-TUE  
Molle R., PO072-MON, PO027-TUE  
Mollnes T., PO308-TUE  
Mollnes T. E., PO304-TUE  
Molloy C., AS184  
Molnár É., PO530-MON, PO031-WED  
Moloney E., PO019-TUE  
Momi S., AS174, AS199  
Momot A., PO150-WED  
Monagle P., AS104, AS105, OR224, PO087-MON, PO449-MON, PO607-MON, PO427-TUE, PO432-TUE, PO596-TUE, PO500-WED  
Monahan P., PO166-MON  
Monahan P., PO032-MON, PO052-WED  
Monahan P., OR162  
Mondal N., OR338  
Mondon P., PO311-TUE  
Mondoro T., PO096-TUE  
Monia B., AS059  
Monia B., AS219, OR049, OR286  
Monje D., PO607-TUE  
Monkman J., OR044  
Monreal M., OR074, OR381, PO469-MON, PO608-MON, PO631-WED  
Monroe D., PO426-WED  
Monroe D., OR239, OR319, PO153-MON, PO273-MON, PO550-TUE, PO052-WED  
Montague S., PO415-MON, PO289-TUE  
Montague S., PO393-TUE  
Montalvão S., PO145-WED  
Montalvão S. A., PO286-MON  
Montaner J., OR314  
Montani N., OR030  
Monteiro C., PO212-TUE  
Monteiro R., PO068-MON  
Monteiro R., PO133-MON  
Montermini L., PO393-WED  
Montero Hernández C., PO485-TUE  
Montes R., PO488-TUE  
Montgomery R., PO222-WED  
Montgomery R., OR089, OR204, PO659-MON  
Montmartin A., OR055, PO262-WED  
Montoya M., OR328, PO475-MON  
Montoya M., PO434-TUE  
Montoya M., PO479-MON  
Mooberry M., AS153

Moons K., PO583-TUE, PO584-TUE  
Moore D., PO019-TUE  
Moore D., PO431-WED  
Moore G., AS133  
Moore G., PO037-MON, PO418-TUE, PO633-TUE  
Moore G., PO666-TUE  
Moore J., AS114  
Moore R., PO476-MON  
Moore S., OR112, OR275, PO428-MON, PO461-WED  
Moore S., OR272  
Moorehead P., AS191, PO426-TUE  
Moorlag M., PO025-MON  
Moorthy V., OR382  
Mor E., PO001-WED  
Moraes E., PO189-TUE, PO002-WED, PO023-WED  
Moraes L., PO398-MON  
Morag I., PO659-TUE  
Morais K., PO107-MON  
Morais S., PO442-MON, PO318-TUE  
Moraleda J. M., PO497-WED  
Morandin S., PO385-MON  
Morange P.-E., AS045  
Morange P., OR012  
Morange P., AS014, PO441-MON, PO443-MON, PO493-WED, PO559-WED, PO564-WED  
Morange P.-E., AS206, OR266, OR324, PO263-TUE  
Mor-Cohen R., OR289  
Moreira L., PO626-TUE  
Moreira M., PO333-MON  
Moreira P., PO002-WED  
Moreira R., PO318-TUE  
Morel J., PO263-TUE  
Morel J., PO035-WED  
Morel O., AS039  
Morel-Kopp M.-C., OR002, PO433-MON, PO421-TUE  
Morell D., PO441-TUE  
Morell M., PO514-WED  
Morelli B., OR093, PO126-WED  
Morelli V., PO577-WED  
Morelli V., OR150  
Morengi M., PO483-TUE  
Moreno M., PO487-TUE  
Moreno M., PO023-TUE, PO242-WED  
Moret A., PO579-WED  
Morettini A., PO067-MON  
Moreva O., PO624-TUE, PO357-WED

## Authors Index

**Morfini M.**, AS122, OR346, OR389, P0262-MON, P0256-TUE  
**Morgan N.**, AS054  
**Morgan N.**, AS011  
**Mörgelin M.**, AS040  
**Morgione S.**, P0352-TUE, P0399-WED, P0400-WED  
**Mori J.**, OR183, P0434-WED  
**Mori M.**, P0173-TUE  
**Mori M.**, P0233-TUE, P0211-WED  
**Mori T.**, OR051  
**Moriguchi J.**, OR216  
**Moriguchi-Goto S.**, P0552-MON  
**Morikawa Y.**, OR340  
**Morin C.**, P0262-WED  
**Morishima Y.**, OR316, P0353-MON, P0357-TUE, P0458-TUE  
**Morishita E.**, P0599-MON  
**Morita D.**, OR340  
**Moriyama T.**, P0455-WED  
**Mørk M.**, P0343-MON  
**Moroi M.**, P0441-WED  
**Morongova A.**, P0249-TUE, P0022-WED  
**Morowski M.**, AS218  
**Morrell C.**, OR166, OR241  
**Morrell C.**, OR042, P0032-TUE  
**Morris R.**, P0156-WED  
**Morris T.**, P0201-TUE, P0644-WED  
**Morris T.**, P0476-MON  
**Morrison H.**, OR073  
**Morrison K.**, OR020  
**Morrissey J.**, OR351  
**Morrissey J.**, OR353, OR354, P0001-TUE, P0451-WED, P0543-WED, P0544-WED  
**Morrissey J.**, P0300-TUE, P0336-WED  
**Morser J.**, AS031, AS029, P0465-WED  
**Morth J. P.**, P0557-TUE  
**Mos I.**, P0596-MON  
**Mos I.**, OR191, P0597-MON  
**Moscardo A.**, P0414-MON  
**Moscardo A.**, P0062-MON  
**Moschetti V.**, OR320  
**Moschonas I.**, P0452-WED  
**Mosier M.**, P0182-MON, P0191-TUE, P0192-TUE, P0337-TUE, P0344-WED  
**Most P.**, OR274  
**Mostaguir K.**, P0587-TUE  
**Mota N.**, P0042-MON, P0055-WED  
**Motokawa S.**, OR051

**Motovska Z.**, P0364-WED  
**Motta G.**, P0179-TUE  
**Motte S.**, P0598-MON, P0668-TUE  
**Mottier D.**, OR146, OR149, OR323, P0512-MON, P0655-WED  
**Motwani J.**, AS054, AS011  
**Mouapi K. N.**, OR372  
**Moueminoglou N.**, OR262  
**Moumneh T.**, P0579-TUE  
**Mouquet F.**, P0662-TUE  
**Moussa S.**, P0542-MON  
**Moustafa F.**, OR381  
**Moustafa F.**, P0587-TUE  
**Mowinckel M.-C.**, P0311-MON, P0178-WED  
**Mowla A.**, P0533-TUE  
**Muazzam I. A.**, P0127-TUE  
**Muczynski V.**, AS062, OR246, P0206-WED  
**Mueller J.**, P0066-TUE  
**Mueller K.**, AS099  
**Mueller-Cohrs J.**, P0418-WED  
**Muench S.**, P0243-WED  
**Mufti A.**, OR406  
**Mugusi F.**, P0063-WED  
**Muhl L.**, P0510-TUE  
**Muia J.**, OR365  
**Muiña B.**, P0439-MON, P0552-WED  
**Muir I.**, AS016  
**Mukaddam A.**, P0207-TUE  
**Mukhametova L.**, P0113-MON  
**Mukhametova L.**, P0213-MON  
**Mukharyamova K.**, P0197-MON  
**Mukhi N.**, P0265-TUE  
**Mulder A.**, P0346-WED  
**Mulders G.**, P0282-MON  
**Mulla G.**, P0496-TUE  
**Mullens M.**, P0033-WED  
**Muller A.**, OR315  
**Muller D.**, P0075-MON  
**Muller S.**, P0440-MON  
**Müller A.**, P0163-MON, P0218-WED  
**Mullier F.**, OR055, OR126, P0092-MON, P0063-TUE, P0269-TUE, P0125-WED, P0134-WED, P0167-WED  
**Mulliez S.**, P0384-TUE  
**Mulpas M.-C.**, P0457-WED  
**Mumford A.**, AS054, OR386, P0502-MON, P0521-WED  
**Muminoglu N.**, P0590-MON  
**Mumoli N.**, P0502-TUE, P0640-WED  
**Munakata J.**, P0312-MON

**Mundell S.**, AS054, P0065-MON  
**Munder M.**, P0591-MON  
**Mundkur L.**, AS025, AS027, AS232, AS202, OR006, OR008, P0083-MON, P0098-WED  
**Muñoz A.**, P0126-TUE  
**Munoz Martin A.**, P0103-TUE  
**Munroe-Peart S.**, OR285, P0095-MON  
**Muntean W.**, P0453-MON, P0464-MON  
**Münzel T.**, P0513-TUE, P0102-WED, P0478-WED  
**Münzer P.**, OR114, P0412-MON, P0449-WED  
**Muoio A.**, OR197  
**Murabito J.**, P0593-TUE  
**Murai T.**, P0505-TUE  
**Murakami A.**, P0377-MON  
**Muramatsu T.**, P0213-TUE  
**Murasaki K.**, P0399-MON  
**Murata M.**, P0386-WED  
**Murata M.**, P0151-MON, P0486-TUE, P0560-WED  
**Mueller-Cohrs J.**, P0418-WED  
**Muresan A.**, P0099-MON  
**Murphy C. L.**, P0437-MON  
**Murphy D.**, P0669-TUE  
**Murphy J.**, P0116-WED, P0597-WED  
**Murphy L.**, P0267-TUE  
**Murphy P.**, P0502-WED  
**Murray J.**, P0457-MON  
**Murray S.**, OR049  
**Murru V.**, P0068-WED  
**Murugesan G.**, P0494-WED  
**Musa F.**, OR045  
**Musgrave K.**, P0447-MON  
**Musial J.**, P0074-MON, P0500-TUE, P0070-WED  
**Musiaf J.**, P0048-MON, P0069-WED  
**Mussio D.**, P0474-TUE  
**Musso M.**, P0644-TUE  
**Mustafin I.**, AS156  
**Musumeci L.**, AS006, OR278  
**Muszbec L.**, P0521-WED  
**Muszbec L.**, P0224-MON, P0530-MON, P0550-MON, P0516-TUE, P0031-WED, P0087-WED, P0187-WED  
**Mut D.**, P0474-WED  
**Mutch N.**, P0225-MON  
**Mutch N.**, AS204, P0189-WED  
**Muth M.**, P0094-MON  
**Muthard R.**, OR207  
**Muttucumaru N.**, P0601-MON  
**Muttucumaru T.**, P0601-MON  
**Muyldermans S.**, OR399

## Authors Index

**Muzychenko V.**, P0586-TUE  
**Mwirigi A.**, P0603-MON  
**Myers B.**, OR064, P0175-TUE  
**Myers D.**, P0030-MON  
**Myers O.**, OR064  
**Myklebust C.**, P0118-MON  
**Myklebust C. F.**, P0557-TUE  
**Myklebust C.**, P0123-MON, P0453-TUE  
**Myrén K.-J.**, P0170-MON, P0171-MON, P0299-WED  
**Nabi S.**, P0650-WED  
**Nabiullina R.**, AS156  
**Nader H.**, P0291-MON  
**Nadir Y.**, AS096, P0126-MON, P0563-WED  
**Naess I.**, OR345  
**Naess I. A.**, AS083, OR129, OR134, P0104-TUE, P0111-TUE, P0112-TUE  
**Nagae C.**, P0233-TUE, P0211-WED  
**Nagamine K.**, P0320-WED  
**Nagasato T.**, P0399-TUE  
**Nagaswami C.**, P0026-MON, P0212-WED  
**Nagler M.**, OR432, P0314-WED  
**Nagy Jr B.**, P0077-MON, P0482-WED  
**Nagy-Baló E.**, P0087-WED  
**Nahas W.**, P0433-TUE  
**Nahed B.**, P0601-WED  
**Nahiriak S.**, P0455-MON  
**Naik M.**, AS175, AS183  
**Naik U.**, AS175, AS183  
**Nair J.**, OR010, P0082-MON  
**Nair S.**, P0153-WED  
**Naito S.**, P0462-TUE, P0463-TUE  
**Naito S.**, P0041-MON, P0357-MON, P0020-WED, P0057-WED  
**Naitoh K.**, P0486-WED  
**Najarro K.**, OR042  
**Najmi N.**, P0384-MON  
**Nakagaki T.**, P0441-WED  
**Nakagawa I.**, P0058-WED  
**Nakahara S.**, OR051  
**Nakajima Y.**, P0674-TUE  
**Nakamura M.**, OR051  
**Nakamura S.**, P0491-WED  
**Nakamura Y.**, P0151-MON, P0560-WED  
**Nakano H.**, OR142  
**Nakashima T.**, P0399-TUE  
**Nakata Y.**, P0151-MON, P0486-TUE, P0560-WED  
**Nakazawa Y.**, OR340  
**Nakazono E.**, P0545-MON

**Nakkinkun Y.**, P0675-MON, P0647-TUE, P0268-WED, P0613-WED, P0643-WED  
**Naldini G.**, OR396  
**Naldini L.**, AS088  
**Nalin F.**, P0385-MON  
**Namestnikov Y.**, P0057-TUE  
**Nandi M.**, P0459-WED  
**Nandurkar H.**, AS212  
**Nante G.**, OR132, P0077-TUE  
**Naoki T.**, P0108-WED  
**Napirei M.**, P0583-MON  
**Napoleone L.**, OR396  
**Napolitano M.**, P0117-TUE, P0650-TUE, P0614-WED  
**Narata A. P.**, P0064-MON  
**Nardelli G. B.**, P0515-MON  
**Nardo B.**, P0611-TUE  
**Narjoo C.**, P0672-WED  
**Nash G.**, P0393-TUE  
**Natesirinikull R.**, P0275-TUE, P0446-TUE  
**Navani S.**, OR046  
**Navarrete Villarruel A.**, P0138-WED  
**Navarro R.**, P0441-TUE, P0514-WED  
**Navarro S.**, P0093-MON, P0534-MON, P0536-MON, P0344-TUE, P0558-TUE  
**Navarro-Fernández J.**, OR076, OR370  
**Navarro-Ruan T.**, AS122, P0262-MON  
**Nawadkar V.**, P0207-TUE  
**Nawarawong W.**, P0647-TUE  
**Nawroth B.**, P0665-TUE  
**Nayak D.**, P0164-MON  
**Nayak S.**, P0512-TUE  
**Nayiager T.**, P0463-MON  
**Neal R.**, P0175-TUE  
**Neary E.**, OR218  
**Neceva V.**, P0544-MON, P0535-WED  
**Nechipurenko D.**, P0436-WED  
**Nedelec Gac F.**, P0411-TUE  
**Nedergaard-Petersen S.**, P0121-WED  
**Needham J.**, P0064-TUE, P0220-TUE, P0369-TUE, P0130-WED, P0417-WED  
**Neel A.**, P0016-WED  
**Neelamegham S.**, AS063, OR334, P0430-MON, P0045-WED  
**Neerman-Arbez M.**, AS002, P0217-MON, P0485-MON  
**Neeses K.**, P0660-MON  
**Neeses K.**, P0188-MON

**Neff A.**, P0277-MON, P0298-WED  
**Negrier C.**, OR029, OR347, P0149-MON, P0156-MON, P0157-MON, P0488-MON, P0067-TUE, P0198-WED, P0253-WED  
**Négrier C.**, P0484-MON, P0501-MON, P0229-TUE, P0273-WED  
**Negrotto S.**, AS173, P0012-MON  
**Nehmiz G.**, P0376-TUE  
**Neira Vidal V.**, P0358-TUE  
**Nekkal M. S.**, P0637-TUE  
**Nekkal S.**, P0494-MON, P0242-TUE, P0276-WED, P0520-WED  
**Nelemans P.**, P0645-MON  
**Nelissen R.**, P0532-MON  
**Nelson A.**, P0097-TUE, P0109-TUE  
**Nelson M.**, P0398-TUE  
**Nemes L.**, OR212  
**Nemeth B.**, P0573-WED, P0625-WED  
**Németh A.**, P0443-TUE  
**Neo J. K.**, P0663-WED  
**Negrier C.**, P0257-TUE  
**Nery J. G.**, P0322-TUE  
**Nesbitt W.**, P0443-WED  
**Neto-Neves E.**, P0033-MON  
**Neufeld E.**, AS122, OR022, P0262-MON, P0239-TUE  
**Neufeld E.**, P0457-MON, P0458-MON  
**Neumann D.**, P0627-WED  
**Neumayer C.**, P0559-MON  
**Neunziger R.**, P0094-MON  
**Neven B.**, P0440-MON  
**Newall F.**, P0449-MON, P0607-MON, P0596-TUE, P0500-WED  
**Newman D.**, OR058  
**Newton P.**, P0297-TUE  
**Newton P.**, P0110-MON  
**Ng C.**, P0660-MON  
**Ng E.-P.**, P0323-TUE  
**Ng H. S.**, P0529-MON  
**Ng H. J.**, P0012-TUE, P0074-TUE, P0615-TUE, P0663-WED  
**Ng L.**, P0464-WED  
**Nguyen G.**, OR165  
**Nguyen H.**, P0456-WED  
**Nguyen H.**, P0394-MON, P0448-WED  
**Nguyen J.-P.**, OR192  
**Nguyen P.**, OR055, P0263-TUE, P0457-WED  
**Nguyen P. N.**, AS039  
**Nguyen T.-H.**, P0456-WED  
**Nguyen T.-H.**, P0298-MON  
**Nguyen T.**, OR056



## Authors Index

Ni H., AS153  
**Ni H.**, AS168, OR031, OR139, PO326-WED, PO328-WED  
**Ni R.**, AS216, AS219, OR286, OR302, PO403-MON  
**Ni Ainle F.**, OR218  
**Nicham F.**, PO045-TUE  
**Nichele I.**, PO473-WED  
**Nichol M.**, PO238-MON  
**Nichols T.**, AS120, PO048-WED  
**Nichols T.**, OR178, PO046-TUE  
**Nicholson-Goult L.**, AS124  
**Nickles K.**, PO657-MON  
**Nicolas P.**, PO512-MON  
**Nicolosi F.**, OR297  
**Niebl P.**, PO312-TUE, PO418-WED  
**Niebler R.**, OR058  
**Niederwanger C.**, PO330-WED  
**Niego B.**, OR380  
**Niekrens C.**, PO195-WED  
**Nielsen A.**, PO140-TUE  
**Nielsen L.**, OR036  
**Nielsen P.**, PO140-TUE  
**Nielsen T.**, PO130-MON  
**Nieman M.**, PO571-WED  
**Niessner A.**, OR123  
**Nieswandt B.**, AS068, AS092, AS094, AS169, AS218, AS228, OR017, OR081, OR169, OR170, OR181, OR405, OR416, PO436-MON, PO505-MON, PO129-TUE, PO526-TUE  
**Nieto R.**, OR321  
**Nieuwland R.**, AS038, PO342-MON  
**Nijdam A.**, OR102  
**Nijziel M.**, OR013  
**Nikolic Nielsen L.**, PO285-WED  
**Nikolovski S.**, PO121-TUE  
**Nilsson G.**, PO013-MON  
**Nilsson P.**, PO564-WED  
**Nimbargi R.**, PO176-MON  
**Ninet J.**, OR186  
**Ning S.**, PO595-MON  
**Ninivaggi M.**, PO272-MON, PO546-MON, PO072-TUE  
**Ninomiya H.**, PO381-WED  
**Nisal A.**, PO176-MON  
**Nisgav Y.**, PO285-TUE  
**Nishigori N.**, PO674-TUE  
**Nishimura N.**, PO515-TUE, PO528-TUE  
**Nishimura S.**, OR084, PO354-TUE, PO428-WED  
**Nishioka J.**, PO284-TUE, PO335-TUE  
**Nishiyama T.**, OR352

**Nitti C.**, PO626-MON, PO373-WED  
**Nivet-Antoine V.**, PO038-TUE  
**Njerve I. U.**, PO042-TUE  
**Njølstad I.**, AS046, OR071, OR075, OR120, OR254, OR267, OR293, OR392, PO594-TUE, PO561-WED, PO638-WED  
**Nnachi O.**, PO529-TUE  
**Noble S.**, NUR014, OR130, PO097-TUE, PO109-TUE, PO110-TUE, PO156-WED  
**Nobre Fernandes S.**, PO012-WED  
**Nobre Junior V.**, PO313-TUE  
**Nobuo A.**, PO153-WED  
**Noda M.**, PO205-WED  
**Noelia V.**, PO444-TUE  
**Noethen M.**, PO202-WED  
**Noetzli L.**, OR431  
**Noga T.**, PO455-MON  
**Nogami K.**, AS017, PO244-MON, PO491-MON, PO652-MON, PO666-MON, PO668-MON, PO088-TUE, PO145-TUE, PO165-TUE, PO224-TUE, PO018-WED, PO113-WED, PO347-WED  
**Noguchi K.**, AS145, PO203-MON  
**Noguchi K.**, PO545-MON  
**Noh J.-Y.**, PO115-MON  
**Nokes T.**, PO317-TUE  
**Nokes T.**, PO629-WED  
**Nolan B.**, PO237-MON, PO280-MON, PO435-TUE  
**Nolli S.**, OR397  
**Nolte M.**, PO152-MON, PO411-MON  
**Nolte M.**, PO273-MON  
**Nomura T.**, PO432-WED  
**Nonent M.**, OR146, PO655-WED  
**Norberg E.-M.**, OR187  
**Norby C.**, PO568-TUE  
**Nørby P.**, PO541-WED  
**Nordenholz K.**, PO377-TUE  
**Nordholm-Carstensen A.**, OR230  
**Norimichi T.**, PO108-WED  
**Noris P.**, PO438-MON, PO473-WED  
**Norling Olsen E.**, PO285-WED  
**Norman D.**, PO126-MON  
**Norman K.**, PO180-MON  
**Noronha C.**, PO037-MON  
**Noroosi N.**, AS110  
**Norris L.**, OR360  
**Norton M.**, PO504-MON  
**Notley C.**, OR332, OR409, OR412  
**Nougier C.**, PO159-TUE, PO198-WED  
**Nounopoulos E.**, PO065-WED

**Nouvellon E.**, OR095, OR188, OR190, PO035-MON  
**Novack A.**, OR028, OR029, PO108-TUE  
**Novák M.**, PO564-MON  
**Novakowski S.**, PO421-MON, PO460-WED  
**Novelli C.**, OR093, PO126-WED, PO615-WED  
**Noventa A.**, PO385-MON  
**Noventa F.**, OR256, OR284, OR291  
**Novichkova G.**, PO496-MON  
**Novichkova G.**, PO503-WED  
**Novkovic A.**, PO252-MON  
**Nowak A.**, AS179  
**Nowak J.**, PO136-TUE  
**Nowak M.**, PO453-WED  
**Nowak T.**, PO605-WED  
**Nowak-Goettl U.**, AS104  
**Nowak-Göttl U.**, PO506-WED  
**Nowakowska M.**, PO300-MON, PO345-WED, PO365-WED  
**Noya L.**, PO043-MON  
**Nuesgen N.**, PO191-WED, PO202-WED  
**Nugent D.**, PO298-WED  
**Nunes F.**, PO663-TUE, PO479-WED  
**Nunes F.**, PO390-WED  
**Nuñez Toscano M.**, PO138-WED  
**Nunn M.**, OR154  
**Nurden A.**, PO436-MON  
**Nurden A.**, AS014, PO416-MON  
**Nurden P.**, AS014, OR003, OR081, OR169, PO436-MON, PO473-WED  
**Nuttall P.**, OR367  
**Nwagha T.**, PO627-TUE  
**Nwogoh B.**, PO334-TUE  
**Nygren P.**, PO431-WED  
**Nylandsted Krogh T.**, OR414  
**O'Connell N.**, PO280-MON  
**O'Donnell J.**, PO280-MON  
**O'Byrne A.**, PO300-TUE  
**O'Rourke M.**, PO435-TUE  
**Oakley E.**, PO449-MON  
**Oakley M.**, PO285-MON  
**Oberbach A.**, PO169-TUE  
**Obergan T.**, PO308-MON  
**Obergan T.**, PO206-MON  
**Obermann-Slupetzky O.**, OR088  
**Obiorah C.**, PO155-WED  
**O'Brien S.**, PO454-MON  
**Obser T.**, OR335  
**Obydennyi S.**, PO392-TUE  
**O'Byrne A.**, PO021-MON  
**O'Byrne A.**, PO001-TUE

## Authors Index

**Ocariza L.**, PO001-TUE, PO300-TUE  
**Oconnell C.**, PO172-WED  
**O'Connell N.**, PO318-WED  
**Odeberg J.**, OR269, PO559-WED, PO564-WED  
**Odiaman L.**, PO440-TUE  
**Odnoczko E.**, PO278-MON, PO049-TUE, PO235-TUE, PO543-TUE, PO526-WED  
**Odone-Filho V.**, PO431-TUE  
**O'Donnell C.**, PO593-TUE  
**O'Donnell J.**, PO676-TUE, PO318-WED  
**O'Donnell J.**, PO667-TUE  
**O'Donnell J.**, OR182  
**O'Donnell J.**, PO019-TUE  
**Offenberg H.**, PO136-TUE  
**Offermanns S.**, OR244  
**O'Gara F.**, PO395-MON  
**Ogasawara M.**, PO183-MON  
**Ogata N.**, PO672-TUE  
**Ogawa M.**, PO589-MON  
**Ogawa M.**, PO434-MON  
**Ogiwara K.**, PO347-WED  
**Ogiwara K.**, OR332, PO244-MON, PO652-MON, PO678-MON, PO145-TUE  
**Ogwen G.**, PO409-TUE  
**Oh D.**, AS195, OR199, PO168-WED  
**Oh H.-K.**, PO119-TUE  
**Oh M.**, PO309-WED  
**Ohashi A.**, PO106-MON, PO186-TUE  
**Ohashi Y.**, OR142  
**Ohishi K.**, PO486-WED  
**Ohlenforst S.**, PO343-WED  
**Ohlman P.**, AS039  
**Ohlmann P.**, PO572-MON  
**Ohmori T.**, OR084, PO354-TUE, PO428-WED  
**Ohnishi T.**, PO477-WED  
**Ohsugi T.**, PO462-TUE  
**Ohta M.**, PO417-TUE  
**Ojala J.**, OR332  
**Okada Y.**, PO477-WED  
**Okafor I.**, PO386-MON  
**Okamoto S.**, PO386-WED  
**Okamoto T.**, PO185-TUE, PO284-TUE, PO335-TUE  
**Okazaki E.**, PO211-TUE, PO250-WED  
**Okazaki H.**, AS107  
**Okechukwu I.**, PO601-WED  
**O'Keefe D.**, PO649-WED  
**Okigaki M.**, OR115  
**Okoroh E.**, OR134

**Okoye H.**, PO450-MON  
**Okpokam D.**, PO386-MON  
**Okpokam O.**, PO386-MON  
**Oku K.**, PO058-WED  
**Oladapo A.**, PO108-TUE  
**Oláh Z.**, PO550-MON  
**Olaiya A.**, PO368-TUE  
**Oldenburg J.**, AS223  
**Oldenburg J.**, OR103, OR212, OR248, OR347, PO256-MON, PO498-MON, PO631-MON, PO637-MON, PO674-MON, PO219-TUE, PO229-TUE, PO243-TUE, PO244-TUE, PO256-TUE, PO262-TUE, PO480-TUE, PO182-WED, PO183-WED, PO184-WED, PO191-WED, PO202-WED, PO251-WED, PO267-WED, PO343-WED, PO508-WED, PO532-WED, PO676-WED  
**Oldgren J.**, PO362-MON  
**O'Leary C.**, PO406-WED  
**O'Leary J.**, OR360  
**Olgasi C.**, AS088  
**Olie R.**, PO056-MON  
**Olie V.**, PO598-TUE  
**Oliva M. L.**, PO184-TUE, PO054-WED  
**Oliva R.**, PO582-MON  
**Oliveira J.**, PO313-TUE  
**Oliveira L.**, PO286-MON  
**Oliveira C.**, PO054-WED  
**Oliver A.**, PO474-TUE  
**Olivera P.**, PO538-MON, PO056-TUE, PO321-TUE, PO445-TUE  
**Olivera P.**, PO375-TUE, PO407-WED  
**Olivieri O.**, OR050, OR080, PO554-TUE, PO555-TUE  
**Ollivier V.**, PO079.1-MON  
**Ollivier V.**, OR170, OR420, PO330-MON  
**Olsen J. O.**, PO283-TUE, PO333-WED  
**Olsen O.**, OR237, PO561-TUE  
**Olsen R.**, PO328-TUE  
**Olsen Krogh B.**, PO455-TUE  
**Olson N.**, OR238  
**Olson W.**, PO625-MON  
**Omaivboje B.**, PO403-TUE  
**O'Malley P.**, PO374-WED  
**Omarova F.**, OR374  
**Omunakwe H.**, PO155-WED  
**Ondrakova M.**, PO364-WED  
**O'Neil K.**, PO457-MON  
**Onelöv L.**, PO195-MON  
**Oner A.**, PO310-MON  
**Ong W. M. M.**, PO430-TUE

**Ono T.**, OR352, PO351-MON  
**Ono Y.**, PO178-MON  
**Ono-Uruga Y.**, PO386-WED  
**Onselaer M.-B.**, PO101-WED  
**Onundarson P.**, PO412-WED  
**Ooms M.**, PO450-WED  
**Oomura K.**, PO058-WED  
**Oldenburg S.**, PO275-TUE  
**Opastirakul S.**, PO275-TUE  
**Opstad T. B.**, PO293-TUE, PO342-WED  
**Orban C.**, PO501-TUE  
**Orbe J.**, AS230, OR116, PO342-MON  
**Orecna M.**, OR174, PO603-WED  
**Orfeo T.**, AS050, PO576-MON, PO467-TUE, PO425-WED  
**Orfeo T.**, PO371-MON  
**Orihashi Y.**, PO621-MON, PO603-TUE  
**Orlandini F.**, PO585-TUE  
**Orlando C.**, OR079  
**Orlando L.**, PO614-WED  
**Orosz A.**, PO224-MON  
**Orsi F.**, PO066-WED, PO067-WED  
**Orsi F.**, OR263  
**Orsi F.**, OR094, PO145-WED  
**Orsi F.**, PO422-MON, PO531-MON  
**Orsi F.**, PO190-MON  
**Ortiz M.**, OR220, PO480-WED  
**Ortiz C.**, PO435-WED  
**Ortiz Nareto A.**, PO236-WED  
**Ortiz Sánchez J.**, PO485-TUE  
**Ortiz-Costa S.**, PO133-MON  
**Osada M.**, OR404  
**Osaki T.**, OR250  
**O'Shea S.**, PO406-WED, PO639-WED  
**Osim E.**, PO386-MON  
**Osman A.**, AS052  
**Osmarina M.**, PO501-WED  
**Ostapchenko L.**, PO382-TUE  
**Östenson C.-G.**, PO383-TUE  
**Östenson C.-G.**, PO392-WED  
**Østergaard H.**, OR237  
**Osterling Koskinen L.**, PO299-WED  
**Østerud B.**, PO283-TUE, PO333-WED  
**Ota S.**, OR051  
**Otaso J.**, PO068-TUE, PO522-WED  
**Otero A.**, PO042-MON, PO055-WED  
**Otero R.**, PO576-TUE  
**Othman M.**, OR337, PO484-TUE, PO180-WED, PO519-WED  
**Othman N.**, OR060

## Authors Index

O'Toole S., OR360  
**Ottaiano T.**, P0054-WED  
**Otteby K.**, AS040  
**Otten H.-M.**, AS197, OR292, P0624-WED  
**Ou K.**, AS185  
**Oude Egbrink M.**, P0452-TUE  
**Oudega R.**, P0583-TUE, P0584-TUE  
**Ounnoughene N.**, AS164  
**Oury C.**, AS006, OR278, P0407-MON, P0396-TUE  
**Outteridge S.**, OR016  
**Ouvifña S.**, P0043-MON  
**Ouwehand W.**, P0436-MON  
**Ouwehand W.**, P0384-WED  
**Ouweneel A.**, AS208  
**Ouyang Q.**, P0195-TUE  
**Ovanesov M.**, P0560-MON, P0008-TUE  
**Ovanesov M.**, OR174, P0603-WED  
**Overbeck R.**, OR299  
**Overgaard M.**, OR237  
**Overvad K.**, AS083, OR076, OR129, OR345, P0104-TUE, P0111-TUE, P0112-TUE  
**Övsepyan R.**, P0147-WED  
**Övstebo R.**, P0561-MON  
**Owaidah M. T.**, P0164-MON  
**Owaidah T.**, P0148-TUE  
**Own R.**, P0085-MON  
**Oxley N.**, OR398  
**Oyarzabal J.**, AS230, OR116  
**Oymak Y.**, OR262, P0590-MON, P0649-TUE  
**Ozaki Y.**, OR242, OR343, OR404, P0402-MON, P0419-MON, P0417-TUE  
**Ozatli D.**, P0051-WED  
**Ozcan E.**, OR262  
**Ozcan H.**, P0295-WED  
**Ozdemir M.**, P0490-TUE, P0008-WED  
**Ozdemir N.**, OR144  
**Ozdemir N.**, P0275-MON, P0502-MON, P0521-WED, P0525-WED  
**Ozdemir Z.**, P0196-TUE  
**Ozelo M.**, P0286-MON, P0251-WED, P0296-WED  
**Ozelo M.**, AS122, P0262-MON  
**Ozgenel M.**, P0617-TUE  
**Ozgurler Akpinar F.**, P0158-TUE  
**Ozkan C.**, P0301-WED  
**Ozpolat T.**, P0568-TUE  
**Ozsvar Kozma M.**, P0298-TUE  
**Ozturk O.**, P0143-TUE  
**Öztürk Ö.**, P0158-TUE

**P N.**, P0200-MON  
**P'Ng S.**, P0258-TUE  
**Pabinger I.**, AS034, OR227, OR260, OR313, OR357, P0096-MON, P0235-MON, P0236-TUE, P0258-TUE, P0262-TUE, P0122-WED, P0166-WED, P0273-WED, P0391-WED, P0528-WED  
**Pabinger-Fasching I.**, OR347  
**Pacheco E.**, P0318-TUE  
**Pacheco M.**, P0107-MON  
**Pachlinger R.**, P0150-TUE, P0151-TUE  
**Paciaroni M.**, AS226, AS227  
**Padehand W.**, P0436-MON  
**Padayattil Jose S.**, P0372-TUE  
**Paden H.**, P0319-TUE  
**Padilla J.**, AS187, OR076, OR370, P0497-MON  
**Padilla O.**, P0472-WED  
**Padovan L.**, P0091-MON, P0059-TUE, P0114-WED  
**Paes B.**, P0446-MON  
**Pagan B.**, P0469-MON  
**Pagani F.**, OR296  
**Pagani G.**, P0418-MON  
**Pagano M.**, P0079-TUE  
**Page G.**, P0600-MON, P0582-TUE  
**Pagliari M. T.**, P0582-MON  
**Pai M.**, NUR010, P0361-TUE  
**Paikin J.**, P0489-WED  
**Pailo A.**, P0211-TUE, P0250-WED  
**Paiva J.**, P0003-MON, P0004-MON, P0005-MON, P0634-TUE, P0636-TUE, P0652-TUE, P0042-WED  
**Paje D.**, P0541-TUE  
**Paji T.**, P0181-MON, P0027-WED  
**Pak R.**, P0608-TUE  
**Palareti G.**, P0050-MON, P0627-MON, P0639-MON, P0640-MON, P0024-TUE, P0317-WED, P0674-WED, P0675-WED  
**Palazzo A.**, OR082  
**Palazzo C.**, P0142-WED  
**Palige M.**, P0201-WED  
**Palla A.**, OR132  
**Palla R.**, P0500-MON, P0502-MON, P0521-WED, P0524-WED  
**Palmer B.**, OR386  
**Palmer L.**, P0043-MON  
**Palmer S.**, P0180-TUE  
**Palmerini T.**, P0066-MON  
**Palmieri A.**, P0524-TUE  
**Palmisano J.**, P0657-WED  
**Palomo I.**, AS116, P0010-TUE

**Palomo M.**, P0191-MON  
**Palomo De Udaeta M.**, AS044, P0189-MON  
**Palumbo J.**, AS059, P0125-MON  
**Palumbo R.**, P0053-WED  
**Pamuk G.**, P0043-TUE  
**Pamuk O.**, P0043-TUE  
**Pan R.-Y.**, P0265-WED  
**Pan T. Y.**, P0017-TUE  
**Pan X.**, P0245-WED  
**Panchenko E.**, P0199-MON, P0624-TUE, P0356-WED, P0357-WED  
**Panda R.**, P0583-MON  
**Pandya S.**, P0041-TUE  
**Panes O.**, OR220, P0466-WED, P0472-WED, P0480-WED  
**Panes Becerra O.**, P0358-TUE  
**Pang J.**, P0440-WED, P0453-WED  
**Pang N.**, OR249  
**Pang T.**, P0623-WED, P0635-WED  
**Panholzer E.**, P0150-TUE, P0151-TUE, P0152-TUE, P0209-WED  
**Paniccia R.**, OR253, OR396, OR400, P0067-MON, P0365-MON, P0366-MON, P0020-TUE, P0071-TUE, P0076-TUE, P0084-TUE  
**Panicot-Dubois L.**, OR311, P0322-MON, P0022-TUE  
**Panigada M.**, P0338-WED  
**Panizo E.**, P0116-TUE  
**Panizzi P.**, OR423  
**Panju M.**, NUR010, P0361-TUE  
**Pannier B.**, P0033-TUE  
**Panova-Noeva M.**, P0478-WED  
**Pan-Petesch B.**, OR024, OR347, P0512-MON, P0253-WED  
**Pantelev M.**, AS142, OR245, P0496-MON, P0569-MON, P0183-TUE, P0047-WED, P0103-WED, P0436-WED  
**Pantelev M.**, P0067-TUE, P0392-TUE  
**Pantelev M.**, P0503-WED  
**Panzer S.**, P0122-WED, P0528-WED  
**Paola R.**, P0650-TUE  
**Paoletti O.**, OR065  
**Pap A.**, OR326  
**Papapetrou E.**, P0551-TUE  
**Paparo C.**, P0671-WED  
**Papayan L.**, P0057-TUE, P0367-TUE, P0111-WED  
**Papayan L.**, P0503-TUE  
**Papkov V.**, P0073-TUE

## Authors Index

**Pappalardo E.**, OR083, P0580-MON  
**Paramo J.**, AS230, OR116  
**Paramo J.**, P0516-MON  
**Paramo J. A.**, P0342-MON  
**Paramo J.**, P0116-TUE, P0488-TUE  
**Paraskevi B.**, P0102-TUE  
**Parcq J.**, OR314  
**Pare G.**, P0489-WED  
**Paredes R.**, P0355-WED  
**Parent F.**, OR146, OR149, OR192, P0655-WED  
**Paret G.**, P0429-TUE  
**Paréyn I.**, OR087, OR155  
**Pargalava N.**, P0585-WED  
**Parikh S.**, AS166, P0571-WED  
**Parini P.**, P0564-WED  
**Parise L.**, OR280, AS182  
**Parise L.**, P0331-MON  
**Park C.-J.**, P0071-WED, P0427-WED  
**Park H.**, P0035-TUE, P0659-WED  
**Park J. C.**, P0461-TUE  
**Park J.-H.**, P0659-WED  
**Park J.**, P0209-TUE  
**Park M.**, OR303  
**Park R.**, P0471-TUE, P0309-WED  
**Park S.**, P0599-TUE  
**Park S.**, P0035-TUE, P0659-WED  
**Park Y. S.**, P0461-TUE  
**Park Y. S.**, P0300-WED  
**Parker A.**, AS023  
**Parlanti L.**, P0259-TUE  
**Parmar K.**, P0120-MON, P0121-MON  
**Parmer R.**, AS203  
**Parnes A.**, P0239-TUE  
**Parodi G.**, OR396, OR400, P0094-WED  
**Parovichnicova E.**, P0214-TUE  
**Parra R.**, OR144  
**Parra R.**, P0056-TUE, P0243-TUE, P0244-TUE  
**Párrizas M.**, P0187-TUE  
**Parrott M.**, P0423-MON  
**Parry B.**, P0601-WED  
**Parunov L.**, P0150-WED  
**Pasalic L.**, P0075-MON, P0404-MON, P0415-TUE  
**Pasca S.**, P0358-MON, P0614-MON, P0650-TUE, P0029-WED, P0175-WED, P0671-WED  
**Pascreau T.**, P0018-TUE  
**Pasi J.**, P0098-TUE, P0272-WED  
**Pasi K. J.**, OR213

**Paskaleva I.**, P0515-WED  
**Pasquali J.-L.**, OR186  
**Pasqualin T.**, P0211-TUE, P0250-WED  
**Pasqualoto K.**, P0107-MON  
**Passam F.**, P0425-MON  
**Passamonti S.**, AS196, OR083, P0633-WED  
**Passamonti S.**, P0176-WED  
**Passamonti S. M.**, AS195, P0583-WED  
**Pastana A.**, P0034-TUE, P0095-WED  
**Pasterkamp G.**, P0386-TUE  
**Pastore A.**, P0115-TUE  
**Pastori D.**, P0359-MON, P0029-TUE  
**Pastva O.**, P0194-TUE  
**Patarroyo-White S.**, AS192, OR413  
**Patel A.**, P0579-MON  
**Patel C.**, AS018, P0555-WED, P0599-WED  
**Patel H.**, P0374-MON  
**Patel H.**, NUR009, P0390-MON, P0393-MON  
**Patel I.**, P0132-WED  
**Patel I.**, P0432-MON  
**Patel J.**, P0496-TUE  
**Patel J.**, NUR008, OR063, P0347-MON, P0479-TUE  
**Patel K.**, P0512-WED  
**Patel R.**, AS047, OR063, P0558-WED  
**Patel R.**, NUR008, P0347-MON, P0496-TUE  
**Patel R.**, OR310  
**Patel-Hett S.**, P0116-WED, P0597-WED  
**Paternoga I.**, P0477-MON  
**Pathare A.**, P0009-TUE, P0635-TUE  
**Pati H.**, P0272-TUE  
**Patioglu T.**, P0490-TUE, P0008-WED  
**Patiwael S.**, P0352-WED  
**Patrone L.**, P0242-MON, P0260-MON  
**Pattacini C.**, P0222-TUE  
**Patti G.**, P0024-TUE  
**Patzke J.**, P0094-MON  
**Paul D.**, OR274  
**Paul D.**, AS070, P0423-MON  
**Pautus S.**, P0339-TUE  
**Pav J.**, P0621-MON  
**Pavani G.**, OR178  
**Pavlova A.**, OR248, P0219-TUE, P0229-TUE, P0532-WED  
**Pavlova B.**, P0254-WED

**Pavlova B.**, OR088  
**Pavlovskaja Y.**, P0044-TUE, P0106-WED  
**Pavord S.**, AS054, OR064, P0175-TUE  
**Pawelec K.**, P0574-WED  
**Pawlak D.**, P0300-MON, P0345-WED, P0365-WED  
**Pawlinski R.**, AS049, OR048, OR306  
**Payandeh M.**, P0628-TUE  
**Payne J.**, AS159, OR104, OR145, OR386, P0521-WED  
**Payrastra B.**, P0416-MON, P0423-TUE, P0514-TUE  
**Pazzi M.**, P0067-MON, P0366-MON, P0365-TUE, P0477-TUE  
**Pc J.**, P0009-TUE  
**Peake I.**, OR406  
**Peake I.**, AS064, OR086, P0649-MON, P0667-MON, P0676-MON  
**Pease R.**, P0190-WED  
**Pease R.**, AS003, P0096-WED  
**Pedersen L.**, OR098  
**Pedersen S.**, P0130-MON, P0343-MON  
**Pedrazzi P.**, P0264-MON  
**Pedrini S.**, P0671-WED  
**Pedrosa W.**, P0390-WED  
**Peerlinck K.**, OR013, OR144, OR231, P0364-MON, P0142-TUE  
**Peerschke E.**, P0140-WED  
**Peetermans M.**, AS009, AS113, P0364-MON  
**Peeters M.**, P0215-MON, P0519-TUE  
**Peil H.**, P0596-WED  
**Peine S.**, P0583-MON  
**Peiretti F.**, AS014, P0385-WED  
**Peixoto C.**, P0484-TUE  
**Peixoto S.**, P0253-MON  
**Peled E.**, P0126-MON  
**Pelkey G.**, OR056  
**Pelkmans L.**, AS105, OR301, P0089-MON, P0672-MON  
**Pellegrinelli V.**, AS043  
**Pelletier-Galameau M.**, P0628-WED  
**Peltenburg H.**, OR257  
**Pelzing M.**, P0144-TUE  
**Pena E.**, P0017-MON, P0019-MON  
**Penaloza A.**, OR192, OR194, P0598-MON, P0579-TUE  
**Pendleton R.**, P0604-MON  
**Peng C.-T.**, P0452-MON

## Authors Index

**Peng J.**, AS074, OR138, OR261, PO319-MON  
**Pengchata P.**, PO268-WED  
**Pengo V.**, AS037, PO024-TUE, PO077-TUE, PO372-TUE, PO064-WED, PO674-WED, PO675-WED  
**Penigalapati D.**, PO615-MON  
**Penjoyan G.**, PO586-TUE  
**Penka M.**, PO655-MON  
**Pennucci J.**, PO208-TUE  
**Penyige A.**, PO482-WED  
**Pénczes K.**, PO031-WED  
**Pénczes-Daku K.**, PO530-MON  
**Peoch K.**, PO672-WED  
**Pepe C.**, PO644-MON  
**Pepler L.**, AS210  
**Peralta M.**, OR220, PO480-WED  
**Perceau E.**, PO107-TUE  
**Pereira A.**, PO487-TUE  
**Pereira A. C.**, PO158-WED  
**Pereira F.**, PO035-MON  
**Pereira J.**, AS116, OR220, PO466-WED, PO472-WED, PO480-WED  
**Pereira M.**, PO442-MON  
**Pereira Garcia J.**, PO358-TUE  
**Pereira-Flores K.**, AS116  
**Pereiro M.**, PO236-WED  
**Perez K.**, PO190-TUE, PO152-WED  
**Perez-Alenda S.**, PO271-WED  
**Perez-Alvarez S.**, PO198-MON  
**Pérez-Encinas M.**, PO487-TUE  
**Pérez-Rodríguez A.**, PO010-WED  
**Pérez-Sánchez C.**, PO558-TUE  
**Pergantou H.**, PO502-MON, PO437-TUE, PO521-WED  
**Periago A.**, PO439-MON  
**Perin M.**, OR428  
**Perina F.**, PO214-TUE  
**Peris J.**, PO354-MON  
**Perisic L.**, PO564-WED  
**Perkins S.**, PO676-WED  
**Perkmann T.**, AS034  
**Permpikul P.**, PO613-WED  
**Pernod G.**, OR146, OR149, PO095-TUE, PO105-TUE, PO655-WED  
**Pernow J.**, PO013-MON  
**Perot E.**, PO156-MON, PO157-MON  
**Perozziello A.**, PO620-MON  
**Perrier A.**, AS137, OR074, PO587-TUE  
**Perroche S.**, PO045-TUE  
**Perrone D.**, OR300  
**Perry D.**, PO235-MON

**Persson E.**, PO146-MON, PO560-TUE, PO561-TUE  
**Perucci L.**, PO340-WED  
**Perveen H.**, PO539-MON, PO468-WED  
**Pesavento R.**, OR132  
**Peshkova A.**, OR305  
**Penigalapati D.**, PO196-MON  
**Peter K.**, AS184, PO431-MON, PO014-TUE  
**Petermann R.**, PO568-MON, PO575-MON  
**Peters C.**, AS091  
**Peters C.**, AS170  
**Peters L.**, PO423-MON  
**Peters L.**, AS070  
**Peters M.**, NUR004, NUR004, OR013, OR220, PO480-WED, OR389, PO283-MON, PO230-TUE, PO240-TUE, PO251-TUE, PO308-WED  
**Peters R.**, OR413, OR415, PO248-MON  
**Peters T.**, PO546-MON  
**Peter-Salonen K.**, OR432  
**Petersen H.**, PO541-WED  
**Petersen L. C.**, PO455-TUE  
**Petersen M.**, OR036  
**Petersen R.**, PO384-WED  
**Peterson E.**, OR295  
**Petlura C.**, OR007  
**Petrchich W.**, OR281  
**Petrini P.**, OR015, PO255-MON  
**Petris M.**, PO456-MON  
**Petrov V.**, PO019-WED, PO509-WED  
**Petrova O.**, PO470-TUE  
**Petruccelli T.**, PO511-MON  
**Petrucci G.**, OR202  
**Petruzzelli F.**, PO511-MON  
**Petruzziello T.**, AS168  
**Petterson A.-Å.**, PO293-TUE, PO342-WED  
**Petterson T.**, OR128, PO645-WED  
**Pettilä V.**, PO304-MON  
**Peyron I.**, PO226-WED, PO228-WED  
**Peyvandi F.**, AS196, OR005, OR026, OR039, OR083, OR108, OR255, OR394, PO069-MON, PO091-MON, PO164-MON, PO500-MON, PO502-MON, PO503-MON, PO580-MON, PO582-MON, PO592-MON, PO649-MON, PO656-MON, PO663-MON, PO059-TUE, PO090-TUE, PO091-TUE, PO198-TUE, PO574-TUE, PO090-WED, PO114-WED, PO197-WED, PO521-WED, PO524-WED, PO676-WED

**Pezeshekpor B.**, OR248, PO191-WED, PO202-WED  
**Pfaffenberger S.**, PO509-TUE  
**Pfeiff M.**, PO107-WED  
**Pfister S.**, PO094-TUE  
**Pham S.**, OR338  
**Phan M.**, PO523-MON  
**Philbin B.**, PO435-TUE  
**Philip S.**, AS027, OR008  
**Philippe S.**, PO568-MON, PO575-MON  
**Philippou H.**, AS155, OR372, OR433, OR444, PO100-MON, PO180-MON, PO182-TUE, PO188-WED  
**Phillips K.**, PO110-MON, PO297-TUE  
**Phillips M.**, PO165-MON  
**Phoenix F.**, OR016, OR398, PO465-TUE  
**Phua C.**, PO151-WED  
**Piana A.**, PO614-MON  
**Piaserico G.**, PO369-WED  
**Piatek C.**, PO172-WED  
**Piatt R.**, AS070, OR273, OR274, PO003-TUE  
**Pical C.**, PO673-TUE  
**Picard S.**, PO107-TUE  
**Piccioli A.**, OR291  
**Pich S.**, PO516-MON  
**Pichot O.**, AS137  
**Pichugin A.**, OR245  
**Pickering W.**, PO147-TUE  
**Piel G.**, PO142-WED  
**Pieralli F.**, PO640-WED  
**Pierce G.**, PO248-MON  
**Pierce G.**, PO208-TUE, PO678-TUE  
**Pierce G.**, PO237-MON, PO239-MON, PO255-WED  
**Pierobon F.**, PO369-WED  
**Pieroni G.**, OR160, PO644-MON, PO428-TUE  
**Piersma-Wichers M.**, OR100  
**Pierson R.**, PO306-MON  
**Pieters M.**, PO071-MON, PO210-MON, PO214-MON  
**Pieters R.**, OR158  
**Pietrzyk-Nivau A.**, OR234, OR403  
**Pignani S.**, OR179  
**Pignatelli P.**, PO359-MON, PO029-TUE  
**Pike G.**, PO495-MON  
**Pike R.**, PO300-TUE  
**Pilgrim S.**, PO065-TUE  
**Pilgrimm-Thorp A.-K.**, PO420-TUE  
**Pillitteri D.**, PO248-TUE, PO420-TUE

## Authors Index

**Pillois X.**, PO443-MON  
**Pimenta D.**, PO179-TUE  
**Pina E.**, PO354-MON, PO488-TUE  
**Pine P.**, OR318  
**Pineda S.**, PO452-TUE  
**Pinheiro M.**, PO244-WED  
**Pinheiro M.**, PO566-MON, PO189-TUE  
**Pinheiro S.**, PO237-WED  
**Pinho N.**, PO318-TUE  
**Pink R.**, PO247-MON, PO216-TUE  
**Pinnecker J.**, OR405, PO526-TUE  
**Pino M.**, PO414-WED  
**Pinotti G.**, PO115-TUE  
**Pinotti M.**, OR179, OR296, OR297, OR300, OR333, PO158-MON, PO556-TUE, PO557-TUE  
**Pinto P.**, PO207-TUE  
**Pinto R.**, PO012-WED  
**Piot M.**, OR055  
**Piot M.**, OR012, PO262-WED  
**Pipe S.**, OR331  
**Pipe S.**, PO140-WED  
**Piret J.**, PO375-WED  
**Pirtskhelani N.**, PO585-WED  
**Pisa G.**, PO110-TUE  
**Piselli E.**, OR208  
**Pitoc G.**, PO104-MON  
**Pittarello D.**, PO438-TUE  
**Pittman D.**, PO520-TUE  
**Pittman D.**, PO116-WED, PO597-WED  
**Pitukhina N.**, PO023-MON  
**Pizzini A.**, OR197  
**Pizzini A.**, PO264-MON  
**Pizzolato M.**, PO652-TUE  
**Plaimauer B.**, OR151, PO517-TUE  
**Planche V.**, OR003  
**Planinsic R.**, PO017-WED  
**Planquette B.**, PO100-TUE, PO201-TUE  
**Plantier J.-L.**, PO131-TUE, PO311-TUE, PO339-TUE, PO457-TUE  
**Platokouki H.**, AS223, OR141  
**Platokouki H.**, PO502-MON, PO650-MON, PO437-TUE, PO521-WED  
**Platokouki H.**, PO308-WED  
**Platt C.**, OR022  
**Plattfaut C.**, OR439  
**Platton S.**, PO258-WED  
**Pleass H.**, PO623-WED, PO635-WED  
**Plebani M.**, PO077-TUE

**Plesnila N.**, PO177-TUE  
**Plo I.**, OR082  
**Plomann M.**, OR235  
**Ploplis V.**, AS112, OR421, PO305-TUE  
**Plow E.**, PO194-MON  
**Plu-Bureau G.**, OR032, PO527-MON, PO544-TUE  
**Plug T.**, OR441  
**Pluskota E.**, PO194-MON  
**Pluthero F.**, PO403-MON, PO506-MON, PO379-WED  
**Pluthero F.**, OR235  
**Pocard M.**, PO117-MON, PO119-MON  
**Pocard M.**, PO299-MON  
**Pochet L.**, PO172-TUE  
**Podchernyaeva N.**, PO501-WED  
**Podda G. M.**, PO066-MON  
**Podda G.**, PO422-TUE  
**Podgornik H.**, PO181-MON  
**Podoplelova N.**, AS142, PO103-WED  
**Poggi M.**, AS014, PO441-MON, PO385-WED  
**Poggio R.**, PO611-TUE  
**Pohanka A.**, PO360-TUE  
**Pohar Perme M.**, AS101  
**Pohlack-Marsch O.**, PO107-WED, PO137-WED  
**Polack B.**, PO340-MON, PO131-TUE, PO593-WED  
**Polack B.**, PO241-WED  
**Polack B.**, PO223-MON, PO422-WED  
**Polák P.**, PO564-MON  
**Pola ski S.**, PO048-MON  
**Polat A.**, PO143-TUE, PO158-TUE  
**Polat M.**, PO309-MON  
**Poletaev A.**, PO097-MON  
**Poletaev A.**, PO462-MON  
**Polge J.**, PO050-TUE  
**Poli D.**, PO365-MON, PO366-MON, PO614-MON, PO639-MON, PO640-MON, PO071-TUE, PO365-TUE, PO671-WED, PO673-WED, PO674-WED, PO675-WED  
**Póliiska S.**, PO482-WED  
**Polley G.**, OR295  
**Pouard P.**, PO048-MON  
**Pollmann H.**, PO480-TUE  
**Pollock D.**, OR062, PO388-MON  
**Pombo M.**, PO007-TUE  
**Pomero F.**, PO610-TUE, PO613-MON, PO373-WED, PO640-WED

**Pompa M. T.**, PO206-TUE, PO249-WED  
**Pompa T.**, PO355-WED  
**Pompili M.**, PO007-MON  
**Poncellet P.**, PO337-MON, PO340-MON  
**Poncet A.**, PO011-TUE  
**Poncz M.**, PO328-WED  
**Pongtanakul B.**, PO268-WED, PO319-WED  
**Ponnusamy T.**, AS027, OR008, PO083-MON  
**Ponomareva E.**, PO118-WED  
**Ponomaryov T.**, PO325-MON  
**Pons E.**, PO042-MON  
**Pons S.**, PO373-MON  
**Pons V.**, PO321-TUE  
**Pons V.**, PO538-MON, PO056-TUE, PO375-TUE, PO445-TUE, PO407-WED  
**Pontal D.**, PO535-MON  
**Poole A.**, AS141  
**Poole A.**, OR244, OR275, PO458-WED, PO461-WED  
**Poole A.**, AS126  
**Poon M.-C.**, PO440-TUE  
**Popescu I.**, PO501-TUE  
**Popescu M.**, PO501-TUE  
**Popp B.**, PO605-WED  
**Popp M.**, OR017  
**Porreca E.**, AS197, OR292, PO103-TUE, PO624-WED  
**Porro F.**, OR132  
**Porsella R.**, PO092-TUE, PO231-WED  
**Porte R.**, OR070, PO002-MON  
**Porteous R.**, OR310  
**Porter J.**, PO239-TUE  
**Porter J.**, PO297-TUE  
**Portier I.**, OR087  
**Portilla C.**, PO360-WED  
**Portillo A.**, OR321, PO576-TUE  
**Portugal M.**, PO034-WED  
**Posadas-Martinez M.**, PO642-WED  
**Posadas-Martinez M. L.**, PO620-WED  
**Posch F.**, AS034, OR227, OR260, OR357, PO391-WED  
**Posner M.**, PO296-TUE  
**Post J.**, OR257  
**Potze W.**, OR435  
**Pou R.**, PO042-MON  
**Pouard P.**, PO018-TUE  
**Poul H.**, PO128-TUE  
**Poulsen L. H.**, PO293-WED  
**Poulsen L.**, OR212  
**Poulton T.**, PO634-WED

## Authors Index

Pouplard C., AS108, OR055, P0056-WED  
 Pouymayou C., P0440-MON, P0441-MON, P0443-MON  
 Pouymayou K., OR024  
 Prabhala H., P0154-TUE  
 Pradella P., OR093  
 Pradhan S., OR277  
 Praet S., P0267-MON  
 Pragst I., AS218  
 Prakash A., P0531-WED  
 Prakash G., P0200-MON  
 Prakash P., P0521-TUE  
 Prandoni P., OR132, OR195, OR256, OR291, OR326, P0608-MON  
 Prasad J., P0493-MON  
 Prat A., P0324-MON  
 Prat M., OR161  
 Pratikhya P., OR318  
 Pratt K., P0248-MON  
 Pravetoni G., P0574-TUE  
 Preis M., P0248-TUE  
 Preis M., P0137-WED  
 Premjani V., P0135-MON  
 Prenninger T., P0249-MON, P0160-TUE, P0232-WED  
 Prentice D., OR194  
 Presch I., OR088  
 Presles E., OR146, OR149, P0262-WED, P0655-WED  
 Presnyakova M., P0028-WED, P0030-WED  
 Preston R., OR182  
 Pretzell I., P0591-MON  
 Preusser M., OR357  
 Prevot N., AS082  
 Prezoti A., P0034-WED  
 Prezoto B., P0179-TUE  
 Prezotti A., P0286-MON  
 Price M., P0019-TUE  
 Price V., AS158  
 Prigancova T., P0249-TUE, P0371-TUE, P0022-WED, P0061-WED  
 Prince R., P0489-MON  
 Pringle J., AS041  
 Prins M., AS022, AS099, OR256, OR259, OR291  
 Prins M., OR326  
 Priora R., OR253, P0365-MON, P0366-MON, P0071-TUE, P0076-TUE, P0365-TUE, P0477-TUE  
 Prisco D., OR132, OR270, P0226-MON, P0084-TUE  
 Prochaska J., P0356-TUE  
 Prochazka M., P0564-MON, P0542-TUE

Prochazkova J., P0060-TUE, P0542-TUE  
 Procházková J., P0564-MON  
 Prohaska K., P0150-TUE  
 Projahn D., P0091-WED  
 Prokhorova I., P0586-TUE  
 Protti A., OR005  
 Proulle V., AS146  
 Proulle V., P0658-TUE  
 Prout H., P0097-TUE, P0109-TUE  
 Provaznikova D., P0224-WED  
 Provost K., OR146, OR149, P0655-WED  
 Provost P., AS052  
 Prudent M., P0400-TUE  
 Pruner I., P0547-MON, P0159-WED  
 Pruss C., P0656-TUE  
 Pruszczyk P., P0626-MON, P0619-WED  
 Pruthi R., P0484-WED  
 Pruthi R., P0648-MON, P0655-TUE  
 Pruthi R., P0037-WED  
 Prydzial E., AS111  
 Prydzial E., OR271  
 Prydzial E., P0459-TUE  
 Psaty B., P0557-WED  
 Pshonkin A., P0503-WED  
 Puccia G., P0618-WED  
 Puetz J., P0255-WED  
 Puget H., P0620-MON  
 Puig J., P0038-MON  
 Pujadas-Mestres L., P0082-WED  
 Pujol-Moix N., P0473-WED  
 Pula G., P0065-MON  
 Pula G., P0016-MON, P0296-TUE  
 Pulcinelli F. M., P0084-WED, P0316-WED  
 Pulcinelli F. M., P0060-MON  
 Pulcinelli R., P0508-MON  
 Pulskens W., OR124  
 Pun S., P0556-WED  
 Purev T., P0072-WED  
 Puri A., P0603-TUE  
 Purohit A., P0272-TUE  
 Pusateri A., P0467-TUE  
 Puskarich M., P0490-WED  
 Putchakarn P., P0110-WED  
 Puttaiah P., P0531-WED  
 Putti M., P0456-MON  
 Putz M., P0199-WED, P0200-WED  
 Puurunen M., P0593-TUE  
 Puy C., OR353  
 Puzzo F., P0554-TUE

Qi X., OR047  
 Qian K., OR177, P0154-TUE, P0049-WED  
 Qiao S., OR286, OR302  
 Qiao Z., AS109  
 Qin J., P0194-MON  
 Qin J., P0049-WED  
 Qu D., OR031  
 Qu G., P0172-MON  
 Qu L., OR117  
 Quaglia I., P0483-TUE  
 Quaino S., P0145-WED  
 Quan M., P0349-MON  
 Quarroz C., P0101-MON  
 Quartey P., P0502-MON  
 Quecke T., OR439  
 Queen S., OR042  
 Quehenberger P., AS034, P0096-MON, P0236-TUE, P0391-TUE, P0166-WED, P0528-WED  
 Quere I., P0535-MON, P0653-WED  
 Queré I., AS137, OR095, OR188, OR190  
 Querol F., P0271-WED  
 Quesne J., P0568-MON  
 Quilici J., P0493-WED  
 Quinn D., P0172-WED  
 Quintana I., P0533-MON, P0199-TUE  
 Quintanilla M., OR359, P0336-MON  
 Quintavalle G., P0264-MON, P0222-TUE  
 Quirino B., P0043-WED  
 Quiroga T., P0472-WED  
 Quiros F., P0642-WED  
 Quon D., P0235-MON, P0298-WED  
 Qureshi H., P0317-TUE  
 R N., P0009-TUE  
 R. Rosendaal F., P0565-WED  
 Raake W., P0291-MON  
 Rabal O., AS230  
 Rabbolini D., OR002, P0433-MON, P0421-TUE  
 Rabinovich D., OR415  
 Rabinovich O., P0180-TUE  
 Radhakrishnan A., P0057-MON, P0026-TUE  
 Radic Antolic M., P0436-TUE  
 Rädler J., OR335  
 Radojkovic D., P0547-MON, P0159-WED  
 Radossi P., AS122, OR297, P0262-MON, P0369-WED  
 Radovska A., P0224-WED

## Authors Index

Radu C., AS042, OR172, P0341-MON, P0331-TUE, P0332-TUE, P0548-TUE  
 Radu C. M., P0193-MON, P0387-WED  
 Rafailovich M., P0202-TUE  
 Rafeedheen R., P0099-MON, P0041-TUE  
 Raffini L., AS161  
 Rafique A., P0193-WED  
 Rafowicz A., OR141  
 Ragni M., OR088, OR090, OR201, P0255-WED  
 Ragni M., P0277-WED  
 Ragoonanan V., P0379-MON, P0383-MON  
 Rahbek-Nielsen H., P0219-WED  
 Rahimi A., P0247-TUE  
 Rahimi K., P0600-WED  
 Rahmouni S., AS006, OR278  
 Raichand S., P0019-TUE  
 Rainey J., P0030-MON  
 Rainger G., P0408-MON  
 Raio L., AS163  
 Raja P., P0347-TUE  
 Rajapakse S., P0021-WED  
 Rak J., P0094-TUE, P0393-WED  
 Rak J., OR047  
 Rakhe S., P0116-WED, P0597-WED  
 Rakic L., P0387-MON  
 Rallapalli P., P0676-WED  
 Ramael S., OR320  
 Raman Madatha V., P0164-MON  
 Ramanjappa M., P0083-MON  
 Ramaoun M., P0494-MON, P0242-TUE, P0520-WED  
 Ramasheuska I., P0629-TUE  
 Ramasubramoni A., P0065-MON  
 Ramberg C., P0338-MON  
 Ramberg C., P0304-TUE, P0308-TUE, P0328-TUE, P0329-TUE, P0396-WED, P0572-WED  
 Rameau P., OR082  
 Ramirez L., P0454-MON  
 Ramirez L., P0543-MON  
 Ramon L. A., P0093-MON, P0536-MON  
 Ramón L., P0344-TUE  
 Ramón L., P0534-MON  
 Ramos M., P0360-WED  
 Ramperti N., P0075-WED  
 Rampinini F., P0126-WED  
 Ramsey P., P0555-WED  
 Ramström S., P0294-MON, P0571-MON  
 Ramzy D., OR216

Rana H., P0615-MON  
 Ranagarajan S., P0009-WED  
 Ranaldo G., AS088  
 Ranalli P., OR202  
 Rånby M., P0367-MON  
 Rancan E., P0614-MON  
 Rance J., NUR014  
 Rancon F., P0107-TUE  
 Rand J., AS033, P0408-WED  
 Rand J., AS037  
 Rand M., AS078, P0426-TUE  
 Rand M., P0388-TUE, P0390-TUE  
 Randi A., AS061  
 Randi A., OR410  
 Rangarajan K., P0009-WED  
 Rangarajan S., AS122, OR015, OR213, P0237-MON, P0247-MON, P0262-MON, P0064-TUE, P0198-TUE, P0216-TUE, P0220-TUE, P0369-TUE, P0130-WED, P0310-WED, P0417-WED  
 Ransinan J., P0437-WED  
 Ranzato B., P0225-TUE  
 Rao A. K., AS067, AS125  
 Rao L. N., OR008  
 Rao T. L. N., AS027  
 Raquet E., P0596-WED  
 Rashid A., P0539-MON, P0468-WED  
 Raskob G., P0613-TUE  
 Raskob G., OR199, OR259, P0608-TUE, P0637-WED  
 Ramael S., OR320  
 Raskob G., P0353-TUE, P0409-WED  
 Raslova H., AS014, OR082  
 Rasmussen C., P0136-TUE  
 Rasmussen L., P0343-MON  
 Rasmussen M., OR230  
 Raso S., P0117-TUE, P0614-WED  
 Rastogi A., P0540-MON, P0005-WED  
 Rat A.-C., OR186  
 Ratasvuori M., P0106-TUE  
 Rathbun S., P0449-TUE, P0157-WED  
 Ramirez L., P0543-MON  
 Ratzinger F., P0391-TUE  
 Raubertas R., P0074-WED  
 Rauch A., AS134, OR219, P0662-TUE, P0513-WED  
 Rauch R., P0667-WED  
 Rauchensteiner S., P0271-MON, P0274-WED, P0283-WED, P0291-WED  
 Rausch A., P0174-WED  
 Rauscher S., P0559-MON  
 Raut M., P0625-MON  
 Rauter I., P0259-MON

Rauzi F., OR341, P0400-MON  
 Ravanat C., P0572-MON  
 Ravibabu R., P0363-TUE  
 Raviv G., P0099-MON  
 Raya A., AS088  
 Rayes J., P0289-TUE  
 Rayès J., P0226-WED  
 Raymer R., P0048-WED  
 Raynard S., P0102-MON  
 Razouki Z., P0619-TUE  
 Re R., P0610-TUE  
 Rea C., P0454-TUE  
 Read D., P0243-WED  
 Realubit R., P0408-WED  
 Reardon S., P0204-TUE  
 Rebecca L., AS047, P0558-WED  
 Rebello R., P0595-MON  
 Rebibo-Sabbah A., P0389-WED  
 Recht M., AS129, P0239-MON, P0285-MON, P0251-WED, P0297-WED, P0298-WED  
 Reddel C., P0149-WED  
 Reddy E., AS168  
 Reddy E. C., P0388-TUE  
 Reding M., P0277-MON  
 Reding M., OR101  
 Redondo Izal A., P0474-TUE  
 Rees H., P0211-MON, P0212-MON, P0331-WED  
 Reeves B., OR048  
 Refaei M., P0592-TUE  
 Regan I., P0435-TUE  
 Regan L., P0045-MON  
 Regar E., P0078-MON  
 Regina C., P0258-TUE  
 Reglinska-Matveyev N., AS149  
 Regnault V., OR186  
 Regnault V., OR091, P0122-MON, P0031-TUE, P0033-TUE  
 Reheman A., AS168  
 Reich H., OR216  
 Reichel J., P0128-MON  
 Reicheltova-Riedelova Z., P0194-TUE  
 Reijers J., P0592-WED  
 Reilly P., OR320, P0362-MON  
 Reina A., P0614-WED  
 Reiner A., OR238  
 Reiner M., P0027-MON  
 Reinhardt C., P0397-MON, P0099-WED  
 Reinhart C., P0182-WED, P0183-WED  
 Reiningger A., OR014  
 Reipert B., AS191, P0152-TUE, P0160-TUE, P0232-WED, P0284-WED  
 Reipert B., AS221, P0236-TUE

## Authors Index

Reipert B., PO249-MON  
 Reis G. P., PO270-TUE, PO499-WED  
 Reis G., PO043-WED  
 Reis M., PO261-WED  
 Reiss C., PO397-MON, PO419-TUE  
 Reitsma P., OR266, PO623-MON, PO660-TUE, PO582-WED  
 Reitsma P., AS056, OR147, PO144-MON, PO562-MON, PO616-MON, PO539-WED, PO570-WED  
 Reitsma P., PO620-TUE, PO666-WED, PO668-WED  
 Reitter E.-M., OR227, PO166-WED  
 Reitter-Pfoertner S., PO236-TUE  
 Reitter-Pfoertner S., PO283-MON  
 Remijn J., PO389-TUE, PO642-TUE, PO470-WED  
 Remijn J., PO072-TUE  
 Remotti L., PO039-MON, PO629-MON  
 Ren J., PO382-WED  
 Ren M., AS147, OR249, PO070-MON  
 Renchi Y., AS075, OR136, OR264, PO320-MON, PO276-TUE, PO566-TUE  
 Rendina A., PO349-MON  
 Rendo P., PO167-MON, PO257-MON  
 Rene O., PO440-MON  
 Renné T., AS008, OR193, PO178-TUE  
 Renné T., PO583-MON  
 Rentz A., PO138-TUE  
 Reny J.-L., AS128, OR397, PO011-TUE  
 Reperant C., OR205  
 Repping S., PO510-MON  
 Resta D., PO179-WED  
 Reutelingsperger C., PO104-WED  
 Reuveny R., PO474-MON  
 Revel-Vilk S., PO427-TUE, PO429-TUE, PO475-WED  
 Revenko A., AS059  
 Reverter J., PO488-TUE  
 Reverter J.-C., PO435-MON  
 Revill C., AS205, PO182-TUE  
 Rewerts C., PO125-MON  
 Rey J.-B., PO105-TUE  
 Rey M., OR020  
 Reyes N., PO637-WED  
 Reyon D., OR039  
 Reyssat M., PO376-WED  
 Rezaee F., PO323-TUE  
 Rezaie A., PO560-MON  
 Rezaie A., PO333-TUE  
 Rezanía S., PO490-WED  
 Rezende M., PO211-TUE, PO250-WED  
 Rezende S., PO522-MON  
 Rezende S., PO034-WED  
 Rezende S. M., PO614-MON  
 Rhodes S., PO362-TUE  
 Ria L., PO671-WED  
 Ribeiro A., PO313-TUE  
 Ribeiro D., PO562-WED  
 Ribeiro D., PO313-TUE  
 Ribeiro J., PO341-TUE  
 Ribeiro T., AS039  
 Ricaño-Ponce I., PO580-MON  
 Riccardi F., PO264-MON  
 Riccardi L., PO007-MON  
 Rice P., OR398  
 Richard-Jourjon V., PO579-TUE  
 Richards M., AS159  
 Richards M., OR104, OR145, OR386  
 Richardson A., PO623-WED, PO635-WED  
 Riches W., PO641-MON  
 Richter C., OR039  
 Richter C., PO475-WED  
 Ricklin D., PO186-WED  
 Riddell A., PO295-MON, PO370-TUE, PO014-WED, PO353-WED, PO617-WED  
 Ridger V., PO188-WED  
 Ridger V., AS155  
 Ridha E., OR382, PO638-MON  
 Riedel T., PO238-WED  
 Riedel B., PO149-WED  
 Riederer M., OR020, PO022-TUE  
 Riedl J., OR227, OR357, PO122-WED  
 Riera-Mestre A., AS099  
 Rietbrock S., AS084, OR294, PO124-TUE  
 Rietveld I., PO562-MON, PO616-MON  
 Rieubland C., PO485-MON  
 Rigano J., PO048-TUE  
 Rigg R., PO440-WED, PO453-WED  
 Righini M., AS137, AS197, OR034, OR195, OR292, PO100-TUE, PO587-TUE  
 Rigsbee N., PO048-WED  
 Rijken D., PO665-MON  
 Rijken D. C., PO209-MON  
 Rijkman D., PO214-MON  
 Riklin E., PO601-WED  
 Riley R., PO019-TUE  
 Rimac V., PO144-WED  
 Rincon-Tome N., PO082-WED, PO610-WED  
 Rinde L., OR071, OR254, OR293, OR392, PO594-TUE  
 Rios D., PO023-WED  
 Rios D., PO002-WED  
 Riquelme P., PO472-WED  
 Risom Kristensen S. R. K., PO130-MON  
 Ritterhaus C., PO073-TUE  
 Riva F., PO654-TUE  
 Riva N., AS195, OR195, PO614-MON, PO611-TUE, PO405-WED, PO671-WED  
 Riva S., PO574-TUE  
 Rivard G.-E., OR377  
 Rivard G., OR141  
 Rivard G., PO670-MON  
 Rivard G., PO151-WED  
 Rivard G.-E., OR217, PO165-WED, PO282-WED  
 Rivera J., OR368, PO184-MON  
 Rivera J., AS011, OR221, PO439-MON, PO497-MON  
 Rivera-Amaya M., PO445-WED  
 Rivolta G., OR144  
 Rivolta G. F., PO264-MON, PO222-TUE  
 Rizvi B., PO539-MON, PO468-WED  
 Rizzo M. A., PO355-MON  
 Rizzo M., NUR007  
 Roach G., PO507-MON  
 Roach P., PO628-WED  
 Roach R., OR135  
 Robb S., PO180-WED  
 Robbel L., PO146-TUE  
 Robbins A., OR130  
 Robert S., OR311, OR315  
 Robert-Ebadi H., OR034  
 Robert-Ebadi H., PO587-TUE  
 Roberts A. J., PO312-WED  
 Roberts A., PO358-WED, PO359-WED  
 Roberts L., AS047, OR063, OR073, PO479-TUE, PO496-TUE, PO558-WED  
 Roberts L., NUR008, PO347-MON  
 Roberts R., PO139-WED  
 Robertson J., PO420-WED  
 Robertson J., PO118-TUE  
 Robin P., AS082  
 Robinson M., PO173-MON, PO161-TUE, PO233-WED  
 Robledo R., AS070  
 Robles-Carrillo L., PO445-WED, PO446-WED  
 Robson K., PO518-TUE  
 Robson S., PO306-MON  
 Rocca E., OR315  
 Rocca B., OR202  
 Roccatello D., PO068-WED  
 Rocha M., PO313-TUE  
 Rocha T., PO472-TUE  
 Rocha T. R., PO034-TUE, PO095-WED  
 Rochoael N., PO133-MON  
 Roche-Nagle G., PO467-MON, PO473-MON  
 Rocino A., AS222  
 Rode F., OR110, OR414  
 Roder H., PO431-WED  
 Rodger M., AS077, OR053, OR384, PO467-MON, PO473-MON, PO630-WED, PO647-WED  
 Rodger M., AS139  
 Rodgers R., OR104  
 Rodgers G., PO038-WED  
 Rodorigo G., PO264-MON, PO627-MON  
 Rodriguez J., AS230, OR116  
 Rodriguez K., AS195  
 Rodriguez M., PO068-TUE  
 Rodriguez R., AS077  
 Rodriguez V., PO454-MON  
 Rodriguez M., PO355-WED  
 Rodríguez León I., PO285-WED  
 Rodríguez-Acosta A., PO190-TUE  
 Rodríguez-Castro K., PO193-MON, PO114-TUE  
 Rodríguez-Huerta A., PO474-TUE  
 Roelofs J., OR124, PO287-TUE, PO442-WED  
 Roepstorff K., OR036, OR110, PO285-WED  
 Roest M., PO143-MON, PO246-MON, PO584-MON, PO072-TUE, PO386-TUE, PO389-TUE, PO470-WED  
 Rogers G., PO148-MON  
 Rogers G., OR107  
 Rogolino A., PO586-WED  
 Rogozina A., PO630-MON  
 Rojas A., OR220, PO480-WED  
 Rojas H., PO187-MON  
 Rojas-Fernandez C., NUR013  
 Rojas-Saunero P., PO642-WED  
 Rojnuckarin P., PO266-TUE, PO606-TUE, PO584-WED  
 Rokicka M., PO317-TUE  
 Rokni Zadeh H., PO186-MON  
 Roldán V., PO552-WED  
 Rolfe S., PO367-WED  
 Rolim D., PO212-TUE  
 Roll P., OR315  
 Rolland C., PO095-TUE  
 Rolland M., PO118-TUE  
 Rollin J., AS108  
 Roma C., AS201  
 Romagnoli E., OR197  
 Romagnuolo I., PO477-TUE, PO586-WED  
 Romanov V., OR144, PO261-MON  
 Romashevskaya I., PO206-TUE, PO249-WED  
 Rome E., OR059  
 Romecin P., PO435-WED, PO497-WED  
 Romecín P., PO229-MON  
 Romeder-Finger S., PO229-WED  
 Romera M., PO497-MON  
 Romero A., PO620-WED  
 Romero M., PO646-TUE, PO652-TUE  
 Romero V., PO466-WED, PO472-WED  
 Romier B., PO457-WED  
 Romiszewski M., PO575-WED  
 Roncal C., PO342-MON  
 Rondina M., PO227-MON  
 Rondina M., OR243  
 Rondina M., PO604-MON  
 Rongfeng F., OR264, PO320-MON, PO566-TUE  
 Rønnekleiv O., PO432-MON  
 Rönquist-Nii Y., PO363-MON, PO360-TUE  
 Ronzitti G., PO158-MON  
 Rose E., AS178, PO571-TUE  
 Roosendaal G., PO241-MON  
 Roosendaal G., OR102  
 Roostaie S., PO247-TUE, PO600-WED  
 Roques C., PO079.1-MON  
 Rosa J.-P., OR003, OR205, OR234, PO444-WED  
 Rosa T., PO250-WED  
 Rose A., PO657-WED  
 Rosén P., PO146-MON  
 Rosén S., PO146-MON  
 Rosenberg A., OR325  
 Rosenberg N., PO192-MON, PO171-TUE, PO225-WED, PO324-WED  
 Rosencher N., OR283  
 Rosendaal F., AS138, AS196, OR083, OR131, OR135, OR266, OR345, OR392, PO522-MON, PO524-MON, PO525-MON, PO617-MON, PO567-WED, PO582-WED  
 Rosendaal F., OR255, PO069-MON, PO090-WED  
 Rosendaal F., AS083, OR148, OR150, OR322, OR394, PO532-MON, PO616-MON, PO525-TUE, PO601-TUE, PO223-WED, PO539-WED, PO562-WED, PO573-WED, PO577-WED, PO625-WED, PO641-WED  
 Rosendaal F., OR129, OR393, PO164-MON, PO514-MON, PO526-MON, PO104-TUE, PO111-TUE, PO112-TUE, PO494-TUE, PO495-TUE, PO557-WED, PO568-WED  
 Rosendaal F. R., OR391  
 Rosenfeldt L., AS059  
 Rosenplänter K., PO483-WED  
 Rosenthal D., PO083-WED  
 Roshal M., PO128-MON  
 Rosholm A., PO250-MON  
 Rosing J., OR374, PO023-WED  
 Rosinus N., PO513-TUE  
 Ross C., PO164-MON, PO306-WED, PO531-WED  
 Ross E., PO173-MON, PO161-TUE, PO233-WED  
 Ross R., PO656-TUE  
 Rossaint R., OR067, PO314-TUE  
 Rosselló E., PO354-MON  
 Rossetti L., PO378-WED  
 Rossi E., AS087  
 Rossmann H., PO593-MON, PO569-TUE, PO570-TUE  
 Rosu G., PO310-WED  
 Roth N. J., PO605-WED  
 Rothaus Sørensen K., OR036  
 Rothschild C., OR025, OR143, PO501-MON  
 Rottensteiner H., PO517-TUE  
 Rottensteiner H., OR151, OR153, OR155, PO571-TUE  
 Rotz H., OR159  
 Rouault C., AS043  
 Rouillon C., OR091  
 Roumenina L., PO226-WED  
 Rousse N., OR219, PO662-TUE  
 Rousseau A., PO116-MON  
 Rousseau A., OR438, PO108-MON, PO102-TUE  
 Rousseau F., PO134-TUE  
 Russel-Robert V., AS164, OR144  
 Rousset M., PO398-WED  
 Rousso D., PO065-WED  
 Routledge M., PO245-WED  
 Rovin B., PO571-WED  
 Rovira M., PO189-MON, PO191-MON  
 Rowley J., OR243  
 Rowsell H., PO629-WED

## Authors Index

Robson S., PO306-MON  
 Rocca E., OR315  
 Rocca B., OR202  
 Roccatello D., PO068-WED  
 Rocha M., PO313-TUE  
 Rocha T., PO472-TUE  
 Rocha T. R., PO034-TUE, PO095-WED  
 Rochoael N., PO133-MON  
 Roche-Nagle G., PO467-MON, PO473-MON  
 Rocino A., AS222  
 Rode F., OR110, OR414  
 Roder H., PO431-WED  
 Rodger M., AS077, OR053, OR384, PO467-MON, PO473-MON, PO630-WED, PO647-WED  
 Rodger M., AS139  
 Rodgers R., OR104  
 Rodgers G., PO038-WED  
 Rodorigo G., PO264-MON, PO627-MON  
 Rodriguez J., AS230, OR116  
 Rodriguez K., AS195  
 Rodriguez M., PO068-TUE  
 Rodriguez R., AS077  
 Rodriguez V., PO454-MON  
 Rodriguez M., PO355-WED  
 Rodríguez León I., PO285-WED  
 Rodríguez-Acosta A., PO190-TUE  
 Rodríguez-Castro K., PO193-MON, PO114-TUE  
 Rodríguez-Huerta A., PO474-TUE  
 Roelofs J., OR124, PO287-TUE, PO442-WED  
 Roepstorff K., OR036, OR110, PO285-WED  
 Roest M., PO143-MON, PO246-MON, PO584-MON, PO072-TUE, PO386-TUE, PO389-TUE, PO470-WED  
 Rogers G., PO148-MON  
 Rogers G., OR107  
 Rogolino A., PO586-WED  
 Rogozina A., PO630-MON  
 Rojas A., OR220, PO480-WED  
 Rojas H., PO187-MON  
 Rojas-Fernandez C., NUR013  
 Rojas-Saunero P., PO642-WED  
 Rojnuckarin P., PO266-TUE, PO606-TUE, PO584-WED  
 Rokicka M., PO317-TUE  
 Rokni Zadeh H., PO186-MON  
 Roldán V., PO552-WED  
 Rolfe S., PO367-WED  
 Rolim D., PO212-TUE  
 Roll P., OR315  
 Rolland C., PO095-TUE  
 Rolland M., PO118-TUE  
 Rollin J., AS108  
 Roma C., AS201  
 Romagnoli E., OR197  
 Romagnuolo I., PO477-TUE, PO586-WED  
 Romanov V., OR144, PO261-MON  
 Romashevskaya I., PO206-TUE, PO249-WED  
 Rome E., OR059  
 Romecin P., PO435-WED, PO497-WED  
 Romecín P., PO229-MON  
 Romeder-Finger S., PO229-WED  
 Romera M., PO497-MON  
 Romero A., PO620-WED  
 Romero M., PO646-TUE, PO652-TUE  
 Romero V., PO466-WED, PO472-WED  
 Romier B., PO457-WED  
 Romiszewski M., PO575-WED  
 Roncal C., PO342-MON  
 Rondina M., PO227-MON  
 Rondina M., OR243  
 Rondina M., PO604-MON  
 Rongfeng F., OR264, PO320-MON, PO566-TUE  
 Rønnekleiv O., PO432-MON  
 Rönquist-Nii Y., PO363-MON, PO360-TUE  
 Ronzitti G., PO158-MON  
 Rose E., AS178, PO571-TUE  
 Roosendaal G., PO241-MON  
 Roosendaal G., OR102  
 Roostaie S., PO247-TUE, PO600-WED  
 Roques C., PO079.1-MON  
 Rosa J.-P., OR003, OR205, OR234, PO444-WED  
 Rosa T., PO250-WED  
 Rose A., PO657-WED  
 Rosén P., PO146-MON  
 Rosén S., PO146-MON  
 Rosenberg A., OR325  
 Rosenberg N., PO192-MON, PO171-TUE, PO225-WED, PO324-WED  
 Rosencher N., OR283  
 Rosendaal F., AS138, AS196, OR083, OR131, OR135, OR266, OR345, OR392, PO522-MON, PO524-MON, PO525-MON, PO617-MON, PO567-WED, PO582-WED  
 Rosendaal F., OR255, PO069-MON, PO090-WED  
 Rosendaal F., AS083, OR148, OR150, OR322, OR394, PO532-MON, PO616-MON, PO525-TUE, PO601-TUE, PO223-WED, PO539-WED, PO562-WED, PO573-WED, PO577-WED, PO625-WED, PO641-WED  
 Rosendaal F., OR129, OR393, PO164-MON, PO514-MON, PO526-MON, PO104-TUE, PO111-TUE, PO112-TUE, PO494-TUE, PO495-TUE, PO557-WED, PO568-WED  
 Rosendaal F. R., OR391  
 Rosenfeldt L., AS059  
 Rosenplänter K., PO483-WED  
 Rosenthal D., PO083-WED  
 Roshal M., PO128-MON  
 Rosholm A., PO250-MON  
 Rosing J., OR374, PO023-WED  
 Rosinus N., PO513-TUE  
 Ross C., PO164-MON, PO306-WED, PO531-WED  
 Ross E., PO173-MON, PO161-TUE, PO233-WED  
 Ross R., PO656-TUE  
 Rossaint R., OR067, PO314-TUE  
 Rosselló E., PO354-MON  
 Rossetti L., PO378-WED  
 Rossi E., AS087  
 Rossmann H., PO593-MON, PO569-TUE, PO570-TUE  
 Rosu G., PO310-WED  
 Roth N. J., PO605-WED  
 Rothaus Sørensen K., OR036  
 Rothschild C., OR025, OR143, PO501-MON  
 Rottensteiner H., PO517-TUE  
 Rottensteiner H., OR151, OR153, OR155, PO571-TUE  
 Rotz H., OR159  
 Rouault C., AS043  
 Rouillon C., OR091  
 Roumenina L., PO226-WED  
 Rousse N., OR219, PO662-TUE  
 Rousseau A., PO116-MON  
 Rousseau A., OR438, PO108-MON, PO102-TUE  
 Rousseau F., PO134-TUE  
 Russel-Robert V., AS164, OR144  
 Rousset M., PO398-WED  
 Rousso D., PO065-WED  
 Routledge M., PO245-WED  
 Rovin B., PO571-WED  
 Rovira M., PO189-MON, PO191-MON  
 Rowley J., OR243  
 Rowsell H., PO629-WED

## Authors Index

Roy P.-M., AS082, OR192, OR194, OR384, PO579-WED  
**Royer B.**, PO440-MON  
**Rozen L.**, PO081-TUE  
**Rozenfeld I.**, PO471-WED  
**Ruan C.**, OR117, OR419, PO425-TUE, PO039-WED, PO259-WED, PO533-WED  
**Ruan Z.**, OR018  
**Ruangrongrat S.**, PO275-TUE  
**Rubak P.**, PO394-TUE, PO406-TUE, PO407-TUE  
**Rubinstein M.**, PO429-TUE  
**Rubio M.**, OR379  
**Ruchutrakool T.**, PO643-WED  
**Ruchutrakool T.**, PO647-TUE, PO268-WED, PO613-WED  
**Ruckert M.**, PO231-MON  
**Rudianto R.**, PO141-MON  
**Rueda J.**, PO536-MON  
**Ruehl H.**, PO343-WED  
**Ruf W.**, PO397-MON  
**Ruggeri Z.**, PO148-WED  
**Ruhittel S.**, OR123  
**Rui M.**, AS168  
**Ruiz M. M.**, OR220, PO480-WED  
**Ruiz Giardín J. M.**, PO485-TUE  
**Ruiz-Sáez A.**, PO274-WED, PO523-WED  
**Ruiz-Sáez A.**, AS122, PO262-MON  
**Rumbaut R.**, PO497-TUE  
**Rumyantsev S.**, PO569-MON  
**Ruocco L.**, PO671-WED  
**Rupa-Matysek J.**, PO125-TUE, PO170-WED  
**Rusen L.**, PO272-WED  
**Rusen L.**, PO293-WED  
**Russo A.**, PO412-MON  
**Russo L.**, PO339-MON, PO622-TUE, PO179-WED  
**Russo M.**, PO483-MON  
**Rutherford S.**, PO221-TUE  
**Rutkauskienė G.**, PO532-WED  
**Ru-Yu P.**, PO304-WED  
**Ryan K.**, PO280-MON, PO318-WED  
**Rydz N.**, PO227-TUE  
**Rye-Holmboe I.**, OR267, PO494-TUE, PO638-WED  
**Ryerson L.**, PO460-MON  
**R thlisberger B.**, PO635-MON  
**Saad E.**, PO563-WED  
**Saadín K.**, PO099-MON  
**Sabagh M.**, PO640-TUE  
**Sabater-Lleal M.**, PO559-WED  
**Sabatier F.**, AS085  
**Sabatino D.**, OR165

**Sabbah A.**, PO325-TUE  
**Sabi E.**, PO517-WED  
**Sabraa A.**, PO083-TUE  
**Sabrkhany S.**, PO452-TUE  
**Sabroe I.**, OR016  
**Saccullo G.**, PO117-TUE, PO614-WED  
**Sacha P.**, PO238-WED  
**Sadeghi N.**, PO374-WED  
**Sadeghian S.**, PO090-WED  
**Sadeghi-Khomami A.**, PO102-MON, PO150-MON  
**Sadler J. E.**, AS178, OR365  
**Sáez C.**, AS116  
**Safarpour M. M.**, PO490-MON  
**Safaryan L.**, PO573-MON  
**Sage T.**, PO398-MON  
**Saggiolato G.**, OR030, PO193-MON  
**Sagheer S.**, PO633-MON  
**Saharov G.**, PO563-WED  
**Sahin F.**, PO266-MON, PO237-TUE, PO238-TUE  
**Sahin K.**, OR097  
**ahin C.**, PO264-WED  
**Sahlberg K.**, PO177-WED, PO178-WED  
**Said H.**, OR159  
**Saidenberg E.**, PO024-WED  
**Saidenberg E.**, PO320-TUE  
**Saiki Y.**, PO653-TUE  
**Sainati L.**, PO456-MON  
**Saini H.**, PO267-TUE  
**Saini S.**, PO623-TUE  
**Saito K.**, PO653-TUE  
**Saito S.**, PO233-MON  
**Sakai M.**, OR352, PO351-MON  
**Sakai R.**, PO167-TUE  
**Sakai T.**, PO547-WED  
**Sakai T.**, PO017-WED  
**Sakata A.**, OR084, PO354-TUE, PO428-WED  
**Sakatsume K.**, PO653-TUE  
**Sakimoto S.**, PO351-MON  
**Sakuma I.**, PO357-MON  
**Sakuragi M.**, PO320-WED  
**Sakurai Y.**, AS167, PO438-WED  
**Salaj P.**, PO194-TUE, PO247-WED  
**Salamé E.**, OR428  
**Salas E.**, PO516-MON  
**Salas J.**, OR415  
**Salas Q.**, PO354-MON  
**Salas S.**, PO107-TUE  
**Salaun P. Y.**, OR146, OR149, PO655-WED  
**Salaun P.-Y.**, AS082, PO628-WED  
**Salazar A.**, PO190-TUE

**Salazar E.**, PO190-TUE, PO152-WED  
**Salcioglu Z.**, PO265-MON, PO459-MON, PO279-WED  
**Salcioglu Z.**, PO313-MON  
**Saldanha L.**, AS216  
**Sales M.**, PO198-MON  
**Salib M.**, NURO10, PO361-TUE  
**Salicio A.**, AS230  
**Salim M.**, PO263-WED  
**Saliou D.**, PO542-MON  
**Saller F.**, PO489-MON  
**Saller F.**, PO339-TUE  
**Salles-Crawley I.**, OR044  
**Salles-Crawley M. M.**, PO036-WED  
**Salles-Crawley I. I.**, PO139-MON  
**Salloum-Asfar S.**, PO558-TUE, PO539-WED, PO548-WED, PO549-WED, PO552-WED, PO570-WED  
**Salman B.**, PO537-MON, PO507-TUE  
**Salomon O.**, PO192-MON  
**Salomon T.**, PO253-MON  
**Salu B.**, PO184-TUE  
**Saluk J.**, PO212-MON, PO332-WED  
**Salvador S.**, PO355-WED  
**Salvail D.**, PO081-WED  
**Salviato R.**, PO369-WED  
**Samaha C.-M.**, OR283, PO350-TUE  
**Samani N.**, PO542-WED  
**Samba C.**, PO542-MON  
**Sambado L.**, PO518-WED  
**Sambo A.**, PO296-WED  
**Samelson-Jones B.**, AS120, PO160-MON  
**Sameshima N.**, PO552-MON  
**Samis J.**, PO135-MON  
**Samko A.**, PO356-WED  
**Sampaio M.**, PO626-TUE  
**Sampaio M.**, PO054-WED  
**Sampaio S.**, PO212-TUE  
**Sampol J.**, PO337-MON  
**Samson A.**, OR037  
**Samudra A.**, AS212  
**Sanak M.**, PO074-MON, PO500-TUE, PO070-WED  
**Sanchez J.-C.**, OR397  
**Sanchez J.**, AS230  
**Sanchez O.**, AS082, OR146, OR149, OR192, PO201-TUE, PO655-WED  
**Sánchez Guiu M. I.**, PO439-MON, PO497-MON  
**Sánchez Guiú I.**, AS054, AS011

## Authors Index

**Sanchez Luceros A.**, PO039-MON, PO629-MON  
**Sanchez-Luceros A.**, PO634-TUE, PO636-TUE, PO652-TUE  
**Sanchez-Luceros A.**, PO003-MON, PO004-MON, PO005-MON, PO042-WED  
**Sánchez-Luceros A.**, PO646-TUE  
**Sánchez-Méndez J. V.**, PO497-MON  
**Sand C.**, PO459-WED  
**Sanda N.**, PO491-WED  
**Sander K.**, PO429-MON, PO565-MON  
**Sanders L.**, PO452-TUE  
**Sanders Y.**, AS079, OR021, OR203  
**Sanders Y. V.**, PO651-MON  
**Sandgaard Pedersen E.**, PO131-WED  
**Sandhu J.**, PO464-WED  
**Sandhu T.**, PO275-TUE  
**Sandoval C.**, OR220, PO480-WED  
**Sandoval Gonzalez A. C.**, PO164-MON  
**Sandoval-Cooper M.**, OR421  
**Sandset P.**, AS218, OR072, PO478-MON, PO295-TUE, PO600-TUE, PO177-WED, PO178-WED  
**Sandset P. M.**, AS136, OR317, OR440, PO109-MON, PO118-MON, PO123-MON, PO311-MON, PO453-TUE, PO556-TUE, PO557-TUE  
**Sanhes L.**, PO501-MON  
**Sanjay A.**, PO429-WED  
**Sanna G.**, PO068-WED  
**Sano H.**, AS030  
**Sansot M.**, PO411-TUE  
**Santagostino E.**, AS222, OR015, OR108, OR212, OR346, OR347, OR350, PO091-MON, PO164-MON, PO235-MON, PO250-MON, PO090-TUE, PO091-TUE, PO258-TUE, PO114-WED, PO197-WED, PO251-WED, PO253-WED, PO267-WED, PO303-WED  
**Santalucia P.**, PO574-TUE  
**Santamaria A.**, PO321-TUE, PO474-TUE  
**Santamaria A.**, PO538-MON, PO056-TUE, PO375-TUE, PO445-TUE, PO407-WED  
**Santana M.**, PO135-TUE  
**Santhakumar A.**, PO498-WED  
**Santiago-Germán D.**, PO073-MON, PO523-TUE  
**Santoro C.**, PO534-TUE

**Santoro C.**, AS222, OR015, PO162-TUE, PO200-TUE, PO259-TUE, PO650-TUE, PO654-TUE, PO473-WED, PO534-WED  
**Santoro R.**, AS222, AS195, PO352-TUE, PO650-TUE, PO399-WED, PO400-WED  
**Santos L.**, PO404-WED  
**Santos M.**, PO062-MON, PO414-MON  
**Santos R.**, PO508-MON, PO476-TUE  
**Santos R.**, PO472-TUE  
**Santos S.**, PO390-WED  
**Santos X.**, PO567-MON  
**Sanyal A.**, OR435  
**Sap J.**, OR183  
**Sapharikas E.**, PO014-MON  
**Sapin A.-F.**, PO075-TUE  
**Sara C.**, PO347-TUE  
**Saracevic M.**, PO502-MON, PO521-WED  
**Saracini C.**, PO086-MON, PO094-WED  
**Saraeva N.**, PO054-MON  
**Sarafanov A.**, AS142, PO493-MON  
**Sarafanov A.**, OR163, PO196-WED  
**Saraiva E.**, PO133-MON  
**Saraiva S.**, OR094, PO066-WED, PO067-WED  
**Saralidze T.**, PO277-TUE, PO337-WED  
**Saralidze T.**, PO277-TUE  
**Sarbayani A.**, PO600-WED  
**Sardo L.**, NURO12  
**Sargsyan L.**, PO573-MON  
**Sarin A.**, PO383-WED, PO487-WED  
**Sarin S.**, PO005-WED  
**Sarin S.**, PO540-MON  
**Sarmento A.**, PO404-WED  
**Sarr D.**, AS114  
**Sartain S.**, AS213  
**Sartorello F.**, OR078, PO387-WED  
**Sartori F.**, OR050, OR080, PO554-TUE, PO555-TUE  
**Sartori M.**, PO456-MON  
**Sartori M. T.**, PO611-TUE  
**Sartori M.**, PO602-MON, PO627-MON, PO317-WED  
**Sasaki T.**, OR242, OR404, PO402-MON  
**Sasanakul W.**, PO540-TUE, PO647-TUE, PO275-WED  
**Sashindranath M.**, OR380  
**Sasmaz I.**, PO254-TUE, PO301-WED, PO302-WED, PO530-WED

**Sato T.**, AS017  
**Sato T.**, OR051  
**Sato Y.**, PO167-TUE  
**Sato Y.**, PO552-MON  
**Satoh K.**, OR242, OR404, PO402-MON, PO417-TUE  
**Sato-Utida H.**, OR343  
**Satterthwaite A.**, PO315-WED  
**Satti M.**, PO133-WED  
**Sauer T.**, PO177-WED  
**Saunders J.**, PO649-WED  
**Saut N.**, AS014, PO436-MON, PO441-MON, PO443-MON  
**Savage J.**, OR275  
**Savchuk O.**, PO382-TUE  
**Savic A.**, PO251-WED  
**Savigny S.**, PO047-TUE  
**Savinkova I.**, PO537-TUE  
**Savion N.**, PO396-MON  
**Saw Y.**, PO413-WED  
**Sawada H.**, PO515-TUE, PO528-TUE  
**Sawamura A.**, PO178-MON  
**Saxena K.**, PO261-TUE  
**Saxena P.**, PO540-MON, PO005-WED  
**Saxena R.**, PO316-MON, PO480-MON, PO272-TUE, PO529-WED  
**Sayani S.**, PO402-WED  
**Saydam G.**, PO266-MON, PO237-TUE, PO238-TUE  
**Sayilan Sen H.**, PO265-MON, PO459-MON  
**Sayles M. J.**, PO392-MON  
**Sbrojavacca R.**, PO373-WED  
**Scalambrino E.**, PO091-MON, PO059-TUE, PO114-WED, PO176-WED  
**Scalet D.**, OR050, OR296, OR300  
**Scarabin P.-Y.**, OR032, PO527-MON  
**Scaramozza M.**, PO266-WED  
**Scarpazza O.**, PO385-MON  
**Scarvelis D.**, AS139, PO641-MON  
**Scavone M.**, OR019, PO086-WED  
**Scazziota A.**, PO373-MON  
**Scekic M.**, PO052-TUE  
**Schaefer F.**, PO589-MON  
**Schäfer A.**, PO058-MON, PO013-TUE  
**Schäfer K.**, PO513-TUE, PO102-WED  
**Schäfer W.**, PO605-WED  
**Schäffeler E.**, PO667-WED  
**Schalla S.**, PO348-MON, PO416-WED  
**Schaller M.**, PO412-MON

## Authors Index

Schaller M., P0581-MON, P0564-TUE  
Scharf R., P0394-MON, P0448-WED, P0456-WED  
Scharf R. E., P0413-MON, P0420-MON  
Scharf R. E., P0418-MON  
Scharf R. E., P0417-MON  
Scharf R., AS221  
Scharf R., OR077, OR329, P0539-TUE  
Scharrer I., P0591-MON, P0593-MON, P0570-TUE  
Schattner M., AS173, P0012-MON  
Schattner M., P0323-MON  
Schedel A., P0383-WED, P0487-WED  
Scheidler A., P0094-MON  
Scheiflinger F., AS221, OR151, P0249-MON, P0150-TUE, P0151-TUE, P0152-TUE, P0160-TUE, P0517-TUE, P0199-WED, P0201-WED, P0209-WED, P0232-WED, P0284-WED  
Scheiflinger F., OR364  
Schein J., P0625-MON  
Schellenberger V., OR413, OR415  
Schellong S., P0356-TUE, P0378-TUE, P0613-TUE, P0646-WED  
Schemper M., P0236-TUE  
Schenk A., OR059  
Schenk B., P0330-WED  
Schenk J. F., P0013-WED  
Schenk M., P0398-MON, P0506-MON  
Schenk S., P0152-MON  
Scheres L., P0514-MON, P0498-TUE  
Schernthaner G., OR313  
Schernthaner G., OR313  
Schieman C., P0619-MON  
Schiebl S., AS094, AS169  
Schillemans M., AS118  
Schimmel M., P0326-MON  
Schinco P., AS088, AS222, P0303-WED  
Schini-Kerth V., AS039  
Schipper I., P0532-MON  
Schiviz A., OR151, P0199-WED  
Schlagenhauf A., P0453-MON, P0464-MON  
Schlammadinger A., P0550-MON, P0031-WED  
Schledzewski K., OR409  
Schlegel N., P0436-MON, P0440-MON  
Schleifer M., P0065-TUE

Schlichting E., P0178-WED  
Schlosser J., P0605-WED  
Schmid E., P0412-MON  
Schmidbauer S., P0146-TUE, P0194-WED  
Schmidt E.-M., P0412-MON  
Schmidt M., P0107-MON  
Schmidt S., P0094-MON  
Schmitt V., P0593-MON  
Schmitz C., AS068  
Schmohl M., OR320  
Schneewind O., AS113  
Schneider H., OR042  
Schneider J., AS099, P0607-TUE  
Schneider L., P0619-MON  
Schneppenheim R., OR086, OR152, OR335, P0174-MON, P0649-MON  
Schnorbus B., P0483-WED  
Schnurr T., P0392-MON  
Schober A., P0612-WED  
Schobess R., P0093-TUE  
Schöchli H., P0612-WED  
Schoenegger E., P0152-TUE  
Schoenwaelder S., P0443-WED  
Schoenwaelder S., OR037  
Schoergenhofer C., P0391-TUE  
Schoeters J., P0364-MON, P0142-TUE  
Scholz R., P0248-TUE  
Schemper M., OR304, P0517-MON, P0093-TUE, P0248-TUE, P0480-TUE, P0044-WED, P0148-WED  
Schoormans S., OR021, OR203, P0680-TUE  
Schopohl D., P0291-WED  
Schörgenhofer C., P0612-WED  
Schotte T., P0579-TUE  
Schouten H., P0584-TUE  
Schramm W., P0253-TUE  
Schreck U., P0191-WED  
Schreiber K., P0045-MON, P0578-WED  
Schrenk G., P0223-TUE, P0199-WED, P0201-WED, P0270-WED  
Schreuder M., AS056  
Schrijvers L., P0230-TUE  
Schrijvers M., NUR004  
Schroeder J., P0222-WED  
Schroeder V., P0303-TUE, P0185-WED, P0186-WED  
Schroeder V. S., P0181-WED  
Schroeter M., P0102-WED  
Schrum J., P0174-MON  
Schubert W., P0536-WED  
Schueler E., P0646-WED  
Schuett K., AS231, P0465-TUE

Schuetz E., P0549-WED  
Schuh A., P0653-MON, P0638-TUE  
Schuhmacher J., AS018  
Schuhmann M., P0526-TUE  
Schulman J., P0297-MON  
Schulman S., AS077, AS195, NUR010, NUR012, OR061, OR069, OR200, OR282, OR383, AS097, P0297-MON, P0614-MON, P0355-TUE, P0361-TUE, P0378-TUE, P0604-TUE, P0611-TUE, P0613-TUE, P0646-WED  
Schulman S., P0635-MON  
Schulte S., P0146-TUE, P0596-WED  
Schultz N., OR317  
Schulz A., P0478-WED  
Schulz M., P0256-MON  
Schulze H., OR081, P0505-MON  
Schumacher A., OR125  
Schurer J., P0314-TUE  
Schurgers E., OR301, P0025-MON, P0072-TUE  
Schurgers L., P0395-WED  
Schurgers L., P0104-WED  
Schuster M., P0151-TUE  
Schutgens R., P0241-MON  
Schutgens R., OR102, P0658-MON, P0283-WED  
Schutgens R., P0272-MON  
Schutgens R. E., P0246-MON  
Schutte A., P0071-MON  
Schutte L., P0351-WED  
Schutte R., P0071-MON  
Schütz E., P0513-TUE  
Schuurmans M., NUR004, P0230-TUE  
Schwartsman B., P0433-TUE  
Schved J. F., P0502-MON, P0551-TUE  
Schved J.-F., P0592-WED  
Schwaab R., P0283-MON  
Schwab M., P0412-MON, P0667-WED  
Schwabe J., P0565-MON  
Schwameis M., P0612-WED  
Schwartz B., P0198-TUE  
Schwartz B., P0664-MON  
Schwartz C., P0257-WED  
Schwartz E., OR014, OR211, P0281-MON  
Schwartz E., P0231-TUE  
Schwartz J., OR173, P0339-WED  
Schwarz T., AS018, P0214-WED  
Schwarzmaier S., P0177-TUE

## Authors Index

Schwenk J., P0559-WED, P0564-WED  
Schwertz H., OR243  
Schwartz H., OR125  
Schwierczek K., P0427-MON, P0419-TUE, P0483-WED  
Schwocho L., OR199  
Sciani J., P0107-MON  
Sciascia S., OR092, P0045-MON, P0068-WED, P0578-WED  
Scirpa L., P0574-TUE  
Sciuccati G., OR160, P0644-MON, P0428-TUE  
Scott D., OR433  
Scott D., P0008-TUE  
Scott J., OR058  
Scott J., AS205, OR444, P0096-WED  
Scroyen I., P0571-TUE  
Scudeller L., P0483-MON  
Scully M., P0586-MON, P0567-TUE  
Senis Y., OR278  
Senis Y., AS069, OR401, AS066, P0377-WED, P0434-WED  
Senis Y., OR183  
Sennblad B., P0559-WED  
Sennesael A.-L., P0125-WED  
Senthong V., P0001-MON, P0080-MON  
Sebastian P., P0146-TUE  
Sebastian S., P0584-MON  
Sedek M., P0227-WED  
Seder D., P0367-WED  
Seeba H., P0404-TUE  
Seeger J., P0232-MON  
Seelig J., P0366-WED  
Segal M., P0474-MON  
Seger C., P0096-MON  
Seguchi S., AS107  
Sehgal A., OR177, OR213, P0154-TUE, P0049-WED  
Seidah N., P0324-MON  
Seidel D., P0214-WED  
Seidi N., P0318-TUE  
Seidl S., P0109-MON, P0510-TUE  
Seifert W., P0643-MON, P0206-TUE, P0629-TUE, P0249-WED  
Seiffert D., P0074-WED  
Seiffert D., P0028-MON, P0349-MON, P0076-WED  
Seigal D., NUR007  
Seignovet C., P0159-TUE  
Seita I., P0161-MON, P0213-TUE  
ekir U., P0268-MON  
Sekiya A., P0599-MON  
Seksarn P., P0254-MON  
Selan C., AS212

Selbitz A., P0343-WED  
Seligsohn U., OR289, P0171-TUE, P0324-WED  
Seljeflot I., OR251, P0079-MON, P0030-TUE, P0042-TUE, P0293-TUE, P0342-WED  
Sellami M., P0062-WED  
Selmeczi A., P0550-MON, P0031-WED  
Selton-Suty C., P0546-TUE  
Selvam S., OR023  
Semeniak D., P0505-MON  
Semeraro F., OR065, P0338-WED  
Semeraro N., P0503-MON, P0338-WED  
Semple J., AS071  
Semple J., OR139, P0302-TUE  
Sen H., P0279-WED  
Sener S., P0221-MON  
Sengupta T., P0342-TUE  
Seni G., P0035-WED  
Senis Y., OR278  
Senis Y., AS069, OR401, AS066, P0377-WED, P0434-WED  
Senis Y., OR183  
Sennblad B., P0559-WED  
Sennesael A.-L., P0125-WED  
Senthong V., P0001-MON, P0080-MON  
Sebastian P., P0146-TUE  
Sebastian S., P0584-MON  
Sedek M., P0227-WED  
Seder D., P0367-WED  
Seeba H., P0404-TUE  
Seeger J., P0232-MON  
Seelig J., P0366-WED  
Segal M., P0474-MON  
Seger C., P0096-MON  
Seguchi S., AS107  
Sehgal A., OR177, OR213, P0154-TUE, P0049-WED  
Seidah N., P0324-MON  
Seidel D., P0214-WED  
Seidi N., P0318-TUE  
Seidl S., P0109-MON, P0510-TUE  
Seifert W., P0643-MON, P0206-TUE, P0629-TUE, P0249-WED  
Seiffert D., P0074-WED  
Seiffert D., P0028-MON, P0349-MON, P0076-WED  
Seigal D., NUR007  
Seignovet C., P0159-TUE  
Seita I., P0161-MON, P0213-TUE  
ekir U., P0268-MON  
Sekiya A., P0599-MON  
Seksarn P., P0254-MON  
Selan C., AS212

Serra S., P0172-TUE  
Serrão L., P0239-WED  
Serrato T., P0033-TUE  
Seth T., OR066, P0164-MON, P0480-MON, P0272-TUE  
Settapiboon R., P0584-WED  
Settasatian C., P0001-MON, P0080-MON  
Settasatian N., P0001-MON, P0080-MON  
Seuser A., P0290-WED  
Séverin S., P0514-TUE  
Severinsen M., OR345  
Severinsen M., OR129, P0104-TUE  
Severinsen M., AS083, P0111-TUE, P0112-TUE  
Sevestre M., P0095-TUE  
Sevivas T., AS187, OR076  
Sevivas T., OR370  
Sevfert J., P0307-TUE, P0404-TUE  
Seynabou F., P0542-MON  
Seyve L., P0223-MON, P0241-WED, P0422-WED  
Sezgin Evim M., P0268-MON, P0156-TUE  
Shabalina A., P0535-TUE  
Shah A., OR376  
Shah A., OR011  
Shah G., P0559-TUE  
Shah H., P0602-TUE  
Shah M., P0445-MON  
Shah V., P0579-MON  
Shah V., AS077  
Shahani T., P0186-MON  
Shahzad K., P0129-TUE  
Shaju L., P0531-WED  
Shaker J., OR010  
Shamsi T., P0134-TUE, P0549-TUE, P0181-WED  
Shanker J., P0082-MON  
Shanley C., P0180-TUE  
Shantsila E., P0325-MON  
Shao Y., P0492-WED  
Shao Z., P0465-MON  
Shapira I., P0579-MON  
Shapiro A., P0523-MON  
Shapiro A., OR028, P0235-MON, P0277-MON, P0502-MON, P0286-WED, P0521-WED  
Shapiro S., P0603-MON  
Sharabi-Nov A., P0471-WED  
Sharda A., P0425-MON  
Shargall Y., P0619-MON  
Shariff S., P0595-TUE  
Sharma A., P0202-WED

## Authors Index

**Sharma A.**, OR009, PO084-MON, PO040-TUE  
**Sharma A.**, AS212  
**Sharma M.**, PO516-WED  
**Sharma R.**, AS160  
**Sharon N.**, PO324-WED  
**Shash D.**, PO613-TUE  
**Shaverdi M. R.**, PO600-WED  
**Shaverdi S.**, PO247-TUE  
**Shaverdi Niasari M. R.**, PO247-TUE  
**Shavit J.**, OR039  
**Shavit J.**, OR331  
**Shaw J.**, OR310, PO641-MON, PO320-TUE  
**Shawkat S.**, PO196-MON  
**Shaya S.**, AS216  
**Sheehan J.**, PO175-MON  
**Sheffield W.**, OR425  
**Shelar T.**, PO207-TUE  
**Shelke P.**, PO176-MON  
**Shen J.**, PO331-MON  
**Shen L.**, PO176-TUE  
**Shen M.-C.**, PO245-MON, PO226-TUE, PO274-WED  
**Shen W.**, OR137  
**Shendure J.**, OR298  
**Shenkman B.**, PO396-MON, PO055-TUE, PO062-TUE  
**Shenoy A.**, PO363-TUE  
**Shenoy V.**, PO424-MON  
**Shepherd A.**, OR108  
**Shepherd L.**, OR200  
**Sherath M.**, PO555-WED  
**Sherif J.**, PO677-TUE  
**Sherman A.**, OR107, PO220-WED  
**Shestopal S.**, OR163, PO196-WED  
**Shetty S.**, PO207-TUE  
**Shevchenko A.**, PO329-WED  
**Shi H.**, PO608-TUE, PO266-WED  
**Shi P.**, OR210  
**Shi P.**, PO105-WED  
**Shi Q.**, PO222-WED  
**Shi W.**, PO132-MON  
**Shi X.**, OR018  
**Shi Y.**, OR007  
**Shiba T.**, PO300-TUE  
**Shibata Y.**, OR051  
**Shibeko A.**, PO560-MON  
**Shida Y.**, PO652-MON, PO666-MON, PO668-MON, PO224-TUE, PO347-WED  
**Shih A.**, PO570-MON  
**Shih C.-C.**, PO085-WED  
**Shih N.**, PO336-TUE  
**Shiller E.**, PO019-WED

**Shim Y.-J.**, PO164-TUE, PO280-TUE  
**Shima M.**, AS017, AS015, PO151-MON, PO244-MON, PO491-MON, PO652-MON, PO666-MON, PO668-MON, PO088-TUE, PO145-TUE, PO165-TUE, PO205-TUE, PO224-TUE, PO018-WED, PO113-WED, PO205-WED, PO347-WED  
**Shimaoka M.**, PO185-TUE  
**Shimizu C.**, PO455-WED  
**Shimizu H.**, PO441-WED  
**Shimizu I.**, PO173-TUE  
**Shimizu M.**, OR051  
**Shin S.-H.**, PO599-TUE  
**Shin S.**, PO115-MON  
**Shin-Nan C.**, PO304-WED  
**Shinohara K.**, OR051  
**Shinozawa K.**, PO161-MON, PO213-TUE, PO006-WED, PO204-WED  
**Shintome M.**, PO173-TUE  
**Shiota N.**, OR051  
**Shirafuji N.**, PO380-TUE  
**Shirahata A.**, OR142  
**Shirai T.**, OR242, OR343, OR404, PO402-MON  
**Shirakawa R.**, PO653-TUE  
**Shirani P.**, PO533-TUE  
**Shivakumar S.**, OR282  
**Shixiang Z.**, PO394-WED  
**Shmeleva V.**, PO503-TUE  
**Sholzberg M.**, PO150-MON, PO274-MON, PO151-WED, PO248-WED  
**Shpitionkova O.**, PO501-WED  
**Shrestha A.**, PO287-WED  
**Shresthna A.**, PO591-MON  
**Shu L.**, PO321-WED  
**Shubina T.**, PO206-MON, PO308-MON  
**Shu-Hsia H.**, PO304-WED  
**Shukla S.**, PO519-WED  
**Shulutko A.**, PO661-WED  
**Shupp J.**, OR426  
**Shustova O.**, PO327-TUE  
**Shvelidze T.**, PO277-TUE, PO337-WED  
**Siboni S.**, OR026, PO502-MON, PO663-MON, PO090-TUE, PO091-TUE, PO521-WED  
**Siboni S. M.**, PO656-MON, PO650-TUE  
**Sibrowski W.**, PO015-TUE  
**Sickmann A.**, PO499-MON  
**Sicot G.**, PO376-WED  
**Siddiqui A.**, PO195-MON  
**Siddiqui M.**, OR435

**Siddons S.**, PO511-WED  
**Sidhu J.**, OR350, PO241-TUE  
**Sidhu M.**, OR167  
**Sidonio R.**, PO512-WED  
**Sidorova M.**, PO281-TUE, PO290-TUE  
**Sie P.**, PO440-MON  
**Sié P.**, PO345-MON, PO501-MON, PO423-TUE  
**Siebert M.**, PO382-MON  
**Siegel D.**, PO355-MON, PO616-WED  
**Siegbahn A.**, OR046, OR312, PO563-MON, PO330-TUE, PO552-TUE  
**Siegemund A.**, OR304, PO517-MON, PO093-TUE, PO169-TUE, PO044-WED, PO148-WED  
**Siegemund T.**, OR304, PO517-MON, PO093-TUE, PO169-TUE, PO044-WED, PO148-WED  
**Siegerink B.**, OR255, PO069-MON  
**Siegerink B.**, AS138  
**Siebert G.**, PO263-MON  
**Siegmund B.**, PO283-MON  
**Siekman J.**, PO200-WED  
**Siekman J.**, PO249-MON  
**Siemens R.**, PO180-WED  
**Sienko S.**, PO354-WED  
**Sigaud M.**, PO016-WED  
**Sigh J.**, AS019  
**Sigl-Kraetzig M.**, PO256-MON, PO290-WED  
**Siguret V.**, OR196, PO350-TUE, PO672-WED  
**Sikorska A.**, PO278-MON, PO549-MON, PO032-WED, PO526-WED, PO536-WED, PO588-WED  
**Silva A.**, PO269-WED  
**Silva A.**, PO663-TUE, PO237-WED  
**Silva F.**, PO523-MON, PO508-TUE  
**Silva M.**, PO663-TUE, PO237-WED, PO479-WED  
**Silva M. V.**, PO189-TUE, PO002-WED  
**Silva M.**, PO426-TUE  
**Silva R.**, PO663-TUE, PO237-WED  
**Silva G. C.**, AS039  
**Silva M. C.**, PO239-WED  
**Silvari V.**, PO406-WED  
**Silveira A.**, PO231-MON, PO333-MON, PO135-TUE  
**Silveira A.**, OR269, PO559-WED, PO564-WED  
**Silveira J.**, PO145-MON

## Authors Index

**Silveira J.**, PO397-WED  
**Silver R. M.**, AS020  
**Silvestri E.**, PO226-MON  
**Sim D.**, PO026-MON, PO212-WED, PO213-WED, PO553-WED  
**Sim E.**, PO628-MON  
**Sim Y.**, PO218-MON, PO219-MON, PO221-MON  
**Simak J.**, OR174, PO603-WED  
**Simeoni I.**, OR176, PO384-WED  
**Simic Vojak S.**, PO144-WED  
**Simioni P.**, AS042, OR078, OR172, PO061-MON, PO193-MON, PO341-MON, PO456-MON, PO515-MON, PO114-TUE, PO315-TUE, PO331-TUE, PO332-TUE, PO438-TUE, PO524-TUE, PO548-TUE, PO127-WED, PO387-WED  
**Simioni P.**, OR366  
**Simmons K.**, AS231  
**Simon A.**, OR213  
**Simon A.**, OR271  
**Simon S.**, PO181-TUE  
**Simpson C.**, OR200  
**Simpson K.**, PO096-WED, PO190-WED  
**Simpson K.**, AS003  
**Simpson M.**, AS054, AS011  
**Simpson M.**, PO193-WED  
**Simpson M.**, PO262-TUE  
**Sims C.**, PO608-WED  
**Simsekylmaz S.**, PO091-WED  
**Sinegre T.**, PO075-TUE  
**Siner J.**, AS120  
**Singer A.**, PO319-TUE  
**Singer D.**, PO613-TUE  
**Singer H.**, PO191-WED  
**Singh I.**, PO498-WED  
**Singh K.**, PO533-TUE  
**Singh K.**, OR041  
**Singh K.**, OR258, PO472-MON  
**Singh R.**, PO542-WED  
**Singla A.**, PO041-TUE  
**Sinha R.**, PO577-MON  
**Šinigoj P.**, PO360-TUE  
**Sinkov S.**, PO466-TUE, PO586-TUE  
**Sinnamon A.**, AS185  
**Sion K.**, PO656-WED  
**Sioufi J.**, PO366-TUE  
**Siqueira L.**, PO595-TUE  
**Siqueira L. H.**, PO422-MON, PO531-MON  
**Sirachainan N.**, PO540-TUE, PO275-WED  
**Siragusa S.**, OR027, PO117-TUE, PO614-WED

**Siriboonrit U.**, PO613-WED  
**Sirotkina O.**, PO444-MON  
**Sisson M.**, PO353-TUE  
**Sisson M.**, PO409-WED  
**Sitko G.**, PO074-WED  
**Siudut J.**, PO105-MON, PO536-TUE, PO677-WED  
**Sivera P.**, PO671-WED  
**Sjouke B.**, PO028-TUE  
**Skarpen E.**, PO557-TUE  
**Skelton S.**, OR108  
**Skeppholm M.**, OR187, PO368-MON, PO412-WED  
**Skipper M.**, PO394-TUE, PO406-TUE  
**Skjelbakken T.**, OR120, PO561-WED  
**Skjeldestad F. E.**, PO472-MON  
**Skjeldestad F.-E.**, OR134, OR258  
**Skov S.**, OR036, OR040  
**Skowronska M.**, PO581-MON, PO564-TUE  
**Skretting G.**, OR440, PO109-MON, PO118-MON, PO123-MON, PO453-TUE, PO556-TUE, PO557-TUE, PO178-WED  
**Slade J.**, NUR003  
**Slagsvold C. E.**, AS136  
**Slatter D.**, PO353-WED  
**Slaughter M.**, OR338  
**Slavik L.**, PO564-MON, PO060-TUE, PO542-TUE  
**Sled J.**, OR031  
**Sleeman M.**, PO605-MON, PO590-TUE  
**Sletten M.**, PO178-WED  
**Sloane D.**, OR247, OR299  
**Slothuus U.**, OR349, PO139-TUE  
**Slovak M.**, PO341-TUE  
**Småbrekke B.**, OR071, OR254, OR293, OR392, PO594-TUE  
**Smadja D.**, AS087, PO513-WED  
**Smadja D.**, AS086  
**Smalisz-Skrzypczyk K.**, PO574-WED, PO575-WED  
**Smejkal P.**, AS133, PO655-MON  
**Smetanina N.**, PO097-MON  
**Smiers F.**, AS079  
**Smiers F.**, OR389  
**Smirnova O.**, PO057-TUE, PO367-TUE, PO111-WED  
**Smith B.**, OR109  
**Smith C.**, PO048-TUE  
**Smith C.**, AS114  
**Smith C.**, PO600-MON, PO582-TUE  
**Smith D.**, PO625-MON

**Smith E.**, OR392, OR393, PO519-MON, PO524-MON, PO525-MON, PO526-MON, PO493-TUE, PO494-TUE, PO495-TUE, PO567-WED, PO568-WED  
**Smith G.**, OR127  
**Smith H.**, OR028  
**Smith J.**, PO662-WED  
**Smith J. M.**, PO201-MON  
**Smith K.**, PO367-WED  
**Smith K.**, OR372, PO465-TUE  
**Smith K.**, AS003, PO190-WED, PO243-WED  
**Smith K.**, OR410  
**Smith L.**, PO167-MON, PO257-MON  
**Smith M.**, AS130  
**Smith N.**, OR431  
**Smith N.**, NUR005  
**Smith N.**, OR034, OR133, OR266  
**Smith N.**, PO557-WED  
**Smith O.**, OR182  
**Smith R.**, PO073-TUE  
**Smith S.**, OR415  
**Smith S.**, OR178  
**Smith S.**, PO300-TUE  
**Smith S.**, OR353, PO001-TUE, PO451-WED, PO543-WED, PO544-WED  
**Smith S.**, OR354  
**Smith T.**, PO459-TUE  
**Smith V.**, PO107-WED  
**Smith W.**, PO071-MON  
**Smits L.**, PO157-TUE, PO218-WED, PO234-WED  
**Smoyer W.**, PO571-WED  
**Smyth E.**, PO400-MON, PO398-TUE  
**Smyth S.**, OR419  
**Sneeboer M.**, PO611-MON, PO335-WED  
**Snoeren I.**, PO405-MON  
**Soares A.**, PO239-WED  
**Soboci ska-Mirska A.**, PO575-WED  
**Sobrinho T.**, OR116  
**Södergren A.**, PO571-MON  
**Soejima K.**, AS178, PO441-WED  
**Soendergaard H.**, OR040  
**Sofi F.**, PO086-MON, PO039-TUE  
**Sohn D.-W.**, PO035-TUE  
**Söker M.**, PO264-WED  
**Söker S.**, PO264-WED  
**Sokollik C.**, PO485-MON  
**Sokolova L.**, PO118-WED  
**Sokolowska E.**, PO300-MON, PO345-WED, PO365-WED



## Authors Index

Sokolowska B., PO648-TUE  
Solari F., PO499-MON  
Sola-Visner M., OR232  
Soldatenkov V., PO111-WED  
Soldatenkov V., PO503-TUE  
Solecka B., PO675-TUE  
Soler M., PO439-MON  
Solernou A., PO243-WED  
Solheim S., OR251, PO079-MON, PO030-TUE, PO042-TUE  
Solimeno L., PO261-TUE  
Solomon T., OR392, OR393, PO519-MON, PO524-MON, PO525-MON, PO526-MON, PO493-TUE, PO494-TUE, PO495-TUE, PO567-WED, PO568-WED  
Solyboss S., AS077, OR282  
Somajo S., OR369  
Sommer J., PO208-TUE  
Sommerer P., PO647-MON, PO195-WED  
Sommerville L., PO104-MON  
Sonet A., PO167-WED  
Song J., PO471-TUE, PO309-WED  
Song Y.-J., PO471-TUE  
Song Y., PO278-TUE, PO323-WED  
Songnyu R., PO254-MON  
Sonia B., PO444-TUE  
Sonmez M., PO088-WED  
Sónmez T., PO091-WED  
Sonneveld M., AS181, OR364  
Sood M., AS211  
Soomro A., OR377  
Sorensen A., OR237  
Sorensen B., OR177, OR213, PO154-TUE  
Sorensen E., OR338  
Sørensen B., PO454-TUE  
Sørensen H., OR098  
Sori F., PO600-WED  
Soria J., PO117-MON, PO119-MON  
Soria J., PO516-MON  
Soria J. M., PO126-TUE, PO217-WED  
Soria J. M., PO543-MON, PO559-WED  
Soriani F., PO340-WED  
Soroka V., PO576-WED  
Sorrentino A., PO572-WED  
Sorvillo N., PO227-WED  
Sothihikul D., PO254-MON  
Soto G., PO466-WED  
Soto J., PO355-WED  
Soto M., OR220, PO480-WED

Sottilotta G., PO303-WED  
Soucie M., OR162  
Soule E., AS151  
Souri M., OR250  
Sousa J., PO212-TUE  
Sousa L., PO237-WED  
Sousa L., PO663-TUE  
Sousa L., PO340-WED  
South K., PO036-WED  
Souto J., OR076  
Souto J. C., PO559-WED  
Souto J. C., PO543-MON, PO126-TUE, PO217-WED  
Souza L., PO397-WED  
Sovershaev M., AS028, PO572-WED  
Sovershaev T., AS028, OR047  
Spåls-Abrahamsson Y., PO263-WED  
Span L., PO431-WED  
Spanner P., PO356-TUE  
Spanoudaki A., PO102-TUE, PO587-WED  
Sparkenbaugh E., AS049, OR306  
Spath B., PO251-MON, PO174-WED  
Spavor M., PO465-MON  
Speck E., OR139, PO302-TUE  
Spectre G., PO383-TUE, PO392-WED  
Speers H., PO481-MON, PO588-TUE  
Speidl W., AS200, PO282-TUE  
Speidl W., OR123, PO185-MON, PO301-TUE  
Spek C. A., PO164-WED  
Spöker M., PO550-MON  
Spencer A., OR229  
Spencer F., OR395, PO578-TUE  
Spencer F., OR282  
Spencer H. T., PO203-WED  
Spencer Chapman M., PO258-WED  
Sperr W., PO612-WED  
Spiezia L., AS042, OR078, OR172, PO061-MON, PO341-MON, PO456-MON, PO114-TUE, PO315-TUE, PO331-TUE, PO332-TUE, PO438-TUE, PO524-TUE, PO127-WED  
Spinewine A., PO125-WED  
Spinola A., PO318-TUE, PO626-TUE  
Spinola A., PO442-MON  
Spigir R., AS016  
Sponagle K., AS191, AS192, OR409, OR412, PO291-TUE, PO679-TUE  
Spotts G., PO286-WED

Spronk H., PO056-MON  
Spronk H., OR067, OR225, PO348-MON, PO097-WED, PO104-WED, PO349-WED, PO416-WED  
Spronk H., PO092-WED  
Spronk H., PO470-MON  
Spronk H., PO143-MON  
Spyropoulos A., PO362-MON, PO654-WED  
Spyropoulos A., PO521-MON  
Spyropoulos J., PO654-WED  
Squatrito D., PO226-MON  
Squire S., PO269-WED  
Squizzato A., PO610-TUE, PO613-MON, PO028-TUE  
Sramek A., OR391  
Sripraya P., PO120-TUE  
Srivastava A., PO664-MON, PO245-TUE, PO153-WED  
Srivaths L., PO445-MON, PO567-MON  
St. Angelo Iii J., PO329-WED  
St. John A., PO372-WED  
St. John A., PO375-WED  
St. Ledger K., PO089-TUE, PO262-TUE  
Stächele J., PO263-MON  
Staels B., AS201, OR219, PO662-TUE  
Stafford A., PO138-MON  
Stafford A., AS154, AS219, OR057, OR286, OR290, PO403-MON, PO170-TUE  
Stain A. M., AS078  
Stålesen R., PO383-TUE, PO392-WED  
Stalinska K., PO365-WED  
Stalker T., OR038, OR207  
Stalker T., PO467-WED  
Stallmann D., OR252  
Stam J., OR118, PO525-TUE  
Stampfuss J., AS104  
Stanek J., OR157  
Stanford S., PO083-TUE  
Stang L., PO086-TUE  
Stangier J., OR320, PO376-TUE  
Stangl A., PO107-WED, PO137-WED  
Starigk J., PO383-WED  
Stariкова I., PO338-MON, PO572-WED  
Staritz P., PO215-TUE  
Starke R., OR410  
Stasyshn O., PO260-MON  
Stasyshyn O., OR215, PO206-TUE, PO262-TUE, PO249-WED  
Stasyshyn O., PO643-MON, PO629-TUE

## Authors Index

Staudt M., PO091-WED  
Stausholm-Møller A. K., PO130-MON  
Stavermann C., PO395-TUE  
Stavik B., OR440, PO109-MON, PO118-MON, PO123-MON  
Stearns-Kurosawa D., PO564-TUE  
Steede S., PO194-WED  
Steele M., PO426-TUE, PO440-TUE, PO563-TUE  
Stefanini L., AS070, PO423-MON  
Stefanska-Windyga E., PO049-TUE, PO235-TUE  
Steggewentz B., OR054  
Stegner D., AS094, OR017, OR169, OR181, OR405, OR416, PO505-MON, PO526-TUE  
Steiner B., OR020  
Steinitz K., AS191, PO243-TUE, PO244-TUE, PO286-WED  
Steinke W., PO214-WED  
Stellin G., PO438-TUE  
Stemmelin G., PO180-TUE  
Stender S., PO509-MON  
Stennicke H., OR237  
Stensballe J., PO482-MON  
Stentoft J., PO406-TUE  
Stépanian A., PO672-WED  
Stephan B., PO013-WED  
Stephenson J., PO521-MON  
Stephenson T., PO634-WED  
Sterk P., PO335-WED  
Sterling S. P., PO360-WED  
Stern J., PO006-TUE  
Stern S., PO372-WED  
Sterz F., PO612-WED  
Stevano A., OR161  
Stevenazzi C., PO474-TUE  
Stevens J., PO592-WED  
Stevenson B., AS128  
Stevenson W., OR002, PO433-MON, PO421-TUE  
Stevic I., OR373, PO350-MON, PO139-WED  
Stewart A., PO580-TUE  
Stewart S., OR218  
Stewart S., PO580-TUE  
Stewart T., PO580-TUE, PO581-TUE  
Sticchi E., OR270, PO477-TUE, PO586-WED  
Stidl R., PO200-WED  
Stiell I., OR198  
Stieltjes N., AS164, PO501-MON  
Stikarova J., PO238-WED  
Štikarová J., PO194-TUE  
Stinson J., OR328, PO475-MON, PO434-TUE

Stivala S., PO027-MON  
St-Louis J., OR028, OR217, PO282-WED  
Stoilova-Mcphie S., PO192-WED  
Stojkovic S., PO185-MON, PO559-MON  
Stokhuijzen E., OR389, PO240-TUE, PO510-WED  
Stokol T., AS060, PO112-MON  
Stoldt V., PO394-MON, PO448-WED, PO456-WED  
Stoldt V. R., PO413-MON, PO417-MON, PO418-MON, PO420-MON  
Stoll G., AS068, AS094, AS228, OR169, PO526-TUE  
Stoner J., PO523-MON, PO449-TUE, PO517-WED  
Stoof S., PO267-MON, PO282-MON  
Stoof S. C., PO351-WED  
Stopa J., OR417, PO425-MON  
Stopa J., PO346-TUE, PO551-WED  
Storey R., OR398  
Storey R., OR016  
Stoute H., PO105-WED  
Stowers A., PO089-TUE  
Straat R., PO349-WED  
Straat R., PO123-WED, PO609-WED  
Stradal T., AS169  
Strader M., OR174  
Strahs A., OR213  
Strauss T., PO429-TUE, PO659-TUE  
Strawbridge R., OR269, PO559-WED  
Strayhorn D., PO331-MON  
Streif W., PO481-WED  
Strelkov S., OR443  
Strelkova I., PO028-WED, PO030-WED  
Strickland D., PO493-MON  
Strike K., PO380-MON  
Stritt S., AS068, AS169, AS228, OR081, OR416, PO436-MON  
Strong J., PO601-MON, PO580-TUE, PO581-TUE  
Stroobants A., PO401-WED, PO410-WED  
Struble E., PO008-TUE  
Struck H., PO305-WED  
Strukov A., PO620-MON  
Strukova S., PO281-TUE, PO290-TUE, PO537-TUE  
Strulovitch C., NUR009, PO390-MON, PO393-MON  
Stubblefield W., PO227-MON  
Study Group W.-Q., PO639-TUE

Stufano F., PO663-MON  
Stuleva N., PO052-MON, PO589-WED  
Stumpo D., OR085  
Stunnenberg M., PO326-MON  
Sturgeon S., OR037  
Sturk A., PO401-WED  
Sturm R., OR047  
Stuth E., OR058  
Su J., PO039-WED, PO533-WED  
Su J., PO220-WED  
Subramanaian D., PO479-TUE  
Subramaniam S., AS218  
Subramanian S., PO306-WED, PO531-WED  
Subramanyam B., PO213-WED  
Subramanyan B., AS018  
Such G., PO014-TUE  
Suchon P., OR324  
Suda T., PO386-WED  
Suehisa E., PO120-WED  
Sueldo E., PO092-TUE, PO146-WED, PO231-WED  
Suffritti C., PO178-TUE  
Suganuma Y., PO432-WED  
Sugi T., PO167-TUE  
Sugimoto M., PO671-MON, PO205-WED  
Sugita N., PO505-TUE  
Suidan G., PO004-TUE  
Suissa S., OR385, PO577-TUE  
Sukarova Stefanovska E., PO287-MON  
Sukhanov V., PO470-TUE  
Suleiman L., OR358  
Sullenger B., PO104-MON  
Sullenger B., AS151  
Sullivan A., PO088-MON  
Sumarov A., PO496-WED  
Sumi H., PO216-MON, PO462-TUE, PO463-TUE  
Sun B., OR342  
Sun H., OR249  
Sun J., PO292-WED  
Sun J., PO032-MON, PO166-MON, PO052-WED  
Sun M.-F., OR287, OR288  
Sun T., OR265, PO451-TUE  
Sun Y., OR418, PO462-WED  
Sun Y., OR261  
Sundaramoorthi H., OR402, PO034-MON  
Sundarsingh A., PO153-WED  
Sung L., PO454-MON  
Sungur M., PO591-TUE  
Suntsova M., PO496-MON  
Surbek D., AS163  
Suri V., PO200-MON

## Authors Index

Suriano L., PO671-WED  
Suriñach J. M., PO321-TUE  
Surov S., PO047-WED  
Surov S., PO147-WED  
Suryanarayan D., OR061  
Suryanarayan D., PO355-TUE  
Susanna L., PO240-MON  
Susen S., AS134, AS201, OR024, OR025, OR219, PO345-MON, PO662-TUE, PO513-WED  
Sussman M., OR390  
Sutherland M., OR271  
Sutttnar J., PO238-WED  
Sutttnar J., PO194-TUE  
Suvajdzic-Vukovic N., PO252-MON  
Suwanawiboon B., PO675-MON, PO345-TUE, PO647-TUE  
Suwanawiboon B., PO268-WED, PO643-WED  
Suylen D., PO037-TUE  
Suylen D., PO411-MON  
Suzuki E., PO515-TUE, PO528-TUE  
Suzuki K., OR352  
Suzuki K., PO185-TUE, PO284-TUE, PO335-TUE  
Suzuki K., PO173-TUE  
Suzuki N., PO434-MON  
Suzuki N., PO211-WED  
Suzuki T., PO161-MON, PO213-TUE, PO006-WED, PO251-WED  
Suzuki T., PO041-MON, PO357-MON, PO020-WED, PO057-WED  
Suzuki Y., AS030  
Suzuki-Inoue K., OR242, OR343, OR404, PO402-MON, PO419-MON  
Svensson A., OR237, PO541-WED  
Sveshnikova A., AS142  
Sveshnikova A., PO392-TUE  
Svirin P., PO019-WED, PO509-WED  
Swai M., PO063-WED  
Swartz D., AS063  
Sweigert P., PO112-WED  
Swerdlin R., PO512-WED  
Swieringa F., AS204, PO411-MON, PO499-MON, PO155-TUE, PO675-TUE  
Swinnen M., PO002-TUE  
Sword-Buster A., PO637-WED  
Swystun L., OR332, PO679-TUE  
Swystun L., OR412, PO291-TUE  
Swystun L., OR409  
Syed A., AS171  
Syed A., AS051

Syed D., PO182-MON, PO293-MON, PO305-MON, PO334-MON, PO346-MON, PO191-TUE, PO192-TUE, PO337-TUE, PO331-WED, PO332-WED, PO339-WED, PO344-WED, PO374-WED  
Sykora K.-W., PO442-TUE  
Sylman J., PO188-MON  
Syrigos K., PO102-TUE  
Syvannarath V., OR170, PO330-MON  
Szabo A., AS025, AS232, OR006, PO098-WED  
Szabó L., AS004, PO240-WED  
Szafarczyk D., OR077  
Szczepaniak P., PO246-WED  
Szczubialka K., PO300-MON, PO345-WED, PO365-WED  
Szecsi P., PO509-MON  
Székely E., PO516-TUE  
Szkotak A., PO086-TUE  
Szollosi R., PO098-MON  
Szopi ski P., PO609-TUE  
Szołkowski T., PO279-TUE  
Szők T., PO077-MON  
Tablin F., PO006-TUE, PO007-TUE  
Taboukouyou A., PO375-MON  
Tabuchi Y., PO085-TUE  
Tadokoro S., OR340  
Tafur A., PO449-TUE, PO508-TUE, PO157-WED  
Tafur A., PO523-MON  
Tafur A., OR127  
Tafuro E., PO071-TUE  
Taga S., PO173-TUE  
Tagalakis V., OR385, PO577-TUE, PO647-WED  
Tagariello G., PO266-WED, PO369-WED  
Tagawa S., PO172-WED  
Tagliaferri A., AS222, OR144, PO264-MON, PO283-MON, PO222-TUE, PO650-TUE, PO253-WED, PO303-WED  
Tagzirt M., AS201  
Taher M., PO085-MON  
Taher M., PO148-TUE  
Tahtakesen T., PO313-MON  
Tai W.-S., OR031  
Tait C., PO291-WED  
Tait R., OR135  
Tait R., PO271-MON  
Tait R. C., PO283-WED  
Tajer C., PO621-TUE  
Takach Lapner S., AS023  
Takacs N., PO509-TUE  
Takagi A., PO151-MON, PO486-TUE, PO560-WED

Takagi Y., PO151-MON, PO486-TUE, PO560-WED  
Takagishi N., PO661-TUE  
Takahashi H., AS017  
Takahashi N., PO486-WED  
Takahashi N., PO041-MON, PO357-MON, PO020-WED, PO057-WED  
Takayama S., PO211-WED  
Takeo E., PO120-WED  
Takeyama M., PO666-MON, PO668-MON, PO224-TUE  
Taki M., AS017, PO205-TUE, PO233-TUE, PO211-WED  
Talarmain P., PO645-TUE  
Talavera E., OR092  
Talbot K., PO459-TUE  
Talbot T., PO098-TUE  
Taliaferro J., OR207  
Talks K., PO502-WED  
Talks K., AS054  
Tall F., AS164  
Talmon M., AS088  
Tamamyan G., PO573-MON  
Tamara S., PO208-MON  
Tamarin I., PO217-TUE  
Tamary H., PO475-WED  
Tamborini Permunián E., PO405-WED  
Tamminga R., AS079, PO255-WED  
Tamura R., AS143  
Tamura S., OR242, OR404, PO402-MON, PO455-WED  
Tan C. W., PO012-TUE, PO074-TUE  
Tan S., PO326-TUE  
Tan S., OR318  
Tan S., OR415, PO248-MON  
Tan S. C., PO413-WED  
Tanaka K., PO017-WED  
Tanaka K., OR352, PO351-MON  
Tanaka M., PO351-MON  
Tanck M., OR015  
Tandakha D., PO542-MON  
Tandon N., PO611-WED  
Tang A., PO317-TUE  
Tang C., AS026, PO022-MON  
Tang L., PO162-MON, PO132-TUE, PO492-TUE, PO213-WED, PO569-WED  
Tang L., PO246-TUE  
Tang W., OR266  
Tang Y.-H., PO522-TUE  
Tangada S., PO223-TUE, PO270-WED

## Authors Index

Tange J., PO648-MON, PO655-TUE  
Tanka-Salamon A., PO240-WED  
Tantánate C., PO040-MON  
Tantry U., PO076-MON, PO099-MON, PO041-TUE  
Tantucci C., OR315  
Tao M.-H., PO029-MON  
Tao M., OR419  
Tao Y., AS051  
Tarakhovskiy A., PO434-WED  
Tarandovskiy I., OR174, PO603-WED  
Tararano I., PO150-WED  
Tarantino E., PO005-TUE  
Tarantino G., PO614-WED  
Tardy B., AS082, OR012, OR055, PO107-TUE, PO262-WED  
Tardy B., OR012, OR055, PO263-TUE, PO262-WED  
Tarrant J., PO007-WED  
Tartaglione R., OR202  
Tartari C., PO179-WED  
Tartari C., PO339-MON  
Tasneem S., OR377  
Tatonetti N., PO408-WED  
Tatour M., AS096  
Tatsumi K., PO505-TUE  
Tautz L., OR278  
Tavil B., PO505-WED  
Tavkar P., PO153-WED  
Tawara S., PO547-WED  
Tay J., PO324-TUE, PO540-WED, PO546-WED  
Tay J., PO101-TUE  
Tay E., PO413-WED  
Tayfun F., PO525-WED  
Tayfun V., PO051-WED  
Taylor M., PO037-WED  
Taylor P., PO190-TUE  
Tchaikovski S., PO518-MON  
Tcherniantchouk O., OR216  
Te Roller L., PO642-TUE  
Tee L., AS069, PO434-WED  
Tegegn T., OR174, PO603-WED  
Tegtmeier R., PO449-WED  
Teitel J., PO151-WED  
Teitel J., AS122, PO150-MON, PO262-MON, PO274-MON, PO248-WED  
Teitell J., PO286-WED  
Teixeira A., PO340-WED  
Teixeira C., PO179-TUE  
Teixeira-Carvalho A., PO333-MON  
Teliga-Czajkowska J. M., PO536-WED, PO588-WED  
Tellier Z., PO501-MON

Temperilli F., PO060-MON, PO084-WED, PO316-WED  
Ten Brinke A., PO227-WED  
Ten Cate A., PO314-WED  
Ten Cate H., PO056-MON, PO645-MON  
Ten Cate H., OR067, OR096, OR119, OR427, OR430, AS024, PO143-MON, PO348-MON, PO466-MON, PO470-MON, PO348-TUE, PO004-WED, PO033-WED, PO092-WED, PO097-WED, PO314-WED, PO416-WED, PO478-WED  
Ten Cate - Hoek A., PO092-WED  
Ten Cate-Hoek A., PO056-MON  
Ten Cate-Hoek A., OR427, OR430, PO348-MON, PO416-WED  
Ten Cate-Hoek A., PO466-MON, PO471-MON  
Ten Cate-Hoek A., PO470-MON  
Ten Wolde M., PO466-MON, PO470-MON  
Teng Z., PO657-WED  
Tenna A., PO447-MON  
Teraa M., PO389-TUE  
Terenteva V., PO183-TUE  
Ternisien C., AS134, OR024, OR025, PO639-TUE, PO645-TUE, PO664-TUE, PO016-WED  
Termissien A., PO535-MON  
Terpolilli N., PO177-TUE  
Terrasi J., PO203-TUE  
Terrisse A.-D., PO514-TUE  
Tersago D., OR363  
Tersteeg C., OR151, OR153, PO401-MON, PO571-TUE  
Teruel-Montoya R., PO558-TUE, PO552-WED  
Teruel-Montoya R., OR221, PO497-MON, PO338-TUE, PO539-WED  
Teruya J., OR056, PO631-TUE  
Teske G., PO442-WED  
Tesoro T., PO083-WED  
Testa S., OR065, PO639-MON, PO640-MON, PO059-TUE, PO197-TUE, PO671-WED  
Teste B., PO376-WED  
Testen A., OR366  
Texter K., OR157  
Thabane L., AS122, PO261-MON, PO262-MON, PO463-MON  
Thacil J., AS054  
Thakore J., PO075-WED  
Thaler B., AS200, PO282-TUE, PO301-TUE

Thaler J., OR313, OR357, PO391-WED  
Thälín C., PO171-WED  
Thalji N., PO415-WED  
Thalji N., PO632-MON  
Thanos C., OR247, OR299  
Thati M., PO129-TUE  
Thaweekhot T., PO040-MON  
Théâtre E., OR278, PO407-MON  
Theilwell C., OR445  
Theogene A., OR384  
Theophil R., OR439  
Theophilus B., OR086  
Theresa C., PO421-WED  
Therkelsen M., PO121-WED  
Thérond P., PO437-WED  
Therwath A., PO117-MON, PO119-MON  
Theunissen M., PO350-WED  
Thiede B., PO557-TUE  
Thiele B., PO669-MON  
Thielmann I., AS094, AS218, PO129-TUE  
Thim L., OR414  
Thippayanuraksakul P., PO606-TUE  
Thiranos J.-C., PO263-TUE  
Thiry M., OR278  
Thivillier C., PO546-TUE  
Thom J., PO669-TUE  
Thom K. E., PO302-MON  
Thomas A., OR104  
Thomas J., OR056  
Thomas M., PO586-MON  
Thomas M., OR016  
Thomas S., PO404-MON  
Thomas S., OR401  
Thomas T., OR433  
Thomassen M., PO518-MON  
Thomassen M. C., PO002-WED, PO023-WED  
Thomassen S., PO617-MON, PO348-TUE, PO349-TUE  
Thompson A., PO248-MON  
Thompson E., PO377-TUE  
Thomson M., PO375-WED  
Thon J., OR232  
Thongnoppakhun W., PO345-TUE  
Thorack U., OR125  
Thorn Clausen J., PO455-TUE  
Thornton D., PO580-TUE, PO581-TUE  
Thórólfsson M., PO219-WED  
Thorsson O., PO240-MON  
Threeswaran R., PO021-WED  
Thulin A., OR312  
Thulin Å., OR046, PO330-TUE  
Tian J., PO447-WED

## Authors Index

Tiantian S., AS075, OR264, PO566-TUE  
Tichelaar V., OR258, PO338-MON, PO472-MON, PO304-TUE, PO328-TUE, PO396-WED  
Tichelaar V., PO641-WED  
Tichelaar Y. V., PO346-WED  
Tidwell R., PO426-WED  
Tiede A., AS221, PO256-MON, PO259-MON, PO251-WED, PO272-WED  
Tiede C., AS231  
Tiefenbacher S., PO173-MON, PO161-TUE, PO216-WED, PO233-WED  
Tien J., OR295  
Tientadaku P., PO040-MON  
Tiftik E., PO591-TUE  
Tijssen M., OR231  
Tikhonova N., PO113-MON  
Till S., PO201-WED, PO284-WED  
Tilley D., PO135-MON  
Timmis A., PO085-WED  
Timp J., PO601-TUE  
Timp J., OR322, PO223-WED, PO573-WED, PO641-WED  
Timur A., PO494-WED  
Timur C., PO230-MON  
Tinholt M., PO177-WED, PO178-WED  
Tinnmouth A., PO024-WED  
Tipll S., PO201-WED  
Tiscia G., PO453-TUE  
Tiscia G., PO511-MON, PO513-MON  
Tisi Baña M., PO522-WED  
Tissot J.-D., PO400-TUE  
Titaeva E., PO199-MON, PO624-TUE, PO357-WED  
Tittl L., AS098, PO477-MON, PO636-MON  
Tjonneland A., OR345  
Tjonneland A., AS083, OR129, PO104-TUE, PO111-TUE, PO112-TUE  
Toda M., PO173-TUE  
Toderici M., AS187, OR370  
Todesco A., PO456-MON  
Toelen J., PO364-MON, PO142-TUE  
Toennesen E., PO124-WED  
Tognoni G., PO338-WED  
Toh C., PO578-MON  
Toh C.-H., OR004, OR168  
Tokessy M., PO320-TUE  
Toku M., PO120-WED  
Tolen N., PO532-MON  
Tomasevic Z., PO159-WED  
Tombak A., PO591-TUE

Tomberg K., OR361  
Tomczyk M., AS030  
Tomer A., OR055, PO268-TUE  
Tomescu D., PO501-TUE  
Tomi B., PO547-MON  
Tomin D., PO252-MON  
Tomiyama Y., OR340, PO320-WED  
Tomkowski W., PO311-WED  
Tomlinson D., AS231  
Tomlinson M., OR276  
Tomokiyo K., OR142  
Tonai T., OR051  
Tonello C., OR195, PO385-MON, PO624-WED  
Toogeh G., PO247-TUE, PO600-WED  
Topalov N., PO135-WED  
Toret E., OR262  
Tormene D., OR078, OR172, PO341-MON, PO515-MON, PO548-TUE  
Torramadé S., AS044  
Torregrosa J. M., OR221  
Torres R., PO038-MON  
Torri V., PO579-MON  
Tortella B., PO257-MON  
Torti M., OR115, OR183, PO450-TUE, PO429-WED  
Toschi V., PO378-WED  
Tosetto A., PO639-MON, PO649-MON, PO216-WED, PO671-WED, PO674-WED, PO675-WED  
Toshio D., PO108-WED  
Toshiyuki S., PO108-WED  
Tosi F., OR050, OR080, PO554-TUE, PO555-TUE  
Toso R., PO172-MON  
Toth N. K., PO516-TUE, PO087-WED  
Toti F., AS039  
Toulon P., PO448-MON  
Toussaint O., PO134-WED  
Toussaint-Hacquard M., OR055  
Touzé E., OR379  
Towery K., OR434  
Tozawa K., PO386-WED  
Trabandt A., PO554-WED  
Traby L., PO077-WED  
Tracy P., PO145-MON  
Tracy P., PO140-MON, PO133-TUE  
Tracy R., OR238  
Trahtman P., PO569-MON  
Trajanovic M., AS022  
Trajkova Antevska Z., PO287-MON  
Trajkova-Antevska Z., PO288-WED  
Tran H. T. T., OR317

Tran H., OR229, PO468-MON, PO618-MON  
Tran K., AS018  
Tran L., PO033-TUE  
Tran O., PO625-MON  
Tran S., AS040  
Tran T., OR281  
Tranholm M., PO147-MON  
Traore A., PO276-MON  
Tratar G., AS101  
Travers R., OR351  
Travers R., PO336-WED, PO544-WED  
Treffon J., PO157-TUE  
Tregouët D.-A., PO441-MON  
Tregouët D., OR266  
Tregouët D.-A., AS014  
Tregouët D., OR324  
Tréguët D., PO559-WED, PO564-WED  
Tréguët D.-A., AS045, AS206, OR148  
Tremoli E., PO005-TUE, PO378-WED  
Trenor C., PO458-MON  
Trepát X., PO010-MON  
Trevarrow B., OR059  
Trichet C., PO440-MON  
Tricker A., PO648-MON  
Trigatti B., AS210  
Tosetto A., PO639-MON, PO649-MON, PO216-WED, PO671-WED, PO674-WED, PO675-WED  
Tripathi S., PO352-WED  
Tripepi G., PO618-WED  
Tripkovic N., PO250-MON  
Tripodi A., PO091-MON, PO059-TUE, PO114-WED, PO674-WED, PO675-WED  
Trippodis Y., PO657-WED  
Triscott M., PO088-MON, PO360-MON, PO050-TUE, PO054-TUE  
Tromeur C., OR146, OR323  
Troscid A. M. S., PO561-MON  
Trossaert M., OR025, PO639-TUE, PO016-WED  
Trost Z., PO618-TUE  
Trowbridge R., PO367-WED  
Truit E., PO112-WED  
Trujillo J., PO488-TUE  
Trujillo T., PO356-MON, PO622-MON, PO377-TUE  
Trujillo-Santos J., OR074, OR381, PO608-MON  
Truong V., AS045, AS206  
Tryggvason K., OR332  
Tsay C.-H., PO226-TUE, PO289-WED  
Tsay H.-J., PO430-WED  
Tsay J., OR134

## Authors Index

Tsai J.-R., PO226-TUE, PO289-WED  
Tsai W., PO245-MON  
Tsakiris D., PO243-TUE, PO244-TUE  
Tsao E., PO237-MON, PO678-TUE  
Tsao-Wei D., PO172-WED  
Tsay W., OR348  
Tselepis A., PO452-WED  
Tseneklidou-Stoeter D., PO293-WED  
Tseng C.-P., OR344, PO430-WED  
Tseng T.-C., PO328-MON  
Tsuda H., PO545-MON  
Tsuda T., PO545-MON  
Tsui H., PO151-WED  
Tsukamoto K., PO351-MON  
Tsukiji N., OR242, OR404, PO402-MON, PO419-MON  
Tsunaka M., PO106-MON  
Tu Q., AS036  
Tucker A., PO085-WED  
Tucker E., AS209  
Tucker E., OR049, OR353, PO543-WED  
Tucker E., PO177-TUE  
Tückmantel C., OR011  
Tueckmantel C., PO274-WED  
Tufano A., PO534-TUE  
Tuffigo M., PO416-TUE  
Tugcu D., PO265-MON, PO313-MON, PO315-MON, PO459-MON, PO279-WED  
Tulchinsky M., PO577-TUE  
Tuncbilek O. F., PO143-TUE  
Tunstall O., AS159, OR104, OR145, OR386  
Turan N., PO617-TUE  
Ture S., OR166, OR241  
Ture S., PO032-TUE  
Turecek P., PO200-WED  
Turecek P., PO129-WED, PO229-WED  
Turecek P., PO223-TUE, PO199-WED, PO232-WED, PO270-WED  
Turhan A., PO196-TUE  
Turitto V., PO677-TUE  
Turk U., PO266-MON, PO237-TUE, PO238-TUE  
Turkmen C., PO295-WED  
Turnbull R., PO429-MON, PO565-MON, PO464-WED  
Turner N., AS213  
Turpie A., OR096, OR119, PO607-TUE  
Turro E., OR339, PO436-MON, PO384-WED  
Tuttle A., PO426-TUE

Tutwiler V., OR305, PO424-MON  
Tuysuz G., PO525-WED  
Tweddell J., OR058  
Tyagi S., PO272-TUE  
Tynngard N., PO401-TUE  
Tynngård N., PO571-MON  
Tzakos A., PO452-WED  
Tzoran-Rosenthal I., PO389-WED  
Uaprasert N., PO266-TUE, PO584-WED  
Ucar M., PO591-TUE  
Ucbilek E., PO591-TUE  
Uchitel I., PO496-WED  
Uchiyama S., PO477-WED  
Udomkiat P., PO643-WED  
Udvari A., PO550-MON  
Ueda T., PO322-WED  
Ugarte A., AS230  
Uhl C., PO484-WED  
Uhlén M., PO564-WED  
Uhligh S., PO383-WED  
Uitte De Willige S., PO665-MON  
Uitte De Willige S., OR374, PO209-MON  
Ukajefo E., PO627-TUE  
Ulaga B., PO082-TUE  
Ulehlova J., PO060-TUE, PO542-TUE  
Úlehlová J., PO564-MON  
Ullman M., PO238-MON  
Ulrich N., PO150-TUE, PO151-TUE  
Ulrichs H., OR363  
Ulusoy A., PO230-MON  
Umemura K., PO193-TUE  
Umit E., PO617-TUE  
Unal E., PO490-TUE, PO008-WED  
Unal S., PO505-WED, PO507-WED, PO508-WED  
Undas A., PO105-MON, PO536-TUE, PO625-TUE, PO246-WED, PO677-WED  
Ung A., AS134  
Unkrig S., PO343-WED  
Unlu B., PO554-MON  
Unruh D., AS028, OR047  
Unsworth A., PO450-WED  
Unsworth A., PO398-MON  
Untiveros P., PO225-MON  
Upadhyay A., PO296-TUE  
Uppugunduri S., PO401-TUE  
Uprichard J., NUR002  
Uprichard S., PO053-WED  
Urano T., AS030  
Urban A., PO100-WED  
Urbanak J., PO454-WED  
Urbanus R., AS035, PO063-WED

Urbanus R., PO584-MON, PO389-TUE  
Urbanus R., PO072-TUE  
Urbanus R. T., PO246-MON  
Urdanibia I., PO190-TUE  
Urgo J., PO256-WED  
Usanga E., PO386-MON  
Usui M., PO486-WED  
Utne K., OR072, PO600-TUE  
Utset T., PO025-WED  
Uyanik M., PO043-TUE  
Uzlova S., PO460-TUE  
V S. C., PO363-TUE  
Vaara S., PO304-MON  
Vaccarino A., AS195  
Vacher J., PO190-WED  
Vadasz B., OR031, PO328-WED  
Vadivel K., PO165-MON  
Vaewpanich J., PO540-TUE  
Vaezzadeh N., AS216, OR286, PO403-MON  
Vainchenker W., OR082  
Vaishnav A., OR213  
Vaiyapuri S., AS167, PO506-MON, PO438-WED  
Vajen T., PO091-WED, PO395-WED  
Valades-Mejía M., PO523-TUE  
Valades-Mejía M. G., PO073-MON  
Valadier J., PO197-TUE  
Valcarce I., PO538-MON  
Valdrè L., PO264-MON, PO317-WED  
Valente G., OR161  
Valente S., OR253, PO020-TUE, PO024-TUE  
Valenti R., OR396, OR400, PO094-WED  
Valentino L., OR211, PO231-TUE  
Valentino L., PO129-WED  
Valeri F., AS088  
Valgimigli M., PO078-MON  
Vallad-Hix C., PO618-TUE  
Valles J., PO062-MON, PO414-MON  
Valois M., PO054-WED  
Van Adrichem R., PO625-WED  
Van Adrichem R., PO532-MON  
Van Aelst B., PO604-WED  
Van Alphen F., PO227-WED  
Van Alphen F., AS058, PO510-WED  
Van Beers J., PO349-WED  
Van Bekkum T., PO660-TUE  
Van Belle E., AS134, AS201, OR219, PO662-TUE  
Van Berkel T., AS189  
Van Beusekom H., PO078-MON

## Authors Index

Van Bladel E. R., PO246-MON  
Van Breevoort D., AS118  
Van Dam W., PO410-WED  
Van De Ree M., OR257  
Van De Wetering M., OR158  
Van Delden H., PO584-TUE  
Van Den Abeelen L., PO591-MON  
Van Den Berg H. M., PO260-WED  
Van Den Berg H., AS193  
Van Den Berg H., AS223, OR141  
Van Den Besselaar A., PO634-MON  
Van Den Biggelaar M., AS058, AS118, AS121, PO510-WED  
Van Den Bosch M., AS141  
Van Den Bosch M., PO458-WED  
Van Den Dool E.-J., PO401-WED, PO410-WED  
Van Den Eshof B., AS058  
Van Den Ham R., OR430  
Van Den Hoven P., PO651-WED  
Van Der Bom J., AS079, OR021, OR203  
Van Der Bom J., OR013, OR015, PO283-MON, PO308-WED  
Van Der Bom J., OR389, PO607-WED  
Van Der Flier A., OR415  
Van Der Hoeven J., PO651-WED  
Van Der Hulst T., OR191, PO596-MON, PO651-WED  
Van Der Meer F., PO623-MON, PO665-WED  
Van Der Meer F., PO634-MON  
Van Der Meer F., OR387, PO251-TUE, PO620-TUE, PO648-WED, PO651-WED, PO666-WED, PO668-WED  
Van Der Meijden P., PO056-MON  
Van Der Meijden P., PO411-MON, PO675-TUE  
Van Der Meijden P., AS204, PO155-TUE  
Van Der Poll T., AS007, PO335-WED  
Van Der Sluijs C., AS056  
Van Der Sluis I., OR158  
Van Der Stoep M., PO405-MON  
Van Der Veken P., PO218-MON  
Van Der Ven A., PO063-WED  
Van Der Zee A. G., PO346-WED  
Van Der Zwaan C., PO227-WED, PO510-WED  
Van Dreden P., OR047, OR438, PO108-MON, PO116-MON, PO292-MON, PO102-TUE, PO473-TUE, PO163-WED  
Van Duren C., PO680-TUE  
Van Eck M., AS208, PO405-MON

Van Eck-Smit B., PO598-MON  
Van Eeuwijk J., OR405  
Van Eeuwijk J., PO526-TUE  
Van Egmond L., PO349-WED, PO350-WED  
Van Eickels M., OR119  
Van Es J., OR191, PO596-MON, PO597-MON, PO598-MON, PO100-TUE  
Van Es N., AS197, OR191, OR292, PO596-MON, PO103-TUE, PO624-WED  
Van Galen K., OR102, PO658-MON  
Van Geet C., OR231  
Van Geet C., PO650-MON  
Van Gorp R., PO104-WED  
Van Heerde W., OR011, OR021, OR203, PO257-TUE, PO468-TUE, PO680-TUE  
Van Holten T., PO389-TUE  
Van Hylckama Vlieg A., AS138, AS196, OR083, OR148, OR268, OR322, OR391, OR394, PO617-MON, PO498-TUE, PO601-TUE, PO223-WED, PO539-WED, PO565-WED, PO625-WED  
Van Kralingen K., OR257  
Van Lent M., PO502-MON  
Van Leuven C., PO070-TUE  
Van Leuven K., PO592-WED  
Van Loon L., PO546-MON  
Van Meel R., PO072-TUE  
Van Mens T., PO510-MON  
Van Moort I., PO208-WED  
Van Oerle C., PO645-MON  
Van Oerle R., OR225, PO097-WED, PO349-WED, PO416-WED  
Van Oerle R., PO348-MON  
Van Ommen C., AS161  
Van Ommen C. H., OR158  
Van Ommen H., AS102  
Van Puffelen J., OR203, PO680-TUE  
Van Rein N., OR098, OR131, PO532-MON, PO620-TUE, PO648-WED, PO665-WED, PO666-WED, PO668-WED  
Van Roermund P., PO241-MON  
Van Ryn J., OR067, OR356, PO364-MON, PO078-TUE, PO314-TUE, PO414-WED  
Van 'T Veer C., AS007  
Van Veen J., PO313-WED  
Van Velzen A., OR122  
Van Velzen A., OR013, OR015, OR389, PO283-MON, PO308-WED  
Van Vliet I., PO668-WED

Van Vlijmen B., PO570-WED  
Van Vlijmen B., AS208  
Van Vugt S., PO614-TUE  
Van Vugt S., PO366-WED  
Van Vulpen L., PO241-MON  
Van Willigem W., PO350-WED  
Van Wissen S., AS197, OR292  
Van Zaane B., OR268  
Vanassche T., AS009, AS113  
Vanbelle E., PO513-WED  
Vancraeynest D., PO101-WED  
Vandahl B., PO285-WED  
Vande Castele N., PO215-MON, PO286-TUE  
Vande Walle J., PO589-MON  
Vandekerckhove P., PO604-WED  
Vandenberghen H., PO151-WED  
Vandenbrielle C., AS009, AS176, OR418, PO462-WED  
Vandenbulcke A., AS178  
Vandeputte N., AS178, OR155  
Vandereyken M., AS006  
Vandergouwe L., PO086-TUE  
Vanderslice N., PO165-MON  
Vandersmissen I., AS176  
Vangala R. K., OR009, PO084-MON, PO040-TUE  
Vangenechten I., AS133, PO655-MON, PO666-TUE, PO668-TUE  
Vangunst S., PO440-TUE, PO563-TUE  
Vanhaesebroeck B., PO514-TUE  
Vanhoorelbeke K., AS178, OR087, OR151, OR153, OR155, OR365, PO401-MON, PO517-TUE, PO571-TUE  
Vanni S., PO626-MON  
Vanoverschelde J.-L., PO101-WED  
Varadarajan R., PO164-MON  
Varadi K., PO223-TUE, PO270-WED  
Varfolomejev S., PO213-MON  
Varga-Szabó V. J., AS004  
Varjú I., AS004  
Varkila N., PO162-WED  
Varma M., PO314-MON, PO551-MON, PO579-MON, PO274-TUE, PO327-WED  
Varma S., PO200-MON  
Varma N., PO200-MON  
Varnado S., OR059  
Varon D., OR183  
Vartholomatos G., PO551-TUE  
Vasbien M., PO373-TUE  
Vashchenko L., PO206-TUE, PO249-WED  
Vashi V., PO621-MON  
Vasiliev S., PO496-MON

## Authors Index

Vasina E., PO395-WED  
Vasovski M., PO354-WED  
Vasques F., PO061-MON, PO315-TUE, PO127-WED  
Vasquez B., PO439-TUE  
Vassal P., PO107-TUE  
Vasse M., PO163-WED  
Vasudev M., OR382  
Vatopoulou T., PO559-TUE  
Vavilova T., PO444-MON  
Vaziri B., PO374-WED  
Vazquez F., PO620-WED, PO642-WED, PO664-WED  
Vazquez F., PO467-MON, PO473-MON  
Vdovin V., PO258-MON, PO214-TUE, PO019-WED  
Veca V., PO007-MON  
Vedovati M., PO626-MON  
Vedovati M. C., AS099, PO072-MON, PO370-MON, PO027-TUE, PO423-WED  
Veeger N., OR100  
Veenstra L., PO056-MON  
Veerman H. C., PO651-MON  
Veerman K., PO105-WED  
Vehamme P., PO469-MON  
Velander W., PO165-MON  
Velasquez E., PO616-TUE  
Veldman A., PO241-TUE, PO257-TUE, PO258-TUE, PO596-WED  
Velic A., PO412-MON  
Velichko D., PO466-TUE  
Velkova E., PO535-WED  
Veltmeijer M., PO468-TUE  
Vene N., AS101, PO360-TUE  
Venegas-Pino D., PO105-WED  
Venemans-Jellema A., OR035  
Venisse L., OR422, PO545-WED  
Venkatchala S., PO083-MON  
Venkatesan S., PO529-WED  
Venosi S., PO200-TUE  
Ventura D., PO315-WED  
Ventura Pereira J., PO418-MON  
Venturelli U., PO358-MON, PO175-WED  
Vera M., PO184-MON, PO187-TUE  
Vera Morandini M., PO039-MON  
Vera Morandini M. P., PO629-MON  
Verbeek-Knobbe K., PO468-TUE  
Verbout N., AS209  
Verbruggen B., PO208-WED  
Verdecchia P., PO370-MON, PO423-WED  
Vergin C., OR262  
Vergin C., PO590-MON

Vergura P., PO511-MON  
Verhaar M., PO389-TUE  
Verhagen A., AS016  
Verhamme P., AS009, AS113, AS176, AS197, OR195, OR292, OR418, PO364-MON, PO614-MON, PO462-WED  
Verheijen I., PO123-WED, PO609-WED  
Verheijen L., PO675-TUE  
Verhenne S., OR087, OR155  
Verheugt F., PO614-TUE  
Verheugt F., OR119, PO366-WED  
Verhezen P., PO349-WED  
Verhezen P., PO033-WED  
Verhoef D., AS056, OR147, PO144-MON  
Verhoef S., AS189  
Verkholomova F., PO661-WED  
Verma S., OR041  
Vermeersch E., PO401-MON  
Vermeire S., PO215-MON, PO286-TUE  
Verschuren F., OR194, PO587-TUE  
Verso M., PO370-MON, PO423-WED  
Versteeg H., PO554-MON  
Versteeg H., OR047  
Vervaeke A.-L., PO398-WED  
Vesley S., OR152  
Vesper P., PO107-WED, PO137-WED  
Vestergaard B., PO590-WED  
Vettore G., PO372-TUE  
Veyradier A., PO645-TUE  
Veyradier A., AS134, OR024, OR025, PO639-TUE, PO664-TUE  
Veyrie N., AS043  
Viallard J.-F., PO416-TUE  
Viana M., PO179-TUE  
Vibede E., PO124-WED  
Vibert F., PO308-TUE  
Vicens J., PO642-WED  
Vicente C., PO133-MON  
Vicente V., AS187, OR076, OR221, OR359, OR368, OR370, PO336-MON, PO439-MON, PO497-MON, PO338-TUE, PO558-TUE, PO549-WED, PO552-WED  
Vichitrachaneekorn R., PO266-TUE  
Vicini P., PO512-TUE  
Vida V., PO438-TUE  
Vidal F., PO543-MON  
Vidili G., AS195  
Vidmar G., PO616-TUE  
Viganò F., PO515-MON

Vignoli A., PO339-MON  
Vijay R., PO153-WED  
Vijayan K. V., OR277  
Vik A., OR075, OR254, OR258, OR267, OR293, PO472-MON, PO494-TUE, PO638-WED  
Vikhe P., PO397-TUE  
Vikhe P., PO385-TUE  
Vila V., PO579-WED  
Vilalta N., PO217-WED  
Vilaseca A. B., PO491-TUE  
Vilchevska K., PO262-TUE  
Villaca P., PO286-MON, PO211-TUE, PO250-WED  
Villacorta-Torres J., PO263-TUE  
Villalobos-Menuey E., PO103-MON, PO662-WED  
Villalta S., OR132, OR256, OR291  
Villani M., PO511-MON, PO513-MON  
Villarroel Del Pino L., PO358-TUE  
Villoutreix B., OR369  
Vincelli J., PO479-MON  
Vincenot A., PO440-MON  
Vincentelli A., AS134, AS201, OR219, PO662-TUE  
Vinciguerra C., OR143, PO198-WED  
Vindt Holm M., PO110-TUE  
Viola F., PO203-TUE, PO368-WED  
Viola M., PO079-TUE  
Violeta D., PO544-MON  
Violi F., OR396, PO359-MON, PO029-TUE, PO094-WED  
Vischjager M., PO532-MON  
Visconte C., PO450-TUE  
Visetin S., PO331-TUE, PO332-TUE  
Vishwabandya A., PO153-WED  
Visonà A., OR132  
Visser M., PO157-TUE, PO395-TUE, PO218-WED, PO234-WED  
Visser-Koldenhof M., PO642-TUE  
Vitale J., PO502-TUE, PO640-WED  
Viviana A., PO068-TUE  
Vivien D., AS032, AS117, OR314, OR379, PO532-TUE, PO370-WED  
Vizintin Cuderman T., AS101  
Vlasveld T., OR257  
Vliegen H., PO619-WED  
Vodolazkaia A., PO142-TUE  
Vogel C.-W., PO226-WED  
Vogel M., PO564-TUE  
Vogely C., PO658-MON  
Vogely H., PO241-MON  
Vögtle T., AS228, OR416

## Authors Index

**Voigt C.**, OR346, OR347, OR350, PO253-WED  
**Voigt K.**, PO445-MON  
**Voigt Lauridsen S.**, PO131-WED  
**Voigtländer M.**, PO251-MON  
**Voisin S.**, OR029, PO016-WED  
**Vojnovic I.**, PO085-WED  
**Volf I.**, PO427-MON  
**Vollan H. K.**, PO177-WED, PO178-WED  
**Volot F.**, OR012, OR024  
**Volpicelli P.**, PO200-TUE, PO259-TUE, PO534-WED  
**Von Arbin M.**, PO530-TUE, PO171-WED  
**Von Auer C.**, PO591-MON, PO593-MON, PO569-TUE, PO570-TUE  
**Von Depka E.**, PO654-MON, PO665-TUE  
**Von Depka M.**, PO654-MON, PO665-TUE  
**Von Depka Prondzinski M.**, OR347  
**Von Drygalski A.**, PO266-WED  
**Von Hundelshausen P.**, PO091-WED  
**Von Krogh A. S.**, OR152  
**Von Mackensen S.**, PO253-TUE, PO639-TUE, PO256-WED, PO305-WED  
**Von Tengg-Kobligh H.**, OR432  
**Voorberg J.**, AS118, AS121, PO660-TUE, PO227-WED  
**Vorobev A.**, PO122-TUE, PO123-TUE, PO173-WED  
**Vorobyeva N.**, PO204-MON, PO630-MON, PO044-TUE, PO381-TUE, PO538-TUE, PO106-WED  
**Vorobyeva N.**, PO199-MON  
**Voroshilina E.**, PO147-WED  
**Vos H.**, OR147  
**Voskanyan A.**, PO573-MON  
**Vosnakis C.**, PO065-WED  
**Vossen C.**, PO656-WED  
**Vossen C.**, PO539-WED  
**Voto L.**, PO059-WED  
**Voutsis M.**, PO285-MON  
**Vries M.**, PO056-MON, PO645-MON  
**Vries M.**, PO143-MON  
**Vu T.**, AS219, OR286, OR290, PO220-MON, PO170-TUE  
**Vucicevic S.**, PO159-WED  
**Vu kovi B.**, OR131  
**Vuillez J.-P.**, PO628-WED  
**Vuimo T.**, PO047-WED  
**Vuimo T.**, PO147-WED  
**Vukovic V.**, PO121-TUE

**Vulih D.**, OR127  
**Vyivantseva A.**, PO054-MON  
**Vysniauskaite M.**, PO343-WED  
**Wada H.**, PO486-WED  
**Wada T.**, PO178-MON  
**Wagenaar G.**, PO570-WED  
**Wagenvoord R.**, OR224, PO290-MON, PO004-WED  
**Wagenvoord R.**, PO143-MON  
**Wagner B.**, AS124  
**Wagner D.**, PO171-WED  
**Wagner D.**, PO321-MON, PO089-WED  
**Wagner D.**, AS180, PO329-MON  
**Wagner E.**, PO165-WED  
**Wahedi M.**, AS118  
**Wahi R.**, PO334-MON, PO332-WED, PO411-WED  
**Wahl D.**, AS036, OR091, OR186, OR189, PO031-TUE  
**Wahlgren M.**, PO294-MON  
**Waisman G.**, PO642-WED  
**Wakamiya N.**, PO020-WED  
**Wakefield C.**, AS078  
**Wakefield T.**, PO030-MON  
**Walborn A.**, PO182-MON, PO192-TUE  
**Walenga J.**, PO291-MON, PO292-MON  
**Walenga J.**, OR173, PO305-MON, PO339-WED, PO411-WED  
**Walker B.**, OR114, PO412-MON, PO449-WED  
**Walker D.**, OR101  
**Walker I.**, PO276-MON  
**Walker I.**, OR429, PO095-MON, PO087-TUE  
**Walker I.**, OR285, PO500-MON, PO643-TUE, PO524-WED  
**Walker R.**, PO063-WED  
**Wallén H.**, PO368-MON, PO530-TUE, PO171-WED, PO392-WED  
**Wallentin L.**, PO362-MON  
**Waller A.**, PO571-WED  
**Waller A.**, PO397-TUE  
**Waller A.**, PO385-TUE  
**Wallisch M.**, AS209, OR049  
**Wallstedt M.**, PO367-MON  
**Walvik N.**, OR069  
**Walsh C.**, PO248-MON  
**Walsh C.**, PO149-MON  
**Walsh T.**, OR244  
**Waltenberger J.**, PO015-TUE  
**Walter O.**, PO272-WED  
**Walter U.**, PO397-MON, PO427-MON, PO419-TUE, PO099-WED, PO483-WED  
**Walters H.**, OR060

**Walton B.**, PO021-MON  
**Waltz D.**, AS059  
**Walzog B.**, OR416  
**Wan Q.**, PO205-MON  
**Wang K.**, PO433-WED  
**Wang A.**, PO136-MON, PO137-MON  
**Wang C.**, PO449-MON  
**Wang C.**, PO605-TUE  
**Wang C.**, OR113, OR210, PO433-WED  
**Wang G.**, OR282  
**Wang G.**, PO022-MON  
**Wang G.**, OR004, OR168  
**Wang H.**, PO424-MON  
**Wang H.**, PO388-TUE, PO390-TUE  
**Wang H.**, PO492-MON, PO195-TUE  
**Wang H.**, PO179-MON, PO132-TUE  
**Wang H.-J.**, PO265-WED  
**Wang J.-D.**, PO137-TUE  
**Wang J.**, PO660-TUE  
**Wang J.**, OR390  
**Wang K.**, OR113, OR210, PO388-WED  
**Wang L.**, PO306-TUE  
**Wang M.**, PO177-MON, PO179-MON  
**Wang M.**, PO237-MON, PO277-MON, PO262-TUE, PO297-WED, PO298-WED  
**Wang P.-N.**, PO476-WED  
**Wang P.**, AS182  
**Wang P.**, OR280  
**Wang Q.**, PO162-MON, PO132-TUE  
**Wang R.**, PO036-TUE  
**Wang S.**, OR048  
**Wang S.**, OR279  
**Wang T.-F.**, PO545-TUE  
**Wang X.**, PO220-WED  
**Wang X.**, PO014-TUE  
**Wang X.**, PO028-MON  
**Wang X.**, PO385-TUE  
**Wang X.**, PO372-WED, PO375-WED  
**Wang X.**, OR164, OR210, PO228-MON, PO492-MON, PO176-TUE, PO195-TUE, PO252-TUE, PO333-TUE  
**Wang Y.**, PO329-MON  
**Wang Y.**, PO382-WED  
**Wang Y.**, PO132-MON  
**Wang Y.**, PO306-TUE  
**Wang Y.**, PO588-MON  
**Wang Y.**, AS168, AS153  
**Wang Z.**, PO011-MON, PO425-TUE, PO039-WED, PO533-WED

## Authors Index

**Wang Z.**, PO288-TUE  
**Warad D.**, PO484-WED  
**Ward C.**, OR002, PO433-MON, PO421-TUE  
**Ward L.**, PO475-MON  
**Ward R.**, PO389-MON  
**Wareing A.**, NUR002  
**Warkentin M.**, NUR013  
**Warner M.**, OR217  
**Warner T.**, OR341  
**Warner T.**, PO414-TUE  
**Warner T.**, PO085-WED  
**Warren V.**, PO621-MON  
**Warzocha K.**, PO609-TUE  
**Wasilewski R.**, PO278-MON  
**Watanabe A.**, PO433-TUE  
**Watanabe T.**, PO058-WED  
**Waters E.**, PO046-TUE  
**Waters E.**, AS019, PO454-TUE  
**Watpool I.**, OR310  
**Watras M.**, PO347-MON  
**Watson C.**, PO349-MON  
**Watson C.**, PO216-WED  
**Watson D.**, PO317-TUE  
**Watson H.**, PO225-MON, PO368-TUE  
**Watson P.**, PO565-MON  
**Watson S.**, PO289-TUE, PO511-TUE  
**Watson S.**, AS054, AS011, AS092, PO511-TUE  
**Watson S.**, AS069, AS124, OR276, OR401, PO408-MON, PO415-MON, PO393-TUE, PO434-WED, PO492-WED  
**Watson S.**, PO289-TUE  
**Watson S.**, OR416  
**Watson S. P.**, PO497-MON  
**Watt B.**, PO368-TUE  
**Watts M.**, PO649-WED  
**Watts R.**, PO248-MON  
**Watzka M.**, PO498-MON, PO631-MON, PO637-MON  
**Waye J.**, OR377  
**Wearn C.**, OR121  
**Wearn C.**, PO393-TUE  
**Webb V.**, PO600-MON, PO582-TUE  
**Webber K.**, PO502-WED  
**Weber C.**, PO037-TUE, PO091-WED, PO395-WED  
**Weber E.**, OR020  
**Webster S.**, PO667-MON, PO676-MON  
**Webster S.**, AS064, OR086  
**Wecht B.**, PO094-MON  
**Weeks S.**, OR443  
**Wegener E.**, PO427-TUE

**Wei D.**, PO129-TUE  
**Wei H.**, PO113-TUE  
**Wei Q.**, PO246-TUE  
**Wei S.**, PO129-MON  
**Weickert L.**, PO657-MON  
**Weigel G.**, PO096-MON  
**Weik M.**, PO140-WED  
**Weinberger D.**, PO285-TUE  
**Weisel J.**, OR305, PO026-MON, PO424-MON, PO212-WED  
**Weisel J.**, AS156  
**Weiss A.**, PO434-WED  
**Weiss N.**, AS098, PO477-MON, PO636-MON  
**Weiss T.**, PO030-TUE  
**Weitz D.**, AS154  
**Weitz I.**, PO172-WED  
**Weitz J.**, PO489-WED  
**Weitz J.**, PO135-MON, PO376-TUE  
**Weitz J.**, AS154, AS219, OR286, OR290, OR302, PO138-MON, PO220-MON, PO403-MON, PO130-TUE, PO170-TUE, PO608-TUE  
**Weitz J.**, OR057, OR442, PO353-TUE, PO409-WED  
**Welding K.**, OR040, PO141-TUE  
**Wells P.**, AS077, AS206  
**Wells P.**, AS045, PO641-MON  
**Wells P.**, AS099, OR200, OR259  
**Wells P. S.**, PO371-WED, PO669-WED  
**Wells P.**, OR384, PO647-WED  
**Welsh J.**, OR038  
**Welsh J.**, OR207  
**Weiters I.**, OR004, OR168  
**Wen Y.**, OR018  
**Wendelboe A.**, PO637-WED  
**Weng T.-F.**, PO452-MON  
**Wenjie L.**, AS075, OR136, OR264, PO566-TUE  
**Wenjuan Z.**, PO394-WED  
**Wermes C.**, PO259-MON, PO647-MON, PO665-TUE  
**Werneck C.**, PO133-MON  
**Werner I.**, PO091-WED  
**Werner S.**, PO662-MON, PO664-MON  
**Werstuck G.**, PO105-WED  
**Werstuck G.**, OR007  
**Werth S.**, AS098, PO477-MON, PO636-MON, PO103-TUE, PO624-WED  
**Werwitzke S.**, AS221  
**Wesche J.**, OR307, PO413-TUE  
**Westein E.**, AS184, PO431-MON  
**Westerman D.**, PO149-WED

**Westfield L. A.**, OR365  
**Westmark P.**, PO175-MON  
**Weston-Davies W.**, OR154  
**Westwood J.-P.**, PO567-TUE  
**Wettstein M.**, PO236-MON  
**Wetzels R.**, PO645-MON  
**Wetzels R.**, PO348-MON, PO349-WED, PO350-WED, PO416-WED  
**Wetzels R.**, PO123-WED, PO609-WED  
**Wexler R.**, PO349-MON  
**Weyer V.**, PO593-MON  
**Weyrich A.**, OR085, PO423-MON, PO604-MON  
**Weyrich A.**, OR243  
**Wham T.**, PO173-MON, PO161-TUE, PO233-WED  
**Wheatcroft S.**, AS205  
**Wheeler R.**, PO504-WED  
**White A.**, PO210-WED  
**White B.**, PO280-MON, PO318-WED  
**White M.**, PO174-TUE  
**White N.**, PO372-WED, PO556-WED  
**White N.**, PO375-WED  
**White O.**, AS143  
**White R.**, OR325, PO358-WED, PO359-WED  
**White T.**, PO309-TUE  
**Whiteford J.**, OR341  
**Whiteheart S.**, OR419  
**Whiteheart S. "**, AS123  
**Whiteman M.**, PO400-MON  
**Whitlock R.**, OR057, PO489-WED  
**Whyte C.**, AS204  
**Wiangnon S.**, PO120-TUE  
**Wickham A.**, PO074-WED  
**Wicklund B.**, PO516-WED  
**Widimsky P.**, PO364-WED  
**Wiegand G.**, PO667-WED  
**Wieland I.**, PO647-MON, PO442-TUE  
**Wielders S.**, PO470-MON  
**Wiemann M.**, PO163-MON, PO218-WED, PO234-WED  
**Wiemers T.**, PO487-WED  
**Wiest I.**, PO487-WED  
**Wietrzyk J.**, PO365-WED  
**Wiewel-Verschueren S.**, PO346-WED  
**Wiggins K.**, PO557-WED  
**Wiinberg B.**, OR036, OR040, PO046-TUE, PO141-TUE, PO052-WED  
**Wijeyewickrema L.**, PO300-TUE  
**Wijgaerts A.**, AS013, OR231  
**Wijmenga C.**, PO580-MON

## Authors Index

Wik H., OR072, PO600-TUE  
Wik H. S., PO478-MON, PO295-TUE  
Wilcox D., OR342  
Wild P., PO356-TUE  
Wild P., PO478-WED  
Wilde J., AS054  
Wildeboer B., PO642-TUE  
Wilkins M., PO094-MON  
Wilkins J., AS168  
Willem B., PO104-WED  
Williams C., AS141, OR275  
Williams C., OR244  
Williams C., AS126  
Williams C., PO110-MON  
Williams M., AS159  
Williams M., AS054, OR104, OR145, OR386  
Williams P., PO173-MON, PO161-TUE, PO233-WED  
Williams P., PO156-WED  
Williams R., PO083-TUE  
Williams S., OR159, OR328, AS157, PO475-MON, PO118-TUE, PO446-TUE, PO545-TUE  
Williams V., PO204-TUE  
Williamson A., PO502-MON, PO521-WED  
Willis R., PO064-WED  
Wilms E., PO099-WED  
Wilsgaard T., AS046, OR075, OR120, OR254, OR392, OR393, PO519-MON, PO524-MON, PO525-MON, PO526-MON, PO493-TUE, PO494-TUE, PO495-TUE, PO567-WED, PO568-WED  
Wilson E., PO288-MON  
Wilson M., AS045, AS066  
Wilson S., PO149-WED  
Wilts D., PO100-TUE, PO164-WED  
Winburn I., PO256-MON  
Winckers K., PO617-MON, PO348-TUE, PO349-TUE  
Winder A., PO611-TUE  
Windyga J., OR088, OR144, PO278-MON, PO549-MON, PO049-TUE, PO235-TUE, PO543-TUE, PO648-TUE, PO011-WED, PO026-WED, PO032-WED, PO526-WED, PO536-WED, PO588-WED  
Wingate J., PO631-TUE  
Wing-Lun E., PO075-MON  
Winter M., PO657-WED  
Winters J., PO037-WED  
Wiseman A., PO487-MON  
Wishart C., PO182-TUE

Wisman P. P., PO386-TUE, PO389-TUE  
Wismer M., PO028-MON  
Wisniewski T., PO256-WED  
Wisniewski A., PO278-MON, PO549-MON, PO609-TUE, PO648-TUE, PO026-WED, PO032-WED, PO526-WED  
Witke W., OR416  
Witkoff B., OR362  
Witkop M., PO277-MON, PO297-WED, PO298-WED  
Witsch T., OR252, PO089-WED  
Witter L., PO112-MON  
Wittevrongel M.-C., OR231  
Witzel R., PO146-TUE  
Wlodawer A., PO184-TUE  
Wohner N., PO553-TUE  
Wojta J., AS200, OR123, PO185-MON, PO559-MON, PO002-TUE, PO282-TUE, PO301-TUE, PO509-TUE  
Wojtasi ska E., PO170-WED  
Wolberg A., PO021-MON, PO046-TUE  
Wolberg A., AS153  
Wolf D., PO493-WED  
Wolf K., AS068, AS228, OR169  
Wolfsegger M., PO254-WED  
Wolfson T., PO476-MON  
Wolgast L., AS037  
Wolko D., PO253-WED  
Wolzt M., PO077-WED  
Wong G., PO267-TUE  
Wong J., PO669-TUE  
Wong K. L., PO606-MON  
Wong M., PO622-MON  
Wong P., PO349-MON  
Wong S. L., PO329-MON  
Wong W. H., PO012-TUE, PO074-TUE  
Wongprasert C., PO643-WED  
Wongswadiwat Y., PO461-MON  
Wongwerawattanakoon P., PO540-TUE, PO275-WED  
Woo C., PO269-WED  
Wood M., PO400-MON  
Woodhams B., AS042, OR050, OR172, PO341-MON, PO114-TUE, PO331-TUE, PO332-TUE, PO554-TUE, PO555-TUE, PO127-WED  
Woodhams B., OR047  
Woodhouse G., PO356-MON  
Woodle S., PO603-WED  
Woods A., PO634-TUE, PO636-TUE, PO646-TUE, PO652-TUE  
Woods A., PO003-MON, PO004-MON, PO005-MON, PO042-WED

Woods A., PO267-TUE  
Woods G., AS160, OR157  
Woods N., PO557-WED  
Woods R., OR058  
Woods T., OR429, PO095-MON, PO087-TUE  
Woods T., OR285, PO643-TUE  
Wool G., PO049-MON, PO025-WED  
Woolley A., PO085-TUE, PO136-WED, PO141-WED  
Worthington M., PO588-TUE  
Wozniak E., PO284-MON  
Wozniak M., PO454-WED  
Woznica-Karczmarz I., PO255-WED  
Wright F., PO172-MON  
Wright G., OR418  
Wright G., PO021-TUE  
Wright J., PO542-WED  
Wright P., PO653-MON, PO638-TUE  
Wróbel A., PO311-WED  
Wroblewski S., PO030-MON  
Wrzyszc A., PO454-WED  
Wu C., OR442  
Wu C., AS023, OR295, PO592-TUE  
Wu H., PO592-MON, PO572-TUE  
Wu H., OR362, PO587-MON, PO588-MON, PO573-TUE  
Wu H., OR362, PO587-MON, PO588-MON, PO573-TUE  
Wu J., PO213-WED  
Wu J., AS147, OR249, PO070-MON, PO205-MON  
Wu J., PO467-WED  
Wu J., PO136-MON, PO137-MON  
Wu J., PO426-TUE  
Wu J., PO269-WED  
Wu J., PO292-WED  
Wu K.-H. W., PO452-MON  
Wu Q., AS072  
Wu R., OR140, PO317-MON, PO246-TUE, PO292-WED  
Wu S., OR232  
Wu S., OR085  
Wu W., PO028-MON  
Wu X., OR164, PO195-TUE  
Wu X., AS037  
Wu X., OR113, OR210, PO433-WED  
Wu X., PO246-TUE  
Wu Y.-M., PO050-WED  
Wu Y., OR355  
Wu Y., PO431-WED  
Wu Y.-F., PO448-TUE  
Wu Y., PO492-TUE

## Authors Index

Wu Y., PO132-TUE  
Wu Z., OR338  
Wu Y., PO287-WED  
Wulff Nielsen A. K., PO090-MON  
Wun T., OR325  
Wutzelhofer L., OR123  
Wynckel A., PO263-TUE  
Wynn T., PO242-MON, PO260-MON  
Wynne H., OR099  
Wyseure T., PO519-TUE  
Xenarios I., AS128, OR397  
Xi M., AS122, PO262-MON  
Xi X., OR018, PO492-MON  
Xia J., AS154  
Xia L., PO425-TUE  
Xia M., AS025, AS232, OR006, PO098-WED  
Xian Z., OR136, OR264, PO320-MON, PO276-TUE, PO566-TUE  
Xiang B., OR419  
Xiang H., PO210-TUE  
Xiang Y., PO673-MON  
Xiao B., OR018  
Xiao J., PO292-WED  
Xiao N., OR249  
Xiao X., PO432-MON  
Xiaofan L., AS075, PO566-TUE  
Xie F., PO432-MON  
Xie W., PO426-MON  
Xiong S., PO288-TUE  
Xiong Y., OR014, OR211, PO642-MON, PO108-TUE, PO231-TUE  
Xu M., AS074, AS168, OR138, OR261, PO319-MON, PO326-WED  
Xu W., PO165-MON  
Xu X., AS168  
Xu Y., OR200, PO646-MON  
Xu Y., PO026-MON, PO212-WED  
Xu Y., OR306  
Xue F., AS109  
Xue L., OR209  
Xue M., PO188-TUE  
Xue Yan C., PO109-MON  
Ya F., PO382-WED  
Yabes J., OR201  
Yabes J., OR090, PO277-WED  
Yacobovich J., PO475-WED  
Yada K., PO652-MON, PO666-MON, PO668-MON, PO088-TUE, PO165-TUE, PO224-TUE  
Yadav M., PO200-MON  
Yadegari H., PO184-WED  
Yadegari Baharanchi H., PO674-MON  
Yagi H., PO040-WED  
Yakimenko A., OR245

Yakovlev S., OR371  
Yakovlev V.N. V., PO113-MON  
Yakushkin V., PO327-TUE  
Yamada S., OR051  
Yamaguchi K., PO477-WED  
Yamaguchi K., AS145, PO203-MON  
Yamaguchi Y., AS031  
Yamamoto K., OR347  
Yamamoto T., PO380-TUE  
Yamanouchi J., PO055-MON  
Yamasaki N., PO233-MON  
Yamashita A., PO233-TUE, PO211-WED  
Yamashita A., PO552-MON  
Yamashita H., PO399-TUE  
Yamashita M., PO672-TUE  
Yamaura Y., PO351-MON  
Yamazaki M., PO477-WED  
Yamazaki S., PO211-WED  
Yan H., PO176-TUE  
Yan J., PO330-TUE  
Yan K., AS147, PO070-MON  
Yan R., PO273-TUE  
Yanachkov I., PO021-TUE  
Yanagida Y., PO178-MON  
Yang A., OR355  
Yang C., PO259-WED  
Yang F., AS026  
Yang J., OR018  
Yang J., PO278-TUE, PO323-WED  
Yang L., AS075, OR264, PO566-TUE  
Yang L., PO333-TUE  
Yang L., PO304-WED  
Yang M., PO269-WED  
Yang R., AS109, AS073, OR001, OR265, PO451-TUE, PO292-WED, PO323-WED  
Yang S., OR362, PO587-MON, PO588-MON, PO572-TUE, PO573-TUE  
Yang S.-F., PO029-MON  
Yang S.-J., PO029-MON, PO050-WED  
Yang S., PO677-TUE  
Yang X., AS056  
Yang Y., OR249, PO205-MON, PO382-WED, PO447-WED  
Yang Y., OR279  
Yang Y., PO125-MON  
Yang Y., OR045  
Yang Y., PO529-MON, PO504-TUE  
Yang Y., PO605-TUE  
Yang Y.-L., PO031-MON  
Yang Z., OR279  
Yao G.-Q., PO426-MON

Yao J., AS184  
Yao M., OR342  
Yao Y., PO303-MON  
Yaoh H., PO652-MON, PO347-WED  
Yap E. S., OR322, PO606-MON, PO223-WED, PO413-WED  
Yaras S., PO591-TUE  
Yarwood B., PO673-TUE  
Yastrubinskaya O., PO651-TUE  
Yasuda S., PO058-WED  
Yasui Y., PO465-MON  
Yasukawa M., PO055-MON  
Yatagai C., PO462-TUE, PO463-TUE  
Yating H., AS075, OR264, PO276-TUE, PO566-TUE  
Yatomi Y., PO061-TUE  
Yau J., OR041  
Yavelov I., PO069-TUE  
Yazicioglu I., PO301-WED  
Ye S., OR419  
Yee A., AS090, OR331, OR361  
Yee D., OR349  
Yee D., PO644-TUE  
Yee T., OR015  
Yegneswaran S., PO555-WED, PO599-WED  
Yeh C., PO138-MON, PO130-TUE  
Yeh G.-C., PO226-TUE, PO289-WED  
Yeheskel A., OR289  
Yen C.-T., PO031-MON  
Yeon J. H., AS075, PO375-WED  
Yerov O., PO073-TUE  
Yeung J., AS217  
Yhap M., AS158  
Yi A. K., PO139-WED  
Yildiz L., PO051-WED  
Yilmaz A., PO521-WED  
Yilmaz D., PO254-TUE, PO302-WED  
Yilmaz E., PO008-WED  
Yin H., AS143  
Yin O., PO621-MON  
Yilmaz A., PO502-MON  
Ylönen A., PO304-MON  
Yoder M. C., PO020-MON  
Yoe J., PO579-MON  
Yokoyama K., PO322-WED  
Yones H., PO347-MON  
Yoneyama K., AS017  
Yoneyama T., PO477-WED  
Yoo J., PO471-TUE, PO309-WED  
Yoon H. J., PO168-WED  
Yoon H.-J., PO164-TUE, PO489-TUE, PO300-WED  
Yoon J.-H., PO599-TUE

## Authors Index

Yoon J. H., PO309-WED  
Yoon S. S., PO599-TUE  
Yoon S.-S., PO035-TUE, PO659-WED  
Yoruk A., PO230-MON  
Yoshida H., AS017  
Yoshida K., PO335-TUE  
Yoshida M., PO041-MON, PO357-MON, PO020-WED, PO057-WED  
Yoshida Y., PO672-TUE  
Yoshizawa H., PO113-WED  
You C., OR212  
You M., PO638-MON  
Youbare I., OR031, PO328-WED  
Youk J., PO659-WED  
Young C., AS160  
Young D., OR104, PO622-WED  
Young G., AS104, AS122, OR156, PO164-MON, PO237-MON, PO239-MON, PO262-MON, PO439-TUE, PO255-WED, PO506-WED  
Young J., PO227-TUE  
Young J., AS160  
Young J., PO603-MON  
Young L., PO374-TUE  
Young P., PO493-MON  
Yoxtheimer L., AS130  
Yu H., PO129-MON  
Yu I.-S., PO029-MON, PO031-MON, PO050-WED  
Yu L. X., OR031  
Yu P., PO034-TUE, PO095-WED  
Yu P., AS210  
Yu Y., AS074, OR138, OR261, PO319-MON  
Yu Z., PO039-WED, PO259-WED, PO533-WED  
Yuan C., AS146  
Yuan Y., PO332-MON, PO443-WED  
Yuan Z., OR259  
Yue H., PO113-TUE, PO394-WED  
Yue M., OR279  
Yuen L., PO623-WED, PO635-WED  
Yuldasheva N., AS205, PO096-WED  
Yusa S.-I., PO300-MON  
Yusen R., OR074, OR321, PO576-TUE  
Yusuf S., PO362-MON  
Zabczyk M., OR398, PO368-MON  
Zbczyk M., PO105-MON, PO536-TUE, PO625-TUE, PO246-WED, PO677-WED  
Zabolotskikh I., PO466-TUE, PO586-TUE  
Zadrio R., PO436-TUE

Zadro R., OR378, PO144-WED  
Zaffaroni M., OR161  
Zaharyan E., PO213-MON  
Zahavi A., PO285-TUE  
Zahedi R., AS068, PO419-TUE  
Zahedi R., PO499-MON  
Zak M., OR348  
Zakar M., PO595-WED  
Zakas P., PO203-WED  
Zalvidea D., PO010-MON  
Zaman F., PO099-MON, PO078-TUE  
Zamora C., PO621-MON  
Zander N., PO107-WED  
Zandstra J., PO584-MON  
Zane F., PO483-MON, PO580-WED  
Zanetto A., PO114-TUE  
Zaninetti C., PO438-MON  
Zanolini D., OR106, OR161  
Zanon E., AS222, OR027, OR030, OR144, PO225-TUE, PO650-TUE, PO303-WED  
Zapletal O., AS133, PO655-MON  
Zapletal O., PO502-MON  
Zapponi K., PO066-WED  
Zapponi K., PO422-MON  
Zarà M., PO450-TUE  
Zardo L., PO369-WED  
Zarfati M., PO335-MON  
Zarrabi F., PO247-TUE  
Zarrin A., NUR013  
Zarrineh P., PO186-MON  
Zateyshchikov D., PO135-WED  
Zavrelova J., PO655-MON  
Zawadski C., OR219, PO662-TUE  
Zawadzki C., AS201, OR024  
Zawilska K., PO614-MON, PO011-WED  
Zazeri G., PO322-TUE  
Zbikowski P., PO279-MON  
Zdravic D., OR031, PO328-WED  
Zdziarska J., PO011-WED  
Zebardast J., PO247-TUE, PO600-WED  
Zebari R., PO356-MON  
Zeerleder S., PO326-MON  
Zeinati C., PO439-TUE  
Zeissink B., PO391-MON  
Zeldin D., OR341  
Zeller T., PO478-WED  
Zeltser D., PO631-WED  
Zemlyanskaya O., PO624-TUE, PO357-WED  
Zemrak W., PO367-WED  
Zenclossen A., PO518-MON  
Zeng M., AS147, PO070-MON  
Zeng M., PO205-MON

Zeng W., PO132-TUE, PO492-TUE, PO581-WED  
Zeping Z., PO276-TUE  
Zerbiniati P., PO193-MON  
Zerbiaw A., PO079-TUE  
Zetterberg E., PO240-MON, PO080-TUE, PO228-TUE, PO263-WED  
Zeuthen N., PO267-WED  
Zeuthen N., PO251-WED  
Zeytun H., PO264-WED  
Zhai Z., PO605-TUE  
Zhang B., OR180  
Zhang B., PO111-MON, PO132-MON  
Zhang C., AS063, PO430-MON  
Zhang D., AS073, OR136, PO451-TUE  
Zhang G., OR383  
Zhang G., OR419  
Zhang J., PO375-WED  
Zhang J., PO439-WED  
Zhang J., PO433-WED  
Zhang L., OR001, PO451-TUE  
Zhang L., PO447-WED  
Zhang L., PO202-TUE  
Zhang L., OR001  
Zhang N., OR018  
Zhang S., PO409-MON  
Zhang W., PO015-MON, PO259-WED, PO533-WED  
Zhang X., AS109, PO451-TUE  
Zhang X. Z., PO529-MON  
Zhang X., PO336-WED  
Zhang Y., PO409-MON  
Zhang Y., OR350, PO241-TUE  
Zhang Y., PO439-WED  
Zhang Z., PO605-TUE  
Zhao L., AS031  
Zhao M., PO597-WED  
Zhao X.-Y., AS018  
Zhao Y., PO012-TUE  
Zhao Y., OR117  
Zhao Y., PO292-WED  
Zhao Y., AS072  
Zhaoyue W., PO113-TUE, PO394-WED  
Zharkov P., PO462-MON  
Zharkov P., PO503-WED  
Zhen Y., PO246-TUE  
Zheng C., OR180  
Zheng G.-Y., PO029-MON  
Zheng S., PO409-MON  
Zheng X. L., OR407  
Zheng Y., AS115  
Zhong J., PO252-TUE  
Zhou A., PO359-TUE  
Zhou H., OR407

## Authors Index

Zhou H., PO318-MON, PO278-TUE, PO323-WED  
Zhou J., AS216, AS219, OR286, PO403-MON, PO170-TUE  
Zhou J., PO621-MON, PO603-TUE  
Zhou J., PO195-TUE  
Zhou P., PO340-TUE  
Zhou S., OR178  
Zhou S., AS120  
Zhou W., PO298-MON  
Zhou X., OR443  
Zhou X., PO028-MON  
Zhou Z., AS109  
Zhu W., PO340-TUE  
Zhu C., AS055  
Zhu G., AS168, OR031, PO326-WED, PO328-WED  
Zhu H., PO431-WED  
Zhu J., OR365  
Zhu X., OR018  
Zhu L., AS026, PO022-MON  
Zhu M., OR180  
Zhu S., OR351  
Zhuravleva E., PO008-MON, PO548-MON  
Zi M., OR168  
Zicari A., PO316-WED  
Zidani N., PO494-MON, PO242-TUE, PO637-TUE, PO276-WED, PO520-WED

Zide R., AS077  
Zieger B., PO419-TUE  
Zielinski C., OR260, PO166-WED  
Zierler S., AS068  
Zijlstra F., PO078-MON  
Zilberman-Rudenko J., PO543-WED  
Zilberstein L., PO513-WED  
Zimmerman G., PO604-MON  
Zimmerman G., OR243  
Zimmermann M., PO673-TUE  
Zimmermann R., PO215-TUE  
Zingali R., PO239-WED  
Zitomersky N., AS180  
Zivelin A., PO225-WED  
Zivony Y., PO471-WED  
Ziyatdinov A., PO126-TUE, PO217-WED  
Zoghlami C., AS034  
Zohrabyan D., PO573-MON  
Zollner S., AS016, PO596-WED  
Zöllner H., OR307, PO413-TUE  
Zondag M., NUR012  
Zondag W., OR257  
Zoppellaro G., PO077-TUE, PO372-TUE  
Zorio E., PO536-MON  
Zotova I., PO135-WED  
Zotz R., OR077, OR329, PO539-TUE

Zourikian N., PO282-WED  
Zozulya N., PO214-TUE, PO651-TUE  
Zrinski Topic R., PO436-TUE  
Zubairova L., AS156  
Zucker M., OR289, PO171-TUE  
Zuckerman L., PO346-MON  
Zuckermann A., PO185-MON, PO509-TUE  
Zuckier L., PO628-WED  
Zufferey A., OR397, PO302-TUE  
Zugaib M., PO508-MON, PO476-TUE  
Zuily S., AS036, OR186, OR189  
Zulfikar B., PO275-MON, PO295-WED  
Zulfikar B., PO649-TUE  
Zulian P., PO385-MON  
Zuo B., AS072  
Zupan I., PO181-MON, PO027-WED  
Zupancic-Salek S., OR378  
Zuurbier S., OR118, PO525-TUE  
Zwaginga J. J., PO607-WED  
Zwicker J., PO346-TUE  
Zwingerman N., AS045, AS206



# THE LARGEST INTERNATIONAL MEETING FOR THE GLOBAL BLEEDING DISORDERS COMMUNITY

Sign up for the newsletter at [www.wfh.org/congress](http://www.wfh.org/congress)



FEDERACIÓN MUNDIAL  
DE HEMOFILIA  
2016 CONGRESO MUNDIAL  
24-28 DE JULIO

Hosted by / En colaboración con:



Organized by / Organizado por:



**May 25-28, 2016**  
**62<sup>nd</sup> Annual SSC Meeting**  
**Montpellier, France**

Jean-François Schved, President

**[www.ssc2016.org](http://www.ssc2016.org)**

Join the Conversation Using #SSG2016



**Please visit us at Booth 1036!**



**Save the date for the next ISTH Scientific and Standardization Committee (SSC) meeting in Montpellier, France, from May 25 – 28, 2016.**

The 62nd Annual SSC Meeting of the ISTH will be devoted to the discussion of diagnostic standards, disease nomenclature and classification, and the latest research on bleeding and thrombotic disorders. SSC 2016 will continue the tradition of offering dedicated education and plenary sessions to complement the in-depth presentations of the work in progress by the SSC subcommittees and working groups. A must-attend event in the field of thrombosis and hemostasis, you are welcome to participate and get involved!

The program will include the following topics: Animal, Cellular, and Molecular Models; Biorheology; Control of Anticoagulation; Disseminated Intravascular Coagulation; Factor VIII, Factor IX and Rare Coagulation Disorders; Factor XI and the Contact System; Factor XIII and Fibrinogen; Fibrinolysis; Genomics in Thrombosis and Hemostasis; Hemostasis & Malignancy; Lupus Anticoagulant/Phospholipid-Dependent Antibodies; Pediatric/Neonatal Hemostasis and Thrombosis; Plasma Coagulation Inhibitors; Platelet Immunology; Platelet Physiology; Perioperative Thrombosis and Hemostasis; Predictive and Diagnostic Variables in Thrombotic Disease; Vascular Biology; Von Willebrand Factor; and, Women's Health Issues in Thrombosis and Hemostasis.

**Mark your calendars to join us for SSC 2016!**

**SAVE THE DATE!**





# 2017

JULY 8-13

# TRANSCENDING SCIENTIFIC BOUNDARIES

# BERLIN, GERMANY



TRANSCENDING SCIENTIFIC BOUNDARIES

## Save the Date for ISTH 2017!

You are invited to attend the **XXVI<sup>th</sup> Congress of the International Society on Thrombosis and Haemostasis (ISTH)**. Held in **Berlin, Germany**, from **July 8 –13, 2017**, the ISTH 2017 Congress will be the foremost meeting in thrombosis, hemostasis and vascular biology and will be attended by thousands of the world's experts.

Join us in Transcending Scientific Boundaries at ISTH 2017!

[www.isth2017.org](http://www.isth2017.org)

Visit the ISTH at Booth 1036!